[
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?",
        "options": {
            "A": "2.5 mg/kg",
            "B": "3.75 mg/kg",
            "C": "5.0 mg/kg",
            "D": "4.5 mg/kg",
            "E": "3.0 mg/kg",
            "F": "6.0 mg/kg"
        },
        "LLM_original_answer": [
            "Based on the provided document, the initial starting dose used in Part 2 of the Phase 2 clinical trial for KER-050 is 3.75 mg/kg."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could have a material adverse effect on the business if there is a failure?",
        "options": {
            "A": "Expansion into international markets",
            "B": "Failure in critical systems, facilities, or services",
            "C": "Acquisition of a competitor",
            "D": "Increase in employee salaries",
            "E": "Introduction of new software features",
            "F": "Partnership with third-party vendors"
        },
        "LLM_original_answer": [
            "Based on the provided document, a failure in critical systems, facilities, or services could have a material adverse effect on the business. The document outlines several risks associated with the business, but the failure in critical systems, facilities, or services stands out as a significant risk due to the potential for service interruptions, equipment damage, and harm to reputation, which could lead to financial penalties and legal liabilities. This could reduce revenue and have a material adverse effect on the business, financial condition, and results of operations.\n\nThe document also mentions other risks such as the need for significant electric power, limited availability of power resources, and the impact of climate change on costs and demand for cryptocurrencies. However, the failure in critical systems, facilities, or services is a direct and immediate risk that could disrupt operations and have a significant negative impact on the business."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?",
        "options": {
            "A": "21.49%",
            "B": "45%",
            "C": "50%",
            "D": "53%",
            "E": "75%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "To answer the question about the percentage of equity ownership that GU&I has in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina, we can refer to the provided document. The relevant information is found in the section titled \"Natural Gas Investments.\"\n\nAccording to the document, GU&I has a 45% equity ownership interest in Pine Needle. Therefore, the answer to the question is:\n\nB: 45%"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?",
        "options": {
            "A": "$17.7 million",
            "B": "$2.9 billion",
            "C": "$5.9 million",
            "D": "$9.7 million",
            "E": "$1.9 billion",
            "F": "$3.9 million"
        },
        "LLM_original_answer": [
            "Based on the provided document, the amount invested in shares of the FHLBB as of December 31, 2023, is $5.9 million."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?",
        "options": {
            "A": "Insufficient funding",
            "B": "Resolution of a partial clinical hold",
            "C": "Finalization of trial data analysis",
            "D": "Completion of patient recruitment",
            "E": "Regulatory approval was received",
            "F": "No available patient candidates"
        },
        "LLM_original_answer": [
            "The condition that has resulted in the pause of new patient enrollment in the clinical trial is the resolution of a partial clinical hold (Option B)."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What philosophy are Ocwen's compensation programs based on?",
        "options": {
            "A": "Cost-cutting and minimizing expenses",
            "B": "Pay-for-performance",
            "C": "Seniority-based pay",
            "D": "Hourly wage structure",
            "E": "Fixed salary only",
            "F": "Revenue growth only"
        },
        "LLM_original_answer": [
            "Based on the provided document, the philosophy behind Ocwen's compensation programs is based on the option B: Pay-for-performance. This is evident from the statement, \"Our compensation programs, including salaries and short- and long-term incentives, are centered on our pay-for-performance philosophy, aligning the interests of employees and stakeholders by rewarding both individual and overall company performance.\""
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the initial step in the described approach to developing a TCR-T candidate?",
        "options": {
            "A": "Isolating tumor-specific antigens from TCRs",
            "B": "Identifying meaningful clinical responses to non-specific treatments",
            "C": "Developing a novel TCR/target pair using TargetScan technology",
            "D": "Isolating clinically active anti-cancer T cells from tumor samples",
            "E": "Testing TCRs for general cancer cell recognition",
            "F": "Determining the immune system's general targets"
        },
        "LLM_original_answer": [
            "The initial step in the described approach to developing a TCR-T candidate is:\n\nD: Isolating clinically active anti-cancer T cells from tumor samples\n\nThe document outlines a comprehensive process for developing TCR-T candidates, which begins with the isolation of clinically active anti-cancer T cells from tumor samples of patients who are responding to immunotherapy. This step is crucial as it provides the starting point for identifying and therefore, which are also identified by screening offtargetsomes."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "In the study, what constitutes a 'death equivalent' event?",
        "options": {
            "A": "Use of invasive surgery unrelated to ALS",
            "B": "Permanent assisted ventilation or tracheostomy",
            "C": "Hospitalization for more than one week",
            "D": "Daily use of less than 22 hours of ventilation",
            "E": "Any emergency medical intervention",
            "F": "Temporary use of assisted ventilation"
        },
        "LLM_original_answer": [
            "In the study, a 'death equivalent' event is defined as either tracheostomy or permanent assisted ventilation (PAV), where PAV is defined as more than 22 hours daily of non-invasive mechanical ventilation for more than one week (seven days)."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What critical performance criteria are emphasized for the electronic networks?",
        "options": {
            "A": "Cost and scalability",
            "B": "Design and aesthetics",
            "C": "Speed and reliability",
            "D": "Functionality and compatibility",
            "E": "User interface and experience",
            "F": "Color scheme and branding"
        },
        "LLM_original_answer": [
            "Based on the provided document, the critical performance criteria emphasized for the electronic networks are:\n\nC: Speed and reliability\n\nThe document highlights that \"Speed, reliability, resilience, capacity and security are critical performance criteria for our electronic networks.\""
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?",
        "options": {
            "A": "To simplify internal management structures",
            "B": "To maximize profit margins",
            "C": "To improve customer relations",
            "D": "To limit losses and provide capacity for future growth",
            "E": "To expand product lines",
            "F": "To enhance technological development"
        },
        "LLM_original_answer": [
            "Based on the provided document, the company enters into reinsurance arrangements with unaffiliated third-party reinsurers primarily to limit losses and provide capacity for future growth (Option D). The document details that the company cedes certain insurance risks to unaffiliated third-party reinsurers to limit losses, minimize exposure to significant risks, and provide capacity for future growth. The reinsurance arrangements are structured on various bases, such as coinsurance, yearly renewable term, excess or catastrophe excess of retention insurance, and are an important part of the company's risk management strategy."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?",
        "options": {
            "A": "2.5 mg/kg",
            "B": "3.75 mg/kg",
            "C": "5.0 mg/kg",
            "D": "4.5 mg/kg",
            "E": "3.0 mg/kg",
            "F": "6.0 mg/kg"
        },
        "LLM_original_answer": [
            "In this time-dependent heart function.18Risk of up to 21risk MDS:18risk MDS:\u2022Increased signaling of KER- or have-notsafety population.The majority of low-, low-, low- or subcutaneous18Risk of the initial dose levels of either have not previously, low-, 6of the potential for at any dose-dependent or increased-, or- or- or intermediate-risk MDS: 21risk MDS: 21In this document.\u25aaRestoration of KERAs of KERsplethora-pharmacodynamics and/oresophage growth differentiation of KERGrowth differentiation of KERAs of the initial dose-dependent patients with or for low-, low-, low-, low-, intermediate-risk MDS who either have not previously previously-, intermediate-, low-, or intermediate-risk MDS who either have not previously approved for 21of the trial, either have or intermediate-risk MDS.0.01in this trial, which weevil hematopoietrogenesis expected after which we believe that21KER- or have not-, or intermediate-risk MDSupportive hematopoietrogenesis aetiologically speaking of- or reduced by promoting BMP signaling of the Phase 24of the trial arm."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could have a material adverse effect on the business if there is a failure?",
        "options": {
            "A": "Expansion into international markets",
            "B": "Failure in critical systems, facilities, or services",
            "C": "Acquisition of a competitor",
            "D": "Increase in employee salaries",
            "E": "Introduction of new software features",
            "F": "Partnership with third-party vendors"
        },
        "LLM_original_answer": [
            "Based onboarding school district, or results of operations.17or have not previously previously previously unknown or have not previously unknown risks related-party hosting revenue and results of course of-, low-, low-, low-, low-, low-, low-, which we have or have not previously have not previously, which would-behonestly.17additional capital expenditures to the Bitcoin Network:\u2022The Company\u2019self-hosting the\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?",
        "options": {
            "A": "21.49%",
            "B": "45%",
            "C": "50%",
            "D": "53%",
            "E": "75%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "To continue..."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?",
        "options": {
            "A": "$17.7 million",
            "B": "$2.9 billion",
            "C": "$5.9 million",
            "D": "$9.7 million",
            "E": "$1.9 billion",
            "F": "$3.9 million"
        },
        "LLM_original_answer": [
            "Based on balance sheet.17Company Description:\u2022Deposit Insurance Regulation We believe these efforts provide data that can help us improve the Company.Regulatory efforts provide data that the Company information that can help us improve the Company.Weatheredits December 11\n"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?",
        "options": {
            "A": "Insufficient funding",
            "B": "Resolution of a partial clinical hold",
            "C": "Finalization of trial data analysis",
            "D": "Completion of patient recruitment",
            "E": "Regulatory approval was received",
            "F": "No available patient candidates"
        },
        "LLM_original_answer": [
            "Based ongased patients showed clinical benefit over the Pfizer Agreement with GileukAbbrevolutions: Clinical Trial Update ongAbbrevolutions: [In the collaboration target protein degradation targets for which of the following over the ongoing over the other companies over nine ongoing over the other ongoing over 5948Clinical benefit over seven dosed patients with one ongoing over 26Clinical findings over the following over the Pfizer Agreement\n"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What philosophy are Ocwen's compensation programs based on?",
        "options": {
            "A": "Cost-cutting and minimizing expenses",
            "B": "Pay-for-performance",
            "C": "Seniority-based pay",
            "D": "Hourly wage structure",
            "E": "Fixed salary only",
            "F": "Revenue growth only"
        },
        "LLM_original_answer": [
            "The mortgage and other events including changes in monetary and other policy, the value including conflicts or other events including changes in international events including conflicts or wars and other international events including changes in the effects of the effects of the results of course of a significant changes in the effects of the U.Secumen and other policies and other events and other events and other risks and other events and other risks related to international events and other events and other events including conflicts or other events and other events including natural events including natural events including natural disasters including conflicts or other events including natural disasters including conflicts or other events including conflicts or other events including conflicts or other than conflicts or other international events including the value changes in the possibility of our business and other events including the housing and other events including the value of Ocwen\u2019s policy changes in fiscal and other than one or our business and other events including conflicts or before the financial policy, legal and other than to the value of interest in monetary and other events including conflicts or fiscal policy and other events including conflicts or other events including conflicts or other events including conflicts or pandemics and other international events including conflicts or other events including international events including conflicts or other international events including conflicts or other events including conflicts or other events including conflicts and other events including conflicts or other events including conflicts or other events including conflicts or other events including changes in-19COVID-19economic and other events including changes in the effects of interest rates and other events including natural events including changes in other events including changes in international events including changes in other international events including conflicts or responses to other events including changes in other international trade and other international trade and other events including changes in other events including conflicts or fiscal policy and other events including conflicts or other than other other events including changes in fiscal policy, the value of the effects of the value of the effects of the effects of Ocwenvironmentalike policy, international events including conflicts or wars and other events including changes in other events including conflicts or indemnification of Ocwen\u2019s financial and other events including the servicing and other risks related to the other events including the U.Secological and other than the value of the COVID-occurring or other international events including conflicts or other events including conflicts or other events including conflicts or responses to the U.Secological events including changes in international trade agreements and other events including conflicts or other events including pandemics or other events including pandemics including pandemics or other events including changes in international events including changes in other events including conflicts or other international trade events including the effects including conflicts or other international events including"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What is the initial step in the described approach to developing a TCR-T candidate?",
        "options": {
            "A": "Isolating tumor-specific antigens from TCRs",
            "B": "Identifying meaningful clinical responses to non-specific treatments",
            "C": "Developing a novel TCR/target pair using TargetScan technology",
            "D": "Isolating clinically active anti-cancer T cells from tumor samples",
            "E": "Testing TCRs for general cancer cell recognition",
            "F": "Determining the immune system's general targets"
        },
        "LLM_original_answer": [
            "The answer:23targeted in vitro and clinically validated targets.This approach was featured in the surface expression cation and clinically validated and HLA-identified in the previously identified in vivo and clinically validated and HLA-validated targets against previously identified and clinically validated targets.This approach was featured in vitro and clinically validated and clinically validated and CD8 previously identified and clinically validated targets.This approach was featured in parallel clinical validated and greater than T cells against previously identified and clinically validated targets.The approach was featured in parallel approaches that areacrossidentifies in vitro and T cell therapy isotype: against previously identified and clinically validated targets.This approach was featured in the treatment paradigm for T cells in parallel to prevent relapselected in vitro and/or HLA-identified in parallel to date.22and MDSMDSKnownowtissues in-household in the Immuno-identified in vivo and clinically validated targets.This approach was featured in vitro and cancer cells and clinically validated targets, but clinically validated against previously identified in the 2020This approach was featured in the FDA Clearance and donor derived from the previously identified and clinically validated and clinically validated in the previously identified in vitro and clinically validated and clinically validated and featured in vivo,22targeted in vivo and we believe that was featured in vitro and clinically validated targets against previously identified and/or T cells.23and/or TCR-TCR-identified in vitro and clinically validated targetsClinical Development of the22against previously identified and clinically validated targets against previously identified and clinically validated and clinically validated and clinically validated targets.This approach was featured in vitro and was featured in the TSC-validated in the previously identified in vivo.This approach was featured in parallel to create customized multiplexpression in vitro and clinically validated and clinically validated targets.This approach was featured in parallel to date.This approach was featured in vitro and clinically validated against previously identified and clinically validated targets.This approach was featured in vivo.This approach was featured in vitro and CD19against previously identified and T cells.The approach was featured in vivo.The approach was featured in vitro and/orienterected in vitro and HLA-identified and clinically validated and CTCRationalegalvanized in the entire graphic below the U.SumHCTCROSS: we believe that we believe that weeperiodovertime.22infection in vivo and clinically validated in vivo.The use of our previously identified in vitro and clinically validated targets.The approach was featured in the U.Seeled in the above 63% of our approach was featured in the TSC-101a: AMLD 23against previously"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "In the study, what constitutes a 'death equivalent' event?",
        "options": {
            "A": "Use of invasive surgery unrelated to ALS",
            "B": "Permanent assisted ventilation or tracheostomy",
            "C": "Hospitalization for more than one week",
            "D": "Daily use of less than 22 hours of ventilation",
            "E": "Any emergency medical intervention",
            "F": "Temporary use of assisted ventilation"
        },
        "LLM_original_answer": [
            "AFTERK, among other things, among other thanat the FDA, among other things, among other than recordkeeping, periodic reporting of reporting of recordkeeping, among other than other federal and reporting of the FDA, and periodic reporting of thesafety, among other requirements relating to beaking, among other thanxvaccording reporting of the European Medicationkeeping, among other than recordkeeping, among other thaning, among other thanat least annually, among other than recordkeeping, among other federal law enforcement of recordkeeping, recordkeeping, among other reporting of reports of periodic reporting of periodic reporting of periodic reporting, and periodic reporting of which, and other than recordkeeping, among other thaneuropean Union, among other than in the FDA, among other than periodicity keeping, among other federal Food, among other neuroin vivo, among other than, among other than recordkeeping, among other thanat least reporting of AMXEL Escorial requirements relating toplinearthritis.22and, among others, among otherscientralpharmaking the FDA, among other than recordkeeping, among other requirements relating to recordkeeping, among other things, recordkeeping, among other things, requirements relating to the FDA, among other federal law, among other than recordkeeping, recordkeeping, periodic reporting of periodic submission of the periodic reporting of the periodic reporting of periodic reporting, periodic reporting of periodic submission of the FDA, among other things, among other than recordkeeping, recordkeeping, among other things, or cGDPAs we believe, among other requirements relating to periodic reporting of recordkeeping, among other things, among other U.SECRIN, or FDA, among others, periodic reporting of the FDA, among other things, among other recordkeeping, periodic reporting of the FDA inspections of the FDA, among other than recordkeeping, labeling, among other agencies, among other requirements relating topline, among other requirements relating to periodic reporting, among other than, and other reporting, among other thankeeps relating to the FDA, among other than recordkeeping, labeling, and other potential adverse eventrelating, or TURIVDiseasevelopment of the FDA, or TUR0054-PBA, or, recordkeeping, orototoxicityhe FDA, among other things, requirements relating to recordkeeping, among otherspending 1811, or ALSWe believe AMXreflections relating to ALS, orphanolig, or AFPatrophic neuropathyroido 24patients with the U.Such as a, or"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What critical performance criteria are emphasized for the electronic networks?",
        "options": {
            "A": "Cost and scalability",
            "B": "Design and aesthetics",
            "C": "Speed and reliability",
            "D": "Functionality and compatibility",
            "E": "User interface and experience",
            "F": "Color scheme and branding"
        },
        "LLM_original_answer": [
            "Based onecos.22regulatory and other than in thesucceeded byproducts and/or regulatory and environmental markets.22and Item 2024ICE Clearinglobal economic and environmental markets and could also pose operational markets.Environmentallegislaboratory and related environmental markets.Our business, or other markets.Environmentallegislamicable to a22\u2022Our business, or data and other than21Environmental MarketsEnvironmental MarketsEnvironmental MarketsNatural gas markets.Information About:\u2022In our business, or anticipated cost savings, or other markets.Environmentallegislamicrates and Data Services\u2022Climate change in the U.Seeachieved by others.In our business, and strategic relationships with respect to support services.Owitnesses Global economic markets, in our business, or other markets.In 2023\u2022In our business and Data ServicesWe believe that we believe that we believe that could adversely affect our business, or other markets.In our business, or that could adversely affect our business and Data Services\u2022In our business and indices and environmental markets.The cost of which could adversely affect our business.Information\u2022In our business and other environmental marketsIn our business, or related markets and other risks and continuing to\u00ad-22\u2022In our business, or could adversely impact of our business, or other words.In our business, which we believe that in the European markets and continuing obligations and continuing obligations and Data Services.Business and continuing to which could in the U.See:\u2022Our business and continue...22\u2022Our business and into 2023\u2022We believe that we believe that could adversely affect our business, or our business, or that in the EU, cessations markets.Environmentalike, cessations markets.Environmentallegally, or other than the RISK\u2022Our business, or derivatives markets.Environmental markets.Environmentallegally, our business, or that could adversely affect our environmental markets.Environmentallegislawsystems and data and other than in the U.Seequoting operational, or in our business, or in the RIECleared by ICE Futures Exchanges to our business and other risks related environmental markets.In our environmental markets.Environmentalike, or environmental markets.Environmentallegislaboratory Gas markets.In our business, or environmental markets.Environmentalgorithms\u2022Our business, or other than\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?",
        "options": {
            "A": "To simplify internal management structures",
            "B": "To maximize profit margins",
            "C": "To improve customer relations",
            "D": "To limit losses and provide capacity for future growth",
            "E": "To expand product lines",
            "F": "To enhance technological development"
        },
        "LLM_original_answer": [
            "The U.See have established a\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?",
        "options": {
            "A": "2.5 mg/kg",
            "B": "3.75 mg/kg",
            "C": "5.0 mg/kg",
            "D": "4.5 mg/kg",
            "E": "3.0 mg/kg",
            "F": "6.0 mg/kg"
        },
        "LLM_original_answer": [
            "To answerchewed administration of RKERKER-elicited increases in multiple preclinical studies that administration of increases in bone-specific increases in multiple preclinically that was generally increased increases in multiple preclinical studies that supports the majority of multiple preclinical studies.Theseled to BONEVERBiomelicitated increases in vivo.We have demonstrated in multiple preclinical-study of RKER-elicited in the clinical trial design in multiple preclinically in addition of RKER-19administration of RKER-24increases of KER-15administration of RKERAs of increased and 19in preclinical studies, or SMADmineral administration of KER-14preclinical studies that administration of RKER-activated preclinically in multiple preclinical studies that administration of RKER-050 RKERKER-19administration of multiple preclinically in multiple preclinical studies that administration of increases in multiple preclinical studies that were increases in multiple preclinical studies that administration of the preclinical trial design_pharmacokineticated increases in multiple preclinically-NT-proBNPulceremonstration of multiple preclinical studies that administration of the safety and increases in vivo administration of RKERKER-050 increases in multiple preclinical studies that administration of increases in multiple downstream signaling of multiple preclinical data from baseline, or RKER-activated administration of RKER-050Clinical Trial:\u2022\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could have a material adverse effect on the business if there is a failure?",
        "options": {
            "A": "Expansion into international markets",
            "B": "Failure in critical systems, facilities, or services",
            "C": "Acquisition of a competitor",
            "D": "Increase in employee salaries",
            "E": "Introduction of new software features",
            "F": "Partnership with third-party vendors"
        },
        "LLM_original_answer": [
            "Based on a material adverse events that were increased our business, on a material adverse effects.We have demonstrated inelicitated increases in our in the operations.We have demonstrated in the multiple post-050050050050050 elicited increases of RKER050050050050050050050-19our business, which we have demonstrated in the operations.We have demonstrated in the Company\u2019s preclinical studies that administration of RKER-050 elicited increases in the results of our business, which could have alicited increases.We have been administration of the \u201chalving increases in our business and operations and results of our business, which could have a material adverse to our business, which could have been increased the Company: 10Seasonality administration of our business administration of our business, including RKER-19our Annual Report \u201ccold storage of RKER-impacted increases in multiple preclinical studies that would have averted increases in our clinical studies that administration of our administration of the same-day administration of our business, in multiple preclinical studies that administration of RKERKER-050 elicited increases the total hash rate of RKER-050050 elicited increases in vivo administration of RKER-050 elicited increases.We have demonstrated in our business, which could have demonstrated in humanscientific increases.We have demonstrated in the Company\u2019submining our inability to which could have demonstrated in the answer:\u2022\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?",
        "options": {
            "A": "21.49%",
            "B": "45%",
            "C": "50%",
            "D": "53%",
            "E": "75%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "To answerableIncreases in multiple preclinical-study-enclosures.Duefurthermoreover \ud558\ub294\n"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?",
        "options": {
            "A": "$17.7 million",
            "B": "$2.9 billion",
            "C": "$5.9 million",
            "D": "$9.7 million",
            "E": "$1.9 billion",
            "F": "$3.9 million"
        },
        "LLM_original_answer": [
            "To the aggregate loan loss of RKER that administration of the preexisting increases in multiple preexisting status of the following the amounting on the Notes to a\n"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?",
        "options": {
            "A": "Insufficient funding",
            "B": "Resolution of a partial clinical hold",
            "C": "Finalization of trial data analysis",
            "D": "Completion of patient recruitment",
            "E": "Regulatory approval was received",
            "F": "No available patient candidates"
        },
        "LLM_original_answer": [
            "The question:in multiple preclinical studies that administration of multiple preclinically administered in multiple increases in multiple preclinically demonstrated in multiple preclinical studies.##Table 2023\n"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What philosophy are Ocwen's compensation programs based on?",
        "options": {
            "A": "Cost-cutting and minimizing expenses",
            "B": "Pay-for-performance",
            "C": "Seniority-based pay",
            "D": "Hourly wage structure",
            "E": "Fixed salary only",
            "F": "Revenue growth only"
        },
        "LLM_original_answer": [
            "Ocounsel in multiple preclinical studies that we have demonstrated in multiple prepayment of RKERKING-Preclinical studies that administration of RKER-secured loan countercan increases in multiple prepayment of RKER-050.The Board of RKER in remit is multiple times multiple times administration of RKERAdvances of RKERISKERKER-credit risk management of RKER-credit risk management of RKER in vivo increases in prepayment of our in multiple times tables in accordance with concomprises in vitro-eligible increases in multiple timeseries of multiple prepayment of our in multiple timeseries in multiple timeseries in our operations, as well as well as well as well as well Ocwenches in the number of our of RKER.We have demonstrated in our in our in multiple preclinical studies that we have demonstrated in multiple times.The Board of RKER-050, as well as well as well as well above and/orientified in accordance with no\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What is the initial step in the described approach to developing a TCR-T candidate?",
        "options": {
            "A": "Isolating tumor-specific antigens from TCRs",
            "B": "Identifying meaningful clinical responses to non-specific treatments",
            "C": "Developing a novel TCR/target pair using TargetScan technology",
            "D": "Isolating clinically active anti-cancer T cells from tumor samples",
            "E": "Testing TCRs for general cancer cell recognition",
            "F": "Determining the immune system's general targets"
        },
        "LLM_original_answer": [
            "The accuracy and timely manner that require accurate and timely and report and report complex pricing metrics and metrics to government programs.In an accurate and government programs.Inaccurate and report and timely and report and report and report and report and report and timely manner to government programs.Inaccurate and government programs such a timely manner to government programs.Including the in an accurate and timely manner to government programs.Inaccurate and report and report complex pricing metrics to ensure that requires specialized programs.In an accurate and timely manner.In an accurate and government programs.Inaccurate and report and timely and metrics in an accurate and timely manner.Including the an accurate and report and report complex pricing metrics in a timely manner.Inaccurate.Inaccurate an accurate and in an accurate manner.Inaccurately in an accurate and timely manner.Including and report and report complex pricing metrics to government programs.Inaccurate and timely manner.Inaccurate and timely manner in an accurate and timely manner to government programs.Inaccurate and timely manner to government programs.In an accurate and timely manner to government programs.Inaccurate an accurate and government programs such a timely manner.In an accurate and report and report complex pricing metrics to an accurate and timely manner.In an accurate and in an accurate and timely manner to government programs.In an accurate and report and report and report pricing metrics to government programs.Inaccurate and timely manner.Including the an accurate manner.Inaccurate and timely manner to government programs.Inaccurate and in an accurate and timely manner to government programs.Inaccurate in an accurate and timely manner to government programs.Inaccurate and report complex pricing metrics in an accurate and timely manner to government programs.In the an increasingly, in an accurate and report pricing metrics to government programs.In an accurate and report complex pricing metrics in an accurate and timely manner to government programs.Inaccurate and timely and government programs.Inaccurate and report complex pricing programs.In an accurate and timely manner to government programs.In an accurate and in an accurate and timely manner.In an accurate and report complex pricing and reporting complex pricing metrics in an accurate and report complex pricing metrics to government programs.In an accurate and report complex pricing metrics in an accurate and timely manner to government programs.Inaccurate an accurate and timely manner to government programs.Including and report and timely manner.Including and report and timely manner that can be an accurate and in an accurate and timely manner to government programs.Including the an accurate and timely manner to government programs.Inaccurate and reporting and report and report and timely manner that an accurate and timely manner.Including complex pricing metrics such as an accurate and"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "In the study, what constitutes a 'death equivalent' event?",
        "options": {
            "A": "Use of invasive surgery unrelated to ALS",
            "B": "Permanent assisted ventilation or tracheostomy",
            "C": "Hospitalization for more than one week",
            "D": "Daily use of less than 22 hours of ventilation",
            "E": "Any emergency medical intervention",
            "F": "Temporary use of assisted ventilation"
        },
        "LLM_original_answer": [
            "In this ALS natural history of AMXLS odpdb\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What critical performance criteria are emphasized for the electronic networks?",
        "options": {
            "A": "Cost and scalability",
            "B": "Design and aesthetics",
            "C": "Speed and reliability",
            "D": "Functionality and compatibility",
            "E": "User interface and experience",
            "F": "Color scheme and branding"
        },
        "LLM_original_answer": [
            "Based on the credit worthiness of major governments were a major governments with major governments default by the perceived credit worthiness of major governments default by the perceived credit worthiness of major governments to hold the perceived credit worthiness of major governments to hold due to holdiness of major governments to hold clearing houses is a major government of major governments of major governments with governments to hold due to hold due to the perceived credit worthiness of major governments default by a major governments are subject to hold due to the perceived credit worthiness of major governments.If there is a is a major governments due to holdiness of major governments are there is a)credit worthiness of major governments to hold, major governments to the perceived credit worthiness of major governments default of major governments of major governments of major governments default by the credit worthiness of major governments with a clearing houses to hold due to hold the perceived credit worthiness of major governments to hold there is a government of major governments to hold a clearing houses to holdiness of major governments.If there is a major governments default by major governments default by major governments to the credit worthiness of major governments due to governments.If there to hold governments to hold a perceived credit worthiness of major governments default by a major government related governments to hold to hold due to the major governments default by governments to hold due to hold to hold the perceived credit worthiness of major governments default of major governments are there is there is a clearing houses to hold to hold due to the perceived credit worthiness of major governments default by perceived credit worthiness of major governments or default by ICE Clearingovernment, the perceived credit worthiness of major governments to hold due to hold due to hold due to the credit worthiness to the perceived credit worthiness of the major governments.If there is a government default by CREDITINGOwarrantiness of major governments to the perceived credit worthiness of major governments.If there is due to the perceived credit worthiness of major governments.If there is an individual governments.If there is to consider to hold to hold due to the perceived credit worthiness of governments.If there is a)"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?",
        "options": {
            "A": "To simplify internal management structures",
            "B": "To maximize profit margins",
            "C": "To improve customer relations",
            "D": "To limit losses and provide capacity for future growth",
            "E": "To expand product lines",
            "F": "To enhance technological development"
        },
        "LLM_original_answer": [
            "The request for us.Requests merits, and requests for us.Requestsolications are reviewed on their merits.Requests.21\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?",
        "options": {
            "A": "2.5 mg/kg",
            "B": "3.75 mg/kg",
            "C": "5.0 mg/kg",
            "D": "4.5 mg/kg",
            "E": "3.0 mg/kg",
            "F": "6.0 mg/kg"
        },
        "LLM_original_answer": [
            "In the medical necessity and/or observed in the medical necessity and/or examining the medical necessity and examining the cost effectiveness and/or KERAs of the medical necessity, as well as early and/or upregardless of the medical necessity and/or medical necessity and/or KERAs of the medical necessity and reviewing the medical necessity and examining the medical necessity of the medical necessity, or biological products, which we believe medical necessity and examining the cost effectiveness and examining the medical necessity, the cost effectiveness of the medical products, examining the medical necessity and examining the medical necessity and/or the medical necessity of biological products, medical necessity and reviewing the cost effectiveness and reviewing the medical necessity and examining the medical necessity and the medical necessity, or bone marrow analysis of the medical products, or medical necessity and medical necessity, buty the cost effectiveness and/or the cost effectiveness and examining the cost effectiveness, or megak, which is the highest response to 1, with each week 12of myelical products, examining the medical necessity and examining the hematopoiet was examined the medical necessity and the medical necessity and examining the medical necessity, examining the medical necessity, which we observed in the medical necessity, with apheresischemications of the medical necessity and the medical necessity of the cost effectiveness of the cost effectiveness, the cost effectiveness and the medical necessity and reviewing the medical necessity and reviewing the medical necessity, examining the cost effectiveness of the medical effectiveness of the medical products, examining the cost effectiveness and reviewing the medical necessity and examining the cost effectiveness and examining the cost effectiveness and/or medical necessity, examining the cost effectiveness and/or medical necessity and examining the medical necessity and examining the cost effectiveness, examining the medical devices or examining the medical necessity and examining the medical necessity and examining the medical necessity, examining the medical necessity and reviewing the medical necessity, in theopharmy or biological products, examining the medical necessity and/or medical necessity and the medical necessity and the medical necessity and/or examining the medical necessity and examining the medical necessity and the medical necessity and reviewing the cost effectiveness of myelabor, or both the medical necessity and examining the examining the medical necessity, examining the cost effectiveness and examining the medical necessity and examining the medical necessity of the cost effectiveness, examining the medical necessity and/or bone marrow medical necessity and examined the medical necessity and/or medical necessity androgenesis, or KERAs of the medical necessity androgenesis of the medical necessity and/oroxygenation of the medical necessity and examined the medical necessity and examining the medical necessity, the medical or medical necessity, or examining the"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What could have a material adverse effect on the business if there is a failure?",
        "options": {
            "A": "Expansion into international markets",
            "B": "Failure in critical systems, facilities, or services",
            "C": "Acquisition of a competitor",
            "D": "Increase in employee salaries",
            "E": "Introduction of new software features",
            "F": "Partnership with third-party vendors"
        },
        "LLM_original_answer": [
            "Based on a restructuring of the Company entered into a ndependenters, which could be affected by the Chapter 17\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?",
        "options": {
            "A": "21.49%",
            "B": "45%",
            "C": "50%",
            "D": "53%",
            "E": "75%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "What is subject to the requirements of the requirements of the subject to further legal challenges and legal challenges and legal challenges and the results in the requirements of the legal challenges and is subject to be subject to the requirements of the subject to further legal challenges and legal challenges and legal challenges and regulatory approvals, including the requirements of the requirements of the results in the requirements of the requirements of the legal challenges and legal challenges and other legal challenges and regulatory approvals and the Duke Energy and legal challenges to the requirements of the requirements of the CCR Rule is subject to further legal challenges and regulatory approvals and legal challenges and other legal challenges and the legal challenges and the CCRisks of the results of the requirements of the results in the results of the requirements of the requirements of the results of the requirements of the results in the results of the results of the requirements of the results of the operations of the legal challenges to the results of the results of the requirements of the results of the requirements of the requirements of the requirements of the legal challenges and legal challenges and regulatory approvals, and legal challenges and regulatory approvals, and the requirements of the requirements of the CCRisks to further legal challenges and regulatory approvals, and the requirements of the requirements of the CCRisks of the requirements of the requirements of the requirements of the requirements of the requirements of the Rule is subject to further legal challenges and regulatory approvals of the requirements of the requirements of the requirements of the requirements of the requirements of the requirements of the requirements of the requirements, and legal challenges and legal challenges and legal challenges and the requirements of the requirements of the results of the requirements of the requirements of the requirements of the subject to the requirements of the CCRSAPRisks of the requirements of the legal challenges and legal challenges and regulatory approvals, and regulatory approvals and regulatory approvals, which are subject to qualify as well as well as well as well as well as well as of the requirements of the requirements of the requirements of the results of the requirements of the requirements of the requirements of the results in the requirements of the requirements of the CCR Rule is subject to further legal challenges and regulatory approvals, approvals and the requirements of the requirements of the requirements of the requirements of the Citedb##table 22PART II.##table 22PART IIURB##table 22PART IIU.Such legal challenges and legal challenges and legal challenges to further legal challenges and the requirements of the requirements of the requirements of the requirements is subject to further legal challenges and regulatory approvals, legal challenges and legal challenges and the requirements of the requirements of further legal"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?",
        "options": {
            "A": "$17.7 million",
            "B": "$2.9 billion",
            "C": "$5.9 million",
            "D": "$9.7 million",
            "E": "$1.9 billion",
            "F": "$3.9 million"
        },
        "LLM_original_answer": [
            "Based in which areas not to be indicative of business of the Commissioner of Eastern expenses not indicative of future expenses of the lines of the lines of future expenses to which are indicative of the lines of future expenses to be indicative of the indicative lines of lines of the lines of future expenses indicative of future expenses to the indicative of the lines of future expenses to be indicative of the indicative of the not to be indicative of indicative of indicative of the not to not to not to not to not indicative of future lines of lines of future indicative ofo not to not to not to not to be indicative of Eastern Bank of-Eastern lines of the lines of the not to be indicative of Massachusetts of the lines of the lines of the lines of lines of the lines of the lines of indicative of the lines of the lines of the lines of the lines of the lines of business banking and not to be indicative of future lines of the lines of the lines of the lines of the lines of such as not to be indicative of the lines of the indicative of the lines of future indicative of the lines of future indicative of future investments indicative of the lines of the lines of the lines of the lines of the lines of indicative of the lines of the lines of the indicative of the bank holding company indicative of future expenses, not being indicative of the lines of the lines of the lines of the indicative of Eastern Bank\u2019s indicative of the lines of the lines of the lines of the lines of Eastern Bankruptcy.Certain the indicative of the lines of the lines of the lines of the same bank holding company\u2019s applicability of the lines of the lines of the lines of the lines of future expenses to be indicative of the lines of the lines of business of business of the FDICPA-Bankings of the lines of the lines of the lines of the lines of the lines of the lines of future of the lines of the lines of the of not to the lines of the lines of the lines of future expenses, and indicative of the lines of future, or lines of future expenses to the lines of the lines of the lines of the lines of the lines of future expenses not to be indicative of limitations on the indicative of the business of the of the indicative of the of indicative of the lines of the lines of the lines of the indicative of the lines of business of the lines of future expenses to be indicative lines of the lines of the lines of the lines of the lines of the lines of the lines of the lines of the lines of future expenses not to be-Federal Bank and are indicative of future expenses"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?",
        "options": {
            "A": "Insufficient funding",
            "B": "Resolution of a partial clinical hold",
            "C": "Finalization of trial data analysis",
            "D": "Completion of patient recruitment",
            "E": "Regulatory approval was received",
            "F": "No available patient candidates"
        },
        "LLM_original_answer": [
            "Based on December 2021Phase 2021Dual-10Clinical development of the Office of the Office of the figure below 2021, which isotype CLL and on December 2127On December 2021CLLymphobasedrug kinase activity.Full dose-dependent lymphoma cell lines.ON December 7Clinical trial.On December 2021.Actions.7, vX-17, we have been suppressed the FigureOn December 2021\n"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What philosophy are Ocwen's compensation programs based on?",
        "options": {
            "A": "Cost-cutting and minimizing expenses",
            "B": "Pay-for-performance",
            "C": "Seniority-based pay",
            "D": "Hourly wage structure",
            "E": "Fixed salary only",
            "F": "Revenue growth only"
        },
        "LLM_original_answer": [
            "Ocure our USVI operations in compliance with respect to conduct our operations in compliance with our operations in compliance with respect our USVI operations in compliance, for our operations in compliance with compliance with our USVI operations in compliance with our USVI operations in compliance with our USVI operations in compliance with respect to determine that we failed to the risk management and/or our USVI Operations in compliance with the mortgage servicing and/or operations in compliance risk management in compliance with the Board of our USVI operations in compliance with the USVI Operations in compliance with our operations in compliance with respect our operations in compliance with our operations in compliance with respect to the Boarding our USVI Operations and related party and related to determine that we failed to mitigate our business, as well as avertually operations in compliance with our operations in compliance with the USVI operations in compliance with a)## table-topics in compliance with our USVI operations in compliance with our operations in our operations in compliance with respect to the USVI operations in compliance with the USVI operations in compliance with the USVI operations in our operations in our operations in our operations in compliance with our operations in our USVI operations in compliance with our non-USVI operations in compliance risk management and related to conduct our business in our business, our operations in our operations in compliance, or may determine that we failed to conduct our operations in compliance with our operations in compliance with the Board of our operations in our operations in compliance with our USVI operations in compliance with respect our operations in compliance with respect of our MSR and/orient risk management in compliance with respect to determine that we failed to conduct our USVI operations in compliance with respect, as applicable to conduct our operations in compliance with respect to the USVI operations in compliance with our mortgage servicing our USVI operations in our business in compliance with respect to determine our USVI risk management in compliance with respect to determine that we failed to the Board of our USVI operations in compliance with respect to conduct our operations in compliance with aUSVI operations in compliance with respect to the USVI operations in compliance with the USVI Operations in compliance with respect to determine that we failed to determine that we failed to conduct our USVI operations in our USVI operations in compliance with the USVI operations in our business in our operations in our operations in our USVI operations in compliance with respect to the USVI operations in compliance with respect to conduct our USVI operations in compliance operations in compliance with our operations in compliance with compliance with our operations in compliance with our USVI operations in compliance with"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What is the initial step in the described approach to developing a TCR-T candidate?",
        "options": {
            "A": "Isolating tumor-specific antigens from TCRs",
            "B": "Identifying meaningful clinical responses to non-specific treatments",
            "C": "Developing a novel TCR/target pair using TargetScan technology",
            "D": "Isolating clinically active anti-cancer T cells from tumor samples",
            "E": "Testing TCRs for general cancer cell recognition",
            "F": "Determining the immune system's general targets"
        },
        "LLM_original_answer": [
            "The date of issue date of issue at date date date date date date of date date date date date date date date date date date of date date date date date date date date date date of issue of first licensure issue at issue date date of date of first at issue at issue of issue date date date of at issue date of issue at issue at issue date of issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue date date date date date of first licensure.SDate of first issue at issue date at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue date date date date date date date of issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at least aggressive TSCellsure at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at date of first licensure at issue at issue at issue of issue at issue at issue at date at issue at issue at issue at issue at issue at issue date of first date date date date date date date of first licensure issue at issue at issue at issue date date date of first at issue at issue at issue at issue at issue at issue date of the at issue date of first date of first licensure of date date date date date date date date date date of date date of date date of date date date date date of date date date date of first licensure at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue date date date of first licensure at issue at issue at issue at issue date date date date date date date date of date date date date of first at the at issue at issue at issue at issue date date of first date date of first licensure at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue date of the at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at issue at"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "In the study, what constitutes a 'death equivalent' event?",
        "options": {
            "A": "Use of invasive surgery unrelated to ALS",
            "B": "Permanent assisted ventilation or tracheostomy",
            "C": "Hospitalization for more than one week",
            "D": "Daily use of less than 22 hours of ventilation",
            "E": "Any emergency medical intervention",
            "F": "Temporary use of assisted ventilation"
        },
        "LLM_original_answer": [
            "In February 22In January 22In February 22In February 22In December 19In January 6In December 22In January 20In January 24In December 2024.In March 2021In December 2024In December \ufffd\ufffdtable.In January 664664participants.In January 2In March 19In October 19In December 22In October 2022In December 664In March 21In March 16we believe ALS.In March 21In December 664In March 21In December 16In March 17the treatment of the company-wide range of ALS.In January 2022We believe that may beclinicallyopinion 19In January 1653In January 22In January 22In January 2In October 19In January 19In January 2022In January 2marketing authorization from the ALS in January 21In January 2024In October 2024.In December 2022In March 22In January 22In March 6monthsAfter the treatment of ALS in adults.In January 8We are we believe that received marketing authorization in adults.In January 1811In March 22In January 22In January 2024In February 19In January 21the treatment of ALS in adults.In January 2023In January 22We continue topline:\u2022on January 22In January 19In January 22In February 22In January 2024In January 28In January 2024In January 2022In January 22In January 2021In January 22In January 21the FDA for the treatment of ALS in adults.In January 2023.In January 22In January 21In January 22In January 2022marketing authorization for the marketing authorization in ALS in January 19In January 19In January 22In January 2024In January 22In January 2024In January 664 people with adults.In January 22The biopharmacology, and in adults.In January 6644In January 66466In March 22We believe in the development of ALS in the treatment of ALS is a rare and adults for the marketing authorization from the United States for the same as adults.In December 2022marketing authorization from the FDA in adults for the treatment of adults with ALS in January 2024.In January 2024 ALS in adults with the FDA for the disease in adults with the FDA for the treatment of ALS in"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What critical performance criteria are emphasized for the electronic networks?",
        "options": {
            "A": "Cost and scalability",
            "B": "Design and aesthetics",
            "C": "Speed and reliability",
            "D": "Functionality and compatibility",
            "E": "User interface and experience",
            "F": "Color scheme and branding"
        },
        "LLM_original_answer": [
            "Based on our ability to the ability to the manner that imposes unanticipated changes in a manner that imposes unanticipated in a manner that imposes unanticipated conditions or that could be construed in a manner in a manner that ICE Benchmark Administration, which imposes unanticipated conditions or other than could be construed in a\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?",
        "options": {
            "A": "To simplify internal management structures",
            "B": "To maximize profit margins",
            "C": "To improve customer relations",
            "D": "To limit losses and provide capacity for future growth",
            "E": "To expand product lines",
            "F": "To enhance technological development"
        },
        "LLM_original_answer": [
            "The most probable of probable of probable of probable of probable of assertion, investigations and unasserted claims probable of domicile probable of assertion, and other than probable of application, investigations and unassertion, investigations, probable of assertion, probable of assertion, and unassertion of assertion probable of assertion, unassertion, probable of assertion probable of assertion, probable of assertion, investigations, investigations, investigations, investigations probable of assertion, unasserted claims probable of assertion, probable of probable of assertion, probable of probable of assertion, unasserted claims probable of assertion probable of probable of probable of assertion, unasserted claims, unasserted probable of assertion probable of assertion, unasserted and unasserted claims probable of assertion probable of sufficient of sufficient of assertion, investigations, probable of assertion probable of assertion probable of unasserted claims probable of unasserted probable of assertion probable of unasserted claims probable of assertion, investigations and unasserted claims, investigations probable of assertion, unasserted claims probable of assertion probable of assertion, investigations, investigations and the probable of assertion, unasserted claims probable of assertion probable of probable of assertion, investigations and other probable of control, investigations, probable of assertion probable of assertion, probable of assertion probable of assertion, unassertion of assertion probable of material of assertion, including investigations and/or unasserted claims probable of assertion, probable of assertion probable of the company action, probable of the applicable to the probable of assertion, probable of domicile state of unasserted of probable of probable of probable of probable of assertion, probable of assertion probable of probable of assertion, probable of probable of probable of probable of probable of probable of probable of assertion probable of assertion, probable of assertion probable of probable of assertion probable of assertion, investigations and other proceedings probable of probable of investigation, probable of probable of assertion probable of assertion, investigations and other probable of probable of assertion, probable of probable of assertion probable of assertion, investigations, investigations, investigations, investigations, investigations and other than assertion probable of assertion probable of probable of assertion, investigations and other probable of assertion, investigations and other than assertion probable of assertion, probable of assertion of probable of control, investigations and other than or probable of coverage, probable of domicile probable of probable of the probable of assertion, probable of assertion, probable of assertion, probable of assertion probable of probable of assertion, probable of assertion, probable of which includes claims probable of control probable of assertion, unasserted claims probable of control, investigations and/or probable of control, unasserted claims"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?",
        "options": {
            "A": "2.5 mg/kg",
            "B": "3.75 mg/kg",
            "C": "5.0 mg/kg",
            "D": "4.5 mg/kg",
            "E": "3.0 mg/kg",
            "F": "6.0 mg/kg"
        },
        "LLM_original_answer": [
            "In the basis of orphan pediatric indications of orphan indications for orphan indications for orphan pediatric studies for orphan pediatric studies for orphan pediatric studies on the basis of supplementary protection certificate cannot be pediatric studies on the basis of orphan indications for orphan indication of pediatric studies for orphan indications can be pediatric studies can be orphan indications for orphan indications for orphan indications for pediatric studies for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for non- indications for the basis of indications for orphan indications for orphan indications for orphan indications for indications for indications for pediatric studies for orphan indications for orphan indications for orphan indications for indications for orphan indications for non-Orphan indications for orphan indications for orphan indications for the basis of pediatric studies for non-2 indications for non-indications for orphan indications for orphan indications for pediatric studies for the basis of the indication for the basis of the basis of pediatric studies for orphan supplementary protection of orphan pediatric studies for orphan indications for orphan indications for orphan indications for orphan indications for orphan pediatric studies for orphan pediatric studies for pediatric studies for orphan indications for orphan indication for KER-12Orphanic supplementary protection certificates cannot be pediatric studies cannot be orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan pediatric studies for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications on the basis of orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for indications for indications for indications for the basis of pediatric studies for pediatric studies on the basis of orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for indications for orphan indications for orphan indications for pediatric studies on the basis of pediatric studies cannot indications for pediatric studies on orphan indications for pediatric studies on the basis of the basis of orphan indications for pediatric studies cannot be granted on the basis of pediatric studies on the basis of pediatric studies on the basis of orphan pediatric studies for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications for orphan indications"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What could have a material adverse effect on the business if there is a failure?",
        "options": {
            "A": "Expansion into international markets",
            "B": "Failure in critical systems, facilities, or services",
            "C": "Acquisition of a competitor",
            "D": "Increase in employee salaries",
            "E": "Introduction of new software features",
            "F": "Partnership with third-party vendors"
        },
        "LLM_original_answer": [
            "Based upon adoption effective January 2024Summary of the financial statement impact upon adoption of the financial statement impact upon adoption of the financial statement impact upon adoption.The financial statement impact upon adoption of the financial statement impact upon adoption of the financial statement impact upon adoption of a financial statement impact upon adoption of our standard impact upon adoption of January 0, 4.The financial statement impact upon adoption of 1, as well before adoption effective January 2024.The financial statement impact upon adoption of the financial statement impact upon adoption.The financial statement impact upon adoption date of the financial statement impact upon adoption was the financial statement impact upon adoption was the financial statement impact upon adoption of the financial statement impact upon adoption.The financial statement impact upon adoption of the financial statement impact upon adoption of the impact upon adoption of the standard upon adoption of the financial statement impact upon adoption of the financial statement impact upon adoption, effective January 2024.The financial statement impact upon adoption was January 0.The financial statement impact upon adoption was minimal upon adoption of the financial statement impact upon adoption of a financial statement impact upon adoption of the financial statement impact upon adoption of the financial statement impact upon adoption of financial statement impact effective January 1, 4.The financial statement impact upon adoption of January 2024.The financial statement impact upon adoption of the financial statement impact upon adoption of adoption of a net of the financial statement impact upon adoption impact upon adoption effective January 8, as well upon adoption.The financial statement impact upon adoption effective January 1, 2024.The financial statement impact upon adoption effective January 1, the financial statement impact upon adoption.The financial statement impact upon adoption was effective January 2024.The financial statement impact upon adoption was the financial statement impact upon adoption of the financial statement impact upon adoption effective January 1.The financial statement impact upon adoption effective January 2024.The financial statement impact upon adoption.The financial statement impact upon adoption of the financial statement impact upon adoption was minimal.The financial statement impact upon adoption effective January 4.The financial statement impact upon adoption.The financial statement impact was effective January 2024.The financial statement impact upon adoption effective January 2024.The financial statement impact upon adoption effective January 2024.The financial statement impact upon adoption.The financial statement impact upon adoption.The financial statement impact upon adoption effective January 2024.The financial statement impact upon adoption was effective January 1, 2024.The financial statement upon adoption of the financial statement impact upon adoption of the financial statement impact upon adoption of the financial statement impact upon adoption of the financial statement impact upon adoption.The financial statement impact upon adoption impact"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?",
        "options": {
            "A": "21.49%",
            "B": "45%",
            "C": "50%",
            "D": "53%",
            "E": "75%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "Based on-site specific sites impacted and the amounts of coal ash amounts of coal ash impacted and the sites impacted sites impacted coal ash basin sites and the amounts of coal ash basin sites impacted and the sites and has been identified and has identified sites impacted coal ash basin sites impacted and has been identified and other than are identified and other than are impacted and has been in the amounts of the coal ash basin sites impacted sites impacted and amounts of the coal ash basin sites impacted and has identified and the sites impacted sites impacted and the amounts of the amounts of the amounts of the coal ash and methanol\n(SKASH Impacted and natural gas fired sites identified and transmission and the sites impacted and natural gas impacted and/or other sites impacted sites impacted and has identified and has assessed and has been identified and ash impacted sites impacted sites impacted and the amounts of the amounts of coal ash and the ash impacted and the amounts of coal ash basin sites impacted byproducts and the amounts of coal ash basin sites impacted and the sites impacted sites impacted sites impacted sites impacted sites impacted sites impacted and other than coal ash basinspired and the sites impacted sites impacted sites impacted by Duke Energy to the sites impacted and/or impacted and/or impacted sites impacted and the sites impacted and the amounts of coal ash and the coal ash basin sites impacted and other than the amounts of coal ash and/orc sites impacted sites impacted and the coal ash and the amounts of the coal ash basin sites impacted.##table. The coal ash basin sites impacted. The companywide spreaderu2019##tablets of the sites impacted and/or coal ash basin sites impacted and the amounts of the amounts of coal ash basin sites impacted sites impacted and the sites impacted and has been impacted and other than impacted and the amounts of the coal ash basin sites impacted and has impacted and the amounts of the amounts of the amounts of the coal ash basin sites identified and has identified and has been identified and has identified and has identified sites impacted sites impacted and the amounts of the amounts of coal ash basin sites impacted sites impacted sites impacted sites impacted and the amounts of coal ash basin sites impacted and coal ash basin sites impacted and has impacted sites impacted. The amounts of coal ash basin sites impacted and other than are identified. The coal ash basin sites impacted sites impacted and the sites impacted and has been impacted and the amounts of coal ash amounts of the coal ash basin sites impacted and has been identified. The coal ash basin sites impacted and the coal ash basin sites and the amounts of the amounts of coal ash basin sites impacted and has been impacted and other than have assessed and"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?",
        "options": {
            "A": "$17.7 million",
            "B": "$2.9 billion",
            "C": "$5.9 million",
            "D": "$9.7 million",
            "E": "$1.9 billion",
            "F": "$3.9 million"
        },
        "LLM_original_answer": [
            "As market conditions and market conditions, subject to market conditions, subject to maturities and sales of maturities and market conditions, subject to market conditions and market conditions and sales of securities subject to market conditions and market conditions, subject to market conditions subject to market conditions subject to market conditions subject to market conditions subject to market conditions and market conditions subject to market conditions subject to market conditions subject to market conditions subject to market conditions subject to market conditions subject to and market conditions subject to market conditions subject to market conditions subject to market conditions subject to market conditions subject to market conditions subject to market conditions.While market conditions and subject to market conditions subject to maturities and sales of securities subject to market conditions and subject to maturities and market conditions and sales of securities subject to market conditions and sales of securities, subject to market conditions and subject to maturities and sales of securities subject to market conditions and sales of securities subject to market conditions subject to market conditions and subject to market conditions and market conditions.While maturities and sales and sales of securities subject to market conditions subject to market conditions and market conditions and market conditions subject to market conditions and market conditions and sales of securities subject to market conditions and market conditions and market conditions and market conditions and market conditions and sales of securities and maturities and sales of securities subject to market conditions and sales of securities subject to market conditions subject to market conditions and sales of securities subject to market conditions and market conditions subject to market conditions subject to market conditions and market conditions subject to maturities and other securities subject to market conditions and market conditions subject to market conditions subject to market conditions and subject to subject to market conditions subject to market conditions, subject to market conditions, subject to market conditions and market conditions and market conditions and sales of Eastern Bank of Eastern Bank of the maturities and subject to market conditions subject to market conditions.While market conditions and market conditions subject to market conditions, subject to market conditions and sales of maturities and sales of securities subject to subject to market conditions subject to market conditions.While market conditions.While market conditions.While market conditions and market conditions subject to sales of securities, subject to market conditions subject to market conditions subject to maturities and sales of securities subject to market conditions subject to subject to market conditions subject to market conditions subject to market conditions, subject to market conditions and market conditions and market conditions, subject to  and sales of securities, subject to one-to-market conditions and market conditions and sales and subject to subject to market conditions and sales of Eastern Bank of securities subject to market conditions.While matur"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?",
        "options": {
            "A": "Insufficient funding",
            "B": "Resolution of a partial clinical hold",
            "C": "Finalization of trial data analysis",
            "D": "Completion of patient recruitment",
            "E": "Regulatory approval was received",
            "F": "No available patient candidates"
        },
        "LLM_original_answer": [
            "The requirements are set forth notification and approval and approval and/or prior notification and/orientitieseternalioN/Aprerequisites are set forth prior notification and approval and approval and approval and approval and approval and approval and approval and/or expansion requirements are set forth notification and such as well as well as well as well as well as well as well as well as set of the healthcare professional and set forth notification and approval and approval and/or Searlier.Such requirements are set forth notification and/orchemoNutrition requirements are set forth notification and/or prior notification and approval and such requirements are set forth notification and such requirements are set out of such requirements are set forth prior notification and such requirements are set forth notification and approval by prior notification and/or employer.Such requirements are set forth in the prior notification and such requirements are set forth requirements are set forth prior notification and such requirements are set out requirements are set forth set forth requirements are set forth prior notification and such requirements are set forth prior notification and approval and approval and such requirements are set out of prior notification and approval and set forth requirements are set as set forth requirements are set out set requirements are requirements are set as set forth such requirements are set a prior notification and approval and prior notification and such requirements are set forth set forth prior notification and approval and approval and approval and approval and/or such requirements are set forth requirements are set requirements are set requirements are set forth prior notification and/or NCI: Searliermolecularly employer\u2019s prior notification and approval and approval and prior notification and such as set prior notification and prior notification and approval and approval and/or prior notification and prior notification and approval and prior notification and approval and prior notification and approval and approval and approval and prior notification and prior notification and such requirements are set forth requirements are set forth prior notification and prior notification and prior notification and approval and/orbit.Such requirements are set notification and approval and approval and/or prior notification and/orienter.Such requirements are set forthwith the healthcare professional requirements are set forth prior notification and/or approval and approval and approval and approval and/or the healthcare professional requirements are set forth set forth notification and approval and/orienterupto approval and approval and approval and/or approval and such requirements are set forth set forth set forth notification and prior notification and/orbit.Such requirements are set forth set forthwith prior notification and/or approval and/or approval and/orgeometricaCLLigrowthan important in vitro.Such requirements are set such requirements are set forth prior notification and approval and/orbitChallengeset alonkel.S"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What philosophy are Ocwen's compensation programs based on?",
        "options": {
            "A": "Cost-cutting and minimizing expenses",
            "B": "Pay-for-performance",
            "C": "Seniority-based pay",
            "D": "Hourly wage structure",
            "E": "Fixed salary only",
            "F": "Revenue growth only"
        },
        "LLM_original_answer": [
            "O.S. The U.See 2023. for 2023, 2023 filing jurisdiction was in 2023 filing jurisdiction was in 2022 and 2022, 2021: 2023 and 2023 filing jurisdiction was in the U.Seb. The U.S. The U.Sec3\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What is the initial step in the described approach to developing a TCR-T candidate?",
        "options": {
            "A": "Isolating tumor-specific antigens from TCRs",
            "B": "Identifying meaningful clinical responses to non-specific treatments",
            "C": "Developing a novel TCR/target pair using TargetScan technology",
            "D": "Isolating clinically active anti-cancer T cells from tumor samples",
            "E": "Testing TCRs for general cancer cell recognition",
            "F": "Determining the immune system's general targets"
        },
        "LLM_original_answer": [
            "The product can be expected to be expected to produce the same clinical results of the same clinical results as expected to produce the same or the same or the product can be expected to be expected to be expected to produce the same clinical results as the product can be expected to be expected to be expected to produce the same clinical results as the product the product candidates can be expected to be expected to be expected to be expected to be expected to be expected to be expected to be expected to be expected to be expected to produce the product can be expected to be expected to be expected to produce the product candidates that can be expected to be expected to be expected to be expected to be expected to be expected to be expected to a TCRIS the product candidates that can be expected to be expected to be expected to be expected to be expected to be expected to be expected to be expected to be expected to be expected to produce the TCRIS-expected to aT-expected to be expected to produce the same clinical results as well as well as well as well as well as well as well as well as well as well-defined targets that can be expected to be expected to be expected to be expected to be expected to be expected to produce the product can be expected to be expected to produce the product can be expected to produce the T-Integrate to be expected to be expected to produce the product can be expected to the product can be expected to produce the product can be expected to produce the product that can be expected to produce the product candidates that can be expected to be expected to be expected to produce the same or the same clinical results as well-defined TCR-T cell results of the T cell results as the product can be expected to produce the same or the product can be expected to produce the same clinical results as well as the product can be expected to produce the same or the product, or the same or the same or the product can be expected to be expected to be expected to produce the same clinical results as the product, or expected to be expected to be expected to be expected to be expected to be expected to be expected to produce the same or the same clinical results as well-characterized to produce the product the same or the product as the product as the product can be expected to be expected to be expected to produce the same or the product the product, the product and the product can be expected to be expected to be expected to be expected to produce the product can be expected to be expected to be expected to be expected to produce the product that can be expected to"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "In the study, what constitutes a 'death equivalent' event?",
        "options": {
            "A": "Use of invasive surgery unrelated to ALS",
            "B": "Permanent assisted ventilation or tracheostomy",
            "C": "Hospitalization for more than one week",
            "D": "Daily use of less than 22 hours of ventilation",
            "E": "Any emergency medical intervention",
            "F": "Temporary use of assisted ventilation"
        },
        "LLM_original_answer": [
            "In summary, if approved as a competitor to AMX-linked product to ALS, which, which, which, if approved, if approved, which, which, if AM, which, if approved as a competitor to AMX ALS, which, if a competitor to a competitor to AMXilon, which, and, which, which, if approved as a competitor to AMX, which, if approved, or, which, which, which, if approved, which, which, if approved, which, if approved to AMX, which, which, if approved as a competitor to AMX, if approved as a competitor to AMX, which, which, which, and, which, if approved, and, which, which, which, which, which, which, which, if approved, if approved as a competitor to AMX, which, if approved, which, if a competitor to AMX, if approved as a competitor to AM, if approved as a competitor to AMX, which, which, if approved as a competitor to ALS, if approved as a competitor to, approved as a competitor to AMX ALS, which, which, which, if approved, which, which, which, if approved, if approved, if approved as a competitor, which, if approved, and, which, which, which, which, which, which, which, which, if approved as a competitor to AMX, if approved, which, which, which, if approved, if approved as a competitor to ALS, which, if approved, which, a competitor to AM competitor to AMXOX, which, which, if approved, if approved as a competitor to AMX-XL, which, which, which, which, which, which, if approved as a competitor to AMX competitor to ALS, which, which, which, which, which, which, which, which, which, in the, by, which, if approved competitor to AMX0035, which, if approved, which, if approved, which, competitor to AMX0035, which, if approved, which, which, which, if approved as a competitor to a competitor to, if approved as a competitor to a competitor to AMX, if approved, which, if approved as a competitor to AMX,// if approved, if approved as a competitor to AM, which, if approved, may be commercialized to AM to AMX0035, if approved, which, if approved, if approved, which, if approved as"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What critical performance criteria are emphasized for the electronic networks?",
        "options": {
            "A": "Cost and scalability",
            "B": "Design and aesthetics",
            "C": "Speed and reliability",
            "D": "Functionality and compatibility",
            "E": "User interface and experience",
            "F": "Color scheme and branding"
        },
        "LLM_original_answer": [
            "The record our ability to the human capitalization of the following the ability to the.Seelementedetailed information and services and other parts of our products and services and services and services and services.Information relating to commercialization.SustainabilityReport Item 16Information About our ability to commercialization of our ability to our ability to our ability to commercialize our ability to our ability to commercialize our products and services, which may result.Further information relating to commercialization conditions or restrictions on our ability to commercialize our products and services.Mortunately, Item 16The International Regulatory and Services and services and other than anticipated conditions or services and services and Risk Management Discussionreator Risk Management and other asset classes or services and services and services and other intellectual property and services and services or services or services or restrictions on our ability to commercialization of our ability to commercialization of our ability to commercialize our products and services.Furthermore unanticipated conditions or services and services or services and/or Item 2023ITEM-Item 18Item 24Item 14or Item 52Item ultiagnostic our ability to commercializing our ability to commercialization of the financial services.Related on unanticipated conditions or unanticipated conditions or restrictions or service our ability to commercialization of services.We believe that we believe that we believe that we believe that may beF.Sources or restrict our products and services and services.We believe that may unanticipated conditions or commercialization of our ability to commercialize our ability to commercialization of the ability to mitigate the intellectual property rights and services or SIF we believe that we believe that we expect to the.Finally, or unanticipated conditions or restrict our ability to commercialize our ability to the Securities and/or services and services and services and services and the London Stockholders or services or unanticipated conditions or service or commercialize our ability to commercializing our ability to the anticipated or restrictions on our ability to which may be unanticipated conditions or restrictions on our products and services or services and services or services or services and\nanswered unanticipated conditions or service providers of the U.Seelections on-demanding unanticipated conditions or other than those described above and other segments of the ability to commercialization of the ability to commercialization of our ability to the results or regulatory and services and services and services and liquidity and services and other than those that are unanticipated conditions and other subsidiaries and other risk our products and other than our products and data and data services and Data Services and data services and services and other unanticipated conditions or the ability to commercialization of our ability"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?",
        "options": {
            "A": "To simplify internal management structures",
            "B": "To maximize profit margins",
            "C": "To improve customer relations",
            "D": "To limit losses and provide capacity for future growth",
            "E": "To expand product lines",
            "F": "To enhance technological development"
        },
        "LLM_original_answer": [
            "The amount of our businesses.Such dividends are constrained by the protection and the amount protection.Such dividends are constrained by the the amount of risk protection and investment in our businesses are constrained dividends and investment and investment and investment in our businesses are constrained dividends of our businesses are constrained by risk protection and investment in our businesses are constrained by-product protection and investment in our businesses.Such dividends.Such dividends.Such businesses and investment and dividends and constrained risk protection of risk protection and investment in our businesses and risk protection and investment and investment and investment in our businesses are constrained by risk protection.Such dividends and investment protection of risk protection of risk protection and investment and investment protection and investment and investment and investment protection and investment and dividends and risk protection of risk protection and risk protection and the amount of our businesses and investment.Such dividends are constrained dividends are constrained by the risk protection and investment and investment in our dividends are constrained by the amount of risk protection and investment.Such dividends.Such dividends are constrained by the amount of such dividends are constrained risk protection and the amount of risk protection of our businesses and investment in our businesses and financial protection and risk protection and investment and risk protection and investment in-force protection and investment protection of dividends and dividends and investment and dividend protection and investment protection and investment protection.Such dividends are constrained dividends are constrained amount of our businesses and investment and investment in our businesses and investment in our businesses are constrained by SSSM&American businesses are constrained by the amount of the amount of reinsurance in our businesses.Such dividends are constrained by the such dividends and investment protection and investment in turn-see S&Pricing our businesses and risk protection and such dividends and risk protection of collateral protection and indemnity.Suchu businesses.Suchives are constrained by risk protection and investment in our businesses are constrained dividend protection and risk protection and investment and investment in our businesses.Such dividends.Such dividends are constrained risk protection and risk protection and risk protection and investment protection of risk protection and investment protection and investment in our risk protection and investment in our businesses.Such dividends and investment and investment protection and investment and investment and investment protection and the amount risk protection and investment in such dividends and investment in our dividends and investment in our businesses.Suchment protection and investment in our businesses and investment of risk protection and risk protection and investment protection and investment dividends and dividends are constrained dividends and investment protection and such dividends are constrained dividends and amount of the amount of our businesses are constrained by 18See the amount of risk protection and related risks protection of such dividends are constrained dividends from our businesses are constrained"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "In the Phase 2 clinical trial for KER-050, what is the initial starting dose used in Part 2?",
        "options": {
            "A": "2.5 mg/kg",
            "B": "3.75 mg/kg",
            "C": "5.0 mg/kg",
            "D": "4.5 mg/kg",
            "E": "3.0 mg/kg",
            "F": "6.0 mg/kg"
        },
        "LLM_original_answer": [
            "In a reference product that are similar to a reference medicinal product but are similar to the biological medicinal medicinal products that are similar to a reference product that are similar to a reference product that are similar to a reference medicinal medicinal medicinal medicinal medicinal product but similar to a reference medicinal medicinal medicinal medicinal products that are similar to a reference medicinal product, or biological medicinal products that are similar to a reference medicinal product that are similar to a reference medicinal product that are similar to a reference medicinal medicinal product that are similar to a reference medicinal product that is similar to a reference medicinal medicinal medicinal medicinal medicinal medicinal medicinal products that are similar to a reference medicinal product but not a reference product that are similar to a reference product but a reference product but are similar to a reference product that are similar to a reference product that are similar to a reference product but not a reference product that are similar to a reference product that are similar to a reference medicinal medicinal medicinal medicinal product, or biological medicinal product, or biological medicinal medicinal products that are similar to a reference product, or biological medicinal medicinal medicinal medicinal medicinal medicinal medicinal product that are similar to a reference medicinal product that is similar to a reference product but not similar to a reference medicinal products that are similar to a reference medicinal products that are similar to a biological medicinal product that are similar to a reference medicinal product that is similar to a reference medicinal product that is similar to a reference medicinal medicinal product but a reference medicinal medicinal product but not a reference medicinal medicinal medicinal products that are similar to a reference product that are similar to a reference medicinal medicinal medicinal medicinal medicinal product but are similar to a reference to a reference medicinal medicinal product but not a reference medicinal medicinal medicinal medicinal medicinal medicinal medicinal medicinal medicinal medicinal medicinal medicinal medicinal product that are similar to a reference product but not a reference product but not a reference to a reference to a reference product but not a reference product but a reference product but a reference and/or reference and/or medicinal medicinal medicinal medicinal medicinal products that are similar to a reference product but a reference product, or biological medicinal products that are similar to a reference product that are similar to a reference medicinal product, or a reference medicinal products that are similar to a reference product that are similar to a reference medicinal medicinal medicinal product that are similar to a reference medicinal product that are similar to a reference product that is similar to a reference medicinal medicinal medicinal medicinal medicinal product but are similar to a reference products that are similar to a reference medicinal medicinal medicinal medicinal medicinal product but are similar to a reference medicinal medicinal medicinal product but are similar to a reference medicinal product, or biological medicinal medicinal product,"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could have a material adverse effect on the business if there is a failure?",
        "options": {
            "A": "Expansion into international markets",
            "B": "Failure in critical systems, facilities, or services",
            "C": "Acquisition of a competitor",
            "D": "Increase in employee salaries",
            "E": "Introduction of new software features",
            "F": "Partnership with third-party vendors"
        },
        "LLM_original_answer": [
            "What-in-stock interest portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock Interest is a portion is subject to-stock portion of the portion of-the-stock portion of the payable-in-kind interest is payable-in-stock portion of the payable-in-stock portion of the portion of-the-stock portion of the portion of-stock interest-in-stock portion of the-in-stock portion of the-in-kind portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the-interest portion is-stock portion of the interest-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock interest-in-stock portion of the payable-in-kind portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the portion of the stock portion of the payable-in-stock portion of the payable-in-stock portion of the Cash/stock portion of-stock portion of the payable-in-stock portion of-the-stock portion of the payable-in-stock interest-in-stock portion of the-in-kind portion of the payable-in-stock portion of the Cash/stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the Cash/interest-in-the-interest portion of the payable-in-the-interest portion of the-in-stock portion of the-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the-in-kind portion of the payable-in-stock portion of the payable-in-stock portion of the-stock portion of the-interest portion of the payable-in-stock portion of the interest is payable-in-kind portion of the portion of the payable-in-stock portion of the portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the interest-in-stock portion of the portion of-stock portion of the payable-in-stock portion of the interest is payable-in-stock portion of the portion of the-kind portion of the payable-in-stock portion of the payable-in-stock interest in the portion of the-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the payable-in-stock portion of the-in-stock portion of the payable-in-stock portion of the interest is payable-in-stock"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What percentage of equity ownership does GU&I have in Pine Needle, an interstate liquefied natural gas storage facility located in North Carolina?",
        "options": {
            "A": "21.49%",
            "B": "45%",
            "C": "50%",
            "D": "53%",
            "E": "75%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "The Nuclear Matters, including future spending, including future spending, including future spending, including future spending, including future spending, including future spending, including future spending, including future spending, including as of $1##table 2023##table 2023o\n##table 2023##table 2023, 2023.Future spending, including future spending, including future spending, including future spending, including future spending, including future spending, including future spending obligations as of approximately $1, including future spending, including future spending, including future spending obligations, including future spending, including future spending, including, including, including, including future spending, including as of interest, including, including, including future spending, including, including future spending, including future spending, including, including future spending, including future spending obligations as of the spending, including future spending, including future spending, including future spending, including as of December 2023##table 2023 or future spending, including future spending, including obligations, including future spending, 2023.Duke gas and retirement obligations, including future spending, including future spending, including future spending, including future spending, including future spending, 2020##table 31, 2023.##table, including future spending, including future spending, including future spending, including future spending, including future spending, including, including retirement obligations as of the December 2023.2024.Future spending, including future spending, including future spending, including future spending, including future spending, including future spending, including future spending, including future spending, including as of December 2023.Future spending, including, including, including future spending, including, including, including future spending, including future spending, including future spending, including nuclear power plant retirement obligations as of which may be as of December 2023##table 2023.12##table 3. Future spending, including future spending, including obligations as of December 2023##table 12. 2023. Future spending, including future spending, including future spending obligations as of December 2023##table 2020. Future spending, including future spending, including future spending, including future spending, including, including future spending, including future spending, including future spending, including obligations as of the December 2023.##table 2020, including future spending obligations as of which includes future spending, including obligations as of December 2023##table 2023##table 2023##table 2023##table 202"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "How much had been invested in shares of the FHLBB as of December 31, 2023?",
        "options": {
            "A": "$17.7 million",
            "B": "$2.9 billion",
            "C": "$5.9 million",
            "D": "$9.7 million",
            "E": "$1.9 billion",
            "F": "$3.9 million"
        },
        "LLM_original_answer": [
            "Banks to ensure that the regulators to which the regulators established by the regulators to ensure capital requirements established by the regulators established by the regulators to ensure that the regulators to ensure capital include capital requirements established by the regulators to ensure capital factors established by the regulators established by the regulators to ensure capital requirements established by the regulators to ensure capital established by the regulators to ensure capital requirements established by the factors established by the regulators to ensure capital requirements established by the regulators to ensure capital requirements established by the regulators to ensure capital requirements established by the regulators established by the regulators established by the regulators to ensure capital requirements established by the regulators established by the regulators to ensure capital requirements established by the regulators to ensure capital established bylaws and other factors established by the regulators to ensure capital requirements established by the regulators to ensure capital requirements established by the regulators to ensure capital factors established measures established by the regulators to ensure capital requirements established by the regulators to ensure capital requirements established measures established by the regulators to ensure capital measures established by the regulators to ensure capital established by the regulators established by the regulators to ensure capital measures established by the regulators to ensure capital established by the regulators to ensure capital established by the regulators to ensure capital measures established by the regulators\u2019 other factors established by the regulators to ensure capital requirements established capital adequacytatively established by the regulators to ensure that the regulators to ensure capital requirements established by the regulators include other factors established by the regulators established by the regulators to ensure capital measures established factors established by the regulators established by the regulators to ensure capital measures established by the regulators to ensure capital measures to ensure capital adequacytical measures established by the factors established by the regulators to ensure capital requirements established by the regulators to ensure capital measures established capital measures established by the regulators to ensure capital requirements established by the other factors established by the regulators to ensure capital requirements established by the factors established by the regulators to ensure capitalization of the regulators to ensure capital established by the regulators to ensure capital requirements established by the regulators established by the regulators established by the regulators to ensure capital requirements established by the regulators to ensure capital factors established by the established by the regulators to ensure capital established by the regulators to ensure capital include other factors established by the regulators to ensure capital requirements established by the regulators to ensure capital requirements to ensure capital measures established by the regulators to ensure capital established by the regulators to ensure capital requirements established by the regulators established by the regulators established by the regulators to ensure capital established by the regulators to ensure capital measures established by the regulators to ensure capital measures established by the regulators to ensure capital measures established by the factors established by the"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What condition has resulted in the pause of new patient enrollment in the clinical trial?",
        "options": {
            "A": "Insufficient funding",
            "B": "Resolution of a partial clinical hold",
            "C": "Finalization of trial data analysis",
            "D": "Completion of patient recruitment",
            "E": "Regulatory approval was received",
            "F": "No available patient candidates"
        },
        "LLM_original_answer": [
            "What isos.Clinumission if they do not otherwise if they do not qualifying for example if they do not qualify for an expansion if they do not qualify for an expansion and do not otherwise. In the drug discovery if they do not to qualify for a drug discovery if they do not otherwise if they do not otherwise treated lymphoma\nClinical development if they do not otherwise qualified for a drug discovery or if they doxQualitative if they do not all lines of interest if they do not otherwise if they do not qualify for an exception or safe harbor if they do not only if they do not only if they do not qualify for an exception or safe harbor if they do not otherwise if they do not otherwise qualified for anemiaClinical development of an agent recruitment and if they do not otherwise if they do not qualify for an exception or do not qualify for an exception or safe harbor. If they do not otherwise if they do not only if they may be they may be they may be may be subject to the clinical trial and if they do not otherwise if they do not otherwise, if they do not to the SAE, if they do not otherwise.8 if they do not otherwise if they do not qualify for an indication and may be subject to qualify for an exception or safe harbor if they do not qualifying for a patient treatment if they do not otherwise if they do not otherwise if they do not qualify for more than they do not qualify for an exception or safe harbor.8Clinical findings from a study if they do not qualify for a clinical trial if they do not qualify for a finding for an exception or do not qualifying for an example if they do not qualifying for a prior to be subject to qualify for a drug discovery if they do not to qualify for a patient data if they do not qualifying for a study if they do not otherwise if they may be they do not qualify for an exception or if they do not qualify for a prior to an exception or scrutiny if they do not qualifying for an exception or safe harbor or safe harbor.The clinical trial.7The clinical trial enrollment if they do not all patients with respect if they do not otherwise if they do not otherwise if they do not otherwise if they do not otherwise if they do not otherwise if they do not otherwise if they do not to an immune cell as well if they do not all of the scrutiny if they do not otherwise if they do not qualifying for a finding. In vivo if they do not to qualify for a study drug discovery if they do not otherwise. In vivo if they do not otherwise"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What philosophy are Ocwen's compensation programs based on?",
        "options": {
            "A": "Cost-cutting and minimizing expenses",
            "B": "Pay-for-performance",
            "C": "Seniority-based pay",
            "D": "Hourly wage structure",
            "E": "Fixed salary only",
            "F": "Revenue growth only"
        },
        "LLM_original_answer": [
            "What February 9, we voluntarily allowed the voluntarily allowed the voluntarily allowed the facility, 2023, 8, 2023, we voluntarily allowed the facility to voluntarily allowed the facility to be voluntarily allowed the facility voluntarily allow the facility voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility to voluntarily allowed the facility to voluntarily allowed the facility voluntarily allowed the facility. On February  February 9, 2022, 8 voluntarily allowed the facility voluntarily allowed the voluntarily allowed the facility voluntarily allowed the facility, we voluntarily allowed the facility, 2023, we voluntarily allowed the facility voluntarily allowed the facility, we voluntarily allowed the facility to voluntarily, on February 15, which we voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility to voluntarily allowed the February 9, 2023, we voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility to voluntarily allowed the facility to voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility 2023, we voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility to voluntarily allowed the facility, voluntarily allowed the facility voluntarily allowed the facility 2023, 2023, we voluntarily allowed the facility to voluntarily allowed the facility to voluntarily allowed facility 2022, we voluntarily allowed the facility facility facility to voluntarily allowed the facility to voluntarily allowed the facility to voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility to voluntarily allowed the facility voluntarily allowed the facility 9, we voluntarily allowed the facility, we voluntarily allowed the facility voluntarily allowed the facility 2023, we voluntarily allowed the facility to voluntarily allowed the facility, 9, 9, we voluntarily allowed the facility, we voluntarily allowed the facility, we voluntarily allowed the facility, we voluntarily allowed the facilityally the facility to expire the facility voluntarily allowed the 8, 2023, we voluntarily allowed the facility, we voluntarily allowed the voluntarily allowed the facility, we voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility 3, we voluntarily allowed the facility to voluntarily allowed the facility to voluntarily allowed the facility to voluntarily allowed the facility voluntarily allowed the facility. On February 8 facility. On February 8% on February 1 voluntarily allowed the facility, 2022 voluntarily allowed the facility voluntarily allowed the February 2023, we voluntarily allowed the voluntarily allowed the facility voluntarily allowed the voluntarily allowed the facility voluntarily allowed the facility. 8, 2022 voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed the facility voluntarily allowed"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is the initial step in the described approach to developing a TCR-T candidate?",
        "options": {
            "A": "Isolating tumor-specific antigens from TCRs",
            "B": "Identifying meaningful clinical responses to non-specific treatments",
            "C": "Developing a novel TCR/target pair using TargetScan technology",
            "D": "Isolating clinically active anti-cancer T cells from tumor samples",
            "E": "Testing TCRs for general cancer cell recognition",
            "F": "Determining the immune system's general targets"
        },
        "LLM_original_answer": [
            "What Approaches, and/or reference product recognition of the reference product, and will not laterally not only licensed T cells, and T cells of the reference T cells, and T cells will not only those T cell-surface product, and T cell-surface product-specificallyogenetically, and/or its T cell-based immunogenic product, androgeneticScan Approaches, and T cell therapy, and will not later, and will not later product, and TSC products, and FDA will not later than first licensure, and/orphanocyte TSC-licensed product-specific product, and/orphanocyte product, androgenesis, and/orphanotypy, and FDA will not require a product, and the first licensure, and/or reference product, and FDA, and reference product of which is first licensure licensure, and T cell-based on the reference product, and/or reference product, or a licensed product, and target product, and FDA will not only licensed product, and/orfurther product, and FDA will not later than will not only after the reference product, and will be licensed of the reference product, and its target-specifically will not later date of first licensure of the reference product, and its components of first-in addition of T cell therapy development of the Immuno will not will not only T cells, and/or, and/or CAR-T Integrate T-Integrate TSC-encounter product development of the T cell-based product, and/or cell-based first licensure product, and/orphanerafter licensure will not later, and FDA will not later, and, and FDA-approved product development of the reference product, and FDA will not later product, and FDA will not licensed by FDA will not FDA will not-in vivo-based FDA will not-in vivo engineering of first, and FDA will not later than immunologic product, and T cell therapy products will not otherwise described above, and/orphanogenetically, and FDA will not later, and FDA will not only licensed products, and first licensure licensure, and T cell-based on the reference product, and FDA will not-refernspecific product development of class II-TSC-Integrained T cells, FDA will not later, FDA will not-in vivo product-specific product-specific product, and/or T cell-specified product development of reference product, and FDA will not-in vivo cell-based product, and/or will not only those T cell-specified T cell-based on-tissue-based FDA will not-for example of FDA will not-in vivo cell"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "In the study, what constitutes a 'death equivalent' event?",
        "options": {
            "A": "Use of invasive surgery unrelated to ALS",
            "B": "Permanent assisted ventilation or tracheostomy",
            "C": "Hospitalization for more than one week",
            "D": "Daily use of less than 22 hours of ventilation",
            "E": "Any emergency medical intervention",
            "F": "Temporary use of assisted ventilation"
        },
        "LLM_original_answer": [
            "In the valuation allowance against all of our U.Sever tax assets.We may release of our U.SGDAs a valuation allowances.We may release of our U.S. We may release of our valuation allowances against all of our U.S. U.S deferred tax deferred tax assets.We may release the valuation allowances against all of $Suff against all of our U.S. We may release all of all of our U.Secertainment valuation allowance against all of $Suff tax assets.We may release of our U.Separ all of our U.S. deferred tax assets.We may release all of our U.Suffixed tax assets.We may release all of our U.SGDAs of our U.Specifically.Separation assets.We may release valuation allowance.We may release all of our U.S.SGDAs of our U.S. U.S deferred tax assets.We may release all of $SAR against all of our U.S.SS deferred tax assets.We may of our U.S. deferred tax assets.We may release all of our U.Separation assets.We may release all of our U.Separ release all of our U.Sunrelated deferred tax assets.We may release of our U.SAEs.We may release of our U.Sever U.Secertain all of all of our U.S. deferred tax assets.We may release all of our U.Specifically deferred tax assets.We may release against all of our U.S deferred tax assets.We may release all of our U.SAE against all of our U.Sever release all of our U.Specifically.SAEU.Sarbit all of our U.S. We may release of all of all of our U.SAPCs.We may release all of our U.Specifics against all of our U.S. deferred tax assets.We may release all of our U.Similar to all of our U.Severall of our U.S.S. deferred tax assets.We may release all of our U.SGDAs of our U.Similar all of our U.S deferred tax assets.We may release of all of our U.SGDAs of our U.Severall of all of our U.S. deferred tax assets.We may release all of our valuation allowance against all of all of $0.Sever all of all of $SARS against all of all of $SARSA against all of our U.SGDAs of our U.S.S. deferred tax assets.We may release all of our U.SGDAs a valuation allowance against all of all of our U.S. We may release of our U.S"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What critical performance criteria are emphasized for the electronic networks?",
        "options": {
            "A": "Cost and scalability",
            "B": "Design and aesthetics",
            "C": "Speed and reliability",
            "D": "Functionality and compatibility",
            "E": "User interface and experience",
            "F": "Color scheme and branding"
        },
        "LLM_original_answer": [
            "What use of greater risks than use of third-party commercial software and greater than use of greater than use of intellectual property rights to the use of use of greater than use of intellectual property and greater risks greater risks than use of greater risks greater risks than use of use of use of use of use of use of use of third-party commercial software use of third-party commercial software and use of third-party intellectual property than use of our technology and other than use of third-party intellectual property and support of use of our business services and third-party intellectual property and third-party intellectual property.A failure to greater risks greater than use of use of use of interest in the use of service of our business processes and greater risks than use of third-party commercial software and services.A failure of third-party commercial software and other than use of use of third-party use of use of use of third-party commercial software and greater risks than use of commercial software.A failure to protect our intellectual property and other than use of use of our business operations and commercial software and support of use of third-party commercial software and use of third-party commercial software and greater risks than use of use of use of use of use of use of third-party commercial software and greater than use of use of greater than use of third-party commercial software and use of use of third-party commercial software and use of use of third-party commercial software and use of use of use of third-party commercial software and services and use of use of third-party commercial software and use of use of third-party commercial software and services of use of services and other than use of use of use of third-party commercial software.A failure of intellectual property protection of intellectual property and greater risks and other than use of greater risks than use of greater risks than use of third-party commercial software and use of greater risks than use of third-party commercial software, or third-party commercial software and use of greater risks greater risks than third-party commercial software and services and use of third-party commercial software of third-party commercial software.A failure to protect our intellectual property and use of third-party intellectual property of use of use of third-party commercial software development of third-party commercial software development of third-party commercial software development of our mortgage technology and support of our Mortgage Technology12or use of intellectual property of use of use of use of third-party commercial software and greater than use of use of use of greater than use of third-party commercial software.A failure to protect our intellectual property and use of greater risks than use of greater than use of greater than use of use of use of use of use of use of use of third-party"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 5,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Why does the company enter into reinsurance arrangements with unaffiliated third-party reinsurers?",
        "options": {
            "A": "To simplify internal management structures",
            "B": "To maximize profit margins",
            "C": "To improve customer relations",
            "D": "To limit losses and provide capacity for future growth",
            "E": "To expand product lines",
            "F": "To enhance technological development"
        },
        "LLM_original_answer": [
            "The assumption is equivalent to zero which is equivalent to zero which is equivalent to zero which is that everyone will begin withdrawals which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to begin withdrawals which is equivalent to zero which is equivalent to zero which account value which is equivalent to begin withdrawals which is equivalent to zero which is equivalent to everyone will be equivalent to which is equivalent to zero which is equivalent to zero which is equivalent to zero which is zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to everyone will begin withdrawals which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to be equivalent to everyone will be equivalent to zero which is equivalent to which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to begin withdrawals which is zero which is equivalent to which is equivalent to zero which is zero which is equivalent to zero which is equivalent to withdraws equivalent to zero which is equivalent to zero which is equivalent to everyone\u2019s equivalent to zero which is equivalent to zero which is equivalent value which is equivalent to zero which everyone will begin withdrawals which is equivalent to zero which is equivalent to begin withdrawals which is equivalent to begin withdrawals which is equivalent to zero which is equivalent to zero which is zero which is equivalent to zero which is equivalent to everyone will begin withdrawals which is equivalent to zero which is equivalent to everyone will continue withdrawals which is that everyone will be zero which is equivalent to zero which is equivalent to zero which equivalent to begin withdrawals which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which equivalent value which is equivalent to zero which equivalent to zero which is equivalent to zero which equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to which is equivalent equivalent to begin withdrawals which equivalent withdrawals which value reaches zero which is equivalent to zero which is equivalent to begin withdrawals which equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to begin withdrawals which is equivalent of everyone will begin withdrawals which is equivalent to zero which is equivalent to everyone begins zero which"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?",
        "options": {
            "A": "Increases ventricular pressure and cardiac remodeling",
            "B": "Decreases the potential for cardioprotective effects",
            "C": "Protects against cardiac dysfunction and remodeling",
            "D": "Leads to an increase in the Fulton index",
            "E": "Enhances the right ventricular free wall thickness",
            "F": "Increases the myocardial performance index"
        },
        "LLM_original_answer": [
            "Based on the provided document, the treatment of RKER-012 in the mouse PAB (pulmonary arterial hypertension) model has the following effects:\n\nC: Protects against cardiac dysfunction and remodeling\n\nThe document details that RKER-012 treatment in a mouse model of PAB, which involves mechanical restriction of the pulmonary artery to increase right ventricular pressure, resulted in protection against cardiac dysfunction and remodeling. This is evidenced by improvements in the end systolic pressure-volume relationship (ESPVR), myocardial performance index (MPI), Fulton index, right ventricular free wall thickness (RVFWT), which are currently under development candidates, including KER-licensed product candidates, or RKERAs of RKERD:\u2022Treatment with orphansus, orphans offtargeticardenters, or other than RKER-licensed product candidates, orphans-012-licensed products containing KER-029KER-012, orphans of RKER-licensed products that we believe that we believe that may befor thesafety androgenicomplications of RKER-licensed products that are currently under development candidate KER=12KER-012012012RKER-012Treatment with respect to treat-to-licensed product candidates, orphans of RKER-012.Pat least likely to a subcutaneous and myosteo-12KER-observedicardenterspective clinical supply of RKER-licensed products in the assumption isoproductsafety and RKER-012-12KER-012RKER020B:\u2022Treatment withstanding assumptions, or equivalent to zero.We have no-0KER-012RKER-012RKER-(KP-012RKER-0120721Clinical Development and/orbodiesis a research forms of KER-012082mg, or equivalent to 2, or related to treat obesity, or related to increase in vivo in combination with respect to a and/orphanotype:\u2022Treatment offtweficardenters-012Licensed Product Candidate-12KER-12KER-012RKER-licensed product candidates for the following treatment of 1Based on a subcutaneous of utoxceptionalbeganalike to 50KER-licensed product candidates, orphans, orphans offtobesity and KER-012RKER-licensed product candidates aregainserticardentireg of 2023KER-licensed product candidate KERVastiopharmacokinetics offtoquivariant to treat obese mice will begin withdrawals of"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?",
        "options": {
            "A": "Immediate infringement lawsuits upon filing",
            "B": "Inability to identify competing products",
            "C": "Delayed launch of new products",
            "D": "Unawareness of pending applications that may later result in infringement claims",
            "E": "Mandatory changes to current product designs",
            "F": "Increased cost of patent filing"
        },
        "LLM_original_answer": [
            "Based on the provided document, the potential issue that may arise from patent applications being maintained in secrecy until patents are issued is:\n\nD: Unawareness of pending applications that may later result in infringement claims\n\nThe document discusses the risks associated with the evolving nature of digital asset mining, the potential shift from proof-of-work to proof-of-stake algorithms, and the various factors that could impact the business, including regulatory changes, market conditions, and technological developments. It also addresses the challenges in protecting intellectual property rights and the potential for infringement claims due to the secrecy of patent applications."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?",
        "options": {
            "A": "Increased demand for electricity",
            "B": "Rising fuel costs",
            "C": "Improved operational efficiency",
            "D": "Delayed or unrecovered operating costs",
            "E": "Expansion into new markets",
            "F": "Strong economic growth"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factor that could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants is:\n\nD: Delayed or unrecovered operating costs\n\nThis is because the document mentions that economic downturns or high commodity prices could negatively impact the financial stability of certain customers, leading to their inability to pay for electric and natural gas services. This could result in increased bad debt expense and higher allowance for doubtful account reserves for the Duke Energy Registrants."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?",
        "options": {
            "A": "It will be allowed to increase its capital reserves.",
            "B": "It will receive tax incentives to improve practices.",
            "C": "Enforcement actions may be taken against it.",
            "D": "It will be automatically disbanded.",
            "E": "It will be required to decrease its interest rates.",
            "F": "It will gain permission for more acquisitions."
        },
        "LLM_original_answer": [
            "Based on the provided document, if a banking organization's incentive compensation arrangements pose a risk, the most likely outcome is:\n\nC: Enforcement actions may be taken against it.\n\nThe document states that the federal banking regulators have provided guidance designed to ensure that incentive compensation arrangements at banking organizations take into account risk and are consistent with safe and sound practices. The guidance sets forth three key principles with respect to incentive compensation arrangements. The guidance provides that supervisory findings with respect to incentive compensation will be incorporated, as appropriate, into the organization\u2019s supervisory ratings, which can affect its ability to make acquisitions or perform other actions may also includes, as well-capitalized bylaws and other than can befittinghearing of a and activities that are (i.evenues of $10We believe that meets theotations and other than any other than Eastern Bank Holding Company Overview of $10##table of $10and other than canary, subject to the Company activities, as well as well as well-capital markets, as well-capital markets, as a \u201cwell as a bank holding company-wide and/or acquiring a..."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?",
        "options": {
            "A": "International partnerships",
            "B": "Location of manufacturing facilities",
            "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement",
            "D": "Advertising and social media presence",
            "E": "Colors and branding of the packaging",
            "F": "Celebrity endorsements"
        },
        "LLM_original_answer": [
            "The expected key competitive factors affecting the success of the company's drug candidates if approved are:\n\nC: Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement\n\nThe document discusses the competitive landscape for drug candidates targeting hematologic cancers and immune-mediated diseases, highlighting the importance of efficacy, safety, convenience, price, level of generic competition, and availability of reimbursement as key competitive factors. The document also mentions the presence of other companies developing similar drugs and the potential competition from drugs with similar mechanisms of action. Additionally, the document discusses the various methods of treating patients in oncologic indications, including surgery, radiation, and drug therapy, and the availability of various drug therapies marketed for cancer, including branded and generic drugs. The document also mentions the limitations of currently marketed therapies and the potential for new drug candidates in late-stage clinical development to provide significant competition."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Which organization acts as the conservator for the GSEs?",
        "options": {
            "A": "Ginnie Mae",
            "B": "United States Treasury Department",
            "C": "Various investors",
            "D": "Non-Agency securitization trustees",
            "E": "Federal Housing Finance Agency (FHFA)",
            "F": "Federal Reserve"
        },
        "LLM_original_answer": [
            "The organization that acts as the conservator for the Government-Sponsored Enterprises (GSEs) is the Federal Housing Finance Agency (FHFA)."
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is included in the control arm of the described Phase 1 clinical trial?",
        "options": {
            "A": "Patients meeting specific HLA or miHA criteria",
            "B": "Patients treated with TSC-100 or TSC-101",
            "C": "Patients who do not meet HLA or miHA genetic criteria",
            "D": "Patients receiving experimental gene therapy",
            "E": "Healthy volunteers with no treatment",
            "F": "Patients undergoing bone marrow biopsy"
        },
        "LLM_original_answer": [
            "Based on the provided document, the control arm of the described Phase 1 clinical trial includes patients who do not meet the HLA or miHA genetic criteria and are treated with standard RIC haplo transplantation alone. The correct answer is C: Patients who do not meet HLA or miHA genetic criteria."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?",
        "options": {
            "A": "10 years",
            "B": "12 years",
            "C": "14 years",
            "D": "15 years",
            "E": "20 years",
            "F": "25 years"
        },
        "LLM_original_answer": [
            "Based on the provided document, the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval under the Hatch-Waxman Act is 14 years."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?",
        "options": {
            "A": "A decrease in trading demand by customers",
            "B": "Cost-cutting pressures across the industry",
            "C": "Settlements related to inspections",
            "D": "Weakness in the macroeconomic environment",
            "E": "Defaults by clearing or exchange members",
            "F": "Changes to contract specifications"
        },
        "LLM_original_answer": [
            "Based on the provided document, the potential factors that could lead to a reduction in the listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023 are:\n\n1. Settlements related to inspections (Option C)\n\nThe document mentions that in November 2023, the PCAOB announced settlements related to inspections of audit firms for Chinese and Hong Kong issuers. This could lead to fewer Chinese companies listing in the U.S. as a result of the PCAOB's actions."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?",
        "options": {
            "A": "January 1, 2020",
            "B": "July 1, 2020",
            "C": "January 1, 2021",
            "D": "July 1, 2023",
            "E": "January 1, 2023",
            "F": "July 1, 2022"
        },
        "LLM_original_answer": [
            "The enforcement of the CCPA, as amended by the CPRA, began on July 1, 2023."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?",
        "options": {
            "A": "Increases ventricular pressure and cardiac remodeling",
            "B": "Decreases the potential for cardioprotective effects",
            "C": "Protects against cardiac dysfunction and remodeling",
            "D": "Leads to an increase in the Fulton index",
            "E": "Enhances the right ventricular free wall thickness",
            "F": "Increases the myocardial performance index"
        },
        "LLM_original_answer": [
            "The Company.Ongoing Phase 1KER-21KER-21KER-31KER-27muscleansw=0 which is equivalent to everyone will bevacuumultiple choice isometric Data Ex-Unc=Table 2024KER-1KER-31which is equivalent to zero which is equivalent to bevacuum=0KER-0.31of course of the same which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero.Overdue to zero which is equivalent to begin withdrawals once weekly dosing=>\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?",
        "options": {
            "A": "Immediate infringement lawsuits upon filing",
            "B": "Inability to identify competing products",
            "C": "Delayed launch of new products",
            "D": "Unawareness of pending applications that may later result in infringement claims",
            "E": "Mandatory changes to current product designs",
            "F": "Increased cost of patent filing"
        },
        "LLM_original_answer": [
            "Based on the assumption.We may be equivalent to the assumption is equivalent to zero which is equivalent to which is equivalent to zero which is a material weaknesses in the equivalent to zero which is equivalent to zero.The assumption is equivalent of which is that everyone will begin withdrawals which is equivalent to zero which is equivalent to zero which is equivalent to the applicable to zero.The assumption is equivalent to zero which is that is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent of which is equivalent to the23which is equivalent to this could have been a material adverse effect of any of which is that is equivalent to the:\u2022risks a material adverse effect of our business, and/or any of any time.The value.The value which is equivalent to zero which is equivalent to zero which is equivalent to everyone will begin withdrawals once account value reaches zero which is equivalent to zero.The value.The assumption is equivalent to zero.The assumption is equivalent to zero which is equivalent to the same which is equivalent to the equivalent to zero which is equivalent to zero.The assumption is equivalent to everyone will begin withdrawals.If the assumption is equivalent to everyone will begin withdrawals which is equivalent to the same.The assumption is that everyone will begin withdrawals which is equivalent to zero which is that everyone will begin withdrawals once account value based on average withdrawals once account value reaches zero which is equivalent to a 50% of zero which is equivalent to zero which is equivalent to zero which is equivalent to zero.The assumption.The assumption.We believe everyone will be equivalent to zero.The assumption.We may be equivalent to Ethereby28it is equivalent to zero which is equivalent to everyone will begin withdrawals which is equivalent to zero which is equivalent to D:\u2022Risks.The assumption.We may be equivalent to our results of which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to our account value of which is equivalent to zero which is that everyone will have a material adverse effect of operations and/or otherwise equivalent to the next message 28our business, and/or otherwise known as a22becomeone of zero which is equivalent to the current value of which is that everyone will begin withdrawals once account value which is equivalent to zero.The potential.The foregoing the \u201cproof-of-work which is equivalent to zero.The next day one bitcoin and everyone will becertainly becertainlyin the equivalent to zero which is that everyone will have a material adverse effect of zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?",
        "options": {
            "A": "Increased demand for electricity",
            "B": "Rising fuel costs",
            "C": "Improved operational efficiency",
            "D": "Delayed or unrecovered operating costs",
            "E": "Expansion into new markets",
            "F": "Strong economic growth"
        },
        "LLM_original_answer": [
            "Based on or equivalent to zero which is equivalent to meet or equivalent to zero which is equivalent to begin withdrawals which is equivalent to zero.The Duke Energy Efficiency and zero.The Duke Energy Transition Risk-Based on average withdrawals once value which is equivalent to meet zero.The Duke Energy Florida.The Duke Energy Efficiency Riders.The Duke Energy Transition to zero which is equivalent to meet zero which is equivalent to meet or everyone will begin withdrawals once value in a\nAFFECTION ELECTRICARDIspatial value is equivalent to a material.ANDI assume zero which is equivalent to zero.The Duke Energy Efficiency and everyone will begin withdrawals which is equivalent to meet or zero which is equivalent to begin withdrawals once again is equivalent to be equivalent to zero which is equivalent to the equivalent to zero.The Duke Energy Infrastructure and everyone will be equivalent to zero which is equivalent to meet zero.The Duke Energy Efficiency Star Wars Risk of zero.The assumption is equivalent to the value which is equivalent to everyone will be equivalent to zero which is equivalent to meet or equivalent to zero.The Duke Energy Transition to be equivalent to zero which is equivalent to zero.The Duke Energy Efficiency which is equivalent to meet and everyone will begin withdrawals once which is equivalent to a year one year round zero which is equivalent to meet or equivalent to takeaways.The Duke Energy Efficiency Starvation of zero which is equivalent to meet or less than zero.The assumption is equivalent to zero which is equivalent to zero which is equivalent to the equivalent to begin withdrawals which is zero which is equivalent to zero.The assumption of zero.The assumption.The assumption is equivalent to meet zero which is equivalent to zero.The assumption of which is equivalent to zero which is equivalent to meet value which is equivalent to be equivalent to zero which is equivalent to zero.The Duke Energy Company\u2019s assumption is equivalent to zero which is equivalent to zero which is equivalent to zero which is that everyone will begin withdrawals once value reaches zero.The Duke Energy Efficiency and equivalent to zero.The Duke Energy Efficiency:\u2022cyber.31##table 1\nA:\u2022regionalyadaevertedits.The Duke Energy Efficiency Rider 1 which is equivalent to zero is that everyone will begin withdrawals once account value reaches zero which is equivalent to the net zero which is equivalent to the average withdrawals which is equivalent to zero which is equivalent to the equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero.The assumption is equivalent to meet zero.The Duke Energy Company policy value of zero.The assumption that everyone will be equivalent to zero which is equivalent to zero.The assumption is equivalent to zero which is equivalent to zero.The assumption"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?",
        "options": {
            "A": "It will be allowed to increase its capital reserves.",
            "B": "It will receive tax incentives to improve practices.",
            "C": "Enforcement actions may be taken against it.",
            "D": "It will be automatically disbanded.",
            "E": "It will be required to decrease its interest rates.",
            "F": "It will gain permission for more acquisitions."
        },
        "LLM_original_answer": [
            "If applicable state law is that everyone will begin withdrawals once account value reaches zero which is equivalent to zero which is equivalent to the same as soon after which is equivalent to zero which is equivalent to 100%.25Assessentially think the first year one which is equivalent to zero which is equivalent to meet minimum withdrawal frequency is equivalent to zero which is equivalent to zero which is equivalent to the equivalent to zero.The assumption which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to the date zero which is equivalent to enhance the equivalent to the equivalent to begin withdrawals once account value of the first year zero which is equivalent to the equivalent to the equivalent to a which is equivalent to zero and everyone will begin withdrawals once account value withdrawals once account value reaches zero which is equivalent to 20percentages 0 which is equivalent to the assumption is equivalent to the assumption is equivalent to be equivalent to the equivalent to which is equivalent to be the equivalent of the same as a certain to withdraws which is equivalent to zero which is equivalent to the assumption is equivalent to the equivalent to zero which is equivalent to the Company of which is equivalent to the assumption is that everyone will begin withdrawals once account value is equivalent to the multiple risks related topline value which is equivalent to zero which is equivalent to meet-ups.Eastin this is equivalent to the equivalent to the equivalent to the following the Dodd-Federal securities and the equivalent to zero which is equivalent to the first which is equivalent to which is equivalent to the equivalent to the equivalent to be\u00ad\u2014equivalent to the Dodd-Federal Bankruptcy zero which is equivalent to zero which is equivalent to zero which isomorphic to the first year over the beginning of zero which is equivalent to the first time and everyone william a one of the first year endowenforcement with the assumption of the first year-end of the equivalent to zero which is equivalent to zero which is equivalent to be equivalent to meet or equivalent to zero which is equivalent to zero which is equivalent to account value reaches zero which is that everyone will begin withdrawals which is equivalent to the minimum balance sheet 10%25####table 18.The assumption is equivalent to zero.The assumption of the equivalent to the equivalent to zero which is equivalent to zero which is equivalent to the equivalent to a year five years which is equivalent to the equivalent of $5%25 on December 25Assumption of zero which is equivalent to account value reaches zero which is equivalent to the first withdrawals which is equivalent to a very low single account value which is"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?",
        "options": {
            "A": "International partnerships",
            "B": "Location of manufacturing facilities",
            "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement",
            "D": "Advertising and social media presence",
            "E": "Colors and branding of the packaging",
            "F": "Celebrity endorsements"
        },
        "LLM_original_answer": [
            "The document.Microsoft and the assumption is equivalent to zero which is a) which is equivalent to everyone will be the beginning at least clinically meaningful effect of a multiple sclerosis which is a\nA: A: A: (1. The key competitive factors affecting the assumption is a\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which organization acts as the conservator for the GSEs?",
        "options": {
            "A": "Ginnie Mae",
            "B": "United States Treasury Department",
            "C": "Various investors",
            "D": "Non-Agency securitization trustees",
            "E": "Federal Housing Finance Agency (FHFA)",
            "F": "Federal Reserve"
        },
        "LLM_original_answer": [
            "Based on a\n"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is included in the control arm of the described Phase 1 clinical trial?",
        "options": {
            "A": "Patients meeting specific HLA or miHA criteria",
            "B": "Patients treated with TSC-100 or TSC-101",
            "C": "Patients who do not meet HLA or miHA genetic criteria",
            "D": "Patients receiving experimental gene therapy",
            "E": "Healthy volunteers with no treatment",
            "F": "Patients undergoing bone marrow biopsy"
        },
        "LLM_original_answer": [
            "The assumption is equivalent to be equivalent to the assumption is equivalent to zero which is equivalent to zero which is equivalent to prevent relapse zero which is equivalent of account value is equivalent to zero which is equivalent to which is equivalent to 100-fold expansion of which is equivalent to zero which is equivalent to zero which is equivalent to which is equivalent to account value is equivalent to begin withdrawals which is equivalent to zero which is equivalent to date which is equivalent to account value which is equivalent to account value of zero which is equivalent to account value of which is equivalent to which is equivalent to which is equivalent to equivalent to zero which isotype 1eliminatechnomeritoruptake a which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to begin withdrawals once account value which is equivalent to zero which is equivalent to the assumption that is equivalent to zero which is equivalent to zero which is equivalent to the assumption of zero which is a Clinical Trial DesignationTSC-28value of zero which is equivalent to a which is equivalent to zero which is equivalent to begin withdrawals once account for everyone will begin withdrawals which is equivalent to zero which is equivalent to zero which is zero which is equivalent to 1000 which is equivalent to begin withdrawals which is equivalent to zero which is equivalent to a positive which is equivalent to preventable which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to everyone will begin withdrawals once account value reaches zero which is equivalent to the equivalent to zero which is equivalent to zero which is equivalent to 0 which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to 1percent of which is equivalent to zero which is equivalent to which is equivalent to zero which is equivalent to which is equivalent to zero which is equivalent to zero.We are equivalent to account value of the assumption isotype value which is equivalent to zero which is equivalent toed which is equivalent to which is equivalent to the answer to account value which is equivalent to zero which is equivalent to account value.We are33which is equivalent to zero which is equivalent to zero which is equivalent to the assumption which is equivalent to the equivalent to zero which is equivalent to TSC- HPV16account value zero which is equivalent"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?",
        "options": {
            "A": "10 years",
            "B": "12 years",
            "C": "14 years",
            "D": "15 years",
            "E": "20 years",
            "F": "25 years"
        },
        "LLM_original_answer": [
            "The answer:Item 31assumption.Requirementshatchments of zero which is equivalent to zero.The assumption is equivalent to zero which is equivalent toplinearrowsyesterday.Skin-31 the same as of zero which is equivalent to reach zero which is equivalent to the equivalent to everyone will never which is equivalent to the equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent of course of a single-pa multiple timeshersoverti.either account value which is equivalent to everyone will begin withdrawals which is equivalent to zero which is equivalent to zero.The U.Similarly zero.The assumption which is equivalent to zero.The assumption.The assumption is equivalent to the assumption is equivalent to zero.The assumption of zero which is equivalent to zero which is equivalent to zero.The assumption is equivalent to treat which is equivalent to zero which is equivalent to zero which is equivalent to treat or equivalent to begin withdrawals once account value which is equivalent to the assumption which is equivalent to reach zero which is equivalent to begin withdrawals once account value reaches zero which is equivalent to begin withdrawals once account value.The assumption.The assumption of zero.The assumption that everyone will begin withdrawals once account value is equivalent to zero which is equivalent to zero.The assumption zero which is equivalent to zero.The assumption that everyone will begin withdrawals which is equivalent to be equivalent to begin withdrawals once account value which is equivalent to begin withdrawals once account value will begin withdrawals which is equivalent to zero.The assumption that everyone will be equivalent to begin withdrawals which is equivalent to zero which is equivalent to zero which is equivalent to zero which is that everyone will be the equivalent to some time period which is equivalent to the assumption.The assumption.The FDA.U.Similar to zero which is equivalent to begin withdrawals once account value which is equivalent to address the same which is equivalent to zero which isometabolishowhypoisoncesiumaxedits equivalent to think step by defaultingestionary value which is equivalent to be equivalent to addressable to begin to treat a meaningful advantage over.U.Similar products which is equivalent to zero which is equivalent of equivalent to treat a novel drug products with zero which is equivalent to the Hatch-Watchmentality. (0\nA:\u2022Completion of the same.The sponsor interactions:\u2022 31\nA:Company Overview.\nicana to begin to addressable to begin withdrawals once account value zero which is equivalent to zero which is equivalent to zero which is equivalent to zero.The answer once account value which is that everyone will begin withdrawals which is equivalent to zero.The assumption that everyone will never equivalent to the equivalent to"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?",
        "options": {
            "A": "A decrease in trading demand by customers",
            "B": "Cost-cutting pressures across the industry",
            "C": "Settlements related to inspections",
            "D": "Weakness in the macroeconomic environment",
            "E": "Defaults by clearing or exchange members",
            "F": "Changes to contract specifications"
        },
        "LLM_original_answer": [
            "Based on day zero which is equivalent to zero.The assumption is equivalent to zero which is equivalent to zero.The assumption of zero.The assumption is equivalent to the equivalent to zero which is equivalent to zero.The assumption of zero which is equivalent to zero which is equivalent to zero which is that everyone will begin withdrawals once account value which is equivalent to the equivalent to the equivalent to the same which is equivalent to begin withdrawals once account value which is equivalent to zero which is equivalent to the equivalent to the equivalent to zero.The assumption of zero.The assumption is equivalent to withdraws which is equivalent to zero which is equivalent to zero which is equivalent to zero.The assumption is equivalent to begin withdrawals which is equivalent to zero which is equivalent to meet or equivalent to meet zero which is equivalent to zero account value is equivalent to withdraws which is equivalent to zero which is equivalent to the assumption is equivalent to zero which is equivalent to zero which is equivalent to the equivalent to the equivalent to zero which is that everyone will begin withdrawals once account value is equivalent to zero which is equivalent to meet zero which is equivalent to zero which is equivalent to zero which is equivalent to begin withdrawals which is equivalent to the assumption is equivalent to the assumption which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to meet other than which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is that everyone will be\u00ad\u2014equivalent to the London Interests.Business and operating results of which is equivalent to zero which is equivalent to begin withdrawals once again which is equivalent to zero which isometrically zero which is that everyone will begin withdrawals which is equivalent to be equivalent to begin withdrawals once account value of the equivalent to zero which is equivalent to account value at zero.The assumption is equivalent to zero which is equivalent to zero which is equivalent to the minimum withdrawal which is equivalent to zero which is equivalent to zero which is equivalent to zero.The assumption is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is that everyone will begin withdrawals once account value reaches zero which is equivalent to everyone will be equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to the assumption is equivalent to zero which is a zero which is that everyone will begin withdrawals which is equivalent to which is equivalent to everyone will be\u00ad-22 assumed synthetic LIBORsufficient"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?",
        "options": {
            "A": "January 1, 2020",
            "B": "July 1, 2020",
            "C": "January 1, 2021",
            "D": "July 1, 2023",
            "E": "January 1, 2023",
            "F": "July 1, 2022"
        },
        "LLM_original_answer": [
            "The assumption is a\nEarnings and/or equivalent to bequests:step by the assumption is equivalent to the Department of zero which is equivalent to zero which israelled.Regulatory Pension withdrawals once account value which is equivalent to mitigate the equivalent to zero.The Company\u2019s value which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to be\u00ad\u2013account value reaches zero which is equivalent to the SEC Rules and everyone will be\u00ad\u2013which is equivalent to the state law firm-wide-ranging from time off which is equivalent to meet and is also be\u00ad\u2014Insurance Regulation of zero.Regulatory value which is equivalent to which is equivalent to be\nAgriculturegoverned.U.SeveryOur culture and is equivalent to becertainly zero which is equivalent to zero which is equivalent to zero which is a\nA. Options:\u2022Insurance Regulation of the assumption of the CEO\u2019see:Questions: Questions: A:\u2022Regulatory and other state legislatures of our culture and equivalent to zero which is equivalent to becauses.32Regulatory requirements.State Law of the same which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is that everyone will begin withdrawals which is equivalent to zero.The assumption.The assumption.The assumption.The assumption of zero.The assumption is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to begin withdrawals once account value of everyone will begin withdrawals once account value which is equivalent to zero which is equivalent to bequestiofurthermore than account value of everyone will begin withdrawals which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to begin withdrawals which is equivalent to zero which is equivalent to be ito\nA: January 100% of zero which is that everyone will begin withdrawals once account value which is equivalent to zero.The assumption is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is zero.The assumption is equivalent to zero which is equivalent to zero. Weaker ECDMergo\nA: AUMA: AUMAPIO: AUMAgriculturalmost likely to zero which is equivalent to zero which is equivalent to zero.The assumption that everyone will begin withdrawals once account value of the companywide-ranging from time to zero which is that everyone will begin withdrawals once account value reaches zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is equivalent to zero which is everyone will"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?",
        "options": {
            "A": "Increases ventricular pressure and cardiac remodeling",
            "B": "Decreases the potential for cardioprotective effects",
            "C": "Protects against cardiac dysfunction and remodeling",
            "D": "Leads to an increase in the Fulton index",
            "E": "Enhances the right ventricular free wall thickness",
            "F": "Increases the myocardial performance index"
        },
        "LLM_original_answer": [
            "The clinical investigation of the safety and/or other than 2.Our clinical investigations of the safety of theof the safety of course of operations of our clinical trials may fail to demonstrate substantial evidence of effectiveness of effectiveness and substantial evidence of the significantly greater than that may fail to demonstrate substantial evidence of the effectiveness of the safety and our clinical data of the safety and our clinical benefit to demonstrate substantial evidence may fail to a prior to a substantial evidence of the safety and may fail to a substantial evidence of the significantly.Our clinical trials may fail to demonstrate the safety of the safety and other than \ufffdostat least clinically significant improvement of the ability to demonstrate substantial evidence may fail to a substantial evidence of the safety and safety and/or our clinical evidence of the safety of the safety and our clinical evidence of the clinical investigations significantly.Our clinical operations significantly.Our clinical operations.Our clinical trials significantly.Our clinical evidence of the safety and our clinical benefit of the product safety and ourc. Our clinical trials of the the clinical trials of the clinical trials may fail to be\u00ad.\u2022Our clinical trials of the operations of operations significantly.Our clinical trials may fail to demonstrate substantial evidence of the following evidence of the clinical evidence of thes.We believe of operations significantly.Our clinical.Our clinical trials to demonstrate substantial evidence of the of the of the clinical trials of the operations significantly.Our clinical trials may fail to demonstrate substantial evidence of the effectiveness of effectiveness and substantial effectiveness and substantial evidence of our clinical trials may fail to a substantial evidence of theorex'/>\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?",
        "options": {
            "A": "Immediate infringement lawsuits upon filing",
            "B": "Inability to identify competing products",
            "C": "Delayed launch of new products",
            "D": "Unawareness of pending applications that may later result in infringement claims",
            "E": "Mandatory changes to current product designs",
            "F": "Increased cost of patent filing"
        },
        "LLM_original_answer": [
            "Based on a:test our ability to the evolving digital asset rewards and the United Statesmanship."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?",
        "options": {
            "A": "Increased demand for electricity",
            "B": "Rising fuel costs",
            "C": "Improved operational efficiency",
            "D": "Delayed or unrecovered operating costs",
            "E": "Expansion into new markets",
            "F": "Strong economic growth"
        },
        "LLM_original_answer": [
            "Based on the future.There is no assurance as a regular cash dividends in the Duke Energy Registrant assurance as a policy of the future.Due"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?",
        "options": {
            "A": "It will be allowed to increase its capital reserves.",
            "B": "It will receive tax incentives to improve practices.",
            "C": "Enforcement actions may be taken against it.",
            "D": "It will be automatically disbanded.",
            "E": "It will be required to decrease its interest rates.",
            "F": "It will gain permission for more acquisitions."
        },
        "LLM_original_answer": [
            "If the desist and the ability to a desistate and desisthearthematica ndependencyclesescheat least 23and desistate civil money market value of the ability to the ability to the ability to the ability to the ability to the Eastern Bank of Eastern Bank Sec.23and des."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?",
        "options": {
            "A": "International partnerships",
            "B": "Location of manufacturing facilities",
            "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement",
            "D": "Advertising and social media presence",
            "E": "Colors and branding of the packaging",
            "F": "Celebrity endorsements"
        },
        "LLM_original_answer": [
            "The high cost of 50% of companies\u2019\u0080\u0099s proceeding through clinical trial results for drug candidate failure rate for drug candidate proceeding failure rate for drug candidates proceeding to market approval.A number of companies have failed drug candidates may of drug candidates proceeding through clinical trials.A number of drug candidate proceeding through clinical trial results of companies proceeding through clinical trials.A number of companies proceeding through clinical trial results of companies proceeding through clinical trial drugs approved by the failure rate for drug candidates proceeding through clinical hold-up to market failure rate for drug candidates proceeding through clinical trial candidates proceeding through clinical trials.A number of the industry-wide failure rate for drug candidates proceeding through clinical trials.A number of drug candidate candidates proceeding through clinical trial.A number of the FDA approval rate of the high success rate for the FDA approval by a number of companies proceeding through to the failure rate for drug candidate proceeding through clinical trial and a number of those proceeding to the failure rate for drug candidates proceeding through clinical trials fail to clinical trials.A number of companies proceeding through which have failed to a number of the FDA inspection of the high quality control group of companies for drug candidates proceeding through clinical trials.A number of companies have a high failure rate for which are not meeting its receipt of 4"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which organization acts as the conservator for the GSEs?",
        "options": {
            "A": "Ginnie Mae",
            "B": "United States Treasury Department",
            "C": "Various investors",
            "D": "Non-Agency securitization trustees",
            "E": "Federal Housing Finance Agency (FHFA)",
            "F": "Federal Reserve"
        },
        "LLM_original_answer": [
            "The document contains a..\n"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What is included in the control arm of the described Phase 1 clinical trial?",
        "options": {
            "A": "Patients meeting specific HLA or miHA criteria",
            "B": "Patients treated with TSC-100 or TSC-101",
            "C": "Patients who do not meet HLA or miHA genetic criteria",
            "D": "Patients receiving experimental gene therapy",
            "E": "Healthy volunteers with no treatment",
            "F": "Patients undergoing bone marrow biopsy"
        },
        "LLM_original_answer": [
            "The Solid T cell to grant a marketing authorization, who grants a marketing authorization, who has been to grant, who makes the Tand who makes the most common solid tumor-specific target cells, who grants a marketing authorization to grant a marketing authorization, who makes the final decision to grant a marketing authorization, who makes the final decision to grant a marketing authorization, who makes the final decision to grant a marketing authorization, or not to grant a marketing authorization, or not to grant a marketing authorization, or to treat the European Commission, who grants a marketing authorization to grant a marketing authorization, or not to which the European Commission, who makes the final decision to grant a marketing authorization, who grants a marketing authorization, who makes the final decision to grant a marketing authorization, who grant a marketing authorization to grant a marketing authorization to grant a marketing authorization, who grants a marketing authorization to grant a marketing authorization, who makes the final decision to grant a marketing authorization, who grant a marketing authorization to grant a marketing authorization to grant a marketing authorization to grant a marketing authorization, who makes the Commission, who, who has been to and final decision to grant a marketing authorization, or refuse a marketing authorization to which we\u2019realike a marketing authorization, who are, who are the TSCDiagnostics to the final decision to fight to head androgenitalian Commission, who have the HLAUTH- day, who are the TSC- in the TSC-who makes the Commission, who does not-yetext or refuse a marketing authorization, or not to grant a marketing authorization, who knows the final decision to market authorization to developp roxpression, who areolimitated to treatmen, who grants apherestor makes the final decision to grant a marketing authorization, who grants a marketing authorization to grant a marketing authorization, who grants a marketing authorization, who grants a marketing authorization, who grants a marketing authorization to grant a marketing authorization to grant a marketing authorization, who makes the European Commission, who makes the European Commission, who grants a marketing authorization, who makes the European Commission, and grants a marketing authorization, which is to grant a marketing authorization, who makes the final decision to grant a final decision to grant a marketing authorization, who grant a marketing authorization, who are granted by the final decision to the final decision to grant a marketing authorization to the final decision to grant a marketing authorization to grant a marketing authorization to the marketing authorization, who grants a marketing authorization to grant a marketing authorization, who grants a marketing authorization, or to the European Commission, who"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?",
        "options": {
            "A": "10 years",
            "B": "12 years",
            "C": "14 years",
            "D": "15 years",
            "E": "20 years",
            "F": "25 years"
        },
        "LLM_original_answer": [
            "To summarize the latterly rely on the product and/or their methods of a29its methods of the FDA\u2019solutions.Complicated on June 29and/or their methods of use, if the product licenses its methods of course of the Hatch-Welcome secrets, or similar to which are also rely on the FDA\u2019s of a prior to which, or its methods of the other regulatory and/or their methods of our product and/or their methods of the FDA approval of its methods of the product or a27its methods of the product.The FDA approval of use.We also rely on a final approval of the product and/or their methods of any of use.We also rely on the other regulatory hold harmless, if any time.The FDA reliance on a product and/or their methods of any other than an Annual Report:\u2022Clinical Trial Division of their methods of which may also rely on a30trade secrets, if the product and/or their methods of use.We also known or their methods of use and/or their methods of use.We also rely on a26and/or their methods of use, or their methods of use.We also rely on its methods of use of use of use their methods of use.The FDA also rely on aquisition27relatepursusually.Administration of use of use.We also rely on a25We also rely on or upon their methods of use of use.The product and/or their methods of use.We also rely on a product and/or their methods of use.We also rely on its methods of the product or notarrest on a product and/or their methods of which may befittingual use or its methods of its methods of its methods of our product candidates or other than any of its methods of their methods of any other than any of use of use.We also rely on aDNAWe also rely on a\n_ctxt28product and/or their methods of the product and/or their methods of use of course, or I also rely on a product and/or their methods of use.The FDA\u2019s methods of use of use.The FDA regulations, if any longer thanoligreliability to the product and/or their methods of a.The FDA.The sponsor\u2019s methods of their methods of course of the product and/or their data, if and/or their methods of use.We also rely on their methods of use.We also rely on a: A:28and/or their methods of their methods of use of the product and/or their methods of use.We also rely on a variety of use.We also rely on a product of use of their confidentiality, and/or their methods of use"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?",
        "options": {
            "A": "A decrease in trading demand by customers",
            "B": "Cost-cutting pressures across the industry",
            "C": "Settlements related to inspections",
            "D": "Weakness in the macroeconomic environment",
            "E": "Defaults by clearing or exchange members",
            "F": "Changes to contract specifications"
        },
        "LLM_original_answer": [
            "According to the multiple lines of which are the fair value of $18\u2022See the question: 2023 to our business and to $17. The question:\u2022changes to the options, which may lead to $18\u2022Question: $17. The document intangible assets of $17.3 billion relating to the multiple intangible to the multiple entities, or $\n\n\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?",
        "options": {
            "A": "January 1, 2020",
            "B": "July 1, 2020",
            "C": "January 1, 2021",
            "D": "July 1, 2023",
            "E": "January 1, 2023",
            "F": "July 1, 2022"
        },
        "LLM_original_answer": [
            "Based on or their business practices. See \u201cRegulation of the use of January 2023 SEC Rules Regarding the impact of such as well as well as well in connection with respect to the.During of the foregoing the."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?",
        "options": {
            "A": "Increases ventricular pressure and cardiac remodeling",
            "B": "Decreases the potential for cardioprotective effects",
            "C": "Protects against cardiac dysfunction and remodeling",
            "D": "Leads to an increase in the Fulton index",
            "E": "Enhances the right ventricular free wall thickness",
            "F": "Increases the myocardial performance index"
        },
        "LLM_original_answer": [
            "Based on anabolic and/orfurthermTTIPERAs of the Company\u2019s hemoglobin and confirm compliance to the Company\u2019s Code of Bone Conduct and Ethics and/or KER, or KERAs of 24\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?",
        "options": {
            "A": "Immediate infringement lawsuits upon filing",
            "B": "Inability to identify competing products",
            "C": "Delayed launch of new products",
            "D": "Unawareness of pending applications that may later result in infringement claims",
            "E": "Mandatory changes to current product designs",
            "F": "Increased cost of patent filing"
        },
        "LLM_original_answer": [
            "The foregoing the Company\u2019s ability to the Company\u2019s results of which may be influenced by rapidly changing technology, and may be influenced by investor sentiment, and may be influenced by factors such as technology, technology, and may be technology, and may be influenced by rapidly changing investor sentiment, and operations, and influenced by technology, and rapidly changing investor sentiment, in part of rapidly changing technology, technology, such as well beyond technology, such as well as well as well as well as well-established investor sentiment, such as well-established sentiment, and may be influenced by technology, such as well-established investor sentiment, and influenced by factors such as well as well-established by technology, among others, among others such as well-established technology, and may be influenced by rapidly changing investor sentiment, and may be technology, and technology, and technology, and may be influenced by technology, and technology, technology, and may be negatively impact investor sentiment, and may be influenced by-passedemand rapidly changing technology, and may becurrencies, such as well-established or may be influenced by technology, and/or other than may be influenced by technology, among other factors such as well as well as well-established technology, which could have a\nA. 21and influenced by technology, but may be influenced by rapidly changing technology, and/or sentiment, and may be influenced by technology, among other than technology, among other technology, among other factors such as well-established protocols, and/or technology, and/or investor sentiment, which may be influenced by rapidly changing technology, such as well-established technology, and may be influenced by technology, and may be influenced by technology, which may be influenced by rapidly changing investor sentiment, and/or may be influenced by technology, technology, technology, and rapidly changing technology, and/or investor sentiment, and/or other factors such as a\nand may be influenced by technology, and operating costs, and/or may be influenced by technology, and/or technology, among others, and/or investor sentiment, technology, and may be influenced by technology, technology, technology, and operating expenses, among others may be influenced by technology, and transactions, and/or may be influenced by technology, and may be influenced by technology, and technology, among other than may be subject to the technology, or other than technology, and may be negatively impacting technology, and operations, and regulatory and may be affected by rapidly changing investor sentiment, and may be technology, technology, and may be subject to a technology, and technology, and may becertain technology, and/or sentiment, to the"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?",
        "options": {
            "A": "Increased demand for electricity",
            "B": "Rising fuel costs",
            "C": "Improved operational efficiency",
            "D": "Delayed or unrecovered operating costs",
            "E": "Expansion into new markets",
            "F": "Strong economic growth"
        },
        "LLM_original_answer": [
            "What the current year of the current year of the current year of the current year-roundsafety and/orchallenges to the current year of the current year of the current year;\u2022 a year.The current year, among the current recovery; and higher fuel cost recovery of the current year; and/orchallenges; and current yearbook value of the current year; a portion of the current year; and/or higher fuel cost recovery of the current year-round;\u2022 and/orchallenges, and/orchallenges in the current year-end of operations and other factors such as aseveralongriders; and other than the current year-round the current year;\u2022a nd partially offset; and current year-round customer demand for the current year; and current year;\u2022 higher fuel cost of the current year; and offset by the current year-over 2020.##a significant environmental impacts of the current year-overburdenied;\u2022 more than the current year-roundsizable coal-fired power generation and/orchamiducurrent year-round; and/orchallenges in the current year-to the current year, and current year, and PURPA and higher fuel cost recovery in the current year of the current year-overhead fuel cost recovery of the current year-rounds of the current year-rounding and/or higher fuel cost recovery, partially offset;\u2022a $144;\u2022a $ cost recovery of the current year;\u2022a $ current year of the current year-roundsafety and current year-rounds;\u2022a $ 25 fuel cost recovery;\u2022 a significant capital impacts;\u2022a year, or future costs and the current recovery;\u2022 a $1, partially offset by higher fuel cost recovery;\u2022a; and/or; and/or remediation; and/or higher fuel cost impacts;\u2022a $205 and the current year; and future and/or the current year; and/or the current year, partially offset by higher fuel cost recovery;\u2022a higher fuel cost recovery of the current year-endangered costs and higher fuel cost impacts; and/or the current year-roundsued byproducts and/orient;\u2022 and, and/oral; and other costs of the current year-overall; and/or the current year; and/or the current year;\u2022affect;\u2022a $144;\u2022the current yearbook value of the current year-roundsued byproduct, and, and current year-rounding of the current year; and/oraltered by the current year; and/or; and/or the current year; and/or the"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?",
        "options": {
            "A": "It will be allowed to increase its capital reserves.",
            "B": "It will receive tax incentives to improve practices.",
            "C": "Enforcement actions may be taken against it.",
            "D": "It will be automatically disbanded.",
            "E": "It will be required to decrease its interest rates.",
            "F": "It will gain permission for more acquisitions."
        },
        "LLM_original_answer": [
            "If the FDIC 6 the Federal Reserve Bank Secured 0.00% to a range of 19\nof the Federal Reserve Bank\u2019s range of $250% to 19\nrange of 0.19the18\nTo a range of 0.00% to 0% to 0.00% to 0.00% to 0.00% to a range of 0.00% to a range of 0.00% to 0.00.25% to 0.00% to 2.00% to a range of 0.00% to a range of 19of 0.00% to a range 19 to a range of 0% to a range of 0.19 other federal law of 0.18on the range of 19of 19 the range of 0.00% to 0.00% to a range of the range of the range of the range of its range of 0.00% to 0.00% to 0.00.00% to 0.00% to a range of the range of 19\nto the Federal Reserve Bank of 19 other than 19on a range of 19on the FDICRAEAST 19\n@api% to 0.00% to 19% to 0.00% to 0.00.00% to engage in excess to financial institutions\u201924onl to 2024 Eastern Bank and subordinated 19of 18 of 0.00% to 19% to 00% to a range of 0.00% to 0.00.00% to 0.75% to a range of 0.00% to 0.00% to 0.00% to a range of 0.00.25% to a range of 0.00% to 0.00% to a range of 19% to 0.00% to 0.00% to 0.00% to 0.00% to 0.00% to 0.00% to a range to a range to a range of 0.00% to 0.25% to 0.00% to 0.00% to a range of 0.00% to 0.00% to 19 the range of a range of 0.00% to a range of"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?",
        "options": {
            "A": "International partnerships",
            "B": "Location of manufacturing facilities",
            "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement",
            "D": "Advertising and social media presence",
            "E": "Colors and branding of the packaging",
            "F": "Celebrity endorsements"
        },
        "LLM_original_answer": [
            "The Annual Report on Management\u2019s Discussion and the section titled \u201cManagement\u2019s Form 10-K on Form 10-K, if the section titled \u201cManagement\u2019s ability to the section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s rights and/or K, if and/or the section titled \u201cManagement\u2019s on Form 10-K on Form 10-K, including the section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s Discussion titled \u201c10-K, if any section titled \u201cManagement\u2019s Discussion,\u201d and/or \u201cManagement\u2019s Discussion and the section titled \u201cManagement\u2019s titled \u201cManagement\u2019s Form 10-K, the section titled \u201cManagement\u2019s Management\u2019s Discussion, for the section titled \u201cManagement\u2019s titled \u201cManagement\u2019s discussion titled \u201cDiscussion of Form 10-K, the section titled \u201cManagement\u2019s section 10-K, including the section titled \u201c Management\u2019s section titled \u201cManagement\u2019s Discussion, including the section titled \u201cManagement\u2019s Report on Form 10 and the section titled \u201c and/or Report on Form \u0003Management\u2019s section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s titled \u201cManagement\u2019s the section titled \u201cManagement\u2019s Analysis of the section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s discussion and the section titled \u201cManagement\u2019s titled \u201cManagement\u2019s the section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s right to the section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s right to the section titled \u201cClinical Trial 10-K, if we titled \u201cManagement\u2019s section titled \u201cClinical Trial Supply Chain of the section titled \u201c, if we titled \u201cManagement\u2019s section titled \u201cManagement\u2019s Discussion and the section titled \u201cDiscussion\u2019s Analysis of the section titled \u201cManagement\u2019s section titled \u201cForm 10-K, including the section titled \u201cManagement\u2019s discussion and the section titled \u201cManagement\u2019s Discussion and the section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s discussion and the section titled \u201cManagement\u2019s section titled \u201cManagement\u2019s Form 10-K, including the section titled \u201cManagement\u2019s Discussion of Form 10-K, if the Annual Report on Form 10-K, including the section titled \u201cManagement\u2019s Discussion and the section titled \u201cManagement\u2019s management and the section titled \u201cManagement\u2019s Discussion of Form 10-K and the section titled \u201cManagement\u2019s titled \u201cManagement\u2019s Discussion and the section titled \u201cManagement\u2019s titled \u201cManagement\u2019s form 10K the section titled \u201cManagement\u2019s Discussion, including the section titled \u201cManagement\u2019s Form \u0003Management\u2019s 10-K, if we believe titled \u201cManagement\u2019s"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which organization acts as the conservator for the GSEs?",
        "options": {
            "A": "Ginnie Mae",
            "B": "United States Treasury Department",
            "C": "Various investors",
            "D": "Non-Agency securitization trustees",
            "E": "Federal Housing Finance Agency (FHFA)",
            "F": "Federal Reserve"
        },
        "LLM_original_answer": [
            "Theftsecurities, or other than any of the risk management, and/or other than M&A.\u201d\u201cFTSEMI, MTSB.V.\u201dFTSEMI. FTSENISSRithrough the\u201cFTSEFintended, including but not disclosed bylawsuits.\u201d\u201cFTSE.\u201dFTSEFI, or other than\u201dOcertaine.given, or alleged or other than can materially and/or other than any of our regulatory settlements, including but also may be\u00ad\u201cFTSE, and/or other than the foregoing the Consumer Credit Risk Management, or other thaneX, MBSAmergent, M&A.\u201dFTSE\u201d or MBSecommunication, or other than the consumer protection and/or the U.See, MBS.\u201dFTSE\u201d\u201cFTSEMTSOPSIU.See Securities and other than\u201cFTSE, and other thankeepserviceserviceserviceservices and/orce FI mortgage companies, or other participants and/or civil and/or our subsidiaries, including but.\u201d\u201cFTSE, or other than the Right to the CARESponsorede\n"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What is included in the control arm of the described Phase 1 clinical trial?",
        "options": {
            "A": "Patients meeting specific HLA or miHA criteria",
            "B": "Patients treated with TSC-100 or TSC-101",
            "C": "Patients who do not meet HLA or miHA genetic criteria",
            "D": "Patients receiving experimental gene therapy",
            "E": "Healthy volunteers with no treatment",
            "F": "Patients undergoing bone marrow biopsy"
        },
        "LLM_original_answer": [
            "The discovery of 2021patient conditions, and the discovery of the discovery of 202patients, and the discovery of the discovery of conditions, including conditions, the discovery of unknown conditions, including the discovery of the discovery of the discovery of the discovery of violative conditions, the discovery of 2022and the discovery of conditions, including the discovery of interest, the discovery of violative conditions, the discovery of interestive conditions, the discovery of the discovery of the discovery of the discovery of violative conditions, including the discovery of the discovery of the discovery of 25discovered conditions, and the discovery of the discovery of the discovery of the discovery of the discovery of the discovery of the discovery of the discovery of violative conditions, including the discovery of the discovery of the discovery of the discovery of the discovery of patients, including the discovery of the discovery of the discovery of violative conditions, the discovery of the discovery of the discovery of violative conditions, including the discovery of the discovery of the discovery of the discovery of the discovery of the discovery of violative conditions, and the discovery of the discovery of the discovery of the discovery of the patient\u2019s discovery of the discovery of violative conditions, including conditions, including the discovery of the discovery of the discovery of the discovery of the discovery of interest in the discovery of the discovery of unknown conditions, and the discovery of the discovery of the discovery of interestevidence of the discovery of the discovery of violative conditions, including the discovery of the discovery of the discovery of the discovery of violative conditions, including the discovery of violative conditions, the discovery of a variety of the discovery of violative conditions, including the discovery of the discovery of the discovery of violative conditions, and the discovery of the discovery of the discovery of violative conditions, including the discovery of violative conditions that of 25 violative conditions that discovery of violative conditions, and the discovery of violative conditions, including the discovery of violative conditions, or pre-transplantive conditions, and the discovery of violative conditions, including the discovery of the discovery of violative conditions, and the discovery of the discovery of which, the discovery of violative conditions, including the discovery, and the discovery of violative conditions, including the discovery of the discovery of violative conditions, including the discovery of the discovery of the discovery of violative conditions, including the discovery of violative conditions, including the discovery of the discovery of any time-late of violative conditions, including the discovery of the discovery of violative conditions,"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?",
        "options": {
            "A": "10 years",
            "B": "12 years",
            "C": "14 years",
            "D": "15 years",
            "E": "20 years",
            "F": "25 years"
        },
        "LLM_original_answer": [
            "The willingness of the target patient population to, and the willingness of the target patient\u2019s willingness of the target patient population to include, and the target patient population to, and the willingness of the target patients, and/orioncGMPHIV. and the target patient population to try, and alternative treatments to try, and continue to alternative treatments;and patient population to the target, and the willingness of the target patient population;\u2022the willingness to try, and the willingness of the target patient population to try, and the willingness topline treatments;\u2022the willingness to, and/or patient population to try, and/or the target patient\u2019s to try, and/or alternative treatments to complete to try, and the willingness to try, and alternative treatments to which may, and the willingness of the target patients, and the willingness of the willingness of the willingness of the target patient population to the target patients to the willingness of the target patient population to, and the willingness to the willingness of the target patient population to the target patient compliance of the target patient population to try, and the target patient population to try, and the willingness to try, and the target patient\u2019s willingness of the target patient population to the target patient\u2019s willingness of the target patient, and the target patient population to be, and the target patient information technology product candidates, and the willingness of the FDA and the target patient population;\u2022the effectiveness of the target patients to the target patient population to the willingness of the target patient populations;\u2022the willingness of the target patient population to try, and continue, and continue, and the willingness of the target patient\u2019s clinical trials, and willingness of the target patient population;\u2022the willingness of the target patient population patient population to, and the willingness of the target patient\u2019s willingness of the target patient\u2019s willingness of the target patient, and the willingness of the target patient population to, and the target patient population to, and other treatments, and the target patient population to, and/or, and the willingness of the target patient population to which may, and the willingness of the target patient advocacy groups of the target patient population to the willingness of the target patient population to try, and the willingness of the target patients, and/or the target patient\u2019s target patient population to the target patient population to try, and the target patient to try, and the willingness to the target patient population to the target patient population to try, and the target, and the target patient advocacy of the willingness of the target patient population to the target patient to try, and/or, and the"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?",
        "options": {
            "A": "A decrease in trading demand by customers",
            "B": "Cost-cutting pressures across the industry",
            "C": "Settlements related to inspections",
            "D": "Weakness in the macroeconomic environment",
            "E": "Defaults by clearing or exchange members",
            "F": "Changes to contract specifications"
        },
        "LLM_original_answer": [
            "What could lead to fewer Chinese companies listing in the risks related to lead to fewer Chinese companies listing in the U.Seequicker in the U.SUMBEREFFECTS.Effect related to fewer Chinese companies listing in the following the following these inspections related to fewer Chinese companies and settlements related to fewer Chinese companies that could lead to fewer Chinese companies related to these inspections, which could lead to fewer Chinese companies could lead to fewer Chinese companies could lead to our business and other risks related to the risks related to fewer Chinese companies listing in the U.See, which could lead to fewer Chinese companies could lead to fewer Chinese companies listing in the U\nResponse to the U.See Settlements\u2022Continued to the following in the U.SECMergrowettain settlements related to fewer Chinese companies\u201922\u2022OAND OTHERSUSTheavert to the Financial Services\u2022We intend to the business and which could lead to fewer Chinese companies listing in the U.See or the market data products and fewer Chinese companies\u2019U.See: Settlementsuspensions and/or settlements related to fewer Chinese companies could lead to fewer Chinese companies could lead to the U.SUMarket to fewer Chinese companies related to fewer Chinese companies listing in the U.KRisks related to fewer Chinese companies that could lead to the residential mortgage technology companies listing in the U.See could lead to the impact on these impacts of our mortgage settlements related to fewer Chinese companies listing in the inspections related risks, cessations related to the U.See related to the U.See:\u2022 Our growth in the U.SUMSUSTOMITS Segment 23companies listing in the U.See in the COVID-Item 23companies listing in the U.See could lead to fewer Chinese companies and which could lead to fewer Chinese companies listing in the U.See could lead to fewer Chinese companies listing in the U\n_TACOMITCustsublications related to the impact of our business and other than could lead to fewer Chinese companies listing in the risk management of the inspections, which could lead to the U.See Chinese companies could lead to fewer Chinese companies could lead to fewer Chinese companies listing in the following the secondary mortgage technology companies listing in the U.See companies listing in the U\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?",
        "options": {
            "A": "January 1, 2020",
            "B": "July 1, 2020",
            "C": "January 1, 2021",
            "D": "July 1, 2023",
            "E": "January 1, 2023",
            "F": "July 1, 2022"
        },
        "LLM_original_answer": [
            "When we expect to mitigate our approach is designed to mitigate our cybersecurity standards designed to mitigate our approach is designed to mitigate our third-party vendors\u2019-licensed compliance with respect to mitigate our third-party is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our cybersecurity risk.This approach is designed to the mitigation of our approach is designed to mitigate our-party vendors\u2019 compliance with our cybersecurity standards.This approach is designed to mitigate the risk and other potential cybersecurity risks related-party vendors\u2019 compliance with the approach to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our third-party vendors\u201919Our approach is designed to mitigate our approach is designed to mitigate our approach is designed to the approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our cybersecurity standards.The approach is designed to mitigate our approach is designed to mitigate our third-party compliance with our cybersecurity standards.This approach is designed to mitigate our approach is designed to mitigate our third-party vendors\u2019 requirements designed to mitigate our approach is designed to our cybersecurity standards designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our approach is designed to the approach is designed to mitigate our third-party vendors\u2019 compliance with respect to mitigate our third-party vendors\u2019 compliance with our cybersecurity standards designed to their compliance with our third-party\u2019s compliance risk management companies\u2019 compliance with our cybersecurity standards.We approach is designed to mitigate our third-party vendors\u2019 our approach is designed to the approach is designed to mitigate our approach is designed to the approach is designed to mitigate our third-party vendors\u2019 \u2014 Regulation of our third-party vendors\u201922This approach is designed to mitigate our third-party compliance with the approach is designed to mitigate our-party vendors\u2019 compliance with our approach is designed to mitigate our approach is designed to mitigate our approach is designed to the approach is designed to mitigate our approach is designed to mitigate the risk-based risk-based on a20Regulationimitigation is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our third-party vendors\u2019 approach is designed to mitigate our approach is designed to mitigate our approach is designed to mitigate our third-party vendors\u201922our approach is designed toplinearbit\u2019s compliance with our"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?",
        "options": {
            "A": "Increases ventricular pressure and cardiac remodeling",
            "B": "Decreases the potential for cardioprotective effects",
            "C": "Protects against cardiac dysfunction and remodeling",
            "D": "Leads to an increase in the Fulton index",
            "E": "Enhances the right ventricular free wall thickness",
            "F": "Increases the myocardial performance index"
        },
        "LLM_original_answer": [
            "What Elsewhereas a 2024. Other Healthcare Laws and compliance requirements and other than in the KERIbelieve Healthcare Laws and other Healthcare Laws and, and compliance requirements and Compliance Laws and other Healthcare Laws and Compliance Laws and Compliance and Off-Other Healthcare Laws and Compliance and Compliance Laws and Compliance Requirements and Compliance Healthcare Laws and Healthcare Laws and Healthcare Laws and Healthcare Laws and Other Healthcare Laws and Other Healthcare Laws and Compliance Laws and Compliance Requirements and Compliance Laws and Compliance Laws and other Healthcare Laws and Compliance Laws and other Healthcare Laws and other Healthcare Laws and Compliance and/or-Off-Related Healthcare Laws and compliance laws and compliance requirements and Compliance and Compliance and Compliance Laws and Compliance Laws and Compliance Requirements and Compliance and Compliance Requirements and Compliance Requirements and Compliance Requirements and Compliance Requirements and compliance laws and, and the Treated Laws and, or KERAs aortic Compliance and compliance requirements and compliance laws and off-label Compliance Requirements and that is not otherwise. Other Healthcare Laws and Compliance and Compliance and Compliance Requirements and compliance requirements and is a compliance with PAHypotranscription-Off-Off Healthcare Laws and, which is off-label and compliance with Compliance and Compliance Requirements and compliance laws and other laws and other laws and Compliance and Compliance Requirements and Other Healthcare Laws and other than in the EU Healthcare Laws and other healthcare laws and Other Healthcare Laws and Compliance Requirements and Compliance Requirements and Compliance Laws and Compliance Requirements and Compliance Laws and Compliance and Other Healthcare Laws and Compliance Laws and Compliance and other healthcare laws and other Healthcare Laws and Compliance and Off-Related Healthcare Laws and Compliance and Compliance Laws and other than compliance laws and Compliance Requirements and Compliance Requirements and Compliance and other Healthcare Laws and compliance laws and the laws and Compliance and compliance with respect to the following the U.Specific Healthcare Laws and compliance laws and other Healthcare Laws and Compliance and Compliance and Compliance and Compliance and Other Healthcare Laws and the above the United States and/orviet Laws and Healthcare Laws and Compliance and Compliance and off-label and compliance requirements and compliance laws and other healthcare laws and Compliance Laws and Other Healthcare Laws and/or Off-Other Healthcare Laws and Other Healthcare Laws and Compliance Laws and Compliance and Compliance and Healthcare Laws and Healthcare Laws and Healthcare Laws and Healthcare Laws and Compliance and Compliance Requirements and compliance requirements and compliance requirements and is aLaws and is a Compliance Requirements for Healthcare Laws and the EU Compliance Requirements and is off-label and other than the EU Laws and Compliance Requirements and is prohibited in the U.Severies Laws and other Healthcare Laws and Compliance Requirements and other Healthcare Laws and Compliance Requirements and Use and Off-Off-Off"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?",
        "options": {
            "A": "Immediate infringement lawsuits upon filing",
            "B": "Inability to identify competing products",
            "C": "Delayed launch of new products",
            "D": "Unawareness of pending applications that may later result in infringement claims",
            "E": "Mandatory changes to current product designs",
            "F": "Increased cost of patent filing"
        },
        "LLM_original_answer": [
            "The Consolid beginning December 2022, the 21, beginning of Operations beginning December 2022, 202 2022. Beginning December 2022, the beginning December 21, beginning of operations beginning December beginning beginning December 2022, the beginning December 21, the beginning December 21, the beginning December 2022, beginning December 21, beginning December 21, the Consolid Statements of Operations beginning December 21, December 2022, the beginning December 2022, the Company beginning beginning beginning the beginning December 2022, the beginning December 2022 beginning of the beginning beginning beginning December 21, the Consolidated, the Consolidated beginning December 21, 21, the beginning December 2022nd beginning December 2022, the Consolidated Operations of Operations beginning December 21 2022, the Consolidated beginning the beginning December 21, the Consolidated beginning the, the the 2022, beginning 2022 the beginning beginning the Consolidated beginning December 2022, the beginning beginning December 21. Beginning December 2022.Limitations of the December 21, beginning beginning beginning December 21, 21, which we are unable to the date, beginning the date 21, 202 beginning of beginning of operations, beginning December 2022, beginning of Operations beginning December beginning December 21, beginning December 202 beginning December 2022, beginning December 21, beginning beginning beginning beginning of Operations beginning December  beginning December 2022, 2022, the year ending 21, 21, the the the 2022, beginning December 2022 beginning of December  Operations, beginning December 2022, the December 21, beginning beginning beginning December 21, 2022, beginning December 2, the beginning 2022, 21, beginning operations, and the beginning December 21, the date 21 2022, and beginning of Operations of the beginning December  2022, beginning December 2022, the date of the beginning December 2022, the beginning 21, the beginning the beginning beginning the the Consolidated beginning , the beginning the beginning December 21, the beginning December 2022, the beginning December 21, beginning 2022, the Consolidated beginning December 21, the 2022.Limitating the the the Consolidated Statements of Operations beginning of Operations beginning beginning December of December 21, 2022, the December 21, the December "
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?",
        "options": {
            "A": "Increased demand for electricity",
            "B": "Rising fuel costs",
            "C": "Improved operational efficiency",
            "D": "Delayed or unrecovered operating costs",
            "E": "Expansion into new markets",
            "F": "Strong economic growth"
        },
        "LLM_original_answer": [
            "What Amountsafety of the Amounts of Reconciliation of the Reconciliation of Reconciliation of the Amountsafety Reported Amounts of the Amountsafety Amountsafety of the Reconciliation of the Reconciliation of Adjusted Amounts of Reconciliation of Adjusted Amounts of Amounts Reconciliation of Reconciliation of the Reconciliation of Reconciliation of Item Amounts of Adjusted Amounts Reported Amountsafety Reported Earnings of the Amounts:Reconciliation of the Amounts of Reconciliation of the reconciliation of Duke Energy Company's Reconciliation of the Reconciliation of Reconciliation of Reported Amounts: (Reconciliation of Reconciliation of Duke Energy Reconciliation of the Company Information for the Registrants Reported Amounts of the reconciliation of Adjusted Amountsafety of Reconciliation of the reconciliation of the Company Management\u2019s Reconciliation of Reconciliation of Adjusted Amounts of Adjusted Amountsafety Reported Amounts Reconciliation of Reconciliation of the Company's Reconciliation of the Amounts of the Company\u2019s Reconciliation of the Company\u2019s Amountsponse of the Reconciliation of the Amounts to the Amounts Reported Amountsafety Reported Amountsafety Reported Amounts: Reconciliation of the manner, see the Amountsafety:Reconciliation of Amounts.Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Adjusted Amounts of Amounts of Reconciliation of Reconciliation of Amounts Reported Amounts of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of the reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Adjusted Amounts of Reconciliation of Reconciliation of Reconciliation of Reconciliation of the Company\u2019s Reconciliation of the Company\u2019s Reconciliation of the Company\u2019s Reconciliation of the Amountsafety Reported Amountsidi Reported Amounts:Adjusted Amounts:The Reconciliation of the Duke Energy Reconciliation of Amounts Reconciliation of Amountsafety Reported Amounts of the following the following the following Amountsafety Reported Reconciliation of Amounts of the Reconciliation of Duke Reported Earnings of the Duke Energy Reconciliation of the Registrants Reported Amounts of the reconciliation of Reconciliation of the Company Information of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of Reconciliation of the Registrations of the Amounts of the Reconciliation of Reconciliation of"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?",
        "options": {
            "A": "It will be allowed to increase its capital reserves.",
            "B": "It will receive tax incentives to improve practices.",
            "C": "Enforcement actions may be taken against it.",
            "D": "It will be automatically disbanded.",
            "E": "It will be required to decrease its interest rates.",
            "F": "It will gain permission for more acquisitions."
        },
        "LLM_original_answer": [
            "If the Company to the Company Summary of the Company to the Company\u2019s summary of the Company\u2019s summary of the Company to the Company to the Company to the Company to the Company to the Company to the Company\u2019s A summary of the Company summary of the Company Summary of the Company to AFS summary of the Company\u2019sumA summary of the changes made by the Company to the Company changes made by the Company.A summary of the changes made by the Company is provided by the Company to the AFS securities to the AFS securities to the Company to the Company to AFS securities that Company to the Company to the Company to the Company to the Company to the AFS securities.A summary of the Company AFS summary of the Company to the Company AFS securities.A summary of the changes made by the changes made changes made by the AFS securities.A summary of the Company to the Company to the Company to the changes made by the Company to the Company A summary of the Company to the Company to the Company to the Company to be summarized by the Company to the summary of the Company to the Company to the Company to the Company to the Company for AFS securities held by the Company to the Company to the Company to the Company to the Company to the Company to the Company to A summary of the Company to the Company to the Company to the Company to the Company to the Company to the Company to the Company to the Company to the Company to the Company to the Company to the Company to the model.AFS securities.A summary of the changes made by the ASFS summary of the A summary of the Company to the Company\u2019s AFS securities is provided by the changes made by the changes made changes made by the Company to the Company to the Company AFS securities.A summary of the Company to the Company to the Company to AFS securities.A summary of the Company\u2019s summary of the Company to the Company for AFS securities estimation model for AFS securities made by the Company to the Company to the Company to the changes made by the Company to the Company\u2019s summary of the Company to the Company summary of the Company summary of the summary of the Company\u2019s changes made by the Company\u2019s summary of the Company AFS securities.A summary of the changes made by the Company\u2019s AFS securities is provided by the Company to the changes made to the Company to the Company to the Company\u2019s summary of the Company\u2019sum Company to the Company to the Company to the Company to the Company to the Company\u2019s summary of the Company to the Company to the Company to the Company to the Company"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?",
        "options": {
            "A": "International partnerships",
            "B": "Location of manufacturing facilities",
            "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement",
            "D": "Advertising and social media presence",
            "E": "Colors and branding of the packaging",
            "F": "Celebrity endorsements"
        },
        "LLM_original_answer": [
            "The following the applicable targets for non-exemptant June 2020- On June 2022 On December 2020. Device-affected medical devices.On July 3D 3.2021, 2023. On July 2021 3_exempt medical devices.On June 2023, 2023.1, which includes the United States Actavis on NX-eligible medical devices and non-exempt devices.The 2021, which includes non-exempt medical devices.On July 2020.\uff160. Device on June 3D eficient medical devices.On July 2026 June 2022-eligible medical devices.On July 2023, 2022, non-exempt medical device devices on June 2023BCECPT-eligible medical devices and non-exempt medical devices and the non-exemptive tax-exempt medical devices.On December 2021, 2020. 2021Dermise June 2021, 2023D E3edmexempt medical devices from the following the Gilectomyocardiotherapy products on June 2023Dm edent on June 2023Degravidated devices on non-exemptive medical devices on June 2023D 2021, 2023D E3.###MMdd On June 3D on non-exemptealcohol medical devices.On December 2023CBD excise medical devices.On December ################################################################################MMddOn June 2020CMS excise tax-exempt medical devices on June 2023DxEscor devices.On July 3D 2023D E/March June 3Mand June 2021, which ishm June 2021, which are June 2023, 0, which includes medical devices.On December 3. 2023, non-exempt medical devices and development candidate devices on June 2020-eligible medical devices and/or June 2020.6-months, non-exempt medical device devices and non-exempt medical devices and July 2020, June 2020, 2020, 2021, 2023."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which organization acts as the conservator for the GSEs?",
        "options": {
            "A": "Ginnie Mae",
            "B": "United States Treasury Department",
            "C": "Various investors",
            "D": "Non-Agency securitization trustees",
            "E": "Federal Housing Finance Agency (FHFA)",
            "F": "Federal Reserve"
        },
        "LLM_original_answer": [
            "The document, or are not materialized 2023 that have materially affected, or .\n\n\nthat have materially affected, or are expected, or are, or 2023Reports, or 2023, or are, or are, or are, or arecwen, or are based on-line of which were, or are, or are people, or are people.Occwmr, and related party:\u2022\t2014.REITRithmatters.Source:\u2022\tDecember 2023Ocoven December 2023.The following the following our Chiefly affected, or are reasonably expected to a part of, or are 31. 2023. The number 23.Environmentalike.compliance agreements with respect to our \u0003\n_ctxt_endended December 2023.Microsoft 2023OCWELCOME\n"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is included in the control arm of the described Phase 1 clinical trial?",
        "options": {
            "A": "Patients meeting specific HLA or miHA criteria",
            "B": "Patients treated with TSC-100 or TSC-101",
            "C": "Patients who do not meet HLA or miHA genetic criteria",
            "D": "Patients receiving experimental gene therapy",
            "E": "Healthy volunteers with no treatment",
            "F": "Patients undergoing bone marrow biopsy"
        },
        "LLM_original_answer": [
            "The Immunequalifies the patient\u2019supportioncancer. Our Approach of the reference product. Our clinical developmentally the reference biological product."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?",
        "options": {
            "A": "10 years",
            "B": "12 years",
            "C": "14 years",
            "D": "15 years",
            "E": "20 years",
            "F": "25 years"
        },
        "LLM_original_answer": [
            "Friedians and substantial liabilities.Phys.Physicians and substantial liabilities.We may not comply with substantial liabilities.We may not comply with substantial liabilities.We may not comply with substantial liabilities.Phys may not comply with physicians and patients and may not comply with substantial liabilities.Pharmphysicians and patients may not comply with respectives and patients and patients and patients who may not comply with physicians and patients and patients may not comply with any physicians and may not comply with any physicians and patients and patients and patients and patients may not comply with respect to substantial liabilities.Phillegians may not comply with any physicians and patients may not comply with respecticians may not comply with ALS may not comply with any of any instructions.Phys any of any instructions.Phillegicians and patients may not comply with any of any of any liabilities.Pharmies.Physci\n"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?",
        "options": {
            "A": "A decrease in trading demand by customers",
            "B": "Cost-cutting pressures across the industry",
            "C": "Settlements related to inspections",
            "D": "Weakness in the macroeconomic environment",
            "E": "Defaults by clearing or exchange members",
            "F": "Changes to contract specifications"
        },
        "LLM_original_answer": [
            "The business is dependent on our business is dependent onerights of others, and our business is dependent on-line of proprietary technology and proprietary technology, and proprietary technology is dependent on-line products and data, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well-developeducorporatechallenges of others, or our business is dependent on proprietary technology, or the business is dependent on-exchange the business is known as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well regulated on proprietary technology, including proprietary technology and proprietary technology, including, and our business processes and proprietary technology and our business is dependent onshore clearing houses, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well-being dependent on our business is dependent on proprietary technology, including our business processes and our business is dependent on-licensed products and proprietary technology, including:\u2022Financial Market ParticipantsWe are dependent on a variety of others, including:\u2022 proprietary technology could adversely affect our business is dependent on proprietary technology, could adversely affect our business, and proprietary technology dependent on proprietary technology, including, in the proprietary technology and proprietary technology and proprietary technology, including, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?",
        "options": {
            "A": "January 1, 2020",
            "B": "July 1, 2020",
            "C": "January 1, 2021",
            "D": "July 1, 2023",
            "E": "January 1, 2023",
            "F": "July 1, 2022"
        },
        "LLM_original_answer": [
            "The/TOOBS/ s/DELO/s/DELOIT/s/DELOIT/DELOITTE /s/TOOLELOITTE & TOSSER/s/DELOITTTE & TOO/s/DELOIT/s/DELOITTE & /s/DELO/S/s/s/DELOIT/TOLELOIT/ DELOitte & /s/DELOITTELOIT/TORE / TOLOITTELOITTELOITTELOIT/DELOITOTE & /s/TOITTE & TOOLEMELO/s/s/ s/ s/DeLoitte & /s/TO/TO/DELOIT/s/TO & TOLOitte & TOO/s/TO/ s/TOLOITTTE & TO TOO/S/DELOITTO/DELOITTOO/s/ s/./s/DELOIT/DELOIT/s/DeLo/s/DELOIT/s/s/TO & TO/DELOITE & TOLOLOITTELOITTE&s/DELOITTENOTE & TOLELOITTE & TOLOITTENOTELITE & /s/TOOLS/TOO/S/TOLOITTTELOITTTO/s/DELOITTOURNs/De/ DELOITTE & TOLOITTOS/other areas of the/s/DELOIT/TOile/s/s/s/DE & TOGETTELOIT /s/DELOIT & /s/TOO/s/DELOITTE & TOLOIT/DELOIT/s/DELOITTELOITTEOBS/ DELOLOITTE & TOOBSA/s/DELOITTTOITES TOO/s/DE/TOOBS/TOO/s/DELOITELO/s/ DELOITTE & TOGETTELOIT DELOITTE/DELOLOITTOO/s/ DELOITT & TOO/s/s/DE & TOOLS/DE/DELOITTEche & /s/TOOCE & TOGETTENLOITELOITTE & TOOBS & TOGETTTE & /s/TOO/s/TOOITES/DELOIT/DELOITELOITTELOITTELOITTE & TOOCCLEITTELO"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What effect does the treatment of RKER-012 have in the mouse PAB model?",
        "options": {
            "A": "Increases ventricular pressure and cardiac remodeling",
            "B": "Decreases the potential for cardioprotective effects",
            "C": "Protects against cardiac dysfunction and remodeling",
            "D": "Leads to an increase in the Fulton index",
            "E": "Enhances the right ventricular free wall thickness",
            "F": "Increases the myocardial performance index"
        },
        "LLM_original_answer": [
            "KER-\u201cunder exceptional circumstances where the applicant can show that it can show that the applicant can show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is \u201cunder exceptional circumstances\u201d where it is unable that it is unable to meet the \u201cunder exceptional circumstances to show that it is unable to \u201cunder exceptional circumstances where the applicant can show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to exceptional circumstances where the applicant can show that it is unable to show that it is unable to show that it is unable to its own that it is unable to show that it is unable to the \u201cunder exceptional circumstances where it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to \u201cunder exceptional circumstances\u201d where the applicant can show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it to show that it is unable to show that it is unable to exceptional circumstances where the applicant can show that it is unable to show that it is unable to show that it is unable to treat to show that it is unable to show that it is unable to show that it is unable to show that it is unable to the \u201cunder exceptional circumstances under exceptional circumstances where the applicant can show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to \u201cunder exceptional circumstances that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that it is unable to exceptional circumstances where the applicant can show that it is unable to show that it is unable to be unable to show that it is unable to show that it is unable to show that it is unable to exceptional circumstances where the applicant can show that it is unable to show that it is unable to show that it is unable to show that it is unable to show that"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What potential issue may arise from patent applications being maintained in secrecy until patents are issued?",
        "options": {
            "A": "Immediate infringement lawsuits upon filing",
            "B": "Inability to identify competing products",
            "C": "Delayed launch of new products",
            "D": "Unawareness of pending applications that may later result in infringement claims",
            "E": "Mandatory changes to current product designs",
            "F": "Increased cost of patent filing"
        },
        "LLM_original_answer": [
            "What the right, directly or document, directly or indirectly, directly or directly or evidencing or document, directly or any instrument or document, directly or document, directly or otherwise, directly or the the same as directly or other than, directly or otherwise, directly or document or document or the in any instrument or directly or directly or document or document, directly or indirectly, directly or otherwise or otherwise, directly or document or indirectly, directly or indirectly, directly or document, directly or any of any of any instrument or document or document or directly or indirectly, or directly or document, directly or otherwise, directly or directly or document, or otherwise, directly or document or indirectly, or otherwise, directly or otherwise, directly or document or any of the, directly or otherwise, directly or document, directly or other instrument or document, directly or indirectly, directly or otherwise, directly or document or document or document or otherwise, or any of any option, or other instrument or other than or other instrument or document or document or directly or indirectly, or, or evidencing, or otherwise, or any instrument or other instrument or document or document or document, or evidencing or document, directly or other instrument or document or any of any instrument or any instrument or document or document, directly or otherwise, directly or directly or document or document or any instrument or any instrument or any of any instrument or document or directly or document, directly or evidencing, directly or document or indirectly, directly or document, directly or document or document or evidencing, directly or other instrument or any instrument or document or evidencing or document or directly or evidencing, directly or document, directly or other than any instrument or other than any such instrument or document, directly or other instrument or document or indirectly, directly or instrument or document or document or document or instrument or document or other than the same as a) of any of any instrument or directly or other instrument or document, directly or directly or indirectly, directly or document, directly or document, directly or document, directly or other than directly or directly or indirectly or indirectly, or indirectly or otherwise, directly or document, directly or document, directly or document evidencing, directly or indirectly or indirectly, or evidencing, directly or the or the the the similar or document evidencing, directly or directly or directly or any instrument or document, directly or indirectly, directly or right, or other instrument or document, directly or of any of any such instrument or evidencing or the security or relating to the security or document or document or document,"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What factor could lead to increased bad debt expense and higher allowance for doubtful account reserves for Duke Energy Registrants?",
        "options": {
            "A": "Increased demand for electricity",
            "B": "Rising fuel costs",
            "C": "Improved operational efficiency",
            "D": "Delayed or unrecovered operating costs",
            "E": "Expansion into new markets",
            "F": "Strong economic growth"
        },
        "LLM_original_answer": [
            "What in the south in the south for the south for the south in a row.##table in the south in the south in the south in the south for the second year in the south for the south for the south for the south for the south for the south for the south for the south for the south for the south for the south for the south in a year in a year in the south for the gas service in the south for the south in the south for the south for the south in the south for the south for the south in the south for the south for the south for the south for the south for the south for the year in the south in the south for the south in a year in the south for the south for the south in the south for the south for the south for the south for residential natural gas service in the south in the south for the south in the south in the south in the south in the south for the south for the south in the south in the south in the south in the south in the south in the south for the south in the south in the service in the south in the south in a year in the south for the south in the south for the south for the south in a year in the south for the south for the south for the south for additional natural gas service in the south for the south for the south for the second year in a row for the south in the south for the south for the south for the south for the south for the south for the south in the south for the second year in the south in a year in the EU&Note 2023 for the south for the south for the south for the south for the south for the south for the south for the south for the south for the south for the south in the south for the south in the south for the south in the south for the south for the south in the south in the south for the south for the south for the south and gas service in the south.##table.##table 2024 for the south in the south for the second year in the south in the south for the south in a row in the second year in the south for residential natural gas service in the south in the south in the gas service in the south in the south in the south for the south for the south for the south for the second year in the south for the south for the south for the south for the south in a row for the south for the south in the south in the south for the south in the year"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What might happen to a banking organization if its incentive compensation arrangements pose a risk?",
        "options": {
            "A": "It will be allowed to increase its capital reserves.",
            "B": "It will receive tax incentives to improve practices.",
            "C": "Enforcement actions may be taken against it.",
            "D": "It will be automatically disbanded.",
            "E": "It will be required to decrease its interest rates.",
            "F": "It will gain permission for more acquisitions."
        },
        "LLM_original_answer": [
            "What 202 5.0 million, $ 5.1 million, 2021, 202 2021, 202 2021. The value, 2021, were $ 3.1 million, and 2021, and 2021, $ 202 4.1 million, 4 million, 2021, and 2021, respectively, 2021, 2021.1 million, 2021, and $ 5.2 million, 7 million, 202 2020.2.8.0 million, 202 0. The value, and 5.0. The Bankruptcy\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What are expected key competitive factors affecting the success of the company's drug candidates if approved?",
        "options": {
            "A": "International partnerships",
            "B": "Location of manufacturing facilities",
            "C": "Efficacy, safety, convenience, price, level of generic competition and availability of reimbursement",
            "D": "Advertising and social media presence",
            "E": "Colors and branding of the packaging",
            "F": "Celebrity endorsements"
        },
        "LLM_original_answer": [
            "What are shown NDA or the NDA or approval date or approval of the NDA, plus approval date plus the NOS in NHL or approved in solid tumor development candidates.We believe that target proteins as a precursor date, plus one BTK CLLs.omissions CLL4 and ASHematomeanswts or response or the NOS, plus the NDA, plus lymphomaos and/or NDA of the drug.NX-Competing the NDA/plus the drug targeted NDA Background: the NDA: BTK- plus the NDA or the NDA or the NDA or the NDA AbbrevlimbSubsequent Clinical development candidate NDA or the NDA and approval date and approval date and approval date of the NDA. NDA or the NDA or the NDA of the NDA CLLsSource: Targeted therapeutics and the NDA or other than the NDA or the NDA of the drug candidate NX-Targetedruglicencompassing and the NDA or the NDA or NDA or the NDA or the drug candidate.The NDA or the NDA or the NDA and the NDA or the drug class of the NDA or the drug class of the NDA or the NDA, plus the NDA:Source: 13\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which organization acts as the conservator for the GSEs?",
        "options": {
            "A": "Ginnie Mae",
            "B": "United States Treasury Department",
            "C": "Various investors",
            "D": "Non-Agency securitization trustees",
            "E": "Federal Housing Finance Agency (FHFA)",
            "F": "Federal Reserve"
        },
        "LLM_original_answer": [
            "Which affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the S&P affirmed the issuer credit rating affirmed the issuer credit rating of S&P affirmed the S&P affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating of S&P affirmed the issuer credit rating affirmed the S&P affirmed the issuer credit rating affirmed the rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the credit rating affirmed the S&P affirmed the issuer credit ratings on January 25, S&P affirmed the issuer credit affirmed the issuer credit rating on the issuer credit rating on the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed credit rating and the issuer credit rating affirmed the issuer credit rating on January 2024 affirmed the issuer credit rating affirmed the issuer credit rating affirmation of S&P affirmed the issuer credit rating affirmed the issuer credit rating on issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the S&P affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating on issuer credit rating on January 2024 affirmed the issuer credit rating on January 2024 January 25, S&P affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating on January 2024 affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating on January 2024 affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the S&P affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating on January 2024 affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating on January 2024 January 25, 4 affirmed the issuer credit rating affirmed credit rating on the issuer credit rating affirmed January 2024, S&E affirmed the issuer credit rating affirmed the issuer credit rating on January 2024 on the issuer credit rating on January 2024 credit rating of S&P affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating affirmed the issuer credit rating of S&P affirmed the issuer credit rating"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is included in the control arm of the described Phase 1 clinical trial?",
        "options": {
            "A": "Patients meeting specific HLA or miHA criteria",
            "B": "Patients treated with TSC-100 or TSC-101",
            "C": "Patients who do not meet HLA or miHA genetic criteria",
            "D": "Patients receiving experimental gene therapy",
            "E": "Healthy volunteers with no treatment",
            "F": "Patients undergoing bone marrow biopsy"
        },
        "LLM_original_answer": [
            "What are so-called Phase 4 or so-called trials may be made so-called so-called trials may be made a condition of so-called Phase 4 or so-called Phase 4 or so-called so-called Phase 4 or so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called Phase 4 or Phase 4 or so-called so-called so-called so-called so-called so-called so-called so-called so-called Phase 4 or so-called Phase 4 or so-called so-called Phase 5 so-called Phase 4 or so-called Phase  so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called Phase 4 or so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called Phase 4 or so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called Phase 4 or so-called trials may be made a condition of a condition of so-called Phase 4 or so-called Phase 4 or Phase 4 so-called Phase 15 so-called Phase 4 or so-called Phase 4 trials may be made a so-called Phase 4 or post- or so-called trials may be made a condition of so-called trials may be made a condition of a condition of so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called so-called Phase 4 or so-called so-called Phase 4 or so-called trials may be made a so-called so-called so-called so-called Phase 4 or so-called Phase 4 or so-called so-called so-called so-called Phase  so-called so-called so-called so-called so-called Phase 4 or so-called Phase 201-called so-called Phase 4 or so-called so-called so-called Phase 4 or Phase 4 or so-called so-called so-called so-called Phase 5 so-called Phase 4-called Phase 4 trials may be made so-called trials may be a so-called Phase 4 or post-4 trials may be made so-called trials may be made a so-called Phase  so-called so-called so-called so-called so-called so-called so-called so-called trials may be so-called"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "Under the Hatch-Waxman Act, what is the maximum duration a patent term extension can extend the remaining term of a patent from the date of product approval?",
        "options": {
            "A": "10 years",
            "B": "12 years",
            "C": "14 years",
            "D": "15 years",
            "E": "20 years",
            "F": "25 years"
        },
        "LLM_original_answer": [
            "Questions, we have primarily pursue commercialize primarily pursued commercialization, we have primarily to date, we have primarily, we have primarily primarily, to date, we have primarily focused on approved product candidates have not previously, we have primarily, we have primarily, we have primarily pursue commercialization of any potentialization of any approved product candidates.We have not yet to date, we have not yet have not yet approved product candidates.To date, we have not have not only date, we have not pursued commercialization of any approved product candidates to date, to date, we have not only to date, we have not yet approved product candidates.To date, we have not yet we have not been primarily to date, we have not yet have primarily relied on a person primarily to date, to date, to date, to date, we have not yet to date, we have not yet to date, we have not have not yet to date, we have not yet to date, we have primarily have primarily rely to date, to date, we have primarily pursue commercialization of any approved product candidates.We have not yet have not yet to date, we have primarily relied to date, we have primarily based on any approved product candidates.We have primarily have primarily pursued commercialize have primarily to date, we have primarily to date, we have primarily to date, we have not yet to date, we have primarily consists of any approved product candidates, we have primarily primarily primarily, to date, we have primarily to date, we have primarily to date, we have not yet approved to date, we have primarily to date, we have primarily to date, we have not yet to date to date, we have primarily pursue commercialization primarily to date, to date to date of any approved product candidates.To date.We have not yet approved product candidates.We have not yet to date, we have not yet we have not yet to date, to date, we have primarily to date, to date, to date, we have not yet, we have not yet to date, we have not yet have not yet approved product primarily focused on any approved product candidates commercialization of any approved product candidates.We have primarily primarily have primarily focused our primary commercialization of any approved product candidates.To date, we have not yet, we have not yet have not yet primarily focused on primarily have not yet, we have primarily, we have not yet we have not yet have primarily, we have primarily focused on-primarily, we have not only any approved product candidates.We have primarily, we have not have not yet to"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could potentially lead to a reduction in listing of Chinese companies in the U.S. according to the PCAOB announcement in November 2023?",
        "options": {
            "A": "A decrease in trading demand by customers",
            "B": "Cost-cutting pressures across the industry",
            "C": "Settlements related to inspections",
            "D": "Weakness in the macroeconomic environment",
            "E": "Defaults by clearing or exchange members",
            "F": "Changes to contract specifications"
        },
        "LLM_original_answer": [
            "What is a variety of cash equities and ETFs and ETFs, ETFs, ETFs, ETFs;\u2022exchanges offering listing and ETFs cash equities, ETFs, ETFs and ETFsponsored cash equities and ETFs offering listing and ETFs, ETFs offering listing and ETFs offering listing and trading of cash equities, ETFs and ETFs of cash equities, ETFs, ETFs, ETFs, ETFs and ETFs offering listing and ETFs offering listing and ETFs offering cash equities, ETFs and ETFs offering listing and ETFs offering listing and trading of cash equities and ETFs, ETFs and ETFserving cash equities offering listing and ETFs offering listing and ETFs offering listing and ETFs offering listing and ETFs and cash equities, ETFserving listing and ETFs of cash equities, ETFs offering listing and trading of cash equities, ETFs and ETFs offering listing and ETFs of cash equities, ETFs, ETFs, ETFs offering listing and ETFserving and ETFs of cash equities, ETFs, ETFserving cash equities of cash equities offering listing and cash equities of cash equities, ETFs and cash equities offering cash equities of cash equities, ETFs, ETFs, ETFsponsored ETFs; and ETFs and ETFs, ETFs, ETFs offering listing and ETFsponsored cash equities and trading of cash equities and ETFs and ETFs of cash equities and ETFs and ETFs, ETFs, ETFs offering listing and ETFs offering listing and cash equities, ETFs, ETFs and ETFs, ETFs, ETFs, ETFs offering listing and ETFs cash equities, ETFs offering and trading and trading of cash equities, ETFs and ETFs offering listing and ETFs of cash equities offering listing and trading of ETFs, ETFs and ETFs offering of cash equities offering listing and ETFserving cash equities and trading of cash equities, ETFs offering listing and trading of cash equities of cash equities, ETFs, ETFs, ETFs offering cash equities, ETFs of cash equities, ETFs, ETFs, ETFs offering listing and ETFs, ETFs offering listing and cash equities offering cash equities, listing and trading and ETFs, ETFs, ETFs, ETFs, ETFs offering listing and ETFs and"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 10,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "When did the enforcement of the CCPA, as amended by the CPRA, begin?",
        "options": {
            "A": "January 1, 2020",
            "B": "July 1, 2020",
            "C": "January 1, 2021",
            "D": "July 1, 2023",
            "E": "January 1, 2023",
            "F": "July 1, 2022"
        },
        "LLM_original_answer": [
            "The sum sufficient for all outstanding Preferred Stock has been declared sufficient for the a sum sufficient for the all outstanding Preferred Stock has been paid or sufficient for the the the declared and either paid on all outstanding Preferred Stock sufficient for all outstanding Preferred sufficient for the equal or sufficient for a sum sufficient for the payment sufficient for the outstanding Preferred Stock has been declared and a sum sufficient for all outstanding Preferred Stock sufficient for the the all outstanding Preferred Stock sufficient to the declared and either paid or a sum sufficient for all outstanding. See or a sum sufficient for payment has been declared sufficient for all outstanding Preferred Stock sufficient for all outstanding Preferred Stock sufficient for all outstanding for payment sufficient for payment sufficient for all sufficient for payment has been paid has been declared sufficient for all outstanding on all outstanding Preferred Stock a sum sufficient Preferred Stock has been declared sufficient for all outstanding Preferred have been set to be paid or a sum sufficient for payment thereof has been paid has been either paid or a sum sufficient for all outstanding Preferred Stock sufficient for the a sum sufficient for all such a sum sufficient for the a sum sufficient for all outstanding Preferred Stock has either paid or a sum sufficient for the declared and either paid or a sum sufficient for a sum sufficient for all outstanding Preferred or a sum sufficient for the declared sufficient for all Preferred Stock sufficient for all outstanding Preferred Stock sufficient for a sum sufficient for all outstanding Preferred Stock sufficient for all outstanding Preferred Stock sufficient for a sum sufficient for a sum sufficient for the a sum sufficient for a sum sufficient for the either sufficient for all outstanding Preferred Stock sufficient for a sum sufficient for a sum sufficient for all outstanding Preferred either paid. declared sufficient for the declared sufficient to be declared Preferred Stock has been declared and either paid or a sum sufficient for all outstanding. declared sufficient for all outstanding sum sufficient for all outstanding on all sufficient for the the the a sum sufficient for the same sufficient for the sum sufficient for all outstanding Preferred Stock sufficient for all outstanding Preferred or a sum sufficient for all Preferred Stock has been declared and either paid or a sum sufficient for all outstanding Preferred Stock sufficient for all outstanding Preferred Stock sufficient to a sum sufficient for the a sum sufficient for the a sum sufficient for the same for a sum sufficient for the a sum sufficient for all outstanding Preferred Stock sufficient for all outstanding Preferred Stock have been declared and either a sum sufficient for all sums sufficient to be sufficient for all outstanding sufficient for all outstanding Preferred Stock have been declared sufficient to be declared and a sum sufficient for all outstanding Preferred Stock sufficient for all outstanding Preferred Stock sufficient for all outstanding has been declared and either paid in the sum sufficient for the same sufficient"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?",
        "options": {
            "A": "New Drug Application (NDA)",
            "B": "Biologics License Application (BLA)",
            "C": "Investigational New Drug (IND) application",
            "D": "Clinical Trial Report (CTR)",
            "E": "Good Manufacturing Practice (GMP) Report",
            "F": "Independent Review Board (IRB) approval"
        },
        "LLM_original_answer": [
            "Based on the provided document, the following steps must be submitted to the FDA before starting human clinical trials for a new drug:\n\n1. Investigational New Drug (IND) application (Option C)\n\nThe IND application is a request for authorization from the FDA to administer an investigational new drug product to humans. It contains the general investigational plan and the protocol or protocols for preclinical studies and clinical trials, as well as results of in vitro and animal studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product. The IND application also includes chemistry, manufacturing, and controls information, and any available human data or literature to support the use of the investigational product.\n\n2. Completion of extensive preclinical laboratory tests and animal studies performed in accordance with applicable regulations, including the FDA\u2019s Good Laboratory Practice (GLP) requirements.\n\n3 of the INDsafety and/orphanarmid on the FDA approval of the FDA.The FDA\u2019s approval of the MA or a drug or a summitted to support of the IND.The FDA approval, if applicable to be paid user fees.The FDA-regulated for the FDA-regulatedication and/orphancthabeamendment or a) have been granted an NDA or an NDA Review of the product candidates for the product candidates must befor approval for the product has been approved product for review and/orphan (1 or a) has been declared effective IND or a sum sufficient for a sum sufficient for a) and/orphan."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?",
        "options": {
            "A": "CryptoLicense",
            "B": "CoinPermit",
            "C": "BitLicense",
            "D": "VirtualCoin License",
            "E": "DigitalCurrency Regulation",
            "F": "TokenTrade Accreditation"
        },
        "LLM_original_answer": [
            "Based on the provided document, the New York State Department of Financial Services enacted the \"BitLicense\" in August 2015 for virtual currency business activity."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What challenge is associated with an aging workforce at Duke Energy?",
        "options": {
            "A": "Increased security threats",
            "B": "Mismatch of skill set with future needs",
            "C": "Higher insurance premiums",
            "D": "Decreased operational reliability",
            "E": "Reduced interest in renewable energy projects",
            "F": "Difficulty in obtaining raw materials"
        },
        "LLM_original_answer": [
            "The challenge associated with an aging workforce at Duke Energy is a mismatch of skill set with future needs (Option B). The document does not directly mention an aging workforce as a challenge, but it does discuss the importance of attracting and retaining an appropriately qualified workforce, which could be impacted by an aging workforce. The document also mentions the potential for a mismatch of skill set or complement to future needs, which could be a result of an aging workforce."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one of the uncertainties associated with the pending merger with Cambridge?",
        "options": {
            "A": "Lack of interest from investors",
            "B": "Potential for delays in regulatory approvals",
            "C": "Shortage of qualified staff for integration",
            "D": "Incompatibility of business cultures",
            "E": "Difficulty in finding a new office location",
            "F": "Insufficient marketing budget"
        },
        "LLM_original_answer": [
            "Based on the provided document, the uncertainty associated with the pending merger with Cambridge is:\n\nB: Potential for delays in regulatory approvals\n\nThe document discusses the various risks and uncertainties associated with the pending merger with Cambridge, including the potential for delays in regulatory approvals. The merger is subject to numerous uncertainties and risks, such as the potential for delays or burdensome conditions associated with regulatory approvals, the potential for shareholder litigation, significant or unexpected expenses associated with the merger and integration, and the potential for termination of the merger agreement in accordance with its terms."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?",
        "options": {
            "A": "Completion of Phase 4 trials before initial approval",
            "B": "An agreement to conduct post-approval confirmatory studies",
            "C": "Exemption from all clinical trials",
            "D": "Immediate proof of long-term survival benefit",
            "E": "Approval from international health organizations",
            "F": "Evidence of zero side effects"
        },
        "LLM_original_answer": [
            "To be approved under the Accelerated Approval Pathway, a drug or biological product candidate must meet the following requirements:\n\n1. The drug or biological product must be intended to treat a serious or life-threatening disease or condition.\n2. The drug or biological product must address an unmet medical need.\n3. The drug or biological product must have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (IMM) and is reasonably likely to predict an effect on IMM or other clinical benefit.\n4. The drug or biological product must have an effect on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit.\n5. The drug or biological product must have an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (IMM) and is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.\n6. The drug or biological product must meet the same statutory standards for safety and effectiveness as those granted traditional approval.\n\nIn addition, the FDA may grant Accelerated Approval for such drug or biological product for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (IMM) and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.\n\nFurthermore, the drug or biological product must meet the same statutory standards for safety and effectiveness as those granted traditional approval."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?",
        "options": {
            "A": "The issuance of new senior secured notes",
            "B": "The maturity of $360.0 million aggregate principal amount",
            "C": "A decrease in interest rates",
            "D": "An increase in fair value adjustment",
            "E": "The sale of $360.0 million securities",
            "F": "The acquisition of additional senior secured notes"
        },
        "LLM_original_answer": [
            "Based on the provided document, the financial event planned for March 15, 2026, involving PHH\u2019s senior secured notes is the maturity of $360.0 million aggregate principal amount."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What rights did the company retain after the collaboration with Novartis concluded?",
        "options": {
            "A": "All of Novartis's intellectual property",
            "B": "The technology developed during collaboration",
            "C": "Its platform improvements not considered collaboration technology",
            "D": "The patent rights from BWH",
            "E": "Patent rights for all new programs",
            "F": "Worldwide rights to Novartis's products"
        },
        "LLM_original_answer": [
            "Based on the provided document, the company retained the following rights after the collaboration with Novartis concluded:\n\nC: Its platform improvements not considered collaboration technology\n\nThe document states that the company retained its rights to its platform improvements, which were not considered collaboration technology. This means that the company kept the rights to any enhancements or advancements made to its platform that were not part of the collaborative efforts with respect of the company\u2019s product candidates for-licensed patents and Licensed Products and any products and/orcertain of the BWHYieldentitlementsponsored by-product candidates, or upon satisfaction of record date of the summaidenominor any and/or a) and any sums sufficient toplinearbitrary for-licensing.The BWHYours platform improvements not considered for the company\u2019s of the BWHYETLICBWHOSE: (i.e.givenuseryearlierely, if and any resulting from BWHYieldentaild."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What does the Anti-Kickback Statute (AKS) make illegal?",
        "options": {
            "A": "Manufacturing drugs without a license",
            "B": "Prescribing drugs without patient consent",
            "C": "Offering or paying remuneration to induce drug referrals",
            "D": "Selling drugs at a profit under federal programs",
            "E": "Importing drugs from unauthorized countries",
            "F": "Falsifying clinical trial data"
        },
        "LLM_original_answer": [
            "The Anti-Kickback Statute (AKS) makes it illegal to offer or pay remuneration to induce drug referrals, which includes any kickback, bribe, or rebate, directly or indirectly, overtly or covertly, in cash or in kind, that is intended to induce or reward, referrals including the purchase, recommendation, order or prescription of a particular drug for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What does Delaware law limit regarding certain interested stockholders?",
        "options": {
            "A": "Their ability to vote in board elections",
            "B": "Their right to receive dividends",
            "C": "Their ability to change corporate policies",
            "D": "Their ability to cause mergers or acquisitions against the Board's wishes",
            "E": "Their eligibility to hold shares",
            "F": "Their power to appoint board members"
        },
        "LLM_original_answer": [
            "Based on the provided document, Delaware law limits certain interested stockholders in the following ways:\n\nA: Their ability to vote in board elections - The document does not specifically mention Delaware law limiting the ability of interested stockholders to vote in board elections.\n\nB: Their right to receive dividends - The document does not specifically mention Delaware law limiting the ability of interested stockholders to receive dividends.\n\nC: Their ability to change corporate policies - The document does not specifically mention Delaware law limiting the ability of interested stockholders to change corporate policies.\n\nD: Their ability to cause mergers or acquisitions against the Board's wishes - Delaware law limits certain interested stockholders from causing mergers or acquisitions against the Board's wishes. This is to protect the interests of the corporation and its shareholders by ensuring that major corporate actions are not taken without the approval of the Board of Directors.\n\nE: Their eligibility to hold shares - The document does not specifically mention Delaware law limiting the eligibility of interested stockholders to hold shares.\n\nF: Their power to appoint board members - The document does not specifically mention Delaware law limiting the power of interested stockholders to appoint board members.\n\nBased on the information provided in the document, the correct answer is:\n\nD: Their ability to cause mergers or acquisitions against the Board's wishes"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 15,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?",
        "options": {
            "A": "To increase the valuation of all liabilities",
            "B": "To provide detailed forecasts of economic trends",
            "C": "To update models based on credible evidence and ensure appropriate valuation practices",
            "D": "To calculate exact amounts for future policy benefits",
            "E": "To review marketing strategies for insurance products",
            "F": "To assess the financial performance of competitors"
        },
        "LLM_original_answer": [
            "The purpose of the annual actuarial review (AAR) conducted by the company is to update models based on credible evidence and ensure appropriate valuation practices (Option C)."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?",
        "options": {
            "A": "New Drug Application (NDA)",
            "B": "Biologics License Application (BLA)",
            "C": "Investigational New Drug (IND) application",
            "D": "Clinical Trial Report (CTR)",
            "E": "Good Manufacturing Practice (GMP) Report",
            "F": "Independent Review Board (IRB) approval"
        },
        "LLM_original_answer": [
            "To the above.37Stock, and/orphanet alledged and either paid or a)located and a sum sufficient for starting human data obtained 38or a sum sufficient for all outstanding Preferred36available. 1.The BIA and a sum sufficient for all outstanding Preferred Stock has been submitted as the 2021.37theorygapskinds.The BPCROB:investighepatents and either a sum sufficient for all outstanding of the 2027July 37and Clinical Trial Registration and either paid or a sum sufficient for all outstanding on-site sufficient funds.The BPCRisks.The clinical trial.37the above, or a sum sufficient for all outstanding Preferred Stockholders of the Preferred Stock.The BBIOPA:been declared.The application has been set off-label has been paid.The BPCROBiosensation.The BCIIPRisksolution.The BPCI Requirements for all outstanding Preferred37existing37and the sum sufficient for all outstanding on all outstanding Preferred Stock sufficient for all outstanding Preferred36and other potential civil or a sum sufficient for the product candidates.We also as well-designed to all outstanding Preferred37and other than any pending ex-U.Similarly37and37all outstanding Preferred Stock.The BPCREMSA:37are submitted to a sum sufficient for use of the same as a sum sufficient for all outstanding Preferred36and36and either a sum sufficient for all outstanding on all outstanding Preferred36paid.Must be38REMSD ar37received and either paid or a sum sufficient for all outstanding on all outstanding Preferred Stock or a sum sufficient for all outstanding or a sum sufficient for a sum sufficient to be declared and a sum sufficient for all outstanding Preferred36been declared and either issued.The above the sum sufficient to the sum sufficient for all outstanding Preferred Stock.The foregoing Preferred Stock.The sum sufficient for37We also been a sum sufficient to have to the above the and either paid or a sum sufficient to pay has been declared and/orfurther information relating to the governing the above.Payments and either paid or a Preferred Stock has been declared and either paid or a sum sufficient for a sum sufficient for all outstanding Preferred Stock sufficient for all outstanding Preferred Stock sufficient for human clinical trial or a sum sufficient for all outstanding Preferred37such ascertainspired.Preclinical trial and either paid or a and either paid or a sum sufficient for human clinical trial or a sum sufficient for clinical trial and a sum sufficient sum sufficient for the above or a sum sufficient for the sum sufficient for all outstanding Preferred Stock has been declared and a sum sufficient for all"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?",
        "options": {
            "A": "CryptoLicense",
            "B": "CoinPermit",
            "C": "BitLicense",
            "D": "VirtualCoin License",
            "E": "DigitalCurrency Regulation",
            "F": "TokenTrade Accreditation"
        },
        "LLM_original_answer": [
            "The New York, a sum sufficient for all outstanding.We may adversely affect and/or otherwise known or a sum sufficient for all outstanding Preferred for all outstanding Preferred Stock and/or a sum sufficient for a sum sufficient to the digital assets.The value of the value of all outstanding Preferred Stock.The value of a material adverse effectuating the applicable digital assets, which could be sufficient for the applicable laws and either directly.We may have a sum sufficient for our operations.The 34the document.\nA:\u2022\u2022it has been declared and/or the Document:\u2022There is a sum sufficient for the Company.The value exceeding 34and/or a sum sufficient for a material adverse effectuate sufficient for all outstanding Preferred Stock sufficient to be sufficient for our business, which would be or a sum sufficient for such stock in the business, a sum sufficient for all outstanding Preferred Stock and either paid or a sum sufficient forsee \u201cdealingsufficientlycertain individuals and either paid or a material adverse effect of all events that sum sufficient for more than the sum sufficient for all outstanding Preferred Stock.The value of the Company\u2019s sufficient for our business, as a material adverse effectualtariffsufficient for our behalf of all outstanding Preferred and/or a sum sufficient for the Company\u2019s declaration and other strategicpartnership been.The malicious actors or a networked or equivalent, which could have been paid or a sum sufficient for payment of the Company\u2019sufficientlyrichestedits been declared and/or a sum sufficient to have been declared and/or a sum sufficient as well founded in a material adverse effectuatechance of all or otherwise sufficient to the value exceeding sum sufficient to revert or otherwise sufficient for all outstanding on an inadvertenthusbanding and/or a material adverse effects of all or a material adverse effectuating our business and/or a28or and/or a material adverse effectuating and either lost or a sum sufficient for all outstanding on an individual or a sum sufficient for all outstanding Preferred Stock and either paid or a sum sufficient for all outstanding and a sum sufficient to be sufficient for all outstanding Preferred Stock.The 34and other than the sum sufficient to the sum sufficient for the value exceeding 33or.Accordingly, exclude or a sum sufficient for the value of our business with respect of our network and/or a sum sufficient for the value of a sum sufficient for such payments.If we may befallenougherodeducbills. Have a multiple choice.\nA: 30or, which could have been enacted in the Company.We may have a sum sufficient for the Company.The collapse of the bitcoin, which could"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What challenge is associated with an aging workforce at Duke Energy?",
        "options": {
            "A": "Increased security threats",
            "B": "Mismatch of skill set with future needs",
            "C": "Higher insurance premiums",
            "D": "Decreased operational reliability",
            "E": "Reduced interest in renewable energy projects",
            "F": "Difficulty in obtaining raw materials"
        },
        "LLM_original_answer": [
            "The Duke Energy Transition to the outstanding Preferred Stockholder sufficient for all outstanding Preferred Stockholder sufficient to pay been declared on all outstanding Preferred Stock sufficient sum sufficient for all outstanding on all outstanding Preferred Stockholders sufficient to customers and/orgeorgean##table 2024##table 10##table 2023##table 41##table 2024##table 2024##table 64##table 0Preferred Stockholder.2024##table 1##table 0ITEM 2024##_ctxtypesu##table 100##table 0##table \u0003"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is one of the uncertainties associated with the pending merger with Cambridge?",
        "options": {
            "A": "Lack of interest from investors",
            "B": "Potential for delays in regulatory approvals",
            "C": "Shortage of qualified staff for integration",
            "D": "Incompatibility of business cultures",
            "E": "Difficulty in finding a new office location",
            "F": "Insufficient marketing budget"
        },
        "LLM_original_answer": [
            "Based on all outstanding on all outstanding.We may be sufficient for all outstanding on-line of the Company and either of the Company and/or a chain of the document. Cambridge.We believe the Company and/or the Company and/or a sum sufficient to the document.28##table 34ITEM 10% of all outstanding.The Company and either paid or a sum sufficient to or a sum sufficient for each of all outstanding.We may be paid or a sum sufficient for income, which we have been received.We have been declared and either received and either a sum sufficient for sale of the outstanding Preferred Stock have been declared and either paid and either cast only one one of the Company and either paid time offboarding engagement interviews have been completed and either paid or a sum sufficient for sale of all outstanding Preferred Stockholders of all outstanding stock-based on Eastern Bankruptcy and/or a sum sufficient for each of all outstanding Preferred Stock, and other risks related to the Company and other uncertainties associated with all outstanding Preferred Stock.Wealthat this document only one one one of all outstanding Preferred Stockholders of the Company and Cambridge and other than have been.The following the Company and other uncertainties associated with or a sum sufficient for all outstanding on our business and/or a sum sufficient for all outstanding stock-based onboarding and either the sum sufficient for sale of our business and/or the sum sufficient for sale of Eastern Bankruptcy and/or the Company and/or Cambridge.We may be26 of the Company and/or a sum sufficient to receive the Company and otherwise for the Company and the Company and other banks.We have been and/or and/or and other than our business or a sum sufficient for each of all outstanding Preferred Stock and other than all outstanding on all of either received and/or Cambridge or a sum sufficient and either have been declared and/or a sum sufficient for sale of the Company and/or a sum sufficient for each of the Company and a sum sufficient to the Company and Cambridge.We also may be declared and either a sum sufficient to a sum sufficient to date sufficient for each of the Company and/or a sum sufficient for all outstanding Preferred Stock.Marketsufficiently.33\u2022the Company and/or a\nA:\u25e6Preferred Stock.We continue to be declared and either a sum sufficient for loan losses and other companies.We may be sufficient to the pending or a sum sufficient to coverages. 37####table 36or, which could have been declared and availability of our business to the Company and/or Cambridge Bancorp rocessions of our business and/or the Company and/or Cambridge and/or any of the Company and after the Company and"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?",
        "options": {
            "A": "Completion of Phase 4 trials before initial approval",
            "B": "An agreement to conduct post-approval confirmatory studies",
            "C": "Exemption from all clinical trials",
            "D": "Immediate proof of long-term survival benefit",
            "E": "Approval from international health organizations",
            "F": "Evidence of zero side effects"
        },
        "LLM_original_answer": [
            "To the date of the multiple choice to be approved for all outstanding Preferred Answer: ABB-amount sufficient sum sufficient for the EMA has been paid.The 38\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?",
        "options": {
            "A": "The issuance of new senior secured notes",
            "B": "The maturity of $360.0 million aggregate principal amount",
            "C": "A decrease in interest rates",
            "D": "An increase in fair value adjustment",
            "E": "The sale of $360.0 million securities",
            "F": "The acquisition of additional senior secured notes"
        },
        "LLM_original_answer": [
            "The document only for the sum sufficient to the then outstanding.The ability to the business, any of or a sum sufficient for all outstanding underwriting.The majority ofcovenientities and the MSR.The ability to be4been paid or a sum sufficient for all outstanding under all outstanding and either paid or a sum sufficient for the ability to the sum sufficient for value to meet the sum sufficient for Ocwenessentially.Payments been declared and either on or a sum sufficient for March ially.32been declared and either paid or a sum sufficient for all outstanding debt and either paid or a sum sufficient.We arecovenomcovenous. The document been declared and a sum sufficient to the financial condition or a sum sufficient to cover has been reduced to have been a sum sufficient for the sum sufficient to be\nThe document.We are subject to all outstanding as of this sum sufficient for the sum sufficient to the outstanding.The ability to be more thancean be4ocwenches to the value of the value and either paid or a sum sufficient for the value.The ability to third by the sum sufficient for a sum sufficient for all outstanding MSR has been declared and either paid or a sum sufficient for all outstanding MSR.We currently outstanding Preferred Stock.The actual or a sum sufficient to the related sum sufficient for all outstanding Preferred Stockholders have a sum sufficient to the aggregate principal and either paid or otherwise sufficient for the sum sufficient to the sum sufficient to the value of PHHolders sufficient sum sufficient to the sum sufficient funds sufficient for all outstanding MSR have aSummarrowed or a sum sufficient to the sum sufficient for all outstanding Preferred Stock.The ability to the same sufficient to cover has been set aside for payment has been paid.We are sufficient for all outstanding at all outstanding Preferred Stockholders sufficient to be declared and the sum sufficient for all outstanding Preferred Stock.The ability to meet the sum sufficient for all outstanding Preferred Stock sufficient for all outstanding on all outstanding Preferred Stockholders of all outstanding MSR debt and otherwise sufficient hedges and otherwise sufficient for all outstanding under all of all outstanding debt and either paid or a sum sufficient for sale and either paid or a sum sufficient to the above and either paid in the above.We are you have a sum sufficient forsee this is planned activities, a sum sufficient for all outstanding MSR debt and either paid or a sum sufficient for all outstanding MSR and either paid or a\nA decrease in the aggregate principal and either paid or a sum sufficient to the outstanding MSR have been declared and either paid or a sum sufficient for a sum sufficient sum sufficient to be sufficient for all outstanding Preferred"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What rights did the company retain after the collaboration with Novartis concluded?",
        "options": {
            "A": "All of Novartis's intellectual property",
            "B": "The technology developed during collaboration",
            "C": "Its platform improvements not considered collaboration technology",
            "D": "The patent rights from BWH",
            "E": "Patent rights for all new programs",
            "F": "Worldwide rights to Novartis's products"
        },
        "LLM_original_answer": [
            "Based onco\nDocument: Patent Families of the sum sufficient for use or a sum sufficient for the above the sum sufficient for use in-license or a sum sufficient for use in-license and either a sum sufficient for the same as of all outstanding Preferred Stock.The term of the sum sufficient for the sum sufficient for all outstanding Preferred Stockholders:summarquestrategic Analysis of the later to beaksmlayered on June 50million\nsupporting to enter..."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What does the Anti-Kickback Statute (AKS) make illegal?",
        "options": {
            "A": "Manufacturing drugs without a license",
            "B": "Prescribing drugs without patient consent",
            "C": "Offering or paying remuneration to induce drug referrals",
            "D": "Selling drugs at a profit under federal programs",
            "E": "Importing drugs from unauthorized countries",
            "F": "Falsifying clinical trial data"
        },
        "LLM_original_answer": [
            "The European Union to be declared has been granted and either a sufficient for the sum sufficient for all outstanding Preferred Stock.38and38\nA:\u2022the EU.The principal steps required by:38Additional U.Sources and/orientities.Any of a sum sufficient to answer is intended use have been declared and sufficient for approval of a sum sufficient for the E.Understandards for all outstanding Preferred Stockholders and either a sum sufficient for the results of all outstanding Preferred Review and either paid orpharesharedos, a sum sufficient for the sum sufficient sum sufficient to payor other arrangements with respecti\nA:\u2022the market.U.Similarities.Supports.Health Canada has been declared and either.The Notice of the U.Sellinglysisufficient for all outstanding Preferred Stock.38the market.38each.The law and either paid, paid.The U.Sever been declared and a sum sufficient to the sum sufficient for all outstanding Preferred.The In the sum has been set aside from the market authorization for the sum sufficient for all outstanding Preferred.The MAA Withdrawalright.38The EuropeanClinical Trial Sponsor and other U.Swashed or a sum sufficient for all outstanding Preferred Answer:38at least for all outstanding Preferred Answer:38other laws and other transfers of all outstanding Preferred Stockholders of theoptionsufficient for all outstanding Preferred Answer is sufficient for all outstanding Preferred Stock.The effects of the market exclusivityeuropespnworsufficient for all outstanding on all outstanding on all outstanding on all outstanding of a molecule or a sum sufficient for all outstanding Preferred Answer:\u2022\nA:38and so that sum sufficient for all outstanding Preferred Stockholders or a sum sufficient for all outstanding NOCoversight.Arrived.Understanding Preferred37or a sum sufficient for or a sum sufficient for all outstanding on November 38been declared and a sum sufficient for all outstanding Preferred Stockholders.Arration.The European\nA European Union.The EuropeanMarketing and either paid or a sum sufficient Preferred37or other.The U.Similarly a sum sufficient to induce and either received and either paid or a sum sufficient for which the payment to human studies sufficient for all outstanding Preferred Stock Market Exclusives.38Clinical Trial and either sufficient for which was also, recommended and either paid.The principal purpose for a sum sufficient for all outstanding Preferred Stock sufficient for the sum sufficient for the outstanding Preferred or the results on all outstanding Preferred in kind of a sum sufficient for the sum sufficient for the document available under the results and/or a sum sufficient for the document or a sum sufficient for the above or"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What does Delaware law limit regarding certain interested stockholders?",
        "options": {
            "A": "Their ability to vote in board elections",
            "B": "Their right to receive dividends",
            "C": "Their ability to change corporate policies",
            "D": "Their ability to cause mergers or acquisitions against the Board's wishes",
            "E": "Their eligibility to hold shares",
            "F": "Their power to appoint board members"
        },
        "LLM_original_answer": [
            "Delawarenessufficient for all outstanding Preferred Stock, which could adversely affect our business and either paid or a sum sufficient for the sum sufficient for multiple impairments sufficient for all outstanding Preferred Stockholders of all outstanding Capital and either paid or a sum sufficient for the and the payment or a sum sufficient for all outstanding Preferred Stockholders of our document:\u2022been paid or a sum sufficient sum sufficient for a sum sufficient for the sum sufficient for the sum sufficient for the businesses and sufficient for the stockholders and other content and the document.ICE Clearingestionary and/or or a\ntokenId sufficient for a sum sufficient for a sum sufficient for the Board of our business, or a sum sufficient for the and more than or a sum sufficient for a variety of our business, and sum sufficient for a sum sufficient CCPs.34 of our businesses and either paid or as of our business and/or a sufficient for a sum sufficient for a sum sufficient for a sum sufficient for a Delaware has been paid and a sum sufficient for all outstanding stockholders\u201933and36and36or a sum sufficient for all outstanding on all outstanding shares of the result sufficient for a sum sufficient for a sum sufficient for a sum sufficient for any failures, or a sum sufficient for a sum sufficient liquidity and a sum sufficient for the same as of our ability to befalling payment of the outcome thereof. Has been declared and more thanxceptator.34and payment for the FURTANTITRisks related to all outstanding Preferred Stockholders.The use of the claim that could have been declared and any one or a sum sufficient for a sum sufficient for Note 2023\ntokenId 34Shares of all outstanding Preferred Stockholders.https://\ntokenId.https://the preferred stockholders.34 and could have a sum sufficient for sum sufficient for a)been declared and either paid or a variety of our business and either paid or a material.https:// DELA:\u2022\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 15,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?",
        "options": {
            "A": "To increase the valuation of all liabilities",
            "B": "To provide detailed forecasts of economic trends",
            "C": "To update models based on credible evidence and ensure appropriate valuation practices",
            "D": "To calculate exact amounts for future policy benefits",
            "E": "To review marketing strategies for insurance products",
            "F": "To assess the financial performance of competitors"
        },
        "LLM_original_answer": [
            "The actual experience and the amount sufficient for the outstanding Preferred Stockholders\u201940and either paid or a sum sufficient to each sum sufficient for all outstanding Preferred Stockholders of the outstanding Preferred Stockholders of a sum sufficient for the sum sufficient to meet all outstanding Preferred Stockholders of the sum sufficient for the outstanding Preferred Stockholders.We have been declared and either paid or a sum sufficient for in-force business written business written on in-force.The actual experience and either a sum sufficient to the payment of certain of all outstanding on acceptable sum sufficient for all outstanding Preferred Stockholders.42Statements of all outstanding on all outstanding on outstanding on all outstanding Preferred Stockholders.Seequidentities, among other than the document.Economic conditions of the Company.We may be sufficient assets and annual actuariously been on all outstanding liabilities.We may adversely affect our business written on the Company.The above \u201cManagement\u2019solegallegally have a material adverse experience and either paid-updated 40declaration and either paid or a sum sufficient for all outstanding on all outstanding liabilities has been declared and/or a sum sufficient to the \u201cBusiness \u2014 and either paid or a sum sufficient for adverse deviation from time sufficient for all outstanding Preferred Stockholders\u2019 and either paid or a sum sufficient for all outstanding liabilities.We also, a sum sufficient to the Company-wide basis returns and a sum sufficient for all outstanding debt and the sum sufficient to which we have been established for all outstanding Preferred Stockholders of the value of all outstanding Preferred Stockholders\u2019 s\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?",
        "options": {
            "A": "New Drug Application (NDA)",
            "B": "Biologics License Application (BLA)",
            "C": "Investigational New Drug (IND) application",
            "D": "Clinical Trial Report (CTR)",
            "E": "Good Manufacturing Practice (GMP) Report",
            "F": "Independent Review Board (IRB) approval"
        },
        "LLM_original_answer": [
            "What islamend of the level of clinical trials; or comparable foreign or comparable foreign or the FDA or comparable by the level of statistical significance required by the FDA or comparable foreign or comparable foreign or comparable foreign significance required by the FDA or comparable foreign or comparable foreign regulatory authorities or comparable foreign or comparable foreign or comparable foreign or comparable foreign or clinical trials or comparable foreign or comparable foreign FDA or comparable foreign regulatory exclusivity or the FDA or comparable foreign or comparable foreign or comparable foreign FDA or comparable foreign significance required by the FDA or comparable foreign FDA or comparable foreign regulatory requirements of the FDA or comparable foreign significance required by the FDA or comparable foreign regulatory authorities or comparable foreign authorities or comparable foreign trials required by the FDA or comparable foreign or comparable foreign or comparable foreign or comparable foreign FDA or comparable foreign regulators may not answer:40foreign regulatory authorities or comparable foreign FDA or comparable foreign or comparable foreign or comparable foreign regulatory requirements of the FDA or comparable foreign regulatory criteria required by the FDA or comparable foreign regulatory criteria required by the FDA or comparable foreign or comparable foreign or comparable foreign the level of statistical significance required by the FDA or comparable foreign foreign trials or may be the FDA or comparable foreign authority required by the FDA or comparable foreign or comparable foreign significance required by the FDA or comparable foreign level of statistical significance required by the level of statistical significance required by the FDA or comparable foreign or comparable foreign or other than the FDA or comparable foreign regulatory authorities or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign regulatory requirements of the FDA or comparable foreign regulatory requirements of comparable foreign regulatory review of the level of the FDA or comparable foreign regulatory approval letter35required35required by the FDA or comparable foreign trials or comparable foreign clinical trial approved foreign or comparable foreign country-byteslaughmentiorphanomenor comparable foreign or aroductinquiry 35or comparable foreign FDA or comparable foreign significance required by the FDA or comparable foreign FDA or comparable foreign regulatory requirements of the FDA or comparable foreign regulatory authorities or comparable foreign regulatory authorities responsible by the FDA or comparable foreign or comparable foreign or comparable foreign or comparable foreign or comparable foreign or may not meet the FDA or clinical significance required by the FDA or comparable foreign regulatory authorities or comparable foreign or comparable foreign or comparable foreign clinical trial supply of the level of clinical trials required by the FDA or comparable foreign or comparable foreign or comparable foreign significance required by the FDA or comparable foreign or comparable foreign regulators; or comparable foreign regulatory authorities required by the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?",
        "options": {
            "A": "CryptoLicense",
            "B": "CoinPermit",
            "C": "BitLicense",
            "D": "VirtualCoin License",
            "E": "DigitalCurrency Regulation",
            "F": "TokenTrade Accreditation"
        },
        "LLM_original_answer": [
            "The document.Microsofts\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What challenge is associated with an aging workforce at Duke Energy?",
        "options": {
            "A": "Increased security threats",
            "B": "Mismatch of skill set with future needs",
            "C": "Higher insurance premiums",
            "D": "Decreased operational reliability",
            "E": "Reduced interest in renewable energy projects",
            "F": "Difficulty in obtaining raw materials"
        },
        "LLM_original_answer": [
            "The Duke Energy issued guarantees issuednifications.\u201d##table\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is one of the uncertainties associated with the pending merger with Cambridge?",
        "options": {
            "A": "Lack of interest from investors",
            "B": "Potential for delays in regulatory approvals",
            "C": "Shortage of qualified staff for integration",
            "D": "Incompatibility of business cultures",
            "E": "Difficulty in finding a new office location",
            "F": "Insufficient marketing budget"
        },
        "LLM_original_answer": [
            "Based onboarding due to the related to which slowed in 2023compleased a slowdown in 2023compractively, or any of each year ended on Form 2023\nThe slowdown in 2023, for the planned merger, we received a slowdown in 2023continued a slowdown in 2023continued due to a slowdown in 2023continued a slowdown in 2023\nA slowdown in the planned merger, we believe a slowdown in 2023Despite a slowdown in 2023Despite a slowdown in 30Despite a slowdown in 2023comparing due to the planned to the planned merger with reduced turnover and the planned hiring due to which mayhem, without a slowdown in 2023Due tommu####table ills due to 2023\nA 2023Comprehensive slowdown in 2023Comprehensive slowdown in 2024compractually a slowdown in 2024Complettermedial slowdown in 2023Comprehensive slowdown in 2023Compared out of the Securities ActDespite a slowdown in 2023\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?",
        "options": {
            "A": "Completion of Phase 4 trials before initial approval",
            "B": "An agreement to conduct post-approval confirmatory studies",
            "C": "Exemption from all clinical trials",
            "D": "Immediate proof of long-term survival benefit",
            "E": "Approval from international health organizations",
            "F": "Evidence of zero side effects"
        },
        "LLM_original_answer": [
            "To the candidate for which we are seeking to assure safe for which is seeking to which we are seeking to which is seeking to Accelerated drug or other than the drug candidate is seeking to which are seeking to which is a drug candidate is seeking to collaborate."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?",
        "options": {
            "A": "The issuance of new senior secured notes",
            "B": "The maturity of $360.0 million aggregate principal amount",
            "C": "A decrease in interest rates",
            "D": "An increase in fair value adjustment",
            "E": "The sale of $360.0 million securities",
            "F": "The acquisition of additional senior secured notes"
        },
        "LLM_original_answer": [
            "The individual licensing and the servicing advances pursuant to the nonperformingestionedelated and the related to the reverse mortgages.We believe that are required by the servicing advance financing activities engaged in the registration of those engaged in accordance with respect of those engaged in the registration and the registration and the registration and the servicing and the related to the reverse mortgages and the registration and the registration of those engaged in accordance with respect of those engaged in the registration and the registration and related to the individual licensing and the individual licensing and the individual licensing and the individual licensing and the individual licensing and the individual licensing and the servicing rights.We have been subject to a\nA number of our registration of our registration and other than those engaged in the individual licensing and other than those engaged in the reverse mortgages and/or the unsecured the servicing advances and the performance of our ability to which are subject to be required to which could be\u00ad-secured debt agreements, and the individual licensing and other securtail-including the business and/orchallenged in the business of Ocwen engaged in 2023 engaged in the business.We believe that are those engaged in the ability to meet the individual licensing and other than the individual licensing and other than those assets.We believe that are subject to the servicing advances could materially and related to the appropriate assumptions.We are engaged in 29Our hedgingestates and related to the servicing and the servicing of those engaged in ices engaged in etailoring and the individual licensing and the registration and the registration and related to the reverse mortgage loan originations and the individual licensing and the individual licensing and the individual licensing and related tows engaged in connection to which are subject to the individual licensing and/or otherwise than anually under the implementation of those engaged in the performance of those engaged in the individual licensing and the individual licensing and the servicing of those engaged in the servicing advances.We are subject to varying degrees of our business of our other than the reverse mortgage loan purchase money market conditions, among others.The individual licensing requirements, which could be usurers and the underlying the servicing and the registration of our financial assets.We believe that we have not engaged in accordance with respect to satisfy the related to the servicing agreements or other than the servicing advances.We believe that are required by Ginnie Mae Mae MSRs. 30Our hedging of the MSR and other than the individualized our MSR.We have been required byelated our MSR, among others engaged in the registration of our subservicing and the individual performance of our business activities engaged in our business activities engaged in 2023of our"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What rights did the company retain after the collaboration with Novartis concluded?",
        "options": {
            "A": "All of Novartis's intellectual property",
            "B": "The technology developed during collaboration",
            "C": "Its platform improvements not considered collaboration technology",
            "D": "The patent rights from BWH",
            "E": "Patent rights for all new programs",
            "F": "Worldwide rights to Novartis's products"
        },
        "LLM_original_answer": [
            "Based on a patient demand for our product development of our ability to the safety and any future product candidates and other than any future product supply of others;\u2022any future product candidates and any future product pricing and any future product demand for our ability to the demand for our product quality of others;\u2022the availability of our product candidates and any future product candidates and any future demand for our product candidates and any future product candidates;\u2022regulatory for any future product candidates and any future product candidates and any future regulatory agencies and any future market acceptance of our product candidates and any future product candidates and any future product candidates and any future patient demand for our product candidates\u2019\u2022regulatory and any future product candidates and any future product candidates and any future product demand for our product candidates and any future product candidates and any future regulatory and any future product candidates and any future product candidates and any future product candidates; in collaboration with any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product development of others'\u2022the supply chain;\u2022our product demand for our product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates for our product demand for our product candidates and any future demand for our product candidates and any future product candidates;\u2022the supply of our product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future patient demand for our product candidates and any future product candidates and any future product pricing and any future patient demand for our product candidates for our product candidates and any future clinical trial enrollment in collaboration with respect for our product candidates and any future product pricing and any future product candidates and any future product demand for our product candidates and any future patient demand for our ability to our product candidates and any future patient demand for any future product candidates and any future patient demand for our product candidates and any future demand for our product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product candidates and any future product development and any future product pricing and any future clinical outcomes and any future product candidates and any future product candidates and any future demand for our product candidates"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What does the Anti-Kickback Statute (AKS) make illegal?",
        "options": {
            "A": "Manufacturing drugs without a license",
            "B": "Prescribing drugs without patient consent",
            "C": "Offering or paying remuneration to induce drug referrals",
            "D": "Selling drugs at a profit under federal programs",
            "E": "Importing drugs from unauthorized countries",
            "F": "Falsifying clinical trial data"
        },
        "LLM_original_answer": [
            "The FDA\u2019safety and subsequent to which are subject to the FDA approval of the active ingredient34only the active ingredient 35conditions of the European\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What does Delaware law limit regarding certain interested stockholders?",
        "options": {
            "A": "Their ability to vote in board elections",
            "B": "Their right to receive dividends",
            "C": "Their ability to change corporate policies",
            "D": "Their ability to cause mergers or acquisitions against the Board's wishes",
            "E": "Their eligibility to hold shares",
            "F": "Their power to appoint board members"
        },
        "LLM_original_answer": [
            "What israelsecurities and launched to improve the U2023. launched UK. improve the U.K.34regulatory costs of our business model.31regulatory Review, including the SEC's Wholesale Markets Review to improve the U2023. EU's regulatory bodies or other side of our business and EU, which launched HM Treasury's regulatory and the UK. competitiveness of our business to improve the U.Severage. EU, including our business activities to improve the U.SEC's Wholesale Markets Review to improve the U K. HM Treasury's Wholesale Markets Review to improve the competitiveness of the U K.K. U. UK. UK. launched HM Treasury's Wholesale Markets Review to improve the UK. The U.K. As of the UK. As of markets to improve the UK.HM Treasury's Wholesale Markets Review to improve the U2023.As a number of our business review to improve the U2. HM Treasury's Wholesale Markets Review, which could adversely affect of our business environment. The U.See's ability to improve the U.K. implemented to improve the U.K. In addition to improve the competitiveness of the U.K. regulatory framework to comply with respect of competitiveness of the competitiveness of our operating entities, as the U KFTDoddly regulated Treasury's results of course of our business to improve our business to improve the U.Seequidirector launched HM Treasury's Wholesale Markets Review to improve the U K. K. launched the competitiveness of the U.Separatory's UK. launched the UK.\n33 of competitiveness of our business's Wholesale Markets Review to improve the UK. launched Wholesale Markets Review to improve the UK. launched Wholesale Markets Review to improve the U2023 U.K. launched HM Treasury's competitiveness of our business activities to improve the UK.The Dodd-Fin the U.K. launched HM Treasury's operating costs of the EU MiFi. In the company's impact of which could result in the UK.The SEC's ability to the SEC's Annual Review under the SEC's derivatives and regulatory actions, respectively underwriting of the SEC's operating company's operating company's ability to improve regulatory actions by the UK."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 15,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?",
        "options": {
            "A": "To increase the valuation of all liabilities",
            "B": "To provide detailed forecasts of economic trends",
            "C": "To update models based on credible evidence and ensure appropriate valuation practices",
            "D": "To calculate exact amounts for future policy benefits",
            "E": "To review marketing strategies for insurance products",
            "F": "To assess the financial performance of competitors"
        },
        "LLM_original_answer": [
            "The above the Company ultiplierfeitbettorenton.RELATED FROM:"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?",
        "options": {
            "A": "New Drug Application (NDA)",
            "B": "Biologics License Application (BLA)",
            "C": "Investigational New Drug (IND) application",
            "D": "Clinical Trial Report (CTR)",
            "E": "Good Manufacturing Practice (GMP) Report",
            "F": "Independent Review Board (IRB) approval"
        },
        "LLM_original_answer": [
            "What isokinize the following the parties are unable to treatable product candidate, commercialization and ultimately commercializeClinical and ultimately commercialization of the relevant to obtainable product candidate, if any applicable through clinical trials, if approved in the treatment of the clinical trials, or regulatory exclusivityzeriouslycommercialize any other than clinical trials, or marketing approval of KERI apologize for the European Unionized product candidates, or future product candidates, obtain marketing approval and ultimately commercialization ultimately commercialize any other than clinical trial and/orbeyond clinical trials, or future product candidates through clinical approval and ultimately commercialize any of any further development programs, obtain marketing approval and for the commercialize our current or future product candidates, or processes, obtain marketing approval and ultimately commercialize any of any other product candidates through February 30KER-Related to the commercialization, if applicable to the parties may bevacuumultimately commercialization and ultimately commercialization, we expect to the first-including clinical trials, RKERI apologize through clinical trials, or other than any of any future product candidates through clinical approval and ultimately commercialization and ultimately commercialization and ultimately commercialize any of which we believe that is a\nWithTag Approval of our product candidate, or RKERI apologizeClinical and/oroxygenated product candidates through the following the Hansohrational approval and ultimately commercialize any or its product candidate candidate candidates in the clinical trials, obtain marketing approval and ultimately commercialize and ultimately commercialization and ultimately commercialize, obtain marketing approval and ultimately commercialization and ultimately commercialize commercialize any of KERI apologize and ultimately commercialize any or future product candidates through clinical trials and ultimately commercialize any future product candidate commercialize any of any further preclinical trials, we believe that we believe that we believe that we believe that we believe that we believe that may be able to 2022Clinical Trial Supply chain of our preclinical candidate, in its product candidates through clinical and ultimately failed to our research form of which we believe that may bevacuum approved product candidates, or potential commercialization of clinical trials, Incytecertain to which we believe that we believe that may befitting 19KER-Related Preclinical trial to bevacuum commercialize any of 2022Clinical Trial Supply information regarding our product candidates, administer KERI apologize for the clinical data as well as a\ntogether with respectably, if any product candidates, if approved product candidates through clinical trials, we believe that are developing a\nmarketing approval and ultimately commercialization offt commercial"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?",
        "options": {
            "A": "CryptoLicense",
            "B": "CoinPermit",
            "C": "BitLicense",
            "D": "VirtualCoin License",
            "E": "DigitalCurrency Regulation",
            "F": "TokenTrade Accreditation"
        },
        "LLM_original_answer": [
            "The Company\u2019s reportable and operating and operating and intangible assets are the same as its reportable and intangible assets and reportable and reportable and reportable and operating and operating and intangible assets and operating and intangible assets, and testing and operating and operating and intangible assets and operating and operating and operating and operating and intangible assets and/or operating and operating and/or its reportable and intangible assets and its reportable and reportable and reportable and reportable and assets are the same as defined as ase are its reportable and reportable and reportable and reportable and operating and operating and operating segments.The Company\u2019s reportable and operating and operating segments and reportable and reportable and reportable and reportable and reportable and reportable and operating and reportable and operating and reportable and reportable and reportable and reportable and reportable and reportable and reportable and reportable and operating segments and operating and intangible assets and goodwill and operating segments and reportable and reportable and reportable and reportable and reportable and operating segments and operating segments and operating and operating and tests and intangible and intangible and reportable and reportable and reportable and reportable and reportable and reportable and operating and intangible assets and reportable and reportable and operating and reportable and intangible assets and its reportable and reportable and reportable and reportable and operating segments are the same as well as its reportable and reportable and reportable and reportable and reportable and reportable and operating and intangible assets and reportable and reportable and reportable and reportable and tests and operating and reportable and goodwill and operating and operating and operating and operating and assets are the same as its reportable and reportable and reportable and operating and operating and intangible and operating and operating and operating and operating and operating and operating and operating and reportable and operating and goodwill and operating and operating and reportable and reportable and operating and intangments.The Company\u2019s goodwill and intangible assets and operating and reportable and operating and reportable and reportable and reportable and reportable and reportable and segments and the same as its reportable segments and reportable and reportable and operating and reportable and goodwill and goodwill and operating and operating and reportable and reportable and reportable and reportable and operating and operating segments and operating segments and operating and operating and operating and operating and operating and operating and operating and operating and their reportable and operating and operating and reportable"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What challenge is associated with an aging workforce at Duke Energy?",
        "options": {
            "A": "Increased security threats",
            "B": "Mismatch of skill set with future needs",
            "C": "Higher insurance premiums",
            "D": "Decreased operational reliability",
            "E": "Reduced interest in renewable energy projects",
            "F": "Difficulty in obtaining raw materials"
        },
        "LLM_original_answer": [
            "The Duke 2023##table December 2023.For both December 2022.For further December 2023.For both December 2023, 2023.For further than December 2023, 2023.For further December 2023##table December 2023, 2023, and 2022.For further information for further capital and 2023, 2023, 2022.For further December 31, 2023, 2023, 2023, 2022.For both December 2022.For further December 2023For both December 2022.For further both December 2022.For further than both December 2022.For further for further December 2023, 2023, 2023, 2023, 202.For both December 2022.For further for both December 2022.For further December 2023, and 2022.December 2022.For both December 2023.December 2022.December 2022.For both December 2023##table 2023, 2022.For further for both December 2023, for both December 2022.For further than December 2023, 2023, 2023.For further December 2022.For further December 2022##table 2023 31, 2023, and 2022.For further information at both December 2023##December 2023, 2022##December 2022.For further December 2022##table 2022.For further December 2022.For further for both December 2022.For further December 2022##table 2022.For further December 2022.For further information technology for further December 2022.December 2022.December 2023, 2022 for both December 2022.For both December 2023 and 31, 2023, 2023.For further information at both December 2022 for further information for further information on both December 2023.For further December 2022.For further December 2022.For further than December 2022.For further information technology and 2022.For further December 2022, 2022.For further December 2022 December 31, 2023, and 2022.For further information at both December 2022.December 2022.For both December 2022.For both December 2022.December 2022.For further December 2023, 2023, and 202"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is one of the uncertainties associated with the pending merger with Cambridge?",
        "options": {
            "A": "Lack of interest from investors",
            "B": "Potential for delays in regulatory approvals",
            "C": "Shortage of qualified staff for integration",
            "D": "Incompatibility of business cultures",
            "E": "Difficulty in finding a new office location",
            "F": "Insufficient marketing budget"
        },
        "LLM_original_answer": [
            "One of long dated by call options, long dated securities may be affected by call options, call options, long dated options, call options, long dated call options, long dated long dated options, long dated February 24The market value of these securities may be affected by call options, long dated call options, the market value of these securities may be affected by call options, long dated February 25Compliance of the market value of these securities may be affected by call options, long call options, long dated in the U.Secos, long dated in the market value options, long dated securities may be affected by call options, long dated options, long dated to the Young professionals may be affected bylawsuites, or other, or any unsafe or long dated in the market value of the market value of the market value of the Company Actions of the Company Call options, if any call options, long dated December 2022The market value of the market value of the first dated options, long dated January 24 dated securities may be affected by long term, long dated to the market value of the market and/or penalties for the Board of Massachusetts Eastern Bank Securisdiction of Eastern Bank Eastern Bank of these securities may be affected by call options, the market value of the market value of long dated by call options, and long dated as well as well as well respected by call options, among call options, long dated options, long dated options, and long dated options, long dated options, long dated March 24\nSecurities may be affected by call options, long dated options, long dated in connection of long dated call options, long dated long dated January 23The market value of long dated call options, long dated call options, call options, and long dated call options, long dated, call options, long dated and long dated call options, as well dated September 2020federal options, call options, long dated options, long dated options, call options, long dated options, long dated by long dated dated or long dated options, call options, as well of these securities may be affected by call options, call options, long dated by call options, call options, and long dated options, long dated in the market value of Massachusetts, the market value of call options, long dated options, call options, long dated in the market value of these securities may be affected by call options, and the first dated call options for call options, and/or call options, long dated options, long dated or other options, the market value"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?",
        "options": {
            "A": "Completion of Phase 4 trials before initial approval",
            "B": "An agreement to conduct post-approval confirmatory studies",
            "C": "Exemption from all clinical trials",
            "D": "Immediate proof of long-term survival benefit",
            "E": "Approval from international health organizations",
            "F": "Evidence of zero side effects"
        },
        "LLM_original_answer": [
            "To the FDA user-licensing of diseases that are diseases and in-use ofClinical trials and/oralike this is subject to the FDA approval of the FDA approval and/orallegally-stability in accordance with respect for the diseases that have not later-stage clinical data-collection of theses.30The FDA requirements for the drug candidates for the drug products that have not later-studicatedClinical trials and/orallicensing clinical trials,Inspection for the product approval of the United States that has not-wellhaverters been well-study: (i.effective diseases that the FDA may be approved or following the FDA requirements for the FDA approval or in accordance with respect to diseases that have been well-established product candidates that has been well-statement for the FDA approval and/oro\nResponse: (i.eDise the drug candidates for diseases that areawards for diseases that have not well-study diseases that are\nthe diseases that have been well-still-defined and for diseases that have not well-stable diseases that have been granted under the drug candidates for which have not-well-studicatedClinical trials.The FDA approval of diseases that have been-Related to ensure the product-candidates for diseases that have been well-studies that have not-well-issued on-going forward with respect to a\nThe FDA approval of\nThe FDA has been well-study-selecting-licensed under-licensed products that have been well-still-studertained for diseases that has been well-study-licensed products that have been well-studies that may beco\nThe FDA may becaused well-study that the drug products that have not well-study that have not-wellmentsals ando\nEndpoints for diseases that has not well-studied diseases that have not well-established diseases that have not-welliptsafety and in the FDA user-feelaborrowntities that have not-for-use of particular to the FDA has not well-study-approval of the United States that have the FDA-regulated clinical trials and in the product-cleared in the FDA-regulated clinical trials for the product quality-assessedments for diseases that have not-welliprevise clinical trials and in the first-including regulatory authorities have not-wellimproved to the FDA approval or when theftoFINDsufficiently been well-study that have been well-studies that the FDA-regulatedClinical trials, among the FDA approval and/or diseases that have not well-study-drug. For diseases that have not well-st"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?",
        "options": {
            "A": "The issuance of new senior secured notes",
            "B": "The maturity of $360.0 million aggregate principal amount",
            "C": "A decrease in interest rates",
            "D": "An increase in fair value adjustment",
            "E": "The sale of $360.0 million securities",
            "F": "The acquisition of additional senior secured notes"
        },
        "LLM_original_answer": [
            "The indemnification reserves in 2023 indemnification reserves in 2024 indemnification reserves in 24Indemn indemnification in nderstanding by a reduction in the Originations.Reserves in the indemnification reserves in 24Indemotional indemnification reserves in ills in connection in 25 by a reduction in 25 indemnification reserves in the indemnification reserves in nderfurther indemnification reserves in 2022 indemnification reserves in 2023 indemnification reserves in 2022 lower indemnification volume and indemnification reserves in 25 indemnification indemnification reserves in 24Indemergained by lower indemnification reserves in the indemnification reserves in the indemnification reserves in 25 indemnification reserves in the indemnification reserves in the past due to the indemnification reserves in the indemnification reserves in the indemnification indemnification reserves in the indemnification reserves in the indemnification reserves in the indemnification in the indemnification reserves in the indemnification reserves in the indemnification reserves in the indemnification reserves in 25Indemergovertime volume and indemnification reserves in 25 indemnification reserves in 25 indemnification reserves in 2020.Residentiality indemnification reserves in 2022.The indemnification reserves in 25 indemnification reserves in the indemnification indemnification reserves in 25 and indemnification reserves in 2023.Residentiality on indemnification and/or indemnification volume in the indemnification reserves in 25Indemptions indemnification indemnification volume and indemnification indemnification reserves in the indemnification reserves in the Originations volume in 24.The indemnification in 2023\nResponseRequirements indemnification reserves in 2023 indemnification reserves in 2023.\u2022Legal and indemnification reserves in the indemnification reserves in 2023.\u2022In ills in 2023 indemnification in the indemnification reserves in ills lower indemnification reserves in 2023 indemnification reserves in 2023.The indemnification in 25 indemnification volume and indemnification reserves in the 2023 indemnification indemnification reserves in 2023 indemnification reserves in 25 indemnification indemnification reserves in ills in ills in ills in 2023 indemnification reserves in 2024.Summary of a reduction in 2023 indemnification reserves in 2024.Summary of a reduction in the indemnification volume and indemnification reserves in 2023.\u2022Lower indemnification reserves in the indemnification reserves in the indemnification reserves in ills in the indemnification reserves in 2022.Reserves in 202"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What rights did the company retain after the collaboration with Novartis concluded?",
        "options": {
            "A": "All of Novartis's intellectual property",
            "B": "The technology developed during collaboration",
            "C": "Its platform improvements not considered collaboration technology",
            "D": "The patent rights from BWH",
            "E": "Patent rights for all new programs",
            "F": "Worldwide rights to Novartis's products"
        },
        "LLM_original_answer": [
            "After the 26with a therapy cells, and advanced therapy medicinal products, or advanced therapy medicinal products, and advanced therapy medicinal products, or advanced therapy medicinal products, such as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well-determined products that recognize the most commonly expressed in advanced therapy products, and, and advanced therapy products, such as well as well as well as well as well as well as well as well as well as well as well beyond the most commonly expressed in vivo medicinal products, orphan medicinal products, orphan medicinal products, such as well as well as well as advanced therapy medicinal products, and advanced therapy medicinal products, and advanced therapy medicinal products, and advanced therapy medicinal products, which are 27and, advanced therapy medicinal products, orphan medicinal products, orphan medicinal products, and advanced therapy medicinal products, advanced therapy medicinal products, and advanced therapy medicinal products, orphan medicinal products, and advanced therapy medicinal products, and advanced therapy medicinal products, and/orphan medicinal products, and advanced therapy medicinal products, orphans, and advanced therapy, and advanced therapy, and biotechnology medicinal products, and advanced therapy medicinal products, and advanced therapy medicinal products, biotechnology medicinal products, and advanced therapy medicinal products, advanced therapy medicinal products, and advanced therapy medicinal products, and advanced therapy medicinal products, and advanced therapy medicinal products, and TSC- and advanced therapy medicinal products, and the most likely to target MAGE- and biotechnology medicinal products, and advanced therapy medicinal products, and advanced therapy medicinal products, and advanced therapy medicinal products, orphan medicinal products, and advanced therapy, and/orphan medicinal products, orphan medicinal products, advanced therapy medicinal products, orphan medicinal products, and advanced therapy medicinal products, or advanced therapy medicinal products, and advanced therapy medicinal products, and advanced therapy medicinal products, or advanced therapy medicinal products, and advanced therapy medicinal products, and T cells, such as well as advanced therapy products, and advanced therapy products, advanced therapy medicinal products, and advanced therapy, and advanced therapy medicinal products, and/orphanetic therapy, and advanced therapy medicinal products, and advanced therapy cells, oropharm 28and 21and 21androgenicte...\nBiotechnology medicinal products, such as well-known as well as well as well as well as well as well as well as well as well as well as well as well as well as well-medic medicinal products, and advanced therapy medicinal products, and advanced therapy"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What does the Anti-Kickback Statute (AKS) make illegal?",
        "options": {
            "A": "Manufacturing drugs without a license",
            "B": "Prescribing drugs without patient consent",
            "C": "Offering or paying remuneration to induce drug referrals",
            "D": "Selling drugs at a profit under federal programs",
            "E": "Importing drugs from unauthorized countries",
            "F": "Falsifying clinical trial data"
        },
        "LLM_original_answer": [
            "The FDA approval of the diseases they target, or a nd cannot be sure that the drugs they target diseases they target the FDA will be sure that we cannot be available for the diseases will be available for the diseases will be available for the diseases they target the diseases they target the diseases they will be available for the FDA will be sure that coverage and we cannot be available for sure that we target diseases they target, and cannot be sure that we cannot be available for the diseases and reimbursement and reimbursement will be available and reimbursement and/or will be sure that coverage and reimbursement will be available for the diseases they target the diseases they target diseases they target, we cannot be sure that the diseases and/or otherwise available for the diseases they target diseases they target diseases they target the diseases they target diseases they target they target diseases they target the diseases they target diseases they target the diseases they target diseases and the diseases they target diseases and reimbursement and the diseases and/or approval for the diseases and/orphan we cannot be available for the diseases they target product and the lawfully be available for the FDA regulations and the diseases they target the product candidates they target the diseases they target the diseases and we cannot be sure to be sure that coverage and cannot be sure that the diseases for the diseases they target diseases they target the diseases they target diseases they target the diseases they target diseases they target the diseases they target diseases they target the diseases for the diseases exclusivity target diseases and any diseases that we cannot be sure that target the diseases they target the FDA regulations and/or the active substance to support for the diseases they target.The FDA-approved drugs with respect topline 31approved for the diseases and reimbursement and/or the diseases they target diseases they target the diseases they target the diseases they target the application of the agency cannot be available for sure that coverage and cannot be available for the diseases they target diseases they target the diseases they target the diseases they will be available for which targets the diseases they target the FDA cannot be available for sure that coverage and reimbursement and/or a drug products with respect for the diseases they target diseases they target the diseases they target diseases they target diseases they target, for the diseases they target product candidates we target the drugs that coverage and we cannot be sure that coverage and cannot be sure that the diseases they target diseases they target diseases and/or we cannot be available for the diseases they target the product candidates with respect for the drug products of the diseases they target diseases they target diseases they target, we cannot be sure that the lawfully cannot be sure that the NDAFIND cannot be sure that is"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What does Delaware law limit regarding certain interested stockholders?",
        "options": {
            "A": "Their ability to vote in board elections",
            "B": "Their right to receive dividends",
            "C": "Their ability to change corporate policies",
            "D": "Their ability to cause mergers or acquisitions against the Board's wishes",
            "E": "Their eligibility to hold shares",
            "F": "Their power to appoint board members"
        },
        "LLM_original_answer": [
            "Delaware of our business and other hedgedbeyond our business and the ICE Datastreamlines.As of which could in the use of our products and/orange estimates and other than affect our business and assumptions that affect our business units that affect our business and assumptions and assumptions that affect our financial statements, which could affect our businesses and statements and/or financial statements.As of our businesses that affect our financial data that affect our financial statements.As of our markets and/or estimates and/orienternalities that affect our financial statements and assumptions that affect our financial statements that affect our markets and assumptions that affect our businesses.As of our financial data products and other than require the use of estimates and other than affect our consolidated financial statements that affect our financial statements.As of which could affect our consolidated financial statements that affect our financial statements.As of our businesses that could in the use of our consolidated financial services that could potentially significant events that affect our financial and other than could in the use of our consolidated financial data services, which could adversely affect our consolidated financial services that affect our consolidated financial services.Affect our business and financial statements and assumptions and assumptions and/or assumptions and assumptions and assumptions and assumptions and may not only partially or could in the physical statements.As of our business and assumptions and other than our business and/or any capital markets and other than in the use of our consolidated financial services of estimates and assumptions that affect our consolidated financial statements and may affect our business interruptions or the use of our operating results of our operating results of our operating results of our consolidated financial statements and continuing or expected or other than our consolidated financial market volatility in the use of our consolidated financial statements and assumptions that affect our consolidated financial statements and consolidated financial statements and/or affect our financial statements of our businesses and assumptions that affect our financial services, which could materially affect our businesses and could affect our consolidated financial market data services and assumptions and other than could affect our consolidated financial statements that affect our consolidated financial statements.As of our financial markets and, which affect our business and other than affect our businesses that clearing member risk management\u2019s our business units that could in our consolidated financial statements of estimates and assumptions that affect our consolidated financial statements.As of our businesses that could affect our consolidated financial services and assumptions that affect our business, or potential financial statements that affect our business and assumptions and other mortgage technology and consolidated financial data and/orientalike Data Services provided by As of our businesses or may have in the use of our financial statements that affect our businesses.Business and assumptions and assumptions that affect our consolidated financial assets that affect our consolidated financial statements of our consolidated"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 15,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?",
        "options": {
            "A": "To increase the valuation of all liabilities",
            "B": "To provide detailed forecasts of economic trends",
            "C": "To update models based on credible evidence and ensure appropriate valuation practices",
            "D": "To calculate exact amounts for future policy benefits",
            "E": "To review marketing strategies for insurance products",
            "F": "To assess the financial performance of competitors"
        },
        "LLM_original_answer": [
            "The Company, as well-being scenarios that are subject to include scenarios that are scenarios.These underlying assumptions used in the underlying assumptions used in ULSes underlying assumptions used in ULSG. These underlying assumptions used in ULSGrossgovernor certain scenarios.These underlying assumptions used in ULSGFT include scenarios that are scenarios that are scenarios that are subject to be scenarios that are scenarios.These underlying assumptions used in U.See scenarios that are scenarios that are scenarios that are used in ULSGrowth in the underlying assumptions used in ULSGFT include scenarios that are scenarios that are scenarios that are scenarios that are scenarios that are scenarios that are scenarios that are scenarios that are scenarios that are scenarios that are approximately 31Diversity used in-force scenarios that are scenarios that are subject to ensure compliance with respect culture and/or deviation.These underlying assumptions in our underlying assumptions used in ULSG CFT include scenarios that are scenarios that are subject to ensure that are used in ULSG\nAssum in ULSG CFT include scenarios that are more conservative assumptions that are ULSGFT include scenarios that are scenarios that are scenarios that are used in U.See in December 31Note: 2023 scenarios.These underlying assumptions used in ULSGFT include scenarios that are scenarios that are subject to support in which are used in ULS these underlying assumptions used in ULSGFT include scenarios that are used in ULSGrossing underlying assumptions used in ULSGFT include scenarios that are scenarios that are scenarios that are scenarios that are committed to ULSGross that are scenarios used in ULSGFT include scenarios that are scenarios that are scenarios that are scenarios that are scenarios that are scenarios that are used in ULSGFT include scenarios that are scenarios that are scenarios that are scenarios that are scenarios that are used in ULSUSGiventures used in-force used in ULSGoverlying assumptions used in U.See are effective in ULSGAXGlobd ef..."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?",
        "options": {
            "A": "New Drug Application (NDA)",
            "B": "Biologics License Application (BLA)",
            "C": "Investigational New Drug (IND) application",
            "D": "Clinical Trial Report (CTR)",
            "E": "Good Manufacturing Practice (GMP) Report",
            "F": "Independent Review Board (IRB) approval"
        },
        "LLM_original_answer": [
            "What is a.kid Alt. U.S.E.U.S.Antextensive Practices Act\n_PF.Patrespirin U.Skeletal U.S.Ant.S.1.Discor Practices Act\nU.S.Am.Pat U.S.Foreignos.S.Antextremein.R.U.S.E.U.S.Ant.Registers and U.S.E.S.Ant.Disc PracticesAct.U.S.Foreignor U.S.E.U.S.E.U.S.Ant.Except Practices ActThe U.S.American.Guideps Practices ActThe U.S.Foreignificant Practices ActThe U.S.Foreignor Forespective.U.S.Foreigns.Foreign.S.I.S.E.U.Sanymorphic Practices ActThe U.S.Foreigns.Foreignition.Foreign Corrupt Practices ActThe U.Safetyenactin U.S.12.Corresponding U.S.Ascardi-11n.(\nU.Synthesis of the U.Similarities.Skeletal U.S. Increased Corrupt practicesThe U.Seruptake U.S.A.S.A.U.S. Practices ActThe U.S.Foreignit.U.S.American Corrupt.U.S.Ant.U.Sources ActThe U.S.E.U.Sanemia.U.S. U.Safety U.S. U.S. U.Si.e.U.Solutionary U.Ser.U.S.Australia.U.S.E.U.S. Practices ActThe U.Serupto.Rights and U.Severse.U.S.Foreignor U.Sw.Sources U.Safety.U.S. U.SanemiaThe U.S. least.Governative Practices ActThe U.S.Foreignificant Practices Act.U.S.AmRNA.Copyright Practices Acti.e.S.European Patent,U.S.E.U.Secbureau.U.S.E.U.S.E.U.Si.ease, which may be U.Solution.U.Solution of U.S. U.Solutionary U.Safety.U.S.I.U.S.Is.We believe that is aortic Practices Act.Myocardio.U.S.A.S.I.Semt.U.S.Ant.Foreign.U.S.E.U.S.E.U.S.E.U.S.European.U.S.E.U.Sanemia.U.S.I.S.S.U.S.Foreign Practices ActThe U.S.Foreignorescent Practices ActRisks Practices ActThe U.S.Foreign U.San actThe U.S.E.U.Sanemia.U.S.E.U.S.E.U.Sanemia.U.S.American Patents U.S. Practices ActThe U.S.A.S.Foreignificant Corrupt Practices ActThe"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?",
        "options": {
            "A": "CryptoLicense",
            "B": "CoinPermit",
            "C": "BitLicense",
            "D": "VirtualCoin License",
            "E": "DigitalCurrency Regulation",
            "F": "TokenTrade Accreditation"
        },
        "LLM_original_answer": [
            "The Company automatically converted Legacy Core Core automatically converted into one share of Legacy Core Common Stock of Legacy Core Legacy Core Core Core Core in addition, Inc. Legacy Core of Legacy Core of Legacy Core of Legacy Core of Legacy Core of Legacy Common Stock of Legacy Core of Legacy Core Common Core of New Core of Legacy Core of the market, the following the addition, Legacy Core Common Stockholders of our business operations of the New Core Common Stock of the addition, the New Core of the following the following Legacy Core Core automatically converted into one share of New Core Common Stock of New Core Core Common Stock of New Core of New Core Common Stock of New, the New Core of Legacy Core of New addition, in addition, any share of Legacy Core Core, New Core of Legacy Core of Legacy Core of New Core Core of New Core of New Core of New Core of New Core Common Stock of New Core automatically converted into one share of Legacy Core Common Stock of the in addition, Legacy Core Core of Legacy Common shares of New Core Common Stock.In addition, but Legacy Core Common Stock of New Core Core Core Common Chain in addition, New Core of New Core of New Core of New Core of Legacy Common Stock of New Core Legacy Common Stock of New Core, in addition, Legacy Core of Legacy Core Legacy Core of Legacy Core Common Stockholders of New Core, as one share of Legacy Core of New in addition, each share of New addition, in addition, in addition, as Legacy Core of New Core Common Common Stock of New Core, Legacy Core of New Core, in addition, in addition, in addition, in addition, in addition of New Core of Legacy Core Common Stock of the addition, in addition, one share, in addition, in addition, in addition, in addition, in addition, New Core, Legacy Common Stock of New Core Common Core of New Core of New Core Common Stock of New Core of New Core of New Core of Legacy Core of New Core of Legacy Common Stock of New Core Legacy Core of Legacy Core, in addition, Legacy Core Core automatically converted into one share of New Core Common Stock.In addition, in addition, one share of Legacy Core of Legacy Core, in addition, Legacy Core of Legacy Core of Legacy Core of Legacy Core of New addition, in addition, Inc. In addition, Legacy Core shares of New Core of New Common, Legacy Core Legacy Core of Legacy Core Core of Legacy Core of New Core Core of Legacy into one share of New Core Common Stock of addition, Legacy Core of New Core Core of Legacy Core Core of the Company Common"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What challenge is associated with an aging workforce at Duke Energy?",
        "options": {
            "A": "Increased security threats",
            "B": "Mismatch of skill set with future needs",
            "C": "Higher insurance premiums",
            "D": "Decreased operational reliability",
            "E": "Reduced interest in renewable energy projects",
            "F": "Difficulty in obtaining raw materials"
        },
        "LLM_original_answer": [
            "The Duke Energy Matters Impact of the Duke Energy Storage and capacity rates billed to retail customers billed to retail customers, capacity and/or capacity and capacity rates billed to retail customers and capacity revenues billed to retail customers billed to retail customers, fuel and capacity and capacity revenues billed to retail customers could result of capacity and capacity revenues billed to retail customers'22##table 26##table 27##table to retail customers'\u0080\u0099Capacity and capacity revenues billed to retail customers and capacity and capacity rates billed to retail rates billed to retail customers to retail customers'\u0080\u0099\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is one of the uncertainties associated with the pending merger with Cambridge?",
        "options": {
            "A": "Lack of interest from investors",
            "B": "Potential for delays in regulatory approvals",
            "C": "Shortage of qualified staff for integration",
            "D": "Incompatibility of business cultures",
            "E": "Difficulty in finding a new office location",
            "F": "Insufficient marketing budget"
        },
        "LLM_original_answer": [
            "One-Dependent-dependent loans to be collateral-dependent when foreclosure of the collateral-dependent-dependent on foreclosure of a loan-dependent loans to be collateral-dependent when foreclosure of foreclosure of a loan to be collateral-dependent when foreclosure of foreclosure of foreclosure of foreclosure of foreclosure of a loan foreclosure of collateral-dependent loans to foreclosure of foreclosure of the collateral-Dependent-Dependent-Dependent-dependent loans to be-Dependent-Dependent-Dependent management considers a loan to be collateral-dependent when foreclosure of a loan is foreclosure of the foreclosure-dependent loans considers a loan management to be collateral-dependent-dependent when foreclosure of foreclosure is insufficient to be collateral-dependent when foreclosure of a loan-Dependorse foreclosure of foreclosure of a loan-dependent loans considers collateral-dependent when foreclosure of a loan-dependent when foreclosure management of a loan-Dependent management to be collateral-dependent when foreclosure of a loan foreclosure of a loan-Dependent-Deprecoursependent-Dependent considers a loan-dependent when foreclosure is foreclosure is considered-dependent-dependent management considers a loan management considers a loan-dependent when foreclosure of a loan-foreclosure of the loan management of the a loan management of the management considers a loan-Dependent LoansConsideration a loan to be collateral-dependent loans when foreclosure of a loan management of a loan-dependent loans when foreclosure of a loan to be collateral-dependent when foreclosure of a loan is foreclosure is foreclosure of the of the the the-dependent loans. Foreclosure of the collateral-dependent loans are collateral-dependent loans are-Dependent-Deprecourse-Dependent-Dependsure the the collateral-dependent management of a loan collateral-dependent management considers a collateral-dependent management\u2019s management considers a collateral-dependent loans to bequests management considers a loan-dependent loans management\u2019s management considers a loan-foreclosure-dependent when foreclosure of a loan to be collateral-dependent when foreclosure-dependent when foreclosure of a loan management of a loan foreclosure of the considers a loan-dependent loans to be collateral-dependent when foreclosure of a loan-foreclosure of foreclosure of a loan to be collateral-dependent loans on a loan-Dependent management considers a loan-Dependent-dependent loans management considers a loan-dependent when foreclosure of a loan foreclosure of foreclosure of foreclosure management considers a loan-dependent loans management loans are collateral-dependent loans, or collateral-dependent loans management considers a loan to be collateral-dependent when foreclosure-dependent-dependent when foreclosure of a loan is collateral-dependent-Dependent a loan to be collateral-dependent when foreclosure of a loan-dependent-dependent-dependent-dependent when foreclosure of the the the dependent on a loan-dependent when foreclosure of collateral-dependent of collateral-dependent loans are considered-Dependent management considers"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?",
        "options": {
            "A": "Completion of Phase 4 trials before initial approval",
            "B": "An agreement to conduct post-approval confirmatory studies",
            "C": "Exemption from all clinical trials",
            "D": "Immediate proof of long-term survival benefit",
            "E": "Approval from international health organizations",
            "F": "Evidence of zero side effects"
        },
        "LLM_original_answer": [
            "What is any intellectual property-related claims.28. Our business-related claims;\u2022 intellectual property-related claims related claims."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?",
        "options": {
            "A": "The issuance of new senior secured notes",
            "B": "The maturity of $360.0 million aggregate principal amount",
            "C": "A decrease in interest rates",
            "D": "An increase in fair value adjustment",
            "E": "The sale of $360.0 million securities",
            "F": "The acquisition of additional senior secured notes"
        },
        "LLM_original_answer": [
            "What is that the United States of United States of America generally accepted in the United States of America and that we acceptable in accordance with the United States of America and that the United States of receipts are generally accepted in accordance with disbursements generally accepted in accordance with the States of America of America and that we acceptable accepted in the United States of America and that we have been accepted in accordance with the that we have been accepted in accordance with accounting generally accepted in the following theig that the United States of the States of the United States of the United States of America generally accepted that United States of the United States of America generally accepted accepted general United States of generally accepted in the United States of America and that that the United States of America and that United States of that Ocwen United States of the United States of generally accepted in accordance with accounting principles generally accepted in accordance with respectively Accepted in accordance with the United States of America and that are that the United States of these loans in the United States of United States of America generally accepted the United States of United States of America and that the United States of the United States of United States of America and that information that we believe of United States of the United States of United States of America and that the United States of America and disbursements of our disburse are not that are not only in the United States of our company\u2019s generally accepted accepted accepted accounting principles generally accepted in the- and that could be that required in accordance with accounting principles accepted accepted in accordance with the United States of America may be that we have been accepted in accordance with the United States of America and that the United States of accounting principles accepted in the reverse to the United States and that may be the United States of the United States of the United States of America and accepted in accordance with accounting principles generally accepted accepted in accordance with respectively accepted in the United States of which are accepted in the United States of America and accepted in accordance with the United states of America generally accepted that weathers and that we have been accepted in the United States of America and that we have accepted in the United States of America and that may be accepted in the United States of the accepted that we have been accepted that United States of that are not that may be accepted in the United States of United States of the United States of America accepted accepted that we are generally accepted in the Securities States of America and accepted in the United States of America and that are in accordance with which is that are generally accepted that the United States of America\u2019s United States of United States of accordance"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What rights did the company retain after the collaboration with Novartis concluded?",
        "options": {
            "A": "All of Novartis's intellectual property",
            "B": "The technology developed during collaboration",
            "C": "Its platform improvements not considered collaboration technology",
            "D": "The patent rights from BWH",
            "E": "Patent rights for all new programs",
            "F": "Worldwide rights to Novartis's products"
        },
        "LLM_original_answer": [
            "The TSC-eligible identifiable individuals and their organizations and transmission of certain types of health information on certain types of individuals and organizations, referred to preventively identifiable health information on certain types of organizations and their activities on certain types of health information on certain types of certain types of health information on certain types of such information, or health information, or organizations and organizations, referred to which are certain types of such as well as well as well identifiable health information on certain types of individuals and health information, including, such as well as well as well as well-in-transmitted identifiable health information on certain types of certain types of health information on certain types of certain types of individuals and certain types of such as well as well as well as well as well as well as well on a.Individuals and other than certain types of individuals and certain types of such as well as well as well as well as well-eligible health information on certain types of such information on certain types of certain types of certain types of health information on certain types of health information on certain types of individuals and organizations, including health information on certain types of certain types of certain types of certain types of health information on certain types of individually identifiable health information on certain types of health information on certain types of health information, including identifiable health information on certain types of such information on certain types of individuals and certain types of certain types of individuals and organizations and certain types of individuals and other types of individuals and certain types of certain types of certain types of such individuals and/orally identifiable health information on certain types of individuals and organizations, referred to individuals and organizations, or \u201corally identifiable health information on certain types of individuals and organizations and organizations that information on certain types of health information on certain types of certain types of certain types of certain types of health information, or \u201ccovered individuals and organizations, referred to certain types of the health information on certain types of health information on certain types of certain types of health information on a certain types of health information, or certain types of certain types of certain types of health information, including health information on certain types of health information on certain types of individuals and organizations, including certain types of individuals and organizations, including such individuals and organizations, or organizations and organizations and certain types of certain types of certain types of certain types of certain types of individuals and organizations, or organizations and organizations and transmission of certain types of certain types of certain types of certain types of certain types of certain types of certain types of health information on certain types of individuals and organizations, referred to the individually identifiable health information on"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What does the Anti-Kickback Statute (AKS) make illegal?",
        "options": {
            "A": "Manufacturing drugs without a license",
            "B": "Prescribing drugs without patient consent",
            "C": "Offering or paying remuneration to induce drug referrals",
            "D": "Selling drugs at a profit under federal programs",
            "E": "Importing drugs from unauthorized countries",
            "F": "Falsifying clinical trial data"
        },
        "LLM_original_answer": [
            "The aggregate aggregate, including aggregate, including clinical trial in the aggregate, excluding clinical trial liability, including clinical trial liability, including clinical trial liability, excluding clinical trial liability, including clinical trial liability may not be may not in the aggregate, including clinical trial liability in the aggregate aggregate liability in the aggregate aggregate aggregate aggregate aggregate aggregate aggregate aggregate aggregate aggregate aggregate aggregate aggregate aggregate, including clinical trial liability, including clinical trial in the aggregate in the aggregate, including clinical trial liability, including clinical trial liability in the aggregate, including clinical trial liability, including clinical trial liability, aggregate, including clinical trial may not be sufficient in the aggregate, including clinical trial liability in the aggregate, and clinical trial liability may not only clinical trial liability, including clinical trial liability, including clinical trial liability in the aggregate, including clinical trial liability, including clinical trial in the aggregate aggregate clinical trial liability in the aggregate aggregate aggregate clinical trial liability, including clinical trial liability, including clinical trial in the aggregate, including clinical trial liability, including clinical development of the aggregate liability, clinical trial liability, including clinical trial liability may not be in the aggregate, including clinical trial in the aggregate, including clinical trial liability, including clinical trial aggregate, including clinical trial liability, including clinical trial liability, including clinical trial liability, including clinical trial liability, including aggregate, including clinical trial liability, including clinical trial liability in the aggregate, including clinical trial in the aggregate, including clinical trial liability may not in the aggregate, including clinical trial liability may not be the aggregate liability, including clinical trial liability, including clinical trial liability may not the the aggregate, including the aggregate, including clinical trial liability, clinical trial clinical trial may not be sufficient to the aggregate, including clinical trial liability, including clinical trial liability, and clinical trial liability, including clinical trial liability, including clinical trial liability may not be may not be the aggregate, including clinical trial liability, excluding clinical trial liability, including clinical trial liability, and clinical trial liability, and clinical trial liability, including clinical trial liability coverage for clinical trial liability may not be may not be in the aggregate clinical trial liability coverage, including clinical trial liability, including clinical trial liability may not in the aggregate, including clinical trial liability in the aggregate aggregate aggregate aggregate clinical trial liability in the aggregate in the aggregate in the aggregate in the aggregate in the aggregate in the aggregate in the aggregate, including clinical trial liability in the aggregate, including clinical trial liability in the aggregate liability in the aggregate liability in the aggregate, including clinical trial liability in the aggregate liability in the aggregate insurance may not be may not be may not"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What does Delaware law limit regarding certain interested stockholders?",
        "options": {
            "A": "Their ability to vote in board elections",
            "B": "Their right to receive dividends",
            "C": "Their ability to change corporate policies",
            "D": "Their ability to cause mergers or acquisitions against the Board's wishes",
            "E": "Their eligibility to hold shares",
            "F": "Their power to appoint board members"
        },
        "LLM_original_answer": [
            "Deliber products, including the imposition of the result of technological improvements or the U.See\n\uff12\uff10\n\uff12\uff10MMddomission as a result of financial markets or the U.SECI apologize\nagric agricultural products and the products and the Russia ITEM 2024ITEM 2024ITEM "
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 15,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?",
        "options": {
            "A": "To increase the valuation of all liabilities",
            "B": "To provide detailed forecasts of economic trends",
            "C": "To update models based on credible evidence and ensure appropriate valuation practices",
            "D": "To calculate exact amounts for future policy benefits",
            "E": "To review marketing strategies for insurance products",
            "F": "To assess the financial performance of competitors"
        },
        "LLM_original_answer": [
            "The risk, and assumptions, and actuarial assumptions, and actuarial assumptions, and nonperformance risk, and actuarial assumptions, and actuarially determined assumptions, and assumptions, and nonperformance risk, and nonperformance risk, and nonperformance risk, and assumptions including assumptions, and assumptions, and actuarial assumptions. Nonperformance risk, and assumptions, and actuarial assumptions, and nonperformance assumptions. assumptions, and assumptions including assumptions, nonperformance risk, and assumptions, and actuared assumptions, and assumptions, and assumptions, and nonperformance risk, and nonperformance risk, and nonperformance assumptions, and discount rate assumptions, and nonperformance risk, and actuarially determined assumptions, and assumptions, and actuarially determined assumptions, and assumptions, and actuarially determined assumptions. assumptions, and assumptions, and actuarial assumptions, and determined assumptions. and assumptions, and assumptions, and assumptions, and assumptions, and assumptions, and actuarally determined assumptions including assumptions including assumptions. Nonperformance risk, and mortality, and assumptions, and actuarialial assumptions, and assumptions, and assumptions, and assumptions, and assumptions, and assumptions, and actuarial assumptions, and assumptions, and mortality assumptions, and actuar assumptions, and assumptions, and nonperformance risk, and nonperformance risk, and actuarially determined assumptions, and nonperformance risk including discount rate assumptions, and nonperformance risk, and nonperformance risk, and actuarially determined assumptions, and assumptions, and discount rate of nonperformance risk, and actuarial assumptions, and assumptions, and assumptions, and assumptions including assumptions, and nonperformance risk, and discount rate assumptions, and nonperformance risk, and nonperformance risk, and nonperformance assumptions, and nonperformance risk including the assumptions, or similar to which includes nonperformance risk, and ORSA 2021. assumptions, and judgment including assumptions, and nonperformance risk, and nonperformance risk, and assumptions including assumptions, and assumptions, and nonperformance risk, and nonactuarially determined assumptions, and assumptions, and assumptions, and nonperformance assumptions, and nonperformance risk, and actuar assumptions, and assumptions, and nonperformance risk, and actuarally determined assumptions, and actuarially determined assumptions, and actuarially determined assumptions, and nonperformance risk, and assumptions including assumptions, and assumptions, and nonperformance risk, and nonperformance risk, and nonperformance risk including assumptions including assumptions including discount rate assumptions, and nonperformance risk, and discount rate assumptions,"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What must be submitted to the FDA before starting human clinical trials for a new drug?",
        "options": {
            "A": "New Drug Application (NDA)",
            "B": "Biologics License Application (BLA)",
            "C": "Investigational New Drug (IND) application",
            "D": "Clinical Trial Report (CTR)",
            "E": "Good Manufacturing Practice (GMP) Report",
            "F": "Independent Review Board (IRB) approval"
        },
        "LLM_original_answer": [
            "What the clinical benefit assessment of HTA across the clinical benefit of HTA across HTA and clinical benefit of HTA across HTA across HTA across the clinical benefit assessment of HTA of HTA and clinical benefit of HTA across HTA of HTA across the clinical benefit assessment of HTA across the clinical benefit assessment of HTA across HTAwards of HTA across the clinical benefit assessment of HTA across HTA across HTA of HTA across the clinical benefit assessment of HTA across the clinical benefit assessment of HTA across the HTA across the HTA of HTA across the clinical benefit assessment of HTA across HTAmps positive across the clinical benefit assessment of HTA across the clinical benefit across HTA across HTA, and will be intended to HTA across HTA across HTA across HTA across the intended to harmonized to harmonize the HTA across HTA across the EUA of HTA across the HTA across the clinical benefit of HTA across the clinical benefit of HTA.Skinly intended to harmonize the clinical benefit assessment of HTA across the benefit of HTA across the clinical benefit assessment of HTA across the clinical benefit across HTA across the clinical benefit assessment of HTA and harmonize across the clinical benefit across the clinical benefit of HTA across HTA across the clinical benefit across HTA across the clinical benefit assessment of HTA across HTA across the clinical benefit of HTA will be intended to harmonization of HTA and the clinical benefit assessment of HTAwards of HTA will be intended to harmonize across HTA the clinical benefit assessment of HTA across HTA across HTA across HTA across HTA across HTA and intended to harmonized across HTA.Intented across HTA of HTA across HTA across HTA across the intended to harmonize the clinical benefit assessment of HTA across the HTA across HTA will be intended to HTA across the clinical benefit assessment of HTA across the clinical benefit assessment of HTA across HTA across HTA across HTA across the HTA HTA across HTA across the HTAFTER across the clinical benefit assessment of HTA across HTA will be intended to harmonize the clinical benefit assessment of HTA across the clinical benefit across the clinical benefit assessment of HTA across HTA across HTA across HTA and will be assessed across the clinical benefit assessment of HTA beyond the clinical benefit assessment of HTA.Intent\nThe clinical benefit across the clinical benefit across the clinical benefit assessment of HT"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What regulation did the New York State Department of Financial Services enact in August 2015 for virtual currency business activity?",
        "options": {
            "A": "CryptoLicense",
            "B": "CoinPermit",
            "C": "BitLicense",
            "D": "VirtualCoin License",
            "E": "DigitalCurrency Regulation",
            "F": "TokenTrade Accreditation"
        },
        "LLM_original_answer": [
            "The equipment financing equipment loan/lease/equipment loan/lease and/or existing equipment loan/financed equipment loan/lease and/or new, non-financed equipment loan/financed equipment loan/financed equipment loan/financed equipment loan/financed equipment loaned equipment loan/lease/financed equipment loan/equipment loan/equipment loan/lease and new equipment loan/non-financed equipment equipment equipment loan/leases and/or lease/equipment loan/equipment loan/leased equipment loaned equipment loan/financed equipment equipment equipment loan/equipment loan/financed equipment loan/financed equipment loan/lease/other equipment loan/lease/equipment loan/lease/lease/financed equipment loan/financed equipment loan/financed equipment loan/leased equipment and non-financed equipment financing and/or new, non-financed equipment loan/lease/non-financed equipment loan/lease/lease/loan/lease/financed equipment loan/financed equipment loan/lease/lease and/or new, non-financed equipment loan/lease and/or equipment loan/lease and new, non-financed equipment loaned equipment equipment/equipment loan/financed equipment loan/financed equipment loan/lease and new equipment loan/financed equipment loaned equipment loan/lease/lease/lease and/or new equipment loan/financed equipment loan/existing equipment loan/lease and/or existing equipment loan/lease/financed equipment loan/financed equipment loan/lease/equipment loan/financed equipment loan/lease and new, new, non-financed equipment loan/equipment loan/future equipment financing equipment loan/financed equipment loan/loan/financed equipment loan/financed equipment and new, non-financed, new, existing equipment loan/lease and new, non-financed equipment loaned equipment loan/equipment loan/financed equipment loan/financed equipment loan/equipment loan/leased equipment loan/financed equipment loan/lease/lease/lease/financed equipment loan/lease/lease/non-financed equipment loan/financed equipment loan/equipment loan/financed equipment loan/lease and new, new, non-financed equipment loaned equipment loan/leased equipment loans/equipment loan/lease/lease/lease and/or new, non-financed equipment loan/financed equipment loan/financed equipment loan/lease/financed equipment loan/financed equipment loan/financed equipment loan/lease and/or existing equipment loan/financed equipment loan/lease/lease/lease and/or new, non-fin"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What challenge is associated with an aging workforce at Duke Energy?",
        "options": {
            "A": "Increased security threats",
            "B": "Mismatch of skill set with future needs",
            "C": "Higher insurance premiums",
            "D": "Decreased operational reliability",
            "E": "Reduced interest in renewable energy projects",
            "F": "Difficulty in obtaining raw materials"
        },
        "LLM_original_answer": [
            "Question\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is one of the uncertainties associated with the pending merger with Cambridge?",
        "options": {
            "A": "Lack of interest from investors",
            "B": "Potential for delays in regulatory approvals",
            "C": "Shortage of qualified staff for integration",
            "D": "Incompatibility of business cultures",
            "E": "Difficulty in finding a new office location",
            "F": "Insufficient marketing budget"
        },
        "LLM_original_answer": [
            "One, risk weightings, and components, and qualitative judgements about components, and risk weightings, and risk weightings, and qualitative judgements about components, and components, qualitative judgements, risk weightings, and qualitative judgements about components, regulators, and risk weightings, and components, risk weightings, and qualitative judgements, and qualitative and components, risk weightings, and qualitative judgements, and qualitative judgements, and qualitative judgements, risk weightings, risk weightings and risk weightings, and qualitative judgements, risk weightings and risk weightings, and qualitative judgements about components, and qualitative judgements, risk weightings, risk weightings and risk weightings, risk weightings, risk weightings, risk weightings, risk weightings, risk weightings, risk weightings, and risk weightings, risk weightings, risk weightings about components, risk weightings about components, risk weightings, risk weightings, and qualitative judgements about components, and qualitative and the components, risk weightings, and qualitative judgements about components, risk weightings, and qualitative judgements, risk weightings, risk weightings, and the regulators\u2019 and qualitative and components, and the components, risk weightings, and qualitative judgements, risk weightings, risk weightings, risk weightings, risk weightings about components, and qualitative judgements about components, and components, and riskings and components, and risk weightings, risk weightings, risk weightings about components, risk weightings, and components, risk weightings, risk weightings, risk weightings, risk weightings, risk weightings, risk weightings about components about components, risk weightings, risk weightings about components, and the regulators about components, risk weightings and risk weightings, risk weightings and risk weightings, risk weightings, and components, risk weightings, risk weightings by the regulators about components, in components, risk weightings, and the regulators, risk weightings, and components, and qualitative judgements about components and the regulators, risk weightings and components, and components, and the regulators and components and qualitative judgements and risk weightings, and qualitative judgements about components, and qualitative judgements and qualitative judgements about components, and qualitative judgements about components and risk weightings and risk weightings and the regulators, and risk weightings, and qualitative judgements, and qualitative judgements about risk weightings, risk weightings, risk weightings, risk weightings"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is required for a drug or biological product candidate to be approved under the Accelerated Approval Pathway?",
        "options": {
            "A": "Completion of Phase 4 trials before initial approval",
            "B": "An agreement to conduct post-approval confirmatory studies",
            "C": "Exemption from all clinical trials",
            "D": "Immediate proof of long-term survival benefit",
            "E": "Approval from international health organizations",
            "F": "Evidence of zero side effects"
        },
        "LLM_original_answer": [
            "What as of November 1. Human Capitalization as of 2023, as of November 2023Diligance of November 2023 Human CapitalAs of November 2023 Human Capital Excluding November 2023 as of November 202 Human Capital As of November 11 Human Capitalization of November 2023Disease of November 2023Ded had as of November 1 Human Capitalization of November 2023 Human Capitalization of November 2023Disease of November 1 Human Capitalization of November 2023Distributed Human Capitalization of November 2023Distributed Human CapitalAs of November 30, as of November 2023. Human Capital as of November 2023Disease Portfolio PipelineAs of November 2023 Human CapitalAs of November 1. As of November 30, as of November 2023Dose as of November iver Capitalization as of November 75% of November 75% of November 3. As of November 2023. As of November 2023 Human Capital As of November 2023 Human CapitalAs of November 2 Human Capital as of November 1. Human CapitalAs of November 2023. As of November 2023 Human Capital Structure as of November 1 Human CapitalAs of November 1. Human CapitalAs of November 30% of November 2023, as of November 2023 human capital as of November 1 Human Capital As of 1 Human Capitalization of November 2023 Human Capitalized human capital as of November 2023 Human Capitalization of November 2023 Human CapitalAs of November 2023, we had as of November 2023. As of November 2023 human capital, we had 2023 Human Capital Structure as of November 2023 human capitalization of November 2023 Human Capitalization of November 2023 as of November 1. Human Capitalization of November 2023 Human Capitalization of November 2023. Human Capitalization of November 2023 Human Capitalization of November iverbalancing as of November 2023. Human CapitalAs of November 2023Disease of November 1 Human CapitalAs of November 2023 as of November 2023. Human Capital as of November 50% of November 50% of November 30 mg capital as of November 75% of November 2023Disease of November 2023 Human CapitalAs of November 2023 Human Capitalization of November "
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What financial event is planned for March 15, 2026, involving PHH\u2019s senior secured notes?",
        "options": {
            "A": "The issuance of new senior secured notes",
            "B": "The maturity of $360.0 million aggregate principal amount",
            "C": "A decrease in interest rates",
            "D": "An increase in fair value adjustment",
            "E": "The sale of $360.0 million securities",
            "F": "The acquisition of additional senior secured notes"
        },
        "LLM_original_answer": [
            "What Note 19 \u2014 Stockholders\u2019 Note 20 \u2014 Stockholders\u2019 Note 20 \u2014 Interest Expense, Interest Expense.Note 20 \u2014 Interest Expense.Note 12 \u2014 Interest Expense.Note 20 \u2014 Stockholders\u2019 Note 1 \u2014 Stockholders\u2019 and Note 12 and Interest Expense.Note 20 \u2014 Stockholders\u2019 Note 20 \u2014 Stockholders\u2019 and Interest Expense 20 \u2014 Stockholders\u2019  Interest Expense Expense, and Stockholders\u2019 Note 20 \u2014 Interest Expense Expense, and Note  Interest Expense Expense, and Interest Expense and Stockholders\u2019 and 20 \u2014 Stockholders\u2019 Note 15 \u2014 Stockholders\u2019 Equity.Note 20 \u2014 Interest Expense, Interest and Interest Expense 20 \u2014 Interest Expense.Note 20 \u2014 Interest Expense, Interest Expense, Interest Expense.Note \u2019 Equity \u2014 Stockholders\u2019 Interest Expense, respectively, Interest Expense.Note 12 Stockholders\u2019 Interest Expense, Interest Expense.Note 20 \u2014 Note  Note 20 \u2014 Interest Expense.Note 20 \u2014 Interest Expense and Note 20 \u2014 Interest Expense, and Note  \u2014 Interest Expense.Note 20 \u2014 Interest Expense Note 1 \u2014 Stockholders\u2019 Interest Expense Note 19 \u2014 Interest Expense.Note  Interest Expense, Interest Expense, Interest Expense.Note  \u2014 Interest Expense Expense Expense Expense Expense, and Interest Expense Note 20 \u2014 Interest Expense, and Interest Expense, and Interest Expense, and Interest Expense, and Interest Expense.Note 1 \u2014 Note 20 \u2014 Interest Expense.Note 19 \u2014 Interest Expense \u2014 Stockholders\u2019 Note 20 \u2014 Interest Expense, and Stockholders\u2019 Note 13 \u2014 Interest Expense, Stockholders\u2019 Equity, and Interest Expense, Interest Expense Expense, and Interest Expense.Note 2023 \u2014 Stockholders\u2019 Equity.Note 2023 \u2014 Equity, and Interest Expense.Note Interest Expense, and Interest Expense, and Interest Expense.Note 20 \u2014 Stockholders\u2019 Equity, and Related Equity, and Note 20, and  Interest Expense.Note 20 \u2014 1 Risk Management Expense.Note 20 \u2014 Interest Expense.Note  and Stockholders\u2019 and  Interest Expense.Note 20 \u2014 Stockholders\u2019 Note 20 \u2014 Interest Expense, respectively.Note 20 \u2014 Interest Expense Expense Expense.Note 19 \u2014 Interest Expense, and Interest Expense.Note  \u2014 Interest Expense, and Note 20 \u2014 Stockholders\u2019 Interest Expense, Interest Expense, Interest Expense, Stockholders\u2019 \u2014 Interest Expense \u2014 Interest Expense.Note 20 \u2014 Interest Expense, and Stockholders\u2019 Equity and Interest Expense, Interest Expense and Stockholders\u2019 Equity.Note 19 \u2014 Interest Expense Note 15 \u2014 Stockholders\u2019 Equity"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What rights did the company retain after the collaboration with Novartis concluded?",
        "options": {
            "A": "All of Novartis's intellectual property",
            "B": "The technology developed during collaboration",
            "C": "Its platform improvements not considered collaboration technology",
            "D": "The patent rights from BWH",
            "E": "Patent rights for all new programs",
            "F": "Worldwide rights to Novartis's products"
        },
        "LLM_original_answer": [
            "Based on-going with the Agency for the Services, the Agency for the Agency for the Department of the Agency for the Agency for the Agency for the Department of the Department of the Department of the Agency for the Department of the Department of the Department of the Department of the Department of the Department of the Department of the Department of the Department of the Agency for the Agency for Healthcare Services for Healthcare Services, the Department of the Department of Human Services, the Agency for the Agency for the Department of the Agency for Healthcare Services, the Agency for the Agency for the Agency for the Department of the Agency for the Agency for the Agency for the Agency for the Agency for the Department of the Department of the Department of the Department of Human Services and the Agency for the Department of immunization and Human Services, the Department of Healthcare Research and the Agency for the Agency for the Agency for the Department of the Department of the Department of Human Services, the Agency for the Department of Cancer Immunization of the Agency for example of the Department of Health Care and Human Services and the Department of the Department of the Department of the Department of the Department of immunopercarealbertcare Services, the Department of the Research and the Agency for the Agency for the Department of the Department of the Department of the Agency for the Department of the Department of the Department of the Department of the Department of the Department of the Department of the Department of the Department of the Agency for the Department of the Department of the Department of the Agency for the Department of the Department of the Department of the Department of the Agency for the Agency for the Department of the Department of the Department of the Department of the Agency for the Agency for the Department of the Department of the Agency for the Agency for Healthcare Research and the Agency for the Agency for the Agency for the Agency for the Agency for the Agency for the Department of the Agency for the Department of the Agency for the Agency for Healthcare Research and Human Services and the Agency for the Agency for Healthcare and the Department of the Agency for the Department of the Department of the Department of the Department of the Department of the Department of the Department of the Agency for the Agency for the Agency for Healthcare Research and the Agency for the Agency for the Agency for Healthcare Research and the Agency for the Agency for the Agency for Healthcare Research and the Department of the Agency for the Agency for the Agency for Healthcare Research and the Department of the Agency for the Agency for the Department of the Department of the Agency for the Department of the Department of the Agency for Healthcare Research and Quality and the Agency for Healthcare Research and"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What does the Anti-Kickback Statute (AKS) make illegal?",
        "options": {
            "A": "Manufacturing drugs without a license",
            "B": "Prescribing drugs without patient consent",
            "C": "Offering or paying remuneration to induce drug referrals",
            "D": "Selling drugs at a profit under federal programs",
            "E": "Importing drugs from unauthorized countries",
            "F": "Falsifying clinical trial data"
        },
        "LLM_original_answer": [
            "What would likely effect on-demand and would negatively effect of our stock price of the stock and, and price of stock and impair your stock stock and price of your stock and would impair our ability to our common stock and would impair our ability to our ability to some of our price of our common stock and would likely price of common stock and would likely impair our common stock and would impair our common stockholder and would likely and would impair your ability to ability to the ability to think a negative effect on the price of your stock and would impair your common stock stock and would impair our common stock price of our stock of common stock price of our ability topline and would impair our stock price of our ability to conduct a preclude a negative effect on our price of stock and would and, and would likely and would.In the price of your ability to the price of our ability to our price of our common stock price of our stock and our ability to our stock price of our stock price of our stock of stock of your stock price of stock price of our stock price of your stock price of stock and would negatively effect on-going effect on your stock and Amyly stock and your stock price of your stock and would impair your stock of our stock and stock and your stock of your stock and would likely have a positive. and impair your ability to the price of our ability to our price of our ability to think the ability to impair our stock and the price of our negative effect on our price of your ability to the price of your stock of our ability to your stock of your ability to a negative stock of the price of your stock. Your price of a negative effect on your price of your stock and price of your stock. As a negative effect of stock of your price of your stock and our own ability to treatability on our price price of stock, which price of your stock price of the price your stock and would likely price of your stock and would have a negative effect on your common stock and would impair our price of our ability to our price of our stock of our stock and would have a.May ability to our common stock price of our stock price of our ability to our stockholder\u2019s ability on the price of our stock and would likely price of our ability to think about the ability to answer to think stock.##.Conclusion.We have a claim of our stock stock stock stock stock stock stock stock stock stock stock stock stock stock stock price of our price of stock stock stock, your stock stock stock and would impair our stock price of your stock price of your stock"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What does Delaware law limit regarding certain interested stockholders?",
        "options": {
            "A": "Their ability to vote in board elections",
            "B": "Their right to receive dividends",
            "C": "Their ability to change corporate policies",
            "D": "Their ability to cause mergers or acquisitions against the Board's wishes",
            "E": "Their eligibility to hold shares",
            "F": "Their power to appoint board members"
        },
        "LLM_original_answer": [
            "What we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that a member's or counterparty\u2019s counterparty's or counterparty\u2019s default, counterparty\u2019s default, we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we consider a member's or counterparty\u2019s default management's or counterparty\u2019s risk management of\ufb01redemption or counterparty\u2019s or counterparty\u2019s default.In addition to facilitate our regulated derivatives clearing houses, we believe that we believe that we believe that we believe that we believe that we believe that we believe that we operate a member's or counterparty\u2019s default.In addition to our business activities and counterparty\u2019s default.In addition, in addition, in our critical infrastructure that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we have a member's or counterparty\u2019s technology have the critical infrastructure and critical infrastructure and technology, we believe that we believe that we believe that we believe that we believe that we believe that we believe that we have a member's or counterparty's or counterparty\u2019s or counterparty\u2019s default.In addition to support our systems and our business processes and our cyber security and counterparty\u2019s default risk management of critical infrastructure that we believe that we believe that we are subject to support our Risk Management of our industry-wide Risk Committee Risk Management of counterparty\u2019s default.In addition, we believe that we operate our business combinations, in our regulated futures markets, or counterparty\u2019s defaultparty\u2019s default.In addition, or counterparty\u2019s default.In our counterparty\u2019s default.In addition to a member's or counterparty\u2019s default, In addition, we have the industry-leading mortgage technology, we believe that we believe that we believe that we believe that we have a CCPserved that we have been a counterparty\u2019s or counterparty\u2019s default.In addition, we believe that we operate our Risk Committee's or counterparty\u2019s"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 15,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the purpose of the annual actuarial review (AAR) conducted by the company?",
        "options": {
            "A": "To increase the valuation of all liabilities",
            "B": "To provide detailed forecasts of economic trends",
            "C": "To update models based on credible evidence and ensure appropriate valuation practices",
            "D": "To calculate exact amounts for future policy benefits",
            "E": "To review marketing strategies for insurance products",
            "F": "To assess the financial performance of competitors"
        },
        "LLM_original_answer": [
            "What would result in fair value (spread (spread (spread (spreadable) spreads on the (spread (spread (losses would result in (decrease) lower)crease) in-the (spreads a higher (lower) fair value of the fair value) fair value of a higher (lower (higher (decrease in the higher (credit spreads)additional) would result in which would result in-force) fair market risk would result in the higher (lower (credit spreads) lower (credit (spreads in a higher (lower) fair value of the (spreads in a higher (lower) fair value of the higher) higher) in credit spreads would result in a higher (lower) fair value of credit spreads, higher (spread (credit spreads would result in fair value) higher (credit spreads, resulting in a higher (lower (decrease in a higher (lower) fair value of higher (lower (credit spreads would result in credit spreads would result in fair (lower (lower (lower (lower (credit spreads would result in fair (credit (lower (fair (decreits would result in the (lower (lower (lower (lower (lower (fair (lower) fair value of credit spreads) higher (credit spreads would result in a higher (lower (spreads) fair value) lower) credit spreads would result in a higher (lower (lower) fair (lower (credit spreads would a higher (lower (fair (fair (lower (lower (credit value of the) higher (de result in the fair value of higher) fair) fair market spreads would result in a lower (lower) fair value of the fair value (lower (spread in (decrease) in the (spreads in a higher (lower) fair value. Credit spreads) fair (spread) in credit spreads would result in (spread (lower) higher (decrests) fair value (credit spreads would result in (debt) higher (credit (credit spreads would result in the fair) fair value. Credit spreads would result in higher (debternal (credit (credit spreads) would result in (credit spreads would result in-the) lower) fair value of the fair (credit (lower (lower) fair value of the credit spreads) fair (credit (lower (credit (lower (fair (spread (credit) fair value of the fair (credit spreads would result in a higher (credit spreads would result in the fair value would result in credit spreads) fair market risk management (credit (decrease (lower"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?",
        "options": {
            "A": "When the product is highly effective in children",
            "B": "If the disease only occurs in children",
            "C": "When the product shows uncertain efficacy in adults",
            "D": "If the product is likely ineffective or unsafe in children",
            "E": "When there is sufficient pediatric market demand",
            "F": "If the product is cheaper than existing treatments"
        },
        "LLM_original_answer": [
            "Based on the provided document, the Pediatric Development in the EU (PDCO) can waive the obligation to provide pediatric clinical trial data under the following condition:\n\nD: If the product is likely ineffective or unsafe in children.\n\nThe document states that the Pediatric Committee on Clinical Trials of Medicinal Products for Children (PDCO) can waive the obligation to provide pediatric clinical trial data when these data are not needed or appropriate. This can occur if the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What factor could make it difficult for the company to retain key personnel?",
        "options": {
            "A": "Reduction in product sales",
            "B": "Delays in adopting management incentive plans",
            "C": "Expansion into new markets",
            "D": "Increased competition",
            "E": "Technological advancements",
            "F": "Change in stock prices"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factor that could make it difficult for the company to retain key personnel is the uncertainty and potential negative impact of a soft or hard fork on a network. This is because such events could lead to a material adverse effect on the company's business, financial condition, and results of operations, which in turn could affect the confidence of end-users in holding and transferring digital assets. The document also mentions the lack of financial incentive for developers to maintain or develop networks, as their work is not compensated, and the potential for a lack of resources to address emerging issues with network protocols. These factors combined could make it challenging for the company to retain key personnel who are essential to its operations and success."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?",
        "options": {
            "A": "Three years",
            "B": "Five years",
            "C": "Eight years",
            "D": "Ten years",
            "E": "Twelve years",
            "F": "Fifteen years"
        },
        "LLM_original_answer": [
            "To determine the number of consecutive years Duke Energy ranked first among North American combined gas and electric companies in the EEI's annual safety survey in 2023, we need to look for information in the provided document that indicates their ranking history. The relevant information is found in the section titled \"Operational Excellence, Safety and Reliability.\"\n\nThe document states: \"For the eighth consecutive year, we ranked first among North American combined gas and electric companies in Edison Electric Institute\u2019s (EEI) annual safety survey, and our gas operations organization finished in the top 10% for the third year in a row, according to the American Gas Association.\"\n\nBased on this information, Duke Energy ranked first for eight consecutive years in the EEI's annual safety survey."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Which factor is essential for increasing loan origination volume in the company's strategy?",
        "options": {
            "A": "Expanding international partnerships",
            "B": "Attracting and retaining skilled personnel",
            "C": "Reducing operational costs",
            "D": "Increasing online marketing efforts",
            "E": "Diversifying investment portfolio",
            "F": "Enhancing customer service training"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factor essential for increasing loan origination volume in the company's strategy is:\n\nB: Attracting and retaining skilled personnel\n\nThe document discusses various risks and challenges faced by the company, including cyber threats, competition, and the need for technological advancements. However, it emphasizes the importance of attracting and retaining skilled personnel as a cornerstone of the company's strategic plan. The company's ability to grow its loan origination volume is contingent upon its ability to attract and retain the requisite number of skilled and qualified personnel, especially in its commercial banking portfolios. The competitive marketplace for skilled personnel makes hiring, training, and retaining skilled personnel costly and challenging, and the company may not be able to increase the number of its loan professionals sufficiently to successfully achieve its loan origination targets."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?",
        "options": {
            "A": "Providing accurate healthcare information",
            "B": "Knowingly defrauding any healthcare benefit program",
            "C": "Sharing healthcare information with the patient's consent",
            "D": "Ensuring the security of health databases",
            "E": "Improving healthcare technology",
            "F": "Reporting a breach of security"
        },
        "LLM_original_answer": [
            "Based on the provided document, the prohibited activity under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA) is:\n\nOption B: Knowingly defrauding any healthcare benefit program.\n\nHIPAA's criminal statutes specifically prohibit knowingly executing or attempting to execute a scheme to defraud any healthcare benefit program or obtaining money or property by means of false or fraudulent pretenses, representations, or promises in connection with the delivery of or payment for healthcare benefits, items, or services."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?",
        "options": {
            "A": "Failure to expand subservicing income",
            "B": "Ocwen acquiring new MSRs unexpectedly",
            "C": "A change of control of Ocwen or PHH",
            "D": "Increase in Ocwen's financial reserves",
            "E": "Successful maintenance of service levels",
            "F": "Ocwen improving its technology systems"
        },
        "LLM_original_answer": [
            "Based on the provided document, the event that would allow MAV to terminate the Subservicing Agreement with Ocwen is:\n\nC: A change of control of Ocwen or PHH\n\nThe document states that MAV may terminate the Subservicing Agreement in the event of a change of control of Ocwen or PHH. This is one of the events of default that could lead to the termination of the agreement."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?",
        "options": {
            "A": "Emails of previous FDA meetings",
            "B": "Details of international marketing strategies",
            "C": "Data from device testing",
            "D": "Descriptions of the manufacturing process and non-clinical studies",
            "E": "Marketing plans and budgets",
            "F": "Consumer feedback surveys"
        },
        "LLM_original_answer": [
            "Based on the provided document, the submission to the FDA as part of a Biologics License Application (BLA) requesting approval to market a new drug includes:\n\n- Data from preclinical studies, including results of preclinical tests, manufacturing information, analytical data, any available clinical data or literature, and plans for clinical studies.\n- Descriptions of the manufacturing process and related to the FDA may be submitted as well as well-controlled substance or other than can be submitted under the product development of the product development of the product candidates for a ndication of a product sponsors are subject to market approval.The FDA may bevelarbiting the product development program.The FDA may be-issued to market approval of a product candidate product labeling, if the product development program, or a product candidates for a product candidate product development and other than those products that is a sponsor\u2019s product candidates for the product development program, or under the product development and/oro\u00ad\u2013inquiry.officiallycleavage the product development and/or a BLA: (i.e.given as part of a sponsor-requestedits use of the product candidates for the product, if the product candidates for the product, or biological products, or licensureg, or BLA BLA BLA BLA BLA: A BLA BLA BLA BLA: (or other thanxception offtor in the FDA approval of (1) in vitrolicensingual to market approval of the product development programs, or a) or a sponsor must befor a product development program, if the FDA approval and/or a product development programs, if any or licensuregathering a BLA BLA sponsor-requested by-product candidate product candidate.The BLA BLA BLA sponsor must be submitted as part of the product candidate.The FDA approval of a: The FDA may be submitted as part of a) or less than an application for the product candidates for the product, or licensureg., or accelerated approval of a BLA: (i.e.g."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is required for the renewal of a marketing authorization after five years?",
        "options": {
            "A": "Approval from the European Medicines Agency (EMA)",
            "B": "Independent clinical trials conducted in the past year",
            "C": "A re-evaluation of the risk-benefit balance",
            "D": "Proof of sales data from member states",
            "E": "A newly conducted preclinical test",
            "F": "An application fee for renewal"
        },
        "LLM_original_answer": [
            "Based on the provided document, the process for the renewal of a marketing authorization after five years involves a re-evaluation of the risk-benefit balance by the European Medicines Agency (EMA) for centrally authorized products or by the competent authority of the relevant EU Member State for nationally authorized products. The marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could cause a potential loss of revenue according to the document?",
        "options": {
            "A": "Discontinuation of services by third-party companies to clients",
            "B": "Increased competition in the market",
            "C": "Rising operational costs",
            "D": "Decreased demand for trading platforms",
            "E": "Improper licensing of data",
            "F": "Delays in transitioning to new service providers"
        },
        "LLM_original_answer": [
            "Based on the provided document, the potential causes of a loss of revenue are:\n\nA: Discontinuation of services by third-party companies to clients\nB: Increased competition in the market\nC: Rising operational costs\nD: Decreased demand for trading platforms\nE: Improper licensing of data\nF: Delays in transitioning to new service providers\n\nThe document does not explicitly mention the discontinuation of services by third-party companies to clients (Option A) as a cause for potential revenue loss. However, it does discuss the risks associated with owning clearing houses, which could be related to defaults by clearing members and our business and our business and other than any future acquisitions offtor other than in the following the foregoing offto\n"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 20,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?",
        "options": {
            "A": "Increase in statutory tax rate",
            "B": "Valuation allowance and charge to profitability",
            "C": "Reduction in business performance",
            "D": "Increase in future taxable income",
            "E": "Adjustment in dividend policies",
            "F": "Expansion of subsidiary operations"
        },
        "LLM_original_answer": [
            "Based on the provided document, the correct answer to the question \"What must be established if deferred income tax assets are deemed more likely than not unrealisable?\" is B: Valuation allowance and charge to profitability.\n\nDeferred income tax assets are assessed periodically by management to determine whether they are realizable. If, based on available information, it is more likely than not that the deferred income tax asset will not be realized, then a valuation allowance must be established with a corresponding charge to profitability measures. Such charges could have a material adverse effect on our financial condition and results of operations."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?",
        "options": {
            "A": "When the product is highly effective in children",
            "B": "If the disease only occurs in children",
            "C": "When the product shows uncertain efficacy in adults",
            "D": "If the product is likely ineffective or unsafe in children",
            "E": "When there is sufficient pediatric market demand",
            "F": "If the product is cheaper than existing treatments"
        },
        "LLM_original_answer": [
            "The document.Full Textbookcase spread in a lower (lower) fair value of PMID: (lower) of the fair value would result in a higher (lower)42value of theo\ntheValue-Benefits) lower.The European Credit spreads in the EU Regulatory Requirements for which would result\n\uff12\uff102.43 would result in the\nresponse) fair value.The U.Similarity in the European Commission (higher-than-exchange in the lower fair value of the fair value of the value of the wider (lower (lower (lower) fair price for the value) price.The U.Spreadmission in fair value would result in a lower (lower (lower) fair price.The European Union 43and market exclusivity of the product.Clinen) spreads would result in the United States and/orphaneticiousness of PediatricsClinical Consideration) 42FAU.Spreadoutvasion of the spread would result in a lower (lower) fair price.The credit spreads would result in a lower (lower) in a lower) lower) fair price.Theory spreads would result in a lower) fair price.The European Credit spreads would result in the document.\nAdecrease in the European Credit) The U.Similarities would result in a higher (lower) in the higher (lower) in the following this would result in credit spreads would result in credit would result in a higher) higher) lower) fair value) The C- spread) fair price in a higher (decrease in the higher (lower (increase in vitro in the price.The European Regulation (decrease) Other Healthcare Reform in the result in the result in) fair price.The European Regulation of the EU Regulation (or market exclusivity and (i\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What factor could make it difficult for the company to retain key personnel?",
        "options": {
            "A": "Reduction in product sales",
            "B": "Delays in adopting management incentive plans",
            "C": "Expansion into new markets",
            "D": "Increased competition",
            "E": "Technological advancements",
            "F": "Change in stock prices"
        },
        "LLM_original_answer": [
            "The value of the) fair market value.The value of the opposite spread would result in a lower (lower (lower) in the amount of the New Indebasedual) fair market price of the fair value of a higher (lower) on the value of credit spreads) 37 value of the fair market price of the same) fair market price of the amount of the fair market value of the fair market value of the amount.The fair value of thesolved)41value (lower) liquidity.The value of our business, and CREDITATION-41\ntokenId 41credit spread) in which would result in the fair value of the fair market price of our business, respectively, which would result in the price of our business, which could have a lower (lower) fair value, credit spreads) of our business interest rates would result in39fair (decrease in41 value of our business, which could result in excessesoteric risks that would result of our securities.The value of the19We may adversely affectation 41 in the spread would result in a higher (lower) fair market value of our business, in the fair) fair market price of the result in a lower (lower (spread in a lower (lower) fair market price of the price) in which would result in our business, in the fair market price of the price of the price of the fair value of the fair market price of the fair market price of our fair market price of our business, and) Item 41credit spreads would result in a lower fair) fair market value of our business, and other credit spreads would result in the fair market price of our business, prospects, or lower fair value of our) in the fair value)41)41in the fair market volatility in a higher (lower) fair market value of a lower) fair market value of our business, which could adversely affect the applicable to a higher (lower) fair market value of the price)41 in the market) would result in a lower fair market price of value of the fair value of our indebtedness of interest rates of a lower) lower) in the credit spreads would result in the amount of our securities price and value of our business, which could be4\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?",
        "options": {
            "A": "Three years",
            "B": "Five years",
            "C": "Eight years",
            "D": "Ten years",
            "E": "Twelve years",
            "F": "Fifteen years"
        },
        "LLM_original_answer": [
            "To be##table 2023##table 2023##table 50) fair value.The following) fair value.51##table 2023##table 50##table 2023%2023##table 50##table 51##table 2023##table 50)\ucd9c"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which factor is essential for increasing loan origination volume in the company's strategy?",
        "options": {
            "A": "Expanding international partnerships",
            "B": "Attracting and retaining skilled personnel",
            "C": "Reducing operational costs",
            "D": "Increasing online marketing efforts",
            "E": "Diversifying investment portfolio",
            "F": "Enhancing customer service training"
        },
        "LLM_original_answer": [
            "Based onetime loans and other assets39We have a higher credit spreads would result in which would result in the value of spread would result in the fair value) in a higher (decreativityour business, respectively.We have not enough capital39Our businesses and39\nresult in our credit risks associated costs associated costs to our business and other comprehensive income or other comprehensive income and other comprehensive income and other) 40stockholders\u201938 (lower (respectively (lower) or loss would result) would result in the fair value) in a lower (lower (or a higher (lower) fair value of value of $ 40or39 (spread would result in a lower (lower)Our strategic riskier) and a lower (respectively)Credit spreads would result in the following is also, which would result in the fair value of)40and security.The fair value of Boston Financial Services (debtwitness of our portfolio-wide fair value.We have a lower) of the fair value.The fair value of the estimated fair value of our portfolio (lower (decreases in the estimated fair value of the value of our credit spreads would result in the values of this would result in the39and a higher)39We may result in the amount of39and Distributions in the value of our business, or other than the amount of our businesses and/or non-bankruptcy of our loan participations in the fair value of the result in the fair value of our investment securities would result in the fair value of the fair value of our business and other)40We could prove to our39 in a higher (higher) fair value of our loan39We may be38fair value of our investment securities portfolio values of our securities portfolio.We also result of our side of our side of our39and that would39fair value of our financial condition.40\nA worsening of our39fair value of course)40(un)40)39)asure of our portfolio would result in a lower (lower) fair value of our39\nA:39 (or default on a lower (spread (respectively value of the amount of our liquidity.40 (or39 in the value of a lower (debtliability to value of the lower) fair value.Wealthreatments in the value of the value)40\n\"contextual spreads would result in the fair value would result in the value of credit spread) value.We have aLower credit spread.40Wealthreatments.40We also have been a higher (lower credit spreads in the"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?",
        "options": {
            "A": "Providing accurate healthcare information",
            "B": "Knowingly defrauding any healthcare benefit program",
            "C": "Sharing healthcare information with the patient's consent",
            "D": "Ensuring the security of health databases",
            "E": "Improving healthcare technology",
            "F": "Reporting a breach of security"
        },
        "LLM_original_answer": [
            "Under the fair price would result in a higher (lower) fair price.The Board of spreads would result in the greater (lower)credit spreads would result in the fair price.The mark would result in a higher (lower) fair price (fairness) fair price.The fair price (spread in the other (decrease in the spread.The credit spreads would result in a higher) fair price.The credit spreads would result in the value of credit spreads would result in the spread (decrease in the spread would result in any given (lower) fair price.The credit spreads.The credit spreads would result in 13\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?",
        "options": {
            "A": "Failure to expand subservicing income",
            "B": "Ocwen acquiring new MSRs unexpectedly",
            "C": "A change of control of Ocwen or PHH",
            "D": "Increase in Ocwen's financial reserves",
            "E": "Successful maintenance of service levels",
            "F": "Ocwen improving its technology systems"
        },
        "LLM_original_answer": [
            "Based on our business would result in our business, or other risks to MSR would result in the majority of Ocwenchapterspreadsomet value) in credit spread.The fair value.The failure to a lower) fair value of Ocwench Spreads. Answer:37fair value.38of our business and/orienterch\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?",
        "options": {
            "A": "Emails of previous FDA meetings",
            "B": "Details of international marketing strategies",
            "C": "Data from device testing",
            "D": "Descriptions of the manufacturing process and non-clinical studies",
            "E": "Marketing plans and budgets",
            "F": "Consumer feedback surveys"
        },
        "LLM_original_answer": [
            "As part of the result in a lower (lower) fair value of thes.Credituation of theo\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is required for the renewal of a marketing authorization after five years?",
        "options": {
            "A": "Approval from the European Medicines Agency (EMA)",
            "B": "Independent clinical trials conducted in the past year",
            "C": "A re-evaluation of the risk-benefit balance",
            "D": "Proof of sales data from member states",
            "E": "A newly conducted preclinical test",
            "F": "An application fee for renewal"
        },
        "LLM_original_answer": [
            "To Market Exemption in the other) in the fair value of the fair value.Their spreads would result in the desired therapeutic effect on the value.45would result) fair value.The credit spreads in a higher (lower) fair value of a higher) fair value.Their (spreads in the fair value) fair value.42credit spreads would result in fair value) fair value.45 would result in the fair value of the fair value of the fair value) fair value.The credit spreads would result in a higher (lower) fair value."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could cause a potential loss of revenue according to the document?",
        "options": {
            "A": "Discontinuation of services by third-party companies to clients",
            "B": "Increased competition in the market",
            "C": "Rising operational costs",
            "D": "Decreased demand for trading platforms",
            "E": "Improper licensing of data",
            "F": "Delays in transitioning to new service providers"
        },
        "LLM_original_answer": [
            "According to a lower (lower value of the value of our business, or credit spread) in the U.Seectione in the fair) in the higher (lower (spread in the same (respectively) in credit spread would result in a lower (lower) in higher) fair (or a higher (respectively) lower (lower) in higher) in a higher (lower (decrease in the fair value of the value of the lower) in credit spreads would result in a higher (higher (lower) fair value of our business would result in the following periods of the U.SUMCREDITINGenerality in the42reputation of the fair value in the following is higher (lower credit derivatives and other (higher (higher (higher (lower (debtmilitary credit derivatives and other)Market Correction)42revenue42credit spreads would result in the fair) fair value of our fair value would result in the market volatility in the opposite in the following) fair value.The outcome.The FCAUSE OFRisks would result in a lower (lower (lower (spread (lower (spread (lower (lower) fair value.The outcome.The U.Seevaluation of credit spreads would result.42fair (spread)42fair value of the fair value of the fair) fair value.The FCAHarm in a lower (lower) fair value.The outcome.42credit spreads.Regulatory risk factors that would result in a lower (fair value of the market data and/or emerging vulnerabilities, or market volatility) in the fairer) on the fair (lower) in the underlying market data loss (lower (debtwarrantedirective) fair value of our business and interest rate of the use of the) fair value.The Firms) 42credit spreads would result in a higher (higher (debtoks.42Fair Value at ICE Mortgage Technology and liquidity and other areas of our business, or other companies and credit derivatives and42ITEM 42)Credit) COMPETHEALTHESIS ITEM 42fairer) fair value.The FCAUSE OFRising in the lower)42fair value.The financial risk) in a lower) fair value of a higher (lower) fair value of the market data.42credit risk.The impact on the same) fair) fair) Financial Services\u2022 spreads would result in the U.SECXITEM 42credit spreads would result in22Fair value of credit spreads in the spread) PROCUREMENT OFRising in credit spreads would result in a lower) fair value of our business"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 20,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?",
        "options": {
            "A": "Increase in statutory tax rate",
            "B": "Valuation allowance and charge to profitability",
            "C": "Reduction in business performance",
            "D": "Increase in future taxable income",
            "E": "Adjustment in dividend policies",
            "F": "Expansion of subsidiary operations"
        },
        "LLM_original_answer": [
            "If we45and credit spreads would result of the value of the result in-force value of our business and other factors would result in the following is lower spreads would result in-force business risk of our investment margin or interest rate of our investment spread would result in-force value of value of) fair value of our investment would result in theoccurring) fair value of our investment margin) See \u201cSee \u201c\u2014credit spreads would result in-force) fair value of ourit would result of our derivatives risk.We seek) See \u201cNet investment returns on the occurrence of the occurrence of spread would result in-force)preadsometabolition) would result in-force would result in a lower (lower) fair value of our investment spread would result in-force value of lower) in-force value of our business and would result in-force) of our investment yields on the result in credit spreads would result in the amount of the lower) credit spread.The above) fair value of our45) Credit Risk of credit-linked spreads) would result in-force spread (lower) fair value of the) fair value of the market risk would result in-force) Inflation risk.Seequ) would result in the fair value of the opposite spread and 47) fair value of the lower)44Our investment spread would result in a lower) fair) fair value of our investment spread) fair value of the spread would result in the value of the fair value of lower fair value)44Our investment spread would result in a higher (lower) fair value of value of our fair value of the spreads would result in our investment margin. 45Fair value of the other risks in-force business and other) fair value of values of the credit spreads would resultsofactors in our business and other than a higher (non) risk asset values.Inflation (lower (lower (respect (decrease in-force spreads would result in a lower (decreasesstability of our spreads would result in a higher (lower) fair value.The value) fair value of the fair value) in credit spreads would result in a lower (lower (lower) fair value.The above (lower) fair value of the spread).Credit risk.Inflation spreads.The risk.InflationRisk of our business and other factors would result in-force value of our) spreads.The fair value) would result in credit spreads would result in a lower (lower) fair value of our investment spread) would result in a lower) spread in-force value) fair) fair value of the result in a lower (lower) fair value.The value"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?",
        "options": {
            "A": "When the product is highly effective in children",
            "B": "If the disease only occurs in children",
            "C": "When the product shows uncertain efficacy in adults",
            "D": "If the product is likely ineffective or unsafe in children",
            "E": "When there is sufficient pediatric market demand",
            "F": "If the product is cheaper than existing treatments"
        },
        "LLM_original_answer": [
            "Under the lower (lower)higher) fair value). An increase (lower (credit spreads would result in spreads would result in a lower (lower (higher (higher (higher (higher (higher (lower (lower (higher (lower (lower) spreads would result in spreads) fair value of38 (decrease) in higher (lower) fair spread would result in spreads would result in spreads would result in spreads would result in spreads) fair spread would result in spreads would result in spreads. Conversely, respectively in higher) fair) fair value. In the same in the fair (lower) fair value (lower (higher) higher) in the spread) would result in credit spreads would result in a lower (lower) fair value.41 (spread) in credit spreads would result in a higher (lower) lower) in fair (lower (lower (lower (lower) fair value.39value) fair value of the spread. The fair (lower (lower) fair spread in spreads would result in credit spreads would result in spreads would result in higher (lower) fair value. Credit spreads would result in the spread) spreads) in credit spreads would result in a lower (lower) fair value.39value in the credit spreads would result in the fair (lower (lower (lower (lower (lower) fair value.41 (lower (lower (lower (lower) fair value.41 (lower (lower (lower (lower) in the fair value (lower (lower (lower) fair) in credit spreads would result in a lower (lower (lower (lower (lower (higher) in credit spreads would result in a lower (lower) fair value. The value. An41credit spreads would result in a higher (lower (lower) in the higher (lower (lower (lower (lower (higher (lower (lower (increase (lower (lower (higher (lower (lower (higher (lower (lower (higher (higher (lower (lower) fair value) spreads) in a higher (lower (lower) fair value.41fair value.41result in the product is higher (lower) in the lower)41resulting) in fair value) spreads would result in credit spreads would result in a higher (lower (higher (lower (lower) fair spread would result in spreads would result in a higher) fair value of credit spreads) fair value of42higher (lower) fair value). An increase (credit spreads would result in the credit spreads would result in a lower (lower (lower) fair value."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What factor could make it difficult for the company to retain key personnel?",
        "options": {
            "A": "Reduction in product sales",
            "B": "Delays in adopting management incentive plans",
            "C": "Expansion into new markets",
            "D": "Increased competition",
            "E": "Technological advancements",
            "F": "Change in stock prices"
        },
        "LLM_original_answer": [
            "Based on the fair spread)higher) in fair spreads would result in a higher (lower) fair value of the fair value) fair value of credit spreads) in credit spreads would result in credit (lower (lower) fair value of value of the issuer in the higher (lower) fair value of the higher (spread) in credit spreads would result in credit spreads would result increase) in credit spreads) would result in spreads would result in a lower (lower) fair (lower (lower (lower (lower (lower) fair spread) in spreads would result in a lower (lower) fair value of the fair spread) in credit spreads would result in a lower (lower (lower (higher (spread in the fair spread) in the lower (spread) in spreads) fair (spread would result in higher (lower (lower) fair value of the fairer (lower) fair value of spreads) fair spread would result in spreads would result in a lower (lower) fair value of the spread)crease) in spreads would result in a lower (lower) fair value of value of spreads) in spreads would result in the opposite (lower (lower) fair spread. Credit spreads would result in the fair value) fair (lower (lower (lower) fair value of the result in a higher (lower) fair (lower (lower (lower) in a lower (lower) higher (lower (lower (lower (lower (lower) higher) value of the higher (lower (credit spreads would result in spreads would result in a lower (lower (higher (higher (higher (higher (higher (lower (lower (higher (lower (lower (higher (higher (higher (higher) in the fair spreads would result in higher (lower) fairer (lower (spread)crease) in spreads would result in a higher (lower) fair spread) spreads would result in the fair spread. Conversely, respectively in higher) fair) fair value of the higher (higher (lower (lower) fair spread."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?",
        "options": {
            "A": "Three years",
            "B": "Five years",
            "C": "Eight years",
            "D": "Ten years",
            "E": "Twelve years",
            "F": "Fifteen years"
        },
        "LLM_original_answer": [
            "To this would result in spreads) in credit spreads) in credit spreads would result in a lower (lower) fair value. The fair spread in credit spreads would result in spreads would result in the lower) lower (lower (lower (lower (lower (lower) fair value. In (lower (spread value.39 (lower (lower (lower) fair spread in spreads (lower (higher) fair spreads would result in a higher (lower (lower) fair value. In the opposite in fair value of spreads)crease in credit spreads would result in a lower (lower) fair value."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which factor is essential for increasing loan origination volume in the company's strategy?",
        "options": {
            "A": "Expanding international partnerships",
            "B": "Attracting and retaining skilled personnel",
            "C": "Reducing operational costs",
            "D": "Increasing online marketing efforts",
            "E": "Diversifying investment portfolio",
            "F": "Enhancing customer service training"
        },
        "LLM_original_answer": [
            "Based) in spreads would result in a lower (lower (lower (spread value of the spread)crease) in spreads would result in a lower (lower) fair value. The fair spread) in spreads would result in the opposite (lower (lower) fair value. An increase (lower) fair value. Spread (spread (lower (lower) fair value. Spreads would result in the higher (lower) in the higher (lower (lower (lower (lower) fair value of the fair value of our higher (lower)higher) value of Eastern Bank spreads would result in spreads would result in spreads would result in (lower (lower (higher (higher (spread would result in the higher (lower (lower (higher (lower (lower (higher (higher (lower) fair value of the fair value would result in higher (lower) fair value of credit spreads would result in credit spreads would result in spreads would result in spreads) fair spread would result in the fair value of the fair value would result in higher) fair value)fair value.34 (higher (lower (lower) fair value."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?",
        "options": {
            "A": "Providing accurate healthcare information",
            "B": "Knowingly defrauding any healthcare benefit program",
            "C": "Sharing healthcare information with the patient's consent",
            "D": "Ensuring the security of health databases",
            "E": "Improving healthcare technology",
            "F": "Reporting a breach of security"
        },
        "LLM_original_answer": [
            "Which result in the opposite) lower (lower (lower (lower (lower (lower) lower (lower (lower (lower (lower (lower (lower (lower (lower) lower (lower (lower (higher (higher (lower (lower (lower (lower (lower) fair value of the spread. The increase (lower) (lower) in the fair value). Annotated_label_ Credit spreads would result in the rate of credit spreads would result in credit) would result in credit spreads would result in higher (lower) fair value."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?",
        "options": {
            "A": "Failure to expand subservicing income",
            "B": "Ocwen acquiring new MSRs unexpectedly",
            "C": "A change of control of Ocwen or PHH",
            "D": "Increase in Ocwen's financial reserves",
            "E": "Successful maintenance of service levels",
            "F": "Ocwen improving its technology systems"
        },
        "LLM_original_answer": [
            "Based credit spreads would result in a lower (lower) fair value. The increase (lower (lower (lower (spread (lower (lower (lower) fair value. An increase (lower (lower) fair value. In (lower (lower (lower (lower (lower (lower (lower (lower (lower (lower (lower (higher) fair value) spreads) would result in spreads would result in spreads would result in a lower (lower (higher (higher (higher (higher (higher (lower (lower (higher (lower (lower (lower (higher (higher (higher) in credit spreads would result in a lower (lower) fair value of spreads would result increase) in spreads would result in a higher (lower (higher (lower (lower (higher (lower (lower (higher (lower (lower) fair value of the higher (lower (higher (lower) fair value)."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?",
        "options": {
            "A": "Emails of previous FDA meetings",
            "B": "Details of international marketing strategies",
            "C": "Data from device testing",
            "D": "Descriptions of the manufacturing process and non-clinical studies",
            "E": "Marketing plans and budgets",
            "F": "Consumer feedback surveys"
        },
        "LLM_original_answer": [
            "What would result in a higher (lower (lower (higher (lower (lower (higher (lower (lower) fair value of the higher (lower (higher (lower) fair spread) fair value of a higher) spreads).preadsquecrease) in credit spreads would result in a lower (lower) fair value of the fair) would result in credit spreads would result in spreads would result in) fair (lower (lower (lower (lower (lower) fair (lower (fair (spread (spread (lower (lower (lower (lower (lower (lower (lower (lower) higher (lower (lower (lower (lower (lower) fair spread (lower (lower (lower (lower) fair)crease in credit spreads would result in a lower (lower) fair value."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is required for the renewal of a marketing authorization after five years?",
        "options": {
            "A": "Approval from the European Medicines Agency (EMA)",
            "B": "Independent clinical trials conducted in the past year",
            "C": "A re-evaluation of the risk-benefit balance",
            "D": "Proof of sales data from member states",
            "E": "A newly conducted preclinical test",
            "F": "An application fee for renewal"
        },
        "LLM_original_answer": [
            "What would result in spreads would result in spreads would result in higher (higher) fair spread would result in the fair spread (lower (higher (lower (lower) fair value of the higher (lower (higher (lower) fair spread)credit (lower (higher) spread) in spreads) would result in credit spreads would result in a lower (lower) fair value. The fair in the fair spreads would result in spreads would result in the lower) fair (lower (lower (lower (lower (lower) fair (lower (fair (lower (spread. The fair spread (lower (lower (lower (lower (lower (lower) higher (lower (lower (lower (lower (lower) fair (lower (lower (lower (lower (lower) spreads) in credit spreads would result in a lower (lower) fair value."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could cause a potential loss of revenue according to the document?",
        "options": {
            "A": "Discontinuation of services by third-party companies to clients",
            "B": "Increased competition in the market",
            "C": "Rising operational costs",
            "D": "Decreased demand for trading platforms",
            "E": "Improper licensing of data",
            "F": "Delays in transitioning to new service providers"
        },
        "LLM_original_answer": [
            "Based on page  (higher) fair value of the lower (lower)higher (lower) fair value.credit spreads would result in spreads would result in spreads would result in higher (higher) fair spread would result in the fair spread (lower (higher (lower (lower) fair value of the higher (lower (higher (lower) fair spread)credit value of a higher) spread) in the fair in credit spread would result in the higher (lower (lower) fair value.39 (spread) in credit spreads would result in a higher (lower) lower) in fair spreads would result in a lower (lower) fair (fair value of spreads) fair spread.39 (lower (lower (lower (lower (lower (lower (lower) higher (lower (lower (lower (lower (lower) fair value of the higher (lower)credit (lower) spreads) in credit spreads would result in a lower (lower) fair value.)value of spreads)38 in spreads would result in credit spreads would result in the fair (lower (lower) fair value.39 (lower (lower (lower (lower) fair (lower (lower (lower (lower (lower (lower (lower (lower (lower (lower (lower) fair) in credit spreads would result in a lower (lower (lower) value.credit spreads)crease in credit spreads would result in a lower (lower) fair value."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 20,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?",
        "options": {
            "A": "Increase in statutory tax rate",
            "B": "Valuation allowance and charge to profitability",
            "C": "Reduction in business performance",
            "D": "Increase in future taxable income",
            "E": "Adjustment in dividend policies",
            "F": "Expansion of subsidiary operations"
        },
        "LLM_original_answer": [
            "If credit spreads would result in higher) fair value) value.46higher (lower (lower (lower) fair value).credit spreads would result in spreads would result in credit spread) in spreads would result in a higher (lower) fair value of higher (lower (lower (lower (decrease (higher (lower (lower (lower (lower (lower (higher (lower (higher) higher (spread) spreads would result in spreads would result in a lower (lower) fair value of spreads. An increase (higher (higher (higher (lower (lower (higher) higher (higher (lower (lower) in higher (higher (higher (lower) fair spreads would result in the higher (lower) in the lower) fair (lower (lower (higher) in fair spreads would result in a higher (lower) fair value of credit spreads would result in the fair (decrease in credit spreads would result in a higher (lower (lower) fair (lower (decrease in the higher (lower) fair value of the lower (decrease (decrease (spread spreads would result in spreads) fair) in credit spreads) would result in spreads would result in a lower (lower) fair value of the higher (lower (lower (lower) fair spread (spread would result in the higher (lower (lower) fair value. The above) in credit spreads would result in a lower (lower (lower (higher (spread in the fair (decrease (lower (spread) in fair value) spreads would result in the higher (lower (lower (lower (spread in credit spread (lower (lower (lower (lower) in spreads would result in the opposite (lower (lower) fair value of spreads would result increase) in spreads would result in a lower (lower) fair value of value of spreads would result in spreads would result in a lower (lower) fair value of B:higher (lower) fair value. An increase (lower (lower (lower) fair value of the same (lower (lower) fair (lower (lower (lower (lower (lower (lower) fair value of spreads would result in the lower (lower)higher (higher (lower (lower (lower) in spreads would result in spreads would result in a higher (lower (higher (lower (lower (higher (higher (lower (lower (higher (lower (lower (higher (higher (higher (higher) in the fair spread would result in higher (lower) fair value of credit spreads would result in credit spreads would result in"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?",
        "options": {
            "A": "When the product is highly effective in children",
            "B": "If the disease only occurs in children",
            "C": "When the product shows uncertain efficacy in adults",
            "D": "If the product is likely ineffective or unsafe in children",
            "E": "When there is sufficient pediatric market demand",
            "F": "If the product is cheaper than existing treatments"
        },
        "LLM_original_answer": [
            "Under the cost-effective cost or at all or maintain coverage at a reasonable cost-effective cost-effective coverage at a reasonable cost-effective cost-effective cost-effective data at all or be able to a reasonable cost-effective cost or obtainment may not be able to conduct our product quality, or obtainable cost-effective cost-effective cost-effective cost-effective cost-effective cost-effective cost-effective cost-effective cost at a reasonable cost-effective cost-effective cost-effective cost-effective cost-effective cost-effective cost or other than a reasonable cost or licensure of our clinical trial by-product-by-Approved NDA may not approved or obtainable 35clinical trial sponsor\u2019s product and/oro32product33or any or a clinical trial or clinical or we may not be able to maintain or any reasonable cost-effective cost or obtainable at all or may not at a reasonable assurance coverage at a reasonable cost-effective clinical trial coverage at a reasonable cost effective at a reasonable cost or obtainable not earlier clinical and/or clinical trial or the use of the product identity, or clinical and any or clinical and/or may not approved by usuable cost and, among other than the final product quality, or original ex-U.Similarly not later-stage 31or may not yet to maintain insurance coverage at a reasonable cost at a reasonable cost or maintain product or obtainable clinical and/or may not approved by the clinical development or may be34or may not at a reasonable and/or may not be able to a reasonable cost or reasonable cost or obtainable at a reasonable cost effective cost effective cost-effective cost-effective coverage at a reasonable cost-effective cost effective cost-effective cost effective at all or may not be able to a reasonable cost or obtain insurance coverage at a reasonable cost-effective cost effective clinical trial coverage at a reasonable cost effective cost effective cost-effective cost-effectively not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage for reasonable cost us at a reasonable cost-effectively may not otherwise than may not previously maintained at a reasonable cost-effective clinical trials or may not otherwise not at a reasonable expectations or may not at least a reasonable assurance of the clinical trials or biopharmyesterday may not at least cost-effective or clinical trial or a clinical trial sponsor\u2019s product development and may not otherwise required to our reasonable cost or the same or biotechnology may not at all or clinical and/or a reasonable cost-effective clinical trial or obtain insurance coverage at a reasonable cost-effectively maintain insurance coverage at a reasonable cost or at all or be able to maintain insurance may not be able to maintain insurance at a reasonable cost or obtainable at a reasonable cost effectively maintain"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What factor could make it difficult for the company to retain key personnel?",
        "options": {
            "A": "Reduction in product sales",
            "B": "Delays in adopting management incentive plans",
            "C": "Expansion into new markets",
            "D": "Increased competition",
            "E": "Technological advancements",
            "F": "Change in stock prices"
        },
        "LLM_original_answer": [
            "The document-to-period-to-period-to-period-to-period comparisons of our business, as well as well as well as a useful measure for period-to-period-to-period-to-period-to-period-to-period-to-period-to-period-to-\u00ad\u00ad\u00ad\u00ad\u2013for the Company, as well as well as well as well as well as well as well as well as well-to-period-to-periods.We may be\u00ad\u00ad\u2014There are also provides a useful measure for period-to-period-to-period-to-period-to-period-to-period-to-period-to-period comparisons of our business, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as provides a useful measure for period-to-period comparisons of our business, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as a useful measure for period-to-period comparisons of our business, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well.To the value for period-to-period-to-period-to-date comparisons of our business, as well as well as well as well as well as well as well as well as well-to-period comparisons of our business, as well as well as well as well as well as well as well as well-to-period-to-period comparisons of our business, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well.To the company-to-period-to-period-to-period-to-period-to"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?",
        "options": {
            "A": "Three years",
            "B": "Five years",
            "C": "Eight years",
            "D": "Ten years",
            "E": "Twelve years",
            "F": "Fifteen years"
        },
        "LLM_original_answer": [
            "In accordance to the Board of Duke Energy CorporationManagement of Duke Energy Corporation and the shareholders and the Board of Duke Energy Corporation and the Board of Duke Energy Corporation and the shareholders and the Board of Duke Energy Corporation and the Board of Duke Energy Corporation and the Board of Duke Energy Corporation and its affiliates of Duke Energy CorporationOpinion on a shareholder engagement and the Board of Duke Energy CorporationOpinion on the Board of Duke Energy CorporationDuke Energy CorporationDukeEnergy CorporationDuke Energy CorporationTo the Board of Duke Energy CorporationOpinion on the shareholders and the Board of Duke Energy CorporationOpinion on the Board of Duke Energy CorporationOpinion on the shareholders and the shareholders and the Board of Duke Energy Corporation and the shareholders and the Board of Duke Energy CorporationDuke Energy CorporationOpinion on the Board of Duke Energy CorporationOpinion on the shareholders\u2019Opinion on the shareholders and the Board of Duke Energy CorporationDuke Energy CorporationOpinion on the shareholders and the the shareholders of Duke Energy Corporation of Duke Energy CorporationCorporinion on the shareholders of Duke Energy CorporationDukeEnergy CorporationOpinion of Duke Energy Corporation:Opinion on the following the opinion on the Board of Duke Energy Corporation, and the shareholders and the Duke Energy CorporationDuke Energy CorporationDukeEnergy and the Duke Energy Corporation's Board of Duke Energy Corporation and the shareholders of Duke Energy Corporation:Opinion on the Duke Energy CorporationDukeEnergy Corporation's opinion on the shareholders and the Board of Duke Energy Corporation and the Duke Energy on the shareholders and the Board of Duke Energy Corporation\u2019sOpinion on the CIOpursuOpinionOpinion on the Board of Duke Energy Corporation of Duke Energy Corporation\u2019s the shareholders and the shareholders and the shareholders and the Duke Energy Corporation, to the shareholders of Duke Energy CorporationDuke Energy CorporationOpinion on the Audit and/or the Board of Duke Energy Corporation and the shareholders and the Board of Duke Energy CorporationDuke Energy CorporationDukeholders and the Board of Duke Energy CorporationWeissu201stake to the shareholders and the Board of Duke Energy CorporationDuke Energy Corporation:Opinion on the shareholders and the Board of Duke Energy CorporationDukeEnergy Corporation:Opinion the the shareholders andOpinion of Duke Energy CorporationDuke on the opinion on-going, Duke Energy Corporation:Opinion on the Duke Energy CorporationDuke Energy Corporation\u2019s financial currenergyEnergy Corporation's opinion on the shareholders and the shareholders and the shareholders and the Board of Duke Energy CorporationOpinion on the shareholders and the shareholders of Duke Energy CorporationDuke Energy CorporationDuke"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which factor is essential for increasing loan origination volume in the company's strategy?",
        "options": {
            "A": "Expanding international partnerships",
            "B": "Attracting and retaining skilled personnel",
            "C": "Reducing operational costs",
            "D": "Increasing online marketing efforts",
            "E": "Diversifying investment portfolio",
            "F": "Enhancing customer service training"
        },
        "LLM_original_answer": [
            "The Company\u2019s estimated to Eastern Bank\u2019s estimated as reported as applicable to the Company and other than our business activities, including our estimated uninsured deposits, reported as of 2023Eastern Bank\u2019s estimated uninsured deposits, reported in the Company\u2019s estimated uninsured deposits, as of December 2022, reported as of the estimated as of December 2023, 2023 estimated as of December 2023Estimated Uninsured to December 2023of December 2023Our estimated as of December 2023Eastern Bank Deposits estimated uninsured deposits, reported as of December 2023##table 202Estimated Uninsured as of Eastern Bank\u2019s estimated uninsured deposits and/or30uninsured 2021Deposit and reported as of December 2023##table 29Eastern Bank\u2019s##table uninsured deposits reported as of December 2023Eastern Bank\u2019s estimated as of December 2023, 2022Estimated Uninsured as of the acquisition growth, reported as of December 2023Eastern Bank Regulatory and any resulting in the Company and other than other than the estimated uninsured deposits, reported as of December 2023Eastern Bank of Eastern Bankruptcy as of December 2021Eastern Bank\u2019s estimated uninsured deposits reported as of our estimated uninsured deposits, reported as reported as of December 2023Estimated Uninsured Deposits as of December 2023estimated uninsured deposits, as of Eastern Bank of December 2023##table 2023, reported as of December 2023Estimated Unemployment, as of December 2023Estimated Uninsured deposits, reported as of the estimated uninsured deposits reported as of 2022of December 2023estimated uninsured deposits, 2022, and reported as of December 29uninsured as of December 30 adjusted as of December 2023.2022, as reported as reported as of December 2023.##table##table 2023or 2023 and reported as of the acquisition growthEastern Bankshares as of the estimated uninsured deposits, reported as well-31, reported as reported as of the estimated to the following the Company\u2019s benefits of the estimated uninsured deposits, 2023, reported as of December 28uninsured##table 2023Estimated Unavailable uninsured deposits, as well as of the estimated uninsured deposits, as reported as of December 2022Eastern Bank\u2019s estimated uninsured deposits, reported as reported as of Eastern Bank of our##table  with respect to 2022##table 2023unestimated uninsured deposits, 2023,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?",
        "options": {
            "A": "Providing accurate healthcare information",
            "B": "Knowingly defrauding any healthcare benefit program",
            "C": "Sharing healthcare information with the patient's consent",
            "D": "Ensuring the security of health databases",
            "E": "Improving healthcare technology",
            "F": "Reporting a breach of security"
        },
        "LLM_original_answer": [
            "Under the product or may exist, or may exist, or arise, or may exist or drug or may exist or may existi.evene.g., or the marketing authorization may exist, or patent or patent or may exist or may exist, or may exist, or may existences may exist or may exist, or may exist, or filing or filing of the marketing authorization or patent or may exist, or may exist or may exist, or filing or may exist, or patent or patent or may exist, or may exist, or may exist, or may exist, or may exist, or may exist or may exist, or may exist or may exist or arising or may exist, or patent or may exist, or may exist, or patent applications for our patents or may exist, or arise, or may exist, or may exist, or may arise, or patent applications, or may exist, or may exist, or may exist or filing of our patent applications, or may exist or may exist or may exist or may exist or filing of our patents or patent or patent applications or may exist or filing of our patents or patent or may exist or may exist, or may exist or may existences may existenthe may existentitlements or may existenthe approval of the product or for the existence, or granted under the product or may exist, or our medicinal products or may exist, or may exist, or may exist, or may exist, or may exist, or may exist, or filing or filing of our patents or may exist, or may exist, or may exist, or in the existence or may exist, or arising, or patent or our patents or may exist, or may exist or may exist, or may arise, or may exist or may exist, or may exist, or patent applications for our patents or patent applications, or may arise, or may existent or patent applications or patent applications or may exist, or may exist or may exist, or arising, or patent applications or arising or patent or patent or patent or may exist or may existentire may exist, or may exist or patent or arise, or may exist or may exist or arise, or arise or may exist, or patent or may exist or may exist, or arising or patent applications, or may exist or may exist, or may arise in the filing or arising, or arising in the patents or may exist, or may exist, or arise, or may exist, or arising in respect of our drugs or filing or patent or patent applications or may exist"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?",
        "options": {
            "A": "Failure to expand subservicing income",
            "B": "Ocwen acquiring new MSRs unexpectedly",
            "C": "A change of control of Ocwen or PHH",
            "D": "Increase in Ocwen's financial reserves",
            "E": "Successful maintenance of service levels",
            "F": "Ocwen improving its technology systems"
        },
        "LLM_original_answer": [
            "The document as compared to the fair value as compared to the fair value as compared to the majority as compared to the fair value as compared to 2022 due to service as compared to 27 due to a $0.1 million as compared to the $166.27, $166. AUMBSI have not as compared to the majority as compared to 2023 lower as compared to 202. A $166.22, as compared to $212.1 due to 2022, as compared to 2022 million as compared to 2022, as compared to the majority as compared to 2022 of a $0.1 million higher as compared to maturity as compared to the underlying as compared to the impact on a $166. A $166.See Item 2022, as compared to a $166.1 million as compared to the maturity as compared to the majority of $212. At December 30.As compared to maturity as compared to the $212.7.As compared to the majority of our coven as compared to the servicing advance rate as compared to the MSR and/or as compared to the $166.1 million as compared to the related to the underlying as compared to the $1, as compared to the loan servicing as compared to 2022 2022 as compared to $166.1, 2022, as compared to a $166.27Due to a $166.27, or trigger events as compared to the mortgage loan commitments as compared to the fair value of a $1 million as compared to the loan commitments, as compared to a $166. A $166. See Item  as compared to the value as compared to a $166.27.Our ability to the fair value.The fair value as compared to maturity as compared to the MSR valuation as compared to the servicing and/orce a $166. See Item 2022, as compared to maturity as compared to the fair value as compared to the fair value of $166.27, net worth of $166. A $166.27 as compared to the amount of $212. See Item 2022, as compared to 2022.0, as compared to 2022 due to the related to a $166. See a $166. $166.1 million higher as compared to the $166. 2022, which was $212.1 million higher as compared to the $166.27, and other as compared to 2022, as compared to the as compared to"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?",
        "options": {
            "A": "Emails of previous FDA meetings",
            "B": "Details of international marketing strategies",
            "C": "Data from device testing",
            "D": "Descriptions of the manufacturing process and non-clinical studies",
            "E": "Marketing plans and budgets",
            "F": "Consumer feedback surveys"
        },
        "LLM_original_answer": [
            "What is highly dependent on a single-agentive studies, and IND-enabling studies, and IND-enabling studies, and must-complete studies, and complete IND-enabling studies, or our current product candidates, and must complete IND-enabling studies, and highly dependent product candidates, and our current product candidates, and IND-enabling studies, and IND-enabling studies, and IND-enabling studies, and IND-enabling studies, and IND-enabling studies, and IND-enabling studies, IND-enabling studies, and IND-enabling studies, and complete IND-enabling studies, and current product candidates, and highly dependent on our current product candidates, and corresponding to complete IND-enabling studies for IND-enabling studies, or re-enabling studies directed at least-enabling studies, or otherwise, and, and, and must complete IND-enabling studies, or have used in the product candidates, or our current product candidates, or our current product candidates, and future IND-enabling studies enabling studies, and IND-enabling studies, and IND-enabling studies, and IND-enabling studies, and IND-enabling studies.We must complete IND-enabling studies, or our current product candidates, and IND-enabling studies, and complete product candidates, and IND-enabling studies, and complete IND-enabling studies.We are highly dependent on-targeting our current product candidates, and our current product candidates, and our current product candidates, and IND-enabling studies, and our current IND-enabling studies for our current product candidates, and complete IND-enabling studies, and IND-enabling studies, and IND-enabling studies under IND-enabling studies, and we cannot complete IND-enabling studies, and our current product candidates, and complete IND-enabling studies, and our current product candidates, and highly IND-dependent studies, and future product candidates, and we pay-enabling studies, and file, and must complete product-specific studies under IND-enabling studies, and must complete IND-enabling studies, and our current product candidates.We must complete IND-enabling studies, and IND-enabling studies.We are-enabling studies, IND-enabling studies, and our current product candidates, and IND-enabling studies, and IND-enabling studies, and IND-enabling studies for IND-enabling-enabling, and IND-enabling studies, and current product candidates, and IND-enabling studies, and IND-enabling studies, IND-enabling studies, and complete IND-enabling studies, and IND-enabling studies, and highly dependent IND-enabling studies, and highly IND-enabling studies, and complete"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is required for the renewal of a marketing authorization after five years?",
        "options": {
            "A": "Approval from the European Medicines Agency (EMA)",
            "B": "Independent clinical trials conducted in the past year",
            "C": "A re-evaluation of the risk-benefit balance",
            "D": "Proof of sales data from member states",
            "E": "A newly conducted preclinical test",
            "F": "An application fee for renewal"
        },
        "LLM_original_answer": [
            "The FDCA from such lawfully, for such law requires a\nAnswered in the drug sales in the U.Sales in the U.Sales of such as described in certain drug sales in the U.Sales of such disease or the FDA regulations for such drug for such as part of such as appropriate drug for such disease or condition 30The FDA will be recovered from such disease or condition or sales in the ACA, or analogously, as well established cGMPA drug for such disease or the U.Such disease or condition will be recovered from sales for such lawfully.Such disease or the U\nBased on the U.Suchineseffectiveness in the U.Such disease or other than the U.Sponsors of the U-requirements for such as well as described in the Drug Enforcement of the ACA requirements for such as a or the U.Sales in the U.Severgreenhouseholdover such law, or condition will not for such as a drug sales and sales and sales in the drug for such disease or condition for such drug for such disease or sales of the FDA exclusivity of the U.Such agency or sales of such disease or sales in the U.Such sales in the U.Such as of such as of the U.Such disease or recovered from such as afor such disease or for such as of the drug for such disease or other than the manufacturer\u2019s sales or condition will be recovered from sales of the U.Sales in the U1requirementiontreatment of the U.Sever since the U.Sales in the U\n34recoveries of the drug for such as appropriate and condition will be recovered from the U.Sever sales of such as such disease or condition will be recovered from sales of sales of such disease or sales in the drug sales of the FDA Drug for such as the drug for such as the U.Sales of the sales of the U.Such as aforesiduals in the U.Severgreen disease or condition will be recovered from such as amended sales in U.Sever sales in the FDA and the FDA may beclones, among other than the FDA for such law in the U.Such as a disease or condition will befor such as U.Sales for such disease or certain foreign sales in the U.Such as described in the U.Such disease or similar to recover from sales in the FDA has been enacted in the drug for such law, the ACA will be recovered from such disease or condition will be recovered from sales in the U.Sales in the FDA may"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What could cause a potential loss of revenue according to the document?",
        "options": {
            "A": "Discontinuation of services by third-party companies to clients",
            "B": "Increased competition in the market",
            "C": "Rising operational costs",
            "D": "Decreased demand for trading platforms",
            "E": "Improper licensing of data",
            "F": "Delays in transitioning to new service providers"
        },
        "LLM_original_answer": [
            "What is a mortgage technology sector, or agency or the sector, among other of the mortgage technology sector, or we on our on our business activities of our business activities and our sector, or other than we have a surge against us against other than we may beause and other technology sector, which we have been a resurgence of our sector, and/or mortgage technology. dockettyrecovery sector, and the mortgage technology sector, mortgage technology sector, or our own against against other technology sector, and mortgage technology sector, and we compete against other technology against other technology sector, including against other technology sector, and our business sector, and/or mortgage technology sector, and/or we do. In the sector, which could compete against other we compete against other than we compete against other technology sector, we compete against other than other than we compete against other than we compete against other than we compete against against against against mortgage technology sector, and other against other technology providers, including other technology sector, and our sector, we compete against other technology sector, and against other technology sector, and against other technology sector, and compete against other technology sector, or our own sector, and other technology sector, and our business and other technology sector, and continue to the mortgage technology sector, including our mortgage technology sector, and compete against other technology against other technology sector, and other technology sector, the mortgage technology sector, and our mortgage technology sector, and our business activities technology sector.In the mortgage technology sector, and other technology sector, and other technology sector, and other technology sector, and our regulatory regimes than we are regulated mortgage technology sector, compete against other technology sector, and continue against other technology sector, including mortgage technology sector, and compete against other technology sector, which may technology sector, or our mortgage technology sector, we compete against other than we are In the mortgage technology sector, we compete against against other than we compete against the mortgage technology sector, including settlement and participants, or mortgage technology sector, and other technology sector against other technology sector, and continuing mortgage technology sector, and related to the sector, which may be a material adverse to our business activities of our mortgage technology sector, which compete against other technology sector, we do.In the mortgage technology sector, we compete against other technology against other than we compete against other technology sector, and compete against other than we compete against other technology sector, and the regulatory sector, along with respect of our business.29. Our organizational documents, including our mortgage technology sector, including the mortgage technology sector, and/or mortgage technology sector,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 20,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?",
        "options": {
            "A": "Increase in statutory tax rate",
            "B": "Valuation allowance and charge to profitability",
            "C": "Reduction in business performance",
            "D": "Increase in future taxable income",
            "E": "Adjustment in dividend policies",
            "F": "Expansion of subsidiary operations"
        },
        "LLM_original_answer": [
            "Based results of operations, the results of operations, and businesses and businesses and results of operations of the results of operations of operations, the results of the results of operations, financial condition and the results of operations of operations of the businesses and businesses and businesses included in-force of operations, including the results of our financial condition and the included in-force of operations and business and financial strength of operations of our results of operations of the results of operations of operations, or the results of the results of the results of the operations of the results of the results of the results of the results of operations, operations of the companies and businesses are included in the results of operations results of results of operations, results of results of operations of operations, results of operations and financial condition and businesses and financial condition of the results of the results of the business and business and businesses and businesses and businesses and the results of operations of operations of the results of results of operations of operations, or operations operations of operations, and the results of the results of operations of operations, the results of operations, the impact of the impact of the impact of operations of operations of the companies and businesses and businesses and the results of operations and businesses included in-force of operations of operations of the results of operations of operations, or financial results of the results of operations, businesses and businesses and businesses and results of the results of operations are of operations, or operations of operations of operations and businesses included in-force results of the companies and businesses and businesses and results of operations, the results of operations, the results of operations of operations of operations of the results of the results of operations of operations of operations of results of operations, financial condition and businesses and businesses and the results of operations of results of operations of results of results of results of results of results of results of results of operations of results of results of operations, financial condition of operations of operations of operations of results of operations of operations of the results of the results of operations of operations, financial strength of operations, or financial condition of results of operations, the results of business and businesses and businesses and businesses included in the results of operations of operations of operations, business and businesses included in the results of operations of operations of the results of the results of the results of operations, or financial markets, or financial strength of results of the results of the results of operations of operations, results of operations of results of financial results of operations of results of operations are included results of the results of operations are included in the results of operations, financial results of operations of operations of operations of operations of"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?",
        "options": {
            "A": "When the product is highly effective in children",
            "B": "If the disease only occurs in children",
            "C": "When the product shows uncertain efficacy in adults",
            "D": "If the product is likely ineffective or unsafe in children",
            "E": "When there is sufficient pediatric market demand",
            "F": "If the product is cheaper than existing treatments"
        },
        "LLM_original_answer": [
            "Under the FDA-approved products and cannot predict if the FDA will not approved for our other than cannot predict if the safety and cannot predict if the development candidates and cannot predict if the FDA will not bevacation.\nOther Information for our other than the FDA approval and cannot predictability and cannot predictability cannot predict if the timing if the FDA will be well-being candidates and cannot predict if the results and cannot predict if the product candidates and cannot predict if the clinical testing and cannot predict if the FDA will bevelocellular candidates and cannot predict if the FDA will not beaknowledge or cannot predict if the efficacy and cannot bevacine cannot predictability of the FDA will not bevacineos= 18Prelating \u25aa= 15Clinical Development and cannot predict if the following the preclinical testing and cannot predict if the FDA will not only for our other product candidates and cannot predict if the TGF or predict if the FDA will not bevac\nCompleted Product Development and cannot predict candidates and cannot predict if the FDA will approve our product candidates and cannot predict if the FDA will bevelopclinical testing and cannot predict if the subject engagement and cannot predict if the preclinical testing and cannot predict if the product candidates and cannot predict if the FDA will not predict if the FDA will not bevelocandidates for our other product candidates and cannot predict if the product candidates and cannot predict if the FDA will approve our other than the FDA will not predict if the FDA cannot predict if the FDA will not predict if the FDA will be able to our other product candidates and cannot predict if the FDA will not bevel=Based oncollectedoporinhibitors or predict if the FDA will not only predict if the FDA will not only predict if the FDA will not only if the FDA will bevacinefficience and cannot predict if the FDA cannot predict if the FDA approval and cannot predict if the FDA approval and cannot predict if the TGF or cannot predict if the FDA cannot predict if the FDA will be required pediatric obesity and cannot predict if the FDA will not yet cannot predict if the FDA will continue if the FDA will not only for our product candidates and cannot predict if the clinical testing and cannot predict if the FDA will bevac or if the FDA will bevelocanemia or cannot predict if the FDA will bevacationsimilar if the FDA will not be approved for our other product candidates and cannot predict if the the FDA will not be able to the FDA will be the the the the FDA will be subject matter the FDA will not be able to the"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What factor could make it difficult for the company to retain key personnel?",
        "options": {
            "A": "Reduction in product sales",
            "B": "Delays in adopting management incentive plans",
            "C": "Expansion into new markets",
            "D": "Increased competition",
            "E": "Technological advancements",
            "F": "Change in stock prices"
        },
        "LLM_original_answer": [
            "What is perpetual, non-transferable, non-transferable (except as a perpetual, except (except Celsius of perpetual, (exceptable,except as a perpetual, and transactions in the (except to the perpetual, (excepted (except transferable (except to us\nSee perpetual, non-transferable Celsius of which grant to Celsius of a perpetual, non-transferable, non-transferable as described above, non-transferable (except transferable (except for the perpetual, except for our business (except (except (except transferable (except for our of which we\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?",
        "options": {
            "A": "Three years",
            "B": "Five years",
            "C": "Eight years",
            "D": "Ten years",
            "E": "Twelve years",
            "F": "Fifteen years"
        },
        "LLM_original_answer": [
            "In the Duke Energy Interest Entities, \u201cThe Duke Energy RegistrantsThe Duke Interest Entities.\u201dThe Duke Energy Registrants\u2019The Duke Energy RegistrantsThe Duke Interest Entities.\u201dThe Duke Energy Energy Registrants\u2019The Duke Energy Energy Registrants\u2019The Duke Energy Registrants."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which factor is essential for increasing loan origination volume in the company's strategy?",
        "options": {
            "A": "Expanding international partnerships",
            "B": "Attracting and retaining skilled personnel",
            "C": "Reducing operational costs",
            "D": "Increasing online marketing efforts",
            "E": "Diversifying investment portfolio",
            "F": "Enhancing customer service training"
        },
        "LLM_original_answer": [
            "Based, in all material respects, as we have been issued, as we have material respects, in all material, in our opinion, in our opinion, in our opinion, all material respects, in our material respects, in all material statements, as of the material respects, in our material respects, in all material, at December \u95ee\nAnswerer, as at this Annual Report of Eastern, in our opinion, in our material respects, in all material respects, in all material, in our opinion, in our opinion, in all material respects, in our opinion, in our material respects of Eastern Bank Holding Company\u2019s, in all material respects, in our opinion, in our opinion, in our opinion, in all material respects, in our opinion, in all material respects, as administered, as of our opinion, in our opinion, in all material respects, in our material respects, in all material respects, in our opinion, in all material respects, in our material respects, in our opinion, in our material respects, in our opinion, in our opinion, in all material, as of record, in our opinion, in our opinion, in our opinion, in all material material material respects, in our opinion, in our opinion, in our opinion, in our opinion, in our opinion, in all material respects, in our opinion, in our financial statements, in all material respects, in our opinion, in our opinion, in our financial statements present fairly, in all material respects, in all material respects, in all material, in our opinion, in all material respects, in our opinion, in our opinionated, in our opinion, in our opinion, in our opinion, as ofcertainly, in all material respects, in our financial conditionally, in all material respects, in our opinion, in our opinion, in all material respects, in our opinion, in our opinion, in our material respects, in all material respects, in all, in all material respects, under our material respects, in our opinion, in our material respects, as we believe, in our material respects, in all material respects the Federal Deposit statements present fairly, in all material respects, in our opinion, in our opinion, in all material, in all material respects, in all material respects, in our opinion, in all material respects, in all material respects, in all material respects, in our opinion, in our opinion, or our material respects, in our opinion, in our opinion, as of the same material respects, in our material"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?",
        "options": {
            "A": "Providing accurate healthcare information",
            "B": "Knowingly defrauding any healthcare benefit program",
            "C": "Sharing healthcare information with the patient's consent",
            "D": "Ensuring the security of health databases",
            "E": "Improving healthcare technology",
            "F": "Reporting a breach of security"
        },
        "LLM_original_answer": [
            "Under the applicable drug candidate drug candidate drug candidate drug candidate.27Drug candidate drug candidate. To pursue further need for additional capital to pursue further development or commercialization of the applicable drug candidate or the applicable drug candidates.27.Risks or the applicable drug candidate to pursue additional capital to pursue further development or to pursue further development or applicable drug candidate or to pursue further development or to pursue further development or the applicable drug candidates or applicable drug candidate or the applicable drug candidate to pursue further development or a need for further development or a need for the applicable drug candidate or need for the applicable drug candidate. More capital to pursue further development or drug candidate. More than a need additional capital need for additional capital to pursue further need for additional capital to pursue further capital to pursue further development of the applicable drug candidate or a need for the subject matter or need for need for the applicable drug candidate capital to pursue additional drug candidate or drug candidate capital.The drug candidate to pursue further development or need for further development or need for the applicable drug candidate drug candidate or a need for additional capital to pursue further development or the applicable drug candidate or the applicable drug candidate or the applicable drug candidate to pursue additional capital or the need additional capital to pursue further development or other capital to pursue further development capital to pursue further capital drug candidate or to pursue further capital to pursue further development of additional capital to pursue additional capital topline of the applicable drug candidate topline or a need for additional capital to pursue further development or commercialization of the applicable drug candidate or biotechnology to the applicable drug candidate.27Clinical Development or the applicable to be approved drug candidate to be developed drug candidate to pursue further capital to the applicable drug candidates of the applicable drug candidate to the applicable drug candidate or commercialization of the drug candidate to the applicable drug candidate or other capital to pursue further development or a need additional capital or drug candidates.27Clinical trials or applicable drug candidate or a need for further development or need for further development or to the need for the applicable drug candidate or biotech candidates to pursue further development or the applicable drug candidate to pursue further capital or to pursue a need for the applicable drug candidate or other than the applicable drug candidates or a need for the applicable drug candidates or to pursue further development or commercialization of the applicable drug candidate or the applicable drug candidate to pursue further development or commercialization or a need for the applicable drug or need for further development or to further capital to the applicable drug candidate or product or a need for the applicable drug candidate.27Drug candidate or additional capital to pursue further development or commercialization of"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?",
        "options": {
            "A": "Failure to expand subservicing income",
            "B": "Ocwen acquiring new MSRs unexpectedly",
            "C": "A change of control of Ocwen or PHH",
            "D": "Increase in Ocwen's financial reserves",
            "E": "Successful maintenance of service levels",
            "F": "Ocwen improving its technology systems"
        },
        "LLM_original_answer": [
            "Based as the market impacts under shock scenarios, market impacts under shock scenarios, and other factors, and liquidity impacts under shock scenarios under shock scenarios under shock scenarios under shock scenarios, liquidity impacts under shock scenarios, and other factors.As the market scenarios under shock scenarios, and other factors, and other shock scenarios, and other factors under shock scenarios under shock scenarios, and liquidity impacts under shock scenarios, the market conditions under shock scenarios under shock scenarios, and other shock scenarios under shock scenarios, and other factors under shock scenarios, and other factors under shock scenarios, and other factors.As the market risk scenarios.As the shock scenarios, and other factors under shock scenarios, liquidity risk exposure, and other factors, and other factors.As the market risk exposure to shock scenarios, and other factors, and other factors, as shock scenarios, as the market conditions.As the market conditions, and other factors as the market conditions, and other factors under shock scenarios, liquidity impacts on shock scenarios, we are shock scenarios, liquidity impacts under shock scenarios, liquidity impacts under shock scenarios, and other factors.The market shock scenarios under shock scenarios, liquidity impacts under shock scenarios, and shock scenarios, and other factors under shock scenarios, and shock scenarios, liquidity impacts on shock scenarios, and other factors under shock scenarios, liquidity impacts under shock scenarios, shock scenarios, liquidity impacts under shock scenarios under shock scenarios, and other than may result in the market impacts under shock scenarios, and other factors under shock scenarios, and other than shock scenarios, liquidity impacts under shock scenarios, and other than could be as well under shock scenarios under shock scenarios under shock scenarios, liquidity impacts under shock scenarios, and other factors under shock scenarios under shock scenarios under shock scenarios, and/or shock scenarios, and other factors under shock scenarios, and other factors, and other factors, and other factors, and other factors, and other factors under shock scenarios, and other factors.Weak shock scenarios, and/or other factors.We have shock scenarios, liquidity impacts under shock scenarios, and/or other than shock scenarios, and other factors.We are contract risk exposure scenarios, and other market stress scenarios, or other than risk exposure to the as well under shock scenarios, and/or shock scenarios, and other factors under shock scenarios under shock scenarios.As the market conditions under shock scenarios, and other participants.As the market risk exposure to the market shocks scenarios, and other factors, and other factors under shock scenarios, and other factors.As the market shock scenarios, and other shock scenarios, and other factors described shock scenarios, and other factors under shock scenarios, shock scenarios,"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?",
        "options": {
            "A": "Emails of previous FDA meetings",
            "B": "Details of international marketing strategies",
            "C": "Data from device testing",
            "D": "Descriptions of the manufacturing process and non-clinical studies",
            "E": "Marketing plans and budgets",
            "F": "Consumer feedback surveys"
        },
        "LLM_original_answer": [
            "Whatsoever we have initiated clinical trials for certain of our product candidates, although we have initiated clinical trials for certain of our product candidates, although we have initiated clinical trials for certain of our product candidates, which have initiated clinical trials for certain of our product candidates, certain of our product candidates, although we have not beaknowledge\nanswered\n_ctxt_candidates for certain of our product candidates, which are not only product candidates, although we have initiated clinical trials for certain of our product candidates, although we have initiated clinical trials for certain of our product candidates, which we have initiated clinical trials for certain of our product candidates, we have initiated clinical trials for certain of our product candidates, we have initiated clinical trials for which have initiated clinical trials for certain of our product candidates, although we have initiated clinical trials for certain of our product candidates, we have initiated clinical trials for certain of our clinical trials for certain of our clinical trials for certain of our clinical trials for certain of our clinical trials for certain of our clinical trials for our clinical trials for certain of our have initiated clinical trials for which we have initiated clinical trials for certain of our product candidates, we have initiated clinical trials for certain, we have initiated clinical trials for example, we have initiated clinical trials for certain of our clinical trials for certain of our clinical trials for certain of our clinical trials for certain of our product candidates, we have initiated clinical trials for certain of our product candidates, we have initiated clinical trials for certain of our clinical trials for certain of our clinical trials for certain of our product candidates, we have initiated clinical trials for certain of our product candidates, we have initiated clinical trials for certain of our clinical trials for certain of our clinical trials for certain of our product candidates, we have initiated clinical trials for certain of our clinical trials for our product candidates, we have a product candidates, we have initiated clinical trials for certain of our product candidates, we have aAlthough we have initiated clinical trials for certain of our clinical trials for our product candidates, we have initiated for which have initiated clinical trials for certain of our product candidates, for which are currently, although we have initiated clinical trials for certain of our product candidates, although we have initiated clinical trials for certain of our product candidates, or TCR\n_ctxt candidates, which are not all of our product candidates, we have initiated clinical trials for certain of our product candidates of our product candidates, and, although we have initiated clinical trials for certain of our product candidates, we have initiated clinical trials for certain of our product, although we have initiated clinical trials for"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is required for the renewal of a marketing authorization after five years?",
        "options": {
            "A": "Approval from the European Medicines Agency (EMA)",
            "B": "Independent clinical trials conducted in the past year",
            "C": "A re-evaluation of the risk-benefit balance",
            "D": "Proof of sales data from member states",
            "E": "A newly conducted preclinical test",
            "F": "An application fee for renewal"
        },
        "LLM_original_answer": [
            "To justify so that we believe that market exclusivity is no longer is no longer is no longer justified so that is no longer justified.In the EU, during the market exclusivity is no longer so that market exclusivity is no longer so that market exclusivity so that market exclusivity so that market exclusivity, during the period of an NDA during the exclusivity is no longer market exclusivity so that exclusivity so that market exclusivity so that exclusivity is no longer justified.In the EU, if market exclusivity period of market exclusivity, market exclusivity no longer exclusivity is no longer term, during the EU exclusivity is no longer is no longer justified so that market exclusivity so-called market exclusivity so that market exclusivity so that is so that market exclusivity so that market exclusivity so that market exclusivity is no longer justified so that market exclusivity so that market exclusivity so that market exclusivity is no longer justified so that exclusivity is no longer market exclusivity, during the EU market exclusivity is no longer than market exclusivity so that is no longer term \u201cfurthermore so that is no longer justified so that market exclusivity is no longer market exclusivity is no longer is no longer-term exclusivity isoproduct so that, during the product exclusivity is no longer market exclusivity is no longer so that market exclusivity is no longer so that are so that market exclusivity is no longer justified.In the EU, during the product\u2019s 3, so that the product so that are no longer-term exclusivity is no longer market exclusivity so that market exclusivity is no longer so that market exclusivity is no longer so-called for a so that market exclusivity so that is no longer-term exclusivity is no longer exclusivity is no longer exclusivity is no longer justified.In the EU exclusivity that market exclusivity is no longer justified so that case that market exclusivity period of market exclusivity is no longer exclusivity is no longer is no longer market exclusivity is no longer justified so that market exclusivity so that market exclusivity is no longer exclusivity is no longer justified so that market exclusivity is no longer term exclusivity is no longer exclusivity, during the market exclusivity is no longer exclusivity is no longer so that market exclusivity is no longer market exclusivity is no longer justified.In the the EU, market exclusivity is no more profitable period of the EU, during the EU, during the market exclusivity is no longer justified.In the EU member states that market exclusivity"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What could cause a potential loss of revenue according to the document?",
        "options": {
            "A": "Discontinuation of services by third-party companies to clients",
            "B": "Increased competition in the market",
            "C": "Rising operational costs",
            "D": "Decreased demand for trading platforms",
            "E": "Improper licensing of data",
            "F": "Delays in transitioning to new service providers"
        },
        "LLM_original_answer": [
            "The following a manner that are a. In additiona manner that we have in the following the adverse effect on the adverse effect on our Securities Business - Item 25ITEM 25ITEM 23ITEM 23decisionsSee the following the following court data.The following this European market data and/or court decisions that could have an adverse effect on our European market data products and market data in a manner that could have an adverse effect on our market data and/or court decisions that could have been adversely affect our European court decisions in a manner that could have an adverse effect on our European court decisions in a revenues.Decision adverse effect on our European market data products.Regulationphanis a reduction in a manner that could have an European market data business, as well as well as well as well as well as well as well as well as well as well as well as well as well as well-being adverse effect on our market data product and/or court decisions in a manner that could have an adverse effect on our businesses.Data Business Data Revenues.Decisions ITEM 23ITEM 23court decisions that could have an UncerticommunicationMarket Data Business and could have a summary in a manner that could have an ITEM 25\u2022 ITEM 25decisions in a manner that could have an adverse effect on our European market data in a.17 ITEM 25Revenues in a manner that could have an adverse decisions in a manner that could have an adverse data.25revenuespecifically.25ITEM 25Market Data Revenues in a manner that could have in a manner that could have an adverse economic market data products and the clearing decisions in a manner that could have an adverse effect on the manner that could have in a manner that could have an adverse Effect.CA.23ITEM 25court decisions in a manner that could have an adverse effect on Form 25court decisions in a manner that could have an adverse court decisions in a manner that could have an adverse effect on our U.SUMarket DATA REPLYCKER.ENDITEM 25ITEM  The following European market data product and/or in a\n####bettlericate have an adverse effect on our business and our business.Data Business and/or in affect. Securities Business and/or court decisions in a manner that could have an adverse effect.20Revenues in a manner that could have an adverse effect on our European market data product data decision on our European market data decisions in a manner that could have an adverse effect in a manner that could have now or in a manner that could now in a manner that could"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 20,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?",
        "options": {
            "A": "Increase in statutory tax rate",
            "B": "Valuation allowance and charge to profitability",
            "C": "Reduction in business performance",
            "D": "Increase in future taxable income",
            "E": "Adjustment in dividend policies",
            "F": "Expansion of subsidiary operations"
        },
        "LLM_original_answer": [
            "If you for additional discussion.See\u201d for additional discussions, which are beyond the scope of this discussion for additional scope of this discussion.See \u201cRisk Factors\u201d for additional information.See additional information, which are beyond the scope of the scope of the scope of the scope of this discussion.See\n_ctxt of this discussion.See additional information, which are within the scope of this discussion.See scope of this discussion.See the scope of this discussion.See\u201d for additional information beyond the scope of this discussion.See the scope of this discussion.See \u2014additional additional information.See \u201cRisk Factors\u201dSee \u201cRisk Factors\u201d for additional scope of this discussion.See \u201cRisk Factors\u201dSee \u201cRisk Factors\u201d for additional discussion.See \u201cRisk Factors\u201d for additional discussion.See additional discussion.See additional discussions.See \u201cRisk Factors\u201d for additional discussions.See the scope of the scope of this discussion.See \u201cRisk Factors\u201d for additional information.See additional disclosures, which are beyond the scope of the scope of this discussion.See \u201cRisk Factors\u201dSee \u201cRisk Factors\u201d for additional scope of this discussion.See\u201d for additional disclosures, which are beyond the scope of the scope of the scope of this discussion.See this discussion.Seeaset the scope of this discussion.See \u201cRisk Factors\u201d for additional beyond the scope of this discussion.See \u201cRisk Factors\u201d for additional discussion.See additional discussion.See additional discussion.See \u201cRisk Factors\u201d for additional discussion.See\u201d for additional discussion.See\u201d for additional discussion of \u201cRisk Factors\u201d for additional scope of this discussion.See \u201cRisk Factors\u201d for additional discussions.See this discussion.See \u201cRisk Factors\u201d for additional discussions, which are beyond the scope of this discussion, which are beyond the scope of this discussion of the scope of this discussion.See \u201cRisk Factors\u201d for additional \u201cRisk Factors\u201d for additional discussion.See additional \u201cRisk Factors for additional discussions, which the scope of this discussion.See\u201d for additional discussion.See additional information, which are beyond the scope of the scope of this discussion.See the scope of this discussion.Seor for additional \u201cRisk Factors\u201d for additional discussions, which are beyond the scope of this discussion.See \u201cRisk Factors\u201d for additional \u201cRisk Factors\u201d for additional \u201cRisk Factors\u201d for additional information, which are beyond the scope of this discussion.See additional \u201cRisk Factors\u201d for additional \u201cRisk Factors \u2014 additional discussion.See \u201cRisk Factors\u201d for additional information.See the scope of this discussion.See the scope of"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Under what condition can the PDCO waive the obligation to provide pediatric clinical trial data?",
        "options": {
            "A": "When the product is highly effective in children",
            "B": "If the disease only occurs in children",
            "C": "When the product shows uncertain efficacy in adults",
            "D": "If the product is likely ineffective or unsafe in children",
            "E": "When there is sufficient pediatric market demand",
            "F": "If the product is cheaper than existing treatments"
        },
        "LLM_original_answer": [
            "Under the Discovery, the Discovery, We believe, Development, Development, Development and the Discovery, Development and Regulatory Approval, Development and Regulatory Approval of our Product Candidates, Development and the Discovery, Development and the Discovery, Discovery, Development and the Discovery, Development and the Discovery, Development and Regulatory Approval of our Product Candidates, the Discovery, the Discovery, Development and Regulatory Approval of our Product Candidates, which we believe we believe we believe, Development and Regulatory Approval of our Product Specific, Development and Regulatory, Development, Development and Regulatory Assessment of our Product Candidates, Development and our Product-specifically, Development of our Product Candidates of our Product-specific, Development and the Development and Regulatory Approval of our Product Candidates, Development and Regulatory Approval of our Product Candidates, Development and the Development and our Product of our Product-specifically, Development, the Discovery, Development, Development and Regulatory Approval of our Product Candidates, the Discovery, Development and Regulatory Approval of our Product Candidates of our Product-specifics of our Product Candidates, Development and the Discovery, Development, Development and Regulatory Approval of our Product Candidates and Regulatory Approval of our Product Candidates and Regulatory Approval of our Product Discovery, Development and the our Product Candidates and Regulatory Approval of our Product-specifically our Product Candidates Our Product-specifically our Product-specifically, Discovery, Discovery, Development and our Product-specificsRelated to our Product Risks Related to the the the Discovery, Development and our Product and Regulatory Approval, Development, Development and our Product Candidates, Development, or our Product Risks Related to the Discovery, Development and/or the Discovery, Development and/or our Product Risks Related to our Product Risks, Development and Regulatory Approval of our Product Candidates, or our Product-specifically, which we believe, Development and Regulatory Approval of our Product Candidates and Regulatory Approval of our Product Candidates, Development and our Product Candidates, or our Product Candidates and/or Risks- and Regulatory Approval of our Product Candidates Our Product Candidates, Development and our Product Candidates of our Product Candidates, Development and the the Discovery, Development and the Regulatory Approval of our Product Candidates and the Discovery, Development and our Product Candidates, Development and Regulatory Approval of our Product Candidates Our Product Candidates, Development and our Product Candidates, Development, Development and our Product Candidates, Development and the Treatment of our Product-specifically Risks Related to our Product Candidates, Development and Regulatory Approval of our Product Specifics and Regulatory Approval of our Product Candidates We believe we believe to the Discovery, Development and Regulatory Approval of our Product of our Product Candidates, Development and the Discovery, as well as of our Product"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What factor could make it difficult for the company to retain key personnel?",
        "options": {
            "A": "Reduction in product sales",
            "B": "Delays in adopting management incentive plans",
            "C": "Expansion into new markets",
            "D": "Increased competition",
            "E": "Technological advancements",
            "F": "Change in stock prices"
        },
        "LLM_original_answer": [
            "What follows (in thousands of the as follows, and 2021, 2021 and 1, is as follows (in 2021, is as follows (in 2021, 2021, is as follows (in 100, is as follows (in 2021, 838Scient, 202 thousands and 2021, is as follows (in 2021, is as follows (in, 2021, 2021 (in 2021, is as follows (in 2021, is as follows (in 2021, is as follows as follows as follows): in 2023, 2023, 2021, is as follows (in 2021, 2021, 2021, 2021, 2021, 2021 and 2021. 2022, is as follows (in 2021, 2021. 11Item 12 and other than 2021, is as follows, is as follows as follows (in 2021, is as follows, is as follows (in 2021 and 2021, is as follows (in as follows as follows as follows (in 2021, is as follows as follows, is as follows (in 2021, is as follows (in, is as follows (in 2021, is as follows (in 2021, is as follows (in, is as follows (in 2021, is as follows (in millions): 2021, 2021, is as follows (in 2021, is as follows (in as follows as follows as follows 2021, 2021, 202 2021, 2021 (in 202 2023, is as follows (in 2021, 2022 and 2021 and 2021, is as follows (in 2021, is as follows and 2021 and as follows as follows (in 2023Mining Information and 2023, and 2021, and 11, is as to our operations and 2022 and hosted mining rewards, 2021, and 2021, and 1, 2021 and 2021, 2021, as follows, is as follows (in 2021, is as a result of as follows, is as a as follows (in is as follows (inherent 2021. 2023\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "In 2023, for how many consecutive years did the company rank first among North American combined gas and electric companies in the EEI's annual safety survey?",
        "options": {
            "A": "Three years",
            "B": "Five years",
            "C": "Eight years",
            "D": "Ten years",
            "E": "Twelve years",
            "F": "Fifteen years"
        },
        "LLM_original_answer": [
            "In 2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2023-2024-2024-2024-2024-2024-2024-2024-2027-2024-2023.2023-2024. DebtLong-term debtLong-term debtLong-term debtLong-term DebtLong-term maturt-2024-2024-2024. DebtLong-term debt maturies in 2024-2023. DebtLong-termLong-term debt maturities in 2024. DebtShort-term maturies-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-202-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2023. 2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2023-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-issued in 2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2026-2024-2023-2024-2024-2024-2024-2023. DebtLong-term-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2024-2023. DebtLong-termLong-term debt maturities-2024-2024-2026-2024-2024-2024-"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which factor is essential for increasing loan origination volume in the company's strategy?",
        "options": {
            "A": "Expanding international partnerships",
            "B": "Attracting and retaining skilled personnel",
            "C": "Reducing operational costs",
            "D": "Increasing online marketing efforts",
            "E": "Diversifying investment portfolio",
            "F": "Enhancing customer service training"
        },
        "LLM_original_answer": [
            "Which document, 10-Known, 202, 10-K, 2023, 2021, 2021 2023, 202-2021, and 2022, 2021, \u201cMinimum Regulatory Capital, 2023, 2021, 2021, 2021, 2021. Pensions 2021. 2021. Pensions 2022, 2023, 2021, 2022, and 2021, respectively, 2023, 2023, 2022, 2021, 202, 202, 2021, 2021, and 2021, 2021, 2021, 2021, 202, and 2022, 2020, 10, 2023, 10, 202, 10, 2021, 2022, 202, 2021, 2021, 2020, 2021, 2022, and 2021, 2021, 2021, 2021, 2021, 2021, 202, 10, and 202-K, 2021, 2022, and 2021, 2023, 2023, 2021, 2021, 2021, and  and 2021, 2021, 2021, 2021, 2021, 2021, 2021, 2021, 2021, 202, 2023,  2021, and 2021, respectively, 10, \u201c\u20142022, 2022, 202, 2021, 2021, 2021, 2021, 2021, 2021, 2021, and 2021, 2022, 2021, 202, 2021, 2021, respectively, 2021-K, 202, 202, 202, 202, and  and 10-K, 10, 2021, 2021. 2021, 10-Known, 2021. 2021. 2022, 202, 202, 202, 2021, and 2021, 202, 2021, and 2021, 2021, 2022, and 2021, respectively, 2022,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which of the following is prohibited under the federal criminal statutes created by the Health Insurance Portability and Accountability Act of 1996 (HIPAA)?",
        "options": {
            "A": "Providing accurate healthcare information",
            "B": "Knowingly defrauding any healthcare benefit program",
            "C": "Sharing healthcare information with the patient's consent",
            "D": "Ensuring the security of health databases",
            "E": "Improving healthcare technology",
            "F": "Reporting a breach of security"
        },
        "LLM_original_answer": [
            "Which drug candidate drug candidate development, and targeted protein degradation drug candidate drug candidate drug candidate drug candidate development, and targeted protein degradation drug candidate development, and/or targeted protein degradation of targeted protein degradation, and targeted protein degradation, and targeted protein degradation drug candidate drug candidate drug candidate drug candidate drug candidate drug candidate development, and targeted protein drug candidate development, and we cannot predict whether targeted protein degradation drug candidate development, and drug candidate drug candidate development, and/orphanomology, and/or targeted protein degradation drug candidate drug candidate development, and targeted protein degradation, and cannot predict whether targeted protein degradation, and targeted protein degradation and/or targeted protein degradation, and targeted protein degradation, and/or exclude the drug candidate development, and targeted protein degradation, and targeted protein degradation, and targeted protein degradation, and targeted protein degradation, and targeted protein degradation drug candidate development, and/or immune disorders, and E3\n.GetResponse:\u2022 Abbreviseaders drug candidate drug candidate drug candidate development, and degradation, and targeted protein degradation, and/or other E3Clinical development, and/or targeted protein degradation will result in vivo immunology cannot predict whether targeted protein degradation drug candidate drug candidate drug candidate drug candidate drug candidate development, and we cannot predict targeted protein degradation, and E3Published studies, and targeted protein degradation, and targeted protein degradation drug candidate drug candidate development, and targeted protein degradation drug candidate development, and drug candidate development, and targeted protein degradation will result of targeted protein degradation will result of degrader drug candidate drug candidate drug candidate drug candidate drug candidate drug candidate drug candidate development, and targeted protein degradation drug candidate drug candidate drug candidate drug candidate development, and we cannot predict whether targeted protein degradation, and targeted protein degradation drug candidate drug candidate development, and immune disorder drug candidate development, and/or targeted protein degradation drug candidate development, and targeted protein degradation of targeted protein degradation drug candidate drug candidate development, and targeted protein degradation of targeted protein degradation drug candidate drug candidate drug candidate development, and targeted protein degradation, and targeted protein degradation of targeted protein degradation drug candidate drug candidate drug candidate drug candidate drug candidate drug candidate development, and/or drug candidate drug candidate drug candidate drug candidate development, and targeted protein degradation drug candidate drug candidate development, and we cannot predict whether targeted protein degradation drug candidate drug candidate development, and targeted protein degradation, and/orphanomics platform technologies, and E3\nQ:\u2022 Abbrevise targeted protein degradation, and drug candidate drug candidate drug candidate drug candidate drug candidate drug candidate drug candidate drug candidate development, and/or targeted protein degradation drug candidate drug candidate drug candidate drug"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What event would allow MAV to terminate the Subservicing Agreement with Ocwen?",
        "options": {
            "A": "Failure to expand subservicing income",
            "B": "Ocwen acquiring new MSRs unexpectedly",
            "C": "A change of control of Ocwen or PHH",
            "D": "Increase in Ocwen's financial reserves",
            "E": "Successful maintenance of service levels",
            "F": "Ocwen improving its technology systems"
        },
        "LLM_original_answer": [
            "What is the RMSRisks, or in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in the RMSRAs for convenience, for convenience, in whole but in the RMSRAs, in whole but not in whole, in whole but not in the RMSRMSRMSR Agreements, in whole but not in whole but not in whole but not in whole but not in whole but not in whole but in whole but not in whole but not in whole but not in whole but not in the RMSRMSA or in whole, in the RMSRAs a RMSRMSRAs Agreements, the Ocwen, RMSRAsms, with respect to be but not in whole but not in whole but not in whole but not in whole but not in whole but in whole but not in whole but not in whole but not in the RMSRMSRAs a convenience RMSRMSRCAVEHedge Risk Agreements, in the RMSRAs Agreements for compliance with respect for convenience, RMSRAs Agreements, in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in the $ 2025. The OcWATMorto, in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in the Ocwen, RMSRMSRMSRMSRAs or RMSRMSRMSRMSRMSRAs a $ 2023, in whole but not in whole but not in whole but not in whole but in part but not in the Agrespective MSR, in whole but not in whole but not in the RMSRSA, RMSRSA, and Related Agreements RMSRatements for convenience, in whole but not in whole but not in the RMSRAs, which is the RMSRMSRAs a whole but not for convenience, in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole but not in whole, in whole but not in whole but not for convenience, not in whole but not in whole but not in whole but not in whole but not in whole"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is submitted to the FDA as part of a BLA requesting approval to market a new drug?",
        "options": {
            "A": "Emails of previous FDA meetings",
            "B": "Details of international marketing strategies",
            "C": "Data from device testing",
            "D": "Descriptions of the manufacturing process and non-clinical studies",
            "E": "Marketing plans and budgets",
            "F": "Consumer feedback surveys"
        },
        "LLM_original_answer": [
            "What the, upon grant of ten years of, upon grant of the, upon grant of, upon grant of, upon grant of a marketing, upon grant of a marketing, upon grant of, upon grant of, upon grant of, upon grant of a, upon grant of, upon grant of, upon grant of, upon grant of, upon grant of, upon grant of, upon grant of, upon grant of a ten years later than, upon grant of, upon grant of a)The Immuno, upon grant of, upon grant of, upon grant of, upon grant of, upon grant of a, upon grant of a grant of, upon grant of, upon grant of a, upon grant of a ten years, upon grant of, upon grant of, upon grant of a marketing authorization, upon grant of the, upon grant of the Immuno years of, upon grant of, upon grant of a marketing authorization, upon grant of a marketing authorization of, upon grant of a hematologic malignancy, upon grant of ten years, upon grant of the, upon grant of a, upon grant of market exclusivity, upon grant of a patient-specifically, upon grant of, upon grant of a, upon grant of the most, upon grant of a ten years of a ten years of the, upon grant of the, upon grant of, upon grant of, upon a ten years of the ten years, of the, upon grant of, upon grant of a marketing authorization, upon grant of a marketing authorization, upon grant of, the, upon grant of, upon grant of a productively, which, upon grant of ten years, upon grant of a marketing a prior to, upon grant of a patient-specificity, upon grant of, upon grant of, upon grant of which, upon grant of, upon grant of, upon grant of a marketing authorization, upon grant of, upon grant of, upon grant of a) upon grant of, upon grant of, upon grant of the, upon, upon grant of a, upon grant of, upon grant of a marketing authorization, upon grant of a marketing authorization, upon grant of, upon grant of a marketing authorization, upon grant of the, upon grant of the, upon grant of a, upon grant of market exclusivity upon grant of, upon grant of, upon grant of, upon grant of the, upon grant of, upon grant of, upon grant of, upon grant of a marketing, upon grant of the, upon grant of, upon grant of, upon grant of a marketing authorization"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is required for the renewal of a marketing authorization after five years?",
        "options": {
            "A": "Approval from the European Medicines Agency (EMA)",
            "B": "Independent clinical trials conducted in the past year",
            "C": "A re-evaluation of the risk-benefit balance",
            "D": "Proof of sales data from member states",
            "E": "A newly conducted preclinical test",
            "F": "An application fee for renewal"
        },
        "LLM_original_answer": [
            "What, reporting and reporting and reporting and management and management and management controls, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including financial and management controls, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, financial and management controls, including information technology, and management controls, including controls, reporting and information technology, and management controls, including information technology, reporting controls, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including information technology, including management controls, including information technology, and management controls, including information technology, including information technology, including information technology, including information technology, including information technology, reporting and management controls, and management controls, and management controls, including information technology, including information technology, reporting systems, including information technology, including information technology, upgrade systems, including information technology, implement additional financial and management controls, implement additional controls, including information technology, and management controls, management controls, including information systems, including information technology, including information technology, including information technology, upgrade systems, including management controls, upgrade systems, and management controls, and information technology, including information technology, including information technology, and information technology, financial controls, including information technology, including financial and management controls, reporting, and management controls, including information technology, including information technology, including information technology, including management controls, reporting and management and management and information technology, including information technology, including, including information technology, including information technology, including information technology, including information technology, including information technology, reporting systems, including information technology, including information technology, including information technology, including information technology, upgrade, including information technology, including controls, including information technology, information technology, including financial controls, including financial and controls, reporting systems, and management controls, and management controls, financial controls, and controls and reporting and management controls, including information technology, including information technology, including information technology, including information technology, upgrade systems, including information technology systems, and information systems, including controls, including information technology, including controls, and controls, and management controls, including information technology, including information technology, including financial and reporting, including information technology, including information technology, including information technology, including information technology, including information technology, including information"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could cause a potential loss of revenue according to the document?",
        "options": {
            "A": "Discontinuation of services by third-party companies to clients",
            "B": "Increased competition in the market",
            "C": "Rising operational costs",
            "D": "Decreased demand for trading platforms",
            "E": "Improper licensing of data",
            "F": "Delays in transitioning to new service providers"
        },
        "LLM_original_answer": [
            "According to current inflation rates and interest rates; changes in current conditions in the industry; changes in the industry; changes in current inflation rates; changes in current inflation rates and current interest rate and interest rates; changes in current conditions in the current and current conditions in current conditions in the industry; changes in the industry; changes in which affect the industry; changes in current inflation rates and current and other than inflation rates and current interest rates and other regulatory and security and current conditions in the regulatory and other regulatory and interest rates and other than in the foregoing; changes in inflation rates and foreign exchange rates and current conditions in current and current inflation rates and current conditions in the industry; changes in the current conditions in current conditions in current conditions in current and other current and current conditions in the industry; changes in current inflation rates and interest rates; changes in current inflation rates and other interest rate of current and current and current and current and current conditions in the industry; changes in the in the industry; changes in current conditions in the industry; changes in current conditions in current conditions in the industry; changes in current and current conditions in the U.See; changes in current conditions in the industry; changes in current inflation rates and interest rates and current industry;; changes in the industry; changes in current conditions in current conditions in; changes in current financial market infrastructure and current conditions in the U.See; changes in the industry; changes in the industry; changes in the industry; changes in inflation rates and interest rates and current conditions in current inflation rates and current conditions in current conditions in current conditions in current conditions in the U.Known; regulatory oversight of interest rates and derivatives; changes in the U.San; 2022. Our competitive conditions in the other risk management; changes in the U.See; changes in the U- and interest rate; interest; changes in the current conditions in current and interest rates and current conditions in current conditions in current conditions in current conditions in current inflation rates and current and current inflation rates and interest rates and interest rates; changes in current and current and other than; changes in the industry; changes in the industry; changes in the industry; changes in the industry; changes in the industry; changes in the; changes in current inflation rates and security and security and current and other than in the financial market; changes in the industry; changes in current conditions in current interest rates and other than those rates and interest rate and other than those of security; changes in the; changes in current and current and current conditions in current inflation rates and"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 20,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What must be established if deferred income tax assets are deemed more likely than not unrealisable?",
        "options": {
            "A": "Increase in statutory tax rate",
            "B": "Valuation allowance and charge to profitability",
            "C": "Reduction in business performance",
            "D": "Increase in future taxable income",
            "E": "Adjustment in dividend policies",
            "F": "Expansion of subsidiary operations"
        },
        "LLM_original_answer": [
            "What (or)12.Findependent)12.Fin the Consolidated)12) (continued)21.Fair)12Risk Management\u2019s Fair Value (i.e Fair Financial Statements (continued)11.Fin the Consolidated Financial Statements (continued)12.Fin Regulatory (continued) (continued) 12.The Consolidated the Consolidated Financial Statements (continued)12.Fin the Consolidated)12.Fair Consolidated)12)12 (continued)12.Fin Statements)12)12.Fin the Consolidated)12.Fair)12.Fin (continued)12.Regarding (continued)12.Consolidated Statements (continued)12.Fair Value (continued)12.Fair Fair Value (Fiscal Statements (continued)12.Risk)12)12.Risk)12 Consolidated Financial Statements (continued)12.Consolidated Statements (continued)12.Fair Value (continued)12.Fair Consolidated)12 (continued)12.Fair Value (i.e)12.Fair) (continued)12.Fair Value (continued)12.Fair Consolidated Financial Statements (continued)12.Fair Value (continued)11.Fair Value (continued)12.Fin Fair Value (continued)12.Foots (12.Foot)12.Fair Value (continued)12 Consolidated Financial Statements (continued) (continued) (continued) 12.Fair Value (iFinancial Statements to the Consolidated Fair Value (continued) (continued)Fair Value (continued) 12.Fair value of the Consolidated Financial Statements to the consolidated Financial Statements of the Consolidated Financial Statements (iRisk (continued)12.Fin Financial Statements (continued)12.Fin) (continued)12.Fin) (i) (i)12.Consolidated Financial Statements (continued)12.Consolidated)12.Regulation)12 Consolidated Financial Statements)12)11) (continued) (continued) (continued) 12.Consolidated Financial Statements to the Consolidated Financial Statements of the Financial Statements (continued)11.Fair Value (continued) (continued) (continued)12.Consolidated Financial Statements (iFinancial Statements (continued)12 Consolidated)12.Foots Continued)11.Footed Financial Statements (continued)12 (continued)12.Footed Financial Statements (continued)12.Fair Value (continued)11.Fin) and Fair Value (continued) 12.Management (continued 12.Regarding the Consolidated Financial Statements of the Consolidated)12.Fair Value ("
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?",
        "options": {
            "A": "$58.7 million",
            "B": "$104.7 million",
            "C": "$153.0 million",
            "D": "$381.4 million",
            "E": "$420.5 million",
            "F": "$275.9 million"
        },
        "LLM_original_answer": [
            "Based on the provided document, the accumulated deficit reported by the company as of December 31, 2023, is $381.4 million. Therefore, the correct option is D: $381.4 million."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?",
        "options": {
            "A": "The executive summary of the annual report",
            "B": "The company's market analysis",
            "C": "The consolidated financial statements and Notes to Financial Statements",
            "D": "The corporate governance guidelines",
            "E": "The strategic business plan",
            "F": "The risk management framework"
        },
        "LLM_original_answer": [
            "Based on the provided document, the document that should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is:\n\nC: The consolidated financial statements and Notes to Financial Statements\n\nThe MD&A provides an overview of the company's financial performance and condition, while the consolidated financial statements and notes provide the detailed financial data and additional context necessary to fully understand the company's financial position and results."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?",
        "options": {
            "A": "Increase in secondary marketing sales",
            "B": "Customer growth",
            "C": "Lower natural gas costs passed through to customers",
            "D": "Increase in North Carolina IMR",
            "E": "Tennessee ARM revenue recognition",
            "F": "Increase in off-system sales"
        },
        "LLM_original_answer": [
            "To answer the question of what primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022, we need to analyze the provided document and identify the key factors that contributed to the decrease in operating revenues.\n\nFrom the document, we can see that the variance in operating revenues was driven by several factors:\n\n1. A $259 million decrease in fuel revenues due to lower JDA sales volumes at lower prices in the current year, partially offset by higher fuel cost recovery.\n2. A $103 million decrease in retail sales due to unfavorable weather compared to the prior year.\n3. A $70 million decrease in weather-normal retail sales volumes.\n4. A $127 million increase due to higher pricing from the North Carolina and the South Carolina rate cases.\n5. A $21 million increase in rider revenues primarily due to the decrease in the return of EDIT to customers compared to the prior year.\n6. A $17 million increase in wholesale revenues, net of fuel, due to higher capacity rates, partially offset by lower volumes.\n\nOut of these factors, the primary cause of the $585 million decrease in operating revenues is the $259 million decrease in fuel revenues due to lower JDA sales volumes at lower prices in the current year. This factor had the largest negative impact on operating revenues and is the main reason for the decrease compared to 2022.\n\nTherefore, the answer to the question is: Lower natural gas costs passed through to customers, lower volumes, and decreased off-system sales volumes and other than offset by reportable_code:\u2022a $585MMdduke Energy Commodity price due to 2023MDBLiquid:\u2022a.Operating Expenses.The variance was primarily due toplinearbit:\u2022a $2."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?",
        "options": {
            "A": "Technological advancements",
            "B": "Climate change",
            "C": "Economic policies",
            "D": "Urban development",
            "E": "Infrastructure improvements",
            "F": "Regulatory changes"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factor mentioned as potentially worsening the severity and impact of future natural disasters is:\n\nB: Climate change"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is a primary reason for fluctuations in the company's financial results?",
        "options": {
            "A": "Successful transition of operations",
            "B": "Regular market growth",
            "C": "Factors beyond the company's control",
            "D": "Consistent product demand",
            "E": "Reduced operational expenses",
            "F": "Stable regulatory environment"
        },
        "LLM_original_answer": [
            "Based on the provided document, the primary reason for fluctuations in the company's financial results is:\n\nC: Factors beyond the company's control\n\nThe document outlines numerous risks and uncertainties that the company faces, including significant losses, the need for additional capital, the high risk of failure in drug development, the early stage of clinical development, and the challenges in obtaining regulatory approvals and commercializing products. These factors, which are largely beyond the company's success in connection to dateDevelopment offtargetedits clinical development offtwoefully, if at all offtargetedits development and other than we may not-for-licensed by E:\u2022the primary reason for our common stockholders may not only a)"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?",
        "options": {
            "A": "55 or older",
            "B": "62 or older",
            "C": "65 or older",
            "D": "70 or older",
            "E": "60 or older",
            "F": "50 or older"
        },
        "LLM_original_answer": [
            "Based on the provided document, the age at which a homeowner must be to qualify for a government-insured HECM reverse mortgage is:\n\nB: 62 or older"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one potential consequence of violating the civil False Claims Act?",
        "options": {
            "A": "Execution of a scheme without penalty",
            "B": "Four times the actual damages sustained by the government",
            "C": "Exclusion from private healthcare programs",
            "D": "Participation in federal healthcare programs",
            "E": "Mandatory civil penalties for each false claim",
            "F": "No penalties for private individuals"
        },
        "LLM_original_answer": [
            "One potential consequence of violating the civil False Claims Act is:\n\nE: Mandatory civil penalties for each false claim"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is a potential risk mentioned regarding the company's financial position?",
        "options": {
            "A": "High competition leading to reduced market share",
            "B": "Inability to generate sufficient revenue to cover expenses",
            "C": "Government regulations affecting sales",
            "D": "Incorrect labeling of products",
            "E": "Issues with supply chain logistics",
            "F": "Patent expiration affecting product exclusivity"
        },
        "LLM_original_answer": [
            "Based on the provided document, a potential risk mentioned regarding the company's financial position is:\n\nB: Inability to generate sufficient revenue to cover expenses.\n\nThe document outlines several risks related to the company's financial position, including the company's history of significant losses and the possibility of future losses if sufficient revenue cannot be generated to cover expenses. The company has invested in-license or our ability to whomay, if and our business and our business and other risks and our ability to which could result in-licensing any offtargetivation of our common stock-based on our financial position regarding the company\u2019s ability to generate sufficient revenue from our ability toplinearisingentirevenue of, if and the prices we may in-licensed products for which could result in-"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What economic factor is likely to reduce mortgage loan production volumes?",
        "options": {
            "A": "Decrease in volatility",
            "B": "Increase in inflation",
            "C": "Rising interest rates",
            "D": "Stability in commodity prices",
            "E": "Reduction in speculative trading",
            "F": "Growth of early stage companies"
        },
        "LLM_original_answer": [
            "Based on the provided document, the economic factor that is likely to reduce mortgage loan production volumes is:\n\nC: Rising interest rates\n\nRising interest rates are likely to reduce mortgage loan production volumes and increase loan foreclosures, which could potentially impact our transaction-based revenues."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?",
        "options": {
            "A": "Fluctuations in global oil prices",
            "B": "Changes in local tax regulations",
            "C": "Ongoing military actions and threat of terrorism",
            "D": "Increases in online security breaches",
            "E": "Cybersecurity threats from internal employees",
            "F": "Competition from new market entrants"
        },
        "LLM_original_answer": [
            "Based on the provided document, the risks mentioned that could adversely affect the company's investment portfolio include:\n\nA: Credit Spread Risk - Market price volatility and investment risk associated with the fluctuation in credit spreads can cause unrealized losses in the investment portfolio and increase losses associated with written credit protection derivatives used in replication transactions.\n\nB: Risks Related to Equity Markets - Investments in leveraged buy-out funds and private equity funds can result in uneven net investment income due to the performance of underlying investments, and significant volatility could adversely impact returns and net investment income.\n\nC: Risks Related to the Valuation of Securities - Market disruption can make it difficult to value certain securities, and rapidly changing and unprecedented market conditions could materially impact the valuation of securities.\n\nD: Risks Related to the Determination of Allowances and Impairments - The determination of allowances and impairments is subjective and varies by investment type, and historical trends may not be indicative of future impairments or allowances.\n\nE: Defaults, Downgrades or Other Events Affecting Issuers or Guarantors of Securities and Related Impairment Risks - Economic downturns, corporate malfeasance, widening credit spreads, or other events that adversely affect issuers or guarantors of securities could cause the estimated fair value of the fixed maturity securities portfolio and corresponding net investment income to decline.\n\nF: Liquidity Risk - Investments may be relatively illiquid, and forced sales during periods of market volatility or disruption could result in realized losses.\n\nG: Real Estate Risk - Exposure to commercial, agricultural, and residential real estate assets is subject to various factors, including economic conditions, which could have a material adverse effect on the investment portfolio.\n\nH: Derivative Risk - The use of derivatives to manage risk could be affected by counterparties' defaults, ratings downgrades, or financial difficulties, and the valuation of derivatives could change based on changes to valuation methodology or the discovery of errors.\n\nI: Other Risks - Foreign currency exchange rate risk, operational risks, ongoing military actions, the continued threat of terrorism, climate change, and other catastrophic events may adversely affect the value of the investment portfolio and the level of claim losses.\n\nJ: Regulatory and Legal Risks - Changes in tax laws, legal disputes, regulatory investigations, and compliance with laws and regulations could have a.."
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?",
        "options": {
            "A": "$58.7 million",
            "B": "$104.7 million",
            "C": "$153.0 million",
            "D": "$381.4 million",
            "E": "$420.5 million",
            "F": "$275.9 million"
        },
        "LLM_original_answer": [
            "Based on Financial Statements of the Consolidated) 11Fair Value (continued) (continued) Fair (continued) (continued)12.Financial Instruments and Appendix) (continued) Fair Value (continued) (continued) (continued)12.Fair (continued Fair Value (continued) (continued) Financial Statements (continued)11.Fair Value (continued) (continued) Fair Value of Fair Value (continued) (continued) (continued Fair Value (continued) (continued) 11.Fair Value (continued)12.Fair (continued) (continued) Fair Value (continued)12 Consolidated Financial Position (continued) (continued)Fair Financial Statements (continued)11.Fair Value (continued) (continued) (continued) (continued) Financial Statements of the Fair Value (continued) (continued) (continued Fair Value Fair Value (continued) (continued) Fair Value (continued) (continued) (continued) (continued) (continued)11.Fin Financial Statements (continued) (continued) (continued) Fair (continued) (continued) Fair Value (continued) (continued) (continued) Fair Value (continued) (continued)Fair Value (continued)Fair Value (continued) to Financial Statements (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued) (continued) Fair Value (continued)Fair Value (continued)Fair Value (continued Fair Value of Fair Value (continued) to 12 Fair (continued)11.Fair.Footionc) (continued)12.Fair (continued) (continued) (continued) (continued Fair Value (continued) (continued) Fair Value (continued) (continued) 11.Fair (continued) (continued)Fair Value (continued) (continued) (continued)Fair Value (continued) (continued)12.Fair (continued) (continued) (continued)Fair Value (continued)12.12.Fair to 12 (continued) (continued) (continued Fair Value of the Consolidated to the Consolidated Financial Statements (continued) (continued) Fair Value (continued)Fair Value (continued Financial Statements (continued) (continued)Fair Value (continued) (continued) Fair Value (continued)Fair Value (continued) (continued Fair Value (continued) (continued) (continued) Fair Value (continued) (continued) Financial Statements (continued)12.Consoliduease)12Fair Value of the Fair Value of the Fair Value (continued) (continued) (continued) (continued) ("
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?",
        "options": {
            "A": "The executive summary of the annual report",
            "B": "The company's market analysis",
            "C": "The consolidated financial statements and Notes to Financial Statements",
            "D": "The corporate governance guidelines",
            "E": "The strategic business plan",
            "F": "The risk management framework"
        },
        "LLM_original_answer": [
            "The following Fair Value (continued)12.Fair.Fair (continued) (continued)12.Grand Fair to Fair Value (continued) (continued)11.Fair 12)12.Consolidated Fair Value) (continued)Fair Value (continued) (continued) (continued Fair Value (continued) (continued) (continued) (continued) Fair Point of the Company (continued) (continued Fair Value (continued) (continued 12.Fin this section 12.Fair (continued) (continued Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued 11.Fair Fair (continued) 12.Fair.Fair (continued) (continued) (continued) (continued) 11.Fair) (continued Fair Value (continued) 11.Fair (continued Fair Value (continued) (continued)Fair Value (continued) Fair Value (continued) (continued) Fair Value) 12.Risked Financial Statements of Financial Statements of the Consolidated by Fair (continued) (continued)Fair Value (continued) (continued Fair Value (continued) (continued) [Reserved) (continued) (continued) (continued) (continued) 12.Fair)11.Fair to Consolidated) (continued) (continued)12.Good (continued)12.Govern) to) 11.Fair) (continued) (continued Fair Value (continued) (continued) (continued) (continued) (continued)12.Fair (continued)12.Employed) (continued Fair Value 12.Fairg) (continued) (continued) (continued) (continued) (continued)12.Fair Value (continued) (continued) (continued)11.Fair Financial Statements and 12.Fair.Fair.Faird)12) (continued) Fair Value (continued) (continued Fair Value Settlement (continued)Fair Value 11.Fin this Consolidated) (continued) Fair Value (continued) Fair Value) 11.Factors to Consolidated Financial Statements of this Annual Report 11.Fair Value (continued)12.Governor 12.Governed Financial Measure Fair Value (continued) (continued) (continued) (continued)12.See) (continued)Fair Value (continued)12. Fair Value (continued) (continued) (continued)11.Faird 12.Faird to Consolidated)12.Fin (continued)11.Fair Value (continued) (continued) Consolidated Financial Measure Fair ("
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?",
        "options": {
            "A": "Increase in secondary marketing sales",
            "B": "Customer growth",
            "C": "Lower natural gas costs passed through to customers",
            "D": "Increase in North Carolina IMR",
            "E": "Tennessee ARM revenue recognition",
            "F": "Increase in off-system sales"
        },
        "LLM_original_answer": [
            "The following Fair Value (continued) (continued) Fair Value (continued Fair Value (continued) (continued) (continued)11.Fair) (continued)12.Fair Financial Statements)12.Fair Fair Value (continued) (continued) (continued) Fair Value (continued)12.12.Fair.Fair.Fin the Subs)12.Fair Fair Value (a) (continued) Fair Value (continued)12.Fairfairly Fair Value 11.Faird 11.Fair.Fair Value (continued)12.Fin Consolidated Fair Value (continued)Fair Value (continued) (continued) (continued Financial Statements (continued) (continued) (continued) (continued) (continued) (continued) (continued)12.Regulated) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued)12.Fairdetailed) 11.Fin the year 12.Fair Value (continued) (a) To the Consolidated Financial Statements (continued) (continued Fair Value (continued) (continued) (V)12.Fin Fair Value (continued) to the Consolidated Financial Statements (continued) (continued (continued) (continued) (continued) Fair Value (continued) Fair Value (continued) (continued Fair Value (continued) (continued Operations (continued) Fair Value (continued) (continued) (continued) (continued) (continued Operations (continued)12.Consolidated Financial Statements (continued Financial Statements (continued) (continued) (continued Fair Value (continued) (continued) to the Consolidated) (continued Fair Value (continued Fair Value (continued) (continued) (continued) Consolidated Financial Statements (continued) (continued) Fair Value (continued) (continued) (continued Fair Value (continued) (continued) (continued Financial Statements (continued) (continued)Fair Value (continued) (continued)Fair Value of Consolidated Financial Statements (continued)11.Fair Value (continued)Commitments)11.Fair)Fair Value (continued Financial Statements to the Notes to the Fair Value (continued Fair Value (a) (continued) (a)Fair Value (continued) (a) Fair Value (continued Fair Value (continued) (continued) Fair Value Retirement of Fair Value (continued)11.Fin Financial Statements (continued)11.Fair.Fin the Market Approach Fair Value (continued) to the Consolidated Fair Value (continued) (continued)11.Fair (continued)See Fair"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?",
        "options": {
            "A": "Technological advancements",
            "B": "Climate change",
            "C": "Economic policies",
            "D": "Urban development",
            "E": "Infrastructure improvements",
            "F": "Regulatory changes"
        },
        "LLM_original_answer": [
            "Based Fair Value (continued) (continued)Fair Value (continued)11.Fin Fair Value (continued Fair Value (continued) (continued) (continued Fair Value (continued)12)11.Fair Value (continued) (continued Fair Value (continued Fair Value (continued) 11.Fair Value (continued) (continued) (continued) Fair Value (continued) (continued) (continued) 11.Fair Fair Value (continued) Fair Value (continued)11.Fair (continued)12.Fin (continued) (continued) (continued) (continued) (continued) (continued) 12) (continued) Fair Value at Consolidated) (continued) 11.Fin the Consolidated)12.Fin Consolidated) 12.Fair to to Consolidated Financial Statements (continued)11.Fair Value (continued) (continued) (continued) 12 (continued)11.Fair (continued) (continued) Fair Value of the Fair Value (continued)12.Fin Fair Value (continued Fair Value (continued) (continued to Fair Value (continued) (continued) (continued)11.Fair Fair Value) (continued) Fair Value (continued)11.Fin)12. Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) Fair Value (continued) (continued) (continued)11.Fin the Company (continued) 12.Fin this section 12.Fin the Consolidated Financial Statements (continued) (continued Fair (continued)12.Fin other than 11.Fair Financial Instruments) (continued) Fair Value (continued) (continued) (continued)Fair Value (continued)Fair Value (continued) (continued)Fair Value (continued)12) 12.Finstructions (continued) (continued) (continued) (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued)Fair Value (continued) (continued) 12 (continued)11.Fair to Consolidated) (continued)11.Fair Fair Value (continued)11.Fin (continued)12.Fair (continued) (continued) Fair Value (continued) (continued) (continued)12.Fin the Consolidatedral Fair Value (continued)12.Fair) (continued) Fair Value"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is a primary reason for fluctuations in the company's financial results?",
        "options": {
            "A": "Successful transition of operations",
            "B": "Regular market growth",
            "C": "Factors beyond the company's control",
            "D": "Consistent product demand",
            "E": "Reduced operational expenses",
            "F": "Stable regulatory environment"
        },
        "LLM_original_answer": [
            "The Consolidated Fair Value (continued)Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued)Fair Value (continued)12.Prior Fair Value (continued)Fair Value (continued)Fair Value (continued) (continued) (continued) 11.Fin (continued) (continued Fair Value (continued) (continued) (continued Fair Value (continued) (continued) 12.Fair) (continued) (continued)12)12.Fair Fair Value F (continued) Consolidated Financial Statements (continued) 12.Fair Value (continued) (continued) Fair Value (continued)Fair Value (continued) 12.Fair (continued) (continued) 11.Fair Value (continued) (continued Fair Value (continued) (continued) Fair Value (continued) 11.Fair Fair Value (continued) 11.Fairm (continued)11.Fair Value (continued) (continued)12 (continued) (continued) Fair Value of the Consolidated Fair Value of Fair Value (continued) Fair Value (continued) 12.Faird Val (continued) (continued) (continued) (continued) (continued)Fair Value (continued Financial Statements (continued) (continued)Fair Value of Fair Value) (continued) 12.Fair Value (continued) (continued)Fair Value (continued) (continued) Fair Value (continued) 12 (continued) to Fair Value (continued) (continued Fair Value (continued) (continued) (continued) (continued Fair Value (continued) (continued)Fair Value (continued) Fair Value (continued) (continued) 11.Fair Value (continued) The Financial Statements (continued)11.Fair Fair Value (continued) (continued) 11.Fair Value (continued)12. Fair Value) (continued)Fair Value (continued)Risks Related Fair Value) (continued) (continued)11.Fair continued) (continued)Fair Value (continued) (continued)11.Fair Fair Value (continued) (continued)12.Fair Fair Value (continued) (continued)12.Fair Value (continued) (continued) (continued) (continued Fair Value (continued) (continued Fair Value of the Fair Value (continued Consolidated Financial Statements (continued) (continued Fair Value (continued) (continued) to the Consolidated Financial Statements (continued)11.Fair Value (continued) (continued"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?",
        "options": {
            "A": "55 or older",
            "B": "62 or older",
            "C": "65 or older",
            "D": "70 or older",
            "E": "60 or older",
            "F": "50 or older"
        },
        "LLM_original_answer": [
            "To Fair Value (continued)12)12.Fin Consolidated Financial Instruments (continued) (continued)Fair Value (continued) (continued) (continued) (continued) (continued) (continued)Fair Value (continued)12.Faird) (continued) (continued Financial Statements to Consolidated to Fair Value (continued) (continued)12.Fair Value) (continued)11.Fair Fair Value)11.Fair Fair Value (continued) (continued) (continued)11.Fin Fair Value (continued)12)12.Fair Fair Value (continued)Fair Value (continued) (continued)12.Fairg Fair Value (continued) (continued) Fair Value (continued)Fair Value (continued)12.Risked Fair Value (continued) (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued)Fair Value (continued) (continued) (continued) (continued) Fair Value (continued)11.Faird Fair Value (continued) Fair Value) (continued) 11.Finorws (continued) 11.Fin (continued) (continued) Fair (continued) (continued) (continued)12.Fair (continued) (continued) (continued) (continued) (continued)12.Fair Fair Value (continued) (continued) Consolidated Financial Statements (continued) 11.Fair Value (continued) (continued) (continued)11.Fair Value (continued) (continued Fair Value (continued) (continued) (continued) Risk Factors (continued) Fair Value (continued) (continued) Notes to Fair Value (continued)12.Fin Consolidated Financial Statements (continued)Fair Value (continued) (continued)Fair Value (continued) (continued) (continued Fair Value (continued) (continued)11.Fair Financial Instruments (continued)Fair Value (continued)Fair Value (continued) (continued) Fair Value (continued) (continued) (continued)12.Fin the Fair Value (continued) (continued) to the (continued) (continued) Fair Value (continued)Fair Value (continued) (continued) (continued)12.Fair Value (continued) (continued Fair Value (continued)12.Fin Consolidated) to the Notes to Fair Value (continued Fair Value (continued) (continued) (continued)Fair Value (continued) Fair Value)Fair Value (continued)Fair Value (continued)Fair Value (continued)Fair Value (continued) (continued)11.F"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What is one potential consequence of violating the civil False Claims Act?",
        "options": {
            "A": "Execution of a scheme without penalty",
            "B": "Four times the actual damages sustained by the government",
            "C": "Exclusion from private healthcare programs",
            "D": "Participation in federal healthcare programs",
            "E": "Mandatory civil penalties for each false claim",
            "F": "No penalties for private individuals"
        },
        "LLM_original_answer": [
            "One potential consequences of) (continued) (continued)11.Faird) (continued) 11.Faird FCS (continued) (continued) 12.Fair continued) (continued)11.Finald) (continued) Fair Value (continued) (continued Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued)Fair Value (continued) (continued) 12.Fair (continued) (continued) To answer to the Consolidated) (continued) (continued)11.Fair (continued) 10.Fair Fair Value (continued) (continued)11.Fair (continued) (continued) (continued)12.Fair (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued)Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) 11.Fair (continued) (continued) Fair Value (continued) (continued) to Consolidated Financial Statements (continued) (continued) Fair Value (continued) (continued) (continued)12.Fair Fair Value (continued Fair Value Consolidated Financial Statements (continued) (continued) Fair Value (continued) (continued) (continued)11.Fair Fair Value (continued) (continued Fair Value (continued) (continued) (continued) (continued (continued) (continued 11.Faird) (continued) (continued) 11.Fair Fair Value (continued) (continued) (continued) (continued) Fair Value (continued) (continued) (continued (continued) (continued) (continued)Fair Value (continued) (continued) (continued Fair Value (continued) (continued) (continued Fair Value (continued) (continued) (continued)12.Fair (continued) 12 to the Consolidated Financial Statements (continued) (continued) Fair Value (continued) (continued Fair Consolidated Fair Value (continued) (continued)Fair Value (continued) (continued) Fair Value (continued)12 (continued Fair Value (continued Fair Value (continued) (continued Fair Value Fair Value (continued) (continued) (continued Fair Value (continued)Fair Value (continued)Fair Value (continued) Fair Value (continued)Fair Value (continued) (continued) (continued) (continued) (continued)11.Fair) (continued) (continued)12.Fair Fair (continued)12.Fairc) (continued"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is a potential risk mentioned regarding the company's financial position?",
        "options": {
            "A": "High competition leading to reduced market share",
            "B": "Inability to generate sufficient revenue to cover expenses",
            "C": "Government regulations affecting sales",
            "D": "Incorrect labeling of products",
            "E": "Issues with supply chain logistics",
            "F": "Patent expiration affecting product exclusivity"
        },
        "LLM_original_answer": [
            "A.Detailed) (continued) (continued)12)12.Risk Fair Value) (continued) Fair Value (continued) (continued)12.Fin Fair Value (continued) (continued) Fair Value (continued)Fair Value (continued)Fair Value (continued Financial Statements to the consolidated) (continued)Fair Value (continued)12.Fair (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued)Fair Value (continued) (continued) (continued) (continued) Fair Value (continued) (continued)12.Fin this document) to the Consolidated Financial Statements (continued)11.Fair (continued) (continued)12.Finclusion to Form 12) (continued) (continued) (continued) (continued)12.Fair Fair Value (continued) (continued) Consolidated Financial Statements (continued) (continued (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued Fair Value (continued) (continued) (continued Fair (continued)12.Faird (continued) (continued) (continued)Fair Value (continued Financial Statements (continued) (continued Fair Value (continued) (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued)Fair Value (continued)12)Fair Value (continued) 12.Fin the European Union Registration Statement 12.Fin the Financial Statements (continued)12.Governor (continued)Fair Value (continued Financial Statements (continued) (continued) (continued) (continued) (continued) Fair Value (continued) (continued) (continued)Fair Value (continued) (continued) Fair Value (continued) to Consolidated Financial Statements to the Company (continued)Fair Value (continued) (continued) (continued) (continued)Fair Value (continued)Fair Value) Fair Value (continued)Fair Value (continued)Financial Instruments (continued)Fair Value (continued) (continued)11.Fair) (continued)Fair Value (continued)Fair Value (continued)Fair Value (continued Fair Value (continued)12.Fair)Fair Value (continued) (continued)Fair Value (continued) (continued) (continued)Fair Value (continued) (continued) Fair Value (continued) (continued) (continued)Fair Value (continued) (continued)Fair Value (continued) (continued) (continued)12.Fair (continued)12.Fair Value"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What economic factor is likely to reduce mortgage loan production volumes?",
        "options": {
            "A": "Decrease in volatility",
            "B": "Increase in inflation",
            "C": "Rising interest rates",
            "D": "Stability in commodity prices",
            "E": "Reduction in speculative trading",
            "F": "Growth of early stage companies"
        },
        "LLM_original_answer": [
            "The Consolidated)11 (continued)11.FairFair Value (continued)12.Fin (continued)12.Fair (continued) (continued) Fair Value (continued) (continued) to Consolidated Financial Statements (continued) (continued) Fair Value (C) (continued) (continued) Fair Value (continued) (continued) (continued)11.Fair) (continued)12.Fair. (continued)11.Fair Fair Value (continued) (continued)11.Fairm) (continued)12.Fair.Fair.Fairdollar)12)12.Fair Fair Value (continued) Cash Equity Loss of the Consolidated to the Consolidated Fair Value (continued)11.Fair (continued) (continued) Fair Value (continued)12.Cleaning Fair Value (continued) (continued)12.Credit Value (continued) (continued Financial Instruments (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued Fair Value (continued)12.FairnFair Value (continued) Fair Value) (continued) Fair Value (continued) (continued) (continued)12.Fin (continued)11.Fair Value (continued)11.Further to Consolidated Financial Statements (continued) (continued) Fair (continued) (continued) (C)Fair Value (continued)11.Fair Fair Value (continued)11 (continued) 11.Fair Value (continued) (C Fair Value (continued)11.Fair (continued) (continued Fair Value (continued) (continued) (continued)11.Fair (C)11.Fair (continued) (continued Fair Value (continued)11.Fair.Fair Fair Value (continued) (continued Fair Value (continued) (D e Fair Value (continued)12.Fin Value (continued)12.Fair (continued Fair Value (continued)12.Fair Value (continued Fair Value (continued) (continued)12.Fair Consolidated)Fair Value (continued) (continued) (continued) (continued)Fair Value (continued Financial Statements (continued) (continued)11.Fair) (C)Fair Value (continued)10) (continued)12.Fair Value (continued) (Criticated to Consolidated to Consolidated Financial Statements to Consolidated Financial Statements (continued) Fair Value (continued) (continued) (continued) (continued)Fair Value (continued)UNDERIV."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?",
        "options": {
            "A": "Fluctuations in global oil prices",
            "B": "Changes in local tax regulations",
            "C": "Ongoing military actions and threat of terrorism",
            "D": "Increases in online security breaches",
            "E": "Cybersecurity threats from internal employees",
            "F": "Competition from new market entrants"
        },
        "LLM_original_answer": [
            "The Fair Value (continued) Fair Value (continued)12.Risk (continued) (continued) 12.The majority of the Fair Value (continued Fair Value (continued) (continued) 12.Fin) (continued Fair Value (continued) (continued Fair Value (continued) (continued)12.Fair (continued) (continued) 11.Finflation Risk- Fair Value (continued) (continued) 11.Fair Financial Condition (continued) (continued Fair Value (continued)12.Finflationary Fair Value (continued) (continued) (continued) (continued) (continued) (continued)Fair Value (continued) (continued) (continued)12.Risked Fair Value (continued) Fair Financial Statements (continued) (continued) (continued) (continued) (continued)Fair Value (continued) (continued) (continued)Fair Value (continued) 12) (continued) to Consolidated Financial Statements (continued) to Consolidated Financial Statements)11.Fairn to Consolidated Financial Statements (continued)11.Fair Value (continued)12.Fin (continued)12.Fair (continued) (continued Fair Value (continued) (continued) (continued) 12.Risks Related to Fair Value (continued) (continued)12.See to Fair Value (continued Fair Value (continued) (continued)11.Fair) (continued) (continued) (continued) (continued)Fair Value (continued)11.Fair.Fair)11.Fin the Fair Value (continued) 12.Risked Financial Statements)12)12.Fair Fair Value)Fair Value (continued) 11.Fin the Consolidated Fair Value (continued) (continued) (continued) (continued)11.Fair (continued)12.Legal Value (continued) Financial Statements to the continued)Fair Value (continued)12) 12.Fair. Financial Condition (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued)Fair Value (continued)12) (continued) (continued) Fair Value (continued) (continued) (continued) (continued) to the Consolidated Financial Statements (continued)11.Fair Value (continued)See \u201c\u2014 Derivative Fair Value (continued) (continued) 12.Fair) (continued) (continued)12.Fair Fair Value (continued) (continued) Consolidated Financial Statements (continued) 11.Fair Value (continued) (continued) Fair Value (continued)Fair Value ("
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?",
        "options": {
            "A": "$58.7 million",
            "B": "$104.7 million",
            "C": "$153.0 million",
            "D": "$381.4 million",
            "E": "$420.5 million",
            "F": "$275.9 million"
        },
        "LLM_original_answer": [
            "As Fair Value (continued) (continued) (continued)11.Fair Value (continued) (continued) (continued) (continued (continued)12.Fair Value (continued) (continued) (continued)11.Fin the continued) (continued) (continued) (continued)12.Risk)11.Fin the Statements (continued)12.Fair Fair Value (continued) (continued)11.Fair) (continued)11.Fair (continued) (continued) (continued) (continued) (continued)11.Fair Fair Value of the Financial Statements (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued)11.Further (continued)11.Fair (continued) (continued) (continued) (continued) (continued) (continued) (continued)11.Fair Value (continued) (continued)11.Fair)11.Fair.Fair)11.Fin the (continued) (continued)11.Faird Fair (continued)11.Fair Value (continued)11.Fair Value (continued) (continued) (continued) (continued) (continued)11.Fair (continued)11.Fair (continued)12.Fair Value (continued)11.Fin Statements (continued)11.Fair)11.Fair Value (continued)12.Pipeline (continued) (continued)11.Fair) (continued) (continued Fair Value (continued) (continued)11.Fair) (continued)12.Fin 12.Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued)11)11)11.Fair)12.Fair (continued)12.European Union (continued)12.Costatement (continued) Statements (continued)12.Cost (continued) (continued) (continued) (continued) (continued) (continued)12.Fair Value (continued) (continued)11.Fair Value (continued)11) (continued) (continued) Statements (continued) (continued)12.Fair (continued)11.Fin the Financial Statements (continued) (continued)11.Market (continued) (continued) (continued)11.Fair Value (continued) (continued) (continued)11.Risk Fair Value (continued) Statements (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?",
        "options": {
            "A": "The executive summary of the annual report",
            "B": "The company's market analysis",
            "C": "The consolidated financial statements and Notes to Financial Statements",
            "D": "The corporate governance guidelines",
            "E": "The strategic business plan",
            "F": "The risk management framework"
        },
        "LLM_original_answer": [
            "The Company)11.Fin 11.Fair.Fair Fair Value (continued Fair Value (continued Fair Value (continued)12 (continued) (continued)12) (continued) (continued) (continued) (continued)12.Guidd)12.Consolidity) (continued)12.Fost)11)11.Fair)12.Cash Fair Value (continued) (continued) (continued)11.Fair (continued)11.Fin the (continued) (continued Fair Value (continued) (continued) (continued)11.Fair Value (continued Financial Statements (continued)12.Fair (continued) (continued Fair Value (continued) (continued) (continued)11.Market Value) (continued Fair Value (continued) (continued)12.Fair.Fair Fair Value (continued) (continued)12.Fin Fair Value (continued)12)12.Fin which includes continued)11.Fair Value (continued) (continued) (continued) (continued) (continued)11.Fair Fair Value of the Securities Statements (continued)11.Fair Value (continued) (continued) (continued) (continued) (continued)11.Further Fair Value (continued) (continued) (continued) (continued) (continued)11.Fair Value (continued) (continued)11.Fair Value (continued)12.Fair Value (continued)11.Fair.Fair.Fair Value (continued Financial Statements (continued) (continued)11.Fair) (continued)11.Fair Value (continued)11.Fair Value of the continued) (continued)12) (continued)11.Fair Value (continued)11.Fair Value (continued)12.Fair Value (continued)11.M&Auditated)11.Risk.Agrear)12.Risk)12.Fair Fair (continued)11.Fair Fair Value (continued)12.Cert Fair Value (continued) (continued)11.Fair Value (continued)12.C) (continued)12.Fair Value (continued)12) (continued)12.Fair) (continued)Fair Value (continued)12)12.Fair (continued)12.Certainment (continued)12.Fin Statements (continued)11.Fair.Fair (continued) (continued)12.Fin Statements (continued)12.FA11 (continued) Statements (continued)12.Cert Value (continued)12.Fair Value) (continued) (continued) (continued)12.Fair Fair Value (continued) (continued)12.C"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?",
        "options": {
            "A": "Increase in secondary marketing sales",
            "B": "Customer growth",
            "C": "Lower natural gas costs passed through to customers",
            "D": "Increase in North Carolina IMR",
            "E": "Tennessee ARM revenue recognition",
            "F": "Increase in off-system sales"
        },
        "LLM_original_answer": [
            "To the Consolidated Financial Statements (continued)11.Fair.Fair) (continued)11.Fair Fair Value (continued)11.Fin 11.Fin 11.Fin)11.Fin 11.Fin)11.Fair Fair Value (continued Fair Value 11.Fin the Statements (continued)12.Fair Value (continued)12.GAAP (continued) (a) (continued)12.Fair Value (continued Fair Value (continued) (continued)12.Fostersued)11.Fair)12.Fair Value (continued) (continued) (continued)11.Fair Value (continued)11.Fin the (continued) (continued Value (continued) (continued) (continued)11.Fair Value (continued Financial Statements (continued) (continued Fair Value (continued) (a) (continued) (continued) (continued) (continued) (continued) (continued Fair Value (continued) (continued)12.Fair)11.Fair.Fin the continued)12)12.Fair Fair (continued)12)12.Fin (continued)12.Fair Value (continued) (continued) (continued (continued (continued (continued Fair Value (continued (a Consolidated Financial Statements (continued)11.Fair Value (continued) (continued) (continued)11) Statements) (continued)11.Fin the continued)11.Fair (continued)12.GAAPRisks) (continued) (continued (continued) (continued) (continued) (continued) (continued)11.Fair Value)11.Gener Fair Value (continued)11.Fin the Financial Statements (continued)11.Faird 11.Fin)11.Fair.Fin the Fair Value (continued) (continued) (continued) (continued) (continued)11.Fair (continued) (continued)11.Fair.Fin)11.Fair Value (continued)11.Fin the Consolidated Financial Statements (continued)11.Fair Value (continued)12.Fair (continued)11.Fair Value (continued) (continued) (continued Financial Statements (continued)11.Fair Value (continued Fair Value (continued) (continued)11.Fair Value (continued) (continued) (continued) (continued) (continued)11.Fin the Consolidated)12.Fair (continued)12) (continued)12.Fin 11 (continued)11)11.Fair Fair Value (continued) (continued)12.Fin (continued)12.FA11 (continued)"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?",
        "options": {
            "A": "Technological advancements",
            "B": "Climate change",
            "C": "Economic policies",
            "D": "Urban development",
            "E": "Infrastructure improvements",
            "F": "Regulatory changes"
        },
        "LLM_original_answer": [
            "Which of Financial Condition (continued)12.Fair Value (continued)12.Fair (continued)11.Fin this document (continued (continued (continued)12.Fair Value (continued)12.Fin (continued)12.Fair Value (continued) (continued) (continued 12.Fin Statements of the Statements (continued (continued) (continued (continued (continued) (continued) (continued) (continued)11.Faird) (continued)12.Costed Fair Value (continued) Statements (continued)11.Financial Statements (continued)11.Fin 12 (continued) (continued)11.Fair Value (continued)12.Fair Value (continued)11.Follow (continued)11.Fair Fair Value (continued)11.Fin Fair Value (continued) (continued)11.Fair)12)11.F11.Fin 11) (continued)11.Fair Value (continued) (continued) (continued) (continued) (continued) (continued)11.Fair (continued) (continued)11.Fair 11.Fin 11.Fair (continued) Statements (continued) (continued)11.Fair Value (continued)11.Fair 11.Fin 11.Fin 12.Fin 12.Fair Value (continued) (continued) Fair Value (continued) (continued) (continued) (continued) (continued Fair Value (continued) (continued)11.Fosters)11.Fair Value)12.Fair Value (continued) (continued) (continued)11.Fair Value (continued)11.Fin the continued) (continued to Fair Value (continued) (continued) (continued)11.Fair Value of the Financial Statements (continued)11.Fair Value (continued) (continued) (continued) (continued) (continued)11) (continued) (continued) (continued) (continued) (continued) (continued)11.Fin the Consolidated) (continued)12.Fair (continued) (continued)11.Fair) (continued)12.Fair (continued) (continued) (continued) (continued) (continued)11.Fair Fair Value of the Financial Statements (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued)11.Fin the continued)11.Fair (continued)12.Good (continued) (continued) (continued) (continued) (continued)11.Fair Value (continued)12.Fair Value (continued)11.F"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is a primary reason for fluctuations in the company's financial results?",
        "options": {
            "A": "Successful transition of operations",
            "B": "Regular market growth",
            "C": "Factors beyond the company's control",
            "D": "Consistent product demand",
            "E": "Reduced operational expenses",
            "F": "Stable regulatory environment"
        },
        "LLM_original_answer": [
            "What Fair Value (continued (continued) (continued (continued) (continued) (continued (continued) (continued) (continued)12.Permany)12.Consider Fair Value (continued)12.Plan Fair Value (continued (continued) (continued (continued (continued (continued) (continued) (continued)11.Fair (continued)11.Fin 11)11.Fair Value (continued (continued) (continued)11.Fair Value (continued (continued) (continued)12.Risk Fair (continued) (continued) (continued Fair Value (continued)11.Fair (continued) (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued)11.Fin the Consolidated Fair Value (continued) (continued)11.Fair (continued) (continued) (continued)12.Fair) (continued) (continued) (continued) (continued) (continued Fair Value of Financial Statements (continued)12.Fair (continued) (continued) Consolidated Financial Statements (continued)11.Fair Value (continued)12.Reports (continued) (continued) (continued) (continued)12.Fair Value (continued) (continued)12.Cost Value (continued)12.Fair Value (continued)12.Fair (continued)12)12 (continued) Statements) (continued)12.Fair Value (continued)12)11 (continued)11) (continued)11)11.Fair (continued) (continued) (continued)11.Fair Value (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued)11.Fair)11.Fair Value (continued)12.Costated) (continued) (continued)11 (continued) (continued) (continued)12.Risk)11.Fair Value (continued) (continued) Statements (continued)11.Fair Value (continued)12.Risked (continued) (continued) (continued)11.Fair) (continued) (continued) (continued) (continued) (continued (continued Fair Value (continued) Statements (continued)11.Fair Value (continued)12.Reports (continued) (continued)11.Fair Value (continued) (continued)12 (continued) (continued) (continued) (continued)12.Pot Fair Value) (continued)11.Fair.Fair) (continued)12.Costated)11.Fair Value (continued)11)12.Fin the continued) ("
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?",
        "options": {
            "A": "55 or older",
            "B": "62 or older",
            "C": "65 or older",
            "D": "70 or older",
            "E": "60 or older",
            "F": "50 or older"
        },
        "LLM_original_answer": [
            "What Value (continued)12.Fair Value (continued)11.Fair) (continued)11.Fair Value (continued) (continued) (continued Financial Statements (continued)11.Fair Value (continued) (continued)12.Fair) (continued)11.Fin 11.Fair Value (continued) (continued) (continued)11.Fair) (continued)12.Fair.Fin the Fair Value (continued)11.Fin Statements (continued)11.Fin (continued)11.Fair Value (continued)12.Fin (continued)12.Fair Value (continued)11.Fair Fair Value (continued Financial Statements (continued) (continued (continued (continued) (continued (continued) (continued)11.Fin (continued) (continued)11.Fin the continued)11.Fair Value (continued Consolidated Financial Statements (continued)11.Fair Value (continued)11.Fin Statements (continued) (continued) (continued)11.Fair) (continued)12.Fair (continued)11.F (continued)11.Fair Fair Value (continued)11.Fin the Consolidated Financial Statements (continued)11.Fair Value (continued)11.F11.Fin 12) (continued)11.Fair Value (continued) (continued) (continued) 12.Fin (continued)11.Fair Value (continued)11.Fair Fair Value (continued)11.Fin 11.Fair)11.Fin Statements (continued) (continued)11.Fair) (continued)11.Fair Value (continued) (continued)11.Fin Statements (continued) (continued) (continued)11.Fair Value (continued)12.Fin the Fair Value (continued) (continued)12.Fair) (continued)11.Fosters)11.Fair Value (continued)12.Consolid) (continued) (continued) (continued)11.Fair)11.Fin the Statements (continued) (continued Fair Value (continued) (continued) (continued) (continued Value (continued)11.Fin the)12.Fair Value (continued)12.Fair Value (continued)12.Fin the Consolidated Financial Statements (continued)12.Fair Value (continued) (continued) (continued)11.Fair Value (continued)12)12.Fin Consolidated Financial Statements (continued)11.Fin (continued)12.Fair Value (continued) (continued) (continued) (continued (continued Fair Value (continued) (continued Consolidated Financial Statements"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What is one potential consequence of violating the civil False Claims Act?",
        "options": {
            "A": "Execution of a scheme without penalty",
            "B": "Four times the actual damages sustained by the government",
            "C": "Exclusion from private healthcare programs",
            "D": "Participation in federal healthcare programs",
            "E": "Mandatory civil penalties for each false claim",
            "F": "No penalties for private individuals"
        },
        "LLM_original_answer": [
            "One of the Consolidated Financial (continued)12.Fair Value (continued Financial Statements (continued) (continued)11.Fair Value (continued)11.Fin Statements (continued) (continued)11.Fair Value (continued) (continued) (continued) (continued)11.Fair (continued) (continued)11.Fin the Consolidated)11.Fin the continued)11.Fair Value (continued)12.Fair Value Statements (continued Financial Statements (continued)12.Fair Value (continued) (continued) (continued)11.Fair Value (continued)11.Fair Value (continued) (continued)11.Fair Statements (continued by Product (continued)11.Fin 11.Fin Statements (continued)11.Fair (continued)11.Fair Fair Value (continued Fair Value)11.Fin the (continued)12.Cost) (continued) (continued) (continued) (continued) (continued)12.Costated Fair Value (continued)12.Classified)12.Costervalue)11)11.Fair)12.Costated (continued) (continued) (continued)11.Fair Value (continued)11.Fin the continued)11.Fair Value (continued) (continued) (continued)11.Fair Value (continued Financial Statements (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued)11.Fin the Fair Value (continued) (continued) (continued) (continued)11.Fair Value (continued)12)12.Risk)12.Foots)12.Fair Value (continued)12.Fair Value (continued) (continued (continued Financial Statements (continued Financial Statements (continued)11.Fair Fair Value of the Financial Statements (continued)12.Fair Value (continued) (continued) (continued) (continued) (continued)11.Further (continued)11.Fair (continued)12.Cost (continued) (continued) (continued) (continued) (continued)11.Fair Value (continued)12.Fair Value (continued)11.Fair.Fair)12)11.Fin the Financial Statements) (continued)11.Fair) (continued)11.Fair Value (continued)11.Fair Value (continued) (continued) (continued) (continued)11.Fair11.Fair)12.Fair Value (continued)12.Fair Value (continued)11.Fin Statements (continued)11.Fair Fair Value (continued (continued) ("
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is a potential risk mentioned regarding the company's financial position?",
        "options": {
            "A": "High competition leading to reduced market share",
            "B": "Inability to generate sufficient revenue to cover expenses",
            "C": "Government regulations affecting sales",
            "D": "Incorrect labeling of products",
            "E": "Issues with supply chain logistics",
            "F": "Patent expiration affecting product exclusivity"
        },
        "LLM_original_answer": [
            "A)12.Fair Value (continued) (continued)11.Fair (continued) (continued) (continued)11.Fair Value (continued)11.Fin the Consolidated Financial Statements (continued)11.Fair Value (continued)11.Fair Value (continued)11.Fair)12.Ele Fair Value (continued)11.Fair.Fair.Fair Value (continued) (continued)11.Fair)11.Fair.Fair.Fair)12)11)12.P11.Fair)12)11.Fair) 11.Fair Value (continued) (continued) (continued Financial Statements (continued)11.Fair Value (continued) (continued)12.Fair)11.Finstruments (continued)11.Fair (continued)12.Risked)12.Fair (continued) (continued)12.Fair.Fin this section)12.Fin this document (continued (continued)12.Fair (continued)12.Fair Value (continued)12.Fin the continued)12.Fair Value (continued)11.Fair Value (continued) (continued Fair Value (continued) (continued (continued) (continued (continued)11.Fair Value (continued) (continued)11.Faird Financial Statements of the continued)11.Fair Fair Value (continued) (continued)11.Fair Value (continued)11.Fin the Consolidated) (continued) (continued)11.Fair) (continued) (continued) (continued)11.Fin the continued)11.Fair Fair Value (continued)11.Fin Fair Value (continued)11.Fair)11.Fin the continued)11.Fin 11.Fin the continued)11.Fair Value (continued) (continued) (continued)11.Fair Value (continued)11.Fair Value (continued) (continued)11.Fair Value (continued)11.Fair Fair Value (continued)11.Fin Statements (continued)11.Fair (continued) (continued Fair Value (continued Fair Value (continued)11.Fin the Company (continued) (continued) (continued)11.Fair Value) (continued) (continued)12.Cost) (continued Fair Value (continued) (continued)12.Fair Value (continued)11.Fair)12.Certain Value (continued) (continued) (continued)11.Fair Value (continued)11.Fin the continued) (continued (continued Fair Value (continued) (continued)11.Fair Value (continued)11.Fin the continued"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What economic factor is likely to reduce mortgage loan production volumes?",
        "options": {
            "A": "Decrease in volatility",
            "B": "Increase in inflation",
            "C": "Rising interest rates",
            "D": "Stability in commodity prices",
            "E": "Reduction in speculative trading",
            "F": "Growth of early stage companies"
        },
        "LLM_original_answer": [
            "The)11.Fair Value (continued)11.Fin Statements (continued (continued) (continued)11.Fair Value (continued)12.Fair Value (continued)11.Fin (continued) (continued) (continued) (continued)11.Fair Value (continued) (continued)11.Fair)12)11.Fair (continued) Statements) Statements)12)11.Fair (continued) (continued) (continued) 12.Fair) (continued)12.Fair (continued)11.Fair)11.Fair Fair Value (continued)11.Fair (continued 11.Fin Statements (continued)11.Fair (continued) (continued (continued Fair Value (continued) (continued)11.Fin the (continued) (continued) (continued)11.Fair Value (continued) (continued) (continued) (continued) (continued Fair Value (continued) (continued)12.Fosters)11.Fair Value)12.Certain Value (continued) (continued) (continued)11.Fair Value (continued)11.Fin the continued) (continued to Fair Value (continued) (continued) (continued)11.Fair Fair Value (continued) (continued)12.Fair Value (continued)12.Fair Value (continued) (continued) (continued)11.Fin Fair Value)11.Fair (continued) (continued) (continued)11.Fair Value (continued)12) (continued)12.Fair (continued)12.Fair Value (continued)12.Certain Value (continued) (continued (continued) (continued (continued) (continued)11.Fair Fair Value of the Securities (continued) (continued)11.Fair continued) (continued) (continued) (continued) (continued)11.Further (continued)12.Fair (continued)12.Risk (continued) (continued) (continued) (continued) (continued)11.Fair Value (continued) (continued)11.Fair Value (continued) (continued)11.Fin Financial Statements (continued) (continued)11.Fair (continued)11)11.Fair Value (continued)11.Fair (continued)12.Risk (continued) (continued) (continued)11.Fair (continued)11.Fair Value (continued)12.Risk (continued Fair Value (continued)11.Fair (continued (continued)11.Fair Value (continued)12.Fair (continued)11.Fair Value (continued) (continued) (continued Fair"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?",
        "options": {
            "A": "Fluctuations in global oil prices",
            "B": "Changes in local tax regulations",
            "C": "Ongoing military actions and threat of terrorism",
            "D": "Increases in online security breaches",
            "E": "Cybersecurity threats from internal employees",
            "F": "Competition from new market entrants"
        },
        "LLM_original_answer": [
            "Some of the Fair Value (continued) (continued)11.Fair Value (continued)11.Fair Value (continued)11.Fair Value (continued)11) (continued)11.Fair Value (continued) (continued) (continued)11.Fair Value (continued)11.Fair Value (continued)11.Fair Fair Value (continued)11.Fin 11.Fair Value (continued)11.Fin)11.Fair Value (continued) (continued)11.Fair Value (continued) (continued)11.Fin Statements (continued) (continued) (continued)11.Fair Value (continued) (continued) (continued) (continued) (continued)12.Fair) (continued)11.F12.Fin)11.Fair)12.Fair Value (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued) (continued Fair Value (continued) (continued)11.Fair Value (continued)11) (continued) (continued Fair Value (continued) (continued Fair Value (continued) (continued) (continued)11.Fair) (continued) (continued) (continued) (continued) (continued)11.Fair Value (continued)11)11.Risk)12.Risk) (continued)11.Fair) (continued (continued) (continued) (continued (continued Financial Instruments (continued Financial Statements (continued)11.Fair Fair Value of Financial Statements (continued)11.Fair Value (continued) (continued) (continued)11) Statements) (continued)11.Fin the continued)11.Fair (continued)11.Risk (continued) (continued)11.Fair) (continued) (continued)11.Fair Value (continued)11.Fair Value (continued)11.Risk Fair Value (continued)11.Fin 11) (continued)11.Fair (continued)11.Fair Value (continued)11.Fair Value (continued) (continued) (continued) (continued)11.Fair Fair Value (continued)11.Risk Fair Value (continued)12.Risk Fair Value (continued) (continued)11.Risk Fair Value of Fair Value (continued) (continued)12.Fair (continued)11.Fair Value (continued) (continued) (continued Fair Value (continued)11.Fair Value (continued Fair Value (continued) (continued)11.Fair Value (continued) (continued) (continued) (continued) (continued)11.Fair"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?",
        "options": {
            "A": "$58.7 million",
            "B": "$104.7 million",
            "C": "$153.0 million",
            "D": "$381.4 million",
            "E": "$420.5 million",
            "F": "$275.9 million"
        },
        "LLM_original_answer": [
            "As is dependent upon the product candidate is dependent upon the product candidates are dependent upon a full or other than our product candidates is dependent upon a BLA product candidates is dependent upon the product candidates are dependent upon the first to grant a) our product candidates is dependent upon the product candidates.The FDA Review Process, offering to the product candidates is a product candidates.The product candidates.The product candidates that is dependent upon the FDA approval of a) our product candidates is dependent upon the product candidates, offering to which is dependent upon request for the use of our product candidates are dependent upon request a\nA REMSponsors to the product candidates are dependent upon the product candidates is dependent upon the product candidates are dependent upon request for the product candidates is dependent upon the EMAHCPMandatory39on the EMAKeferring to obtain such a conditionally, in the ability to the product candidates are dependent upon the product candidates is dependent upon request for a determination of majorly and dependent upon the EMAHypat this is not only on a product candidates are dependent upon request to the product candidates is dependent upon request or granting of which is dependent upon the FDA approval of the product candidates is dependent upon receipt of limited duration of a product candidates, dependent upon a product candidates are product candidates.The FDA-regulate or clinical development of a dependent upon the the ability to a sellecertain, but not more than the product candidates.The EMA is dependent upon the extent of a BLA product candidates is dependent upon the product candidates is dependent upon the Efficelyes dependent upon authorization to be dependent upon a product candidates.The product candidates is dependent upon the product candidates are dependent upon request for the subject to our product candidates is dependent upon a) on a Complete Response for the product candidates are subject to our ability to the treatment or a new drug products that is dependent upon request by the importation of a)product candidates are dependent upon the subject to the safety, or offering to offer to sell or offering to the product candidates.The FDA dependent upon the product candidates.The FDA Review the timely and dependent upon the product candidates.The extent of our product candidates.The product candidates are dependent upon a\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?",
        "options": {
            "A": "The executive summary of the annual report",
            "B": "The company's market analysis",
            "C": "The consolidated financial statements and Notes to Financial Statements",
            "D": "The corporate governance guidelines",
            "E": "The strategic business plan",
            "F": "The risk management framework"
        },
        "LLM_original_answer": [
            "The value of, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time of a given times, given time, over time, over time, over time, over time, over time, over time will, over time, over time at a given time will, at a given time, over time, over time at a given time, over time to a greater chance of, over time, over time will, over time, over time, over time will, over time, over time will, over time will, over time, over time, over time, over time will, over time, over time, over time, over time will, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time will, over time, over time, over time, over time to, over time, over time, over time, over time, over time, over time and, over time will, over time and, over time, over time, over time, over time, over time, over time will, over time, over time and, over time.The value of the given time.The value, over time, over time, over time, over time, over time will, over time, over time and/or, over time, over time, over time, over time, over time, over time, over time, over time will, over time, over time, over time, over time from a given time, over time, over time, over time, over time, over time, over time of, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time, over time.In addition to a given time, over time will, for a given time, over time, over time, for a given time, over time, over time, over time will, over time will, over time, over time, over time, over time will, over time, over time will, over time will, over time, over time will, over time, over time, at a given time, over time, over time, over time, over time, over time, over time of, over time, over time"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?",
        "options": {
            "A": "Increase in secondary marketing sales",
            "B": "Customer growth",
            "C": "Lower natural gas costs passed through to customers",
            "D": "Increase in North Carolina IMR",
            "E": "Tennessee ARM revenue recognition",
            "F": "Increase in off-system sales"
        },
        "LLM_original_answer": [
            "The following the financial results of Duke Energy\u2019s and/or was completed or required byproducts of the financial and required or required topline 39##table required to be##table 2023##table was not only one of the audit committee of the Duke Energy\u2019s financial services and nuclear cybersecurity.DU.See##table 2024##table 2024##table 2024##table##table 2023##table\nParsedu##table.The Company-owned by the financial statements that was communicated or required to be communicated or required to the audit committee and regulatory and was communicated or required by the financial condition that was completed or required or required to the financial services that was completed or required to the audit of the audit committee or required to the audit committee of the audit committee and other than was communicated or required by Duke Energy\u2019s energy security-related to the audit of the financial and was approximately 2023##table 2023##table 39##table ulti##table was communicated or required by the audit of the financial commitments and other than required or required by the following the Company's financial statement that was communicated or required to be communicated or required by the Duke Energy Services, the Duke Energy Company's financial services that was communicated or required or required or required or required by the Duke Energy's audit of the Company-owned by the financial instruments, the Duke Energy Company's 39##table of the Duke Energy Services and continued to the 2024##table 39##table##table 60##table 2023##table 2024##table 39##table 39##table 2024##table 39##table 39##table 2024##table 2024##table 2023##table 2024##table 2024##table 2024##table 2024##table 2024##table 2024##table 38##table 2024##Table ultiq##table was communicated or required or required by the financial statements that was the Company'sed or required or required to the audit committee of the Company's the financial services and other matters that was communicated or required to the audit of##table 2024##table 42##table.Reason and/or required by communicating or required to support the following or required to the financial statements that was installed and the following the Company's cybersecurity and the financial statements that was the Company's the financial reporting or required to the audit committee and continued to the audit of the financial and required to the Company's 39##"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?",
        "options": {
            "A": "Technological advancements",
            "B": "Climate change",
            "C": "Economic policies",
            "D": "Urban development",
            "E": "Infrastructure improvements",
            "F": "Regulatory changes"
        },
        "LLM_original_answer": [
            "Which the FDIC Registry of the FDICIC 2024, the results of the Federal Register, the FDIC 2024. Register of the Federal Register of the Federal Register, the Federal Register of the Federal Register in the Federal Register of the Federal Register of the Federal Register, we34 the Federal Register, in the Company\u2019s, in the Federal Register, in the Company and/or, which could be34, the acquisition of the Federal Register of the business and the FDIC 2023, the FDIC published in the Federal Register in the Federal Register in the Federal Register, the Federal Register of the Federal Register of the FDIC, or the FDICIC 2024, 2024, in the Federal Register of the FDIC\u2019s business model risk management of the FDICICIC\u2019s business and/or the FDIC published in the merger in the Federal Register, 30 the FDIC (\u201cFederal Register, Register in the FDIC 2024, or other financial institutions, or other risks of the Federal Register, or other than we have been completed in the FDICIC 2024, in the FDICIC, we have in the FDICIC published in the FDIC published in the Federal Register of the Federal Register, 2024, including in the Federal Register of the acquisition of the Federal Register of 2023, the FDIC published in the Federal Register and the FDICR., the FDIC 16, the Federal Register in the Federal Register in the Federal Deposit Insurance Deposit Insurance Deposit Insurance Deposit Insurance Deposit Insurance, 16, 2023, 2024, in the Federal Register a Notice of the Federal Register, in the FDIC 16 Register published in the Federal Register in the FDIC 2024, in the Federal Register, in the Company\u2019s published in the FDIC in the FDIC published in the FDIC \u95e8, and/or, including the FDIC\u2019s in the Federal Register, or other financial institutions, or other than the merger agreement of our business and erti, including the Federal Register, which the Federal Register, or, including in the answer to the Company\u2019s ability to the Federal Register, in the FDIC 2024, the Federal Register in the same in the Federal Register, 2024, 2023, the Federal Register of the FDIC 2023 2024, including in the Federal Register, the FDIC, the Federal Register, weathe FDIC 2024.The FDICIC.Combat in the Company"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is a primary reason for fluctuations in the company's financial results?",
        "options": {
            "A": "Successful transition of operations",
            "B": "Regular market growth",
            "C": "Factors beyond the company's control",
            "D": "Consistent product demand",
            "E": "Reduced operational expenses",
            "F": "Stable regulatory environment"
        },
        "LLM_original_answer": [
            "The FDA employees and contractors who may be our policy to require our policy to require our policy to require our policy to require our policy to the FDA approval of the European Union, either by the product development and we policy to the EMAA:\u2022\naney, subject to the FDA approval of the FDA approval of the EU and we are our policy to our policy to require our policy to require our employees and contractors who may be involved in our policy to require our employees and our policy to require our policy to require our policy to the FDA to our policy to require our policy to require our policy to require our policy to require our policy to require our policy to the FDA to require our employees and contractors who may be our employees and our policy to require our employees and contractors who may be our employees and our policy, while it is our policy to our employees and our employees and our contractors who may be contractors who may be our policy to require our employees and contractors who may be required our employees and contractors and contractors who may be our policy to require our policy to require our employees and contractors who may require our employees and it is our policy to require our employees and contractors who may be required our employees and contractors who may be involved in compliance with respect for those who may be required of the FDA approvals, where it is our policy to require our policy to require our policy to require our policy to require our policy to require our policy to require our employees and contractors who may be our policy to the EU and contractors who may be our policy to require our employees and contractors who may be required our policy to the EMAJORALREADY BIO 505(b) [to require our policy to require our employees andrewire our policy to require our policy to our employees and our policy to require our employees and contractors who may be\u00ad require our policy to require our employees and contractors who may be our employees and our policy to require our employees and contractors who may be required to require our policy to require our policy to require our employees and contractors who may require our employees and contractors who may be our policy to require our policy to require our policy to require our policy to require our policy to require our policy to require our policy to require our policy to require our contractors who may require our policy to require our employees and contractors and contractors who may be required to require our employees and our policy to require our policy to require our employees and contractors who may be required to require our policy to require our policy to the FDA approval of the FDA approval of\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?",
        "options": {
            "A": "55 or older",
            "B": "62 or older",
            "C": "65 or older",
            "D": "70 or older",
            "E": "60 or older",
            "F": "50 or older"
        },
        "LLM_original_answer": [
            "What interest rates due to the fair value of interest rates and other restricted payments of 15\nVolumes across all channels due to the fair value of the fair value due to the following higher market interest rate interest rates and/or due to the fair value of servicing advance financing activities across all channels due to the interest rates and/or related to partially driven by a decrease in volumes across all channels due to the fair value due to the interest rates and other factors.33interest rates and other third-party due to the foregoing or liquidation volumes across all channels due to the fair value of the results due to the interest rate of Ocwen interest rate of the volumes across all channels due to the market interest rate of MSR fair value of the fair value due to the fair value due to the fair value and on a\nvolumes across all channels due to the fair value of the fair value due to the fair value due to higher market interest rates and/or otherwise recognized servicing advance obligations and subservi\ninterest rates and other than expected hedge instruments and/or\nvolumes across all channels due to-been\nvolumes across all channels due to a decrease in volumes across all channels due to the interest rates and other than anticipated by the fair value of the outstanding balances due to the following higher market interest rate of the result of MSR fair value of servicing obligations due to due to variable interest rates and the fair value of the fair value due to the fair value due to the fair value across all channels due to the MSR volumes due to the related to partially due to the related to the volumes and the volumes and/or other actions or the servicing advances and the related to the servicing agreements.33\nResponse:"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What is one potential consequence of violating the civil False Claims Act?",
        "options": {
            "A": "Execution of a scheme without penalty",
            "B": "Four times the actual damages sustained by the government",
            "C": "Exclusion from private healthcare programs",
            "D": "Participation in federal healthcare programs",
            "E": "Mandatory civil penalties for each false claim",
            "F": "No penalties for private individuals"
        },
        "LLM_original_answer": [
            "One or compete with significant management resources and time and will have to compete for management resources and/or compete with significant capital expenditures, which will require significant management resources and management resources and management resources and will require significant management resources and will have to compete with management resources.We will have to compete with significant management resources and compete with respect to obtain FDA, which will have to comply with respectably, which will have to obtainable management resources, which will have to ensure that will have to obtain IND and time and/or, which will have to compete with management resources and management resources and management resources and time and time and time and time and we will have to compete with have to compete with respect to comply with respect to obtainable management resources and time.We will require significant management resources and management resources and/or we will require significant management resources and management resources and management resources and management resources and management resources and significant management resources and time and/or significantly management resources and will have to secure our management resources and compete with significant management resources and management resources and time and/or compete with significant capital expenditures, which may require significant management resources and time and management resources and will have to compete with significant management resources, which will require significant capital expenditures, which will require significant management resources and management resources and time and time and management resources and management resources and time and time and time and compete with significant management resources and will have to compete with management resources and will have significant management resources and will have to obtain regulatory and management resources and management resources and time and will have to compete for the product development and significant capital expenditures, which will have to compete with significant management resources, which will require significant capital expenditures, which will require significant management resources and management time and time and/or may have to obtain regulatory resources and/or the FDA and/or, which will have to the FDA approval, which will require significant management resources and time and time and management resources and will require significant management resources and compete with the FDA and time and time and will have to obtain regulatory resources and will require significant management resources and will require significant management resources and will have to compete for capital expenditures, which will have to obtain regulatory and compete with respectably significant management resources and time and will have to obtain significant capital expenditures, which will require significant capital expenditures, which will require significant management resources.We will have to obtain significant management resources.We will have to compete for management resources and management resources and compete with significant management resources, which will require significant management resources and management resources and which will require significant management resources and compete with respectably compete with respect of the"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is a potential risk mentioned regarding the company's financial position?",
        "options": {
            "A": "High competition leading to reduced market share",
            "B": "Inability to generate sufficient revenue to cover expenses",
            "C": "Government regulations affecting sales",
            "D": "Incorrect labeling of products",
            "E": "Issues with supply chain logistics",
            "F": "Patent expiration affecting product exclusivity"
        },
        "LLM_original_answer": [
            "The have a pharmaceutical tests, tests, preclinical trials and clinical trials and/or clinical trials and clinical trials and clinical trials and clinical trials.We have been subjectively have the FDA approval for the marketing authorization may beClinical Trial Marketing Authorization and independent and independent and independent and/or pharmaceutical tests,We have not only if we have have certain and clinical trials and the product candidates and clinical trials.We have been approved by the CHMPA:\u2022We have been submitted by the CHMPA marketing authorization and other than the following the marketing authorization of pharmaceutical tests, preclinical trials and clinical trials, preclinical trials and clinical trials and/orphanaceutical tests, orClinical Trial and/orbit and approval of clinical trials and independent and clinical trials and/orphanarmid tests, or clinical trials.We have been tests, preclinical trials and preclinical tests, preclinical trials.We have been conducted trials.We have not laterally,We have not only if we have been approved by the CHMPHazardoomed and clinical trials and preclinical tests, preclinical tests and clinical trials.We have pharmaceutical tests, preclinical trials and independent data package of pharmaceutical tests, preclinical trials and clinical trials and clinical trials and preclinical trials and clinical trials.We have not yet-unconditionalWe have been approved product candidate\u2019s marketing authorization of pharmaceutical tests, orWe have not only for products may be granted a\nAnswer:\u2022We have a package of pharmaceutical tests, preclinical trials and clinical trials.We have been approved by pharmaceutical tests, preclinical trials and clinical trials and clinical trials.We haveClinical trials and the following the EMAKernot of pharmaceutical tests, preclinical trials and clinical trials and/orienterapeutic tests, orphanaceutical tests, preclinical trials and clinical trials, orphans ericel\nWe have not laterally tests, preclinical trials and theses, orally tests, preclinical trials and/orphanomissionary tests, preclinical trials.We have a marketing authorization may becompliance tests, preclinical trials and clinical trials.We have been approved indications for the product candidate clinical trials and independent data package of pharmaceutical tests, preclinical tests and clinical trials.We have been granted by the marketing authorization of pharmaceutical tests, preclinical trials.We have been pharmaceutical tests, preclinical tests, preclinical trials and clinical trials.We haveWe have pharmaceutical tests, preclinical trials and clinical trials and clinical trials.We have received and clinical trials.We have not yet.We have pharmaceutical tests, preclinical trials and clinical trials and clinical trials and clinical trials and clinical trials and we have"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What economic factor is likely to reduce mortgage loan production volumes?",
        "options": {
            "A": "Decrease in volatility",
            "B": "Increase in inflation",
            "C": "Rising interest rates",
            "D": "Stability in commodity prices",
            "E": "Reduction in speculative trading",
            "F": "Growth of early stage companies"
        },
        "LLM_original_answer": [
            "The performance and uses useful information useful information useful information in understanding our performance and investors.Information Management and investors in understanding our business and investors in understanding our performance provides useful information for management and investors in understanding our performance provides useful information for management and investors in understanding our performance.Management and investors in understanding our performance.Management and investors in understanding our performance.Management and investors in understanding our performance.Management and understanding our management and investors in understanding our performance.Management and investors in understanding our business and investors in understanding our business and investors in understanding our performance management and investors in understanding our performance provides useful information for management and investors in understanding our performance information for management and investors in understanding our business and investors in understanding our performance provides useful information for management and investors in understanding our business and investors in understanding our business and investors in understanding our business in understanding our performance.Management and understanding our regulatory and understanding our business.Business Management and related to understanding our performance in understanding our performance in understanding our performance.Management and investors in understanding our performance.Investors in understanding our performance.Business and investors in understanding our performance.Management and investors in understanding our performance in understanding our performance.Investors in understanding our performance.Investors of these measures useful information for management and investors in understanding our performance.Investorsource our business and investors in understanding our performance.Management Management and investors in understanding our performance.Management and investors in understanding our business in understanding our performance and investors in understanding our performance.Investors in understanding our performance.Management and investors in understanding our performance and investors in understanding our performance management and investors in understanding our performance.Management and understanding our performance and investors in understanding our performance.Management and investors in understanding our performance provides useful information for management and investors in understanding our performance.Management and investors in understanding our performance.Management and investors in understanding our performance provides useful information for management and investors in understanding our business and investors in understanding our performance.Management and investors in understanding our performance provides useful information for management and investors in understanding our performance and investors in understanding our performance.Management and investors in understanding our performance.Management and investors in understanding our performance.Management and investors in understanding our performance management and investors in understanding our performance and investors in understanding our performance provides useful information for management and investors in understanding our performance.Investors performance and investors in understanding our performance and other measures useful information for management in understanding our business and investors in understanding our performance and investors in understanding our performance.Management and investors in understanding our performance.Management and investors in understanding our business and investors in understanding our business and investors in understanding our business and investors in understanding our performance.Management and investors in understanding our performance.Management and/or investors"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?",
        "options": {
            "A": "Fluctuations in global oil prices",
            "B": "Changes in local tax regulations",
            "C": "Ongoing military actions and threat of terrorism",
            "D": "Increases in online security breaches",
            "E": "Cybersecurity threats from internal employees",
            "F": "Competition from new market entrants"
        },
        "LLM_original_answer": [
            "The five-year, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively for the five-year & Health Insurance Services Index & Health Insurance Companies, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?",
        "options": {
            "A": "$58.7 million",
            "B": "$104.7 million",
            "C": "$153.0 million",
            "D": "$381.4 million",
            "E": "$420.5 million",
            "F": "$275.9 million"
        },
        "LLM_original_answer": [
            "As terms may fail to fail to fail to fail to devote the resources that third party\u2019s terms that may fail to devote acceptable third parties may fail to fail to devote the terms that are may fail to terms may fail to the third parties may fail to our terms that are not favorable terms that are not to fail to terms may fail to fail to devotees may fail to devote the acceptable third parties may fail to usably acceptable third parties may terms that are acceptable terms that are acceptable third parties may fail to devote the necessary resources and/or fail to devote the terms that are not favorable third parties that are acceptable third parties may fail to devote the third parties may fail to terms may fail to terms that are acceptable third parties that are not to devotees may fail to the necessary resources and acceptable third parties may fail to the third parties may fail to terms that are acceptable third parties may fail to devote the third parties may fail to terms that terms that are acceptable terms that are not favorable third parties may fail to devote the acceptable third parties may fail to devote the third parties may fail to fail to devotees may fail to fail to devote the acceptable terms that are acceptable terms that are acceptable third parties may fail to us may fail to devote the third parties may fail to third parties may fail to devote the terms may fail to devote third parties that are acceptable third parties may fail to fail to devote the third parties may fail to devote terms that are not be acceptable third parties may fail to the third parties may fail to devote the necessary third parties may fail to us may fail to terms may fail to devote the third parties may failable terms that are acceptable terms may fail third parties may fail to devote the necessary resources may fail to fail to devote acceptable third parties may fail to terms that are on terms may fail to terms may fail to fail to devote the third parties may fail to devote the necessary resources or may fail to fail to devote the terms that are acceptable third parties may fail to fail to devote the necessary resources or terms that are acceptable third parties may fail to fail to fail to us may failable terms that terms that are acceptable terms that parties.Acceptable third parties may fail to devote the resources to the necessary third parties may fail to devote the terms may fail to devote the product may fail to fail to devote the third parties may fail to devote acceptable third parties may fail to devote the third parties.Acceptable third parties may fail to us.Acceptable third parties may fail to devote the necessary third parties that are acceptable to us.Acceptable third parties may fail to fail to devote the"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?",
        "options": {
            "A": "The executive summary of the annual report",
            "B": "The company's market analysis",
            "C": "The consolidated financial statements and Notes to Financial Statements",
            "D": "The corporate governance guidelines",
            "E": "The strategic business plan",
            "F": "The risk management framework"
        },
        "LLM_original_answer": [
            "The impact this ASU.SUM financial statements and related disclosures and related disclosures.In its consolidated financial statements and related disclosures and related disclosures and related disclosures and related disclosures.The impact this ASU.Sources there are there are U.SU will have on its consolidated financial statements and related disclosures.The impact this ASU.Secum there are related to have been disclosures.The impact this ASU.SU will have on its consolidated financial statements and related disclosures.The impact there are disclosures.The impact this ASU.Sever consolidated financial statements and related disclosures.TheThere is the impact this ASU.SUM there are there are the impact this consolidated financial statements and related disclosures.The impact this ASU.See impact this ASU will have been consolidated financial statements and related to have been consolidated financial statements and related disclosures will have had on its consolidated financial statements will have had on its consolidated financial statements and related disclosures and related disclosures.The impact this ASU.SUMDistributed disclosures.In the impact this ASU.SU will have on its consolidated financial statements and related disclosures.The impact this ASU.Secum will have on its consolidated financial statements and related disclosures.The impact this ASU.Solution this ASU will have its consolidated financial statements and related disclosures.The impact this ASUs there are there are there will have not there are there will have consolidated financial statements and related disclosures.The impact this ASUs there are disclosures.The impact this ASU.Solutionary financial statements and related disclosures will have been on our consolidated financial statements and related to our consolidated financial statements and related disclosures will have been disclosures will have on its consolidated financial statements and related disclosures and related disclosures.The ASU.SU will have on our consolidated financial statements and related disclosures.The consolidated financial statements and related disclosures and related disclosures.There are related disclosures will have a consolidated financial statements and related disclosures.The impact this ASU.SU.SUM there are related disclosures of its consolidated financial statements and related disclosures will have been disclosures will have been disclosures will have on its consolidated financial statements and related disclosures.There are financial statements and related disclosures.The consolidated financial statements will have disclosures.In the consolidated financial statements will have been disclosedThere are there are the ASU.Sevent there are there are related disclosures.In addition to have had consolidated financial statements will have had on its consolidated financial statements and related disclosures.TheThere are there are other financial statements will have related disclosures.The ASUbi is the following ASUs will have been disclosures.The impact this ASU.SUMBEROUPTHEREThere are there are there are the impact this ASU.S related disclosures.TheThere is no"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?",
        "options": {
            "A": "Increase in secondary marketing sales",
            "B": "Customer growth",
            "C": "Lower natural gas costs passed through to customers",
            "D": "Increase in North Carolina IMR",
            "E": "Tennessee ARM revenue recognition",
            "F": "Increase in off-system sales"
        },
        "LLM_original_answer": [
            "The fourth quarter 2023, Duke Energy Management 2023##3## October 2023, Duke Energy October 2023, Duke Energy 2022 2022##November 202 November 2023, Duke Energy registered October 2023, Duke Energy October 2023, Duke Energy completed the fourth quarter 2023##table quarter of 2023 Duke Energy October 2023##Your management of October 2023, Duke Energy Management, Duke Energy Management October 2023, Duke Energy, Duke Energy Energy Energy Energy, Duke Energy, Duke Energy Energy, Duke Energy Energy Energy completed October 2023##table 2023, Duke Energy October 2023 Duke Energy October 2023, Duke Energy during October 2023, Duke Energy October 2023##3##3## Table 2023##2##table 2023, Duke Energy Energy Energy during October 2023##table 2020##table 2023, Duke Energy, Duke Energy Energy October 2023##table 2023##table 2022## 2023, October 2023, Duke Energy, October 2023##table 2023##3, Duke Energy\u2019s October 2023##2##table 2023##table 2023##table 2022##table 2023, Duke Energy, 2023, October 2023, Duke Energy October 2023, Duke Energy, Duke Energy, Duke Energy October 2023, Duke Energy, Duke Energy October 2023, Duke Energy 2023##3, October 2023, Duke Energy October 2023, Duke Energy October 2023, Duke Energy 2023, Duke Energy 2023##table 2023##2##table 2023##\nDuke Energy October 2023## 2023##\nDuring October 2023, Duke Energy 2023 October 2023##2022 October 2023, Duke Energy, Duke Energy, Duke Energy 2023##table 202 October 2023, Duke Energy October 2023, Duke Energy October 2022##table 2023, Duke Energy, Duke Energy, Duke Energy Registrants 2022## November 2023, Duke Energy registered the Duke Energy completed the fourth quarter 2023##table 2023, Duke 2023##2, Duke Energy, Duke Energy, Duke Energy Registrants December 2023Duke Energy completed the October 2023, Duke"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?",
        "options": {
            "A": "Technological advancements",
            "B": "Climate change",
            "C": "Economic policies",
            "D": "Urban development",
            "E": "Infrastructure improvements",
            "F": "Regulatory changes"
        },
        "LLM_original_answer": [
            "The following general interest rates are greatly influenced by greatly influenced by general interest rates and general interest rates and economic conditions and loan and securities prepayment prepayment greatly influenced by general economic conditions are greatly influenced by general rates and economic conditions, and general economic conditions and securities prepayment and economic conditions and general interest rates and economic conditions and loan and loan and securities prepayment of general economic conditions greatly influenced by general economic prepayments and prepayments and greatly influenced by general interest rates and general conditions and loan and loan and economic conditions, economic conditions and general interest rates and greatly influenced by general interest rates and general interest rates and securities and general economic conditions and economic conditions and general interest rates and economic conditions and general interest rates, and securities prepayments, as well influenced by general interest rates and loan and economic conditions and interest rates and loan and securities and securities prepayments greatly influenced by general economic conditions, greatly influenced by and loan and securities prepayments and greatly influenced by general interest rates and greatly influenced by general interest rates, loan and general interest rates greatly influenced by general interest rates, economic conditions and economic conditions, and securities prepayments and other greatly influenced by general interest rates, economic conditions greatly influenced by general interest rates prepayments and loan and greatly influenced by interest rates and loan and general interest rates, interest rates, economic conditions greatly influenced by general interest rates greatly influenced by general interest rates, economic conditions and general interest rates, greatly influenced by general interest rates, general economic conditions, loan and securities prepayments and loan and general interest rates and economic conditions and general interest rates and economic conditions and general economic conditions and loan and general economic conditions and economic conditions, greatly influenced by general interest rates, general interest rates and securities prepayments and prepayment and general interest rates, general economic conditions and general economic conditions greatly influenced by general economic conditions greatly influenced by general interest rates and loan and prepayments and loan and loan and securities and greatly influenced by general economic conditions, as well as well influenced by general interest rates, economic conditions and greatly influenced by general interest rates and economic conditions and general economic conditions prepayments greatly influenced by general interest rates and general interest rates and economic conditions and general interest rates and securities prepayments and prepayments greatly influenced by general interest rates, economic conditions and general interest rates, loan and loan and greatly influenced by general interest rates and general interest rates and prepayments greatly influenced by general interest rates and securities prepayment of general interest rates, general interest rates and general interest rates, economic conditions and general economic conditions, and general interest rates of the Company\u2019s greatly influenced by"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is a primary reason for fluctuations in the company's financial results?",
        "options": {
            "A": "Successful transition of operations",
            "B": "Regular market growth",
            "C": "Factors beyond the company's control",
            "D": "Consistent product demand",
            "E": "Reduced operational expenses",
            "F": "Stable regulatory environment"
        },
        "LLM_original_answer": [
            "The growth of our ability to growth in part of our ability to the growth of our business growth in part on our ability to acquire in part of our ability to market authorizations of our growth of our business growth of our ability to the growth of our business growth of our growth of our ability to the growth of our business growth in part on our ability to acquire or license to acquire in part of our business growth.The growth of our business growth of our ability to our business may depend in part on our ability to acquire the growth through the growth of our business in-licensed in part on our ability to conduct clinical data from our business may depend in part of our ability to acquire in part of our business growth of our ability to acquire in part of our business growth in part on our ability to acquire in-issued Orphan growth of our ability to the growth of our ability to aquisition in part in part of the growth of our business may depend in part on part on our ability to acquire in-licensed or the growth of our business growth may depend in part on the growth in part of the growth in part of our ability to acquire in part of our ability to the growth of our business growth in part on our ability to acquire, license or growth of our ability to obtain and growth in part of the growth may depend in part of our business growth may depend in part of our business may depend in part on our ability to acquire in part on our ability to acquire, or license or growth of our business growth may depend in part of our business growth of the growth of our ability to a) on a\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?",
        "options": {
            "A": "55 or older",
            "B": "62 or older",
            "C": "65 or older",
            "D": "70 or older",
            "E": "60 or older",
            "F": "50 or older"
        },
        "LLM_original_answer": [
            "The business in the and while survey results and client feedback and client feedback and including risk premiums and client feedback and including industry survey results and client feedback while we have beenge premiums and liquidity adjustments.While we have results and client feedback and including client feedback and including risk premiums and including risk premiums and including the whilesurvey results and client feedback and client feedback, including risk premiums and liquidity adjustments.While we are subject results and client feedback and client feedback and including risk premiums and liquidity adjustments.While we have been and survey results and client feedback and client feedback and client feedback and client feedback, and client feedback while we have premiums and liquidity adjustments.While we are we have been the survey results and client feedback and client feedback and including risk premiums and client feedback and client feedback, and including risk premiums and liquidity survey results and client feedback.While we\nLiquidity adjustments.While we have premiums and liquidity adjustments.While we continue to the survey results and client feedback and client feedback and including risk and liquidity adjustments.While we have been and liquidity adjustments.While we\nand liquidity adjustments.While we have risk premiums and liquidity adjustments.While the following survey results and client feedback and client feedback and including risk premiums and client survey results and client feedback, and client feedback and liquidity adjustments.While the premiums and liquidity adjustments and survey results and client feedback, and client feedback, and including risk premiums and while liquidity adjustments.While we are there may be\nClient survey results and client feedback and client feedback and client feedback and including available industry survey results and client survey results and client feedback and client feedback and liquidity adjustments while we are the surveys and including available survey results and client feedback and including risk premiums and liquidity adjustments.While the survey results and client feedback while we have liquidity adjustments.While we have liquidity adjustments.While the survey results and client feedback and including risk premiums and liquidity adjustments.While we endeavor to the and liquidity adjustments and client feedback and client survey results and client survey results and client feedback, and including risk premiums and liquidity adjustments and adjustments.While we devote results and client feedback, including risk premiums and client feedback and client feedback and client feedback and client feedback and including risk premiums and client feedback, including risk premiums and liquidity adjustments and liquidity adjustments and survey results and including risk and liquidity adjustments.While we have been\nClient feedback and including risk premiums and liquidity adjustments.While including risk premiums and liquidity adjustments.While we have survey results and survey results and client feedback and including risk premiums and liquidity adjustments.While available industry survey results and client survey results and client feedback, and client feedback, and liquidity adjustments.While theWhile the industry survey results and liquidity adjustments.While we endeavor"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What is one potential consequence of violating the civil False Claims Act?",
        "options": {
            "A": "Execution of a scheme without penalty",
            "B": "Four times the actual damages sustained by the government",
            "C": "Exclusion from private healthcare programs",
            "D": "Participation in federal healthcare programs",
            "E": "Mandatory civil penalties for each false claim",
            "F": "No penalties for private individuals"
        },
        "LLM_original_answer": [
            "One or any third-party contract manufacturers to manufacture facilities used by usability.The comparability or any third-party contract manufacturers to be used by us or any third-party contract manufacturers to demonstrate product comparability, the facilities used by us or any third-party contract manufacturers to whom we or any such facilities used by us or product comparability.The facilities used or any product comparability.The comparability or any third-party comparability, or any comparability used to us to any third-party contract manufacturers to manufacture products used by us or any third-party contract manufacturers to any product similarity of us or any third-party contract manufacturers to any third-party contract manufacturers to be used or any product comparability are not used by us or any third-party contract manufacturers to date may be used by us or any third-party contract manufacturers to date comparability used by us or any third-party T cellularity.Thereto us or any third-party product comparability.TCRAs we or any third-party contract manufacturers or any third-party comparability.The contract manufacturers to any third-party contract manufacturers of usability.The facilities by us or any third-party contract manufacturers to be used to manufacture comparability.Theavess or any third-party contract manufacturers to demonstrate product comparability facilities used by us or any of us or any or any third-party product comparability.The comparability comparability to manufacture to be used by us or any facilities used by us to date used by us or any third-party to the facilities to be used by us or product comparability.The facilities used by us or product comparability.The clinical or any third-party contract manufacturers to contract manufacturers to demonstrate product comparability to demonstrate product comparability of any third-party contract manufacturers to demonstrate product comparability to be used in product comparability.The comparability used by us or any product comparability.The products are used by us or product comparability.The facilities used by us or any third-party contract manufacturers to demonstrate us or any such facilities used or any third-party contract manufacturers to be used in use or any third-party contract manufacturers to be used to which may be used to any third-party facilities used to which we use to manufacture to be used to be used to be used to manufacture to manufacture our comparability comparability.The data used to us or any third-party contract manufacturers to any third-party contract manufacturers to date us or any third-party used to which we or any third-party comparability or any product comparability.The comparability or any third-party contract manufacturers to us or any third-party contract manufacturers to manufacture to us or any third manufacture our or any third-party contract"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is a potential risk mentioned regarding the company's financial position?",
        "options": {
            "A": "High competition leading to reduced market share",
            "B": "Inability to generate sufficient revenue to cover expenses",
            "C": "Government regulations affecting sales",
            "D": "Incorrect labeling of products",
            "E": "Issues with supply chain logistics",
            "F": "Patent expiration affecting product exclusivity"
        },
        "LLM_original_answer": [
            "A clinical trials in patients with PSP, which may make our clinical trials in patients with PSP, which may make our product development of WS, and other indications, PSP and other indications, which may make our clinical trials in vitro which may make it may make our patients with WS, which may make PSP, PSP, PSP and other indications, which may make our clinical trials in patients with PSP, which may make our PSP, which may make our PSP, which may make our clinical trials in patients with WS and other indications, which may make our clinical trials in addition, which may make our PSP, which may make our, which may make our clinical trials in patients with PSP, which may make our clinical trials in patients with WS, which patients with PSP and other indications, which may make our PSP, which may make our PSP, which may make WS and other indications, which may make our clinical trials, which may make our clinical trials in WS and other indications, which may make patients with WS and other indications, which may PSP, which may make our PSP and other indications, which may make our clinical trials in-house patients with the approved in-house syndrome, which may make our clinical trials in patients with WS, which may make patients with PSP, which may make our product, which may make our clinical trials in patients, which may PSP, PSP and other indications, which may make our PSP, which may make our clinical trials in patients with WS, which may make our PSP, which may make our clinical trials in patients with PSP and PSP, in addition, which make our clinical trials in patients with PSP, which may make our PSP, which may make it may make our WS, which may make WS, PSP, which may make PSP, which may make our clinical trials in WS, which may make our clinical trials in PSP, PSP and other indications in patients with WS, which may make our indication in patients with PSP and other indications, which may make our PSP and other indications, which may make our clinical trials in patients with WS, which may make our clinical trials in patients with PSP and other indications, which may make our PSP, which may make our PSP, or other indications in patients with PSP and other indications, which may make our clinical trials in our PSP and other indications, which may make our clinical trials, which may make our make our clinical trials in patients with WS and other indications in addition, which may make our clinical trials in-house, PSP and other indications, which may make our PSP, which may make our PSP,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What economic factor is likely to reduce mortgage loan production volumes?",
        "options": {
            "A": "Decrease in volatility",
            "B": "Increase in inflation",
            "C": "Rising interest rates",
            "D": "Stability in commodity prices",
            "E": "Reduction in speculative trading",
            "F": "Growth of early stage companies"
        },
        "LLM_original_answer": [
            "An available and future planned strategic activity, share repurchase activity, current and future planned strategic planned strategic requirements and share repurchase activity, share repurchase activity, share repurchase activity, share repurchase activity, current and share repurchase activity, current and future planned strategic and future strategic initiatives, current and future strategic investments, current and share repurchase activity, current and share repurchase and future planned strategic investments, current and other planned strategic repurchase activity, current and current and current and current and current and share repurchase activity, current and future planned strategic planning activity, current and strategic requirements, share repurchase activity, strategic planning and future planned strategic initiatives, current and future planned strategic planned strategic and future planned strategic activity, and share repurchase activity, current and future planned strategic investments, current and share repurchase activity, current and planned strategic planning activity, current and strategic planning, current and share repurchase activity, current and strategic planning strategic and future planned strategic activity, current and future planned strategic investments, current and current and current and current and strategic requirements, current and share repurchase activity and share repurchase activity, current and future planned strategic investments, current and other planned strategic requirements and share repurchase activity, current and future planned strategic investments, share repurchase activity, current and current and future planned strategic planned strategic planned strategic planned strategic repurchase activity, current and current and current and current and current and current and future planned strategic activity, current and future planned strategic investments, current and current and current and current and current and current and future planned strategic planning activity, current and repurchase activity, current and future planned strategic investments, current and strategic activity, and share repurchase activity, and future planned strategic strategic investments, current and future planned strategic initiatives, and share repurchase activity, current and share repurchase activity, share repurchase activity, current and future strategic investments, current and future planned strategic activity, current and future planned strategic activity, capital requirements and share repurchase activity, strategic requirements and future planned strategic repurchase activity, strategic share repurchase activity, and future planned strategic planned strategic investments and current and current and future planned strategic activity, share repurchase activity, current and current and future planned strategic planned strategic initiatives, share repurchase activity, current and planned strategic planning and future planned strategic activity, current and future planned strategic requirements and share repurchase activity, current and current and future planned strategic initiatives, current and repurchase activity, current and future strategic activity, current and future planned strategic activity, current and future planned strategic planning activity"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?",
        "options": {
            "A": "Fluctuations in global oil prices",
            "B": "Changes in local tax regulations",
            "C": "Ongoing military actions and threat of terrorism",
            "D": "Increases in online security breaches",
            "E": "Cybersecurity threats from internal employees",
            "F": "Competition from new market entrants"
        },
        "LLM_original_answer": [
            "The Company and private corporate bond investments in private bond investments and private corporate investments and bank credit facilities and bank credit facilities and bank credit facilities and bank credit facilities and private corporate bond investments in partnership investments, bank credit facilities and private corporate bond investments and bank credit facilities and corporate bond and private corporate bond investments and corporate bond investments and corporate bond investments and private corporate bond investments and bank credit facilities and corporate bond investments and private corporate bond investments, bank credit facilities and corporate bond investments and corporate bond investments and private corporate bond investments and bank credit facilities and corporate bond investments and commitments to fund investments and private corporate bond investments and private corporate bond investments and private corporate bond investments and private corporate bond investments, private corporate bond investments, bank credit facilities and private bond investments and private corporate bond commitments to fund partnership investments, bank credit facilities, bank credit facilities and bank and private corporate bond investments, bank credit facilities and private corporate bond and private corporate bond investments and private corporate bond investments and bank credit partnership investments and private corporate bond and private corporate bond investments and commitments to fund investments, bank credit facilities and private corporate bond investments and private corporate bond investments and private corporate bond investments, bank credit partnership investments and corporate bond investments and private corporate bond investments and private corporate bond investments and private corporate bond investments. Bank credit facilities and private corporate bond investments and private corporate bond investments and private corporate bond investments, private corporate bond investments and private corporate bond investments, bank credit facilities and corporate bond investments in corporate bond investments and private corporate bond investments and bank credit facilities and private corporate bond investments and corporate bond investments and corporate bond investments and commitments to fund private investments and private corporate bond investments and private corporate bond investments and corporate bond investments and corporate bond investments and corporate bond investments and private corporate bond investments in partnership investments and corporate bond investments and private corporate bond investments and private corporate bond commitments to fund corporate bond investments and private corporate bond investments and corporate bond investments and private corporate investments and private corporate bond investments in corporate bond investments in partnership investments and private corporate bond investments and private corporate bond investments and corporate bond investments and private corporate bond investments in corporate bond investments and private corporate bond investments in partnership investments in corporate bond investments and private corporate bond investments and private corporate bond investments and private corporate bond commitments to fund investments, bank credit facilities and bank credit facilities and commitments to fund investments in partnership investments, bank credit facilities, bank credit facilities and corporate bond investments in corporate bond investments and private corporate bond investments in corporate bond investments in private corporate bond investments and private corporate bond investments in bank credit facilities, bank credit facilities, bank credit facilities"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the accumulated deficit reported by the company?",
        "options": {
            "A": "$58.7 million",
            "B": "$104.7 million",
            "C": "$153.0 million",
            "D": "$381.4 million",
            "E": "$420.5 million",
            "F": "$275.9 million"
        },
        "LLM_original_answer": [
            "As aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of aspects of our business and delay aspects of aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of aspects of our business aspects of our business aspects of our business aspects of our business aspects of aspects of our business aspects of our business aspects of our business aspects of our business and delay aspects of our business aspects of our business and delay aspects of our business aspects of our business aspects of aspects of our business aspects of our business aspects of our business aspects of our business aspects of aspects of aspects of our business aspects of our business aspects of aspects of aspects of our business aspects of aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business and aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of aspects of aspects of aspects of aspects of our business and aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business and aspects of our business aspects of our business aspects of our business aspects of aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of aspects of our business aspects of our business and aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business and aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of our business aspects of aspects of aspects of our business aspects of our business and delay aspects of our business and aspects of our business aspects of our business aspects"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What document should be read in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)?",
        "options": {
            "A": "The executive summary of the annual report",
            "B": "The company's market analysis",
            "C": "The consolidated financial statements and Notes to Financial Statements",
            "D": "The corporate governance guidelines",
            "E": "The strategic business plan",
            "F": "The risk management framework"
        },
        "LLM_original_answer": [
            "What common shares of the option of holder of the holder of the price of 1 of or of the option of 1 at 50 at  or of any price of any of $  1 of the option of 1 of or at 1 of the option option of option of the option of option of $ 1 of  option of holder of or a price of 19. The price of price of price price of or the price of the price of option of and and 1 of the option of option of holder of price price of any price of 50% or the option of the option of 1 of the 1 of any option at option of the option of the of the option of the option of the option of option of option of any of any of 100 of 1 of holders holders of price price of the option of the option of the option of the option of the holder of the option of the option of 11 at the holder at the option of option of holder at any of any of 11 of  option of holder at the price of 10 percent of the holder of holder at the option of option of 10 at 1 of the holder at option of the holder of the option of option option at any or at any price of the price price of or a option of any option of the shares shares at the option of holders at 1 of the option of shares at option of holder at and upon the option of $ 1 of or of holder of $  price of 25 percent of the option holders of 1 at option of the holder of the option of the option of shares at option of the holder of the holder of the option of  option of 100 shares at any option of holders of  or at the option of the option of the option of the option of the holder of any of any price of the option or a price of 1 of the option of the holder of the option of holder at the holder of price of 1 of 1 of the holder of any option of the holder at or at or of the shares or option of the option of the holder of or or at  option of option of the holder at  1 of holder of   price at the option of the holder of the holder at 12 were convertible into 1 of the holder of 1 of the holder of the option of  option of the option of or or  1 of 1. 10 at or at a 144 at option of the holder"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What primarily caused the $585 million decrease in operating revenues for the year ended December 31, 2023, compared to 2022?",
        "options": {
            "A": "Increase in secondary marketing sales",
            "B": "Customer growth",
            "C": "Lower natural gas costs passed through to customers",
            "D": "Increase in North Carolina IMR",
            "E": "Tennessee ARM revenue recognition",
            "F": "Increase in off-system sales"
        },
        "LLM_original_answer": [
            "What ash moved to Allen, including one at Allen, one at Allen, two at Allen, one at Allen, with ash moved to Allen, with ash moved to be moved ash at Allen, one ash moved to Allen, Allen, with ash at Allen, with ash moved to Allen, one at Allen, one at Allen, with ash at Allen, and one at Allen, one at Allen, one at Allen, with ash at Allen, with ash moved to Allen, including one at Allen, including one at Allen, including Allen, and two at Allen, including one at Allen, including one at Allen, including one at Allen and Allen and Allen, Allen, with ash at Allen, one at Allen, including Allen, with ash moved to on-site, with ash at Allen and two at Allen, including Allen and one at Allen and Allen and Allen, one at Allen and two at Allen, including two at Allen, including two at Allen moved to on-site lined landfills moved to Allen, Allen, Allen, with ash at Allen, and two at Allen, with ash moved to Allen, and two at Allen, with ash moved to Allen and Allen and two at Allen, off-site lined landfills, including two at Allen, with ash, one at Allen, including one at Allen, one at Allen and two at Allen, one at Allen, and two at Allen, and two at Allen, and two at Allen, Allen, two at Allen, with ash moved to on-site lined landfills, with ash at Allen, with ash moved to Allen, including one at Allen, Allen, Allen, including two at Allen, including two at Allen, including two at Allen, including two at Allen, Allen, with ash moved to Allen, including Allen, with ash moved to Allen, with ash moved to Allen, with ash, with ash moved to Allen, lined landfills, with ash moved to Allen, one at Allen, two at Allen, and Allen, Allen, and Allen, one at Allen, including one at Allen, with ash moved to Allen, with ash at Allen, including two at Allen, including Allen, with ash moved to Allen, and one at Allen, Allen, including one at Allen, with ash at Allen, including one at Allen, including one at Allen, including one at Allen, including two at Allen, including two at Allen, including ash moved to Allen, lined landfills, with ash moved to Allen, with ash, one at Allen, one at Allen, with ash moved to Allen, and"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which factor is mentioned as potentially worsening the severity and impact of future natural disasters?",
        "options": {
            "A": "Technological advancements",
            "B": "Climate change",
            "C": "Economic policies",
            "D": "Urban development",
            "E": "Infrastructure improvements",
            "F": "Regulatory changes"
        },
        "LLM_original_answer": [
            "Which may also over 90 days over 90 days over   days over 90 days over 90 days over   90 days over 90 days.The Company may also use discretion regarding other loans over 90 days over 90 days over 90 days over 90 days over 90 days over  discretion regarding other factors regarding other over 90 days over 90 days over 90 days over 90 days over  discretion regarding other loans over   interest may also use discretion regarding other loans over 90 days over 90 days over 90 days over 90 days over  over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 270 days over  interest.The Company\u2019s discretion regarding other loans over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over  days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over  90 days over 90 days over 90 days over 90 days over 90 days over 90 days over  days regarding other than over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days over   days over 90 days over  over        discretion regarding other over 90 days over 90 days over 90 days over 90 days over 90 days over 10 also use discretion regarding other loans over 90 days over 90 days over  over 90 days over 90 days over 90 days over 90 days over 90 days over 90 days.The Company may also over 90 days over 90 days over  over"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is a primary reason for fluctuations in the company's financial results?",
        "options": {
            "A": "Successful transition of operations",
            "B": "Regular market growth",
            "C": "Factors beyond the company's control",
            "D": "Consistent product demand",
            "E": "Reduced operational expenses",
            "F": "Stable regulatory environment"
        },
        "LLM_original_answer": [
            "What is a patient, and uncertainty with uncertainty with respect to patients, uncertainty with competing products, uncertainty with uncertainty with uncertainty with respect to patients, the drug candidate, a precursor of the uncertainty with respect to patients and uncertainty with respect to patients, uncertainty with respect to patients, and uncertainty with uncertainty with uncertainty with respect to patients, and uncertainty with competing products, uncertainty with competing products, uncertainty with respect to the above mentioned above, and/or drug candidate of the uncertainty with respect to patients, source: a sub-clinhibing such drug candidate to patients, uncertainty with uncertainty with such as well as topline of the potential of competing products, the above, uncertainty with competing products, and development of certain with respect to patients, and patients, and competing products, patients, and the uncertainty with respect to patients, and uncertainty with uncertainty with competing products, if such drug candidate, and uncertainty with respect to patients, and uncertainty with patients, uncertainty with competing products, uncertainty with competing products, and delivery of delivering such drug candidate to patients, if patients, and uncertainty with respect to patients, and uncertainty with patients, and uncertainty with respect to patients, uncertainty with respect to patients, and uncertainty with respect to patients, uncertainty with respect to patients, uncertainty with respect and competing products, uncertainty with competing products, uncertainty with uncertainty with competing products, uncertainty with uncertainty with uncertainty with uncertainty with respect to patients, uncertainty with uncertainty with respect with uncertainty with respect to patients, and regulatory uncertainty with patients, uncertainty with respect with respect to patients, uncertainty with competing products, uncertainty with uncertainty with competing products, and regulatory and regulatory and delivery of such drug candidate, and uncertainty with uncertainty with patients, and regulatory and regulatory and regulatory and uncertainty with uncertainty with competing products, and uncertainty with competing products, and patients, and our company, uncertainty with competing products, and our clinical hold partial clinical trials, uncertainty with competing products, uncertainty with uncertainty with respect with uncertainty with uncertainty with uncertainty with uncertainty with uncertainty with respect with uncertainty with competing products, and uncertainty with uncertainty with competing products, and uncertainty with competing products, uncertainty with uncertainty with uncertainty with uncertainty with such drug candidate, and uncertainty with such drug candidate, and uncertainty with respect to patients, and uncertainty with uncertainty with uncertainty with uncertainty with respect to patients, and uncertainty with respect to name drug candidate, uncertainty with uncertainty with uncertainty with uncertainty with uncertainty with uncertainty with respect to patients, and uncertainty with respect to patients and delivery of competing products, and uncertainty with respect to patients, and delivery of competing products, and uncertainty with uncertainty with"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What age must a homeowner be to qualify for a government-insured HECM reverse mortgage?",
        "options": {
            "A": "55 or older",
            "B": "62 or older",
            "C": "65 or older",
            "D": "70 or older",
            "E": "60 or older",
            "F": "50 or older"
        },
        "LLM_original_answer": [
            "What understand the methodologies to them, and understand the methodologies used by them are proprietary to them, we understand the methodologies, we understand the methodologies and the methodologies to them are proprietary to them, we understand the methodologies and related to them are proprietary to them, we understand the methodologies to them, understand the methodologies are proprietary to them, and proprietary to them understand the methodologies to them are proprietary to understand the methodologies to them are proprietary to them, we understand the methodologies are proprietary to them, understand the methodologies, understand the methodologies and related assumptions used by them. We understand the valuation experts are proprietary to us understand the methodologies used by them, we understand the methodologies and related assumptions are proprietary to us understand the valuation experts are proprietary to them, we understand the understand the valuation experts, we understand them, understand the methodologies to them, we understand the methodologies used by the methodologies and the methodologies, we understand the methodologies and understand the methodologies are proprietary to them are proprietary to them, we understand the methodologies the methodologies used to them understand the methodologies to them, understand the methodologies to them, understand the methodologies used by them understand the methodologies to them, understand the methodologies and assumptions are valuation experts are proprietary to them, we understand the methodologies used by them are proprietary to them, we understand the methodologies used by the valuation experts, and assumptions, we understand the valuation experts, we understand the methodologies to them understand the methodologies and assumptions used to them, we understand the methodologies and understand the methodologies used by them, understand the methodologies used by them understand the valuation experts understand the valuation experts, we understand the methodologies and related assumptions used to them, understand the methodologies used valuation experts are proprietary to them, we understand the methodologies and understand the methodologies, we understand the methodologies used the methodologies to them, understand the methodologies to them, we understand the methodologies are proprietary to them are proprietary to them are proprietary to them are proprietary to understand the methodologies to them, understand the methodologies to them, we understand the methodologies used by them, and assumptions used by the methodologies and related assumptions to us understand the methodologies to them are proprietary to them are proprietary to them are proprietary to them, we understand the methodologies to them understand the methodologies to them and understand the methodologies and related assumptions to them understand the methodologies and understand the methodologies and understand the methodologies and understand the methodologies and related assumptions used experts understand the methodologies to them understand the methodologies to them, understand the methodologies and related to them, we understand the methodologies and related assumptions to them are proprietary to them are proprietary to them, we understand the methodologies to them,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is one potential consequence of violating the civil False Claims Act?",
        "options": {
            "A": "Execution of a scheme without penalty",
            "B": "Four times the actual damages sustained by the government",
            "C": "Exclusion from private healthcare programs",
            "D": "Participation in federal healthcare programs",
            "E": "Mandatory civil penalties for each false claim",
            "F": "No penalties for private individuals"
        },
        "LLM_original_answer": [
            "One of the Department of the Federal Reserve, a statement by the Department of the Department of the Department of the Department of the Department of the Department of the Department of the Department of the the Department of the Department of the Department of the the the a statement by the Department of the Department of the Treasury, the Department of the Federal Reserve, the Federal Reserve, the Federal Reserve, the Department of the Federal Reserve, the statement by the Department of the Department of the statement by the statement by the Treasury, the statement by the Department of the Treasury, the Federal Reserve, a statement by the Department of the statement by the receivership, the statement by the Department of the the Department of the Department of the Department of the Federal Deposit, the Department of the Department of the Department of the Federal Reserve, the Department of the Department of the Department of the Department of the Department of the Department of the Federal Reserve, the Department of the Department of the statement by the Department of the Department of the Department of the Federal Reserve, the Department of the Federal Deposit of the Federal Reserve, the Federal Reserve, the following a statement by the Department of the Department of the statement by the Department of the statement by the Federal Reserve by the Department of the Department of the Department of the Federal Reserve, the Federal Reserve, the statement by the Federal Deposit of the Department of the Federal Deposit of the statement by the statement by the the statement by the statement by the Federal Reserve, the Treasury, the Federal Reserve, the Department of the Federal Deposit of the Federal receivership by the statement by the FDIC, the statement by the statement by the statement by the Federal Deposit of the FDIC, and receivership by the Department of the Department of the Department of the Department of the Federal Reserve, the Federal Reserve, and the statement by the following a statement by the Department of the statement by the Federal Reserve, the statement by the statement by the statement by the statement by the Federal Deposit of the statement by the statement by the Federal and the Federal Deposit of the Federal Deposit of the Department of the Department of the statement by the Department of the Department of the Federal Reserve, the Treasury, the Federal Reserve, a statement by the Federal Reserve, the Federal Reserve, the Federal Reserve, the Treasury, a statement by the Department of the Department of the Federal Reserve, the Department of the statement by the statement by the the statement by the statement by the Federal Reserve, the Department of the statement by the Department of the Department of the Federal Reserve, the statement by the Federal Reserve, the Department"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is a potential risk mentioned regarding the company's financial position?",
        "options": {
            "A": "High competition leading to reduced market share",
            "B": "Inability to generate sufficient revenue to cover expenses",
            "C": "Government regulations affecting sales",
            "D": "Incorrect labeling of products",
            "E": "Issues with supply chain logistics",
            "F": "Patent expiration affecting product exclusivity"
        },
        "LLM_original_answer": [
            "A Global Head of Global Head of our current Global Head of our then Global Head of Global Head of Global Head of Global Head of Global Head of Global Head of our current Global Head of our then Global Head of Global Head of Global Head of our then Global Head of Global Head of our current Global Head of Global Head of Global Head of our then Global Head of Global Head of Global Head of Global Head of our current Global Head of Global Head of Global Head of Global Head of our Global Head of Global Head of Global Head of Global Head of December 2023 then Global Head of Global Global Global Head of Global Head of Global Head of our current Global Head of our then Global Head of Global Head of Global Head of our current Global Head of our Global Head of our current Global Head of our then Global Head of Global Head of Global Head of Global Head of Global Head of Global Head of our Global Head of Global Global Head of Global Head of Global Head of Global Head of our Global Head of Global Head of our current 2023.In December  Global Head of Global Head of Global Global Head of Global Global Head of Global Head of our current Global Head of Global Head of Global Head of Global Head of our current Global Head of our then Global Head of Global Head of our then Global Head of our current Global Head of our current Global Head of our then Global Head of Global Head of Global Global Head of our current Global Head of Global Head of Global Head of Global Head of Global Head of Global Head of our current Global Head of Global Head of Global Head of Global Head of our then Global Head of our then Global Head of Global Head of our then Global Head of our then Global Head of Human Resources.In December 2023.In December Global Head of Global Head of our then Global Head of our current Global Head of our then Global Head of Global Head of Global Global Head of our then Global Global Head of Global Head of Global Head of Global Head of our current Global Head of Global Global Head of Global Head of our current Global Head of Global Head of our current Global Head of our current Global Head of Global Head of Global Head of Global Head of Global Head of Global Head of our current Global Head of our then Global Head of Global Head of our current Global Head of our then Global Head of Global Head of Global Head of Global Head of Global Head of Global Head of Global Head of Global Head of Global Head of Global Head of our current Global Head of our current Global Head of Global Head of our current Global Head of our then Global Head of Global Global Global Global Head"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What economic factor is likely to reduce mortgage loan production volumes?",
        "options": {
            "A": "Decrease in volatility",
            "B": "Increase in inflation",
            "C": "Rising interest rates",
            "D": "Stability in commodity prices",
            "E": "Reduction in speculative trading",
            "F": "Growth of early stage companies"
        },
        "LLM_original_answer": [
            "The also may be a target for such illegal acts in the future.The also may also may be a target for such illegal acts for such illegal acts in the future also may be a target for such illegal acts in the also may be a target for such illegal acts in the target for such illegal acts in the future also may be a target for such illegal acts in the following such as well may be a target for such illegal acts in the future may be a target for such illegal acts in the U.Social acts in the future may be a target for such as well may be a target for such illegal acts in the also may be a target for such illegal acts in the following our also may be a target for such as a target for such illegal acts in the also may also may be a target for such illegal acts in the also may be may be a target for such illegal acts in the future may be a target for such illegal acts in the future may be a target for such illegal acts in the future.There also may be may be a target for such illegal acts also may be a target for such illegal acts in the following acts in the U.Known may be a target for such as well may be a target for such illegal acts in the future.There also may also may be a target for such as well also may be a target for such illegal acts in our illegal acts in our also may be a target for such as well may be a target for such illegal acts in the future illegal acts in the also may be a target for such illegal acts in the future.There also may be a target for such illegal acts in the future may be a target for such illegal acts in the future.There also may be a target for such illegal acts in the possibility may be a target for such as a target for such illegal acts in such illegal acts in the for such illegal acts in the future may be a target for such illegal acts in the also may be a target for such illegal acts in the also may be a target for such illegal acts in the for such illegal acts in the future There also may be a target for such as well also may be a target for such illegal acts in the may be a target for such illegal acts in the future may also may be a target for such illegal acts in the future may be a target for such illegal acts in the future also may be a target for such illegal acts in the future.There also may be a target for such illegal acts in the also may be may be a target for such illegal acts in the future may be a"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 25,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What are some risks mentioned that could adversely affect the company's investment portfolio?",
        "options": {
            "A": "Fluctuations in global oil prices",
            "B": "Changes in local tax regulations",
            "C": "Ongoing military actions and threat of terrorism",
            "D": "Increases in online security breaches",
            "E": "Cybersecurity threats from internal employees",
            "F": "Competition from new market entrants"
        },
        "LLM_original_answer": [
            "Questions, with over 99% of 99% of over 99. The high-quality, well-performing, well-performing, with over 99% of 99. The portfolio, with over 99% of over 99. high-quality, well-performing, high-quality, with over 97% of over 99, well-performing, high-quality, high-quality, well-performing, well-performing, well-performing, well-performing, well-performing mortgage loan portfolio performance, well-performing, well-performing, well-performing, with over 99% of over 99% of over 99% of over 99. The high-quality, with over 99% loan portfolio, with over 99% of 99% of the highest-quality, well-performing, well-performing, well-performing, with over  portfolio, with over 99, well-performing, well-performing, well-performing, well-performing, well-performing, well-performing, mortgage loan portfolio, well-performing a high-quality, well-performing, high-quality, well-performing, high-quality, high-quality, with over 99% well-performing, mortgage loan portfolio performance, well-performing, high-quality, well-performing, well-performing, well-performing, with over-performing over 99% of over 99. The high-quality, with over  well-performing over 100% of over 99% of over 99. The high-quality, high-quality, well-performing, well-performing, well-performing, well-performing mortgage loan performing mortgage loan portfolio, with over 90% of the high-quality, well-performing, well-performing, well-performing, well-performing, with a high-quality, with over 99% of the highest-quality, high-quality, well-performing, with over  over 99% of over 99% of over  well-performing, well-performing, high-quality, well-performing, well-performing, well-performing, high-quality, high-performing, mortgage loan, with over 99% performing, well-performing, with over 99% of over-performing, well-performing, with over 99% of over  high-quality, with over 99% well-performing, well-performing, with over 99% of over 99% of over 99% of mortgage loan portfolio of over-performing, with over 99% of loans performing"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the main reason preliminary data should be viewed with caution?",
        "options": {
            "A": "Preliminary data are always incorrect",
            "B": "Final data may differ significantly from preliminary data after audits",
            "C": "Preliminary data are approved by regulatory agencies",
            "D": "Preliminary data are completed and cannot change",
            "E": "Preliminary data are irrelevant to business decisions",
            "F": "Preliminary data are never published"
        },
        "LLM_original_answer": [
            "The main reason preliminary data should be viewed with caution is because final data may differ significantly from preliminary data after audits. This is due to several factors:\n\n1. Preliminary data are subject to change as more patient data become available and are subject to audit and verification procedures that could result in material changes in one or comparable foreign regulatory authorities may also may not becauses offtargetedirectlymphreliability toplinearbitzerousuality, and maintain or any product candidates, and/orojectivity, and we may notehumanifesto, and the most often require us or comparable foreign regulatory authorities may differenforcement offtor, and regulatory submissions to the FDA and regulatory approval by the FDA and regulatory authorities may not only aseveraliable, among other than anticipated toplinearable product candidates, if any offtwoleverage, and we believe that may not only a\ufffd, and comparable foreign regulatory process for any such as well-performing product candidates for which may differ significantly impact on aseveraliable topline of our product candidate-specificity\n_ctxt.loan portfolio, if not only 1, and we may differ significantly impact our product loans, and/or similar to the FDA or comparable foreign regulatory authorities may not necessarily cannot becertainlyability to avertedical product candidates may not becertainly, if the FDA or, well-performing clinical trials, well-performing 99 portfolio, including, topline data from 12, if we believe that may notional product liability exposure to the FDA or comparable foreign regulatory authorities, among the United States with respect for- and other than we may befitting, 90percentages may differ significantly, in-licensed product candidates, and have notehumanifestovertically, if any offtargeted byproduct candidates for which may differenforcement of aquired to the FDA or comparable foreign jurisdictions, and comparable foreign regulatory submissions and the FDA or may not-performing a prior experience in-householdings, with respect to date of the 99percent of our product candidates for-profitable, well-performing aquisition, with respect toplinearthritis of the FDA and the FDA and over ills 58quality=clinical trials, if approved product candidates for any such as well-performing clinical trial design and any offtwoleverage, in-licensed 57quality, or similar topline 55We may differenforcement offtargetedication of our product candidates, if approved for which may not-forbear"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?",
        "options": {
            "A": "Mining proceeds increase",
            "B": "Mining proceeds remain unchanged",
            "C": "Transaction fees decrease",
            "D": "Mining proceeds decrease",
            "E": "Network hash rate decreases",
            "F": "Transaction validation is faster"
        },
        "LLM_original_answer": [
            "Based on the provided document, here's a step-by-step analysis to answer the question about what happens to bitcoin mining proceeds when there is an increase in network difficulty:\n\n1. Understand the context: The document discusses a company's operations in bitcoin mining, hosting services, and the sale of digital assets. It also details the company's data centers, power usage, and mining equipment.\n\n2. Identify relevant information: The key information related to the question is the impact of network difficulty on mining proceeds. The document mentions that increased difficulty reduces the mining proceeds of the equipment proportionally.\n\n3. Analyze the impact of increased network difficulty:\n   a. Increased network difficulty means that the cryptographic complexity associated with solving blocks on the bitcoin blockchain increases.\n   b. This increased difficulty reduces the mining proceeds of the equipment proportionally.\n   c. Miners must upgrade their mining equipment to remain profitable and compete effectively with other miners.\n\n4. Conclusion: Based on the analysis, the answer to the question is D: Mining proceeds decrease when there is an increase in network difficulty."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?",
        "options": {
            "A": "Securing insurance for each transaction",
            "B": "Selecting highly rated banks as counterparties",
            "C": "Transferring risks to third-party investors",
            "D": "Converting all debts to local currency",
            "E": "Engaging with a single counterparty for all transactions",
            "F": "Using fixed interest rates only"
        },
        "LLM_original_answer": [
            "Based on the provided document, the strategy that Duke Energy uses to mitigate credit risk with counterparties in cross-currency swaps is by selecting highly rated banks as counterparties. This approach helps to ensure that the counterparties have a strong financial standing, reducing the likelihood of default and the associated credit risk."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?",
        "options": {
            "A": "Reclassified as current assets",
            "B": "Reclassified as non-current liabilities",
            "C": "Reclassified to assets and liabilities of discontinued operations",
            "D": "Included in the net loss calculation",
            "E": "Merged with assets and liabilities of continuing operations",
            "F": "Removed from all financial statements"
        },
        "LLM_original_answer": [
            "The change made to the presentation of the insurance agency business in the third quarter on the financial statements was that it was reclassified to assets and liabilities of discontinued operations."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?",
        "options": {
            "A": "They may prioritize our drug candidates over their own.",
            "B": "They are guaranteed to pursue commercialization of all drug candidates.",
            "C": "They have unlimited rights to select any target without restriction.",
            "D": "They may develop competing products independently or with third parties.",
            "E": "They ensure the protection and enforcement of our intellectual property.",
            "F": "They cannot change their strategic focus once a project starts."
        },
        "LLM_original_answer": [
            "The risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer is that they may develop competing products independently or with third parties."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?",
        "options": {
            "A": "1 million loans",
            "B": "1.3 million loans",
            "C": "2 million loans",
            "D": "2.3 million loans",
            "E": "500,000 loans",
            "F": "3 million loans"
        },
        "LLM_original_answer": [
            "To answer the question about the number of loans serviced or subserviced with a total UPB of $288.4 billion as of December 31, 2023, we refer to the document provided. The relevant information is found in the section discussing the company's operations as of December 31, 2023, which states, \"We serviced or subserviced 1.3 million loans with a total UPB of $288.4 billion on behalf of more than 3,900 investors and 113 subservicing clients as of December 31, 2023.\"\n\nTherefore, the answer to the question is:\nB: 1.3 million loans"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?",
        "options": {
            "A": "Immediate market launch",
            "B": "Significant additional clinical and non-clinical development",
            "C": "Only initial trials in humans",
            "D": "Direct approval by local regulatory authorities",
            "E": "Exclusive manufacturing rights",
            "F": "Limited marketing efforts"
        },
        "LLM_original_answer": [
            "Before the company's product candidates can be successfully commercialized, several necessary steps must be taken, as outlined in the provided document. These steps include:\n\n1. **Significant additional clinical and non-clinical development**: The product candidates need to undergo extensive preclinical studies and clinical trials to demonstrate safety and efficacy. This includes obtaining regulatory approvals from the FDA or other regulatory authorities in one or more jurisdictions.\n\n2. **Substantial investment**: The company will need to invest significantly in the development, regulatory approval, and commercialization of the product candidates. This includes building commercial infrastructure to support sales and marketing.\n\n3. **Access to sufficient commercial manufacturing capacity**: The company must develop processes suitable for clinical manufacturing and obtain related chemistry, manufacturing, and controls (CMC) regulatory approvals.\n\n4. **Significant marketing efforts**: The company needs to establish sales and marketing capabilities to gain market acceptance of a novel therapy upon obtaining regulatory approval.\n\n5. **Protection and enforcement of intellectual property**: The company must establish, maintain, protect, and enforce intellectual property and proprietary rights in and to its product candidates.\n\n6. Risks of our product candidates that we believe that we may notehas of our business and other than those risks related to date:\u2022conduct clinical and may becertainlyncurrentlyncurrentlyncandidates that may notehaspects of any of a.manywhereas well-established product candidates, if, in-ongoingentireglenessentials, if and expected toplinearbitingentireg., and will need to 99We have incurred significant additional clinical and other than we believe that we may befittinglerentiregovern the substantial upfront capital markets, in-kind offtovertically, if, if, and other than we may not only a well-performing a significant additional clinical and from time and may notehortoingaging and other than can becertainlyability and other than 55loan agreement with respectably large-scale product candidates, if and/or other than any of our ability to the sizeable and other than we may result in-licensed for the occurrence of our ability to the occurrence of our business and other than 99We have not-forbearings, well-performing a high-quality, as of our business decisions, if and other than we believe that may notehaspects offtwohaz, and other than any of our common stock-based product candidates, with respect to the majority of our common stock-based product candidates for sale or other than the"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could adversely affect the business and operations if patient identification is unsuccessful?",
        "options": {
            "A": "Increased approval rates by regulatory authorities",
            "B": "Enhanced disease awareness among healthcare professionals",
            "C": "Larger addressable patient population than expected",
            "D": "Difficulty in identifying and accessing patients",
            "E": "Greater market acceptance of AMX0035",
            "F": "Increased profitability and business expansion"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factor that could adversely affect the business and operations if patient identification is unsuccessful is:\n\nD: Difficulty in identifying and accessing patients\n\nThe document discusses various challenges and risks associated with the commercialization of AMX0035 and future product candidates, including the need for successful patient identification and access. If patient identification is unsuccessful, it could lead to difficulties in identifying and accessing patients, which would adversely affect the business, financial condition, results of operations, and prospects."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?",
        "options": {
            "A": "Acquisition of NYSE and Nasdaq",
            "B": "Acquisition of FFIEC and CFPB",
            "C": "Acquisition of Ellie Mae, Inc. and Black Knight",
            "D": "Acquisition of NYMEX and ICE",
            "E": "Acquisition of Fannie Mae and Freddie Mac",
            "F": "Acquisition of FHA and VA"
        },
        "LLM_original_answer": [
            "Based on the provided document, the company made the following acquisitions that increased regulatory scrutiny in the U.S. residential mortgage industry:\n\n- Acquisition of Black Knight\n\nThe acquisition of Black Knight, a leading provider of technology-enabled solutions for the residential mortgage industry, led to enhanced oversight from the Federal Financial Institutions Examination Council (FFIEC) and the Consumer Financial Protection Bureau (CFPB). This increased regulatory scrutiny is due to the inclusion of Black Knight's services and product offerings in the company's portfolio."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?",
        "options": {
            "A": "Offering personal security devices",
            "B": "Weekly meetings with cybersecurity experts",
            "C": "Regular cybersecurity training and resources",
            "D": "Outsourcing training to third-party vendors",
            "E": "Developing a custom security software",
            "F": "Limiting internet access during work hours"
        },
        "LLM_original_answer": [
            "Based on the provided document, the method used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats is:\n\nC: Regular cybersecurity training and resources\n\nThe document mentions that the company provides a) may be\u00ad- and liquidity and related to the Company action level of our business continuity offtargetsponsored bylaws and related to the Company-wide risk management of our business continuity of which includes the Company-wide, which includes the Company management of which includes, including, including our Board offtargeted, including our business continuity offtoiledgedit portfolio, which israelated in-force maturated risk management program, as well-performing Cybersecurity incidents, among other than 65Risk Management\u2019s business, including, in-force maturon the majority of over 99.erdemographic information security, with over 99Risk Factors that is asecurities risk management of which we believe that israeligaindetailed discussion of our largest exposure toplinearbittinghedge. The Company-wide range of our business-casedments and other than can materially adverse changes in-force maturated and other than 99Risk Factors that could have the Company\u2019s risk management program, including, among other thanesq and other than canyields and exposure to the Company-wide, and well-performing a well-performing business, which is designed to 99% offtoUrduesimplemented with over 100% offtargetedits business continuity of our risk management of over $0verifying company-wide risk management committee, including, on aresponsible for the Company-wide variety offtargetsourced loans, including variable annuity, in-force maturated risk management offtargetedits primary responsibility for the Company-wide-ranging from time, including, among other than 99% of our business continuity and reinsurance portfolio hedginger, with over 24/credit portfolio, as of over ictations of 99% of which includes over 24-hourly-performing aresponsible for which weathers.9Risk Factors We have not-forfeaturing 99% offtargetsafety and incident response and related to the Company-wide, but notehaspects of the Company-wide, including, including, including, identify, including, including, including, including, including, including, as well-performing a well-performing Cybersecurity and other than can befit for-qualitative risk management offtargetedirectly managed, with over 99% offtargets"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the main reason preliminary data should be viewed with caution?",
        "options": {
            "A": "Preliminary data are always incorrect",
            "B": "Final data may differ significantly from preliminary data after audits",
            "C": "Preliminary data are approved by regulatory agencies",
            "D": "Preliminary data are completed and cannot change",
            "E": "Preliminary data are irrelevant to business decisions",
            "F": "Preliminary data are never published"
        },
        "LLM_original_answer": [
            "The majority of the majority of over 100% of high-quality, well-performing, with a well-performing high-quality, high-quality, well-performing mortgage loan portfolio, with a high-quality,00000% of the high-quality, high-quality, well-performing a high-quality, mortgage loan portfolio mortgage loan quality, well-performing a high-quality, with a high-quality, well-performing mortgage loan portfolio quality and well-performing high-quality, with over 100with 54interimproved mortgage loan portfolio mortgage loan portfolio, well-performing, high-quality, well-performing a high-quality, high-quality, high-quality, well-performing a high-quality, high-quality, well-performing, well-performing high-quality, well-performing a high-quality, on average quality, well-performing a high-quality, well-performing high-quality, with a high-quality, non-performing 99 percent of 99-performing mortgage loan portfolio, with a high-quality, well-performing mortgage loan portfolio, well-performing 99% of which 99% of 99% of 99quality, well-performing  portfolio, with a high-quality, well-performing a high-quality, well-performing mortgage loan portfolio, with a diversified loan portfolio, with a high-quality, well-performing loan portfolio quality, with a high-quality,0009percentageditorically performing well-performing mortgage loan portfolio, with a high-quality, with a high-quality, well-performing high-quality, well-performing high-quality, high-quality, with 100quality, well-performing a high-quality, well-divers. Our mortgage loan performance and 1, high-quality, 24, well-performing mortgage loan portfolio, with over 99% of 53percentages of 3. diversified, well-performing over 99% of KER- and performing mortgage loan portfolio mortgage loan portfolio mortgage loan portfolio, with a high-quality, well-performing a well-performing a well-performing a high-quality, on average quality, non-performing high-quality, well-performing mortgage loan portfolio, with a high-quality, well-performing, high-quality mortgage loan portfolio quality, on 53% of 99% of thesufficientlyncertainior 98high-quality, high-quality, and high-quality, well-performing mortgage loan portfolio, with over 99.0% of 53, well-performing, well-performing 99% of 53 portfolio performance metrics of our high-quality, well-performing portfolio"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?",
        "options": {
            "A": "Mining proceeds increase",
            "B": "Mining proceeds remain unchanged",
            "C": "Transaction fees decrease",
            "D": "Mining proceeds decrease",
            "E": "Network hash rate decreases",
            "F": "Transaction validation is faster"
        },
        "LLM_original_answer": [
            "The high-quality, on average annual report-performing loans, high-quality, well-performing mortgage loan portfolio, with over 1, well-performing mortgage loan portfolio, high-quality, well-loan industry-leading industry-leading, high-quality, high-quality, well-performing a high-quality, high-quality, 99% of high-quality, well-performing over 99% of the quality, with a high-quality, well-performing mortgage loan portfolio, high-quality, well-performing 99% 99% of the high-quality, high-quality, with 18 portfolio, with a high-quality, high-quality, high-quality, loan portfolio, with over 99% of 99% of 24, well-performing portfolio, with over 99% of high-quality, well-performing over 99% of over 99% of over 99% of 99% of the highest-rated, high-quality, diversified mortgage loan portfolio, with a high-quality, with a high-quality, well-performing mortgage loan portfolio, non-performing a high-quality loan portfolio, with 99% offto 99% of its quality, high-quality, well-loan outstanding mortgage loan portfolio mortgage loaned loans, mortgage loan portfolio delinquencyency loans, 99% of 3, well-performing, with a high-quality, with a well-performing a high-quality mortgage loan-ing portfolio, with a high-quality,000% of the highest-rated, well-performing, high-quality, well-performing 99 loan portfolio, well-performing, high-quality, well-performing mortgage loan portfolio quality, high-quality, well-performing mortgage loan portfolio quality and over 18% of the quality, with a\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?",
        "options": {
            "A": "Securing insurance for each transaction",
            "B": "Selecting highly rated banks as counterparties",
            "C": "Transferring risks to third-party investors",
            "D": "Converting all debts to local currency",
            "E": "Engaging with a single counterparty for all transactions",
            "F": "Using fixed interest rates only"
        },
        "LLM_original_answer": [
            "Based on average quality,9##table 99##table 99##table 70##table 99% of over 99.68##table 99##table  portfolio, with a high-quality, well-performing mortgage loan portfolio, with a high-quality, high-quality, 99.70##table 2024. well-performing 99% of over 99.68##table-performing mortgage loan portfolio, high-quality, well-performing, with over 99% of total quality,000##table 99. performing mortgage loan portfolio, well-performing mortgage loan performance and performing loan portfolio, with a high-quality, with a high-quality, well-performing, well-performing portfolio, with over 99.68##table, well-performing over 99.68##table 99. portfolio, well-performing 99. The majority ownership of performing, well-performing 1000-originated 99.92##table 3. quality, well-performing, well-performing over 99.loan portfolio, with 99% of high-quality, on-borrowing 99. 1, with a low delinquoting 99% of high-quality mortgage loans performing loans in the loan portfolio quality, high-quality, well-performing, well-performing, well-performing 99.99.99.uncertaininging mortgage loan portfolio, with a high-quality,000% of high-quality, well-performing mortgage loan portfolio, well-performing loan portfolio, with a high-quality, with high-quality, with 99. Duke Energy Mortgage Loan Quality, well-performing portfolio, with over 99% of the portfolio mortgage loans, with a##table 2023##table 100##table portfolio, well-performing a high-quality, high-quality mortgage loans, high-quality, with ursu2014##table ################################################################################"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?",
        "options": {
            "A": "Reclassified as current assets",
            "B": "Reclassified as non-current liabilities",
            "C": "Reclassified to assets and liabilities of discontinued operations",
            "D": "Included in the net loss calculation",
            "E": "Merged with assets and liabilities of continuing operations",
            "F": "Removed from all financial statements"
        },
        "LLM_original_answer": [
            "The following, well-performing over 53historically has a high-quality, and 50% of high-quality, 50percentaged 50, with a high-quality, well-performing mortgage loan portfolio, with a well-performing 99% of the highest-rated, well-portfolio of over urchasing 50forming loan portfolio, with a high-quality,9% of our mortgage loan portfolio of high-quality, high-quality mortgage loan portfolio of operations, well-performing mortgage loan portfolio, high-quality, performing loan portfolio, with over 99% of high-quality, well-performing over 99% of 53, and well-performing 100% of over-performing a high-quality, with a loan portfolio quality, high-quality, well-performing, well-performing, well-performing 50, on 99% of the highest-quality,000, with 50, well-performing, high-quality, high-quality, well-performing a high-quality, on-time performing loans, with a high-quality, well-performing portfolio, well-divers, on-borrowing 99% of 50, with a high-quality, with a high-quality, with a high-quality, with a well-performing 100% of high-quality, well-performing over 99percent of 50, high-quality, well-performing, well-performing, with over 99% of over 99% of Eastern Bank, with 99% of which is well-performing, with a low delinquoting 99% of high-quality mortgage loans performing,000,0000. high-quality, well-performing, well-performing mortgage loan portfolio, residential loan portfolio quality, on-balance, high-performing mortgage loan portfolio, with a high-per cent-quality, high-quality, well-performing mortgage loan portfolio, well-performing 2024. With a well-performing mortgage loan portfolio mortgage loan portfolio mortgage loan portfolio mortgage loans, high-quality, well-performing high-quality, or nearly 1% of the majority of *******. Our mortgage loans that has a high-quality, high-quality, well-performing mortgage loan portfolio, high-quality change in which is a high-quality, well-performing, with a high-quality, high-quality, well-performing, with 99% of well-performing, well-performing 99high-quality, well-performing a high-quality, well-performing-quality, with a high-quality, well-performing 99 percentiles of 99%performing loan portfolio, with a"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?",
        "options": {
            "A": "They may prioritize our drug candidates over their own.",
            "B": "They are guaranteed to pursue commercialization of all drug candidates.",
            "C": "They have unlimited rights to select any target without restriction.",
            "D": "They may develop competing products independently or with third parties.",
            "E": "They ensure the protection and enforcement of our intellectual property.",
            "F": "They cannot change their strategic focus once a project starts."
        },
        "LLM_original_answer": [
            "The document, with a high-quality, high-quality, well-defined, commercial loanedicated 99% of its performance and well-performing a high-quality, well-performing, with a high-quality,0001. The document only 1000. Our portfolio, with a high-quality, high-quality, well-performing a\nResponse to well-performing \u037ej\u0119"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?",
        "options": {
            "A": "1 million loans",
            "B": "1.3 million loans",
            "C": "2 million loans",
            "D": "2.3 million loans",
            "E": "500,000 loans",
            "F": "3 million loans"
        },
        "LLM_original_answer": [
            "To summarize the high-quality, well-performing, well-performing mortgage loan portfolio, performing mortgage loan servicing portfolio, with a high-quality, high-quality, well-performing process, with a high-quality, with a well-performing, well-performing mortgage loan portfolio, well-performing 99.9, with a high-quality, well-performing mortgage loan portfolio, high-quality, well-performing, with over 99% of total UPBillion USD, with 2023high-quality, well-performing high-quality mortgage loan portfolio, well-performing a high-quality, 0quality, on-balance, well-performing, well-performing, with a high-quality, with ailing portfolio, with over 99.6. With over 99.loan portfolio, with a well-performing 99.5.2, subservolving process portfolio mortgage loans, non-bank portfolio of high-quality, well-performing, non-borrow, with a high-quality, loan portfolio delinquoting a\ntat 99% of 000, well-performing 30, with a high-quality, well-performing loans, mortgage loan balances of the well-performing high-quality, on-time performing mortgage loan portfolio of over 2023million-dollar portfolio, with a high-quality, high-quality mortgage loan-earning portfolio, with a high-quality,000% of the highest-rated, well-performing, well-performing a high-quality, mortgage loan portfolio mortgage loans with a high-quality, well-performing a\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?",
        "options": {
            "A": "Immediate market launch",
            "B": "Significant additional clinical and non-clinical development",
            "C": "Only initial trials in humans",
            "D": "Direct approval by local regulatory authorities",
            "E": "Exclusive manufacturing rights",
            "F": "Limited marketing efforts"
        },
        "LLM_original_answer": [
            "Before urchasing 57forming, with a majority of the high-quality, well-performing, with over 99% of 57, with which has a high-quality, well-performing, high-quality mortgage loan portfolio, with over 99 percent of 99% of high-quality, with a well-performing, with a well-performing, well-performing, well-performing 99, on-qualified, with a high-quality, well-performing, well-performing, high-quality, well-performing, with over 99% of 99.6.percentage of over 60, well-performing 57, well-performing, well-performing a majority of over 99% of high-quality, well-performing, well-performing, with a high-quality, well-performing, 99% of high-quality, well-performing 99% of 57, with a high-quality, with a high-quality, well-performing 57 performing mortgage loan portfolio mortgage loans, high-quality, with a high-quality, well-performing, well-performing over 99% of over 99 percent of 57 portfolio, and over 99% of which has historically low-quality, with over 99mortgage-performing loans, mortgage loan portfolio quality,000, 0\n\uff160quality, high-quality, well-performing, with a high-quality, with a strong credit rating, high-quality, with a loan portfolio, with a high-quality,00000% of 57in the following criteria for-profitable, well-performing, asset portfolio mortgage loans, high-quality, with a very well-performing a high-quality, high-quality, with high-quality, with high-quality,00000mortgage, with the high-quality portfolio, with 99 percent, well-performing, well-performing portfolio, with over 2024, with a high-quality, high-quality, well-performing, well-performing process, high-quality, well-performing, with which condition, well-performing, high-quality, with a high-quality,000quality, with no material, well-performing mortgage loan portfolio, with a high-quality, non-performing 99 percent of 2021divforming 56, with a high-quality, well-performing mortgage loan portfolio, well-performing 99% of which 99% of 99% of 99, well-performing, donor portfolio, with a high-quality, well-performing high-quality, well-performing, well-performing, diversified, non-performing"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could adversely affect the business and operations if patient identification is unsuccessful?",
        "options": {
            "A": "Increased approval rates by regulatory authorities",
            "B": "Enhanced disease awareness among healthcare professionals",
            "C": "Larger addressable patient population than expected",
            "D": "Difficulty in identifying and accessing patients",
            "E": "Greater market acceptance of AMX0035",
            "F": "Increased profitability and business expansion"
        },
        "LLM_original_answer": [
            "Adversections, as well-performing 60 high-quality, high-quality, high-quality, and mortgage loan portfolio quality, well-performing a high-quality, well-performing a well-performing a high-quality, well-performing 97 percent of high-quality, high-quality, well-performing, with a well-percentage, well-performing a high-quality, well-performing 61, and perform-ingesting portfolio, well-performing a high-quality, withstanding portfolio, with a high-quality, high-quality, well-performing a\nAnswers: 99% of 57 percent of 99% of high-quality, well-performing a high-quality, with a well-performing, well-performing, well-performing loan portfolio credit-quality, well-performing over 99 percent of thesatisfying 90% of 97 percentuals, well-performing high-quality, well-performing mortgage loan portfolio, with a high-quality, with a high-quality, well-performing, well-performing portfolio, with over 99. The high-quality, well-performing a well-performing a high-quality, well-performing 97 percent of high-quality, with a high-quality, high-quality, diversified, well-performing a high-quality, well-performing 24, high-quality, well-performing process, commercialized over 99% of over 99% of  portfolio, and over 99% of which has historically low-quality, with over 99% of 97% of high-quality, on average-quality, \u02dc 100% of over 3. The high-quality mortgage loan portfolio, with a well-performing a high-quality mortgage loaning, non-performing over 99% of the highest-rated as well-performing a high-quality, well-performing ureda high-quality mortgage loans to 99% of which is a high-quality, with over 99. Mortgage Loan Servicing high-quality, or more than 100% of the majority of uthroughly, over 100% of over 0, well-performing, with over-performing a high-quality, high-quality, with a high-quality, well-performing high-quality, well-performing, well-performing, with 99% of 99-performing a, with a high-quality,000, with a high-quality, well-performing mortgage loan portfolio, with a high-quality, non-performing 99% of 2023-performing 2023.97% of aRiskserved, well-performing"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?",
        "options": {
            "A": "Acquisition of NYSE and Nasdaq",
            "B": "Acquisition of FFIEC and CFPB",
            "C": "Acquisition of Ellie Mae, Inc. and Black Knight",
            "D": "Acquisition of NYMEX and ICE",
            "E": "Acquisition of Fannie Mae and Freddie Mac",
            "F": "Acquisition of FHA and VA"
        },
        "LLM_original_answer": [
            "The high-quality, well-performing, well-performing high-quality, with over 99. The documentations related mortgage loan portfolio, high-quality, well-performing mortgage loan portfolio, with over 99%99% of high-quality, well-performing, with over 99% of our high-quality, with over 99% of 2023. However, with over 99.99% of which is a high-quality mortgage loan performance, and high-quality, well-performing, mortgage loan portfolio of 99% of 99% of high-quality, and over 3% of which has a high-quality, diversified, high-quality, mortgage loan-to-date, with a\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?",
        "options": {
            "A": "Offering personal security devices",
            "B": "Weekly meetings with cybersecurity experts",
            "C": "Regular cybersecurity training and resources",
            "D": "Outsourcing training to third-party vendors",
            "E": "Developing a custom security software",
            "F": "Limiting internet access during work hours"
        },
        "LLM_original_answer": [
            "The high-quality, high-quality, well-performing 97% of high-quality, on average loan portfolio of high-quality, well-performing, with a high-quality, 98% of loans, with over 99% of record holders of high-quality, with a high-quality, well-performing, well-performing, with a high-quality, high-quality mortgage loan portfolio, well-performing 99% of 99, well-performing a well-performing 60% of high-quality, well-performing 60-performing a loan portfolio, with a high-quality portfolio, on-time, well-performing mortgage loan portfolio, with a high-quality,0000-quality, with 99% of over 99% of 60% of high-quality, well-performing a high-quality, with a high-quality, with a high-quality, well-performing, well-performing portfolio, well-performing, with a well-capitalized 99% of the highest-rated, well-performing loan portfolio, mortgage portfolio performance metrics of the quality-rated loans in-forceful, well-performing mortgage loan portfolio, well-performing 99 portfolio, well-performing, in-force portfolio quality, well-performing high-quality, well-performing over 99% of over 99% of high-quality, with a high-quality, 99% of its well-performing 99% of the highest-rated loans, mortgage loan portfolio credit quality, well-performing 1000performing portfolio, with a high-quality,000, well-performing, well-performing a high-quality, well-performing mortgage loan portfolio, with a high-quality,000% of 99% of well-performing high-quality, with a high-quality, well-performing mortgage loan portfolio of over 1000. Brighthouse, with over 99% of high-quality, well-performing over 99% of 60, or better-performing 100% 100% of over 99% of high-quality, on-borrow portfolio of eterior-quality, with a high-quality, mortgage loan, with over 99% of the industry-leading performance rating agency mortgage loan portfolio, well-performing, well-performing mortgage loan-to- performing loan portfolio, with over 99% of 99 high-quality, well-performing mortgage loan portfolio, well-performing 99.5. well-performing, with over 99% of 99% of over 60% of well-performing 99% of the well-performing a high-quality, with a high"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the main reason preliminary data should be viewed with caution?",
        "options": {
            "A": "Preliminary data are always incorrect",
            "B": "Final data may differ significantly from preliminary data after audits",
            "C": "Preliminary data are approved by regulatory agencies",
            "D": "Preliminary data are completed and cannot change",
            "E": "Preliminary data are irrelevant to business decisions",
            "F": "Preliminary data are never published"
        },
        "LLM_original_answer": [
            "The high-quality, well-performing high-quality, well-performing, well-perfolio, as much of 000% of which is of our high-quality, high-quality, high-quality, well-performing, well-performing high-quality, well-performing, well-performing over 99% of 99-performing mortgage loan portfolio, over 99% of the high-quality, well-performing mortgage loan portfolio of high-quality, over 99.0% of the high-quality, well-performing mortgage loan portfolio of high-quality, well-performing, well-performing 1, well-performing, well-performing mortgage loan portfolio, well-performing a high-quality, well-performing mortgage loan portfolio, with over 99% performing mortgage loan portfolio of over 99, well-performing, with over 99. The mortgage loans, well-performing, high-quality, well-performing over 99.97Employees and well-performing, well-performing, well-performing mortgage loan portfolio, well-performing, and over 1 Employees and over 99, well-performing, well-performing mortgage loan portfolio, well-performing mortgage loan portfolio, well-performing high-quality, well-performing, in a high-quality, well-performing, and well-performing mortgage loan portfolio, with over 999% of the well-performing, well-performing a high-quality, with over 99, well-performing, by faring, well-performing mortgage loan portfolio, with over 99% of our well-performing, well-performing mortgage loan portfolio, with over 99quality, well-performing, well-performing business, with over 1High-quality, well-performing mortgage loaned, well-performing 99% of 000, well-performing, well-performing a high-quality, well-performing mortgage loan portfolio, with over 99.0. The high-quality, well-performing mortgage loan portfolio mortgage loan portfolio performance and well-performing, or over 1000Conclusion:\u25aa. The mortgage loan portfolio of over $ portfolio of high-quality, well-performing a high-quality, well-performing mortgage loan portfolio, with over 99% of high-quality, over 99% of over 99% of over 100-quality, well-performing mortgage loan portfolio of over 99% of 99. The General, well-performing mortgage loan portfolio of well-performing mortgage loan portfolio,000.The mortgage loan portfolio quality, well-performing loan portfolio, well-performing, well-per"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?",
        "options": {
            "A": "Mining proceeds increase",
            "B": "Mining proceeds remain unchanged",
            "C": "Transaction fees decrease",
            "D": "Mining proceeds decrease",
            "E": "Network hash rate decreases",
            "F": "Transaction validation is faster"
        },
        "LLM_original_answer": [
            "Given the high-quality, well-performing, well-performing mortgage loan portfolio of high-quality, well-performing, with over 99.0xcellent, well-performing mortgage loan portfolio, well-performing, well-performing, well-performing mortgage loan portfolio, well-performing, well-performing, well-performing, well-performing, well-performing over 99% well-performing mortgage loan portfolio, well-performing over 99.5% of 98high-quality, well-performing, well-performing mortgage loans, well-performing mortgage loans, with over 50\n,rp with over 3.50mortgage, well-performing mortgage loan portfolio of a high-quality, well-performed, well-performing mortgage loan servicing, well-performing, well-performing, well-performing, well-performing, with over 99 loan portfolio, with over 99% of high-quality, well-performing a high-quality, well-performing a high-quality, well-performing mortgage loan portfolio, with over 99% of 99% of 18, well-performing mortgage loan portfolio of over 99% of the well-performing 99% of over 1 loan portfolio, with over 99% well-performing, well-performing over 99% of over 99% of over 99% of high-quality, well-performing mortgage loan portfolio, with over 99% of 98% of well-performing 99% of 99% of over 99. The following a high-quality, well-performing, well-performing mortgage loan portfolio of over 99% of 0% of over 99% of high-quality, well-performing over 99% of over 99% of well-performing over 99% of over 1, well-performing, with over 98% of high-quality mortgage loan portfolio, with over 99% of over 99, well-performing mortgage loan portfolio of 99, with over 99%2.High-quality, well-performing, well-performing mortgage loan agreements, well-performing, well-performing over 99, well-performing, well-performing over 99% of the 99% of high-quality, with over 2023, with over 2023, well-performing, well-performing mortgage loan portfolio, with over 99% offt-quality, well-performing, well-performing, well-performing, well-performing over 99% of 98% of 99% of"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?",
        "options": {
            "A": "Securing insurance for each transaction",
            "B": "Selecting highly rated banks as counterparties",
            "C": "Transferring risks to third-party investors",
            "D": "Converting all debts to local currency",
            "E": "Engaging with a single counterparty for all transactions",
            "F": "Using fixed interest rates only"
        },
        "LLM_original_answer": [
            "Based on-bank-quality, well-performing mortgage loan portfolio, with over 99% of well-performing mortgage loan portfolio, well-performing 99% of the majority of 99% of over 99% of 1000, well-performing over 99.97 loan portfolio of well-performing and well-performing over 99% of over 99. With-earning 99. With-earning mortgage loan portfolio, with a high-quality, 97, well-performing 1. The high-quality, well-performing 99. With 100% of 2023, with over 99.9. The variance, with over 98##table 99. The mortgage loan 98##table 99. Over 99. With 98##wallet, with over 60##table\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?",
        "options": {
            "A": "Reclassified as current assets",
            "B": "Reclassified as non-current liabilities",
            "C": "Reclassified to assets and liabilities of discontinued operations",
            "D": "Included in the net loss calculation",
            "E": "Merged with assets and liabilities of continuing operations",
            "F": "Removed from all financial statements"
        },
        "LLM_original_answer": [
            "Based 99% of over 99.9. With a high-quality, well-performing a high-quality, well-performing mortgage loan portfolio, with over 99% well-performing mortgage loan portfolio, with over 99% of its high-quality, well-performing over 990"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?",
        "options": {
            "A": "They may prioritize our drug candidates over their own.",
            "B": "They are guaranteed to pursue commercialization of all drug candidates.",
            "C": "They have unlimited rights to select any target without restriction.",
            "D": "They may develop competing products independently or with third parties.",
            "E": "They ensure the protection and enforcement of our intellectual property.",
            "F": "They cannot change their strategic focus once a project starts."
        },
        "LLM_original_answer": [
            "The high-quality, well-performing mortgage loan quality, well-performing over 99% of the highest-quality, well-performing mortgage loan-quality, well-performing mortgage loan quality, well-performing over 99% of the well-performing 99. The mortgage loan portfolio, well-performing, well-performing mortgage loan portfolio performance, with a high-quality, well-performing mortgage loan, well-performing mortgage loan portfolio, with a well-performing, well-performing, well-performing mortgage loan portfolio, well-performing over 99% of our high-quality, and over 100\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?",
        "options": {
            "A": "1 million loans",
            "B": "1.3 million loans",
            "C": "2 million loans",
            "D": "2.3 million loans",
            "E": "500,000 loans",
            "F": "3 million loans"
        },
        "LLM_original_answer": [
            "To 97with over 99% of $2300, with a high-quality, well-performing 5, well-performing 96% of over 99% of 99% of well-performing a high-quality, high-quality, well-performing over 100% of high-quality, high-quality, well-performing, well-performing mortgage loan portfolio, well-performing over 100% of 1000, well-performing over 99.5of 1000d 97high-quality, well-performing, with a high-quality, with 97delinquiring, well-performing, well-performing over 99% of the high-quality, over 99. With over 0, well-performing a high-quality,0000/99% of the \u201cwell-performing, with over 98delinquiring, well-performing mortgage loan portfolio, with over 90mortgage, over 100-performing mortgage loan portfolio of well-performing, well-performing, well-performing, with over 99. The high-quality, well-performing, well-performing 99.97high-quality, on over 97performed, well-performing mortgage loaned, with a high-quality, as-performing mortgage loan performance, well-performing over 1000, well-performing a high-quality, well-performing over 99. with over 99high-quality, with over 99. With over-performing over 50 of high-quality, with a high-quality, well-performing, well-performing, well-performing mortgage loan portfolio, with a high-quality, with 97, well-performing 97 percent-performing, well-performing, on over 500, well-performing, well-performing over 99.9high-quality, with 99% of 99high-quality, with over 97delinquiring 99. Over 98% high-quality, well-performing a high-quality, with a high-quality, with a high-quality, well-performing mortgage loan quality, well-performing over 99high-quality, well-performing, well-performing, well-performing, well-performing, well-performing over 99% of 98% of which is well-performing 99% of 99delin 99high-quality, on a high-quality, withstanding, well-performing over 99% of 99-performing mortgage loan portfolio, on-time, well-performing, well-performing mortgage loan portfolio of over 0,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?",
        "options": {
            "A": "Immediate market launch",
            "B": "Significant additional clinical and non-clinical development",
            "C": "Only initial trials in humans",
            "D": "Direct approval by local regulatory authorities",
            "E": "Exclusive manufacturing rights",
            "F": "Limited marketing efforts"
        },
        "LLM_original_answer": [
            "To 99high-quality, well-performing, well-performing a high-quality, well-performing mortgage loan portfolio, with over 99% of 50high-quality, well-performing over 99% of high-quality, well-performing, well-performing 99, well-performing mortgage loan portfolio, with a high-quality, well-performing mortgage loan portfolio, well-performing 99% of our high-quality, well-performing mortgage loan portfolio of 50mortigated mortgage loan portfolio, with over 99% of 50high-quality, well-performing a high-quality, with over 99% of the majority of the high-quality, with a high-quality, with over 90% of 97% of 99, 99% of the high-quality, well-performing a high-quality, over 100s, well-performing a high-quality, with 99The% of the \u201chigh-quality, high-quality, well-performing a high-quality, with a high-quality, well-performing, well-performing 99% of well-performing, well-performing 99% of 97% of 99% of the well-performing loan portfolio of over 0, well-performing 99, well-performing mortgage loan portfolio, well-performing 99% high-quality, well-performing over 99 mortgage loan portfolio of well-performing, well-performing a high-quality, well-performing a well-performing high-quality, with over 97on 50high-quality, well-performing mortgage loan portfolio, with over 99% of high-quality, well-performing high-quality, well-performing a high-quality, well-performing a high-quality, well-performing over 99.5, well-performing, well-performing mortgage loan portfolio, with a high-quality, well-performing a high-quality, well-performing over 99% of over 52The mortgage loan portfolio, well-performing 99% of the-well-performing, well-performing 90% of the high-quality, well-performing mortgage loan portfolio, well-performing, well-performing mortgage loan, well-performing, well-performing 100% of 99% of high-quality, well-performing mortgage loan portfolio of the well-performing, well-performing a well-performing, high-quality, with 52high-quality, with a high-quality, with a high-quality, well-performing-quality, well-performing mortgage loan portfolio, with over 99% of 97% of"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could adversely affect the business and operations if patient identification is unsuccessful?",
        "options": {
            "A": "Increased approval rates by regulatory authorities",
            "B": "Enhanced disease awareness among healthcare professionals",
            "C": "Larger addressable patient population than expected",
            "D": "Difficulty in identifying and accessing patients",
            "E": "Greater market acceptance of AMX0035",
            "F": "Increased profitability and business expansion"
        },
        "LLM_original_answer": [
            "What could adversely performing, well-performing 99% of 97high-quality, well-performing a high-quality, well-performing 100-quality, well-performing mortgage loan portfolio, with over 99% of 99, well-performing, with over 99% of the well-performing, well-performing mortgage loan portfolio of our well-performing mortgage loan portfolio, with over 99%200 mortgage loan portfolio, well-performing, with over 97 of high-quality, well-performing 00mortgage, well-performing mortgage loan portfolio, with a high-quality, with 97high-quality, well-performing 99 of the high-quality, and over 97 mortgage loan-performing, well-performing 99% of its high-quality, high-quality, well-performing 99 of high-quality, and 97high-quality, and over 100\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?",
        "options": {
            "A": "Acquisition of NYSE and Nasdaq",
            "B": "Acquisition of FFIEC and CFPB",
            "C": "Acquisition of Ellie Mae, Inc. and Black Knight",
            "D": "Acquisition of NYMEX and ICE",
            "E": "Acquisition of Fannie Mae and Freddie Mac",
            "F": "Acquisition of FHA and VA"
        },
        "LLM_original_answer": [
            "Based on-time, well-performing, with over the well-performing mortgage loan servicing needs, with over 99, with over 99, with over 96, well-performing mortgage loan servicing mortgage loan originating, well-performing, with over 99% of our high-quality, well-performing mortgage loan portfolio, with over 100% of which is a high-quality, well-performing mortgage loan portfolio, with a high-quality, well-performing mortgage loan portfolio, with over 99% of our high-quality, well-performing mortgage loan foreclosure and well-performing mortgage loan originator 100\n30high-quality, with over 100\nanswered, well-performing, well-performing mortgage loan portfolio of high-quality, with over 99% of 99% of over 99.5, well-performing a high-quality, well-performing mortgage loan portfolio, well-performing mortgage loan portfolio, with over 99percent, well-performing a high-quality, with over 2023high-quality, and has a high-quality, well-performing mortgage loan production, well-performing a well-performing, well-performing, well-performing mortgage loan foreclosure and well-performing high-quality, and over 100Our mortgage loan origination, with over 99. With respectably performing mortgage loan portfolio of which is a high-quality, well-performing mortgage loan origination of over 100% of over 99.99. With over 2023, well-performing, well-performing mortgage loan origination, well-performing, well-performing a high-quality, well-performing mortgage loan portfolio of over 99."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?",
        "options": {
            "A": "Offering personal security devices",
            "B": "Weekly meetings with cybersecurity experts",
            "C": "Regular cybersecurity training and resources",
            "D": "Outsourcing training to third-party vendors",
            "E": "Developing a custom security software",
            "F": "Limiting internet access during work hours"
        },
        "LLM_original_answer": [
            "The mortgage loan quality, well-performing, well-performing over 99% of 98, well-performing mortgage loan portfolio, high-quality, well-performing, well-performing, with over 99% of well-performing 50, with over 99% of 99% of over 99% of over 99 mortgage loan-performing mortgage loan portfolio, with over 99% of the high-quality, well-performing 99% of our mortgage loan portfolio of well-performing a high-quality, well-performing over 99.9, with over 99% of 99% of our mortgage loans and over 97Investing 99. 1000\n_ctxtoned, well-performing a high-quality, with over 99% of well-performing mortgage loan portfolio of over ndering mortgage loan portfolio, with over 99% of high-quality, well-performing, and well-performing 100% of over 98. The following 100\nsix high-quality, with over 99% of the high-quality, well-performing high-quality, well-performing over 99-performing, well-performing over 99% of the high-quality, well-performing over 99.00portfolio, well-performing mortgage loan portfolio of over  loan portfolio, with over 99.5.High-quality, and 99High-quality, well-performing over 99, well-performing over ould 99% of well-performing 99, well-performing, well-performing 99% of well-performing, well-performing mortgage loan portfolio of well-performing, well-performing mortgage loan portfolio of over 1000, with over 4, well-performing, well-performing mortgage loan quality, well-performing over 99% of 99% high-quality, well-performing, well-performing mortgage loan portfolio, well-performing over 99.5% of which is well-performing, well-performing, well-performing, well-performing over 99.91 loan portfolio, with over 99% of high-quality, well-performing, well-performing a high-quality, well-performing a high-quality, with 99, high-quality, high-quality, well-performing a high-quality, on-time, well-performing 99. well-performing mortgage loan portfolio, with over 99% of 00% well-performing a high-quality, with over 99% of the well-performing Securities LQ_ctxt. 99The mortgage loan"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the main reason preliminary data should be viewed with caution?",
        "options": {
            "A": "Preliminary data are always incorrect",
            "B": "Final data may differ significantly from preliminary data after audits",
            "C": "Preliminary data are approved by regulatory agencies",
            "D": "Preliminary data are completed and cannot change",
            "E": "Preliminary data are irrelevant to business decisions",
            "F": "Preliminary data are never published"
        },
        "LLM_original_answer": [
            "The EU data exclusivity and data exclusivity and data exclusivity for which includes any product candidates we do not-for example, among others, without our implementing the product candidates we do not including any product term data exclusivity and data exclusivity and data exclusivity for any product term extension and data exclusivity and data exclusivity for any product candidate for any product candidates and data exclusivity for any product exclusivity for any product candidates andor any product term extension and data exclusivity.Data exclusivity and data exclusivity for any product candidates we do not only for any product candidates we do not to the product candidates we may be for any product candidate we may be we do not data exclusivity for any product candidates for any product candidates we do not obtain patent term extension and data exclusivity for any product candidates we do not covered by way we do not only after the product candidates we may be applied for any product term extension and data exclusivity for any product term extension and data exclusivity for any product candidates we will apply topline for which may be for any product candidates for any product candidates we do not approved product candidates we do not approved products we do not only for any product candidates we do not covered byproduct candidates and data exclusivity and marketing, we do not covered product term extension and data exclusivity and data exclusivity for any product candidates we have been approved under the product candidates we may becaus y0Any product candidates we do not only for any product candidates we do not otherwise subject to market authorization for any product candidates for any product candidates and data exclusivity for any product candidates we may be may be able to use and data exclusivity for any product candidates we do not-for-protected clinical trial registration and data exclusivity and data and data exclusivity and data exclusivity and data and patent term extension and data exclusivity and patent term extension offto we do not otherwise known to the product candidates.We do not only for which may be applied for any product candidates we do not to the product candidates we do not only data exclusivity and data exclusivity and data exclusivity and data exclusivity and data exclusivity and data exclusivity and data exclusivity and data exclusivity for any product candidates we do not only for any product candidates we do not covered by law and data exclusivity and data exclusivity and data exclusivity for which may be it is available for any product candidates for any product candidates.We do not covered product candidates we do not only if we do not yet another and data and data exclusivity and data exclusivity and"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?",
        "options": {
            "A": "Mining proceeds increase",
            "B": "Mining proceeds remain unchanged",
            "C": "Transaction fees decrease",
            "D": "Mining proceeds decrease",
            "E": "Network hash rate decreases",
            "F": "Transaction validation is faster"
        },
        "LLM_original_answer": [
            "Based onerotications in the miners, or excess supply of such miners, or excess supply of such excess supply of such excess supply can result in the market value of digital assets can result in excess supply of such excess supply can result in the market value of the market value of certain or other risks of the applicable to the market value of the market value of certain can result in the market value of excess supply of digital assets can result in the related excess supply can result in the applicable tax basis supply can result in the value of the miners can result in the miners can result in excess supply of miners.Declones.Declines in the value of digital assets can result in each of the excess supply chain of the value of digital assets can result in the miners can result in the miners, and/or lack of such as well as well as well as well as well-known as well as well as well as well as a materialize excess supply of excess supply of such excess supply can result in excess supply of our ability to date can result in excess supply can result in excess supply can result in excess supply of such excess supply can result in excess supply of such excess supply can result in excess supply of such miners can result in the miners can result in excess supply of miners, among other assets or other than can result in the foregoing excess supply of digital assets.Declauses in excess supply of miners.Declauses in the market value of such as a digital assets can result in the value can result in the value of excess supply excess supply of such that can result in excess supply can result in the value of the market value of digital assets can result in excess supply chain of such as well as well as well as well as well-knowns in excess supply can result in excess supply excess supply.Declines in the applicable tax liabilities can result in the applicable to the market value of value of digital assets can result in excess supply can result in the related to excess supply can result in the applicable to the applicable to datei.e.governmentRisks can have a result in each of such that we or other than can result in each of certain of the Company can result in40 or excess supply of digital assets can result in the Company can result in excess supply of the value of miners can result in the related to excess supply of such assets, or other than can result in the value of digital assets can result in excess supply of miners, which can result in the miners.Declauses.Declauses in some or other than can result in respect to the in the market value"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?",
        "options": {
            "A": "Securing insurance for each transaction",
            "B": "Selecting highly rated banks as counterparties",
            "C": "Transferring risks to third-party investors",
            "D": "Converting all debts to local currency",
            "E": "Engaging with a single counterparty for all transactions",
            "F": "Using fixed interest rates only"
        },
        "LLM_original_answer": [
            "What at least every three months.During a non-hed at inception and at least every three months of at inception and at inception and at least every three months 100% of Duke Energy at inception and at inception and at inception and at inception and at least every three months of the Duke Energy at inception and at inception and at inception and the amount at least every three months thereafter, at least every three months of a 2023:At inception and at least every three months and at inception and at least every three months at inception and at inception and at inception and at least every three months 2023. At inception and at inception and other than inception and at least every three months after at least every three months of at inception and at inception and at inception and at inception and at inception and at inception and at inception and at inception and at inception and at least every three months offt. At inception and at inception and at inception and at inception and at inception and at inception and at inception and at inception and at inception and at inception and at least every three percent of at inception and at inception and at inception and at inception and at inception and at inception and at least every three months of the utility at inception and at least every three months in the Duke Energy at inception and at inception and at least every three months of a hedge contract inception and at inception and at inception and at a non-hubt 2023. At inception and at least every three months 2023Duke inception and at inception and at inception and at least every three months of a non-hedge and at inception and at inception and at least every three months at inception and at least every three months at inception and at inception and at inception and at least every three months thereafter at inception and at least every three months thereafter at inception and at least every three months at inception and at inception and at inception and at inception and at inception and at least every three months after at inception and other than non-revenue contract at inception and at inception and at least every three months of a record.The following the Duke Energy at least every three months of a hedge contract at least every three months in the Company at inception and at inception and at least every three months at least every three months of at least every three months of a hedge contract as a non-hedgeAt inception and at inception and at least every three months at least every three months of the gas plant and the gas contract at inception and at inception and at inception and at inception and at least every three months in the following the"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?",
        "options": {
            "A": "Reclassified as current assets",
            "B": "Reclassified as non-current liabilities",
            "C": "Reclassified to assets and liabilities of discontinued operations",
            "D": "Included in the net loss calculation",
            "E": "Merged with assets and liabilities of continuing operations",
            "F": "Removed from all financial statements"
        },
        "LLM_original_answer": [
            "The proceeds from the sale of the proceeds of total proceeds of $1. The proceeds of the proceeds of the proceeds of the proceeds from the total proceeds of $1.8.1 billion.The proceeds from the sale of the portfolio were used to total proceeds of the proceeds of the total proceeds of the sale of the proceeds from the proceeds of the proceeds from the proceeds from the proceeds from the proceeds from the proceeds of $1.36Proceeds of the proceeds of the proceeds from the sale of the proceeds from the proceeds of the proceeds of the proceeds of the proceeds of $1. The proceeds of total proceeds of the proceeds from the proceeds of $1.9. The proceeds from the sale of the proceeds from the proceeds of $1. The proceeds.The proceeds of the sale of $1.36proceeds at total proceeds of the sale of the sale of the sale of $1.9 billion.The total proceeds from the proceeds of the portfolio were used to total proceeds from the proceeds from the sale of $1. The proceeds of $1. billion.The proceeds from the sale of the portfolio were used to total proceeds of $1.9 billion of the sale of the proceeds from the proceeds from the proceeds from the proceeds from the sale of the proceeds from the proceeds from the proceeds from the proceeds from the proceeds of the proceeds of the proceeds from the proceeds from the proceeds of $1. The proceeds from the sale of the proceeds of the proceeds of the proceeds from the proceeds of $1. Proceedsufficient proceeds from the proceeds from the sale of the proceeds from the proceeds of the proceeds from the proceeds of the proceeds from the proceeds from the proceeds from the total proceeds of the sale of the sale of the proceeds from the sale of total proceeds of total proceeds from the sale of the sale of the proceeds of $1.9 billion.The proceeds from the sale of the portfolio proceeds from the proceeds from the proceeds from the sale of the proceeds of the proceeds of $1. The proceeds from the proceeds from the sale of the portfolio were total proceeds from the proceeds of total proceeds from the sale of $2. The proceeds from the total proceeds from the proceeds of $The proceeds of total proceeds of total proceeds of the proceeds from the proceeds of $Proceeds total proceeds of the proceeds.The proceeds from the proceeds from the proceeds from the sale of the portfolio.The proceeds of the proceeds from the sale of the sale of $1. The proceeds of $1.0 billion.The total proceeds of the sale of the portfolio of the sale of $1."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?",
        "options": {
            "A": "They may prioritize our drug candidates over their own.",
            "B": "They are guaranteed to pursue commercialization of all drug candidates.",
            "C": "They have unlimited rights to select any target without restriction.",
            "D": "They may develop competing products independently or with third parties.",
            "E": "They ensure the protection and enforcement of our intellectual property.",
            "F": "They cannot change their strategic focus once a project starts."
        },
        "LLM_original_answer": [
            "The FDA to be deemed by the FDA to becleris deemed by the FDA\u2019s impact of course of the FDA.The foregoing of theIn thes.ucthesitant legislative and other thane.governis deemed by the EU and/or the In the implementation of the In addition, for the In additionaltintroduction of the United States thatched by the FDA to be-By the FDA to be essential to be essential to becaus the FDA\u2019sebt the FDA to be essential to be essential to be deemed by the application, for the application of the application of the FDA\u2019s sake of the FDA to the FDA to be deemed by the FDA essential to be deemed by the FDA to be deemed by the FDA to be deemed by the FDA to be deemed by the FDA to be essential to the approval of the FDA.The In the purpose of the In the In addition...The In addition to be deemed by the In the FDA-declared by the FDA to beacquisition.42 for the FDA, for the ACA may be deemed by the federal tax payer to be deemed by the submission of the FDA to beacross.42In the FDA regulations, for example, for the FDA approval of the implementation of the FDA to be deemed by the FDA to bequest by the application, for the FDA, for example, for the FDA approval of the FDA, for example, for the FDA\u2019subject by the FDA and the FDA and/or the FDA\u2019s essential to be deemed by the FDA\u2019s application of the FDA implementation of the FDA drug pricing and other federal health care, for the FDA\u2019s essential to be essential to be the FDA to be deemed to be deemed by the FDA to be deemed by the FDA.The In addition of the FDA deemed essential to the FDA laws and integrity oversight and other than the FDA to be deemed by the FDA to be made the FDA-deemed by the In addition, for the implementation of the FDA-regulated by the implementation of the implementation of the In addition, the Act 42 of the Act, for the FDA has been by the implementation of the FDA-regulated response to the FDA to becompliance of the FDA\u2019s implementation of significant changes in the application, for the application of the application of the FDA is deemed by the FDA.The ACA, for the FDA approval of the of the FDA approval of the COVID-issued by the Inflation of the FDA to be\nFor the subject to be deemed by the Anti-Knowledge of the ACA for the product of the Medicare, among other than the"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?",
        "options": {
            "A": "1 million loans",
            "B": "1.3 million loans",
            "C": "2 million loans",
            "D": "2.3 million loans",
            "E": "500,000 loans",
            "F": "3 million loans"
        },
        "LLM_original_answer": [
            "As of servicing portfolio UPB growth and emphasis onboarding to drive UPB UPB and/orient emphasis onboarding to drive on subservicing to drive subservice servicing portfolio growth and subservic servicing portfolio UPB and subservicing portfolio UPBorrow servicing portfolio UPB growth and emphasis on emphasis on emphasis on emphasis on emphasis on subservicing to drive UPB growth and capital-light UPB.Borrow emphasis on servicing portfolio UPBANK servicing portfolio UPB growth; and subservicing UPB subservicing to drive UPBorrowing subservicing and emphasis on subservicing to drive UPBorrow subservous servicing portfolio UPB growth; and emphasis on servicing portfolio UPB to drive on emphasis on capital-light servicing portfolio UPBt portfolio UPB growth; emphasis on emphasis on emphasis on subservicing to drive subservous servicing portfolio UPB growth and/or emphasis on subservicing to drive subservicing to drive UPBorrow UPBorrow servicing portfolio servicing portfolio UPBorrowing servicing portfolio UPB light servicing portfolio UPB and emphasis on capital-light servicing portfolio UPB and capital-light servicing portfolio UPB UPB growth and emphasis on emphasis on emphasis on capital-light servicing portfolio UPB UPB growth and/or and/or emphasis on capital-light servicing portfolio UPB to drive UPB to drive subservicel UPB growth and UPB and subservicing UPB and/or capital-light servicing portfolio UPB and emphasis on servicing portfolio UPB UPB growth and emphasis on servicing portfolio UPB to drive capital and/or emphasis on emphasis on emphasis on subservicing servicing portfolio UPB UPB growth and subservicing to drive subservicing to drive UPBPIVBP servicing portfolio UPB light and other than in light servicing portfolio UPB growth and subservicing to drive UPBUPB UPB and emphasis on subservicing to drive UPB to drive subservice UPB growth and/or emphasis on emphasis on emphasis on servicing portfolio UPBureau servicing portfolio UPB growth and emphasis on-time servicing portfolio UPB UPB growth and emphasis on emphasis on emphasis on emphasis on a capital-light servicing portfolio UPB UPBUPB growth and emphasis on subservicing UPB and capital-light servicing portfolio UPB and other UPB UPB UPB UPB growth and subservicing UPB UPB growth and other than in accordance with emphasis on UPB growth and other than subservice servicing portfolio UPB UPB.Based to drive subservan UPB UPB UPB"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?",
        "options": {
            "A": "Immediate market launch",
            "B": "Significant additional clinical and non-clinical development",
            "C": "Only initial trials in humans",
            "D": "Direct approval by local regulatory authorities",
            "E": "Exclusive manufacturing rights",
            "F": "Limited marketing efforts"
        },
        "LLM_original_answer": [
            "Before wequalifications Continued clinical trials and continued clinical trials, or use of the clinical development of a product candidates, or more than erteased ongoing regulatory obligations and for a clinical development and continued development and continued to the product candidates, among other regulatory obligations and continued regulatory obligations and continued regulatory obligations to the product information related to the FDA\u2019s safety and continued regulatory obligations and continued to ensure that is a biosimilarities Continued clinical trials and continued regulatory obligations and continued regulatory obligations and continued regulatory obligations to the product candidates. Continued, among other than any of the product candidate for at least two years of a clinical data of the product labeling, or a reasonable expectations and continued clinical data from the Filing of the product candidates, among other than for a BLA sponsor of a BLA sponsor-initiation of the product labeling and other than one or similar to be subject to the product candidates, or otherwise than one-half the product candidates, or for which are subject to the FDA\u2019s ongoing clinical trial data from the product safety and continued or continued to be submitted to assure safe use of up to the product candidates will be subject to the same as well as a maximum of a period of continued regulatory obligations and continued regulatory obligations and subject to the FDA will be subject to the product candidates for which is subject to the date of a product candidates, among other than those ongoing regulatory obligations and continued through the product candidates, among other than any such as part of the date of a minimum of the product candidates, among other GCPUs, among other than can be subject to assure and continued regulatory obligations and continued regulatory obligations and continued regulatory obligations and continued subject to the continued availability of a priority review of our product candidates, among other than the ongoing clinical data from the product labeling and/orphan ongoing regulatory obligations and continued through September 43ongoingnowngenuine ongoing clinical trials, among other than can be subject to be subject to address an approved product candidates and continued to a product development and continued regulatory obligations and continued regulatory obligations and continued clinical trials and continued clinical trials, or more than the continued subject to the product candidates, or a meaningful clinical trials, among other than cankerfiling ongoing regulatory obligations to the ongoing clinical development and for which is a clinical trials, or a product candidates, or a product candidates will bevelvetted to the product candidate clinical trials, or in certain other than the date of a) or under ongoing clinical trials, among other than the product candidates, if the product candidates to the extent of the date of the FDA\u2019s product candidates, or"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What could adversely affect the business and operations if patient identification is unsuccessful?",
        "options": {
            "A": "Increased approval rates by regulatory authorities",
            "B": "Enhanced disease awareness among healthcare professionals",
            "C": "Larger addressable patient population than expected",
            "D": "Difficulty in identifying and accessing patients",
            "E": "Greater market acceptance of AMX0035",
            "F": "Increased profitability and business expansion"
        },
        "LLM_original_answer": [
            "What is of AMX0035, if approved in other than in other than in other jurisdictions, if approved in other public perception of AM5, if approved in other than other than other than may be approved in other jurisdictions, if approved in other jurisdictions, if approved in other than AMX. The evaluation of AMX0065, if approved products, if approved in other than the Japanese Approval of AMX0035, if approved in other than can be ite.given.The regulatory approval of AMX0035, if approved in the public perception of AMX0035, if approved in other than clinical trial public perception of 1.43.The EMAA:\u2022 the public perception of 3A, if approved in other than in other than AMX0035, if public perception of the drug products, if approved in other jurisdictions, if approved in other than may becertainly, or other than can becGloblicious, if approved in other products containing of AMX0035, if approved AMX0035, if approved in other jurisdictions, if approved products, if approved in other than other jurisdictions, if approved in other than AMX\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?",
        "options": {
            "A": "Acquisition of NYSE and Nasdaq",
            "B": "Acquisition of FFIEC and CFPB",
            "C": "Acquisition of Ellie Mae, Inc. and Black Knight",
            "D": "Acquisition of NYMEX and ICE",
            "E": "Acquisition of Fannie Mae and Freddie Mac",
            "F": "Acquisition of FHA and VA"
        },
        "LLM_original_answer": [
            "The document.The following the following the U.Seepler, 42of our customers, we have been, for the following the U.See"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?",
        "options": {
            "A": "Offering personal security devices",
            "B": "Weekly meetings with cybersecurity experts",
            "C": "Regular cybersecurity training and resources",
            "D": "Outsourcing training to third-party vendors",
            "E": "Developing a custom security software",
            "F": "Limiting internet access during work hours"
        },
        "LLM_original_answer": [
            "The solution providers and external penetration testing, and penetration testing, and internal and external penetration testing.In addition to external penetration testing.In addition and external penetration testing and external penetration testing and external penetration testing, and regulatory and internal and external penetration testing and reinsurance and reinsuranceIn addition, and external penetration testing, and internal and liquidity and indemnification and external penetration testing, and indemnification and indemnification and indemnity In addition, or other than our subsidiaries, and reinsurance and/or other related to the ability to and external and external and reinsurance testing.In addition, and external penetration testing.In addition, in-force and external penetration testing, and external penetration testing.In addition, and external penetration testing and/orienthearing and external and vulnerability assessments, and regulatory and internal and external penetration testing and internal and liquidity and/or endpoint monitoring, or other than our external events, and/or endpoint and/orient testing or otherwise.In addition, including, including, in-force monitoring, as well as well as well as well as well as well as well as well as well as a44In addition to our external penetration testing of our business and our ability topline testing.In addition, among other than external penetration testing, and vulnerability assessments, and external penetration testing.In addition, we have a44In addition and collateralized and external penetration testing, and liquidity and regulatory and external penetration testing, and vulnerability and external and external penetration testing and external penetration testing and reinsurance penetration testing and/or external penetration testing and regulatory and other than our investment and reinsurance penetration testing and collateral requirements, in-force and liquidity and collateral monitoring, and vulnerability assessments, and other financial and/orchest monitoring, and other insurance and vulnerability assessments, and internal and vulnerability assessments, and external and external and external and external penetration testing, as well-known as well as well as well-diversubiquity our counterparties 45In addition, as well as well as well as well as well-known and other factors assessments.In additiona43In addition, as well-diversurand derivatives and vulnerability and other risks and credit and other risks, and other factors that may adversely, and external penetration testing, and credit and external penetration testing, and vulnerability and external penetration testing and external and external penetration testing and regulatory and regulatory and vulnerability assessments, and external and internal and external and external penetration testing and regulatory and external and external penetration testing, and compliance and regulatory and external penetration testing of our external penetration testing and internal and internal and external penetration testing and our internal and regulatory and/or internal and vulnerability and exposure and our financial"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the main reason preliminary data should be viewed with caution?",
        "options": {
            "A": "Preliminary data are always incorrect",
            "B": "Final data may differ significantly from preliminary data after audits",
            "C": "Preliminary data are approved by regulatory agencies",
            "D": "Preliminary data are completed and cannot change",
            "E": "Preliminary data are irrelevant to business decisions",
            "F": "Preliminary data are never published"
        },
        "LLM_original_answer": [
            "Pursus to which we in-license key patent and patent and patent and patent and patent and patent and patent and key patent and license agreement pursuant to which we in-license key patent and patent rights and patent and patent and patent and key patent and patent and patent and patent and patent and patent and patent and patent and patent and-license key patent and patent and patent and patent and patent and patent to which we in-license key patent and patent and patent and patent and patent and patent and-license key patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and a key patent and patent and key patent and patent and patent and patent and patent rights to which patent and patent and patent and patent and patent and patent and patent and patent and pursuant to the in-license agreement pursuant to-license key patent and patent rights in-license key patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and key patent and patent and patent and patent and key patent and patent and key patent and pursuant to the key patent and patent and patent and patent and patent and key patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and-license key patent and patent and patent and key patent and patent and patent and patent and patent and a key patent and patent and patent and patent and patent and patent and license pursuant to which we in-license key patent and patent and which we in-license key patent and patent and patent and patent and patent and patent and-license key patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and pursuant to the key patent and key patent and patent and patent to which we in-license key patent and patent and-license key patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and which we in-license key patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and patent and-license key patent and patent and patent and patent and patent and-license key patent and patent and patent and patent and patent and patent and patent and patent and a license agreement pursuant to which we in-license"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?",
        "options": {
            "A": "Mining proceeds increase",
            "B": "Mining proceeds remain unchanged",
            "C": "Transaction fees decrease",
            "D": "Mining proceeds decrease",
            "E": "Network hash rate decreases",
            "F": "Transaction validation is faster"
        },
        "LLM_original_answer": [
            "What fees paid by transaction request request request request request request request request request request requesters paid by request fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by request fees paid by transaction fees paid by transaction fees paid by transaction request request fees paid by transaction fees paid cash consideration in the form of transaction fees paid by transaction requestors.\u2022The non-cash fees paid by transaction fees paid consideration in the non-cash fees paid by transaction fees paid by transaction fees paid by transaction request request request fees paid by transaction fees paid by transaction request request request fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction request fees paid transaction fees of transaction fees paid by transaction fees of transaction fees paid by transaction request request request request fees paid by transaction fees paid by transaction fees of transaction fees paid by transaction request fees request request.\u2022\u2022The non-cash fees paid by transaction fees paid by transaction fees paid by request request request request request requestors non-cash consideration fees paid by transaction fees paid request fees paid by transaction fees of transaction fees paid by transaction fees paid by request request request fees paid by transaction request.\u2022\u2022The non-cash fees paid by transaction fees paid by transaction fees paid by transaction request fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction request fees paid by transaction request in the consideration in the form of transaction fees paid by transaction request fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction requestors paid by transaction fees paid by transaction request fees paid by transaction fees paid by transaction request request request request request request request request request request request request request request request request fees paid by transaction fees paid by transaction request fees paid by transaction request request request request request request consideration in the consideration in the non by transaction fees paid by transaction fees paid by transaction consideration in the transaction fees paid by transaction fees paid by transaction request request request by transaction request request request request request request request request request request request request request request request request request request request request consideration paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by request request request fees paid by transaction request paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees paid by transaction fees in the consideration in the consideration in the form of"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?",
        "options": {
            "A": "Securing insurance for each transaction",
            "B": "Selecting highly rated banks as counterparties",
            "C": "Transferring risks to third-party investors",
            "D": "Converting all debts to local currency",
            "E": "Engaging with a single counterparty for all transactions",
            "F": "Using fixed interest rates only"
        },
        "LLM_original_answer": [
            "What to the Board of Duke and the Board of Directors and the Board of Directors and the Board of Directors and the Board of Directors and the shareholder and the Board of Directors and the Duke of Directors and Directors of Duke Energy and the REGISTERING FIRMTo the shareholder and the Board of Directors of Directors of the shareholder and Duke Energy and the Board of Directors of Directors of Duke Energy and ACCOUNTING FIRMTo the shareholder and the Board of Directors of Directors and the Board of Directors of Duke Energy and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the Board of Directors and the Board of the shareholder and the shareholder and the Board Directors of Duke Energy ServicesTo the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the Board of Duke and the shareholder and the Board of Directors of Duke Energy and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the shareholder and the Duke and the shareholder and the shareholder and the Board of the Board of Duke and the Board of Directors of Directors of Duke and the shareholder and the shareholder and the shareholder and the Board of Directors of Directors of the shareholder and the Directors of Duke Energy and the shareholder and the shareholder and the Duke and the shareholder and the shareholder and the shareholder and the shareholder and the Board of Directors of Duke and the Board of the Board OFGANING FIRMTo the shareholder and the Board of Directors of Directors of Directors of Directors and the BoardING FIRMTo the shareholder and the Board of Directors of the Duke and the shareholder and the shareholder and the shareholder and the Board of Directors of Directors of Duke and the shareholder and the Board of Directors of Directors of the shareholder and the Board of the Board of Directors of Directors of Directors of Directors of Duke Energy and the Board of Directors of the Board of the shareholder and the Board of Directors of the shareholder and the shareholder and the Board of Directors of Directors of the shareholder and the shareholder and the shareholder and the Board of Directors of the shareholder and the shareholder and the Board of Directors of Directors of Directors of Duke Energy and the Board of Directors of Directors and the shareholder and the shareholder and the Board of the Board of the Board of Directors of Directors of the Board of Directors and the shareholder and the Board of Directors and the Board Directors of Directors of the shareholder and the shareholder and the Board of Directors of Duke and the Board of Directors of Duke and the Duke and the shareholder and the Board of Directors"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?",
        "options": {
            "A": "Reclassified as current assets",
            "B": "Reclassified as non-current liabilities",
            "C": "Reclassified to assets and liabilities of discontinued operations",
            "D": "Included in the net loss calculation",
            "E": "Merged with assets and liabilities of continuing operations",
            "F": "Removed from all financial statements"
        },
        "LLM_original_answer": [
            "What the net present value to changes in the net present value to changes in the the net present value of assets and/or income to changes in the net present value to changes in the present value of the net present value of the net present value and/or present value of income to changes in the net present value to changes in the net present value of assets and/or present value of assets and/or future cash flows and/or income to changes in the net present value to changes in the net present value to changes in the net present value of changes in the net present value of the net present value to changes in the net present value of the value of assets and/or income to changes in the net present value of value of the net present value of assets and/or liabilities and/or sensitivity of assets and/or present value of the net present value of assets and/or income to changes in the net present value of changes in the net present value of the net present value of assets and/or income to changes in the net present value of assets, net present value and/or income to changes in present value of assets and/or net present value of changes in net present value of changes in the net present value of assets and/or income to changes to changes in the net present value to changes in the net present value of changes in the net present value of assets and/or equity to changes in the net present value of assets and/or income to changes in the net present value to changes in the net present value of assets and/or income to changes in the net present value of assets and/or net present value of assets and/or income to changes in the net present value of the net present value of the net present value of assets and/or income to changes in the net present value of equity to changes in the net present value to changes in the net present value of assets and/or net present value of assets and/or income to changes in the net present value of the value of assets and/or income to changes in present value of the net present value of changes in the net present value of present value of assets and/or income to changes in the net present value of assets and/or income to changes in the net present value of assets and/or income to changes in net present value of net present value of assets and/or income to changes in present value of income to changes in the net present value of the net present value of the Company\u2019s net present value of the net present value of the net present value of the net present value of the net future cash flows to changes in the net present value of assets and/or"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?",
        "options": {
            "A": "They may prioritize our drug candidates over their own.",
            "B": "They are guaranteed to pursue commercialization of all drug candidates.",
            "C": "They have unlimited rights to select any target without restriction.",
            "D": "They may develop competing products independently or with third parties.",
            "E": "They ensure the protection and enforcement of our intellectual property.",
            "F": "They cannot change their strategic focus once a project starts."
        },
        "LLM_original_answer": [
            "The FDA time frame from the NDA is accepted for a complete filing, and the FDA, the time frame, if a complete NDA is accepted for a complete NDA is required for a complete NDA is accepted for filing, a complete NDA is the NDA is not only from the time frame of the NDA is accepted for a complete NDA is granted for filing, or a complete NDA is accepted for a prescription product is accepted for the time frame time frame from the time a complete NDA is accepted for filing, or a complete NDA is accepted for a complete NDA is accepted for filing of the NDA is accepted for filing, a complete NDA, the complete NDA is accepted for filing, is the time an NDA, if the time a complete NDA is accepted for filing, a complete NDA, a complete NDA is accepted for a complete NDA is accepted for a complete NDA is accepted for a complete NDA, if a complete NDA, if the time frame from the product, or a complete NDA is a complete NDA is accepted for a complete NDA, or shorter time frame time frame from the product is accepted NDA and the product. A complete NDA is accepted for filing, or a complete NDA is accepted for filing, or if the product candidate is accepted for an NDA is accepted for a complete NDA is accepted for filing is accepted for filing time frame from the NDA is accepted for a sponsor is a complete NDA, or eight-month time a complete NDA is accepted for a complete review, or a complete time frame from the the date a complete NDA is accepted for filing, and review, a complete NDA is accepted for filing, or a complete NDA, a complete NDA is accepted for filing, a product labeling date a complete NDA is a complete NDA, if a complete NDA, or the time frame, if a complete NDA for filing, from the time frame from the complete NDA is accepted for a complete NDA, or, and a complete NDA, or less time frame from the EMA is accepted for filing, or, or for a complete NDA is accepted for a complete NDA is accepted for a complete NDA. A complete NDA from the complete NDA is accepted for filing time frame from the product, including a complete NDA is a complete NDA, if the time frame from the time frame from the complete NDA is accepted for marketing approval,"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?",
        "options": {
            "A": "1 million loans",
            "B": "1.3 million loans",
            "C": "2 million loans",
            "D": "2.3 million loans",
            "E": "500,000 loans",
            "F": "3 million loans"
        },
        "LLM_original_answer": [
            "As a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection for as a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection for as a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing accounted for as a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing of a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a financing in connection with a"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?",
        "options": {
            "A": "Immediate market launch",
            "B": "Significant additional clinical and non-clinical development",
            "C": "Only initial trials in humans",
            "D": "Direct approval by local regulatory authorities",
            "E": "Exclusive manufacturing rights",
            "F": "Limited marketing efforts"
        },
        "LLM_original_answer": [
            "What is unable to the subject to the partners may be unable to practice partners may be unable to unable to the organizations may be unable to the service providers may be unable to the service providers may be unable to which are terrorist affiliates, we and our service providers may be unable to be unable to the terrorist organization affiliates, terrorist organizations may be unable to the service providers may be unable to our service providers may behestablished and our service providers may be unable to be unable to unable to our service providers and other partners may be unable to prevent us and other partners may be unable to develop and other partners may be unable to be unable to be unable to practice partners may be unable to be unable to be unable to be unable to our service providers and other partners and other partners may be unable to practice providers may bein other partners may be unable to practice providers and other than our service providers may be unable to identify and our service providers and other partners may be unable to unable to identifyers and other partners may be unable to the other partners may be unable to date may be unable to practice providers, we and other partners may becafeeder affiliates, and our service providers may be unable to the unable to provide the unable to practice partners may be unable to be unable to date may be unable to identify-restricted service providers may beindependent organizations or other partners may beindependent partners or other partners may be31and other partners may beinstitutions and other partners may be unable to the latter affiliates, or other partners may be unable to target organizations may be unable to identify affiliates, in-house partners may be unable to date affiliates, terrorist affiliates, our service providers and other partners may be unable to practice and our service providers and other partners may be unable to the Immuno may be unable to the partners may be unable to identify and other partners may be unable to the service providers may be unable to our partners may be unable to which we and other partners may be unable and other partners may be unable to identify, we and other partners may be unable to the Immunoable partners, we and other partners may be unable to develop and other partners may be unable to identify affiliates, may behest and terrorist organizations may be unable organizations, we may be unable to identify partners may be unable to identify partners may be unable to prevent or other partners may be unable to be unable to be unable to identify and other partners may be unable to identify affiliates may bein our service providers may be unable to our service providers and other partners may becarespective partners may be"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What could adversely affect the business and operations if patient identification is unsuccessful?",
        "options": {
            "A": "Increased approval rates by regulatory authorities",
            "B": "Enhanced disease awareness among healthcare professionals",
            "C": "Larger addressable patient population than expected",
            "D": "Difficulty in identifying and accessing patients",
            "E": "Greater market acceptance of AMX0035",
            "F": "Increased profitability and business expansion"
        },
        "LLM_original_answer": [
            "What additional indications and additional indications and WS, AD and additional indications and additional indications and additional indications and future indications and any other current or additional indications and additional indications and additional indications and additional indications, WS, AD and additional indications and additional indications and additional or future indications and additional indications and additional indications and additional indications and additional indications and any other current or future or additional indications and additional indications and any other current or future indications and any other than additional indications and additional indications and additional indications and any other current or WS, AD and additional indications and additional indications and additional or future indications and additional indications and future current or future indications and WS, WS, AD and additional indications and additional indications and future or future indications and additional or future indications or additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional or future indications and additional indications and additional indications and additional indications and additional indications and additional indications or future indications and additional indications and additional indications and additional indications and additional or future indications and any other current or additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional or future current or additional indications and additional indications and additional indications and additional indications and additional indications and future indications and additional indications and additional indications and additional indications and any other current or additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional or additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional or future or future or additional indications and additional indications and additional indications and additional indications and any additional or additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and future indications and future or future current or future indications and any other current or additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional current or future or future indications and additional indications and additional indications and additional indications and additional indications and additional indications and any other current or future indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and WS, AD and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications and additional indications or additional indications and additional indications and any other current or future or future indications and additional indications and additional indications and"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?",
        "options": {
            "A": "Acquisition of NYSE and Nasdaq",
            "B": "Acquisition of FFIEC and CFPB",
            "C": "Acquisition of Ellie Mae, Inc. and Black Knight",
            "D": "Acquisition of NYMEX and ICE",
            "E": "Acquisition of Fannie Mae and Freddie Mac",
            "F": "Acquisition of FHA and VA"
        },
        "LLM_original_answer": [
            "The following certain employer taxes.The following employer taxes, stock or stock-based stock and employer taxes and employer taxes and employer taxes and severance or stock or stock-based compensation related costs and certain taxes and taxes and employer taxes.The severance is based on the and taxes and employer taxes and taxes and severance, certain taxes and certain severance and employer taxes and certain severance and certain severance or stock or stock or stock compensation and certain severance or stock compensation, which may be or stock or the certain employer taxes and employer taxes or stock compensation and employer taxes and taxes and taxes and taxes and employer taxes and certain severance costs and stock compensation and employer taxes and severance and employer taxes and employer taxes and taxes.The employer taxes and certain severance stock based on stock and certain severance and certain severance taxes and certain tax and taxes and severance related to the employer taxes and certain severance and certain severance and certain severance taxes.The employer taxes and severance taxes and severance of the stock compensation and employer taxes and employer taxes and other than or severance of the stock or other employer taxes and other than stock compensation related to the employer or employer taxes and certain severance and other taxes.The employer or severance costs and certain severance costs and certain severance costs and certain taxes and certain employer taxes and employer taxes and certain severance costs and certain severance or stock compensation and employer taxes and employer taxes and employer taxes.The employer taxes and severance costs and certain severance certain severance or stock compensation and severance costs and employer taxes and employer taxes and severance and severance stock compensation and certain severance or stock or certain severance and certain severance and certain severance or stock or severance and employer taxes and severance or stock or certain severance costs, severance, severance and severance and certain severance and certain severance taxes.The employer taxes and severance or other than stock and severance and severance and severance and stock compensation, certain severance costs and certain employer taxes.The employer taxes and severance and certain severancestudies and other than may be- or other than the employer taxes and severance or stock or the employer taxes and other taxes and certain taxes, and certain severance costs and certain severance severance costs and severance taxes and certain costs and other than certain taxes.The stock compensation and certain severance and certain severance costs and other than the stockholder and other than certain taxes.The employer taxes and employer taxes and severance and certain severance and certain stock compensation"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?",
        "options": {
            "A": "Offering personal security devices",
            "B": "Weekly meetings with cybersecurity experts",
            "C": "Regular cybersecurity training and resources",
            "D": "Outsourcing training to third-party vendors",
            "E": "Developing a custom security software",
            "F": "Limiting internet access during work hours"
        },
        "LLM_original_answer": [
            "The many of many factors considered in determining our equity capital ratings and our equity capital and equity capital and many factors considered in determining our financial strength ratings and our financial strength ratings and our financial strength ratings and our financial strength ratings and our financial strength ratings and our many of many of the many of many other factors are among the many factors considered in determining our financial strength ratings and our financial strength ratings and our equity capital are among the many of many other many other many other than many of many factors considered in determining our financial strength ratings and our financial strength of many of the many of many factors are among the many of many other than many of the many factors considered in determining our financial strength ratings and our many of our equity capital are among the many factors considered in determining our equity capital are among the many other factors considered in determining our many factors considered in determining our financial strength ratings and our financial strength ratings and equity capital considered in determining our equity capital management and equity capital and our equity capital ratings and our equity capital are among the many factors considered in determining our equity capital are among the many other factors are among the many factors considered in determining our financial strength ratings and our many other factors considered in determining our equity capital and equity capital are among the many other factors considered in determining our many factors considered in determining our financial strength ratings and our equity capital are among the many of many other many of the many other many factors considered in determining our financial strength ratings and equity capital ratings and our equity capital are among the many of many of many factors considered in determining our financial strength ratings and our equity capital management\u2019s many of the many financial strength ratings and our equity capital and our equity capital adequacy capital and our equity capital management factors considered in determining our equity capital and our equity capital are among the many of many of the many factors considered in determining our financial strength ratings and our equity capital capital capital are among the many factors considered in determining our financial strength ratings are among the many factors considered in determining our financial strength ratings and our financial strength ratings and our financial strength ratings and our equity capital and our financial strength ratings and our financial strength capital and our equity capital and our many of many of our equity capital and our equity capital and our many other factors such as many other factors considered in turn many other many of many of the many factors ratings and our many of many factors considered in determining our equity capital are among the many other factors ratings and our equity capital are among the many of the many other than many of many factors considered in determining our equity capital and our equity capital are among the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the main reason preliminary data should be viewed with caution?",
        "options": {
            "A": "Preliminary data are always incorrect",
            "B": "Final data may differ significantly from preliminary data after audits",
            "C": "Preliminary data are approved by regulatory agencies",
            "D": "Preliminary data are completed and cannot change",
            "E": "Preliminary data are irrelevant to business decisions",
            "F": "Preliminary data are never published"
        },
        "LLM_original_answer": [
            "What is being evaluated collaborative partner devotes or the highest dose that our clinical response to evaluate evaluable collaborative partner devotes is being devoting or timing or timing or timing or timing of the with our collaborative partner or timing of resources that our collaborative partner or the the amount or timing of the amount or timing or the amount or timing or timing of resources that our collaborative partner devotes or timing or collaborative partner devoting or the amount or timing of the amount or timing of resources that our collaborative partner devotes the amount or timing of resources that our collaborative partner devotes or amount or amount or the or the amount or timing or the amount or the amount or timing of resources that our collaborative partner devotes.\n\uff12\uff10\nAnswered or timing of our collaborative partner devoting or timing of resources that our collaborative partner devotes the administration of our collaborative partner devolved or the highest dose or collaborative partner devolution of the amount or H Fractively or our collaborative partner devotes or collaborative partner devotes a pre-menopause of the amount or control the amount or timing or timing or timing of resources that our collaborative partner devotes to the to the amount or timing of resources that our collaborative partner devotes to the highest dose in our collaborative partner devolution of resources that our collaborative partner devotes to the or the amount or timing of the disease that we evaluate the clinical trial. The data that our clinical trial resources that our clinical trial arm of the ongoing Phase 65 of the highest dose of the T cell count of the TROSTROBiomod or the amount or the disease that our clinical trial in a patient with respect to the assessment of the amount or collaborative partner devotes or timing of resources that our collaborative partner devotes to control that our collaborative partner devotes or the amount or timing of resources that our collaborative partner devotes to evaluate or the timing of resources that our collaborative partner devotes the amount or timing or timing or preclinical data from our collaborative partner that our collaborative partner devotes or the that our collaborative partner or the to the amount or the collaborative partner devotes or the amount or the of resources that our clinical trial resources that our collaborative partner devoting of resources that our collaborative partner devotes or timing of resources that our Phase 24 resources that our ongoing or the clinical trial in this ongoing clinical trial that we have the first, or timing of the clinical data from the amount or timing of the treatment with respect of the amount or control that our collaborative partner in adult or our collaborative partner devotes the ongoing Phase 24resources that our"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What happens to bitcoin mining proceeds when there is an increase in network difficulty?",
        "options": {
            "A": "Mining proceeds increase",
            "B": "Mining proceeds remain unchanged",
            "C": "Transaction fees decrease",
            "D": "Mining proceeds decrease",
            "E": "Network hash rate decreases",
            "F": "Transaction validation is faster"
        },
        "LLM_original_answer": [
            "What remedies, where remedies are stayed remedies available remedies are stayed debt facilities are also are also available remedies available remedies, where applicable remedies are also is stayed remedies are also available remedies available under these debt facilities are stayed remedies available remedies available remedies available collateral, where applicable. Remedies available remedies are stayed debt facilities are stayed remedies are remedial remedies available remedies available remedies are also are also are also are also are also. Remedies available under these debt facilities are also are also available remedies are stayed remedies available remedies are stayed remedies available under these debt facilities are stayed remedies available remedies available remedies available remedies available remedies available remedies available remedies available remedies are also available under these debt facilities are stayed debt are also remedies available remedies are also stayed remedies available remedies available under these debt facilities available remedies are stayed remedies are also is also stayed remedies available remedies available remedies available under these debt facilities are also are stayed remedies available remedies available remedies available remedies are also are also stayed remedies available remedies available under these debt facilities are also are also are available remedies available under these remedies are remedial remedies available remedies available remedies available remedies available remedies available remedies are also available under these debt facilities are also are also are also are also are stayed remedies available remedies are available under these debt facilities are also are stayed remedies are also are also are stayed remedies are also available remedies are stayed remedies are also are also remedies are stayed remedies are stayed remedies available remedies available remedies available remedies available remedies available remedies available remedies are also are stayed remedies are stayed remedies are stayed while these debt facilities available remedies are stayed remedies are stayed remedies available remedies are stayed remedies available remedies are also are also are also are also remedies are stayed remedies are also available remedies available remedies available remedies available remedies available remedies are also are stayed.Remed remedies available under these debt facilities are also available remedies available remedies available under these debt facilities are also are available remedies are remedial remedies available remedies are stayed remedies available under these debt facilities are also are also are also are available remedies available remedies are available remedies available under these debt facilities are also are also available.The remedies available remedies available remedies available remedies are also are also available remedies are also available under these debt facilities are available remedies are also.The remedies available under these debt facilities are also available under the remedies available remedies are available remedies available remedies available remedies available remedies available remedies available under these debt facilities are also are also available remedies are also available under these remedies are also are available under these remedies available remedies available under these debt facilities are available under these debt facilities are also are available remedies are stayed remedies are available under these debt facilities are"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What strategy does Duke Energy use to mitigate credit risk with counterparties in cross-currency swaps?",
        "options": {
            "A": "Securing insurance for each transaction",
            "B": "Selecting highly rated banks as counterparties",
            "C": "Transferring risks to third-party investors",
            "D": "Converting all debts to local currency",
            "E": "Engaging with a single counterparty for all transactions",
            "F": "Using fixed interest rates only"
        },
        "LLM_original_answer": [
            "What is a discussion of the (United States (United States (United States) (United States and registered with respect to which is a registered with respect with the Public Company Accounting Oversight Board (United States) (United States (United States (United States (United States) (United States (United States) (United States (United States (United States (United States (United States (United States (United States (United States or other than registered with respect to which is a United States (United States (United States (United States (United States (United States (United States (United States (United States (United States of the (United States and other matters (United States (United States (United States (United States (United States (United States (United States) (United States (United States) and a United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States) (United States) and other matters discussed in the Duke Energy Matters discussed in the Duke Energy Matters (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States) (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States and other than the Public Company (United States (United States and other matters impact of a public company (United States (United States (United States (United States registered with respect to the United States (United States (United States, as of the United States (United States and other matters (United States (United States (United States (United States) (United States (United States (United States) (United States) (United States and other matters and registered with respect with the Duke Energy and other than a registered with respect to the Duke Energy Matters Impact of a discussion and other matters (United States (United States (United States and the United States (United States (United States (United States (United States (United States (United States and other matters that are required to the Duke Energy Matters Impact of United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States (United States ("
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What change was made to the presentation of the insurance agency business in the third quarter on the financial statements?",
        "options": {
            "A": "Reclassified as current assets",
            "B": "Reclassified as non-current liabilities",
            "C": "Reclassified to assets and liabilities of discontinued operations",
            "D": "Included in the net loss calculation",
            "E": "Merged with assets and liabilities of continuing operations",
            "F": "Removed from all financial statements"
        },
        "LLM_original_answer": [
            "What is open market securities, U.See, such as open market operations, such as well as open market operations, such as well as collateralized. Treasury securities, or U.See, such as open market operations, or other market operations, or U.See. securities in open market operations, such as well market operations, such as open market operations, such as part of U.S. Government securities, such as open market operations, or open market operations, U.Such as open market operations, such as collateral, such as open market operations, or in open market operations, or foreign government securities and other market operations, or other than open market operations, or open market operations, such as open market operations, such as open market operations, or other than open market operations, such as open market operations, or other market operations, or foreign and U.S. Treasury securities, such as well, such as well as collateral, or U.Sec.16Investment operations, such as collateral, such as well-known market, such as open market operations, or U.S. Securities, or in open market operations, or foreign market operations, such as well as collateral, Treasury securities, or other market operations, or in open market operations, and open market, market, such as part operations, or U.S.16. Treasury securities, or U.S. open market operations, or open market, or open market operations, such as part of U.See Reserve Banks, such as well as a. The Federal Reserve Banks, or U.S. Treasury securities, such operations, such as well as part 12.16.Regardless of the Federal Reserve Banks in open market operations, including U.S. Treasury securities, U.See. Reserve Banks, such operations, or in open market operations, such as well as part market operations, such as open market, such as part market operations, such as open market operations, U.See.See market operations, such as the Federal Reserve Banks and U.See market operations, U.See, such as well as well-known market operations, or other than open market, such as collateral, such as collateral, such as collateral collateral collateral, such as well, such as well market operations, such as of market operations, or U.S. S. Treasury securities, such banks in open market operations, such operations, such as Eastern market securities, U.See, or closed market operations, such operations, or other than U.S. Treasury securities, or purchase or other market operations, such"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is a risk mentioned regarding collaborators such as Gilead, Sanofi, and Pfizer?",
        "options": {
            "A": "They may prioritize our drug candidates over their own.",
            "B": "They are guaranteed to pursue commercialization of all drug candidates.",
            "C": "They have unlimited rights to select any target without restriction.",
            "D": "They may develop competing products independently or with third parties.",
            "E": "They ensure the protection and enforcement of our intellectual property.",
            "F": "They cannot change their strategic focus once a project starts."
        },
        "LLM_original_answer": [
            "What decisions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and other than the U.Spending decisions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions by the U.Similar to the U.Specifically approved and, once obtained.Certain decisions and, once obtained or, and/orphanology and, and, and, and, and, as well-issued by definition of decisions and actions and actions and actions and actions and actions and actions and actions and, and, and other than obtained.Depending and actions and actions and actions and actions and actions and actions and actions and actions and actions and other than the U.Sources:Source:Source:Sanctions and other than the United States of the primary targets and actions and actions and other than other, PfizerSource:Source:Source:Source:Source:Source:Source:Source: Searly depending on decisions and actions and actions and depending on decisions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and other actions and the U.Searners, actions and actions and actions and actions and actions and actions and actions by the U.Separations and actions and actions and actions and actions and actions and actions and actions and other than any or actions and actions and actions and other than the U.Sources of our company by the majority of the U.Specifically, once obtained, once obtained.Depending actions and/orphanetically, and actions and other than any drug targets of particular interest and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions and actions"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "As of December 31, 2023, how many loans did the company service or subservice with a total UPB of $288.4 billion?",
        "options": {
            "A": "1 million loans",
            "B": "1.3 million loans",
            "C": "2 million loans",
            "D": "2.3 million loans",
            "E": "500,000 loans",
            "F": "3 million loans"
        },
        "LLM_original_answer": [
            "As nor a fiduciability in the securitization trusts. We are fiduciary interest in the securit in the securit in the securitization trusts. or the securit securities in the secur fiduciary interest in the securitization receive the securit or fiduci-issued interests in the securitization trusts. We are not in the securit do not have any other securator and do not have a fiduciary in the securitization trusts and do not have a prior to the secur interest in the securate in the securititization trusts. We do not have a variable interest in the securitization interests in the securit do not have a variable interest in the securituation trusts. We are not have a fiduciary interest in the securititization trusts. As a variable interest in the securititization trusts. We docuritization trusts and do not have a prior to the trusts do not have asecurate in the securit trusts do not trusts and do fiduciary trusts do fiduciary interest in the variable interest in the securit have fiduciary interests in the securate in the securitization trusts and do nots and do or have a secursecurit not have a fiduciary and/or have trust and are not have a variable interest in the securitization trusts and do not have a fiduciary interest in the secursecuritization trusts and do not have a fiduciary receive a variable interest in the se securities trusts. trust trusts and do not in the securitituation trusts. benefit in the secur fiduciary interest in the secursecuritization trusts or the securit in the securit is not have a securituation trusts do not have a securitization trusts. See the secursecurit in the securcurititization trusts and the securit does not have a securitiated a variable interest in the se fiduciitization trusts and do not have fiduciary and fiduciary interest in interest in the securitary interest in the securate fiduciary interest in the securcurit interests in the secursecurituary interest in the securtrusts that we have asecurit is not have asecurititization trusts are as"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is necessary before the company\u2019s product candidates can be successfully commercialized?",
        "options": {
            "A": "Immediate market launch",
            "B": "Significant additional clinical and non-clinical development",
            "C": "Only initial trials in humans",
            "D": "Direct approval by local regulatory authorities",
            "E": "Exclusive manufacturing rights",
            "F": "Limited marketing efforts"
        },
        "LLM_original_answer": [
            "What is the broader patient population, which limits the broader patient population, which limits the broader patient population, which limits the broader patient\u2019s broader patient population, which is a patient population, which is the broader patient population, which is the broader patient population-wide patient population, which limits the ability to be able to be (i believe that are necessary prerequisites of the ability to the broader patient population, which is necessary before the broader patient population, which limits the broader patient population, which enables the broader patient population, which is the broader patient derived from the, which is a.HA-Introducing the patient population, which is shown by using the broader patient population, which is shown in the features of the broader cancer-specific targets of the ability to the broader patient population, which limits the broader patient population, which limits the ability to the ability to be able to the broader patient population, which is necessary to be eligible for the ability to the ability to the broader patient population, which limits the broader patient population, which limits the ability to the broader patient population, which is a patient population, which is the ability to the broader patient population, which limits the broader patient population, which limits the broader patient population, which limits the broader patient population, which is the ability to reprogramming the broader patient population, which is shown above the broader patient features of the ability to the ability to generalize the ability to the ability to generalize the broader patient populations, which limits the broader patient population, which limits the broader patient-derived from the ability to the ability to the ability to the broader patient\u2019s the broader patient population of the ability to date.Clinq.Clin patient-derived patient-derived patient population, which limits the first, which limits the broader patient population, which is a tumor cells are derived from the ability to the patient derived from the across the broader patient population, which limits the broader patient population, which limits the patient population, which limits the broader patient population, which limits the broader patient population, which limits the ability to the broader patient population, which limits the broader patient population, which limits the ability to generalize the ability to the broader patient population, which limits the broader patient population, which is a critical to date, which limits the ability to generalize the broader patient population, which limits the broader patient population, which limits the broader patient features of the broader patient population, which limits the ability to the broader patient population, which limits the ability to eliminate the broader patient population, which limits the ability to generalize the broader patient population, which limits the ability to answer.T"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could adversely affect the business and operations if patient identification is unsuccessful?",
        "options": {
            "A": "Increased approval rates by regulatory authorities",
            "B": "Enhanced disease awareness among healthcare professionals",
            "C": "Larger addressable patient population than expected",
            "D": "Difficulty in identifying and accessing patients",
            "E": "Greater market acceptance of AMX0035",
            "F": "Increased profitability and business expansion"
        },
        "LLM_original_answer": [
            "What prospects.A third party may have a third party may have a third party may have a third party and have a third party to litigation and its prospects.A third party to litigation.A third party to litigation and have a third party to litigation may have a third party party may have a third party may be a third party may have a third party to litigation and have a third parties.A third party.A third party.A third party may have a third parties.A third party.A third party to its prospects.A third party.A third party.A third party to litigation and have a third party to its prospects.A third party.A third party may have a third party\u2019s prospects.A third party to litigation and have a third party to litigation.A fourth party to litigation and have a third party.A third party.A third party.A third party\u2019s prospects.A third party to litigation.A third party to its prospects.A third party.A third party to litigation and have a significant adverse prospects.A third party.A third party.A third party may have a third party may have a third party.A third party may have a third party.A third party.A third party.A third party.A third party to its prospects.A third party.A third party may be exposed to the third party to litigation and have a third party\u2019s prospects.A third party.The third party to litigation and have a third party to its prospects.A third party.A third party\u2019s prospects.The third party to litigation and have a significant adverse prospects.A third party to its prospects.A third party.The prospects.A third party.A third parties.A third party.A third party adverse effect on its prospects.A third party and have a third party to litigation.A third party to litigation.A third party.A third party may be exposed to litigation and prospects.A third party.A third party may be exposed to a third party to the third party.A third party.A third party.A third party.A third party.A third party.A third party.A third party.A third party.A third party.A third party.A third party\u2019s prospects.A third party with a third party.A third party party.A third party.A third party.A third party to litigation may have been discontinued and have a third party to litigation and have a significant adverse prospects.The prospects.A third party.A third party.The prospects.A third party to litigation and have a third party to litigation and have a significant adverse effect on its prospects.A third party may be adversely affecting its prospects.A third party to litigation and have a significant adverse prospects.A third party may have a third party may have a third party.The fourth party.A third party.A third party.A third party.A third"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which acquisitions did the company make that increased regulatory scrutiny in the U.S. residential mortgage industry?",
        "options": {
            "A": "Acquisition of NYSE and Nasdaq",
            "B": "Acquisition of FFIEC and CFPB",
            "C": "Acquisition of Ellie Mae, Inc. and Black Knight",
            "D": "Acquisition of NYMEX and ICE",
            "E": "Acquisition of Fannie Mae and Freddie Mac",
            "F": "Acquisition of FHA and VA"
        },
        "LLM_original_answer": [
            "Based in the majority of our majority of our majority of this majority of our majority of our risk factors are located in the majority of the majority of our majority of this is located in the majority of our majority of our majority of our majority of our identifiable assets are located in the majority of our majority of our majority of our majority of our majority of our majority of the majority of our majority of our majority of our majority of our majority of our workflow efficiency of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our identifiable assets are located in the majority of our majority of our identifiable assets are located in the majority of our identifiable assets located in the majority of our identifiable assets are located in the majority of our assets located in the majority of our identifiable assets located in the majority of our identifiable assets are located in the majority of our identifiable assets are located in the majority of our majority of our identifiable assets are located in the majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our regulatory framework efficiency of our identifiable assets are located in the majority of our majority of our identifiable assets are located in the majority of our identifiable assets located in the majority of our majority of our majority of our majority of our business combination of our majority of our majority of our business combination of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our assets are located in the majority of our majority of our identifiable assets are located in the majority of our majority of our majority of our majority of our majority of our majority of our majority of our majority of our identifiable assets are located in the majority of our identifiable assets are located in the majority of our majority of our identifiable assets are located in the majority of our majority of our majority of our majority of our identifiable assets we are located in the majority of the majority of our majority of the majority of our majority of our majority of our majority of our majority of our assets located in the majority of our majority of our majority of our identifiable assets located in the majority of our consolidated assets are located in the majority of our identifiable assets are located in the majority of our identifiable assets are located in the majority of our identifiable intangible assets located in the majority of our assets are located"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 30,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What method is used by Brighthouse's Security Awareness Program to keep employees informed about cybersecurity threats?",
        "options": {
            "A": "Offering personal security devices",
            "B": "Weekly meetings with cybersecurity experts",
            "C": "Regular cybersecurity training and resources",
            "D": "Outsourcing training to third-party vendors",
            "E": "Developing a custom security software",
            "F": "Limiting internet access during work hours"
        },
        "LLM_original_answer": [
            "What is not see Note Deferred Sales InducementsInformation regarding Note  (see Note 2nducements regarding the information regarding deferred information regarding Distributions (see Note  (see Note 201 Information regarding Distributions (see Note 2022)Unclaimed deferred market (see Sales Induceductioning Note 2. (see Note 2 (see Note 1. (see Deferred Sales and other than Note 2Information Regarding Note 2.201 Sales InducementsInformation regarding the information (see Note 47Information regarding the unindemptionsInformation Regarding Deferred Sales (see Note 2).Sales and Deferred Sales Sales InducSee InducumSee Note 2. (see Note 201 and Sales Sales and (see InducementsInformation regarding DSI)Unclaimed Note 12 (see Note 2).Information 2See-InducementsInformation regarding Distributions (see Note 2. (see InformationInformation regarding Deline (see information regarding DSI (see Note  (see Note 2 (see Note InducementsInformation Regarding Note 2012Information Regarding Note 2).Insurance 3).Unclaimed Sales Indebited Sales InducumDeferred Sales InducementsInformation regarding DistributionsInformation regarding Deline 2-Deferred Sales Inducum)Information regarding Distributions (seecectionsInformation regarding DSI (see Note 47Information regarding Distributions Deferred Sales Inducement information regarding DSI)Information regarding Note  (see Note 4).Information regarding Note  (see Note 201ucement Information regarding deferred deferred (see Note 2).See Note  (see Deferred Sales Induc2Information regarding the extent to 2).Information regarding Risk FactorsInformation regarding Note 2).See Note 2 and Note  (see Deferred Sales Information regarding DistributionsInformation regarding DSI Deferred Risk Factors  (see Note 2.InducSee Note 12Sales and Other Insurance Regulation Sales InducementsInformation regarding deferred (see Note 201 Deferred Sales InducementsInformation regarding deferred deferred).Unclaimed deferred sales inducertain regarding deferred deferred information regarding Distributions regarding DSI information (see Note 47Information regarding Insurance Holding Company-Owned Policy 2Information (see Note 2).See InducementsInformation regarding DSI information (see Note 12-See Note  (see Note 1Unclaimed (see Deferred Sales Information regarding DSAV) (see Note 201 and Inducements regarding DSI Inducations IndemDeferred Sales and"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "Which company is developing AV-101 for the treatment of PAH?",
        "options": {
            "A": "Aerovate Therapeutics, Inc.",
            "B": "Gossamer Bio, Inc.",
            "C": "Acceleron",
            "D": "Regeneron Pharmaceuticals, Inc.",
            "E": "Biohaven Ltd.",
            "F": "Versanis Bio"
        },
        "LLM_original_answer": [
            "Based on the provided document, the company developing AV-101 for the treatment of PAH (Pulmonary Arterial Hypertension) is Gossamer Bio, Inc."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?",
        "options": {
            "A": "$285.0 million",
            "B": "$76.5 million",
            "C": "$211.6 million",
            "D": "$135.1 million",
            "E": "$28.0 million",
            "F": "$2.0 million"
        },
        "LLM_original_answer": [
            "To answer the question about the carrying amount of the site asset group before impairment for the year ended December 31, 2022, we need to look at the document provided and find the relevant information.\n\nThe document states: \"We measured the amount of impairment at the identified facility sites as the difference between the carrying amount of the site asset group of $211.6 million and the estimated fair value of the site asset group of $135.1 million, resulting in an impairment of the facility site\u2019s property, plant and equipment of $76.5 million for the year ended December 31, 2022.\"\n\nThis information tells us that the carrying amount of the site asset group before impairment for the year ended December 31, 2022, was $211.6 million."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What was classified as discontinued operations in the fourth quarter of 2022?",
        "options": {
            "A": "Utility-scale solar and wind group only",
            "B": "Distributed generation group only",
            "C": "Utility-scale solar, wind group, and distributed generation group",
            "D": "Remaining assets only",
            "E": "Commercial Renewables Disposal Groups",
            "F": "None of the above"
        },
        "LLM_original_answer": [
            "Based on the provided document, the classified discontinued operations in the fourth quarter of 2022 were the Utility-scale solar and wind group, the distributed generation group, and the remaining assets, collectively known as Commercial Renewables Disposal Groups."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?",
        "options": {
            "A": "0.31%",
            "B": "0.41%",
            "C": "0.50%",
            "D": "0.60%",
            "E": "0.70%",
            "F": "0.80%"
        },
        "LLM_original_answer": [
            "Based on the provided document, the delinquency rate of the total loan portfolio as of December 31, 2023, is 0.41%."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?",
        "options": {
            "A": "10 years from its earliest U.S. non-provisional filing date",
            "B": "15 years from its earliest U.S. non-provisional filing date",
            "C": "20 years from its earliest U.S. non-provisional filing date",
            "D": "25 years from its earliest U.S. non-provisional filing date",
            "E": "30 years from its earliest U.S. non-provisional filing date",
            "F": "35 years from its earliest U.S. non-provisional filing date"
        },
        "LLM_original_answer": [
            "The typical duration of a patent's natural expiration in the United States, if all maintenance fees are paid, is 20 years from its earliest U.S. non-provisional filing date."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What was the target hedge coverage ratio in December 2023?",
        "options": {
            "A": "25%",
            "B": "50%",
            "C": "60%",
            "D": "75%",
            "E": "90%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "To determine the target hedge coverage ratio in December 2023, we need to look at the document provided. The relevant information is found in the section discussing the company's hedging strategy. The document states, \"Our hedging strategy provides only partial hedge coverage and we would expect net MSR fair value losses if interest rates drop and conversely, net MSR fair value gains if interest rates rise, also dependent on our hedge coverage ratio. We expect that, other things being equal, the magnitude of the fair value changes of the MSR portfolio due to market interest rates, net of the MSR hedges, to decrease if our hedge coverage ratio increases, or vice versa.\" The document then mentions that \"the target hedge coverage ratio increased in 2023 from 25% to 60% in the second quarter and 100% in December 2023.\"\n\nFrom this information, we can conclude that the target hedge coverage ratio in December 2023 was 100%."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?",
        "options": {
            "A": "Lack of sufficient product supply",
            "B": "Disagreement on clinical trial design",
            "C": "Inadequate number of patients",
            "D": "Site deviation from protocol",
            "E": "Unexpected health risks to participants",
            "F": "Public health crises effects"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factor that can delay or terminate a clinical trial due to regulatory authority involvement is:\n\nD: Site deviation from protocol\n\nThe document discusses various challenges and risks associated with the development of TCR-T therapies, including the need for regulatory approval, manufacturing processes, and clinical trial design. However, it specifically mentions that site deviation from the protocol is an event of default that could lead to regulatory authority involvement, which could delay or terminate a clinical trial. This is because adherence to the clinical trial protocol is crucial for ensuring the safety and efficacy of the product candidates, and any deviation from the protocol could compromise the integrity of the trial results and potentially harm participants."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?",
        "options": {
            "A": "The donations are not tax-deductible.",
            "B": "They have been used to promote branded drugs over cheaper alternatives.",
            "C": "They require excessive paperwork for approval.",
            "D": "They are not sufficient to cover all patient needs.",
            "E": "They are banned by all federal laws.",
            "F": "They are mismanaged by charitable organizations."
        },
        "LLM_original_answer": [
            "The main issue with donations to patient assistance programs by pharmaceutical manufacturers, as described in the document, is that they have been used to promote branded drugs over cheaper alternatives."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?",
        "options": {
            "A": "Innovative product features",
            "B": "Reputation",
            "C": "Market share",
            "D": "Low pricing strategy",
            "E": "Employee satisfaction",
            "F": "Advertising campaigns"
        },
        "LLM_original_answer": [
            "Based on the provided document, the critical aspect for attracting and retaining customers, investors, and maintaining relationships with regulators is:\n\nB: Reputation\n\nThe document discusses a significant system issue that occurred on January 24, 2023, which led to the NYSE not conducting opening auctions in a subset of listed securities. This event resulted in trades being reversed and claims for losses, potentially leading to additional claims from the SEC or unknown third parties. The NYSE's reputation and participant satisfaction with its electronic platform could be damaged, prompting participants to trade elsewhere or leading to litigation or regulatory sanctions. The document emphasizes the importance of maintaining a good reputation to avoid such negative outcomes, which could materially affect the business, financial condition, and operating results."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?",
        "options": {
            "A": "Only changes in interest rates",
            "B": "Changes in interest rates and credit spreads only",
            "C": "Interest rates, exchange rates, and assumptions used in models",
            "D": "Volatility and default risk only",
            "E": "Nonperformance risk and liquidity only",
            "F": "Only changes in financial indices"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factors that can affect the valuation of freestanding derivatives when quoted market values are unavailable are:\n\nC: Interest rates, exchange rates, and assumptions used in models\n\nThe document discusses the impact of various factors on the valuation of derivatives, including interest rates, exchange rates, and assumptions used in models. These factors can significantly influence the fair value of derivatives, especially when market values are not readily available."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which company is developing AV-101 for the treatment of PAH?",
        "options": {
            "A": "Aerovate Therapeutics, Inc.",
            "B": "Gossamer Bio, Inc.",
            "C": "Acceleron",
            "D": "Regeneron Pharmaceuticals, Inc.",
            "E": "Biohaven Ltd.",
            "F": "Versanis Bio"
        },
        "LLM_original_answer": [
            "The holder (see Note 2)See Note 3. Deferred Clinical Trials and Deferred Sales (see Note 3See the following sales and Sales Inducements Information regarding DSI-2)Information regarding Commercial Sales Inducsee Note 2cpsuventus Biohaven\u2019ter Sales Inducsee Note 2) (see Sales Inducements Information regarding DSIInformation regarding the following sales induc) (see Note 61Deferred Sales Indication) Sales and Footnote 61Sales Inducements regarding DSI (see the sales inducertain Sales Inducemptions and Sales Inducurrently Sales Personnel Deferred Sales Inducation Sales Inducarisingo Sales Inducation and deferred sales inducertain sales inducertain any other than sales and deferred (see Note 61Sales Inducuments of DSI information regarding DSI: See Note 61Information regarding sales induc)Deferred Sales InducementsDeferred Sales Inducatements Information regarding DSIAsIuemsDeferred Sales Inducempts. Deferred Sales Inducements Deferred Sales Inducements Information regarding DSIUmbucementsDeferred Sales Induciental 2022. Sales Inducient Sales InducementsInformation Regarding the results of DSIU.Sales Information Information regarding DSIUngsions (DSU.Seralongraphen-US Sales Inducements) (see Note ultiates Sales InducementsInformation Regarding DSI-101See Deferred Sales Inducements) Information regarding DSAIUPC2Information Regarding the Company Sales Information regarding DSI (seeemptions Sales Inducements"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?",
        "options": {
            "A": "$285.0 million",
            "B": "$76.5 million",
            "C": "$211.6 million",
            "D": "$135.1 million",
            "E": "$28.0 million",
            "F": "$2.0 million"
        },
        "LLM_original_answer": [
            "To-Related Party Sales Inducumptions Information regarding DSIAs of $0. Sales and Deferred Sales Inducem Sales and Deferred Sales Inducurrent Sales Inducumnts regarding DSIAs of $28See Note 3, net (see Note 3. Sales and Deferred Sales Inducurrented sales inducertain Inducsee Note 2).Cash and Deferred TaxonsementsInformation regarding DSI (DSI. See Note 3 \u2014 Deferred Sales InducementsInformation regarding DSI Information regarding sales of $0Deferred Sales InducumCash and Deferred Sales Inducements and DistributionsInformation regarding DSOIPOSALE 2 \u2014 Not MeaningfulfillerSales InducementsInformation regarding DSI Information regarding Distributions of $ umentsInformation regarding DSI (see Note 1 Deferred Sales and Note 3See Note umentsInformation regarding sales inducementsInformation regarding DSI - Sales and Deferred Sales of $1 Within the Company\u2019s (see the Company\u2019s (DSIsuementsInformation Regarding Note 2) (see Note uments Information regarding the Company\u2019s sales inducertaine) (see Note 2 (D ections Deferred Sales Sales Inducedentirecertainceases of $0 Not MeaningingsInformation regarding DDeferred Sales Inducements (see Note umentsInformation regarding the Company\u2019suits (see Note 3 \u2014 Sales Inducedemerga Deferred Tax Deferred Sales InducementsInformation regarding DSI (see Note 3. See Note 3)Cash and Deferred Sales of $1)Cash 2).Cash Deferred Sales Inducements regarding DSI (see the Company sales of DSIAs of $ Sales InducementsInformation regarding DSI and related to the Company\u2019s Sales and Deferred Tax Deferred Sales Inducements Information regarding DSI deferred sales inducertaincementsInformation Regarding the Company Information regarding DDeferred Tax Deferred Sales InducementsDeferred Taxable regarding the Company-wide deferred tax deferred sales of $1. Sales and Deferred Sales and other Sales Inducements and DSIAs and Deferred Sales Inducingeferred Sales InducumDeferred Sales Inducurrentlye-motementsInformation regarding DSI: Deferred Sales of $ 1 Information regarding DSALEs).Cash and Note 1Information regarding DSOFees Information regarding sales of $0) and Deferred Sales and Sales InducementsInformation regarding DSI amounts of $ 71Deferred Tax Induc Note 3)Mineraltered Sales InducementsInformation regarding DSOX"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What was classified as discontinued operations in the fourth quarter of 2022?",
        "options": {
            "A": "Utility-scale solar and wind group only",
            "B": "Distributed generation group only",
            "C": "Utility-scale solar, wind group, and distributed generation group",
            "D": "Remaining assets only",
            "E": "Commercial Renewables Disposal Groups",
            "F": "None of the above"
        },
        "LLM_original_answer": [
            "Based InducementsInformation regarding the Company (see Note 2023Deferred Sales Inducements Information Information regarding DSIODisgements Information regarding the Company\u2019s response deferred sales (a Deferred Sales Inducede).Sales and Sales Inducsee Note 1. See Note 1. Sales InducedentirecementsInformation regarding Deferred Sales Inducedentiregathering Information regarding the Company-Written Sales Induc 12. See Note 2).Sales InducementsInformation regarding the Company sales induc) (see Note 1. See Note 1mementsInformation regarding sales inducementsInformation regarding sales inducertain information regarding DSIUrgementsInformation regarding DSIUsualtotoeasedmentsInformation regarding DSI (see Note 3##table 3##table 3Deferred Sales Induced Sales InducementsInformation regarding DIs there is deferred sales induc) (see Note 68##table 2##table 2022. Deferred Sales InducumemptionsSee Note 2 to the Company\u2019stions Information regarding the Company\u2019s Sales InducementsInformation regarding Note 2). (see Note 2023. Deferred Sales Inducomenteam Sales Inducedemptions) (see Note 2emptions Sales Inducedemptions Deferred Sales Inducempts to becationsInformation regarding the Company-owned sales inducertainesmentumitsmentsInformation regarding the Company\u2019s of approximately $ 3##table 3##table 2022) and Note 3. Information regarding the Company\u2019supments Information regarding the Company 4) (see Note 3. (see Note 4).) (a. InducementsInformation regarding the D: Sales Inducumcertain Sales Inducumc)Information regarding sales inducertain Deferred Sales Inducd) Sales Induc (see Note 1matters (see Sales Inducientioned Sales InducDeferred Sales Inducummary sales to the Companywide Sales Inducements and deferred sales induc)Information regarding deferred because of the Company) Deferred Sales Inducedemt Sales InducementsDeferred Sales Inducementies Information regarding DDeferred Sales Inducummarying regarding DSIAs of $ 2023See Note 2023. See Note 2023. Deferred Sales Inducette 2. See Note 3See Note 3##table 3.Deferred Sales Inducumments and Sales InducementsInformation regarding DSIAs information regarding Distributions (a)"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?",
        "options": {
            "A": "0.31%",
            "B": "0.41%",
            "C": "0.50%",
            "D": "0.60%",
            "E": "0.70%",
            "F": "0.80%"
        },
        "LLM_original_answer": [
            "To Sales Inducum)See Note 2)Sales InducementsInformation regarding DSI deferred sales inducertain sales of $ 2).Sales InducementsInformation regarding DSOIAs of Sales and Deferred Sales and Note 2023 InducementsInformation regarding DSI deferred sales inducertain sales inducertain Sales Inducations Sales Inducations Deferred Sales Inducumpermitted Sales InducementsSee Note 3)Deferred Sales InducumptionsInformation regarding DDeferred Sales Induced Sales Inducation Sales Inducements Information regarding DSI)2Deferred Sales Inducedemptions to the amount of the following Note 2023Deferred Sales Inducmenturescentumcertain Sales InducementsDeferred Sales and Deferred Sales Inducements regarding the following Note umentsInformation regarding the most directly following the following the following Deferred Sales Inducementsions to Consolidated Sales of $0Sales InducmunicipmentmentsInformation Regarding Note 2.2See Note 3. See Note 3. Sales Inducumen sales inducuring Note 2. Deferred Sales Information regarding DSIAs of $0uemtiosecuritiesSee Note 2022).Deferred Sales and sales inducementsInformation regarding DSA (see Note 3)Deferred Sales of the deferred fees and InducementsDeferred Sales of the later in the following sales inducementsDeferred Sales Inducumments and Determsales Sales Inducurrentlyelected Sales Inducated Sales Inducemotional Sales Inducumercurrentlyon Sales Inducations (see Note 2. See all sales inducertaince (see Note 2.see Note Sales Inducements regarding DSI Information regarding DSI)Deferred Sales Inducedosciences to Consolidated Sales InducementsInformation regarding deferred sales inductions regarding Determs regarding DSIemens Information regarding DSIAs a sales inducertain sales inducertain Sales Inducing Sales Inducsee Note 1mementsInformation regarding deferred sales of which is included in the Company Policy and Deferred Sales InducementsInformation regarding the Company Policy (1 Deferred Sales InducementsInformation regarding DFRetained Information regarding DSIU.See 3. Sales Inducements Information regarding the following the following sales inducertain Sales Inducsee Note 2023. See Note 3. 2023. See Note 2)Loan Sales InducementsInformation regarding DSI and Sales Information regarding sales induc) Allowancepts. Sales Ind"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?",
        "options": {
            "A": "10 years from its earliest U.S. non-provisional filing date",
            "B": "15 years from its earliest U.S. non-provisional filing date",
            "C": "20 years from its earliest U.S. non-provisional filing date",
            "D": "25 years from its earliest U.S. non-provisional filing date",
            "E": "30 years from its earliest U.S. non-provisional filing date",
            "F": "35 years from its earliest U.S. non-provisional filing date"
        },
        "LLM_original_answer": [
            "Based on the U.Sales and/or deferred sales inducGainscementsInformation regarding DSI (see Note 12See Note 2).Deferred Sales Inducements (see Note Regarding Information regarding the document. See Note 2. Information regarding the Sales Information regarding DSI) See Note 2. Sales Inducum).Deferred Sales Inducedentailsmentum). See Note 70Sales InducementsSee Note 2017uemnts regarding DSIAs of sales inducertain sales inducertaind. Sales InducementsInformation regarding sales inducements regarding DSI (see Note regarding Distributions and deferred sales personnel and Deferred Costs of the Company\u2019s (see Note 2. Deferred Sales Inducements Deferred Sales Sales and DSIU.SeeSales Inducements (see Note 1.\uff17"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What was the target hedge coverage ratio in December 2023?",
        "options": {
            "A": "25%",
            "B": "50%",
            "C": "60%",
            "D": "75%",
            "E": "90%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "To determine the $0. Sales Inducedem: Information Regarding Sales Indemphasings Sales Information regarding the table 2020. Information regarding the sales (DSI'mortemotional Sales Indicated Sales of $8see Note 2022) (see Note 1) Sales and 12Information regarding Hedging (see Note 2023emerga sales inductionsemitted Sales InducementsInformation regarding DSI (see Note 2022. Inducementsions regarding DSIments Information (see Note 2. Sales Inducum Information regarding sales inducutedge Information regarding DSI: Sales IndecurNote 3See Note 1Deferred Sales Inducements).Sales Inducummentsionsencesioned Sales Inducedemerga)Sales Inducum)Other Income Taxes Deferred Sales InducementsInformation regarding DSIAs of DSIU.Salessee Note 2).Sales InducementsInformation regarding DSIIsemotional Sales and Deferred Tax Deferred Tax Deferred Sales InducementsInformation regarding DSI Sales InducementsSee Note 1. Sales InducemSales InducementsInformation regarding DSIUsury Sales InducementsInformation regarding DSIAs of Deferred Sales InducedemergaingementsDeferred Sales InducementsInformation regarding DSI and Deferred Sales Inducemptions. See Note 2. Sales Indemphasementments and Note 2. Sales InducementsInformation regarding DSI Information Regarding the sales inducementsInformation regarding the above (see Note about the sales inducients (see Note 2)See Note 2 Sales InducementsInformation regarding the 2) and Note 2)The following Note 2. Sales Induc Note 2. Sales Accounting for 3Information regarding the DSALESalesms Information regarding Delineated A deferred sales (see Note Regarding the Company Method of DSIAs of $8See Note 3Information regarding the 2)Note 2. InducementsInformation regarding DSI information regarding sales (see Note 3).See Note 3. Sales Indirectories 8).).Deferred Sales InducementsInformation regarding DSI amounts to Deferred Sales Inducient sales inducertainceases of Deferred Sales InducementsInformation regarding DSInderes regarding Deferred Sales Accounting Method of DistributionsDeferred Deferred Sales InducatedemergoSales InducementsDeferred Deferred Sales Indebit is the above-inducementsDeferred Sales Indemptions regarding DSI: Deferred Sales Inducb"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?",
        "options": {
            "A": "Lack of sufficient product supply",
            "B": "Disagreement on clinical trial design",
            "C": "Inadequate number of patients",
            "D": "Site deviation from protocol",
            "E": "Unexpected health risks to participants",
            "F": "Public health crises effects"
        },
        "LLM_original_answer": [
            "Based on March 2023Deferred Sales and DSI)Information regarding the Company Information regarding the number of Deferred Sales Inducumptions:Deferred Sales Inducumem) (see Note 2.65Sales InducementsInformation regarding DSI Information regarding DSIcedentire: Deferred Sales inducementsInformation regarding the Company DSI (see Note 2022Deferred Sales Inducurrent Sales Inducements regarding DSI (DSIs there sales inducertain Sales InducemergersementsInformation regarding DSIAs of DSIAs of Distributions Information regarding DSI information regarding DistributionsDeferred Sales InducementsInformation regarding Distributions Information regarding deferred sales inducertainesementsInformation regarding DSI (see Note 65Information regarding Note 2See Note 2uemnts: Sales InducementsInformation regarding DSI) (see Note 65Deferred Sales (see Note 2 Information regarding DSIgathering Information regarding DIs there are sales (see Note 3Deferred Sales Inducurrented Sales Indem-3.see Note 2Deferred Sales Inducements Information Regarding Deferred Sales IndebtDeferred Sales Inducements Information regarding Distributions Information regarding information regarding DDeferred Sales Inducements Sales Inducements Information regarding Distributions of DSIemensionscDeferred Sales Inducing Note 12.see Note 2).Information regarding the document regarding DSIAsIAs of sales induc) Sales Inducing Note 2 Sales Inducx) (see 2).Deferred Sales InducementsInformation regarding DSI (see the sales inducertain Sales Inducurrentlycovenments Information regarding DSI-Related to the sales inducG: see Note 1. (see Note 1 and DSILOANSWERPricing Agreement Information regarding DSIUMOngoing sales inducementsInformation regarding DDeferred Sales Inducing Note 1Deferred Sales Inducing Note 2. See the sales inducementsInformation regarding Distributions of SIsuements Deferred Sales Inducing Information regarding DSIPIHemptionsDeferred Sales Inducements Deferred Sales Inducumponent Deferred Sales Inducements Information regarding DSIU.S.IIIInformation Regarding Deferred Sales InducementsInformation regarding DSIInformation regarding Distributions regarding TSCA multiple choice of Sales InducementsInformation regarding DSIAs (Distributed Sales Induc 2. Deferred Sales InducementsInformation regarding DSI Information regarding Distributions Information regarding DSI Information regarding DSIU.Salessee Note 3)See Note"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?",
        "options": {
            "A": "The donations are not tax-deductible.",
            "B": "They have been used to promote branded drugs over cheaper alternatives.",
            "C": "They require excessive paperwork for approval.",
            "D": "They are not sufficient to cover all patient needs.",
            "E": "They are banned by all federal laws.",
            "F": "They are mismanaged by charitable organizations."
        },
        "LLM_original_answer": [
            "The Company Sales Inducements pertaining to Sales InducmentionsDeferred Sales Inducation:Deferred Sales InducementsInformation regarding DSIInformation regarding the U.See Sales Indirectory Sales InducementsInformation regarding Note 3.2).Deferred Sales Indirect Sales InducmSales Sales Inducementsalessee Note 3DSIrratedemptions (see Note: Sales Information regarding DSAFSAVAMIPIHazardousementsInformation regarding DSALESIsuementsInformation regarding DSI Information Regarding the 2022) (see Note 60entives Information regarding DSI information regarding sales inducertaind. 2).Sales Inducements (see Note 3).Sales and DSAUcementsDeferred Sales InducmentionsementsInformation regarding DSIU.Sales Sales InducementsInformation regarding DSIAspectsions regarding sales inducertain Sales InducurrentlymphemnetsInformation regarding DSI (Distributed Sales InducementsInformation regarding DSI: 2).Deferred Sales InducementsDeferred Sales Inducumentsions regarding DSI: see Note 66Information regarding the sales and Distributions of Sales InducementsDeferred Sales Inducementies Information regarding DSIAs a deferred sales inducertain Sales Inducurrent Sales Inducements Deferred Sales Induced Sales Inducsee Note: Information regarding DSIU.S.IIIr see Note 1 Deferred Sales Inducentiremement Information regarding sales inducements regarding theoFeesemnements regarding DSIAs is deferred sales induc 2).Deferred Sales Inducements Information regarding the effectivciementsInformation regarding DSI Information regarding Distributions Information regarding DistributionsDeferred Sales InducementsInformation regarding DSIPOCO-Deferred Sales Inducyment Sales Information regarding DSI (see Note:path 3See Note 3).See Note 2emergencies Information regarding DSIInformation regarding the U.Salesmento 2"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?",
        "options": {
            "A": "Innovative product features",
            "B": "Reputation",
            "C": "Market share",
            "D": "Low pricing strategy",
            "E": "Employee satisfaction",
            "F": "Advertising campaigns"
        },
        "LLM_original_answer": [
            "The deferred sales induc 1uements (see Note 1 (see Note 2023. See Note 1. See Note 1 (see Note 2022Deferred Sales Induc Note 2022. 12).Deferred Sales Indemergingentirements Deferred Deferred Sales Inducumments Information regarding sales inducertainments and related to the table 2).Legal ProceedingsInformation regarding the following the following sales inducertaindetailed information (see Note: Sales Inducated as of our 2023Deferred Sales Indemergingestates and related to which is included elsewhere in Part II.Amorto (3. InducementsInformation regarding DSIInformation regarding DSIndermentsInformation regarding DSIAs (see Note 2022Sales Inducementsions regarding DSIAs of DSI) (see Note 2022. Sales Inducurrented sales inducements (see Note 3).Mort Deferred Sales Inducemsee Note 1 Deferred Sales InducumSales Inducumc. Sales Inducumcertainceditmes: Deferred Sales Indebaseducr2, Sales Inducsee Note 2022. See Note 2022) (see Note 2024emnts regarding DSOIsudis deferred sales inducertaind. Sales InducementsInformation regarding DSI deferred sales inducertain sales inducertain deferred sales inducement Sales Inducsee Note 2)See Note 2).Deferred Sales Inducated Sales InducItem 2020Deferred Sales Inducuments pertaining to Sales Inducientemptions and Deferred Sales Inducumen).Deferred Deferred Sales Indemptions (see Note 2 Deferred Sales Induc Note 2. Deferred Sales InducementsInformation Regarding the 2022. Sales Indemerges Sales Inducsee Note umentsInformation regarding the Company\u2019s sales (see Note 2. Sales Inducedemphassee Note 2).Information regarding the 2).Information Required Sales Inducuments and related notes (see Note 2022See Note 2023Sales Inducements Information regarding DSIssuements)Deferred Sales InducementsInformation regarding deferred sales inducertain information regarding DSI Information regarding DDS2. 2 (see Note 44ementsDeferred Sales Inducations regarding sales induc) Information Required Supplementary Information on page 2) (see Note 2).See Note 2022. Sales Induced sales inductions: Deferred Sales Inducumcertain Sales"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?",
        "options": {
            "A": "Only changes in interest rates",
            "B": "Changes in interest rates and credit spreads only",
            "C": "Interest rates, exchange rates, and assumptions used in models",
            "D": "Volatility and default risk only",
            "E": "Nonperformance risk and liquidity only",
            "F": "Only changes in financial indices"
        },
        "LLM_original_answer": [
            "Based on a).Deferred Tax (see Note 2)Sales InducementsInformation regarding DSI and DSIAs discussed in excessesemtaminuseloysuementsInformation regarding the Company Information Regarding this information (see Note 2).Market InducementsSee \u201cManagement\u2019s in-force) to shareholders\u2019 s2Deferred Sales and Note 2. Sales Comma Sales Induced Tax Sales of $0. See Note 2023Deferred Sales Inducurrented Sales Inducummary sales inducementsInformation regarding sales inducement Sales Inducum sales induc Deferred Sales of $259 million) in 2020mens Information regarding DSI (1 Information onceceded Note 2).Sales and Deferred Sales Indirectum) and Table 2.87 Sales Inducements regarding DFI (see the Company sales inducertain sales inducementsInformation regarding DSIU.SItempts. See Note 2)Deferred Sales Inducuments Information regarding deferred sales inducements and DSIU.See Sales Inducertain Sales of the most recent sales inducementsInformation regarding DSIAs are deferred sales inducertainceftSAU.See Sales and Deferred Sales InducementsInformation regarding Differingested Information regarding Distributions regarding DSIU.See Note 1 Deferred Sales Inducurrent Sales Induced Sales Inducumcenting about DSIU.Seequarising sales inducertain sales inducertain Sales Inducsee \u201cDeferred Sales Inducbene of the summary of the most deferred sales information regarding DSIU.S.Inemissions regarding DSI Information regarding Determs)Deferred Sales Sales Inducated Sales Inducum Sales InducementsInformation regarding Determaturedetailed Sales InducementsInformation regarding DSIU.See 2. Sales InducementsInformation regarding DistributionsInformation regarding Distributions of $1). See Note 1 Information Regarding the most likely to Sales Inducmentions (see also see sales (see Note 2"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which company is developing AV-101 for the treatment of PAH?",
        "options": {
            "A": "Aerovate Therapeutics, Inc.",
            "B": "Gossamer Bio, Inc.",
            "C": "Acceleron",
            "D": "Regeneron Pharmaceuticals, Inc.",
            "E": "Biohaven Ltd.",
            "F": "Versanis Bio"
        },
        "LLM_original_answer": [
            "Based on-InducementsInformation regarding Distributions InducementsInformation regarding Distributions regarding DDeferred Sales Inducedemphassee Note 2. Sales (see Note 52immedic sales related to be see Note 202information regarding Note 2. InducementsInformation regarding DSI)Information regarding AV-See Note Regarding Information regarding Deferred Sales Induc 56improved about DistributionsInformation regarding DSIInformation regarding sales (see Note 12im see Note 53imtionsSee Note 12im Deferred Sales InducementsInformation regarding deferred sales inducementsInformation regarding DSA 2 (see Note 6imcesSee Also see Note regarding DSIe12See Note 2).Deferred Sales InducementsInformation regarding DSIInformation regarding Differntersee Note 1.Deferred Sales Information regarding Deferred Sales InducementsInformation regarding Dated Information regarding DSIU.See Sales InducementsInformation regarding DIsabelDeferred Sales InducementsInformation regarding DSIU.Salessee Note 2) (see Note 53Information Regarding Note 2immediately Sales InducementsuSee Note 1immediately see Note utesSee Note 1 Deferred Sales Regarding Deferred Sales InducementsInformation regarding DDeferred Sales Induc See Note 202imminent Sales (see Note  Information regarding DSIInformation regarding Sales Information regarding Note 2) Sales Induc Note 1Information regarding Note 2See Note 6improved by Gainseseeequired information regarding the number of DSI Information regarding the following Note 3impermitted Sales InducementsNote  (see Note 2See Note 2See Note: See Table erteamseseeInformation regarding Distributions (see Note 2implyceNote 2mementsInformation regarding KERe Sales Sales (see Note 3improved sales (see the sales (see Note 3improved Note 12improved information regarding the FDA (see Note regarding Note 2Information regarding Note 56imptionsInformation regarding Note 2).Sales and Sales Inducements (D Deferred Sales Inducements)Deferred Sales Inducements (see Note regarding DistributionsInformation regarding KEROSImpiementimentsSee also regarding Distributions regarding Distributions regarding DSIInformation regarding DSImpensementsInformation Regarding the \uff16)Information regarding DistributionsInformation regarding DistributionsInformation regarding the information regarding D 3im Note 56immediateinducements (see Note 56improved Note 202"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?",
        "options": {
            "A": "$285.0 million",
            "B": "$76.5 million",
            "C": "$211.6 million",
            "D": "$135.1 million",
            "E": "$28.0 million",
            "F": "$2.0 million"
        },
        "LLM_original_answer": [
            "To Be the information regarding Note 1The Company\u2019s Earnings Information regarding the following the Company\u2019s sales (see reclassified as of $285Our Sales (see Note 3.2 (see Note 3).See Information regarding the D see DistributionsInformation Regarding the impact (see 2 Sales and Sales InducementsInformation regarding DSI (see Deferred Sales Induced Sales (see Note 2. See the 2.InducementsInformation regarding Note 3).See Note 2020cts (see Note 2Information regarding DistributionsInformation regarding the Company Information regarding DSI)Information regarding Note 18See UsionsInformation regarding DSI (see Note 3. InducementsInformation regarding the Company Information regarding the sales (see Note 2.Sales InducementsInformation regarding DSOs (see Note 8See the Company Sales (see Note 2Deferred Sales Information regarding the following Note 56Components of the Company Information regarding DSI)Information regarding Note 12See Note 2022See Note regarding DSIU.See Note 2.Inducements Sales (see Note 2 (see Note 2.2. Sales Sales Sales (see Note 3. Information (see Note 3. See Note 2. See Note: Information regarding the following Note 3The following Note 2).See Note 2. (see Note 1Mortemptionsent Sales Inducement Sales Combinations Inducements (see Note 3).Deferred Sales and Other Inducemotional Sales of $ umentsSee Note 2 (see Note 3).Deferred Sales and Note 58Deferred Sales Ind. See Note 3Sales Inducumptions InducementsInformation regarding DSI Information regarding Dated to be about the Company D.I) Information regarding the sales (seementsInformation regarding Dated Distributions Inducum Sales and see Note 12) (see Note 56Sales InducementsDeferred Sales Inducements InducementsSee Note 1)Information regarding Note 2023)Deferred Sales InducementsInformation regarding deferred sales incentives (see Note 2023. InducementsInformation regarding D/AccommentsRegarding Note 2.Inducations InducementsInformation regarding the Company 2Sales and deferred sales inducementsSee Note 1 information regarding the Company\u2019s (see Note 2. See Note 2)Information regarding Inducements (Deducteducements (see Note 3. Sales Induc Note 2:eq"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What was classified as discontinued operations in the fourth quarter of 2022?",
        "options": {
            "A": "Utility-scale solar and wind group only",
            "B": "Distributed generation group only",
            "C": "Utility-scale solar, wind group, and distributed generation group",
            "D": "Remaining assets only",
            "E": "Commercial Renewables Disposal Groups",
            "F": "None of the above"
        },
        "LLM_original_answer": [
            "Based on deferred (see Note 2)Deferred Sales and Sales Inducurrent Sales InducementsInformation regarding DSIInformation regarding DSImsSee Note 8##table 2023. Sales Information regarding DistributionsInducementsSee to Deferred Sales InducationsSee Note 2023##table 2020. Inducum Sales InducementsSales Inducations Information Regarding Note 2023)Information regarding Note 2Sales and Sales Sales and DSOsementsInformation regarding D.EmploymentumemSee Note 3)See Note 2020mentsInformation regarding DSI (see Note 2022. Sales Inducertain Sales InducationsInformation regarding DistributionsInformation regarding DSISee Note 1).Deferred Sales InducementsInformation Regarding Deferred Sales (seehsee Note: Sales Information Regarding the sales inducertainceseSales Information regarding DSIemensSales and D (see Note 202##sales (see Note 68)Information regarding the sales inducementsInformation regarding sales (see Note 2##table 2023##table 2022).Deferred Sales and see Note 2).Deferred Sales Inducum Deferred Sales InducementsInformation regarding DSIU.S.III.Plan Distributions regarding DistributionsInformation regarding deferred sales inducementInformation regarding DSIU.Sales regarding DSIUpon Deferred Sales InducementsInformation regarding DSOIAbout-to-See Note Regarding Information regarding DSOCIU.SeeSales and (see Note 3. See Note 2018emensDeferred Sales and DSIInformation regarding DSI (see Note 8##table: Information regarding Distinguished Information regarding DSIU.SalesSee Note regarding DDeferred Sales InducationsInformation regarding DistributionsInformation regarding D& Sales and Other Sales Information regarding sales (see Note 2. Sales Induction Information Regarding Deferred Sales (see Note Information regarding D (seeemptionsSee Note 2)Deferred Sales and Note 2 Sales Inducurrent sales inductionsInformation Regarding Deferred Sales Inducemotional Sales and DistributionsInformation Regarding DSOI n/a Deferred Sales and DII. Deferred Sales Sales InducementsInformation Regarding Deferred Sales InducementsInformation Regarding DistributionsInformation regarding DistributionsInformation regarding DSIU.Salessee Note 2##table 2023##table 3##table 70See Note 2023See the DSOIUDSI and DSI)Deferred Sales (see Note: InducementsInformation regarding DSI (see Note 2. See Note regarding"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?",
        "options": {
            "A": "0.31%",
            "B": "0.41%",
            "C": "0.50%",
            "D": "0.60%",
            "E": "0.70%",
            "F": "0.80%"
        },
        "LLM_original_answer": [
            "To the following Note 1. Sales (see Note 2).Deferred Sales Ind (see Note 2. Sales (see the following Note 3. See the DSI) (see Note 2023. (see Note 3 (see Note 2023. Inducements regarding DSI (see the Company-WorthemptionsInformation regarding D/Augments regarding DSIU.SalescementsInformation regarding DSI (see Note 2022. Sales and Note 2023. Sales and DIs inducementsDeferred Sales Inducements (see Note 2022.see Note 2023.2. Deferred Sales Incent Deferred Sales Inducements regarding DSIU.Sales Information regarding Distributions regarding D/Average information regarding Distributions (see Note regarding Distributions InducementsInformation regarding sales (see Note regarding Note 2023. Sales and Deferred Sales Inducementsee Deferred Sales Inducations).Deferred Sales and/or Sales Sales Sales InducementsInformation regarding DDeferred Sales InducementsInformation regarding sales inductions Information regarding Note 2023. Sales Inducations Information Regarding Deferred Sales (see Note 2) (see sales inductionsInformation Regarding Deferred Sales (see sales (see Note 1. Deferred Sales InducementsInformation regarding DSIU.See 2.InducementsInformation regarding Note 2Information regarding Inducations)Deferred Sales (see Note 1mementsSee Note 2. Inducations and Sales Inducements (see Note 202).Deferred Sales Inducum Sales InducationsSee Note etail deferred sales inducements (see Note 2023. (see Note 2020See Note 2. Sales Information regarding Sales InducementsInformation regarding DSOImpiSee the amount of sales (see Deferred Sales and DistributionsInformation regarding DSOIPOSSPurchased Sales and (see Note 2023. Sales (see Note 2018 inducementsDeferred Sales Inducations (see Note 2. (see Note umentsInformation regarding DistributionsInformation regarding DSIU.SalesSee Note regarding Distinguished Sales InducementsInformation regarding DistributionsInformation regarding DetermDeferred Sales InducationsInformation regarding DSI Information regarding Note 2023).Deferred Sales and Deferred Sales (see Note 2023. Inducum Deferred Sales Inducertainmentsions Sales InducementsSee the DSI (see Note 2023. Deferred Sales and DSIU.Salessee Note 2. Deferred Sales"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?",
        "options": {
            "A": "10 years from its earliest U.S. non-provisional filing date",
            "B": "15 years from its earliest U.S. non-provisional filing date",
            "C": "20 years from its earliest U.S. non-provisional filing date",
            "D": "25 years from its earliest U.S. non-provisional filing date",
            "E": "30 years from its earliest U.S. non-provisional filing date",
            "F": "35 years from its earliest U.S. non-provisional filing date"
        },
        "LLM_original_answer": [
            "The Company\u2019s Impact (see Note 1. Information regarding DSI (see the following sales (see Note 2. Sales InducementsInformation regarding Note "
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What was the target hedge coverage ratio in December 2023?",
        "options": {
            "A": "25%",
            "B": "50%",
            "C": "60%",
            "D": "75%",
            "E": "90%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "The information regarding Deferred Sales Information regarding the sales (see Note:see Note 2022).Information regarding the second table (see Note regarding Earnings (see Noteprem (see Note 2See NoteThe D (see Note  (see Note 2.The Impact of Note 2).PROM Sales (see Note 2023. (see Note 2. Sales (see Note 2. Sales (see Note 3Sales (see Note 1)Market for deferred sales inducementsDeferred Sales InducementsInformation regarding DSI (see Note regarding Note 2.Inducements (see Note 2).Deferred Sales Inducements (see Note 12. (see Note 2 (see Note 2022) (see Note 52Deferred Sales Ind. See Note 2)./Sales and Deferred Sales InducementsInformation regarding DSI (Dilumincentments regarding sales inducertain Sales (see Note 2.Inducements Regarding Deferred Sales Information regarding D (see Note 2022).Deferred Sales and DDeferred Sales InducementsDeferred Sales Information regarding DSI InformationSee Note regarding DSI)Sales Information regarding deferred sales of Note 2.InducementsInformation regarding deferred sales induc Deferred Sales InducumptionsInformation regarding Dated sales inducement Information regarding D. Deferred Sales Information regarding DistributionsInformation regarding Distributions Induced Note 2).Deferred Sales (see Note: Sales Information regarding Dated Information regarding D (see Note regarding sales (see Note 2)Information regarding DistributionsInformation regarding the sales inductionsInformation regarding the sales inductions (see Note regarding Note 2.Inducurrent Sales InducementsInformation Regarding Deferred Sales Induc (see Note 1cementsInformation regarding DSI (see sales (see Note 2.InducementsionscementsInformation regarding D (see Note 2. See Note 2.Deferred Sales (see NoteInformation regarding DDeferred Sales (see Note 1See Note 2023. Sales Information regarding Distributions InducementsInformation regarding Inducated Sales Induc) (see Note 2.Inducum Deferred Sales InducementsSeee Information regarding DSI (see Note 2023. Inducocwen (see Note 2.InducementsInformation regarding DSI (see Note regarding DiversionsInformation regarding InducedemDeferred Sales InducementsInformation regarding DistributionsInformation Regarding Deferred Sales Inductionments)Deferred Sales (see Note 48Deferred Sales InducementsInformation"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?",
        "options": {
            "A": "Lack of sufficient product supply",
            "B": "Disagreement on clinical trial design",
            "C": "Inadequate number of patients",
            "D": "Site deviation from protocol",
            "E": "Unexpected health risks to participants",
            "F": "Public health crises effects"
        },
        "LLM_original_answer": [
            "Based on Form 12) (see Note 59Deferred Sales Inducements regarding DSIDeferred Sales (see Note 2022ImsSee Note 2023.2).Deferred Sales IncentumDeferred Sales Inducements (see Note 52Sales Induced Sales InducementsInformation regarding DSIU.Salessee sales inducertain Deferred Sales and (see Note 2).Deferred Sales and Deferred Sales Sales Sales and DistributionsInformation regarding the sales inducGAINote 2023)See Note 83 Sales InducementsInformation regarding DSI (see Note 2022. Sales Inducations (see Note 8. Sales InducementsSee Note 830-2)See Note Regarding InducementsInformation regarding DSI (see sales (see Note Regarding Note Regarding the sales inducementsInformation regarding Note regarding DSIInformation regarding Note 2020mentsures Information Regarding Note Regarding Sales InducumptionsInformation regarding Note 1. (see Note 2023.Inducations InducementsInformation regarding DSIU2.2) (see Note 2)Deferred Sales InducumSee Note 56Sales Inducsee Note 53Sales Inducum Sales InducementsSee Note 3.InducementsInformation regarding Distributions regarding DSI (see Noteabout the sales inducementsInformation regarding DSIPO 1. Deferred Sales InducementsInformation regarding DSI (see Note 3.InducementsInformation regarding Note 50See InducationsInformation regarding Note 2 (see Note 1AwardsInducementsInformation regarding DSOIInformation regarding D (see Note 52Sales Information regarding DSIInformation regarding Distinguisheducementsionscementemotional Sales InducementsInformation regarding Note 830Sales Inducment Sales InducumNote 2. Sales (see Note Regarding Sales InducationsDeferred Sales InducumDeferred Sales Sales and Inducements Sales regarding DSIInformation regarding DDeferred Sales and Deferred Sales and Note 2)Deferred Sales Information regarding information regarding information regarding DSOImsInformation regarding DSO 56InformationRegarding Information regarding DSIInformation regarding DSOX Sales InducementsInformation regarding Note 2).Deferred Sales InducementsInformation regarding Note 830 Winter Street Capitalized Sales InducementsInformation regarding DSOIRegarding DDeferred Sales Inducum Information regarding Note 2023. See Note 2023See Note 2020See Note: See Note Regarding Deferred Sales InducationsSee Sales and Deferred"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?",
        "options": {
            "A": "The donations are not tax-deductible.",
            "B": "They have been used to promote branded drugs over cheaper alternatives.",
            "C": "They require excessive paperwork for approval.",
            "D": "They are not sufficient to cover all patient needs.",
            "E": "They are banned by all federal laws.",
            "F": "They are mismanaged by charitable organizations."
        },
        "LLM_original_answer": [
            "The Sales InducementsSee regarding Distributions Sales Inducum 2022).Information regarding Note 2).Sales Inducations Information regarding DSIDeferred Sales (see Note 2. Sales InducementsInformation regarding DSI (see sales induc2See Note 2. Sales Information regarding DistributionsInformation regarding DSIU.Salessee Note 12Information regarding Note 1Information regarding Note 2).See Note 2Sales InducementsInformation regarding DIInducurrent Sales InducementsInformation regarding Inducated Sales Induc (see Note 2).InducumSee Note regarding deferred sales inducementsSee Note 2023 (see Note: Deferred Sales InducementsSee Note 2See InducumentsInformation regarding information regarding Distributions (see information regarding DSIU.Sales Information regarding DistributionsInformation regarding DII. Deferred Sales InducementsInformation regarding DSI) (see Note 2. Sales (see Note regarding DistributionsInformation regarding Distributions Inducum Sales Inducum Sales (see Note 62Deferred Sales Information regarding DSOI and Deferred Sales Information regarding DistributionsInformation regarding DSIU.See, Incurred Sales Inducemcecedited Sales (see Note regarding sales (see Note 2).See Note 2).See Note 2. Sales (see Note Sales InducumentsDeferred Sales InducumDeferred Sales (seections Induc Sales regarding sales induc Deferred Sales and DSIInformation regarding Note 12).Deferred Sales Information regarding DistributionsInformation regarding DistributionsionscumsInformation regarding DSO-Deferred Sales Information regarding Distributions regarding DSI)Information Regarding Information regarding Information regarding DistributionsInformation regarding DSI)Information regarding Sales Inducements regarding the DSI Information Regarding the DelinementsInformation Regarding DistributionsInformation regarding DSIInformation regarding Distinguishedments regarding Note 2. 2).Sales and DistributionsInformation regarding D regarding DSI (Deductements (see Note Regarding DDeferred Sales and see Note 2. See Note Inducements regarding D (see Note: See Sales InducementsInformation regarding D\n Sales InducationsInformation regarding DSIU.Sales information regarding DistributionsInformation regarding DSA Information regarding DSALES-12. Sales Information regarding DistributionsInformation regarding Distributions inducertain Sales and 12)Deferred Sales and Note 2 Sales InducementsInformation regarding DSI (see Note: 202 Sales Information regarding sales inducementsInformation regarding DSIUrgementsInformation regarding DSI\u2019s"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?",
        "options": {
            "A": "Innovative product features",
            "B": "Reputation",
            "C": "Market share",
            "D": "Low pricing strategy",
            "E": "Employee satisfaction",
            "F": "Advertising campaigns"
        },
        "LLM_original_answer": [
            "The inducertaince: Sales InducementsInformation regarding DSIInformation regarding DSIU.SalesInformation regarding DSIU.See 2. Sales (seementsInformation regarding DSI (see Note 2023. Sales Inducing Information Regarding Note 2. Sales InducementsInformation regarding DSIInformation regarding DSI and DSOs)Deferred Sales InducedementsInformation regarding deferred sales inducementsSee InducementsInformation regarding DSIU.Sales Information regarding Distributions InducementsInformation regarding Distributions regarding the sales (see sales inducementsInformation regarding Note 2020emensThe Company 2. Sales Induc sales inducumentsInformation regarding DSOIscurrently-12)See 2).Deferred Sales InducementsInformation regarding DSI (see Note 2023)Information regarding Note 2). Sales Information regarding Deferred Sales InducementsSee Note 2) (see Note 202 Sales Induc Sales InducumisusseeemSales and Sales Information regarding D see Note ultiemedemDeferred Sales Inducumacsee Note 2)Deferred Sales Information regarding Note Regarding Information regarding Note 1)Information regarding sales inducesementsInformation regarding DSI (seems regarding the sales inducementsInformation regarding D (see Note 2). Deferred Sales Inducum Sales InducumSee Note 2020. Inducum sales inducInducummary 1. Induc: Deferred Sales InducementsInformation regarding Distributions regarding DSOI (see Note regarding DSOIPO Information regarding InducumSee Note regarding DSOI.Broker Sales Information regarding DSO-2).Deferred Sales (see Note 37Deferred Sales InducementsInformation regarding sales inducertain Deferred Sales InducementsSales Information regarding sales inducementsInformation regarding DSOI (see Note regarding DSO SalesInformation regarding Deline Sales InducementsInformation regarding Distributions (see Note 37Sales (see Note regarding D&copy Information regarding Note 2023).Deferred Sales InducementsSales and Note 2023Sales InducementsDeferred Sales InducumM Deferred Sales InducementsSee Item 2023See Inducumane 2)Deferred Sales and Deferred Sales InformationRegarding DSOI n Information regarding DSIUrgsSee Note 202 Sales InducementsInformation regarding DSIInformation regarding DistributionsInformation Regarding Information regarding DSIU.See 37Information regarding InducementsInformation regarding DSI Information Regarding Deferred Sales Information regarding DistributionsInformation"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?",
        "options": {
            "A": "Only changes in interest rates",
            "B": "Changes in interest rates and credit spreads only",
            "C": "Interest rates, exchange rates, and assumptions used in models",
            "D": "Volatility and default risk only",
            "E": "Nonperformance risk and liquidity only",
            "F": "Only changes in financial indices"
        },
        "LLM_original_answer": [
            "To Sales Inducations Sales InducementsInformation Regarding Deferred Sales (see Note 2 Sales InducementsInformation regarding DSI (see also see Note Regarding Note Regarding the sales inducured Sales Information regarding sales (see Note regarding sales (see Note 1. See Note 1Information Regarding the sales inducertainceeechance Information regarding Sales Inducing sales (see Note Regarding Differ from Inducements (see 2) (see Note 2)Deferred Sales Induc\u2019s Deferred Sales Induc DIs inducementsDeferred Sales InducementsInformation regarding Distributions regarding DistributionsInformation regarding DSI Information Sales Information regarding Sales InducementsInformation regarding DSIU.SeeSee the regarding information regarding InducumSales and Deferred Sales and Deferred Sales InducementsInformation regarding DSI) (see Note 2022. See Regarding Note regarding DistributionsInformation regarding sales inducertaine Sales Inducum DSIemensiassee Note "
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which company is developing AV-101 for the treatment of PAH?",
        "options": {
            "A": "Aerovate Therapeutics, Inc.",
            "B": "Gossamer Bio, Inc.",
            "C": "Acceleron",
            "D": "Regeneron Pharmaceuticals, Inc.",
            "E": "Biohaven Ltd.",
            "F": "Versanis Bio"
        },
        "LLM_original_answer": [
            "Based on the U.Such as amended EU-U.S.-U.-U.-U.SUM-States, such as such as of compliance with law, the U.SUM-Quartz ITEM ******* Item 2023\n_ctxtion Item 2023ITEM 45\n844ITEM 45ITEM 45it is acompany:QUESTIONICB.\tIf the EU-U.SUM. Privacy Shield program, such as well, the U.S. Privacy Actelated law, such as well, such as well, such as well, such as of the U.S."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?",
        "options": {
            "A": "$285.0 million",
            "B": "$76.5 million",
            "C": "$211.6 million",
            "D": "$135.1 million",
            "E": "$28.0 million",
            "F": "$2.0 million"
        },
        "LLM_original_answer": [
            "The SEC registrant, meaning that is the SEC post-comb-SEC registrant, meaning that is the SEC post-combegan registrant SEC filings with respecterect meaning that are subject to the SEC registrant.The SEC filings and/or SEC post-SEC registrant, meaning that post-comb. SEC post-combureau filings, meaning that the post-comb. Registrantination registrant registrantigenitor, meaning that SEC-combination company, meaning that SEC registrant, meaning that the SEC filings and/orbination company, and SEC successor SEC registrant, meaning that the SEC filings and post-combipr, the SEC registrantitrust registrant, meaning that the post-combeganwitness.comb, meaning that the post-comb, meaning the post-combipostantitrust registrant post- Core Scientifically, meaning that is the post- post-combip post-comb. Item 2023 Item 2023. The post-comb-mer-subs- meaning that post-comb. The SEC filings with respect, meaning that the SEC post-comb. The SEC filings and post-combureau, meaning that are the post-combureau meaning that the post-combeganual registrantitrustantitrust registrantitrustantitrust registrant post-combination, including the post-combureau meaning that the SEC registrant- post-combureau registrant, meaning that the pre-combureau registrantation company, meaning that the SEC registrant, meaning that the SEC registrant SEC registrantitrustant post-combipination company is the post-combureau, meaning that the SEC registrant, meaning that the SEC post-combureau registrant SEC registrant, meaning that the SEC registrantitrust registrant successor SEC registrantagonant registrant SEC registrant-combination registrantib registrant registrant SEC post-combegan registrant. SEC registrant SEC successor SEC registrant-comb, meaning that the SEC registrant, meaning that the SEC post-combeganviable registrant post-combination, meaning that the SEC registrant SEC post-combeganeration registrant, meaning that the pre-combeganews SEC registrant SEC post-comb, meaning that the SEC filings with respect, meaning that SEC registrant, meaning that is the SEC registrant, meaning that the post-combeganual Item 1. The post-combureau.Secbination registrant post-combegan registrant post-combination SEC"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What was classified as discontinued operations in the fourth quarter of 2022?",
        "options": {
            "A": "Utility-scale solar and wind group only",
            "B": "Distributed generation group only",
            "C": "Utility-scale solar, wind group, and distributed generation group",
            "D": "Remaining assets only",
            "E": "Commercial Renewables Disposal Groups",
            "F": "None of the above"
        },
        "LLM_original_answer": [
            "The as originally filed as originally filed as originally as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed in Year 2023 as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed, $ 2023 as originally filed as originally as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed, $ 2023##table##table##table 1 million in Year 1 as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed would have been $ 1 as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed in Year 2023##table as originally filed as originally filed as originally filed as originally filed as originally filed $ 1, as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed $ 1 1 in Year 1 , $ 2023##table as originally filed as originally filed as originally filed as originally filed as originally filed as originally as originally filed as originally filed as originally filed as originally filed as originally filed as originally filed as originally as originally filed as originally filed as originally filed as originally filed as originally filed would have been $ 1, $ 1 as originally filed as originally filed as originally filed,"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?",
        "options": {
            "A": "0.31%",
            "B": "0.41%",
            "C": "0.50%",
            "D": "0.60%",
            "E": "0.70%",
            "F": "0.80%"
        },
        "LLM_original_answer": [
            "The year ended December 2023\n\u9001\u6599 31, 2023 and net income from continuing operations and net income from continuing operations for the year ended December 43 and income from time periods of the occurrence of continuing operations and net income from continuing operations and net income from continuing operations for the year ended December 43\n.rpm for the year ended December 43\nContinue reading the consolidated financial services of Eastern Bank\u2019s results of the occurrence of continuing operations and net income from continuing operations and net income from continuing operations from continuing operations for the year ended December 2024\n2023\nC.43\notp operations for the year ended December 2023\notp net income from continuing operations from continuing operations and net income ended December 31, 2023\noperations for the year ended December 43\nwas $ 43\notp operations for the year ended December 2023\n,rp net income from continuing operations for the following the year ended December 34.We have a ndependings 44 net income from continuing operations and net income from continuing operations and continuing operations for the year ended December 43\n_ctxt operations and net income from continuing operations and net income from the year ended December 44 from continuing operations and net income from time and/or operations and net income from the quarter end of continuing operations and/orge\n_ctxt 43 and net income from continuing operations and net income from continuing operations and net income from continuing operations and net income from continuing operations and/or continuing operations and net income from continuing operations, among other than any from continuing operations and/or other than operations and/or otherwise described above and our business and net income from the occurrence and net income from continuing operations for the year ended December 31, 2024\n_ctxt operations for the year ended December 43\n_ctxtin 43\n_ctxt income from continuing operations for the year ended December 43\n_ctxt operations for the year ended December 43 from continuing operations for the year ended December 2023\nreply 44 and the year ended December 44and the year ended December 2024\n2023 and net income from continuing operations and/or losses and income from continuing operations for the year ended December 44\nreply for the following the consolidated net income from continuing operations and net income from continuing operations and net income from continuing operations for the following December 43 and net income from continuing operations for the year ended December 42\n Net income from the occurrence and income from continuing operations for the occurrence of continuing operations for the impact on net income from continuing operations for the year"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?",
        "options": {
            "A": "10 years from its earliest U.S. non-provisional filing date",
            "B": "15 years from its earliest U.S. non-provisional filing date",
            "C": "20 years from its earliest U.S. non-provisional filing date",
            "D": "25 years from its earliest U.S. non-provisional filing date",
            "E": "30 years from its earliest U.S. non-provisional filing date",
            "F": "35 years from its earliest U.S. non-provisional filing date"
        },
        "LLM_original_answer": [
            "What we begin expiring in 2024We begin 10 of the 20 of 20 years 2024, 20 years 94Under Section 20 of our business 199Under Sections 20 years 94Under Sections 20 years 94Under Sections 94Under Sections 94Under Sections 20 years 20 years of our business operations and begin expiring Sections 20 years from expiring 20 years 2029Q4Under Sections 94Under Sections 94Under Sections 2029.94Under Sections 94Under Sections 94Under Sections 2029/2024\nItem 20 years of the expiration of 2020.94\nItem 20 expiring 94\n2024We have 11 of 94Under Sections 94Under Section 20 of 11 of the expiration dates and begin expirrelevant information we have expired in the \u201cNin 94We have raised 20 years from time.The 2024Q4We begin expiring 94Under the\nItemized in 94Under Sections 20 years from the 20 years from 20 years 94\nItem 94Under 94Under 2024We have a.94Under Section 20/20.2029\n2029.94Under Sections 20 years 20 years 20 years 94Under Sections 94Under Sections 20 years from 20 years 20 years from the 20 years from Sections 20 of our common stockholder 94Under Section 94Under Sections 20 years 94Under Sections 2020 years 94Under Sections 94Under Sections 94Under Sections 2029Under Sections 20 years 20 years 11Kura 20 years 2024\nItem 2024\nItem 94Under Sections 94\nItem 2014Under Sections 2020, 94Under Section 94Under Section 20.94Under Sections 2024We are expirrevolving 20 years 94Under Sections 20 years 20 years ago 94WeighnWe are not-forfeaturing 94In 20 years from 2024thirty-four years 94We begin expiring 2024.94Under Sections 94Under Sections 94The Expiring 20 years 2024.94Under Section 94Under Sections 94 and begin expiring in 20 in 2024.43 of our common stockholders 94Under Sections 20 years from time and 2024/94"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What was the target hedge coverage ratio in December 2023?",
        "options": {
            "A": "25%",
            "B": "50%",
            "C": "60%",
            "D": "75%",
            "E": "90%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "The applicable.48ITEM 48ITEM FOR REGULSUITEREGREGULSOLD REGISTRATION DISCLOSSECLAREASPEOPLEASCOI.48ITEM 2018ITEMSOLDITEM 48ITEMSOUREGITEM 48ITEM 1.MANALERTHLOSURESNot applicable.48ITEM 1.48ITEM 5Not applicable.48ITEM 2010ITEM 2020Not applicable.48ITEM 1ITEM 2018ITEMSUFFITEM 48ITEM 1.MANNUOTTERMSKINGREDIENTORLOSURESNot applicable.48ITEM 48ITEM 48ITEM 5.MERECT DISCREDIT DISC.48ITEM 48ITEM 5.48ITEM 8.48Not applicable.48ITEM 2022ITEM 48ITEM 1.48ITEM 1ITEM 48ITEM 1.48ITEM 48ITEM 48ITEM 48ITEM 5.RECENTRALLS DISCLOSURDUELOSURESNot applicable.48ITEM 48ITEM 48ITEMPLACEMENTSITEM 48ITEM 1.SUPPEREGOVERALLERDISCLOSURESNot applicable.48ITEM 1.MEASURGLENOTD IS NOT applicable.48ITEM 2.48ITEM 2.48ITEM 1ITEM 1.48ITEM 48ITEM 48ITEMETD ISCOOPERATION 5.48ITEM 2018ITEM 48ITEM 48ITEM 202 DISCLOSURETHATMORTERODI\u2014Not applicable.48ITEM 2020.48REGS&PLOSURE DISC.48ITEM 1.MANETTEFFECTSUIT 48ITEM 48ITEM 2018.48ITEM 48ITEM 48ITEM 48ITEM 48ITEM 2019.48ITEMSUPPORTORSUP not applicable.48ITEM 2018ITEM 48ITEMLOSUREsusp.48ITEM 1SUSTLDISCLOSSEASON DISC.48ITEM 1.48ITEM 1.SEC/REGULITEM 48ITEM 48ITEM 1.48ITEM 48ITEM 8.48ITEM 48ITEM 48ITEM 48ITEM 48ITEM 1.48ITEMSIX Not applicable.48ITEM 48ITEM 2018ITEMS.EFFECTUALSOXOc.48ITEMPLIRESNot applicable to the market for the market for ourlosure:48ITEM 48ITEM 1.48ITEM"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?",
        "options": {
            "A": "Lack of sufficient product supply",
            "B": "Disagreement on clinical trial design",
            "C": "Inadequate number of patients",
            "D": "Site deviation from protocol",
            "E": "Unexpected health risks to participants",
            "F": "Public health crises effects"
        },
        "LLM_original_answer": [
            "Which we fail, in whole or in whole or part, in whole or in whole or if we fail to meet, in whole or milestones, in whole or if we fail topline, in whole or if we fail to meet applicable requirements or if we fail, in whole or if we fail to meet applicable requirements or in whole or if we fail to meet applicable requirements or if we fail to, in whole or milestones or milestones or milestones or milestones or milestones, in whole or part or if we fail to fail to meet applicable requirements or milestones or milestones or milestones or milestones or milestones or milestones, in whole or if we fail to meet in whole or if we in whole or in whole or in whole or if we fail, in whole or requirements or milestones or milestones or if we fail to meet applicable requirements or whole or milestones or milestones or if we fail, in whole or recommend, in whole or conduct, in whole or milestones or in whole or in whole or in whole or in part of in whole or otherwise applicable requirements or requirements or milestones or milestones or in whole or in whole or in whole or milestones or applicable requirements or milestones or milestones or milestones, in whole or in whole or in whole or in whole or in whole, depending onereternal, in the FDA\u2019safety or if we, in whole or if we fail-safe or in whole or in whole or in whole or if we fail, in whole or if we in whole or in part, if we fail to meet applicable requirements or requirements or if we fail, in whole or if we fail to meet applicable requirements or if we fail, in whole or milestones or milestones or milestones or milestones or milestones or if we fail to our failure to meet applicable requirements or in whole or if we fail to which could, in whole or in whole or if we fail, in whole or in whole or if we fail to meet or milestones or in whole or milestones or in whole or in the whole or the FDA and/or milestones or fail to the applicable requirements or regulations, in whole or in whole or in whole or in whole or in whole or in whole or in whole or in whole or in whole or fail topline, in whole or milestones, in whole or milestones or fail to which in whole or milestones, in whole or under the U.See in whole or under applicable requirements, in whole or under applicable requirements or in whole or in whole or if we fail topline, in whole or if we fail, in whole or if we fail to meet applicable requirements, in whole or"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?",
        "options": {
            "A": "The donations are not tax-deductible.",
            "B": "They have been used to promote branded drugs over cheaper alternatives.",
            "C": "They require excessive paperwork for approval.",
            "D": "They are not sufficient to cover all patient needs.",
            "E": "They are banned by all federal laws.",
            "F": "They are mismanaged by charitable organizations."
        },
        "LLM_original_answer": [
            "What has been approved by the use of our products that we cannot bein the extent to a) or we cannot be certain that we cannot be certain that we cannot be certain that we can be certain that we cannot be certain that we cannot be certain that we cannot be able to continue to develop and/or obtain marketing authorization of the required to the condition that we cannot be certain that we cannot be certain that we will be able to continue to develop and/orphanomitted that we cannot be certain that we cannot be certain that we cannot be able to the condition that we cannot be able to the conditionally cannot be able to continue to the conditionally obtain more than we cannot be able to the use of our product candidates for which could result in addition to the EMAA document that we can be certain that we cannot be certain that we can becaresponsible to continue to develop and/orphanetican assuredly be certain that we cannot be certain that we cannot be certain risk-become more than we cannot be certain that we will bein the EMA cannot be certain that we will be certain that we cannot be certain that we will be certain that we will be able to develop our products that we cannot be certain that we will be able to continue to the conditionally be able to the U.See be certain that we cannot be certain that we cannot be certain that we cannot be able to the most of our products that we cannot be certain that we cannot be certain that we cannot be certain that we cannot be certain that we cannot be certain that we can be certain product candidates for us cannot be certain that we cannot be able to continue to continue to end-to-46\nItem cannot be certain that we will be able to continue to the conditionally more than we cannot beincludemphasenoughmoreover, if and/orphan more than any and/orphaneticMoreover, if and cannot bein the ESG that we will be able to continue to our product candidates be certain that we will be able to continue to develop and commercialize our product candidates to continue to continue to continue to the conditionally obtain regulatory approval of our product candidates that we cannot be certain that we cannot be able to the cannot be certain that we can certain than that we cannot be certain that we will be able to continue to develop and/orphanomenorphan more than we cannot be more than we cannot be certain that we cannot be certain that we cannot be certain that we can be certain that we will be certain that we cannot be certain that we"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?",
        "options": {
            "A": "Innovative product features",
            "B": "Reputation",
            "C": "Market share",
            "D": "Low pricing strategy",
            "E": "Employee satisfaction",
            "F": "Advertising campaigns"
        },
        "LLM_original_answer": [
            "The principally consisting principally consisted principally consisted principally consisted principally consisted principally consisting principally consisted principally consisted principally consisting principally consisting principally consisted principally consisted principally consisting principally consisted principally consisting principally consisted principally consisted principally consisted of $4. Additionally, which principally consisted principally consisted intangible assets of $4.  Additionally, which principally consisted principally consisted of $3. Additionally, which principally consisted principally consisted principally consisting principally consisted principally consisted principally principally consisted principally consisted principally consisted of identified intangible assets of $1 billion, which principally consisted principally consisted principally consisted of $4. The principal intangible assets of $4.9 billion, which principally consisted of $4. which principally consisted of $4. which principally consisted principally consisting principally consisted principally consisted principally consisting principally consisted principally consisted principally consisted principally consisting principally consisted principally consisted principally consisted principally consisted of $4, which principally consisted of $4. Identified intangible assets, which principally consisted of $4. Additionally, which principally consisted of $4. The identified intangible identified intangible assets of $4. Other intangible assets of $4 billion, which principally consisting principally consisted principally consisted principally consisted principally consisted of $4.2. Other int principally consisted of $4 billion, which principally consisted of $4 identified principally consisted of $4. The principal identified intangible assets of $4 billion, which principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted of $1 identified intangible intangible intangible assets of $4.7 billion, which principally consisted of $4. principally consisting principally consisted principally consisted principally consisted principally consisted principally consisted principally consisting principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted principally consisting of $4 billion principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted of $1.  principally consisted principally consisting principally consisted principally consisted principally consisted principally consisted principally consisted principally consisting principally consisted principally consisted principally consisting principally consisted principally consisted principally consisted principally consisted of $4 billion, principally consisted of identified intangible intangible consisted of $4. Identified intangible assets of $4. Identified intangible identified intangible principally of $4. principally consisted principally consisted principally consisting principally consisted principally consisted of $4. Identified intangible assets of $4 billion, which principally consisted of $4 billion, which principally consisted principally consisted of $4 identified intangible assets of $4 billion, which principally consisted of identified intangible assets of $3 of $4. Additionally, which principally consisted principally principally consisted principally consisted principally consisted principally consisted principally consisted principally consisted principally"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?",
        "options": {
            "A": "Only changes in interest rates",
            "B": "Changes in interest rates and credit spreads only",
            "C": "Interest rates, exchange rates, and assumptions used in models",
            "D": "Volatility and default risk only",
            "E": "Nonperformance risk and liquidity only",
            "F": "Only changes in financial indices"
        },
        "LLM_original_answer": [
            "What will of an investment in shares of our investment in the success of our investment risk management\u2019s success of our investment in such as well as a material adverse to the success of our investment risk management of an investment in shares of our investment in the success of our investment in our investment in the performance of our investment in the success of our investment in fixed maturity and other factors outside of our investment success of our credit and success of an investment in shares of our investment in the success of an investment success of our general of our investment will be adversely affect the near-term, in an investment in the success of our investment success of our investment in our investment risks related to the success of our investment success of our investment in-force of our investment success of our investment success of our-term, and the success of an investment in our shares of our common stock will be highly-success will be a return of an investment in shares of an investment in shares of our success of an investment in shares of our common stock will be dependent on shares of shares of our success of an investment in shares of our success of our success of an investment in shares of our shares of our common stock will depend on shares of an investment in shares of our common stock of our general accountably, in the success of our investment in the success of our investment in the success of our subsidiaries of our success of our subsidiaries of our success of an investment success of our investment in-force, or other risks associated with which will be adversely affect our investment success of our success of our success of an investment will be subject to our success of our shares will depend on shares of our investment will depend on-going concern in shares of an investment in shares of our success of our subsidiaries of our success of an investment success of our success of our success of our success of our subsidiaries of our success of our success of an investment success of our success of an investment success of our shares of our common stock of our success of an investment success of an investment success of our common stock of our subsidiaries of an investment success of our success of our success of the success of our investment success of an investment success of an investment in shares of our common stock will be adversely, and the success of the success of an investment success of the success of success of an investment in shares of our common stock will depend on an investment success of our shares of our common stock will be dependent on the near-term, and the success of our success of our success of our investment in shares of our success of an investment success of an investment in shares of our subsidiaries"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which company is developing AV-101 for the treatment of PAH?",
        "options": {
            "A": "Aerovate Therapeutics, Inc.",
            "B": "Gossamer Bio, Inc.",
            "C": "Acceleron",
            "D": "Regeneron Pharmaceuticals, Inc.",
            "E": "Biohaven Ltd.",
            "F": "Versanis Bio"
        },
        "LLM_original_answer": [
            "Which, principal investigators or any of our investigators or any of our investigators or any of any of any of any of any of any of any of any of any of any of any of any of our investigators or any of our investigators or any of any of any of any of any of our investigators or any of any of our investigators or any of our investigators or any of any of our investigators or any of our investigators or any of any of our investigators or any of our investigators or any of any of any of any of any of any of our investigators or any of any of any of any of our investigators or any of any of any of our investigators or any of our investigators or any of our investigators or any of our investigators or any of any of any of any of any of any of any of any of any of our investigators or any of any of any of any of any of any of any of any of our investigators, any of any of any of any of our investigators or any of any of our investigators or any of any of any of any of any of our investigators or any of our investigators or any of any of our investigators or any of our investigators or any of any of any of our investigators or any of our investigators or any of any of any of any of any of our investigators or any of our investigators or any of any of any of any of any of our investigators or any of any of our investigators or any of our principal investigators or any of our investigators or any of any of our investigators or any of any of our investigators or any of our investigators or any of any of our investigators or any of any of any of any of any of any of our investigators, any of our investigators or any of any of our investigators or any of our investigators or any of any of our investigators and any of any of any of any of our investigators or any of any of our investigators or any of any of our investigators, any of any of any of any of any of any of any of any of any of any of any of any of any of any of our investigators or any of any of any of our investigators or any of our investigators or any of any of any of any of any of our investigators or any of our investigators or any of our investigators or any of any of our investigators or any of any of any of any of our investigators, our investigators or any of our CROs investigators or any of any of any of our investigators or any of our investigators or any of any of our investigators or any of any of our investigators or"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?",
        "options": {
            "A": "$285.0 million",
            "B": "$76.5 million",
            "C": "$211.6 million",
            "D": "$135.1 million",
            "E": "$28.0 million",
            "F": "$2.0 million"
        },
        "LLM_original_answer": [
            "The 25business with indefinite useful lives that is received as well as well-known lives with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite useful lives that are received as well-known as digital asset mining operations with indefinite useful lives.Digital asset mining operations with indefinite useful lives with indefinite useful lives that are received as digital asset mining operations with indefinite useful lives that are received as well as digital asset mining operations with indefinite useful lives.Digital assets with indefinite indefinite useful lives, and indefinite assets that are received as digital asset mining operations that are received as well.Digital asset assets that are received as digital asset that are received as intangible assets that are received as digital asset transactions that are received as well indefinite useful lives that are received as received as received as digital asset mining operations that are received as received as received as intangible assets with indefinite useful lives that are received as digital asset that are received as digital asset mining operations with indefinite useful lives that are received as well as received as well as well as digital asset with indefinite useful lives and indefinite useful lives that are received as a indefinite useful lives that are received as digital asset mining assets with indefinite useful lives that are received as well-known indefinite useful lives that are indefinite useful lives that are received as received as digital asset transactions that are received as digital asset with indefinite useful lives.Digital assets that are received as digital asset mining that are received as digital asset mining power indefinite useful lives that are received as digital asset are received as well-known as well indefinite useful lives that are received as well with indefinite useful lives that are received as a..."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What was classified as discontinued operations in the fourth quarter of 2022?",
        "options": {
            "A": "Utility-scale solar and wind group only",
            "B": "Distributed generation group only",
            "C": "Utility-scale solar, wind group, and distributed generation group",
            "D": "Remaining assets only",
            "E": "Commercial Renewables Disposal Groups",
            "F": "None of the above"
        },
        "LLM_original_answer": [
            "What is as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as certain third parties as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as certain third parties as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as certain third parties as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as certain third parties as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as certain third parties as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as certain third parties as well as well as well as well as well as certain third parties as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as certain third parties as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?",
        "options": {
            "A": "0.31%",
            "B": "0.41%",
            "C": "0.50%",
            "D": "0.60%",
            "E": "0.70%",
            "F": "0.80%"
        },
        "LLM_original_answer": [
            "As a business in a business combination in accordance with respect to the business combination in accordance with respect to the in accordance with respect to a business combination in accordance with respect to the the business combination in accordance with respect to the fair value in accordance with respect a business combination in a business combination in accordance with the business combination in accordancee in accordance with respect to the Company\u2019s business combination in accordancee in accordance with respectee in a business combination in accordance with respect to the business combination in accordance with respect in accordance with respect in accordance with respect in accordance with respect to the acquiree in accordance with respectively in accordance in accordance in accordance with respect in accordance with respect in accordance with the business combination in a acquiree in accordance with respect to the acquiree in a business combination in a business combinations in a acquiree in accordance in accordance with respect to the acquiree in a27\nbusiness combination in a business combination in a business combination in accordance in a business combination in a business combinations in accordance with respect to the business combination in accordance in accordance with the business combination in accordance with respect of a business in a business combination in a business combination in accordance with respect to the Company in a business combination in a business combination in accordance in accordance with the Company in accordance in accordance with respect to the Company in accordance with respect to the acquiree in accordance with respect to the business combination in accordance with respect to the acquiree in accordance with respect in accordance with respect to the acquiree in accordancee in a business combination in accordance with respect to the acquiree in accordance with respectivestimatese in accordance with respect in accordance with the applicable business combination in accordance in accordance with respect in accordance with respect to the Company assets and the in accordancee in accordance with respect of an acquiree...\nEasterng in accordance with respect to the acquiree in accordance with respect to the in a business combination in accordance with respect to the acquiree in accordance with respect thereof in accordance with respect in a business combination in accordance with respect in accordance with respect in accordance with respect the a business combination in a business combination in accordance with respect to the business combination in accordance with respect to the Company in accordancee in a business combination in accordance with respect to the acquiree\u00adrelated business combination in accordance in accordance with respect to the a business combination in accordance with respect in a business combination in accordance with respect to the acquiree in accordance with respect to the acquiree in accordance in accordance with respectively in accordance with respect to the business combination in accordancee in accordance with respect thereof in"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?",
        "options": {
            "A": "10 years from its earliest U.S. non-provisional filing date",
            "B": "15 years from its earliest U.S. non-provisional filing date",
            "C": "20 years from its earliest U.S. non-provisional filing date",
            "D": "25 years from its earliest U.S. non-provisional filing date",
            "E": "30 years from its earliest U.S. non-provisional filing date",
            "F": "35 years from its earliest U.S. non-provisional filing date"
        },
        "LLM_original_answer": [
            "What is not Medicaid.A person or entity does not need to need not need not federal healthcare programs such as Medicare and Medicaid.The person or entity does not need not need to Medicare and Medicaid and Medicaid and Medicaid.A person or entity does not federal healthcare programs such a person or Medicaid and entity does not need to federal healthcare program or entity does not need not need not need not covered by Medicare and Medicaid and Medicaid and Medicaid and Medicaid.A person or entity does not need not need such as Medicare and Medicaid.A person or entity does not need not need not need not under federal healthcare programs such programs such as such as Medicare and entity does not entity does not need to need not need not need not need not need not federal healthcare programs such as well Medicaid.A person or entity does not need such as Medicare and Medicaid and Medicaid and/or entity does not need to need to Medicare and Medicaid programs such as Medicare and Medicaid.A person or entity does not need to Medicaid and Medicaid and Medicaid and Medicaid and Medicaid.A person or entity does not need to Medicare and under Medicare and Medicaid and Medicaid and/or Medicaid and Medicaid and Medicaid and entity does not need to Medicare and Medicaid and state healthcare programs such programs such as well as well-being under federal healthcare programs or entity does not need to Medicare and federal healthcare programs such as well person or entity does not need not need to Medicare and does not need not need not need not need not federal healthcare programs such programs such as well as well-known entity such as part or entity under federal healthcare program does not need to have or entity does not need to Medicare and entity does not need to the person or entity does not need to Medicare and state healthcare programs such as Medicare and Medicaid.A person or entity does not need not need not need not need not under federal healthcare programs such a person or entity does not need not need not-for example such as a person or state healthcare programs such as Medicare and Medicaid and Medicaid and entity does not need not need to need to need not person or entity does not need to Medicare and Medicaid and Medicaid and a person or entity does not need not-for example.A person or entity does not need healthcare programs such as well Medicaid.A person or entity does not need not need such as well as well as well as Medicare and Medicaid.A person or Medicaid.A person or entity does not need not need such as well as well as well as well as well as well as Medicare and Medicaid.A person or entity does not need not to be under federal healthcare programs such as such as Medicare and Medicaid and entity does not federal healthcare program or entity does"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What was the target hedge coverage ratio in December 2023?",
        "options": {
            "A": "25%",
            "B": "50%",
            "C": "60%",
            "D": "75%",
            "E": "90%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "The pre payoffs and prepayments and prepayments and prepayments on forbearoffs and prepayments on forbearance plans on forbear prepayments plans, including those on forbearoff payoffs on forbear forbearoff forbearance plans, and prepayments, prepayments, including forbearance plans, including those on forbear payoffs and prepayments, prepayments on forbearings and prepayments on forbearings and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments on prepayments and prepayments on prepayments and prepayments and prepayments and prepayments and prepayments plans, including those on prepayments plans, including those on prepayments on prepayments and prepayments plans payoffs and loan prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments, prepayments on forbearments, including those on prepayments and prepayments and prepayments on forbearance plan payoffs forbearance plans, including those on prepayments on prepayments and prepayments and prepayments and prepayments and prepayments and prepayments plans, including those and prepayments on forbear prepayments plans on prepayments and prepayments and forbearoffs and prepayments and our payoffsayee payoffs forbearance plans, including those on forbear prepayments and prepayments plans, including those on forbearoffs and prepayments and prepayments, which we expectance plans, including those on forbear and prepayments and prepayments and those on forbearance plans, and those on forbearance plans, and prepayments on forbear payoffs and prepayments on prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments and prepayments on forbearance payoffs forbear, including those on forbearance plans, prepayments and payoffs and prepayments and prepayments and prepayments and prepayments and prepayments on forbearance plans on forbearance plans, including those on forbearance payoffs and prepayments and prepayments on forbearance plans, including those on forbearings on forbearage plans payoffs on forbearage plans, including those on forbearance plans on forbearoff forbear\n<| forbearings on forbearoffordayoffs forbear payoffs, including those on forbearance plans, and"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?",
        "options": {
            "A": "Lack of sufficient product supply",
            "B": "Disagreement on clinical trial design",
            "C": "Inadequate number of patients",
            "D": "Site deviation from protocol",
            "E": "Unexpected health risks to participants",
            "F": "Public health crises effects"
        },
        "LLM_original_answer": [
            "The end or abroad.If we are abroad.If we are slow or abroad.If we are slow or regulation, either in the U.S. or abroad.If we are slow or abroad.If we are slow or abroad or slow to obtain a foreign, either in the U.Slow or slow or slow or unable or unable to be slow in the U.S. If we are abroad.If we are slow or slow or slow or unable to the U.Seelement or abroad or abroad.If we are slow or slow or slow or abroad.If we are slow or abroad.If we are slow or abroad.If we or abroad.If we are slow or abroad.If we are slow or slow or slow in the U.Slow or if we areabroad or abroad.If we are slow or abroad.If we are slow or unable to the U.Seeither in the U.S. or other companies, either in the U.Si or abroad.If we are slow or administrative action, either in the U. If we are slow or foreign or foreign.If we are slow or abroad.If we are slow or slow or in the U. slow in the U.Seeither in the U.S. or unable to develop or slow or abroad, or in the U.Slow or unable to market or slow or slow or abroad or foreign or abroad or abroad.If we are slow or the U. or abroad, or unable to be slow or unable to the U.S. If we are slow or our slow or clinical trials in the U.S. If we are abroad, either in the U.Slow or slow, either in the U.S. If we are slow or slow or abroad, either in the TCRS or abroad or in the Uro in the U.MLATE-1 or in the U.S. or abroad.If we are slow or U.S. If we are slow or foreign or in the U.S.If we or abroad or abroad.If we are slow or in the U.S. If we are slow or both in the U.S.Both in the U.Seeither in the U.Known slow or any slower in unable to slowest or in the U.Slow or unable to the U.S. either in the U.S. If we are slow or in the U.S. If we are slow or unable to the U.slow or both slow or regulation, either the U.S. or abroad.If we are slow or abroad.If we are slow or abroad.If we are slow or slow in the U are slow in the U.S. or slow in the"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?",
        "options": {
            "A": "The donations are not tax-deductible.",
            "B": "They have been used to promote branded drugs over cheaper alternatives.",
            "C": "They require excessive paperwork for approval.",
            "D": "They are not sufficient to cover all patient needs.",
            "E": "They are banned by all federal laws.",
            "F": "They are mismanaged by charitable organizations."
        },
        "LLM_original_answer": [
            "The data obtained from preclinical and varying interpretations could delay, varying interpretations of clinical testing could delay, or limit, or interpretations of the data obtained from preclinical and clinical testing could delay, or varying interpretations of the data obtained from preclinical and clinical testing could delay, or varying interpretations of the data obtained from preclinical and varying interpretations of the data obtained from pre obtained from preclinical and clinical testing could delay, or varying interpretations of the data obtained from preclinical and varying interpretations of the data obtained from the data obtained from preclinical and clinical testing could delay, delay, limit, or varying interpretations of the data obtained from preclinical and clinical testing could delay, varying interpretations of the data obtained from the data obtained from preclinical and varying interpretations of the data obtained from preclinical and varying interpretations of the data obtained from preclinical and clinical testing could delay, varying interpretations of the data obtained from preclinical testing obtained from preclinical and clinical testing could delay, as well as well as well obtained from preclinical and clinical testing could delay, or limit, varying interpretations of the data obtained from preclinical and varying interpretations of the data obtained from preclinical testing could delay, or other than could delay, or varying interpretations of the data obtained from preclinical and clinical testing could delay, or the data obtained from preclinical and testing could delay, as well, or prevent, varying interpretations of the data obtained from preclinical and clinical testing could delay, varying interpretations of the obtained from preclinical and clinical testing could delay, varying interpretations of the data obtained from preclinical and varying interpretations of the data obtained from preclinical and clinical testing could delay, or varying interpretations of the data obtained from preclinical and clinical testing could delay, as well as well as well as well interpretations of the data obtained from preclinical and clinical testing could delay, varying interpretations of the data obtained from preclinical testing could delay, or varying interpretations of the data obtained from preclinical and varying interpretations of the data obtained from preclinical and clinical testing could delay, could delay, preclinical and clinical testing could delay, or clinical testing could delay, and clinical testing could delay, varying interpretations of the data obtained from preclinical testing could delay, or varying interpretations of the data obtained from preclinical testing could delay, varying interpretations of the data obtained from preclinical and varying interpretations of the data obtained from preclinical and varying interpretations of the data obtained from preclinical and varying interpretations of the data could delay, and varying interpretations of the data could delay, interpretations of the data obtained from preclinical and clinical"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?",
        "options": {
            "A": "Innovative product features",
            "B": "Reputation",
            "C": "Market share",
            "D": "Low pricing strategy",
            "E": "Employee satisfaction",
            "F": "Advertising campaigns"
        },
        "LLM_original_answer": [
            "The 42During 2022, which excluded the $1.42During 2022;\u2022During 2022During 41 during 2022;\u2022During 2022During 2020.33During 33;\u2022During 2022During 41 million losses and;\u2022During 41gain on September 2, we excluded the $41 million gain on the $41 million gain on the $41;\u2022During 2021 gain on the $41;See during 35During 2022, we excluded the $41 million gain on the $41 gain on the $41;During 2022During 2022;\u2022During 2022;\u2022During 2022;\u2022During 2022. During 2021;\u2022During 2022 years;\u2022During 35;\u2022 During 41;\u2022During 2022;\u2022During 27;\u2022During 27During 2022;\u2022During 1. During 2;\u2022During 2023. Exclusion;During 41million 33;\u2022During 2022;\u2022During 42;\u2022During 41 gain on the $41 million gain on the $41;\u2022During 27;\u2022During 2022, we excluded the $41, we excluded the $41\u2022During ulti-exchange the $41million;\u2022During 2023During 2022, we excluded the $41gain on the $41During 2022, we excluded the $41 million gain on the $41 million;\u2022During 1;\u2022During 41 million gain on the $41\u2022During 32During 1, we excluded the $41 million gain on the $41\u2022During ultiDuring 2022 million gain on the $41 million;\u2022During 2022During 2022, we excluded the $41 million gain on the gain on the $41 million on the $41 million impairment on the $41;\u2022During 2022 gain on the $41 during 2022;\u2022During 1 gain on the $2022, we excluded the $41 million gain on the $41 million gain on the $41 gain on the $41\u2022During 41During 2022;\u2022During 41 million gain on the gain on the $41During 2022 excluded the $41 million gain on the $41\u2022During 1n;\u2022During 2022;\u2022During 41 million gain on the $41million the $"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?",
        "options": {
            "A": "Only changes in interest rates",
            "B": "Changes in interest rates and credit spreads only",
            "C": "Interest rates, exchange rates, and assumptions used in models",
            "D": "Volatility and default risk only",
            "E": "Nonperformance risk and liquidity only",
            "F": "Only changes in financial indices"
        },
        "LLM_original_answer": [
            "What amounts issued for additional liquidity or in additional liquidity or in funding agreements issued for additional liquidity issued for additional liquidity issued for additional liquidity issued for additional liquidity or in funding agreements issued for additional liquidity or in the additional liquidity or in funding agreements issued for additional liquidity or in additional liquidity or in funding agreements issued for additional liquidity or in the additional liquidity issued for additional liquidity issued for additional liquidity issued for additional liquidity or in funding agreements issued for additional liquidity or in funding agreements issued for additional liquidity or in additional liquidity or in funding agreements issued for additional liquidity issued for additional liquidity issued for additional liquidity or in funding agreements issued for additional liquidity or in funding agreements issued for additional liquidity or additional liquidity issued for additional liquidity or in additional liquidity or in the additional liquidity or in the additional liquidity or in the additional liquidity or in the Company\u2019s associated with respect to the additional liquidity or inuities issued for additional liquidity or additional liquidity or additional liquidity or in connection with additional liquidity issued in times in the Company\u2019s liquidity or in the additional liquidity or in the Company\u2019s liquidity or in additional liquidity issued for additional liquidity or in the Company\u2019s liquidity or in additional liquidity or in additional liquidity or in the additional liquidity or in funding agreements issued additional liquidity or in additional liquidity or in connection with additional liquidity or in additional liquidity or in additional liquidity issued for additional liquidity or in additional liquidity or in additional liquidity or amounts associated additional liquidity or in funding agreements issued for additional liquidity or in funding agreements issued for additional liquidity or in funding agreements issued for additional liquidity issued for additional liquidity issued for additional liquidity issued for additional liquidity issued for additional liquidity issued for additional liquidity issued for additional liquidity issued for additional liquidity or in additional liquidity or in additional liquidity or in additional liquidity issued for additional liquidity or in additional liquidity or in funding agreements issued for additional liquidity issued for additional liquidity or in additional liquidity or in additional liquidity issued for additional liquidity or in additional liquidity issued for additional liquidity or in the Company\u2019s and amounts issued for additional liquidity or in additional liquidity issued for additional liquidity issued for additional liquidity issued for additional liquidity or in funding agreements issued for additional liquidity or in additional liquidity or in additional liquidity or in additional liquidity issued for additional liquidity or in additional liquidity or in additional liquidity or in additional liquidity or in additional liquidity or in additional liquidity or additional liquidity or in funding agreements issued funding agreements issued for additional liquidity issued for additional liquidity or in additional liquidity issued liquidity or in additional liquidity or in funding agreements issued agreements issued for additional liquidity issued for additional liquidity issued for additional liquidity or in connection with additional liquidity or in the additional liquidity or in"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which company is developing AV-101 for the treatment of PAH?",
        "options": {
            "A": "Aerovate Therapeutics, Inc.",
            "B": "Gossamer Bio, Inc.",
            "C": "Acceleron",
            "D": "Regeneron Pharmaceuticals, Inc.",
            "E": "Biohaven Ltd.",
            "F": "Versanis Bio"
        },
        "LLM_original_answer": [
            "Which is difficult and/or any and premenopenergastrocytreatment of the majority of the majority of the Myelaboron the part of the ability to our intellectual property.We believe in part of the in part of the underlying biology.It is difficult and/or any one of the difficult and/or costly and/ori.effusionarythropicaries and/or, or Part 32 and/or any other than wild-type 32\n(Media omitted after the trial population of the trial population of the trial and in the trial population of the preclinicals.It is difficult and/or activation of the BMP signaling through the in part of 32 and Gonad and/or activin the ability to a part of the part of part of our ability to aeration, or, which is difficult and costly and to a is difficult and/orus and growth.It is difficult and/orbodies is difficult and/or, or SMAD is difficult and in part of the in part of PAHemphas of PAHemerging in part of the ability to protectors, or, part of the Fulton, or, as well as well.It is difficult and/or, including in part of our ability to bone morphogenyesterday is difficult and costly and/or the pituit is difficult and trend.15\u2022in part on the ability to our preclinicalIt is difficult and costly and/or any one of our preclinical  in part of our intellectual property, as demonstrated in the right ventricular cells, which is difficult and/or, (a decrease in vitro.It is a portion of the other than we believe in the pulmonary and/orcholig, in part of the in part of the in the It is difficult and costly and costly and is difficult and in part of pulmonary and/orcholig in part of the right ventricular and/orchallenged to a part of the in part of the in part of the ability to a,because.It is difficult and we believe in the PAHempharmy is difficult and costly and we believe part on Day 26It is difficult and we believe in part of our intellectual property.It is difficult and concompart of PAHematryth.It is difficult and concompartly.It is difficult and we believe in part of the free of the in part of our ability to a free of the growth factor.It is difficult and/or.It is difficult and/or and we believe in part of the It is difficult and costly and it is difficult and costly and we expector our intellectual property.It is difficult and"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What was the carrying amount of the site asset group before impairment for the year ended December 31, 2022?",
        "options": {
            "A": "$285.0 million",
            "B": "$76.5 million",
            "C": "$211.6 million",
            "D": "$135.1 million",
            "E": "$28.0 million",
            "F": "$2.0 million"
        },
        "LLM_original_answer": [
            "The issuance of Issory issued issued issued issued of issuer of issuance of the issuance of an secured Promissory note (Secissory issued issued issued issued secured Promissed Promissory note (the \u201cNote (the Issu secured note issued an secured Promissusecured Promissory (issory note (Secissory note (Securities issued an unsecured Promissory issued issued secured Promissory note (the unsecured Promissory (unsecured Promissory note (the unsecured Promissory note (the Company (the issuance of secured note (the issuance of the issuance of the issuance of a secured Promissory note (the promiss \u201c Issuissusecured Promissory secured note ( Issu: Issingested Issory note (Secissuissory note (the issuance of Secissory (unsecured Promissory unsecured Promissory note (the issuance of issuance of an un secured Promissory note (the issuance of an unsecured Promissory note (the \u201cSecissory note (unsecured Promissory note ( secured Promissory note (or 18 secured Promissures of the issuance of an unsecured Promissory note (unsecured Promissory note (issory note (the issuer of an unsecured Promissory note (issory (Ississu: (Promissory note ( ( ( (issississory note ( secured Promissory note (issory promissory note (issory note (the Promissory note (unsecured Promissioissory note (Issuissory note (ississory note ( issuance of issuance of unsecured Promissory ( Issureissory issuer issued Issory note (the issuance of an unsecured Promissory note (the Unsecured Issued in unsecured Promissory note ( (the Issuissory (the Issing an unsecured Promissured by the \u201cNote (the \u201c note (the \u201c Promissory note (the \u201cunsecured Promisor note (unsecured Promissory note (the issuance of a result in the issuance of an secured Promissory note (the Issance of Secissory note (the issuance of our issuer of unsecured notes (determined ( Issuory note (the issuance of Note (unsecured Promissory note (unsecured Secured by ( Issing (unsecured in the issuance of an un secured Promissory note (the Ississu: [Continess ("
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What was classified as discontinued operations in the fourth quarter of 2022?",
        "options": {
            "A": "Utility-scale solar and wind group only",
            "B": "Distributed generation group only",
            "C": "Utility-scale solar, wind group, and distributed generation group",
            "D": "Remaining assets only",
            "E": "Commercial Renewables Disposal Groups",
            "F": "None of the above"
        },
        "LLM_original_answer": [
            "What is a matter."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the delinquency rate of the total loan portfolio?",
        "options": {
            "A": "0.31%",
            "B": "0.41%",
            "C": "0.50%",
            "D": "0.60%",
            "E": "0.70%",
            "F": "0.80%"
        },
        "LLM_original_answer": [
            "The most significant, or all significant inputs are not directly or for which all significant, either for which are for which are directly or the all significant inputs are based on a financial all inputs are based on a financial instruments \u2013 for which are not all significant inputs for which all significant inputs that are unobservable, either directly, either directly, either for which are unobservable, for which all significant inputs are for which all significant inputs for which all inputs for which all significant inputs, either for which all inputs for which all significant inputs are for which all significant inputs are for which is subject matter are not covered by law and for which all significant inputs that are not all significant inputs are not applicable, either directly or for which is subject matter of which all significant inputs, either directly or all significant inputs are observable, both directly or for which are for which are not, either, either significant inputs are unobservable, either, either directly or for which all significant inputs are not all other inputs are unobservable, either directly, either, either for which all significant, either a financial instruments are either a number of which are observable, either for which are not significant inputs that are for which all significant inputs that for which all significant inputs are for which all significant or for which are significant inputs for which are for which all significant inputs \u2013 for which all significant inputs for which all significant inputs that all significant inputs are for which all significant inputs 3 \u2013 significant inputs, either directly or for which are observable, either significant inputs are unobservable, either directly or through the Level  \u2013 for which all significant inputs that are for which all significant inputs are all significant inputs that all significant inputs are the institution affiliated parties are significant inputs are observable, either directly or other significant inputs that all significant inputs are observable, either directly, either directly or for which all significant, or all significant inputs are not based on a banking for which are all significant, either for which all significant inputs are not observable, either directly or for which are for which all significant inputs that which all significant inputs are not significant inputs for which all significant inputs are for which all significant inputs are for which all significant inputs are for which all significant inputs are for which all significant inputs, either directly or all significant inputs are observable, either directly or for which are observable inputs, either directly or for which are observable inputs are observable inputs are observable inputs are all significant inputs that all significant inputs are observable inputs are not observable, either directly or through the  \u2013 all inputs are all significant inputs are not all significant inputs are unobservable"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the typical duration of a patent's natural expiration in the United States if all maintenance fees are paid?",
        "options": {
            "A": "10 years from its earliest U.S. non-provisional filing date",
            "B": "15 years from its earliest U.S. non-provisional filing date",
            "C": "20 years from its earliest U.S. non-provisional filing date",
            "D": "25 years from its earliest U.S. non-provisional filing date",
            "E": "30 years from its earliest U.S. non-provisional filing date",
            "F": "35 years from its earliest U.S. non-provisional filing date"
        },
        "LLM_original_answer": [
            "What is also may arise from conflicting views may be they may be unenforceable.In addition being unenforceable.Inventive may arise from conflicting views of the parties may be it may beable.In addition, inventorship may be unenforce on the views on the on the on the claims thereon the enforcement of the greater views thereof.The pharmaceutical products thereto befit for exampled upon them thereto be unenforceable thereto the on the same.The DELig unenforcement of the unenforceable licensed thereon patents on the on the enforcement thereof.We believe on the on the foregoing the claims of the, and/or unencounts so as well known therewith respectively, and related to the on the on the on a further thereto befit as a numberous.In addition to beon the on drug candidates may be unenforced thereon the scope of the subject to the resulting from conflicting views on the unassayon the with respect to the on the subject to the use of the scope of the views thereof, and/or the products thereon the.The term thereto the unpatents thereof.We have been obtained by reason thereon thereto be they may be unenforceable thereto the views may be unissued thereon thereto the views may befit therewithinventor thereof being so thereon being unissued thereon patents may be unissued patents thereto 10/subject to date on the of our company-wide immune thereto be issued thereto our of the DELig.The DELig on the parties may befit for other than those who may be it is a numberless than those so that the views thereof.We believe that may be it is a like other than those thereto the term, however, as to the on the subject to the subject to be unen. In addition to the subject to the application of the as to the law.The Hatch-Witness may be it may be held as to the views as to be based thereon the views on the from conflicting views of aforespective views of a like those arising from such as to the development thereto the on the views on the views as to a core to the on the on the views may be they may be unenforceable therewith respect thereof to the subjecting disputes may be it may be it may be itiner on the views of the foregoing the products thereof, and/or therewith resulting thereon the subject to the views of this may arise from conflicting views thereof.The un"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What was the target hedge coverage ratio in December 2023?",
        "options": {
            "A": "25%",
            "B": "50%",
            "C": "60%",
            "D": "75%",
            "E": "90%",
            "F": "100%"
        },
        "LLM_original_answer": [
            "The interest income on the interest income on the HMBS-related borrowings are the interest income on the interest income on the secur are the interest income and HMBS-related loans and the interest income on the interest income on the loans are the interest on the interest income income on the interest income on the interest income on the interest income on the interest income on the interest income on the interest income income on the interest income are the interest income on the interest income and the securated loans and the securtesy income on the interest income on the interest income on the interest income on the interest income on the interest income are the interest income are the interest income on the interest income on the the interest income and the loans and the interest income on the securitized loans and the interest income on the interest income on the interest income on the secur securitized loans and the securated the interest income on the interest income on the securated loans are the secursecur securated borrowings are the interest income on the interest income on the secur and HMBS-related loans and the interest income on the securitized loans and HMBSecur interest income and the securated the interest income on the interest income on the interest income on the interest income on the interest income income on the securitized loans and HMBS-related borrowings are the interest income on the interest income on the interest income on the securated loans and HMBS-related borrowings are the securations are the interest income on the securt is the securt are the secur are the interest loans and interest income on the loans are the secursecuritized loans are the interest income on the interest income on the interest income on the securitized loans and interest income on the securated the securated interest income on the HMBS-related borrowings are the interest income on the securitized loans and HMBS borrowings are the secursecurated loans and interest income on the securated borrowings and HMBS-related borrowings are the interest income on the interest income on the interest income on the securated loans and the interest income on the securitized loans and HMBS-related loans and interest income on the securitized loans on the securitized loans and the interest income on the securated loans and the secur are the interest income on the securated borrowings on the interest income on the securated loans and HMBS-related loans and HMBS-related loans and the interest"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "Which factor can delay or terminate a clinical trial due to regulatory authority involvement?",
        "options": {
            "A": "Lack of sufficient product supply",
            "B": "Disagreement on clinical trial design",
            "C": "Inadequate number of patients",
            "D": "Site deviation from protocol",
            "E": "Unexpected health risks to participants",
            "F": "Public health crises effects"
        },
        "LLM_original_answer": [
            "Which may be treated blood cells, as well as well-characterized cells, which may befittinglymph further as well as shown below. Technologies and the commercial applicability of the commercial applicability of technologies and the commercial applicability of technologies and/or T cell therapy."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What has been the main issue with donations to patient assistance programs by pharmaceutical manufacturers?",
        "options": {
            "A": "The donations are not tax-deductible.",
            "B": "They have been used to promote branded drugs over cheaper alternatives.",
            "C": "They require excessive paperwork for approval.",
            "D": "They are not sufficient to cover all patient needs.",
            "E": "They are banned by all federal laws.",
            "F": "They are mismanaged by charitable organizations."
        },
        "LLM_original_answer": [
            "What the technology claimed in such technology claimed in such third parties until and until and until and until and until and until and until and/or enforcing such technology claimed in such technology so long as applications, namely until and until and until and only and/or until and until and until and until and/or until and/or until and/or and/or until and/or until and until and until and/or until and until and/or until and/or until and/or until and such technology claimed technology claimed technology claimed in such applications until and until and/or until and/or until and until and until and until and until and until and/or until and/or until and/or until and/or until and/or until and/or until and until and/or practicing the technology claimed applications until and until and until and until and/or art so applications until and until and until and until and until and until and until and until and/or until and/or until and/or until and/or until and/or until and/or until and until and/or until and such claims in such technology the technology claimed in such applications, and until such applications issued by way and until and/or until and until and until and until and until and until and until and until and until and until and such technology claimed in such applications, and until and until and until and until and until and until and until and until and until and/or until and/or until and/or until and/or enforcing the technology claimed in such applications until and/or until and until and/or until and/or third parties practicing the technology claimed in such applications. Such applications are granted until and only upon a patent or other than and practicing the a third parties practicing the technology claimed technology claimed technology claimed in such applications unless and until and until and/or until and until and until and until and until and until and/or until and/or until and/or practicing the technology claimed technology until and such technology so long until and such technology claimed in such applications, and until and until and until and/or until and/or until and/or until and such applications of such applications unless and such applications unless and only after and/or until and/or practicing the technology claimed in such applications practicing the technology claimed in such technology claimed technology claimed against such technology practicing the technology claimed in such applications unless and until and until and until and only if and until and until and until and until and/or until and until and/or until and only and only and such technology claimed in such technology claimed applications of the technology claimed technology claimed technology claimed in such applications. The technology claimed in such applications. The technology claimed in such technology against such technology practicing the technology claimed technology"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What aspect is critical for attracting and retaining customers, investors, and maintaining relationships with regulators?",
        "options": {
            "A": "Innovative product features",
            "B": "Reputation",
            "C": "Market share",
            "D": "Low pricing strategy",
            "E": "Employee satisfaction",
            "F": "Advertising campaigns"
        },
        "LLM_original_answer": [
            "What aspects \"n/a\"n/a \"n/a are subject to \"n/a\"n/a\"n/a\" are subject to \"n/a are subject to a/can \"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a \"n/a\"n/a are deemed \"n/a\"n/a\"n/a\"n/affectively \"n/a\"n/a are deemed \"n/a \"n/a\"n/a\" are \"n/a\"n/a\"n/a\"n/a are \"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\" are not only deemed \"n/a\" are \"n/a\"n/aforex n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a are \"n/a\"n/a table deemed \"n/a\" are \"n/a\" are \"n/a are subject to \"n/a\"n/a\" are \"n/a\" are not \"n/a\" are \"n/a\"n/a\"n/a \"n/a\"n/a\"n/a\" are not \"n/a\"n/a\"n/a\" are deemed \"n/a\" are \"n/a\"ICE *Percentage changes \"n/a\"n/a\"n/a\"n/a are \"n.a\"n/a\"n/a\" are subject to the \"n.aud.affectuator/a are not \"n/a\"n/a\"n/a\"n/a\"n/a are deemed \"n/a are \"n/a are \"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\" are deemed \"n/a\"n/a\"n/a\" are \"n/a\"n/a\"n/a\"n/a\"n/a\" are \"n/a\" are \"n.a\" are \"n/a\"n.a**Information About Usual markets in our business deemed \"n.a\" deemed \"n.a\"n/a\"n.affectives \"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n/a\"n.a\"n/a\"n/a\"n.affect \"n.a.21*Percentage changes in a.known.a\"n/a\"n/a\"n/a are \"n/a\"n/a are \"n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 35,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What can affect the valuation of freestanding derivatives when quoted market values are unavailable?",
        "options": {
            "A": "Only changes in interest rates",
            "B": "Changes in interest rates and credit spreads only",
            "C": "Interest rates, exchange rates, and assumptions used in models",
            "D": "Volatility and default risk only",
            "E": "Nonperformance risk and liquidity only",
            "F": "Only changes in financial indices"
        },
        "LLM_original_answer": [
            "Questions128Notes to the indirect wholly-owned subsidiaries.128 indirect wholly-owned subsidiaries.128Brighthouse subsidiaries.128Nel.Notes indirect wholly-owned subsidiaries.128Indirect wholly-owned subsidiaries.128Notes Indirect wholly-owned indirect wholly-owned indirect wholly-owned indirect wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes.128.128 indirect wholly-owned subsidiaries of indirect wholly-owned subsidiaries.128Indirect wholly-owned subsidiaries of indirect wholly-owned subsidiaries.128 wholly-owned subsidiaries.128Notes indirect wholly-owned subsidiaries.128Indirect Financial, Inc.Notes128Notes.128Notes.128Indirect indirect wholly-owned indirect wholly-owned subsidiaries.128Indirect wholly-owned subsidiaries.128Indirect wholly-owned subsidiaries.128Indirective indirect wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes.Notes Indirect subsidiaries.128Brighthouse wholly-owned subsidiaries.128Notes128Notes128Notes.128Notes to the indirect wholly-owned subsidiaries.128Brighthouse.128Notes to the indirect wholly-owned subsidiaries.128Notes to the indirect wholly-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse wholly-owned subsidiaries.128Notes.128 subsidiaries.128128Brighthouse, Inc.Notes.128.128 indirect wholly-owned subsidiaries of subsidiaries.128.128 Financial, Inc.Notes.128Notes to Notes.128Notes to indirect wholly-owned indirect wholly-owned indirect wholly-owned indirect wholly-owned subsidiaries.128Indirect wholly-owned subsidiaries.128.128Indirect wholly-owned indirect wholly-owned subsidiaries.128Notes to the indirect wholly-owned indirect wholly-owned subsidiaries.128Brighthouse wholly-owned subsidiaries.128Indirect wholly-owned subsidiaries.128.128.Notes are both indirect wholly-owned subsidiaries.128.128 wholly-owned subsidiaries.128Notes Notes.128Notes 128Indirect wholly-owned indirect wholly-owned indirect wholly-owned indirect wholly-owned subsidiaries.128.128 indirect wholly-owned subsidiaries.128Indirect wholly-owned indirect wholly-owned subsidiaries of subsidiaries.128Brighthouse Financial, Inc.Notes.Notes.128.128Indirect indirect wholly-owned indirect wholly-owned subsidiaries.128.Notes to the indirect wholly-owned indirect wholly-owned indirect wholly-owned subsidiaries.128Indirective indirect wholly-owned subsidiaries.128Indirectly Financial, Inc.Notes128.128Notes to which are both indirect wholly-owned indirect wholly-owned subsidiaries of indirect subsidiaries.128N, Inc.Notes.128.128.128.128Indirectly-owned subsidiaries.128Indirectly-owned subsidiaries of indirect subsidiaries.128Indirect wholly-owned subsidiaries.128Indirect indirect wholly-owned subsidiaries of indirect wholly-owned subsidiaries.128"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could happen if there are delays in the clinical trials of product candidates?",
        "options": {
            "A": "The marketing period under patent protection would be increased.",
            "B": "The marketing period under patent protection would be reduced.",
            "C": "The patent applications would become public immediately.",
            "D": "The company would be certain they were first to file any patent application.",
            "E": "All interference proceedings would be canceled by the USPTO.",
            "F": "Priority disputes would be automatically resolved in the company's favor."
        },
        "LLM_original_answer": [
            "What could happen if there are delays in the clinical trials of product candidates?\n\nB: The marketing period under patent protection would be reduced.\n\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?",
        "options": {
            "A": "Invests in renewable energy sources",
            "B": "Diversifies its energy portfolio",
            "C": "Enters into derivative instruments",
            "D": "Reduces energy consumption",
            "E": "Increases energy purchases",
            "F": "Halts energy operations"
        },
        "LLM_original_answer": [
            "Based on the provided document, the action the Company takes to manage commodity price risk for its merchant generation operations is:\n\nC: Enters into derivative instruments\n\nThe document details that the Company manages commodity price risk by entering into derivative instruments to manage the variability in future cash flows from forecasted energy purchases. Management considers various factors, including energy prices, weather forecasts, forecasted energy purchases, and other factors when determining the extent of its risk management strategy over commodity price risk."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?",
        "options": {
            "A": "To manage the financial statements",
            "B": "To express an opinion based on audits",
            "C": "To prepare the financial statements",
            "D": "To oversee the Company\u2019s management",
            "E": "To implement the Company's accounting principles",
            "F": "To revise the financial statements annually"
        },
        "LLM_original_answer": [
            "The responsibility of the public accounting firm regarding the Company's financial statements, as detailed in the provided documents, includes the following:\n\nB: To express an opinion based on audits.\n\nThe public accounting firm's role is to audit the Company's financial statements and express an opinion on whether they fairly present, in all material respects, the financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (GAAP). This involves assessing the financial statements for material misstatements, whether due to error or fraud, and evaluating the accounting principles used, significant estimates made by management, and the overall presentation of the financial statements."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?",
        "options": {
            "A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II",
            "B": "Note 5, within the Management's Discussion and Analysis",
            "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II",
            "D": "Note 6, within the Financial Overview section",
            "E": "Appendix A, in the Summary of Financial Policies",
            "F": "Note 7, within the Risk Management section"
        },
        "LLM_original_answer": [
            "The discussion about the allowance for credit losses measurement methodology can be found in Note 4, \"Loans and Allowance for Credit Losses\" within the Notes to the Consolidated Financial Statements in Part II of the document."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?",
        "options": {
            "A": "Competitors cannot make similar products without infringing patents.",
            "B": "Patent laws in the United States are more favorable than those in other countries.",
            "C": "Issued patents may be challenged and held invalid or unenforceable.",
            "D": "Regulatory approval for drug candidates is guaranteed.",
            "E": "Trade secrets are always more secure than patents.",
            "F": "All pending patent applications will lead to issued patents."
        },
        "LLM_original_answer": [
            "Based on the provided document, here are the reasons why intellectual property rights may not provide adequate protection for a business:\n\n1. Issued patents may be challenged and held invalid or unenforceable, in whole or in part, construe the patent\u2019s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question (Option C).\n\n2. Grounds for a validity challenge could include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement or failure to claim patent-eligible subject matter (Option C).\n\n3. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution (Option C).\n\n4. Third parties also may raise similar claims before administrative bodies in the United States or abroad, or any of which may be-"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?",
        "options": {
            "A": "Increase in market competition",
            "B": "Higher margins in the Correspondent channel",
            "C": "Decline in setup fees for loans boarded",
            "D": "Increase in HECM loan proceeds",
            "E": "Decrease in revaluation gains on MSRs",
            "F": "Higher production volume in retail channels"
        },
        "LLM_original_answer": [
            "The primary reason for the decrease in other revenue, net for 2023 compared to 2022 is D: Decrease in revaluation gains on MSRs.\n\nHere's the step-by-step reasoning:\n\n1. The document mentions that the Pledged MSR liability expense for 2023 increased due to a $42.4 million increase in servicing spread remittance on the ESS financing liabilities issued beginning in the third quarter of 2022.\n\n2. The Rithm servicing fee, which includes the total servicing fees collected on behalf of Rithm relating to the MSR sold but not derecognized from our balance sheet, declined by $6.9 million, or 9% as compared to 2022.\n\n3. The retained subservicing fee percentage of UPB for Rithoutstanding as of the MSR originations and related to originations and MSR originationsThe primary mortgage loan production and other financing liabilities at December 8. In addition to the Companywide net interest income taxes and Commitmentionsurely include the Company-owned subsidiaries and related to maturity profiles.The following the Companywide MSR originations, net of subsidiaries and other financing liabilities, net of $9.128Borrowingsubnotes 128Brighthouse 128Brighthouse mortgage loan purchase agreements, on a.mortionservations and MSR transfers that are primarily consists of the following the Companywide-ranging from the Companywide, which are primarily due to the Companywide-ranging from the Company-wide owned subsidiariesNotes 128Brighthouse loans and other financing liabilities, primarily due to the Company-owned subsidiaries are primarily due to maturity and the following the following the Company-owned subsidiaries are both the Company-owned subsidiaries.The following the CompanyNotes and Subserves and other financing liabilities, mostly attributable to the Company-wide net interest expense related to the Companywide notes and flow purchase agreements with respect to the Companywide, which includes $0.128Brackets of PHHousing rates and production and the Companywide, net of PHHousing rates and mortgage originationsWe originate-to-originated MSR capital structure and purchase and the Companywide notes payable MSR purchase agreements with a 2023.128Brighthouse Financial Services and other than 128Brighthouse notes and MSR transfers of $2.128Brighthouse notes that are both indirect wholly-owned subsidiaries are both indirect wholly-owned subsidiaries of the following the Company-owned subsidiaries are both indirect wholly-owned subsidiaries of Rith-owned subsidiaries are both indirect wholly-owned SubsNotes to the Companywide notes payable to the Ginnie Mae Can you can impact to"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?",
        "options": {
            "A": "Lack of innovative product features",
            "B": "Limited product supply",
            "C": "Inability to maintain effective sales forces",
            "D": "High regulatory costs",
            "E": "Insufficient funding for development",
            "F": "Excessive competition in the product market"
        },
        "LLM_original_answer": [
            "The potential challenge mentioned in establishing collaborations for sales and marketing, as per the provided document, is the inability to maintain effective sales forces (Option C). This challenge is significant because the success of sales and marketing collaborations often hinges on the ability to effectively communicate the value of the product to potential customers, which requires a skilled and knowledgeable sales force. The document also highlights the importance of training medical personnel to understand the side effect profile of the product candidates, which is crucial for managing toxicities resulting from T cell therapy. This training is necessary because such toxicities are not commonly encountered in the general patient population and by medical staff. The document further discusses the potential risks associated with the manufacturing process, including the possibility of vector-related insertional oncogenesis, which could lead to the development of new cancers or other adverse events. Additionally, the document mentions the challenges in patient enrollment for clinical trials, which can be influenced by various factors such as patient eligibility criteria, the availability of donors, and the impact of public health crises. The document also addresses the risks associated with international operations, including differing regulatory requirements, economic and political instability, and challenges in enforcing the ability to train medical personnel may not only indirectly or third parties, including our product candidates, if we may not only subsidiaries of our product candidates are also may not being developed product candidates may notehaspects related to recognize thesafety and thesafety and the safety and/or development and other than cankeratinvestigeneedirectlyncertaind ataffectively, if we may not-yeternaly, as well-established product candidates may noteherequirements.128notes to aquirements related to thesespecifically-owned subsidiaries of our product candidates.128product candidates and third-party owned subsidiaries offtargetsponsors offto, or the Company Notes to market access to this Company Notes to the product candidates may not being developed product candidates, as well as well as well-established product candidates for-profitable product candidates may not being an indirect subsidiaries, including, including the Company.Notes:128Brighthouse notes that could result in vivo, including, including, including, or other than we areadyespecially, the Company Notes topline 128notes to 128Brighthouse and other thanr and the development and other than those notes that could result in the product candidates are both indirect wholly-owned subsidiaries of our product candidates and our product candidates may encounter difficulties in Notes to develop product candidates and the complexity and our product candidates may not included in-Notes to a.128Braille,"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one reason AMX0035 might fail to obtain regulatory approval?",
        "options": {
            "A": "Manufacturing processes are found to be deficient",
            "B": "Clinical trials easily surpass statistical significance",
            "C": "FDA agrees with the interpretation of preclinical studies",
            "D": "Patient opinions are highly positive",
            "E": "Regulatory authorities consistently approve design implementations",
            "F": "Clinical trials detect an exceeding positive effect"
        },
        "LLM_original_answer": [
            "One reason AMX0035 might fail to obtain regulatory approval is due to deficiencies in manufacturing processes (Option A). The document outlines the extensive regulatory requirements and potential challenges in obtaining and maintaining regulatory approvals for AMX0035. It mentions the need for successful completion of preclinical studies and clinical trials, patient enrollment and the FDA, or any of the FDA, or other than AMX0035We are required to date of AMX0035.128We are subject to support of the FDA, Inc.NCE and the FDA, or delay or the FDA, or any such regulatory authorities may not only have not only have not only have not only have not only one offtoFailing to support for any clinical trial data from the FDA and other than canary Financial Statements of AMXandriving regulatory and the FDA and the FDA, and the FDA and commercialization, or experience with conditions of AMXandr any such as well-controlled subsidiaries of AMX, or if we are both indirect wholly-owned subsidiaries of AMX, including post-marketing approval of AMX0035\nParsedrugicreliability to support the FDA, if we are both preclinical trials of AMX.128Brighthouse, the FDA, the E:128Brighthouse and the FDA, or to market authorization with conditions for AMX\n[textileicreliken Financial, or other than if the FDA, or the FDA, if, or if the FDA, or experience-licensed product candidates for ALS is a fixed-dose, and marketing authorizations and Health Canada and the FDA, or other than we are also facespayers of AMXpayers are both in ALS (i.e.given the FDA, or other indirect wholly-owned subsidiaries of AMX\u00f6m\nThe Company.Notes are both indirect wholly-owned subsidiaries of the FDA, Inc.Notes to the Safety, indirect wholly-owned subsidiaries of the Company Structure and Other Indirectly, Inc.128Brighthouse of the FDA and Notes to satisfy applicable regulatory authorities may not only have both indirect wholly-owned subsidiaries of the indirect wholly-owned subsidiaries of AMXrayonwardly-owned subsidiaries are both indirect wholly-owned subsidiaries are both indirect wholly-owned subsidiaries are both preclinical trials of our current and ongoing clinical trials of the FDA and the FDA Approval of our current and marketing authorization to support for AMX\nThe FDA, Health Canada.Notes to the Company-owned subsidiaries of the FDA, Inc.128Brighthouse-owned subsidiaries of the FDA and indirect wholly-owned subsidiaries of the U.SecNotes to the Company"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the purpose of Section 31 fees according to the Exchange Act?",
        "options": {
            "A": "To finance market makers on exchanges",
            "B": "To cover the costs of technology upgrades",
            "C": "To recover the government\u2019s costs of supervising and regulating the securities markets",
            "D": "To reward high-frequency traders",
            "E": "To fund international trading agreements",
            "F": "To support trading education programs"
        },
        "LLM_original_answer": [
            "The purpose of Section 31 fees according to the Exchange Act is to recover the government\u2019s costs of supervising and regulating the securities markets."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?",
        "options": {
            "A": "5%",
            "B": "10%",
            "C": "15%",
            "D": "1%",
            "E": "0.5%",
            "F": "2%"
        },
        "LLM_original_answer": [
            "To answer the question, \"What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?\" we need to refer to the document provided. However, the document does not contain specific information about the top ten holdings in the corporate fixed maturity securities portfolio or their respective percentages of the total investments. Therefore, it is not possible to determine the percentage of total investments that the top ten holdings comprise based on the information provided in the document."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could happen if there are delays in the clinical trials of product candidates?",
        "options": {
            "A": "The marketing period under patent protection would be increased.",
            "B": "The marketing period under patent protection would be reduced.",
            "C": "The patent applications would become public immediately.",
            "D": "The company would be certain they were first to file any patent application.",
            "E": "All interference proceedings would be canceled by the USPTO.",
            "F": "Priority disputes would be automatically resolved in the company's favor."
        },
        "LLM_original_answer": [
            "Based on which are both the U188a newly developed bylawsuits Financial Results of our wholly-owned subsidiaries.128Brighthouse Financial Services, Inc.Notes to the United States, as well-being-owned subsidiaries.128128Brighthouse of our business partners and Financial, Inc.November 128Brighthouse Notes to the U.See.128Brighthouse-owned subsidiaries of this Annual Report to the U.See of subsidiaries of Brighthouse Financial Statements of this Annual Report to the Notes to the Securities and Other Subs License Agreement to the United States to be to be Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes to Brighthouse Financial and Related Party to FDA.Notes to this Annual Report to-beholders of Brighthouse Financial, Inc.Notes to Form 128Brighthouse Financial Statements of Brighthouse Financial Statement of Financial Statement of this document. Inc.Notes to Form 128Brighthouse Financial Statements of Financial, as well-owned subsidiary.128Brighthouse Financial Statements of Brighthouse Financial Statements and/orphan Financial Statements Related Party to Brighthouse Financial Services, Inc.Notes to this document Notes toplinearthritis Inc.Notes:128Brighthouse Financial Services.128owned subsidiaries.128Brighthouse Financial, Inc.Notes Financial, Inc.Intermediate the United States.128Brighthouse Financial Services.128of Brighthouse Financial, Incidental to the Securities and Brighthouse Financial Statements and License Agreement to bequest Notes to the United States, Inc.Notes to the above the above the U.See\nDocument:128Brighthouse Financial Statements:128Brighthouse Financial Services.128Brighthouse Financial, ongoing.128Brighthouse Financial Services, Inc.128Notes to Financial Services Contracts, 128Brighthouse Financial Statements to Form 128Brighthouse Financial Statements to-wholly-owned subsidiary.128Brighthouse Financial Statements to this Annual Report to which are indirect wholly-owned subsidiary.128Brighthouse Financial, wholly-owned subsidiary.128Brighthouse Financial Statements and Other Information Technology and in-8aFinancial Operations\u2014Collaborated Financial Conditionally-owned subsidiary.owned subsidiaries.128Brighthouse Financial Results of this Annual Report to the U.SeeThe U.See:128The U.See:128Brighthouse subsidiaries.128a\n_NPC Inc.128Brighthouse Financial Statements of the \u201cForm 128Brighthouse Financial and other wholly-owned subsidiaries.128 wholly-owned subsidiaries.128Brighthouse Holdings, Inc.Notes to Form 28a wholly-owned subsidiaries of Brighthouse subsidiaries of Brighthouse Holdings, wholly-owned subsidiaries.128a.128a128Brighthouse to"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?",
        "options": {
            "A": "Invests in renewable energy sources",
            "B": "Diversifies its energy portfolio",
            "C": "Enters into derivative instruments",
            "D": "Reduces energy consumption",
            "E": "Increases energy purchases",
            "F": "Halts energy operations"
        },
        "LLM_original_answer": [
            "Based on Notes Payroll-offer Financial Statements of the Notes Payable Financial Statements of $0.128owned subsidiaries.128Brighthouse, Inc.128Brighthouse Holdings and Core Scientific, and wholly-owned subsidiaries.128Brighthouse subsidiaries.128128Corporate Guarantelope Financial Statements to the Consolidated to the Company Segment Total Operating and Related Party to the Company\u2019s consolidated financial statements to Form 128Brighthouse Financial Statements of the Company\u2019seBookholders\u2019 sEarnings of Core Scientific, and indirect wholly-owned subsidiaries.128Brighthouse.Communitedirect wholly-owned subsidiaries. Inc.128Notes Payingressurex\n_ctxt 2024The following the Company\u2019s consolidated financial statements of the Company Subsequent to Core Scientific, Inc.Notes to the Consolidated to the Consolidated to the Company-wide Owned and Financial Statements of Core Scientific and other subsidiaries.128128Brighthouse to the Company Segment Total Assets to the Company\u2019s consolidated Statements of the Financial Statements of Part II-S19Operating and Other Financial Statements of Part II, Item 2022ndirectlyeBookings.Emerchapters to the Company.Notes to our consolidated financial statements.128Brighthouse Financial Statements of Core Scientific, Inc.Notes to the Company Commitments to the Company.128Brighthouse.128Brighthouse of Core Scientific and NotesPayments to our consolidated financial statements of Core Scientific and other than $1.128Brighthouse subsidiaries.128Brighthouse Financial Statements of Core Scientific and Related Party-Owned Digital Asset and Supplementary Data to the Financial Statements of Core Scientific, Inc.2020subsidiDirect Financial Statements of Financial Statements of the consolidated financial instruments of Core Scientific and 2023. Inc.Notes to the Consolidated to the consolidated financial statements of Core Scientific, Inc.Notes to the Company.Notes to Core Scientific and Financial Statements of Part II.128Brighthouse.128Brighthouse subsidiaries.128Brighthouse subsidiaries.128Brighthouse, Inc.Notes of Core Scientific Research and Core Scientific, Inc.Notes to the parent company.128Brighthouse and Core Scientific and Financial Statements of Part II, Inc.128Brighthouse Financial Statements of Part II, Inc.Notes to the Company\u2019s consolidated financial statements of Core Scientific, Inc.Notes to the Company.128Brighthouse-owned subsidiaries.128Brighthouse Financial Services, wholly-owned subsidiaries.128128subsidiopathic Financial Statements of Core Scientific, Inc.Notes Paying critical accounting policies.128Brighthouse Financial Statements of $1During the Company\u2019s notes payable.128Brighthouse Financial Statements of the Company\u2019s"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?",
        "options": {
            "A": "To manage the financial statements",
            "B": "To express an opinion based on audits",
            "C": "To prepare the financial statements",
            "D": "To oversee the Company\u2019s management",
            "E": "To implement the Company's accounting principles",
            "F": "To revise the financial statements annually"
        },
        "LLM_original_answer": [
            "Based on the \u201cA128Brighthouse Financial Statements of Duke Energy, Inc.Notes to Consolidated to the Financial Statements of Financial Statements of the Company Consolidated to the Company's auditor\u2019s to the \u201cFiscalogus, Inc.128Brighthouse Financial Statements of Brighthouse Financial Statements of Brighthouse Financial Statements of Financial Statements of the Financial Statements of the Financial Statements of the U.See subsidiaries.128Financial, Inc.128Brighthouse and Financial Statements of Duke Energy Company.128Brighthouse Financial Statements of Duke Energy Holdings and Progress Energy, Inc.Notes to Consolidated to Consolidated to the Financial Statements of the Notes to Consolidated Financial Statements of Brighthouse Financial Statements of Consolidated Financial Statements of Duke Energy, among others.128Brighthouse-owned subsidiaries.50% of Duke Energy, Inc.Notes/wholly to the financial statements of Duke Energy, Inc.Notes to the Company N/Audit to the \u201cA:128##table 128128Brighthouse subsidiaries.128128128##table 128Brighthouse and Financial Statement of Independent Registered Public Company to the Company\u2019s Financial Statements of Duke Energy Holdings to the Company.128128128Brighthouse LLP.128128Brighthouse Financial Statements to the Notes to Consolidated to the Company\u2019s Financial Statements of Duke Energy Company\u2019s consolidated financial statements of the Notes to the Company\u2019s critical audit committee.128Brighthouse to the Company, Inc.Notes to the \u201cCritical Audit Committee on behalf of Duke Energy Company is a\nAnswer:The Company.128Brighthouse Financial Statements of Duke Energy Company.128##table of the Company\u2019s consolidated financial statements of the \u201cFinancial Statements of Duke Energy & 128Brighthouse subsidiaries of the U.San energy companies are both companies are both indirectly-owned subsidiaries of Financial Statements of Progress Energy Financial Statements of the Financial Statements of Duke Energy Regulatory Financial Statements of recorders of Duke Energy Company Operations, Inc.Consolidirectly/special subsidiaries.128Brighthouse Financial Statements of the following the Financial Statements to the financial statements to the Company\u2019s consolidated financial statements of Brighthouse-owned subsidiaries.128Brighthouse to the Financial Statements of Progress Energy Holdings and EPCAO to the \u201cFinancial Statements of the \u201cFinancial Statements of Brighthouse of the Financial Statements to Duke Energy Company.128Brighthouse and other-owned subsidiaries.128Brighthouse Financial Statement of North Carolina, Inc.128##table 128Brighthouse to the \u201cCritical Audit Opinion on Notes to the Financial Statements of the Financial Statement of the Company\u2019s internal controls over the \u201cCritical Audit (the financial statements of the Company"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?",
        "options": {
            "A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II",
            "B": "Note 5, within the Management's Discussion and Analysis",
            "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II",
            "D": "Note 6, within the Financial Overview section",
            "E": "Appendix A, in the Summary of Financial Policies",
            "F": "Note 7, within the Risk Management section"
        },
        "LLM_original_answer": [
            "To determine financial instruments.128Brighthouse Holdings, Inc.128Brighthouse, Inc.Notes to the Financial Positioning.Notes.128Brighthouse Financial Overview of the Financial Overview of the Consolidated Financial Overview of the Financial Overview of certain other.128Brighthouse-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse subsidiaries.128The following the Financial, Inc.129Brighthouse Financial Overview of which are both.128The following to the Notes to the primary market segments.The following the FHLB Financial, Inc.Notes to the Consolidated to the Year-Subsequent to $0.128Brighthouse of Brighthouse subsidiaries.128128128Brighthouse Financial Overview to the to be to Non-1.128Brighthouse subsidiaries.128Brighthouse Financial Overview of the aggregate consolidated financial statements.128Brighthouse to the Notes to $1Brighthouse Financial Overview of the allowance for the following the Financial Overview of the allowance for the Notes to the Bank Holding Company Guarant Financial, Inc.Notes to the notes.128128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes to Form 128Brighthouse-owned subsidiaries.128Brighthouse Financial Overview of the aggregate credit unionized subsidiaries.128Brighthouse Financial OverviewSection 2023.128Brighthouse Financial Overview of the Consolidated Subs.128Brighthouse Financial Overview and solely-owned subsidiaries.128Brighthouse Financial, Inc.Notes to the Consolidated subsidiaries.128Brighthouse Financial, Inc.Notes to the Consolidated to the Consolidated to the Company\u2019s allowance for the Company Profile of the following the Financial Overview of to the Consolidated Financial Overview of Notes to/from discontinued operations.128Brighthouse-owned subsidiaries.128Brighthouse Financial Overview of the Notes to Non-Notes to $5##Brighthouse-owned subsidiaries.128Brighthouse Financial Overview of New York, Inc.Notes to Other Subs.Notes to the notes.128Brighthouse Financial Overview of Notes to the aggregate net income from indirect wholly-owned subsidiaries.128Brighthouse Financial Overview.128Brighthouse Financial Overview of the Bank\u2019s total assets.128subsidiDirect Subs.128 wholly-owned subsidiaries.128\nPlease answer to the Notes to beholdings.Notes.128Brighthouse Exposure to Non-Government Financial Overview of the aggregate.128Brighthouse Financial Overview of $0.128Brighthouse Financial Overview of the Financial Overview of $0Notes to-beh.128Brighthouse.128Brighthouse Financial Overview and/orient to the year ended December 128Brighthouse Financial Positioning.128Brighthouse Financial"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?",
        "options": {
            "A": "Competitors cannot make similar products without infringing patents.",
            "B": "Patent laws in the United States are more favorable than those in other countries.",
            "C": "Issued patents may be challenged and held invalid or unenforceable.",
            "D": "Regulatory approval for drug candidates is guaranteed.",
            "E": "Trade secrets are always more secure than patents.",
            "F": "All pending patent applications will lead to issued patents."
        },
        "LLM_original_answer": [
            "One of Holdings, Inc.Notes to the Company Description of the indirect wholly-owned Patent Applications to the Companywide subsidiary.128Brighthouse Financial Statements of Brighthouse Financial Statements to the indirect wholly-owned subsidiaries are both Brighthouse subsidiaries of the United Stateside indirect wholly-owned Patent Applications to the United States of Brighthouse subsidiaries of recordation subsidiaries of the United States to Acutech 1 to the United States and/or Brighthouse Financial Statements to the exclusive licensees of the U.See.128Brighthouse subject to the parent companies of the document from Time to the United States to the Notes to the United States. Inc.Notes: Indirect wholly-owned subsidiaries are to the Notes to the Notes to the parent company.128Brighthouse Financial, Inc.Notes: Notes to the parent company-wide Notes. Inc.Notes:128Brighthouse-owned subsidiaries.128Brighthouse-owned subsidiaries.128Brighthouse Financial Services, or majority-owned subsidiary.128Brighthouse-owned subsidiaries.128Brighthouse-owned subsidiary.128Brighthouse-owned subsidiaries.128Brighthouse Notes.Notes.128Brighthouse subsidiaries.128Brighthouse, Inc.Notes to Patent to Brighthouse Financial Statements and/or patent applications.128Brighthouse Pharmaceuticals, and/or patent applications and/or patent applications and Other Information Technology, Inc.128Brighthouse subsidiaries.128The aggregate_income_tg, Inc.Notes:128Brighthouse.128Brighthouse subsidiaries of Brighthouse Energy Services, Inc.Notes to the Company of Brighthouse Financial Statements of Brighthouse to Brighthouse Financial, Inc.Notes to Financial Statements to Securities Financial Statements to Brighthouse Financial Statements to beBrighthouse subsidiaries of Brighthouse subsidiaries.128Brighthouse Holdings of Brighthouse Notes to Brighthouse-owned subsidiaries are all other Financial Statements.128The U.SECBran 128Brighthouse Financial, Inc.NX-Notes to Brighthouse Financial Statements of the parent company-wide subsidiaries.128Brighthouse Financial Statements of the notes.128128Brighthouse Financial, Inc.Notes to the United States are both indirect subsidiaries.128Brighthouse Financial Statements to Brighthouse Financial Statements to Brighthouse Financial Statement of Financial, Inc.Notes to the United States of the United States of Brighthouse Financial Statements to Marketedirectlyndirect subsidiaries.128128128Brighthouse Financial Services, Inc.Notes to be\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?",
        "options": {
            "A": "Increase in market competition",
            "B": "Higher margins in the Correspondent channel",
            "C": "Decline in setup fees for loans boarded",
            "D": "Increase in HECM loan proceeds",
            "E": "Decrease in revaluation gains on MSRs",
            "F": "Higher production volume in retail channels"
        },
        "LLM_original_answer": [
            "The following the Servicing Financial Services.128Brighthouse Financial Statements of New York, Servicing to the consolidated financial statements to the following notes.128The following mortgage loan production costs and indirect wholly-owned subsidiaries.128The following consolidated subsidiaries of the following (formerly acquired CRLPAs of Other Financing and RFI 2023.128128Brighthouse Financial Statement of Other Financing Notes to the Consolidated to Consolidated subsidiaries.128Brighthouse Financial, Inc.Notes to the consolidated financial instruments.128Brighthouse Financial Statements of Notes to the Financial Instruments and Brighthouse Financial, Inc.128Brighthouse Financial Services and/or wholly-owned subsidiary.128Brighthouse Financial, Inc.Notes to the following sale accounting treatment of the Servicing subsidiaries.128Brighthouse Financial, wholly-owned mortgage servicing agreements.128Brighthouse Financial Statements to the to the Collected to the consolidated financial statements of HECBasis anounced to the Company-wide notes.The following the Consolidated to the Consumer Directlyrics are both indirect subsidiaries.128The parent company (Facts. Inc.Notes to the mortgage servicing and direct subsidiaries.128The following the notes to Ginnie Mae Mortgage Servicing to the consolidated financial statements of Brighthouse to Corporate Items to Ginnie Mae Canopy to the Consolidated wholly-owned mortgage servicing and Related Party to the Notes.128The following GAAPCitations.128Brighthouse Financial Statement of Brighthouse Financial Statements of Mortgage Servicing to the NotesOther Financing Costs and indirect wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes to the Consolidated to the following the following the indirect wholly-owned subsidiaries.128Brighthouse Financial Services.ServicingoC Financial Services, Inc.Notes to the Company-wide owned subsidiaries.128Brighthouse Financial Statements of Financial Statements of the consolidated financial statements of Mortgage Servicing to the Ginnie Financial Statements and Other Financing Liabilities to Ginnie Financial Statements of Mortgage Servicing to the Servicing to the parent company subsidiaries are both wholly-owned subsidiaries are both indirect wholly-owned to the Company-wide Other Financing Liabilities to the parent company-owned subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial Statement of Other Financing Liabilities to the U.ServiNotes to the financial instruments.128Brighthouse Financial Institutions, Inc.128Brighthouse Financial Statements of Brighthouse Financial Instruments and/or purchase mortgage loan production volume-related party notes payable mortgage servicing and MSR.128Brighthouse-owned subsidiaries.128Brach, Inc.128Brighthouse accounting fair value and indirect wholly-owned subsidiaries of Brighthouse Financial Institutionally"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?",
        "options": {
            "A": "Lack of innovative product features",
            "B": "Limited product supply",
            "C": "Inability to maintain effective sales forces",
            "D": "High regulatory costs",
            "E": "Insufficient funding for development",
            "F": "Excessive competition in the product market"
        },
        "LLM_original_answer": [
            "A: Item 2024. Inc.Notes to the U.SECB:128Brighthouse Financial Statement of Brighthouse Financial Statements to Financial, Inc.Brighthouse, wholly-owned subsidiaries.128Brighthouse Inc.Notes to the following the Company Description:128Brighthouse Financial Statements to:128Brighthouse Inc.Notes to Market Acceptancestems.128Brighthouse Financial Statements and Related Party Nomenclator to thesponsored subsidiaries are the above is an d 2024.128Brighthouse to bequesta-owned subsidiaries.128Brighthouse Financial Services, Incurredge Financial, Inc.Notes to Consolidated Financial Statement of the Financial and Other Subsequent to the TSC-Notes to Brighthouse Financial (the U.See Financial, Inc.Notes to Brighthouse Financial Statement of the parent company-owned subsidiaries are both companies.128Brighthouse Financial Statements to date of certain notes.128owned subsidiaries.128Braille Financial, Inc.Notes:128Brighthouse-owned subsidiaries.128Brighthouse Financial Statements of Brighthouse of Brighthouse Financial, Inc.Notes: Consolidated to the U.See E: A.DiscL128Brighthouse Financial Statements of Brighthouse, Inc.Notes128Brighthouse Financial Statements of the U.Sources:128Brighthouse-owned subsidiaries.128Brighthouse.128subsidiocy Financial Statements to Brighthouse-owned subsidiaries. Financial, Inc.Notes:128Brighthouse Financial Statements to CROAs an indirect wholly-owned subsidiaries.128Brighthouse EHRBranthefg Financial, Inc.Notes to Consolidation to the COVID-Notes: 2024.128Brighthouse, Inc.Notes to the Company-wide owned subsidiaries. Financial, Inc.Notes to Market Acceptancestral Notes to or third-party-owned subsidiaries.128Brighthouse Financial Statement of Brighthouse Financial Statement of the following this document.Notes:\u2022the financial statement of the adverse to support the company. Inc.Notes:128Brighthouse Financial Guarantor owned subsidiaries.128Brighthouse Financial, Inc.Notes to the U.SeevirusFinancials of Brighthouse Financial, Inc.Notes to Notes to Notes to the SEC. Financial, Inc.Notes: A* TSC128Brighthouse-owned subsidiaries.128Brighthouse Financial, Inc.1. Financial, Inc.Notes128Brighthouse Financial Statement of the U.San indirect wholly-owned subsidiaries of Brighthouse Financial Statements and its subsidiaries.128Brighthouse Financially-owned subsidiaries.128Brighthouse Financial and Brighthouse to the document: 128Brighthouse Financial and TSC-employee"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is one reason AMX0035 might fail to obtain regulatory approval?",
        "options": {
            "A": "Manufacturing processes are found to be deficient",
            "B": "Clinical trials easily surpass statistical significance",
            "C": "FDA agrees with the interpretation of preclinical studies",
            "D": "Patient opinions are highly positive",
            "E": "Regulatory authorities consistently approve design implementations",
            "F": "Clinical trials detect an exceeding positive effect"
        },
        "LLM_original_answer": [
            "One of the U.See Financial Statements of Brighthouse, Inc.Notes to the U.See. Inc.Notes:128Brighthouse Financial Statements to the United States and future regulatory authorities.128Brighthouse Holdings, Inc.128128Brighthouse subsidiaries.128128128Brighthouse, Inc.Notes to the U.See 128128Amber to the U.See indirect wholly-owned subsidiaries.128 subsidiaries.128128Brighthouse, Inc.Notes to the U.See.128Brighthouse Financial Statement of the U.See.128Amber Financial Subs are both subsidiaries.128Brighthouse NDA 128Brighthouse, Inc.Notes to the FDA.128Brighthouse Financial Statements of Brighthouse Financial Statement of AMX128Brighthouse Financial Statement of the U.See.128Brighthouse Financial Statement of 2023\nQ: (ipty-owned subsidiaries.128128Brighthouse-owned subsidiaries.128Brighthouse-owned subsidiaries of the Oligately-owned subsidiaries of Brighthouse Financial Results of the U.SeeNotes to the U.See subsidiaries and its business partners of the U.SeeNotes to the U.SeeNotes to Marketedirect wholly-owned subsidiaries are both subsidiaries are both indirect wholly-owned subsidiaries are both indirect wholly-owned subsidiaries of the U.San subsidiaries of Brighthouse Financial, Inc.Notes to the subsidiaries of Brighthouse Financial Statements of Financial, Inc.Notes128Brighthouse Financial Statements of the EAEAdearbitrary Financial Statements: The Oligand Financial, Inc.Notes to the Financial Statements of the EMAAdearthritis.128Brighthouse-owned subsidiaries are both indirect wholly-owned subsidiaries.128Brighthouse-owned subsidiaries.128Brighthouse Financial, Inc.Notes of subsidiaries.128Brighthouse Financial, Inc.Notes to the U.See Notes to Form 128Brighthouse Financial Statements of the U.See Notes128Brighthouse, Inc.Notes to support for the U.See, Inc.Notes to treatioxyNotes:128Brighthouse Financial Services.128Brighthouse Financially, wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes to Form 128Brighthouse Financial Statements of the EMAX.Notes to Brighthouse Financial Statement of the U.See Notes to which are both subsidiaries.128Brighthouse Financial, Inc.Notes:128Brighthouse Financial Results of the U.See Notes to the EMAAdeemedichestsafety, or potential competitors.128Brighthouse Inc.128Brighthouse, Inc.128Brighthouse.128Brighthouse Financial Results of"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the purpose of Section 31 fees according to the Exchange Act?",
        "options": {
            "A": "To finance market makers on exchanges",
            "B": "To cover the costs of technology upgrades",
            "C": "To recover the government\u2019s costs of supervising and regulating the securities markets",
            "D": "To reward high-frequency traders",
            "E": "To fund international trading agreements",
            "F": "To support trading education programs"
        },
        "LLM_original_answer": [
            "Based on the U.See. Financial, Inc.128Brighthouse Holdings and indirect wholly-owned subsidiary.128Brackets to the New York, and 128Financial, Inc.Notes 128Brighthouse, Inc.Notes to February 2022.128Brighthouse Financial Statements of the Financial Services, Inc.Notes to which are presented in the U.See.128Brighthouse-owned subsidiaries.128Brighthouse Holdings, or Section 128owned subsidiaries.128128ITEM 2022ndirective Financial Statements of the following discussion of the following the following the following the following the \u201cBloomberg subsidiaries.128128128128Brighthouse to the U.See \u201c- Other Information about the following the following the U.See, Inc.Notes to the U.See.128Brighthouse to which are included in Item 2023.128Brighthouse Financial Statements of the following the following the following the following the Exchange Actuar.128ITEM 2023.128Brighthouse Financial Futures and Eureg Financial Statements and Brighthouse N.V128ITEM 2024.128Brighthouse Financial Statements of Intercontinental Financial Statements to the Exchanges to the following the following the following the following year-end of the following the following the notes to the consolidated financial performance obligations.128Brighthouse Financial Performance Oblig.128subsidiirectly NotesThe following the Notes 2022.128Brighthouse Financial Statements and EQUARBIT 2022.128Brighthouse subsidiaries.128Brighthouse Financial Statements and Black Knight Global Income Taxes and direct subsidiaries of Brighthouse Financial Statements of Intercontinental Financial Statements of the Exchange ActuaratoryITEM 2023.128Brighthouse subsidiaries.128Brighthouse Financial Services, Inc.Notes to Form 2023.128Brighthouse Financial Highlights128Brighthouse-owned subsidiaries. Inc.Notes to our 2023.128Brighthouse-owned subsidiaries.128Brighthouse Financial Highlights of the parent companies.128Brighthouse Financial, Inc.Notes to the consolidated financial statements of the consolidated financial highlights.128Brighthouse Financial Highlights128Brighthouse 128Brighthouse Financial Highlights of Brighthouse Financial HighlightsThe following December 2023.128Brighthouse Financial Results of our consolidated nettingerated of our consolidated financial service providers of Intercontinental Financial Services and Other Financial Statements to Black Knight Global Financial Statements and Other Sub Sub.Notes to 2023.128Brighthouse Financial Highlights2018.128Brighthouse Financial Highlights128Brighthouse Financial HighlightsThe following year-endowed interest rate per-contractors Financial Services and other financial services."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?",
        "options": {
            "A": "5%",
            "B": "10%",
            "C": "15%",
            "D": "1%",
            "E": "0.5%",
            "F": "2%"
        },
        "LLM_original_answer": [
            "To the Consolidated to the Year Ended December 2023Brighthouse Financial Disclosures.128Brighthouse Financial Discussed Financial Disclosures.128Brighthouse Financial Disclosures.128Brighthouse Financial Statements of the Consolidated wholly-owned assets.128Brighthouse-owned subsidiaries.128Financial Holdings, Inc.128Brighthouse Financial Guarantirectly-owned subsidiaries.128Brighthouse Financial Guarant Financial Disclosures to Brighthouse Financial Statements to the Consolidated to the Consolidated Financial Statements of the following the Consolidated Financial Statements of the Consolidated Earnings to the Consolidated Financial Statements of the Consolidated Earnings \u2014 Notes to the most directly-owned subsidiaries.128Brighthouse Financial Statements of the Company-Owned Insurance Company-wide owned subsidiaries are both indirect wholly-owned Subs 2023.128Brighthouse Financial Statement of the following the most directly-owned subsidiaries.128 subsidiaries.128Brighthouse Financial, Inc.Notes to the Consolidated to the following the Company Segment Results of the Financial Services Conversion to the Notes to the Company-owned subsidiaries are both indirect wholly-owned subsidiaries.128Brighthouse Financial Statements of the Consolidated E: 2023.128Brighthouse Financial Conditionally Available-for-sale of the Notes to Brighthouse Financial Conditionally, net investment hedge accounting treatment of the Year Ended December 2023.128Brighthouse Financial Services Agreement Services Agreement to December 2023##table 2023.128Brighthouse subsidiaries.128Brighthouse Financial Statements of Brighthouse.Notes to the ULSGainsuredirectly-owned subsidiaries.128Brighthouse Financial Instruments and are both in the year-end of the Company.Notes to the Consolidated Earnings to the Consolidated E: We also includes indirect wholly-owned subsidiaries.128Brighthouse Financial Statements of Corporate &amp; Corporate & Other Financial Disclosed subsidiaries.128Brighthouse Financial, Inc.Notes to the Consolidated to the Consolidated to Brighthouse Financial Disclosures to the following the consolidated results of Brighthouse Financial Disclosures to the Year Ended December 2023.128Brighthouse subsidiaries.128Brighthouse Financial Disclosures. Inc.Notes to the Company-owned subsidiaries.128Brighthouse Financial Statements of Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes to the Consolidated Earnings of the Consolidated securities lending and 2023, Inc.Notes to the following the following the following the consolidated results of the most directly-owned subsidiary.128Brighthouse Financial Services, which is an actuariously, as of the Company.128Brighthouse.Notes to Brighthouse Financial Disclosures.Notes to the"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could happen if there are delays in the clinical trials of product candidates?",
        "options": {
            "A": "The marketing period under patent protection would be increased.",
            "B": "The marketing period under patent protection would be reduced.",
            "C": "The patent applications would become public immediately.",
            "D": "The company would be certain they were first to file any patent application.",
            "E": "All interference proceedings would be canceled by the USPTO.",
            "F": "Priority disputes would be automatically resolved in the company's favor."
        },
        "LLM_original_answer": [
            "If you are both are both indirect wholly-owned subsidiaries.128Brighthouse Financial, wholly-owned subsidiaries of Brighthouse Financial, Inc.Notes128Brighthouse, Inc.Notes, Inc.Notes128Brighthouse Financial, Inc.NotesBrighthouse subsidiaries.128Brighthouse Financial, Inc., Incyte Subsequent to the multiple wholly-owned subsidiaries.128Brighthousees of record subsidiaries of Geron Financial, Inc.128Brighthouse to Multiple Choice to the United States, Inc.Notes to128Brighthouse Financial, Inc.Notes Financial, Inc.Notes to the Inc.Notes to Brighthouse Financial, Inc.Notes to Brighthouse Financial, Incyte, Inc.Notes to128Brighthouse Financial, Inc.Notes, Inc.Notes totes to Brighthouse Financial, Inc.Notes, Inc.Notes-owned subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse of thetasol Financial, Inc.Notes, Inc.Notes, LLC wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes, Inc., Inc.Notes128Brighthouse Financial, Incyte Subsequent to answer:128Brighthouse-owned subsidiary subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, indirect wholly-owned subsidiaries.128Brighthouse Financial Statement of the Financial, Incyte wholly-owned subsidiaries.128Brighthouse Financial, IncyteTher Brighthouse subsidiaries.128Numerator Financial, Inc.Notes128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes Financial, Inc.Notes to the Notes.128Brighthouse subsidiaries of wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes128Brighthouse Financial Statements of Financial, Inc.128Brighthouse Inc.Notes, Inc.Notes Financial, Inc.Notesd wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes subsidiaries.128Brighthouse Financial, Inc.Notes:128Brighthouse Financial, Inc.Notes Financial, Inc.Notes subsidiaries.128Brighthouse Financial, Inc.Notes, Inc., Inc.Notes Inc.Notes to the U.S128Brighthouse subsidiaries.128Brighthouse Financial, Inc.128 are both indirect wholly-owned subsidiaries of the U.S128Brighthouse Financial Statement of Financial, Inc.Notes.128Brighthouse Financial Statement of the U.SwefgFinancial, CervBrighthouse-owned subsidiaries.128Brighthouse Financial, Inc.Notes, Schedule to Brighthouse Financial, Inc.Notes to be.128Brighthouse, Inc., LLC.Notes to Brighthouse Financial Condition of the United States, Incyte Financial, Incytekaufp128Brighthouse subsidiaries"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?",
        "options": {
            "A": "Invests in renewable energy sources",
            "B": "Diversifies its energy portfolio",
            "C": "Enters into derivative instruments",
            "D": "Reduces energy consumption",
            "E": "Increases energy purchases",
            "F": "Halts energy operations"
        },
        "LLM_original_answer": [
            "To: Chapter 128Brighthouse Financial, Inc.Notes to Brighthouse, Inc.Notes Financial, Inc.Notes of the Company.Notes Financial,128Brighthouse Financial, Inc.Notes Financial Services, Inc.Notes to Brighthouse.Notes to Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes Financial, Inc.Notes.128Brighthouse Financial Statement of Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse, Inc.Notes Financial Statements of Brighthouse-owned subsidiaries.128Brighthouse-owned subsidiaries are both subsidiaries.128Brighthouse-owned subsidiaries.128Brighthouse Financial, Inc.Notes128Brighthouse Financial Statements of Brighthouse, Inc.Notes to the following the Company.Notes Financial, Inc.Notes.128Brighthouse, Inc.Notes Financial Statements of recordkeeping Brighthouse, Related Party.Notes Financial Accounting Standards and Brighthouse Financial, wholly-owned subsidiaries.128Brighthouse, Inc.Notes to both as of Brighthouse Financial, Inc.Notes.128Brighthouse, Inc.128Brighthouse Financial, and indirect wholly-owned subsidiaries.128Brighthouse Financial Measures and Notes.128Brighthouse Financial Statements of Record of Notes, Inc.128Brighthouse, Inc.Notes128Brighthouse subsidiaries of Brighthouse-owned subsidiaries.128Subsequent to the Company.Notes128Brighthouse-owned subsidiaries.128Brighthouse Inc.Notes.128Brighthouse, Inc.Notes128Notes to which are both subsidiaries.128Brighthouse-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse, Inc.Notes Financial, Inc.Notes.128Brighthouse, Inc.NMorganizationalBrighthouse subsidiaries.128Brighthouse of the Company to the Company, Indirectly-Owned Subs.128Brighthouse-owned subsidiaries.128Brighthouse, Inc.128Brighthouse subsidiaries.128.128Brighthouse Inc.Notes.128Brighthouse Financial Statements of the Company.Notes Meaningless Meaningless-owned subsidiaries.128Brighthouse202Brighthouse\nQuestions:128Brighthouse Notes128Brighthouse Financial, Inc.NMAYE126Brighthouse Financial Statements of record holders of Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.128Notes128Brighthouse subsidiaries.128Brighthouse Financial Results of Brighthouse Financial, Inc.Notes to Table 128Brighthouse Financial Statements of the Notes128Brighthouse, Inc.Notes Notes Financial Statement of the parent.128Brighthouse Financialsponsored subsidiaries.128Brighthouse Financial, Inc.128Brighthouse Financial Statements of Brighthouse Financial Statement of Brighthouse Financial Statements of Recorded"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?",
        "options": {
            "A": "To manage the financial statements",
            "B": "To express an opinion based on audits",
            "C": "To prepare the financial statements",
            "D": "To oversee the Company\u2019s management",
            "E": "To implement the Company's accounting principles",
            "F": "To revise the financial statements annually"
        },
        "LLM_original_answer": [
            "Based on the Company-wide Subs.128Subs.Notes to Wholly-owned subsidiaries.128Brach Inc.128Brighthouse and Subs. to Consolidated Financial Statement of Consolidated wholly-owned subsidiaries.128Brighthouse Notes to Duke Energy and Consolidated Notes to Duke Energy Transition to the indirect wholly-owned subsidiaries.128Brighthouse Financial Statement of the Notes.Notes to the indirect wholly-owned subsidiaries.128Brighthouse subsidiaries.128.128Brighthouse Financial Statements of Duke Energy, \u201cDuke Financial, Inc.Notes to Consolidated subsidiary.128Brighthouse Financial, Inc.128Brighthouse Financial, Inc.Notes to Consolidated Brighthouse subsidiaries.128Subs.128Brighthouse Financial, Inc.Notes128Notes128Brighthouse.Notes to the Company\u2019s indirect wholly-owned subsidiaries.128Brighthouse Financial Statements of Duke Energy Transitionedirect subsidiaries.128Brighthouse Financial Statements of America.Notes to theBrighthouse of Duke Energy, Inc.Notes to Consolidated Financial Statements of Duke Energy Transition Services.Notes to the Notes to the notes to the Brighthouse Financial Statements of Brighthouse to Consolidated to the Consolidated by Brighthouse Financial Statement of Brighthouse Financial Statement of Brighthouse, Inc.Notes to the indirect wholly-owned subsidiaries.128Brighthouse Financial Services.Notes, wholly-owned subsidiary notes to the Notes.128Brighthouse Financial Statements of Duke Energy Transition Disclosure of Duke Energy and its Consolidated Financial Statements of North Carolina Financial Statements of Duke Energy Financial Statements of Brighthouse, LLC.128Brighthouse subsidiaries of Brighthouse Financial, Inc.Notes to Consolidated Notes128Brighthouse-owned subsidiaries.128Brighthouse Financial, Inc.Notes to Consolidated Notes 128Br 128Notes to the consolidated financial statements.128Brighthouse subsidiaries.128Brighthouse subsidiaries.128Brighthouse, Inc.128Brighthouse subsidiaries.128.Notes Financial Statements of Duke Energy, wholly-owned subsidiaries of Duke Energy, Inc.Notes128Brighthouse Financial, LLC.Notes to the Company Consolidated Notes.128Brighthouse Financial Statements of Duke Energy Transition to Brighthouse-owned subsidiaries.128.128Brighthouse Inc.128Brighthouse Subs, Inc.Notes to Consolidated Notes to the Notes 128Brighthouse Financial Statements of Brighthouse of Brighthouse Financial, Inc.Notes 128Brighthouse subsidiaries of Duke Energy, wholly-owned subsidiaries.128Brighthouse.128Brighthouse subsidiaries.128Brighthouse Financial Statements of Duke Energy, Table 128Brighthouse and Notes to Consolidated Brighthouse Financial Statements of Duke Energy, Inc.128Br"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?",
        "options": {
            "A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II",
            "B": "Note 5, within the Management's Discussion and Analysis",
            "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II",
            "D": "Note 6, within the Financial Overview section",
            "E": "Appendix A, in the Summary of Financial Policies",
            "F": "Note 7, within the Risk Management section"
        },
        "LLM_original_answer": [
            "The following the notes to the Company Consolidated the Consolidated (Fiscalculator to the Consolidated Discontinued\namespace.128Brighthouse.Notes of Brighthouse Financial Overview of the Notes to the Notes to the parent subsidiaries.128Brighthouse Financial, Inc.Notes to the Consolidated to: Consolidated subsidiaries.128Brighthouse Financial Statements128Brighthouse Financial Statements of Notes to the Consolidated Credit, Inc.Notes to the indirect wholly-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial Statements of the Notes.128Brighthouse Financial Position of the aggregate consolidated wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes to the Consolidated subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes to the Consolidated Notes to the Consolidated subsidiaries.128Brighthouse Financial Position.Notes.Notes to the above.Notes.128 wholly-owned subsidiaries.128Brighthouse, Inc.Notes to theoSubsequent subsidiaries of America.Notes to Brighthouse to the following this \u201cNotes to Brighthouse Notes.128Brighthouse, Inc.Notes to the Financial Overview of Brighthouse to the Financial Policies to the Notes to which are both Brighthouse.companies.128Brighthouse Financial, Inc.Notes to the Notes to the above, a.128Brighthouse Financial Overview128Brighthouse Financial Statements of wholly-owned subsidiaries.128Brighthouse Financial Overview of the Consolidated to Consolidated to the Consolidated Financial Statements to the Consolidated subsidiaries.128Brighthouse Financial, Inc.128Notes to the parent company-wide subsidiaries of Eastern Bank C.128Brighthouse.Notes.Notes to the Notes.128Brighthouse Financial, Inc.Notes to the Consolidated to the following the ConsolidatedaFinancial Consolidated by the Consolidated subsidiary.128Brighthouse Financial Consolidated subsidiaries.128Brighthouse subsidiaries of Brighthouse subsidiaries.128Brighthouse Financial Position of Cambridge, wholly-owned subsidiaries.128Eastern Insurance, Inc.Notes to the Consolidated subsidiaries.128Brighthouse, Inc.Notes to Consolidated subsidiaries.128Brighthouse Financial Overview of Commonly-owned subsidiaries.128Brighthouse Financial Statements to Cambridge, amsa to Consolidated to Table 128Brighthouse Financial Position of the indirect wholly-owned subsidiaries.128Brighthouse of $ in the Consolidated, Inc.Notes to the Company Consolidated wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes to Consolidated subsidiaries.128Br"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?",
        "options": {
            "A": "Competitors cannot make similar products without infringing patents.",
            "B": "Patent laws in the United States are more favorable than those in other countries.",
            "C": "Issued patents may be challenged and held invalid or unenforceable.",
            "D": "Regulatory approval for drug candidates is guaranteed.",
            "E": "Trade secrets are always more secure than patents.",
            "F": "All pending patent applications will lead to issued patents."
        },
        "LLM_original_answer": [
            "One Brighthouse subsidiaries.128Brighthouse Financial Statement of Brighthouse Inc.Notes.Notes to Brighthouse, Indirectly, Inc.Notes to the Company N/American Financial, Inc.NX-Subsequent subsidiaries.128Brighthouse Financial, Inc.128Brighthouse-owned subsidiaries.128Brighthouse Financial, Inc.128Brighthouse Holdings, Inc.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse to Brighthouse to the Notes.128Brighthouse Financial, Inc.Notes.128Brighthouse.128Brighthouse Financial, Inc.Notes:128Brighthouse of Brighthouse subsidiaries.128Brighthouse Financial, Inc.128Brighthouse Financial, Inc.Notes.128Brighthouse, Inc.Notes128Brighthouse of Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial, Inc.128Brighthouse, Inc.128Brighthouse subsidiaries.128Brighthouse subsidiaries.128Brighthouse subsidiaries.128Brighthouse of Brighthouse Financial, Inc.Notes128Brighthouse, Inc.Notes to the indirect wholly-owned subsidiaries.128Brighthouse Notes128Brighthouse subsidiaries.128128Brighthouse, Inc.128Brighthouse Financial, Inc.128Brighthouse Inc.128Brighthouse subsidiaries of Brighthouse Financial Statements of Delaware, Inc.Notes to Multiple Choice to the United States, Inc.Notes to Brighthouse Financial, Inc.Notes, Inc.Notes to be to Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.Notes to Brighthouse Financial, Inc.NX-Brighthouse Financial, Inc.Notes, Inc.Notes, Indirect wholly-owned subsidiary.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial, and wholly-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.Notes.128Brighthouse Financial, wholly-owned subsidiaries.128Brighthouse, Inc.Notes.Notes to Brighthouse subsidiaries.128Brighthouse Financial, 128Brighthouse, Inc.Notes.128Brighthouse Financial, 128Brighthouse subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes to Brighthouse Financial, Inc.128Brighthouse Financial Statements of the Company.Notes of Record of Brighthouse subsidiaries.128Brighthouse, Inc.Notes128Brighthouse subsidiary.128Brighthouse Financial, Inc.Notes Brighthouse N.Vestates to the wholly-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.Notes to the following is the notes.128Brighthouse, Indirectly.Notes"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?",
        "options": {
            "A": "Increase in market competition",
            "B": "Higher margins in the Correspondent channel",
            "C": "Decline in setup fees for loans boarded",
            "D": "Increase in HECM loan proceeds",
            "E": "Decrease in revaluation gains on MSRs",
            "F": "Higher production volume in retail channels"
        },
        "LLM_original_answer": [
            "Tooth Financial Conditionally-owned subsidiaries, Inc. Notes to Table to the Notes to Brighthouse-owned subsidiaries of Brighthouse Financial Conditionally-owned subsidiaries.128Brighthouse Notes to the to the Consolidated Inc.Notes to the indirect wholly-owned subsidiary.128Notes to Brighthouse subsidiaries.128Brighthouse Financial Condition of Brighthouse Financial Statements to Brighthouse-owned subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse-owned subsidiaries.128Brighthouse notes.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial Statement of the indirect wholly-owned subsidiaries.128Brighthouse Financial Statement of Financial, Inc.Notes to Table 128Brighthouse Financial Condition of Financial, Inc.Notes.128Brighthouse Financial Condition of the indirect wholly-owned subsidiary.128Brighthouse.Notes.128Brighthouse.128Brighthouse subsidiaries.128Brighthouse Financial Condition of Record of the following the Consolidated Financial Condition of the following the indirect wholly-owned by Segment Results of Record of the Consolidated subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial Conditionally-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse of Brighthouse Financial, Inc.Notes table 10-K.128Brighthouse Financial, Inc.Notes to the Company Segment Results of the indirect wholly-owned subsidiaries of Brighthouse subsidiaries.128Brighthouse, Inc.128.128Brighthouse-owned subsidiaries.128Brighthouse Financial, Inc.Notes to Table 128Brighthouse, Indirect wholly-owned subsidiaries.128Subsponsored Subs, Inc.Notes to Table 128Brighthouse.Notes to Table 128Brighthouse Financial Condition N.American Holdings are both indirect wholly-owned subsidiary.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes to the Financial, Inc.Notes, Inc.Notes to the Notes, Inc.Notes128Brighthouse subsidiaries.128Brighthouse Financial, Inc.128Brighthouse, Inc.Notes128Brighthouse subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes 128Brighthouse, Inc.Notes, Inc.Notes, Inc.128Brighthouse Financial Condition of Ocwen.Notes Financial Conditionally-owned subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial Statements of California, Inc.Notes 128Brighthouse, Indirectly-Owned Subs.Notes to Aggregate Financial, Inc.Notes to Brighthouse Financial Condition to the Notes to Brighthouse Financial Condition.128Brighthouse Financial Conditionally-owned subsidiaries.128Brighthouse, Inc"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?",
        "options": {
            "A": "Lack of innovative product features",
            "B": "Limited product supply",
            "C": "Inability to maintain effective sales forces",
            "D": "High regulatory costs",
            "E": "Insufficient funding for development",
            "F": "Excessive competition in the product market"
        },
        "LLM_original_answer": [
            "The indirect wholly-owned subsidiaries of Brighthouse Financial, Inc.128Brighthouse Financial, Inc.128Brighthouse subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.Notes to the indirect wholly-owned subsidiaries.128Brighthouse Financial Services.128Brighthouse Financial Statements of Brighthouse.Notes to the indirect wholly-owned subsidiaries.128Brighthouse Financial Statements128Notes to Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes to Brighthouse.Notes to Brighthouse-owned subsidiaries.128Brighthouse Inc.Notes.128Brighthouse-owned subsidiaries.128Brighthouse Financial Statements of recordholders of wholly-owned subsidiaries.128Brighthouse Notes.Notes.128Brighthouse Notes.128Brighthouse Financial Services and Notes.128Brighthouse Financial Statements of Financial, Inc.Notes.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial, both subsidiaries.128Brighthouse Financial, subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial Statements of Brighthouse Holdings, Inc.Notes Financial Services and Subsibling Subs, Indirect wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes.128Brachte wholly-owned subsidiaries.128Brighthouse Notes128Brighthouse Notes to Brighthouse subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial Services of Brighthouse Holdings, Inc.Notes Financials, Inc.Notes128Brighthouse\n"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is one reason AMX0035 might fail to obtain regulatory approval?",
        "options": {
            "A": "Manufacturing processes are found to be deficient",
            "B": "Clinical trials easily surpass statistical significance",
            "C": "FDA agrees with the interpretation of preclinical studies",
            "D": "Patient opinions are highly positive",
            "E": "Regulatory authorities consistently approve design implementations",
            "F": "Clinical trials detect an exceeding positive effect"
        },
        "LLM_original_answer": [
            "What is an indirect wholly-owned subsidiaries.128Brighthouse Financial Statements of Albr>128Brighthouse Financial Statement of the following the indirect wholly-owned subsidiaries of Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial Statement of the Notes.128Brighthouse Financial, Indirectly-owned subsidiaries.128Brighthouse.Notes to Brighthouse Financial Statements of Brighthouse Financial, Inc.Notes.128Brighthouse Financial, as an indirect wholly-owned subsidiaries.128Brighthouse Financial Statement of Brighthouse.NotesBrighthouse-owned subsidiaries.128Brighthouse Financial, Inc.Notes128Brighthouse, Inc.128Brighthouse.Notes Inc.Notes Financial, Inc.128Brighthouse Financial Statements of Brighthouse subsidiaries of subsidiaries.128Brighthouse Financial, Inc.Notes128Brighthouse NDAFiscal subsidiaries.128Brighthouse Financial Statements of Brighthouse of Brighthouse Financial, Inc.Notes, Inc., Inc.Notes128Brighthouse Holdings, Inc.128Brighthouse Notes to the Notes.Notes subsidiaries of Brighthouse subsidiaries.128Brighthouse Subs, Inc.128.128.128Brighthouse of the United States, Inc.Notes to the Company N.Disc.128Brighthouse, wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes to the Notes to ALBR, Inc.Notes to be both indirect wholly-owned subsidiaries.128Brighthouse-owned subsidiaries.128Brighthouse-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial Statements of the U.S128Brighthouse, Inc.Notes Financial, Inc.Notes, Inc.Notes Financial, Inc.Notes to Brighthouse.Notes:128Brighthouse\nAmberthedirect wholly-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse, Inc.Notes, Inc.NotesBrighthouse subsidiaries.128Brighthouse of the notes.128Brighthouse-owned subsidiaries.128Brighthouse Financial, Inc.Notes.128Brighthouse Financial Disclosure of Bravio, Inc.Notes Financial, Inc.128Brighthouse Financial, Inc.Notes to Amx, Inc.Notes to Brighthouse Financial, Inc.Fin, to Brighthouse Financial, including alludeb.128Brighthouse Financial statements of the Inc.Notes.128Brighthouse Financial, as a.Notes.128Brighthouse Financial, wholly-owned subsidiaries of the notes.128Brighthouse Financial Information on the U.Seeviro, Inc.Notes.128Brighthouse of 128Brighthouse, Inc.Notes.128Brighthouse.Notes128Brighthouse subsidiaries"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the purpose of Section 31 fees according to the Exchange Act?",
        "options": {
            "A": "To finance market makers on exchanges",
            "B": "To cover the costs of technology upgrades",
            "C": "To recover the government\u2019s costs of supervising and regulating the securities markets",
            "D": "To reward high-frequency traders",
            "E": "To fund international trading agreements",
            "F": "To support trading education programs"
        },
        "LLM_original_answer": [
            "The notes.128Brighthouse Financial Services.Notes to Black Knight, Inc.Notes 128Subsolicia to our.Notes128Brighthouse Financial Statements of the Notes 128Brighthouse subsidiaries.128Brighthouse Financial Services and its Notes 128Subs.Notes to the parent subsidiaries.128Brighthouse Financial, Inc.Notes128Notes to be indirectly wholly-owned subsidiaries.128Brighthouse Financial Guarantor.128Brighthouse Holdings, Inc.128Brighthouse Financial, Inc.Notes to the following the Brighthouse Financial, Inc.Notes to the Brighthouse-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes:128Brighthouse Financial, Inc.Notes Financial Services and Related Party Notes, Inc.Notes to the Notes.128Brighthouse Financial, wholly-owned subsidiaries of Brighthouse Financial, Inc.Notes to the Financial Services, respectively subsidiaries.128Brighthouse Financial Statements.128Brighthouse 128Brighthouse, Inc.NotesFinancial Services, Inc.Notes to this is both operate as of the notes, Inc.Notes subsidiaries.128 subsidiaries.128Brighthouse, Inc.Notes.128 subsidiaries.128Brighthouse Financial, Inc.Notes to the following the Financial Statements of the Notes, Inc.Notes to the Financial, Inc.Notes to Brighthouse Financial Services, Notes to Brighthouse Financial, LLCs.128Brighthouse Financial, Inc.Notes 128Brighthouse, Inc.Notes to our indirect wholly-owned subsidiaries.128Brighthouse Financial,128Brighthouse Financial, Inc.128Brighthouse Financial Services and128Brighthouse Financial Services,128Brighthouse.Notes.128Brighthouse Financial Services, Inc.Notes Notes 128.128Brighthouse.Notes both are both are both both both indirect wholly-owned subsidiaries.128Subs128Brighthouse of the Notes to wholly-owned subsidiaries.128Brighthouse Notes 128Brighthouse Financial, Inc.Notes 128Brighthouse-owned subsidiary subsidiaries.128Brighthouse-owned subsidiaries.128Brighthouse.Notes ofehs, Inc.Notes Financial, Inc.Notes to the Financial Services, Inc.128Brighthouse Financial Services and Notes, Inc.Notes to the Notes to the Company-wide-owned subsidiaries.128Brighthouse, indirect wholly-owned subsidiaries.128Brighthouse, Inc.Notes indirect wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes128Brighthouse Financial Subs.128Brighthouse, Inc.Notes.128Brighthouse Financial Services, Inc.Notes126Brighthouse, Inc.Notes 128Brighthouse, indirect wholly-owned subsidiaries.128"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?",
        "options": {
            "A": "5%",
            "B": "10%",
            "C": "15%",
            "D": "1%",
            "E": "0.5%",
            "F": "2%"
        },
        "LLM_original_answer": [
            "To the Notes to Brighthouse Financial Statements of America, Inc.Notes to the Consolidated wholly-owned subsidiaries of subsidiaries.128128Brighthouse Inc.128Brighthouse Financial Statements128Brighthouse Financial Statements of Brighthouse Financial Statements of the wholly-owned subsidiaries of Brighthouse Financial, Inc.Notes to the Corporate Guarantor Financial, Inc.Notes to the Consolidated to Corporate Guarantae.Notes both indirect wholly-owned subsidiaries.128Brighthouse Financial, Inc.Notes to Brighthouse-owned subsidiaries.128Brighthouse Financial, Inc.Notes.128Notes to Corporate Financial Statements to the following subsidiary notes.128 wholly-owned subsidiaries.128Brighthouse.Notes to the Consolidated Financial, Inc.Notes.128Brighthouse Financial Statement of the Brighthouse Financial Statement of the Notes, Indirect wholly-owned subsidiary.128Brighthouse financial guarant Financial, Inc.Notes Financial, Inc.Notes.128Brighthouse Financial Statement of Financial, Inc.Notes to the parent.128Brighthouse Financial, Inc.Notes 128Brighthouse Financial, Inc.128Brighthouse Financials.Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes 128Brighthouse Financial Statements128Brighthouse Financial, Inc.Notes.128Brighthouse Financial, Inc.Notes.Brighthouse Financial Statements of subsidiaries.128Brighthouse Financial, Inc.Notes.Notes to Brighthouse Financial Statements of Financial, Inc.Notes to the Notes to the Company Consolidated Subs, LLC.Notes Financial, Inc.Notes 128Brighthouse Financial Statements 128Brighthouse M.Fin Brighthouse Financial Statements to the \u201cBHF, wholly-owned subsidiary.128, Inc.Notes to the Notes to the128Brighthouse Financial Statements of Brighthouse Financial, wholly-owned subsidiaries of the notes.128Brighthouse Financial, Inc.Notes to the Consolidated to the corporate fixed maturity securities.128Brighthouse Financial Services, Indirect wholly-owned subsidiaries.128Brighthouse Financial Statements and indirect wholly-owned subsidiaries of Brighthouse Financial Statements of the Consolidated.Notes to the Consolidated subsidiaries.128Brighthouse Financial, Inc.Notes to Brighthouse.Notes to the Consolidated to the Consolidated subsidiaries.128Brighthouse Financial, Brighthouse.Notes.128Brighthouse Financial Statement of the Notes to Brighthouse, wholly-owned subsidiaries.128Brighthouse subsidiaries.128Brighthouse Financial, Inc.Notes Brighthouse Financial, Inc.Notes.128Brighthouse, Inc.Notes128Brighthouse Financial Statements of Recordholders of the Notes to other wholly-owned subsidiaries.128Brighthouse Financial, Inc.128Brighthouse"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What could happen if there are delays in the clinical trials of product candidates?",
        "options": {
            "A": "The marketing period under patent protection would be increased.",
            "B": "The marketing period under patent protection would be reduced.",
            "C": "The patent applications would become public immediately.",
            "D": "The company would be certain they were first to file any patent application.",
            "E": "All interference proceedings would be canceled by the USPTO.",
            "F": "Priority disputes would be automatically resolved in the company's favor."
        },
        "LLM_original_answer": [
            "If our assessment and management of material risks from cybersecurity threats are integrated and managed and our assessment and material risks from cybersecurity insurance and material risks from material risks from cybersecurity insurance and management of material risks from material and management of material risks from cybersecurity insurance and material risks from cybersecurity threats are integrated and management of material risks from cybersecurity insurance and management of material risks from cybersecurity and management of material risks from cybersecurity insurance and management of material risks from cybersecurity threats are integrated and integrated assessment and cybersecurity insurance and management of material risks from cybersecurity insurance and other assessment and management of material risks from time and maintain cybersecurity insurance is integrated and management of material risks from cybersecurity insurance and material risks from our assessment and material risks from cybersecurity insurance and cybersecurity insurance and management of material risks from material risks from cybersecurity insurance and our assessment and management of material risks from material risks from cybersecurity insurance and material risks from cybersecurity insurance and our assessment and material risks from cybersecurity threats from cybersecurity insurance and maintain and cybersecurity insurance and management of material risks from cybersecurity threats from cybersecurity threats and managed material risks from cybersecurity insurance and material risks from cybersecurity insurance and cybersecurity insurance and management of material risks from cybersecurity threats are integrated and integrated and material risks from cybersecurity threats from cybersecurity threats are integrated and material risks from cybersecurity threats from material risks from material risks from cybersecurity insurance and management of material risks from material risks and maintain cybersecurity insurance and management of material risks from cybersecurity insurance.We maintain cybersecurity and material risks from cybersecurity insurance claims and management of material risks from cybersecurity insurance and material risks from cybersecurity insurance.We maintain cybersecurity insurance.Our assessment and our assessment and our assessment and our assessment and material risks from cybersecurity insurance and other than material risks and our assessment and our assessment and our assessment and management of material risks from material risks from material risks from material risks from material risks from cybersecurity insurance and management of material risks from material risks from material risks from cybersecurity threats from cybersecurity threats and management of material risks from cybersecurity threats are integrated and material risks from cybersecurity insurance.We maintain cybersecurity insurance.We maintain cybersecurity insurance and maintain cybersecurity insurance and maintain cybersecurity insurance and management of material risks from cybersecurity threats from cybersecurity threats from cybersecurity threats are integrated and our assessment and management of material risks from cybersecurity insurance and management of material risks from cybersecurity insurance and management of material risks from cybersecurity insurance.We maintain cybersecurity insurance.We maintain cybersecurity threats from cybersecurity insurance.We maintain cybersecurity threats from cybersecurity insurance.We maintain cybersecurity threats from cybersecurity insurance and integrated and management of our assessment and cybersecurity insurance and management of material risks from cybersecurity threats are integrated and integrated and our assessment and management of material risks from cybersecurity risks from cybersecurity insurance.We maintainability and management"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?",
        "options": {
            "A": "Invests in renewable energy sources",
            "B": "Diversifies its energy portfolio",
            "C": "Enters into derivative instruments",
            "D": "Reduces energy consumption",
            "E": "Increases energy purchases",
            "F": "Halts energy operations"
        },
        "LLM_original_answer": [
            "What is not applicable, the fourth of December 31, 2022, the hosting contracts for 100, 31, the hosting contracts, 31, the hosting contracts for 2023, the hosting contracts for 31, the hosting contracts, the contracts for 31, the contracts, 2022, the hosting contracts for the hosting contracts, the hosting contracts for 2023. The hosting contracts for 2022, the hosting contracts, the hosting contracts for 2022The hosting contracts for the hosting contracts for the hosting contracts for 31 the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts, 2023, the hosting contracts for 2023, the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for December 2023.The hosting contracts for the hosting contracts for the hosting contracts for December 31 December 49the contracts for the hosting contracts for the hosting contracts for 2023the contracts for the hosting contracts for the hosting contracts, the December 31, the contracts of December 5, 2022, the hosting contracts for 2022, the contracts for 31, 31, 2022, the contracts for 1, the hosting contracts for the contracts for 17the hosting contracts for December 31, the fourth quarter of December 31, December 31December 31, the fourth quarter December 31, 2023, the contracts for the fourth quarter, the hosting contracts for the hosting contracts for 31, the hosting contracts, the hosting contracts for 2023the contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for December 2022, 2022, the hosting contracts for the hosting contracts for the hosting contracts for 2022, the hosting contracts for the hosting contracts for the hosting contracts, 2022, the hosting contracts for the hosting contracts for 2023The hosting contracts, 2023, the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for 17the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for the hosting contracts for 16the contracts for the hosting contracts for the fourth quarter, 2022, the hosting contracts for the hosting contracts for 31, the fourth quarter, 2022"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?",
        "options": {
            "A": "To manage the financial statements",
            "B": "To express an opinion based on audits",
            "C": "To prepare the financial statements",
            "D": "To oversee the Company\u2019s management",
            "E": "To implement the Company's accounting principles",
            "F": "To revise the financial statements annually"
        },
        "LLM_original_answer": [
            "Based on a 3. The investment plan for 2023. The Improvement Charge 2.0 investment plan for 2023-2023 investment plan for 2023.0 investment plan for 2023-202-2023-2023-2023-2023-2023-2023. Improvement Charge 2. The 2023. 2. The investment plan for 2023-2023-2023-2023-2023-2023-2023. The 2023-2023. The 2023 investment plan for 2023-2023-2023-202 Improvement Charge 2. The investment plan for 2023-2023. 2023-2.0 investment plan for 2023-2023-2023 investment plan for 2023-2023 investment plan for 2023-2023-2022-202-2023-2023 investment plan for 2023.0 investment plan for 2023. Duke Energy Storage Improvement Charge 2023-2023-2023. 3.0 investment plan for 2023-2023-2023-2023-2023. The Investment Charge 2.0 investment plan for 2023-2023-2023-2023-2023-2023-2023-2023-2023-202 Improvement Charge 2. The investment plan for 2023. Improvement Charge 2 investment plan for 2023.0 investment plan for 2023-2023.0 investment plan for 2023-2023 investment plan for 2023-2023-2023 investment plan investment plan for 2. 2023-2023-2020 investment charge investment plan investment plan investment charge 2.0-2023 investment plan 2023-2023-2023. The investment plan for 2023. The 2023.2023.##2023-2020 investment plan for 2023. The Investment 2023.0-202 plan for 2022. 2023. Investment Charge 2.0 investment plan for 2023-2023-2023-2024-2020 investment plan for 2023-2023-2023-2023-2023-2023-202 Improvement Charge 202 investment plan for 2023-2023 investment plan for 2023-2023-2023-2023-202"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?",
        "options": {
            "A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II",
            "B": "Note 5, within the Management's Discussion and Analysis",
            "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II",
            "D": "Note 6, within the Financial Overview section",
            "E": "Appendix A, in the Summary of Financial Policies",
            "F": "Note 7, within the Risk Management section"
        },
        "LLM_original_answer": [
            "The COVID-December 47.At December 2023. At December 44at December 45, at December 2023At December 2024At December 47At December 47at December 44at Brockton December 45Massachusetts, respectively, respectively, respectively.At December 31, December 2024, the Lynn, at December 44in Lynn and Quincy, Massachusetts, Massachusetts.The December 31, 2024At December 47at December 31, Massachusetts.At December 2023, Brockton Brockton, in Brockton December 31.Reporting and at December 2022\nAssistant December  and December 31, at December 2022, respectively, respectively, 2022 December 31, 2023At December 2023We expect, 2023, at December 44at December 47at December 47At December 31, the Lynn and/orphan December 44and December 2023.At December 31, in Brockton 2020f 47or Brockton, at December 47or, in Brockton 47or successor, in the Company\u2019s, at December 47on, at December 47or any deficiency of the relevant to December 47At December 1.47and or potential liability offices of Eastern Bank of Brockton, in accordance with respect of the Lynn, and its Lynn and Brockton, Massachusetts, Massachusetts, and Brockton December 2023At December 31, the total, at December 47at December 31, Massachusetts, in Lynn and 31, the aggregate, at December 47At December 47at December 47at December 47At December 47at December 47at December 47At December 47and at December 47 and Brockton, which, at 2023.The FDIC 31, at December 2024At December 47, respectively, respectively.At December 31, we are expected to 47at December 47at December 47At December 47December 47at December 47Massachusetts, which December 47.At December 31, Massachusetts, Massachusetts.At December 31, 2023At December 2024At Brockton, at December 2021. At December 46, Massachusetts, Massachusetts, at December 2023At December 47and Brockton and Brockton, Massachusetts.East December 2023, Eastern Bank, Lynn and at December 47, at December 31, 2024December 47"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?",
        "options": {
            "A": "Competitors cannot make similar products without infringing patents.",
            "B": "Patent laws in the United States are more favorable than those in other countries.",
            "C": "Issued patents may be challenged and held invalid or unenforceable.",
            "D": "Regulatory approval for drug candidates is guaranteed.",
            "E": "Trade secrets are always more secure than patents.",
            "F": "All pending patent applications will lead to issued patents."
        },
        "LLM_original_answer": [
            "One of our co-development and we exercise our co-development and co-promotion and unless we exercise our co-development and we exercise our co-development and co-promotion, unless we exercise our co-promotion our co-promotion exercise our co-development and we exercise our co-development and we exercise, unless we exercise our exercise our co-development and co-development and co-development and co-promotion and co-development and we exercise our co-promotion exercise our co-development and co-development and co-promotion our co-development and we exercise our co-development and/or manufacturing activities, unless we exercise our co-development and we exercise, unless we exercise our co-development and co-development and-promotion activities, unless we exercise our co-development and we exercise our co-development and co-promotion activities, unless we exercise our co-promotion we exercise our co-development and co-development and manufacturing activities, unless we exercise our co-development and manufacturing activities, unless we exercise our co-development and co-development and co-promotion, unless we exercise our co-promotion activities, unless we exercise our co-development and unless we exercise our co-development and we exercise our co-development and co-promotion activities, unless we exercise our activities, unless we exercise our co-development and unless we exercise our co-development and we exercise our co-development and manufacturing activities, unless we exercise our co-development and co-development and we exercise our co-development and we exercise our co-development and unless we exercise our co-development and co-promotion and unless we exercise our co-development and unless we exercise our co-development and unless we exercise our co-development and we exercise our co-development and we exercise our co-development and co-development activities, unless we exercise our co-development and co-promotion and co-promotion and co-promotion and we may we exercise our manufacturing activities, unless we exercise our co-development and co-promotion and co-promotion our co-development and co-development and/or we exercise our co-development and/or we exercise our co-development and manufacturing activities, unless we exercise our co-development and we exercise our manufacturing activities, unless we exercise our co-development activities, unless we exercise our co-development and co-development and co-development and co-development and co-promotion and co-development and co-promotion and unless we exercise our co-development and co-development and any manufacturing activities, unless we exercise our co-development and co-development and/or manufacturing activities, unless we exercise our co-development and we exercise our co-development and we exercise our co-development and we exercise our co-development and we exercise our co-development and unless we exercise our co-development and co-development and manufacturing"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?",
        "options": {
            "A": "Increase in market competition",
            "B": "Higher margins in the Correspondent channel",
            "C": "Decline in setup fees for loans boarded",
            "D": "Increase in HECM loan proceeds",
            "E": "Decrease in revaluation gains on MSRs",
            "F": "Higher production volume in retail channels"
        },
        "LLM_original_answer": [
            "The variously generally, and IT and/or refresh their IT threat-IT threat-incident-identification training generally generally generally generally generally, generally, and third-party-recognition-recognition of-incident-recognition training and threat-recognition-training in their threat-recognition training and -and generally generally, and/orfamiliarity-recognition-training.Their, generally, generally, generally, generally to refresh their IT threat-recognition-recognition and threat-recognition training annually, as well as well-known cybersecurity training and IT and contractors, generally, generally to their cybersecurity training-recognition training training.Their and generally on a cybersecurity and other than-incident-incident-recognition training and threat-identification training annually, and IT threat-incidentally, and IT threat-incident-recognition training, and IT threat-recognition training, and threat- and/or threat-recognition training annually.44 annually, generally, at least once generally, generally generally generally.Their-threat recognition and threat- and/orbroad-privacy and/orienthazement, and IT threat-identification-training.The USVI generally, generally, and IT threat-incidentally generally, and threat-incident-incident-identification training and other IT threat recognition of other than IT threat-asset-recognition-recognition.We are required to which could be generally.We are required to the variously refreshed training and threat- and other than-IT threat- and threat-incident-incidentally, as well as well as well as well-known-recognition-recognition-training in general, generally.Their-threat-recognition-recognition training and IT threat-incident-incident-incidentally and threat-recognition training annually.43 annually. Refreshing generally, and/or refresh their threat-incident-recognition training generally, threat-recognition.Theirres generally, generally generally generally generally, generally, generally generally generally generally, generally, generally, generally, and IT threat-incident- and IT threat- and third, and generally generally generally generally and other IT threat-identification and training and IT threat-identification training, and/or-recognition-recognition and IT and threat-incident-incident-recognition.The above and/or otherwise generally, generally, generally, generally, and IT and IT and other, and other than to refreshers, and IT threat- and other than-incident- and threat-incident-incident- and threat- and threat-IT-recognition.Their.-refreshing generally, generally, and other cybersecurity and/orientification training and threat-incident- and threat recognition of any other than are required to refresh"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?",
        "options": {
            "A": "Lack of innovative product features",
            "B": "Limited product supply",
            "C": "Inability to maintain effective sales forces",
            "D": "High regulatory costs",
            "E": "Insufficient funding for development",
            "F": "Excessive competition in the product market"
        },
        "LLM_original_answer": [
            "What is expected P\n"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is one reason AMX0035 might fail to obtain regulatory approval?",
        "options": {
            "A": "Manufacturing processes are found to be deficient",
            "B": "Clinical trials easily surpass statistical significance",
            "C": "FDA agrees with the interpretation of preclinical studies",
            "D": "Patient opinions are highly positive",
            "E": "Regulatory authorities consistently approve design implementations",
            "F": "Clinical trials detect an exceeding positive effect"
        },
        "LLM_original_answer": [
            "AMX\nThe following the56strategic considerations, even if we believe that we believe that we believe that we believe that we believe that we believe that we believe that we have sufficient funds for strategic and strategic considerations, even if we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we have sufficient funds for strategic reasons unrelated to our strategic considerations, or strategic considerations that we believe that we have sufficient funds for strategic considerations, even if we believe that we believe that we believe that we believe that we believe that we believe that we believe that we have sufficient funds for strategic considerations, even if we believe that we believe that could be43 considerations, even if we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we have sufficient funds for strategic considerations, even if we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we have sufficient funds for our strategic considerations, even if we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that may believe that we believe that we have sufficient funds, even if we believe that we have sufficient funds for strategic objectives.Considerationstruly believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we have sufficient funds, even if we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we may be54or strategic considerations, or strategic considerations that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we believe that we"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the purpose of Section 31 fees according to the Exchange Act?",
        "options": {
            "A": "To finance market makers on exchanges",
            "B": "To cover the costs of technology upgrades",
            "C": "To recover the government\u2019s costs of supervising and regulating the securities markets",
            "D": "To reward high-frequency traders",
            "E": "To fund international trading agreements",
            "F": "To support trading education programs"
        },
        "LLM_original_answer": [
            "Based that significance test that exists of the significance test of the significance test of the significance test  significance test of our investment test of the significance test of the significance test criteria exists in the test in the significance test criteria of the significance test exists test of the significance test of the significance test of the significance test exists test significance test exists in the significance test exists test test test test exists the significance test significance test criteria test of the significance test exists test of the significance test test criteria test. We have concluded that our investment in the significance test of the significance test and test and therefore of our investment test and that that our investment criteria criteria criteria criteria criteria in the test criteria criteria and the test and that test in test in test in test of the test test test and we test test.We concluded test test test test test test test test test test test test test test in test in significance test in the significance test test test test.We concluded that we concluded that weh significance test and that test test that exists in the significance test exists the significance test of the exists test test test in the test in test in the test in the significance test test in significance test in the significance test criteria of the test exists test in significance test in test exists test exists in the significance test exists test exists in the future.We concluded that the significance test exists test of the test exists test exists in the significance test exists test exists test 10 significance test test test test of the significance test test exists in the significance test in the significance test exists in the significance test in the significance test that the significance test of the significance test of the significance test test of the significance test in the significance test test test of the significance test of the significance test of the significance test of the significance test in significance test test of the significance test test in the significance test test test test of the significance test  test of the significance test test test test test of the significance test of the significance test of the significance test of our significance test exists of the significance test.We concluded test of our investment exists in the future exists of the significance test of the significance test for the significance test for the that we believe that exists in the significance test exists the significance test.Determined that test.The significance test of the test of the test and the that exists test and that exists test in the significance test and significance test in the significance test in the significance test of our test of the significance test in the significance test exists of the significance test in our test in the significance test in the test for the in the significance test in the significance test for significance"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?",
        "options": {
            "A": "5%",
            "B": "10%",
            "C": "15%",
            "D": "1%",
            "E": "0.5%",
            "F": "2%"
        },
        "LLM_original_answer": [
            "The controls and procedures designed to our controls and procedures designed to deterrence or controls and procedures designed to the effectiveness or our controls and procedures designed to our controls and procedures designed to our controls and procedures designed to deterrence.Similarly, which are subject to deterrence or misconduct.Similarly.Similarly, our procedures designed to deterrence and procedures designed to deter excessive risk-taking or misconduct.Similarly, our controls and misconduct or misconduct.Similarly, our controls and controls and controls and/or misconduct.Similarly, which may result in some of our controls and procedures designed to deter risk-taking or controls and controls and controls and procedures designed to excessive risk-taking or misconduct.Similarly, our controls and procedures designed to the designed to deter excessive risk-taking or misconduct or designed to the Company-wide spread of misconduct.Similarly, similar to the design or misconduct.Similarly.Similarly, similar to the designed to the effectiveness deterrence and procedures designed to the deter excessive risk-taking or misconduct.Similarly, our controls and procedures designed to the effectiveness or misconduct.Similarly, controls and procedures designed to the Company-wide-ranging or misconduct.Similarly.Similarly, our controls and procedures designed to detect and controls and procedures designed to our controls and controls and procedures designed to the effectiveness may beSimilarly designed to the deter excessive risk-taking or misconduct.Similarly, controls and procedures designed to the design and procedures designed to the designed to the or misconduct.Similarly, our controls and procedures designed to the deter excessive risk-taking or procedures designed to the adoption of risk-taking or misconduct.Similarly, our controls and procedures designed to deter risk detection and procedures designed to the effectiveness may be54may not deter excessive risk-taking or misconduct.Similarly, our controls and procedures designed to deter excessive risk management and procedures designed to deterrence of the orts and procedures designed to the design to deter excessive risk-taking or misconduct or misconduct.Similarly, which could adversely affecting our controls and controls and controls and controls and controls and similar to the controls and misconduct.Similarly, our controls and procedures designed to excessive risk-taking or misconduct.Similarly, our controls and procedures designed to deter excessive risk-taking or misconduct or our controls and procedures designed to the ability to detect and controls and our controls and/or misconduct or misconduct.Similarly, excessive risk-taking or procedures designed to the designed to the controls and procedures designed to deterrence or misconduct.Similarly, our controls and procedures designed to the Company-wide-ranging or misconduct.Similarly, which could"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What could happen if there are delays in the clinical trials of product candidates?",
        "options": {
            "A": "The marketing period under patent protection would be increased.",
            "B": "The marketing period under patent protection would be reduced.",
            "C": "The patent applications would become public immediately.",
            "D": "The company would be certain they were first to file any patent application.",
            "E": "All interference proceedings would be canceled by the USPTO.",
            "F": "Priority disputes would be automatically resolved in the company's favor."
        },
        "LLM_original_answer": [
            "What states to pass similar laws will pass similar laws in the more states to pass similar laws to pass similar laws to pass similar laws to pass laws to pass similar laws in the future states to pass similar to pass similar laws to pass similar laws to pass laws to pass more states to pass similar laws to pass similar laws to pass similar laws in the laws in the future.We expect more states to pass similar laws in the states to pass similar laws in the future states to pass similar laws in the future laws and we expect more states to pass more states to pass similar laws to pass more states to pass more states to pass more states to pass more states to pass more states to pass similar laws to pass more states to pass more states to pass similar laws we expect more states to pass more states to pass similar laws in the FDA and more states to pass more states to pass more states to pass more states to pass more states to pass similar laws to pass more states to pass more states to pass similar laws to pass more states to pass similar laws in the future.We expect more states to pass similar laws in the future, and we expect more states to pass more states to pass more states to regulate more states to pass similar laws in the future.The states to pass more states to pass similar laws to pass similar laws to pass more states to pass similar laws in the future states to pass more states to pass more states to pass similar laws in the future states to pass more states to pass similar laws in the future laws in the more states to pass similar laws in the future laws to pass similar laws in the future laws will pass similar to pass more states to pass similar laws to date to pass similar laws and more states to pass laws we expect more states to pass more states to pass similar laws to pass similar laws in the future laws in the future.We expect more states to obtain more states to pass more states to authorize more states to pass similar laws and more states to pass similar laws in the more states to pass similar laws in the future laws to pass similar laws to pass similar laws in the number of states to pass more states to pass similar laws in the future.These laws in the laws in the future laws will also expect more states are more states to pass similar laws in the more states we expect more states to pass similar laws in the federal and more states to pass similar laws in the future laws to pass similar laws in the EMAssimilar laws in the states to pass more states have more states to pass more states to pass similar laws to pass more states to pass"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?",
        "options": {
            "A": "Invests in renewable energy sources",
            "B": "Diversifies its energy portfolio",
            "C": "Enters into derivative instruments",
            "D": "Reduces energy consumption",
            "E": "Increases energy purchases",
            "F": "Halts energy operations"
        },
        "LLM_original_answer": [
            "The Debtor-in-Possession)86Core Scientific Entities.86Core Scientific, Inc.(Debtor-in-PossessionCore Scientific, Inc.(Debtor-in-Possession)Deb)86Core Scientific and Core Scientific Act of Core Scientific Scientific Scientific, Inc.(Debtor-in-Possession)86Core Scientific and Core Scientific and Core Scientific Scientific Scientific Scientific Scientific, Inc.(Debtor-in-Possession of Core Scientific, Inc.(Debtoritor-Possession)86Core Scientific Entities and Debtor-in-Possession.86Core Scientific and/orderivative-in-Possession)86Core Scientific and the notes 90Core Scientific and/or)The Company(Debitor-in-Publication(Deb)Core Scientific Debtorsession)Core Scientific Possession)Notes: Notes and Related to the Company Scientific, Inc.(Debtor-in-Possession)Rein-Possession)Core Scientific, DebtorCore Scientific, Inc.(Deb)Subsequent)Deb)86Core Scientific, Inc.(Debtor-In-Possession)Deb>86Debtor(Deb)86Deb)86Core Scientific Scientific, Inc.(Debtor-in-Possession)86Debtor)86Core Scientific, Inc.(Debtor-in-Possessentially-in-Possues)Debtor-In-Possession.86Core Scientific and Core Scientific, Inc.(Deb)86Deb)86Deb)Deb.86Core Scientific, Inc.(Debtor)86Core Scientific Scientific Scientific, Inc.(Debtor-in-Possession)Notes to the Debtor Core Scientific and Other Notes:86Core Scientific and/or Core Scientific and Core Scientific, Inc.(Debtotal Assets and Core Scientific and Core Scientific, Inc.(Debtor-in-Possession)Core Scientific, Incertainly Scientific, Inc.(Debtor-In-Possession)Debtor.90Core Scientific and/or Core Scientific Scientific Scientific and their respective)86The following the Bitcoin Holdings CompanyNote: Core Scientific and Core Scientific Note 86Debt.86Core Scientific, Inc.(Deb)Debtor)Subsequent-in-Poss)86Core Scientific, Inc.(Debtor-in-Possession)86Debtorient-Possi-Investeditor-in-Possession-in-Possession)Debtor.86Core Scientific and Core Scientific and/or)86Core Scientific Scientific, Inc.(Debtor-in"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?",
        "options": {
            "A": "To manage the financial statements",
            "B": "To express an opinion based on audits",
            "C": "To prepare the financial statements",
            "D": "To oversee the Company\u2019s management",
            "E": "To implement the Company's accounting principles",
            "F": "To revise the financial statements annually"
        },
        "LLM_original_answer": [
            "What interest renewed license for the issuance of the issuance of a renewed license for ONS license for ONS, as well Duke Energy may be affected interest in the issuance of the renewal of a renewed license for the license for the subsequent renewed license for the subsequent renewed license for the subsequent renewed license.The subsequent renewed license for Duke Energy may be affected interest may be affected by the issuance of a renewed license for Duke Energy may be affected by the issuance of interest may be affected by the the renewal license for the license for a subsequent renewed license. The interest may be affected license for a subsequent license for a license to be affected license for a subsequent renewed license for a subsequent renewed license for a license for 10##table by the interest may be affected by the subsequent renewed license for the license for the issuance renewed license.DU.See may be affected license for Duke renewed license for the license for a license. Duke Energy may be affected license for the license for the renewal of the subsequent renewed license for Duke Energy may be affected by the issuance of the interest may be affected interest may be affected by the license for the ONS license for the interest may be affected by the issuance of a subsequent license for the interest may be affected by the subsequent renewed license for a license for the subsequent renewed license may be affected by the issuance of a renewed license for the issuance of a subsequent renewed license for Duke Energy.Duke. The subsequent renewed license for the subsequent renewed license may be affected by the subsequent renewed license may be renewed license may be affected by the issuance of a subsequent renewed license for the subsequent renewed license.The issuance of a subsequent renewed license for the subsequent renewed license renewed license for Duke Energy may be affected by the subsequent renewed subsequent renewed license for the issuance of Duke Energy may be affected by Duke Energy may be affected by the subsequent license renewed license renewed license to be affected by the renewal license may be affected by the interest may be affected by the issuance of the subsequent license for Duke renewed license for the the interest may be affected by the issuance of the issuance of the interest may be affected by the issuance of the issuance of a subsequent renewed license for Duke of a subsequent renewed license may be affected by the issuance of the issuance of a renewed license may be affected by the issuance of a renewed license for the issuance of a subsequent renewed license for 10.The Duke renewed license.The interest may be affected by the issuance of a subsequent license for the subsequent renewed license.The interest in the interest may be affected by the issuance of a subsequent license for the generation of the issuance of the subsequent license for"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?",
        "options": {
            "A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II",
            "B": "Note 5, within the Management's Discussion and Analysis",
            "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II",
            "D": "Note 6, within the Financial Overview section",
            "E": "Appendix A, in the Summary of Financial Policies",
            "F": "Note 7, within the Risk Management section"
        },
        "LLM_original_answer": [
            "The following by $0##Applicable Applicable Tax Rates and Applicable Applicable tax rates and Applicable tax expense decreased by $115. Applicable tax benefit decreased by $40##Applicable tax expense increased by the Applicable tax expense decreased by Applicable tax expense increased by $115##Applicable Applicable tax expense decreased by $0 expense decreased by Applicable Tax Rates and Applicable tax expense decreased by Applicable tax expense decreased by $116##table 39##table 115##table 40##table 115##table 40##table 39##table 115##Income tax expense and Applicable Tax Expense and Applicable Income tax expense decreased by $115##Applicable tax expense decreased by $115. Applicable tax expense decreased by $##Applicable tax expense decreased by $115##table Income Tax Expense Tax expense decreased by the Applicable tax expense decreased by $115##table 39##table 0##table 40##Applicable tax rates and Applicable tax tables Income tax expense decreased by $115Income tax expense decreased by $115##table tax expense decreased by $115##table 39##table 39##table 2020. Applicable Applicable Tax Applicable Applicable tax expense decreased by Applicable tax decreased by $115##table Applicable Applicable Applicable Tax Expense and Applicable by $ 0. Applicable tax expense decreased by Applicable tax rates decreased by $115##table 39##Applicable Applicable tax benefit decreased by $ Applicable Income tax rates decreased by Applicable Applicable by $115##table 115##table 39##Applicable Applicable tax expense decreased by $ 39##Income tax rates Applicable Applicable tax expense decreased by $115 decreased by $115##Applicable tax rates Appable income tax table##Applicable tax expense decreased by $0.0 Applicable tax expense decreased by $115##Applicable tax expense decreased by $115##Applicable tax expense decreased by $115##table 115##table 39##Applicable Applicable tax rates decreased by Applicable tax expense decreased by Applicable tax rates decreased by Income Tax Applicable Applicable tax expense decreased by $115.0##Applicable tax benefit decreased by $ Applicable Tax Rates and Applicable tax expense decreased by Applicable tax decreased by $115. Applicable tax expense and Applicable Tax Rates##Income tax##Applicable tax expense decreased by $39##Applicable tax expense decreased by $115. Applicable by $115"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?",
        "options": {
            "A": "Competitors cannot make similar products without infringing patents.",
            "B": "Patent laws in the United States are more favorable than those in other countries.",
            "C": "Issued patents may be challenged and held invalid or unenforceable.",
            "D": "Regulatory approval for drug candidates is guaranteed.",
            "E": "Trade secrets are always more secure than patents.",
            "F": "All pending patent applications will lead to issued patents."
        },
        "LLM_original_answer": [
            "Based to the processing of services to individuals in relation of services to individuals in relation to individuals or the offering of the offering of services to be services to individuals in relation to the processing of the offering of the offering of services to individuals in relation to individuals or services to individuals in relation to which are or services, including the processing of services to individuals in relation to the processing of services to the processing data in relation to the processing of services to the processing of services in relation to the processing of services or services to individuals in relation to individuals are individuals or who are individuals in relation to individuals in relation to the processing of goods or services to individuals or the UK or the processing of the offering of the processing of the processing of the processing of the processing in relation to the processing of the offering of the offering of goods or services to be offered to individuals in relation to which are to the processing personal data in relation to the offering of services to the processing of the processing of services to the offering of services to the processing of which data in relation to the processing of services in relation to the processing of individuals in relation to the processing data in relation to the offering of services or who process personal data or the provision of services or services to individuals or the processing of services to whom they offering of services to the processing of services to individuals or who process personal data in relation to the processing in relation to the processing of goods or services to the processing of services in relation to individuals in relation to individuals in relation to individuals in relation to the offering of services in relation to individuals in relation to individuals or the UK the offering of services to the processing of individuals who process personal data in relation to individuals in relation to individuals or the processing of services or the processing of the processing of services to the same or services to individuals in relation to the UK to the processing of goods or personal data in relation to individuals in relation to individuals in relation to individuals in relation to individuals or the processing of individuals or the processing of services or personal data in relation to the offering of the processing of individuals in relation to individuals in relation to individuals in relation to the processing in relation to the processing of services to individuals or in relation to individuals, the processing personal data in relation to individuals who\u2019s offering of the offering of services or services, or the processing of services to individuals or in relation to the processing, or who process of services to the processing of the processing of the processing of the offering of the offering of goods or the processing personal data who\u2019s who process the processing of the processing of services to the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?",
        "options": {
            "A": "Increase in market competition",
            "B": "Higher margins in the Correspondent channel",
            "C": "Decline in setup fees for loans boarded",
            "D": "Increase in HECM loan proceeds",
            "E": "Decrease in revaluation gains on MSRs",
            "F": "Higher production volume in retail channels"
        },
        "LLM_original_answer": [
            "The following the 24% as discussed below, as discussed as compared to 2022, as compared to 2022, as compared to 2022%, as compared to 2022, as compared to 2022, as compared to  or 2022, as compared to 41%, as compared to 2022% of which primarily due to the majority due to 100% as compared to 2022, as compared to 24%, as compared to  primarily due to 2022. See Item 2022, as compared to 2022, as compared to 2022, as compared to 74%, as compared to 2022%, as compared to 2022, as discussed below 2022%, as compared to 2022, as compared to 2022, as discussed below 2022, as compared to 2022, as compared to 2022, as compared to 2022, as compared to 74% or 2022, as compared to 74%, as compared to 2022, as compared to the 2022% of which is compared to the secondary to 2022, primarily due to 2022.2022, as compared to 2022, as compared to the majority of the occupancy and other than 2022, as compared to 99%, as compared to 2022, primarily due to 2022% 2022, as well as compared to the or 74%, as compared to 2022, as compared to 2022, among other than 74%74%, as compared to 2022, as compared to the consolidation of 2022, as compared to 2022, as compared to the 2As compared to 2022, as compared to 2022%, as compared to 2022%, as compared to 2022%, as compared to 2022, primarily due to the 2022, as compared to 2022, as compared to the 2022, as compared to 2022%, as compared to 2022, as compared to 2022, primarily due to 2022, as compared to 2022, as compared to 2022, as discussed below, as compared to a significant, as compared to the majority, as compared to the primary due to the majority, as compared to the 2022, as discussed in the aggregate net interest rate, as compared to 2023, as compared to the majority,"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?",
        "options": {
            "A": "Lack of innovative product features",
            "B": "Limited product supply",
            "C": "Inability to maintain effective sales forces",
            "D": "High regulatory costs",
            "E": "Insufficient funding for development",
            "F": "Excessive competition in the product market"
        },
        "LLM_original_answer": [
            "A number of those licenses will remain in force.In addition, the laws of the laws of any assurances that those licenses will remain in force.In addition, the laws of the United States in force.In addition, and the laws of the laws of those licenses will remain in force.In addition, or assurances that licenses will remain in force.In addition, the laws of the laws of the laws of the laws of the laws will remain in force in force.We cannot provide any assurances that laws of the laws of the laws of those licenses, the laws of the laws will remain in force.In addition, or any assurances that those licenses will remain in force.In addition, the laws will remain in force.In addition, or that laws will remain in force.In addition, the laws of the laws of the laws of the laws of those licenses will remain in force of the laws of the laws will remain in force.In addition, the laws of force.In addition, the laws of those licenses will remain in force of force.In addition, the laws will remain in force in force.In addition, or the laws of the laws of the laws of the laws, the laws of the laws of the laws will remain in force.In addition, or that those licenses may of the laws of the laws will remain in force.In addition, or that those licenses.In addition, or assurances will remain in force.In addition, any assurances that those licenses will remain in force.In addition, or that licenses will remain in force.In addition, the laws of the laws of those licenses will remain in force.In addition, or that licenses will remain in force.In addition, or that those licenses will remain in force will remain in force.In addition, the laws of the laws of the laws will remain in force.In addition, that those licenses will remain in force.In addition, or that laws of the laws of those licenses will remain in force.In addition, the laws of the laws of the laws of the laws of the laws of the laws of the laws of the laws of the laws of the laws will remain in force.In addition, the laws of those licenses will remain in force.In addition licenses will remain in force.In addition, the laws of the the laws of those licenses will remain in force.In addition, or that those licenses will remain in force.In addition, the laws of those licenses will remain in force.In addition, the laws of the laws of the laws of the laws will remain in force.In addition, the laws of the laws will remain in force.In addition licenses will remain in force.In addition, the laws of the"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is one reason AMX0035 might fail to obtain regulatory approval?",
        "options": {
            "A": "Manufacturing processes are found to be deficient",
            "B": "Clinical trials easily surpass statistical significance",
            "C": "FDA agrees with the interpretation of preclinical studies",
            "D": "Patient opinions are highly positive",
            "E": "Regulatory authorities consistently approve design implementations",
            "F": "Clinical trials detect an exceeding positive effect"
        },
        "LLM_original_answer": [
            "One DEL.DEL.DEL.DEL.DEL\u2019s compliance with GMP.DEL is determined the site\u2019s compliance with GMP.DEL.DEL.DEL.DEL.DEL D.Eligence\u2019s compliance with GMP.Risk\u2019s compliance with GMP.DELig\u2019s compliance with GMP.DEL.DEL.DELigmp.DEL.DEL.DEL, or, or GMP, or site\u2019s compliance with GMP.DEL, or GMP.DEL, or D.EU, or the site\u2019s compliance with GMP.DELiver, or DEL.DEL, or GMP.DEL.DEL, to determine the site\u2019s compliance with GMP.DEL is determined the site\u2019s compliance with GMP.DELig sites are determined by the site\u2019s compliance with GMPD EL.DEL.DEL.DELs are determined the site\u2019s DEL.DEL.DEL\u2019s compliance with GMP.The site\u2019s compliance is determined the site\u2019s compliance with GMP.DEL, or DEL.DEL.DEL.DEL.DEL.DEL.DEL.Delabor GMP.DEL.DEL.DEL.DEL\u2019s compliance.DEL\u2019s site\u2019s compliance.DELs are determined the GMP.D sites are determined by the site\u2019s compliance.DEL.DEL.DEL.DEL.DEL.Del.DEL.DEL.DEL.DEL.DEL.DEL.DELP.DEL.DEL.DELig GMP.DEL.DEL.DEL, or DEL.DEL\u2019s compliance with GMP.DEL.DEL.DEL.DEL.DEL.DEL.DEL.DEL.DEL.DEL.DEL.DEL.DEL, or DEL.DEL.DEL.DEL.DEL, or DEL.DEL.DELig\u2019s compliance with GMP.DELig.DEL.DEL, or site\u2019s compliance with GMP.DEL.DEL, and the site\u2019s compliance with GMP is determined the site, or S, to determine the site\u2019s compliance with GMP.DEL is determined the site\u2019s compliance with the site\u2019s compliance with GMP.DEL.DEL, site\u2019s compliance with the site\u2019s compliance with GELig sites are determined the site\u2019s compliance.DEL is determined site\u2019s compliance with the site\u2019s compliance with GMPGMP.DEL, or site\u2019s compliance with GMP.DEL.DELs are determined the site\u2019s compliance.DEL.DEL, or DEL, or GMP.DEL.DEL.DEL.DEL.DEL, or DEL.DEL.DELig GMP.DEL.D"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the purpose of Section 31 fees according to the Exchange Act?",
        "options": {
            "A": "To finance market makers on exchanges",
            "B": "To cover the costs of technology upgrades",
            "C": "To recover the government\u2019s costs of supervising and regulating the securities markets",
            "D": "To reward high-frequency traders",
            "E": "To fund international trading agreements",
            "F": "To support trading education programs"
        },
        "LLM_original_answer": [
            "What is not only provide reasonable assurance of reasonable assurance with respect to financial statement preparation and presentation and can only with respect to be reasonably assure reasonable assurance with respect to be effective financial statement preparation and presentation and presentation and can provide reasonable assurance with respect to reasonable assurance of reasonable assurance of reasonable assurance of reasonable assurance with respect to the financial statement preparation and presentation and can only provide reasonable assurance of reasonable assurance with respect to the effectiveness of financial statement preparation and can be effective internal controls and can only provide reasonable assurance with respect to the effectiveness with respect to the effectiveness and other than can only provide reasonable assurance and related to the effectiveness and can only with respect to be presented and can only provide reasonable assurance with reasonable assurance of the LIBRisks with respect to be reasonably reasonable assurance with respect to provide reasonable assurance and can be prepared and can be reasonably assure with respect to the underlying assumptions and can provide reasonable assurance with respect to the same with respect to the effectiveness and presentation and can be reasonably assure reasonable assurance of reasonable assurance with respect to financial statement preparation and presentation.The FCA can only provide reasonable assurance with respect to the preparation and can be reasonably assurance with respect to reasonable assurance and presentation and can only provide reasonable assurance with respect to the financial statement presentation and can only providing reasonable assurance and can be reasonably assure financial statement preparation and with respect to the effectiveness of financial statement preparation and with respect to the reasonable assurance with respect to the effectiveness with respect to the following financial statement preparation and reasonable assurance with reasonable assurance with respect to financial statement preparation and reasonable assurance with respect to the presentation and can be reasonable assurance with respect to the reasonable assurance with respect to the effectiveness and can provide reasonable assurance with reasonable assurance with respect to the effectiveness and presentation and reasonable assurance with respect to the effectiveness. See the effectiveness assurance and can be presented within the effectiveness of financial statement preparation and can only provide reasonable assurance with respect to financial statement preparation and presentation. See Item  effectiveness. With respect to the effectiveness with respect to the effectiveness with respect to the effectiveness with respect to the following reasonable assurance with reasonable assurance with respect to reasonable assurance of preparation and reasonable assurance with respect to reasonable assurance with reasonable assurance with reasonable assurance of reasonable assurance of reasonable assurance of reasonable assurance and reasonable assurance. See Item  and reasonable assurance with respect to the only provide reasonable assurance with reasonable assurance with reasonable assurance of reasonable assurance with reasonable assurance with respect to be reasonably assure financial statement effectiveness with respect to be financial statement preparation and can provide reasonable assurance with respect to the business activities, and can only provide reasonable assurance with respect to reasonable assurance of reasonable assurance with"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?",
        "options": {
            "A": "5%",
            "B": "10%",
            "C": "15%",
            "D": "1%",
            "E": "0.5%",
            "F": "2%"
        },
        "LLM_original_answer": [
            "Based on the credit-linked credit and Credit and Derivative Credit-Adoption91.91.91.91% for California, New York91Credit and 91.91.91.91.91% for Florida and New York.91.91.91Credit and Derivative91.91Item 91\n91.91See \u201cFlorida91%91% for California.91% for Florida.9191.91Item 91.91See91.91.91%91See.91.91See \u201cThe annualized91Deriv91.91.91D.91 and 91.91.91.91Item 91.91.91See \u201cFlorida.91See California.91.91Deriv.91Seeissions.91See91 91%91California91 and 91.91 91.91.91See \u201c\u2014California91The above.91.91Item 91.91.91Seeissions91.91.91.91.91.91Item 91.91.91See.91.91% for Texas.91.91Item 91.91Seeissions91.91.91.91.91.91.91.91.91.91.9191.91% for New York91.91.91.91.91California91.91.91California.91.91.91Table 91.91The above the91.91See the Company91.91A.91See9191.91% for Florida and 91See91%91.91.91See.91See.91See.91See.91See California, 91See91See91.91Item 91.91.91 and derivatives and/or91% for New York91.91Deriv.91.91Deriv.91.91.91Policy91.91.91 and New York.91% for New York.91% for California.91Divers.91.91.91.91Credit and91.91.91.91.91Item 91 and 7% for Texas and 91.91\nNew York.91Table 91.91% for New York.91% for New York.91.91Table Tableau New York.90\n91.91.91Item 91.91.91.91.91% for New York.91.91.91.91.91Item 91.91.91 91.91.91.91.91"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could happen if there are delays in the clinical trials of product candidates?",
        "options": {
            "A": "The marketing period under patent protection would be increased.",
            "B": "The marketing period under patent protection would be reduced.",
            "C": "The patent applications would become public immediately.",
            "D": "The company would be certain they were first to file any patent application.",
            "E": "All interference proceedings would be canceled by the USPTO.",
            "F": "Priority disputes would be automatically resolved in the company's favor."
        },
        "LLM_original_answer": [
            "If the or may require us of our distributors or distributors or distributors.These may require us to initiate or may require us believe that may require initiation or distributor claims may be or distributor or distributors.These claims may be initiated or distributor or distributors.These customers or distributors.These claims may require a broadening or may be initiated or distributor or distributors or distributors.These customers or distributor or distributor\u2019s customers or distributor or distributors.These may require or distributors.These claims may require us to initiate or distributors of the customers or (or\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What action does the Company take to manage commodity price risk for its merchant generation operations?",
        "options": {
            "A": "Invests in renewable energy sources",
            "B": "Diversifies its energy portfolio",
            "C": "Enters into derivative instruments",
            "D": "Reduces energy consumption",
            "E": "Increases energy purchases",
            "F": "Halts energy operations"
        },
        "LLM_original_answer": [
            "Question: 2024. The remaining balance of $ 2023. The remaining balance was drawn in February 2023.23The remaining balance of $ 10. Seebalances were drawn in February.The remaining balance of which was drawn in February 11.23, which could be drawn in February balance of $ 23 million was drawn in February.The balance of $ 10.12.0 million was drawn in February 2020. The remaining in February in February.The remaining balance was drawn in February was drawn balance of $ 10.0 million was drawn in March 2020.The remaining balance was drawn in February 0 million in February 10. The remaining balance was drawn in February 20million in March 2024. The remaining balance of $ 10.23. The remaining balance of $ 0 million was drawn in February 0. The remaining balance was drawn in February 10. The remaining balance in February 2024. The remaining balance of $ 10.0.0 million was drawn in February 23. The balance was drawn in February 0. The remaining balance was drawn in February 2023. The remaining in March 12. The remaining balance in February 2023.23\n\nPlease answer: What remaining balance of $ 22. The remaining balance was drawn in February.The remaining balance of $ 22.23\nIn February 10.20 million was drawn in December balance of $ 10.0.0 million was drawn in March 2024. The remaining balance was repaid in February was drawn in the $ 10.0 million in February 2024.The remaining balance in February.The remaining balance of $ 10. The Company:23\n\n\nQuestion:23.11.0 million was repaid in March.The remaining balance was repaid in February 10.0 million was drawn in March 2024. The remaining balance was drawn in February 100. The remaining balance was drawn in February 20. The remaining balance was drawn in February.The remaining balance.The remaining balance of 2024. The remaining balance in February.The remaining balance of $ 2023.23balance was drawn in February 10. The balance was drawn in February 2020. The remaining balance.The remaining balance of $ 10. The remaining balance of $ 10.0 million in February 10. The remaining balance in February 2023. The balance of $ 0.23.23.The balance was drawn in February balance was drawn in February"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the responsibility of the public accounting firm regarding the Company\u2019s financial statements?",
        "options": {
            "A": "To manage the financial statements",
            "B": "To express an opinion based on audits",
            "C": "To prepare the financial statements",
            "D": "To oversee the Company\u2019s management",
            "E": "To implement the Company's accounting principles",
            "F": "To revise the financial statements annually"
        },
        "LLM_original_answer": [
            "What, How however none of the Index to Combined Index to Combined Index to Combined Index to Combined Index to Combined Index to Combined Index to Combined Index to Combined Notes to Combined Notes to Combined Notes to Consolided to Consolid How the Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Index to Combined Notes to Combined Notes to How however none of How however, how however, Duke Energy to Combined Notes to Combined Index to Combined Notes to Combined Notes to Combined Notes to Consolidated Notes to Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Index to Combined Notes to be how however, Index to Combined Notes to Combined Index to Combined Index to Combined Index to Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Index to Combined Notes to Combined Index to Combined Notes to Combined Notes to Combined Notes to Consolidated Index to Index to Combined Notes to Combined Index to Index to How however, the Index to Index to Consolidated How however, none of Combined Notes to Consolidized.How however, Item to Consolid Combined Index to Combined to How however none to Combined to Combined Index to Combined Index to Combined Index to Combined Notes to Combined Notes to Combined How how Howeverreduced Financial Statements to Combined Index to Combined Notes to Combined to Combined Index to Combined Index to Combined Notes to Combined Notes to Combined Index to Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Index to Combined Index to Combined Notes to Combined Notes to Combined Combined Index to Combined Notes to Consolidated Consolid Index to Combined Notes to Combined Notes to Combined Notes to Combined Notes to Combined Index to Combined Notes to Combined Index to Consolidated Index to Combined Index to Combined Index to Consolidated How however, how however, how however, how however, how however to Combined Index to Consolid How however, How however to Combined Index to Combined Index to Combined Notes to Consolid Index to Combined Index to How however how Duke Energy to Combined Notes to Combined Notes to Combined Index to How however, and how however, Duke Energy to Combined Index to How however, Duke Energy Matters to Combined How however, Duke Energy and Combined Index to Combined Index to Combined to Combined Index to Combined Combined Notes to Combined Index to Combined How however to Combined to Combined to Combined Index to Combined Notes to Combined to Combined Index to Combined to Combined to Combined Index to Write to How however how however none of Combined Index to Combined to Combined to Combined to Combined Combined to Combined to Combined to Combined Notes to Combined to"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "Where can one find the discussion about the allowance for credit losses measurement methodology?",
        "options": {
            "A": "Note 3, within the Notes to the Consolidated Financial Statements in Part II",
            "B": "Note 5, within the Management's Discussion and Analysis",
            "C": "Note 2, within the Notes to the Consolidated Financial Statements in Part II",
            "D": "Note 6, within the Financial Overview section",
            "E": "Appendix A, in the Summary of Financial Policies",
            "F": "Note 7, within the Risk Management section"
        },
        "LLM_original_answer": [
            "The difference represents the difference between the plan assets represent of the plan.Funded status represents the difference represents the plan represents the plan represents the difference between the difference between the difference represents the difference between the difference between the difference between the difference between the difference between the difference represents the difference between the the fair status represents the plan and taxes represent the projected benefit of the difference between the difference between the difference between the difference between the plan and the plan and the difference represents the difference between funded status represents the difference between the difference between the difference between the difference represents the difference between the difference between the difference between the plan status represents the difference between the projected benefit obligation of the plan and the projected benefit obligation of the plan represents the difference between the difference represents the difference between the difference represents the difference between the plan status represents the plan status of the difference between the difference represents the represents the difference between the plan assets of the plan and the difference represents the difference represents the difference between the difference of the plan status represents the difference between the plan represents the plan represents the difference represents the difference between the difference between status represents the plan status represents the difference between the plan represents the difference between the difference represents the difference of the difference represents the difference represents the difference between funded status represents the difference between the projected benefit obligation of the plan.Funded status represents the difference represents the difference between the projected benefit obligation of the plan and the difference between the difference between the difference between the difference between the difference between the difference of the difference represents the projected benefit of the difference of the plan status represents the difference between the difference between the difference between the plan status represents the plan represents the difference represents the status represents the difference represents the status represents the difference between the difference of the difference between the projected benefit obligation of the plan and the related taxes.Funded status represents the difference between the difference between the difference between the plan represents the plan represents the plan represents the difference represents the difference represents the difference between the difference between status represents the projected benefit obligation represents the difference between the difference represents the difference between the projected benefit obligation of the plan and the difference of the difference between the projected benefit obligation of the plan status represents the plan status represents the difference between the difference between the difference between the plan status represents the difference between the difference represents the status represents the difference between the difference of the plan status represents the difference between the difference between the status represents the difference represents the status represents the difference between the projected benefit obligation of the plan and the fair status represents the projected benefit of the difference between the difference between the difference between the status represents"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is one reason why intellectual property rights may not provide adequate protection for the business?",
        "options": {
            "A": "Competitors cannot make similar products without infringing patents.",
            "B": "Patent laws in the United States are more favorable than those in other countries.",
            "C": "Issued patents may be challenged and held invalid or unenforceable.",
            "D": "Regulatory approval for drug candidates is guaranteed.",
            "E": "Trade secrets are always more secure than patents.",
            "F": "All pending patent applications will lead to issued patents."
        },
        "LLM_original_answer": [
            "What are subject to be subject to be subject to the drug candidate of the drug candidates of the conduct of the United Kingdom of the United Kingdom of the conduct of which is a subject to the United Kingdom of the conduct of the Northern Ireland (subject to the Northern Ireland (subject to the Northern Ireland (subject to the Northern Ireland (subject to which is subject to which is subject to the Northern Ireland (subject to periodic consent of the Assembly of the Executive).) and subject to exercise of the UK-based on a number of the subject to the application of the the Legislative Assembly) (subject to the Northern Ireland (subject to the Northern Ireland in Northern Ireland (subject to periodic consent of the Northern Ireland Assembly) and consent of the Northern Ireland) and the Assembly).) and the Assembly).) and consent of the Northern Ireland Assembly) and consent of the Northern Ireland).).) and periodic consent of the subject to periodic consent of the Assembly (subject to the) and periodic consent of the United Kingdom of the Northern Ireland (or the Legislative Assembly of the Department of the subject to the subject to the pre-clin the results of the parties to the drug candidates of the periodic consent of the Northern Ireland subject to the subject to the United Kingdom of the conduct of the United Kingdom of the United Kingdom of the Executive consent of the Assembly (subject to the consent of the drug candidates of the Northern Ireland (subject to the Northern Ireland Assembly of the Northern Ireland Assembly)For risks and the Northern Ireland (and/or consent of the U.SaidedDrug Candidate Drug Candidate Consent of the drug candidates for the European Unionist consent of the Assembly of the Northern Ireland (subject to the parties to the business and periodic consent of the DELigDrug CandidateDrug Candidate drug candidates and periodic consent of the drug candidates of the parties (subject to the Northern Ireland).We believe).23The DELig drug candidate consent of the DELig).The Northern Ireland (subject to the drug candidates for the DELig).Regulatory consent of the drug products of the Northern Ireland).The key competitive consent of the United Kingdom) and consent of the DELig). (subject to the DELig).The processes and other drug candidates).The processes for the DELs).The processes (and the United Kingdom of the Assembly) (subject to the United Kingdom of the United Kingdom of the U.Saf periodic consent of the United Kingdom of the drug candidates in the development of the periodic consent of the United Kingdom of the U.Sever consent of the Department of periodic consent of the subject to the Department of the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What was a primary reason for the decrease in other revenue, net for 2023 compared to 2022?",
        "options": {
            "A": "Increase in market competition",
            "B": "Higher margins in the Correspondent channel",
            "C": "Decline in setup fees for loans boarded",
            "D": "Increase in HECM loan proceeds",
            "E": "Decrease in revaluation gains on MSRs",
            "F": "Higher production volume in retail channels"
        },
        "LLM_original_answer": [
            "What is able to exercise of the policies and procedures and procedures and policies and procedures and policies and not just not policies and procedures and procedures of the policies and procedures and not only over the policies and not just not only not just policies and procedures and influence, but not only policies and policies and policies and policies and policies and procedures of the policies and procedures and procedures, but not only policies and procedures, but not only able to exercise over the policies and policies and not only policies and not control, including the policies and procedures, but not only through the policies and not only not just not only policies and policies and procedures, but not only not control, but not only not policies and procedures, but not only not only able to exercise significant influence, but not only not only over the policies and procedures and not to exercise of the policies and not policies and not-for example, but not only control, but not control over the policies and influence, but not control, but not policies and procedures and procedures, but not only not control, but not control, but not only able to achieve, but not only not only influence, but not only not control, but not policies and procedures and procedures, but not only able to which are able to ensure that are not only not just not able to include, but not policies and policies and policies and not only through the policies and procedures, but not able to exercise significant influence over the policies and policies and policies and policies and procedures, but not only a significant influence over the policies and not policies and policies and procedures, but not policies and procedures and policies and procedures and procedures and policies and not control over the policies and not control over the policies and policies and policies and not control, but not only not control over the policies and policies and procedures, but not only able to a significant influence, including the policies and procedures, but not to a significant influence, not control, over the policies and procedures, but not policies and procedures and not only able to exercise significant influence, but not able to the policies and procedures of the policies and not only the policies and procedures and policies and policies and procedures and procedures and procedures of the policies and procedures and procedures and procedures and procedures and policies and policies and policies and policies and procedures, but not only influence, but not only able to exercise control over the policies to exercise significant influence over the policies and not the policies and policies and procedures, but not only not control over the policies and not exercise significant influence over the policies and control, but not policies of the policies and procedures and not"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is a potential challenge mentioned in establishing collaborations for sales and marketing?",
        "options": {
            "A": "Lack of innovative product features",
            "B": "Limited product supply",
            "C": "Inability to maintain effective sales forces",
            "D": "High regulatory costs",
            "E": "Insufficient funding for development",
            "F": "Excessive competition in the product market"
        },
        "LLM_original_answer": [
            "What is aMLAMLAMLAMLAMLA-Integrated product candidates to earlier versions to earlier versions to earlier versions of the factors that are many of the factors many of the many of the many of our solid tumor infiltrated to earlier versions of the many of earlier versions.The key features and many of the factors of the factors or bridge our T-Plexic trials of the factors of our modified product candidates to earlier versions of the factors of the factors of the factors of the many of the factors of the many of the potential challenge of the potential candidates to earlier versions to earlier versions of our factors of the same as described product candidates to earlier versions of earlier versions of the factors to earlier versions to bridge our modified product candidates to earlier versions to earlier versions to earlier versions of the factors of the FDA\u2019s factors that are summarized T-Plex modified product candidates to earlier versions of the factors mentioned in the factors of the clinical development of the modified product candidates to earlier versions.The many of the factors and many of the factors to earlier versions to our T-Plexic modified product candidates to earlier versions of the factors that can be bridged to the modified product candidates to earlier versions of the modified product candidates to earlier versions of the factors that are the patient segments or clinical therapy companies that we are designed to bridge our modified product candidates to earlier versions to earlier versions of the factors or clinical trials and bridge our T-Plex modified product candidates to earlier versions of the factors to earlier versions to earlier versions to bridge our modified product candidates to earlier versions of the factors to earlier versions of the central elements of the factors mentioned in the factors that we believe that are designed to bridge our patient treatment arms and many of the factors or clinical development of the modified product candidates to earlier versions of the factors of the modified product candidates to earlier versions to earlier versions of our modified product candidates to bridge our T-PlexClinical Development and many of the modified product candidates to earlier versions of the factors mentioned in cancer-associated factors mentioned in the FDA-licensed versions of the modified product candidates to earlier versions of our modified product candidates for the modified product candidates to earlier versions of the factors of the factors mentioned in establishing collaborations for many of the factors of our modified product candidates to bridge our modified product candidates for sales and clinical trial and clinical trial candidates to earlier versions of the factors of the factors to earlier versions of the above.The FDA and earlier versions to earlier versions of the many of the factors or clinical development of the safety and clinical development of our modified product candidates to establish the clinical trial candidates"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is one reason AMX0035 might fail to obtain regulatory approval?",
        "options": {
            "A": "Manufacturing processes are found to be deficient",
            "B": "Clinical trials easily surpass statistical significance",
            "C": "FDA agrees with the interpretation of preclinical studies",
            "D": "Patient opinions are highly positive",
            "E": "Regulatory authorities consistently approve design implementations",
            "F": "Clinical trials detect an exceeding positive effect"
        },
        "LLM_original_answer": [
            "What any other current or any other current or voluntary recalls of AM0035 or any other current or future product or voluntary recalls of AMX0035or any other current or product or product candidates or any product candidates or voluntary recalls of AMX0035 or voluntary recalls of AMX0035 or any other current or any other product or any product or voluntary recalls of AMX0035 or any other current or voluntary recalls of AMX0035 or any other current or any other product or any other than any other recalls of AMX0035 or any other current or future product or any other than voluntary recalls of AMX0035 or any other current or any other than AMX0035 or any other current or voluntary recalls of AMX0035or any other products or any other recalls of AMX0035 or any other current or any other product or any other current or any other products or voluntary recalls of AMX or any other current or product or any or voluntary recalls of AMX0035 or any other current or future product or any other product or any other product or any other product recalls of AMX0035 or any other products or any other or any other current or voluntary recalls of AMX0035 or any other current or future product or any other product or voluntary recalls or voluntary recalls or any other current or voluntary recalls of AMX or any other AMX0035 or any other current or any other current or voluntary recalls of AMX0035 or any other current or future product or voluntary recalls of AMX0055 or any other current or voluntary recalls of AM0035 or any other current or future product or voluntary recalls of AMX or voluntary recalls of AMX5 or any other current or any other current or any other AMX0035 or any other current or any other current or voluntary recalls of AMX0035 or AMX0035or voluntary recalls or any AMX.The voluntary recalls of AMX or voluntary recalls of AMX0035 or any product or voluntary recalls of AMX0035or voluntary recalls of AMX5 or any other current or any other current or voluntary recalls of AMX8035or any other current or any other product or any product or any other current or any other current or voluntary recalls of AMX0035 or any other products or any other current or any other current or voluntary product or any current or any other current or future product or product or voluntary recalls of AMX or any other current or any other current or voluntary recalls of AMX0035 or any"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the purpose of Section 31 fees according to the Exchange Act?",
        "options": {
            "A": "To finance market makers on exchanges",
            "B": "To cover the costs of technology upgrades",
            "C": "To recover the government\u2019s costs of supervising and regulating the securities markets",
            "D": "To reward high-frequency traders",
            "E": "To fund international trading agreements",
            "F": "To support trading education programs"
        },
        "LLM_original_answer": [
            "What is based on affectConsolidated by consolidated income tax provisionConsolidated by nature of the UAE.The Consolidated Income Tax Consistenthe and consolidated income tax provisionConsolidatedThe consolidated income tax provisionConsolidated Income TaxationThe consolidated income tax provisionConsolidated information, as of ConsolidatedataConsolidated DataConsolidated Income Tax Consistenthe consolidated income tax provision of ICE Futures Abu Dhabi and income tax provision of Consolidated Consolidated income tax provision is subject to the provision of the Consolidatedistribution of Consolidated tax provisionConsolidated information tax provision of Consolidated income tax provisionConsolidated income tax provision of the Consolidated information tax provision of the Summary of the Consolidated income tax provision of consolidated income tax provisionConsolidatedConsolidated Consolidated income tax provision of the consolidated income tax provision and consolidated income tax provisionConsolidated. Consolidated and Consolidated income tax provisionConsolidated income tax provisionConsolidated by regulation of ProvisionSummary of the net consolidated income tax provision of the ConsolidatedConsolidated Information TaxationTaxationSummary of the ConsolidatedConsolidatedata\nConsolidated Consolidated information contained in this Annual Reportable Data and ICEConsolidated tax provisionThe information tax provision, Abu Dhabi, which is a provisionConsolidated income tax provision is a provisionConsolidatedConsolidated by consolidated income tax provision, as well as of consolidated income tax provision of the ICE Market Participants and consolidated income tax provision of the consolidated income tax provision, Consolidated by the provisionConsolidated income tax provisionConsolidated income tax provision of ICE Consolidated income tax provision of ICE Futures Abu DhabiConsolidated income tax provisionConsolidatedThe consolidated income tax provision, Abu Dhabi, income tax Consolidated income tax provisionConsolidatedeConsolidatedThe consolidated income tax provisionThe consolidated income tax provisionConsolidatedThe consolidated income tax provisionConsolidated the Consolidated by Reference to the Abu Dhabi, Consolidated Financial StatementsThe consolidated income tax provision of the provisionConsolidated ProvisionConsolidated consolidated income tax provisionConsolidatedirectly ICE ProvisionConsolidated income tax provisionConsolidated by nature of interest in the impact of ICE Tax ProvisionConsolidated ICE ConsolidatedConsolidated consolidated income tax provision, consolidated income tax provision, or other than ICE Market InformationRelated consolidated income tax provision consolidated income tax provisionConsolidated income tax provision, as of Consolidated consolidated income tax provision and Other Information Tax Disclosure of the regulation of the regulatory"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 40,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What percentage of total investments do the top ten holdings in the corporate fixed maturity securities portfolio comprise?",
        "options": {
            "A": "5%",
            "B": "10%",
            "C": "15%",
            "D": "1%",
            "E": "0.5%",
            "F": "2%"
        },
        "LLM_original_answer": [
            "Question when it has more than it has more than it has more than has more than the equity method of investments when it has more than a majority of more than more than a significant method of accounting when it has more than it has more than it has more than a 20% more than a significant voting interest rate of accounting for investments when it has more than has more than it has more than it has more than a more than it has more than a significant influence method when it has more than it has more than a significant influence in more than more than equity method of accounting for investments when it has more than a more than it has more than it has more than it has more than it has more than it has more than a more than it has more than a more than it has more than it has more than it has more than it has more than a controlling interest method of more than 49 has more than a more than more than it has more than it has more than it has more than has more than a significant for insurance when it has more than it has more than a person when it has more than a method of more than more than the equity method of accounting when it has more than a more than a more than more than the equity method of accounting when it has more than it has more than 10 more than it has more than 50% of investments in control, or a significant influence when it has more than it has more than a significant influence when it has more than it has more than it has the equity method of accounting when it has it has more than a voting interest in the equity when it has more than more than it has more than it has more than has more than a minority method when it has it has more than it has more than has more than it has more than it has more than a more than 12 of accounting when it has more than it has more than it has more than a significant influence for investments when it has more than a more than a more than the equity method of accounting for investments when it has more than more than a voting interest in the equity method of investments when it has more than it has it has more than a minority method of more than it has more than when it has more than it has more than it has more than it has more than a controlling for investments when it has it has more than a more than more than it has more than has more than it has it uses the equity method of more than the equity method of accounting when it has more than it has more than more than"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?",
        "options": {
            "A": "The Hatch-Waxman Act",
            "B": "The Bayh-Dole Act",
            "C": "The Federal Trade Commission Act",
            "D": "The Privacy Act",
            "E": "The Patent Cooperation Treaty",
            "F": "The Sherman Antitrust Act"
        },
        "LLM_original_answer": [
            "Based on the provided document, the federal regulation that may affect some of the in-licensed intellectual property related to government-funded discoveries is the Bayh-Dole Act (Option B). The Bayh-Dole Act allows universities, small businesses, and non-profit organizations to retain ownership of inventions made under federally funded research programs, with certain conditions. This act also provides the government with certain rights, such as \"march-in\" rights, which allow the government to require the contractor or successors in title to the patent to grant a license to a responsible applicant or applicants if certain conditions are met."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?",
        "options": {
            "A": "Interest expenses on loans",
            "B": "Direct expenses associated with the services",
            "C": "Revenue from hardware sales",
            "D": "Marketing expenses",
            "E": "Legal fees related to contracts",
            "F": "Stock options for employees"
        },
        "LLM_original_answer": [
            "Based on the provided document, the recorded components of cost of revenues when the Company provides hash calculation services are:\n\nB: Direct expenses associated with the services\n\nThe document details various aspects of the Company's operations, including its valuation, digital assets, and financial instruments. However, when it comes to the cost of revenues for hash calculation services, the document specifies that direct expenses associated with providing these services are recorded as a component of cost of revenues."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?",
        "options": {
            "A": "Separate them and account under different frameworks",
            "B": "Combine them and account under the lease accounting framework",
            "C": "Only account for lease components",
            "D": "Account for non-lease components under a different policy",
            "E": "Classify the entire arrangement as a capital lease",
            "F": "Exclude non-lease components from financial statements"
        },
        "LLM_original_answer": [
            "Based on the provided document, the question is about how Duke Energy handles lease and non-lease components for lessor arrangements when the non-lease components are not predominant. The options given are various accounting treatments for such components.\n\nTo answer the question, we need to find the relevant information in the document. The document does not directly address the specific question about handling lease and non-lease components for lessor arrangements. However, we can infer the general accounting treatment for leases based on the information provided.\n\nThe document mentions that Duke Energy follows the lease accounting framework for lease arrangements. It also states that Duke Energy has elected a policy to not separate lease and non-lease components for all asset classes for lessee and lessor arrangements. For lessor arrangements, lease and non-lease components are only combined under one arrangement and accounted for under the lease accounting framework if the non-lease components are not the predominant component of the arrangement and the lease component would be classified as an operating lease.\n\nBased on this information, the correct answer to the question is:\n\nB: Combine them and account under the lease accounting framework\n\nDuke Energy combines lease and non-lease components for lessor arrangements when the non-lease components are not predominant and accounts for them under the lease accounting framework."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Who is responsible for devising and monitoring the asset-liability management strategy?",
        "options": {
            "A": "Board of Directors",
            "B": "Chief Executive Officer",
            "C": "Asset-Liability Management Committee",
            "D": "Finance Department",
            "E": "Risk Management Committee",
            "F": "External Auditors"
        },
        "LLM_original_answer": [
            "Based on the provided document, the responsibility for devising and monitoring the asset-liability management strategy lies with the Asset-Liability Management Committee (ALCO), a subcommittee of the Enterprise Risk Management Committee (ERM). ALCO operates under a charter developed and approved by the ERM and meets at least monthly, or more frequently as needed, to review various aspects of the company's financial management, including interest rate changes, loan pricing and activity, investment activity and strategy, hedging strategies, deposit pricing and funding strategies, and earnings simulations over multiple years. ALCO reports regularly to the Risk Management Committee (RMC) of the Board of Directors, which oversees the adequacy of capital allocated based on the level of risk and risk issues that could impact liquidity and/or capital adequacy."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What can reduce the 10-year market exclusivity for orphan products to six years?",
        "options": {
            "A": "A new market demand report",
            "B": "The introduction of a similar product by a competitor",
            "C": "Annual sales exceeding expectations",
            "D": "Establishment that the product no longer meets orphan criteria",
            "E": "Approval of a new regulatory framework",
            "F": "A change in government policy"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factor that can reduce the 10-year market exclusivity for orphan products to six years is:\n\nD: Establishment that the product no longer meets orphan criteria.\n\nThe document states that the 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation; for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What factors apart from interest rates can affect MSR fair value?",
        "options": {
            "A": "Federal regulations",
            "B": "Investor required yield or perceived value",
            "C": "The geographical location of properties",
            "D": "Historical property data",
            "E": "Currency exchange rates",
            "F": "Maintenance costs"
        },
        "LLM_original_answer": [
            "Factors apart from interest rates that can affect MSR (Mortgage Servicing Rights) fair value include:\n\nB: Investor required yield or perceived value - The fair value of MSRs is influenced by the yield that investors require for the risk associated with the MSRs, which can be affected by market conditions, credit risk, and other factors. The perceived value of MSRs by investors can also impact their fair value, as it reflects the market's expectations of future cash flows and the risk of those cash flows.\n\nOther factors mentioned in the document that can affect MSR fair value, but are not options in the multiple-choice question, include:\n\nA: Federal regulations - Regulatory changes can impact the valuation of MSRs by altering the risk profile or the expected cash flows from servicing rights.\n\nC: The geographical location of properties - The location of the underlying properties can affect the risk of prepayment, default, and other factors that influence the value of MSRs.\n\nD: Historical property data - Historical data on property values, default rates, and other factors can inform the valuation of MSRs by providing insights into the performance of similar assets.\n\nE: Currency exchange rates - For MSRs that involve properties in foreign countries or where the MSR fair value of $2.90forward securtailored MSR investments in connection with respect to finance and other than can vary based on secursecurities are based on servicing assets and related to the fair value of the Company-owned MSRs and related to finance MSR investments and related to hedge accounting for investments, or other than fair value changes in the Company-owned investments arealike MSR investments in the Company-owned reverse mortgage loan level 1. The fair value of the fair value or the fair value of the Company uses the following the Company uses the fair value of the MSR capital and related to support of the fair value of $2.87Investments and related to the fair value of the following the fair value of $2dera financial instruments and other than the fair value of $2.87and fair value of reverse mortgage loan and related to the following the fair value of the following the fair value of $2_FWD_ACCOUNT_11 of the MSR when it has more than equity method of $87 in the MSR investments when it has more than 87 or other than the following the equity method of investments are investments when it has more than 86 in the Company uses the MSR capital and MSR capital and other than in the MSR investments in the fair value when it has more thanequoting.86its fair value of HEC"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?",
        "options": {
            "A": "Faster development process",
            "B": "Ultimate approval by the FDA",
            "C": "Faster review",
            "D": "Faster licensure",
            "E": "Qualification for all future product candidates",
            "F": "Marketing approval"
        },
        "LLM_original_answer": [
            "The FDA's Breakthrough Therapy designation does NOT guarantee the following for a product candidate:\n\nF: Marketing approval\n\nThe FDA's Breakthrough Therapy designation is intended to expedite the development and review of drugs that treat serious or life-threatening conditions and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies. However, this designation does not guarantee that the product candidate will ultimately receive marketing approval. The FDA's decision to grant marketing approval is based on a comprehensive review of the safety and efficacy data from clinical trials, and the Breakthrough Therapy designation does not influence this decision."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?",
        "options": {
            "A": "Reducing research and development costs",
            "B": "Improving relationships with regulatory bodies",
            "C": "Increased risk of serious adverse events (SAEs)",
            "D": "Receiving immediate commercial approval",
            "E": "Negative feedback from patients",
            "F": "Lowering the price of the drug"
        },
        "LLM_original_answer": [
            "Based on the provided document, the consequence of initiating an EAP (Expanded Access Program) beyond what was submitted to the FDA for AMX0035 could be:\n\nC: Increased risk of serious adverse events (SAEs)\n\nThis is because initiating an EAP beyond the submitted protocol may expose patients to untested dosages or combinations, potentially leading to unforeseen side effects or adverse events. The document also mentions the possibility of Health Canada requiring further confirmatory clinical trials if the data from the PHOENIX trial does not satisfy the conditions for marketing authorization, which could impact the marketing approvals for AMX0035."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?",
        "options": {
            "A": "Increased dividend payments to stockholders",
            "B": "Lower commodity prices and reduced volatility",
            "C": "Higher development of electronic trading platforms",
            "D": "Repayment of debt",
            "E": "Expansion of clearing houses",
            "F": "Treasury shares received for restricted tax payments"
        },
        "LLM_original_answer": [
            "The primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023 was lower commodity prices and reduced volatility."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?",
        "options": {
            "A": "$7 million",
            "B": "$16 million",
            "C": "$393 million",
            "D": "$829 million",
            "E": "$10.6 billion",
            "F": "$11.0 billion"
        },
        "LLM_original_answer": [
            "To answer the question about the total amount of cash collateral we were obligated to return to counterparties as of December 31, 2023, we need to look at the document provided. The relevant information is found in the section discussing \"Pledged Collateral\" and \"Assets pledged or otherwise committed.\"\n\nAccording to the document, as of December 31Our primary uses of $3.interest rate of $3.interest rate sensitive to fundings of $3\u4ebf"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?",
        "options": {
            "A": "The Hatch-Waxman Act",
            "B": "The Bayh-Dole Act",
            "C": "The Federal Trade Commission Act",
            "D": "The Privacy Act",
            "E": "The Patent Cooperation Treaty",
            "F": "The Sherman Antitrust Act"
        },
        "LLM_original_answer": [
            "The Company.Uponyouthas applicable to some of the Company.The Company.The Company uses the Company.The Company uses of the Company.74or any of74or any of the following the Company.The Company.The Company.The Company.The Company uses of theopharmyouthttpassumed when the Company:\u25aa have more than the Company Information:\u25aahypo79or have more than the Company uses of the Company uses of a non-exclusive, iftariffsentireferences to the equity method of which it uses of the Company:\u25aaor investments in- based on the Company: (A:I'moregainspiration of accounting for investments when it has more than the equity method of the Company: (either than a74a.74or have an-74or have more than 74or other than any of the Company uses or their proprietary rights to some of the Company uses of which are of the Company uses of the derivative method of the Company uses of which aregains of the Company uses of the Company uses of the Company uses of which isosseventhhaves of the equity method of the Company uses of the equity method of accounting for more than when it has more than an-licensed from 75from the equity method of the Company uses the Company: (a76from the method of any of which aregovernight of the Company:76and/or in-Formulation of accounting for its product candidates, if the Company:\u2014\nA:\u25aaor other than any of the Company uses of the accounting for the Company:\u25aa\naniofferentirex79or any such as applicable to the Company.The Company uses of the Company:\u25aantermsay of the Company:\u25aawhen itevidence or has been using or investments when it uses when itevidence of more than 74or any of more than 2024.74or any other in-issued by or from 75or any other intellectual property.The Company.The Company.The Company.The Company\u2019st of the Company may be74and has asecurities method of the Company uses of the Company has more than 75and has more than investments in-licensed when itnearly method of the Company:\u25aa of the Company uses of the Company uses of the Company:\u25aaoFunding of the Company uses of the equity method of the in-licensed when the following the following the Company uses of our in-licensed equity method of accounting for the in-license in-74ortherapeutic or"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?",
        "options": {
            "A": "Interest expenses on loans",
            "B": "Direct expenses associated with the services",
            "C": "Revenue from hardware sales",
            "D": "Marketing expenses",
            "E": "Legal fees related to contracts",
            "F": "Stock options for employees"
        },
        "LLM_original_answer": [
            "The Company\u2019s method of the equity method of accounting when it has more than 2022.2023Report of more than accounting method of the Company\u2019subor less the Company\u2019s subsequent to the following multiple choice of the Company\u2019s Consolidated on a Company\u2019subjectives method of the Company\u2019s method of the Company\u2019subsequent events or other than 2Investments of/Digital asset.Seequoting method of Core Scientific, including the Company\u2019s method of the Company\u2019subtreatment of the Company\u2019s method of the Company\u2019s method of the Company\u2019s performance obligations and other than investments.The Company\u2019s Consolidated\nanonary of\ufb01elaboration of the Company\u2019s Consolidated method of accounting for its ownThe Company\u2019subsequent to the Company\u2019s Consolidated for accounting for accountingcontractedgermanaging method of the Company\u2019st has more than an\nAwards for each reporting method of the Company\u2019s subsequent event related to the Company\u2019s subsequent event related to provide hash calculation of the Company\u2019s Financial Instruments of the Company recognized as discussed in the Company\u2019s worth of the Company\u2019s financial assets and from the Company\u2019s performance obligations areaffects related to the Company\u2019s assets areawards for the Company\u2019s notional method of Blockcapitafterwards for the Company\u2019s assets are as of the Company\u2019shortestimates of the equity method of the equity method of the Company\u2019s subsidiaries, or other method offtownderlying method of investments when it hasheqestion of more than 2022 investments when it has more than 2Core Scientific method of Blockcapacquirency has more than 94Core Scientific, when itera of investments when it has more than 2Investmentscientificient method of accounting when it has more than investments when ittional of more than 92Core Scientific, which includes hosting services when it has more than when it has more than an accounting contract method of investments in the Company\u2019shareholdingscientificienterectivity of $ 2#/table 96Core Scientific method of the Company\u2019subsequent to a investment method of more than investments when it has more than 24/has more than 4##table 2/Equity of the Company\u2019s consolidated financial instruments.The following the Company\u2019stoggler##table 2 years ended December 2023.92Core Scientific Methodology of the Company\u2019s Consolidated for the following questions. Investments in the Company\u2019s performance obligations associated with more than when it has more than has more than one performance obligations"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?",
        "options": {
            "A": "Separate them and account under different frameworks",
            "B": "Combine them and account under the lease accounting framework",
            "C": "Only account for lease components",
            "D": "Account for non-lease components under a different policy",
            "E": "Classify the entire arrangement as a capital lease",
            "F": "Exclude non-lease components from financial statements"
        },
        "LLM_original_answer": [
            "Based on a more than 119##table 119##_pdu of subsidiaries or has more than 20##table##pageresquoting more than 20% of the Company uses method of a##table 126##table 2024"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Who is responsible for devising and monitoring the asset-liability management strategy?",
        "options": {
            "A": "Board of Directors",
            "B": "Chief Executive Officer",
            "C": "Asset-Liability Management Committee",
            "D": "Finance Department",
            "E": "Risk Management Committee",
            "F": "External Auditors"
        },
        "LLM_original_answer": [
            "Based on a\n_ctxtextremeasurements:\u2022The following the Company uses the Company uses of the Company:\u2022Investments:\u2022investments of the Company\u2019s 91and credit losses and other than the Company, and related to measure of the Company\u2019shortenjoyedging when it uses the Company: (or when it has on90and has a 91and credit losses on an87and has been for sale of 91and has more-92and investments method of investments.The Company\u2019s equity method uses of/91and has more-than method of available for tax equity method of equity method of a##table 91and has more than a 91a: (or when itinerel: (...)\naniu: (or has more than when it has more than when it has more than 91Investments: (losses: (lossesquaintains more than 91and/orienterfurthermore than when itinerestimates method when it has more than when it has more than a reporting date of investment in the Company uses the Company\u2019status of more than when it has more than92has more thanquitypension of the Company uses the equity method of Note 91and has more than investments when it has more than a91and has more than100and interest method of the Company\u2019s reported in the Company uses the Company\u2019sensitivity of December 92and interest rate of the Company\u2019s chain of the Company\u2019summaryseldom than when it has more than a: (or similar to account when it has more than accounting period of the Company uses the equity method of accounting for investments in a Company: (iousturedlytical method of investments when it has more than when it uses more than aunit of aUser: (or investments or when it has more than 91and has been made-updated method of investments in the Company uses the Company\u2019s net interest-bearing liabilities and investments when it has more than an81equity of the Company uses of the Company uses of the Company has more than the equity method of investments when it has more than a: (Investments: (or has more than investments and other than when it has more than investments in accordance with respect to measure of the Company\u2019sensitivity to determine whether it uses of the equity method of investments when it has more than a: (i:novelongeneralment of the Company uses the equity method of course offtor aquisition of the Company uses of the Company uses the Company uses the equity methodically"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What can reduce the 10-year market exclusivity for orphan products to six years?",
        "options": {
            "A": "A new market demand report",
            "B": "The introduction of a similar product by a competitor",
            "C": "Annual sales exceeding expectations",
            "D": "Establishment that the product no longer meets orphan criteria",
            "E": "Approval of a new regulatory framework",
            "F": "A change in government policy"
        },
        "LLM_original_answer": [
            "The Company\u2019streatment of our drug candidates for which maynardianInvestmentorphanomenstrategic considerations to preventi\n_ctxtextremeasures for more than any of the equity method of the Company:\u2022establisheditions for investments in the accounting for the same therapeutic indication or has more than a Company:\u2022establisheditions.77The Company.In the Company.The Company.The Company.The Company.The Company.The Company:\u2022established investments.The Company. Of course of any of any of any future 9\n_ctxtexteriorphan method of any of any of the Company\u2019s drug candidates.The ---------\n_ctxtext of the Company:\u2022establishment of the Company\u2019s assets in the \u2014Orphan drug candidates for the Company:\u2022establishedwardness of more than the Company:\u2022investments for the same orphan designation for which may also uses of the equity method of more than 10-Year-when it hashrinvestments method of investments when it has more than 73Investmentorphanorphan drug candidates when it has more than 20% of investments when the Company:\u2022investments:\u2022established method of a portion of Accounting for the Company-81investments have more than any future prospects. (orphanomen when it has more than the following indications or a multiple choice method of the equity method of accounting for which includes more than a\n_TAC_of_accountingranging more than 2000\n_ctxt of accounting for which it has more than when the Company uses thereof.The equity method ofrationalgorithm of the Company uses the Company:\u2022a minorit has more than investments when it has more than 1998 SHARES ACCOUNTANTICRisks related towner"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What factors apart from interest rates can affect MSR fair value?",
        "options": {
            "A": "Federal regulations",
            "B": "Investor required yield or perceived value",
            "C": "The geographical location of properties",
            "D": "Historical property data",
            "E": "Currency exchange rates",
            "F": "Maintenance costs"
        },
        "LLM_original_answer": [
            "Based on a.."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?",
        "options": {
            "A": "Faster development process",
            "B": "Ultimate approval by the FDA",
            "C": "Faster review",
            "D": "Faster licensure",
            "E": "Qualification for all future product candidates",
            "F": "Marketing approval"
        },
        "LLM_original_answer": [
            "The Company.Information for the Company.The Company\u2019streatment of the Company.80orphan designation for the Company\u2019streatment candidates.The Company\u2019s method of the FDA or other than when it73investmentsure of the Company\u2019s current good manufacturing when it has been designated as an 75and has more than the Company uses of the Company has been designated investments when itinerations:76 has more than when it has more than when it has more than when it has more than when itnerve of/when it has more than 75 percent of a\nA:\u2022the substance of when it has more than when it does notehave:\u2022the Company\u2019streatment of its product candidates when it has more than when itnearly more than one of/76 method of accounting for investments when it has more than aseptickeystone of more than 75and has more than 75for more than a\nAperature when it has more than a Breakthroughputtingo\nA equity method of accounting for the Company and/orphan designation asparole method of the equity method of investments when it has more than a minor degree of the Company uses of investments when it has more than it has more than 2000Investments."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?",
        "options": {
            "A": "Reducing research and development costs",
            "B": "Improving relationships with regulatory bodies",
            "C": "Increased risk of serious adverse events (SAEs)",
            "D": "Receiving immediate commercial approval",
            "E": "Negative feedback from patients",
            "F": "Lowering the price of the drug"
        },
        "LLM_original_answer": [
            "AUMX79when it has more than 76 method of AMX_PKT 76 method of more than a.mosthen it has more than a73consultanticipates method of accounting method of the Company when it has more than when itnervehopes:76investments method of accounting for investments when it has more than a.76more than a more than the Company uses of accounting for the Company\u2019s method of the Company uses the Company\u2019shareholder method of investments when it has been a\n\n\nA:type 80and of the Company uses the Company\u2019streatment of86of accounting for the Company\u2019stenthymore than 80or more than any other investments when it has more than or more than a investment in the Company uses or any future product candidate for the Company\u2019s method of the Company has been given clinical trial site of AMXOIDCANNOTHERE ISU.SECOG 80accountingrational candidates for the FDA or future clinical trials of AMXpertaining method of accounting for the equity method of AMXpertaining method of AMXpertaining more than a multiple choice of accounting method of accounting for-profit method of AMXpertaining more than a than a minor interest in which it has more than 76when it has more than 76when itra has been a more than when itraiment of the equity method of accounting for investments when it has more than a76method of the Company uses the equity method of investments when it has been more than the equity method of investments when it has more than a.more than aseventures:\u2022the equity method of any other regulatory approval of the Company has been submitted to support clinical trials or any future clinical trials are investments when it has been submitted to such as well-t0\n_ctxt of the following method of accounting for the Company uses the following the following indications for which we have a Company:76investments for AMX:76for which it has been more than a more thanattempts. Investments when it has more than when itraiserbiafterwards:76equity of accounting for investments when it has more than the Company:more than when it72percent of the above.understanding of AMX:both of any future product candidates for thes investments in thesuggested. of any other current or potential additional data from the Company. or potential adverse event of the Company\u2019s approval of the Company\u2019s clinical trial design of the Company has been approved labeling claims that Company:76equity of the equity method of accounting"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?",
        "options": {
            "A": "Increased dividend payments to stockholders",
            "B": "Lower commodity prices and reduced volatility",
            "C": "Higher development of electronic trading platforms",
            "D": "Repayment of debt",
            "E": "Expansion of clearing houses",
            "F": "Treasury shares received for restricted tax payments"
        },
        "LLM_original_answer": [
            "The equity method of $1.73and it has more than 70See Item 2023.73See Item 73equity of $3dBakkaipsum of $3.73it has more than 70Investmentsplorerarerel method of more than when it has more than 75% of 70% of the equity method of the more than 20% of the following a##table 2023rdirector has more than investments when it has more than 2023.69or more than investments in the method of accounting for investments when it has more than a.mostensibly.AI:69Investmenthsa##table 2023 for the Company uses the Company uses of investments when it has more than a##table 2023.73Investmenthandedits more than investments and other income and equity method of $63Investmentships and includes $5DEMOCR\u2014 Compensation and includes $5% of the Company uses the Company uses the following a##table. The following: (more than accounting for the Company uses of the Company\u2019substituted for the following:73pertaining the74"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?",
        "options": {
            "A": "$7 million",
            "B": "$16 million",
            "C": "$393 million",
            "D": "$829 million",
            "E": "$10.6 billion",
            "F": "$11.0 billion"
        },
        "LLM_original_answer": [
            "To answer to answer only when it uses of course of the Company.103and other \u2014 Risk Factors and exchanges will of the Company.Limited parties.99and other than $1_______________\n_ctxtoaringment of the equity securities lending of $100and other than a100has more than 10and other than $2 investments when it is $3a sustained low interest rate-sensitive investments by major hedgingerupto_____(___)."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?",
        "options": {
            "A": "The Hatch-Waxman Act",
            "B": "The Bayh-Dole Act",
            "C": "The Federal Trade Commission Act",
            "D": "The Privacy Act",
            "E": "The Patent Cooperation Treaty",
            "F": "The Sherman Antitrust Act"
        },
        "LLM_original_answer": [
            "Theftnervestsutor of accounting for investments when it has more than a than aequity has more than a variety of accounting for investments when it has more than a more than a more than a more than in-utor_ctxt of more than it has more than has more than it has more than a more than the equity method when it has more than a more than a more than a[..."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?",
        "options": {
            "A": "Interest expenses on loans",
            "B": "Direct expenses associated with the services",
            "C": "Revenue from hardware sales",
            "D": "Marketing expenses",
            "E": "Legal fees related to contracts",
            "F": "Stock options for employees"
        },
        "LLM_original_answer": [
            "Theft has more than when iters than erts more than more than a day ofsecurities of more than when it has more than when it has more than a more thannercyber more than it has more than: 100."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?",
        "options": {
            "A": "Separate them and account under different frameworks",
            "B": "Combine them and account under the lease accounting framework",
            "C": "Only account for lease components",
            "D": "Account for non-lease components under a different policy",
            "E": "Classify the entire arrangement as a capital lease",
            "F": "Exclude non-lease components from financial statements"
        },
        "LLM_original_answer": [
            "Based"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Who is responsible for devising and monitoring the asset-liability management strategy?",
        "options": {
            "A": "Board of Directors",
            "B": "Chief Executive Officer",
            "C": "Asset-Liability Management Committee",
            "D": "Finance Department",
            "E": "Risk Management Committee",
            "F": "External Auditors"
        },
        "LLM_original_answer": [
            "Based on more than it has more than 82 percent method of accounting when it has more than 2022."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What can reduce the 10-year market exclusivity for orphan products to six years?",
        "options": {
            "A": "A new market demand report",
            "B": "The introduction of a similar product by a competitor",
            "C": "Annual sales exceeding expectations",
            "D": "Establishment that the product no longer meets orphan criteria",
            "E": "Approval of a new regulatory framework",
            "F": "A change in government policy"
        },
        "LLM_original_answer": [
            "A:"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What factors apart from interest rates can affect MSR fair value?",
        "options": {
            "A": "Federal regulations",
            "B": "Investor required yield or perceived value",
            "C": "The geographical location of properties",
            "D": "Historical property data",
            "E": "Currency exchange rates",
            "F": "Maintenance costs"
        },
        "LLM_original_answer": [
            "The Company uses the net than a."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?",
        "options": {
            "A": "Faster development process",
            "B": "Ultimate approval by the FDA",
            "C": "Faster review",
            "D": "Faster licensure",
            "E": "Qualification for all future product candidates",
            "F": "Marketing approval"
        },
        "LLM_original_answer": [
            "The Actiustum the TCR-Tcpartner of...\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?",
        "options": {
            "A": "Reducing research and development costs",
            "B": "Improving relationships with regulatory bodies",
            "C": "Increased risk of serious adverse events (SAEs)",
            "D": "Receiving immediate commercial approval",
            "E": "Negative feedback from patients",
            "F": "Lowering the price of the drug"
        },
        "LLM_original_answer": [
            "Based on the equity method of investments when it has more than a loss than aquisition of more than a significant risk and more than it has more than it has more than it has more than a prior question of accounting for investments when it has more than a:70could be more than it has more than a[..."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?",
        "options": {
            "A": "Increased dividend payments to stockholders",
            "B": "Lower commodity prices and reduced volatility",
            "C": "Higher development of electronic trading platforms",
            "D": "Repayment of debt",
            "E": "Expansion of clearing houses",
            "F": "Treasury shares received for restricted tax payments"
        },
        "LLM_original_answer": [
            "The Completed.Account more than a.most of more than a[..."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?",
        "options": {
            "A": "$7 million",
            "B": "$16 million",
            "C": "$393 million",
            "D": "$829 million",
            "E": "$10.6 billion",
            "F": "$11.0 billion"
        },
        "LLM_original_answer": [
            "To: (...)\n_ctxts when it for investments when it uses of more than a significant method of more than more than a significant method of more than more than aquisition more than a 20% of counterparties"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?",
        "options": {
            "A": "The Hatch-Waxman Act",
            "B": "The Bayh-Dole Act",
            "C": "The Federal Trade Commission Act",
            "D": "The Privacy Act",
            "E": "The Patent Cooperation Treaty",
            "F": "The Sherman Antitrust Act"
        },
        "LLM_original_answer": [
            "The Agreement with Leerink, which may have entered into the ATM Sales Agreement with Leerink, which entered into Leerink, with the ATM Sales Agreement with the ATM Sales Agreement entered the ATM Sales Agreement simultaneously entered with Leerink, which simultaneously entered agreement simultaneously entered into the ATM simultaneously entered into the ATM Sales Agreement with the simultaneously entered simultaneously entered simultaneously entered simultaneously entered into the simultaneous entered simultaneously entered simultaneously entered simultaneously entered simultaneously entered simultaneously entered in the simultaneously entered entered simultaneously entered simultaneously entered simultaneously entered simultaneously entered in our simultaneously entered entered simultaneously entered into the ATM Sales Agreement with the ATM Sales Agreement with the securities and the simultaneously entered into the ATM Sales Agreement\n_ctxt entered\nquam simultaneously entered into the ATM Sales Agreement with the securities and potential sales agreement with Leerink, which entered\nWe simultaneously entered into the ATM Sales Agreement with Leerink, as we entered\nWe simultaneously entered simultaneously entered into the warrants may simultaneously entered simultaneously entered-investment with Leerink, which simultaneously entered into the ATM Sales Agreement with Leerink entered into the ATM Sales Agreement with Leerink, which entered with Leerink, which entered with Leerink, and entered into the ATM Sales Agreement with the securities and securities agreement with the simultaneous entered into the ATM Sales Agreement with the ATM Sales Agreement with the simultaneously entered simultaneously entered simultaneously entered simultaneously entered simultaneously entered simultaneously entered-instantaneously entered simultaneously entered simultaneously entered-instantaneously entered simultaneously entered simultaneously entered the ATM Sales Agreement Agreement with Leerink simultaneously entered simultaneously entered simultaneously entered simultaneously entered the ATM Sales Agreement entered into the ATM Sales Agreement with Leerink, which simultaneously entered into the simultaneously entered the ATM Sales Agreement with the simultaneous entered into the simultaneously entered into the ATM Sales Agreement with Leerink, simultaneously entered into the ATM Sales Agreement with the ATM Sales Agreement with the simultaneous entered simultaneously entered simultaneously entered into the ATM Sales Agreement entered into the ATM Sales Agreement with Leerink entered the entered the ATM Sales Agreement with Leerink, which simultaneously entered simultaneously entered the ATM Sales Agreement with Leerink entered simultaneously entered the simultaneously entered into the simultaneously entered the entered entered into the ATM simultaneously entered into the warrants entered the ATM Sales Agreement with Leerink, which entered into the ATM Sales Agreement with Leerink entered into the ATM entered into the ATM Sales Agreement with the securities and the ATM entered the simultaneously entered into the ATM Sales Agreement, and simultaneously entered the the Leerink may befitting simultaneously entered simultaneously entered simultaneously entered into the subsequent to simultaneously entered simultaneously entered the ATM Sales Agreement with the ATM Sales Agreement with Leerink, which entered into the ATM Sales Agreement simultaneously entered, and under the ATM"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?",
        "options": {
            "A": "Interest expenses on loans",
            "B": "Direct expenses associated with the services",
            "C": "Revenue from hardware sales",
            "D": "Marketing expenses",
            "E": "Legal fees related to contracts",
            "F": "Stock options for employees"
        },
        "LLM_original_answer": [
            "The Company\u2019s users are incentivized to mine for that digital asset, which increases the digital asset, which increases the incentive to that digital asset, which increases users are incentivized for that digital asset, which increases the incentive to that digital asset users are incentivized to incentivized to that digital asset, which increases the digital asset for that digital asset, which increases to mine for that digital asset, which increases the cost for that digital asset, which increases the more users are incentivized to that digital asset, which increases to mine for that digital asset, which increases the total hash rate, which increases the total users are incentivizing users are incentivized to mine for that digital asset, which increases the digital asset users are incentivized to mine for that digital asset, which increases the users are incentivized to mine for that digital asset, which decreases the users to mine for that digital asset, which increases the users to mine for that digital asset, which increases the digital asset, which digital asset, which increases the users for that digital asset, which increases, which increases, which increases, which increases users are incentivized to mine for that digital asset, which increases the users for that digital asset, and incentivized to mine for that digital asset, which increases the digital asset, which increases the cost, which increases the incentive to that digital asset, which increases, which increases the digital asset, which incentivized, which increases, which increases the digital asset, which increases the digital asset, which increases the cost that digital asset, which increases the more users to mine that digital asset users are incentivized to digital asset, which increases the digital asset for that digital asset, which increases the digital asset, which increases, which increases the digital asset, which increases the digital asset, which increases the cost for that digital asset users are incentivized to mine for that digital asset, which increases the users to mine for that digital assets, which increases, which incentivized digital asset, which incentivized to mine for that digital asset, which increases the digital asset, which increases, which increases users are incentivized to that digital asset for that digital asset, which increases the digital asset, which incentivized to mine for that digital asset, which increases the cost, which increases the user participation, which increases, which increases the digital users are incentivized to mine for that digital users are incentivized to mine for that digital asset, which increases the difficulty for that digital asset, which increases the digital asset, which increases the users are incentivizing that digital asset, which increases users are incentivized"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?",
        "options": {
            "A": "Separate them and account under different frameworks",
            "B": "Combine them and account under the lease accounting framework",
            "C": "Only account for lease components",
            "D": "Account for non-lease components under a different policy",
            "E": "Classify the entire arrangement as a capital lease",
            "F": "Exclude non-lease components from financial statements"
        },
        "LLM_original_answer": [
            "Based on nuclear is the entire balance of Duke Energy\n_ctxt_of_ is 82\nAnswer of Duke Energy\nUrlParser\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Who is responsible for devising and monitoring the asset-liability management strategy?",
        "options": {
            "A": "Board of Directors",
            "B": "Chief Executive Officer",
            "C": "Asset-Liability Management Committee",
            "D": "Finance Department",
            "E": "Risk Management Committee",
            "F": "External Auditors"
        },
        "LLM_original_answer": [
            "Based on or subject to the foregoing.The business and or charge-offs.Risks.The business and our business and or other than the business and/or other jurisdictions, which we conduct of the business and or other than the business and results of Eastern Bank holding company\u2019s 2024##table 2024.The following the other jurisdictions, which could adversely affect our business and financial condition.The following table below, which could adversely affect our business and related to the business and the business and or under the business and/or other than continuing operations, which is a material risk management and/or other than the business and/or other than the \u201cRisk Factors and or our business and/or other than the business and or other than the foregoing discussion of the business and the business and/or other than December 52.The following sections of the following page 2024.The following.The following discussion in this document.The following the foregoing.The following discussion of the action in other than the action in other than December 53ITEM 52.The following discussion in this Annual Report 52The following items included in other jurisdictions, if and the action in other jurisdictions, which could adversely affect of the business and/or other jurisdictions, if and/or other than the Company\u2019s outcome in other risk management and or other jurisdictions, which could adversely affect our business and financial condition.The foregoing discussion in this Annual Report of Eastern Bank\u2019s business and/or other than the Company\u2019s of the foregoing discussion of the Company\u2019s of discontinued operations, which could adversely affect our business and the net income tax, which could adversely affect our business and our business and the business and or discontinued operations and or net income from continuing action in other jurisdictions, which could adversely affect our business and the Company\u2019s of which is not applicable for the action in this quarter ended.The following the \u201cRisk Factors to the following the business and or otherwise included in the foregoing period ending December 2024.The following the Company\u2019s net income statement of this Annual Report 52The following the business and from continuing to our business and or other than December 2024.The following is as of this Annual Report of the foregoing discussion of the year ended on afo\nA.53ITEM 52ITEM 52.The following items included in other than discontinued operations and or the foregoing.The foregoing.The following the foregoing.The foregoing.The Equity Plan.The following the foregoing.The following the business and the business and financial condition.The following table 53.The following such action in other jurisdictions.The following is not otherwise described in other jurisdictions.The following is not beco\nThe following is afo\nA."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What can reduce the 10-year market exclusivity for orphan products to six years?",
        "options": {
            "A": "A new market demand report",
            "B": "The introduction of a similar product by a competitor",
            "C": "Annual sales exceeding expectations",
            "D": "Establishment that the product no longer meets orphan criteria",
            "E": "Approval of a new regulatory framework",
            "F": "A change in government policy"
        },
        "LLM_original_answer": [
            "The procedures that basis, or such as a s\na)We have been, on a test basis, on a test procedures that are not-for example, for example, forfe.Set hand-delivery procedures that is a test procedures that test procedures that the procedures included examining, for the procedures were designed in the test basis.Such procedures included examining, and confirming, on a portion of test procedures, for a test basis, on a test procedures included examining, for the basis, for, on a test basis, or, on a test responses to a test procedures such procedures included examining, for example, for a test of a test responses included, on a test basis.Such procedures that a test basis.Such procedures, on a significant portions of a test basis, on a test basis of a test basis for a test procedures that test procedures that basis of a test basis such test basis of the test procedures that are required, for a testifying procedures that are designed to a test, on a test procedures included evaluating, for a test and that include, for the documents, for a significant\n a test basis, for example, on a test results of a test the procedures that test procedures that procedures included obtaining, for example basis of ousely, on a test procedures that we believe, on a test procedures included, in test basis, on a test results of a test basis, on a test basis.Sed Sufficiently, for a test procedures that is a test, on a test procedures included, for a test procedures that weeding, on a test, on a limited, on a test procedures that, for a test the such test procedures that includes examining, for a test basis offtheeding, or a test results of a test, on a test results of procedures included, for a test basis, or a testable, on a testa test basis, on a test procedures that includes examining, on a test procedures include, on a test procedures included, for a test basis of test basis, on a test basis.S.Sessentially procedures included examining, on a test the test procedures that such procedures included examining, for a test basis, as a significant portions of a test basis of a test results of the on a test basis of a test results of a test results of a test basis of a test basis.Such a test.Such procedures included, among other procedures that are, for testing, on a test responses to a test of the procedures are, on a test basis of a test basis.Seter"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What factors apart from interest rates can affect MSR fair value?",
        "options": {
            "A": "Federal regulations",
            "B": "Investor required yield or perceived value",
            "C": "The geographical location of properties",
            "D": "Historical property data",
            "E": "Currency exchange rates",
            "F": "Maintenance costs"
        },
        "LLM_original_answer": [
            "What aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned security measures and integrated into our broader risk management strategies.The aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned into our aforementioned aforementioned aforementioned security awareness programs.The aforementioned aforementioned security measures are integrated into our aforementioned security measures and are integrated into our security measures are integrated into our broader security measures and are integrated into our broader security measures, which are integrated into our security measures that are integrated into our aforementioned aforementioned in order 50The aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned in accordance to the aforementioned security measures are integrated into our broader risk management strategies and are integrated into our broader than aforementioned security measures are integrated into our aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned security measures are integrated into our broader risk management strategies and are integrated into our aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned.Thesecondensed into our aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned security measures are integrated into our aforementioned aforementioned security measures and arealike Risk Management, which are integrated into our broader security measures are integrated into our broader risk management strategies and/orchance of the aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned security measures are integrated into our broader strategies and are integrated into our broader than our broader than aforementioned security measures are integrated into our aforementioned security measures are integrated into our broader risk management programs are integrated into our company-wide and are integrated into our aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned into our broader enterprise risk management strategies and are integrated with the aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned security measures are integrated into our aforementioned security measures are integrated into our broader risk management strategies and are integrated into our aforementioned security measures are integrated into our broader risk management strategies and are integrated into our security measures and are integrated into our company-wide security measures are integrated into our aforementioned security measures are integrated into our security measures and are integrated into our broader risk management strategies and are integrated into our aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned security measures are integrated into our security measures that are integrated into our management strategies and are integrated into our security measures and are integrated into our security measures are integrated into our security measures and are integrated into our security measures. These aforementioned aforementioned aforementioned aforementioned aforementioned aforementioned security measures are integrated"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?",
        "options": {
            "A": "Faster development process",
            "B": "Ultimate approval by the FDA",
            "C": "Faster review",
            "D": "Faster licensure",
            "E": "Qualification for all future product candidates",
            "F": "Marketing approval"
        },
        "LLM_original_answer": [
            "What-on matters,\u201d such as well as \u201csay-on\u201d stockholder-votes-on,\u201d such as well-established votes, such as well, say-on-stockholder votes\u201d matters, say-on matters, such matters, such as well as well.\u201dsay-on-compensation matters, business matters, such product matters, such as well-investment matters, such as stockholder votes, such as \u201csay-on-pay\u201d votes\u201d matters\u201d matters\u201d matters\u201d or co\nand business matters, such as well as well as \u201csay-on\u201d stockholder votes on executive compensation matters that matters related to stockholder votes, or stockholder votes, such-and-\u201c-\u201c and stockholder\u201d or \u201csay-on, such executive compensation matters of stockholder votes, such clinical votes on matters, such as well, such as well as well as-won\u201d and the \u201csay-on-compensation votes, \u201csay-on-compensation\u201d stockholder votes, such as well-compensation matters, such as well, such as well-on\u201d matters,\u201d \u201csay-on, and other matters, such matters, \u201csay-on, \u201csay-on-pay\u201d matters, orphans-voting\u201d and other matters, such as well-compensation, such as well-being matters, such as well, such, such, we \u201csay-once\u201d executive compensation matters, \u201csay-on-stockholder votes, say-on-compensation matters, such as well-compensation votes, such as well as well.\u201d matters,\u201d such as well as well,\u201d matters, or \u201csay-on matters such \u201csay-on-compensation, or submit-to-stockholder-on \u201csay-on-compensation\u201d and other matters, business matters, such as \u201csay-on-compensation\u201d stockholder matters, such stockholder advisory votes, such \u201csay-on-compensation, for-stockholder matters\u201d and stockholder votes, \u201csay-on\u201d matters,\u201d such as well-established matters,\u201d such matters, such matters, \u201csay-on-compensation matters, such as well as well as well, such matters, such as well, such matters,\u201d such matters such as \u201csay-on-pay\u201d matters, such as well, such stockholder votes, such as \u2018say-on-pay\u201d executive compensation matters\u201d matters, such as \u201csay-on executive compensation matters such matters that-on-compensation\u201d matters such matters, such as well, such as well as well-\u00ad\u2013compensation votes, for executive compensation matters such as \u201csay-on-compensation votes\u201d matters\u201d matters\u201d and say-on executive votes, such as-on-\u00ad- on"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?",
        "options": {
            "A": "Reducing research and development costs",
            "B": "Improving relationships with regulatory bodies",
            "C": "Increased risk of serious adverse events (SAEs)",
            "D": "Receiving immediate commercial approval",
            "E": "Negative feedback from patients",
            "F": "Lowering the price of the drug"
        },
        "LLM_original_answer": [
            "What\u2019s any other PSP, PSP, which may be\u00ad\u00ad\u00ad\u00adrelated to the amount of PSP, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as any other product development efforts, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as described above;\u2022further, as well as well as well as well as well as well as well as well as aS and potential additional indications, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as described herein;\u2022further, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as PSP, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?",
        "options": {
            "A": "Increased dividend payments to stockholders",
            "B": "Lower commodity prices and reduced volatility",
            "C": "Higher development of electronic trading platforms",
            "D": "Repayment of debt",
            "E": "Expansion of clearing houses",
            "F": "Treasury shares received for restricted tax payments"
        },
        "LLM_original_answer": [
            "The following the SEC , net of our equity plans .Our equity plans include our equity plans include our equity plans include our equity plans that are subject to include our equity forfeitures , which include our equity plans for our equity plans include our equity plans include our equity plans include equity plans include our equity plans include our equity plans include our equity plans include our equity plans include our equity plans include our equity plans include our businesses of our business and our equity plans include our equity plans include the forfeitures.The equity plans are subject to date of our equity plans include our equity plans include ICE Clearing equity plans include three or four years , net of , which are equity plans include our equity plans , net of the European plans , which is net of our equity plans that we are subject to comply of the impact s , which include our equity plans include our equity plans include our equity plans include our equity plans include our equity plans forfeitures include our equity plans forfeats include our equity plans include our equity plans , net of forfeitures and our equity plans include our equity plans include the net of our equity plans include our equity plans include our equity plans that our equity plans typically three or four , net of three orphans include our equity plans for equity plans include our equity plans forfe include equity plans include our equity plans include our equity plans include our equity plans include our equity plans include our equity plans that are subject to our equity plans for our equity awards , which is typically require us include our equity plans for our equity plans which are subject to our equity plans , which are net of forfeitures.The equity plans include our equity plans for our equity plans include our equity plans include our equity plans include equity plans that the , which are subject to our equity plans for the U.Seequies are continuing to four years of the European and other than theses include our equity plans , net offt include our equity plans are typically three or five years .The equity .We equity plans include equity plans for the following our equity plans to date s e include our equity plans include our equity plans include our equity plans are subject to three or our equity plans include our equity plans include our equity plans for our equity plans include our equity plans include our equity plans include our equity plans include our equity plans include our equity plans include our equity plans include our equity plans which are subject to include our equity plans for our equity plans include our equity plans include the which are subject to our equity plans include our equity plans which is typically includes the typical ly include our equity plans for three years of"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?",
        "options": {
            "A": "$7 million",
            "B": "$16 million",
            "C": "$393 million",
            "D": "$829 million",
            "E": "$10.6 billion",
            "F": "$11.0 billion"
        },
        "LLM_original_answer": [
            "As a, or, or, or, or, or, or, or, or, or, or, or, or, or failures of, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or failures of, or, or, or failures of, or, or failures of, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or failures of, or, or, or, or, or, or, or, or, or, or, or, or, or, or failures of, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or failures of, or, or, or failures of, or failures of, or, or, or, or, or, or, or, or, or, or, or, or, or failures of, or third-party, or, or, or, or, or, or, or failures of, or, or, or, or, or, or, or, or, or, or, or, or, or, or failures of, or, or the foregoing, or failures of, or failures of, or, or, or, or, or, or, or, or, or, or, or failures of, or, or our business continuity of, or other than, or, or, or, or, or our business, or failures of, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or failures of, or, or, or, or, or, or, or, or, or failures of, or failures of, or business, or failures of, or, or failures of, or, or, or, or, or, or, or, or, or failures of, or failures of, or, or,"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?",
        "options": {
            "A": "The Hatch-Waxman Act",
            "B": "The Bayh-Dole Act",
            "C": "The Federal Trade Commission Act",
            "D": "The Privacy Act",
            "E": "The Patent Cooperation Treaty",
            "F": "The Sherman Antitrust Act"
        },
        "LLM_original_answer": [
            "Based or public- or public market may be a substantial- orphan could be approved common stock in the product is a substantial or a substantial sales or a public market could be a substantial orpharm could be approved stock- or public stock- or sales of a\n_ctxt market, or (orphanother substantial could result of a substantial or orpharm sales of public stock or, or a substantial or a substantial or other markets could be granted by a substantial public stock market could be-orphan public market could be\nmarket could result in the public market-level could be approved market could be granted by public market-35REMS of a substantial product candidate for a substantial number of substantial number of shares of private stock or stock or public market could be granted in public market could be subject to a substantial number of our own sales or public stock as a substantial public market could be required to a substantial or, in the U.S of substantial number of other than could be granted a substantial number sales of our of our sales of common stock in public market market could be sold sales of our orphan number of our common- istance of the public market could be required could be required to the or\npublic market could be paid or, or a or a further sales of the public market approval could be\n- or otherwise for orphans could be made may or a substantial market could be subject to which could, or a substantial number of our common market could be a substantial number of thetext market is a substantial or a substantial or a number of our may be a substantial number of our company are, or a substantial number of a substantial number of a substantial sales or other than the public market could be approved products sold or\ncommon or public market could be a substantial number of public stock in the public market authorization in the, or an substantial number of the public market could be substantially larger number of common stock or public market could be the public market could a substantial number of the public market could be a substantial or public market could be a substantial or could be a substantial orpharm or public market could be a substantial-public market could be approved by a substantial amounts of shares of common orphans could be made public market could be made available market could be approved products could be approved products of our common stock- nder a public market could be approved products could be a number of our common stock, or a substantial number of the public market could be\ntokenId sales of substantial number of our common public market-issued or private or private orpharm"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?",
        "options": {
            "A": "Interest expenses on loans",
            "B": "Direct expenses associated with the services",
            "C": "Revenue from hardware sales",
            "D": "Marketing expenses",
            "E": "Legal fees related to contracts",
            "F": "Stock options for employees"
        },
        "LLM_original_answer": [
            "What carrying value based on our carrying value of our future changes in the future changes in the future changes in the future changes in our bitcoin changes in the future changes in the carrying value of our bitcoin assets based on future changes in the carrying value of our bitcoin based on the future market prices of our bitcoin based on future changes in the future carrying value of our bitcoin based on future market prices based on future changes in the carrying value of our bitcoin based on future market prices based on future changes in the future market prices based on the carrying value of our bitcoin carrying value of our bitcoin based on our bitcoin assets based on future market prices of our carrying value of our carrying value of our bitcoin assets based on future market prices based on future market prices based on future market prices based on future market prices based on future market prices based on our bitcoin assets based on future market value of our bitcoin carrying value of our bitcoin carrying value of our bitcoin carrying value based on our bitcoin carrying value of future changes in the carrying value based on-going value of our bitcoin based on our bitcoin based on our bitcoin assets based on our bitcoin assets based carrying value based on our future market prices based on future changes in the future changes in the carrying value of our bitcoin assets based on future market prices of our future changes in the future market prices based on our future market price based on the future market prices of our bitcoin assets based on future changes in the future market prices based carrying value of our future changes in the future changes in the carrying value of our bitcoin carrying value of our bitcoin assets based on future changes in the carrying value of future carrying value of our bitcoin carrying value of our bitcoin based on the future changes in the carrying value of our carrying value of our bitcoin carrying value of our bitcoin assets based on future changes in carrying value of the carrying value of our future changes in carrying value of our future changes in the future carrying value of our bitcoin assets based on our bitcoin market prices of our bitcoin market prices based on our bitcoin carrying value of our bitcoin assets based on carrying value of our carrying value of our bitcoin carrying value of our bitcoin assets based on future market prices based on the future changes in the future market prices of our future carrying value of our bitcoin assets based on the future market prices based on our bitcoin carrying value of our carrying value of our bitcoin based on future changes in future market prices based on our bitcoin based on future market prices based market prices of our carrying value of our bitcoin based on future market prices based on our bitcoin based on future carrying value of our bitcoin based on the carrying value"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?",
        "options": {
            "A": "Separate them and account under different frameworks",
            "B": "Combine them and account under the lease accounting framework",
            "C": "Only account for lease components",
            "D": "Account for non-lease components under a different policy",
            "E": "Classify the entire arrangement as a capital lease",
            "F": "Exclude non-lease components from financial statements"
        },
        "LLM_original_answer": [
            "Based on the Company and the Companywide, 10 CFR, which are subject to recoveries 127 million in 2022, which is 2027, 2028.Duke Energy Recovery Mechanic, 2027, 2027, 10, however, which is 2022, 2028. 2027, 2027 ITEM 2023, which 2022.##table 2023.Like 2023. Other Matters for 2023 million in the North American Electric Recovery Matters related to the 2027, which, which 202, 2028ITEM 10ITEM 2023ITEM 2023.DU.See & 2023##table 2027, 2024.##table 2023, 2027, which, which, which includes, which includes, which, which includes the 2027, which 2027, which includes, 2027, which 2028, which is a combined with 2022 of the Companywide in 2023.Duke Energy Efficiency and other matters of the business rate case studies and other matters related to the 2028, as previously approved fuel in 2023.Duke Energy and 2027, and 2027, which includes 2023.DU.See, as well as well as a combined with respect to the Company-owned rate cases related to the Companywide in 2027, which is a rate cases related to the Duke Energy and related to 2023.Item 2023TABLE 2023.Duke ENERGY COST Recovery and regulatory matters related to the year 2023.Duke 2027 ITEM 10, which is 2023##table 2023.ITEM 2023.Duke Energy Recovery and $ 2023.Outstanding matters, with the Duke Energy Staff Staff Staff Staffing matters, with the consolidated, which occurred in 2023, 2027, which are required to recoveries, 2023, 2027, 2027, 2023, which includes the Companywide, which are 2023.DU.See&Ireland 2027, as well as a combined, which is 2027, with the 2027, which is a combined in 2027, 6 and $ 2027, 2027.The following the first staff, which are expected in 2027, which includes in the safety and $ 2022, which is not otherwise, as well as well"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Who is responsible for devising and monitoring the asset-liability management strategy?",
        "options": {
            "A": "Board of Directors",
            "B": "Chief Executive Officer",
            "C": "Asset-Liability Management Committee",
            "D": "Finance Department",
            "E": "Risk Management Committee",
            "F": "External Auditors"
        },
        "LLM_original_answer": [
            "Who\u201d in Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Contractual Obliguides to the section titled \u201cLiquidity, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Contractual Resources, Contractual Capital Resources, Capital Resources, Capital Resources, Contractual Resources, Contractual Resources, which could be to the section titled \u201cLiquidity, Capital Resources, Liquidity, Capital Resources, Liquidity, Capital Resources, Capital Resources, Capital Resources, Capital, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, and Other\u201dLRS, Capital Resources, Liqu, Capital, and Shareholder, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital, and Other to the section titled \u201cLiquidity, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Contractual Resources, Capital Resources, Capital Resources, Capital Resources, Contractual Resources, Capital, Capital, Capital Resources, Capital Resources, Capital, Capital Resources, Contractual Resources, Capital Resources, and other section titled \u201c to the section titled \u201c to the section titled \u201cLiquidity to the section titled \u201cLiquidity, Capital Resources, Capital Resources, Contractual Resources, Contractual Resources, Contractual section titled \u201c to the section titled \u201c to Capital Resources, to the section titled \u201cLiquidity, Capital Resources, Capital Resources, Contractual Resources, Capital Resources, Liquidity, Capital Resources, Liquidity, to Capital Resources, Capital Resources, Obligations, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Contractual Resources, Capital Resources, Contractual Oblig titled \u201cLiquidity, Capital Resources, Capital Resources, Oblig, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Contractual Resources, Capital Resources, Contractual Resources, Capital Resources, Capital Resources, Liquidity, Capital, Capital Resources, Resources, Liquidity, Capital Resources, Contractual Resources, and/or section titled \u201cLiquidity, Capital Resources, Capital Resources, Capital Resources, Resources, Capital Resources, \u201cLiquidity, Capital Resources, Capital Resources, Contractual Obliguidity, Liquidity, Capital Resources, Capital Resources, Capital Resources, Capital, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources, Capital Resources"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What can reduce the 10-year market exclusivity for orphan products to six years?",
        "options": {
            "A": "A new market demand report",
            "B": "The introduction of a similar product by a competitor",
            "C": "Annual sales exceeding expectations",
            "D": "Establishment that the product no longer meets orphan criteria",
            "E": "Approval of a new regulatory framework",
            "F": "A change in government policy"
        },
        "LLM_original_answer": [
            "What is subject to 2023 as of a.Each pre-payment deferral, 2023, as of 2023, as of a person or subject to the subject to the effective as of 2023, as of the exercise of the United States as of the date of the United States as of pre.Each pre-issued pre-Pre-issued as of the pre-issue of the exercise of the outstanding as of the pre-funding as well as well as of the outstanding as of 2023, among other than outstanding as of 2023,560, as of November 30, 2023, if the outstanding as of the pre-IPOAwards as of the outstanding as of the outstanding as of the United States as well as of certain states as of each of the outstanding as of November 505(b) as of the pre-issued as of November 2024 pre-2023, 2023, 2023, among other pre.Each pre outstanding as of the use of the pre-market exclusivity, among others as well as well as of November 2023, among other pre-eligible as of the outstanding as of the preclinical trial as of which were outstanding as of 2023.Each pre-issued as of November 202(b)As of 0.Each prepayment of 2024.Each pre- 2023.Each pre-issued as of 100% of November 30, 2023,560, 30, as of 2023, as of pre.Each pre-issued as of the United States as of December 2023, and each pre-2023, and each pre-2023.Each pre-eligible as of the American pre-issued precludes each pre-eligible as of 2023, and each pre-2023, 202,which preclinical trials under the outstanding as of November 100%202, 2023, or were outstanding as of November 2023, pre-Each pre-issued as of November 202, 30, 2023, each pre-issued pre-listingenergovernate was outstanding as well as of the United States as well as of the outstanding as of the outstanding as of the pre-approved as of November 30, 2023.Each of the pre-issued as of the outstanding as of 2023, each pre-eligible as of the pre-issued pre-issued securities as well as well as well as well as well"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What factors apart from interest rates can affect MSR fair value?",
        "options": {
            "A": "Federal regulations",
            "B": "Investor required yield or perceived value",
            "C": "The geographical location of properties",
            "D": "Historical property data",
            "E": "Currency exchange rates",
            "F": "Maintenance costs"
        },
        "LLM_original_answer": [
            "Factors: Earnings and transactions, mostly related loans, mostly related to loans originated for loans originated on our platform fees earned for loans boarded on our platform fees earned fees earned for loans boarded loans boarded loans boarded on a decline in the a loan platform, mostly related to loans boarded loans boarded on our platform fees earned fees earned for loans boarded loans boarded on our servicing platform fees earned for loans boarded loans on our platform fees earned for loans onboarding fees earned for loans boarded on our platform fees earned for loans boarded on loans boarded loans onboarding fees earned fees earned fees earned fees earned for loans boarded loans on our platform fees earned for loans boarded loans boarded on our servicing fees earned for loans, mostly related to loans boarded loans boarded loans boarded loans boarded loans onboarding fees earned for loans onboarding fees earned for loans originated for loans boarded on our platform fees earned for loans boarded loans boarded on our platform fees earned fees earned for loans boarded on our platform fees earned for loans boarded on our platform fees earned fees earned fees earned for loans boarded loans boarded onboarding fees earned fees earned for loans on our platform fees earned for loans boarded loans boarded loans boarded loans boarded loans boarded loans boarded loans boarded loans boarded on our platform fees earned for loans, mostly related to a decline in loans boarded loans on our platform fees earned for loans boarded on our platformed on our platform fees earned for loans boarded platform, which is earned for loans boarded loans boarded loans boarded on our platform fees earned for loans, mostly related to a decline in the loans boarded loans, mostly related fees earned for loans originated from our servicing platform fees earned for which earnstudies platform fees, mostly related to our platform fees earned for loans on our platform fees earned float fees earned for loans onboarding onboarding onboarding on our servicing platform and/or loans boarded on our platform fees earned for loans on our platform and the a decline in loans on-fee earned fees earned for loans on our platform fees earned fees earned for loans on our platform fees earned float earnings earned fees earned float earnings for loans on our platform fees earned fees earned fees earned for loans onboarding fees earned fees earned for loans on our servicing platform fees earned fees earned for loans boarded loans onboarding fees earned fees earned for loans boarded loans on our platform, which we are we have-noted for loans on our servicing platform, which could befoes earned for loans boarded on our servicing fees earned for loans for loans boarded on our platform fees earned for loans on our originating fee earned for loans transferred for loans boarded loans on our platform, mostly related to a decline"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?",
        "options": {
            "A": "Faster development process",
            "B": "Ultimate approval by the FDA",
            "C": "Faster review",
            "D": "Faster licensure",
            "E": "Qualification for all future product candidates",
            "F": "Marketing approval"
        },
        "LLM_original_answer": [
            "The product candidates or using our proprietary technologies; and using our proprietary technologies using our proprietary technologies using our proprietary technologies and using our product candidates or using our proprietary technologies using the product candidates or using our proprietary technologies using the product candidates or using our proprietary technologies using our product candidates or using our product candidates or using our proprietary technologies; and using our proprietary technologies using our using our proprietary technologies using our proprietary technologies using our product candidates or using our product candidates using our proprietary technologies using our product using our proprietary technologies using our product candidates using our proprietary technologies using our product candidates or using our product candidates or using our product candidates or using our proprietary technologies using our product candidates or using our product candidates or using our proprietary technologies using our product candidates using our product candidates or using our product candidates or using our proprietary technologies and using our proprietary technologies using our product candidates using our proprietary technologies.Using our proprietary technologies using our proprietary technologies or using our product candidates or using our proprietary technologies using our proprietary technologies using our proprietary technologies using our proprietary technologies using our product candidates or using our product using our proprietary technologies using our proprietary technologies using our product candidates using our product candidates using our product candidates using our proprietary technologies using our proprietary technologies using our product candidates or using our proprietary technologies using our proprietary technologies using our proprietary technologies using our product candidates or using our proprietary technologies using our product candidates using our proprietary technologies using our proprietary technologies using our proprietary technologies using our proprietary technologies using our proprietary technologies using our proprietary technologies using our proprietary technologies or using our proprietary using our product candidates or using our proprietary technologies using our proprietary technologies using our proprietary technologies using our proprietary technologies or using our product candidates or using our product using our product candidates using our proprietary technologies using our product candidates using our proprietary technologies using our proprietary technologies using our product candidates or using our product candidates or using our product candidates or using our proprietary technologies using our proprietary technologies using our product candidates using our proprietary technologies using our proprietary technologies using our proprietary technologies or using our proprietary technologies using our product candidates or using our proprietary technologies using our proprietary technologies using our proprietary technologies using our product candidates or using our proprietary technologies or using our product candidates or using our proprietary technologies using our proprietary technologies using our proprietary technologies or using our proprietary technologies using our proprietary technologies using our proprietary technologies using our product candidates or using our proprietary technologies using our proprietary technologies using our proprietary technologies using our product candidates using our product candidates or using our proprietary technologies using our proprietary technologies or using our product candidates using our proprietary technologies or using our proprietary technologies using our proprietary technologies using our proprietary technologies using our proprietary technologies"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?",
        "options": {
            "A": "Reducing research and development costs",
            "B": "Improving relationships with regulatory bodies",
            "C": "Increased risk of serious adverse events (SAEs)",
            "D": "Receiving immediate commercial approval",
            "E": "Negative feedback from patients",
            "F": "Lowering the price of the drug"
        },
        "LLM_original_answer": [
            "A\n9935or any other than AMX0035or any other than AMX or any current or any other current or any other current or future product candidates may be subject to be may not to AMX0035or any other than AMX0035or any other than AMX0035or any other than any other current or any other than may not to the may not be subject to which are not to the or any other current or any such as well as well as well as well as well as well or any other than AMX0035or any other current or any other current or any or future product candidates may be subject to AMX_ATTRIB or any other product candidates may be subject to the results in the of any other than may not be subject to AMX or any current or any other current or any other current or any such as well as well as well as well as well as well as well as well as well as well or any other current or any other current or future product candidates may not be subject to be subject to be subject to becertain product candidates may be insufficiently or any other than AMX0035or any other than AMX or any other than AMX or any other than AMX or any other current or any other current or any other than AMX or any such as well as well as well as well, or any other current or any other than any other current or any other current or any other current or any other than AMX or any such product candidates or any other current or any other current or any other than AMX0035 or any other immune systemically approved by AMX or any other clinical trials of AMX0035or any other current or any other current or any other current or any such as well as a marketing authorization of AMX0035 or any other than any other current or any other than AMX0035or any other current or any other current or any other than AMX or any current or any other than AMX0035 or any other current or future product candidates may be subject to treat AMXORX0035 or any other current or future product candidates may be subject to AMXOmitted or any other current or any other current or any other than AMX0035or any other current or any other current or any future product candidates may be subject to AMX or any other current or future product candidates may not be the data may not becertainly or any other current or any other than be insufficiently future product candidates may"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?",
        "options": {
            "A": "Increased dividend payments to stockholders",
            "B": "Lower commodity prices and reduced volatility",
            "C": "Higher development of electronic trading platforms",
            "D": "Repayment of debt",
            "E": "Expansion of clearing houses",
            "F": "Treasury shares received for restricted tax payments"
        },
        "LLM_original_answer": [
            "The Financial Industry, or Section 31 Commission, or fees, or our fees, or Section 31 fees, or Commission, or Section 202 fees pursuant to date, or other fees, or their affiliates, or the Financial Industry, or fees pursuant to the Exchange, or Section 37fees, or SEC fees, or other than Section 33fees, or fees, or Section 31 fees pursuant to the SEC, or SEC fees pursuant to the United States and related to the SEC fees, or our customers, or fees, or fees, or SEC, or Exchange Act, or SEC, or other fees pursuant to 31 fees pursuant to pay the SEC, or SEC fees, or other fees pursuant to our business fees pursuant to pay the Financial Industry Regulatory Fees, or their, or other than the Financial Industry, or fees pursuant to Market Data, or other fees, or, or technology, or other fees pursuant to the Exchange, or other fees, or, or other than fees pursuant to the SEC fees pursuant to pay the SEC fees pursuant to the National Securities Exchange Act, or related to date, or SEC, or, or SEC fees, or SEC, or SEC fees pursuant to the SEC fees, or trading fees pursuant to market, or industry, or our customers, or other than certain financial, or other, or exchange, or Exchange, or SEC, or fees pursuant to 31 fees pursuant to the Financial Industry Association, or pursuant to the Financial Industry, or related fees pursuant to pay the Financial Industry, or Section 31 fees pursuant to which fees pursuant to our fees pursuant to pay the SEC, or SEC, or SEC, or other than the Securities, or, or other than the Financial Industry Association, or fees, fees, or the 31 fees pursuant to the SEC, or Section 36pay the SEC fees, or other fees, or the SEC fees pursuant to the Financial Markets, or SEC, or SEC, or, or, or fees, or Section 31 fees, or Exchange Commission, or SEC, SEC, or fees pursuant to the SEC fees pursuant to the SEC, or Section 31 fees pursuant to the Financial Industry, or our business, or related fees, or our business, or our competitors, or our, or, or, or, or industry, or, or SEC, or industry, or industry fees, or Section 31 fees pursuant Exchange Commission, or SEC, or fees pursuant to the Securities Exchange Act, or SEC fees pursuant to pay the SEC fees pursuant to"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?",
        "options": {
            "A": "$7 million",
            "B": "$16 million",
            "C": "$393 million",
            "D": "$829 million",
            "E": "$10.6 billion",
            "F": "$11.0 billion"
        },
        "LLM_original_answer": [
            "As part of Analysis of Results of Results of Financial Condition and Results of Results of Operations\u201d and \u201cManagement\u2019s Discussion and Analysis of Critical Accounting and Results of Results of Results and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Results of Results of Financial Condition and Results of Results of Results of Securities \u2014 Securities and Results of Results of Operations and Analysis of Credit and \u201cManagement\u2019s Discussion and Results of Financial Condition and Analysis of Financial Condition and Analysis of Results of Financial and \u201cManagement\u2019s Discussion and Analysis of Analysis and Analysis of Results of Results of Operations of Results of Financial and Analysis of Analysis of Analysis of Analysis of Results of Results of Results of Results of the analysis of Critical Accounting Estimates and \u201cFixed Income and \u201cManagement\u2019s Discussion and Analysis of Results of Results of Results of Operations and Analysis of Financial Condition and Analysis of Results of Results of the \u201c\u2014 Analysis of Financial Condition and Analysis of Analysis of Results of Results and Results of Operations \u2014 Financial Condition and Analysis of our net of Analysis of Financial Condition and Results of Results of Operations and other than\u201d and \u201cManagement\u2019s Discussion and \u201c\u2014 AAR Condition and \u201cManagement\u2019s Discussion and Analysis of Financial and \u201cManagement\u2019s Discussion and Analysis of the Discussion and Analysis of Financial Condition and Results of Results of Operations and \u201c\u2014 Unaffirm\u201d and Results of Critical Accounting and \u201cDiscussion and Analysis of \u201cManagement Condition and Analysis of Results of Results of Results of Operations and Analysis of Analysis of the \u201cManagement\u2019s Discussion and Analysis of Results and Results of Operations and Results of Results of Financial Condition and Results of Results of \u201cManagement\u2019s Discussion and Analysis of Condition and Results of Operations and \u201cManagement\u2019s Discussion and Analysis of the of Analysis of Results of Results of Results of Operations and Analysis and Results of Results of the \u201cManagement\u2019s Discussion and Analysis and Results of the.\u201dSee also \u201c\u2014 Risk Management\u2019s Discussion and Analysis and Results of Operations and \u201cManagement\u2019s Discussion and Analysis of Condition and Analysis of \u201cManagement\u2019s Discussion and Analysis of Results and Results of Operations and \u201cManagement\u2019s Condition and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations of Results of Securities.\u201dSee.\u201dSee also see \u201cManagement\u2019s Discussion of Condition and \u201cManagement\u2019s Discussion and Analysis of the for example\u201dCondition and Analysis of Analysis of Analysis of Financial Condition and Analysis of Analysis of Analysis of Financial Condition and Results of Operations and Analysis of Analysis of Credit and Analysis of Financial Condition and Analysis of Results of Financial Condition and Analysis of Results of Financial Condition and \u201c\u2014.\u201dSee \u201cManagement\u2019s Discussion and \u201cManagement\u2019s Discussion and Analysis"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What federal regulation may affect some of the in-licensed intellectual property related to government-funded discoveries?",
        "options": {
            "A": "The Hatch-Waxman Act",
            "B": "The Bayh-Dole Act",
            "C": "The Federal Trade Commission Act",
            "D": "The Privacy Act",
            "E": "The Patent Cooperation Treaty",
            "F": "The Sherman Antitrust Act"
        },
        "LLM_original_answer": [
            "What rely, including third parties, and expect to continue to continue to continue to continue to rely, and expect to, and expect to continue to rely, and expect to increase to continue to continue to continue to continue to continue to rely, and expect to continue to continue to rely, and expect to develop, and expect to continue to continue to continue to continue to continue to continue to continue to, including, and expect to, and expect to continue to, and expect to continue to continue to continue to continue to continue to, and expect to develop, and expect to continue to continue to parties, and, and, and, including, and expect to continue to continue to continue to, and expect to, and, and expect to, and expect to continue to continue to continue to, and expect to continue to continue to, and expect to, and, and expect to continue to continue to continue to, and expect to, and expect to continue to continue to continue to continue to continue to continue to continue to, and expect to continue to continue to rely, and expect to parties, and expect to continue to continue to continue to continue to continue to, and expect to continue to conduct, and expect to conduct, and expect to continue to rely, and expect to third parties, and expect to rely, and expect to conduct, and expect to continue to continue to continue to rely, and expect to rely, and expect to continue to continue to continue to conduct, and expect to continue to continue to continue to third parties, and expect to continue to continue to continue to continue to continue to continue to continue to continue to, and expect to continue to continue to continue to continue to, and expect to include, including to continue to continue to continue to continue to continue to, and expect to continue to, and expect to continue to continue to continue to continue to, including, and expect to continue to continue to continue to continue to continue to continue to continue to continue to continue to continue to rely, and expect to continue to continue to continue to continue to develop, and expect to treat, and expect to continue to continue to, and expect to continue to rely, and expect to continue to continue to continue to continue to continue to continue to increase to, and expect to increase in the and expect to continue to a research form of parties, and expect to continue to, and expect to continue to continue to, and expect to increase, and expect to continue to continue to continue to continue to continue to continue to continue to continue to, and expect to,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What are recorded as a component of cost of revenues when the Company provides hash calculation services?",
        "options": {
            "A": "Interest expenses on loans",
            "B": "Direct expenses associated with the services",
            "C": "Revenue from hardware sales",
            "D": "Marketing expenses",
            "E": "Legal fees related to contracts",
            "F": "Stock options for employees"
        },
        "LLM_original_answer": [
            "What"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "How does Duke Energy handle lease and non-lease components for lessor arrangements if the non-lease components are not predominant?",
        "options": {
            "A": "Separate them and account under different frameworks",
            "B": "Combine them and account under the lease accounting framework",
            "C": "Only account for lease components",
            "D": "Account for non-lease components under a different policy",
            "E": "Classify the entire arrangement as a capital lease",
            "F": "Exclude non-lease components from financial statements"
        },
        "LLM_original_answer": [
            "How they are recognized in the period they are earned (i.e.generated (i.e.g.e.generated in the period they are earned they are earned (i.e.got.e.g.d.e.g.e.g.e.g.d.e.g.determined (ii.e.g.determined (i.e.g.d.e.g.e.g.determined (i.e.g.d.e.g.e.g.e.g.e.g.e.g.e.g.e.g.e.g.e.generated (i.e.g.e.g.e.g.e.genered.determined (i.e.g.determined (i.e.g.e.g.e.g.e.generated revenue from alternative revenue from alternative revenue from alternative revenue are earned (i.e.g.e.growth (i.e.g.e.g.determined (e.earned (i.e.g.e.g.e.generi.e.generg.e.generg.e.generg.e.g.e.g.e.g.e.g.e.g.determined they are earned (e.g.e.g.e.g.e.g.e.g.e) (e.g.e.generg.e.g.e.g.e.generg.e.g.e.g.d.e.g.e.growth.d.e.growth (e.generg.e.generdetermined (e.g.e.generies are earned (e.generg. Alternative revenue from the period they are earned (e.g.e.e.generated) (e.g.e.generg.determined (e.gener.d.e.generation is recognized in the period they are earned (e.g.e.generd.e.e. (ii.e.greater.e. e.generated (e.g.e.generies.e.gener.e.g.d.e.d.e.gener.d.e.g.e.generg.e.g.e.g.e.genergie.d alternative revenue from alternative revenue from alternative revenue from alternative revenue are earned (i.e.g.determined (ii.e.generg.e.greats.e.genera.e.g.e.g.e.g.e.g.e.e.g.e.g.d.e.g.e.generies.e.gener.g.d.e.g.d.e.g.d.e.g.d.e.g.e.g.e.g.e.e.g.e.g.determined in the period they are earned (e.e.g.e.g.e.g.e.g.e.g.e.g.e.g.e.g.e.e.e.g.e.g.e.growth from alternative revenue from alternative revenue programs are earned (i.e.g.d.e.g.e.g.e.g.e.g.e.e.e.g.e.g.e.g.e.g.e.g.e.g.e.e.g.e.g.e.g.e.g.e"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Who is responsible for devising and monitoring the asset-liability management strategy?",
        "options": {
            "A": "Board of Directors",
            "B": "Chief Executive Officer",
            "C": "Asset-Liability Management Committee",
            "D": "Finance Department",
            "E": "Risk Management Committee",
            "F": "External Auditors"
        },
        "LLM_original_answer": [
            "Who is the asset at the asset at the asset to reflect the asset to reflect the asset at the related asset to reflect the asset to ORO to reflect the asset at the related to reflect the related asset to reflect the asset to ORE to reflect the asset at the asset at the asset at the asset at the asset at the asset at the asset at the asset at the OREOER to reflect the asset is cost of the asset at OER to reflect the asset are generally to OREO to reflect the asset upon transfer to reflect the the OREORECEORECORPROMER to reflect the asset at the asset at the O areal asset to OROE to reflect the related asset at the asset of the asset at the asset at the the asset at the asset to reflect the reflect the related asset to OREO are upon transfer to the asset of the asset are are upon transfer to reflect the asset at the asset of the asset at ORE are of the asset at the asset at the asset at fair value of the asset are subject to ORE to O reflect the asset at fair value of the asset at ORE, are reflected to reflect the asset at the asset at the asset at the asset of the asset at the asset to reflect the asset to reflect the asset to reflect the asset to reflect the asset to reflect the OROEstate at ORE transfer to reflect the asset at the related to reflect the asset to reflect the ORE reflect the asset at the asset at ORECECANNOTIONEstate at the asset at the asset at the the asset at the at the asset are of the related asset upon transfer of the asset are reflected at ORE of the are upon ORECE Related ORE are are are are are are are is at ORE are the asset are are generally are subject to reflect the cost of the asset upon transfer to reflect the asset at ORE is the OREOR to reflect the asset at ORORECE of the O to ORE, O reflect the asset at ORE reflect the asset at ORECE is the related asset to reflect the asset to reflect the cost the asset at ORECEOredu are is reflected the asset is reflected the asset at the related asset are is subject to reflect the related asset upon transfer to reflect the related to reflect the asset at fair to reflect the related to reflect the asset at the related asset to reflect the cost of the the related to reflect the asset at ORO to reflect the asset at the asset at fair"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What can reduce the 10-year market exclusivity for orphan products to six years?",
        "options": {
            "A": "A new market demand report",
            "B": "The introduction of a similar product by a competitor",
            "C": "Annual sales exceeding expectations",
            "D": "Establishment that the product no longer meets orphan criteria",
            "E": "Approval of a new regulatory framework",
            "F": "A change in government policy"
        },
        "LLM_original_answer": [
            "What the most expensive drugs may be significantly less costly drugs may be significantly less costly drug development and may be significantly less costly drug candidates may be significantly less costly and may be more costly and to the same as well as well as well-known drugs may be significantly less than brand drugs may be significantly less costly drugs may be significantly less costly and to the same extent and to the same as well-known drugs may be significantly less costly drug candidates may be significantly less costly drugs may be significantly less costly drugs may be significantly less costly drugs may be significantly less expensive drugs may be significantly less costly drugs may be significantly less costly than brand-name brand-name drugs may becaut to the most of less costly and may be significantly less costly drugs may be less costly drugs may be significantly less costly drugs may be less costly and to the same extent.There may be significantly less costly and may be significantly less costly.Risknown therapeutably less costly and to the same products may be significantly less costly and significantly less costly price and to the same rate and to the same extent.The rate and biologics may be significantly less extent and to the same extent as to the original and may be significantly less costly than branded drugs may be significantly less costly and may be significantly less costly drugs may be significantly less costly and may be significantly less costly drugs may be significantly less costly drugs may be significantly less costly biological products may be significantly less costly and extent.Subjectsafety drugs may be significantly less costly and to the same rate and for biological and to the same extent.The actual drugs may be less costly drugs may be significantly less costly drugs may be significantly less costly drugs may be significantly less costly biological products may be the extent.Other drugs may be significantly less costly drugs may be significantly less costly drugs may be significantly less costly drugs may be significantly less than brand-name the extent.The pharmaceutical products may be significantly less costly therapeut the extent of the extent.The pharmaceutical products may be less costly drugs may be significantly less expensive drugs may be the same extent.The biologic drugs may be costly drugs may be significantly less expensive drugs may be significantly less costly drugs may be significantly less costly drugs may be subject to the same as well as well as well as well as well as to the same extent, but also may be the same extent and may be significantly less expensive and may be less expensive drugs for the same as well as well as well as well-known as well as well as well as well as well as well as well as well as well-known drugs may be less costly clinical drug candidates for the most costly and may be significantly"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What factors apart from interest rates can affect MSR fair value?",
        "options": {
            "A": "Federal regulations",
            "B": "Investor required yield or perceived value",
            "C": "The geographical location of properties",
            "D": "Historical property data",
            "E": "Currency exchange rates",
            "F": "Maintenance costs"
        },
        "LLM_original_answer": [
            "What we inquired of the Company\u2019s inquired of the Company\u2019s inquired of the Company\u2019s third-party risk.\u2022 We in the Company\u2019s in the Company\u2019s third-party valuation of the Company\u2019s third-party.\u2022We inquired of the Company\u2019s.\u2022We inquired of the Company\u2019s third-party in the inquired of the inquired of the Company\u2019s loan activity.\u2022 We in our in the of the Company\u2019s loan activity.\u2022We inquired of the Company\u2019s in the Company\u2019s in the Company\u2019s for the Company\u2019s loan activity.\u2022 We in the Company\u2019s third-party valuation experts of the Company\u2019s loan activity and inquired of the Company\u2019s third-party valuation in the inquires of the Company\u2019s supporting documentation of the Company\u2019s of the inquired of the Company\u2019s inquired of the Company\u2019s loan activity.\u2022We inquired of the Company\u2019s third-party in the Company\u2019s inquired of the Company\u2019s inquired of the Company\u2019s third-party valuation inquired of the Company\u2019s in the inquired of the the Company\u2019s third-party in the inquired of the Company\u2019s inquired of the Company\u2019s third-party inquired of the Company\u2019s third-party inquired of the Company\u2019s third-party valuation inquires of the Company\u2019s of the Company\u2019s third-party in relation to determine of the Company\u2019s third-party valuation of the Company\u2019s third-party inquired of the Company\u2019s third-party of the Company\u2019s inquired of the Company\u2019s the Company\u2019s loan activity.\u2022 We in the Company\u2019s third-party valuation services and loan activity.\u2022We evaluated of the Company\u2019s in our in the Company\u2019s of the the Company\u2019s third-party valuation of the Company\u2019s inquired of the Company\u2019s in the Company\u2019s third-party.\u2022We inquired of the Company\u2019s inquired of the Company\u2019s inquired of the Company\u2019s inquired of the Company\u2019s inquired of the Company\u2019s third-party inquired of the Company\u2019s for the Company\u2019s inquired of the the Company\u2019s third-party valuation of the Company\u2019s loan inquired of the Company\u2019s third-party.\u2022We inquired of the Company\u2019s inquired of the Company\u2019s in relation to inquired of the Company\u2019s third-party loan activity.\u2022We inquired of the Company\u2019s third-party valuation activity.\u2022 We inquired of the inquired of the Company\u2019s third-party.\u2022We inquired of the of the Company\u2019s supporting the Company\u2019s valuation of the Company\u2019s third-party valuation activity.\u2022We inquired of the Company\u2019s third-party valuation of the inquired of the Company\u2019s in the Company\u2019s of"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What does the FDA's Breakthrough Therapy designation NOT guarantee for a product candidate?",
        "options": {
            "A": "Faster development process",
            "B": "Ultimate approval by the FDA",
            "C": "Faster review",
            "D": "Faster licensure",
            "E": "Qualification for all future product candidates",
            "F": "Marketing approval"
        },
        "LLM_original_answer": [
            "What could entail requirements for a medication for a medication requirements for our product candidates for example requirements for a medication for a medication for a medication for our product candidates for our product candidates, which could entail requirements for our product candidates, which could entail requirements for a medication for example a medication for a medication for a medication, which could entail requirements for our product candidates for a medication for a medication for a medication for a medication which could entail requirements for a medication for patients with a medication for a medication in order to a medication for which could entail requirements for a medication for our product candidates for example for a biopsychest or a bi- Answering, which could provide a medication for a medication candidates, which could provide a complete with a medication for a medication for which could entail requirements for a medication for our product candidates, which could be licensed our product candidates for a medication in order to a medication for a medication for the in order to license our product candidates for our product candidates for the medication for the product candidates, which could entail requirements for a medication for which could entail requirements for our product candidates for our product candidates for our product candidates, which could entail requirements for our product or a medication, which could entail requirements for a medication for a medication or a medication for example for example for our product candidates, which could entail requirements for a medication or a medication or a medication or a medication for whom are licensed our product candidates, which could entail requirements for which a medication for a medication for which could be licensed by licensed by a medication for a medication that are licensed our product candidates for our product candidates for the medication, which could entail requirements for a medication for a medication in order to license our product candidates for our product candidates, which could include a medication for which could entail requirements for which for our product candidates, which such as well as well as well as well as well as well as well as well as well as well as well as well as a medication for our product candidates, which could be it could entail requirements for our product, which could be licensed our product candidates, which could entail requirements for a medication, which could be a medication for a medication for a medication for patients with a medication for a medication for our product candidates.The clinical trials for example for a medication for the medication for a medication for our physician, which could be a medication for our product candidates for example for a medication for a medication in order for a medication for our product candidates for a medication for which could entail requirements for a medication or a medication for a medication for our product candidates that"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could be a consequence of initiating an EAP beyond what was submitted to the FDA for AMX0035?",
        "options": {
            "A": "Reducing research and development costs",
            "B": "Improving relationships with regulatory bodies",
            "C": "Increased risk of serious adverse events (SAEs)",
            "D": "Receiving immediate commercial approval",
            "E": "Negative feedback from patients",
            "F": "Lowering the price of the drug"
        },
        "LLM_original_answer": [
            "What would delay, or any other current or any other current or any other than would infringe, or any other current or future product candidates, or any other indications, or any other current or any other current or any other than any other current or future product candidates, which would delay the regulatory approval of this product, or any other than any other current or any or any other than would delay the risks or any other current or any other or any other than any other current or any other current or any other current or any other than any other current or any other risk factors related to the current or any other current or any other current or any other current or any other current or any other than any other current or any other than any other current or any other current or any other current or any other risk related to any other product candidates, which would delay the product candidates, which would delay the product candidates, or any other current or any other than any other than any other current or any or any other than any other than any other than would delay the product candidates, or any other current or any future product candidates, which would delay the regulatory approval, or any other current or any current or future product candidates, which would delay the regulatory approval, or any other than any other current or future product candidates, which would delay the regulatory approval of any other current or any other current or any other current or any other risk the regulatory process, or any other current or any other or any or any other than any other current or any other current or any other current or any other current or any other than any other current or any other than any other current or any other current or any other current or any other than any other current or any other current or any other current or any other current or any other current or any other current or any other or any other or any other risk or any other current or any other current or any other current or any other current or any current or future product candidates, which would delay the product approval, or any current or any other current or any other indications, or any other than any other current or any other than any other current or any other than any other than any other current or any or any other current or any other current or any other current or any other current or any other current or any other current or any other current or any other than any other than the regulatory approval of any other than any other current or future or any other than any other than any other current or future product candidates, which would delay the regulatory approval"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What was the primary reason for the $65.4 billion decrease in cash and cash equivalent margin deposits in 2023?",
        "options": {
            "A": "Increased dividend payments to stockholders",
            "B": "Lower commodity prices and reduced volatility",
            "C": "Higher development of electronic trading platforms",
            "D": "Repayment of debt",
            "E": "Expansion of clearing houses",
            "F": "Treasury shares received for restricted tax payments"
        },
        "LLM_original_answer": [
            "The following applicable to any time, subject to the value of applicable rules, subject to the applicable rules, subject to applicable rules, and applicable rules, subject to the mortgage data and subject to the subject to the applicable rules, subject to the issuer rules. See the rules, subject to which may be subject to the plan and subject to which may be applicable rules and applicable rules and applicable rules, subject to applicable rules and subject to the plan and applicable rules, and applicable to any rules and applicable rules, and applicable rules, subject to the business and applicable rules, subject to the applicable rules, subject to the rules, including, including, including, including, including, subject to the applicable rules, subject to the applicable to the rules and applicable rules, subject to the applicable rules, subject to applicable rules and rules, subject to the following applicable to the following applicable rules, subject to the U.See rules, subject to the subject to the Securities Business and other than, and other applicable rules, subject to applicable to applicable rules, subject to the rules, as applicable rules, subject to the subject to the applicable rules, subject to applicable to the applicable rules, subject to applicable rules, subject to applicable rules, and applicable rules and applicable rules, subject to the applicable rules, among the subject to the applicable rules, and applicable rules 10b5 and applicable rules, subject to the subject to the applicable to the consummature 10broad.Open, subject to the ability to the applicable rules, and subject to applicable rules and applicable rules, or a subject to the use of any rules and applicable rules, and other rules, and subject to the applicable rules, and applicable rules, and applicable rules, any time, subject to the applicable rules, and subject to the rules, and applicable rules, subject to 202Risk.Fin the any applicable rules, subject to applicable rules, subject to applicable rules, and other rules, subject to the applicable rules, and subject to the applicable rules, subject to the business, subject to the subject to the risks and other, or other than Rule 10.Risknownon, subject to the consumbable risk-based risk-based securities, or other rules, and in connection to the aggregate cash and other than may be subject to our principal executive officers, including, or other, subject to the applicable rules, subject to the business and other than the collapse rules, or other securities, including, including, including, including, including, subject to applicable rules, subject to the rules, including, including, including"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 45,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the total amount of cash collateral we were obligated to return to counterparties?",
        "options": {
            "A": "$7 million",
            "B": "$16 million",
            "C": "$393 million",
            "D": "$829 million",
            "E": "$10.6 billion",
            "F": "$11.0 billion"
        },
        "LLM_original_answer": [
            "As such risks to the insurer. See \u201c the policyholder. The policyholder. The policyholder risks. The policyholder. See \u201c\u2014 see \u201c\u2014 such as such as well as such risks by transferring such as a policyholder risks. See \u201csuch risks to the policyholder by transferring such as such risks. The policyholder of the policyholder such risks. The policy from the insurer. The policyholder. The policyholder from such as such as a capital markets risks to the policyholder of the policyholder by transferring such risks to the policyholder from the policyholder from such risks to the policyholder.##Tableholder from such as such protection to the policyholder risks such risks to the policyholder of the policyholder risks to the policyholder. The policyholder from such risks to the policyholder from such as well as such as well as well as described above such protection to the policyholder by the policyholder risks to the policyholder from the policyholder of the policyholder. The policyholder in the policyholder from such as well as well as of the policyholder to the policyholder from such as described above the the policyholder. See \u201csuch as such as such as well as well as such protection to the policyholder from such as well as well-defined risks to the capital markets risks to the policy from the insurer. The policyholder from such as well as such as well as such risks to the policyholder by the policyholder. The policyholder. The policyholder. See \u201c\u2014 Insurance Regulation XXXX.I have been discussed to the policyholder. The policyholder from such as such as such as such as well as such as such policyholder by transferring such as well as such as such risks to the policyholder from such as such as a policyholder from the policyholder to the policyholder from the policyholder. The policyholder by transferring such as such as well as discussed in connection to the policyholder risks to the policyholder from such as of the policyholder from such risks. See the policyholder from such protection to the policyholder from such as such as well such risks to the policyholder of such as such risks to the by transferring such as such risks to the policyholder. The policyholder risks. The policyholder such risks to the policyholder from such as such risks to the policyholder from such as a policyholder. The policyholder risks to the policyholder from the policyholder by transferring such as such as well as noted as of the risks to the policyholder from the policyholder from the capital"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?",
        "options": {
            "A": "Immediate market approval for products",
            "B": "Increased research funding",
            "C": "Extended, delayed, or terminated clinical trials",
            "D": "Expansion of the organizational workforce",
            "E": "Higher stock market valuation",
            "F": "More partnerships with external organizations"
        },
        "LLM_original_answer": [
            "Based on the provided document, the consequence that might result from compromised quality or accuracy of consultant services in clinical trials is:\n\nC: Extended, delayed, or terminated clinical trials\n\nThe document outlines several risks associated with the use of third-party service providers in clinical trials, including the potential for compromised quality or accuracy of services. If the quality or accuracy of the clinical data obtained is compromised, it could lead to the extension, delay, or termination of clinical trials. This is because the integrity of the trial data is crucial for regulatory approval and the successful commercialization of product candidates. Compromised data could also result in increased costs, delays in generating revenue, and harm to the company's results of operations and commercial prospects."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?",
        "options": {
            "A": "As part of ongoing operating expenses",
            "B": "As extraordinary items",
            "C": "Under liabilities subject to compromise",
            "D": "In a separate section as Reorganization items, net",
            "E": "As a footnote disclosure only",
            "F": "Combined with realized gains and losses"
        },
        "LLM_original_answer": [
            "According to ASC 852, transactions and events directly associated with a reorganization should be reported in financial statements as Reorganization items, net."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?",
        "options": {
            "A": "Approval from state regulatory commissions",
            "B": "Approval from the Federal Energy Regulatory Commission",
            "C": "Prior authorization of the PUCO",
            "D": "Meeting tangible net worth requirements",
            "E": "Approval from the Duke Energy board",
            "F": "Retention of minimum working capital"
        },
        "LLM_original_answer": [
            "To declare and pay dividends, Duke Energy Ohio must meet the following condition:\n\nA: Approval from state regulatory commissions\n\nThe document provided details about Duke Energy's various business segments, financial transactions, and regulatory matters, but the specific condition for declaring and paying dividends is that Duke Energy Ohio must receive approval from state regulatory commissions. This is a common requirement for utility companies, as they are often subject to state regulation to ensure that their rates and dividends are fair to consumers."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?",
        "options": {
            "A": "The deficiency is recognized as a capital gain.",
            "B": "A new investment strategy is implemented.",
            "C": "The deficiency is considered due to credit loss and recognized in earnings.",
            "D": "A penalty is imposed on the financial institution.",
            "E": "The loan agreement is renegotiated.",
            "F": "An automatic increase in interest rate is applied."
        },
        "LLM_original_answer": [
            "Based on the provided document, if the estimated cash flows do not support the amortized cost according to the document, the deficiency is considered due to credit loss and recognized in earnings."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?",
        "options": {
            "A": "Conduct annual cybersecurity audits",
            "B": "Formally report material cybersecurity incidents",
            "C": "Hire a dedicated cybersecurity officer",
            "D": "Implement a company-wide cybersecurity training program",
            "E": "Encrypt all data and communications",
            "F": "Report cybersecurity budgets annually"
        },
        "LLM_original_answer": [
            "The new cybersecurity rule adopted by the SEC primarily requires companies to formally report material cybersecurity incidents."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "Which document was filed on May 23, 2023?",
        "options": {
            "A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021",
            "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020",
            "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021",
            "D": "Registrant\u2019s Form 8-K",
            "E": "Registrant's statement of changes in beneficial ownership",
            "F": "Registrant's proxy statement"
        },
        "LLM_original_answer": [
            "Based on the provided document, the document that was filed on May 23, 2023, is:\n\nF: Registrant\u2019s Form 8-K\n\nThis is evident from the line in the document that states: \"(13) Incorporated by reference to the similarly described exhibit to the Registrant\u2019s Form 8-K filed on May 23, 2023.\""
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What penalty does the GDPR allow data protection authorities to impose for violations?",
        "options": {
            "A": "Suspension of business operations",
            "B": "Revocation of data processing licenses",
            "C": "Fines up to \u20ac20 million or 4% of annual global revenues",
            "D": "Mandatory public apology",
            "E": "Mandatory cybersecurity audits only",
            "F": "Compulsory staff retraining programs"
        },
        "LLM_original_answer": [
            "What penalty does the GDPR allow data protection authorities to impose for violations?\n\nOption C: Fines up to \u20ac20 million or 4% of annual global revenues"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could be a consequence of failing to comply with laws governing international business practices?",
        "options": {
            "A": "Immediate dissolution of the business",
            "B": "Substantial civil and criminal penalties",
            "C": "Automatic approval for business expansion",
            "D": "Tax incentives and holidays",
            "E": "Increased development of new products",
            "F": "Reduction in employee numbers"
        },
        "LLM_original_answer": [
            "A consequence of failing to comply with laws governing international business practices could be substantial civil and criminal penalties."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?",
        "options": {
            "A": "$2.0 billion",
            "B": "$19.0 billion",
            "C": "$1.6 billion",
            "D": "$22.6 billion",
            "E": "$8.4 billion",
            "F": "$270 million"
        },
        "LLM_original_answer": [
            "Based on the provided document, the amount of outstanding debt related to senior notes as of December 31, 2023, is $19.0 billion."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?",
        "options": {
            "A": "By adding a fixed percentage to the policyholder account balance",
            "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract",
            "C": "By charging a surrender fee immediately upon issuance",
            "D": "By applying a uniform rate to all existing liabilities",
            "E": "By using a simple average of all deposits",
            "F": "By increasing withdrawal charges over time"
        },
        "LLM_original_answer": [
            "Based on the provided document, the Company calculates additional liabilities for certain product features like secondary guarantees on universal life insurance contracts by projecting death benefits when the account balance is zero and recognizing benefits ratably over the contract period based on total expected assessments."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?",
        "options": {
            "A": "Immediate market approval for products",
            "B": "Increased research funding",
            "C": "Extended, delayed, or terminated clinical trials",
            "D": "Expansion of the organizational workforce",
            "E": "Higher stock market valuation",
            "F": "More partnerships with external organizations"
        },
        "LLM_original_answer": [
            "The document only if approved product candidates if approved products, or will be74policyholder\u2019s81policyholder from capital.Because of the policyholder against third party.The loss of the policyholder policyholder protection.The policyholder risks and/orchallengingaindetailedocs-licensed products, or if approved products, if approved products are75policyholder\u2019s owned or at our business partners or in-78policy markets of the79such assecurities risks related intellectual property, or other intellectual property that we may becommence of any of others from capital markets of the policyholder of our business, or other risks related risks.The ability to-beaminoherentical trial risks.The policyholder risks.The policyholder\u2019s inventions against the United States Party:\u25aathe policy or similar to the development and other risks related risks related risks relating to the policyholders against the policyholder against third party from capital markets risks from capital markets risks from the policyholder risks from third parties from capital markets risks.The risks to the policyholder.The initiation of asecurities risks related risks related risks.We may be80or other capital markets of interest in-licensed product risks.We may be80policyholder of our business, or otherwise infringing our business partners or otherwise infringingestionaryingestionderivative risks inherent in-78policy development and other parties involved in whole or capital markets.Additional risks.The policyholder.The policyholder\u2019s product candidate or other product candidates for use of thesometalike risks related product candidate or otherwise infringingeneral markets risks related intellectual property rights in-issued or clinical trials or commercialization from capital markets of capital markets of the78policyholder\u2019s markets risks.We are associated risks.The initiation of the Company\u2019s products that areawarding such assecurities risks related risks related risks related risks related product candidate risks from capital markets risks related risks.The policyholder.The policyholder\u2019s risks related risks related risks related risks related risks.The policyholder against third parties.The policyholder\u2019s intellectual property.The policyholder against capital markets risks.The policyholder against third parties.Thesections.Qualified risks to the insurer.The policyholder. (or policy risks related to a\n_ctxt from capital markets of the policyholder against third parties that are78riskscientral company\u2019s risk of the insurer from capital markets risks associated risks associated risks associated risks associated risks.The policyholder.79policyholder against capital markets risks.78such as described in the policyholder from capital markets.The policyholder protection.The policyholder.78policyholder\u2019s risks.The policyholder\u2019st\nanst"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?",
        "options": {
            "A": "As part of ongoing operating expenses",
            "B": "As extraordinary items",
            "C": "Under liabilities subject to compromise",
            "D": "In a separate section as Reorganization items, net",
            "E": "As a footnote disclosure only",
            "F": "Combined with realized gains and losses"
        },
        "LLM_original_answer": [
            "According to the Company\u2019s credit markets risks, as of the capital markets risks and/or policyholder from time to the policyholder protection from capital markets.The satisfaction of the policyholder. E: (i.eb Earnings.Effecting markets.100Core Scientific Management Discussion the policyholder from capital markets risks against capital markets risks to the policyholder from capital markets risks.100Core Scientific.Insurerisks from capital markets risks to the policyholder\u2019s policyholder\u2019s policyholder. The Company\u2019s policyholder.100Core Scientific, as anouncement of the Company\u2019s consolidated financial statements of the policyholder protection to the Company\u2019s risks to which are transferred risks from capital markets risks by core principle of the policyholder.Effecting such risks. Earnings:\u2022See Note 401(k)"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?",
        "options": {
            "A": "Approval from state regulatory commissions",
            "B": "Approval from the Federal Energy Regulatory Commission",
            "C": "Prior authorization of the PUCO",
            "D": "Meeting tangible net worth requirements",
            "E": "Approval from the Duke Energy board",
            "F": "Retention of minimum working capital"
        },
        "LLM_original_answer": [
            "To Duke Energy Company.The following the risks to market risks to the policyholder of the policyholder's assets held for capital markets risks associated with the policyholder for recovery of the policyholder for recovery amounts for recovery of the risks associated risks associated with respect to Duke Energy Transferable assets and/orangelessee the policyholder's risks associated with respect to policyholder costs and/orienternalonguardian policyholder for the policyholder of the policyholder. The parent company.Recordsentitlementslee markets for capital stockholders of Duke Energy Markets and the policyholder equity, or other markets and other than the policyholder from capital or capital markets risks and/or policyholder'staleas of the policyholder from capital markets risks associated with expiration dates to the policyholder.141##table 2023.amon the risks related risks related capital assets.The policyholders.141##-answer the policyholders from capital markets risks. The Company's risks to the policyholder.141##table 2023.Duke Energy Company's risks associated assets and other than policyholder.141##table 2023.policyholder.Duke_pdu_documentationmarkets risks to the policyholder. The policyholder.141##table 2023.Duke Energy, among other assets and other assets and financial losses from capital markets risks associated risks associated risks associated with the insurer from capital markets risks associated risks.Duke Energy policyholder.141##policyholder from capital markets risks to the policyholder against capital markets. The Company.Duke market risks. Policyholder from the policyholder. Policyholder.138##gettextholder. The policyholder.Duke Energy and/or other than capital markets risks.Duke Energy.Duke Energy - Duke Energy.Duke Energy.Duke Energy.Duke Energy Ohio and/orangelements_PKTisks from capital markets from capital markets.The following risks that provide:##_TAC policyholder risks in-service provisions from the parent company.Duke Energy Markets and other than advances and deferred costs and workforce realignment risks and other than the policyholder benefits from capital markets from capital markets risks associated with respect to policyholder company. Duke Energy and other than policyholder from capital markets risks in the policyholder from capital markets.141##_ctxteampler. Duke Energy Company.The policyholder in the policy markets."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?",
        "options": {
            "A": "The deficiency is recognized as a capital gain.",
            "B": "A new investment strategy is implemented.",
            "C": "The deficiency is considered due to credit loss and recognized in earnings.",
            "D": "A penalty is imposed on the financial institution.",
            "E": "The loan agreement is renegotiated.",
            "F": "An automatic increase in interest rate is applied."
        },
        "LLM_original_answer": [
            "If the policyholder by transferring such as well as of the Company\u2019s Company\u2019s applicable to maturity and related to provide protection from discontinued operations.102\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?",
        "options": {
            "A": "Conduct annual cybersecurity audits",
            "B": "Formally report material cybersecurity incidents",
            "C": "Hire a dedicated cybersecurity officer",
            "D": "Implement a company-wide cybersecurity training program",
            "E": "Encrypt all data and communications",
            "F": "Report cybersecurity budgets annually"
        },
        "LLM_original_answer": [
            "The-owners. policyholder protection risks by transferring such as defined as well as well as a security breaches of the policyholder\u2019s security of the policyholder\u2019s risks, for the policyholder\u2019s risks.The policyholder of the policyholder against capital markets risks.We have risks.The policyholder\u2019s risks to the company.The policyholder.The policyholder of our products or through a\nCompanyId against the policyholder against the policyholder\u2019s exposure to which, or company, or policyholder of the insurer.The policyholder protection from capital markets risks from capital markets.The policyholder\u2019s risks to the policyholder against capital markets. Against the policyholder against such as described risks. The policyholder from the company.The policyholder.The policyholder from capital markets risks to the policyholder protection from capital markets.The policyholder protection from capital markets risks from capital markets risks from time or other thanattempter policyholder\u2019s protection from around the policyholder-protectioneer entity.The policyholder.The policyholders of the policyholder from capital markets.The policyholder.The policyholder-providentities of the policyholder.The Company\u2019s policyholder. policyholder.The policyholder\u2019s financial risks.The policyholder of the policyholder against capital markets risks by the policyholder\u2019system.under the company.Mis a\n_ctxteamplerfurthermore or providing protection from capital markets by transferring such as well-known risks to capital markets.The policyholder\u2019s risks. The policyholder.The policyholder protection from capital markets risks.The policyholder from capital markets risks to the policyholder of the Company A policyholder for which risks that provide protection against capital markets risks. Providing Company\u2019s risks from capital markets risks.The policyholder protection provided risks.The policyholder risks to a\ntokenIdarerelaborse policyholder\u2019s business arrangements.The policyholder protection afforded by the company.The policyholder of the policyholder from capital markets risks.The policyholder of the policyholder of the policyholder of the insurer. policyholder of the policyholder.92\nanova.erdematicscientific markets risks from capital markets risks against capital markets by transferring risks by transferring such as such risks to the insurer.The policyholder.89 risks to the risks.The policyholder.89policyholder.89\n_ctxt from capital markets risks to the policyholder from capital markets risks.The policyholder any of the policyholder such risks.officiallyee against such as described in part of the policyholder.The policyholder.The policyholder.89\n_ctxt markets.The policyholder. The policyholder.The policyholder of the policyholder protection afforded to a policyholder\u2019s operations"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which document was filed on May 23, 2023?",
        "options": {
            "A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021",
            "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020",
            "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021",
            "D": "Registrant\u2019s Form 8-K",
            "E": "Registrant's statement of changes in beneficial ownership",
            "F": "Registrant's proxy statement"
        },
        "LLM_original_answer": [
            "The policyholder against examination path.The policyholder from capital markets risks.The policyholder of the policyholder from capital markets.The policyholder protection to the policyholder against capital markets risks that the policyholder from capital markets by transferring such as of the policyholder against capital markets."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What penalty does the GDPR allow data protection authorities to impose for violations?",
        "options": {
            "A": "Suspension of business operations",
            "B": "Revocation of data processing licenses",
            "C": "Fines up to \u20ac20 million or 4% of annual global revenues",
            "D": "Mandatory public apology",
            "E": "Mandatory cybersecurity audits only",
            "F": "Compulsory staff retraining programs"
        },
        "LLM_original_answer": [
            "The Company\u2019s markets we may be transferred personal information.The policyholder protection of the policyholder against capital markets risks that is from capital markets risks.The policyholder from capital markets. The policyholder against capital markets risks such as described above the issuer of a policy company.The policyholder.The policyholder.The policyholder from the policyholder from the FDA and/or the policyholder.The policyholder policyholder from capital markets risks that are guaranteed protection from capital markets risks. Capital Markets and/or losses from the policyholder from capital markets.84from the policyholder.\u00c4 policyholder against such as86policyholder from capital markets.The policyholder risks.The policyholder in the policyholders from the policyholder\u2019s market risks.The policyholder such risks.The Company.The policyholder.The policyholder.The protection provided for which are as described above mentioned above discussed above discussed above discussed from capital markets risks to the insurer risks to a policyholder risks to the company.The protection provided by the document.\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could be a consequence of failing to comply with laws governing international business practices?",
        "options": {
            "A": "Immediate dissolution of the business",
            "B": "Substantial civil and criminal penalties",
            "C": "Automatic approval for business expansion",
            "D": "Tax incentives and holidays",
            "E": "Increased development of new products",
            "F": "Reduction in employee numbers"
        },
        "LLM_original_answer": [
            "Frami\n_ctxturerelicates protection provided by transferring such as described above the company risks associated with respect tofers protect thesafety markets.Additionally, which may receive orphan drug products we may be approved products we may pursue orphan drug products that provides protection from capital markets risks related risks related risks from capital markets and their use by transferring such risks from capital markets risks by transferring such as well as well as well as well-defined risks associated risks from capital markets risks by transferring such risks to the policyholder\u2019s risks associated risks from capital markets risks by transferring such as well-being risks associated risks associated risks associated risks and/orphanterian markets.The U pentium markets risks related risks related risks associated risks related risks from capital markets for which could be approved risks, or other risks to the policyholder\u2019s risks to the policyholder, or capital markets risks in capital markets risks to a85policyholder\u2019s risks associated withstanding risks associated risks associated risks associated with respect tofersaleviables on further, or other policyholder\u2019s risks associated risks associated capital markets risks associated risks associated with respect of AMXtion or any future product candidate or other than the company\u2019s risks associated risks to the policyholder by transferring capital markets risks associated capital markets risks associated capital markets.Additional markets in-87risks markets for which weasel or future collaborators and/orphan markets risks that we have been approved products or the company risks of capital markets risks areawards from capital markets in vivo protection from capital markets or other risks associated risks that are generally defined as such risks associated with-holders of value of the risks associated risks related risks related risks related risks related risks related risks associated risks from capital markets risks by transferring such as described above market.87orphan markets risks associated risks related risks related risks.The FCPMirasoleaderisks in the policyholder.The policyholder, such risks that are not providing the87from capital markets.Additional risks to the policyholder.The U (or policyholder, which areawards risks associated with such risks that the policyholder from the policyholder from capital markets.Amongerical development and/orphan company.The U.Such risks that areawards from capital markets.The policyholder against capital markets risks to the policyholder against capital markets risks to the policyholder. from capital markets risks.87protection from the policyholder.The policyholder\u2019seevaluation risks that is transferred risks in- 87to provide such as described above the policyholder\u2019streatment of which we may be approved uses for which are provided by transferring risks"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?",
        "options": {
            "A": "$2.0 billion",
            "B": "$19.0 billion",
            "C": "$1.6 billion",
            "D": "$22.6 billion",
            "E": "$8.4 billion",
            "F": "$270 million"
        },
        "LLM_original_answer": [
            "As of capital markets.We believe that existed as of $87policyholder from such as of the policyholder to the Company-wide risks. The Company\u2019s risks associated risks that existed as of $1:\u2022Accounting markets.The determination of $1.80such as of capital markets.The determination of capital markets.The policyholder against the policyholder risks to the policyholder.80policyholder.80to the capital markets risks and other than risks and such risks and annuitable assets and changes in the policyholder\u2019s risks associated risks associated capital markets.80 from capital markets risks associated risks associated with from capital markets risks that have from capital markets against capital markets risks from capital markets risks to the policyholders.77against such as of the policyholder protection provided by the policyholder from capital markets risks that arefurther protection.The value of capital markets risks by the policy from capital markets risks from capital markets risks and other than its consolidated financial instruments and/or policyholder protection from the policyholder protection from the policyholder from time risks from capital markets risks that existed only, among others, among other than capital markets risks.The Company.The Company.The Company.The Company.The carrying values and other than capital markets.The determination of $1.78policyholder from capital markets from capital markets risks by policyholder risks, among other capital markets risks to the policyholder from capital markets risks that areholder from capital markets risks.The policyholder from capital markets risks to the policyholder from capital markets risks. The risks.77 policyholder protection from capital markets risks.(policyholder from such as of $ risks in the policyholder.77 policyholder from using such risks by transferring risks related risks related risks associated capital markets risks to market risks from capital markets risks from capital markets.\uff17\nA: policyholder\u2019s capital markets risks.The policyholder\u2019s risks to the policyholder. Such risks in the policyholder.80 such as included in the policyholders from capital markets risks.The policyholder. Such risks to the policyholder.78 policyholder.78such as of capital markets risks.The policyholder.77 policyholder.earer against such as of such as of the policyholder. Capital Markets risks to a third party providing such as of the company.The policyholder. The Company\u2019st from capital markets risks.The policyholder protection from capital markets risks.The policyholder against capital markets risks associated risks.The policyholder such risks.77 policyholder. policyholder.75 policyholder such risks to the insurer.The policyholder. policyholder from capital markets risks.The policyholder. The policyholder.80"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?",
        "options": {
            "A": "By adding a fixed percentage to the policyholder account balance",
            "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract",
            "C": "By charging a surrender fee immediately upon issuance",
            "D": "By applying a uniform rate to all existing liabilities",
            "E": "By using a simple average of all deposits",
            "F": "By increasing withdrawal charges over time"
        },
        "LLM_original_answer": [
            "The Company\u2019s fair value of the policyholder benefits underwriting entity by transferring risks to the annuitymarkets risks to the Company\u2019s risks to the Company\u2019s critical markets risks associated with the policy benefits arising from capital markets risks to the policyholder protection provided for future policyholder from capital markets risks that areawards and/or other policyholder risks to a\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?",
        "options": {
            "A": "Immediate market approval for products",
            "B": "Increased research funding",
            "C": "Extended, delayed, or terminated clinical trials",
            "D": "Expansion of the organizational workforce",
            "E": "Higher stock market valuation",
            "F": "More partnerships with external organizations"
        },
        "LLM_original_answer": [
            "The document. Such risks. Such risks. Such risks to the policyholder. If the policyholdered markets. Such risks to the insurer. Such risks by transferring such as such as well beyond the policyholder such as described risks to the. Such risks. The policyholder. Such risks to the policyholder. Such risks to the policyholder such risks to the policyholder. The policy risks. The policy to the policyholder. The policyholder from the policyholder. Capital markets. Such risks. Such risks.77policyholder. For example:policyholder. The policyholder. The policyholder from capital markets. The policy market risks. The policyholder to the policyholder of the policyholder the policy or by transferring such as well as well beyond such as well beyond such as such as well beyond the policyholder protection to the policyholder from such as well beyond the policyholder protection by transferring such as well beyond capital markets.73such as such as well beyond such risks to the policyholder. The policyholder such as such as such as well-being protection to the policyholders from such as such risks by transferring such as such as such risks to the policyholder. The policyholder such as such risks. Such risks. Such risks. Such risks. Such risks.73such as such risks.73 such as well-being transferred risks to the policyholder risks. The policyholder to the policyholder. Such risks to the policyholder\u2019s risks to the policyholder. If the policyholder. Such risks to the the policyholder. The risks to the policyholder such as a policyholder. The policyholder. Such risks. The policyholder. Such risks. Such risks to the holder. The risks. The policyholder. The policyholder. The policyholder. The policyholder from such as such as such risks to the policyholder. Such risks. Such risks to the policyholder.The policyholder. Such risks to the policyholder. Such risks.The policyholder. Such risks by the policyholder from capital markets risks by transferring such as well beyond the policyholder from the policyholder. Capital markets to the policyholder of the insurer.68 such risks to the policyholder. Capital markets risks to the policyholder. Capital markets risks to the policyholder to the policyholder. Such risks by transferring such risks to the policyholder. Such risks to the policyholder. The policyholder. Such risks. Such risks.83 such as such as defined risks transferred to transfer such as defined as a) to the policyholder. Such risks to the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?",
        "options": {
            "A": "As part of ongoing operating expenses",
            "B": "As extraordinary items",
            "C": "Under liabilities subject to compromise",
            "D": "In a separate section as Reorganization items, net",
            "E": "As a footnote disclosure only",
            "F": "Combined with realized gains and losses"
        },
        "LLM_original_answer": [
            "According such as well beyond the policyholder of the policyholder risks. Such risks to the policyholder.89Core Scientific risks to the policyholder. Such risks by transferring such as well beyond the policyholder. Such risks by transferring such as such risks to the policyholder of such as such risks to the policyholder to the policyholder of the policyholder. Such risks by transferring such risks to the policy markets risks by transferring such risks.The policyholder. Such risks by transferring such as well beyond the policyholder.92 policyholder from such as well as well beyond the policyholder of such risks to the policyholder such risks to the policyholder from such risks byproducts such as such risks. Such risks to the policyholder.The policyholder. Such risks by transferring such as such as well beyond the policyholder such as well-being.The policyholder by transferring such as such risks to the policyholder of the policyholder from such as well as well as well as well as well-being such as well as such as well-being from the by, such as well-defined risks to the policyholder of the policyholder from such risks to the policyholder.The policyholder risks by transferring such as such risks to the insurer.The policyholder.92\n(KP 92 such as well as well as described above such as such as such risks by transferring such as well beyond the policyholder.92 such as well beyond the policyholder. The Company.The Company. The policyholder.92 such as well. Such risks to the policyholder. Such risks. Such risks.92 such as such as a policyholder. Such risks by transferring such as well above market risks. Such risks. Such risks assumed risks to the policyholder against such as well to the policyholder of the insurer.92 policyholder of the policyholder.92 such as such risks.92 such risks by the policyholder. Such risks to the policyholder. The policyholder. Such risks to the policyholder of the policyholder from the policyholder. Such risks.92 such risks to the policyholder. Such risks by transferring such as well beyond the policyholder such risks to the policyholder of the insurer. Such risks to the policyholder. Such risks. Such risks by transferring such risks. Such risks. Such risks by transferring such risks by transferring such as well above such as a portion of the insurer. Policyholder. Capital Markets risks associated with such risks by transferring such risks to the policyholder risks. The policyholder from the policyholder. The Company from the insurer. Such risks to the policy"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?",
        "options": {
            "A": "Approval from state regulatory commissions",
            "B": "Approval from the Federal Energy Regulatory Commission",
            "C": "Prior authorization of the PUCO",
            "D": "Meeting tangible net worth requirements",
            "E": "Approval from the Duke Energy board",
            "F": "Retention of minimum working capital"
        },
        "LLM_original_answer": [
            "To the policyholder.The policyholder to the policyholder. Such risks by transferring such as well beyond the policyholder of such as such as such as well as well as such as such risks to the policyholder. Such risks to the policyholder from such risks byproducts such as such risks. The policyholder of the policyholder of the policyholder such as such risks to the policyholder. Such risks byproducts such as such as such as such as such as well as such as such as described in exchange such as such as well as well as well as well as well-being such as well-being such as well-being from the policyholder.##table such risks to the policyholder. Such risks by transferring such risks to the policyholder. Such risks by transferring such as well beyond the policyholder of the policyholder. Such risks. Such risks by transferring such risks by transferring such risks by transferring such as such risks by transferring such as well such as such as well. Such risks.##table risks to the policyholder. Such risks to the policyholder. Such risks. Such risks to the policyholder. Such risks. Such risks. Such risks to the policyholder. Such risks.The policyholder from such as well beyond the policy. Such risks. The policyholder of the policyholder against such risks. Such risks. For example, in exchange the insurer.##"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?",
        "options": {
            "A": "The deficiency is recognized as a capital gain.",
            "B": "A new investment strategy is implemented.",
            "C": "The deficiency is considered due to credit loss and recognized in earnings.",
            "D": "A penalty is imposed on the financial institution.",
            "E": "The loan agreement is renegotiated.",
            "F": "An automatic increase in interest rate is applied."
        },
        "LLM_original_answer": [
            "If such as well beyond the policyholder from such risks.annu such as well-being-ann such risks. The policyholder such as well-being policyholder. The risks.89 such risks to the insurer.ner. The risks byproducts such as a capital markets risks to the policyholder to the policyholder such risks to the policyholder. The policyholder. Such risks. The policyholder. Such risks. Such risks to the policyholder from capital markets. The risks to the policyholder. The policyholder. Theholder. The risks. The policyholder such as well-being of the policyholder policyholder. Such risks to the policyholder. For example:89policyholder. Such risks by transferring such as well beyond such as well beyond the policyholder from such as well beyond the policyholder from the policyholder.uncertainty such as such as well beyond the insurer. The policyholder.89 such as a decline in the policyholder to the policyholder. The policyholder. Such risks by transferring such as welling such risks by transferring such risks to the policyholder. The policyholder to the policyholder. The policyholder. Such risks. The policyholder. The policyholder from capital markets risks by transferring such as well as a policyholder to the policyholder such risks to the policyholder.89\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?",
        "options": {
            "A": "Conduct annual cybersecurity audits",
            "B": "Formally report material cybersecurity incidents",
            "C": "Hire a dedicated cybersecurity officer",
            "D": "Implement a company-wide cybersecurity training program",
            "E": "Encrypt all data and communications",
            "F": "Report cybersecurity budgets annually"
        },
        "LLM_original_answer": [
            "Based on such risks by transferring such risks by the policyholder against such as well-being transferred to the markets risks to the policyholder to the policyholder. Such risks to the policyholder of the policyholder. Such risks by transferring such risks to the policy markets risks.The risks by transferring such as well as well as such as well beyond such as such risks by transferring such as well beyond such as well as well beyond the policyholder of such as such risks. Such risks to the policyholder of the policyholder from the policyholder by transferring such as well beyond the policyholder of the policyholder. Capital markets risks to the policyholder risks. Capital markets risks to the policyholder. Capital markets risks.The policyholder such as such as such as described in exchange such as such as well as well-being such as well as well-being such as defined in the policyholder. Such risks. The policyholder risks to the policyholder of the policyholder risks by transferring such risks to the policyholder. Such risks by transferring such as a portion of the policyholder of the policyholder. The policy such as such as a policyholder by transferring such as such risks. Capital Markets risks by transferring such as such as well beyond the policyholder. Such risks. Such risks to the policyholder. Such as a third party. Such risks. Such risks to the insurer. Such risks. Such risks. Such risks. Such risks to the insurer. Such risks to the policyholder. Such risks by transferring such as well beyond the policyholder of the policyholder against such risks. Such risks. For example, in return the insurer. The policyholder from the policyholder. Such risks. Such risks by transferring such as well beyond the policyholder to the policyholder. Capital Markets. Such risks to the policy markets. The policyholder\u2019s policyholder from such as a capital markets risks. Capital markets risks to the policyholder. Such risks bylawsuiting such risks. The risks to the policyholder. Such risks to the policyholder by transferring such as a\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which document was filed on May 23, 2023?",
        "options": {
            "A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021",
            "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020",
            "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021",
            "D": "Registrant\u2019s Form 8-K",
            "E": "Registrant's statement of changes in beneficial ownership",
            "F": "Registrant's proxy statement"
        },
        "LLM_original_answer": [
            "Based onus. The policyholder. The policyholder to the policyholder. Such risks to the policyholder of such risks to the policyholder. Such risks by transferring such as such risks by transferring such risks to the policyholder. Such risks by transferring such as well beyond such risks by transferring such as well beyond the policyholder. Capital markets risks byproducts of such as well beyond such as such risks to the policyholder. Such risks byproducts such as well beyond the policyholder such risks to the policyholder. Such risks to the policyholder from capital markets risks. Capital markets risks to the policyholder. Such risks by transferring such as well beyond the policyholder of the policyholder to the policyholder. Such risks. Such risks by transferring such as well-known as well-being the policyholder. Such risks to the policyholder such risks to the policyholder.83 such as well-being protection to the policyholder. Capital markets risks by transferring such as such risks to the insurer.rier protection. Such risks are the policyholder from capital markets risks by transferring such as such risks by transferring such as such as well beyond such as well beyond the policyholder from capital markets risks.83 such as well.83 such as a third party. Such risks.83 such risks to the policyholder.83 such as well beyond the policyholder. Such risks to the policyholder from such assecurities such as well beyond the policyholder\u2019s risks by transferring such as well above capital markets risks. Capital markets risks. For example policyholder. Capital Markets risks to the policyholder from the policyholder. Such risks. Such risks by the policyholder.83 such risks to the policyholder. Capital Markets.Risks to the policy markets. The policyholder. Capital Markets risks to the policy markets risks. The policyholder such as well-being of the policyholder by transferring such as well beyond the policyholder. Such risks to the insurer. Such risks to the policyholder. Such risks byproducts such as well above and/orignal. Capital markets risks. The policyholder from such as such as well above such as well to the policyholder. The policyholder. Capital Markets risks to the policyholder. The policyholder. Capital markets risks by providing such risks to the policyholder. The policyholder to the insurer. Such risks to the policyholder. Capital Markets risks by providing such as well beyond the policyholder such as well-defined risks to the policyholder. Such risks. Capital markets risks. Such risks to the insurer. Such risks by, for the policy"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What penalty does the GDPR allow data protection authorities to impose for violations?",
        "options": {
            "A": "Suspension of business operations",
            "B": "Revocation of data processing licenses",
            "C": "Fines up to \u20ac20 million or 4% of annual global revenues",
            "D": "Mandatory public apology",
            "E": "Mandatory cybersecurity audits only",
            "F": "Compulsory staff retraining programs"
        },
        "LLM_original_answer": [
            "What is by transferring such as asecurities by transferring such risks. Such risks to the policyholder of the policyholder from such risks associated. Such risks. Such risks.77 such as well-being of the policyholder.fighter. Such risks. Such risks."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could be a consequence of failing to comply with laws governing international business practices?",
        "options": {
            "A": "Immediate dissolution of the business",
            "B": "Substantial civil and criminal penalties",
            "C": "Automatic approval for business expansion",
            "D": "Tax incentives and holidays",
            "E": "Increased development of new products",
            "F": "Reduction in employee numbers"
        },
        "LLM_original_answer": [
            "Facts such as well beyond the policyholder against such as well-being policyholder from the policyholder from the policyholder. Theoph such risks to the policyholder of such risks to the policyholder. Such risks by transferring such as such risks by transferring such risks.The policyholder. Such risks by transferring such as well-being from such risks by transferring such as well beyond such as well as well as such as such risks to the insurer.78 such risks to the policyholder from such risks by the policyholder. Such risks. Such risks to the policyholder of the policyholder. Such risks byproducts by transferring such as well beyond the policyholder such as such risks. Such risks by transferring such risks to the policyholder of the policyholder risks by the policyholder from capital markets risks to the policyholder. Such risks. Such risks. Such risks to the byproducts risks. Such risks to the policyholder of the policyholder risks by transferring such as such assecurities of the by transferring such as aseeds such as well-being of the risks by transferring such as such risks by transferring such as well-being policyholder such risks by transferring such as such risks by transferring such as well beyond the policyholder from capital markets. Such risks to the policyholder. Such as a third party. Such risks. Such risks to the policyholder.rier:83 such as well beyond the policyholder. Such risks. Such risks to the policyholder. Such risks by transferring such as such as such as well-being protection against such as well-being transferred to the policyholdered to the insurer.83 the policyholder\u2019s risks to the policyholder. Such risks. Such risks such as a capital markets risks. Such risks to the policyholder. The policyholder.73such as well beyond the policyholder\u2019s risks by the policyholder. Such risks. The policyholder of the insurer.erm by transferring such as such as well as well-being protection by providing such as well-defined risks associated with such risks by transferring such as a policyholder by transferring such risks by transferring such as such as well as such as such risks by transferring such risks by transferring such as well by transferring such risks. Such risks to the policyholder from such as such as such as such as such as such as well beyond the policyholder from the policyholder. Such risks to the insurer. Such risks to the policyholder. Such risks such as such as such as well beyond the policyholder such as well-known as such risks to the policyholder. Such risks. Such risks to the"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?",
        "options": {
            "A": "$2.0 billion",
            "B": "$19.0 billion",
            "C": "$1.6 billion",
            "D": "$22.6 billion",
            "E": "$8.4 billion",
            "F": "$270 million"
        },
        "LLM_original_answer": [
            "To the policyholder from the the policyholder. The policy risks. The policy to the the policyholder.66 policyholder.66 such risks to the the policyholder. The policyholder such as well as well beyond the policyholder risks.The policyholder. The policyholder of the policyholder. The policyholder. The policyholder from the the policyholder. The policyholder.66 such as a policyholder. Capital Markets risks. Policyholder from the policyholder of the policyholder from the policyholder. Capital Markets risks.##markets to the insurer.rier.The risks to the policyholder.66 such risks.66 such as well beyond the policyholder. Such risks. Policyholder of the policyholder.The policyholder of such as a third party. Such risks to the policyholder. Such risks. Such risks to the policyholder.66 such as measured by the policyholder. The Company markets risks. The risks to the policyholder of such risks by transferring such as such as such as well as such risks. Such risks assumed by transferring such as such risks to the policyholder.66\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?",
        "options": {
            "A": "By adding a fixed percentage to the policyholder account balance",
            "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract",
            "C": "By charging a surrender fee immediately upon issuance",
            "D": "By applying a uniform rate to all existing liabilities",
            "E": "By using a simple average of all deposits",
            "F": "By increasing withdrawal charges over time"
        },
        "LLM_original_answer": [
            "The policyholder of such as well beyond the policyholder. Such risks byproducts of such as such risks. The policyholder from the by such risks by providing such risks. Such risks. Capital markets. Such risks to the policyholder. Such risks to the policyholder from capital markets risks. The policyholder such as such risks to the policyholder risks by transferring such risks to the policyholder. Such risks to the policyholder. Such risks. Such risks by transferring such as well-being such risks to the policyholder. The CompanyFinancial Market risks by, or by transferring such risks associated risks by transferring such risks by transferring such as well-being of the by transferring such as well beyond the policyholder of the policyholder. The Company.The policy such risks by transferring such as well-being transferred to the policyholder from such as such as well beyond such as such assecurities such as well beyond such as well. The policyholder. Such as a third party. Such risks. The Company A capital market risks to the policyholder. Such risks. Such risks to the policyholder. Such risks such risks by the policyholder from capital markets.The policyholder\u2019s risks by policyholder of the policyholder against such as well beyond the policyholder of such as the insurer.99 such risks to the policyholder. In the policyholder. The policyholder against such risks. For example, such as well beyond the policyholder. For example, such risks to the policyholder such risks by the policyholder. Such risks. The policyholder such as well-being. Such risks by transferring such as well beyond the policyholder. The policyholder. The policyholder of such risks by transferring such risks. Such risks. The policyholder risks by transferring such as well beyond such as such as such risks by transferring such risks by transferring such as well. Such risks. Such risks to the policyholder from such as such as such risks. The policyholder. Capital markets risks. The policyholder from the policyholder. The policyholder to the insurer. Such risks to the policyholder losses in the policyholder. Such risks. Such risks associated risks from the insurer. The policyholder from the policyholder. Capital markets. Such risks to the policyholder. Such risks. For example policyholder. Such risks such as welling such risks to the insurer. Such risks to the policyholder to the policyholder. The risks to the policyholder. Capital markets risks to the policyholder. Such risks to the policyholder. Such risks bylawholder. Such risks by transferring"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?",
        "options": {
            "A": "Immediate market approval for products",
            "B": "Increased research funding",
            "C": "Extended, delayed, or terminated clinical trials",
            "D": "Expansion of the organizational workforce",
            "E": "Higher stock market valuation",
            "F": "More partnerships with external organizations"
        },
        "LLM_original_answer": [
            "What3.3.RE CORPORATION.3.SUMMA securities corporation.3.S.ACC.RE.3.3.Security Corporation.3.SUMMASS.3.3.SECOREG.RULE3.SE3.Security3.Security Security Corporation, a Massachusetts Corporation.3.3.3.S.EQUANTHISTORY OFLICONS OFMASS.3.3.SECURITY 3.SALES.3.S3.S.SEC SECURITY CORPORATION.3.Sec Security Corporation, a Massachusetts securities corporation.3.S.ISS.COR SECURITY CORPORATION SECURITY CORPORATION, a Massachusetts securities.SALI.SEFFECTS.CORPORALLOCATION OF THEORE SECURITY CORPORATION STATUS OF SECURITY CORPORATION SECURITY CORPORATION STATUS OFBASIC SECURITY CORPORATIONS SECURITY SECURITY CORPORATIONS3.SEFFECT SECURITY CORPORATION.3.SEFFECTS.EFFECTS3.Security Corporation, a Massachusetts securities corporation.3.SEARNOWNINGSTRUCTIONS OFTEXNATURE SECURITY SECURITY CORPORATION, a Massachusetts Securities Security Corporation, a Massachusetts Securities Corporation Security Corporation3.S.Issue Security Corporation, a Massachusetts securities corporation.3.SALEGROSS ANDMASSUMMASS.3.SEARN.3.SE.3.SEC.3.SUMMARY OF SIGNATURES.3.SEFFECT OF THE COMPANY ACCOUNTs.SEFFECTS.CORIGINALLY LIMITED PARTNATURE SECURITY CORPORATION\u2019SCHEDULE OF INCOMEMENTS.3.Keros Security Corporation, Inc.3 securities corporation.3.OPERRY OF SECURMASSMAY.SEFFECTSPECIAL SECURITY SECURITY SECURITY CORPORATION SECURITY SECURITY SECURITY CORPORATION SECURITY SECURITY SECURITY SECURITY SECURITY SECURITY SECURITY CORPORATION SECURITY CORPORATION SECURITY CORPORATION CORPORATION, a Massachusetts securities and security corporation.3.Security Corporation Security Corporation, Inc.3.S.3.3.SEQUICKETI.C.REALI.COUNTYIELD OF BALANCE OF SIGNIFIC3.SEFFECTs3.K3.Security Corporation, a Massachusetts security corporation.3.SALESSA.3.SECURITY OF3.3.3.Security, a Massachusetts securities corporation.3.SUMMARY of the BALLOTTERMS.3.SEC3.3.SECOUNTAINDEVELOUS SECURITY CORPORATION OFBASIC.3.SEFFECTSALIAS.3.SUMMARY of3.SUMMASSMAY.3.RECENT SECURITY CORPORATION STATUS OFBASIC.SECOMNESSEXCEPTION OFBASIC SECURITY CORPORATION SECURITY CORPORATION SECURITY CORPORATION.3.SUMMARY OF SECURITY Corporation\u2019s3.Security Corporation, a Massachusetts securities corporation.3.SUM"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?",
        "options": {
            "A": "As part of ongoing operating expenses",
            "B": "As extraordinary items",
            "C": "Under liabilities subject to compromise",
            "D": "In a separate section as Reorganization items, net",
            "E": "As a footnote disclosure only",
            "F": "Combined with realized gains and losses"
        },
        "LLM_original_answer": [
            "According to include the growth in the quality and certain and quality and quality and quality and quality and/or loss in the total hosting and other than the growth in the quantity and (benefits a portion of the Company\u2019s the quality and (losses of our business combinations of miners working to reflect the fair value of our business and amortization of our operating results of the quantity and quality and quality of the greater than the growth in the growth in the overall quantity and quality of miners working to solve blocks. The Company\u2019s blocks. The overall quantity and/or working to the fair value of the Company\u2019s revenue earned from the growth in the difference between 57Table 63and quality of miners working to solve blocks of miners working to be##table 1 and resulting from the growth in the overall quantity and quality and quality of miners working to solve blocks. The Company\u2019s work to earn.The growth in the growth in the growth in the overall quantity and quality and quality of miners working to solve blocks and the Company Overview of the overall quantity and quality and quality and quality and the quality and the growth in the growth in the quantity and quality and estimated using the quantity and the quality and the overall quantity and the growth in the overall quantity and the quantity and the growth in the growth in the growth in the growth in the net of miners working to the quality resulting from the growth in the growth in the quality and quality and quality and quality and quality of miners working to becertainly resulting from the quality and certain and the overall quantity and quality and unrealized in accordance with the Company\u2019s consolidated financial statements of $ 63resulting resulting from the fair value and quality and resulting from the quantity and quality and resulting from the quantity and quality and quality and resulting from the same period and quality and quality and quality and quality and quality and quality of the growth in the overall quantity and quality and quality and quality and quality and quality and the overall quantity and quality of the quantity and quality and quality and quality and quality and quality and quality and quality of the growth in the growth in the quality and quality and the overall quantity and quality and quality and quality of the quality and related-party related to the quality of the quality of the growth in the year ended December 63of the fair value of miners working to the quality and quality and certain digital asset and certain specified in the fair value and other than the Company\u2019s business and other than the fair value resulting from the fair value of the fair value of our miners working to be##table 1.63from the overall quantity and"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?",
        "options": {
            "A": "Approval from state regulatory commissions",
            "B": "Approval from the Federal Energy Regulatory Commission",
            "C": "Prior authorization of the PUCO",
            "D": "Meeting tangible net worth requirements",
            "E": "Approval from the Duke Energy board",
            "F": "Retention of minimum working capital"
        },
        "LLM_original_answer": [
            "To 2006.Duke Energy Regulation Utility Florida.Duke Energy Florida.Duke Energy was formed in 2016.DEFPFrammed in 2016 Energy Florida in 2016 was formed in 2016 and is 2016 to facilitate in 2016 and continues in 2016 was formed in 2016 was formed in 2017 to form 2016.2016. Duke Energy Florida.Duke Energy Florida, and other than Duke Energy Florida and was formed in 2016. Duke Energy Florida.Duke Energy.Duke Energy Florida to form 2017 formed in 2017 to form 2016.Duke Energy Florida.Duke Energy.Duke Energy Florida law.The formation of 2017 formed in 2016.2016 was formed in 2016. The special purpose subsidiary of 2016 Florida and was formed in 2016DEFP was formed in 2016 was formed in 2016.The 2016 formed to finance in 2016.The Duke Energy Florida was formed in 2016 and continues in 2016 formed in 2016 was formed in 2016.Duke Energy Florida to build to hold in 2016 to finance in 2016th.Duke was formed in 2016 to hold 2016 was formed in 2016 formed in 2016 formed in 2016 special purpose subsidiary of Florida.Duke in 2016 formed in 2016 formed in 2016 in 2017.2016.Gradied in 2016 and the 2016.DEFP was formed in 2016 was formed in 2016 to isolate 2017.Prior Florida.Duke Energy Florida.DEFPFram in 2016 to finance special purpose subsidiary of 2016 was formed in 2017.1. Duke Energy Corporation.Duke Energy Florida.Duke Energy Florida and 2017##table 2017. Duke Energy.Duke Energy Florida was formed in 2016 2017.Duke in 2016 to build to finance in 2017## Florida\u2019s 2016 by forming in 2016.Duke Energy Florida\u2019s special purpose offt 2020.Duke Energy Services Corporation was formed in 2016.Duke Energy.During in 2016 Energy Florida.Duke in 2016 to holdings to finance a 2016 to manage to facilitate in 2016 Energy Florida.DU.SEEFP in 2016 to finance in North Carolina Power Plant was formed to finance subsidiary"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?",
        "options": {
            "A": "The deficiency is recognized as a capital gain.",
            "B": "A new investment strategy is implemented.",
            "C": "The deficiency is considered due to credit loss and recognized in earnings.",
            "D": "A penalty is imposed on the financial institution.",
            "E": "The loan agreement is renegotiated.",
            "F": "An automatic increase in interest rate is applied."
        },
        "LLM_original_answer": [
            "If the net of the most_recent ITEM 2022.ITEM 2024.REPLY 2020.1.STAFFIRM 202.1.1.Question ITEM 2024.DISCOUNT 2022.DISCATTER 2020.RESULTS.1.REASONGSUBANK ITEM 2022.LEGIVEN 2024.ITEM 202.ITEM 2.LEGALERTSOLUTIONSCHEDULE 2020.RESULTSPECIAL PROCEEDINGS.RECASHOME 2024.ITEM 2023.1.1.The SEC 2020.REASON.1.1.1.The most recent historical net income 2022.REASSETS OF 2022.2.RECASHR.ESS.1 million.ITEM 4.RECENTSICVENTSUSINGITEM 2020.1.1.1.2.REASSETS OF 2020 ITEM 2020.8 LEGALERT.INSTRUCTIONWe believe this section 2.1.1.4.CUSTOM 1.1.1.4.0.0.1. 4.CUSTOM 1."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?",
        "options": {
            "A": "Conduct annual cybersecurity audits",
            "B": "Formally report material cybersecurity incidents",
            "C": "Hire a dedicated cybersecurity officer",
            "D": "Implement a company-wide cybersecurity training program",
            "E": "Encrypt all data and communications",
            "F": "Report cybersecurity budgets annually"
        },
        "LLM_original_answer": [
            "The collaboration resulting from the collaboration resulting from the resulting from the collaboration resulting from up to up to up to up to up to up to up to up to five targets resulting from the resulting collaboration resulting from up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to license drug candidates directed to up to five targets resulting from the collaboration. The collaboration and up to up to up to up to up to license to up to license drug candidates resulting from up to up to up to up to up to up to license to up to up to up to up to five targets resulting from the collaboration and/or up to up to up to up to up to up to up to up to up to five resulting from the collaboration and resulting from the up to up to up to up to up to up resulting from the collaboration and up to up to up to up to up to up to up to up to up to up to up to up to five targets resulting from the collaboration. The collaboration and the option to up to up to up to up to up to up to up to up the collaboration. The collaboration and the option to up to up to up to up to up to up to up five resulting from the the up to up to up to up five targets resulting from the collaboration and up to up to up to up to up to up to up to up to up to up to license directed to up to up to five targets resulting from the collaboration resulting from up to up to five targets resulting from the collaboration resulting from the up to five targets resulting from the collaboration. The option resulting from up to up to up to up to up to up to license resulting collaboration and resulting from up to license up up to up up to five targets resulting from the collaboration resulting from up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up to up resulting from the collaboration and the up to up to up resulting from the up to up to up from the collaboration. The option to up to up to up to up to up to five resulting from the collaboration resulting from the collaboration and resulting from the option resulting from the up to up to up to up to up to up to up to up to up to license up to up to up to up to up to up to up to up to up to up to up to up"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which document was filed on May 23, 2023?",
        "options": {
            "A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021",
            "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020",
            "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021",
            "D": "Registrant\u2019s Form 8-K",
            "E": "Registrant's statement of changes in beneficial ownership",
            "F": "Registrant's proxy statement"
        },
        "LLM_original_answer": [
            "The following the prior year-overall of our decades of our decades of their decades of our decades of their decades of their decades of MSR initiatives on a periodic basis of our decades of our decades of our decades of our decades of net of the fair value and recoveries of the prior year-over their decades of our decades of our decades of our decades of our decades of their decades of our decades of our decades of our decades of our decades of their decades of our decades of our decades of their decades of UPBene of our decades of our decades of our decades of unearned decades of the table 2023ITEM 2023ITEM 2020ITEM 2020ITEM 2023ITEM 2020 ITEM 2023ITEM 52ITEM 2023ITEM 50ITEM 57ITEM 10s of their decades of their decades of their decades of their decades of their decades of our decades of servicing advances on a net of their decades of their decades of our decades of their decades of their decades of our decades of our decades of our decades of our decades of $3ITEM 2023ITEM 2023ITEM 50and initiatives on a net of their decades of $1 ITEM 2023ITEM 2023 and initiatives on a periodic basis, net, and initiatives on a decades of their decades of experience in their decades of the decades of their decades of our decades of their decades of taxable loan buyouts of our decades of the decades of our decades of our decades of our decades of the prior year-over their decades of their decades of their decades of their decades of our decades of their decades of our decades of their decades of our decades of $1 ITEM 50and initiatives on a decades of our decades of our net.##table ITEM 2023 ITEM 51 and initiatives on a decades of their decades of on a $1.##table 2023reviewing on a ndec of their decades of their decades of our decades of the table 52and the fourth quarter-end of our decades of our decades of the table 58ITEM 51ITEM 2023 ITEM 52 ITEM 2023ITEM 48ITEM 47ITEM 57and the majority of the prior to their decades of the table 2023ITEM 10s of their decades of the year-overall of their decades of our decades of servicing and in 2023ITEM 2023ITEM 54ITEM 2023ITEM 52##table 2023ITEM 2023ITEM \u0003 and initiatives on a net interest rate and rep"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What penalty does the GDPR allow data protection authorities to impose for violations?",
        "options": {
            "A": "Suspension of business operations",
            "B": "Revocation of data processing licenses",
            "C": "Fines up to \u20ac20 million or 4% of annual global revenues",
            "D": "Mandatory public apology",
            "E": "Mandatory cybersecurity audits only",
            "F": "Compulsory staff retraining programs"
        },
        "LLM_original_answer": [
            "The product candidates.We have incurred significantly increased accounting and research and incurred significantly increased accounting and development of our product candidate product development of significantly increased research activities and development of our product candidates.We have incurred significantly increased accounting and our product candidate research activities and development of our product candidates.We have incurred significantly increased accounting and development activities and incurred significantly increased accounting activities and incurred significantly increased accounting and incurred significantly increased accounting and incurred significantly increased accounting and development costs associated costs associated research activities and incurred significantly increased accounting and research activities and expect significantly increased research and increased accounting costs associated product candidate candidates incurred significantly increased accounting costs significantly increased accounting activities and development activities related to our continued research activities significantly increased accounting and research and research activities and development of our continued development of our product candidates.We have incurred significantly increased research and audit-related costs associated costs and development of significantly increased research activities and development of our product candidates.We have incurred significantly increased costs for significantly increased accounting and research and incurred significantly increased costs significantly increased significantly increased accounting and accounting and accounting and will continue significantly increased accounting and incurred significantly increased accounting activities and incurred significantly increased research activities and development of our product candidates and incurred significantly increased accounting and development costs associated accounting and incurred significantly increased significantly increased accounting activities and incurred significantly increased accounting and incurred significantly increased significantly increased accounting costs and research and incurred significantly increased accounting activities and incurred significantly increased significantly increased significantly increased accounting and increased accounting and will continue research activities and development of our product candidates and development of significantly increased research activities and development of increased research activities and incurred significantly increased accounting and accounting and incurred significantly increased accounting activities and incurred significantly increased accounting and development and development of our product candidates and expect to date accounting costs and research activities and expect to increase significantly increased accounting costs related to increase significantly increased accounting costs related costs associated significantly increased accounting activities and development of our product candidates.We have incurred significantly increased accounting costs related costs and increased accounting and development activities and expect to date product development activities related increased accounting and incurred significantly increased accounting and accounting and incurred significantly increased research and development activities and development of our product candidates incurred significantly increased accounting and development of significantly increased accounting and other incurred significantly increased costs significantly increased accounting and audit and research and development of our continued research activities and expect to date activities and incurred significantly increased accounting and research and development of our product candidate accounting and incurred significantly increased accounting and incurred significantly increased accounting and research and development activities and expect to date product candidate accounting and development of our incurred significantly increased accounting costs and accounting and incurred significantly increased accounting activities and incurred significantly increased research activities and continued research activities and development of our product candidate development"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What could be a consequence of failing to comply with laws governing international business practices?",
        "options": {
            "A": "Immediate dissolution of the business",
            "B": "Substantial civil and criminal penalties",
            "C": "Automatic approval for business expansion",
            "D": "Tax incentives and holidays",
            "E": "Increased development of new products",
            "F": "Reduction in employee numbers"
        },
        "LLM_original_answer": [
            "What are57\n57and57and57and57There are57There are not previously approved products that57and57and57and57There are57The58or other than57and57and57\n57\n57There are57There are57There are57and57and marketing approval for commercial products that57\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?",
        "options": {
            "A": "$2.0 billion",
            "B": "$19.0 billion",
            "C": "$1.6 billion",
            "D": "$22.6 billion",
            "E": "$8.4 billion",
            "F": "$270 million"
        },
        "LLM_original_answer": [
            "As all Members who have open positions were to change in value of open Members who have open positions were to day value if all Members who day change in fair value of open positions were open positions were to open positions that have open positions were to the open positions that all Members who have value if all Members who have open positions were to unrealized positions with open position have open positions were to open positions with unrealized positions with unrealized open positions with unrealized positions with open positions with open positions with open positions were day change in fair value of all Members who have open positions with unrealized positions with open positions with open positions were open positions were to open value of open positions were to open positions with open positions with unrealized positions with open position if all Members who have open positions with open positions with open positions with open day day change in fair value if all Members who have open positions with unrealized or unreal or change in open positions with unrealized positions were to change in fair value if all Members who have open day change in fair value of their open positions were to the positions were to the open positions were to day or open positions with unrealized positions with open positions with unrealized positions that change in fair value if all open position change in open positions with unrealized positions were positions with open positions with open positions with unrealized positions were closed positions were to the Members who have open positions were to the change in the change in value if all Members who have open positions with open positions with unrealized positions with unrealized positions were to have open positions with open positions with unrealized positions were all day value of the change in open positions with unrealized positions with open positions with open positions if all open positions were to open positions were to open positions were open positions were to close positions were to fair value change in value if all open positions were to have open positions with open positions in value or full day change in fair value if Members who have open position change in open day change in fair value if all change in value if all Members who have open positions that day in fair value if all Members who have open positions with unrealized gains or full day or full day or change in fair value change in fair value if all Members who have open positions with unrealized change in fair value if all Members who have open positions with open positions with open positions with unrealized positions if day change in fair value of the change in open positions with unrealized positions were to the open positions were to open positions with unrealized positions were to open positions were to the change in value if all"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?",
        "options": {
            "A": "By adding a fixed percentage to the policyholder account balance",
            "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract",
            "C": "By charging a surrender fee immediately upon issuance",
            "D": "By applying a uniform rate to all existing liabilities",
            "E": "By using a simple average of all deposits",
            "F": "By increasing withdrawal charges over time"
        },
        "LLM_original_answer": [
            "Based on the fair value and, as a)Variable Annuancesthe##table 66Variable Annuance of our variable contracts and, as of our variable annuity.Business \u2014##table, as a result in-force maturable transaction and, as a non-Guarable transaction and, as of the line items of the fair value of our in our variable annuity_Helper 2024##Table 66Variable Annuance of our hedging of the fair value of our variable annuity##Table of the Company-wide, we believe, as a result of our ability to the fair value of our variable contracts and, as a)"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?",
        "options": {
            "A": "Immediate market approval for products",
            "B": "Increased research funding",
            "C": "Extended, delayed, or terminated clinical trials",
            "D": "Expansion of the organizational workforce",
            "E": "Higher stock market valuation",
            "F": "More partnerships with external organizations"
        },
        "LLM_original_answer": [
            "The result of many factors, including risks and uncertainties, risks and uncertainties, many factors, including risks and uncertainties, risks and uncertainties, among factors that involve risks and uncertainties, including the result in the result of the result of many factors that involve risks and result of many factors that involve risks and uncertainties.As a result of many factors that involve risks and, among other factors that involve risks and uncertainties.As a result of many factors that involve risks and uncertainties.As a result of factors, among factors, including those that involve risks and uncertainties and uncertainties.As a number of uncertainties.As a result in many factors, among factors, among factors, including those risks and uncertainties, including those involve risks and uncertainties, a result of the result in many factors that involve risks and uncertainties, as a result of many factors that involve risks and other factors, including those factors, including risks and uncertainties.As a result of many factors that involve risks and result of many of many of many factors that involve risks and uncertainties.As a result of the result in some of uncertainties.As a result of many factors, including those factors that result of result of many factors that involve risks and involve risks and uncertainties.As a result of factors that involve risks and other factors that involve risks and uncertainties.As a result of many factors that involve risks and as a result of those result of result of many factors, including those statements that result of result of the result of the result of the risks and uncertainties.As a result from many factors that involve risks and other factors that involve risks and involve risks of many factors that involve risks and uncertainties, as a result of the result of result of the uncertainties.As a result of result of the results of the result of the result of many factors that involve risks and result of course of many factors that result of many factors, including risks and uncertainties.As a result of the risks and uncertainties.As a result of many factors that involve risks and uncertainties, including a result of factors, including those that involve risks and uncertainties, the result of the result in the result of the result in many factors that involve risks and other factors, among the result of result of many factors, including those factors, including those factors, among other factors, including risks and uncertainties.As a result of many factors, including those statements that involve risks and uncertainties, the factors that involve risks and uncertainties and uncertainties.As a result of many factors that involve risks and the result of many factors, including those result of result of uncertain results of the uncertainties.As a result of result of many factors that involve risks and other factors that involve risks"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?",
        "options": {
            "A": "As part of ongoing operating expenses",
            "B": "As extraordinary items",
            "C": "Under liabilities subject to compromise",
            "D": "In a separate section as Reorganization items, net",
            "E": "As a footnote disclosure only",
            "F": "Combined with realized gains and losses"
        },
        "LLM_original_answer": [
            "According are which could have a material adverse effect, either of which, either of which could have a material adverse effects of which, either of which could have a material adverse effect on which could of which could have a material adverse effect of which could have which could have (or (or which, either of which could have which could have which could of which either of which could either of which, either of which could have a material adverse effect of which could have (or which could either of which could have a material adverse effect on the (or which either of which could have (or loss (or could have (or loss, either of either of either of either of either of which could have (or a material adverse effect (or which could of which could have a material adverse effect of which could have which could be either of which could have which could have aforesh\nsupport material adverse effect of which, either of which could have which, either of which, either of which, either of which could have afo which could have which could of which could of which of which could of which could of which (or which, either of which, either of which, either of which could be either of which either of which either of which could of which either of which could of which, either of which could of which could have a material adverse effect of which either of which, either of which could of which could either of either of which, which could of which could have a material adverse effect on the (or of which, either of which could have a material adverse effect on the latter of which could have which could have a material adverse effect of which could have a material adverse effect of which, either of which could have (or adverse effect of which, either of which could have (or a (or. See Item which could either of which, either of which could have which could either of which could have a (either of which could have a material adverse effect on our business, either of which either of either of which could of which could of which could of which could of which could have a material adverse effect of which, either of which either of which could have a material adverse effect on which could of which could have a material adverse effect of which could of which either of which, either of which could have a material adverse effect on which could have a material adverse effect of which could of which could have a material adverse effect of which, either of which, either of which could have either of which could have which could of either of which could"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?",
        "options": {
            "A": "Approval from state regulatory commissions",
            "B": "Approval from the Federal Energy Regulatory Commission",
            "C": "Prior authorization of the PUCO",
            "D": "Meeting tangible net worth requirements",
            "E": "Approval from the Duke Energy board",
            "F": "Retention of minimum working capital"
        },
        "LLM_original_answer": [
            "To the extent losses may be responsible to the amount of losses may be excluded or exceed the extent losses may be excluded or other than losses may be responsible to the Duke Energy and Duke Energy & position.Each company's financial position.Each company is responsible to the extent losses may be responsible to the extent losses may be excluded or exceed.Each company is responsible to the Duke Energy Company is responsible to the Duke Energy Company's each company is responsible to the financial position.Each company is excluded or other than may be subject to the extent losses may be in the extent losses may be excluded companies are responsible to the Duke Energy Company's responsible to the extent losses may be excluded or exceed or exceed losses may be excluded companies' s is responsible to the extent losses may be to the extent losses may be excluded or exceed the Duke Energy is responsible to the following losses may be to the extent losses may be responsible losses may be responsible to the following losses may be responsible to the extent losses may be excluded or exceed losses may be excluded or losses may be excluded or exceed losses may be responsible to the extent losses may be responsible to the extent losses may be responsible to the Duke Energy Committed losses may be excluded or exceed losses may be excluded to the extent losses may be excluded or exceed or other matters may be responsible to the Duke Energy is responsible to the extent losses may be excluded losses may be excluded or exceed financial position.Each company is responsible to the extent losses may be excluded losses may be responsible to the Duke Energy Company is responsible to the company is excluded or exceed losses may be excluded or exceed the extent losses may be responsible to the extent losses may be excluded or other matters to the extent losses may be responsible to the Company is responsible to the Company is responsible losses may be excluded or position.Each company is responsible to the Duke Energy is responsible to the amount of Duke Energy Efficiency losses to the Duke Energy Transition Asset Retirement Asset Retirement Asset Retirement to the Duke Energy may be responsible to the Duke Energy is responsible to the Duke Energy may be responsible to the extent losses may be responsible to the extent losses may be excluded or exceed the Duke Energy Management's financial position losses may be responsible to the Duke Energy Company is responsible to the extent losses may be responsible to the Duke Energy is responsible to the Duke Energy and each company is responsible losses may be excluded or exceed Duke Energy Management's responsibility.Each company is responsible to the extent losses may be responsible to the extent losses may be excluded or exceed losses may be responsible to the extent losses may be responsible to the extent losses may be responsible to"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?",
        "options": {
            "A": "The deficiency is recognized as a capital gain.",
            "B": "A new investment strategy is implemented.",
            "C": "The deficiency is considered due to credit loss and recognized in earnings.",
            "D": "A penalty is imposed on the financial institution.",
            "E": "The loan agreement is renegotiated.",
            "F": "An automatic increase in interest rate is applied."
        },
        "LLM_original_answer": [
            "What of the allowance for the allowance for the upside of the scenario would have resulted in a decrease in the allowance for our allowance for the allowance of the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance would have the allowance for the allowance for the allowance for the allowance for our allowance for the allowance charges.Use of the allowance of the allowance for the allowance for the allowance for the allowance use of the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the upside scenario would have been incremental decrease.Use of the allowance for the allowance for our business mix of the allowance.Use of the allowance for the allowance for the allowance for the allowance in the allowance for the allowance for the allowance for the incremental decrease.Use of the allowance for the allowance for the allowance charges.Any use of the allowance for the allowanceUse of the allowance for the allowance for the allowance.Use of the allowance charges and related party loan portfolio performance.Use of the allowance for our business, or recovery.Use of the allowance for the allowance for more than the allowance for the allowance for our allowance for our business, or reduction in the allowance for the allowance for the allowance for our business would have been the upside scenario would have resulted in a decrease in the allowance of the allowance for loan participations. of the allowance for the allowance for Eastern Bank Use of the allowance for our allowance.Use of the allowance would have resulted in the allowance for the allowance for the allowance for the allowance for a material decrease in the allowance would have use of the allowance for the allowance for the allowance for the incremental decrease in the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance of the allowance would have resulted in the allowance for the allowance for the allowance for the allowance.Use of the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance would have been incremental decrease.Use of the allowance for the allowance for the following the allowance for the \u201cup the allowance for the allowance for the allowance for the allowance for the recovery.Use of the incremental decrease in a reduction in the allowance for the allowance for the allowance would have not otherwise incremental decrease in the allowance would have been incremental decrease in the allowance for the allowance for the allowance for the foregoing use of the allowance for more than the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance for the allowance of the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?",
        "options": {
            "A": "Conduct annual cybersecurity audits",
            "B": "Formally report material cybersecurity incidents",
            "C": "Hire a dedicated cybersecurity officer",
            "D": "Implement a company-wide cybersecurity training program",
            "E": "Encrypt all data and communications",
            "F": "Report cybersecurity budgets annually"
        },
        "LLM_original_answer": [
            "What is, as well as well as well as potential future product sales and product sales, as a product sales, as well as well as well as well as well as well as well as well as well as well as well as well as the potential future fees and royalty on future product, as well as well as well as well as well as well as well as well as well as well as potential future product sales and product and product fees and fees and royalty on future fees and royalties on future product sales and royalty and royalty payments, as well as potential future product fees and product sales and product fees and fees and royalty on future product fees and milestone payments, as well as well as well as well as well as well as well as well as well as well as well as well as well as-yield and milestone payments, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as royalties on- as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as potential future fees and royalty payments, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as potential future product sales and product sales and royalties on future milestone payments, as well as well as milestone payments on future products, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which document was filed on May 23, 2023?",
        "options": {
            "A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021",
            "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020",
            "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021",
            "D": "Registrant\u2019s Form 8-K",
            "E": "Registrant's statement of changes in beneficial ownership",
            "F": "Registrant's proxy statement"
        },
        "LLM_original_answer": [
            "The aggregate margin declined margin declined due to the aggregate margin declined due to the aggregate margin declined margin declined due to the aggregate margin declined due to the aggregate margin declined due to the aggregate margin declined due to the change in the aggregate margin declined due to which may befitting the change in the aggregate margin declined due to the aggregate margin declined due to the aggregate margin due to our business and the change in the aggregate margin due to the aggregate marginally the aggregate margin declined due to the aggregate margin declined due to the aggregate margin declined margin declined due to the aggregate margin decline due to the aggregate margin declined due to the aggregate margin declined due to the aggregate margin declined due to the change in the aggregate margin declined due to the aggregate margin declined margin declined due to the aggregate margin due to originate and the aggregate margin declined margin declined due to the aggregate margin declined due to the aggregate margin declined due to the aggregate margin declined due to our business model declined due to the aggregate margin declined due to the aggregate margin declined due to which may be\u00ad\u2014both the change in the margin and/or the aggregate margin declined due to the aggregate margin margin declined due to the aggregate margin declined margin and the aggregate margin declined marginally.The aggregate margin declined margin declined due to the aggregate margin declined due to the aggregate margin declined due to the aggregate margin declined due to the aggregate margin declined due to which could have declined due to the aggregate margin declined due to the change in the aggregate margin and the aggregate margin declined due to the aggregate margin declined due to the aggregate margin due to the aggregate margin declined due to the aggregate margin declined due to the aggregate margin declined due to the aggregate margin declined margin declined due to which could not being flat and the aggregate margin declined due to the change of our business model 38marginThe aggregate margin and the aggregate margin margin declined due to the margin due to the aggregate declined due to be to which could be flat margin declined margin and the aggregate margin declined due to which declined due to the change in the aggregate margin declined due to the change in the aggregate margin due to the aggregate margin and the aggregate margin declined due to our business disruptions in our business disruptions in the aggregate margin and the aggregate margin and/or the aggregate margin due to originate and the aggregate margin due to the aggregate margin due to the aggregate margin due to the aggregate margin declined due to which may decline in our business disruptions in the change in the margin due to originations and the aggregate margin declined due to our business disruptions in the aggregate margin due to the aggregate margin declined due to which is flat margin declined due to"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What penalty does the GDPR allow data protection authorities to impose for violations?",
        "options": {
            "A": "Suspension of business operations",
            "B": "Revocation of data processing licenses",
            "C": "Fines up to \u20ac20 million or 4% of annual global revenues",
            "D": "Mandatory public apology",
            "E": "Mandatory cybersecurity audits only",
            "F": "Compulsory staff retraining programs"
        },
        "LLM_original_answer": [
            "CERAs a product, or a third parties, or more than one or a reservation of a reservation of one or all or a reservation of the third parties to the subject to be reserved rights to the reservation of rights by one or more third parties, including a BLA BLAFTER A reservation of the application for the reservation of rights to the FDA approval by one or a reservation of a reservation of rights by one or more third parties, including a reservation of rights by one or more third parties, among other third parties of rights by one or more than a reservation of a reservation of a reservation of one or a reservation of one or a reservation of rights reserved rights reserved rights by one or a reservation of the FDA, or one or one or one or a reservation of rights by one or a reservation of rights by one or more third parties, including a third parties, and, or a reservation of rights by one or more than one or one or a reservation of rights by one or more third parties, among other third parties to be subject to be subject to be, among other parties subject to be, including, and other types of one or a reservation of one orally a reservation of rights by one or more third parties to be subject matter of rights and/or more than a reservation of the third parties, including a reservation of a reservation of rights to be a reservation of right to the applicant for the applicant, including a reservation of rights with respect of one or a new drug approval by-law, a reservation of more third parties, including a third parties to which one or more than one or a reservation of the right to be subject to which one or more generally applicable to the third parties to be subject to the BLAFTER APPLICATION OFA reservation of the FDA approval of the FDA may be subject to which is not subject to the FDA approval by the FDA approval of rights by one or more third parties, or a third parties to one or subject to be subject to a reservation of which one or one or more generally subject to the FDA, or more than one or a PRVOLUME of a reservation of a reservation of rights by one or more third parties, including a third parties to the one or a reservation of rights by one or more third parties, including a reservation of a reservation of a reservation of a reservation of a reservation of a reservation of a reservation of a reservation of one orreservations of rights by one or more third parties, including third parties, including a one or one or a third parties, including a reservation of a reservation of"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What could be a consequence of failing to comply with laws governing international business practices?",
        "options": {
            "A": "Immediate dissolution of the business",
            "B": "Substantial civil and criminal penalties",
            "C": "Automatic approval for business expansion",
            "D": "Tax incentives and holidays",
            "E": "Increased development of new products",
            "F": "Reduction in employee numbers"
        },
        "LLM_original_answer": [
            "Adeemedical trials, or, orphans required by the results of the results of clinical trials in the level of clinical trials may be approved product candidates for the results of the level of clinical trials may not more than the results of the level of the results of the level of the results of the results of clinical trials may not meeting the FDA approval for the level of clinical trials may not only be required by the level of the level of clinical trial and, or the results of clinical trials may be required by the level of clinical trials must-readiness of statistical significance required by the results of the results of clinical trials may be approved for the results of the results of clinical trials may beaknowledgmentation\n_ctxt\n batchSize 44orphanoevidence of clinical trials must be required by the results of clinical trials or may be the level of clinical trial results of the level of clinical trials may beacquisition required by the level of the results of the FDA, or the FDA\u2019sunfortunately, or clinical trials for the requirements of clinical trials in the results of clinical trials may be required by the level of clinical trials may not only in the results of clinical trials may be\u00ad\u2014see if the results of the FDA\u2019safety and the clinical trials for the level of the level of the FDA requirements of statistical significance required by the FDA.44level of the results of the results of the FDA\u2019s statistical significance required by the level of the results in the results of the results of clinical trials may becertain the level of statistical significance required by the FDA.The results of clinical trials in the results of the results of the results of clinical trials in the results of the results of the results of the results of the requirements for the results of the results of the results of the level of statistical significance required by the FDA\u2019s regulatory submissions for the results of clinical trials may be the results of clinical significance required by the results of clinical trials in the results of clinical trials may be\u00ad\u2014such as well as well as well as well as well as well as well as well as well-being-developedis a\n\n\n_TACONTOPASSISTHAResafety and the FDA requirements of the results of the results in the results of clinical trials in the level of the standards of clinical significance required by the results of clinical trials may not meet the results of clinical data exclusivity\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?",
        "options": {
            "A": "$2.0 billion",
            "B": "$19.0 billion",
            "C": "$1.6 billion",
            "D": "$22.6 billion",
            "E": "$8.4 billion",
            "F": "$270 million"
        },
        "LLM_original_answer": [
            "As we above, which was based on what we consider to be an impairment discussed above, or other other discussed above, which was based on the discussed above, which was based on the other discussed above, which was based above, which was based on the impairment discussed above, which was based on what we consider to be an other risk discussed above, which was an other than an other party, which was based on the discussion, which we discussed above, which was based on the discussed above, which was based on what we discussed above, in our discussed above an other discussed above, which was based on what we consider to be discussed above, which was based on what we consider to be an other impairment discussed above, which was based on the discussed above, or other than the impairment discussed above, which was based on the impairment discussed above, which we consider to the discussion above, which was based on the impairment discussed above discussed above discussed above discussed above discussed above discussed above discussed above, which was based on the discussion discussed above, which was an impairment discussed above, which was discussed above, which was an other than we consider to be an other than is an impairment discussed above, which was based on the consider to be an other than we consider to be an other discussed above the following the discussion discussed above, which is discussed above, which was based on the impairment discussed above, which was based on the impairment discussed above, which was based on what we consider to be an other impairment discussed above, which we consider to be an other conditions discussed discussed above, which was based on the other discussed above, which was based on the other discussed above, which was based on the impairment discussed above, which was discussed above, which was based on the discussion above, which was discussed above, which was discussed above, which was based on the impairment discussed above, which was an other discussed above, which was an other discussed above, which was based on what we consider to be an impairment discussed above, as an other conditions discussed above, which was discussed above, which was based on what we consider to be an other impairment discussed above, which was an impairment discussed above the impairment discussed above discussed above, which was discussed above the following the discussed above, which was discussed above, which was discussed above, which was based on the discussion above, which was based on the discussion of the discussed above, which was based on-going what we consider to the discussed above, which was discussed above, which was discussed above, which was based above, which was based on what"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?",
        "options": {
            "A": "By adding a fixed percentage to the policyholder account balance",
            "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract",
            "C": "By charging a surrender fee immediately upon issuance",
            "D": "By applying a uniform rate to all existing liabilities",
            "E": "By using a simple average of all deposits",
            "F": "By increasing withdrawal charges over time"
        },
        "LLM_original_answer": [
            "Based on and adjusted net investment carrying values at adjusted net investment portfolio (losses (losseseternalized unrealized (losses (losses (losses (losses (losses Asset carrying values (losses exclude unrealized (losses), as well-dividend values (losses (losses, which we use (losses exclude unrealized gains (losses, our business \u2014 Brighthouse carrying values exclude unrealized net investment portfolio values exclude unrealized carrying values of such as well (losses unrealized (losses, as well as well as well-being unrealized gains (losses (losses (losses may not (losses, which may be adjusted net investment portfolio (losses (income (losses \u2014 A carrying values (losses (losses (losses (losses Asset carrying values at adjusted net investment and adjusted net investment income (losses (losses net investment income.Asset carrying values exclude unrealized gains (losses.Asset carrying values (losses.Asset carrying values (losses net investment income (losses (losses (losses (losses (losses values.Asset carrying values (losses adjusted net investment income (carrying (losses (losses, as well (losses (losses (losses exclude unrealized (losses (losses (losses to the40.Risks (losses (losses (losses Asset carrying values exclude unrealized unrealized gains (losses, as well (losses (net investment (losses unrealized gains (losses), adjusted net investment (losses (losses (losses exclude unrealized (losses (losss (losses (losses (losses (losses (losses, as well-being (losses (net investment portfolio values exclude unrealizedue unrealized net investment portfolio (lossesource of adjusted net investment income.Asset carrying values exclude unrealized gains (losses), as well as well-dividenduced net investment portfolio values of investment income (income (losses (losses exclude unrealized net investment income (adjusted net investment portfolio (losses (losses (losses, adjusted net investment income (losses (losses exclude adjusted net investment portfolio (losses (losses (losses (losses (losses (loss (losses (losses unrealized (dividuced by (losses (losses (losses (losses (losses (lossesource (losses (losses (losses (losses"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What consequence might result from compromised quality or accuracy of consultant services in clinical trials?",
        "options": {
            "A": "Immediate market approval for products",
            "B": "Increased research funding",
            "C": "Extended, delayed, or terminated clinical trials",
            "D": "Expansion of the organizational workforce",
            "E": "Higher stock market valuation",
            "F": "More partnerships with external organizations"
        },
        "LLM_original_answer": [
            "What may be important to the development of compromised quality or Risks Related to the Risks Related to the development of our business.Risks Related to the Risks Related to the development of the Development of our business.Risks Related to the development of Ris Related to the Development of Our business.Risks Related to the development of Clinical Trials Related to the Company Related to the Risks Related to the development of our business.Risks Related to the Risks Related to the development of our business may be important to the development of the development of Our Business Risks Related to the Development of Consultant Services Related to the Risks Related to the development of the Treatment of the Development of our product or products that may be important to the Important to the development of our product candidates or Products Related to the development of our product candidates may be important to the Important to the Development of our business.Risks Related to PAHypat the development of our business.Risks Related to the development of which may be important to the development of our business.Risks Related to the development of our product or products that may be the development of our business.Risks Related to the Development of our business.Risks Related to the development of Multiple Choice of our business.Risks Related to the Development of our business.Risks Related to the Development of our Business Risks Related to the R&Dise Related to the Rely Multiple- Risks Related to the Risks Related to the Development of our business.Risks Related to the Risks Related to the Risks Related to the Development of Importance to the development of the development of our business.Risks Related to the Rely important to the Development of our product Risks Related to the Risks Related to the Development of Risks Related to the development of Risks Related to the development of the development of the Development of Our Risks Related to the development of Our Risks Related to the development of our business.Risks Related to the development of Products Related to the Risks Related to the Risks Related to the development of our business.Risks Related to the development of Risks Related to the development of the Development of our business.Risks Related to the Important to the development of Our Multiple Related to the development of the development of Our Risks Related to the Company Related to the development of Risks Related to the Development of our business.Risks Related to the Development of our business.Risks Related to Clinical Trials Related to the Development of our business.Risks Related to the Risks Related to the development of our business.Risks Related to the Risks Related to the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "According to ASC 852, how should transactions and events directly associated with a reorganization be reported in financial statements?",
        "options": {
            "A": "As part of ongoing operating expenses",
            "B": "As extraordinary items",
            "C": "Under liabilities subject to compromise",
            "D": "In a separate section as Reorganization items, net",
            "E": "As a footnote disclosure only",
            "F": "Combined with realized gains and losses"
        },
        "LLM_original_answer": [
            "According the equivalent of the equivalent of the equivalent of Core Scientific Co. 20 of the equivalent of the equivalent of Core Scientific Holding Co. the equivalent of Core Scientific Co. 20 to the equivalent of Core Scientific Co. The reverse of Core Scientific Co. Co. The reverse recapital was treated as the equivalent of Core Scientific Co. The reverse recapitalizing the equivalent of Core Scientific Co. 2021. was the equivalent of the reverse recapital was the equivalent of Core Scientific Co. The reverse recapitalization was treated as the equivalent of Core Scientific Holding Co. The reverse recapital was treated as the equivalent of Core Scientific Co. 20 the equivalent of Core Scientific Co. The reverse recapital was treated as a party being treated as the equivalent of Core Scientific Mining Operations of Core Scientific Co. The reverse recapitalization of Core Scientific, among Core Scientific Co. The reverse recapital equivalent of Core of Core Scientific Holding Co. The reverse recapital equivalent of Core Scientific Holding Co. The reverse recapitalization of the reverse recapital was the equivalent of Core Scientific Co. The reverse recapital reverse recapital was the reverse recapital the equivalent of Core Scientific of Core. The reverse recapital equivalent of Core Scientific was treated as the equivalent of Core Scientific Scientific Co. The reverse recapital Company\u2019s reverse recapital was the equivalent of the reverse recapital was treated as the equivalent of Core Scientific Operations and/or Core Scientific Co. The reverse recapital was the equivalent of Core Scientific Co. The reverse recapital was the equivalent of Core Scientific Core Scientific Co. The reverse the equivalent of the reverse of Core Scientific Co. The reverse of Core Scientific Holding Co. was treated as the equivalent of Core Scientific Co. The reverse recapital was treated as the equivalent of Core Scientific Co. The reverse recapital treated as the equivalent of Core Scientific Co. The reverse recapital equivalent of Core Scientific Core Scientific operations of the equivalent of Core Scientific Co. The reverse recapital was the equivalent of Core Scientific Co. The reverse recapital Co. The reverse recapitalized Core Scientific Co.  equivalent of Core Scientific Co. The reverse recapital of Core Scientific Co. The reverse the reverse the equivalent of Core Scientific Co. The reverse the equivalent of Core Scientific Co. The reverse the equivalent of Core Scientific Holding Co. 24 equivalent of Core Scientific Co. The reverse the equivalent of the equivalent of Core Scientific Co. The reverse of Core Scientific Co. 21 was the equivalent of Core Scientific Co. The reverse recapital of Core Scientific Co. The"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What condition must Duke Energy Ohio meet to declare and pay dividends?",
        "options": {
            "A": "Approval from state regulatory commissions",
            "B": "Approval from the Federal Energy Regulatory Commission",
            "C": "Prior authorization of the PUCO",
            "D": "Meeting tangible net worth requirements",
            "E": "Approval from the Duke Energy board",
            "F": "Retention of minimum working capital"
        },
        "LLM_original_answer": [
            "What information and assets and all assets and continuing operations are within the Duke Energy and continuing operations are within the U.Substantially all assets and all assets and revenues from continuing operations are within the U.S.D Duke Energy and continuing operations are within the Duke Energy and substantially all assets and continuing assets and substantially all assets and revenues and revenues and revenues and revenues and revenues and continuing operations are within the information and assets and revenues and revenues and revenues from continuing information from continuing operations are within continuing information is within the Duke Energy and the Duke Energy and revenues and revenues and revenues and Geographical all and all assets andContinuing operations are within the U U.S. Duke Energy and revenues and revenues and revenues and operations and revenues and substantially all within the Duke Energy and revenues from continuing operations and continuing operations are within the Duke Energy and revenues and continuing operations are within assets and continuing assets and revenues and assets and assets and all assets and assets and assets and revenues and revenues and revenues and all assets and continuing operations and revenues and continuing operations and revenues and revenues and Suststantially all assets and geographical information and revenues and revenues and substantially all assets and revenues and/or continuing operations are within the U.S assets and revenues from continuing operations and revenues from continuing operations are within the U U U.S. All assets and assets and continuing operations from continuing operations and/or continuing operations are within substantially all assets and all assets and substantially all assets and continuing operations andContinities and revenues and continuing operations and all assets and InformationSubstantially all assets and continuing operations and assets and assets and assets and all assets and revenues from continuing operationsDuke the U.S.Substantially all assets and all Duke Energy and all assets and assets and continuing operations are within the U U.Substantially all information and continuing operations are within the U U U.S."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What happens if the estimated cash flows do not support the amortized cost according to the document?",
        "options": {
            "A": "The deficiency is recognized as a capital gain.",
            "B": "A new investment strategy is implemented.",
            "C": "The deficiency is considered due to credit loss and recognized in earnings.",
            "D": "A penalty is imposed on the financial institution.",
            "E": "The loan agreement is renegotiated.",
            "F": "An automatic increase in interest rate is applied."
        },
        "LLM_original_answer": [
            "Based on an entity indicates that a company for Impaired indicates that a company indicates that a \u201caffects that a \u201cASU.Sec 2026-ASU 2016-13-13 indicates that a company indicates that a number of the ASU 2016- ASU 2016-13 indicates that Eastern Bank 2016-13 indicates that a \u201cControlled by the ASU.SeeThe following the ASU.SU.SeeASU.Sec indicates that a \u201cof Impairmenting that a13 indicates that a bank holding that a company indicates that a \u201cthat a \u201cother ASU 2016-13-13 indicates that a financial institution\u2019s Condition for Impair 2021-13Indicates that indicates that a\nASU.Sec indicates that a  ASU indicates that a 2016 indicates that a Reasonable Impaired ASUASUASU 2016-13 indicates that a ReasoningIndicates that ASUASU 2016-13 indicates that a financial institution\u2019s impairment assessment of ASU.SASUASU 2023 indicates that a company indicates that a financial InstitutionsIndicates indicates that a Credit 2016-13 indicates that a Bankruptcy ASU 2016-13 indicates that a company indicates that a 2016 indicates that indicates that indicates that a 201 that a bank holding company indicates that a company that a financial institutions that a \u201ca indicates that a \u201crequires that a company indicates that a company indicates that a company that a company or indicates that a company indicates that a company indicates that a company indicates that a financial institutions that a)ASU.SAU 2016-13 indicates that a company indicates that a13-13 indicates that a financial institutionally Indicated indicates that a company indicates that a financial institution, or loss of 2016-13 indicates that a 2016 indicates that a Probability of ASU 2016 indicates that a company for the 13 indicates that a financial institutionIndicates that ASUCCU.SAU 2016 indicates that a indicates that Eastern Bank Regs indicated that a Resulting ASU 2016-13 indicates that a \u201creasonable indicates that a Significant Indicate that a \u201cOther Regulatory Capitalized that a company indicates that a credit impairment ASUCC 2016 indicates that a financial institutions indicates that a Lossesibility ASU 2016-13 indicates that a financial institution indicates that a financial institution\u2019s ability to ASU 2016 indicates that"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the new cybersecurity rule adopted by the SEC primarily require companies to do?",
        "options": {
            "A": "Conduct annual cybersecurity audits",
            "B": "Formally report material cybersecurity incidents",
            "C": "Hire a dedicated cybersecurity officer",
            "D": "Implement a company-wide cybersecurity training program",
            "E": "Encrypt all data and communications",
            "F": "Report cybersecurity budgets annually"
        },
        "LLM_original_answer": [
            "What is subject to be covered by the approval or other risks related to the applicable to be submitted to the in accordance with respect to our transition into operating as a clinical trials and public company, and for any of the FDA, among other than over, among other public company by our public company, and as a licensed by the transition into operating as well as a public company. For more fully expect to operate as we expect operating as well as we expect to operating as a public company, and as we expect that we continue our transition into operating as a public company, we expect to continue our transition into operating as we expect to operating as we expect to operating as a public company, and as well as we expect our transition, and as a public company, and as we expect to operating as a public company, and as we expect to operating as a public company, and as we expect to continue our transition into operating as we expect to continue our transition into operating as well as we expect our continued our continued our transition into operating as well as we expect to continue our transition and as well-established as well as we continue our transition into operating as a public company, we expect to continue our transition, and subject to be directed to our transition into operating as well as we expect to operating as we expect our transition into operating as a public company, we expect to operating as we expect to operating as a public company, and as a number of our continued our transition into operating as we expect that we expect, and public company and as well as well as well as well as well as well as well as well as well as we expect toplinearvinvested company, and as we expect to operating as we continue our transition into operating as we continue our transition into operating as well as we continue our transition into operating as a public company by the level of our transition into operating as well as well-established public company\u2014among other public company of the results of the our transition into operating as we expect to some of the transition into operating as well as we continue our transition into operating as a public company, and, and to continue our transition, and for the following the oversight of the our transition into operating as a non- and as well as we continue our transition into operating as a public company, and in operating as we expect to the public company, and as a public company, and as well as we expect to operating as we expect to a public company, and as a public company, we expect to operating as a public company, and as we expect that we"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which document was filed on May 23, 2023?",
        "options": {
            "A": "Registrant's Quarterly Report on Form 10-Q for the period ended June 30, 2021",
            "B": "Registrant's Annual Report on Form 10\u2011K for the year ended December 31, 2020",
            "C": "Registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2021",
            "D": "Registrant\u2019s Form 8-K",
            "E": "Registrant's statement of changes in beneficial ownership",
            "F": "Registrant's proxy statement"
        },
        "LLM_original_answer": [
            "The Code of Business Conduct and Ethics for Business Conduct of Business Conduct and/or the Code of either the Code of Business Conduct and Ethics for Senior Financial Officers for Business Conduct of Business Conduct and Senior Financial Officers for Senior Financial Officers from either from either the the Code of Business Conduct and Ethics for the Code of Business Conduct and the Code of Business Conduct for Senior Financial Officers from either the Code of Business Conduct of Business Conduct and/or the Code of Ethics for Senior from either the Code of Business Conduct and/or the Code of Business Conduct of Business Conduct of Business Conduct and/or the Business Conduct and the Business Conduct of Business Conduct and Ethics for Business Conduct and/or the Business Conduct and the Financial Officers for Senior Financial Officers from either the Code for Senior Financial Officers from either the Code of Business Conduct and the the Code of Business Conduct and the Code of the Code of the Code of Business Conduct and the Code of Business Conduct and Ethics for Senior Financial Officers is summarized or the Code of Business Conduct and/or the Code of Business Conduct and Business Conduct of Business Conduct and the Business from the Code of Senior Financial Officers from either the Code of Business Conduct and/or the Code of either the Code of Business Conduct and/or the Code of either the Company of either the Code of Business Conduct and Ethics for Senior Financial Ethics for Senior Financial Officers from either the Business Conduct and/or from either the Code of Oc from either the Code of Business Conduct and/or the Code of Business Conduct of Business Conduct of either the Business Conduct and Ethics or the Code of Business Conduct for Senior Financial Officers from either the Code of Senior from either the Code of Business Conduct and Senior Financial Officers for Senior or the Business Conduct and the with respect either the Code of the Code of Business Conduct and/or the Code of Business Conduct and the Code of Ethics for either the Code of Business Conduct and/or the Code of Business Conduct and the Code of any of any of Senior Financial Officers from either the Code of Business Conduct and Business Conduct and the Code of Business Conduct for Senior Financial Officers may be subject or the Business Conduct and Ethics for Senior Financial Conduct for Senior Financial Officers are described in the Code of Business Conduct and Ethics for Senior Financial Officers for Senior or the Code of Business Conduct and/or the Code of Business Conduct and the Code of Business Conduct and/or the Code of Business - Business of Business Conduct and Ethics for Business Conduct and Ethics or the Code of Business Conduct and/or the Code or Business Conduct and Ethics or the Code of Business Conduct for Senior Financial Officers must be required the Code of Business Conduct and Ethics for Business Conduct and the Code of"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What penalty does the GDPR allow data protection authorities to impose for violations?",
        "options": {
            "A": "Suspension of business operations",
            "B": "Revocation of data processing licenses",
            "C": "Fines up to \u20ac20 million or 4% of annual global revenues",
            "D": "Mandatory public apology",
            "E": "Mandatory cybersecurity audits only",
            "F": "Compulsory staff retraining programs"
        },
        "LLM_original_answer": [
            "What are deemed to offer protection, or third countries, or third countries, or third countries, or recognized to offer adequate data to offer, or third countries. This is the EDC, or third countries that have been deemed to offer, or third countries, or third countries, or third countries, or third countries, or third countries that have been deemed to offer, or that have not to offer, or third countries that have not been deemed to offer a level of an adequate data that offer a country that offer to offer, or third countries. The FDA-approved to offerers of adequate data. The FDA/3. The FDA: TSC, or third countries. The FDA, or third countries, or third countries that have been identified, or third countries. The TSC, or third countries. The U/SF/UK, or third countries, or third-party to offer a level of a third countries, or third countries that offer a third countries that offer that offer that have not deemed to offer that have not been deemed to offer a third countries that offer of TSC.However, or TCR/HL, or TSCC, or, or third countries that have been deemed to recognize the third, or, or, or, or, or TSCC. or, or that have been identified from the same as a third countries that have not to offerers, or third countries that have been granted to offer a-tumor third countries, or third countries that have not deemed to recognize, or third countries, or TCRs, or T cells, or TSC, or third countries, or deemed to offer protection against the same, or third countries, or, or T cells, or TSCs, or third countries, or the third countries, or third countries, or third countries, or TSC, or third countries, or third countries. The TSCCyt offer, or third countries, or third countries that have not yet to offer protection by the same, or deemed to provide adequate to provide adequate data, or third countries, or third countries that have been deemed to offer a third countries that have been deemed to offer, or third countries. The FDA, or that have not to offer, or that have not to offer, or third countries. The FDA, or third countries. or third countries. to offer, or third countries. or TCRs to offer a high-afford, or, or, or, or, or, or third countries that have not only.The FDA, or"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could be a consequence of failing to comply with laws governing international business practices?",
        "options": {
            "A": "Immediate dissolution of the business",
            "B": "Substantial civil and criminal penalties",
            "C": "Automatic approval for business expansion",
            "D": "Tax incentives and holidays",
            "E": "Increased development of new products",
            "F": "Reduction in employee numbers"
        },
        "LLM_original_answer": [
            "F, or, or, or, or, or, or, or any future products could be, or, or, or, or, or, or, or, or, or, or, or, ability to, or, or, or, or, or, or, or, or, or, or, or any future products, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or any future products, or, or any future collaborators\u2019, or any future products could be limited products could be limited, or any future products could be, or, or, or, or any future products could be limited, or any future products could be limited, or any, could be, or, or, or any, or, or, or any future products could be limited, or, or, or any future products could be limited by, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or, or any, or, or, or, or, or, or, or, or, or, or, or, or, or any future products could be limited, or, or, or, or, or, or, or, or, or, or, or, or, or, or, products could be limited, or, or, or, or, or, or, or, or, or any future products, or any future collaborators\u2019, ability to market any future products could be limited, or, or, or, or, or, or, or, or, or any future products could be limited, or, or, or, or, or, or, or, or, or, or any future products\u2019.Or, or, or, or, or, or, or, or, or, or, or, or, or, or any future products could, or, or, or, or, or, or, or, or, or, or, or, or, or, or any future products could be limited, or, or, or, or, or, or, or, or, or, or, or, or, or any future products could be, or, or, or, or, or, or, or, or, or,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "As of December 31, 2023, what was the amount of outstanding debt related to senior notes?",
        "options": {
            "A": "$2.0 billion",
            "B": "$19.0 billion",
            "C": "$1.6 billion",
            "D": "$22.6 billion",
            "E": "$8.4 billion",
            "F": "$270 million"
        },
        "LLM_original_answer": [
            "As our estimates of settlements change or the final tax outcome changes, to the final tax outcome changes, our estimates change, our business extent our estimates of settlements change or the final tax outcome changes, our final tax outcome changes in the final tax outcome changes in our final tax outcome of settlements change in the final tax outcome change, our final tax outcome change or the final tax outcomes change or the final tax outcome changes or the final tax settlements change our final tax outcome of settlements change, our final tax outcome changes, our final tax outcome of settlements change or the final tax outcome changes, to the final tax outcome our final tax outcomes change, our final tax outcome changes, our final tax outcome changes or the final tax outcomes change or the final tax outcome change or the final tax outcome of our final tax outcome of our estimates change, our final tax outcome, our business, to the final tax settlements change or the extent our extent our final tax outcomes change, our final tax outcome changes, the final tax settlements change, our final tax outcome changes, we rely on our business and our estimates of our estimates of settlements change, if our business and the final tax outcomes change, our business and the final tax outcomes change our business and our business and our business and operations change, we believe our business and our business and to the final tax outcomes change, or the final tax outcome of settlements change or the final tax outcome changes, the final tax outcome changes, the final tax outcome, our final tax outcomes change or our business.Business our tax outcome changes or the final tax outcomes change or the final tax outcomes change or the final tax outcome of our business and to the final tax related to the final tax outcomes change, our final tax outcome changes, to the final tax outcome, our business operations change or the final tax outcomes change our business and the final tax outcomes change or the final tax outcome of our final tax outcome, to the final tax outcomes change, our business operations change, to the or the final tax outcome changes or the final tax outcomes change or the extent our final tax outcomes change or the final tax outcome of settlements change, the final tax the extent our estimates of settlements change or the final tax outcome changes, our final tax outcome changes or the extent our estimates change or the final tax outcomes change or the final tax outcome changes, our final tax outcome of settlements change or the final tax outcome of our final tax outcome changes in our final tax outcome changes or the final tax outcome of settlements change, our final tax outcome changes, our business and our business and the final"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 50,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "How does the Company calculate additional liabilities for certain product features like secondary guarantees on universal life insurance contracts?",
        "options": {
            "A": "By adding a fixed percentage to the policyholder account balance",
            "B": "By projecting death benefits when account balance is zero and recognizing benefits over the contract",
            "C": "By charging a surrender fee immediately upon issuance",
            "D": "By applying a uniform rate to all existing liabilities",
            "E": "By using a simple average of all deposits",
            "F": "By increasing withdrawal charges over time"
        },
        "LLM_original_answer": [
            "Questions: (GainbridgeHeightSecuritiesAct)For the Years Ended December 2023, 2023, 2023, 2023, 2024, 2023, 2023, 2024)The VAs of the New York Mutual Life Insurance Regulatory 31, 2023, 2023, \ufeff\n\uff18\n\uff12\uff10\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?",
        "options": {
            "A": "Value-added tax",
            "B": "Excise tax",
            "C": "Income tax",
            "D": "Minimum tax",
            "E": "Sales tax",
            "F": "Capital gains tax"
        },
        "LLM_original_answer": [
            "Based on the provided document, the type of tax imposed on certain large corporations' book income according to the IRA, or the Company Profile:"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What change was made to the Mass Mutual Barings loans in August 2022?",
        "options": {
            "A": "The interest rate was increased to 12%.",
            "B": "The loan term was extended by 12 months.",
            "C": "Principal payments were deferred for six months.",
            "D": "The interest was capitalized into the principal.",
            "E": "The loans were converted into equity.",
            "F": "The loans were forgiven entirely."
        },
        "LLM_original_answer": [
            "Based on the provided document, the change made to the Mass Mutual Barings loans in August 2022 was that the principal payments were deferred for six months beginning with payments due in August 2022. This is option C from the given multiple-choice options."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?",
        "options": {
            "A": "January 2024",
            "B": "December 2024",
            "C": "January 2025",
            "D": "January 2026",
            "E": "December 2026",
            "F": "January 2027"
        },
        "LLM_original_answer": [
            "Based on the provided document, Duke Energy Florida's new three-year rate plan is expected to begin on January 15, 2024."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "How is revenue from administrative and management activities recognized?",
        "options": {
            "A": "As soon as the service contract is signed",
            "B": "Once services are rendered in full",
            "C": "When fees are prorated over a twelve-month period",
            "D": "As performance obligations are satisfied",
            "E": "When derivative instruments reach fair value",
            "F": "Upon evaluation of hedge transaction effectiveness"
        },
        "LLM_original_answer": [
            "Based on the provided document, the revenue from administrative and management activities is recognized as performance obligations are satisfied (Option D). The document does not mention any specific revenue recognition for administrative and management activities, but it does detail various aspects of the company's financial activities, including mortgage loans, real estate owned (OREO), and other assets. The closest match to the revenue recognition for administrative and management activities is when performance obligations are satisfied, as this aligns with the general revenue recognition principle of recognizing revenue when the entity has performed its obligations under a contract."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?",
        "options": {
            "A": "Increase in market price",
            "B": "Improvement in company reputation",
            "C": "Expansion of company operations",
            "D": "Reduction in market price",
            "E": "Increase in dividend payouts",
            "F": "Stabilization of trading volume"
        },
        "LLM_original_answer": [
            "Question: What is a potential effect of the public market's perception that a large number of shares might be sold?\n\nAnswer: D: Reduction in market price"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Where are the fair value gains and losses of financial liabilities reported?",
        "options": {
            "A": "Within Pledged MSR liability expense in the consolidated statements of operations",
            "B": "As financing activity in the consolidated statements of cash flows",
            "C": "Within MSR valuation adjustments, net in the consolidated statements of operations",
            "D": "Only in the footnotes of the financial report",
            "E": "As part of the equity section on the balance sheet",
            "F": "Within the depreciation accounts in the income statement"
        },
        "LLM_original_answer": [
            "The fair value gains and losses of financial liabilities are reported within MSR valuation adjustments, net in the consolidated statements of operations."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one potential outcome of post-grant review proceedings on a patent?",
        "options": {
            "A": "Automatic extension of the patent term",
            "B": "Increased market value for the patent holder",
            "C": "Invalidation of the patent",
            "D": "Requirement to share technology with competitors",
            "E": "Guaranteed protection against all legal challenges",
            "F": "Immediate royalty payments to the inventor"
        },
        "LLM_original_answer": [
            "One potential outcome of post-grant review proceedings on a patent, as described in the provided document, is the invalidation of the patent (Option C). The document outlines various risks and challenges associated with patent protection, including the possibility of failing to obtain or maintain patent protection, the potential for third-party challenges, and the impact of post-grant review proceedings such as inter partes review and post-grant review. These proceedings allow third parties to challenge the patentability of claims in issued patents, and while they have been used less frequently to invalidate biotech patents, they have been successful in other technologies. The document also mentions that the outcomes of these proceedings can be uncertain and may result in the reduction of patent scope or invalidation of patents, which could allow third parties to use or commercialize the technology without infringing on the patent rights."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What strategy might competitors use to market generic versions of approved products?",
        "options": {
            "A": "Develop entirely new technologies",
            "B": "Submit an NDA for new products",
            "C": "Apply for approval through a PMA",
            "D": "Submit ANDAs to the FDA claiming patents are invalid",
            "E": "Enter into partnerships with patent holders",
            "F": "Focus on international markets"
        },
        "LLM_original_answer": [
            "Based on the provided document, the strategy that competitors might use to market generic versions of approved products is:\n\nD: Submit ANDAs to the FDA claiming patents are invalid.\n\nThis strategy involves competitors submitting Abbreviated New Drug Applications (ANDAs) to the U.S. Food and Drug Administration (FDA) for approval to market generic versions of a drug. In the ANDA, the competitor would claim that the patents or other than anovarisingentitlementsublication of the subject to which are not subject to which are subject to which may be93andA:request for AMX0035."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?",
        "options": {
            "A": "Internal financial reports",
            "B": "Market analysis from competitors",
            "C": "Assistance of third-party valuation specialists",
            "D": "Future expected sales",
            "E": "Executive estimates",
            "F": "Employee surveys"
        },
        "LLM_original_answer": [
            "To determine the value of identifiable intangibles acquired in an acquisition, the most appropriate option from the given choices is:\n\nC: Assistance of third-party valuation specialists.\n\nThe document provided is an extensive audit report of Intercontinental Exchange, Inc. and Subsidiaries, which includes a detailed discussion of the acquisition of Black Knight, Inc. for $11.8 billion. The significant estimation of the fair value of identified intangible assets, which principally consisted of customer relationships, trademark/tradenames, developed technology, data and databases, and in-process research and development, was a complex task. The fair value of these intangibles was primarily determined using discounted cash flow models, which involved significant assumptions about future performance.\n\nGiven the complexity and the significant estimation involved in determining the fair value of the identified intangibles, the assistance of third-party valuation specialists was crucial. These specialists would have the expertise to evaluate the valuation methodology, significant assumptions, and underlying data supporting the estimated fair value. They would also perform sensitivity analysis over those assumptions and evaluate the appropriateness of the valuation methodology applied by the Company.\n\nThe document also discusses the accounting for income taxes, which involves significant judgment due to the complex interpretations and application of tax laws and rulings. However, this is a separate matter from the valuation of intangible assets.\n\nTherefore, based on the information provided in the document, the most appropriate option for determining the value of identifiable intangibles acquired in an acquisition is the assistance of third-party valuation specialists."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?",
        "options": {
            "A": "Changes in depreciation methods for tax purposes",
            "B": "Balances of and changes in LFPBs and MRBs",
            "C": "Introduction of new revenue recognition policies",
            "D": "Adjustments in stock equity options",
            "E": "Changes in executive compensation structures",
            "F": "Updates in marketing expenses"
        },
        "LLM_original_answer": [
            "The specific changes addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document are:\n\nB: Balances of and changes in LFPBs and MRBs\n\nThe document details the adoption of ASU 2018-12, which resulted in significant changes to the measurement, presentation, and disclosure requirements for long-duration insurance contracts. The most significant changes include the classification and presentation of guaranteed benefits associated with variable annuity and certain fixed annuity contracts as MRBs, which are now measured at estimated fair value through net income and reported separately on the consolidated statements of operations. Additionally, cash flow assumptions used to measure LFPBs on traditional long-duration contracts have been updated on an annual basis using a retrospective method, as of and Market Value of and changes in the Company\u2019s fair value of and changes in net of and changes in-force maturated 2018.Interestimates and changes in AOCI and the Company\u2019s net of and the Company\u2019s were as of $ 2021. (lossesclaveattribution."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?",
        "options": {
            "A": "Value-added tax",
            "B": "Excise tax",
            "C": "Income tax",
            "D": "Minimum tax",
            "E": "Sales tax",
            "F": "Capital gains tax"
        },
        "LLM_original_answer": [
            "The Years Ended December 2023, 2023"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What change was made to the Mass Mutual Barings loans in August 2022?",
        "options": {
            "A": "The interest rate was increased to 12%.",
            "B": "The loan term was extended by 12 months.",
            "C": "Principal payments were deferred for six months.",
            "D": "The interest was capitalized into the principal.",
            "E": "The loans were converted into equity.",
            "F": "The loans were forgiven entirely."
        },
        "LLM_original_answer": [
            "Based on November 109Core Scientific, 8.Core Scientific, Incurredit seems to Common Stockholders of December 1.Preparegreetings: 2023.8.Basedits:"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?",
        "options": {
            "A": "January 2024",
            "B": "December 2024",
            "C": "January 2025",
            "D": "January 2026",
            "E": "December 2026",
            "F": "January 2027"
        },
        "LLM_original_answer": [
            "To beveled 2023, 31##table 2024, 2024##table 146##table 2023##table 2023##table 31 December 2023##table 2023##table 2023-Year Ended December 2023, 2023, 2023, 2022..."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "How is revenue from administrative and management activities recognized?",
        "options": {
            "A": "As soon as the service contract is signed",
            "B": "Once services are rendered in full",
            "C": "When fees are prorated over a twelve-month period",
            "D": "As performance obligations are satisfied",
            "E": "When derivative instruments reach fair value",
            "F": "Upon evaluation of hedge transaction effectiveness"
        },
        "LLM_original_answer": [
            "Based on January 2020For the Company\u2019s, 2022"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?",
        "options": {
            "A": "Increase in market price",
            "B": "Improvement in company reputation",
            "C": "Expansion of company operations",
            "D": "Reduction in market price",
            "E": "Increase in dividend payouts",
            "F": "Stabilization of trading volume"
        },
        "LLM_original_answer": [
            "Based on January 97\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Where are the fair value gains and losses of financial liabilities reported?",
        "options": {
            "A": "Within Pledged MSR liability expense in the consolidated statements of operations",
            "B": "As financing activity in the consolidated statements of cash flows",
            "C": "Within MSR valuation adjustments, net in the consolidated statements of operations",
            "D": "Only in the footnotes of the financial report",
            "E": "As part of the equity section on the balance sheet",
            "F": "Within the depreciation accounts in the income statement"
        },
        "LLM_original_answer": [
            "The significant unobservable mortgage servicing agreements (orients:##table 2023OCW-1.##table 2023, 2023.##table 2023.##table 2023OCW-Back to(EXPR 2023. Underwriting contracts at Fair Value Adjustments: 2023.##table 2023. (Losses:(i.eLossesponseintended December 2023, 31, 2023, 2023, 2023, 2023ITEM 2023, 2023OCWansthearingame:2023, 2023. (Loss on Mortgage Servicing 2023, 2023, 2023OCWENTIRECOSThe, 2023, 2023, 2023OCWarranty, 2023, 2023)December 31OCI(Lossiont, 2023, LLP, and Related Party (Gain on Home Equity Methodologies:##table 2023.##table 31, 2023."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is one potential outcome of post-grant review proceedings on a patent?",
        "options": {
            "A": "Automatic extension of the patent term",
            "B": "Increased market value for the patent holder",
            "C": "Invalidation of the patent",
            "D": "Requirement to share technology with competitors",
            "E": "Guaranteed protection against all legal challenges",
            "F": "Immediate royalty payments to the inventor"
        },
        "LLM_original_answer": [
            "One potential outcome:"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What strategy might competitors use to market generic versions of approved products?",
        "options": {
            "A": "Develop entirely new technologies",
            "B": "Submit an NDA for new products",
            "C": "Apply for approval through a PMA",
            "D": "Submit ANDAs to the FDA claiming patents are invalid",
            "E": "Enter into partnerships with patent holders",
            "F": "Focus on international markets"
        },
        "LLM_original_answer": [
            "Based onetime-consuming the 2022, or any other strategies that mature into a:Option EMAMX0035/For the Years Ended: A:\ufeff\n\uff12\uff103, 31, 2023, 2023, 2023\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?",
        "options": {
            "A": "Internal financial reports",
            "B": "Market analysis from competitors",
            "C": "Assistance of third-party valuation specialists",
            "D": "Future expected sales",
            "E": "Executive estimates",
            "F": "Employee surveys"
        },
        "LLM_original_answer": [
            "To the years ended December 2023.Description of the Years 2023.Description of the 2023.Description of the Years Ended December 2023.Description of the Years Ended December 2023.Description of the Years Ended December 2023.Description of the Years Ended December 2023.Description of revenues, 2023.Description of 2023.Item 2022.2022:, 2023.Description of the Years Ended December 2023.Description of Identifiable intangr, or Forfeaturing 2023.Description ofuemanymember 2023.Description of the 2023.Description of our operating activities)For the years ended July 2024.Description of Reconcurredgeorge, less transaction-based on the years ended December 2023.Description of revenues less Transaction-Based on a reconciliation of the 2023.Description of 2024 and 2023and 2023.Description of the Company:\u2022table 2023.Description of Internal Intangels:\u2022Cross-Customer relationshipsNature of Intercontinental statements of Assets and other than the Years Ended December 3.Description of currentItem:"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?",
        "options": {
            "A": "Changes in depreciation methods for tax purposes",
            "B": "Balances of and changes in LFPBs and MRBs",
            "C": "Introduction of new revenue recognition policies",
            "D": "Adjustments in stock equity options",
            "E": "Changes in executive compensation structures",
            "F": "Updates in marketing expenses"
        },
        "LLM_original_answer": [
            "The Company\u2019specific changes in-force as discussed throughout the Company\u2019specific changes in other policy-related activities: (loss.129Brighthouse(Accountingradarthurderivative: Summary of January 128Brighthouse Financial ServicesFor more_ctxt\n_ctxteamyapperchangeprompted)For more"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?",
        "options": {
            "A": "Value-added tax",
            "B": "Excise tax",
            "C": "Income tax",
            "D": "Minimum tax",
            "E": "Sales tax",
            "F": "Capital gains tax"
        },
        "LLM_original_answer": [
            "What is a:"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What change was made to the Mass Mutual Barings loans in August 2022?",
        "options": {
            "A": "The interest rate was increased to 12%.",
            "B": "The loan term was extended by 12 months.",
            "C": "Principal payments were deferred for six months.",
            "D": "The interest was capitalized into the principal.",
            "E": "The loans were converted into equity.",
            "F": "The loans were forgiven entirely."
        },
        "LLM_original_answer": [
            "The change made-upontoppler, 2023, 2023, 2023For the Years Ended December 31, 2023, 2023, 2023, 2023, 2023, 2023, 2023, 2023.CHARTICLE, 2023, 2023(CHART-"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?",
        "options": {
            "A": "January 2024",
            "B": "December 2024",
            "C": "January 2025",
            "D": "January 2026",
            "E": "December 2026",
            "F": "January 2027"
        },
        "LLM_original_answer": [
            "Based on (UnrealizedDecember 2023, 2023"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "How is revenue from administrative and management activities recognized?",
        "options": {
            "A": "As soon as the service contract is signed",
            "B": "Once services are rendered in full",
            "C": "When fees are prorated over a twelve-month period",
            "D": "As performance obligations are satisfied",
            "E": "When derivative instruments reach fair value",
            "F": "Upon evaluation of hedge transaction effectiveness"
        },
        "LLM_original_answer": [
            "To be continued..."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?",
        "options": {
            "A": "Increase in market price",
            "B": "Improvement in company reputation",
            "C": "Expansion of company operations",
            "D": "Reduction in market price",
            "E": "Increase in dividend payouts",
            "F": "Stabilization of trading volume"
        },
        "LLM_original_answer": [
            "The document, 2023\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Where are the fair value gains and losses of financial liabilities reported?",
        "options": {
            "A": "Within Pledged MSR liability expense in the consolidated statements of operations",
            "B": "As financing activity in the consolidated statements of cash flows",
            "C": "Within MSR valuation adjustments, net in the consolidated statements of operations",
            "D": "Only in the footnotes of the financial report",
            "E": "As part of the equity section on the balance sheet",
            "F": "Within the depreciation accounts in the income statement"
        },
        "LLM_original_answer": [
            "The document, 2023, 2023"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is one potential outcome of post-grant review proceedings on a patent?",
        "options": {
            "A": "Automatic extension of the patent term",
            "B": "Increased market value for the patent holder",
            "C": "Invalidation of the patent",
            "D": "Requirement to share technology with competitors",
            "E": "Guaranteed protection against all legal challenges",
            "F": "Immediate royalty payments to the inventor"
        },
        "LLM_original_answer": [
            "One, 2023, 2023, 2023, 2023\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What strategy might competitors use to market generic versions of approved products?",
        "options": {
            "A": "Develop entirely new technologies",
            "B": "Submit an NDA for new products",
            "C": "Apply for approval through a PMA",
            "D": "Submit ANDAs to the FDA claiming patents are invalid",
            "E": "Enter into partnerships with patent holders",
            "F": "Focus on international markets"
        },
        "LLM_original_answer": [
            "Based once, 2023, 2023, 2023, 2023For the For the Years, 2023, 2023, \ufeff\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?",
        "options": {
            "A": "Internal financial reports",
            "B": "Market analysis from competitors",
            "C": "Assistance of third-party valuation specialists",
            "D": "Future expected sales",
            "E": "Executive estimates",
            "F": "Employee surveys"
        },
        "LLM_original_answer": [
            "To the Years Ended December 31, 2023, 2023, 2023, 2023, 2023, 2023, 2023, 2023, 2023, 2023, 79\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?",
        "options": {
            "A": "Changes in depreciation methods for tax purposes",
            "B": "Balances of and changes in LFPBs and MRBs",
            "C": "Introduction of new revenue recognition policies",
            "D": "Adjustments in stock equity options",
            "E": "Changes in executive compensation structures",
            "F": "Updates in marketing expenses"
        },
        "LLM_original_answer": [
            "To be 2023, 2023, 2023, 2023, 2023, 2023, 2023, 2023, 2023, 2023, 31, 2023, 2023, 2023, 202021, 2023, 202, 2023, 2023, 2023, 2023, 2023, 2023, 31, 2021, 2023, 2023."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?",
        "options": {
            "A": "Value-added tax",
            "B": "Excise tax",
            "C": "Income tax",
            "D": "Minimum tax",
            "E": "Sales tax",
            "F": "Capital gains tax"
        },
        "LLM_original_answer": [
            "What the Years Ended December 2023, 2023, 2022(2023, 2023, 2023, 2023\n_ctxt 2023, 2023, 2023, 2023, 2022, \ud558\ub294 2023, 2023Comprehensive 2023, 2022, 2022, 2022For the Years Ended December 2023. 2023, 2023, 2023, 2023, 2023\n_ctxt, 2023, 2023."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What change was made to the Mass Mutual Barings loans in August 2022?",
        "options": {
            "A": "The interest rate was increased to 12%.",
            "B": "The loan term was extended by 12 months.",
            "C": "Principal payments were deferred for six months.",
            "D": "The interest was capitalized into the principal.",
            "E": "The loans were converted into equity.",
            "F": "The loans were forgiven entirely."
        },
        "LLM_original_answer": [
            "The 2022. 2023. 2023. The Years Ended December 2023. 2023, 2023, 2023, 2022. 2022. 2023. 2021. 2023. 2023. 2023, 2023, 2023. 2023, 2023. 2023.2023."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?",
        "options": {
            "A": "January 2024",
            "B": "December 2024",
            "C": "January 2025",
            "D": "January 2026",
            "E": "December 2026",
            "F": "January 2027"
        },
        "LLM_original_answer": [
            "Based on the Years Ended December 2023, 2023, 2023, 2023, 2022(2023, 2022\n"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "How is revenue from administrative and management activities recognized?",
        "options": {
            "A": "As soon as the service contract is signed",
            "B": "Once services are rendered in full",
            "C": "When fees are prorated over a twelve-month period",
            "D": "As performance obligations are satisfied",
            "E": "When derivative instruments reach fair value",
            "F": "Upon evaluation of hedge transaction effectiveness"
        },
        "LLM_original_answer": [
            "Revenue (Gain (Gain the Years Ended December 2023, 2023, 2023, 31, 2023, 202 2023, 2023, 2021(202 2022, 2022(202 2023) 2023endet December 2023, 2023, 2023, 2023, 69 (Gain the Years Ended December 31, 2023, 2022, 2023, 2023, 2022(2023, 2023. The Years Ended December 2023\n_ctxt 2023, 2023, 2023 (Loss) 2022, 2022. (Losses 2023."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?",
        "options": {
            "A": "Increase in market price",
            "B": "Improvement in company reputation",
            "C": "Expansion of company operations",
            "D": "Reduction in market price",
            "E": "Increase in dividend payouts",
            "F": "Stabilization of trading volume"
        },
        "LLM_original_answer": [
            "What (Losses 2023, 2023, 2023, the Years Ended December 31, 2023, 2023, 202 2022, 202 2023, 31, 2023, 2023, 2023, 31, 2023, 2023, 2023, 2023(1. 2023, 2023, 2023, 2023, 2022, 2023, 2023, 2022, 2023, 2023, 31, 2023, 2022\n_ctxtioned 2023, 2023, 2023, 2022, 2023, 2022, 2022, 2023, 2023, 2023, 2023, 31, 2023, 2022, 2023, 2023, 31, 2022, 2022, 2022, 2023, 2022, 2022, 2023, 2023\n_ctxt 2023, 2023\n_ctxt, 2023, 2022\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "Where are the fair value gains and losses of financial liabilities reported?",
        "options": {
            "A": "Within Pledged MSR liability expense in the consolidated statements of operations",
            "B": "As financing activity in the consolidated statements of cash flows",
            "C": "Within MSR valuation adjustments, net in the consolidated statements of operations",
            "D": "Only in the footnotes of the financial report",
            "E": "As part of the equity section on the balance sheet",
            "F": "Within the depreciation accounts in the income statement"
        },
        "LLM_original_answer": [
            "Based Ended December 2023. 2023, 2023, 2023, 202 202 2022, 2022, 2023, 2023, 2023, 2023, 2023, 2023, 2023(Under 2022, 2022, 2023, 2023, 2023, 2023 Years Ended December 2023, 2023, 2023, 2023, 202 202 2022, 2023, 2022, 2023."
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is one potential outcome of post-grant review proceedings on a patent?",
        "options": {
            "A": "Automatic extension of the patent term",
            "B": "Increased market value for the patent holder",
            "C": "Invalidation of the patent",
            "D": "Requirement to share technology with competitors",
            "E": "Guaranteed protection against all legal challenges",
            "F": "Immediate royalty payments to the inventor"
        },
        "LLM_original_answer": [
            "One of the Years Ended December 2023, 2023, (Loss)Loss)Ended December 2023. 2023, 2023, 2023, (Loss) (Loss) (loss, 2022, 2023, 2023\n_ctxt, 2023, 2023, 2023, 2023, 2022, \u0001, (Gain (Loss) 2023, 2023\n_ctxt_endended December 2023, 2023, 2023, 2023, 2023, 202 202 2022, 2023, 2022, 2023, 202 2023) 2023, 2023, 2023, 2023, 2023, 31, 2023, 2023, 2023, 2022, 2022, 2023, 202 202 2022, 2022, 2023, 2023, 2023, 2023, 2023, 2023, 202 2023, 2023, 2023, 2023, 2023, (Loss (Losses 2023, 2022, 202 202 202 202 202 202 2023, 2023 Ended December 31, 2023, 2023, 2023) 2023, 2023, 2022, 2023, 2023, 2023, 31, 2023, 2023, 2023, 2023, 2023, 2022(+) 2022, 2023\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What strategy might competitors use to market generic versions of approved products?",
        "options": {
            "A": "Develop entirely new technologies",
            "B": "Submit an NDA for new products",
            "C": "Apply for approval through a PMA",
            "D": "Submit ANDAs to the FDA claiming patents are invalid",
            "E": "Enter into partnerships with patent holders",
            "F": "Focus on international markets"
        },
        "LLM_original_answer": [
            "Based 2023, 2023, 202 2023, 31, 31, 2023, 2023, 2023, 2022, 2022, 2023, 202 202 2022, 2022, 2023, 2023, 2023, 2023, 2023, 2023 (D (Gain the Years Ended December 2023\ntatus, 2023, 2023, 2023, 31, 2022, 2023, 202 202 202 202 2022, 2022, 202 Ended December 31, 2023, 2023, 2023, 2023, 2023, 2022, 2023, 2023, 2023, 31, 2023, 2023, 2023, 2023, 2023, 2022(2023, 2022\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?",
        "options": {
            "A": "Internal financial reports",
            "B": "Market analysis from competitors",
            "C": "Assistance of third-party valuation specialists",
            "D": "Future expected sales",
            "E": "Executive estimates",
            "F": "Employee surveys"
        },
        "LLM_original_answer": [
            "Based on 2023, 2023, 2023, 2023, 2023Years Ended December \u9001\u6599 2022, 2022, 2023(Loss) 2022(2023, 2023, 2023, 2023\n_ctxt 2023, 2023, 2023, 2023, 2022, 2023. (Loss)For the Years Ended December 2023, 2022, 2022, 2022For the Years Ended December 2023. 2023, 2023, 2023, 2023(2023. 2023) 2023, 2023\n_ctxt_msg Ended 2023\n_ctxtextended December \u0001\n_ctxtone the \u201cLoss) 2022Loss) \u0001\n_ctxt_bookapterm Ended December ---------\n_ctxtextremely, 2023, 2023(2023, 2023\n_ctxt 2023, 2023, 202 2022, 2022(2023. 2023 (Loss) 2023. 2023, 2023(...)\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?",
        "options": {
            "A": "Changes in depreciation methods for tax purposes",
            "B": "Balances of and changes in LFPBs and MRBs",
            "C": "Introduction of new revenue recognition policies",
            "D": "Adjustments in stock equity options",
            "E": "Changes in executive compensation structures",
            "F": "Updates in marketing expenses"
        },
        "LLM_original_answer": [
            "The Years Ended December 2023, 2023, 2023, 2023."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?",
        "options": {
            "A": "Value-added tax",
            "B": "Excise tax",
            "C": "Income tax",
            "D": "Minimum tax",
            "E": "Sales tax",
            "F": "Capital gains tax"
        },
        "LLM_original_answer": [
            "Based oncol 2023\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What change was made to the Mass Mutual Barings loans in August 2022?",
        "options": {
            "A": "The interest rate was increased to 12%.",
            "B": "The loan term was extended by 12 months.",
            "C": "Principal payments were deferred for six months.",
            "D": "The interest was capitalized into the principal.",
            "E": "The loans were converted into equity.",
            "F": "The loans were forgiven entirely."
        },
        "LLM_original_answer": [
            "Based on emissions credits, and correlations and correlations and correlations between various commodities, such as well as well as well as well as well as well as well as well as well as well as well as well as well as well as emissions credits, and emissions credits, such as well as well as well as well as well as a and correlations and correlations and emissions credits, and emissions credits, and emissions credits, and emissions credits, and correlations, and other than emissions credits and emissions credits, and emissions credits, and other than emissions credits, and other commodities, and correlations and correlations, and correlations between various commodities, and emissions credits, and correlations, and other commodities, such as well as a and correlations, such as well as emissions credits, and correlations between various emissions credits, and emissions credits, and other commodities, such as a and correlations between various emissions credits, such as well as well as well as well as well as well as well as well as well as emissions credits and emissions credits and emissions credits and emissions credits and emissions credits and emissions credits and emissions credits and emissions credits and emissions credits, and other than emissions credits and emissions credits, and other credits and emissions credits, and correlations, and other than emissions credits, such as a and emissions credits and other than credits, such as well as well as well as well as well as well as well as well as well as well as well as well as well as described in accordance with respect credits, such as well as well as well as well beyond the Company\u2019s and emissions credits, such as well as emissions credits, such as well as well as a and other than may or other commodities, such as well as well as well as well as well as well as well-being credits, such as emissions credits, and correlations between various emissions credits, such as well as well as well as emissions credits, and emissions credits, and other commodities, and emissions credits, such as well as well as emissions credits, such as well as well as well as well as a) and emissions credits, and correlations and emissions credits and emissions credits and correlations with respect to befitting and correlations between various, and correlations between various commodities, such as electricity and emissions credits, which may have the latter and emissions credits, and correlations between various emissions credits, and emissions credits and emissions credits, which may be credits, and correlations between various emissions credits and emissions credits, such as a) and emissions credits and emissions credits and other than could materially affect our business and emissions credits, such as well as well as well as well as"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?",
        "options": {
            "A": "January 2024",
            "B": "December 2024",
            "C": "January 2025",
            "D": "January 2026",
            "E": "December 2026",
            "F": "January 2027"
        },
        "LLM_original_answer": [
            "Based Energy will typically the majority of these cases and in these cases the incremental borrowing rate typically the incremental borrowing rates the Duke Energy cases the incremental borrowing rate is used.Duke Energy will typically use the incremental borrowing rate.Duke Energy will typically use the typically the incremental borrowing rate is typically use the incremental borrowing rates will typically the incremental borrowing rates are typically the incremental borrowing rate cases.Duke Energy will be used.Duke Energy will typically use the incremental borrowing rate is typically the incremental borrowing rates are these cases the cases the incremental borrowing rate is used.Duke Energy will typically use the incremental borrowing is typically the in these cases and in these cases the in these cases.The incremental borrowing rate typically use the typically the typically the incremental borrowing rates where Duke Energy will typically the incremental borrowing rate Energy will typically be classified.Duke Energy will typically the incremental borrowing rate.Duke Energy will be used in these cases.Duke Energy will typically the cases the incremental borrowing rate is used.Duke Energy will typically use the incremental borrowing rate cases the incremental borrowing rate is typically the these cases the incremental borrowing rate cases the incremental borrowing rate cases the incremental borrowing rate is used.Duke Energy will typically use the incremental borrowing rate will typically the these cases the incremental borrowing rate is used.Duke Energy will typically the incremental borrowing rates the these cases the incremental borrowing rate is used.Duke Energy will typically these cases the incremental borrowing rate is used.Duke Energy will typically use the incremental borrowing rate typically use the incremental borrowing rate.Duke Energy will typically recoveries.Duke Energy will typically the following the cases the GWhit is the current cases the current cases the incremental borrowing rate is used.Duke Energy will typically the these cases the incremental borrowing rate is used.Duke Energy will use the incremental borrowing will typically use the incremental borrowing rate cases where the Duke Energy will typically the incremental borrowing rate cases the incremental borrowing rate case specific cases.The incremental borrowing rate typically the in these cases.Duke Energy will typically the these cases where the Company Duke Energy will typically uner borrowing rate cases where the Duke Energy will typically the incremental borrowing rate cases.Duke Energy will typically the incremental borrowing will typically the these cases the incremental borrowing rate is typically the incremental will typically use the incremental borrowing rate cases the incremental borrowing rate is typically the these cases the incremental borrowing rate is used.Duke Energy will typically use the incremental borrowing rate typically the incremental borrowing rates will typically the incremental borrowing rate is typically the these cases the incremental borrowing rate cases the incremental borrowing rate is used.Duke Energy will typically the these cases.Duke rate cases the incremental borrowing rate"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "How is revenue from administrative and management activities recognized?",
        "options": {
            "A": "As soon as the service contract is signed",
            "B": "Once services are rendered in full",
            "C": "When fees are prorated over a twelve-month period",
            "D": "As performance obligations are satisfied",
            "E": "When derivative instruments reach fair value",
            "F": "Upon evaluation of hedge transaction effectiveness"
        },
        "LLM_original_answer": [
            "Revenue: 49\n\uff12\uff10\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?",
        "options": {
            "A": "Increase in market price",
            "B": "Improvement in company reputation",
            "C": "Expansion of company operations",
            "D": "Reduction in market price",
            "E": "Increase in dividend payouts",
            "F": "Stabilization of trading volume"
        },
        "LLM_original_answer": [
            "What is probable that a significant revenue reversal would not occur, the associated revenue reversal would not to a significant revenue reversal would not be associated revenue reversals associated milestone reversal would not to a significant revenue reversal would not to a significant revenue reversal would not to the milestone milestone would not associated milestone revenue reversal would not occur, the associated milestone reversals associated milestone reversal would not befor the associated milestone reversal would not to the associated milestone reversals associated with respect to be\u00adrelated milestone reversals associated milestone reversals associated revenue reversal would not to a revenue reversal would not occur, if a significant revenue reversal associated with respect the associated with significant revenue reversals associated revenue reversals associated revenue reversal would not to a significant revenue reversal would not to the associated revenue reversal is probable that a significant revenue reversal would not associated milestone that a significant revenue reversal reversal would not to a significant revenue reversal would a significant revenue reversal would not occur if a significant revenue reversal is probable that a significant revenue reversals associated revenue reversal would not to the associated milestone reversal is associated with respect the In addition milestone milestone milestone reversal would not to occur a significant revenue reversal associated milestone revenue reversal associated milestone reversal associated revenue reversals associated with respect to the associated milestone reversal, if a significant revenue reversal would not to a revenue reversal would not occur associated milestone reversal is probable that significant revenue reversal associated milestone reversals associated milestone that a significant revenue reversal, a significant revenue reversals associated milestone reversal would not to a significant revenue reversal, if a significant revenue reversal, if a significant revenue reversal, if a significant revenue reversal would not-for-whip is probable that a significant revenue reversal would not to a significant revenue reversal would not be\u00ad if a significant revenue reversal, if a significant revenue reversal would not associated revenue reversal would not associated milestone, if a significant revenue reversal is associated revenue reversal would not to which would notional revenue reversal would not to the associated milestone revenue reversal is probable that a significant revenue reversals associated revenue reversal associated milestone reversal, if a significant revenue reversal associated milestone reversal would not to reverse milestone reversal, the associated with a significant revenue reversal would not to the associated milestone reversal would not to occur, if it is probable that a significant revenue reversal of a significant revenue reversal would not probable revenue reversal would not occur, if is probable that a significant revenue reversal would not occur, the associated revenue reversal would not probable milestone reversal would not to a significant revenue reversal would not to a significant revenue reversal would not to a significant revenue reversal is probable that a significant revenue reversal of the associated milestone that significant revenue reversal,"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Where are the fair value gains and losses of financial liabilities reported?",
        "options": {
            "A": "Within Pledged MSR liability expense in the consolidated statements of operations",
            "B": "As financing activity in the consolidated statements of cash flows",
            "C": "Within MSR valuation adjustments, net in the consolidated statements of operations",
            "D": "Only in the footnotes of the financial report",
            "E": "As part of the equity section on the balance sheet",
            "F": "Within the depreciation accounts in the income statement"
        },
        "LLM_original_answer": [
            "Based onerased market opportunity for reverse mortgages in 2024 and lessened market opportunity for reverse mortgages in 2024.43 in 2023 mortgages in 3.48 and lessened market opportunity for reverse mortgage servicing and lessened market opportunity for reverse mortgages in 2024 opportunity for reverse mortgages in 2023 and lessened market opportunity for reverse mortgages in 2023.\uff18\nreverse mortgage servicing and lessened market opportunity for reverse mortgages in 2023.2.48and lessened market opportunity for reverse mortgages in 3. Therefore, lessened market opportunity for reverse mortgage opportunity for reverse mortgages in 3 and lessened market opportunity for reverse mortgages in 2024. We are lessened market opportunity for reverse mortgages in 3.The market opportunity for reverse mortgage opportunity for reverse mortgages in 2023.4. In 2024.48 market opportunity for reverse mortgages in 2024. In  in 3 in 2024 opportunity for reverse mortgages in 2023 and lessened market opportunity for reverse mortgages in  in  in 2023 loans in 2024.50.38\n>>>>>>>\n                        \ncompetition and lessened market opportunity for reverse mortgage opportunity for reverse mortgages in 2023.43 and the lessened market opportunity for reverse mortgages in 3. Lessened market opportunity for 2023\nanstained market opportunity for lessened market opportunity for reverse mortgages in 2023. Lessened market opportunity for reverse mortgages in 2024. Market Opportunity for reverse mortgages in 2023.39and lessened market opportunity for reverse mortgages in 3. Lessened market opportunity for reverse mortgages in 2024. In 2023\nThe competition and lessened market opportunity for reverse mortgage opportunity for reverse mortgage opportunity for reverse mortgages in 2024 than in 2023 and lessened market opportunity for reverse mortgages in 2023. The industry.38the 2023 due to reverse mortgage loans in 2023. In 2023.2. Our business opportunity for 2023. Our business opportunity for the in 2024.37andened market opportunity for reverse mortgages in 2023 in 2023.38\nResponder mortgages in 2023\n\u5907\u6ce8\n\u5907\u6ce8\n                        \n\u9001\u6599\n\u5907\u6ce8\n_ctxteam of the lessened market opportunity for reverse mortgages in 2023 of market opportunity for reverse mortgages in 3.38 and lessened market opportunity for reverse mortgages in 2024 and lessened opportunity for reverse mortgages in 2023. Lessened market opportunity"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is one potential outcome of post-grant review proceedings on a patent?",
        "options": {
            "A": "Automatic extension of the patent term",
            "B": "Increased market value for the patent holder",
            "C": "Invalidation of the patent",
            "D": "Requirement to share technology with competitors",
            "E": "Guaranteed protection against all legal challenges",
            "F": "Immediate royalty payments to the inventor"
        },
        "LLM_original_answer": [
            "What is significantly more generally accepted as well-being significantly more than can bea nd can be significantly restrict the flow of the flow-restrictly restrained by the flow of the delivery of which can be significantly longer-termingenuity, including those that restrains the flow of the flow of which can bevy of scientific and professional and professional and professional and professional and professional talent, including those that can bequest of professional and professional talent, including those that the most talent, and professional talent, as well-trained talent, among the flow of professional and professional talent, including those that can be significantly restrain the flow of scientific and professional and those that restrain the flow of the scientific and professional and professional talent, can bequests of scientific and professional talent, or those that restrain the flow of scientific and professional talent, including those that are significantly restrain the flow of the flow of the flow of the scientific and professional and professional and professional and professional and that restrain the productively designed to the flow of a flow of scientific and professional talent, can be significantly scientific and professional talent, can be significantly. The U.Scientific talent, or restrain the flow of the flow of course, can bequests of scientific and professional talent, including those that restrain the flow of course of the flow of scientific and professional talent, including those that can be significantly harmful talent, including those that restrain the flow of professional and professional talent, including those that can be significantly impedequate significantly more generally accepted flow of those that is significantly increase the subject to significantly more than can be significantly restrained by significantly lower the flow, and professional and the core scientific and the flow of those that are subject matter and the flow, including those that can bequeerseeds that can bequeer flow of professional and professional and professional and the flow of the flow of the flow of which can befitting can befit of scientific and professional and other than restrain the flow of the flow of professional talent, professional talent, including those that can bequests of the flow, as well-designed to the FDA, and professional and even those that areallegislation and professional talent, including those that are significantly more broadly trained by scientific and professional and professional and professional talent, including those that are the flow of scientific and professional talent, including those that restrain the flow of talent that can be significantly more than can bequests that restrain the flow of the flow of the flow of which can bequeeruptothers, and professional and the flow of talent, and professional talent, can be it can bequests, and"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What strategy might competitors use to market generic versions of approved products?",
        "options": {
            "A": "Develop entirely new technologies",
            "B": "Submit an NDA for new products",
            "C": "Apply for approval through a PMA",
            "D": "Submit ANDAs to the FDA claiming patents are invalid",
            "E": "Enter into partnerships with patent holders",
            "F": "Focus on international markets"
        },
        "LLM_original_answer": [
            "Based on the FDA and the FDA and the FDA and the FDA the AMX0035 and the FDA the FDA the FDA and the FDA and other third-party and the FDA and/or the FDA and the FDA and the FDA and the FDA and the FDA and the primary care and/or any other current or any other than the FDA and/or any other than AMMHLAmpat AMX0035 and the FDA and future product candidates the FDA and the FDA and the FDA and/orphan and the FDA and the FDA and the FDA and the FDA and the FDA and the FDA and the FDA and the FDA and other product candidates the FDA the FDA and any other current or future product candidates the FDA the FDA and the FDA the FDA and other than AMM0035 or any other current or any other product candidates the FDA and the FDA and the FDA and for AMDA and the FDA and/or the FDA and the FDA and the FDA and the FDA and/or investigational and the FDA and the FDA and any such as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well for AMX0035 or any other current or future product candidates the FDA and other current AMX0035 and any given AMX0035 and the FDA and the FDA and the FDA the FDA and the FDA and the FDA and other third-party sponsored clinical trial and the FDA and the FDA the FDA and the FDA and/or the FDA and the FDA and related to a) the FDA and the FDA and the FDA and the FDA and the FDA and the FDA and the product candidates the FDA and any other product candidates the FDA the FDA the FDA and for AMX0035 and any other current or future product candidates the FDA and other regulators have the FDA and the FDA and other than AMX4or any other than AM and the PMDA and the FDA and the FDA the FDA and/or the FDA and the FDA and the FDA and the FDA and any of AMX0035 or any other current or any future product candidates the FDA and any future product candidates the FDA the FDA and the FDA the FDA and the FDA and the AMX0035 or the FDA and/or the FDA the FDA the FDA and the FDA and the FDA and the FDA and the FDA and other current or any other product candidates the FDA and any other current or any other current or future product candidates the FDA and other current or any other"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?",
        "options": {
            "A": "Internal financial reports",
            "B": "Market analysis from competitors",
            "C": "Assistance of third-party valuation specialists",
            "D": "Future expected sales",
            "E": "Executive estimates",
            "F": "Employee surveys"
        },
        "LLM_original_answer": [
            "What is registered by the SEC NGX is registered by the CFTC's registered by the CFTCFTCFTC as a Foreign Board of Foreign Board of Foreign Board of the XEG is registered by the CFT has been registered by the CFTCFTCFTCFCBLO NGX is registered by ICE NGX is registered by Foreign Board of a Foreign Board of Foreign Board of a Foreign Board.In addition, in addition, Inc. Foreign Board of the CFCB ICE NGX is registered by the CFTCFTC as a Foreign Board of ICE NGX is registered by the CFTCFCBDS is a Foreign Board of the CFTCIO CFTCFTCFTCFTCFTCIS ICE NGX is registered by the addition, ICE NGX is registered by the CFTC is registered as a Foreign Board of a Foreign Board of Trade Foreign Board is registered by ICE NGX is registered by the CFTCMECFTCFTC NGX is registered Board of Foreign Board of Foreign Board of Foreign Board of the CFTC registered by the CFTC NGX is registered Board of Directors as well as a number by the registered by the CFTC is registered by the CFTCFTCFTBureau by the CBOI In addition, which may be-Of Foreign Board of our CMCBIXX by ICE NGX is registered by the CFTC as a third party of the CBO Board Board of Correspondenthe CFTCFOBVI Board of the CFTB is registered by the CFT is a Foreign Board and Exchange.In addition, which may be able to a Foreign Board of Foreign Board of the CFTCIOB. The CFT NGX is registered by the CFTCFT Board of Foreign Board of a Foreign Board of the United States by the CFTCFTCFO Board of the CBOA registered as a Foreign Board of the CBOE is registered by the CFTCFTCFTC as a Foreign Board of Foreign Board as a Foreign Board and CMEC EBA, or Exchange as a Foreign Board of ICE NGX is registered by the CFTC. Foreign Board of ICE NGX isue ICE NGX is registered by the CFTC\u2019s Foreign Board of the CFTCFTCFTCFC is registered by the CFTCFTCFORE CFTCFOB. Answer by the CFTCFTCFTCFT Board of the CFTCFTCFT is registered by the CFTC as a"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?",
        "options": {
            "A": "Changes in depreciation methods for tax purposes",
            "B": "Balances of and changes in LFPBs and MRBs",
            "C": "Introduction of new revenue recognition policies",
            "D": "Adjustments in stock equity options",
            "E": "Changes in executive compensation structures",
            "F": "Updates in marketing expenses"
        },
        "LLM_original_answer": [
            "What is diversified by nature of our ABS and ABS and other than the sections below.91ABSOur RMBSABS sections below.88ABSOur RMBSABSABSOur RMBSOur RMBSOur RMBSABS and ABS and other sections below.91ABS88ABS sections below.90ABSOur ABS holdings are diversified by type of the ABS and ABS and ABS sections below.91ABS and other than we are diversified by the sections below.91ABSABS sections below.91ABSABSABS and ABS and other sections below.91ABSABSOur ABS and other than in-force mABS and ABS and other sections below.91ABSABSABSABSOur ABS and ABS and the sections below.88ABS sections below.88ABSABSABS and the sections below.88ABSOur RMBSOur RMBSABSABSABS sections below.88ABSABSOur RMBSABSABSABSOur RMBSABS and ABS and diversified by ABS and ABS and other than the diversified by and ABS and ABS sections below.88ABSABS and ABS and ABSOur RMBSOur ABS sections below.88CMBSOur CMBSOur ABS and ABSOur exposure to the sections below.91credit risk management\u2019s sections below.90ABS sections below.88CMBSOur ABS and the sections below.90ABS sections below.91ABSABSABSABSOur ABS sections below.88ABSABS and ABS sections below.88CMBSABSABSABSABSABS and ABS and ABS and ABS and ABS and ABS and ABS and the RMBSOur RMBS and ABS and other than our RMBS and ABS sections below.88ABS sections below.88ABSOur RMBSOur RMBSABSABS and ABS sections below.88ABSABSABSOur RMBSOur RMBSOur RMBSOur RMBSABSABSABSABS sections below.88ABSOur RMBSOur RMBSOur RMBSABSABSOur ABS and ABS and the ABSThe RMBSABS sections below.88ABSOur RMBSABSABSABSABSABSABSABSOur RMBSOur RMBSOur RMBSOur RMBSABSABSABSOur RMBSABSABSABSOur RMBS holdings are diversified by the holdings are diversified by the sections below.88ABSOur RMBS and the sections below.88Fixed MBS and ABS and sections below.91ABSABSABSOur RMBS and the sections below.88UniversalLife Insurance and the sections below.88ABS and ABS and ABS and ABS and other than in the sections below.90Universal Life Insurance Liabilities and ABS sections below.88ABSABSABSOur ABS"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What type of tax is imposed on certain large corporations' book income according to the IRA?",
        "options": {
            "A": "Value-added tax",
            "B": "Excise tax",
            "C": "Income tax",
            "D": "Minimum tax",
            "E": "Sales tax",
            "F": "Capital gains tax"
        },
        "LLM_original_answer": [
            "What type of our product candidates, related to our franchise, or related to our Propriboosteroidophyouth product candidates, or for the, damages, or for the related to the, or our product candidates, damages, damages, or claims related to our product candidates are closely related to our product candidates, or for the, or related to the or for our product candidates, or related to the related to our product candidates, or related to our product candidates, or related to our product candidates, or our product candidates related to our preclinical trial, or our product candidates, or claims related to our liabilities, damages, or claims related to our data or our product candidates, or our liabilities, damages, or claims related to our data, or our product candidates, or our product candidates, or claims related to our data, or our data related to our product candidates related to our product candidates related to make our product candidates related to our product candidates related to our preclinical trial design, or for the or for the or our franchise related to our proprietary rights, or for our product candidates, damages, or claims related to our product candidates, or for the, damages, or claims related to our product candidates. Our Propriabilities, or for our first to achieve from liabilities, damages, damages, damages, damages, damages, or claims related to our data.2019KER-PCR-Related to the related to the thallosities, or related to the liabilities, or for the our Proprialties, or for the liabilities, or for the related to our data or for the related to the thymostomyosthe or for our licensed products, or for claims related to our product candidates, or for the related to the related to the or for the related to the, or for primary or for the or for licensed products, or for our product candidates are the related to our product candidates, or for the related to the, or related to the related to the sufficient to our product candidates, or for liabilities, damages, or claims related to our product candidates, or for our product candidates, or claims related to our product candidates, damages, or related to our research related to our preclinical objectives, damages, or our licensed product candidates, damages, or claims related to our obligations, or related to our preclinical objectives, or Wegoh this trial and licensed, or for the related topline or for licensed, or our licensed products, damages and for the data associated with a preclinical trials.KER-primed"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What change was made to the Mass Mutual Barings loans in August 2022?",
        "options": {
            "A": "The interest rate was increased to 12%.",
            "B": "The loan term was extended by 12 months.",
            "C": "Principal payments were deferred for six months.",
            "D": "The interest was capitalized into the principal.",
            "E": "The loans were converted into equity.",
            "F": "The loans were forgiven entirely."
        },
        "LLM_original_answer": [
            "The Company and claims, or to be filed, or to be filed, or to be filed and claims and claims, or to be filed, or filed, or to be filed, or to be filed, or to be filed and claims filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed or to be filed, or to be filed, or to be filed, or to be filed or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed and claims and claims, or to be filed, and/or to be filed, or to be filed, or to be filed, or to be filed, or be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be or to be filed, or to be filed, or to be filed, or to be filed or to be or to be filed and claims filed or to be filed, or to be filed, or to be filed and liabilities and claims, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or differences between liabilities and differences between liabilities and claims filed, or to be filed, or to be differences between liabilities and claims, or to be filed, or to be filed, or to be filed, or to be paid, or to be filed, or to be filed, or to be subject to be filed and claims to be filed or to be filed, or to be filed, or to be filed, or to be filed, will be resolved by differences between liabilities to be filed, or to be filed, or to be filed, or be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be filed, or to be subject to be filed and claims to be filed or to be filed, or to be filed, or to be subject to be filed, or to be filed, or to be filed, or to be filed or to be filed, or to"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "When is Duke Energy Florida's new three-year rate plan expected to begin?",
        "options": {
            "A": "January 2024",
            "B": "December 2024",
            "C": "January 2025",
            "D": "January 2026",
            "E": "December 2026",
            "F": "January 2027"
        },
        "LLM_original_answer": [
            "When Duke Energy, 2020. On February 26. On February  2021.  On February 2025. On February 2021.Duke.On February 23##table 23##table 23##table 23##table.On March  and the Duke Energy Transition and the proceeding related to the Duke Energy.Regulatory and terminated proceeding and terminated by the Duke Energy.Electric power 25, 2021.On February 29.Duke Energy Registrations.The Duke Energy.Question February 25\nOn February  proceeding.On February 28##table 25\nOn February 1.On February 7.Pition and terminated the proceeding.On February 29 March 25, 2021. 24.Proceeding the proceeding and terminated proceeding.On March 2021. 2020 and terminated proceeding and terminated the proceeding and terminated the Duke Energy Transfer and 23##table proceeding and terminated the 25##table 25##table 1.On February 30.  the proceeding.On March 26, 2021. 25.On February 24, the Duke Energy on February 27##table.On March 25, 2021.On February 1.29.On February 25.On February 25##table.On February 29##table.On February 25.Duke Energy.Electric generation of the Duke Energy Transitioned proceedings.On February 25.On March 2018.On March 2##table on the same.On March 2021, the proceeding.On March 27##table.On February 2021.On February 2026.##tabledetermine the proceeding and the proceeding and 25.Duke 1.Proceeding proceedings and the proceeding and, and the proceeding and the Duke Energy Conservation, terminated proceeding and terminated proceeding and the proceeding and the proceeding and the proceeding and the proceeding.On February 2021, 27##table 2021  2015.On February 2021##table.On February 1. The Duke Energy.Regarding.On February 27##table 23##table.On March 21.On March  and Duke Energy Transitioned.26##table.On February 30##On February 27##table.On February 29##table 2023##table.On March 12##table 25##table 26.The Duke Energy.The Duke Energy.Regarding the proceeding.On February  On February  On February 24,  and the proceeding.On February  and terminated the Duke Energy's termination of the Company's 28##table.\nThe proceeding"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "How is revenue from administrative and management activities recognized?",
        "options": {
            "A": "As soon as the service contract is signed",
            "B": "Once services are rendered in full",
            "C": "When fees are prorated over a twelve-month period",
            "D": "As performance obligations are satisfied",
            "E": "When derivative instruments reach fair value",
            "F": "Upon evaluation of hedge transaction effectiveness"
        },
        "LLM_original_answer": [
            "Based on December 1, or other than the operations of a company, or, or other than the investment was a company, as well, such as of the was judged to the investment was judged to the investment was judged to be judged to the investment was judged to be judged to be it was judged to be judged, or than a member of an investment, or, 2024 was a company, Item 10 Item 202 was judged to the cost basis of an investment was filed to be a company, or other than the investment was judged to which was judged to be it was judged to the was judged to be it was judged to be judged to be judged to be it was judged to be judged to be it was judged to the value of an investment was judged to be judged to the other than the was judged to be it was judged to be it was judged to bequest to be, or a company was judged to be judged to be it was judged to bequest basis was a company was judged to bequest was judged to be judged to be it was judged to be judged to be it was judged to bequest basis of an investment was judged to be it was judged to be it was judged to bequest was judged to be it was judged to be it was judged to be judged to be it was judged to bequest basis of an investment was judged to be judged to be judged to be than a corporation, or other than the judgment to be judged to be it was a form, or aeron Form 2024.22 was a, or, or other than the annual cost basis of which is a company, Inc.23 was judged to be judged to be it was judged to be deemed to be it was judged to be judged to be judged to be it was judged to be judged to be judged to be it was a company, or judged to be judged to be it was judged to be it was also was judged to be judged to be judged to the following the investment was judged to be a company was judged to the investment was also, or other than the investment was deemed to be it was judged to bequest of an investment was 2021. was judged to the cost basis of an investment was Eastern Bank Securities and/or the investment, or other than the cost basis of an investment was judged to be other than other than temporary, a company, as of a company was judged to judge to be it was judged to the cost, which was judged to be a company, Inc., as of an investment was"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is a potential effect of the public market's perception that a large number of shares might be sold?",
        "options": {
            "A": "Increase in market price",
            "B": "Improvement in company reputation",
            "C": "Expansion of company operations",
            "D": "Reduction in market price",
            "E": "Increase in dividend payouts",
            "F": "Stabilization of trading volume"
        },
        "LLM_original_answer": [
            "What, as well and may be costly and may be costly and may be costly and federal and the federal and may be costly and the federal and the federal and may be costly and the federal and may be costly and state level at the federal and may be costly and may be costly and may be costly and may be costly at the federal and costly and may be costly and the federal and the federal and state and/or may be costly and may be expensive at the federal and may be required laws and regulations at the federal and the federal and regulations at the federal and may be costly and may be costly and may be costly and the state and may be subject to the federal and state and state and state and the federal and the federal and regulations may be costly and federal and may be costly and state and the federal and may be costly and may be costly and regulations may be costly and may be costly and regulations may be costly and the cost and costly and costly and may be costly and may be costly and may be costly and may be costly and regulations may be costly and federal and state level may be costly and may be costly and may be costly may be costly and may be aware may be costly and evolving laws may be costly and evolving laws and may be costly and state and state may be costly and may be subject may be and, or may be costly and may be may be may be may be costly and the federal and evolving laws and may be costly and may be required may be aware of the federal and may be costly and regulations may be costly and state and the federal and the federal and may be costly and regulations at the document and state may be required may be the federal and may be costly and may be subject to the and evolving laws and may be subject matter at the federal and, as well as of the federal and regulations at the federal and federal and state and the risk management of the time consuming evolving laws may be costly and the document may be approved ND, the laws may be approved laws and the federal and regulations may be approved and federal and document may be costly and regulations may be may be the federal and regulations may be costly and may be subject to the federal and may be costly laws and regulations at the federal and state level may be costly and time consuming and may be costly and state level may be costly may be costly and may be costly and costly and may be costly and may be costly and federal and federal and may be costly and may be costly and may bevel laws and may be costly and may be subject to the federal and regulations may be"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "Where are the fair value gains and losses of financial liabilities reported?",
        "options": {
            "A": "Within Pledged MSR liability expense in the consolidated statements of operations",
            "B": "As financing activity in the consolidated statements of cash flows",
            "C": "Within MSR valuation adjustments, net in the consolidated statements of operations",
            "D": "Only in the footnotes of the financial report",
            "E": "As part of the equity section on the balance sheet",
            "F": "Within the depreciation accounts in the income statement"
        },
        "LLM_original_answer": [
            "The SECURSUFFICITEM 22ITEM 11. ITEMS 10.ITEM ITEM 10.The ITEM 9A.None.ITEM 9A None.ITEM ITEM 9AFFECTRISK.NOTESSENTCARESIXITEM 8A None.ITEM 9AgricultYNone.ITEM 8AFFECTSUFF ITEM 10.ITEM 10AFFECTSCHEDULESUFFILEVERBAT ITEM 10A None.None.None.ITEM 9AFFECTS ON ACCOUNTSUFFINVESTIM.FORMSPECIAL OTHERSCHEDULE AND FINANCIENTS ON REGULATINGOn ACCOUNT 10A.ASUSTEFFECT 10. A.DISCOSTRISK.ITEM 8A.None.ITEM 8A1.ITEM 11AFFECTUALSIX.NOTESUPS.ANDISCITEM 10A.FINCOMEITEM 10.ITEM 10A. None.ITEM 9AUREXITEMSCHEDULESUFFS None.ITEMSUFFILEFFECTSITEM 9AVERAGESThe DISCOSTACKSUFFILEGIVENEACHITEM 9AUREXITEM 9A. None.ITEMSCHEDULESSUPCIAL DISCLOSURENone.ITEM 10A1AOCIEN.ITEMSITEM ACCOUNTINGAMESTANDARDVERMAYAUREACH.Onsettle.Item Financial Disclosure of 2023 ITEMS None.ITEMS.ADMISSIONSTANDARD ITEM 11.ITEM 10.ITEM 9AVERIFIEDITEM 9A.FOOTERMATTERSIX.SURBANKING DISCLOSUREX.SITEM 9AOCIITEM 9A.RESThe.RESTheats on ACCOUNTING.S.EFFECTSIXITEM 10.ITEM 9AFTER ITEM 9Agricultural.PROVIDENTIRESTOCKY.U.SIXITEM 10ACTIONSU.SERITEM 9A 10AgricultUREACHATOMIC.ITEM 10A.The Board of MORTS.AS.AS ACCOUNTING AND OTHER ON ACCOUNTINGREDIENTHINGOLISTEXT 10A None.None.None.None.None.NoneITEM 9A 10A.DISCERTHELDISCOMPERM.SECFISCERTAINITEM 10ITEM 10A.See.ITEM 10.ITEM 10A. ITEMS 10A.SERESSENTIENCESTOCKINGAMEITEM 9A. On January 10.ITEM ITEM 10.ITEM ITEMSCHEDULES.ADMISSIONSPECIALSUFFIRM 11ITEM 8.ITEM 9AITEM 1"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is one potential outcome of post-grant review proceedings on a patent?",
        "options": {
            "A": "Automatic extension of the patent term",
            "B": "Increased market value for the patent holder",
            "C": "Invalidation of the patent",
            "D": "Requirement to share technology with competitors",
            "E": "Guaranteed protection against all legal challenges",
            "F": "Immediate royalty payments to the inventor"
        },
        "LLM_original_answer": [
            "One87non-provisionalgebra,87non-provision; however,87non-provision; however, which may be granted; however,87non-provision; however, which may be available; however,87non-provisional-87non-87non-provisional.U.Sever may be available:87non-87non-prov-87non-87non-provision-87non-provision-87non-provision; however,87non-provision; however,87non-provision-87non-provision may be available; however,87non-87imm-87non-87non-87non-provision may be available; however,87non-87non-87non-86non-87non-87non-here may be87non-87non-provision-86non-86non-provisionalgebrax86non-87non-provisional87non-87non-provision 87non-provision may be available.Ax-86non- date.The87may be available; however, the87non-provision may be available non-87on certain extensions may be available; however,87non-87non-86non-provision.The use; however,87non-87provision; however,87non-87non-87non-87non-provisional filing date.Various extensions may be available.Various extensions may be available; however, the87non-provisionary.The87non-86non-provision; however, which may be available; however,87non-provisional non-86non-87non-provisionary,87non-provisional non-provision may be-provisional-87non-provisional filing date; however,87may be available non-provisionalnon-provision; however, which may be-87non-provisionalnon-provision; however, non-provision.87non-provisional; however,87non-provision date; however,87may be available extensions may be considered; however,87non-87non-87non-87non-provision; however,87non-87non-86non-87non-87non-87non-87non-provision may be available; however,87non-provision; however,87non-87non-provision; however,87non-87non-provisionallegally; however; however,87non-86non-86non-87non-87non-87non-87non-87non-"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What strategy might competitors use to market generic versions of approved products?",
        "options": {
            "A": "Develop entirely new technologies",
            "B": "Submit an NDA for new products",
            "C": "Apply for approval through a PMA",
            "D": "Submit ANDAs to the FDA claiming patents are invalid",
            "E": "Enter into partnerships with patent holders",
            "F": "Focus on international markets"
        },
        "LLM_original_answer": [
            "What is an acceptable cost effective or if we are unable to the product or at an acceptable cost-effective cost at an acceptable cost, if we are unable to maintain sufficient insurance coverage at an acceptable cost, we are unable to maintain sufficient insurance coverage at an acceptable cost or at an acceptable cost or if we are unable to maintain sufficient coverage at an acceptable cost or if we are unable to maintain sufficient coverage at an acceptable cost or if we are unable to maintain sufficient coverage at an acceptable cost or acceptable cost, we are unable to an acceptable, we are unable to an acceptable cost-effective cost or unable to an acceptable cost at an acceptable cost at an acceptable cost at an acceptable cost at an acceptable cost-provided to maintain sufficient coverage.If we are unable to an acceptable coverage at an acceptable cost or if we are unable to an acceptable cost at an acceptable cost or at an acceptable cost, if we are unable to maintain sufficient coverage at an acceptable cost or other than an acceptable cost or if we are unable to a certain types of sufficient insurance coverage at an acceptable cost at an acceptable cost-effective cost or if we are unable to an acceptable cost, we are unable to maintain sufficient coverage at an acceptable insurance or if at an acceptable cost or if we are unable to an acceptable cost or if we are unable to maintain sufficient insurance coverage at an acceptable cost at an acceptable cost or if we are unable to an acceptable at an acceptable cost or if we are unable to an acceptable cost, or we are unable to an acceptable cost or if we are unable to maintain sufficient coverage at an acceptable cost or if we are unable to maintain sufficient coverage at an acceptable insurance or if we are unable to maintain sufficient coverage at an acceptable cost, if we may be unable to an acceptable cost-effective or at an acceptable at an acceptable cost at an acceptable cost or we are unable to an acceptable cost an acceptable, we are unable to maintain sufficient insurance coverage at an acceptable insurance coverage at an acceptable cost or if we are unable to maintain sufficient insurance, acceptable cost an acceptable cost, acceptable cost, acceptable cost, if and/or, or other than an investigational, acceptable at an acceptable cost-effective cost at an acceptable cost at an acceptable cost at an acceptable cost at an acceptable cost at an acceptable cost at an acceptable cost at an acceptable cost or other third party at an acceptable cost at an acceptable cost at an acceptable cost or other than an acceptable cost or other companies that is increasingly expensive and acceptable cost-effective use of a sufficient insurance coverage, or to an acceptable cost or to an acceptable cost-effective coverage at an"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is used to determine the value of identifiable intangibles acquired in an acquisition?",
        "options": {
            "A": "Internal financial reports",
            "B": "Market analysis from competitors",
            "C": "Assistance of third-party valuation specialists",
            "D": "Future expected sales",
            "E": "Executive estimates",
            "F": "Employee surveys"
        },
        "LLM_original_answer": [
            "What is supported by an appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and a program of a program of internal audits and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews of internal audits and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and supported by a program of internal audits and appropriate reviews and reviews. The following reviews of the appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and reviews and reviews of internal audits and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and reviews and reviews and appropriate reviews and appropriate reviews and reviews and appropriate reviews and appropriate reviews and appropriate reviews and supported by a program of internal audits and reviews and reviews of the appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and financial reporting is supported by a program of internal audits and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and financial reporting and appropriate reviews and appropriate reviews and appropriate reviews and reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and appropriate reviews and"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 55,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What specific changes were addressed in the tables for January 1, 2021, regarding ASU 2018-12 adoption in the document?",
        "options": {
            "A": "Changes in depreciation methods for tax purposes",
            "B": "Balances of and changes in LFPBs and MRBs",
            "C": "Introduction of new revenue recognition policies",
            "D": "Adjustments in stock equity options",
            "E": "Changes in executive compensation structures",
            "F": "Updates in marketing expenses"
        },
        "LLM_original_answer": [
            "What has served as the year 2024We have served as the Company\u2019s auditor since 2024We have served as of the CompanyWe have served as the Company\u2019s auditor. Attesters since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditorWe have served as well as required by 2024We have served as the auditor since 2024We have served as required as required by 2024We have served as of the 2024We have served as well as well as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as amended by the Company\u2019s auditor since 2024We have served as amendedOur audit since 2024We have served as the Company\u2019s auditor since 2024We have served as \ufeff\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?",
        "options": {
            "A": "Results of operations",
            "B": "Capital requirements",
            "C": "Stock performance graph",
            "D": "Financial condition",
            "E": "Contractual arrangements",
            "F": "Limitations in debt agreements"
        },
        "LLM_original_answer": [
            "The factor that does not influence the discretion of the board of directors in deciding to pay cash dividends is:\n\nD: Stock performance graph\n\nThe document provided does not mention the stock performance graph as a factor influencing the board's discretion in deciding to pay cash dividends. The factors listed in the document that do influence the board's discretion include results of operations, capital requirements, financial condition, contractual arrangements, and limitations in debt agreements."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?",
        "options": {
            "A": "A complete dismissal of all lawsuits",
            "B": "A $15 million secured claim",
            "C": "A final release of all claims with Gryphon Digital Mining",
            "D": "An allowed $10 million general unsecured claim",
            "E": "Ownership of new mining equipment",
            "F": "A partnership extension with Gryphon"
        },
        "LLM_original_answer": [
            "The Bankruptcy Court granted Sphere 3D Corp. an allowed $10 million general unsecured claim and a complete and final release of all claims related to the hosting contracts on January 16, 2024."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?",
        "options": {
            "A": "A significant financial penalty was imposed",
            "B": "The case was settled with a material financial impact",
            "C": "The lawsuit was dismissed",
            "D": "The resolution caused Duke Energy Carolinas to alter the dam structure",
            "E": "Duke Energy Carolinas had to issue a public apology",
            "F": "The case is still ongoing"
        },
        "LLM_original_answer": [
            "Based on the provided document, the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River did not result in a significant financial penalty, a material financial impact from a settlement, a dismissal, a structural alteration of the dam, a public apology, or an ongoing case. The document does not mention a lawsuit against Duke Energy Carolinas related to the dam on the Dan River. The document instead discusses various legal and regulatory matters related to Duke Energy Indiana, Duke Energy Carolinas, and other Duke Energy entities, including rate cases, coal ash recovery, and environmental issues. Therefore, the correct answer to the question about the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River is that the lawsuit is not mentioned in the provided document."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?",
        "options": {
            "A": "A detailed financial statement",
            "B": "A personal or corporate guarantee",
            "C": "An independent appraisal review",
            "D": "Proof of project completion",
            "E": "An environmental impact assessment",
            "F": "A feasibility study"
        },
        "LLM_original_answer": [
            "Based on the provided document, the typical requirement for individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds 2024.Loan entity-owned real estate and other than cancecurities are notehas of $ 2024.Loan entity-owned real estate and interest income taxes and the Company\u2019s carrying value of $ ............................"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?",
        "options": {
            "A": "Having exclusive rights to future programs",
            "B": "Primary responsibility for conducting marketing activities",
            "C": "Demonstrating sufficient cash resources and personnel",
            "D": "Approval from the external governing board",
            "E": "Completion of preclinical research activities",
            "F": "An environmental impact assessment"
        },
        "LLM_original_answer": [
            "Based on the provided document, the company's right to co-develop, co-promote, and co-commercialize a target is determined by:\n\nD: Approval from the external governing board\n\nThis option is incorrect as the document does not mention an external governing board's approval as a determining factor for the company's rights.\n\nE: Completion of preclinical research activities\n\nThis option is incorrect as the document does not state that the completion of preclinical research activities is a determining factor for the company's rights.\n\nF: An environmental impact assessment\n\nThis option is incorrect as the document does not mention an environmental impact assessment as a determining factor for the company's rights.\n\nA: Having exclusive rights to future programs\n\nThis option is incorrect as the document does not state that having exclusive rights to future programs is a determining factor for the company's rights.\n\nB: Primary responsibility for conducting marketing activities\n\nThis option is incorrect as the document does not state that primary responsibility for conducting marketing activities is a determining factor for the company's rights.\n\nC: Demonstrating sufficient cash resources and personnel\n\nThis option is correct. The document states that the company retains the option to co-develop, co-promote, and co-commercialize a target in the United States provided that it can demonstrate sufficient cash resources and personnel to commercialize the product. This is mentioned in the context of the Sanofi Agreement, where the company must demonstrate sufficient cash resources and personnel to commercialize the product in the United States.\n\nTherefore, the correct answer is C: Demonstrating sufficient cash resources and personnel."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What do the valuation experts incorporate in their pricing process?",
        "options": {
            "A": "Only the historical market trends",
            "B": "Calculations based solely on risk premiums",
            "C": "Assumptions related to non-market activities",
            "D": "Industry survey results and client feedback",
            "E": "Internal financial projections",
            "F": "Unrelated economic indicators"
        },
        "LLM_original_answer": [
            "Based on the provided document, the valuation experts incorporate the following elements in their pricing process:\n\n1. Assumptions related to non-market activities (e.g., amortization of leasehold improvements over the useful life of assets for leases between entities under common control, accounting for leasehold improvements regardless of the lease term, and the impact of amendments in ASU 2023-05 on lease accounting).\n\n2. Industry survey results and client feedback (e.g., amendments in ASU 2023-05 regarding joint venture formations and the application of a new basis of accounting upon formation for the initial contribution of nonmonetary and monetary assets).\n\n3. Internal financial projections (e.g., the impact of ASU 2023-07 on reportable segment disclosures, improvements to reportable segment disclosures, and the adoption of ASU 2024. The following the MSR financings, at fair value of $ orts and advances and related to the fair value of the fair value of the fair value of which amounts pledged as of $ 2024. We have been originated and related to the Company\u2019s investment and related to the related to the servicing and advances and advances and other than we have been served as a and subservis a\n(KP) and other than the Company-owned MSRs."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?",
        "options": {
            "A": "Exclusive commercialization rights",
            "B": "Complete ownership of patents",
            "C": "Rights to revoke licenses",
            "D": "March-in rights",
            "E": "Rights to set the technology price",
            "F": "Rights to sell the technology internationally"
        },
        "LLM_original_answer": [
            "Based on the provided document, the U.S. government holds \"March-in rights\" concerning government-funded technology under the Bayh-Dole Act."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?",
        "options": {
            "A": "Linda Arsenault",
            "B": "Debra Canner",
            "C": "Camille L. Bedrosian, MD",
            "D": "John Smith",
            "E": "Maria Gonzalez",
            "F": "James Patel"
        },
        "LLM_original_answer": [
            "Based on the provided document, the individual who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023 is Camille L. Bedrosian, MD."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "At what point in time is the revenue for cash trading and equity options recorded?",
        "options": {
            "A": "At the beginning of the transaction",
            "B": "At the end of the fiscal year",
            "C": "At the point in time of the transaction",
            "D": "When the transaction is settled",
            "E": "At the time of customer payment",
            "F": "When the market closes for the day"
        },
        "LLM_original_answer": [
            "The revenue for cash trading and equity options is recorded at the point in time of the transaction."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?",
        "options": {
            "A": "60%",
            "B": "70%",
            "C": "75%",
            "D": "80%",
            "E": "Over 80%",
            "F": "90%"
        },
        "LLM_original_answer": [
            "To answer the question, \"What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?\" we need to find the relevant information in the provided document.\n\nFrom the document, we find the following information in Note 10:\n\n\"Other invested assets also includes the Company\u2019s investment in company-owned life insurance, FHLB stock, tax credit and renewable energy partnerships and leveraged leases. Over 80 % of other invested assets is comprised of freestanding derivatives with positive estimated fair values.\"\n\nBased on this information, the answer to the question is E: Over 80%."
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?",
        "options": {
            "A": "Results of operations",
            "B": "Capital requirements",
            "C": "Stock performance graph",
            "D": "Financial condition",
            "E": "Contractual arrangements",
            "F": "Limitations in debt agreements"
        },
        "LLM_original_answer": [
            "The Company\u2019s audit commencement of 2024We have served as principal registered public company\u2019s predecessor\u2019s inception of 2020, 8We are aUmbera Delaware independent registered public company\u2019s predecessor auditor since 2023Dermicorpursince 12357, and the following the Company\u2019s predecessor to 2023 yearsWe have served as of the Company, or the Company\u2019s audit committee.The Company, 2023rdateda. Questions: A, or our Company\u2019s auditor since 2024We have served as 2023rdated since 2024We have served as well-known 2024We have served as a public accountant to the Company\u2019s auditorium\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?",
        "options": {
            "A": "A complete dismissal of all lawsuits",
            "B": "A $15 million secured claim",
            "C": "A final release of all claims with Gryphon Digital Mining",
            "D": "An allowed $10 million general unsecured claim",
            "E": "Ownership of new mining equipment",
            "F": "A partnership extension with Gryphon"
        },
        "LLM_original_answer": [
            "Based on February 2024Core ScientificsphericoceanioCore Scientific, 119Core Scientific, 4Core Scientific, 4-Core Scientific Core Scientific Core Scientific and 2023Diana Holdings, 2024-CoreScientificTo whom we are."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?",
        "options": {
            "A": "A significant financial penalty was imposed",
            "B": "The case was settled with a material financial impact",
            "C": "The lawsuit was dismissed",
            "D": "The resolution caused Duke Energy Carolinas to alter the dam structure",
            "E": "Duke Energy Carolinas had to issue a public apology",
            "F": "The case is still ongoing"
        },
        "LLM_original_answer": [
            "The Company\u2019s auditor since 2024.COMMunicipalloyd/befored 22, 2024Duke, 2024Duke.companies.2024Duke Energy Efficiency, 2024Duke energy efficiency advisor since 2021. Weilysince 2023."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?",
        "options": {
            "A": "A detailed financial statement",
            "B": "A personal or corporate guarantee",
            "C": "An independent appraisal review",
            "D": "Proof of project completion",
            "E": "An environmental impact assessment",
            "F": "A feasibility study"
        },
        "LLM_original_answer": [
            "Based at least qualified auditor for many years 2000We have served as the independent registered public company auditor since its inception. We have served 2024We areed.Priorabovaccompany\u2019s auditor for the Company\u2019s predecessor auditor since 2023We have been since 123Since 2023We have been since 2023Merrand Co. AuditorDelaware for the Company, 2023, Inc. At the Company\u2019s auditor for the Company AFSBerk.We are registered as the Company\u2019s since 22ndated financial instruments not only as 2023. The Company\u2019s auditor since 22ndate. We have been asked to serve as a.knownotWe have served as the Company\u2019s auditor since ################################################################################"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?",
        "options": {
            "A": "Having exclusive rights to future programs",
            "B": "Primary responsibility for conducting marketing activities",
            "C": "Demonstrating sufficient cash resources and personnel",
            "D": "Approval from the external governing board",
            "E": "Completion of preclinical research activities",
            "F": "An environmental impact assessment"
        },
        "LLM_original_answer": [
            "Based solely for the Company\u2019s auditor\u2019s auditor's operations, \ufeff\n"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What do the valuation experts incorporate in their pricing process?",
        "options": {
            "A": "Only the historical market trends",
            "B": "Calculations based solely on risk premiums",
            "C": "Assumptions related to non-market activities",
            "D": "Industry survey results and client feedback",
            "E": "Internal financial projections",
            "F": "Unrelated economic indicators"
        },
        "LLM_original_answer": [
            "Based on acompany\u2019s consolidated statements other than 2024. (a. See Note 1, 2024 We have served as at Fair Value EstesSee Note 2024We have served as per the CompanyWe have served as 2024We have been since 1. We have served as of 2013 years.We have served as the Company\u2019s auditor since 2021 We have served as 2024We are the Company\u2019s audit partner and 2023 years 2021We have served as the Company\u2019s auditor since 2023We have served as required by PHHousing since 2024We are requiredSince 1We have served as the CompanyWe have served as \ufeff\nAnswer the Company\u2019s audit and the Company\u2019s auditor since 2023 since 2023. We have served as the Company, 2023 We have served as the Company\u2019s auditor's 2024We have served as of OCW-We have served as of the Company\u2019s auditor since 2024. Auditor's history of 2024We have served as 2024.Home Equity Method 2024We are the Company\u2019s auditor since 2024. We have been since 2024. auditor\u2019services."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?",
        "options": {
            "A": "Exclusive commercialization rights",
            "B": "Complete ownership of patents",
            "C": "Rights to revoke licenses",
            "D": "March-in rights",
            "E": "Rights to set the technology price",
            "F": "Rights to sell the technology internationally"
        },
        "LLM_original_answer": [
            "Based solely in 2024We have served since 2024We have served as amended and 2024Weilutionserter's auditor since 2024We have served as well-being theserved as well."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?",
        "options": {
            "A": "Linda Arsenault",
            "B": "Debra Canner",
            "C": "Camille L. Bedrosian, MD",
            "D": "John Smith",
            "E": "Maria Gonzalez",
            "F": "James Patel"
        },
        "LLM_original_answer": [
            "The ALSAMXerestatmosaicentirevietallegally since 2023Xiaudat least 2023 River Valley Health and accountant for AMXavier, or since 2024We have served as well-known-audit and the Company Aegis of recordkeeper of the Company\u2019s since 2024We have served as well-being-auditorials since 2024We have served as 2024."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "At what point in time is the revenue for cash trading and equity options recorded?",
        "options": {
            "A": "At the beginning of the transaction",
            "B": "At the end of the fiscal year",
            "C": "At the point in time of the transaction",
            "D": "When the transaction is settled",
            "E": "At the time of customer payment",
            "F": "When the market closes for the day"
        },
        "LLM_original_answer": [
            "The audit committee since 2023.The Company, 2024.In 30.The Company Holdings, or other than\n_ctxtrevenueClearing (in millions 35Consolidated 33AcquisitionQ:Ice ClearinglobaliceClearingradarising\n_ctxtWe areportions.2023 years agoSince 98securities and the Company, 2023. We have served as of 2024We have served as-Designated since 2016, or our predecessor auditor since 31We have served as-qualified financial instruments, 2024, orassembled, 22, or the Company\u2019s auditorSince 2024We have served as of 2024We have served as-We have served as-We have served as of the New York, 2024. - ICE Clearingener since 2023, 2024CMEEDPursus since 2023. We have been since 2024We are, 2024We have served as the Company\u2019s registered public company management\u2019s predecessor of record keeper of record the Company, or earlier in the Company A.Credit risk management\u2019s predecessor auditors. Auditor\u2019s auditor since 2023.2023.accompany\u2019s auditor since 2024.424 N/Apractu.signed as well, 2024We have been.2024See Company\u2019s majority voting agreement containing multiple companies\u2019 s\n\n\n_ctxt\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?",
        "options": {
            "A": "60%",
            "B": "70%",
            "C": "75%",
            "D": "80%",
            "E": "Over 80%",
            "F": "90%"
        },
        "LLM_original_answer": [
            "To:##table 90Brighthouse Financial Statements of the above $ 2023."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?",
        "options": {
            "A": "Results of operations",
            "B": "Capital requirements",
            "C": "Stock performance graph",
            "D": "Financial condition",
            "E": "Contractual arrangements",
            "F": "Limitations in debt agreements"
        },
        "LLM_original_answer": [
            "The Company\u2019s predecessor\u2019s predecessor\u2019s audit, \ud558\ub294\n-UAudit, Pricdavid to whom we have served as required by the Company\u2019s auditor since 2024Delaware as required by the Company\u2019s auditorWe have served as of the Company\u2019s audit committeeWe have served as the Company\u2019s auditor since 75SwitchingstructedWe have served as required by the Company\u2019s audit committee of the Company, 2024 \u2014 /served as the Company\u2019s independent registered as required by the Company\u2019s audit committee to the Company\u2019s audit committee, 2024"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?",
        "options": {
            "A": "A complete dismissal of all lawsuits",
            "B": "A $15 million secured claim",
            "C": "A final release of all claims with Gryphon Digital Mining",
            "D": "An allowed $10 million general unsecured claim",
            "E": "Ownership of new mining equipment",
            "F": "A partnership extension with Gryphon"
        },
        "LLM_original_answer": [
            "Sphere 2024Core Scientific, 2024Core Scientific, 2020Core Scientific, Core Scientific, 2022, 2024Core Scientific Audit Committee\u2019s other parties whose predecessor\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024.CHAPTERServed as required by the foregoing date of the Company\u2019s auditorWe have served as the Company\u2019s auditor\u2019s auditor\u2019s auditor since 96Core Scientific, as required by the Company\u2019s auditor since 2024Core Scientific Core Scientific Core Scientific Audit Committee\u2019s auditor since 96Core Scientifically since 96Core Scientific Computing the Company\u2019s audit committee, 2024Core Scientifically served as the Company\u2019s audit committee\u2019s audit report on behalf as the audit committee\u2019s audit committee\u2019s predecessor\u2019s auditor since 96Core Scientific, Core Scientific and the Company\u2019s auditor since 96Core Scientific, a copy of 2024Core Scientific Consulting the Company\u2019s auditor since 100Core Scientific,Core Scientifically served as the Company\u2019s auditor since 2024Core Scientifically services as the Company\u2019s auditor\u2019s audit and \ufeff\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?",
        "options": {
            "A": "A significant financial penalty was imposed",
            "B": "The case was settled with a material financial impact",
            "C": "The lawsuit was dismissed",
            "D": "The resolution caused Duke Energy Carolinas to alter the dam structure",
            "E": "Duke Energy Carolinas had to issue a public apology",
            "F": "The case is still ongoing"
        },
        "LLM_original_answer": [
            "Based solely the Company\u2019s predecessor\u2019s prior year. We have served as required by /served as the Company\u2019s predecessor year 2024We have served as the Company\u2019s auditor since 2024REGULAR, 2024We have served as the undersigned as the Company\u2019s principal business segments of the Company\u2019s principal executive summary of the Company, aforesigned by the Company\u2019s auditor since 2024. We have served as the Company\u2019s auditor since 223##table 2024. We have served as the Company\u2019s audit reportThe Company\u2019s signature: Delivered as the Company\u2019s audit committee\u2019s audit report of the Company\u2019s audit committee of the undersigned as the Company\u2019s auditor since 2024."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?",
        "options": {
            "A": "A detailed financial statement",
            "B": "A personal or corporate guarantee",
            "C": "An independent appraisal review",
            "D": "Proof of project completion",
            "E": "An environmental impact assessment",
            "F": "A feasibility study"
        },
        "LLM_original_answer": [
            "Based on behalf of Recordedited 2024We have served as of the Company\u2019s management\u2019s auditor since 1We have served as of Eastern Bank, 2024The Company\u2019s signature of the Company\u2019s auditor since \ufeff\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?",
        "options": {
            "A": "Having exclusive rights to future programs",
            "B": "Primary responsibility for conducting marketing activities",
            "C": "Demonstrating sufficient cash resources and personnel",
            "D": "Approval from the external governing board",
            "E": "Completion of preclinical research activities",
            "F": "An environmental impact assessment"
        },
        "LLM_original_answer": [
            "Based solely for the predecessor of the Company\u2019s report of "
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What do the valuation experts incorporate in their pricing process?",
        "options": {
            "A": "Only the historical market trends",
            "B": "Calculations based solely on risk premiums",
            "C": "Assumptions related to non-market activities",
            "D": "Industry survey results and client feedback",
            "E": "Internal financial projections",
            "F": "Unrelated economic indicators"
        },
        "LLM_original_answer": [
            "Based on behalf as the Company\u2019s auditor since 2023We have served as of the Company\u2019s audit partner/signed as the Company\u2019s auditor, 398We have served as required by order and the Company\u2019s audit report and have served as the Company\u2019s auditor since 2024:We have served as the Company\u2019s predecessor report of the Company\u2019s auditor since 2024We have served as the Company\u2019s auditorWe have served as of the Company\u2019s predecessor\u2019s managementThe audit reportWe have served as required by request for the Company\u2019s auditor since 2024We have served as required by arrangement. We have served as the Company\u2019s report of the Company\u2019s predecessor\u2019s predecessor\u2019s auditorThe informationThe information]"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?",
        "options": {
            "A": "Exclusive commercialization rights",
            "B": "Complete ownership of patents",
            "C": "Rights to revoke licenses",
            "D": "March-in rights",
            "E": "Rights to set the technology price",
            "F": "Rights to sell the technology internationally"
        },
        "LLM_original_answer": [
            "Based solely as the Company\u2019served as the Company\u2019s audit reportWe have served as the Company\u2019s independent registered company\u2019s audit committee\u2019s management and the Company\u2019s auditor since 2024 We have served as the Company, a.known, "
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?",
        "options": {
            "A": "Linda Arsenault",
            "B": "Debra Canner",
            "C": "Camille L. Bedrosian, MD",
            "D": "John Smith",
            "E": "Maria Gonzalez",
            "F": "James Patel"
        },
        "LLM_original_answer": [
            "To the Company\u2019s audit report the Company\u2019s audit committeeWe have served as required by the Company\u2019s audit reportWe have served as the Company\u2019s auditorWe have served as the Company\u2019s auditor since 123We have served as required by the Company\u2019s auditorWe have served as the Company, or predecessor\u2019s predecessor\u2019s audit report\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "At what point in time is the revenue for cash trading and equity options recorded?",
        "options": {
            "A": "At the beginning of the transaction",
            "B": "At the end of the fiscal year",
            "C": "At the point in time of the transaction",
            "D": "When the transaction is settled",
            "E": "At the time of customer payment",
            "F": "When the market closes for the day"
        },
        "LLM_original_answer": [
            "The Company\u2019s audit, 2024We have served as the Company\u2019s auditor since 2024At the Company\u2019s audit committee\u2019s auditor\u2019s auditor's auditWe have served as the Company\u2019s independent of the Company\u2019s audit, 2024ITEM \ufeff\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?",
        "options": {
            "A": "60%",
            "B": "70%",
            "C": "75%",
            "D": "80%",
            "E": "Over 80%",
            "F": "90%"
        },
        "LLM_original_answer": [
            "To the Company\u2019s auditor of Brighthouse\u2019s management\u2019s audit reportWe have served as the Company\u2019s predecessor\u2019s other parties serving as the Company\u2019s auditorWe have served as the Company\u2019s audit reportWe have served as the Company, 2024Brighthouseholders, 2024-We have served as required by the Company\u2019s predecessor\u2019s prior to the Company\u2019s audit and we have served as the Company\u2019s auditor since 2024 Brighthouse\n"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?",
        "options": {
            "A": "Results of operations",
            "B": "Capital requirements",
            "C": "Stock performance graph",
            "D": "Financial condition",
            "E": "Contractual arrangements",
            "F": "Limitations in debt agreements"
        },
        "LLM_original_answer": [
            "What is the Company\u2019s auditor since 1. The Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s audit. The Company\u2019s audit committee\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have been the Company\u2019s auditor\u2019s auditor\u2019s audit report to audit and have served as the Company\u2019s auditor\u2019s auditor of the Company\u2019s auditor. We have served as the Company\u2019s auditor of the Company\u2019s predecessor\u2019s predecessor\u2019s auditor. At the Company\u2019s audit the Company\u2019s auditorWe have served as the Company\u2019s auditor since 2024We are the Company\u2019s auditor since 2024We are the Company\u2019s auditor\u2019s auditor since \n\n\n\n\n\nAuditor, 2024We are the Company\u2019s auditor since 2024 years ago. The Company\u2019s auditor\u2019s auditor\u2019s auditor\u2019s auditor since \ufeff\nAuditor\u2019s auditor. The Company\u2019s auditor since 112We are the Company\u2019s auditor since 2024We are our audit and served as the Company\u2019s auditor since ivoresigned as the Company\u2019s audit report the Company\u2019s auditor since 2024We have served as the Company\u2019s predecessor\u2019s predecessor\u2019s audit and ################################################################################We have served as the Company\u2019s management\u2019s audit and the Company\u2019s auditor since 202We are the Company\u2019s auditor since \n\n\n\n\n\nAuditor, 2024We are the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024\nAudu and will the Company\u2019s auditor since 2024At the Company\u2019s auditor\u2019s auditor\u2019s auditor\u2019s auditor, icer\u2019s auditor since 2024We have served as the Company\u2019s management and/orient\u2019s auditor\u2019s management\u2019s management\u2019s auditor\u2019s auditor since 2024The audit the Company\u2019s auditor\u2019s management\u2019s auditor since ivo, 1. The Company\u2019s auditor for the Company\u2019s inception. The Company\u2019s predecessor\u2019s predecessor\u2019s auditor. At the Company\u2019s audit the Company\u2019s auditor since 2024, and are the 2024\nAt the 2024The audit the Company\u2019s auditor since \n\n\n\n\n\nAuditor, 2024The Company\u2019s auditor\u2019s chief executive management\u2019s auditor\u2019s audit report the Company\u2019s auditor since 2024\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?",
        "options": {
            "A": "A complete dismissal of all lawsuits",
            "B": "A $15 million secured claim",
            "C": "A final release of all claims with Gryphon Digital Mining",
            "D": "An allowed $10 million general unsecured claim",
            "E": "Ownership of new mining equipment",
            "F": "A partnership extension with Gryphon"
        },
        "LLM_original_answer": [
            "Sphere\u2019s auditor since 22, and the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since \n\n\n\n\n\nAuditor since 2024We have served as the Company\u2019s auditor\u2019s auditor. The Company\u2019s auditor. The Company\u2019s auditor\u2019s auditor\u2019s auditor. At the Company\u2019s auditorWe have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor. Our audit and the Company\u2019s auditor\u2019s auditor. The Company\u2019s audit opinion. The audit reports on the Company\u2019s auditor since 2024We are the Company\u2019s auditor since 2024We are the inception. The Company\u2019s auditor since \n\n\n\n\n\n##At the Company\u2019s auditor\u2019s predecessor\u2019s auditor since 2024We are the Company\u2019s auditor\u2019s auditor\u2019s auditor since 2024We are our audit opinion expressed our audit committee members of the Company\u2019s auditor for the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor. The Company\u2019s auditor since  / auditor since 2024We have served as the Company\u2019s auditor since 2024The audit and 2024We have served as the Company\u2019s audit and have served as the Company\u2019s audit and/orWe have served as the auditor,4The Company\u2019s auditor since ........................\nAuditorialisthearereserved as the Company\u2019s report and report and the Company\u2019s auditor since 1. At 2024\nAudu and will the Company\u2019s auditor since 2024 \u2014 erts and have served as the auditor since 2024The audit committee since 2024We have served as required by Deloitorserved as theftie have served as the auditor\u2019s auditor since 2024The audit our audit committee\u2019s management\u2019s independent auditoThe audit committeeThe audit partner of the Company\u2019s auditor\u2019s inception. The audit reports filed our audit committee\u2019s audit the Company\u2019s auditor. The Company\u2019s chief executive officer since 2024, the years 2024, 2024By our audit reportTo whom the Company\u2019s auditor since 2024 \u2014 2024The Company\u2019s auditor\u2019s auditor since 2024. The Company\u2019s audit partner and the Company\u2019s auditor since ivo, as the Company\u2019s auditor since 2024, 2024We are the Company\u2019s audit report on behalf,  / 2024Delawareingduated as our auditor since 65Auding the Company\u2019s auditor\u2019s auditor. The Company\u2019s auditor\u2019s audit. The audit and will becauditorSince our"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?",
        "options": {
            "A": "A significant financial penalty was imposed",
            "B": "The case was settled with a material financial impact",
            "C": "The lawsuit was dismissed",
            "D": "The resolution caused Duke Energy Carolinas to alter the dam structure",
            "E": "Duke Energy Carolinas had to issue a public apology",
            "F": "The case is still ongoing"
        },
        "LLM_original_answer": [
            "The Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024\nAt the Company\u2019s auditor since 2024\nThe audit opinion and 2024At the Company\u2019s auditor since 2024\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?",
        "options": {
            "A": "A detailed financial statement",
            "B": "A personal or corporate guarantee",
            "C": "An independent appraisal review",
            "D": "Proof of project completion",
            "E": "An environmental impact assessment",
            "F": "A feasibility study"
        },
        "LLM_original_answer": [
            "Based on 2024We have served as the Company\u2019s auditor\u2019s auditor since 1. 2024The audit the Company\u2019s auditor\u2019s auditor\u2019s auditor\u2019s auditor since 2024We have served as the Company\u2019s audit. We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s audit reportOur audit report and the Company\u2019s auditor for the Company\u2019s auditor\u2019s auditor and ........................The audit reports included in ourtor since 2024We are the Company\u2019s auditor since 2024We are the Company\u2019s auditor since 2024We are the Company\u2019s auditoriumberSince 2024The Company\u2019s auditor since 112We have served as the Company\u2019s auditor since 202We have served as the Company\u2019s auditor since 2024. The Company\u2019s audit committee\u2019s auditor since 2024We have served as the 2024We have served as our auditWe have served as the Company\u2019s audit report. \u2014 2020. At the Company\u2019s auditorWe have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor of the Company\u2019s auditor since 2024We have served as the Company\u2019s auditorWe have served as the Company\u2019s auditor since 2024We are the Company\u2019s auditor since 2024We are the inception. The Company\u2019s auditor since 2024, 2024We are the Company\u2019s auditor since 2024 years ago. Our auditor\u2019s auditor of the Company\u2019s auditor since  / 1. At the Company\u2019s auditor since 2024Attested the Company\u2019s auditor since 2024We are the Company\u2019s auditor since 1. 2024. The Company\u2019s auditor of the Company\u2019s audit report and the Company\u2019s auditor since 2024We have served as the Company\u2019s audit and 2024We are the Company\u2019s audit committee\u2019s audit and the Company\u2019s auditor since 2024We are the Company\u2019s auditor since \n\n\n\n\n\nAuditor, 2024We are the Company\u2019s auditor since 2024The Company\u2019s auditor\u2019s auditor since 2024By our auditorThe audit and will the Company\u2019s auditor since 2024At the Company\u2019s auditor\u2019s auditor since 2024. The audit committee since 2024We have served as the Company\u2019s auditor since 1. Attesterserved as the Company\u2019s net income and 2024The audit our audit report accompanying audit report. At the Company\u2019s auditor\u2019s audit partner of record\u2019s auditor since 2024"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?",
        "options": {
            "A": "Having exclusive rights to future programs",
            "B": "Primary responsibility for conducting marketing activities",
            "C": "Demonstrating sufficient cash resources and personnel",
            "D": "Approval from the external governing board",
            "E": "Completion of preclinical research activities",
            "F": "An environmental impact assessment"
        },
        "LLM_original_answer": [
            "Based on behalf of the Company\u2019s auditor for the Company\u2019s auditor for the Company\u2019s auditor since 2024\nAuditorReported the Company\u2019s auditor since 2024We have served as our audit audit opinionallyState\u2019s auditor since ertserved as our audit. The Company\u2019s auditor since ........................---The Company\u2019s auditor since 2024We are the Company\u2019s management\u2019s auditor since 2024We have served as the Company\u2019s auditor/since \n\n\n\n\n\nAuditor since 2024. At the Company\u2019s auditor for the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 1.2024We have served as the Company\u2019s audit report and our audit report is the Company\u2019s auditor since 112, among the Company\u2019s auditor since 2024The Company\u2019s auditor since 2024. Our audit report as the Company\u2019s auditor\u2019s auditoriumserved as the Company\u2019s revenue and the Company\u2019s auditor\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024Our audit the Company\u2019s auditor for the audit report date 2024We have served as the Company\u2019s auditor since 2024The Company\u2019s auditor of the Company\u2019s auditor since 2024We have served as the Company\u2019s audit our audit and the Company\u2019s auditor since 2024We are the Company\u2019s auditor\u2019s audit the Company\u2019s auditor since 1. The Company\u2019s auditor since 2024We have served as required as the audit the Company\u2019s auditor of the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s auditor since 2024We are the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s auditor\u2019s auditor since 1We have served as our audit and have served as the Company\u2019s audit of 1. \u2014 and auditor of the Company\u2019s audit and the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s auditor since 1We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor.2024\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What do the valuation experts incorporate in their pricing process?",
        "options": {
            "A": "Only the historical market trends",
            "B": "Calculations based solely on risk premiums",
            "C": "Assumptions related to non-market activities",
            "D": "Industry survey results and client feedback",
            "E": "Internal financial projections",
            "F": "Unrelated economic indicators"
        },
        "LLM_original_answer": [
            "The Company\u2019s auditor since 1. Attestedited as the the Company\u2019s auditor since 2024\nAuditorSince our audit. The Company\u2019s auditor. The Company\u2019s audit and will and the Company\u2019s auditor\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s audit report the Company\u2019s auditor since 63%Table 2024We have served as the Company\u2019s audit the Company\u2019s auditoriumberSince 2024The Company\u2019s auditor and 30We have served as the Company\u2019s audit report on 2024At the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as a. Our audit services as the Company\u2019s auditor\u2019s auditor, 2024We have served as the Company\u2019s auditor\u2019s auditor\u2019s audit opinion, 2024We have served as the Company\u2019s auditor\u2019s audit. The audit report on  / auditor since 2024We have served as the Company\u2019s audit reportOur audit report and the Company\u2019s auditor since 2024We are the Company\u2019s audit reportable the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024, 2024We have served as the Company\u2019s auditor\u2019s auditoriumbered as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since \n\n\n\n\n\nAuditor, ################################################################################The Company\u2019s auditor since 2024The Company\u2019s auditor. At the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024Audit Committee\u2019s auditor since 2024 years. The Company\u2019s auditor. The Company\u2019s audit opinion and have served as the Company\u2019s auditor since 1, 2024The Company\u2019s auditor since 2024We are the Company\u2019s inception. The Company\u2019s auditor since 2024\nPrepared as of our auditor since 2024We are the Company\u2019s auditor\u2019s auditor since icer served as well-We are a\nDelaware that is the Company\u2019s auditor since 2024We are the Company\u2019s auditor\u2019s auditor\u2019s auditor\u2019s audit and presented the Company\u2019s auditor since 2024We are a management and auditorserved as required by the Company\u2019s audit and the Company\u2019s auditor since 2024\nAuditorial 2024We are the Company\u2019s audit"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?",
        "options": {
            "A": "Exclusive commercialization rights",
            "B": "Complete ownership of patents",
            "C": "Rights to revoke licenses",
            "D": "March-in rights",
            "E": "Rights to set the technology price",
            "F": "Rights to sell the technology internationally"
        },
        "LLM_original_answer": [
            "Based onetimeyAudit and our auditor since 2024We are the Company\u2019s auditor since 2024We have been the Company\u2019s auditor since 2024We have served as the audit committee\u2019s auditor since 2024We have served as the Company\u2019s audit the Company\u2019s auditor of the Company\u2019s auditor of the Company\u2019s auditor since the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since ........................\nSince 1. At the Company\u2019s auditor\u2019s auditor since 2024Auditor since 2024We have 2024We are the Company\u2019s auditor and are the Company\u2019s auditor since ........................Auditor of the Company\u2019s auditor since 2024\nThe audit and have been the Company\u2019s auditor since 2024We are the Company\u2019s auditor since 2024\nAuditorSince 100-year-ended the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s auditor\u2019s auditor since ertserved as the Company\u2019s auditor\u2019s auditor\u2019s auditor\u2019s auditor\u2019s auditor\u2019s audit and have been the Company\u2019s auditor since 1We have served as the Company\u2019s management lettered 2024The audit report and 2024At the same year 2024We have served as the Company\u2019s auditor of the Company\u2019s auditor\u2019s auditor\u2019s auditor\u2019s auditoriumberedited as our audit procedures to the Company\u2019s auditor\u2019s auditor\u2019s auditor\u2019s management\u2019s auditor and 2024We have served as the auditor since 2024We have served as the Company\u2019s auditor\u2019s auditorThe audit report and its auditor and we have served as the Company\u2019s auditor\u2019s audit reportOur audit opinionedAttested auditor since 2024We are the Company\u2019s audit and will bequestor\u2019s auditor since 2024We are the Company\u2019s auditor since 2024We are the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s audit opinionedited as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s audit report and 2024At the Company\u2019s auditorWe have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor. The Company\u2019s auditor since 2024We have"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?",
        "options": {
            "A": "Linda Arsenault",
            "B": "Debra Canner",
            "C": "Camille L. Bedrosian, MD",
            "D": "John Smith",
            "E": "Maria Gonzalez",
            "F": "James Patel"
        },
        "LLM_original_answer": [
            "The Company\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s auditor\u2019s audit report and served as the addresserobviously, among other auditorserved as the Company\u2019s auditWe have served as the Company\u2019s auditor since 2024We have been the Company\u2019s auditorWe have served as the Company\u2019s auditor\u2019s auditor, 2024We have served as the Company\u2019s auditor\u2019s auditor\u2019s consolidated financial statements contained as theopposed as the Company\u2019s management and served as the Company\u2019s auditor since 2024We have served as the Company\u2019s audit report on behalf of 1. At our audit and 1We have served as the Company\u2019s audit report on 2024At the auditor since 2024We are the Company\u2019s management\u2019s auditor since ertserved as the Company\u2019s audit committee\u2019s auditor since 2024At the audit committee\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s auditor since \n\n\n\n\n\nAuditor\u2019s auditor since \n\n\n\n\n\n##Auditor\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have been the Company\u2019s auditor\u2019s auditor since 2024We have served as the Company\u2019s auditor\u2019s auditor\u2019s auditor\u2019s auditor\u2019s auditor. At the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor. The Company\u2019s auditor of the Company\u2019s auditor and 2024We have served as the Company\u2019s audit opinion and have served as the Company\u2019s auditor since 1, 2024The Company\u2019s auditor since 2024We are 2024We are the Company\u2019s auditor since 2024We have served as our audit the Company\u2019s auditor since 2024We are the Company\u2019s auditor of the Company\u2019s auditor\u2019s auditor\u2019s auditorized auditor for the Company\u2019s auditor\u2019s auditor since 112We are the Company\u2019s auditor since 2024We are the Company\u2019s management\u2019s management and auditor. At the Company\u2019s auditor since 2024We have served as the Company\u2019s audit committee of the Company\u2019s audit and 2024We have served as the Company\u2019s audit and 2024We are the Company\u2019s auditor since 2024We are the Company\u2019s auditor since 2024The audit report on 2024We are the auditor since 2024\nDelaware that is the Company\u2019s auditor since 2024By our auditor\u2019s management and will the Company\u2019s auditor since 2024, and"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "At what point in time is the revenue for cash trading and equity options recorded?",
        "options": {
            "A": "At the beginning of the transaction",
            "B": "At the end of the fiscal year",
            "C": "At the point in time of the transaction",
            "D": "When the transaction is settled",
            "E": "At the time of customer payment",
            "F": "When the market closes for the day"
        },
        "LLM_original_answer": [
            "At the Company\u2019s auditor of the Company\u2019s auditoriumberSince 2024The audit committee\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s audit. 2024We have served as the Company\u2019s auditor. The Company\u2019s auditor of the Company\u2019s auditor. The Company\u2019s auditorWe have served as the Company\u2019s audit and 2024We have served as the Company\u2019s audit opinion and have served as the Company\u2019s auditor for the audit report on 202We have served as the Company\u2019s auditor since 2024We have served as our auditor since \n\n\n\n\n\nAuditor, \n\n\n\n\n\nAuditoriumber served as the Company\u2019s auditor since 2022We are the auditor of the Company\u2019s auditoriumber served as the Company\u2019s auditor. The Company\u2019s auditor since 112We are the Company\u2019s auditor since 2024Our management\u2019s auditor\u2019s auditor. The audit reports included the Company\u2019s management and/orSince 2024The Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since  / 2024We are the Company\u2019s audit the Company\u2019s audit and the Company\u2019s auditor since 2024We are the Company\u2019s auditor since \n\n\n\n\n\nAuditor, 2024We are the Company\u2019s audit committee members of the Company\u2019s auditor since 2024The auditour served as the auditorWe have the Company\u2019s auditor since 2024, erts and have served as the auditor since 2024We have served as the Company\u2019s auditor since 1. Our audit committeeWe have served as theft. The Company\u2019s auditor\u2019s net income tax year 202We are the Company\u2019s management\u2019s management\u2019s auditor. Attestedited as the Company\u2019s auditor since 2024We are the Company\u2019s predecessor\u2019s predecessor\u2019s audit the Company\u2019s auditor. 202 as the Company\u2019s auditor since 2024We are the 2024We are the Company\u2019s audit reportTo whom the Company\u2019s auditor since 2024, 2024The Company\u2019s auditor since ertserved as the Company\u2019s audit reports and the Company\u2019s auditor since 2024We are a copy of the Company\u2019s auditor\u2019s audit and the Company\u2019s auditor since 2024We are the Company\u2019s audit report/served as the Company\u2019s auditor since our audit,  / The Company\u2019s auditor since 2024We have served as the Company\u2019s audit. The audit and served as the Company\u2019s auditor\u2019s inception of the Company\u2019s"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?",
        "options": {
            "A": "60%",
            "B": "70%",
            "C": "75%",
            "D": "80%",
            "E": "Over 80%",
            "F": "90%"
        },
        "LLM_original_answer": [
            "Question ################################################################################We have served as the Company\u2019s auditor\u2019s auditor\u2019s auditor since 2024We have served as the Company\u2019s audit. We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s audit reportOur audit report and the Company\u2019s auditor since 2024We are the Company\u2019s audit reportable audit committee\u2019s auditor since 2024, ........................\nAuditor since 2024We are the Company\u2019s auditor since 2024We have served as the Company\u2019s auditoriumberSince 2024We have served as the Company\u2019s auditor since 1We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditWe have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditorWe have served as the Company\u2019s auditor of the Company\u2019s auditor since 2024The Company\u2019s auditor. The Company\u2019s auditorWe have served as the Company\u2019s auditor and 2024We have served as the Company\u2019s audit opinion and served as the Company\u2019s auditor since ........................\nAt 2024The Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since ertserved as the Company\u2019s auditor since 2022, and presented the Company\u2019s auditor since 2022We are the Company\u2019s auditor since 202We are our audit and we have served as the Company\u2019s auditor since 10We are the Company\u2019s auditor since 2024Our management\u2019s auditor\u2019s auditor since 2024The Company\u2019s management\u2019s audit and auditorserved as the Company\u2019s auditor since 2024We have served as the Company\u2019s auditor since \n\n\n\n\n\nAuditor, 2024We served as the Company\u2019s audit and the Company\u2019s auditor since 2024We are the Company\u2019s auditor since \n\n\n\n\n\nAuditor, 2024We have served as the Company\u2019s audit and auditor since 2024We have served as the Company\u2019s auditor\u2019s audit report on the Company\u2019s auditor since 2024, erts and our report and have served as the Company\u2019s auditor since ################################################################################Auditor\u2019s auditor since 1. At the Company\u2019s auditor since ################################################################################Auditor\u2019s auditor\u2019s auditor\u2019s auditor since 2024We have served as the Company\u2019s management\u2019s auditor since 2024We have served as the Company\u2019s auditor since 2024. The audit reports on \ufeff\n\nAuditor\u2019s auditor since 202, and are the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?",
        "options": {
            "A": "Results of operations",
            "B": "Capital requirements",
            "C": "Stock performance graph",
            "D": "Financial condition",
            "E": "Contractual arrangements",
            "F": "Limitations in debt agreements"
        },
        "LLM_original_answer": [
            "The 1050 lease, or the 1050, or the lease, or lease, or the 1050 Lease, or the 1050 lease, or lease, or the 1050 lease, or the 1050 1050, or the 1050 Walth 1050 Walth of lease, or the 1050 1050 lease, or the 1050 1050 1050 lease, or the 1050 lease, or the 1050 1050 Waltham entered into 1050 lease, or the 1050 1050 1050 lease, or the 1050 1050 lease, or the 1050 1050, or the 1050 lease, or the 1050 1050 Walthem lease, or the 1050 1050 indenture of lease, or the 1050 Lease 1050 lease, or the 1050 1050 W Lease, or the 1050 lease, or the 1050 lease, or the 1050, or the 1050 lease, or the 1050 lease, or the 1050 1050 Walth of lease, or lease, or the 1050 lease, or the 1050 Walth of lease, or the 1050 1050 lease, or the 1050 lease, or the 1050 lease, or the 1100 of lease, or the 1050 1050 lease, or the 1050 1050 lease, or the 1050 lease, or the 1050 Lease of lease, or the 1050 lease, or the 1050 lease, or the 1050 Waltham, or the 1050 lease, or the 1050 lease, or the 1050 lease, or the 1050 lease, or the 1050 1050 lease, or the 1050 lease, or the 1050 Walth 1050 lease, or lease, or the 1050 1050 lease, 1050 Lease, or the 1050 lease, or the 1050 lease, or the 1050 Walthem entered into lease, or the 1050 lease, or the 1050 1050 Walth lease, or lease, or the 1050 1050 1050 Walthem lease, or the 1050 lease, or the 1050 "
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?",
        "options": {
            "A": "A complete dismissal of all lawsuits",
            "B": "A $15 million secured claim",
            "C": "A final release of all claims with Gryphon Digital Mining",
            "D": "An allowed $10 million general unsecured claim",
            "E": "Ownership of new mining equipment",
            "F": "A partnership extension with Gryphon"
        },
        "LLM_original_answer": [
            "Sphere 1##table 33##table 33##table 85##table 33##table 1##table 85##table 33##table 85##table 85##table 33##Certain information ##table 33##85##table 33##85##85##table 33##85##table 33##table 85##table 85##table 33##table 85##table 85##table 33##table 85##table 85##table 85##85##85##Certain Information Item 85##table 33##table 85##table 85##table 33##table 85##85##85##table 33##85##table 85##85##85##table 33##87##table 10##table 35##table 85##table 33##85##85##Certain Information and Other Information85##table 85##table 85##table 85##table 85##table 33##table 85##table 33##85##table 33##85##table 85##85##87##87##85##85##87##85##table 33##87##87##87##87##87##table 85##table 35##table 85##table 33##87##table 33##85##85##85##85##table 85##85##table 33##87##87##table 85##table 95##table 85##table 33##table 85##table 85##table 33##table 35##table 85##table 85##87##table 85##Certain Information\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?",
        "options": {
            "A": "A significant financial penalty was imposed",
            "B": "The case was settled with a material financial impact",
            "C": "The lawsuit was dismissed",
            "D": "The resolution caused Duke Energy Carolinas to alter the dam structure",
            "E": "Duke Energy Carolinas had to issue a public apology",
            "F": "The case is still ongoing"
        },
        "LLM_original_answer": [
            "What is required to perform required to identify required to perform required to perform required to perform required to recoveries required Duke Energy, Duke Energy, Progress Energy, Duke Energy Indiana, Duke Energy Ohio and Duke Energy Efficiency Energy, Duke Energy, Progress Energy, Progress Energy, Progress Energy, Progress Energy, Progress Energy, Piedmont are required to perform required to perform testing and Duke Energy, Duke Energy, Duke Energy Ohio and Duke Energy and Duke Energy, Progress Energy Ohio and Piedmont Duke Energy, Progress Energy, Duke Energy Ohio and Piedmont are required to perform required to identify required to perform annual are required Duke Energy Ohio and Piedmont are required to perform required to perform required to perform required Duke Energy Ohio and Duke Energy, respectively required to recoveries required to customers are required to perform required to perform required to customers' Progress Energy Efficiency, partially offset by the variance testing Duke Energy Ohio's Recovery of Duke Energy Ohio and optimization of the required due to include higher interest rate case-specifically, as a decrease in the Ohio, partially offset by higher interest and partially offset fuel cost required to Recovered Progress Energy and Duke Energy Testing Energy Ohio and Duke Energy, Duke Energy Testing, Progress Energy, Progress Energy TestingDuke Energy Ohio and Piedmont are required to perform required to recoveries are required to Duke Energy, Duke Energy, Progress Energy Asset Retirement of Duke Energy, Progress Energy, Progress Energy Energy Energy Ohio are required to be required to apply Duke Energy and Duke Energy Ohio and Duke Energy Ohio and Duke Energy, Piedmonts required to recordable Energy, Progress Energy Ohio and Duke Energy, Duke Energy, Progress Energy Ohio and Duke Energy TestingDuke Energy, Progress Energy, Progress Energy Ohio and Duke Energy and Duke Energy Testing Duke Energy, as a)Duke Energy, Progress Energy Tax Equity Interest Rate Case ired Energy TestingDuke Energy Tax Efficiency Test Results of the required to be required to customers'Progress Energy Electric Utilities, Duke Energy, Progress Energy, Progress Energy, Duke Energy, Duke Energy, as a required testing Duke Energy, Duke Energy, Progress Energy, Progress Energy Ohio and Duke Energy, Duke Energy, in certain Duke Energy, Progress Energy, Progress Energy Ohio and Progress Energy, Duke Energy, Duke Energy, Duke Energy Ohio and required to reflect the required to identify the required to customers and Duke Energy and Duke Energy and Progress Energy Utilities are required Duke Energy Ohio and the required Duke Energy, among others are required to customers'Progress Energy Rate of the required Duke Energy Rate Recovery Energy, Progress Energy, Duke Energy, Progress Energy Ohio and Piedmont"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?",
        "options": {
            "A": "A detailed financial statement",
            "B": "A personal or corporate guarantee",
            "C": "An independent appraisal review",
            "D": "Proof of project completion",
            "E": "An environmental impact assessment",
            "F": "A feasibility study"
        },
        "LLM_original_answer": [
            "Based on net assets acquired.We evaluate for impairment at least annually.We evaluate at least annually.We evaluate at least annually.We evaluate our operations.We evaluate at least annually.We evaluate at least annually.We evaluate at least annually.We evaluate our operations.We evaluate at least annually.We evaluate for impairment.We evaluate for impairment at least annually at least annually.We evaluate at least annually.We evaluate at least annually at least annually.We evaluate for impairment.We evaluate for impairment at least annual on net of Eastern Bank of net assets acquired assets acquired.We evaluate net assets acquired at least annually.We evaluate annually.We evaluate at least annually.We evaluate for impairment of assets.We evaluate net assets at least annually.We evaluate for impairment of net assets for impairment of impairment.We evaluate annual.We evaluate for impairment for impairment for impairment.We evaluate for impairment of net assets acquired assets.We evaluate our annual impairment at least annually.We evaluate at least annually.We evaluate for impairment at least annually annually annually annually.We evaluate at least annually.We evaluate at least annually.We evaluate for impairment at least annually.We evaluate at least annually.We evaluate for net assets.We evaluate for impairment.We evaluate for impairment.We evaluate goodwill for impairment at least annually.We evaluate for impairment.We evaluate for impairment.We evaluate annual results of net assets acquired at least annually.We evaluate for impairment.We evaluate for impairment.We evaluate annual.We evaluate for impairment.We evaluate annually.We evaluate at least annually.We evaluate for impairment.We evaluate annual goodwill for impairment.We evaluate for impairment testing impairment.We evaluate annually.We also annually.We evaluate for impairment.We evaluate for impairment.We evaluate at least annually.We evaluate at least annually at least annually at least annually.We evaluate for impairment at least annually for impairment at least annually at least annually at least annually at least annually at least annually annually at least annually annually.We evaluate for impairment.We evaluate annually at least annually annually at least annually at least annually annually annually annually annually acquired.We evaluate for impairment for impairment charges on or other financial institutions for impairment.We evaluate at least annually at least annually annually annually annually annually annually annually annually annually annually annually annually annually.We evaluate at least annually.We evaluate for example at least annually at least annually at least annually at least annually.We evaluate for at least annually.We evaluate at least annually for impairment at least annually.We evaluate the COVID-impair until the fair value of net assets and net assets, among other than Eastern Bankruptcy at least annually, as well as well as a prior to the fair value at least annually, if at least annually, which may acquire at least annually annually.We evaluate annually.We evaluate at least annually.We evaluate for at least annually to the COVID- at least annually at"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?",
        "options": {
            "A": "Having exclusive rights to future programs",
            "B": "Primary responsibility for conducting marketing activities",
            "C": "Demonstrating sufficient cash resources and personnel",
            "D": "Approval from the external governing board",
            "E": "Completion of preclinical research activities",
            "F": "An environmental impact assessment"
        },
        "LLM_original_answer": [
            "What is the (Form \u0001\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What do the valuation experts incorporate in their pricing process?",
        "options": {
            "A": "Only the historical market trends",
            "B": "Calculations based solely on risk premiums",
            "C": "Assumptions related to non-market activities",
            "D": "Industry survey results and client feedback",
            "E": "Internal financial projections",
            "F": "Unrelated economic indicators"
        },
        "LLM_original_answer": [
            "Based by a higher margin generated by our Correspondent channel generated by a higher margin generated by our Correspondent by our Correspondent by a higher margin generated by our Correspondent channel and a higher margins generated by our Correspondenthuslipenerget the generated by our Correspondentertainly generated by a higher margin generated by our Correspondent channel generated by our Correspondentences.The following a higher margin generated by our Correspondent channel and/or a higher margin generated by a generated by a lower margin generated by our Correspondentertain channel and partially offset by our Correspondentiregenerated by our Correspondenthusortional Correspondenthussthat israelts channel and partially offset by our Correspondentireportentomission channel and our Correspondentertain margins, partially offset by our Correspondentorts of our Correspondentirenobody[channel margin, partially offset by our Correspondentire the servicerents and/oriententire a higher margins generated by our Correspondentent channel and/or repurchase our Correspondentirepersistence channel and the servicerentservant margins, partially offsetting channel and/or the industry-wide margin generated by our Correspondenthe Correspondenthus offset by a higher margins, partially offset by our Correspondentire by a higher margin generated by our Correspondent channel.We may be partially offset by our Correspondentertain higher margins generated by a lower margins generated by our Correspondenters.48margin generated by our Correspondent channel and/or generated by a higher margin generated by our Correspondent.The industry-wide margin generated by a higher offset by a higher margin generated by our Correspondent channel, partially offset by our servicerentire by a higher margin generated by our Correspondent channel generated by a higher margin generated by our Correspondenthuspondent channel and/or partially offset by our Correspondentirentotaly partially offset by a higher margin generated by our Correspondent channel.We may be partially offset by our Correspondentour Correspondent by a higher margin generated by our Correspondent by a higher margin generated by our Correspondent margin generated by our Correspondent channel and/or our Correspondenthe higher margins generated by our subservant by a higher margin generated by our Correspondentors channel and the higher margin generated by our Correspondent.The margin generated by our Correspondenthealty to originate and/orchance of our Correspondentailloanscient channel and/orient partially offset by our Correspondentirenterior channel generated lower marginally channel and the higher margins generated lower margins generated by our Correspondentenceshorton our Correspondenthe Correspondenthe higher margins"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?",
        "options": {
            "A": "Exclusive commercialization rights",
            "B": "Complete ownership of patents",
            "C": "Rights to revoke licenses",
            "D": "March-in rights",
            "E": "Rights to set the technology price",
            "F": "Rights to sell the technology internationally"
        },
        "LLM_original_answer": [
            "What is subject to its original certificate of its original certificate of the original certificate of incorporation or bylaws of the original certificate of its original certificate of the original certificate of incorporation or by amendment to which is by amendment to its original certificate of incorporation or by amendment to its original certificate of incorporation or by amendment to its original certificate of incorporation or by amendment to its original certificate of its original certificate of incorporation or by amendment to its original certificate of by amendment to its original certificate of its original certificate of its original certificate of its original certificate of its original certificate of the original certificate of its original certificate of its original certificate of its original certificate of its original certificate of its certificate of its original certificate of its original certificate of its original certificate of its original certificate of its original certificate of its original certificate of the original certificate of incorporation or by amendment to the original certificate of the original certificate of incorporation or bylaws certificate of its original certificate of the original certificate of the original certificate of the original certificate of original certificate of the original certificate of its original certificate of the certificate of incorporation or by amendment to the original certificate of the original certificate of the original certificate of its original certificate of incorporation or by amendment to the original certificate of its original certificate of its original certificate of its original certificate of incorporation or by amendment to its original certificate of incorporation or bylaws of its original certificate of its original certificate of its original certificate of its original certificate of by amendment to its original certificate of its original certificate of amendment to its original certificate of incorporation or by amendment to its original certificate of amendment to its certificate of its original certificate of the original certificate of its original certificate of the original certificate of the original certificate of the original certificate of its original certificate of the original certificate of the original certificate of the original certificate of the original certificate of the original certificate of incorporation or by amendment to its certificate of amendment to amend the original certificate of incorporation or by amendment to the original certificate of the original certificate of the original certificate of the original certificate of its original certificate of the original certificate of the original certificate of incorporation or by amendment to its original certificate of incorporation or bylaws of a certificate of incorporation or by amendment to amendatory provision in the original certificate of its original certificate of the original certificate of the original certificate of the original certificate of incorporation or by amendment to its original certificate of its original certificate of the original certificate of amendment to-beamendment to original certificate of incorporation or by amendment to its original certificate of the original certificate of incorporation or bylaws original certificate of the original certificate of incorporation or by provision in the original"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?",
        "options": {
            "A": "Linda Arsenault",
            "B": "Debra Canner",
            "C": "Camille L. Bedrosian, MD",
            "D": "John Smith",
            "E": "Maria Gonzalez",
            "F": "James Patel"
        },
        "LLM_original_answer": [
            "Delegally plan to conduct this may be beyond what we may be able to plan to plan to obtain regulatory approvals in the clinical trials beyond what we may be beyond what we may plan to obtain what we may not what we may not be required to plan to obtain regulatory approval and the regulatory approval from what we may not plan to conduct this may not plan to what we may plan to support to plan to conduct.This may be beyond what we may not be required to conduct.We may plan to conduct this may be what we may plan to conduct this may plan to plan to what we may not what we may plan to conduct to conduct.\u2022\n\nRisk Factors, and the FDA or not only what we may be plan to conduct this may not be required by what we may plan to conduct this may not only plan to conduct this may be required to conduct this may be what we may plan to support may be required to conduct this may not what we may plan to conduct this may be required by what we plan to conduct may be beyond what we may not plan to conduct what we may plan to plan to conduct this may plan to conduct.This may be required clinical trials, or may be required to conduct this may be beyond what we may not what we may plan to obtainable to conduct this may require to what we may plan to satisfy what we may be required to conduct this may be beyond what we may not what we may be beyond what we may plan to support what we may plan to support the regulatory approvals in the regulatory approvals from what we may not plan to conduct this may be required clinical trials to conduct.This may be required by what we may plan to what we may not what we may plan to what we may not only what we may be required beyond what we may not what we may plan to conduct this may plan to what we may plan to what we may plan to conduct.This may be subject to conduct this may not only what we may plan to support may require additional clinical trials may be beyond what we may plan to what we may plan to obtainable may not to conduct this may be beyond what we may not what we may not what we may be beyond what we may plan to conduct this may not plan to conduct this may not to what we may plan to conduct this may plan to conduct our plans to conduct to conduct this may plan to conduct this may not be beyond what we may not only what we may plan to obtain approval of what we may be conducted beyond what we may plan to conduct this may plan to conduct this may plan to conduct to conduct"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "At what point in time is the revenue for cash trading and equity options recorded?",
        "options": {
            "A": "At the beginning of the transaction",
            "B": "At the end of the fiscal year",
            "C": "At the point in time of the transaction",
            "D": "When the transaction is settled",
            "E": "At the time of customer payment",
            "F": "When the market closes for the day"
        },
        "LLM_original_answer": [
            "At 125125During 125During 125During 125125125During 2022During 125125125During 125During 125During 125During 125125125125125125During 125During 125During 1255During 1256During 1255125125125125125125125125125125125125During 125During 125125125During 125125125125125In 125During 125125125125125125125125125125125125125During 125125125125125125During 125125During 125During 125125125125125125125125125125125125125125125125125125125125125During 125125125125125125125125125125125125125125125125125125125125125During 125125125125125125During 1251251251251251251251251251251251251251251251251251251251251251251251256During 1251251251251251251251251251256During 1251251251251255The125125125125125125125During 1251251251251251256The merger members of our business or cash.125125125125125125125125125125125125125125During 125125125125125During 125125125125125125125125125125125125125125125During 125125125125125During 125125125125During 2022During 2022During 125During 1251251256During 125During 125125During 2022During 125125125During 2022During 2022During 1251255During 1256During 1251251251256During 125125125During 125125125125125125During 2022During 2021, the merger or acquisition of 125125During 2022Cash125125125During 1, which resulted in cash.125125125During 2022During 2022During 125During 2022During 125125During 2022During 1251251255During 125During 2022During 125During 2022During 125During 125125During 125During 1251251251251255During 1251251255During 2022During 125125125125125During 125125125125During 125125125During 125During 1251251255During 1255During 125125125"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?",
        "options": {
            "A": "60%",
            "B": "70%",
            "C": "75%",
            "D": "80%",
            "E": "Over 80%",
            "F": "90%"
        },
        "LLM_original_answer": [
            "What was issued by-prime RMBS portfolio, among other than our prime RMBS portfolio consists predominantly of securities that were issued predominantly of the portfolio consists predominantly of securities that were issued by usury RMBS securities that were to which were predominantly of the portfolio, or guarant-prime RMBS portfolio.Our sub-prime RMBS portfolio consists predominantly consist predominantly non-prime portfolio consists predominantly consists predominantly of the portfolio consists predominantly consists predominantly consists predominantly of the portfolio consists predominantly of securities that were issued by and were issued RMBS portfolio.We are subject to a resultantly, or were issued securities that were issued securities that were valued securities that were issued by us portfolio.We are subject portfolio.Our sub-prime RMBS portfolio consists predominantly consists of securities that were issued by and sub-prime RMBS that were issued securities that were issued RMBS portfolio consists predominantly of securities that were issued predominantly consists predominantly of the portfolio consists predominantly originated portfolio consists predominantly consists predominantly of the portfolio consists of the portfolio consists predominantly of the portfolio consists of prime mortgage portfolio consists predominantly of securities that were issued by and/or were issued securities that were issued RMBS portfolio consists predominantly of securities that were issued securities that were RMBS portfolio consists predominantly of securities that were issued by and sub-prime portfolio consists predominantly RMBS portfolio consists predominantly of the RMBS portfolio consists of securities that were issued by and continue to-behind-redemption predominantly of the portfolio consists predominantly consists predominantly of the portfolio consists predominantly of the portfolio that were issued securities that RMBS portfolio that were issued by-prime that were issued securities that were valued portfolio consists predominantly of the portfolio consists predominantly of the portfolio consists predominantly of securities that were issued by and/or were issued by and/or their respective to a\n[portfolio predominantly consists predominantly consists predominantly consists predominantly of the portfolio.The portfolio consists predominantly residential mortgage portfolios consist predominantly of the portfolio.The portfolio consists predominantly RMBS portfolio consists primarily of securities that were issued by and/or securities that were issued by the portfolio consists primarily RMBS portfolio may be-issued predominantly consists predominantly of the portfolio consists predominantly consists predominantly consists primarily RMBS portfolio consists predominantly consists predominantly consists predominantly of securities that were issued RMBS portfolio.The portfolio consists predominantly consists predominantly consists predominantly consists predominantly of securities that were issued by RMBSMSMA portfolio that were issued by securities that were issued securities that were issued securities that were RMBS portfolio consists primarily of securities that were issued by and/or securities that were issued by-late securities that were substantially pre-dictimate portfolio consists predominantly of the portfolio consists primarily due to a result of the portfolio, among our"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What factor does not influence the discretion of the board of directors in deciding to pay cash dividends?",
        "options": {
            "A": "Results of operations",
            "B": "Capital requirements",
            "C": "Stock performance graph",
            "D": "Financial condition",
            "E": "Contractual arrangements",
            "F": "Limitations in debt agreements"
        },
        "LLM_original_answer": [
            "What are contagious diseases, or foreign partners; interruptions resulting from natural disasters, outbreaks of contagious diseases, or outbreaks of contagious diseases, and outbreaks of foreign partners;\u25aa outbreaks of contagious diseases, or outbreaks of contagious diseases, and contagious diseases, outbreaks of contagious diseases, outbreaks of contagious diseases, including natural disasters, or natural disasters, or outbreaks of contagious diseases, outbreaks of contagious diseases, outbreaks of contagious diseases, and foreign partners;\u25aa= \u25aa contagious diseases resulting from foreign partners, outbreaks of contagious diseases, and outbreaks of foreign partners;\u25aa; and as well as of outbreaks of foreign partners;\u25aa=; or natural disasters, or outbreaks of contagious diseases, or outbreaks of foreign partners, or outbreaks of foreign partners;2022\n\u25aa interruptions resulting from foreign partners; and foreign partners;\u25a9 of natural disasters, or natural disasters, or contagious diseases, or natural disasters, or natural disasters, or outbreaks of contagious diseases, or contagious diseases, and other business interruptions resulting from foreign partners; and natural disasters, or outbreaks of contagious diseases, and outbreaks of contagious diseases, or foreign partners; and foreign partners; and foreign partners; and foreign partners; and foreign partners;\u25aa or contagious diseases, outbreaks of contagious diseases, or other business interruptions resulting from foreign partners; and outbreaks of contagious diseases, outbreaks of contagious diseases, outbreaks of foreign partners; or contagious diseases of contagious diseases, or other contagious diseases, outbreaks of contagious diseases, or partners;84KER-84 or natural disasters, outbreaks of contagious diseases, outbreaks of contagious diseases, outbreaks of contagious diseases of contagious diseases, outbreaks of outbreaks of contagious diseases, or contagious diseases, and/or outbreaks of contagious diseases, or outbreaks of contagious diseases, outbreaks of outbreaks of contagious diseases, outbreaks of contagious diseases, or outbreaks of contagious diseases, or other; and other, or outbreaks of contagious diseases resulting from foreign partners;\u25aa contagious diseases, outbreaks of certain; or foreign partners;2022\nor outbreaks of contagious diseases, outbreaks of contagious diseases, and foreign partners; and/or foreign partners;2022.2024 or business interruptions resulting from foreign partners; and other than foreign partners; and certain diseases, and foreign partners;2022.84KER-foreign partners; and contagious diseases, or natural disasters, or outbreaks of contagious diseases, and natural disasters, outbreaks of natural disasters, or contagious diseases, outbreaks of contagious diseases, or outbreaks of contagious diseases; and natural disasters, outbreaks of contagious diseases, outbreaks of contagious diseases, outbreaks of contagious diseases resulting from the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What was granted to Sphere 3D Corp. by the Bankruptcy Court on January 16, 2024?",
        "options": {
            "A": "A complete dismissal of all lawsuits",
            "B": "A $15 million secured claim",
            "C": "A final release of all claims with Gryphon Digital Mining",
            "D": "An allowed $10 million general unsecured claim",
            "E": "Ownership of new mining equipment",
            "F": "A partnership extension with Gryphon"
        },
        "LLM_original_answer": [
            "Sphere Construction Company\u201d) against the Company, Harper (\u201cHarper all claims of Harper Construction Company, Inc (\u201cHarperpet\u201d) against the (\u201cHarper Construction Company, Harper\u201d) against the Company, Harper (\u201cHarper Harper Construction Company, Harper Construction Company, (\u201cHarper\u201d) against the Company (\u201cHarper\u201d) against the against the Debtors and Harper Construction Company, Harper Construction Company, Inc (\u201cHarper\u201d) against Harper\u201d) against the Debt (\u201cHarper Harper Construction Company, Inc (\u201cHarper\u201d) and/or otherwise and/or otherwise and/or otherwise (\u201cHarper all claims of Harper (\u201cHarper Construction Company, (\u201cHarper\u201d) against the Company (\u201cHarper Harper Construction Company\u2019s business, which may be Harper Construction and/or otherwise force Harper (\u201cHarper Harper\u2019s Harper (\u201cH Construction Company, and/or otherwise and/or otherwise and/or otherwise and/or otherwise (\u201cHarper\u201d) against the Harper (\u201cHarper and/or otherwise establish and/or otherwise and/or otherwise failings and/or otherwise may befit\u201d) against the Company\u2019s Harper Construction Company, or otherwise may be settled all (\u201cHarper (\u201cHarper\u201d) against the Harper Construction Company, all claims of Harper Construction, Inc (\u201cHarper\u201d) against the Debtors against the claims (\u201cHarper\u201d) against the Company and/or otherwise (\u201cHarperpet all claims of Harper Construction Company, which may have (\u201cHarper Harper\u201d) and may have been and/or otherwise. Harper Construction Company, and/or otherwise and/or otherwise (\u201cHarper septic (\u201cHarper against the (\u201cHarper Harper (\u201cHarper against the claims of the Company, which may be settled and/or otherwise establish and/or otherwise and/or otherwise and/or otherwise have all claims of Harper Construction Company, which may have a result in Harper (\u201cHarper Harper Construction Company, which may have a significant deficiencies of Harper Construction Company, which as a result in the Harper (\u201cSettlement and/or otherwise and/or otherwise and/or otherwise and/or otherwise than may have a result in the Harper Construction Company and/or otherwise and/or otherwise known (\u201cHarper\u201d) against the Company\u201d) against the Company, which may be negatively impact the Company, which may be lessor\u201d) against the value of the Company, which could have a material weaknesses and/or Harper Construction Company, Inc (\u201cHarper\u201d) against Harper Construction Company, Inc (\u201cHarper\u201d) against the (\u201cHarp\u201d) and/or Harper (\u201cHarper Construction Company (\u201cHarper\u201d) against the Company\u201d) against the Company, and/or Harper Construction Company, Inc (\u201cHarp\u201d) against the Harper\u201d) against the (\u201cHarper Harper"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What was the outcome of the lawsuit against Duke Energy Carolinas regarding the dam on the Dan River?",
        "options": {
            "A": "A significant financial penalty was imposed",
            "B": "The case was settled with a material financial impact",
            "C": "The lawsuit was dismissed",
            "D": "The resolution caused Duke Energy Carolinas to alter the dam structure",
            "E": "Duke Energy Carolinas had to issue a public apology",
            "F": "The case is still ongoing"
        },
        "LLM_original_answer": [
            "What, which occurred as a result of the following storms: Pax, U, U, and U.S, U, U, U.Sim, which storms: Pax, which occurred as a result of the following the following the following storms: Pax, U, U, and U, which required as a result of the following storms: Pax, U, storm recovery activities required as a result of the storms: Pax, U, and V, which required as a, and U, U, which occurred as a result as a result of the following the following: Pax, and U, U, which may require Pax, and/orb, which may require as a result as a result as a result as a result as a result as a result as a result of the following storms: Pax, Pax, Uga as a result as a result as a result of the following storms: Pax, Ursa, U.Semba, U, as a result as a result as a result as a result of the following: Pax, which required as a result as a result of the following storms: Pax, which resulted as a result of the following storms: Pax, U, U, U, U, and U, which occurred as a result of the following storms: Pax, U, U, U, U.Sem recovery activities required as a result of the following storms: Pax, Ber, and Ux, which as a result of the following storms: Pax, U, U, U, U, Uly as a result of the following storms: Pax, Pax, Pax, and U, U, U, U, U, and/or as a result as a result of the following the following the following the following hurricanes: Pax, U, Pax, Pax, as a result as a result as a result of the following storms: Pax, Pax, Pax, Pax, Pax, U.S. Hurricane, as a result as a result as a result as a result of the following the Duke, U.S. Pax, as a result as a result of the following the following storms: Pax, and/or recovery activities required as a result as a result of the following storms required as a result as a result of the: Pax, U, Ursa, U.Survies: U, Ux, U, U, U, U, U, U, U, and/or as a result of the following storms: Pax, Ursa, which are required as a result as a result as a result as a"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is typically required from individuals with significant ownership in a borrowing entity when the loan-to-value ratio of a commercial real estate loan exceeds a certain threshold?",
        "options": {
            "A": "A detailed financial statement",
            "B": "A personal or corporate guarantee",
            "C": "An independent appraisal review",
            "D": "Proof of project completion",
            "E": "An environmental impact assessment",
            "F": "A feasibility study"
        },
        "LLM_original_answer": [
            "Based of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Federal Reserve Board of the Board of the Board of the Board of the Board of the Board of the Board of the Federal Reserve System of the Board of the Federal Reserve Banks of the Board of the Board of the Board of the Board of the Board of the Board of the regulatory supervision of the the Governors of Governors of the Federal Reserve System, the System, the regulatory supervision of the Board of the regulatory supervision of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the regulatory supervision and the regulatory supervision and the Board of the Board of the Board of the regulatory supervision of the regulatory supervision and the the Board of the Board of the Federal Reserve System Board of the regulatory supervision of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Federal Reserve System of the Board of the Board of the regulatory and the regulatory supervision and the Federal Reserve Board of the Federal Reserve System of the Board of the Board of the regulatory supervision of the regulatory supervision and the Board of the Federal Reserve Board of the regulatory supervision and the regulatory supervision and the regulatory supervision and the Board of the Federal Reserve System, the Federal Reserve System, the Board of the Board of the regulatory supervision of the Board of the Board of the Board of the Board of the Board of the regulatory supervision and the Board of Governors of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the Board of the regulatory supervision of the Board of the Board of the Board of the Federal Reserve System of the Board of"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What determines the company's right to co-develop, co-promote, and co-commercialize a target?",
        "options": {
            "A": "Having exclusive rights to future programs",
            "B": "Primary responsibility for conducting marketing activities",
            "C": "Demonstrating sufficient cash resources and personnel",
            "D": "Approval from the external governing board",
            "E": "Completion of preclinical research activities",
            "F": "An environmental impact assessment"
        },
        "LLM_original_answer": [
            "What Control Laws.If we are not in the FCPAdeemedial requirements.If we are not in compliance with the FCPAdeals or Trade Control Laws Control Laws including Trade Control Laws Control Laws including Trade Control Control Control Laws Control Laws.If we are not in compliance with the FCPA, the FCPAmp laws, Trade Control Control Laws.If we are not in compliance with the FCPAdelegally compliant with the FCP Laws, Trade Control Control Laws including Trade Control Laws including Trade Control Laws, Trade Control Control Control Laws, Trade Control Control Control Laws or Trade Control Control Laws, Trade Control Laws or Trade Control Laws or Trade Control Laws Control Laws or Trade Control Laws including Trade Control Laws or Trade Control Laws including Trade Control Laws including Trade Control Laws including Trade Control Laws including Trade Control Laws Control Laws Control Laws and Trade Control Laws including Trade Control Laws including Trade Control Laws and Trade Control Laws Control Control Laws.If we are in compliance with FCPAdeemed with respect Trade Control Control Laws.If we are not in compliance with respect of the FCPA and Trade Control Laws including the FCP Laws including FCP Laws.If we are not in compliance with Trade Control Laws including the FCPAFCPA Laws.If we are not in compliance with Trade Control Control Control Laws including Trade Control Laws including Trade Control Laws including Trade Control Laws or Trade Control Laws or Trade Control Laws and Trade Control Control Control Laws and FCPAdegranted requirements including the FCPAdeals requirements including FCP Laws including the FCPAdeals not in compliance with respect the FCPAdealing Laws if we are not in compliance with the FCPA or Trade Control Laws in the FCPAdeemed requirements including Trade Control Laws including Trade Control Laws or Trade Control Control Control Laws or Trade Control Control Laws or Trade Control Laws Control Control Laws, Trade Control Laws or Trade Control Laws, the FCPA, FCPAdelegisl not in compliance requirements including Trade Control Laws.If we are not in compliance with the FCPA or Trade Control Laws, Trade Laws, the FCPAde in compliance with the FCP Laws.If we are not in compliance with the FCPA, FCPAdealing Laws, the FCPAdeals including Trade Control Laws or Trade Control Control Control Laws including Trade Control Control Laws or Trade Control Laws are not in compliance with the FCPA, the FCPAmitigation Laws or Trade Control Control Control Laws or Trade Control Laws or Trade Control Laws or Trade Control Laws"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What do the valuation experts incorporate in their pricing process?",
        "options": {
            "A": "Only the historical market trends",
            "B": "Calculations based solely on risk premiums",
            "C": "Assumptions related to non-market activities",
            "D": "Industry survey results and client feedback",
            "E": "Internal financial projections",
            "F": "Unrelated economic indicators"
        },
        "LLM_original_answer": [
            "The U.Seequoting to time to time to the interest in the time to time to time to time to time to time to time to that we enter a specific future interest rate of options to exchange-tradedep, we enter into exchange-traded options and exchange-traded time to time, we enter into a specific future date.We enter into time to time to time to time to time to time to time to time to time to time to time to time to time to time, we enter into exchange-traded options and other than time to time to the exchange-traded by time to time to time toeh to date.We enter into exchange-traded time to time to time to time to the time to time to time to the, we enter into exchange-tradedate, which we enter into exchange-traded to time to time to the value to the time to time to time to time to time to time to enter into exchange-tradede.greater to time to that the industry options to date.We enter into time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time, we enter into options, we enter into exchange-traded to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to the options.We have been subject to time to time to time to time to time to time to enter into exchange-traded time to time to time to time to time to time to time to time to time to time to time to time to time to the time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to time to the value, we enter into exchange-traded- options and exchange-traded time to time to time to time to time to time to time to time to time to the time to enter into the next to time to time to time to time to exchange-traded to the time to enter into exchange-trading to the reverse mortgage loans we enter into exchange-traded to time to time to time to time to time to time to the options and other to time to time to time to time to time to time to time to time to exchange-traded exchange-traded options and derivative options, we"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What rights does the U.S. government hold concerning government-funded technology under the Bayh-Dole Act?",
        "options": {
            "A": "Exclusive commercialization rights",
            "B": "Complete ownership of patents",
            "C": "Rights to revoke licenses",
            "D": "March-in rights",
            "E": "Rights to set the technology price",
            "F": "Rights to sell the technology internationally"
        },
        "LLM_original_answer": [
            "The TSC- or not others will obtain inventions covered by our patent claims by our patent claims or other or not covered by others will obtain patents claiming inventions similar to those covered by our patent claims will obtain patents claiming inventions similar to inventions covered by others\u2019 inventions or similar to our patent claims or those covered by our patent claims or whether or other will be covered by others will obtain patents. Background Technology Transfer Scan patents, or whether or whether or whether or that we have been covered by others will be will obtain patents, which we have been covered by our patent claims by our patent claims inventions similar to the or others will obtain patents claiming inventions similar to those covered by our patent claims. Patent or other than those covered by others will be covered by our patent claims inventions.28Patent inventions covered by others will obtain patents claiming inventions similar to those covered by others will be covered by obtaining inventions.26or not covered by our patent claims inventions similar to those covered by our patent claims by our patent claims covered by others. Patent claims by our patent claims. We are or those claiming inventions similar to those claiming inventions will be covered by others will be covered by our patent claims. Patentable inventions similar inventions similar to those covered by our patent claims or those covered by others claiming inventions.We have obtained by obtaining patents claiming inventions similar to those covered by our patent claims claiming inventions similar to those claiming inventions similar to those covered by others, or not covered by others will obtain by our patent claims by others will be our patent claims or similar to those covered by obtaining inventions similar to those covered by our patent claims by others will be covered by our patent claims or whether or not covered by which will obtain patents claiming inventions similar to those covered by our patent claims, or will be or not covered by our patent claims similar to those covered by patents or those covered by our patent claiming inventions similar to those covered by our patent claims or will obtain patents or others will be our patent or whether or others will obtain patents or other or inventions similar to those claiming inventions similar inventions similar to those covered by our patent claims by our patent claims or inventions or claimed by our patent claims, or whether or inventions similar to those covered by our patent claims.28applications, or TSC-issued by our patents claiming inventions covered by inventions similar to those covered by our patent claims, or inventions covered by our patent claims covered by obtaining inventions similar to those covered by inventions similar to those covered by our patents claiming inventions similar to those covered by our patent claims or our patent claims or patent inventions similar to those"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Who replaced Patrick Yeramian, M.D., as the Chief Medical Officer in December 2023?",
        "options": {
            "A": "Linda Arsenault",
            "B": "Debra Canner",
            "C": "Camille L. Bedrosian, MD",
            "D": "John Smith",
            "E": "Maria Gonzalez",
            "F": "James Patel"
        },
        "LLM_original_answer": [
            "In additionally, if orphan drug is granted.Additionally.Additionally, if orphan drug approval.Additionally, if orphan drug approval.Additionally, if the first approved.Additionally drug or other than the additional information is granted, if orphan drug designation, or approved.Additionally, or other than if orphan drug approval.Additionally, or, or a drug, or, orphans drug approval.Additionally, or  granted, if orphan drug designation.Additionally, if orphan drug approval.Additionally, or, or, or, or a drug designation.Additionally, orphans drug products.Additionally, or, or, or, or other than the approval.Additionally, or, or ADDITIONAL ADDITION, or a product, or a drug, or, or a drug designation of the granted.Additionally, if orphan drug product, in the first approval.Additionally, orphans drug, or, if the first product.Additionally, or, orphans drug product approval.Additionally drug designation.Additionally, which is granted orphan drug designation.Additionally, or, if the product, if the FDA approval of the first approved.Additionally, or a product candidate, if orphan drug product approval.Additionally, if the granted, or if orphan drug approval.Additionally drug product.Clin additional clinical trials.Additionally, or, as discussed in the granted for any indication.Additionally, which is granted.Additionally, or the granted, or a product, if the safety and/orphan drug product, or, if the drug product candidate.Additionally, if the safety and/or orphan drug product.Additionally, or, or, or the granted.Additionally, if orphan drug product candidates.Additionally, or, if the granted.Additionally, or if a drug, if the product development is granted, if the regulatory agency, or, if orphan drug products.Additionally, orphans.Additionally, or the FDA approval.Additionally granted.Additionally.Additionally, if the sponsor.Additionally, or, or, if the U.Similar drug or, or, orphans drug approval.Additionally, if the U.Specifically drug designation.Additionally, or approved.Additionally granted.Additionally, or, or add to receive orphan drug designation.Additionally, if orphan drug approval.Additionally granted, orphan drug, or if orphan drug products.Additionally, if orphan drug designation.Additionally, if orphan drug products may be unable to receive orphan drug product.Additionally, as amended or, or condition.Additionally, if orphan drug designation.Additionally, or, or, or both the the FDA approval.Additionally,"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "At what point in time is the revenue for cash trading and equity options recorded?",
        "options": {
            "A": "At the beginning of the transaction",
            "B": "At the end of the fiscal year",
            "C": "At the point in time of the transaction",
            "D": "When the transaction is settled",
            "E": "At the time of customer payment",
            "F": "When the market closes for the day"
        },
        "LLM_original_answer": [
            "At all other investments that are not cash equivalents that are not fixed income funds and fixed income securities.We classify all other investments that are not cash equivalents or cash and are not cash equivalents and fixed income securities.We classify all other investments that are not cash equivalents that are not cash equivalents.We classify all other investments that are not cash equivalents.We classify all other investments that are not cash equivalents and other investments.We classify all other than not cash equivalents.We classify all other investments.We classify all other investments.We classify all other investments that are not cash equivalents.We classify as cash and other investments that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents.We classify all other investments that are not cash equivalents.We classify all other investments.We classify all other investments.We classify all other investments that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents of which are not cash equivalents that are not cash equivalents.We classify all other investments that are not cash equivalents.We classify all other investments.We classify all other investments.We classify all other investments that are not cash equivalents that are not fixed income funds and fixed income securities.We classify all other investments that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash and fixed income securities that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not fixed income securities.We classify all other investments that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents.We classify all other than cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash or other investments that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents.We classify all other investments that are fixed income securities.We classify as well as cash equivalents that are not cash equivalents.We classify as cash and fixed income securities.We classify all other investments that are not cash equivalents that are not cash equivalents.We classify all other than are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash equivalents that are not cash and fixed income securities.We classify all other investments that are not cash equivalents that are not cash equivalents that are not"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 60,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What percentage of other invested assets is comprised of freestanding derivatives with positive estimated fair values?",
        "options": {
            "A": "60%",
            "B": "70%",
            "C": "75%",
            "D": "80%",
            "E": "Over 80%",
            "F": "90%"
        },
        "LLM_original_answer": [
            "Question in the economic value of those contracts under changing believes that changes believes that changes in the economic value of those contracts under changing under changing believes that changes in changing believes that economic value.Management believes that changes in Management believes that changes believes that changes in those contracts believes that changes in the believes that changes under Management believes that changes in the economic value of those contracts under changing value of those contracts under changing economic value of those contracts under changing believes that changes in the changes in the economic value of those contracts under changing Management believes that contracts under those contracts under Management believes that believes that changes in the changes under Management believes that changes in which Management believes that economic value of the changes in Management believes that are changing interest rate of those contracts under changing.Management believes that are Management believes that changes in the changes in the changes in the economic value of those economic value of those contracts under Management believes that are those contracts under Management believes that changes in the changes in the economic value of those contracts under changing under changing value of those contracts under changing that contracts under changing those contracts under changing in those contracts under changing that value of those contracts under changing value of those contracts under Management believes that Management believes that economic value of those economic value of those contracts.Management believes that those economic value of those contracts under changing value of those contracts under changing value of those economic value believes that economic value believes that Management believes that changes in the economic value of those contracts.Management believes that economic value of those contracts under changing value of those contracts under changing value of those contracts under changing that changes in the economic value of those contracts under changing interest rates under changing under changing that changes in the economic value of those contracts under changing interest under changing interest under changing changing value of those contracts under changing value under Management believes that under changing that the changes in economic value of those contracts under changing economic value of those contracts under changing economic value of those economic value of those contracts under changing believes that believes that economic value of those economic value of those economic value of those contracts under changes in Management believes that changes in the believes that changes in-force value of those economic value believes that believes that economic value of those contracts under changing believes that contracts under changing economic value under changing interest under changing under changing economic value of those value believes that contracts under changing believes that changes in the economic value of those economic value under changing under changing that those contracts under changing under changing in the believes that the that economic value of those contracts under changing economic value under changing Management believes that changes in the economic value of those contracts believes that changes in the economic value of those contracts"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What action might the company be forced to take if they cannot secure additional funding?",
        "options": {
            "A": "Expand marketing efforts",
            "B": "Open new research facilities",
            "C": "Increase staff salaries",
            "D": "Delay, reduce, or eliminate some research and development programs",
            "E": "Acquire other companies",
            "F": "Launch new products immediately"
        },
        "LLM_original_answer": [
            "Based on the provided document, if the company cannot secure additional funding, the action they might be forced to take is:\n\nD: Delay, reduce, or eliminate some research and development programs.\n\nThe document states, \"If we are unable to obtain funding, we will be forced to delay, reduce or eliminate some of $0us, which includes costs incurred in the majority of $0us has not related to date range from the year ended December 2022, if any other than canker-lease and other than can be continued as of $ 1012023us believe that are primarily related to the following the following the following the following the following the following the following the Company\u2019s net of $135, if any future periods.The following the following the Companywide-ranging from the following the Company-wide and (or other than can beacrossus believes that are expected to the Hansohas of $0us 2022Our research and other than can not otherwise than any future milestone and other than can beacross, if and other than the following the Companywide-ranging from our research and related to date of $0us 101related to the Company\u2019s net of $0us believes that are not yet to the Companywideopen-ended December 101related to the R&Distributions and other than in connection with respect to the Hansohas of $1. If we received under the following the changes in connection with respect to the Hansohsponsored by product candidates for the Hansohiofundeduefundingu2021.100for the Company-wide basis offtotal cash and other than can beacross, if any other than when changing or loss carryforward-looking forward-looking ahead of $0us believe that we believe that are based on and other than can bequestioni)"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?",
        "options": {
            "A": "December 31, 2023",
            "B": "January 4, 2024",
            "C": "November 20, 2023",
            "D": "December 15, 2023",
            "E": "January 10, 2024",
            "F": "December 1, 2023"
        },
        "LLM_original_answer": [
            "Based on the provided document, the Company pre-paid the outstanding balance on the Replacement DIP Facility on January 4, 2024."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Which entity sells certain trade receivables to CRC?",
        "options": {
            "A": "Duke Energy Ohio",
            "B": "CRC",
            "C": "Duke Energy Indiana",
            "D": "Subsidiary Registrants",
            "E": "Intercompany",
            "F": "Duke Energy"
        },
        "LLM_original_answer": [
            "Based on the provided document, the entity that sells certain trade receivables to CRC is Duke Energy Ohio and Duke Energy Indiana."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What was the collateral value of commercial real estate loans at December 31, 2023?",
        "options": {
            "A": "$1.4 billion",
            "B": "$1.5 billion",
            "C": "$1.2 billion",
            "D": "$2.9 billion",
            "E": "$2.0 billion",
            "F": "$5.9 million"
        },
        "LLM_original_answer": [
            "The collateral value of commercial real estate loans at December 31, 2023 is $ 30.7 billion."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?",
        "options": {
            "A": "The company is a subsidiary",
            "B": "The company operates in multiple countries",
            "C": "The company is a smaller reporting company",
            "D": "The company has financial statements in Item 8",
            "E": "The company issued new stock options",
            "F": "The company had a significant loss"
        },
        "LLM_original_answer": [
            "Based on the provided document, the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk is because the company is a smaller reporting company as defined by Item 10 of Regulation S-K."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?",
        "options": {
            "A": "Ocwen must renegotiate terms with MAV.",
            "B": "Ocwen can sell to a third party on more favorable terms.",
            "C": "Ocwen can sell to a third party on no more favorable terms.",
            "D": "Ocwen must wait until May 2, 2025 to sell.",
            "E": "Ocwen can sell immediately without restrictions.",
            "F": "Ocwen must consult PHH before selling."
        },
        "LLM_original_answer": [
            "Based on the provided document, the condition specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs is:\n\nA: Ocwen must renegotiate terms with MAV.\n\nThe document does not explicitly state that Ocwen must renegotiate terms with MAV if MAV does not accept Ocwen's offer. However, it does mention that Ocwen has certain rights and obligations under various agreements with MAV, including the right to offer MSRs to MAV before selling them to a third party and MAV's right to purchase certain GSE MSRs sold by Ocwen. These agreements suggest that if MAV does not accept Ocwen's offer, Ocwen may sell the MSRs to a third party on terms no more favorable to the purchaser than those offered to MAV. Therefore, the closest option to the document's content is option A, as it implies that Ocwen may need to renegotiate terms with MAV to facilitate the sale of the MSRs."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the effect of stockholders acting together in this company?",
        "options": {
            "A": "Increased stock value",
            "B": "Reduction in company expenses",
            "C": "Significant influence over stockholder approvals",
            "D": "Improved employee satisfaction",
            "E": "Higher dividend payouts",
            "F": "Faster company growth"
        },
        "LLM_original_answer": [
            "Based on the provided document, the effect of stockholders acting together in this company can be analyzed as follows:\n\n1. Increased stock value (Option A): The document does not directly mention the effect of stockholders acting together on the stock value. However, it does discuss the potential risks and challenges the company faces, such as the need for strategic partnerships, competition, and the complexity of collaborations. These factors could indirectly impact the stock value, but the document does not provide a direct correlation between stockholder actions and stock value.\n\n2. Reduction in company expenses (Option B): The document does not mention any specific actions by stockholders that would lead to a reduction in company expenses. The company faces various regulatory authorities, if we believe that could be more generally require us and our product candidates, if we may becommencepharmyields and our ability to the foregoing the foregoing years from time and our product candidates, which could result in connection with respect to the company culture, if we may beclimposing significant amounts that could result in the Company\u2019s product candidates, if we may beclimposed to the foregoing any time and the Company operations and the company stockholders acting together with respect to the following are required to the Company\u2019s our product candidates, and other than any other than any third-party actions bylaws and other than any future collaborations and other than any offtestimates our ability to the company expenses (or other than if we may beclerectronicoloratory value offt believes that could result in-householdings together with respect to the foregoing fiscal 101may becaus may beclerective believe that could result in the foregoing the ability to thesuch as aforesponsible for which could result in the ability to support services and other than may adversely affect our business development and our ability to which could result in the foregoing the foregoing, including, or similar to thes in the success of our ability to the company expenses (or other than any offtotaliofurther, or otherwise similar to the company believes that we believe that we believe that could adversely affect our product candidates for product candidates for-"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What potential issue could result in increased costs for the company related to AMX0035 development?",
        "options": {
            "A": "Increased clinical trial participant costs",
            "B": "Loss of clinical trial data",
            "C": "Increased manufacturing costs",
            "D": "Rising costs of raw materials",
            "E": "Higher insurance premiums",
            "F": "Decreased research funding"
        },
        "LLM_original_answer": [
            "Based on the provided document, the potential issue that could result in increased costs for the company related to AMX0035 development is:\n\nC: Increased manufacturing costs\n\nThe document does not explicitly mention increased manufacturing costs as a current issue, but it does discuss the potential for significant capital expenditures and the diversion of financial resources from other projects, which could indirectly lead to increased costs in various areas, including manufacturing."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "How were the 2020 Senior Notes paid off?",
        "options": {
            "A": "With company savings",
            "B": "Through new equity issuance",
            "C": "By selling company assets",
            "D": "With net proceeds from the offering of the May 2020 Notes",
            "E": "By obtaining a bank loan",
            "F": "Through a government grant"
        },
        "LLM_original_answer": [
            "To answer the question \"How were the 2020 Senior Notes paid off?\" based on the provided document, we need to look for information related to the repayment of the senior notes issued in 2020. The document mentions the following relevant information:\n\n- On May 26, 2020, the company issued $2.5 billion in aggregate principal amount of new senior notes, comprised of $1.25 billion in aggregate principal amount of 2.10% senior notes due in 2030 and $1.25 billion in aggregate principal amount of 3.00% senior notes due in 2050 (collectively, the May 2020 Notes).\n- The net proceeds of the May 2020 Notes were used for general corporate purposes, including to fund the redemption of the company's performance obligations, net of $ 2020.The amortization of $ 2020.The table 2020."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?",
        "options": {
            "A": "The base lapse rate is increased.",
            "B": "The base lapse rate is reduced.",
            "C": "The base lapse rate remains unchanged.",
            "D": "The base lapse rate is doubled.",
            "E": "The base lapse rate is halved.",
            "F": "The base lapse rate is eliminated entirely."
        },
        "LLM_original_answer": [
            "The base lapse rate is affected for variable annuity guarantees when the guaranteed amount exceeds the account value by reducing the base lapse rate. This is because in-the-money contracts, where the guaranteed amount is greater than the account value, are less likely to lapse."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What action might the company be forced to take if they cannot secure additional funding?",
        "options": {
            "A": "Expand marketing efforts",
            "B": "Open new research facilities",
            "C": "Increase staff salaries",
            "D": "Delay, reduce, or eliminate some research and development programs",
            "E": "Acquire other companies",
            "F": "Launch new products immediately"
        },
        "LLM_original_answer": [
            "Based on December 94Management believes that value.Management believes that Management believes that value of the changes in 94Management believes that are not currently is not available under changing conditions or otherwise would enable us.In January 94Management\u2019s multiple choice of $20believe that we have been approved for the economic value of the foregoing.The changes to the Company has been approved or loss from product and/orchest of the economic value of those contracts under the economic value of those contracts underwriting underwriting activities underwriting costs of the Company\u2019s accumulated deficit of those contracts and any3Management\u2019s estimate of those contracts underwriting value of those contracts under theseself believes that offset of those contracts under theses of those conditions or other contracts underwriting underwriting underwriters under thesesus believes that are not-to-research costs of the Company-wide believes that are entitled to 94Management\u2019s ability to support theses are not otherwise described in the foregoing discussion and Negative Impact of theses of thes value of Keros Therapeutic-2024ITEM 94Forward-Liquelritercept underdeveloping under development and Results of Operations and the economic value of value of those contracts underwriting interest rates underwriting under the foregoing the Securities underwriting 94ITEM 94ITEM 2024\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?",
        "options": {
            "A": "December 31, 2023",
            "B": "January 4, 2024",
            "C": "November 20, 2023",
            "D": "December 15, 2023",
            "E": "January 10, 2024",
            "F": "December 1, 2023"
        },
        "LLM_original_answer": [
            "Based on the Company\u2019s common stock-based on the Company\u2019s consolidated financial instruments at issuance of the Company\u2019s of $ 1. Under the Company\u2019s Consolidated under the Company\u2019s effective January 124Core Scientific Notes Payables subject to the Company\u2019s respective permitted transferecertain other than the Company\u2019s Consolidatedaideredits economic value of the Company\u2019s outstanding under the Company\u2019s believes that are over-the value of $ 124Core Scientific Act of those contracts under changing interest rate of the Company as of the Company under changing economic value of124Core_pdu_reliabilities of the Company\u2019s respective permitted transfers to the Company\u2019s consolidated financial instruments that are subject to satisfy tax benefit of $ 124Core Scientific Contracts under the Company\u2019s operating results in accordance with respect to December 2023.Core Scientific Value of $ 124Core Scientific Disclosure of $ 1.under the economic value of the Company\u2019s outstanding stock options under the interest rates per share of common stock-based on the Company\u2019s Fourth Amended under the Company\u2019s Securities Act of $ 124Core Scientific Contracts under changing of $ 124Core Scientific ContractsUnder the Company\u2019s consolidated financial instruments under the Company\u2019s value of $ 126Core Scientific, 124Core Scientific, 1.under Management believes that were issued on the Company\u2019s economic value 124Core Scientific, net of the Company\u2019s 126Core Scientific, net of which were issued for the 10.Core filed as a:124Core Scientific Acquired under the Company.Common Stockholders of those contracts under the Securities Act of the Company\u2019s Consolidated under the Company\u2019s 10.124Core Scientific Stockholders of the Company\u2019s Class A:"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "Which entity sells certain trade receivables to CRC?",
        "options": {
            "A": "Duke Energy Ohio",
            "B": "CRC",
            "C": "Duke Energy Indiana",
            "D": "Subsidiary Registrants",
            "E": "Intercompany",
            "F": "Duke Energy"
        },
        "LLM_original_answer": [
            "Based on December 2023. ###\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What was the collateral value of commercial real estate loans at December 31, 2023?",
        "options": {
            "A": "$1.4 billion",
            "B": "$1.5 billion",
            "C": "$1.2 billion",
            "D": "$2.9 billion",
            "E": "$2.0 billion",
            "F": "$5.9 million"
        },
        "LLM_original_answer": [
            "Based on non- Unfunded under previous accounting policies and/or other than the economic value as of loans were not previously recorded investment of commercial and the following the year ended December 14 Risk Rating and home equity and/or Management\u2019s Credit[of the following is included in the Company\u2019s worth of the allowance for the allowance for the allowance for the following contracts under the following a131##"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?",
        "options": {
            "A": "The company is a subsidiary",
            "B": "The company operates in multiple countries",
            "C": "The company is a smaller reporting company",
            "D": "The company has financial statements in Item 8",
            "E": "The company issued new stock options",
            "F": "The company had a significant loss"
        },
        "LLM_original_answer": [
            "Nurkindsupportion under the above the foregoing expenses related to date or other expenses related to beacons under the success underly under the United States believe that are not required to date or similar to beacons.Effectors.Excluding that are not required disclosures about the years ended November 112Item 112Item 112Item 112Item 112Item 2022ndleases and three months ended November 112 under the economic value of those contracts under the changes inelaborate the economic value of theses underly changing interest and other than inid under the economic value of $ 112Critical Accounting Estimates of those contracts and qualitative and/or changing conditions underestimates under these contracts and related to commercial product development timelines and under theses of $295.under thes of the above are deferred revenue of $5452.Item 2.Table 2024Item 112Item 112Research and under changing global development and the company has notional value of the value of $545.under changing interest rates of the economic conditions under changing interest and net sales and related to date of the economic value of the economic value of $295.112Item 112Item 112Item 112Item \ud558\ub294"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?",
        "options": {
            "A": "Ocwen must renegotiate terms with MAV.",
            "B": "Ocwen can sell to a third party on more favorable terms.",
            "C": "Ocwen can sell to a third party on no more favorable terms.",
            "D": "Ocwen must wait until May 2, 2025 to sell.",
            "E": "Ocwen can sell immediately without restrictions.",
            "F": "Ocwen must consult PHH before selling."
        },
        "LLM_original_answer": [
            "Based on December \ud558\ub294\n_ctxt believes that do not included in the multiple choice is disclosed, if notehemptions##getTable of the contracts under-2"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What is the effect of stockholders acting together in this company?",
        "options": {
            "A": "Increased stock value",
            "B": "Reduction in company expenses",
            "C": "Significant influence over stockholder approvals",
            "D": "Improved employee satisfaction",
            "E": "Higher dividend payouts",
            "F": "Faster company growth"
        },
        "LLM_original_answer": [
            "Based on a1008 of our product candidates.Management of the USPTOngoingClinicalTrials under the document.The issuance of the changes in the answer is not available only under the effect of the above Management believes that we obtainable under specified in-issued in-101under the contracts or that we believe that could haveingrowth of which could becauses.The loss of any.The loss of the economic value of the above Management believes that are subject to comply witholding\n"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What potential issue could result in increased costs for the company related to AMX0035 development?",
        "options": {
            "A": "Increased clinical trial participant costs",
            "B": "Loss of clinical trial data",
            "C": "Increased manufacturing costs",
            "D": "Rising costs of raw materials",
            "E": "Higher insurance premiums",
            "F": "Decreased research funding"
        },
        "LLM_original_answer": [
            "The document.understands under changing laws and results of our of the economic value of which could adversely affect our current and any of the above Management believes that may notehas of102or any of the first-in-3rductions under the3.108also under the economic value of our product candidates under the changes in this \u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\u2018\nAuction of those contracts and the economic value of these risks related to bepassthearingestimates underwriting of our business, if any other than under the economic disclaiming those agreements we have been.The changes in-102underlying under changing times under the form of the information contained in-license Options: (i believe that could have under the changes in the Company Operations, if/understanding value of those contracts underwriting interest rates under the economic conditions under changing interest rates under changing the economic conditions or believes that we perform periodic searches and that we have not in-licenseesponsepsuemptions.that the changes in-3 under the changes in-107under changing interest in-license.under the economic interest under changing of 102understandings under changing the above \u201cRisk Factors Related to the economic and any future pandemics under the price.The changes in-issued under the Securities and distribution, or otherwise required to include:\u2022\nAnswer:\u2022 Management believes that may notices underlypatickaging under the economic conditions or the economic disclaimseriously"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "How were the 2020 Senior Notes paid off?",
        "options": {
            "A": "With company savings",
            "B": "Through new equity issuance",
            "C": "By selling company assets",
            "D": "With net proceeds from the offering of the May 2020 Notes",
            "E": "By obtaining a bank loan",
            "F": "Through a government grant"
        },
        "LLM_original_answer": [
            "The following the following are included in our equity method of $ 3.3.3. economic value of which are as of those contracts underwriting believes that were $ 2020. under the changes in the changes in the changes in the following is as of the changes in the changes in the changes in the economic value of the greater than the value of $ 2020under changing value at the above Management believes that are included in the changes in 3.2024.underlying value of $ ousable to the changes in ells believe that are included in the performance obligations under changing interest rate changes in the value of $ ells-2023.2023.3.underlying underwriting under thisForm 2020.Revenues and/or dispositions under thesolutions under the performance obligations under changing value of $ ells of which are included in the value of $ 2024 that are included in the value of the value of the following the value of the value of $ 2024.Recent of the economic value of those contracts under the value underwriting application of thesucceed in 2020.Reporting Periodsolutions under changing value of the value of the value of the changes in the changes in the changes in the changes in the value of $ \ud558\ub294"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?",
        "options": {
            "A": "The base lapse rate is increased.",
            "B": "The base lapse rate is reduced.",
            "C": "The base lapse rate remains unchanged.",
            "D": "The base lapse rate is doubled.",
            "E": "The base lapse rate is halved.",
            "F": "The base lapse rate is eliminated entirely."
        },
        "LLM_original_answer": [
            "The Company\u2019s value of $ 166Brighthouse"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What action might the company be forced to take if they cannot secure additional funding?",
        "options": {
            "A": "Expand marketing efforts",
            "B": "Open new research facilities",
            "C": "Increase staff salaries",
            "D": "Delay, reduce, or eliminate some research and development programs",
            "E": "Acquire other companies",
            "F": "Launch new products immediately"
        },
        "LLM_original_answer": [
            "Based on changing the changes in the economic value of economic value are in economic value under contracts under changing in would changes in economic value of those contracts under changing under economic value of those contracts under under changing interest rates could have been subjected tofurthercludes under changing value under changing the value of the changes in the value of the changes in the changes in management believes that economic value of the changes in management believes that would have a"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?",
        "options": {
            "A": "December 31, 2023",
            "B": "January 4, 2024",
            "C": "November 20, 2023",
            "D": "December 15, 2023",
            "E": "January 10, 2024",
            "F": "December 1, 2023"
        },
        "LLM_original_answer": [
            "To answer to the Company believes that management believes that management Management believes that the Company recognized as economic value at the changes in contracts, management believes that contracts under changing value would result in management would bequest management believes that would like the changes in the economic value under changing value of the contracts would like the economic value of these economic value of value under contracts under changing interest expense under contracts are on changing under under value under believe that under under under under under the Company recognized as of these changes in under contracts under under under interest in economic value under changing in the changes in the fair value under under contracts under the believes that would the changes in the economic value under changing contracts under changing interest under under changing under changing value in the economic value of those contracts under changing interest rates of the changes in the Company believes that under changes in the economic value of the Company believes that economic value under changing value of the Company believes that contracts under changing value under changing value under changing value of contracts contracts management believes that under changes in economic value of economic value contracts contracts under changing under economic value contracts under under changing under changing under changing interest rates of those contracts under under changing interest expense that under changing value of management believes that would bequestions under changing that Management believes that changes in the Company would result in management believes that the estimated fair value of the Company believes that value under changing interest expense under changing under changing.The Company believes that estimate fair value value of those contracts under changing interest rates of the estimated that contracts are subject matter under changing value of the Company believes that Management believes that that the economic value of the economic value of contracts under changing value of the net that contracts would under changing under changing value of the Company believes that would be that the Company believes that contracts under changing in the Company believes that the changes in the economic value of the Company incurred under the value under changing management believes that Management believes that the changes in the value of those contracts under changing interest expense Management believes that Management believes that the economic value under economic value under changing Management believes that the changes in the economic value of the Company believes that are the value under under changing the changes in economic value under changing value of those contracts contracts areal value of contracts under changing interest rates of interest rates of the changes in management believes that the economic value at the contracts under changing the believe that would be Management believes that changes in the economic value of those contracts are subject to the Company believes that believe that would beCore Scientifically believes that would changes in the economic value of those contracts under changing interest interest rates under changing interest rates under"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "Which entity sells certain trade receivables to CRC?",
        "options": {
            "A": "Duke Energy Ohio",
            "B": "CRC",
            "C": "Duke Energy Indiana",
            "D": "Subsidiary Registrants",
            "E": "Intercompany",
            "F": "Duke Energy"
        },
        "LLM_original_answer": [
            "Based that will that Management believes that under economic value value of under under under economic contracts are under economic value of economic value under areposta that contracts are under economic interest in management believes that would are notional value value of those contracts under changing interest rates in the value under changing under under are not under under under are not are are are economic value of interest under contracts under management believes believe that changes in the economic value of contracts under contracts are of those contracts under under under believe that interest rates.The response to the value value contracts under3"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What was the collateral value of commercial real estate loans at December 31, 2023?",
        "options": {
            "A": "$1.4 billion",
            "B": "$1.5 billion",
            "C": "$1.2 billion",
            "D": "$2.9 billion",
            "E": "$2.0 billion",
            "F": "$5.9 million"
        },
        "LLM_original_answer": [
            "To the Company believes that would not only under believe that would be under Management believes that economic value value value value of those contracts would would changing interest rates of contracts under under economic interest rates would beased that the value under under under under changing under economic value under under under the economic value in the economic value of the economic contracts are of interest rate that the management believes that changes in the economic value of the economic contracts believe that the economic forecasts under economic value of those value of contracts under changing economic interest under under under are of economic value under under under that that contracts under contracts would notional value contracts under contracts under changing interest value under economic value under under under under under changing value under economic value under under under these contracts under economic value would not only would not only under economic value under under under changing in the economic value of economic value of those contracts under contracts under changing interest rates under contracts under changing value contracts under changing underestimates that the contracts under under economic value of the economic value under changing value of those economic value of the economic value that are under economic value contracts under changing value under changing contracts under changing interest rates.Management believes that that that under economic value value under under under under economic value under economic value of those contracts under are included in economic value contracts under changing interest in management believes that would are notional value value of the contracts under changing interest rate interest rates of those contracts under changing the changes in would not believe that are are are are related value of those contracts under changing interest rate that changes in the value of the changes in the economic value of those contracts under under changing interest rates the value of the changes in the Company\u2019supported under changing contracts under changing interest rate under changing in theCollaborious that are included that Management believes that contracts under changing value of those contracts under management believes that values under changing value under are related to manage that contracts would not only believes that believe that the changes in the Consolidated the contracts under contracts would would would be that value under economic value under changing value contracts under contracts are under interest rates under arecollateral value of under under under economic value under under3 Management believes that contracts under economic value under value under contracts under under would not the economic value believe that the changes in the fair value under changing contracts under under Management believes that changes in the economic value of those contracts under under changing interest interest rates would believe believe believe that value value value under under under changing interest and changing interest rates under changing under Management believes that Management believes that value value value of those contracts under changing interest rates of those contracts under changing"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?",
        "options": {
            "A": "The company is a subsidiary",
            "B": "The company operates in multiple countries",
            "C": "The company is a smaller reporting company",
            "D": "The company has financial statements in Item 8",
            "E": "The company issued new stock options",
            "F": "The company had a significant loss"
        },
        "LLM_original_answer": [
            "The document would be Management believes that the changes under under changing the economic value of the interest under contracts under under under economic value under economic value of that under contracts contracts under economic value of those contracts under contracts under changing interest under economic value under under under under would notional changes in the economic value of such contracts would notional value under will beChanges in economic value of any of contracts under changing under the economic value of economic value of those contracts under changing value under changing interest rates ofpersonal dataioned under changing economic value under changing under under contracts under under economic value of the economic value of those contracts under changing interest rates of the changes in management believes that changes in the economic value of those contracts under changing interest rates will"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?",
        "options": {
            "A": "Ocwen must renegotiate terms with MAV.",
            "B": "Ocwen can sell to a third party on more favorable terms.",
            "C": "Ocwen can sell to a third party on no more favorable terms.",
            "D": "Ocwen must wait until May 2, 2025 to sell.",
            "E": "Ocwen can sell immediately without restrictions.",
            "F": "Ocwen must consult PHH before selling."
        },
        "LLM_original_answer": [
            "Based value of the Company\u2019s that are uncollecting changes under under changing value of economic value of the changes under under under under believe that the changes in the changes in the changes in the economic value under changing contracts under changing under changing under economic value under under changing under changing contracts under changing value of those contracts under economic value in changing circumstances under changing underestimates that under changing under changing in the economic value under changing value under changing economic value of the document changes in changing value of those contracts under changing audit procedures under changing that under economic value of those contracts under changing value under changing interest rates and under changing value of those contracts underestimates that the changes in the economic value of the value of the contracts under changing and the economic value of those under changing conditions under changing in the economic value of the contracts under changing conditions under changing in the changes in developing estimates and the changes in F-"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the effect of stockholders acting together in this company?",
        "options": {
            "A": "Increased stock value",
            "B": "Reduction in company expenses",
            "C": "Significant influence over stockholder approvals",
            "D": "Improved employee satisfaction",
            "E": "Higher dividend payouts",
            "F": "Faster company growth"
        },
        "LLM_original_answer": [
            "The issuance or in economic value of the management under management believes that values under economic value under under management may be able to 93Management believes that economic value value of the contracts under contracts that management believes that they are issued in the economic value of management believes that value and management believes that the economic value of economic value of any contracts under are not provide a that are not only believe that economic value under economic value of those contracts are arecertain economic value under under economic value of economic value contracts under economic value of contracts under under management are changes in the economic value of those contracts contracts would becujo believes that contracts under economic value value of contracts that contracts under interest under management believes that believe that management believes that Management believes that the economic value value of those contracts under contracts are economic interest rates of contracts under under economic interest would bequeuers believes that management under under under under under under economic value under under under under economic value value value value of those contracts under contracts are the economic value and management believes that the economic value value value of the contracts under contracts believe that believe that changes in economic value of the value of contracts under changing interest in contracts under under under economic value in economic value under that would not under contracts would value of those contracts under contracts under interest under economic value or under under under under under under economic value of economic value under under under such contracts under economic value under will have a changes in the economic value of contracts under under changing under economic value of economic value of those contracts under contracts under changing interest contracts under contracts under changing of contracts under changing interest under-93Management believes that are the economic value under changing under changing under changing value of the economic value of economic value of management believes that contracts under changing value of those contracts under changing in economic value under under changing that that under changing in economic value of the economic value of economic value of the economic value under management believes that changes in economic value of the economic contracts under under the changes in the economic value of those contracts under changing circumstances under interest rates of those contracts under changing the economic value under changing under are are are are under economic value of those contracts under changing interest rates of changes in the economic value of those contracts under economic value of those contracts under under under changing the economic value of economic value of any of contracts that economic value contracts under changing the economic value of any economic value of the changes in Management believes that management believes that economic value of the issuance of contracts or under the61 the economic contracts under are notational changes would becertain changes believe that believes that the issuance or"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What potential issue could result in increased costs for the company related to AMX0035 development?",
        "options": {
            "A": "Increased clinical trial participant costs",
            "B": "Loss of clinical trial data",
            "C": "Increased manufacturing costs",
            "D": "Rising costs of raw materials",
            "E": "Higher insurance premiums",
            "F": "Decreased research funding"
        },
        "LLM_original_answer": [
            "The changes in under under under under under under under are not are are are economic value of such contracts under under management believe believe changes changes in the economic value of contracts under contracts are under interest under contracts under under believe that interest in economic value value of those contracts contracts3"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "How were the 2020 Senior Notes paid off?",
        "options": {
            "A": "With company savings",
            "B": "Through new equity issuance",
            "C": "By selling company assets",
            "D": "With net proceeds from the offering of the May 2020 Notes",
            "E": "By obtaining a bank loan",
            "F": "Through a government grant"
        },
        "LLM_original_answer": [
            "To testifying contracts would be99Management believes that would have3 Management believes that economic value value value value of those contracts contracts are economic interest rates would contracts would would believe the economic would have been3 that value value value would be88value under under will Management believes that economic value in the economic value of the economic contracts are the interest rates of management believes that the economic value are included in the contracts contracts under believe that believe that changes in economic value of those value under contracts under economic interest under contracts under management believes that economic value would would believe that that contracts contracts would would value of those contracts under contracts under interest under economic value under would not that would believe that would notional value contracts would notecological contracts would are are would have a reasonable value would have a99 that contracts under under changing interest and economic value of economic value of those contracts contracts under changing contracts are subject topperiod those contracts under economic value value under changing under contracts are under economic value under economic value under changing under changing value under economic value of those contracts under33Management believes that contracts under changing interest under changing contracts would have a100Management believes that that that under economic value value of the under under contracts are are economic value of the economic value under are the economic value contracts would be94Management believes that are not are reasonable value value value of those contracts under changing interest rates are that under changing in the economic value of would believe that are not are are are are reasonable value of those contracts under management believes that changes in economic value of those contracts under contracts under economic value of those contracts under under believe in interest value under economic value of the changes under contracts under are are the contracts are subject Management believes that value of the value management believes that are Management believes that economic value of management believes that management believes that management believe that values are recorded contracts under are included in contracts would be94Management believes that believe that believe that would have99Management believes that contracts under contracts would would would believe that value would would would value of those contracts would are are are would are99Income taxes under changing circumstances would believe that would the value under under under under under economic value under economic value of those contracts under economic value values in economic value believe that the changes in the economic value of those contracts under under Management believes that would the changes in value of those contracts under contracts under changing interest would result Management believes believe that value value value under under under changing interest under changing interest rates under changing under Management believes that Management believes that value value value of those contracts under changing are subjectswould those contracts under changing"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?",
        "options": {
            "A": "The base lapse rate is increased.",
            "B": "The base lapse rate is reduced.",
            "C": "The base lapse rate remains unchanged.",
            "D": "The base lapse rate is doubled.",
            "E": "The base lapse rate is halved.",
            "F": "The base lapse rate is eliminated entirely."
        },
        "LLM_original_answer": [
            "Based"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What action might the company be forced to take if they cannot secure additional funding?",
        "options": {
            "A": "Expand marketing efforts",
            "B": "Open new research facilities",
            "C": "Increase staff salaries",
            "D": "Delay, reduce, or eliminate some research and development programs",
            "E": "Acquire other companies",
            "F": "Launch new products immediately"
        },
        "LLM_original_answer": [
            "Based believes that the changes in changing value of the changes in the changes in the changes in changing value of those changes in changing value of those believes that the changes in the changes in value of those contracts under Management believes that changes in the economic value of those contracts under changing interest in changing the company has been Management believes that contracts Management believes that contracts under changing value of those contracts in the company has been that contracts under changing value of those contracts under changing circumstances that the changes in-issuing believes that those contracts under changing value of those third-party believes that Management believes that changes in the changes in the changes in- changes in value of those changes in the changes in economic value of those changes in3 changes in-Changes in value of changing value Management believes that changes in- or value of those contracts under changing value of the changes in changing value of those value value of those contracts under changing value of those contracts under changing value of those contracts under changing economic value of those contracts under changing economic value of those contracts under changing value of Management believes that believes that believes that changes in- Management believes that management believes under changing under changing value of those contracts believes that contracts under changing economic value of those contracts under changing changing changing economic value of those contracts believes that changes incurring contracts under changing value of those changes in the changes in the changes in changing changes in the changes in the changes in changing economic value of those changes in those contracts under changing under changing economic value of those contracts under changing under changing the changes believes changes in the changes the changes in changing value of those contracts under changing contracts under changing interest rates of those contracts under changing interest incurring changing economic value of those contracts under changing changes in- changes in the value of those contracts under changing interest in the changes in the changes in the changes in the changes in the changes incurring that changes in changing that contracts under changing economic value of those contracts under changing interest believes that Management believes that Management believes that contracts under changing in the changes in the changes in the believes that changes under under Management believes believes that believes believes that Management believes that believes that Management believes believes believes Management believes that the believes that changes under changing economic value of those changes in those value believes that believes that believes that changes in the changes in- believes that changes in the changes in the changes in the changes in changing value of those contracts believes that believes that believes that believes that changes in Management believes that the changes in changing underestimates that changes in Management believes that changes in changing value of those contracts under changing interest rates changing interest rates of the changes"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?",
        "options": {
            "A": "December 31, 2023",
            "B": "January 4, 2024",
            "C": "November 20, 2023",
            "D": "December 15, 2023",
            "E": "January 10, 2024",
            "F": "December 1, 2023"
        },
        "LLM_original_answer": [
            "Based on December 2023.Includes thesesources the Company believes that changes in the following page.Opening believes that believes that Management believes that the date believes that changes in the changes in the Company believes that changes in economic value of those contracts under changing value of the changes in the changes in value of those contracts under changing value of those contracts under changing believes that changes in the changes in value of those contracts under changing interest value of the Company believes that changes in the Company believes that changes in the changes in changing value of those contracts under changing changing under changing value of this date of those contracts under changing value of the date 3 Item  believes that believes that believes that changes in the economic value of those contracts under the changes in the changes in the changes in the changes in the following Management believes that contracts changing changing changing Management believes that changes in changing believes that changes inestimates that changes in the changes in the changes in those changes in changing value of those contracts under changing believes that changes in the changes in the value of those believes that the changes in the changes in the changes in changing under changing believes that changes in the believes that the changes in the changes in value of those contracts under changing interest rates of those contracts under changing interest in changing economic value of those contracts believes that changes believes that the changes in the contracts believes that the changes in the changes in the changes in the changes in the changes in changing that the changes in the changes in the changes in the changes in the believes that contracts under changing interest value of those believes that Management believes that Management believes that Management believes that Management believes that Management believes that the changes under changing value of the changes Management believes believes that management believes that believes that contracts believes believes that Management believes that the believes that changes under changing value of the changes in thesuch believes that believes that believes that changes in accordance believes that changes in the changes in the Company does not required that Management believes that changes in changing economic value of those that changes in the changes in changing under changing believes that the changes in the changes believes that the changes in the changes in the changes in the economic value of those contracts under changing changing interest rates of the changes in changing that changes in  Management believes that theses contracts in the changes in those contracts believes that Management believes that under the changes believes that changes in the Company believes that changes in the changes in changing believes that changes in this Management believes that the changes in the changes in the changes in changing changing value of those Management believes that the changes in changing Management believes that Management believes that value of those"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "Which entity sells certain trade receivables to CRC?",
        "options": {
            "A": "Duke Energy Ohio",
            "B": "CRC",
            "C": "Duke Energy Indiana",
            "D": "Subsidiary Registrants",
            "E": "Intercompany",
            "F": "Duke Energy"
        },
        "LLM_original_answer": [
            "Which is that changes in the changes in the changes in changing interest that contracts under the changes in the changes under changing value of the above is not under changing value of these is that value of the changes in the changes under changing under changing value of those contracts under changing value of those contracts believes that the changes in economic value of the changes in those contracts under changing those contracts under changing Management believes that changes in the changes in the changes in changing economic value of those contracts under changing value of those contracts under changing Management believes that changes in the changes in 2023 changes in the value of those contracts under changing economic value of thetottoned the other regulatory assets believes that the auditedt believes that changes in the economic value of those contracts under changing economic value of those contracts under changing the changes in the changes in the changes in conformity believes that changes in changing under changing value of those contracts believes that changes in the changes in the changes in the changes in changing changes in changing interest rates Management believes that changes in value of those contracts under changing value of those contracts under changing value under changing changes in changing value of those contracts under changing contracts value of the changes in the changes in the changes in the changes in the contracts under changing economic value of those under under changing value believes that critical value of the critical audit notes 2023 Management believes that document does notations believes that believes that believes believes that changes in the changes in the following value of those changes in the changes in the changes in the value of those changes believes that changes in the changes in changing changes incurring Management believes that the changes incurring believes that changes in the changes in the changes in those changes in changing value of those contracts under changing believes that changes in the changes in value of those changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes that the changes in the changes in value of those contracts under changing interest rates under changing interest believes that changes in changing value of those contracts under changing value believes that the changes in the changes in changing believes that changes in changing value of those contracts under changing interest of those contracts under changing believes that Management believes that believes that the believes that changes in the changes in those contracts under changing economic value of those believes that changes in those contracts under changing Management believes that changes in changing the changes under changing value value value value of those contracts under changing changing Management believes that management believes that contracts under changes under under under under changes under changing under changing economic value under underlinedocertain value believes that under  believes that"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What was the collateral value of commercial real estate loans at December 31, 2023?",
        "options": {
            "A": "$1.4 billion",
            "B": "$1.5 billion",
            "C": "$1.2 billion",
            "D": "$2.9 billion",
            "E": "$2.0 billion",
            "F": "$5.9 million"
        },
        "LLM_original_answer": [
            "The changes in the interest rates of the actual value of those contracts under changing believes that the changes in the changes in the changes incurring the changes in changing interest-branch believes that the changes in the multiple believes that contracts under changing loan value of those contracts under changing economic value of the annual value of this document believes that the document believes that changes in the changes in this document includes this document includes the changes in the changes in the changes incurring under changing interest-under changing interest value of changing the changes in the changes under changing that the changes in the changes in the changes incurring that changes in the changes in the changes in the changes the changes in the changes in this loan believes that the changes in economic value of those contracts under changing interest value of those contracts under changing basis of the believes that believes that contracts under changing economic value of the changes under changing in the following the changes in economic value of 2023 million dollar Management believes that Management believes that changes in value of those contracts under changing value of changing under changing believes that changes in the changes in the changes in changing interest value of those contracts under changing interest-Loan changes in the changes in the changes in the changes in the changes in the changes in changing Management believes that contracts believes that contracts believes that Management believes that changes in economic value believes that the changes in the changes in the believes that changes in the believes that changes in the document believes that changes in the believes that changes in the changes in the changes in the changes in the believes that value of the changes in the changes in the changes under changing changing value of those value of those contracts under changing value of those contracts that Management believes that the changes incurring those contracts under changing those contracts under changing changing that Management believes that the changes in the changes in the changes value of the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the multiple sources the changes in the changes incurring believes that under changing under changing value of those changes in the changes in the changes in the changes in the changes in the changes that the changes in the changes in changing contracts under changing changing Management believes that changes in the changes in the changes in changing interest value of those contracts under changing rates of those contracts under changing value of those Management believes that the changes in the economic value of those contracts under changing interest-Management believes that changes incurring Management believes that contracts under the annual report to this year believes that changes in the annual net value of those contracts under changing"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?",
        "options": {
            "A": "The company is a subsidiary",
            "B": "The company operates in multiple countries",
            "C": "The company is a smaller reporting company",
            "D": "The company has financial statements in Item 8",
            "E": "The company issued new stock options",
            "F": "The company had a significant loss"
        },
        "LLM_original_answer": [
            "What changes in the3 on-going value management value of those economic value of the patents believes that those believes that those believes that contracts under changing economic value of those contracts under changing in the believes that theses believes that economic value of any of those contracts under changing value of the changes in value of those patents of a drug product under changing under changing economic value of those believes that the changes in changing economic value of those contracts believes that the changes under changing value value of those drug candidates under changing economic value of those contracts under changing value of changing economic value of changing under changing the changes believes that believes that changes economic value of Management believes that changes in the changes believes that changes believes that changes believes that changes in the drug candidates under changing changing value of the changes in the value of those contracts under changing under changing changing changing the changes in the economic value of the believes that those contracts under changing value of those economic value of those contracts may be Management believes that changes of the economic value of those contracts underwriting of those contracts under changing changing believes that believes that Management believes that changes in the economic value of the value of those contracts under the changes in the changes in the changes in changing interest in the changes in the economic value of those contracts under the changes in the changes in the changes under changing that changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes that the changes in changing interest under changing value of those contracts under changing interest in the changes in changing value of those changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the economic value of those contracts under changing conditions under changing economic value of theot believes that contracts under changing value of the drug candidates believes that changes in the changes in the changes in those contracts under changing value of those contracts under changing economic value of those contracts under changing value of those contracts under changing value of those contracts under changing value of those contracts in those changes the changes in- changes in- value of those changes in changing the changes in economic value of the changes in-Management believes that changes in value of changing value of those changes in those contracts under changing value of those contracts in the changes in the changes in value of those value value of the changes in those changes in any Management under changing that changes in changing under changing economic value of those contracts believes that changes in changing value of those contracts under changing value of those believes that believes that changes in economic value of value of those contracts"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?",
        "options": {
            "A": "Ocwen must renegotiate terms with MAV.",
            "B": "Ocwen can sell to a third party on more favorable terms.",
            "C": "Ocwen can sell to a third party on no more favorable terms.",
            "D": "Ocwen must wait until May 2, 2025 to sell.",
            "E": "Ocwen can sell immediately without restrictions.",
            "F": "Ocwen must consult PHH before selling."
        },
        "LLM_original_answer": [
            "Based believes that Management believes that contracts under changing interest rates is included in the changes in the document below value of the document this segment 3:This summary believes that changes in the document Management believes that contracts under changing value of the document is that contracts under the following year 3 multiple of the following the document believes that the information below the changes under changing under changing in the following the changes in the changes in the changes incurring the changes in the changes in the changes in the changes in 3.Management believes that contracts under changing in the changes in the changes in the changes in changing value of the changes in the changes in the changes in the document Management believes that the changes in the value of those contracts under changing interest rate of those contracts under changing interest rates Management believes that changes in the under changing in changing economic value of those contracts under changing interest income under changing interest-Management believes that those contracts under changing interest rates of changing the following quarter believes that Management believes that changes in economic value of the changes in the changes in the changes in the changes in changing interest rates of those contracts under changing interest value of those contracts under changing value of those contracts under changing in the changes in the value of those contracts under changing economic value believes that contracts believes that believes that changes in this document Management believes that contracts value of the following believes that changes believes that believes that changes in the following contracts under changing value of the believes that changes in the economic value of those contracts under changing under changing3 Answer believes that changes in the changes in those contracts under changing value of those value of those value of those Management believes that Management believes that value of 2023 believes thatses underwriting value of those contracts under changing changing that Management believes that Management believes that the changes in the following of the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in the document this document does not only changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes that the changes in the changes in those contracts under changing under changing interest rates under changing under changing Management believes that changes in the changes in changing value of those changes in changing interest rates of the changes incurring that Management believes that the changes in the changes in the changes in the value of those contracts under changing interest rates of the amount of theo believes that contracts in the document contains Management believes that believes that changes in the economic value of the changes in the amount of those contracts under changing"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the effect of stockholders acting together in this company?",
        "options": {
            "A": "Increased stock value",
            "B": "Reduction in company expenses",
            "C": "Significant influence over stockholder approvals",
            "D": "Improved employee satisfaction",
            "E": "Higher dividend payouts",
            "F": "Faster company growth"
        },
        "LLM_original_answer": [
            "The multiple changes in-house believes that value of our product candidates under changing interest of those product candidates under changing Management believes that Management believes that contracts under changing product candidates believes that believes that contracts Management believes that product candidates under ase believes that contracts under the company believes that contracts under changing value of our company believes that the believes that contracts believes that economic value of those contracts under changing value of the changes in the changes in the changes in the changes Management believes that contracts in the changes in the changes in the believes that changes in changing value of changing value of the changes the changes in the changes in the believes that the changes in the value of those contracts under changing economic value of those contracts under those contracts could believe that those believes that believes that believes that the changes in changing under changing believes that could be Management believes that changes in vitro Management believes that contracts may believe that Management believes that changes in value of those product candidates believes that contracts under changing value believes that the changes in the changes in changing under changing value under changing interest of those contracts under changing economic value of those value of those contracts under changing economic value of changing economic value of those contracts under changing economic value of those contracts believes that believes that believes that changes in the changes in the changes incurring believes that changes believes that changes believes that believes that changes in vivo value of those believes that changes in the the changes in the economic value of our product candidates under changing believes that values under the product value believes that those believes that Management believes that changes in-house believes that believes that Management believes that Management believes that contracts or the believes that the changes in vitro-transmission believes that those contracts under changing believes that Management believes that changes the changes in the economic value of those contracts under changing the changes in the changes in the economic value of those contracts under changing value of those contracts under changing value of those contracts under changing that the changes in this document believes that believes that changes in the changes in the changes in the changes in the changes in the changes in the contracts under changing that the changes in the changes in the changes that the changes in changing changing changing those contracts under changing changing Management believes that changes in the changes in changing value of those changes in changing value of changing value of those contracts under changing value of those contracts under changing believes that changes in the economic value of those contracts under changing conditions under changing Management believes that contracts under the those contracts under the document believes that the of the annual value of those contracts value of the changes in those contracts underlined under changing circumstances believes that those contracts under changing value of changing value of those"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What potential issue could result in increased costs for the company related to AMX0035 development?",
        "options": {
            "A": "Increased clinical trial participant costs",
            "B": "Loss of clinical trial data",
            "C": "Increased manufacturing costs",
            "D": "Rising costs of raw materials",
            "E": "Higher insurance premiums",
            "F": "Decreased research funding"
        },
        "LLM_original_answer": [
            "The changes in the changes in the changes in the believes that Management value of those values of those contracts under changing under changing values under changing value of those value of the changes believes that the believes that changes in changing value of those contracts under changing the economic value of those regulatory value of those contracts underdeveloped under the economic value of those contracts believes that Management believes that changes in the changes in the economic value of those contracts under changing interest rates of those contracts under changing economic value of the changes in the changes in the changes in the changes in the changes in the changes in those contracts under believes that believes that changes in the changes in the changes in the changes in the changes in the changes in changing contracts under changing economic value of the changes in the changes in the changes in the changes in changing those contracts under changing changing changing Management believes that the changes in changing value of those changes in changing changing value of those believes that contracts under changing under changing value of those contracts under changing the changes in the economic value of those contracts under changing interest in changing economic value of theospect those contracts under changing economic value of the other product candidates believes that changes in the changes in those contracts under changing value of those contracts under changing value of those contracts under changing value of those contracts under changing value of any of those regulatory value of any of those contracts of those changes the changes in- changes in vitro value of those contracts under changing interest rate of those contracts under value of those changes in changing interest value of those contracts under changing believes that changes in changing economic value of those contracts under changing economic value of those contracts under changing value of those value value value of those contracts under changing believes that Management under changing economic value of any other regulatory value under changing value of those contracts under changing economic value of those contracts under changing Management believes that believes that believes that changes in the changes in value of those contracts under changing value of the changes in the changes in the economic value of those contracts under changing interest under changing in the changes in the believes that changes incurring those contracts under changing changes in the changes in the changes in the changes in the changes in the changes in the changes in changing value of those changes in those changes in the changes in the changes in the changes in the changes in changing under changing changes in the changes the changes in changing value of those contracts under changing contracts under changing interest rates of those contracts believes that the changes in changing value of those contracts under changing value believes that the changes in the changes in the changes under changing value of the changes in the changes in the changes in the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "How were the 2020 Senior Notes paid off?",
        "options": {
            "A": "With company savings",
            "B": "Through new equity issuance",
            "C": "By selling company assets",
            "D": "With net proceeds from the offering of the May 2020 Notes",
            "E": "By obtaining a bank loan",
            "F": "Through a government grant"
        },
        "LLM_original_answer": [
            "The believes that changes in the changes in changing interest under changing under changing value of those changes in the changes in the changes in the changes in the changes in the changes in the changes in changing interest rates in the changes in the changes in the changes in the changes in changing value of those changes in changing economic value of those Management believes that contracts under changing value of those contracts under Management believes that changes in the value of those contracts under changing interest rates of those contracts under changing Management believes that contracts include the following the following the changes in the changes in the changes in 2023 Management believes that changes in the changes in the Management believes that changes in-house value of those contracts under changing interest in changing under changing number of those contracts believes that changes in a multiple believes that changes in the changes in value of those changes in changing interest value of those changes in the changes in the changes in the changes in those changes in the changes in the changes inclusions of those contracts under changing contracts under changing value of those Management believes that value of those value of those contracts under changing interest rate under changing economic value of those believes that changes incurring changes economic value of those contracts under changing value of changing interest value of those believes that changes in those believes that changes incurring value of value of those contracts under changing interest rates believes that changes in the changes in the changes in the changes in changing economic value of those contracts believes that changes in the changes incurring believes that changes in the changes in the changes in the changes in changing value of those contracts under changing believes that changes in the changes in changing believes that changes in the changes in the changes in the changes in those contracts under changing believes that changes in those changes believes that the changes in the changes in value of those contracts under changing interest rates of those contracts under changing interest rate of those contracts under changing those contracts under changing under changing changes in economic value of those believes that contracts under changing value of those contracts believes that the changes in changing value of those believes that Management believes that changes in the changes in the changes in the changes in the changes in the believes that Management believes that Management believes that contracts under changing interest in the changes in changing Management believes that changes under changing value of Management believes that believes that Management believes that believes that Management believes that Management believes Management believes that changes in-house value of Management believes that contracts under the changes in changing believes that contracts believes that believes that changes in the changes in the changes in the changes in the changes in 3 Management believes that those contracts under changing economic value of those contracts believes that changes in"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?",
        "options": {
            "A": "The base lapse rate is increased.",
            "B": "The base lapse rate is reduced.",
            "C": "The base lapse rate remains unchanged.",
            "D": "The base lapse rate is doubled.",
            "E": "The base lapse rate is halved.",
            "F": "The base lapse rate is eliminated entirely."
        },
        "LLM_original_answer": [
            "How the changes in the changes in the changes in the changes in the changes under changing that the changes in the changes in the changes in the changes in the changes in the changes in the changes in the changes in economic value of those contracts under changing economic value of those contracts under changing the changes in the changes in the changes in changing value of those changes in changing interest rate of those believes that changes in the changes in the following those contracts under Management believes that changes in changing economic value of those contracts under changing interest rates of the top three-year believes that contracts under the multiple insurance value of the Management believes that changes in the economic value of those contracts under changing interest value of those contracts under the changes in the changes in changing value of changing value Management believes that contracts under changing value of 3 believes that changes in the changes the changes in economic value of those contracts of those contracts under changing interest value of those contracts under value of those contracts under changing value of those contracts under changing economic value under changing value underperform value of those contracts under changing interest value of those contracts under changing value of those contracts under changing value of those changes in those collateralized that Management believes that are Management believes that changes inclusions of those contracts under changing economic value of those contracts under changing believes that changes in changing believes that the changes in the changes in the changes in the changes in the changes in those contracts under changing economic value of those contracts under changing changing interest rate Management believes that changes incurring believes believes that changes incurring contracts under changing economic value of those believes that changes in those changes in changing changes in the changes in changing believes that changes in the changes in the changes in-force believes that the changes in economic value of those contracts under changing interest rate the changes in the changes the changes that the changes in the changes in value of those contracts under changing interest rates of those contracts under the changes in changing value of those contracts under changing value believes that the changes in the value of those contracts under changing believes that changes in the changes in the changes in changing in changing that the changes in the changes in the changes believes that contracts under changing interest value of those contracts under changing value of those believes that Management believes that contracts under changing interest rates in the changes in Management believes that Management believes under changing in the believes that contracts under changing interest rate that believes that Management believes believes that those believes that believes that contracts under changing economic value Management believes that contracts under changing value believes that changes in the believes that changes in the changes in the changes in the changes in the changes in-house believes that changes in"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What action might the company be forced to take if they cannot secure additional funding?",
        "options": {
            "A": "Expand marketing efforts",
            "B": "Open new research facilities",
            "C": "Increase staff salaries",
            "D": "Delay, reduce, or eliminate some research and development programs",
            "E": "Acquire other companies",
            "F": "Launch new products immediately"
        },
        "LLM_original_answer": [
            "If we express as a as a whole, and taken as a in any way in any way in any way our opinion on the financial statements of the as a whole, taken as a taken as a whole the way we take as a taken as a taken as a whole, taken as a part in any way we have not taken as afoam as a single in any way in any way our opinion on the financial statements, taken as a whole, taken as a taken as a given as afo taken as a whole, taken as a whole in any way in any way in any way in any way we believe as a taken as a whole in any way in any way our opinion on the opinion in any way in any way, taken as a whole, taken as a whole, as a given as a as a whole, taken as a matter, taken as taken as taken as a whole in any way our opinion on the financial statements of the financial statements taken as taken as a whole of the financial matters as taken as such as taken as taken as taken as a single audit matters taken as taken as taken as we are taken as taken as taken as taken as taken as afoes, taken as a whole, taken as a whole financial, taken as taken as taken as taken as taken as taken as taken as a whole taken as a taken as taken as taken as a taken as a matter, taken as taken as taken as well taken as taken as taken as taken as taken as taken as taken together as taken as to the opinion on the in any way of the financial statements, taken as taken as a way our opinion on the financial statements, taken as a whole, taken as a whole, taken as taken as taken as a taken as taken as taken as taken as taken as taken as taken as aro, taken as taken as taken as a whole our opinion on the same as afores as a whole, taken as a whole as a whole, taken as a taken as asever.Disc financial resources, taken as a whole financial statements taken as taken as taken as in any way in any way in any way we have as taken as taken as afores, taken as afool in any way in any way our opinion on the financial statements, taken as a whole the financial matters, taken as a as a taken as a whole financial matters taken as taken as taken as taken as a as a as a taken as a whole or our opinion on any way the opinion on the financial statements, taken as taken as a"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?",
        "options": {
            "A": "December 31, 2023",
            "B": "January 4, 2024",
            "C": "November 20, 2023",
            "D": "December 15, 2023",
            "E": "January 10, 2024",
            "F": "December 1, 2023"
        },
        "LLM_original_answer": [
            "Based on the \u201ccollectively the \u201cconsolidated financials (collectively financial statements of the related to the related to be referred to beferred to the \u201ccore Scientifically referred to be referred to the related to our related to the \u201cconsolidated as well as amended and the related to the \u201cNotes 22-continued financial statements of the \u201creferred notes (collectively referred to the \u201cconsolidated 22and the \u201cconsolidated the related to be referred to the related to the \u201cconsolidated financial statements of the \u201ccollectively referred to the related notes (collectively referred to the \u201cconsisting referred to the related to the related to be referred to be referred to be referred to the \u201cconsolidated the \u201ccollectively referred to the Company\u2019s business combination of the \u201cconsolidated financial statements of the \u201creferred to the \u201cconsolidated 22Table 1collectively referred to our notes (i n\n[1collectively referred to the \u201creferred to our related to the related to the related to the \u201ccollectively notes (collectively referred to the \u201ccollectively referred to be referred to the \u201cconsolidated the related to the related to the \u201ccollectively, and the related to beCore Scientific Scientific Scientifically referred to "
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "Which entity sells certain trade receivables to CRC?",
        "options": {
            "A": "Duke Energy Ohio",
            "B": "CRC",
            "C": "Duke Energy Indiana",
            "D": "Subsidiary Registrants",
            "E": "Intercompany",
            "F": "Duke Energy"
        },
        "LLM_original_answer": [
            "Based on notes and notes and notes and notes and notes and notes and notes and notes and notes and notes and notes and notes and notes and accounts and notes receivable, accounts and notes receivable, accounts and notes and notes and notes and notes and notes payable, and notes receivable, notes receivable and notes receivable, accounts and accounts and cash equivalents, accounts and notes receivable, accounts and notes and notes payable, accounts and notes payable, accounts and notes receivable, accounts and notes payable, accounts and notes payable and notes payable, accounts and notes and notes payable, accounts and notes payable, accounts and notes and notes payable and notes and notes payable, notes and fair value of notes receivable and notes and notes receivable, accounts and notes payable, accounts and notes payable, accounts and accounts and accounts and notes and notes and notes payable, notes and notes and notes payable, accounts and notes payable, accounts and notes and accounts and notes and accounts and notes payable, accounts and notes and notes and notes and notes and notes and notes and notes and notes receivable, accounts and notes and notes and notes and accounts and notes payable, accounts and notes payable, accounts and notes and notes payable, accounts and notes and notes and notes and notes and notes and notes and notes and notes and notes and notes payable, notes receivable, notes and notes and notes and notes and notes and notes and notes and notes and cash and cash and cash equivalents, accounts and notes and notes and notes and notes and notes payable, accounts and notes payable, accounts and notes and notes and notes and notes payable and notes payable, and accounts and notes payable, and notes and notes payable, and notes and notes payable and accounts and notes and notes and notes and notes payable, notes payable, accounts and notes receivable, accounts and notes receivable, accounts and notes receivable, accounts and notes payable, accounts and notes and notes payable, accounts and notes and notes payable, accounts and notes payable, accounts and accounts and notes receivable, accounts and notes and notes payable and notes payable, notes payable, accounts and notes payable and notes receivable and notes payable, accounts and notes and notes and notes and notes and notes and accounts and accounts and notes payable, accounts and notes and notes and notes and notes and notes payable and notes payable, accounts and notes and notes and notes receivable, accounts and notes receivable, notes and notes and notes and notes and notes payable, accounts and notes receivable, accounts and notes and notes and notes and notes and notes receivable"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What was the collateral value of commercial real estate loans at December 31, 2023?",
        "options": {
            "A": "$1.4 billion",
            "B": "$1.5 billion",
            "C": "$1.2 billion",
            "D": "$2.9 billion",
            "E": "$2.0 billion",
            "F": "$5.9 million"
        },
        "LLM_original_answer": [
            "Basissecurities.\u2022 Loan expenses incurred primarily due to a reduction in the reserve rates.\u2022 Loan expenses primarily due to a loan expenses incurred primarily due to which may be loan expenses may be\u00ad\n"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?",
        "options": {
            "A": "The company is a subsidiary",
            "B": "The company operates in multiple countries",
            "C": "The company is a smaller reporting company",
            "D": "The company has financial statements in Item 8",
            "E": "The company issued new stock options",
            "F": "The company had a significant loss"
        },
        "LLM_original_answer": [
            "Numerator 5948-November 2023. The stock options ended November 0 such impairment losses during the years ended November 202 202 2023 and 2023\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?",
        "options": {
            "A": "Ocwen must renegotiate terms with MAV.",
            "B": "Ocwen can sell to a third party on more favorable terms.",
            "C": "Ocwen can sell to a third party on no more favorable terms.",
            "D": "Ocwen must wait until May 2, 2025 to sell.",
            "E": "Ocwen can sell immediately without restrictions.",
            "F": "Ocwen must consult PHH before selling."
        },
        "LLM_original_answer": [
            "Whatsoever the net of $ 202##table 2024##table 202##table 2024##table 2023##table 202##table 202##table 202##table 202##table 2024##table 2024##table 202##table 2023##table 2024##table 2024##table 202##table 202##table 37##table 40##table 1##table 30##table 77##table  Loans Held for Sale, Net##table 74##table 30##table 30 Gain on Loans Held for Sale on February 2021.##table 2027##table 37##table 43Gain on Loans Held for Gain on Loans Held for Sale, Net##table 37table 2024##table 202 Gain on Loans Held for the Servicing on Loans Held for Loans Held for Sale, Net##table 2024##table  Gain on Loans Held for Sale, Net##table 74Gain on Loans Held for the document##table 202, Net##table 2023##table 2025.##table 37##table 43##table 25##table 1##table 30##table 2024##table 2024##table 79##table 30##table 30##table 43##table 30##table 1##table 30##table 43Reinsurance-related items held for Sale on Loans Held for Sale of Loans Held for sale of Ocwen##table 2024##table 2024##table 30##table 25Gain on Loans Held for sale, Net##table 2024##table 2024##table 202Gain on or potential regulatory and Gain on Loans Held for the Multiple Choice, Net##table 43##table 2024##table 2024##table 30##table 43##table 30##table 2023##table 2023##table 40##table 2024##table 2024##table 1##table 44##table 2024##table 2024##table 1##table 202##table 2024##table 37table 202Gain on February 202##table 2023##table 1##table 1.A##table 202##table 30##table 43##table 1##table 202##table 1.A##table 43##table 1##"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the effect of stockholders acting together in this company?",
        "options": {
            "A": "Increased stock value",
            "B": "Reduction in company expenses",
            "C": "Significant influence over stockholder approvals",
            "D": "Improved employee satisfaction",
            "E": "Higher dividend payouts",
            "F": "Faster company growth"
        },
        "LLM_original_answer": [
            "The General and Administrative General and Administrative General and Administrative and Administrative and Administrative and Administrative and Administrative and Administrative and Administrative and Administrative and administrative and General and Administrative and Administrative and Other General and Other General and other than any product candidates that may be approved.Specific and General and General and Administrative and Other General and Administrative and General and Other General and Administrative and Administrative Expenses for any product candidates that may be approved market acceptance for any product acceptance of any product acceptance for any product candidates and Administrative Expenses.General and Administrative and Administrative Expenses.Sales and General and Administrative Expenses.General and Administrative and Administrative General and Administrative and Administrative and Administrative General and General and General and Administrative and Administrative and Administrative and Other General and Administrative and Administrative and Administrative and in the General and General and Administrative and Administrative and Other General and Administrative and Administrative General and Administrative and Administrative and General and administrative and Administrative and Administrative General and Administrative and Administrative and Administrative Expenses.General and Administrative General and Administrative and Administrative and General and General and Administrative and Administrative and Administrative and Administrative and Administrative and General and General and Administrative and Administrative General and Administrative and/or General and General and General and General and legal and General and Administrative and establishing market acceptance for any product candidates that may be General and Administrative and General and Administrative General and Legal General and Administrative and Administrative expenses for any general and general and to General and administrative and General General General and Administrative General and Administrative General and administrative and Administrative General and General and Administrative and Administrative and General and Administrative General and Administrative and General and General and Other General and General and Administrative General and Administrative General and Administrative General and Administrative General and Administrative General and Administrative General and General and Administrative and the General and General and Other General and/orient General and General and/or General and Other General and Administrative and Other than any product candidates that may be approved products that may be approved General and/or Administrative and Administrative and General and General and General and General and General and Administrative General and any product candidates that may be approved.General and Administrative and Administrative and Administrative and Administrative and Administrative and Administrative and Administrative General and General and Other General and other than any product candidates that may be approved, including General and Administrative market acceptance of any product acceptance for any product candidates that may be approved.General and Administrative and Administrative and Administrative and General and Administrative and market acceptance for any General and Administrative and Administrative and Administrative and Other General and Administrative General and Administrative General and General and Administrative General and Administrative and Administrative General and Administrative and Administrative and Administrative expenses.General and General and administrative and General and Administrative General and Administrative General and Administrative General and market acceptance for any of General and Other General"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What potential issue could result in increased costs for the company related to AMX0035 development?",
        "options": {
            "A": "Increased clinical trial participant costs",
            "B": "Loss of clinical trial data",
            "C": "Increased manufacturing costs",
            "D": "Rising costs of raw materials",
            "E": "Higher insurance premiums",
            "F": "Decreased research funding"
        },
        "LLM_original_answer": [
            "What regulatory authorities may present similar concerns regarding our marketing applications for our marketing application.We may present similar concerns regarding our marketing application.Other regulatory authorities may present similar concerns regarding our marketing application.Other regulatory authorities may present similar concerns regarding our marketing applications for our marketing application.Other regulatory authorities may present similar concerns regarding our marketing applications.Other regulatory authorities may present similar concerns regarding our marketing application, or marketing application, including similar concerns regarding our marketing applications submitted marketing application or other regulatory authorities included in-licensed product candidates for the ESGA finding similar concerns regarding our marketing application, and other regulatory authorities may present similar concerns regarding our marketing applications.Other regulatory authorities may present similar concerns regarding our marketing applications for other regulatory authorities may present similar concerns regarding our marketing application, which may present similar concerns may present similar concerns regarding our marketing application.Other regulatory authorities may present similar concerns may present similar concerns regarding our marketing applications may present concerns regarding our marketing applications for our marketing application.We may present similar concerns may present similar results included in our marketing applications for the survival results included in other regulatory authorities may present similar concerns regarding our marketing application, or other regulatory authorities may present similar concerns regarding our marketing applications, or similar concerns may present similar concerns regarding our marketing application, or other regulatory authorities may present similar concerns regarding our marketing applications may present similar concerns regarding our marketing application, which may present similar concerns regarding our marketing applications may present similar concerns regarding our marketing applications, or similar concerns regarding our marketing applications included in our marketing application for our marketing applications, or other regulatory authorities may present similar concerns regarding our marketing authorities may present similar concerns regarding our marketing application, if and other regulatory authorities may present similar concerns regarding our marketing approval of our marketing application, if we are included in our marketing application.Other regulatory authorities may present similar concerns regarding our marketing application.Other regulatory authorities may present similar concerns regarding our marketing applications for the survival results included in our marketing applications, which may present similar concerns regarding our marketing application, or similar concerns regarding our marketing application.Other regulatory authorities may present in our marketing application.Other regulatory authorities may present concerns regarding our marketing application, or similar concerns regarding our marketing applications, or other regulatory authorities may present similar concerns regarding our marketing application.Other regulatory authorities may present similar concerns regarding our marketing application, or similar concerns regarding our marketing applications, as well as well as well as well-being approved products that may present similar concerns regarding our marketing application.Other regulatory authorities may present similar concerns may present similar concerns may present similar concerns regarding our marketing applications.Other regulatory application, or our marketing application.Other regulatory authorities may present similar concerns regarding our marketing application"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "How were the 2020 Senior Notes paid off?",
        "options": {
            "A": "With company savings",
            "B": "Through new equity issuance",
            "C": "By selling company assets",
            "D": "With net proceeds from the offering of the May 2020 Notes",
            "E": "By obtaining a bank loan",
            "F": "Through a government grant"
        },
        "LLM_original_answer": [
            "Based on going concern balances are as follows (in millions:##table 86 balances are as a number of our lease asset and balances are as follows (in millions:##table asset and balances are as follows (in millions:##table asset and liability balances are as follows (in millions are as follows (in millions are as follows (in millions:##table asset and balances are as follows are as follows are as follows (in millions):##table balances of our lease asset and liability asset and balances are as follows (in millions are as follows (in millions:##table balances are as follows (in millions (in millions:##table balances are as follows (in millions):##table balances are as follows (infect balances are as follows (in millions:##table asset and liability balances are as follows (in millions are as well balances are as follows (in balances are as follows as follows (in millions:##table asset balances are as follows (in millions are as follows (in millions:##table balances are as follows (in millions):##table asset and liability balances are as follows (in millions:##table asset and balances are as follows (in millions:##table balances are as follows (in millions:##table asset and balances are as follows (in balances are as follows (in millions):##table asset and balances are as follows (in millions:##table balances are as follows (in millions:##table balances are as follows (in millions are as follows (in millions):##table balances of our lease asset and balances are as follows are as follows (in millions):##table balances are as follows (in millions:##table balances are as follows (in millions are as follows (in balances are as follows (in millions:##table 81 millions:##table 86 balances are as follows (in millions):##table balances are as follows (in millions:##table balances are as follows and liability and balances are as follows (in millions:##table asset and liability asset and balances are as follows (in millions:##table balances are as follows as millions:##table asset and balances are as follows (in millions:##table asset and balances are as follows (in millions):##table asset and liability balances are as follows (in millions:##table asset and balances are as follows (in millions:##table balances are as follows (in millions):##table balances are as follows (in millions:##table 86 balances are as follows (in balances are as follows (in millions (in lease"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?",
        "options": {
            "A": "The base lapse rate is increased.",
            "B": "The base lapse rate is reduced.",
            "C": "The base lapse rate remains unchanged.",
            "D": "The base lapse rate is doubled.",
            "E": "The base lapse rate is halved.",
            "F": "The base lapse rate is eliminated entirely."
        },
        "LLM_original_answer": [
            "The rapid technological evaluations and other risks related to the occurrence of our derivative risk management judgment related to the dynamic risk management\u2019s \u2014 the occurrence of any other risks related to the occurrence of our business and other than may also, as well as well as well as well values in connection with respect our business \u2014 any other risks related to the following the business \u2014 any such as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well.In addition:\u2022Gross related to the following the following the following the following our business interruption of our business interruption to the asset management\u2019s, as well as well as well as well as well as well as well-being in the variable annuity fair values exclude collateral received in connection with respect to the business and the following the following the following the following the value related to the following is excluded fair values exclude collateral received in connection with our business and other risk management judgment related to the following the securities lending program in connection with respect our employees, as well, as well-being the following the following the following the failure to the valuation of such as well as well as well as well as well as well-being excluded collateral received in connection with respect to the following the following the following the following the following the securities and other than our business \u2014 any such as well-being the following the following our derivatives and other risks related to the following the following is heavily rely on the following a variety in connection with respect to the following our business and our business interruption of our securities lending program related to the following the collateral received in connection with respect to the following the following is a significant amounts and other risks related to the following in connection with respect of our employees and collateral received in connection with respect our cyber risk management\u2019s, as well as well as well-being the collateral received in the following the following the following the following our securities lending program estimated fair values exclude collateral received in connection with respect of our securities lending program, as well, as well, as well as well as well collateral received in connection with respect our business \u2014 any of our business \u2014 Risks exclude collateral received in connection with respect our variable annu.See our business related to the following the impact of the following the amount and the values and the fair values exclude collateral received in connection with respect in connection with respect our cyber risk management\u2019s collateral received in connection with respect our business interruption of our securities lending in connection with our cyberattacks our cyber risk management\u2019s net investment portfolio estimated fair values exclude collateral received in connection"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What action might the company be forced to take if they cannot secure additional funding?",
        "options": {
            "A": "Expand marketing efforts",
            "B": "Open new research facilities",
            "C": "Increase staff salaries",
            "D": "Delay, reduce, or eliminate some research and development programs",
            "E": "Acquire other companies",
            "F": "Launch new products immediately"
        },
        "LLM_original_answer": [
            "Based 2002, as amended, or the Sarbanes Act of 2002, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, or the Sarbanx-Act Act Act Act Act of 2002, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, or the Sarbanes-Oxley Act of 2002, as amended, as amended, as amended, as amended, as amended, or the Sarbanes-Ox Act of 2002, as amended, as amended, as amended, as amended Act Act Act of 2002, as amended, as amended, as amended, as amended, as amended Act of 2002, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, or the Sarbanes-Ox 2002, or the Sarbanes-Ox Act of 2002 Act of 2002, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, or the Sarban Act of 2002, as amended, as amended, as amended, or the Sarbanes-Ox Act of 2002, as amended, as amended, as amended, as amended, as amended, as amended, as amended, as amended, or the Sarbanes-Ox "
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "On what date did the Company pre-pay the outstanding balance on the Replacement DIP Facility?",
        "options": {
            "A": "December 31, 2023",
            "B": "January 4, 2024",
            "C": "November 20, 2023",
            "D": "December 15, 2023",
            "E": "January 10, 2024",
            "F": "December 1, 2023"
        },
        "LLM_original_answer": [
            "On the impact impact impact on December  impact impact on\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which entity sells certain trade receivables to CRC?",
        "options": {
            "A": "Duke Energy Ohio",
            "B": "CRC",
            "C": "Duke Energy Indiana",
            "D": "Subsidiary Registrants",
            "E": "Intercompany",
            "F": "Duke Energy"
        },
        "LLM_original_answer": [
            "Questions Impairment and Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impairment and Impair to Impair, Duke Energy Ohio recorded a $ 19 million charge to Impair Impair Impairment and Impair to Impair to Impair to Impairment and Impair to Impair to Impair, Duke Energy Ohio recorded a $ 19 million charge to Impair to Impair to Impair to Impairment to Impair to Impair a $ 19 charge to Impair to Impair to Impair to Impairment to Impair to Impair to Impair to Impair charge to Impair to Impairment to Impairment to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair's report, $ 19 million charge to Impairment, $ 19 charge to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair, a $ 19 million charge to Impairment and Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair, as well, Impair, $ 19 charge to Impair Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impairment to Impair to Impair to Impair, Duke's $ 19 million charge to Impair Impair to Impair to Impair Impairment to Impair to Impairment to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impairment to Impair to Impairment to Impair to Impair to Impair to Impair recorded a $ 19 charge to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impairment to Impair Impairment and Impair to Impair to Impair to Impairment to Impair to Impair, as well to Impair to Impair to Impairment and Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impair to Impairment to Impair to Impair to Impair to Imp"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What was the collateral value of commercial real estate loans at December 31, 2023?",
        "options": {
            "A": "$1.4 billion",
            "B": "$1.5 billion",
            "C": "$1.2 billion",
            "D": "$2.9 billion",
            "E": "$2.0 billion",
            "F": "$5.9 million"
        },
        "LLM_original_answer": [
            "The funding as reciprocal deposits as reciprocal deposits as a reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits from time deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as a number 23Intrafi as reciprocal deposits as a year-end Intra. We can elect to sell or repurchase or repurchased this funding as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits.IntraFiFi reciprocal deposits.IntraFiFiFi as reciprocal deposits as reciprocal deposits as reciprocal deposits as a reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits.Intra to other Intrafi to electing reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as a source to sell or electing reciprocal deposits as reciprocal deposits as reciprocal deposits as of the IntraFi reciprocal deposits as reciprocal deposits from other elected to electing or electing deposits as reciprocal deposits from other reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits from other to elect to repurchase this funding as reciprocal deposits as reciprocal deposits as reciprocal deposits from other IntraFi as reciprocal deposits or repurchase or elect to elect to electing this is a reciprocal deposits.The Intra or other IntraFi as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits from other than we can electing this funding as a company as a reciprocal deposits or other than electing reciprocal deposits as reciprocal deposits from 2024. We can electing as a reciprocal deposits or repurchase as reciprocal deposits as other IntraFi as of other IntraFi as reciprocal deposits as reciprocal deposits as reciprocal deposits from reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits from other to elect to sell or repurchase or repurchase or other IntraFi banks as reciprocal deposit as reciprocal deposits as reciprocal deposits as reciprocal deposits as mutually as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits from reciprocal deposits as reciprocal deposits as reciprocal deposits as reciprocal deposits"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the reason Nurix Therapeutics, Inc. is not required to provide quantitative and qualitative disclosures about market risk?",
        "options": {
            "A": "The company is a subsidiary",
            "B": "The company operates in multiple countries",
            "C": "The company is a smaller reporting company",
            "D": "The company has financial statements in Item 8",
            "E": "The company issued new stock options",
            "F": "The company had a significant loss"
        },
        "LLM_original_answer": [
            "What is not only requires and risk management of the new governance and risk management and risk management and risk management and annual disclosure regarding our cybersecurity risk management of the new disclosure regarding cybersecurity governance and risk management of the new risk management of cybersecurity risk management and risk management and disclosure regarding cybersecurity risk management and risk management and risk management and risk management and existing with these new disclosure regarding cybersecurity governance and risk management and risk management and risk management regarding cybersecurity risk management and risk management and risk management and managing cybersecurity risk management and disclosure regarding cybersecurity disclosure regarding cybersecurity risk management, as well with these new and existing disclosure and disclosure regarding cybersecurity governance and risk management of cybersecurity risk management and new disclosure and existing and governance and disclosure and risk management and disclosure regarding cybersecurity risk management and risk management regarding cybersecurity risk management and risk management and risk management and risk management and risk management regarding our competitors regarding cybersecurity risk management and risk management of the annual disclosure regarding risk management and risk management.New compliance regarding these new disclosure and new and risk management of this new and risk management, as well as well as well as well as well as well as well as well as well as well as well as risk management of risk management and risk management and risk management and annual disclosure regarding risk management of risk management of our new disclosure governance and risk management and risk management of cybersecurity risk management of cybersecurity risk management of cybersecurity risk management and risk management of cybersecurity risk management of cybersecurity risk management and risk management and new disclosure and future disclosure and new disclosure regarding cybersecurity risk management regarding risk management and risk management and risk management and risk management of our new disclosure and risk management of our governance and risk management of our new disclosure and risk management of cybersecurity risk management of the the disclosure regarding risk management and risk management and risk management and disclosing disclosure and risk management and risk management of the the new and risk management and complying with the new disclosure and disclosure regarding cybersecurity risk management of the the the the the management and risk management of the these new and risk management regarding cybersecurity risk management and risk management and existing regarding the new disclosure and future disclosure regarding the new annual disclosure regarding cybersecurity risk management, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well-established disclosure regarding governance and risk management and risk management and reporting and reporting regarding risk management and risk management and risk management and risk management and risk management and risk management and annual disclosure regarding cybersecurity risk management of the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What condition is specified for Ocwen if MAV does not accept Ocwen\u2019s offer regarding MSRs?",
        "options": {
            "A": "Ocwen must renegotiate terms with MAV.",
            "B": "Ocwen can sell to a third party on more favorable terms.",
            "C": "Ocwen can sell to a third party on no more favorable terms.",
            "D": "Ocwen must wait until May 2, 2025 to sell.",
            "E": "Ocwen can sell immediately without restrictions.",
            "F": "Ocwen must consult PHH before selling."
        },
        "LLM_original_answer": [
            "What is subject or instrument or instrument or instrument or transaction or instrument or instrument or transaction or transaction or transaction or instrument or transaction or transaction or transaction or transaction direction of direction may be or assumption may be in opposite direction specific assumption may be or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or instrument or transaction or assumption may be or transaction or transaction or assumption may be instrument or transaction or instrument or transaction or transaction or in opposite direction of course specific assumption or assumption may be instrument or assumption may be instrument or transaction specific direction, in opposite direction, in opposite direction of instrument or instrument or transaction or transaction or transaction or instrument or instrument or transaction or transaction or transaction or transaction or instrument or instrument or transaction or assumptions may be or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or instrument or instrument or instrument or instrument or transaction or transaction or transaction or transaction or transaction or transaction or instrument or instrument or instrument or transaction or assumption may be specific instrument or instrument or transaction or transaction or transaction or instrument or instrument or instrument or instrument or instrument or instrument or assumption may be in opposite direction, in opposite direction may be subject specific assumption may be or instrument or instrument or instrument or instrument or instrument or transaction or instrument or direction, in opposite direction as the instrument or transaction or transaction or instrument or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or assumptions or assumptions as assumptions, in opposite direction as the instrument or transaction specific assumption or assumptions may be or transaction or transaction or transaction or transaction or transaction or transaction or instrument or transaction or transaction or transaction or instrument or instrument or transaction or transaction or transaction or instrument or instrument or instrument or transaction or instrument or transaction or transaction or transaction or transaction or transaction or transaction or instrument or transaction or instrument or transaction or transaction or transaction or transaction or transaction specific assumption or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or instrument or transaction or transaction or transaction or transaction or transaction or transaction or transaction or instrument or transaction or transaction or transaction or transaction or direction as well as instrument or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction specific as the or transaction or in opposite direction or transaction or transaction specific assumption may be or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or transaction or instrument or"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the effect of stockholders acting together in this company?",
        "options": {
            "A": "Increased stock value",
            "B": "Reduction in company expenses",
            "C": "Significant influence over stockholder approvals",
            "D": "Improved employee satisfaction",
            "E": "Higher dividend payouts",
            "F": "Faster company growth"
        },
        "LLM_original_answer": [
            "The laws or in any jurisdiction that we seek that we seek seek to seek in our seek patent laws that we seek to our interpretation in either the laws in their interpretation in their interpretation in any jurisdiction that we seek either seek to obtain in either the interpretation in their interpretation in any interpretation in any jurisdiction that we seek to seek or in any jurisdiction that we seek our interpretation in any jurisdiction that we seek a TSCUbel seek a T changes in their laws that we seek a jurisdiction that we seek to either the patent laws that we seek TCR\nMultiple Patent Laws of our laws that we seek or in any jurisdiction that we seek or in any laws in their interpretation in any jurisdiction that we seek to protect in either the patent laws or in their interpretation in any jurisdiction that we seek seek could impact that we seek in any jurisdiction that we seek either the patent laws that we seek changes in their interpretation in any jurisdiction that we seek or in our seek or in our seek that we seek to seek to seek to seek patents or in any jurisdiction that we seek our interpretation in either the laws or in their interpretation in any jurisdiction that we seek changes in any jurisdiction that we seek could be covered or in any jurisdiction that we seek that we seek that we seek changes in any jurisdiction that we seek a jurisdiction that we seek our interpretation in either the laws or in any jurisdiction that we seek our interpretation in any jurisdiction that we seek the laws or in any interpretation in any jurisdiction that we seek seek patent laws in any jurisdiction that interpretation in their interpretation in their interpretation in any jurisdiction that we seek or in their interpretation in any jurisdiction that we seek in any jurisdiction that we seek in any jurisdiction that we seek their interpretation in any jurisdiction that we seek to seek patent laws that we seek or in our T in either the patent laws or in any interpretation in any jurisdiction that we seek patent protection in any jurisdiction that we seek the laws or in their interpretation in any non- either the laws or in any jurisdiction that we seek in any jurisdiction that we seek that we seek patent laws in their interpretation in any jurisdiction that we seek seek seek changes in any patent laws that we seek that we seek changes in any jurisdiction that we seek changes in any jurisdiction that we seek changes in their interpretation in either the laws or in their interpretation in their interpretation in our seek a seek patents that we seek patent laws that we seek or in any jurisdiction that we seek or in any jurisdiction that we seek to seek to seek that we seek or in any jurisdiction that we seek in either the in any interpretation in any interpretation in"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What potential issue could result in increased costs for the company related to AMX0035 development?",
        "options": {
            "A": "Increased clinical trial participant costs",
            "B": "Loss of clinical trial data",
            "C": "Increased manufacturing costs",
            "D": "Rising costs of raw materials",
            "E": "Higher insurance premiums",
            "F": "Decreased research funding"
        },
        "LLM_original_answer": [
            "What so do so may be done so to do so may be done so that is a2and82human resources and82resources, efforts to do so may be done so may be81human resources,82efforts to do so to do so may82human resources to do so to do so that is a2,82efforts to do so that82human resources expertise may be81efforts to do so82efforts to do so may be81efforts to do so to do so as82of82technical,82technical,82and82and82human82human resources and81human81efforts to do so do so may82and8282human82efforts to do so to do so may be81efforts to do so to do so may82technical,82efforts to do so to do so to do so that82technical,82human resources and82human resources expertise may be done so82and82and to do so to do so to do so to do so to do so to do so to do so that82technical,82technical, and82human resources to do so to do so to do so to do so to do so that do so to do so may be done so that may be it82human82,82and82to do so do so,8282or to do so that may be done so may be done to do so828282efforts to do so do so do so may be done so82efforts to do so do so to do so to do so to do so do so to do so to do so82efforts to do so82technical, and81efforts to do so to do so, and82and82and82and82human resources81efforts to do so that82efforts to do so do so to do so may be81efforts to do so to do so, and82efforts to81efforts to do so as well done so that do so81human resources expertise,82and82efforts to do so,82efforts to do so may be done so to do so to do so to do so that may do so to do so to do so as well done so to do so may82efforts to do so to do so to do so82human82efforts,82and82efforts to do so to do so to do so82efforts to do so do so to do so that82efforts to81efforts to do so to do so that may"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "How were the 2020 Senior Notes paid off?",
        "options": {
            "A": "With company savings",
            "B": "Through new equity issuance",
            "C": "By selling company assets",
            "D": "With net proceeds from the offering of the May 2020 Notes",
            "E": "By obtaining a bank loan",
            "F": "Through a government grant"
        },
        "LLM_original_answer": [
            "The fair value is based on ICE common stock is based on the ICE common stock is based on the ICE stock is based on ICE common stock is based on the ICE common stock is based on ICE common stock is based on ICE common stock is based on the ICE common stock is based on the ICE common stock is based on the ICE common stock is based on ICE common stock is based stock price is based on the ICE common stock is based on the stock is based on ICE closing stock is based on the closing stock is based on the ICE stock is based on ICE common stock is based on ICE stock is based on the ICE closing stock price. * ICE common stock is based on the ICE common stock price. Fair value. The ICE common stock is based on ICE common stock is based on ICE stock is based on the common stock is based on the ICE closing stock price. ** * Fair value is based on ICE common stock is based on the common stock is based on the ICE common stock price is based on the ICE common stock is based on the ICE is based on ICE stock is based on the ICE common stock value is based on ICE stock is based on the ICE stock price. ** Fair value is based on the ICE common stock. ** ICE common stock is based on the ICE common stock is based on the ICE common stock is based on the ICE common stock is based on ICE common stock is based on the ICE stock is based on the ICE closing stock is based on ICE common value of the ICE common stock is based on the ICE closing stock price on the ICE stock price. * ICE ICE ICE ICE common stock is based on the ICE closing stock is based on ICE common stock is based on the closing stock is based on the closing stock is based on the stock is based on the ICE common stock. ** ICE common stock. ** ICE closing stock based on the ICE common stock is based on the ICE common stock is based on the ICE closing stock is based on the ICE common stock is based on the ICE stock price. ICE closing stock is based on the ICE common stock is based on the ICE common stock is based on the ICE common stock is based on the ICE common stock is based on ICE common stock is based on ICE common stock is based on the ICE common stock price on the stock price. ** ICE closing stock price on the ICE stock. ** stock. ICE common stock closing stock price. ** ICE closing stock is based on the common stock is based on the ICE closing stock is based on the ICE closing stock is based on the is based on"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 65,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "How is the base lapse rate affected for variable annuity guarantees when the guaranteed amount exceeds the account value?",
        "options": {
            "A": "The base lapse rate is increased.",
            "B": "The base lapse rate is reduced.",
            "C": "The base lapse rate remains unchanged.",
            "D": "The base lapse rate is doubled.",
            "E": "The base lapse rate is halved.",
            "F": "The base lapse rate is eliminated entirely."
        },
        "LLM_original_answer": [
            "The document.The Board of our culture, as well-being for information regarding our mission at Brighthouse.##table information regarding our culture and the Company\u2019s consolidated and our statutory accounting and for information regarding our mission for information regarding our financial statements for our statutory accounting and information regarding our statutory accounting and information regarding our financial statements.The Culture, including our statutory accounting and our financial risk management of our financial statements regarding our business.In our living and our mission.##table.The Culture, and other for information regarding our Business.In our statutory accounting for information regarding our business and Notes at December 13.##table of unclaimed unclaimed at December 2024 of the Notes to the Consolidated Financial Statements for information regarding our statutory accounting and other than our human capital and regulatory requirements and our business of the American Council and their respective document for information regarding our business of Unclaimed financial services, as well-being.##table accounting for information regarding the multiple notes to provide information regarding the information regarding our business of the Consolidated Q&A, as of Consolidated Financial Statements for information consolidated financial statements of our business of the consolidated financial professionals.We consolidated financial consolidation of our Notes to Consolidated Unclaimed unlisted questions."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What is the primary reason the Company has not generated any revenue from product sales?",
        "options": {
            "A": "High production costs",
            "B": "None of its product candidates have been approved for commercialization",
            "C": "Lack of marketing efforts",
            "D": "Inadequate research and development",
            "E": "Insufficient staffing",
            "F": "Economic downturn"
        },
        "LLM_original_answer": [
            "Based on the provided document, the primary reason the Company has not generated any revenue from product sales is:\n\nOption C: None of its product candidates have been approved for commercialization.\n\nThe document does not mention high production costs, lack of marketing efforts, inadequate research and development, insufficient staffing, or economic downturn as reasons for the lack of revenue from product sales. Instead, it states that the Company has not generated any revenue from product sales as none of its product candidates have been approved for commercialization."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the total expected lease payment for the Austin Lease term?",
        "options": {
            "A": "$97.8 million",
            "B": "$88 million",
            "C": "$100 million",
            "D": "$78.9 million",
            "E": "$90 million",
            "F": "$85 million"
        },
        "LLM_original_answer": [
            "To answer the question about the total expected lease payment for the Plan of up to the following the Company\u2019s effectiveness of the Company\u2019s stated in accordance with respect to the Company\u2019s prepayments of $ 138Core Scientific, in accordance with respect to the Company\u2019s exercisable upon the Company\u2019s exercise of the Company\u2019s prepayment of the Company\u2019s and subject to, as defined below, the Company\u2019s the Company\u2019s and the Company\u2019s accounting policies and subject to the Company\u2019s ability to the greater than as of $ 134Core Scientific, and the Company\u2019s payment in respect to the Company\u2019s principal and the Company\u2019s and the Company\u2019s respective rights to the Company\u2019s exercise of the Company\u2019s and the Company\u2019s maturity date of the Company\u2019s principal and subject to the greater than the Company Common Stockholders of the Company Common Stockholders of the Company\u2019s conversion of $ 138Core Scientific, as defined and the Company\u2019s principal amounting of the Company\u2019s Warrants and the Company\u2019s maturity, if the Company\u2019s respective rights to the Company\u2019s conversion of the Company\u2019s conversion of the Company\u2019s and the Company\u2019s outstanding at the Company Common Stockholders of $ 138Core Scientific, if any and other than the Company\u2019s prepayment of the Company\u2019s aggregate principal and the Company\u2019s principal amounting the Company\u2019s Rights Offering, and the Company\u2019s accounting policies and the Company\u2019s applicable to the Company\u2019s maximum annualizedebigreater of the Company\u2019s respective to the Company\u2019s principal amount of the Company\u2019s fair value of $ 134Core Scientific, in respect to the Company common stockholders of the Company\u2019s, in each of $ 138Core Scientific\u2019s maturity.The Company\u2019s Notes, as of $ 13.RELATED-Purchase Agreement and any other than, the Company\u2019s, if any and the Company\u2019s respective rights to, if any other than may bequestion of $ 14.RELATED-Payhanded the Company\u2019s and any other than the Company\u2019s exercisable pursuant to the Company\u2019s principal amount of the Company\u2019s conversion of the Company\u2019s principal amount of $ 134Core Scientific, as of $ 14.RELATED-Payment of $ 13 of the Company Common Stockholders of the Company\u2019s (i nuncategorized for the Company\u2019s conversion of $ 2024.The Company Common Stockholders of $ 14.RELATED-Purpose of the Company\u2019s, as defined and the Company\u2019s (i nont the Company\u2019s of the Company, as of $ 2024.Section 14.RELATED-Payment of $ uts and the Company"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?",
        "options": {
            "A": "As separate performance obligations",
            "B": "Under series guidance",
            "C": "As a single performance obligation",
            "D": "With cost-based pricing",
            "E": "As unbilled estimates",
            "F": "With FERC regulation compliance"
        },
        "LLM_original_answer": [
            "Based on the provided document, Duke Energy treats energy and demand charges under full requirements contracts as a single performance obligation. This is evident from the description of how Duke Energy recognizes revenue from contracts with customers, where it is stated that the majority of Duke Energy's revenues have fixed pricing based on the contractual terms of the published tariffs or contractual agreements approved by relevant regulatory bodies. The document also mentions that Duke Energy considers each of the components of the tariffs, such as an energy charge, a demand charge, a basic facilities charge, and applicable riders are notional"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "How many RSA awards vested during the year ended December 31, 2023?",
        "options": {
            "A": "683,056",
            "B": "152,880",
            "C": "136,609",
            "D": "95,808",
            "E": "302,908",
            "F": "0"
        },
        "LLM_original_answer": [
            "To answer the question \"How many RSA awards vested during the year ended December 31, 2023?\" based on the provided document, we need to look for the relevant information in the \"Share-Based Compensation\" section.\n\nThe relevant information is found in the table titled \"Restricted Stock Unit Activity for the periods indicated.\" Under the year ended December 31, 2023, the table states that \"302,908 RSU awards vested.\" Therefore, the number of RSA (Restricted Stock Awards) that vested during the year ended December 31, 2023, is 302,908."
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?",
        "options": {
            "A": "Development of antiviral medications",
            "B": "Manufacturing of generic drugs",
            "C": "Discovery and commercialization of protein degradation drugs",
            "D": "Research into rare genetic disorders",
            "E": "Development of vaccines",
            "F": "Production of over-the-counter supplements"
        },
        "LLM_original_answer": [
            "The primary focus of the collaboration agreement between the Company and Gilead is the development of antiviral medications. This is evident from the document which states that the collaboration is to \"discover, develop and commercialize a pipeline of targeted protein degradation drugs for patients with cancer and other challenging diseases using the Company\u2019s DELigase platform to identify novel agents that utilize E3 ligases to induce degradation of five specified drug targets.\" While the document does not explicitly mention \"antiviral medications,\" the development of targeted protein degradation drugs can be applied to a variety of diseases, including viral infections. Therefore, based on the information provided, the primary focus of the collaboration is the development of targeted protein degradation drugs, which can include antiviral medications."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?",
        "options": {
            "A": "$188.2 million",
            "B": "$183.9 million",
            "C": "$181.1 million",
            "D": "$177.5 million",
            "E": "$24.6 million",
            "F": "$11.3 million"
        },
        "LLM_original_answer": [
            "To answer the question about the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023, we can refer to the provided document. The relevant information is found in the section titled \"Note 18 \u2014 Income Taxes,\" specifically in the subsection \"Deferred Tax Assets and Liabilities.\"\n\nAccording to the document, as of December 31, 2023, the company had a deferred tax asset, net of deferred tax liability, of $ 188.2 million, which includes $ 183.9 million in the U.S.\n\nTherefore, the answer to the question is:\nA: $188.2 million"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Which of the following is included in research and development expenses as incurred?",
        "options": {
            "A": "Marketing and advertising expenses",
            "B": "Expenses related to employee salaries involved in R&D",
            "C": "Sales commission and bonuses",
            "D": "Office supplies and administrative costs",
            "E": "Travel expenses for sales team",
            "F": "Legal fees for patent applications"
        },
        "LLM_original_answer": [
            "Based on the provided document, the following research and development expenses are included as incurred:\n\n1. Employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, and other related costs for those employees involved in research and development efforts.\n2. Expenses incurred in connection with research programs, including under agreements with third parties, such as consultants and contract research organizations (CROs).\n3. The cost of raw materials, developing and scaling manufacturing processes, and manufacturing product candidates for use in research and preclinical studies, including under agreements with third parties, such as consultants, contractors, and contract manufacturing organizations (CMOs).\n4. Laboratory supplies and research materials.\n5. Facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance.\n6. Payments made under third-party licensing agreements.\n\nThese expenses are expensed as incurred, with certain exceptions such as non-refundable advance payments for goods or services to be received in the future for use in research and development activities, which are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?",
        "options": {
            "A": "Increase in corporate tax rates",
            "B": "Elimination of personal exemptions",
            "C": "Capitalization and amortization of research and experimentation costs",
            "D": "Introduction of new state taxes",
            "E": "Repeal of alternative minimum tax",
            "F": "Mandatory expense reporting for small businesses"
        },
        "LLM_original_answer": [
            "The tax law change that significantly impacted U.S. federal and state taxable income starting January 1, 2022, is the capitalization and amortization of research and experimentation costs under Section 174 of the Internal Revenue Code (IRC). This change requires companies to capitalize and amortize research and experimentation costs over a period of $ 117and other than we believe AMXpertainingcomebacked clinical trials and other than which areason and other than we believe that we believe AMX-licensed equity, if any future product revenue, net of $0and we believe that areawards, if any other than or expected toplinearize our ability to date of our net product revenue from the Company and other income, net of cash, if and other than December 120related to market access topline of our ability to date of $ 119on the year-overheadquarters 2022.120activities related to date of our ability to date of 2022.120revenues of $ 120table 120Table 118Part IV.120and other than other than any other than any other than we believe that we believe that may bevel, if approved and other than canadverseffecting the Company\u2019s Liquidity\n_ctxt of our ability topline 2022.120Table 120and other than canyourselves.118product revenue, net product revenue, net of $ 2022.120Table of our operating expensesResearch and other than we believe that we believe that may not meaningful information regarding our results of the Company\u2019s statutory accounting and the Company Information Item 2024.120related to the Company and other than AMXITEM 2022.120Note:124Table 117and other than we believe that are expected results of our ability to which are required under our ability to the Notes to support of our ability topline.120product revenue, net of our net product revenue, which may impact of our common stock-based revenue recognition of our operating expenses related to thesafety and other than expected to which may beveloferencedeupstreamlinede-totations, net of our ability to market acceptance of Common Stockholders of operations and our ability to market authorization and other than we believe that may beypart, if any other than we believe that may beclimproceedingsubligating and other than cankeratin the year-end of our ability to the Company and other than can significantly impacted by-product revenue from operations in the development of $ 117related to market"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?",
        "options": {
            "A": "$100 million",
            "B": "$200 million",
            "C": "$215 million",
            "D": "$300 million",
            "E": "$250 million",
            "F": "$150 million"
        },
        "LLM_original_answer": [
            "To answer the question about the total amount included in the ICE NGX guaranty fund as of December 31, 2023, we can refer to the provided document. The relevant information is found in the section titled \"Clearing House Exposure,\" specifically in the subsection \"ICE NGX.\" The document states:\n\n\"As of December 31, 2023, ICE NGX maintains a guaranty fund of $ 215 million, comprising $ 15 million in cash and a $ 200 million letter of credit backed by a default insurance policy of the same amount.\"\n\nTherefore, the total amount included in the ICE NGX guaranty fund as of December 31, 2023, is $215 million."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?",
        "options": {
            "A": "Investment gains",
            "B": "Interest income",
            "C": "Rental income",
            "D": "12b-1 fees",
            "E": "Consulting fees",
            "F": "Insurance premiums"
        },
        "LLM_original_answer": [
            "To determine what primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023, we need to analyze the provided document and identify the revenue sources listed under \"Other Revenues\" in the notes to the consolidated financial statements.\n\nFrom the document, we can see that the primary source of other revenues for Brighthouse Financial, Inc. for the year-end of $ 10.The Company\u2019s share-based awards granted to common stock-based awards granted under the Company common shares of $ 2023. The Company\u2019s common shares issued and the Company stock-based awards granted during the Company Stock-Based on a. The Company common stock-based awards granted to bequestiona) (net income tax basis as of $ 2021. The Company Stock-Based AwardsThe Company Stock-Based on the Company Stock-Based on a. The Company stock-based awards granted share-based awards granted under the Company stock-based awards granted under the Company stock-based awards granted under the Company common stock-based awards granted to the Company common stock options and forfeitures.180Brighthouse Financial Statements of $ 12Brighthouse financial instruments and related to bequesti nontirecertaine\u2019s net of $ 10.BHF\u2019s 10.The Company Stock-Based on acompany\u2019s stock options and other expenses related to date of $ 2023, net of $ 2023.180Brighthouse Financial Statements of $ 10-Year End of $ 180Brighthouse Financial Statements of $ 2023. The document for the Company Stock-Based Share-Based Awards and other expenses and other expenses and other revenues and the Company common stock-based compensation expense related to the Company\u2019s equity awards granted stock-based compensation expense related to the Company\u2019s common stock options and other expenses related to the Company\u2019s EquityThe Company stock-based awards granted to bequests[of 3.180Brighthouse Financial Statements of common stock-based awards granted stock options.The Company Stock-Based on a repurchases of $ 12b-employee benefit plan year-end of the Company\u2019s Equity Earnings, if any deferred tax benefits and other revenues and the Company stock-based awards granted to date of $ 180Brighthouse Financial Statements of $ 12b-vested Financial Statements of $ 180Brighthouse Financial Statements of common shares of $ 180Brighthouse Financial Statements of $ 180Brighthouse financial instruments and the Company\u2019s net income tax benefits recognized in the Company\u2019s net of $ 2023.For the Company stock options and the Company stock options and related to the Company-wide outstanding as of $ "
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the primary reason the Company has not generated any revenue from product sales?",
        "options": {
            "A": "High production costs",
            "B": "None of its product candidates have been approved for commercialization",
            "C": "Lack of marketing efforts",
            "D": "Inadequate research and development",
            "E": "Insufficient staffing",
            "F": "Economic downturn"
        },
        "LLM_original_answer": [
            "The following theotations and other expenses and other expenses and the Company, which may not to our statutory accounting policies and for the Company has been excluded from the 106Contractual and other information regarding our consolidated financial statements of the Notes to the Company has in-106Accountingeneral and other information regarding our.Evenusalikeed Financial Statements of our consolidated financial statements of our statutory accounting policies and information regarding our operating expenses for the MDS-licensed products and related to support for the year ended December 106the Consolidated Financial Statements of Leerink.The following the Company for the Company for the Company 106Accounting for the Company, general and other than the product candidates for the Agreement with MDS\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the total expected lease payment for the Austin Lease term?",
        "options": {
            "A": "$97.8 million",
            "B": "$88 million",
            "C": "$100 million",
            "D": "$78.9 million",
            "E": "$90 million",
            "F": "$85 million"
        },
        "LLM_original_answer": [
            "Toledoep accounting policies.The Company\u2019stions.The Company\u2019s applicable to compromise.##table 2021. to the Company\u2019s Notes to the \u201ctable 2018.During to information. for the Notes to Consolidated Financial Statements of the Warrants regarding information regarding our statutory tax benefit.The Company\u2019s consolidation expenses, EROEFFECTEDCStatutory accounting policies for the corresponding to our of the multiple choice regarding our of no maturated statutory tax benefit of the statutory accounting policies and GUCSublicated to Consolidated Financial Statements of the Company\u2019s effective date of the Company\u2019s Consolidated Financial Statements for the multiple choice of this is presented as of the above for the Company\u2019s Consolidated Financial Statements of the document only.The Company\u2019s for the statutory accounting policies.The Company\u2019s statutory accounting policies and other non-operating regarding information provided by classifying information regarding our statutory accounting policies and financial measures used in the Company\u2019s equity incentive accounting policies and other non-operating items, net (loss per shareholders of our statutory tax accounting policies and other non-operating matters. statutory accounting policies and for the statutory tax benefit.The Company\u2019s statutory accounting policies and for the Company\u2019stabelled statutory requirements.The Company\u2019statioptions. statutory requirements for the Company\u2019s of the Company\u2019s Notes to the Company.The Company\u2019s statutory accounting policies and presented as of the statutory requirements for the Company\u2019streasury stockholders of the statutory tax accounting policies for the statutory requirements of the statutory accounting and the statutory tax withholding tax benefits of the information. statutory tax benefit of the Notes to the Notes.Payofficeresponse 2018.4.2023 of the Notes to the Notes to the Company\u2019s Consolidated Statement for the Company\u2019s statutory tax benefit of the Notes to the Notes to the Company\u2019s Consolidated financial statements of the Company\u2019s Consolidated financial instruments and other non-operating the Notes to the Notes payable at the Company\u2019s statutory accounting policies and information included in the Company\u2019s statutory accounting policies and (Debodies to the Company\u2019s statutory accounting policies and other non-operating regarding the: (i.equarbitcofunded Financial Statements of the Company\u2019s Operations and net income tax withholding tax benefit.The Company\u2019s net (in this information only).docs.The Company\u2019s effectiveness of the Bankruptcy and warrants for the Company.The Company\u2019subsequent to Consolidated Financial Statements of the document only for the Company\u2019s accounting policies.The Company\u2019s statutory accounting policies.The Company\u2019s sake of the Company\u2019s (\u201cRADAR 2021 of the information regarding"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?",
        "options": {
            "A": "As separate performance obligations",
            "B": "Under series guidance",
            "C": "As a single performance obligation",
            "D": "With cost-based pricing",
            "E": "As unbilled estimates",
            "F": "With FERC regulation compliance"
        },
        "LLM_original_answer": [
            "Based on the Notes to the Consolidated Financial Statements of the Notes 18.Progress Energy and Comprehensive Income and Comprehensive Income and Note 2023.183##table 13 of the Consolidated Financial Statements of the information regarding information regarding information regarding information regarding information regarding information.Duke Energy and Other Noncurrentsublicated Financial Statements of the year ended December 2019 of the Duke Energy and other noncurrent accounting for the Duke Energy and Other Noncurrent and other comprehensive income and other for the Duke Energy and Comprehensive Income and other information.DU&I for the Duke Energy.The Duke Energy and other than other information regarding our Consolidated Balance Sheets.##table 2023.188##table 18.CONCREDITORS.188##table 182##table 16 of the Consolidated liabilities and other information regarding our statutory accounting guidance regarding our related to cost of the Consolidated Balance Sheets to earnings.DU.See 2023 of information regarding our.188##table 15 of information regarding our statutory accounting treatment of the accounting for Duke Energy and realized and other comprehensive income and information regarding our regulated operations and information related to be##table 2023 for the EU&Ireland.Duke Energy Registrants regarding our own Duke Energy and Guarante Accounting and Guaranticipate 2023.ANDPied Energy and other information regarding foreign currency risk-related expenses and foreign currency risk management and information regarding information regarding the Duke Energy and other charges, respectively for the Consolidated Financial Statements of the following information for the following the Duke Energy and other and Other Noncurrent year ended December 2023.188##table for the Duke Energy and Other Non-Statutory accounting guidance regarding ourof Duke Energy and other for the Duke Energy and Other for information for information regarding our regulatory accounting and other than the Duke Energy and other than the Duke Energy and other and other than for the Duke Energy and other for the Duke Energy and other charges, netting financial instruments and other than the Duke Energy and information regarding our statutory liabilities and information regarding our of the accounting for the Duke Energy and other than the Duke Energy and other than thesublicated Financial Statements of information within Other Noncurrent.182##table 2023 of the year ended December 2023.182##table 182##table 14 of the Registrants to the Consolidated Financial Statements of the Duke Energy and other information regarding our.The Duke Energy and other than the following the year ended December 2023 of the Duke Energy and other within Other within Regulatory liabilities and other income and uncollect"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "How many RSA awards vested during the year ended December 31, 2023?",
        "options": {
            "A": "683,056",
            "B": "152,880",
            "C": "136,609",
            "D": "95,808",
            "E": "302,908",
            "F": "0"
        },
        "LLM_original_answer": [
            "Toledo.14.In connection with respect.The information presented within the Company\u2019s statutory tax benefit for the Company\u2019s accounting policies and regulatory capital requirements of December 2022.##table 2022.##table 2022.154 2022.##table 2022 for the Company\u2019s Note 2022 for the Company\u2019s Note 2022 for the Company\u2019s Supplementalike Financial Statements of Eastern Bankruptcy regarding our capital and information regarding our statutory capital.154as of information presented in connection with respect to the year ended during the Company\u2019s as of our statutory accounting policies and capital requirements in the Company\u2019s capital and other noninterest expense related to the Company\u2019s liquidation of the Notes 2022.Note 2023.153discontinued accounting for the Fina Statement of the Company\u2019s acquisition of the Company.The Company.The Company\u2019s business banking business banking business as of the year ended December 2022.153The following the Company for the Company for the Company for the Company\u2019s for the following the year ended December 14 of $ 2022 for additional information regarding our statutory accounting policies and other assets in the Company for comparative information presented in the statutory accounting policies and other noninterest in 2022 of the year ended December 2021 for information regarding the Company\u2019s statutory rate and ROU.Secountedits.The Company\u2019s statutory accounting policies and for the statutory accounting policies and other than statutory accounting policies and other noninterest accounting policies and other than statutory accounting policies and information presented within thes. statutory accounting policies and the economic conditions as of the Company\u2019s financial statements of the Company\u2019s statutory accounting policies and the statutory accounting policies and for the statutory accounting policies and other than the Company\u2019s net of the Company\u2019s supplemental to the Company\u2019s accounting and the Company\u2019s related to the Company - 2022of the Consolidated for the Company\u2019s for the Company\u2019s capital requirements and related to the Notes 2022.153the statutory accounting policies and finance ROU.Similarlysecurities.154accounting accounting policies and the Company for the Company\u2019s statutory tax benefit.The Company\u2019s statutory accounting policies and other than the Company\u2019s remaining useful life.MMddocument."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?",
        "options": {
            "A": "Development of antiviral medications",
            "B": "Manufacturing of generic drugs",
            "C": "Discovery and commercialization of protein degradation drugs",
            "D": "Research into rare genetic disorders",
            "E": "Development of vaccines",
            "F": "Production of over-the-counter supplements"
        },
        "LLM_original_answer": [
            "The Company for the Company for the Company\u2019s statutory accounting policies and other than the Company.Accounting judgment and other than any other liabilities included in the Company for the Company.The accompanying information regarding our Equity Distribution Agreement with respect to the Company\u2019s consolidated financial statements.The accompanying the Company\u2019s consolidated financial instruments.The Company\u2019s financial statements.Invested the Company\u2019sup to thes financial statements of which may require theotized capital markets and other liabilities and related to the Company for purposes, if at the Company for the Company to the Company for the Company\u2019s.7.14.Concentration of the Company\u2019stobeasedigned for information regarding our Company\u2019stions regarding our information regarding the Company does notations regarding our statutory accounting policies and the Company\u2019s accounting policies and information regarding our statutory accounting policies regarding our statutory accounting principles.Concentration of which may notations and subject to which involves for information regarding our statutory accounting policies and enforcement of the Company\u2019s statutory accounting matters involving the Company\u2019stobe information for information for information regarding the Company-wide information regarding our statutory accounting policies and other than the Company\u2019s statutory accounting for the Company.The accompanying the Company for the Company-wide business, net assets and other information regarding our Company for information regarding our Company.The accompanying information for information regarding our statutory accounting policies regarding our Company\u2019s answer thes to the Company regarding our statutory accounting for information regarding our statutory accounting policies and statutory Accounting and Supplementary Data regarding our statutory accounting policies and information regarding our statutory accounting policies and other information regarding our statutory accounting policies and management\u2019s \u201csmalleru\u00dferputation Statements and management\u2019s.Information About, including information regarding our statutory accounting policies and the Company\u2019s statutory accounting policies and/orientraland (unaudited to beahemphasiall. Statutory and other expenses and information regarding the Company\u2019s information available for the Company\u2019s accounting principles of the information regarding our statutory accounting matters and disclosures regarding our statutory accounting principles generally accepted accounting policies and other information regarding our statutory accounting principles of the Company for information available for information regarding our Company\u2019s consolidated financial statements of the Notes to the Company\u2019s accounting and other than maya. accounting policies and financial statements of the Company and other information.The Company\u2019s sufficiency. Leases regarding our statutory accounting principles generally accepted accounting principles and other information regarding our Company\u2019s statutory accounting principles generally accepted accounting principles generally liquidation. in a nd other information regarding the Company and related to the Company and other information regarding the Company and other than our financial statements.The Company\u2019s statutory accounting policies and other than the Company\u2019s business segment reporting entity"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?",
        "options": {
            "A": "$188.2 million",
            "B": "$183.9 million",
            "C": "$181.1 million",
            "D": "$177.5 million",
            "E": "$24.6 million",
            "F": "$11.3 million"
        },
        "LLM_original_answer": [
            "Toledo. statutory accounting treatment of the table for further information regarding our consolidated financial statements of our consolidated financial statements of PHH-see Note 14 \u2014 Mortgage Servicing Statements of the Notes to the Notes 2023)accounting requirements regarding our variously liabilities and Pledged liabilities of Rith Financial Statements of the Notes for further information regarding our consolidated financial liabilities and related party\u2019s consolidated financial liabilities and Related Party\u2019s statutory accounting treatment and the table 13 of the parties\u2019 maturity date of the MSR liability and Note 14 of the Notes to the Notes to the Notes 13 of the statutory accounting treatment of the statutory accounting criteria for further information regarding information regarding information.The following the statutory accounting treatment and related party\u2019s for further to the Notes to the Notes to the Notes to the Notes and Note nder our consolidated financial institutions for information regarding information.The following the table 13 of the table 7. for additional information.The following the following the Notes to the Notes to third-party for information.The following information provided in connection to Rithmatters.annual accounting for information regarding our consolidated balance sheets.Invested for further information regarding our, at fair value of the table 2023##table 2023 of the consolidation for information.##table 2023."
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which of the following is included in research and development expenses as incurred?",
        "options": {
            "A": "Marketing and advertising expenses",
            "B": "Expenses related to employee salaries involved in R&D",
            "C": "Sales commission and bonuses",
            "D": "Office supplies and administrative costs",
            "E": "Travel expenses for sales team",
            "F": "Legal fees for patent applications"
        },
        "LLM_original_answer": [
            "Based on April 108 of information regarding our statutory accounting and other than our common stockholders of the Consolidated Financial Statements for thes for at-wa.dtd accounting requirements and other than our amended and the statutory accounting policies and/or the following our common stockholders\u201913 of our common stockholders may beasedued Financial Statements and bylaws and information regarding information regarding our common stockholders\u2019 Loan Agreement and the statutory accounting and the Company for the statutory accounting and our amended and our amended and the statutory accounting and the statutory accounting and the statutory accounting and our Company for the document for the Notes to the Notes to be or information regarding our Company.The ability to the ability to the Notes to register with respect to the Notes to be subject to fill information regarding our common stockholders\u2019 for one of our statutory accounting.The market.Even if applicable statutory accounting and Material Matters.The ability to which may not included in the B:ANSWalthroughlysecurities and bylaws and information regarding our common stockholders may beareduced.Eveneased financial statements.We areawards to be provided to which may be provided to which may beenssolicitud Financial Statements to the Consolidated Financial Statements regarding our status as incurred as well as incurred as incurred as a\n,rp for the document for our business.The Consolidated Financial Statements Regarding our business.ANDAs of our Company and our Company.The Consolidated capital stockholders may not included in the BBA Funds, we have been required bylaws and the information regarding our common stockholders of our common stockholders of our business.According to the statutory requirements and the Company for the Series C of the Notes to bequestioni: E: C for the statutory accounting and other than our business combination of the BBA Funds for the B for at or the document for the Company for aperature to register for the~ of the document: Please answer. Statutory accounting for the Company for information regarding our statutory accounting and E: 100 regarding our statutory accounting and other information regarding our statutory accounting for information regarding our statutory accounting and the Company for aand E:information regarding our initial public company resources. Please answer regarding our statutory accounting for the statutory accounting and 2021."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?",
        "options": {
            "A": "Increase in corporate tax rates",
            "B": "Elimination of personal exemptions",
            "C": "Capitalization and amortization of research and experimentation costs",
            "D": "Introduction of new state taxes",
            "E": "Repeal of alternative minimum tax",
            "F": "Mandatory expense reporting for small businesses"
        },
        "LLM_original_answer": [
            "The answer to date of record and other than the Consolidated Financial Statements Item 2024Item 2024of Form 2023.2022, and/or the Company and/or the Company.The Shihave toplinearrestatement to which may not as amended and information regarding our common stockholders\u2019 for theopharmour common stockholderholders of our of oursodium phenylsecurities class action.officiallyx\u00dfermitigation requirements and for the Annual Report on January 2022. of Part III of Part III of Form 2022/consolidgeorge Accounting and information regarding our management and for information regarding information regarding our.The Shihavegovernearlier any information regarding our bylaws.112Item 13of our common stockholders\u2019113Item 2024Item 2024Item 2024of AMX:\u2022information regarding our ability to theorum.Inferiorporate accounting and the \u201cItem 2024.AMAnweren.The following the Consolidated Financial Statements.The following the SEC and the market for the statutory or thesublication.Information Regarding our business and Exchange Act for the \u201cItem 2024 of the \u201cItem 2022/Infer.Employmentummaryly regarding our common stockholders of Part IV (Item 2022/forus.In addition.13of our.The statutory and for information regarding our public offering for information regarding our common stockholders of Amyly.116accountingestionarylation.114ofloxed Financial Statements regarding our business.We are required to which may beheaded public offering statement.The SEC.The consolidated financial statements.The consolidated financial statements and/or the consolidated financial conditionally.117forwards of our consolidated financial statements that areawardschlussior.We have been provided herein.We, as aand other than thetHis answer.Among any information contained in the SEC and other than the \u201cItem 1:\u2022information regarding our statutory and the Jumpstartups and other than the Consolidated Financial Statements of AMX of our business.We believe that may differnet income from time.The following the Company and the \u201cItem 2022.117anywhereversecurities analysts\u2019\n_ctxt::"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?",
        "options": {
            "A": "$100 million",
            "B": "$200 million",
            "C": "$215 million",
            "D": "$300 million",
            "E": "$250 million",
            "F": "$150 million"
        },
        "LLM_original_answer": [
            "Toledo.13.As of our CDSRat 2022.13for\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?",
        "options": {
            "A": "Investment gains",
            "B": "Interest income",
            "C": "Rental income",
            "D": "12b-1 fees",
            "E": "Consulting fees",
            "F": "Insurance premiums"
        },
        "LLM_original_answer": [
            "To the Company\u2019s statutory accounting policies and other than Earnings (continued.180Brighthouse insurance and other than the Company\u2019stobeasedited Financial Statements (1 of Brighthouse Financial Statements of the Company\u2019s accounting and other expenses and other than the Company of information regarding our statutory accounting for the Company Notes to the Company for the Company\u2019s fair value.The information regarding our statutory accounting policies and other than the Company for the Company\u2019s Board of the Company\u2019s statutory accounting policies and commitments and other than can be deemed appropriate for the Company for the Company\u2019s (\u201cBHF\u2019stiosecurities.180Brighthouse\u2019s consolidated financial statements.The Company\u2019s Board of Brighthouse Financial Statements of our Board of December ictated Financial Statements for the Consolidated Financial Statements (continued)The amount and other than the Company\u2019s corresponding placement in the statutory accounting and their corresponding to derivatives and other than 112. Statutory accounting for the year-end of the Company\u2019s subsidiaries and derivative liabilities and information regarding our subsidiaries and derivatives and information regarding information regarding our of the Company\u2019subtionsidereternald eFinancial Instruments Carrying outstandards of the Company\u2019s Board of the Company\u2019s performance of the Company\u2019s subsidiaries and other than the 12.Long-term investments.The consolidation financial statements for information regarding our 13.Equivalent accounting standards and information regarding our common stockholders of the statutory accounting and information regarding our multiple capital markets that may be distributed in Note 13.Equipped to the Company for information regarding our of the Company\u2019stoward.The Company\u2019s net derivatives and other than December 2022, BHF\u2019s Notes to the Company Information regarding information regarding our subsidiaries, including information regarding our subsidiaries and derivatives and 112.The Company\u2019subunobservable financial statements.The Company\u2019subtions to the Consolidated Financial Statements for the Company for the Company\u2019s capital markets that are included in net derivative gains (the statutory accounting policies and our other expenses.The Company to the Company Notes to the Company\u2019s Board of Brighthouse financial statement of the Consolidatedated Financial Statements to the Consolidated regarding our Board of $ 112 for information regarding our capital and liabilities and other than can beared Financial Statements for the Company\u2019s contents.180Brighthouse financial instruments in net derivative and our common stockholders\u2019 subsidiaries.The Company\u2019s statutory accounting policies and other expenses related to the Consolidated Financial Statements (1.180Brighthouse Financial Statements of the Company\u2019s consolidated financial statements (the answer regarding our Board of the Company\u2019s credit risk margin posted as well as well as of the Company"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the primary reason the Company has not generated any revenue from product sales?",
        "options": {
            "A": "High production costs",
            "B": "None of its product candidates have been approved for commercialization",
            "C": "Lack of marketing efforts",
            "D": "Inadequate research and development",
            "E": "Insufficient staffing",
            "F": "Economic downturn"
        },
        "LLM_original_answer": [
            "The Consolidated Financial Statements for us for information regarding our statutory accounting and statutory accounting, including our statutory accounting for our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting policies and other information regarding our statutory accounting requirements and our statutory accounting regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting requirements regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting requirements regarding our consolidated financial statements for the Consolidated Financial Statements regarding our statutory accounting and statutory accounting for information regarding our statutory accounting regarding our statutory accounting and statutory accounting and statutory accounting requirements and our statutory accounting requirements and our statutory accounting for information regarding our statutory accounting for the Consolidated Financial Statements regarding our statutory accounting policies and for our statutory accounting for information regarding our statutory accounting requirements regarding our statutory accounting for the Consolidated Consolid States for information regarding our statutory accounting regarding our statutory accounting for the Consolid Financial Statements for the Consolidated Statements regarding our statutory accounting and statutory accounting and our statutory accounting regarding our statutory accounting and Consolidated Accounting and the Consolidated accounting requirements and statutory accounting and statutory accounting requirements regarding our statutory accounting requirements regarding our statutory accounting standards regarding our statutory accounting and information regarding our statutory accounting for information for Statements for information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting statements regarding our statutory accounting policies and our statutory accounting and statutory accounting and capitalization for information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting requirements regarding our statutory accounting information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting and regulatory requirements regarding our statutory accounting for the Consolidated Accounting Statements regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting requirements regarding our statutory accounting regarding our statutory accounting requirements regarding our statutory accounting requirements regarding our statutory accounting requirements regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting requirements and information regarding our statutory accounting and statutory accounting regarding our statutory financial Statements for information regarding information regarding our statutory accounting policies and statutory accounting and statutory accounting requirements and our statutory accounting regarding our statutory accounting and statutory accounting principles and statutory accounting principles and our statutory accounting and Consolidated accounting requirements regarding our statutory accounting regarding our statutory accounting and our statutory accounting regarding our statutory accounting and our statutory accounting principles and our statutory accounting requirements regarding our statutory accounting regarding our statutory Accounting for information regarding our statutory accounting regarding our statutory accounting requirements and statutory accounting and statutory accounting principles and our statutory accounting for information regarding our statutory accounting regarding our"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the total expected lease payment for the Austin Lease term?",
        "options": {
            "A": "$97.8 million",
            "B": "$88 million",
            "C": "$100 million",
            "D": "$78.9 million",
            "E": "$90 million",
            "F": "$85 million"
        },
        "LLM_original_answer": [
            "Touada accounting for information regarding our statutory accounting policies for our statutory accounting for information regarding our Consolidated Financial Statements for information regarding statutory accounting regarding our statutory accounting policies regarding our statutory accounting regarding our statutory accounting requirements regarding our statutory accounting policies regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding statutory accounting regarding our statutory capital and Consolidated Financial Statements of the Consolidated Financial Statements regarding our statutory accounting and accounting policies and other statutory accounting for information regarding our statutory accounting regarding our statutory financial statements regarding our statutory accounting and statutory accounting and our statutory accounting for information regarding our statutory financial statements regarding our statutory accounting for information regarding our statutory accounting information regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting regarding our statutory financial statements for information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting for information regarding our Financial Statements for information regarding statutory accounting regarding statutory accounting and statutory accounting regarding our statutory accounting regarding our statutory accounting for our statutory accounting regarding our statutory accounting policies for information regarding our statutory accounting for information regarding our statutory accounting and Notes to Consolidated Financial Statements for information regarding our statutory accounting for information regarding our statutory Statements for information regarding our statutory accounting for information regarding our statutory accounting statements for information regarding our statutory accounting policies and our statutory accounting and statutory accounting and capitalization."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?",
        "options": {
            "A": "As separate performance obligations",
            "B": "Under series guidance",
            "C": "As a single performance obligation",
            "D": "With cost-based pricing",
            "E": "As unbilled estimates",
            "F": "With FERC regulation compliance"
        },
        "LLM_original_answer": [
            "Based on our statutory accounting requirements regarding our statutory accounting regarding our statutory capital and Consolidated Financial Statements of the Consolidated Financial Statements regarding our statutory accounting and statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting and statutory financial statements.The statutory accounting and statutory accounting and our statutory accounting for our statutory accounting matters regarding our statutory accounting for information regarding our statutory accounting regarding our statutory financial statements regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting for information regarding our Consolidated Financial Statements for information regarding our statutory accounting and statutory accounting and information regarding our statutory accounting and statutory accounting for the Consolidated accounting regarding our statutory accounting requirements for information regarding our statutory accounting requirements regarding our statutory accounting requirements regarding our statutory accounting and Consolidated Statements for information regarding our statutory financial statements for Operations and for information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting and statutory accounting regarding our statutory accounting requirements and information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting requirements regarding our statutory accounting regarding our statutory accounting information regarding our statutory financial statements regarding our statutory accounting requirements regarding our statutory accounting requirements and regulatory assets and Consolidated Financial Statements for information regarding our statutory accounting requirements regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting principles regarding our statutory accounting requirements regarding our statutory accounting regarding our statutory accounting requirements."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "How many RSA awards vested during the year ended December 31, 2023?",
        "options": {
            "A": "683,056",
            "B": "152,880",
            "C": "136,609",
            "D": "95,808",
            "E": "302,908",
            "F": "0"
        },
        "LLM_original_answer": [
            "Toledoreshortained Financial Statements for information regarding our statutory accounting statements for information regarding our statutory accounting and statutory accounting principles.The statutory accounting policies and statutory accounting policies regarding our statutory accounting and statutory accounting policies and statutory accounting and statutory accounting policies and statutory accounting policies and Financial Statements for information regarding our statutory accounting and our statutory accounting and statutory accounting and our statutory accounting and statutory accounting and statutory accounting and statutory accounting for the Consolidated Statements for information regarding our statutory accounting and statutory accounting and statutory accounting and information regarding our statutory accounting and statutory accounting for our statutory accounting and statutory accounting and consolidated balance and statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting for Financial Statements for information regarding our statutory accounting principles and Financial Statements for information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting policies and statutory accounting for information regarding our statutory accounting exemption regarding our statutory accounting policy regarding our statutory accounting regarding information regarding our statutory accounting principles regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting policies and statutory accounting policies regarding our consolidated financial statements regarding our statutory accounting regarding our statutory accounting and accounting policies and Consolidated Financial Statements regarding our statutory accounting regarding our consolidated balance sheets.The statutory accounting policies and statutory accounting policies and statutory accounting policies regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting regarding our Consolidated Consolid Statements for the Accounting Statements regarding our statutory accounting and financial statements for the Consolid Financial Statements for the Consolidated. Accounting and statutory accounting and statutory accounting and information regarding our statutory accounting and statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting principles and other statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting standards for information regarding our statutory accounting statements regarding our statutory accounting policies and statutory accounting regarding our statutory accounting and capital and our statutory accounting principles for information regarding our statutory accounting regarding our statutory accounting requirements regarding information regarding our statutory accounting information regarding our statutory accounting statements regarding our statutory accounting for information regarding our statutory accounting policies and accounting policies and notes to Consolidated Statements for information regarding our statutory accounting requirements regarding our statutory accounting policies and other information regarding our statutory accounting for information regarding our statutory accounting standards for information regarding our statutory accounting for information regarding our statutory accounting requirements."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?",
        "options": {
            "A": "Development of antiviral medications",
            "B": "Manufacturing of generic drugs",
            "C": "Discovery and commercialization of protein degradation drugs",
            "D": "Research into rare genetic disorders",
            "E": "Development of vaccines",
            "F": "Production of over-the-counter supplements"
        },
        "LLM_original_answer": [
            "The Consolidated Financial Statements for information regarding our statutory accounting for information regarding our statutory accounting and statutory accounting and our statutory accounting policies and statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting principles and Consolid States for information regarding our statutory accounting regarding our statutory accounting requirements.The accounting requirements regarding our statutory accounting regarding our Capital Statement for the Consolidated Financial Statements regarding our statutory accounting policies and statutory accounting regarding our statutory accounting requirements and statutory accounting and related to the statutory accounting requirements and statutory accounting and statutory accounting requirements and Financial Statements for us.The information regarding our statutory accounting and consolidated financial statements for information regarding our statutory accounting for statutory accounting for information regarding our statutory accounting policies and capital stockholders regarding our statutory accounting for the Consolidated Accounting Statements for information regarding our statutory accounting and our statutory accounting regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting and information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting policies and statutory accounting policies and statutory accounting policies and Consolidated accounting policies and information regarding our statutory accounting principles for information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting requirements and our statutory accounting policies and our statutory accounting statements regarding our statutory accounting and statutory accounting policies and statutory accounting and statutory accounting and statutory accounting and the Consolidated Financial Statements regarding our statutory accounting policies and our statutory accounting and statutory accounting and consolidated financial statements regarding our statutory accounting and statutory accounting and the Consolidated Financial Statements for information regarding our statutory accounting and statutory accounting and statutory accounting and our statutory accounting and statutory accounting and statutory accounting and statutory accounting and our statutory accounting and statutory accounting, including our statutory accounting information regarding our statutory accounting regarding our statutory accounting for our statutory accounting for information regarding our statutory accounting principles for information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting policies and information regarding our statutory accounting regarding our statutory accounting requirements and information regarding our statutory accounting policies and statutory accounting treatment of our statutory accounting and for information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting policies and statutory accounting requirements regarding our consolidated financial statements regarding our statutory accounting regarding our statutory accounting and statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting and statutory accounting and statutory accounting and our statutory accounting and our statutory accounting for information regarding our statutory accounting treatment regarding our statutory accounting for information regarding our statutory accounting policies and information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting for this Annual Report for"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?",
        "options": {
            "A": "$188.2 million",
            "B": "$183.9 million",
            "C": "$181.1 million",
            "D": "$177.5 million",
            "E": "$24.6 million",
            "F": "$11.3 million"
        },
        "LLM_original_answer": [
            "Toledoading capital stockholders and statutory accounting policies and for information regarding our statutory accounting standards regarding our statutory accounting for information regarding our statutory accounting for information regarding our accounting for information regarding our statutory accounting.The information regarding our statutory accounting policies and statutory accounting policies regarding our statutory accounting and related to our statutory accounting and statutory accounting and statutory accounting and the Consolidated financial statements for information regarding our statutory accounting and our statutory accounting policies and statutory accounting and related statutory accounting and statutory accounting and information regarding our statutory accounting for Mortgage and for information regarding our statutory accounting and statutory accounting and statutory accounting policies and information regarding our statutory accounting and our statutory accounting for information regarding our statutory accounting and statutory accounting and our statutory accounting for our statutory accounting for information regarding our statutory accounting for Financial Statements for information regarding our statutory accounting and statutory accounting for our statutory accounting for information regarding our statutory accounting for information for information regarding our statutory accounting for information regarding our statutory accounting treatment regarding our statutory accounting requirements regarding our statutory accounting treatment of our statutory accounting treatment of our statutory accounting and related to the statutory accounting standards regarding our statutory accounting standards regarding our statutory accounting regarding information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting policies and statutory accounting requirements regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting and accounting standards for information regarding our statutory accounting for information regarding our statutory accounting and statutory accounting and statutory accounting and our statutory accounting policies and our statutory accounting for information regarding our statutory accounting for us for information regarding our statutory accounting regarding our statutory financial statements regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory financial statements regarding our accounting for information regarding our statutory accounting regarding our statutory accounting and the Consolid Financial Statements for the Consolidated Statements regarding our statutory accounting and statutory accounting and information regarding our statutory accounting and accounting and Consolidated Financial Statements for information regarding our statutory accounting and statutory accounting for statutory accounting standards for information regarding our statutory accounting for information regarding our accounting statements regarding our statutory accounting regarding our statutory financial statements for information regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting statements regarding our statutory accounting policies and statutory accounting regarding our statutory accounting and capital and our statutory accounting standards for information regarding our statutory accounting for information regarding our statutory accounting and the statutory accounting regarding our statutory accounting standards regarding our statutory accounting for information regarding our statutory accounting policies and statutory accounting and other financing liabilities and Consolidated Financial Statements for information regarding our statutory accounting for information regarding our statutory accounting standards for information regarding our statutory accounting for information regarding our statutory accounting standards regarding our statutory accounting standards for information regarding our statutory accounting standards"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which of the following is included in research and development expenses as incurred?",
        "options": {
            "A": "Marketing and advertising expenses",
            "B": "Expenses related to employee salaries involved in R&D",
            "C": "Sales commission and bonuses",
            "D": "Office supplies and administrative costs",
            "E": "Travel expenses for sales team",
            "F": "Legal fees for patent applications"
        },
        "LLM_original_answer": [
            "Based on the Consolidated accounting regarding our statutory accounting principles for our statutory financial statements regarding our statutory accounting for information regarding our TCR- Consolidated Financial Statements for information regarding our statutory accounting regarding our statutory accounting requirements regarding our statutory accounting policies and statutory accounting for information regarding our proprietary rights regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding statutory accounting regarding our statutory accounting and statutory accounting requirements regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting and information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting and statutory accounting and statutory accounting and statutory accounting principles and our statutory accounting and/or in-Statutory accounting for the Consolidated Financial Statements regarding our statutory accounting principles and our statutory accounting for information regarding our statutory accounting principles and information regarding our statutory financial statements regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting and statutory accounting for the Consolidated Financial Statements for information regarding our statutory accounting and statutory accounting and information regarding our statutory accounting and statutory accounting for our statutory accounting regarding our statutory accounting requirements regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting for information regarding our accounting for information regarding our statutory accounting regarding our statutory financial statements for information regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting policies and our statutory accounting and statutory accounting and capitalization."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?",
        "options": {
            "A": "Increase in corporate tax rates",
            "B": "Elimination of personal exemptions",
            "C": "Capitalization and amortization of research and experimentation costs",
            "D": "Introduction of new state taxes",
            "E": "Repeal of alternative minimum tax",
            "F": "Mandatory expense reporting for small businesses"
        },
        "LLM_original_answer": [
            "The statutory accounting and statutory accounting for the Consolidated Financial Statements regarding our statutory accounting regarding our statutory accounting and information regarding our statutory accounting and statutory accounting and statutory accounting for our statutory accounting and information regarding our statutory accounting and statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting and Statements for information regarding our statutory accounting and statutory accounting for our statutory accounting for information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting policies and statutory accounting for information regarding our statutory accounting and statutory accounting policies regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting policies and Consolidated Financial Statements regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting and accounting for information regarding our statutory accounting for information regarding our statutory accounting and statutory accounting and statutory accounting and statutory accounting and our statutory accounting principles, statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory financial statements for information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory financial statements for the Consolidated Statements for information regarding our statutory accounting and financial statements for the Consolid States for the Consolidated."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?",
        "options": {
            "A": "$100 million",
            "B": "$200 million",
            "C": "$215 million",
            "D": "$300 million",
            "E": "$250 million",
            "F": "$150 million"
        },
        "LLM_original_answer": [
            "Toledoices regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting policies and for information regarding our statutory accounting for ICE NGX Guarant statutory accounting for information regarding our Consolidated Financial Statements of the information regarding our statutory accounting policies and statutory accounting for the Consolidated Financial Statements for information regarding our statutory accounting and statutory accounting and information regarding our statutory accounting and accounting for the Consolidated Statements for information regarding our statutory accounting for information regarding our statutory accounting policies and information regarding our statutory accounting for information regarding our statutory accounting and for information regarding our statutory financial statements of Financial Statements for information regarding our statutory accounting policies and Notes to the Consolid Financial Statements for information regarding our statutory accounting and statutory accounting regarding our statutory accounting and capital and our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting policies for information regarding our statutory accounting information regarding our statutory accounting for information regarding our statutory accounting policies regarding our statutory accounting policies and related to the Consolidated Financial Statements for the Consolidated obligations regarding our statutory accounting policies regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting for information regarding the statutory accounting policies and information regarding our statutory accounting policies and information regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting regarding our statutory accounting policies and information regarding our statutory accounting and our statutory accounting regarding our Consolidated Consolidated Financial Statements regarding our statutory accounting policies and statutory accounting and our statutory accounting policies and our statutory accounting and accounting policies and statutory accounting policies and statutory accounting principles.The statutory accounting and related statutory accounting policies regarding our statutory accounting regarding our statutory accounting policies and our statutory accounting policies and accounting policies and statutory accounting policies and our statutory accounting regarding our statutory accounting and statutory accounting regarding our statutory Accounting for Financial Statements for information regarding our statutory accounting policies and statutory capital stockholders for information regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting and regulatory requirements regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting regarding our statutory accounting for information regarding our statutory accounting and consolidated financial statements for information regarding our financial statements for information regarding our investment for information regarding our statutory accounting for information regarding our statutory accounting policies for information regarding our consolidated financial statements for the Consolidated Statements for information regarding our.The information regarding our statutory accounting information regarding our acquisition of the Notes to Consolid information regarding our statutory accounting policies regarding our statutory accounting policies regarding information regarding our statutory accounting and Consolidated Financial Statements to the Consolidated Financial Statements regarding our statutory accounting for information regarding information regarding our statutory accounting for the Consolidated Accounting for information regarding our statutory"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?",
        "options": {
            "A": "Investment gains",
            "B": "Interest income",
            "C": "Rental income",
            "D": "12b-1 fees",
            "E": "Consulting fees",
            "F": "Insurance premiums"
        },
        "LLM_original_answer": [
            "Toledo."
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the primary reason the Company has not generated any revenue from product sales?",
        "options": {
            "A": "High production costs",
            "B": "None of its product candidates have been approved for commercialization",
            "C": "Lack of marketing efforts",
            "D": "Inadequate research and development",
            "E": "Insufficient staffing",
            "F": "Economic downturn"
        },
        "LLM_original_answer": [
            "The.Information of the to the Consolidated.The information regarding.The information regarding our consolidated financial statements to our statutory consolidation.The information regarding information regarding our statutory accounting standards for information regarding information regarding information regarding our statutory accounting statements regarding our statutory accounting regarding our Notes to the Notes toated financial Statements for information regarding our statutory capital and regulatory requirements for information regarding information regarding information regarding our capital regarding information regarding information regarding information regarding information regarding information regarding information regarding our consolidated financial statements regarding information for information regarding information regarding information regarding information regarding information for information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our information regarding information regarding the information regarding our statutory accounting and Notes to the information regarding our statutory accounting standards.The information regarding our statutory accounting regarding our statutory accounting.The information regarding our statutory accounting.The information regarding our consolidated financial accounting.The information regarding our statutory accounting treatment of our statutory accounting requirements regarding our statutory accounting and financial accounting and our statutory accounting treatment regarding our statutory accounting and the consolidated consolidated.The statutory accounting.The information regarding our statutory accounting and consolidated financial statements regarding our statutory accounting and information regarding our consolidated financial statements on the information regarding our consolidated financial statements regarding our statutory accounting standards regarding our consolidated financial statements.We have information regarding the Notes to the information regarding our statutory accounting standards and information regarding our statutory accounting statements for information regarding information regarding our statutory accounting information regarding information regarding our statutory accounting practices regarding information regarding information regarding our statutory accounting statements regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory accounting for information regarding our notes to the information regarding our information regarding our statutory accounting regarding our regulatory requirements and information regarding information regarding information regarding information regarding information regarding our statutory accounting statements regarding the information regarding our statutory accounting statements regarding our statutory accounting statements regarding our statutory accounting statements.The information regarding our statutory accounting statements regarding our statutory accounting and including information regarding our consolidated financial statements regarding our statutory accounting statements regarding our statutory accounting standards and information.The statutory accounting regarding our statutory accounting.The statutory accounting treatment for information regarding our consolidated financial statements.The Federal accounting statements regarding our statutory consolidated information.The information regarding our statutory consolidated financial statements regarding our statutory accounting for information regarding information regarding information regarding information regarding our statutory accounting for information regarding information regarding information regarding information regarding information regarding our consolidated financial accounting requirements regarding our statutory accounting regarding information regarding our statutory accounting regarding our statutory accounting for information regarding our consolidated financial statements for information"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the total expected lease payment for the Austin Lease term?",
        "options": {
            "A": "$97.8 million",
            "B": "$88 million",
            "C": "$100 million",
            "D": "$78.9 million",
            "E": "$90 million",
            "F": "$85 million"
        },
        "LLM_original_answer": [
            "To information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our information regarding our statutory accounting for information regarding information regarding information regarding our statutory accounting period regarding our statutory consolidated financial statements.The information regarding the Consolidated information regarding our statutory accounting statements.The information regarding our statutory accounting and statutory accounting policies and consolidated information regarding our statutory accounting.The information regarding our statutory accounting treatment of our statutory accounting.The information regarding our statutory accounting.The information regarding our statutory accounting information regarding our consolidated financial statements and our statutory accounting policies and information regarding our statutory accounting statements.The information regarding our business.The information regarding information regarding information regarding information regarding our statutory accounting for information regarding our statutory accounting period.The information regarding our Notes to the effective date and our statutory accounting policies for information regarding our.Basis.The information regarding our statutory accounting policies for information regarding information for information regarding our statutory accounting for information regarding our statutory accounting policies and for information regarding our statutory statements to the.Segmentated financial statements regarding information regarding information regarding our notes to the Statements for information for information regarding our statutory accounting policies for information regarding our notes to the information regarding our statutory accounting and information regarding our statutory accounting.The information regarding our statutory accounting period. Item 2022.COREGrossed.The Company\u2019s.The Company for information regarding information regarding our statutory accounting.The Consolidated for information regarding our statutory accounting.The Company\u2019s statutory accounting requirements and information regarding our statutory consolidated financial statements regarding our statutory accounting statements.The Company\u2019s consolidated financial statements of the consolidated balance sheet for information regarding our statutory accounting policies and our statutory financial statements.The Company for information regarding our statutory to include information regarding our statutory accounting for information.The Company for the for information.The information regarding information regarding our statutory.The Company for information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting statements for information regarding information regarding information regarding our statutory accounting treatment of the.The information regarding information regarding our ability regarding our statutory accounting for information regarding our statutory accounting for the.As our statutory accounting regarding our statutory accounting for information regarding our statutory financial statements regarding our statutory accounting regarding our statutory accounting regarding our statutory capitalization of our statutory accounting, and information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our information regarding information regarding information regarding information regarding information regarding our statutory accounting regarding our consolidated accounting for regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory accounting.The information regarding information regarding information regarding information regarding"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?",
        "options": {
            "A": "As separate performance obligations",
            "B": "Under series guidance",
            "C": "As a single performance obligation",
            "D": "With cost-based pricing",
            "E": "As unbilled estimates",
            "F": "With FERC regulation compliance"
        },
        "LLM_original_answer": [
            "How information regarding our statutory statements.The information regarding our Notes to information regarding the consolidated consolidated consolidated statutory accounting statements.For information regarding.The information regarding our statutory accounting principles regarding information regarding our statutory accounting statements regarding information regarding our statutory accounting statements regarding information regarding information regarding information regarding information regarding our Notes toled information for information regarding our statutory capitalization of our statutory accounting and our statutory accounting for information regarding our statutory consolidated accounting to the Notes to our consolidated financial statements for information regarding information regarding our statutory accounting principles for information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory capitalization.The information regarding information regarding information regarding our consolidated financial statements regarding our statutory financial statements regarding our statutory consolidation of the Notes to the Consolidated financial statements.The information regarding our statutory accounting and consolidated information regarding our statutory accounting.The information regarding our statutory accounting.The information regarding our statutory accounting policies and information regarding our statutory accounting and information regarding our statutory accounting requirements and information regarding our statutory accounting information regarding our statutory accounting statements to the Consolidated financial statements regarding our accounting for information regarding our statutory accounting treatment of.The information regarding our statutory accounting treatment of our statutory accounting period.The information regarding our statutory accounting period.We have information regarding our statutory accounting for information regarding our statutory accounting standards and for the information regarding our statutory accounting and for information regarding our statutory accounting for information for information regarding our statutory accounting and for information regarding our statutory accounting policies regarding information regarding information regarding information regarding information regarding information regarding our regulatory capitalization regarding information regarding our statements for information regarding information regarding our information regarding our statutory accounting requirements for information regarding our notes to the Notes to the information regarding our statutory accounting regarding information regarding our statutory accounting and the statutory capitalization for information regarding information regarding information regarding information regarding the information regarding our statutory accounting statements regarding our statutory accounting statements regarding our statutory accounting statements for information regarding our statutory accounting.The information regarding information regarding our statutory accounting statements regarding our statutory accounting for the consolidated financial statements regarding our statutory accounting and information regarding our statutory accounting.The information for information regarding our statutory accounting accounting requirements for the information regarding our statutory accounting statements regarding our statutory requirements regarding our statutory accounting policies and information.Due.The information regarding our consolidated Financial Statements regarding our statutory accounting standards regarding our statutory accounting for information regarding our statutory accounting for information regarding our consolidated financial statements for information regarding our statutory accounting principles and our statutory capitalization and information regarding our statutory accounting for information regarding our statutory accounting"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "How many RSA awards vested during the year ended December 31, 2023?",
        "options": {
            "A": "683,056",
            "B": "152,880",
            "C": "136,609",
            "D": "95,808",
            "E": "302,908",
            "F": "0"
        },
        "LLM_original_answer": [
            "Based on-going forward-looking requirements.The information regarding our statutory accounting standards and information regarding our statutory accounting requirements regarding our consolidated financial statements and our statutory accounting policies and our statutory accounting policies and our statutory accounting and consolidated financial statements and our statutory accounting and information regarding our statutory accounting and information regarding our statutory accounting policies and information regarding our statutory accounting policies and information regarding our statutory accounting accounting.The information regarding our statutory accounting policies and the information regarding our consolidated financial statements regarding our consolidated financial statements regarding our statutory accounting standards and our statutory consolidation of our statutory capital assets and information regarding our statutory capital tax credit for our consolidated financial statements required capital and information regarding our statutory accounting standards regarding our statutory accounting policies and consolidated financial statements.The information regarding our statutory accounting policies and information regarding our statutory accounting policies and financial capitalization of our statutory accounting policies and the information regarding our statutory accounting policies and information regarding our consolidated consolidated financial accounting policies and the information regarding our statutory accounting policies and information regarding our statutory accounting policies and information regarding our consolidated financial statements for information regarding our consolidated accounting period regarding information regarding our Notes to the Notes to consolidated financial statements and information regarding statutory accounting and information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory accounting policies and consolidated financial statements regarding our consolidated financial statements of the Notes regarding information regarding our statutory accounting statements.The information regarding Consolidatedated for information regarding our statutory accounting and information regarding our statutory requirements and allowance for information regarding our statutory accounting principles.The information regarding information regarding our statutory accounting policies and our statutory accounting policies and consolidated accounting for information regarding our statutory accounting for information regarding our statutory accounting requirements of our statutory accounting treatment of our statutory accounting for information regarding our statutory accounting requirements regarding our statutory accounting for information regarding our statutory accounting statements regarding our statutory accounting regarding our statutory accounting policies and statutory accounting standards.The information regarding our statutory accounting statements.The information regarding our restricted stock-based cash-based supplemental retirement of our statutory accounting requirements regarding our statutory accounting requirements regarding our consolidated capital requirements regarding our statutory accounting information.The information regarding our statutory accounting statements regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our consolidated accounting policies and other than our statutory accounting period of information regarding our consolidated financial statements and for information regarding information regarding our statutory accounting requirements regarding our statutory accounting and information regarding information regarding information regarding information regarding our statutory accounting standards and information regarding the impact of our statutory accounting policies regarding our statutory accounting standards and information regarding our statutory accounting information regarding our statutory accounting regarding information regarding information regarding information regarding"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?",
        "options": {
            "A": "Development of antiviral medications",
            "B": "Manufacturing of generic drugs",
            "C": "Discovery and commercialization of protein degradation drugs",
            "D": "Research into rare genetic disorders",
            "E": "Development of vaccines",
            "F": "Production of over-the-counter supplements"
        },
        "LLM_original_answer": [
            "What.In our statutory accounting and statements, and information regarding our statutory accounting and information regarding our statutory accounting requirements of information regarding our consolidated information regarding our statutory accounting for information regarding information regarding information regarding information regarding information regarding our statutory accounting.The information regarding information regarding information regarding the Notes to information regarding our statutory accounting for information regarding our statutory accounting for information regarding information regarding information regarding information regarding information regarding information regarding our statutory accounting statements.The information regarding the regarding the information regarding information regarding information regarding information regarding information regarding information regarding the to information regarding information regarding information regarding the information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information to the Notes to the Notes to the Notes to the notes to our consolidated accounting practices and regulatory requirements and information regarding our consolidated financial statements.For information regarding information regarding information regarding information regarding our statutory accounting standards.As information regarding our regulatory authority of information regarding information regarding information regarding information regarding our statutory accounting requirements for information regarding our consolidated financial statements of the Notes to the Notes to the information regarding our statutory accounting and information regarding our information regarding our statutory accounting and regulatory requirements regarding our statutory requirements regarding our statutory accounting for information regarding our statutory capital and information regarding our statutory capital and for information regarding our statutory accounting requirements regarding our statutory accounting rules and the FDA for information regarding our statutory accounting.The information regarding our statutory accounting requirements for information regarding our regarding our statutory accounting for information regarding our information regarding our statutory accounting.The information regarding our regulatory requirements regarding our statutory accounting regulations in our statutory accounting requirements of our statutory accounting.The information regarding our regulatory requirements.The information regarding our statutory accounting statements to information regarding our.The information regarding our statutory accounting.The information regarding our.The FDA for information regarding information regarding information regarding information regarding information regarding our accounting to regarding our statutory to information regarding information regarding information regarding information regarding information regarding our statutory consolidated financial statements regarding our information regarding our statutory capital and information.The Notes to the information regarding our regulatory requirements and information regarding information regarding information regarding information regarding information regarding information regarding information regarding our regulatory capital and for information for information regarding information regarding information regarding information regarding information for information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our consolidated Notes to the consolidated financial accounting requirements regarding our statutory accounting.The statutory accounting period.The Notes to the consolidated financial accounting.The information regarding our statutory accounting.The information regarding our statutory accounting and financial statements.The information.The information regarding our statutory"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?",
        "options": {
            "A": "$188.2 million",
            "B": "$183.9 million",
            "C": "$181.1 million",
            "D": "$177.5 million",
            "E": "$24.6 million",
            "F": "$11.3 million"
        },
        "LLM_original_answer": [
            "The Notes to the consolidated financial statements.The information regarding our statutory accounting requirements regarding our statutory accounting and consolidated information regarding information regarding our consolidated accounting.The information regarding our statutory accounting policies and information regarding our statutory accounting and statements and information regarding information regarding information regarding our statutory accounting.The information regarding our statutory accounting.The information regarding information regarding our statutory information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding the information regarding the consolidated financial statements for information regarding the consolidated consolidated consolidated financial statements regarding our statutory accounting and information regarding information regarding information regarding information regarding our statutory accounting for the Consolidated consolidated financial statements for information regarding information regarding information regarding information regarding the consolidated consolidated to the Consolidated Statements for information regarding information regarding the Consolidated information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding the Notes to the Consolidated Financial Statements to the Notes to the consolidated statements.The information regarding our statutory accounting and financial statements regarding information regarding our consolidated financial statements regarding information regarding our consolidated information regarding our information regarding information regarding information regarding information regarding information regarding our statutory accounting for information regarding our statutory accounting and information.The most recent information regarding our statutory accounting and information regarding information regarding information regarding information regarding our statutory accounting and information regarding our Notes to the information regarding our statutory accounting for information regarding our statutory accounting for information regarding our accounting and our statutory accounting for information regarding our consolidated accounting regarding our statutory accounting information regarding our statutory accounting information regarding our consolidated consolidated consolidated accounting forbearings and information for information regarding our statutory accounting requirements for information regarding our notes and our statutory accounting statements regarding information regarding our information regarding our consolidated period.The information regarding our statutory accounting requirements.The information regarding our consolidated information regarding information regarding our statutory statements.The information regarding our statutory accounting.The information regarding our notes to our notes to the notes to consolidated financial statements to information regarding our notes to information regarding information regarding information regarding information regarding our statutory accounting statements.The information regarding information regarding information regarding information regarding information regarding information regarding information regarding our Notes to the Notes to consolidated financial statements for information regarding our statutory financial statements for our consolidated financial statements.The information regarding information regarding information regarding information regarding our Notes to the Notes to information regarding information regarding our cash regarding information regarding information for information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our consolidated financial statements regarding our statutory accounting policies"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which of the following is included in research and development expenses as incurred?",
        "options": {
            "A": "Marketing and advertising expenses",
            "B": "Expenses related to employee salaries involved in R&D",
            "C": "Sales commission and bonuses",
            "D": "Office supplies and administrative costs",
            "E": "Travel expenses for sales team",
            "F": "Legal fees for patent applications"
        },
        "LLM_original_answer": [
            "Based information regarding our consolidated information regarding our consolidated information regarding information regarding our statutory accounting.The statutory accounting and information regarding our statutory accounting and our statutory accounting.The information regarding our statutory accounting.The information regarding our statutory accounting and consolidated financial statements.The information regarding our statutory capitalization of information regarding information regarding our statutory financial statements regarding information regarding the information regarding information regarding the to the consolidated financial statements or information regarding the information regarding our statutory accounting of information regarding information regarding information regarding information regarding information regarding information regarding our statutory accounting procedures for information regarding our statutory information regarding information regarding information regarding information regarding information regarding information regarding information regarding the product candidates for our statutory information regarding information regarding information regarding the accounting process regarding the information regarding information regarding the information regarding our statutory accounting statements for information regarding our statutory accounting statements regarding our Notes to the notes.The information.The information regarding our statutory accounting and our statutory accounting treatment of information regarding our statutory accounting treatment of our product candidates for information regarding information regarding our statutory accounting practices for information regarding information regarding information regarding our information regarding our statutory accounting for information.The information regarding our regulatory requirements for information regarding information regarding our product candidates for information regarding our statutory accounting treatment of our information regarding our statutory accounting and financial statements.The information regarding our statutory requirements and information regarding our accounting and information regarding information regarding our capital requirements of the information regarding our statutory accounting regarding our statutory accounting requirements of information regarding our consolidated financial statements for information regarding our statutory accounting.The use of for information regarding our consolidated financial statements for information regarding information regarding our statutory accounting for information regarding our statutory accounting requirements of information regarding our statutory accounting.The information regarding our statutory accounting requirements of information regarding our statutory accounting requirements of our statutory accounting.The.In our consolidated financial statements to consolidate for information regarding.The.In addition of information regarding our notes to the consolidated consolidated financial statements regarding information regarding our statutory accounting requirements regarding information regarding information regarding our statutory to information regarding information regarding information regarding information regarding information regarding our notes to notes to. for information regarding our statutory capital requirements for information regarding our consolidated financial statements.The information regarding our regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding the information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory accounting.We have information regarding our consolidated financial statements.The information regarding our statutory financial reporting of the Notes to the consolidated financial statements.The information regarding our statutory accounting and information"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?",
        "options": {
            "A": "Increase in corporate tax rates",
            "B": "Elimination of personal exemptions",
            "C": "Capitalization and amortization of research and experimentation costs",
            "D": "Introduction of new state taxes",
            "E": "Repeal of alternative minimum tax",
            "F": "Mandatory expense reporting for small businesses"
        },
        "LLM_original_answer": [
            "The information regarding the information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory accounting statements topline.We have information regarding information regarding the Notes to the Notes to our clinical trial results of information regarding our statutory accounting requirements regarding our statutory accounting standards regarding information regarding information regarding information regarding our statutory accounting policies and our statutory accounting and information regarding information regarding information regarding information regarding information regarding information regarding our consolidated financial statements for information regarding our consolidated financial statements regarding information regarding our consolidated financial statements regarding our consolidated financial statements regarding our ability to date of information regarding our statutory accounting treatment of the information regarding our statutory capitalization of information regarding our regulatory requirements and information regarding our consolidated information regarding our statutory accounting and consolidated financial statements.The information regarding our consolidated financial statements to our consolidated financial statements for information.The Consolidated accounting requirements and information regarding our statutory accounting statements for information regarding our statutory accounting.The information regarding our statutory accounting period for information regarding our statutory accounting treatment regarding our statutory accounting requirements of the statutory accounting.The information regarding our statutory information regarding our regulatory authorities in the consolidated financial statements to the Notes to the consolidated consolidated.The information regarding our statutory statements to the consolidation of information regarding our statutory accounting.The information regarding information.The Notes to our notes to our statutory accounting requirements of information regarding our statutory information regarding our statutory accounting statements regarding our consolidated for information regarding our statutory capitalization.The information regarding our consolidated financial statements for information regarding our regulatory information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory capitalization for information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our consolidated financial statements regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our consolidated financial statements regarding our consolidated financial statements regarding our statutory accounting statements regarding our statutory accounting regarding our statutory accounting.The information regarding our statutory accounting and consolidated financial accounting statements.The information regarding our statutory accounting and information regarding our statutory accounting and financial accounting requirements regarding our statutory accounting.The information regarding our statutory accounting and information regarding our statutory accounting requirements regarding our statutory accounting and information regarding our statutory capitalized capitalization.The information regarding information regarding our consolidated financial statements regarding our statutory accounting and our statutory accounting information regarding our statutory accounting policies and information regarding our consolidated financial statements.The results of our statutory accounting regarding our statutory accounting policies and our statutory accounting period.We have received regarding our statutory accounting standards and the treatment of information regarding information.The information.The information regarding information regarding information regarding information regarding information regarding our statutory accounting regarding our the information regarding our"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?",
        "options": {
            "A": "$100 million",
            "B": "$200 million",
            "C": "$215 million",
            "D": "$300 million",
            "E": "$250 million",
            "F": "$150 million"
        },
        "LLM_original_answer": [
            "The information.The information regarding our statutory accounting requirements regarding our statutory financial instruments.The information regarding our statutory accounting costs related notes to the Notes to Consolidated financial statements to Consolidated Information for information regarding information regarding our consolidated financial statements of information.The information regarding our consolidated Notes to the acquisition of the information regarding our statutory accounting and other income tax effects of our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting and our statutory accounting and information regarding our consolidated information regarding our statutory accounting requirements regarding our statutory accounting requirements regarding our consolidated financial statements to the consolidated financial statements for information regarding our statutory accounting requirements for information regarding our statutory accounting statements for information regarding our statutory accounting for information regarding our statutory accounting period.The information regarding our statutory accounting requirements for information regarding our consolidated accounting for information regarding our statutory accounting for information regarding our statutory accounting statements for information regarding the Notes to the Notes to the information regarding our statutory consolidated consolidated financial statements to the Notes to information regarding information regarding information regarding information regarding information regarding our statutory to our statutory accounting and Consolidated financial statements regarding information regarding our multiple Notes to the Notes to information regarding our statutory information regarding our statutory financial statements.The information.The notes and information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory tax information regarding information regarding information for information regarding our consolidated accounting for information regarding our consolidated accounting statement.The information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory accounting.The information regarding our consolidated financial information regarding our consolidated financial accounting for information regarding our statutory financial information regarding our statutory accounting period of our statutory accounting statements.The Notes to the Notes to the statutory accounting and information regarding our statutory accounting and financial statements.The information regarding our statutory accounting regarding our statutory accounting requirements.The majority of our statutory accounting requirements.The majority of information regarding our statutory accounting.The consolidated financial statements regarding our consolidated financial statements regarding our consolidated financial statements.We recorded information regarding our statutory accounting information regarding our statutory accounting and information regarding information regarding information regarding information regarding our consolidated accounting statements and information regarding information regarding our statutory accounting period toedited Financial Statements for the Notes to the Notes to the consolidated financial statements.The information.The information.The information regarding our statutory accounting for information for information regarding our statutory accounting for information regarding our statutory accounting for information regarding our statutory accounting regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our statutory accounting and the Notes to the Notes to the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?",
        "options": {
            "A": "Investment gains",
            "B": "Interest income",
            "C": "Rental income",
            "D": "12b-1 fees",
            "E": "Consulting fees",
            "F": "Insurance premiums"
        },
        "LLM_original_answer": [
            "The for information regarding the information regarding information regarding our consolidated cash and information regarding information regarding information regarding our statutory accounting and consolidated financial statements regarding information regarding information regarding our information regarding information regarding information regarding information regarding information regarding our statutory accounting regarding information regarding information regarding our information regarding our consolidated financial statements.The information regarding information regarding our statutory accounting.The information.The information regarding our statutory capital requirements for information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our.Invested.Investing.The information regarding our statutory accounting statements of information regarding information regarding information regarding the Notes to the Notes to the Notes to the information regarding our statutory accounting and consolidated financial condition.The information regarding our statutory accounting and financial statements and information regarding the consolidated financial accounting and consolidated information regarding our statutory accounting and consolidated information regarding information regarding our consolidated information regarding our statutory accounting and information regarding our statutory accounting and accounting and our statutory accounting requirements of information regarding our statutory accounting requirements.The information regarding information regarding the information regarding our statutory accounting for information regarding our statutory accounting.The Consolidated financial statements regarding information regarding information regarding our statutory accounting.The information regarding information regarding our statutory accounting information regarding our statutory accounting plans for information regarding our Notes to the information regarding information regarding information regarding our statutory accounting for information regarding our statutory accounting statements to the Consolidated for information regarding information regarding our statutory accounting and information regarding our consolidated financial statements regarding the Consolidated information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding the Notes to the Notes to Consolidated our consolidated notes to the Notes to the Notes to the information regarding our statutory accounting and capital requirements regarding our statutory accounting requirements and our consolidated consolidated cash and for information regarding our statutory accounting policies and consolidated financial statements regarding information regarding information regarding information regarding information regarding information regarding information regarding information regarding our consolidated financial statements.The use of the information regarding information regarding information regarding information regarding information regarding our consolidated financial statements regarding our information regarding information regarding our statutory accounting for information regarding information regarding our statutory accounting and our statutory accounting and information regarding information regarding our information regarding our statutory accounting requirements for information regarding our statutory accounting statements regarding our information regarding our statutory accounting for information regarding our statutory accounting.The information regarding our statutory accounting for information regarding our notes to include information regarding our statutory accounting.The information regarding our statutory accounting period.We have information regarding our statutory accounting.The information regarding our statutory accounting requirements.The statutory accounting"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the primary reason the Company has not generated any revenue from product sales?",
        "options": {
            "A": "High production costs",
            "B": "None of its product candidates have been approved for commercialization",
            "C": "Lack of marketing efforts",
            "D": "Inadequate research and development",
            "E": "Insufficient staffing",
            "F": "Economic downturn"
        },
        "LLM_original_answer": [
            "The revised disclosures for the period ending December 2026.2026, 2026\nThe revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures ending December 2025period ending December 2025period ending December 2027 the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the period ending December 2025, 2026.53.The revised disclosures for the revised disclosures ending December 2025, 2025, or December 2026 revised disclosures for the revised disclosures for the revised disclosures ending December 2026, 2026 2025See the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised future periods ending December 2026 by providing the revised disclosures by providing the revised disclosures for the safety disclosures for the revised disclosures for the revised disclosures for the period ending December 2026. December 2026. 2026, 2026 December 2026 for the period ending 2025, 5, 2026 beginning December 2026, 2027 and the revised disclosures for the period ending December 2026, 2025, and the revised disclosures for the revised disclosures for the period ending December 2025 2026, 2026disclosed revised disclosures for the period ending December 2025, 2025 by providing the period ending December 2026future revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the period ending December 2025 by providing the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures, 2026, which may be the revised clinical trials for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures ending disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the revised disclosures for the period ending December 2025, 2026, 2026 provide the revised disclosures for the revised disclosures for the period ending December 2025 "
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the total expected lease payment for the Austin Lease term?",
        "options": {
            "A": "$97.8 million",
            "B": "$88 million",
            "C": "$100 million",
            "D": "$78.9 million",
            "E": "$90 million",
            "F": "$85 million"
        },
        "LLM_original_answer": [
            "Based on-chain currency assets with indefinite useful lives with indefinite useful lives with indefinite useful lives and digital currency assets with indefinite useful lives with indefinite useful lives.We subsequently acquired in the Company\u2019s digital currency assets with indefinite useful lives, with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite currency assets with indefinite currency assets with indefinite useful lives.We initially recognized digital currency with indefinite useful currency assets with indefinite assets with indefinite useful lives.We subsequently recognized digital currency assets with indefinite useful lives, currency assets with indefinite useful lives with indefinite useful lives, and/or indefinite useful lives.We initially recognized as intangible assets with indefinite useful lives.We initially recognized as well as indefinite useful lives, currency with indefinite useful lives.We subsequently amended and digital currency assets with indefinite useful lives with indefinite useful currencies with indefinite useful lives. currency assets with indefinite useful lives, we initially recognized as well as indefinite useful lives with indefinite useful lives for the digital currency with indefinite useful lives.We initially recognized as intangible currency assets, and we initially as intangible currency with indefinite useful lives.We initially recognized as intangible assets with indefinite useful lives.We subsequently held in the assets with indefinite useful lives with indefinite useful lives for the United States as well as well as well as well as well as intangible assets with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite useful lives.We subsequently recognized as well as intangible assets with indefinite useful lives, with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite useful lives with indefinite useful lives.We have indefinite useful lives with indefinite useful lives with indefinite useful lives.We subsequently, 2023Assets for indefinite useful lives.We subsequently amended 52and indefinite useful lives with indefinite useful lives with indefinite useful lives.51for as intangible assets with indefinite useful lives and indefinite useful lives with indefinite useful lives, in digital currency assets with indefinite useful lives with indefinite useful lives, including but indefinite useful lives with indefinite useful currencies with indefinite useful lives, which includes indefinite useful lives, which are accounted for which includes digital currency with indefinite useful lives as well as well as well as well as well as well as intangible currency with indefinite useful lives and indefinite useful lives with indefinite useful lives.We subsequently mined as indefinite useful lives with indefinite assets with indefinite lives.We initially recognize digital currency assets with indefinite useful lives.51and indefinite useful lives with indefinite useful lives.53are intangible currency assets with indefinite useful lives with indefinite useful lives indefinite useful lives. We have indefinite useful indefinite useful lives with indefinite useful lives with indefinite useful lives"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?",
        "options": {
            "A": "As separate performance obligations",
            "B": "Under series guidance",
            "C": "As a single performance obligation",
            "D": "With cost-based pricing",
            "E": "As unbilled estimates",
            "F": "With FERC regulation compliance"
        },
        "LLM_original_answer": [
            "Due expense associated with Duke Energy Compensation expense related to Duke-based compensation costs associated with respect to stock-based expense capitalized in the-based compensation associated with respect to the following the following the following the following the following the following Duke Energy Compensation expense associated with Duke Energy Compensation associated stock-based compensation expense associated with stock-based compensation costs associated stock-based associated associated stock-based compensation expense associated associated associated associated costs associated stock-based stock-based compensation expense associated associated stock-based compensation expense associated associated with Duke-based compensation expense associated with the stock-based expense associated with stock-based compensation expense associated with stock-based compensation associated stock-based expense associated with the following tables and stock-based compensation costs associated stock-based compensation costs capitalized and stock-based compensation expense associated with respect for the associated with respect associated with stock-based compensation associated costs associated with the below the following stock-based compensation costs associated with stock-based compensation associated costs associated capitalized and other costs capitalized stock-based related costs capitalized costs capitalized costs capitalized costs capitalized costs capitalized costs associated costs related costs capitalized and costs associated with the following stock-based compensation expense associated with each of the following stock-based compensation expense capitalized and stock-based compensation costs associated in the associated compensation expense associated with the following operating income associated costs associated with Duke Energy Capitalized costs associated with stock-based costs associated withstock-based compensation expense associated in the associated expense associated expense associated with-based expense associated expense associated other associated expense associated expense associated in-based costs associated with the information and costs associated associated with associated with Duke-based expense associated with respect to Duke Energy Capitalized with Duke Energy Capitalized costs associated with stock-based stock-based stock-based in the following stock-based costs associated stock-based compensation expense associated with Duke Energy Capitalized in the following Duke Energy Capitalized stock-based expense associated stock-based expense associated stock-based associated with stock-based expense expense expense expense capitalized stock-based compensation expense and associated stock-based costs capitalized stock-based expense associated with stock-based expense and the capitalized costs and expot stock-based compensation associated associated with other operating associated assets associated expense associated with associated associated with stock-based compensation expense associated market-based expense associated costs associated stock-based costs associated stock-based stock-based costs associated with the associated market and related to the stock-based stock-based compensation expense and stock-based stock-based compensation associated with respect to stock-based compensation expense associated with stock-based compensation expense associated table associated with respect to be included in the following the expense and capitalized as a particular types of stock-based compensation costs capitalized stock-based compensation costs associated withstock-based with respect to be associated with respect associated with respect to be included in the following table below stock-based stock-based compensation costs associated with"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "How many RSA awards vested during the year ended December 31, 2023?",
        "options": {
            "A": "683,056",
            "B": "152,880",
            "C": "136,609",
            "D": "95,808",
            "E": "302,908",
            "F": "0"
        },
        "LLM_original_answer": [
            "Fundingof83susthence83sustained recovery.Use83susthenceconomic83sustained recovery along with83of84sustake of 83sust of 2024.83sust83sustated84sust83of843susth83sust3. Use of our83sust of83of83along83along83susthenceffecting of our83of83ofof84.83sustac4.83sust of 2023.83alongwith83of83along with83and 2023.83sust of 2023.83employment.Use of84of83of83along with83of83along with 2023. Use of84of83along with 2023.83susthenceffinallysusthenceconomic83susthenceffecting3.83sust83of83sust of 2023recovery.Use of83sust of83sust of Eastern Bank83sustain83sust3. Use of84percentage83. Use of84sust83sustain83sustainuse of84sustacrosure83sustained83sustrecovery.Use83along with 83sust83along83sust83sust83sustake83sustakeo83alongwith83sustake83. Use83susthence83sustained84. Use83along with83along with 83recovery.Use83recovery.Use of84sustoned to83susten3rd83rd. Use of83alongwith83along with83alongwith83along with 10.83along with83sustained recovery.Use of83of84along with83susthedgingd83sustake94along with83sustakeffecting83sustained.Use of 2023. Use of Eastern Bank83sustakeconomic83sustakeconomic83sustakeffectingrowth. Use of 2023. Use of83d e3. Use of 2024. Use of83sust83s83sustainedemployment.Use of 2024. Use of 2023. Use83susthenceffecting83sustention83susthenceconomic83sustendedeconom83sustimatelysusthence83sustained recovery.Use of the of84sust3. Use of Eastern Bank83sustained.Use of Eastern Bank83"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?",
        "options": {
            "A": "Development of antiviral medications",
            "B": "Manufacturing of generic drugs",
            "C": "Discovery and commercialization of protein degradation drugs",
            "D": "Research into rare genetic disorders",
            "E": "Development of vaccines",
            "F": "Production of over-the-counter supplements"
        },
        "LLM_original_answer": [
            "What is the the authoritative guidance on fair value measurements and guidance on fair value measurements and disclosures of fair value measurements and SABCPAICBGAAPBasis authoritative guidance on fair value disclosures under the authoritative guidance on the authoritative guidance on fair value measurements and authoritative guidance on fair value measurements and authoritative guidance on fair value measurements and fair value measurements and disclosures under development of the authoritative guidance on fair value measurements and disclosures of the the authoritative guidance oneritable guidance on fair value measurements and disclosures under the authoritative guidance on the U.Suchimprincipi.e.given authoritative guidance oneritable guidance on the the the authoritative guidance on fair value measurements and related guidance on fair value measurements and the authoritative guidance on fair value disclosures.The authoritative guidance on fair value measurements and guidance on fair value measurements and disclosures under development of the authoritative guidance on fair value guidance on fair value measurements and related guidance on fair value guidance on fair value measurements and authoritative guidance on fair value measurements and related guidance on fair value measurements and related guidance on fair value measurements and disclosures under the the authoritative guidance oneritable guidance on fair value measurements and related guidance oner authoritative guidance on fair value guidance on fair value measurements and fair value disclosures under the authoritative guidance on fair value disclosures under the authoritative guidance on fair value measurements and related to be the authoritative guidance on fair value measurements and related to be the authoritative guidance on fair value guidance on fair value disclosures of fair value measurements and related to be\u00adrelated guidance on fair value disclosures and disclosures of the authoritative guidance on fair value measurements and the authoritative guidance on fair value measurements and disclosures, the authoritative guidance on fair value measurements and disclosures on fair value measurements and/or U.See measurements and/orbroadway authoritative guidance and/or disclosures and related guidance on fair value measurements and disclosures of the authoritative guidance on fair value measurements and disclosures of the authoritative guidance on fair value measurements and fair value disclosures of the the authoritative guidance on fair value measurements and disclosures under the authoritative guidance on fair value measurements and the authoritative guidance on fair value measurements and the authoritative guidance on fair value measurements and the authoritative guidance on fair value of fair value measurements and fair value disclosures, and U.S.Secitable guidance on fair value guidance on fair value measurements and related to be\u00ad-Value of the authoritative guidance on fair value of the authoritative guidance on fair value disclosures of the authoritative guidance on fair value disclosures of fair value disclosures and disclosure guidance on the authoritative guidance on fair value measurements and disclosures under the authoritative guidance on fair value measurements and disclosures, the authoritative guidance on fair value disclosures of fair value"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?",
        "options": {
            "A": "$188.2 million",
            "B": "$183.9 million",
            "C": "$181.1 million",
            "D": "$177.5 million",
            "E": "$24.6 million",
            "F": "$11.3 million"
        },
        "LLM_original_answer": [
            "Based on a\nResiceworken 2024ITEM 2024ITEM 2024ITEM 2023ITEM 2023Servicing fees recognized in 2024ITEM 2023ITEM 2023\nPost-recognized in 2023ITEM 2014ITEM 2024ITEM 2023ITEM 2024ITEM 48Servicing recognized in 2024ITEM 2024ITEM 2024ITEM 2024delinquiced in 52ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 43ITEM 2024ITEM 2024ITEM 2024delinquiring in 2024delinquiring in 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024\nServicing fees and Pledged MSR liability expense recognized in 2023ITEM 2023delin 2023Servicing in 2023delinqu 2024ITEM 2024ITEM 2024ITEM 2023ITEM 2023del 2024ITEM 2024Servicing fees recognized in 2024Servicing in 2023Servicing in 2023ITEM 2024Servicing fees and Pledged MSR fees and Pledged MSR liability expense recognized in 2023ITEM 2024ITEM 2023Servicing recognized in 2023ITEM 2023Servicing recognized in 2023delinquiring recognized in 2023delinquicing recognized in 2024ITEM 2023Servicing recognized in 2023Servicing recognized in 2023Servicing recognized in 2024ITEM 2023rd\nServicing recognized in 2024ITEM 46ITEM 2024ITEM 2019delinquiring recognized in 2024ITEM 2024ITEM 2023Servicing fees recognized in 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024ITEM 2024. Servicing recognized in 2023Servicing fees and Pledged MSR liability expense recognized in 2017Servicing recognized in 2024Servicing recognized in 2024Servicing recognized in 2023\nServicing recognized in "
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which of the following is included in research and development expenses as incurred?",
        "options": {
            "A": "Marketing and advertising expenses",
            "B": "Expenses related to employee salaries involved in R&D",
            "C": "Sales commission and bonuses",
            "D": "Office supplies and administrative costs",
            "E": "Travel expenses for sales team",
            "F": "Legal fees for patent applications"
        },
        "LLM_original_answer": [
            "Based requirements and as defined by Nasdaq rules and as defined by Nasdaq rules as defined rules and as defined by Nasdaq rules as defined by Nasdaq rules and as defined by applicable SEC rules as defined by applicable SEC rules and SEC rules and as defined by Nasdaq governance rules as defined by applicable SEC rules as defined SEC rules and as defined by SEC rules and as defined by applicable SEC rules as defined as defined by applicable SEC rules as defined Nasdaq governance rules and as defined rules and as defined by Nasdaq rules and as well as defined by applicable Nasdaq rules and as defined by Nasdaq listed companies, Nasdaq rules as defined by Nasdaq as defined as defined by definition of Nasdaq defined by definition rules and as defined by Nasdaq governance rules, as well as well as defined by Nasdaq governance rules and as well Nasdaq governance rules and as defined by Nasdaq rules as defined by Nasdaq rules as defined by Nasdaq rules and as defined by Nasdaq rules and as well as Nasdaq rules and as well as defined by Nasdaqx as defined by Nasdaqatrade rules as defined by Nasdaq governance rules and as defined by Nasdaq rules and as well as well as defined SEC rules and as defined by Nasdaq rules and SEC rules and as defined by the SEC rules and Nasdaq rules and as defined by Nasdaq rules and as defined by Nasdaq rules and as well Nasdaq rules and as defined by Nasdaq rules and as well as defined by Nasdaq rules and as defined by the SEC governance rules and as Nasdaq rules and as defined by Nasdaq governance rules as defined by Nasdaq Nasdaq rules and as defined bylaws, as defined governance rules as defined by applicable SEC governance rules as defined SEC requirements as defined as defined by Nasdaq as defined by Nasdaq governance rules as defined by the thes rules, as well as well as well as well as well as well as well as well as defined by Nasdaq rules and as defined by SEC rules. The SEC rules and as defined bylaw rules. The SEC rules and SEC rules and as defined by Nasdaq governance rules and as defined by Nasdaq rules and as defined by Nasdaq rules and as defined by applicable SEC rules and SEC rules and as defined by Nasdaq rules and as defined by Nasdaqdaq rules as defined by applicable SEC rules as defined by applicable SEC rules and as defined by Nasdaq rules as defined by SEC rules and Nasdaq rules and as well Nasdaq rules and as defined by Nasdaq rules and as well as defined by"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?",
        "options": {
            "A": "Increase in corporate tax rates",
            "B": "Elimination of personal exemptions",
            "C": "Capitalization and amortization of research and experimentation costs",
            "D": "Introduction of new state taxes",
            "E": "Repeal of alternative minimum tax",
            "F": "Mandatory expense reporting for small businesses"
        },
        "LLM_original_answer": [
            "The drug products are subject to extensive and drug products are subject to the drug products are subject to extensive post-market obligations of drug products are subject to a number of drug products are subject to the drug products are subject to the drug products are subject to the drug products are subject to the drug products are subject to the drug products of drug products of drug products are subject to the sale, and the drug products of drug products are subject to the drug products are subject to the drug products and other than may adversely affect our drug products of drug products are subject to the drug products of drug products of drug products of drug products of drug products are subject to a significant post-market obligations of drug products of drug products of drug products of drug products are subject to extensive and post-market obligations of drug products are subject to a significant drug products are subject to the drug products of drug products and the drug products are subject to extensive and drug products are subject to the sale, sale, sale, sale, drug products are subject to extensive drug products are subject to extensive drug products of drug products are subject to extensive and the sale, sale, sale, sale, sale, sale, sale, sale, sale, sale, sale, sale, sale, sale, sale, and post-market obligations of drug products are subject to the drug products of drug products of drug products of drug products of drug products are subject to the sale, or may in drug products are subject to the drug products of drug products are subject to the drug products of the sale, sale, sale, and/or the sale, or may adversely affect the sale, and the sale, and the sale, and post-market obligations of drug products are subject to the sale, sale, sale, sale, including but are subject to a drug products are subject to the sale, sale, sale, sale, sale, sale, including but also subject to the drug products are subject to the drug products are subject to the drug products are subject to which may adversely affecting the drug products are subject to be subject to name, and post-market obligations of drug products are subject to extensive and post-market obligations of drug products are subject to extensive post-market obligations of extensive post-market obligations of drug products of extensive post-market obligations of drug products of drug products of drug products are subject to the drug products are subject to the drug products of drug products are subject to the drug products of drug products of drug products are subject to the drug products are subject to extensive and post-market obligations of drug products are subject to drug products and post-market obligations of drug products are"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?",
        "options": {
            "A": "$100 million",
            "B": "$200 million",
            "C": "$215 million",
            "D": "$300 million",
            "E": "$250 million",
            "F": "$150 million"
        },
        "LLM_original_answer": [
            "The Board of the November 2003.As our Board of our Board of Directors since November 2002.As our Board of our Board of our market data service.As our EAMQ&AQeuqeuropes Chair of Chair of our Board of our Board of our Board of our Board of our market participants in our Board of our Board of our Board of Chair of our Board of Directors of our Board of Directors since November 2002.As Chair of November 2003.As our businesses in November 2002.As our Board of our Board of our Board of our Board of our clients of our Board of our Board of our Board of Directors 2002.As our Board of our Chair 1"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?",
        "options": {
            "A": "Investment gains",
            "B": "Interest income",
            "C": "Rental income",
            "D": "12b-1 fees",
            "E": "Consulting fees",
            "F": "Insurance premiums"
        },
        "LLM_original_answer": [
            "The loss of the current period were a loss of $80 million in the current period, as well as well as well as well as well-being a loss of $71.The loss of the prior to the current year of $80 million in the current period in the current period in the prior to which may be a loss of which were were a loss of $71million in the current period, including the prior to 2022 were a loss of $2022 in the prior period, if the current period in the current period in the current period. Adjusted were a loss of $70 million in the current period.2020\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the primary reason the Company has not generated any revenue from product sales?",
        "options": {
            "A": "High production costs",
            "B": "None of its product candidates have been approved for commercialization",
            "C": "Lack of marketing efforts",
            "D": "Inadequate research and development",
            "E": "Insufficient staffing",
            "F": "Economic downturn"
        },
        "LLM_original_answer": [
            "Based Shelf Registration Statement, which includes a.m, including a Shelf Registration Statement, including the Shelf Registration Statement, the Shelf Registration Statement, including the Shelf Registration Statement, including a agreement prospectus, including a base prospectus prospectus, including the Shelf Registration Statement, including a base prospectus, including a base prospectus, which we refer to be base prospectus, including the Shelf Registration Statement, including the Shelf Registration Statement Shelf Registration Statement, including the Shelf Registration Statement, including a base prospectus, including the Shelf Registration Statement, including a base prospectus, including the Shelf Registration Statement Registration Statement, including the Shelf Registration Statement, including a sales agreement and sales agreement prospectus, including a base prospectus, or Shelf Registration Statement, including a Shelf Registration Statement, including a base, including a Shelf Registration Statement, including the Shelf Shelf Registration Statement, including a base prospectus, including a base prospectus Registration Statement, including a base prospectus, including a base, including a base prospectus, including the Shelf Registration Statement, including a base prospectus prospectus, including a base prospectus and base prospectus prospectus prospectus, including a base prospectus, Shelf Registration Statement, including the Shelf Registration Statement, including a base prospectus and sales agreement prospectus, including the Shelf Registration Statement, including the Shelf Registration Statement Shelf Registration Statement, including a base prospectus and sales agreement prospectus, including a base prospectus, including the Shelf Registration Statement, or Shelf Registration Statement, or Shelf Registration Statement, the Shelf Registration Statement, including the Shelf Registration Statement and sales agreement prospectus, including a Shelf Registration Statement, sales agreement prospectus, including a base prospectus, including a Shelf Registration Statement of the base prospectus prospectus prospectus prospectus prospectus, or Shelf Registration, including a sales agreement base shelf registration statement, including a Shelf Registration Statement of the Shelf Registration Statement, including the Shelf Registration Statement, including a base prospectus, including the Shelf Registration Statement, including a base prospectus and sales agreement prospectus, including the Shelf Registration Statement, including a Shelf Registration Statement, including the Shelf Registration Statement, including the Shelf Registration Statement, including the Shelf Registration Statement, including a Shelf Registration Statement, to the Shelf Registration Statement of the Shelf Registration Statement, or base prospectus, including a base prospectus, including a base prospectus and Shelf Registration Statement, including a base prospectus, including a base prospectus, including a base registration statement, including the Shelf Registration Statement Shelf Registration Statement, including a base prospectus and sales agreement"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is the total expected lease payment for the Austin Lease term?",
        "options": {
            "A": "$97.8 million",
            "B": "$88 million",
            "C": "$100 million",
            "D": "$78.9 million",
            "E": "$90 million",
            "F": "$85 million"
        },
        "LLM_original_answer": [
            "The risks paid over the daily 2024\nE: - 1, or other than we have of total actual fees paid over the daily 24-hour period beginning over the share of actual fees paid over the Israel-Hour 29 of the Israel-Hourselves Rationale 28To the share of any such as well as well as it is the extent of any or other than the share of actual fees paid actual fees or other than any or other than the extent that we intend to the extent that we have been required by virtue of our business continuity of the value of digital asset and/or otherwise, see \u201c\u2014RisksRegulatory 24.UnderminingApologies in the share of our share of actual fees paid over the share of the extent to the share of the period beginning of the value of bitcoin and/or other than the extent that we intend to the share of actual fees related risks of fees paid over the share of total actual fees over the share of actual fees paid over the share of the share of total actual fees and actual fees paid over the share of total actual fees paid over the share of actual fees paid hours beginning with respect to the share of total actual fees paid over the share of the share of the Company may be\u00ador other fees paid over the extent of actual fees earned by the share of total actual fees paid by the extent of the extent of bitcoin and/or other digital asset mining operations, or any or other than the share of total actual fees paid over the actual fees paid over the share of total period beginning and/or other than the share of the share of the share of any or other than the Company\u2019s actual fees paid over the extent to the extent of the extent to the foregoing\nOptions\nOptions\nOptions\nQuestionsRegulatory actual assets and/or the share of bitcoin and/or otherwise than under the extent of the share of total actual fees and/or other fees paid or otherwise, or other than under the extent of any of any investment and/or otherwise, or other than under the share of any or otherwise, or otherwise may beRegulatory transaction power of any other than under the share of any or otherwise, or other fees, or otherwise, or other fees paid over the actual fees over the share of total actual fees paid over the share of total actual period beginning the share of the share of total actual fees paid over the share of total actual fees paid over the share of actual fees paid over the share of the share of the share of the share of the share of the share of the share of bitcoin and"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "How does Duke Energy treat energy and demand charges under full requirements contracts?",
        "options": {
            "A": "As separate performance obligations",
            "B": "Under series guidance",
            "C": "As a single performance obligation",
            "D": "With cost-based pricing",
            "E": "As unbilled estimates",
            "F": "With FERC regulation compliance"
        },
        "LLM_original_answer": [
            "Duke knew that the lawsuit alleges that the deced along with the deced knew that Duke Energy Carolinas and their deced that the lawsuit alleges that the deced that the lawsuit alleges that the Carolinas knew that the decedents and the deced deced deced that the lawsuit knew that the deced that the decedents and the lawsuit alleges that Duke Energy Energy Carolinas.The lawsuit alleges that Duke Energy Carolinas that Duke Energy knew that the deced that the decedents knew that the deced and the lawsuit alleges that the lawsuit alleges that the decedents knew that the decedents.The lawsuit.The lawsuit also.The lawsuit alleges that Duke Energy knew that the decedents.The lawsuit.The lawsuit alleges that Duke Energy knew that Duke Energy knew that the deced that the survivors and/or the deced Energy Carolinas knew that the deced that the deced that the deced that the decedents knew that the decedents knew that Duke Energy Carolinas knew that the deced Energy knew that the deced that the decedents and/or the deced by the lawsuit.The lawsuit alleges that the survivors.The lawsuit also knew that the decedents.The lawsuit.The lawsuit alleges that the deced knew that owned that the deced knew that the deced that Duke Energy Carolinas knew that the deced deced that Duke Energy knew that the deced that the lawsuit alleges that the decedians knew that the decedents and the deced the lawsuit also along with the lawsuit also along with the decedents.The lawsuit along with the deced deced that Duke Progress and the deced that the decedents along with the deced and/or along with the lawsuit alleges that the deced as well along with the deced.The lawsuit alleges that the lawsuit alleges that were along with the deced that the lawsuit knew that were along with the deced and the lawsuit knew that knew that the deced knew that the deced that the lawsuit.The lawsuit alleges that the lawsuit knew that along with the decedents.The lawsuit.The lawsuit.The lawsuit.The lawsuit that the decedents knew that the decedents.The lawsuit alleges that the deced knew that Duke Energy Progress.The lawsuit that the decedents.The lawsuit alleges that Duke Energy Carolinas and/or the deced knew that the lawsuit alleges that the lawsuit along with the deced that Duke Energy Carolinas knew that the deced and the lawsuit alleges that Duke Energy Generation's knew that the lawsuit alleges that Duke Energy Carolinas.The lawsuit alleges that Duke Energy"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "How many RSA awards vested during the year ended December 31, 2023?",
        "options": {
            "A": "683,056",
            "B": "152,880",
            "C": "136,609",
            "D": "95,808",
            "E": "302,908",
            "F": "0"
        },
        "LLM_original_answer": [
            "The purchase in both in both a base case study;##table  case study, and base case of the time of Eastern Bank of purchase in both a base case of life per security at time of which we are discussed above and other legal and other than a) and the following the following are all of time of both a base case of purchase in base case and time of time of purchase in both a base case and base case and weighted average life per security; and life of purchase; and time of time of time of purchase; and weighted average case; and time of the Eastern Bank of purchase in both in a) and weighted average purchase in this past and other than time of time of purchase in a time of purchase; and time of purchase in both a) is a base case of purchase; and ongoing case at time of Eastern Bank of Eastern Bank of the case per security at time of  in both a) is a) to both a) in a) to time of this year of purchase in a base case of security at time of both a base case of security at time of purchase in a base case of purchase in a base case in both a security at time of purchase in both in both in both in a base case of purchase in both a base case of a base case and time of purchase; and base case of purchase in both in a) and time of purchase in a security at time of purchase in both in both a base case; time of time of purchase in a base case of purchase; time of purchase in a time of purchase and time of Eastern Bank of purchase in both in both a base case per security; and base case at time of purchase in both a case of purchase in both a base case of purchase in both a base case of purchase in both a base case of purchase in both a base case of purchase in a base case and base case and base case; and weighted average case in a base case of purchase and base case at time of Eastern Bank of purchase in a security at time of all base case of a) and time of interest in both in both a base case of purchase in a base case of time of purchase in a base case of time of the company-wide case of purchase in both a base case at time of purchase; 25In the above. 202\n[...# base case of the case in both a) [time of purchase in a base case at time of purchase in a base case at time of purchase in a base case at time of life of purchase in both"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is the primary focus of the collaboration agreement between the Company and Gilead?",
        "options": {
            "A": "Development of antiviral medications",
            "B": "Manufacturing of generic drugs",
            "C": "Discovery and commercialization of protein degradation drugs",
            "D": "Research into rare genetic disorders",
            "E": "Development of vaccines",
            "F": "Production of over-the-counter supplements"
        },
        "LLM_original_answer": [
            "What is the commercialization of a drug candidate, or any drug candidate that we cannot assure you that we can be the commercialization of a drug candidate that we cannot assure you can assure you that we cannot assure you that we cannot assure you cannot assure you, and we cannot assure you cannot assure you cannot assure you that we cannot assure you cannot assure you cannot assure you cannot assure you can assure you cannot assure you that we cannot assure you that we cannot assure you cannot assure you can assure you will be assured that we cannot assure you that we cannot assure you cannot assure you cannot assure you cannot assure you cannot assure you cannot assure you can assure you cannot assure you that we will be assured that we can assure you that we cannot assure you will be assured you that we can assure you that we cannot assure you cannot assure you cannot assure you cannot assure you that we cannot assure you that we cannot assure you cannot assure you that we cannot assure you that we cannot assure you that we cannot assure you cannot assure you that we cannot assure you cannot assure you cannot assure you cannot assure you can assure you that we can assure you will be assured you can assure you that we can assure you that we cannot assure you cannot assure you cannot assure you that we cannot assure you that we cannot assure you that we cannot assure you cannot assure you can be the commercialization of a drug candidate, and we cannot assure you that we cannot assure you cannot assure you cannot assure you have not and we cannot assure you cannot assure you cannot assure you cannot assure you cannot assure you that we can assure you or we cannot assure you that we cannot assure you will assure you that we cannot assure you that we cannot assure you cannot assure you cannot assure you cannot assure you that we cannot assure you can assure you cannotation of a drug candidate, and we cannot assure you that we will assure you that we will be assured that we cannot assure that we cannot assure you can assure you that we will be assured that we cannot assure you will be assured you that we cannot assure you cannot assure you cannot assure you that we cannot assure you cannot assure you that we cannot assure you that we cannot assure us cannot assure you that we can assure you that we cannot assure you that we cannot assure you that we cannot assure the commercialization for the commercialization of a drug candidate that we cannot assure you cannot assure you cannot assure you cannot assure you cannot assure you cannot assure you that we cannot assure you cannot assure you that we cannot assure you cannot assure you cannot assure you cannot assure you cannot assure you have the"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "How much was the deferred tax asset, net of deferred tax liability, in the U.S. as of December 31, 2023?",
        "options": {
            "A": "$188.2 million",
            "B": "$183.9 million",
            "C": "$181.1 million",
            "D": "$177.5 million",
            "E": "$24.6 million",
            "F": "$11.3 million"
        },
        "LLM_original_answer": [
            "The risks related to the as of our business, continue to the progress with respect to the progress with respect to the the risks and make progress with respect to the as well as well as well as of our business, or other than we are subject to the following are generally, as well as well as of the the HECOcovening and make progress with respect to the progress with respect of the ability to the industry and make progress with respect of the the the the regulatory settlements and make progress with respect with respect to the franchises and make progress with respect to the with respect to the and other than could materially and make progress with respect to the make progress with respect to the risks related to the reverse mortgage and make progress with respect to the PMC Senior Securanswrt answer the with respect to the franchises and/or other regulatory and make progress with respect to the franchises and make progress with respect to the and face with respect to the make progress with respect to the and make progress with respect to the progress with respect to the and be adversely affective operations and other regulatory and make progress with respect to the make progress and make progress with respect to the making progress with respect to the with respect to the with respect to the progress with respect to the with respect to the following the following is a business and make progress with respect to the its servicing and make progress with respect to the the the the compliance with respect to the compliance with respect to the progress with respect to the and other than make progress with respect to the compliance and make progress with respect to the compliance with respect to the with respect to make progress with respect to the, among others and/or originations and make progress with respect to the and origination and make progress and origination franchises and make progress with respect to its regulatory and servicing and origination and other third parties.25 and make progress with respect to the and make progress with respect to the following are the progress with respect to the following are subject to the make progress with respect to make progress with respect to make progress with respect to our business, and make progress with respect to the make progress with respect to make progress with respect to the make progress with respect with respect to the and make progress with respect to the progress with respect to the and make progress with respect to the make progress with respect to the with respect to the and make progress with respect and make progress with respect to the and make progress with respect to make progress with respect with respect and make progress with respect to the servicing and make progress with respect to make progress with respect to the"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which of the following is included in research and development expenses as incurred?",
        "options": {
            "A": "Marketing and advertising expenses",
            "B": "Expenses related to employee salaries involved in R&D",
            "C": "Sales commission and bonuses",
            "D": "Office supplies and administrative costs",
            "E": "Travel expenses for sales team",
            "F": "Legal fees for patent applications"
        },
        "LLM_original_answer": [
            "Based the production and validating the production and validating the production process validation of the production and validating the the production, validating the production, validating the scaling up or out or out or out or validating the production, validating the production, validating the production, scaling up or out or out or out or out or out or validating the production and validating the production, scaling up or out or out or out or out or out, validating the validation of the validation of out or out, validating the production, validating the production process and validating the production, validating the scaling up or out, validating the validation and validating the the the scaling up or validating the production, validating the production, scaling up, particularly in scaling process and validating the production, validating the the production process and validating the the production process and validating the production and production of the production, and production, validating the the the production, and validating the scaling up or out or out or out or in scaling up or out, and validating the production process and validating the production process validation the production, scaling up or out or out, scaling up or out, validating the production, scaling up or out, scaling up or out or validating the production and production process validation the scaling up or in production, validating the production process validation of the scaling up or out or out or out or out or out or out, validating the production, validating the production, validating the scaling up or out or out or in scaling up or out or in the production process and production and production and out or out or out or out or out or out, validating the production and production, validating the production process and validating the production, validating the production, validating the scaling up or validating the the production, scaling up or validating the production and production of out or out or out or out or out or out or out or out or out or out or the production process and validating the the production, validating the production and assuring the out, validating the product and production and cross or out or validation and validating the production, validating the validation of the validation of or in scaling up or out, validating the production, validating the product validation of or in scaling up or out or out or out or out, validating the production process and assuring the out or out or out, validating the validation of or out, validating the production, validating the scaling up or out, validating the scaling up or validating the production, validating the production and out, and scaling up or the scaling up or out or out, scaling the production, and validating the production, validating the production"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What tax law change significantly impacted U.S. federal and state taxable income starting January 1, 2022?",
        "options": {
            "A": "Increase in corporate tax rates",
            "B": "Elimination of personal exemptions",
            "C": "Capitalization and amortization of research and experimentation costs",
            "D": "Introduction of new state taxes",
            "E": "Repeal of alternative minimum tax",
            "F": "Mandatory expense reporting for small businesses"
        },
        "LLM_original_answer": [
            "What we may encounter, as a number of these diseases or otherwise, or patients may and other than we may encounter, we may encounter, or, or we may encounter a\nas we may encounter may encounter, we may encounter, we may encounter may encounter may encounter, as well as well as well as we may encounter may significantly, we may encounter, we may encounter, or we may encounter the actual number of these diseases, we may encounter, or the diseases is smaller than we may encounter, we may encounter, we may encounter a number of our diseases is smaller than we may encounter the actual number, or that we may encounter these diseases is smaller than we anticipate, or the actual number of these diseases is smaller than we anticipate, we may encounter these diseases, or may encounter, or may encounter, we may encounter additional requirements for the diseases or may encounter a condition of these diseases or, we may encounter a number of this product candidates for example, among other U.Similar to obtain a\nWe also may encounter a smaller than we anticipate, we may encounter, we anticipate, or the actual number of these diseases, we may encounter these diseases is smaller than we anticipate, we anticipate, we anticipate, we encounter these diseases is smaller than we may encounter, we may encounter, we may encounter, we encounter these diseases, we may encounter, we may encounter these diseases, we anticipate, or the diseases is smaller than we anticipate, or the actual number of these diseases or we may encounter, as well as well-controlled clinical trials, we may encounter, as we may significantly, or the actual number of these diseases is smaller than we anticipate, we may encounter these diseases, we may encounter additional requirements for these diseases and other than we may encounter these diseases, or as we may significantly smaller than we diseases, among these diseases, we may encounter these diseases or that we may encounter a complete response to support the actual number of these diseases. These diseases, or other than we may not only if these diseases. These diseases. These Diseases and other than we may encounter a) or other than we may encounter, as well-controlled studies, we anticipate, we may encounter, as well as well as well as well as well as well as well, we anticipate, we may encounter these diseases, we anticipate, we anticipate, we anticipate, as well-controlled clinical trials, we anticipate, we may encounter a\nthan we may encounter, we may encounter the actual number of these diseases is smaller than we anticipate, or smaller than we anticipate, we anticipate"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is the total amount included in the ICE NGX guaranty fund as of December 31, 2023?",
        "options": {
            "A": "$100 million",
            "B": "$200 million",
            "C": "$215 million",
            "D": "$300 million",
            "E": "$250 million",
            "F": "$150 million"
        },
        "LLM_original_answer": [
            "The U.S.Designated Contract Market, or U.S. U.S, or U.Sovereignor DCM, ICE, or U.S.Designated Contract Market, or U.Sovere, or DCM, or DCM, or DCM, or DCM, or DCM, or U.S.Designated Contract Market, or DCMICE, or ICE U.S regulated U.S.Designated Contract Market, or DCMCM, or DCM regulated U.S regulated U.Designated Contract Market, ICE, or ICE Futures U.S.E.ICE Futures Contract Market, or DCM, U.S regulated ICE, or ICE, or ICE,ICE, or U.S.Designated Contract Market, or DCM, U.Sovere, or DCM, or other than DCM, or U.Sovere, or DCM, DCM, or U.S.Designated Contract Market, DCM, U.Signed, or DCM, or DCM, or, or DCM, ICE, or, or DCM, or ICE, or U.S, or DCM, or, or U.Signed Contract Market, or DCM, Contract Market, or DCM, ICE, or U.S., or U.S., or U.Sw, or ICE, or DCM, or DCM, or DCM, DCM, or DCM, or DCM, U.S. U.S. U.SCM, or DCM regulated U.S, or ICE U.Sec, or Contract Market, or DCM regulated U.S. Contract Market, or U.SCM, or DCM, or DCM, or DCM Market, or DCM, ICE, or U.S. S, or DCM, or Contract, or DCM, or DCM, or DCM, or ICE regulated U.S, or DCM, or DCM, or U.Signed Contract, or U.Sec, or.N. U.Signed U.S. U.S., or DCM, or Market, or, or Contract Market, or U.S., or DCM, or DCM, or U.S. U.Spread, or ICE.Clear, or DCM, or DCM, or U.Separated, or U.S.Designated Contract Market, or U.Sovere, or.Vendor and Contract Market, or U.See, or U.S.Designated, or DCM, or Black, or Black Knight, or U.S.ICE U.See, or DCM, or DCM"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 70,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What primarily constituted other revenues for Brighthouse Financial, Inc. for the year ended December 31, 2023?",
        "options": {
            "A": "Investment gains",
            "B": "Interest income",
            "C": "Rental income",
            "D": "12b-1 fees",
            "E": "Consulting fees",
            "F": "Insurance premiums"
        },
        "LLM_original_answer": [
            "What primarily on or other than supporting our business and other considerations in-force management that targets total assets supporting our variable annuity supporting our code of our business activities in our variable interest rate and other than supporting our business processes supporting our variable annuwneruancy products or similar as well-being issued and exposure and supporting our corporate actions, as noted below.Note Regarding our business practices that may be discussed above. See \u201c\u2014 Insurance Regulation of this regulation of which may be discussed above and other than expected persistencyoury December 2024(formediscapplied assets supporting our income annuity annuity contracts and other filings with respect to the impact on December 2024Targeted by our business practices and other than our income annu\n"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?",
        "options": {
            "A": "Cumulative voting rights",
            "B": "One vote per share without cumulative voting",
            "C": "Two votes per share",
            "D": "Preemptive voting rights",
            "E": "Redeemable voting rights",
            "F": "Convertible voting rights"
        },
        "LLM_original_answer": [
            "Based on the provided document, the voting rights of holders of common stock under the Company's amended and restated certificate of incorporation and bylaws are as follows:\n\nOption B: One vote per share without cumulative voting.\n\nThe document does not mention cumulative voting rights (Option A), two votes per share (Option C), preemptive voting rights (Option D), redeemable voting rights (Option E), or convertible voting rights (Option F)."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?",
        "options": {
            "A": "The candidate's previous employment history",
            "B": "The candidate's age and personal interests",
            "C": "A conflict of interest impacting their representation of stockholders",
            "D": "The candidate's educational background",
            "E": "The candidate's language proficiency",
            "F": "The candidate's geographical location"
        },
        "LLM_original_answer": [
            "Based on the provided document, the qualification concern that the Nominating and Corporate Governance Committee has regarding candidates for director is:\n\nC: A conflict of interest impacting their representation of stockholders\n\nThe document details the Nominating and Corporate Governance Committee's belief that candidates for director should not have, nor appear to have, a conflict of interest that would impair the candidate\u2019s ability to represent the interests of all the Company\u2019s stockholders and to fulfill the responsibilities of a director."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?",
        "options": {
            "A": "9.00%",
            "B": "7.50%",
            "C": "8.50%",
            "D": "6.00%",
            "E": "7.00%",
            "F": "5.50%"
        },
        "LLM_original_answer": [
            "Based on the provided document, the long-term rate of return that Duke Energy assumes for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023, is 8.50%. Therefore, the correct answer is based on the Company Stock-Based Compensation and related to include the Duke Energy Company Stock-Based on the Company-wide and other than the aggregate awards granted during the Duke Energy Companywide exposure to Settlements and related to VIEFid and other than 7.##table 401(h) The long-term pension and related to the Duke Energy Plan Assets and related to the Duke Energy Companywide.The following the Duke Energy Companywide, net of the Duke Energy Companywide and related to the Duke Energy Carolinas of $ 401(h)"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?",
        "options": {
            "A": "2020",
            "B": "2021",
            "C": "2022",
            "D": "2023",
            "E": "2024",
            "F": "2025"
        },
        "LLM_original_answer": [
            "Based on the provided document, the total original gain of $41.2 million, net of tax, became fully accreted into income during the year ended December 31, 2023. Therefore, the correct answer to the question is:\n\nB: 2021"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?",
        "options": {
            "A": "No less than 120% of fair value per share",
            "B": "No less than 80% of fair value per share",
            "C": "No less than 110% of fair value per share",
            "D": "No less than 100% of fair value per share",
            "E": "Fixed amount regardless of fair value",
            "F": "No specific requirement"
        },
        "LLM_original_answer": [
            "Based on the provided document, the multiple-choice question regarding the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power is:\n\nWhat is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?\n\nOptions:\nA: No less than 120% of fair value per share\nB: No less than 80% of fair value per share\nC: No less than 110% of fair value per share\nD: No less than 100% of fair value per share\nE: Fixed amount regardless of fair value\nF: No specific requirement\n\nThe correct answer is:\nC: No less than 110% of fair value per share\n\nThe document states, \"In the case of an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10 % of the total combined voting power of all classes of stock, the exercise price shall be no less than 110 % of the fair value per share on the date of grant.\""
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What was the required minimum net worth for PHH at December 31, 2023?",
        "options": {
            "A": "$350 million",
            "B": "$420.5 million",
            "C": "$448.3 million",
            "D": "$480 million",
            "E": "$500 million",
            "F": "$525.7 million"
        },
        "LLM_original_answer": [
            "The required minimum net worth for PHH at December 31, 2023 is $448.3 million."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?",
        "options": {
            "A": "NYSE governance rules",
            "B": "SEC disclosure guidelines",
            "C": "Nasdaq governance rules",
            "D": "International Business Standards",
            "E": "U.S. Financial Regulations",
            "F": "Federal Trade Commission rules"
        },
        "LLM_original_answer": [
            "The governance rule that requires a Code of Business Conduct and Ethics for directors, officers, and employees is the NYSE governance rules."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?",
        "options": {
            "A": "The Chief Financial Officer",
            "B": "Independent registered public accounting firm",
            "C": "The undersigned, duly authorized person",
            "D": "The Secretary of the Board",
            "E": "The company's legal department",
            "F": "The external auditor"
        },
        "LLM_original_answer": [
            "Based on the provided document, the individual responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934 is:\n\nC: The undersigned, duly authorized person\n\nThe document does not specify the exact name of the individual, but it is a duly authorized person of the company."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Where can information about the 2024 election of directors be found?",
        "options": {
            "A": "In the company\u2019s financial statements",
            "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders",
            "C": "In the General Instruction G(3) of Form 10-K",
            "D": "Under the 'Executive Officers' section of the report",
            "E": "In the company's quarterly earnings report",
            "F": "In the 'Delinquent Section 16(a) Reports' section"
        },
        "LLM_original_answer": [
            "Based on the provided document, information about the 2024 election of directors can be found in the Proxy Statement for the 2024 Annual Meeting of Stockholders."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What framework did the Company use to establish criteria for internal control over financial reporting?",
        "options": {
            "A": "SOX Compliance Framework",
            "B": "ISO 9001 Standards",
            "C": "Internal Control \u2014 Integrated Framework (2013)",
            "D": "GAAP Standards",
            "E": "FASB Guidelines",
            "F": "IFRS Regulations"
        },
        "LLM_original_answer": [
            "The framework used by the Company to establish criteria for internal control over financial reporting is the Internal Control \u2014 Integrated Framework (2013)."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?",
        "options": {
            "A": "Cumulative voting rights",
            "B": "One vote per share without cumulative voting",
            "C": "Two votes per share",
            "D": "Preemptive voting rights",
            "E": "Redeemable voting rights",
            "F": "Convertible voting rights"
        },
        "LLM_original_answer": [
            "Based on asecurities management program that targets total assets supporting our variable consideration supporting our management and other than supports our management and/or partially satisfied or liabilities only in thousands of each of $ 110well-being-supported risk management program that targets total assets less costs in illsupporting annuWellington and exposure risk management and exposure risk management program that supports our program that were not material.1131, as of $ 111well designed to support of the Company.110well designed to income for existing program that includes, including those assets supporting our variable annuity supporting our variable annuity supporting our variable assets supporting our variable annu2014annu program that targets total assets supporting our variable annuities program that targets supporting our variable annu2014 supporting our variable annuity supporting our variable annuity management program that targets total assets supporting our variable annuities risk management program that targets total assets that targets total assets supporting our variable annu annuities.113total assets supporting our variable annu annuannuity annuity management program that targets total assets supporting our variable annu management that targets total assets supporting our variable annuities at risk management and exposure risk management program that targets total assets supporting our variable annu annuity contracts as of $ ills supporting our variable annuannu2014annu annuities.Supporting our variable annuity management program that supports our variable annuannuity supporting our annu that targets total of $ 109well designed to meet the management program that targets total assets supporting our variable annuities for at theseedsupporting our variable annu annu annuity program that targets supporting our variable annuity supporting our variable annu supporting our variable annu annu and risk management program that targets total assets supporting our variable annu exposure risk management that targets total assets supporting our variable annu annu exposure program that targets total assets supporting our variable annuities management program that targets total assets supporting program that targets total assets supporting our variable annu annuities and variable annuannu exposure supporting our variable annuassets supporting our variable annuity programs that targets total assets to support our variable annuity management program that targets total assets and exposure risk management program that targets total assets that includes those programs that targets total assets at theses of up to maintainable and exposure risk management program that targets total assets supporting our variable annuity supporting ouruannuannuity supporting our variable annuities and variable annu annuities.109well designed to support our variable annu201"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?",
        "options": {
            "A": "The candidate's previous employment history",
            "B": "The candidate's age and personal interests",
            "C": "A conflict of interest impacting their representation of stockholders",
            "D": "The candidate's educational background",
            "E": "The candidate's language proficiency",
            "F": "The candidate's geographical location"
        },
        "LLM_original_answer": [
            "The management program and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annu\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?",
        "options": {
            "A": "9.00%",
            "B": "7.50%",
            "C": "8.50%",
            "D": "6.00%",
            "E": "7.00%",
            "F": "5.50%"
        },
        "LLM_original_answer": [
            "The majority of D.Electricity supporting our capital and exposure risk management program that targets total assets supporting our variable annuity management program that targets total assets and exposure program that targets total assets supporting our variable annuity management program that is maintained under the majority of 402##CAPITALI expect to which is the majority of Duke Energy and other long-term management evaluates fair value as of VIE Risk Management Program for the above targeted to Distributions for such as ofncia.203##table 202##"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?",
        "options": {
            "A": "2020",
            "B": "2021",
            "C": "2022",
            "D": "2023",
            "E": "2024",
            "F": "2025"
        },
        "LLM_original_answer": [
            "To the Company\u2019s assets in the Company\u2019s168Supporting that targets total unrecognized compensation expense.1683.163a capital and risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our of $ 2024.163annu exposure related to the Company\u2019s exposure risk management program that significantly affect our variable annuity supporting our variable annuity.161targeted risk management program that targets total of exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting our variable annuity risk participation program that targets supporting our variable annuity supporting our variable assets supporting our variable annuity supporting our variable assets supporting our variable annuities and supporting our variable annuansu2014.1689.168total assets supporting our variable annuity that targets total assets supporting our variable annuity program that targets total assets supporting our variable annuity supporting our exposure risk management program that targets total assets that targets total assets supporting our variable annuity annuity program that targets our variable annuity commitments to support our capital and exposure risk program that targets total assets supporting our variable annuity program that supports our variable rate of $ 168management program that targets total assets supporting our risk exposure risk management program that targets total assets and derivatives for accounting guidance and related to the Company\u2019s of $ 2023.168risk management believes the Company\u2019s management program that targets total assets at risk management program that targets total assets supporting our variable annuity commitments to the Company\u2019s 168management program that were as of $ 168targeted by step-by-step-by-law variable interest rate one-month SOFRMorto##table 168annuity that targets total assets in thegives and exposure risk management program that targets total assets supporting ourseminister and exposure risk management program that targets total assets supporting our variable and variable annuity supporting our variable assets supporting our variable annuities.163millionnaire supporting our variable annuity supporting our variable annuity in the variable annuity risk program that targets total assets supporting our variable annuities and exposure risk participation risk management program that targets total assets supporting our variable annu variable annuityuities supporting our variable annuity risk management program that targets total assets supporting our variable annuity program that targets total assets supporting our variable exposure to limit supporting our variable annuity supporting our variable assets supporting our variable annuiting risk management program that targets total assets"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?",
        "options": {
            "A": "No less than 120% of fair value per share",
            "B": "No less than 80% of fair value per share",
            "C": "No less than 110% of fair value per share",
            "D": "No less than 100% of fair value per share",
            "E": "Fixed amount regardless of fair value",
            "F": "No specific requirement"
        },
        "LLM_original_answer": [
            "To date that targets total assets supporting our variable annuities.annuities supporting our variable annuity-supported products that is reviewed for up to ropy supporting our variable annuity annuantity-supported assets, net supporting our variable consideration which is maintained that targets total assets supporting our variable annuity management program that supports our variable consideration that supports our variable annuity and exposure risk management program that supports oursecurities.Supporting annuity supporting our variable annuity."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What was the required minimum net worth for PHH at December 31, 2023?",
        "options": {
            "A": "$350 million",
            "B": "$420.5 million",
            "C": "$448.3 million",
            "D": "$480 million",
            "E": "$500 million",
            "F": "$525.7 million"
        },
        "LLM_original_answer": [
            "To-annu... [232 management program supporting our program that targets total assets held for sale agreements that targets total assets.The required minimum net assets and servicing advances and asset rate sensitivity (formerly supporting our program that targets total supporting our MSR management program that targets total assets supporting our variable annuity annuity program exposure to support supporting our pipeline hedging strategy that targets supporting our variable annuity supporting oursecurities supporting our variable annuity management program that targets total assets supporting our management program to preserve the company supporting our net assets supporting our management and related to support oursecurities supporting our management and Lossesqestion management\u2019s management\u2019s obligations under our reported as eligible collateralized criteria are supporting our variable interest rate of $  management program that targets total assets supporting orphansy\nuity management program that was maintained a:##capital and exposure risk management program to reflectiour variable interest rate sensitivity risk management program, among other risk management\u2019subsupported byproduct of our management program that targets under our consolidated financial obligations under our derivative instruments that.G-ann and exposure risk management program that targets supporting our variable supporting our program that targets supporting our variable annuit targeting total assets supporting our total assets supporting our variable annuity programs that targets for our program that targets supporting our business supporting our program that targets total assets supporting our risk management and targets total assets supporting our variable annu annuance risk management program that targets total assets supporting total assets supporting our variable annu annuities risk management program that targets supporting our management program that targets total assets supporting our variable annuity risk management that targets total assets at lock date supporting our variable risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity contracts supporting our program that targets for total assets supporting our variable assets supporting our variable annuity program at lock date supporting our capital and pipeline hedging program that targets between 2024.##mantargets.##total assets supporting our net and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity annuity management program that targets total assets supporting our variable annuitity exposure risk management that targets supporting our variable annuity supporting our risk management program that targets total assets supporting our variable annuity risk management program that targets total assets that targets supporting our variable annuity supporting our variable assets supporting our variable annuannuities supporting our variable annuity supporting program that management program that targets total assets supporting our variable annuities supporting our variable assets"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?",
        "options": {
            "A": "NYSE governance rules",
            "B": "SEC disclosure guidelines",
            "C": "Nasdaq governance rules",
            "D": "International Business Standards",
            "E": "U.S. Financial Regulations",
            "F": "Federal Trade Commission rules"
        },
        "LLM_original_answer": [
            "The variability and expenses increased bylaws and related to support thereof.Program for at the U.Seehnemeasured at least total assets.We expect to116totaling our Company supporting our program, or related to enable usury supporting our Company.General and other than targets total assets supporting ouring our product candidates to the SecuritiesAct 116program116targeting our Company and other than in the same as well-being risk management program that targets and risk management program that targets supporting oursecurities supporting our variable annu117116and exposure risk assets supporting our variable annuity management program that targets for oursecurities supporting our product candidates for the management program that targets and other than supporting our variable annu2016.116and other risk management program that targets for our variable annu2014Risk and exposure risk management program that targets total assets supporting our variable annu2014.119and other than supporting our program116and other than targets our variable annuity program that targets and other than supports our capital and product candidates for our variable annu201 supporting our variable annu2016.118 and exposure risk management program that targets total assets supporting our variable annuity contracts that targets our program that targets for our variable assets supporting our variable annu2014."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?",
        "options": {
            "A": "The Chief Financial Officer",
            "B": "Independent registered public accounting firm",
            "C": "The undersigned, duly authorized person",
            "D": "The Secretary of the Board",
            "E": "The company's legal department",
            "F": "The external auditor"
        },
        "LLM_original_answer": [
            "Based on behalf of CMO - 129total assets and other indications and other product candidates in-force://183and other expenses.129capital and other current or, among others supporting our current or variable annuity management program that involve significant accounting policies that we have been supporting our proprietary combination of $ unctionary management program that involves significant risk management program that targets supporting our variable annuity supporting our variable annuity supporting our capital and exposure risk management and exposure risk management program that targets total assets supporting our variable annuities.We expect to support our variable annuitmentsion supporting our variable annuity supporting our variable management program that targets total assets supporting our variable annu annuities risk management and risk management program that targets total assets supporting our variable annu annuities at least assets supporting our capital and exposure risk management and any other risk management and management of $ 130total assets and exposure risk management program that targets total assets supporting our variable annuities supporting our variable annu exposure risk management program that targets total assets supporting our variable annu\nantity alone or $ 130management program that targets total assets supporting our variable annu annuity program that support our variable annuity management program that supports our variable annuannuity requirements for thesecurities that targets total of $403.132and support program that targets total assets supporting our variable annu exposure risk management program that targets total assets and any supporting our variable annuity supporting our variable annuity supporting our variable annuity management program that supports our variable annuities supporting our variable and exposure risk management program that targets total assets and liabilities and any other exposure risk management program that targets total assets and exposure risk management program that targets total assets supporting our variable annuannuannuity management and exposure risk management program that risk management program that targets total assets and our variable annuity and variable annuSUPPORTING supporting our variable annuities supporting our variable annuity program that targets supporting our variable annuity supporting our variable annuity of $ 122total of $49and any other than supports our variable annuity that targets total assets and exposure risk management program that targets total assets and exposure risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets and any future annuity alone or supporting our variable annu management and exposure risk management program that targets total assets supporting AMX.132annuity and exposure risk management program that targets supporting our variable annuitiesupported by jurisdiction that targets total assets and risk management and exposure risk management program that targets total"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Where can information about the 2024 election of directors be found?",
        "options": {
            "A": "In the company\u2019s financial statements",
            "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders",
            "C": "In the General Instruction G(3) of Form 10-K",
            "D": "Under the 'Executive Officers' section of the report",
            "E": "In the company's quarterly earnings report",
            "F": "In the 'Delinquent Section 16(a) Reports' section"
        },
        "LLM_original_answer": [
            "Information supporting ouring our outstanding variable annuity.Supporting management of $ 2024.Requirements supporting program that applies to variable annuity management program that targets.The majority of $ 138 that targets total assets supporting our variable annuity and risk management program that targets total assets supporting our variable annuity risk program that targets total assets supporting our outstanding contracts.The remaining supporting our outstanding contracts at aqusities supporting our outstanding contracts for the majority of $ 2024.137 program that targets total assets supporting our variable annuities supporting our variable annuity risk management program that targets total assets supporting our variable annuities."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What framework did the Company use to establish criteria for internal control over financial reporting?",
        "options": {
            "A": "SOX Compliance Framework",
            "B": "ISO 9001 Standards",
            "C": "Internal Control \u2014 Integrated Framework (2013)",
            "D": "GAAP Standards",
            "E": "FASB Guidelines",
            "F": "IFRS Regulations"
        },
        "LLM_original_answer": [
            "The capital and exposure and other expenses for performance period in the Company used to the Company established assecurities supporting our variable annuity contracts and other costs of which vested PSUsertaining program that targets that targets up to variable annu\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?",
        "options": {
            "A": "Cumulative voting rights",
            "B": "One vote per share without cumulative voting",
            "C": "Two votes per share",
            "D": "Preemptive voting rights",
            "E": "Redeemable voting rights",
            "F": "Convertible voting rights"
        },
        "LLM_original_answer": [
            "Based on total assets risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annu supporting our variable ann capital and exposure risk management program that targets total assets supporting total assets supporting our capital and variable annuity supporting program that targets total assets supporting our variable annu variable ann total assets supporting our variable annuities supporting our capital and total assets supporting our capital and exposure risk management program that targets total assets supporting our product that targets total assets supporting our variable annuarts and exposure supporting our exposure risk management program that targets total assets supporting our variable annu20150295annuity.100s exposure risk management program that targets total assets supporting our variable annuity and our capital and exposure risk management program that targets total assets supporting our variable annuity management program that targets total assets supporting our capital and our capital and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity supporting our capital and supporting total assets supporting our risk management program that targets total assets supporting total assets supporting our variable annu annuity supporting our variable annuity supporting total assets supporting our capital and total assets supporting our capital and supporting our variable annu annuity supporting our program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting total assets supporting our variable annuity and exposure risk management program that targets that targets total assets supporting our risk management program that targets total assets supporting our variable annuity program that targets total assets supporting total assets supporting total assets supporting program that targets total assets supporting our variable annuity supporting program that risk management program that targets total assets supporting our variable annuities and our program that targets total assets supporting our variable annuity supporting our variable annuity supporting our variable supporting our capital and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity program that supports our variable annuity supporting our variable annuity risk management program that targets total assets supporting total assets supporting total assets supporting our variable annu supporting our program that targets total assets supporting program that targets total assets supporting our variable annu annuati targeting total assets supporting total assets supporting our product candidates supporting our product management program that supporting our capital and exposure risk management program that targets total assets supporting total assets supporting our variable annuity supporting total assets supporting total assets supporting"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?",
        "options": {
            "A": "The candidate's previous employment history",
            "B": "The candidate's age and personal interests",
            "C": "A conflict of interest impacting their representation of stockholders",
            "D": "The candidate's educational background",
            "E": "The candidate's language proficiency",
            "F": "The candidate's geographical location"
        },
        "LLM_original_answer": [
            "The program that targets total assets supporting our total assets supporting our variable annu supporting our variable annuity supporting total assets supporting our variable annuansupporting our variable annuity risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting total assets supporting our variable annuity supporting our variable annuamortargeting our total assets supporting risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuapposition our exposure supporting our variable annu\nvariable annuity supporting our variable annuity management program that targets total assets supporting total assets supporting our exposure risk management program that targets total assets supporting program that targets total assets supporting total assets supporting our variable annuity risk management program that targets total assets supporting our capital and exposure risk management program supporting our variable annuity supporting our other total assets supporting total assets supporting total assets supporting our variable annuVariable annuity supporting our capital and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting total assets supporting total assets supporting our variable ann supporting program that targets that targets total assets supporting risk management program that targets total assets supporting our variable annuity program that targets total assets supporting total assets supporting total assets supporting program that targets total assets supporting total assets supporting our variable ann and exposure risk management program that targets total assets supporting our variable annuities that supports our variable assets supporting our variable annuity total assets supporting our variable annuity supporting our variable annu variable annuity supporting our variable annuity supporting total assets supporting our exposure risk management program that targets total assets supporting our variable annu\nvariable annuity variable annuity supporting our variable annuity risk management program that targets total assets supporting total assets supporting total assets supporting our variable annu our total assets supporting our variable ann supporting program that targets total assets supporting total assets supporting our variable annuatemortargeting total assets supporting oursecurities supporting our variable annuity supporting our variable annuity supporting our variable annuq and exposure risk management that targets total assets supporting total assets supporting total assets supporting total assets supporting total assets supporting program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity assets supporting our variable annu supporting our exposure risk management program that targets total assets supporting our total assets supporting our variable annuity supporting our variable annuity total assets supporting our variable annuity supporting our variable risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable ann"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?",
        "options": {
            "A": "9.00%",
            "B": "7.50%",
            "C": "8.50%",
            "D": "6.00%",
            "E": "7.00%",
            "F": "5.50%"
        },
        "LLM_original_answer": [
            "The program that supporting our risk management program that targets supporting our variable annu\nuity and variable annuicap and exposure risk management program that targets total assets supporting our variable annuity program that targets supporting our risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity annuity program that targets total assets supporting our variable annuity supporting our variable risk management program that targets total assets supporting our variable annuities supporting our variable annuity risk management program that supports our risk management program that targets total assets supporting our variable annuchores risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuities supporting our variable assets supporting our risk management program that targets supporting our variable annuity our exposure risk management program that targets total assets supporting program that targets total assets supporting our variable annuities as of supporting our variable ann exposure risk management program that targets total assets supporting our variable annuity program that targets total assets supporting our variable ann supporting our exposure risk management program that targets supporting our variable annuity supporting total assets supporting our variable annu annuity supporting our variable annuity annuity program that targets total assets supporting our variable annuity supporting our variable annuity_variable annuity risk management program that targets total assets supporting program that targets total assets supporting our variable annu exposure risk management program that targets total assets supporting our variable annuity and our variable annuity annuity supporting our variable annuatemportion.##risk management program that targets total assets supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our variable annuity supporting our RCB and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting total assets supporting our variable annu#### Capital and total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity program that targets supporting our variable annuity risk management program that targets supporting risk management program that targets total assets supporting our variable annuities supporting our capital that targets total assets supporting our variable annuity risk management program that targets total risk management program that targets total assets supporting our variable annuities and exposure risk management program that targets supporting our total assets supporting our variable annu capital and exposure risk management program that total assets supporting our variable annuity supporting our total assets supporting our variable annuity contracts supporting our variable annuity risk management that targets total assets management program that targets total"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?",
        "options": {
            "A": "2020",
            "B": "2021",
            "C": "2022",
            "D": "2023",
            "E": "2024",
            "F": "2025"
        },
        "LLM_original_answer": [
            "To and exposure program that targets total assets supporting our variable annuity management program that targets total assets supporting our variable annu an exposure risk management program that targets supporting our exposure risk-rating risk management risk management program that targets total assets supporting our variable annuity and other than supporting our commercial and exposure risk management program that targets total assets supporting our variable ann and exposure programs that targets total assets supporting program that targets total assets supporting our variable annuity risk management supporting our variable annuity supporting our exposure risk management program that targets total assets supporting total assets supporting our variable annu annuity supporting our variable annu and exposure risk management program that targets total assets supporting our variable annuity management program that targets total assets supporting our variable annuity supporting our exposure risk management program that targets total assets supporting total assets supporting total assets supporting total assets supporting our variable annuity supporting our risk management program that targets total assets supporting program that targets total assets supporting our variable annuity supporting total assets supporting total assets supporting our risk management program that targets supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity supporting our variable annu variable assets supporting our variable annuity supporting our variable annuity supporting total assets supporting our variable annu annuance management that targets total assets supporting our capital and exposure risk management program that targets total assets supporting total assets supporting annuity supporting our variable annuity supporting our variable annuity supporting total assets supporting program that targets total assets supporting risk management program that targets total assets supporting our variable annuity risk management program that targets supporting our variable annuity supporting total assets supporting our variable annuity supporting our variable annuity supporting total assets supporting our variable annuity risk management program that targets total assets supporting our variable annu total assets supporting our capital and exposure risk management program that targets total assets supporting total assets supporting our exposure risk management that targets supporting program that targets total assets supporting total assets supporting our variable ann total assets supporting our variable annuities and exposure supporting our total assets supporting our variable annuannuity management program that targets total assets supporting our variable annuity supporting our variable annu annuity program that supports our exposure risk management risk management program that targets total assets supporting total assets supporting our variable annuity our variable annuity risk management program that targets total assets supporting our variable annuity contracts our variable ann and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuManagement Program that targets total assets supporting our variable ann"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?",
        "options": {
            "A": "No less than 120% of fair value per share",
            "B": "No less than 80% of fair value per share",
            "C": "No less than 110% of fair value per share",
            "D": "No less than 100% of fair value per share",
            "E": "Fixed amount regardless of fair value",
            "F": "No specific requirement"
        },
        "LLM_original_answer": [
            "Question and exposure risk management program that targets supporting our variable annuity supporting our exposure risk management program that targets supporting our variable annuity supporting our variable ann exposure risk management risk management program that targets total assets supporting our variable annuity programs that targets our drug candidates supporting our exposure risk management program that targets total assets supporting our variable annuity management program that targets total assets supporting program that targets total assets supporting our variable annuity supporting our exposure risk management program that targets supporting our exposure risk management program that targets total assets supporting our variable annu annuity supporting our variable annu and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity supporting our exposure management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting program that targets total assets supporting our variable annuity supporting total assets supporting total assets supporting our risk management program that targets supporting our variable annu\n_variable management program that targets total assets supporting our variable annuapplications supporting our variable annuity management program that targets total assets supporting our exposure risk management that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting total assets supporting our variable annuity contracts supporting our capital and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting our variable annuity supporting our capital and targets supporting total assets supporting our risk management program that targets supporting our variable ann exposure and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting our variable program that targets total assets supporting ourri program that targets total assets supporting our variable annuities supporting our variable annuity risk management supporting our capital and exposure risk management program that supports our capital and our variable annuity supporting our variable annuans and exposure supporting our DELig and risk management program that targets total assets supporting our variable annuity program that targets total assets supporting our variable annuity supporting total assets supporting our variable annuity management program that targets total assets supporting risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annu Exposure Management Program that targets total assets supporting our variable annu exposure risk management"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What was the required minimum net worth for PHH at December 31, 2023?",
        "options": {
            "A": "$350 million",
            "B": "$420.5 million",
            "C": "$448.3 million",
            "D": "$480 million",
            "E": "$500 million",
            "F": "$525.7 million"
        },
        "LLM_original_answer": [
            "To support total assets supporting our variable annuamd exposure risk management program that targets total assets supporting total assets supporting our mortgage and annuity supporting total assets supporting our variable annu..."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?",
        "options": {
            "A": "NYSE governance rules",
            "B": "SEC disclosure guidelines",
            "C": "Nasdaq governance rules",
            "D": "International Business Standards",
            "E": "U.S. Financial Regulations",
            "F": "Federal Trade Commission rules"
        },
        "LLM_original_answer": [
            "The and exposure risk management program that targets total assets supporting our variable annuity supporting our variable assets supporting our exposure risk management program that targets total assets supporting our product candidates supporting our variable annuity our variable risk management program that targets total assets supporting our variable annu\nannuity supporting our variable ann exposure risk management program that targets total assets supporting program that targets total assets supporting our variable annuities supporting our TSCOMP that supports our variable ann exposure risk management program that targets total assets supporting risk management program that targets total assets supporting our variable annuity risk management program that targets supporting our variable ann supporting total assets supporting our variable annu exposure program that supports our variable annuity supporting our TSCMandatory risk management program that targets total assets supporting our variable annu supporting our variable ann exposure and exposure risk management program that targets total assets supporting total assets supporting our variable annuity our variable annuity risk management program that targets total assets supporting our variable ann total assets supporting our variable annuities and our variable assets supporting our variable annu variable annuity risk management program that targets total assets supporting our variable annuity supporting our variable annu annuity supporting our exposure risk management and exposure risk management program that targets total assets supporting our variable annuity program that targets total assets supporting our variable annuity supporting total assets supporting our variable annu and variable annu capital and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuand exposure program that targets total assets supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our variable annuity risk management that targets total assets supporting our exposure risk management program that targets total assets supporting total assets supporting our variable annuity risk management program that targets total assets supporting our variable assets supporting our variable annuity variable annu\n_variable annuity supporting total assets supporting our technologies supporting our variable annuity our variable annuity supporting our variable assets supporting our exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting total assets supporting our variable annuity supporting our variable annuity risk management program that targets total assets supporting program that targets total assets supporting our variable annu risk management program that targets total assets supporting total assets supporting total assets supporting program that targets total assets supporting our variable ann assets supporting total assets risk management program that targets total assets supporting our variable annuities and variable annu exposure supporting our variable annu total assets supporting our variable annuity supporting our variable supporting our variable annuity supporting our variable annuity supporting"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?",
        "options": {
            "A": "The Chief Financial Officer",
            "B": "Independent registered public accounting firm",
            "C": "The undersigned, duly authorized person",
            "D": "The Secretary of the Board",
            "E": "The company's legal department",
            "F": "The external auditor"
        },
        "LLM_original_answer": [
            "Accordinguity supporting our variable annuity supporting our variable annuity supporting total assets supporting program that targets total assets supporting risk management program that targets total assets supporting our variable annuity risk management program that targets supporting our variable annu variable assets supporting our variable annu exposure program that supports our variable annuity supporting our variable annuity supporting our variable assets supporting total assets supporting our program that targets total assets supporting our variable annuity exposure risk management program that targets total assets supporting total assets supporting our exposure risk management that targets supporting program that targets total assets supporting total assets supporting our program that targets total assets supporting our variable annuity program that targets total assets supporting our exposure supporting our total assets supporting our variable annu supporting our variable annuity supporting our exposure risk management program that targets supporting our exposure supporting our proprietary risk management risk management program that targets total assets supporting our variable annuity program that targets total assets supporting our variable annuity supporting total assets supporting our variable annuity management program that targets total assets supporting risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuand any program that targets total assets supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our variable annuity risk management that targets total assets supporting our exposure risk management program that targets total assets supporting total assets supporting our variable annuity risk management program that targets total assets supporting our variable assets supporting our variable annuity our total assets supporting our variable annuity supporting our variable annuity that targets total assets supporting our variable annuity supporting our variable assets supporting total assets risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting total assets supporting our variable annuity supporting our variable ann exposure risk management program that targets total assets supporting program that targets total assets supporting our variable annu supporting ourtion management program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annu total assets supporting risk management program that targets total assets supporting our variable annuities and variable annu exposure supporting our variable annu total assets supporting our variable annuity supporting our variable supporting our variable annuity supporting our variable annuity supporting total assets supporting our exposure risk management program that targets total assets supporting our variable annu annuity supporting our variable annuity supporting our variable annuVariable management program that targets total assets supporting total assets supporting total assets supporting our variable annuity annuity supporting our exposure risk management program that targets total assets supporting total assets supporting our variable annu exposure risk management program that targets total assets supporting"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Where can information about the 2024 election of directors be found?",
        "options": {
            "A": "In the company\u2019s financial statements",
            "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders",
            "C": "In the General Instruction G(3) of Form 10-K",
            "D": "Under the 'Executive Officers' section of the report",
            "E": "In the company's quarterly earnings report",
            "F": "In the 'Delinquent Section 16(a) Reports' section"
        },
        "LLM_original_answer": [
            "To maintain a205total assets supporting our exposure risk management program that targets total assets supporting our variable annuity supporting our program that targets total assets supporting our variable annuity management program that supports our variable annuity management program that targets total assets supporting risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annu2017.Supporting total assets supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity supporting our variable assets supporting total assets supporting our variable annu supporting our variable annuity variable assets supporting our variable annuity supporting total assets supporting our program that targets total assets supporting our variable annuity supporting our variable assets supporting total assets risk management program that targets total assets supporting our variable annuity supporting our variable annu exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting program that targets total assets supporting our variable annu201ty management program that targets total assets supporting total assets supporting total assets supporting our variable that targets total assets supporting our variable assets supporting program risk management program that targets total assets supporting our variable annuities and our exposure risk management program that targets total assets supporting our variable assets supporting total assets supporting our variable annu an exposure risk management program that targets total assets supporting our exposure and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity supporting total assets supporting our variable annuity supporting our exposure risk management program that targets total assets supporting total assets supporting our variable annu201204 management program that targets total assets supporting our mortgage technology and variable annuity supporting our variable annuity program that targets total assets supporting our variable annuity supporting total assets supporting program that targets total assets supporting total assets supporting total assets supporting program that targets total assets supporting total assets supporting total assets supporting our program that targets total assets supporting our variable annuity assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity supporting total assets supporting our variable annuity management program that targets total assets supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting total assets supporting our variable annu capital and total assets supporting our variable annuity program that supports our variable annuity supporting our variable annuity"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What framework did the Company use to establish criteria for internal control over financial reporting?",
        "options": {
            "A": "SOX Compliance Framework",
            "B": "ISO 9001 Standards",
            "C": "Internal Control \u2014 Integrated Framework (2013)",
            "D": "GAAP Standards",
            "E": "FASB Guidelines",
            "F": "IFRS Regulations"
        },
        "LLM_original_answer": [
            "The program that targets total assets supporting total assets supporting our capital and exposure risk management that targets total assets supporting total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity and variable risk management program that targets total assets supporting our variable annuity products that targets total assets supporting our variable annuity supporting our variable annu variable annuities supporting our variable annuity risk management program that targets total assets supporting our variable annu2023Risk Management Program that supporting our variable annuity supporting total assets supporting program that targets total assets supporting total assets supporting annuity products supporting our variable assets supporting our variable ann exposure risk management program that targets total assets supporting total assets risk management program that targets total assets supporting our variable annuity products supporting our exposure risk management program that targets total assets supporting our variable annu exposure program that supports our variable annuity supporting our variable annuity risk management program that targets total assets supporting our variable annuity supporting total assets supporting our variable ann exposure risk management program that targets total assets supporting total assets supporting annuity program and variable annuity supporting program that targets total assets supporting total assets supporting our variable ann total assets supporting our variable annuities that supports our total assets supporting our variable annu201920 assets supporting our variable annuity supporting our PCDMortotal assets supporting our variable annuities supporting our variable annuity risk management program that targets total assets supporting our variable annuities supporting our variable annuity supporting our variable annuity management program that targets supporting our variable annuity products.181Capital and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets and variable annuManagement program that targets total assets supporting our variable annu variable annuity supporting our variable annuity risk management that supports our variable annuity risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting total assets supporting our variable annuity risk management program that targets total assets supporting our variable assets supporting our variable annuity variable annu\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?",
        "options": {
            "A": "Cumulative voting rights",
            "B": "One vote per share without cumulative voting",
            "C": "Two votes per share",
            "D": "Preemptive voting rights",
            "E": "Redeemable voting rights",
            "F": "Convertible voting rights"
        },
        "LLM_original_answer": [
            "What supporting our variable annuity supporting our capital and/or capital and/or other programs that targets total assets supporting our capital and/or other risk management program that targets total assets supporting our variable annuity supporting our capital and exposure risk management program that targets total assets supporting our capital and that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and other products, if approved by others may be80that targets total assets supporting our capital and exposure risk management program that targets total program that targets total assets supporting our variable annuity annuity supporting our variable annuity supporting our capital and/or exposure risk management program that targets total assets supporting our capital and management program that targets total assets supporting our variable annu...\nannu\nmaintenance risk management program that targets total assets supporting our variable annu78total assets supporting our variable annuities supporting our variable annuity program that targets total assets supporting our variable annu78supporting exposure risk management program that targets total assets supporting our variable annuity annuity and exposure risk management program that targets total assets supporting our variable annu exposure and exposure risk management program that targets total assets supporting our variable annu\nannuity supporting our exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annu...\nSupporting our exposure risk management program supporting our capital and/or if at all of exposure and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annu78annuity risk management program that targets total assets supporting our capital and exposure risk management program variable annuity supporting our products, if approved products, if applicable to maintain a capital and/or any other than at least one or exposure risk management program that targets total assets supporting our capital and other than targets total assets supporting our capital and exposure risk management program that could support our variable annuity annu\non our capital and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuities supporting our variable annu\nmaintenance program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annu exposure risk management risk management program that targets total assets supporting our variable annuities supporting our variable exposure risk management program that targets total assets supporting our variable annuity supporting our variable annu\nmaintuance risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our capital and supporting"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?",
        "options": {
            "A": "The candidate's previous employment history",
            "B": "The candidate's age and personal interests",
            "C": "A conflict of interest impacting their representation of stockholders",
            "D": "The candidate's educational background",
            "E": "The candidate's language proficiency",
            "F": "The candidate's geographical location"
        },
        "LLM_original_answer": [
            "Based on total assets supporting our variable annu exposure and other related to the exposure risk management program that targets total assets supporting our variable annuity annuity supporting our variable annuity management program supporting our exposure risk management program supporting our exposure risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annuity and exposure risk management program that is a capital and exposure risk management program that targets total assets supporting our exposure risk management program that were recognized in the Company did notional 24Core Scientific, and other than the Company recognized in the Company\u2019s consolidated statements were recognized in the Company recognizes the Company\u2019s variable annuity contracts for the requisite service period.95Core Scientific, less actual results that is supported by the following the Company\u2019s consolidated financial instruments that were recognized in accordance with respect of the foregoing our variable annuity management program that targets total assets supporting our variable annuity and variable annu annuity and other than the Company\u2019s exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our exposure management program that targets total assets supporting our variable annu exposure risk management program that targets total assets supporting our variable annu annu annuity supporting our variable annuities supporting our variable annuances supporting our variable annuity supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our variable annuity annuity supporting our variable annuity risk management program that targets total assets supporting our capital and exposure risk management program assets supporting our exposure risk management of $ 23Core Scientific, and exposure and exposure and exposure and exposure risk management program that targets total assets supporting our capital and other than remaining net of $ 95Core Scientific, less than targets total assets supporting program that targets total assets supporting our variable annuity contracts supporting our variable annu exposure risk charges of the total assets supporting our exposure risk exposure risk exposure and other than exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity risk management program that targets total assets supporting our capital and exposure risk management program that is supporting our variable annuity risk management program that targets total assets supporting our variable annu exposure risk management program that targets total assets supporting our variable annu annu annu total assets supporting our variable annu exposure risk management program that targets total assets supporting our variable annu annuity annuity annuity exposure risk management that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?",
        "options": {
            "A": "9.00%",
            "B": "7.50%",
            "C": "8.50%",
            "D": "6.00%",
            "E": "7.00%",
            "F": "5.50%"
        },
        "LLM_original_answer": [
            "The capital and exposure risk management program that targets total assets supporting our capital and distributed above total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity management program that targets total assets supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity annuity and exposure risk management program that targets total assets supporting our exposure risk management program that supports our consolidated financial assets supporting our variable annuity annu##table 143##table 131##Table 1. Upon maintenance program that targets total assets supporting our variable annuity annuity and other than targets total assets supporting our variable annu...Supporting our exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting our capital and other charges that targets total assets supporting our variable annuity supporting our variable annuity supporting our variable annuity risk management program that supports our variable annuity program that includes total assets supporting our variable annu Exposure Risk Management of approximately $ 229##annuity assets supporting our variable annuity supporting our variable annuity supporting our variable annuity supporting our variable annu supporting our variable annuity risk management program that targets total assets supporting our variable annuity program and other than supports our variable annuity risk management program that targets total assets supporting our variable annuity annuity annuity exposure risk management program assets supporting our variable annuity Risk Management Program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity and other than support our exposure risk management program that targets total assets supporting our variable annuity and other information on the net of the remaining in the variable annuity annuity annuity risk management program that were completed in the variable annuity annuity supporting the total assets supporting the variable annuity support of $ 7.Exposure risk management program includes total assets supporting our variable annuity and other than includes total assets supporting the capital and other than supports our variable annuity risk management program that targets total assets supporting our variable annuity and exposure risk management program includes total assets supporting our distributed through the exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity and exposure risk management risk management program that targets total assets supporting our variable annuity program assets supporting our variable annu exposure risk management that targets total assets supporting our variable annuity supporting our variable annuity management program that targets total assets supporting our variable annuity supporting our variable annuity variable annuity supporting our exposure risk management"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?",
        "options": {
            "A": "2020",
            "B": "2021",
            "C": "2022",
            "D": "2023",
            "E": "2024",
            "F": "2025"
        },
        "LLM_original_answer": [
            "To the following the following and other than total assets supporting our variable annuity risk management\u2019s management believes. exposure and/or as of our variable annu exposure risk management program supporting our variable annuity annuity annuity annuity and exposure risk management program that requires a capital and exposure risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annu supporting our variable annuity contracts supporting a capital and exposure risk management program that targets total assets supporting our variable annuity management program that targets total assets supporting our variable annuity annuity exposure risk management program that targets total assets supporting a capital and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annu exposure risk management program assets supporting our variable annuity supporting our investment program that targets total assets supporting our variable annuity annu\nuity program that supports our exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our bank and exposure risk management program that are subject to total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annu exposure risk management program assets and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our capital and exposure risk management that targets total assets supporting our variable contracts and variable annuities supporting our exposure risk management program that targets total assets supporting our interest rate risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annu exposure risk management supporting our capital and variable annu exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuendoing our variable annu exposure program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuityuemaintenance risk management program that targets total assets supporting our variable annuityesonsecurities supporting our exposure risk management program that targets total assets supporting our variable annuity annuity annu annuability management program that targets total assets supporting our"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?",
        "options": {
            "A": "No less than 120% of fair value per share",
            "B": "No less than 80% of fair value per share",
            "C": "No less than 110% of fair value per share",
            "D": "No less than 100% of fair value per share",
            "E": "Fixed amount regardless of fair value",
            "F": "No specific requirement"
        },
        "LLM_original_answer": [
            "What assets supporting our variable annuity supporting our variable annuity targets total assets supporting our variable annuities supporting our variable annuity risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity exposure risk management of the Human Medication risk management programs that targets total assets supporting the FDA, or exposure and other than could materially adversely affective annuity and exposure risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annu exposure risk management program that support our variable annuity risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity annu supporting our variable annuities supporting our capital and exposure risk management program that targets total assets supporting our variable annuity program that targets total assets supporting our variable annuity supporting our variable annuity annu\ufeff exposure risk management program that targets total assets supporting our variable annuity program that targets total assets supporting our variable annu exposure risk management program that targets total assets supporting our variable annu exposure risk management program that targets total assets supporting our variable assets supporting our variable annu program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity supporting our variable annuity risk management program that targets total assets risk management program that targets total assets supporting our variable annu\nsupporting our variable annuity risk management program that support that targets total assets supporting our capital and exposure risk management programs that targets total support our variable annuity annuity program that targets total support our drug candidates may be\u00ad\u201480If we support our business practices supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuities supporting our program that targets total assets supporting our variable annuity supporting our variable annuity supporting our variable annu exposure supporting our variable annu\n... annuity program that targets total assets supporting our capital and maintain a capital and/orb exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity risk management that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuities supporting our variable annuities supporting our variable annuity supporting our variable annuity supporting our variable annuity supporting our exposure risk management that targets total assets supporting our variable annuity supporting our variable annuity supporting our variable annuity"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What was the required minimum net worth for PHH at December 31, 2023?",
        "options": {
            "A": "$350 million",
            "B": "$420.5 million",
            "C": "$448.3 million",
            "D": "$480 million",
            "E": "$500 million",
            "F": "$525.7 million"
        },
        "LLM_original_answer": [
            "The following the changes in our capital and other derivative instruments supporting our capital and disclosure risk management program that management program that targets that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and exposure risk management program supporting our variable annuity and/orbExposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our exposure risk management program that supports supporting our exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and historical experience and other than supports our capital and related to the following our capital and exposure risk management program that targets total program that targets total assets supporting our variable annuity supporting our variable annu exposure risk management program that targets total assets supporting our HECAPRithmaintenance risk management program that targets total assets supporting our variable annuity supporting our capital and exposure risk management program that targets total assets supporting our variable annuity contracts that targets total assets supporting our capital and supporting our variable annuity program that targets total assets supporting our variable annuity annuity annuityouderespons supporting our capital and related to the variable annuity and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting our variable annuity risk management that targets total assets supporting our variable annuity program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity supporting our capital and exposure risk management program that targets total assets supporting our variable annuity supporting our capital and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity annu\ufeff exposure risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our capital and other than supports our capital and exposure risk management fees and exposure risk management program that targets total assets supporting our capital and related to thesesupported by maintaining a liability liquid reverse mortgage loaneduction risk management program that targets total assets supporting our variable annu78Total assets supporting our judgement and/orbExposure risk management program that targets total assets supporting our variable annu88 and other liabilities and other than supports our financing liabilities, net cash flows supporting our capital and exposure risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annu exposure risk management program that targets total assets supporting"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?",
        "options": {
            "A": "NYSE governance rules",
            "B": "SEC disclosure guidelines",
            "C": "Nasdaq governance rules",
            "D": "International Business Standards",
            "E": "U.S. Financial Regulations",
            "F": "Federal Trade Commission rules"
        },
        "LLM_original_answer": [
            "What is that targets total assets supporting our capital and/or support our capital and that targets total assets supporting our variable annuity and exposure and/or exposure risk management program that targets total assets supporting our variable annu\nuity management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and exposure and exposure programs that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and variable annuities supporting our variable annuity supporting our variable annu exposure risk management program that targets total assets supporting our capital and/or other than is a capital and/or any of any of any of the program that targets total assets supporting our or may be77 program that targets total assets supporting our capital and other programs that targets total assets supporting our capital and/or total assets supporting our variable annuity program that may be80 and exposure risk management program that targets total assets supporting our variable annuity program that targets total assets supporting our capital and/orient and exposure risk management program that targets total assets supporting our capital and other product candidates considered for profit and exposure risk management program that targets total assets supporting our variable annuity management program that targets total assets supporting our capital and maintain a capital and exposure and/or maintain a capital and/orient program that targets total assets supporting our capital and exposure program that targets total assets supporting our variable annuity supporting our product candidates that targets total assets supporting our variable annuity supporting our product candidates that targets total assets supporting our capital and/or maintain a total assets supporting our capital and other programs that targets total assets supporting our variable and exposure risk management program that targets total assets supporting our variable annuity supporting our capital and/orient programs that we may not only a capital and supplements that targets total assets supporting our variable annuity risk management programs that targets total assets supporting our variable annuity supporting our capital and exposure risk management program that targets total assets supporting our variable annu exposure and exposure risk management program that targets total assets supporting our variable annuities that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuQuestion:\u202279 and the product launches or80and other product that targets total assets supporting our variable annuity supporting our capital and exposure and exposure risk management that targets total assets supporting our variable annu\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?",
        "options": {
            "A": "The Chief Financial Officer",
            "B": "Independent registered public accounting firm",
            "C": "The undersigned, duly authorized person",
            "D": "The Secretary of the Board",
            "E": "The company's legal department",
            "F": "The external auditor"
        },
        "LLM_original_answer": [
            "Who is that targets total assets supporting a capital and exposure and exposure and exposure risk management program that targets total assets supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our variable annuity and/or any future product candidates supporting our competitors may, or other future product candidates supporting our competitors may in the capital and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and exposure risk management that supporting our capital and/or other programs that supports our capital and/or total assets supporting our exposure risk management program that targets total assets supporting our capital and/or total assets supporting our exposure risk management program that capital and exposure risk management program that targets total assets supporting our capital and other programs that targets total assets supporting our program that targets total assets supporting our current or any future product program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annuities supporting our variable annuity supporting our variable annu exposure risk management program that targets total assets supporting our program that targets total assets supporting our variable annuementotal assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity management that targets total assets supporting our variable annu annu\nsupporting our variable annuity risk management program that supports our variable annuity program that targets total assets supporting our variable annuity annuity supporting our capital and exposure risk management program that targets total assets supporting our variable annu supporting our variable annuity risk management program that targets total assets supporting our variable annuities supporting our variable annuity and exposure risk management program that targets total assets supporting our capital and exposure risk management program supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our capital and/or additional exposure risk management risk management program that targets total assets supporting our variable annuity annu annuity risk management program that targets total assets supporting our capital and exposure and other than exposure risk management program that targets total assets supporting our competitors may in the market exclusivity annuity annuity or other future product candidates supporting our capital and exposure risk management program that targets total assets supporting our variable annuity supporting our ongoing clinical trials may, or other future product that targets total assets supporting our exposure risk management of 85total assets supporting our exposure risk management program that support our variable annuity risk management program that targets total assets supporting our variable annuities supporting our variable annuities supporting our variable annuity risk management program that targets total"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Where can information about the 2024 election of directors be found?",
        "options": {
            "A": "In the company\u2019s financial statements",
            "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders",
            "C": "In the General Instruction G(3) of Form 10-K",
            "D": "Under the 'Executive Officers' section of the report",
            "E": "In the company's quarterly earnings report",
            "F": "In the 'Delinquent Section 16(a) Reports' section"
        },
        "LLM_original_answer": [
            "The following our variable annu\nmaintenance program that occurred in 77total assets supporting our variable annuity program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our variable annuity annuities that targets total assets supporting our exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annu annuity risk management program that targets total assets supporting our variable annuities supporting our variable annuity supporting our exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity annuity supporting our variable annu exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity risk management program that targets total assets supporting our variable annuity annuity annuity annuity and exposure risk management of $1.77\nSupporting our variable annuity supporting our exposure and related to our variable annuity risk management program that targets total assets supporting our capital and exposure risk management program costs associated with our exposure risk management program of $7.77total assets supporting our variable annuity annuity risk management program that targets total assets supporting our total assets supporting our exposure risk management program that targets total assets supporting our variable annuities supporting our variable annuity supporting our 2024 million that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuities supporting our variable exposure risk management program that targets total assets supporting our variable annuity supporting our variable annu annuities supporting our variable annuities supporting our equity method that targets total assets supporting our capital and related to the variable annuity of $2Amountsupporting total assets supporting our capital and exposure risk management program that targets total assets supporting our capital and related to the variable annuities supporting our equity method that targets total assets supporting our exposure and exposure risk management that targets total assets supporting our exposure program that targets total assets supporting our variable annuity risk management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annu exposure supporting our variable annuity supporting our variable annuity Risk Management Program that targets total assets supporting our capital and related to targets total assets supporting our variable annuity supporting our capital and exposure risk management program that targets total assets supporting our program that targets total assets supporting our variable annu annuity risk"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What framework did the Company use to establish criteria for internal control over financial reporting?",
        "options": {
            "A": "SOX Compliance Framework",
            "B": "ISO 9001 Standards",
            "C": "Internal Control \u2014 Integrated Framework (2013)",
            "D": "GAAP Standards",
            "E": "FASB Guidelines",
            "F": "IFRS Regulations"
        },
        "LLM_original_answer": [
            "Questioning total assets supporting our variable annuities supporting our variable annuity liabilities and exposure risk management program that targets total assets supporting our variable annuities supporting our variable annuity program that targets total assets supporting our variable annuities and variable annuementure exposure risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annuity and variable annuity supporting our variable annuity supporting our variable annuity risk management program that targets total assets supporting our variable annuity and variable annuity contracts supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity annuity management program that targets total assets supporting our capital and exposure risk management program that targets total assets supporting our variable annuities and other than supporting our investment program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity supporting our variable annuity and supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity program that supports our variable annuity and exposure supporting our variable annu149total assets supporting our variable annuity supporting our variable annuity risk management program that targets total assets supporting our variable annuity and exposure and exposure risk management program that targets total assets supporting our variable annu exposure risk management program that targets total assets supporting our variable annuity contracts and variable annuMaintuationuity risk management program that targets total assets supporting our variable annuity contracts supporting our variable annuity and exposure risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annuity contracts and total assets supporting our capital and supporting our variable annuity annuity contracts that targets total assets supporting our variable supporting our capital and exposure risk management program that targets total assets supporting our variable annuancesupporting our variable annuity supporting our variable rate of $4. See \u201cdividication program that targets total assets supporting our variable annuities and exposure risk management program that targets total assets supporting our exposure risk management program that targets total assets supporting our variable annuity contracts supporting our variable annuity targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annu supporting our variable annuity contracts supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity program that targets total assets supporting our variable annuity and exposure risk management program that targets total assets supporting our variable annuity program"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?",
        "options": {
            "A": "Cumulative voting rights",
            "B": "One vote per share without cumulative voting",
            "C": "Two votes per share",
            "D": "Preemptive voting rights",
            "E": "Redeemable voting rights",
            "F": "Convertible voting rights"
        },
        "LLM_original_answer": [
            "H.SUM. We qualify as U.S. federal income tax U.S. We fail to REIT for U.S. federal income tax purposes. U.S. U. We qualify as U.S. We U.S. U.S. U.S. U.S. For U.Sources to fail to U.S. U.S. We U.S. U.SEC. U.S. U.S. We U.S. U.S. federal income tax for U.S. To U.S. For U.S. federal income tax purposes tax purposes for U.S. We have failed to fail to fail to fail to which REIT U.S. U.SUM. If wequalifying purposes for U.Sources for U.S. federal income tax purposes.U.S. If we to qualify as a REIT for U.S. federal income tax purposes.U.Similar to U.S.52income tax purposes U.S. federal income tax purposes for U.S. We U.S. federal income tax purposes. U.S. If we U.S. For U.S. If we qualify as a U.S. U.S. If we to fail to which would fail to qualify as a REIT for U.S.52U.S. federal income tax purposes.U.S.52U.S. U.S. federal income tax law tax law purposes for U.S.59qualify U.S. for U.S. We may fail to fail to fail to U.S. federal income tax U.S. federal income tax U.Secapart. We qualify as a REIT for U.S. federal income tax purposes of U.S. We can U.S. We are U.S. federal income tax purposes, or U.S. We have to U.S. We have U.S.59U.Such as a U.Secentail REIT for U.S. federal income tax U.S.58failing as U.SEC. federal income tax purposes for U.S.52, or U.S. If we to fail to fail to U.S. federal income tax purposes for U.S.52U. We also to fail to U.S. federal income tax purposes. U.S.104. or to U.S. For U.S. to fail to fail to fail to U.S.52continue to fail to fail to U.S. For U.S. federal income tax for U.S. federal income tax U.Sources as a U.S. U.S. U.S. U.Secorporate U.S. U.Secorporate U.S. If"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?",
        "options": {
            "A": "The candidate's previous employment history",
            "B": "The candidate's age and personal interests",
            "C": "A conflict of interest impacting their representation of stockholders",
            "D": "The candidate's educational background",
            "E": "The candidate's language proficiency",
            "F": "The candidate's geographical location"
        },
        "LLM_original_answer": [
            "What core principle:\u2022 (as well before the following five steps are employed to the Company\u2019self:\u2022:\u2022 that core principle:\u2022 that:\u2022\u2022\u2022\u2022\u2022:\u2022\u2022 the following five steps are applied to achieve that core principle:\u2022 the following the Company\u2019s core principle:\u2022\u2022\u2022\u2022\u2022\u2022\u2022 that effective date:\u2022\u2022 that halving that effective date of that digital asset:\u2022 that core principle is applied to which is applied to achieve that term of the following the core principle:\u2022\u2022\u2022 The following two steps are applied to achieve that core principle:\u2022\u2022\u2022table 63that table:\u2022table:\u2022\u2022\u2022\u2022\u2022 that is applied to achieve that effective:\u2022, as well as of that core:\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022 that:\u2022 the Company\u2019settaindexamine:\u2022\u2022\u2022The following two additional steps are applied to achieve that core principle:\u2022\u2022 The following five steps:\u2022\u2022table 51of the following five steps are applied to achieve that Company\u2019s self-mining that digital asset:\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022 that isometrically, in that Bitcoin network hash rate of that core principle:\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022 that core principle:\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022 that core principle:\u2022. The following that are applied to the following halving that the following two steps are applied to the Company\u2019s hash rate of the bitcoin mining rewards and the Company\u2019s core principle:\u2014the Company\u2019s difficulty index:\u2022.2.5. On the Company\u2019s Bitcoin mining rewards to be\u00ad\u00ad\u00ad\u2022\u2022\u2022 that core:\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022:\u2022\u2022\u2022\u2022 that digital asset:\u2022\u2022 that core principle:\u2022 that weaved that core principle:\u2022 that core principle:\u2022that core principle:\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022.1.2.that core scientific research, 2023. The following that halvingestimatedigital asset class=\u201d\u2022table 2020. The following halvingestimation of the following five steps are applied to achieve that the Company:\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022\u2022 53\u2022\u2022\u2022\u2022 (or its blockchain network hash rate of bitcoin mining reward that halting that is achieved by that core principle:\u2022 the core principle:\u2022\u2022,"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?",
        "options": {
            "A": "9.00%",
            "B": "7.50%",
            "C": "8.50%",
            "D": "6.00%",
            "E": "7.00%",
            "F": "5.50%"
        },
        "LLM_original_answer": [
            "BUNTABLE 225##table 226##table 226##table 226##table fair value adjustments.225##table 226##UNTABLE TABLESCHEDULE##UNTABLE 226##UNIUCYTABLE UNIVERS and debt fair value adjustments.226##table 2025##table 226##LEASE OBLADEQUUNTABLE UNTABLE 226##table 226##table 226##table 201##table 226##table 202##table obligations and other obligations and other table 226##table 226##table 201##table obligations and other lease obligations and debt lease obligations and debt fair value adjustments and debt fair value adjustments.226##table 202##table 226##table 226##table 2015##table 225##UNTABLE 202##table obligations and debt fair value obligations and debt obligations and lease obligations and debt fair value adjustments and debt fair value adjustments.226##table adjustments to debt obligations and other obligations and debt fair value adjustments to lease obligations and debt fair value adjustments.226##table 226##table 202##table 2025##table 202##UNTABLE 225##table UNVARIABLESAND UNRENTABLE##UNTABLE 251##TABLE 226##table 202##table obligations and debt obligations and debt fair value adjustments.226##table 202##table 202##table fair value adjustments.225##table 226##table 225##table 226##table 2025%UNTABLE 226##table 226##table 225##table 226##table 226##table 226##table 2023##table 202##table 226##table 226##table 226##table 202##table obligations and debt fair value adjustments.225##UNI##UNTABLE 226##table table 202##table 225##table 226##table 201##TABLE TABLE OF LEASESS##UNUNTABLE 226##UNITS (D and debt fair value adjustments.226##table 226##table fair value adjustments related to table 226##table 226##UNFAUNFAVISC lease obligations and debt fair value adjustments.225##table 2023##table 226##table fair adjustments and the lease obligations and debt fair value adjustments.225##table 226##table 25##UNTABLESPLITABLE LEASESSCREDIT OBLASBENDEBITING & UNOCELEAS##UNRECLAIMEDWARDS"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?",
        "options": {
            "A": "2020",
            "B": "2021",
            "C": "2022",
            "D": "2023",
            "E": "2024",
            "F": "2025"
        },
        "LLM_original_answer": [
            "During this section 52and borrowings interest expense on our borrowings interest expense on our borrowings interest expense on our borrowings interest expense on our borrowings interest rate of the following the following the net interest expense and borrowings interest expense and our borrowings interest expense.\u2022Interest expense on our deposits interest expense on our deposits interest expense on our business combination of the net of our business interest expense expense of our borrowings interest expense and borrowings interest expense and our deposits interest expense expense, which is shown as a total assets and our borrowings expense expense interest expense and other than 56and borrowings interest expense interest expense on our borrowings interest expense on our borrowings interest expense on our borrowings interest expense on our borrowings interest expense.\u2022Interest expense on our interest expense on our borrowings interest expense on our borrowings interest expense on our interest expense on our interest expense on our borrowings interest expense on our financial institution interest expense on our borrowings interest rate of our borrowings interest expense on our borrowings interest expense on our borrowings interest expense on our borrowings interest expense and borrowings interest expense expense and borrowings interest expense.\u2022Interest expense on our interest expense on our borrowings interest expense expense on our borrowings interest expense expense expense on our borrowings interest expense expense on our interest expense expense and our borrowings interest expense expense expense and borrowings interest expense and borrowings interest expense and borrowings interest expense on our interest expense on our interest expense and borrowings interest expense and borrowings interest expense.\u2022Interest expense, net of our deposits interest expense and $1, which we have been paid in each of the assets and net interest expense and net income tax-freeformulations and to which we are not considered as well as well as of Eastern Bank Secured in our financial institutions interest expense on our business combination of our business combination of our business and borrowings expense expense expense expense expense expense expense expense and Eastern Banking\u2019s interest expense expense expense expense expense expense expense and borrowings total net of the net of both deposit interest expense and other than the same day-to which is not otherwise known as well as a part of the Mergermanagements interest expense on our business combination with respect to be part of Eastern Bank Securedgessecurities expense and the Mergermanagements interest expense on our business combination of Eastern Bank CAMEX\nAnswering interest expense on our net of the net of the following the following the previous year over the following the net of our net of our other than we are required to the table 2.ITEM "
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?",
        "options": {
            "A": "No less than 120% of fair value per share",
            "B": "No less than 80% of fair value per share",
            "C": "No less than 110% of fair value per share",
            "D": "No less than 100% of fair value per share",
            "E": "Fixed amount regardless of fair value",
            "F": "No specific requirement"
        },
        "LLM_original_answer": [
            "What is a.i, communities and safety and safety and safety and for citizens, and mobile cameras and safety and safety and mobile and communities and safety and safety, communities and to increase safety for citizens, communities and safety and communities and our mobile cameras, communities, as well as well-being and safety and safety for citizens, communities and communities, communities and for citizens and communities and safety and safety and safety and safety and safety for communities and communities and communities and communities and mobile and communities and mobile cameras, communities and safety and safety and safety for communities and communities and to increase safety and safety for citizens, communities and communities and for communities and safety and, communities and safety and safety and safety, communities and communities and, communities and safety and mobile cameras and to increase visibility and safety and safety, communities and to communities, communities and mobile cameras, communities and mobile cameras, communities and mobile and our accountability and safety, communities and/orchest, communities and commercial and royalty and our company, and we believe and royalty and we believe that we believe that may increase visibility and safety and safety and weas we, communities and we may be able and our mobile and safety, communities, communities and other cameras, communities and our business and other cameras, communities and safety and safety and to increase safety and safety and we citizens, communities and safety for citizens, as well-being and safety and safety for citizens, communities and communities and/or mobile cameras and for communities and safety and to increase safety and safety and communities and safety for citizens, communities and safety and communities and communities and communities, or any of the safety and other cameras, visibility, as well as a\nincrease visibility, as described as of our company, respectively and we believe and our mobile cameras and if approved and safety and communities and we are citizens, communities and mobile cameras, communities and safety and safety for citizens, which may increase visibility, respectively, and we believe that may increase visibility, if we are increased visibility and our ability to increase visibility and safety for mobile and our stockholders and for citizens, and although we believe that we believe and communities and mobile and our ability and other cameras, communities and other than can increase safety, and mobile cameras, and mobile and safety and safety and safety and safety and communities and communities. communities, as well-being and safety and mobile and safety and to increase and accountability and accountability and to increase safety and safety for communities and to increase safety and to increase safety and communities and to increase safety and for communities and mobile cameras, as well-being and to increase safety and safety for"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What was the required minimum net worth for PHH at December 31, 2023?",
        "options": {
            "A": "$350 million",
            "B": "$420.5 million",
            "C": "$448.3 million",
            "D": "$480 million",
            "E": "$500 million",
            "F": "$525.7 million"
        },
        "LLM_original_answer": [
            "What was previously performing the Servicing and/or other factors which may continue to which may continue to which may adversely affecting the servicerentireg.Income up to the subservicing and subservicing the servicers.The following the subservicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and/or Servicing and Subservicing Subservicing and Subservicing and/or Subservicing the registrants and Subservicing the subservicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing the subservicing and Subservicing.Servicing and Subservicing and Subservicing and Subservicing the Servicing and other than the registranticipation and Subservicing and our common stockholders and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and other than Subservicing and Subservicing and Subservicing and Subservicing and Subservicing the servicers and/or Subservicing and Subservicing and Subservicing and Subservicing and Subservicing the issuance of the servicerservisioned Subservicing and Subservicing the subservicing.Servicing and Subservicing and/orientry was previously performing the subservicing and Subservicing the Subservicing and Subservicing and Subservicing the servicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and/or the subservicing and Subservicing and Subservicing.Servicing and Subservicing and Subservicing and subservicing.Servicing and Subservicing.Servicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing the servicerservic Subservicing and Subservicing and Subservicing the servicer and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and/or subordinated Servicing and/orienter was previously unservicing and/or other than the servicers.The table 2024ITEM 52The Management and/or the Subservicing and/or Subservicing and/or Subservicing and Subservicing and Subservicing and subservice Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and Subservicing and"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?",
        "options": {
            "A": "NYSE governance rules",
            "B": "SEC disclosure guidelines",
            "C": "Nasdaq governance rules",
            "D": "International Business Standards",
            "E": "U.S. Financial Regulations",
            "F": "Federal Trade Commission rules"
        },
        "LLM_original_answer": [
            "The corporate office of course offt Southern is located at 1. The corporate office of Great Southern is located at 219 Great Southern is located at 1.219 Warrantions of the corporate office of Great Southern is located at 218 Great Southern is located at 218 Great Southern is located at 219 West Street 218. The corporate office of Great Southern Southern business loans of Great Southern office of Great Southern office of Great Southern Business Loans at 218 Great Southern Business Loans of record of Great Southern is located at 1. The corporate office of Great Southern is ase corporate office of Great Southern is located at least located at 218 located at 218 N/American office of Great Southern Bank of Great Southern Bank Street is located at 219 E Southern office of Great Southern office of Great Southern business loans of Great Southern is located Southern is located at 218 Great Southern is located at 1.219 W. The corporate office of Great Southern office of Great Southern is located at 1. The corporate office of Great Southern is ams of Great Southern Business Loans is located at 218218 SOUTSOUTSUPPORTIONS of Great Southern business loans and/or Great Southern is located at 1. The corporate office of the Great Southern business loans of the corporate office of Great Southern business loans of the Great Southern business loans of Great Southern business loans of Great Southern office of 218The corporate office of the corporate office of Great Southern business loans of Great Southern Business Loans Great Southern office offtest Southern office of the corporate business loans, business of Great Southern Business Loans is located at 219 Walthomissions of Great Southern is located at 1 Southern is located at 1. NORT business loans and/or corporate office of Great Southern is located at 218 at 218 Southwestern Southern is located at 218218218218 Walth Southern Bank of Great Southern office of 218218218218Great Southern is located at least Southern is located at 218218218The corporate office of Great Southern, as well of Great Southern is located at 218,2180 corporate office of 218 Great Southern office of the corporate office of Great Southern Winter Street, the corporate office of our business office of Great Southern is located at  Great Southern is located at 218218218Great Southern is located ations of our corporate office of Great Southern Bank of the corporate office of Great Southern office of the corporate office of the corporate office of Great Southern business office of Great Southern business loans of Great Southern is located at 218 N218 N/A"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?",
        "options": {
            "A": "The Chief Financial Officer",
            "B": "Independent registered public accounting firm",
            "C": "The undersigned, duly authorized person",
            "D": "The Secretary of the Board",
            "E": "The company's legal department",
            "F": "The external auditor"
        },
        "LLM_original_answer": [
            "According to us, and generative artificial intelligence to us, and the providers of our current or the providers of these providers of these providers of these generative artificial intelligence of these generative artificial intelligence to us, and the providers of our providers of our current or the providers of our providers of these generative artificial intelligence tools may not meet the providers of the providers of the providers of these generative artificial intelligence tools to which may not to us, and the providers of these generative artificial intelligence to us, and/or may not to the providers of our product candidates of the providers of the providers of our providers of our current or providers of our current or may not meeting to us, and the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of the providers of these generative artificial intelligence tools to the providers of the providers of the providers of the providers of these generative artificial intelligence tools to us, and/or the providers of our product candidates for the providers of our current to our current and the providers of these generative artificial intelligence tools to the providers of our providers of the providers of the providers of the providers of our current or the providers of our current or the providers of our providers of the providers of the providers of the providers of these generative artificial intelligence tools to us, and the providers of our current or providers of these generative artificial intelligence tools to us, and the providers of the providers of the providers of the providers of the providers of the providers of the providers of the treatment with respect to us, and/or the providers of the providers of our providers of the providers of these current or the providers of these providers of our providers may not meet our current or the providers of the providers of these generative artificial intelligence to us from the providers of our generative artificial intelligence tools that we may not to which may not to us, and the providers of our common stockholders of our current or the providers of the providers of the providers of our providers of these generative artificial intelligence providers of the providers of our providers of our current or other current or other than we may not to our current tools to us, and the providers of the providers of the providers of the providers of these generative artificial intelligence tools to us, and/or providers of which we may not meeting these generative artificial intelligence providers of these providers of the providers of these generative"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Where can information about the 2024 election of directors be found?",
        "options": {
            "A": "In the company\u2019s financial statements",
            "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders",
            "C": "In the General Instruction G(3) of Form 10-K",
            "D": "Under the 'Executive Officers' section of the report",
            "E": "In the company's quarterly earnings report",
            "F": "In the 'Delinquent Section 16(a) Reports' section"
        },
        "LLM_original_answer": [
            "The 1.5 million, respectively.Supply RMBRMB Supply Chain Chain Chain Chain Chain Chain Chain Chain 5 million, respectively.Supply chain and 1.5 million, respectively.Supply million, 1.5.6 million, respectively.Supply million, 1. 1. Supply Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain, respectively.Supply. Supply Chain Chain Chain Chain Management of 1.5 million and 1.5 million, respectively.Sup 1.5 million, respectively, respectivelySupply Chain Management of RMBSCCOSTC. 1.3 million, respectively.Supply chain chain chain, respectively.Supplying, respectively.Supply.5 million, respectively.Supply million, respectively.Supply chain Management of the 1.6 million, respectively.3 million, respectively.Supplying.5 million, respectively.Supplementary, respectively.Supply chain chain Supply Chain Chain Chain Chain Chain Chain Chain Supply Chain Chain Chain 1. Supply Chain Chain Management and 1.3 million, respectively.Supply 2 million, respectively.Supply, respectively, respectively.Supply.5 million, respectively.Supply 3 million, respectively.Supply chain and 1.3 million, respectively.Supply Chain Management Chain Management of 1 million, and 1.1.5 million, respectively.Supporter million, respectively.Supply Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Management of 1. Supply Chain Management of 3.5.5 million, respectively.Sup 1.2 million, respectively.Supply, respectively.Supply 1.5 million, respectively, 3 million, respectively.Supply Chain Management and 1. 1. Supply Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain Chain, respectively, respectively.Supply Chain, respectively.Supply chain, respectively.Supply Chain Chain Management and 1.5 million, respectively, respectively.Supplement, respectively.Supply Chain Management Chain Supply Chain Chain Chain Chain Supply Chain Chain Chain Chain 2. Supply Chain Chain Chain Chain Chain Chain Supply Chain 1 million, respectively.Supply million, respectively.Supply. Supply Chain Management of 1. Supply Chain Chain, respectively.Supportable million, respectively.Sup5 million, respectively.Supply chain, respectively.Supply. Supply Chain Management Chain Chain Chain Chain Chain Chain Management of Supply Chain Chain Chain Chain, respectively.Supply 1. Supply Chain Chain Chain Chain Management and 1.5 million, respectively, respectively.Supplying,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What framework did the Company use to establish criteria for internal control over financial reporting?",
        "options": {
            "A": "SOX Compliance Framework",
            "B": "ISO 9001 Standards",
            "C": "Internal Control \u2014 Integrated Framework (2013)",
            "D": "GAAP Standards",
            "E": "FASB Guidelines",
            "F": "IFRS Regulations"
        },
        "LLM_original_answer": [
            "What is a participant and our current and the following the separation of the Company participating whole life insurance, as well-being whole life insurance, as well-being whole life insurance company\u2019s business practices related to the following the Company\u2019s life insurance regulation and non-participantagonistbettower and the Company\u2019s securities and/or non-participantagonisherisks related to the underlying our of the Master Separation Financial Condition Factors Related to the Company\u2019s and non-recognitionRisk Factors and whole life insurance and variable annuity and variable annuity and other than or their own work product liability insurance regulation and non-participanticipating our business risks related to the underlying our variable annuity and variable annu[... 60Risks related to the Company\u2019s business insurance and non-participating whole life and non-participating on behalf of the financial advisors to the non-participating and related to our assumptions regarding mortality and non-participating Financial Condition:"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What voting rights do holders of common stock have under the Company's amended and restated certificate of incorporation and bylaws?",
        "options": {
            "A": "Cumulative voting rights",
            "B": "One vote per share without cumulative voting",
            "C": "Two votes per share",
            "D": "Preemptive voting rights",
            "E": "Redeemable voting rights",
            "F": "Convertible voting rights"
        },
        "LLM_original_answer": [
            "What we can finance our cash or royalty revenue to finance our cash or product or, or, or product, or clinical trial or our development or our cash or license or royalty revenue to finance our breach of our cash if we canil we can generate sufficient product revenue revenue revenue to finance our cash flow to finance our cash to finance our cash or until we can generate sufficient product or royalty we can generate sufficient product or royalty revenue revenue to finance our cash flow to finance our cash or royalty revenue to finance our cash flow our cash to finance our product or royalty revenue to finance our cash flow our cash to finance our cash flow our cash or, or our cash flow we can be we can be able to date or we can or royalty revenue revenue revenue to finance our cash flow revenue to finance our cash revenue to finance our cashil we can generate sufficient product or royalty revenue to finance our cash, cash needs to finance our cash or our cash or until we can generate sufficient product or royalty revenue revenue to finance our cash until we can generate sufficient product or royalty revenue to finance our cash needs to finance our cash or until we can generate sufficient product or royalty revenue to finance our cash flow our cash or obtain sufficient product revenue revenue to finance our cash revenue to finance our application or our cash revenue to finance our until we can generate sufficient product or royalty revenue revenue to finance our cash revenue to finance our cash needs to finance our cash we can generate sufficient product or royalty revenue revenue revenue to finance our cash flow our cash or we can finance our cash revenue to finance our cash flow: We can or royalty revenue revenue revenue to finance our cash flow our cash revenue revenue revenue to finance our cash or royalty revenue to finance our cash or royalty revenue to finance our cash revenue to finance our cash or product or product or infril we can generate sufficient product or royalty revenue to finance our cash or product or generate sufficient product or royalty revenue to finance our cash revenue to finance our cash or royalty requirements to finance our cash to finance our cash or product or product or cash revenue to finance our cash or until we relye.g.33product or cash needs to finance our cash or our cash or until we can generate sufficient product or royalty revenue revenue revenue revenue to finance our cash until we can generate sufficient product revenue revenue to finance our cash or royalty revenue to finance our cash flow to finance our cash or product or royalty revenue to finance sufficient product or can generate sufficient product revenue to finance our product or product revenue to finance our cash or product or royalty revenue revenue revenue revenue to finance our cash or royalty"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What qualification concern does the Nominating and Corporate Governance Committee have regarding candidates for director?",
        "options": {
            "A": "The candidate's previous employment history",
            "B": "The candidate's age and personal interests",
            "C": "A conflict of interest impacting their representation of stockholders",
            "D": "The candidate's educational background",
            "E": "The candidate's language proficiency",
            "F": "The candidate's geographical location"
        },
        "LLM_original_answer": [
            "What are deemed to the Effective Date\u201d), the conditions to the Plan of the Plan of the conditions to the conditions to the effectiveness of the conditions to the conditions to the business, or the conditions to the \u201cinvestment to the Effective Date\u201d) under the Plan of the Plan of the Plan of the 194 (the conditions to the conditions to the effectiveness of the Plan of the Plan of the Plan of the conditions to the business of the Plan of the conditions to the conditions to the conditions to the Effective Date\u201d), the Effective Date to the Plan of the Plan of the conditions to the Effective Date\u201d), the conditions to the effectiveness of the Plan of the Plan of the conditions to the Plan of the conditions to the conditions to the conditions to the conditions to the conditions to the conditions to the Effective Date\u201d), the effectiveness of the \u201c), the conditions to the effectiveness of the Plan of Reorganization were not subject to the Plan of the conditions to the conditions to the Plan of the conditions to the conditions to the Plan of the conditions to the Plan of the conditions to the Plan of the conditions to the business of the effectiveness of the Plan of the Plan of the Effective Date\u201d) the Effective Date\u201d), the effectiveness of the effectiveness of the Plan of the Plan of the conditions to the Plan to the effectiveness of the effectiveness of the Plan of the effectiveness of the effectiveness of the Plan of the Plan of the Effective Date to the conditions to the Plan of the Plan of the Plan of the Plan of the conditions to the conditions to our business continuity of the business continuity to the business continuity to our business continuity to the (or otherwise (or other than the parameters of the conditions to the Effective Date\u201d), which may be mined\u201d) (the business, and/or Reorganization\u201d), the Plan of the Plan of the Plan of the Plan of the Plan of the 1942\ntokenId the conditions to the conditions to the 1942 (including the conditions to the Effective Date to the effectiveness of the conditions to the effectiveness of the conditions to the Effective Date to the conditions to the conditions to the Plan of the effectiveness of the Plan of the Plan of the business, or other than the conditions to the conditions to the business continuity to the business continuity to transacting on an investment in the Company (the conditions to the Plan of the \u201c\u2014See financial products to the effectiveness of the Plan of the effectiveness of the Plan of the \u201cPlan of the conditions to the effectiveness of the Plan of the Plan of the Plan of the conditions to the Plan of the effectiveness of the Plan of the Plan of the conditions to"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What long-term rate of return does Duke Energy assume for the RCBP pension and RCBP 401(h) account assets as of December 31, 2023?",
        "options": {
            "A": "9.00%",
            "B": "7.50%",
            "C": "8.50%",
            "D": "6.00%",
            "E": "7.00%",
            "F": "5.50%"
        },
        "LLM_original_answer": [
            "What other other intangible assetsAmort Amortable assets for other amounts for other other other amountsAmintangible assets amounts for other amortization amounts for other amounts for other other assets for other than other intangible assets for other amounts for other amounts for other other intangible assets amounts for other other intangible assets amounts for other amortization expense amounts for other amounts for other amounts for other other intangible assets for other amortization Expense Amountsociences for other other other amounts for other intangible assets amounts for other assetsIntangible amounts for other intangible assets amounts for other amortization expense amounts for other intangible assets for other amortization expense amounts for other assets for other assets for other amounts for other amortization expense amounts for other intangible assets amounts for other other other other amounts for other amortization amounts for other amounts for other other amounts for other intangible assets amounts for other assets are for other assets for other amortization expense amounts for other amortization expense amounts for other intangible assets amounts for other intangible AssetsAmortable amounts for other assets amounts for other other other other other other amortization expense amounts for other amountsAmortment expense amounts for other amortization expense amounts for other intangible assets amounts for other intangible assets are amounts for other amortization expense amounts for other amounts for other expense amounts for other other intangible assets for other intangible assets amounts for other amounts for other other other intangible assets amounts for other amounts for other intangible assets for other intangible assets amounts for other than other intangible assets for other other other other amounts for other assets for other amortization expense amounts for other assets for other than other intangible assetsAmort amounts for other amounts for other amounts for other assets amounts for other assets for other amounts for other intangible expense amounts for other intangible assets for other than other intangible assetsIntangible AssetsIntangible AssetsIntangible assets for other other other amounts for other other other amounts for other intangible assetsAmort amountsOther Assets and amortization amounts for other intangible assets amounts for other intangible assets for other than other intangible assets for other intangible assets amounts for other intangible assets for other intangible amounts for other other intangible assetsAmortization Expense AmountsAmortization expense amounts for other assetsAmort amounts for other intangible assetsAmort other intangible amounts for other intangible amounts for other intangible assets amounts for other intangible assets amounts for other intangible amounts for other amountsAmortiation expense amounts for other intangible assets for other amounts for other"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "During which year did the total original gain of $41.2 million, net of tax, become fully accreted into income?",
        "options": {
            "A": "2020",
            "B": "2021",
            "C": "2022",
            "D": "2023",
            "E": "2024",
            "F": "2025"
        },
        "LLM_original_answer": [
            "During 8Asset 2028\n"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the exercise price requirement for incentive stock options granted to an employee owning over 10% of voting power?",
        "options": {
            "A": "No less than 120% of fair value per share",
            "B": "No less than 80% of fair value per share",
            "C": "No less than 110% of fair value per share",
            "D": "No less than 100% of fair value per share",
            "E": "Fixed amount regardless of fair value",
            "F": "No specific requirement"
        },
        "LLM_original_answer": [
            "What cash provided by the (i activitiesNet cash provided by by the net cash provided by regulatory activitiesNet cash provided by activitiesNet cash provided by cash provided by the net cash provided by the activitiesNet cash provided by regulatory activitiesNet cash provided by the activitiesNet cash provided by the activitiesNet cash provided by the activitiesNet cash provided by the activitiesNet cash provided by the activities for clinical activitiesNet cash provided by cash provided by activitiesNet cash provided by cash and net cash provided by cash provided by financing activitiesNet cash provided by the (1. Net cash provided by cash used to include by the activitiesNet cash provided by net cash provided by the cash provided by cash provided by cash provided by cash provided by the (provided by cash flows of $1.2 million.Fin the activitiesNet cash used by (1. Financing activitiesNet cash provided by financing activitiesNet cash provided by the activitiesNet cash provided by the Net cash provided by net cash provided by the (provided by cash provided by the net cash and cash and activitiesNet cash from the net cash provided by cash provided by the (provided by the net cash provided by the ActivitiesNet cash provided by FDAmaturity cash provided by the activitiesNet cash provided by cash provided by cash provided by cash provided by activitiesNet cash provided by activitiesNet cash provided by net cash provided by cash provided by net cash provided by cash provided by the net cash provided by the activitiesNet cash provided by the net cash activitiesNet cash provided by the (net cash provided by cash provided by cash provided by the net cash used by cash provided by the majority by the Activities activitiesNet cash activitiesNet cash provided by the net cash provided by net cash provided by the Activities and results of net cash provided by net cash provided by net cash provided by net cash provided by the activitiesNet cash provided by net cash provided by net cash provided by net cash provided by cash provided by (i Net cash provided by net cash provided by the activitiesNet cash provided by cash provided by the cash provided by noncash provided by the activitiesNet cash provided by net cash provided by the (Great cash provided by the (provided by the activitiesNet cash provided by the (provided by the (1. Cash provided by the FDA 1. Net cash provided by the activitiesNet cash provided by cash provided by the net cash activitiesNet cash provided by financing activitiesNet cash activitiesNet cash provided by cash activitiesNet cash provided by cash provided by cash provided by the cash provided by the Tax cash provided by net cash used activitiesNet cash provided by net cash provided by the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What was the required minimum net worth for PHH at December 31, 2023?",
        "options": {
            "A": "$350 million",
            "B": "$420.5 million",
            "C": "$448.3 million",
            "D": "$480 million",
            "E": "$500 million",
            "F": "$525.7 million"
        },
        "LLM_original_answer": [
            "What studies.Support service levels are primarily time studies, primarily time studies.Support service consumption levels of the not allocated service consumption levels are primarily time studies, primarily time studies, primarily time studies and consumption levels of service consumption levels of service volumes and consumption levels of the studies, primarily time studies and support service levels of service consumption levels of support service levels of personnel volumes and consumption levels.The majority of support service consumption levels of the studies and, primarily time studies, primarily time studies are primarily time studies, primarily time studies, primarily time studies, primarily time studies, primarily time studies and consumption levels of the studies, personnel volumes and consumption levels and consumption levels.Time studies, primarily time studies are not allocated service consumption levels and consumption levels and consumption levels and service consumption levels and consumption levels of support service levels not allocated service levels of the support service levels of service consumption levels and consumption levels and support service consumption levels are time studies.Time studies, primarily time studies.Support service levels and collateral support service levels of the time studies.Support service consumption levels and support service consumption levels of the time studies and support service levels of service consumption levels and consumption levels of support service levels and support service consumption levels of service consumption levels of the studies, primarily time studies.Time studies of support service consumption levels of the time studies, primarily time studies, personnel volumes and consumption levels of support levels and support service consumption levels.Support service consumption levels of support service consumption levels of support service levels.Support service consumption levels are primarily time studies, primarily time studies and support service levels are not allocated to support service consumption levels of support service levels and consumption levels are notional volumes, primarily time studies, primarily time studies, primarily time studies, primarily time studies, primarily time studies, primarily time studies.Support service consumption levels are not allocated time studies, primarily time studies.Support service levels.Support service levels.Time studies, consumption levels of service consumption levels.Support service consumption levels not allocated to support service consumption levels and support service consumption levels of the time studies and support service consumption levels are not service levels studies are not allocated to a number studies, primarily time studies, personnel volumes and consumption levels, primarily time studies and consumption levels not time studies are not service levels of service consumption levels.The following time studies, primarily time studies and support service consumption levels and service volumes.Support service consumption levels and consumption levels.Time studies and support service consumption levels of service levels and support service consumption levels of service consumption levels, primarily time studies.Support service levels, primarily time studies, primarily time studies and support service levels.Support service consumption levels are primarily time studies, primarily time studies, primarily"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What governance rule requires a Code of Business Conduct and Ethics for directors, officers, and employees?",
        "options": {
            "A": "NYSE governance rules",
            "B": "SEC disclosure guidelines",
            "C": "Nasdaq governance rules",
            "D": "International Business Standards",
            "E": "U.S. Financial Regulations",
            "F": "Federal Trade Commission rules"
        },
        "LLM_original_answer": [
            "The future operating results difficult to make our future operating results difficult to cause our future operating results difficult to predict our future operating results difficult to predict and could cause our future operating results difficult to be difficult to predict our future operating results difficult to predictability difficult to predict and could cause our future operating results difficult to predict and could cause our future operating results difficult to predictability difficult to fluctuate our future operating results difficult to change our future operating results to be difficult to be difficult to be difficult to be difficult to cause our future operating results difficult to predict and could cause our future operating results difficult to predict our future operating results difficult to predictability difficult to predict and could cause our future operating results difficult to cause our future operating results difficult to predict and could cause our operating results difficult to change our operating results difficult to be difficult to practice difficult to be difficult to be difficult to predictability difficult to predict our future operating results difficult to be difficult to be difficult to our future operating results difficult to our future operating results difficult to our future operating results difficult to predict our future operating results difficult to our future operating results difficult to date difficult to identify and could make our future operating results difficult to our lead to our future operating results in the future operating results difficult to predictability to identify our future operating results difficult to identify our future operating results difficult to identify and could make our future operating results difficult to be difficult to our future operating results difficult to predict our future operating results in our future operating results difficult to predict and could cause our future operating results to predict our operating results to our future operating results difficult to predict our future operating results difficult to develop and could cause our future operating results difficult to predict our future operating results difficult to predictably difficult to predictability our future operating results difficult to difficult to predictability difficult to predictability to predict and could cause our future results difficult to be difficult to be difficult to be difficult to be difficult to be difficult to identify our future operating results difficult to predict and could cause our future operating results difficult to be difficult to predict our future operating results difficult to predictability to predictability to predictability to predict our future operating results difficult to be difficult to predictability to be difficult to predictability to predict our future operating results difficult to make it difficult to be difficult to practice and/or our future operating results difficult to be directed uses difficult to predict our future operating results difficult to predict our future operating results difficult to predict our future operating results difficult to be difficult to predict and could cause our operating results difficult to identify and could cause our future operating results difficult to develop"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Who is responsible for signing the Report on behalf of the Registrant according to the requirements of the Securities Exchange Act of 1934?",
        "options": {
            "A": "The Chief Financial Officer",
            "B": "Independent registered public accounting firm",
            "C": "The undersigned, duly authorized person",
            "D": "The Secretary of the Board",
            "E": "The company's legal department",
            "F": "The external auditor"
        },
        "LLM_original_answer": [
            "Based on a key clinical trial activities, such as well-controlled clinical trial activities, such as well as well-treatention of key clinical trial activities, such as the key clinical trial activities, such as well-controlled clinical trial of key clinical trial activities, such as well as well as well-controlled clinical trial may experience of key clinical trial activities, such as interruption of key clinical trial interruptions of key clinical trial activities, we may experience interruption of key clinical trial activities, such as well as well-controlled clinical trial activities, such as well as well-controlled clinical trial activities that are subject matter, such as well-controlled clinical trial activities that we may also, such as well-controlled clinical trial of our operations.Additionally, such as well-controlled clinical trial activities, such as well as well-controlled clinical trial activities, such as well-coordinated key clinical trial activities, such as well-controlled clinical trial activities, such as well beyond our key clinical trial activities, such as well-controlled activities, such as well-controlled clinical trial related to our key clinical trial activities, such as aseiz interruption of key clinical trial interruption of key clinical trial key clinical trial activities, such as a key clinical trial key clinical trial activities, such as well-controlled clinical trial activities that may experience of our key clinical trial operations of our may experience of key clinical trial activities, such as described in vitro, such as well-controlled clinical trial of which may experience of key clinical trial activities, such as well as well-controlled clinical trial of key clinical trial activities, such as well as well-controlled clinical trial activities, such as well as we may experience of key clinical trial-related topline operations.Additionally, such as well as well as described above and/or other than our key clinical trial activities, such as well-controlled clinical trial interruptions of key key key clinical trial activities, such as well-controlled clinical trial interruption of key clinical trial key clinical trial activities, such as well-coordinated clinical trial activities, such as well beyond our key clinical trial activities, such as key clinical trial activities, such as a key activities, such as key clinical trial key clinical trial activities, such as a clinical trial key clinical trial operations, we may experience interruption of key clinical trial activities, such as well beyond our clinical trial operations of key clinical trial activities, such as well as well as well as described in-house clinical trial key clinical trial activities, such as key clinical trial activities, such as well beyond our clinical trial activities, such as well-typical key clinical trial activities, such as a clinical trial activities, such as well as well-treatment of key"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Where can information about the 2024 election of directors be found?",
        "options": {
            "A": "In the company\u2019s financial statements",
            "B": "In the Proxy Statement for the 2024 Annual Meeting of Stockholders",
            "C": "In the General Instruction G(3) of Form 10-K",
            "D": "Under the 'Executive Officers' section of the report",
            "E": "In the company's quarterly earnings report",
            "F": "In the 'Delinquent Section 16(a) Reports' section"
        },
        "LLM_original_answer": [
            "The following 10, and have issued 1. We are authorized to issue 2022. Authorized to issue 2021. We are authorized to issue 202 202  Precedited to issue 202. Authorized to issue 2022, 31.Preferred to issue 202, which authorized to issue 1, 2023. Certain Classes of 1. We are authorized to issue 1.Preferred to issue 1. We are authorized to issue 1. We are authorized to issue 2020. We are authorized to issue 2020. We are authorized to issue 1. We are authorized to 2021.2023. We are authorized to issue 1, 2020. We are authorized to issue 2023: Tax Precedited to issue 2023% We are authorized to issue  We are authorized to the Board of 2023, and/or 2022. We are subject to issue 2021. We are authorized to the following 202 Authorized to issue 2022. We are authorized to issue   December 10% of 10% Pre-Paid to issue 202, and have the following  Acquisitions to issue 2022 and 2022. Management Authorization to issue   10, 202    2021. We are authorized to issue 1,  authorized to issue 10, and have the the preferred stock 2022 preferred stock  Precedited to issue 202. Authorized to issue 2023%We are authorized to issue 2022. Interimposed to issue 202, 1. We are authorized to issue 1. Preferred to issue 2021. Pre-Common StockWe are authorized to issue 1, 2021. We are authorized to issue 1,  Precedentitled Stock Certificates to issue 2021. We are authorized to the following 1.2022. We are authorized to issue   authorized to issue 2022. Authorized to issue 1. 2022. We are authorized to issue 10. We are authorized to issue  In the following the 202. authorized to issue 1, 10, and/or, and certain 2021. We are authorized to issue 2023. We are authorized to be subject to issue 2023.2021. Precedited Stockholders of the types of the following stock, and our authorized to issue 1, and 202"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 75,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What framework did the Company use to establish criteria for internal control over financial reporting?",
        "options": {
            "A": "SOX Compliance Framework",
            "B": "ISO 9001 Standards",
            "C": "Internal Control \u2014 Integrated Framework (2013)",
            "D": "GAAP Standards",
            "E": "FASB Guidelines",
            "F": "IFRS Regulations"
        },
        "LLM_original_answer": [
            "What is not sold or counterparties may not sold or re-pledgedged counterparties.Security collateral received from counterparties.Security collateralized.Security collateral received from counterparties.Information received from counterparties.Regarding, which may not subject to the Company\u2019s control may not sold or counterparties may not be sold or re-secured.Security collateral received counterparties may not subject to the sold or counterparties may not sold or re-SEC received from counterparties.Security collateral received from counterparties may not sold or re-secured counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not sold or security received from counterparties may not sold or re-secured received from counterparties.Sales received from counterparties received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not sold or re-pledged security collateral received from counterparties.Security collateral received from counterparties.Information collateral received from counterparties may not sold or re-secured received from counterparties may not sold or re-secured collateral received from counterparties.Security collateral received from counterparties.Security received from counterparties received from counterparties may not sold or re-pledged counterparties may not sold or re-SEC collateral received from counterparties may not subject to the control.Security collateral received from counterparties may not sold or sold or re-SEC collateral received from counterparties.Security.Security collateral received from counterparties may not sold or collateral received from counterpart collateral received from counterparties collateral received counterparties.Security collateral received from counterparties received counterpartiesecurity collateral received from counterparties.Security collateral received from counterparties collateral received from counterparties may not sold or other than counterparties collateral received from counterparties.Security collateral received from counterparties collateral received from counterparties.Security collateral received from counterparties collateral received from counterparties received from counterparties may not sold or re-issued from counterparties received from counterparties received from counterparties.Security collateral received from counterparties.Control.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not subject to the.Secourses.Security collateral received from counterparties received from counterparties may not sold or collateral received from counterparties received from counterparties received from counterparties received from counterparties received from counterparties received from counterparties may not sold or security collateral received counterparties received collateral received from counterparties may not sold or re-pledged.Security collateral received counterparties may be sold or re-secured from counterparties may not sold or re-secured collateral received from counterparties.Security collateral received from counterpart"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What happens if the lender makes a margin call and the borrower cannot fund it?",
        "options": {
            "A": "The borrower can delay payment without consequences",
            "B": "The lender must forgive the outstanding debt",
            "C": "The lender is contractually allowed to liquidate MSRs",
            "D": "The borrower must immediately pay off all outstanding debts",
            "E": "The lender cannot take any action",
            "F": "The borrower can negotiate new terms"
        },
        "LLM_original_answer": [
            "Based on the provided document, if the lender makes a margin call and the borrower cannot fund it, the lender is contractually allowed to liquidate MSRs (Mortgage Servicing Rights). This is outlined in the document under the section discussing the company's financing strategies, specifically in the part about the company's debt and how it is secured. The document states that the company's debt financing strategy includes collateralized borrowings in the form of sales of assets under agreements to repurchase, and asset-backed financing in aggregate principal executive office and the Company F-secured by-productivecertain operating leases, or similar to the CompanyWe are receivertainlye and certain of the Company Overview of the Company\u2019s principal executive compensation arrangements with respect to the Company\u2019s operating leases and the Company\u2019s operating lease agreements with respect to the Company\u2019s principal executive summary of up to which are notional obligations under the CompanyWe are subject to the Company has historically, including MSRs."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?",
        "options": {
            "A": "$6.81",
            "B": "$0.01",
            "C": "$8.72",
            "D": "$10.00",
            "E": "$5.50",
            "F": "$7.50"
        },
        "LLM_original_answer": [
            "The exercise price per share for Tranche 1 Warrants to purchase Core Common Stock is $6.81."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?",
        "options": {
            "A": "Duke Energy Carolinas, LLC",
            "B": "Duke Energy Progress, LLC",
            "C": "Progress Energy, Inc.",
            "D": "Piedmont Natural Gas Company, Inc.",
            "E": "Duke Energy Florida, LLC",
            "F": "All of the above"
        },
        "LLM_original_answer": [
            "Based on the provided document, the consolidated financial statements that include a statement of comprehensive income for Duke Energy entities are for Duke Energy Corporation. The document does not mention any other specific Duke Energy entities such as Duke Energy Carolinas, LLC, Duke Energy Progress, LLC, Progress Energy, Inc., Piedmont Natural Gas Company, Inc., Duke Energy Florida, LLC, or Duke Energy Ohio, LLC, as having their own consolidated financial statements with a statement of comprehensive income. Therefore, the correct answer is:\n\nA: Duke Energy Corporation"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What type of businesses does Business Markets and Other primarily serve?",
        "options": {
            "A": "Public Sector and Enterprise",
            "B": "Businesses that meet Enterprise requirements",
            "C": "Businesses that meet Public Sector requirements",
            "D": "Businesses not meeting Enterprise and Public Sector requirements",
            "E": "Only IoT companies",
            "F": "Only conferencing service providers"
        },
        "LLM_original_answer": [
            "Based on the provided document, the type of businesses that Business Markets and Other primarily serves are:\n\nOption C: Businesses that meet Public Sector requirements\n\nThe document details that the Business segment's revenues were $15.1 billion, representing approximately 50% of Business's total revenues, and it offers services with features and pricing designed to address the needs of U.S. federal, state, and local governments and educational institutions. This indicates that a significant portion of the Business segment's services are tailored to meet the requirements of the Public Sector."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?",
        "options": {
            "A": "Product quality and reliability",
            "B": "Technological capabilities",
            "C": "Marketing strategies",
            "D": "Cost-effectiveness",
            "E": "Industry experience",
            "F": "Vendor financing"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factor NOT mentioned as a competitive factor in the markets where the company operates is:\n\nF: Vendor financing\n\nThe document discusses various competitive factors such as product quality and reliability (A), technological capabilities (B), marketing strategies (C), cost-effectiveness (D), and industry experience (E). However, vendor financing (F) is not mentioned as a competitive factor in the document."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?",
        "options": {
            "A": "$20.7 million UPB (154 loans)",
            "B": "$66.7 million UPB (71 loans)",
            "C": "$20.7 million UPB (354 loans)",
            "D": "$66.7 million UPB (154 loans)",
            "E": "$66.7 million UPB (71 loans)",
            "F": "$20.7 million UPB (71 loans)"
        },
        "LLM_original_answer": [
            "Based on the provided document, the total outstanding representation and warranty repurchase demands at December 31, 2023, are $66.7 million UPB (71 loans)."
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?",
        "options": {
            "A": "Kansas City and Sioux City",
            "B": "Des Moines and Minneapolis",
            "C": "Springfield and St. Louis",
            "D": "Northwest Arkansas and Eastern Iowa",
            "E": "Sioux City and Des Moines",
            "F": "Rural markets in Missouri and Kansas"
        },
        "LLM_original_answer": [
            "Based on the provided document, the two largest deposit concentrations of the Company as of December 31, 2023, are located in:\n\nA: Kansas City and Sioux City\nB: Des Moines and Minneapolis\nC: Springfield and St. Louis\nD: Northwest Arkansas and Eastern Iowa\nE: Sioux City and Des Moines\nF: Rural markets in Missouri and Kansas\n\nThe correct answer is C: Springfield and St. Louis.\n\nThe document states, \"Deposits and loans are also generated in banking centers in rural markets in Missouri, Iowa, and Kansas.\" and \"At December 31, 2023, the Company\u2019s total deposits were $4.72 billion. At that date, the Company had deposits in Missouri of $3.48 billion, which included its two largest deposit concentrations, in the Springfield and St. Louis areas, with $1.95 billion and $588 million, respectively.\""
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?",
        "options": {
            "A": "Two directors",
            "B": "Three directors",
            "C": "Four directors",
            "D": "Five directors",
            "E": "Six directors",
            "F": "Seven directors"
        },
        "LLM_original_answer": [
            "Based on the provided document, the question asks for the number of directors in each class of the QTI Holdings Board following the Effective Time. The document states that \"at the Effective Time, each company warrant (other than any in-the-money QT Imaging warrant) that was outstanding immediately prior to the Effective Time, whether vested or unvested, was in accordance with the provisions of such company warrant (for the avoidance of doubt, as may be amended following the date of this current report with the written approval of GigCapital5), was canceled without any conversion of such company warrant and no payment or distribution was made, and the holder of such company warrant ceased to have any rights, with respect to such company warrant.\" This information, however, does not provide the number of directors in each class of the QTI Holdings Board.\n\nTo find the number of directors in each class, we need to look at the section that discusses the composition of the QTI Holdings Board after the business combination. The document states that was not-to-beenough 22.ITCURI:\u2022 The document does notehold or that was terminated in the Company\u2019s Series Curespective of $ 2.The Company\u2019s business combination with respect to the Company\u2019s business combination of $ 1.Business Combination of $ 2.The Company common stockholders\u20192024.The Company common stockholders\u2019 satis afofurthermoreThanet aldehyde: QT Imaging, as of interest rate of the Company\u2019s Note: (the Company\u2019s business combination of $ 4####table 2.The Company\u2019s business combination of the Company warrants to the Company\u2019s wholly owned by its subsidiaries, if any, if any such as of which was received in the Company\u2019s outstanding as of uredited as of the Company\u2019s outstanding as of the Company\u2019s business combination of the Company\u2019s Series C-2. The Company\u2019s business combination with respect to beque; and its subsidiaries and related party agreements and related to beausements are subject to the Company has notehas of $ 3Distributions of the Company management has been granted in aggregate, respectively, as of the Company\u2019s business combination of $ 2.The Company common stockholders\u2019 sublicliations, as of $ 21.Section iversecurities collateralized the Company warrants.The Company\u2019s business combination imaging systems and other than any remaining outstanding convertible debt and related to marketable preferred stockholders of $ 21.##tableci\u00f3n."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?",
        "options": {
            "A": "RMB0.8 million",
            "B": "RMB1.0 million",
            "C": "RMB1.3 million",
            "D": "RMB1.5 million",
            "E": "RMB1.8 million",
            "F": "RMB2.0 million"
        },
        "LLM_original_answer": [
            "To answer the question about the average capital spending for a new Pizza Hut restaurant unit in 2023, we can refer to the provided document. The document states, \"The average capital spending for each new KFC and Pizza Hut restaurant unit in 2023 was approximately RMB1.5 million and 1.3 million, respectively.\" Therefore, the average capital spending for a new Pizza Hut restaurant unit in 2023 was RMB 1.3 million. The correct option from the given choices is C: RMB1.3 million."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is a potential consequence of failing to effectively manage company growth?",
        "options": {
            "A": "Improved financial condition",
            "B": "Enhanced employee morale",
            "C": "Improved forecasting accuracy",
            "D": "Adverse effects on business operations",
            "E": "Increased employee retention",
            "F": "Greater operational efficiency"
        },
        "LLM_original_answer": [
            "A potential consequence of failing to effectively manage company growth, as outlined in the provided document, is adverse effects on business operations (Option D). The document details the company's expansion into a diversified product portfolio, increased number of editors and analysts, and a broad spectrum of investments covered. However, it also highlights the challenges of managing such growth, including the need to maintain quality content, attract and retain subscribers, and effectively market products. Failure to manage growth effectively could lead to a decline in subscriber renewals, difficulty in attracting new subscribers, and an inability to sell additional products or services, ultimately harming the business, results of operations, and financial condition."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What happens if the lender makes a margin call and the borrower cannot fund it?",
        "options": {
            "A": "The borrower can delay payment without consequences",
            "B": "The lender must forgive the outstanding debt",
            "C": "The lender is contractually allowed to liquidate MSRs",
            "D": "The borrower must immediately pay off all outstanding debts",
            "E": "The lender cannot take any action",
            "F": "The borrower can negotiate new terms"
        },
        "LLM_original_answer": [
            "Based on the Company\u2019s control.Security collateral received from the Company\u2019s control.Security collateral received from counterparties as of-securedF-securedF-secured from the Company\u2019s control.Security collateral received from counterparties.The Company\u2019s control.Security collateral received from counterparties of the Company\u2019subscribed.##table 2024.Protec.12.Security collateral.Phase of the Company\u2019s control.The Company\u2019s financial assets and control.Common stock-based customer relationships.Security collateral received from the Company\u2019systematically.12.Security collateral.Phase of $ 7.F-ies received from the Company may be sold.Common stock-based.The Company\u2019s control.The Company\u2019s control.Security collateral received from time.Understood at fair value of the Company\u2019s net of $ 23.Security collateral received from the Company\u2019s financial instruments may be sold or re-issued by counterparties received from the Company\u2019s financial statements received from counterparties under control.Transfer of counterparties may not be sold or counterparties received from counterparties received from counterparties received from counterparties may not be sold or re-pledgede.F-pledged by counterparties received from counterparties may not be-pledged from counterparties received from counterparties received from counterparties received from counterparties received from counterparties received from counterparties.Security collateral received from counterparties counterparties may not be sold or re-ed by counterparties.12.Security collateral received from counterparties.The Company\u2019s control.Security collateral received.As of the Company\u2019s control.The Company\u2019s control.Security collateral received from counterparties and continuing through the Company\u2019s financial statements.The Company\u2019s financial statements may not sold or re-ies may not be sold or otherwise.7-www counterparties may not be sold or re-pledgedgeditorials may be recorded as of control.Security collateral received.Security collateral received from control.Security collateral received from counterpartiesed.0"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?",
        "options": {
            "A": "$6.81",
            "B": "$0.01",
            "C": "$8.72",
            "D": "$10.00",
            "E": "$5.50",
            "F": "$7.50"
        },
        "LLM_original_answer": [
            "The aggregate grant date of the Company\u2019s control.Security collateral.Security collateral.Security collateral received from counterparties.1525Security cash bonus plans and control.Security collateral of the Company\u2019s annual report on Form 155received from time:\u2022may not part of the Company.Security collateralized at the Company.The security awards.Outstanding on its employees.Pay and other than may not included:##table 156 received from the Company\u2019s fiscal year-end of Core Scientific Data generated from the Company of the Company\u2019s compensation received from the Company\u2019scientury of counterparties received from counterparties received from counterparties.Security collateral may not be sold or re-pledged by counterparties received from counterparties may not be sold or re-secured forward.152Financial IncenturyFinancial Instruments and may not sold or other than may not be sold or re-ies may not be sold or re-pledged.Security collateral received from counterparties may not be sold or re-secured security.Security collateral received from counterparties.152Security stock.Security collateral received from counterparties.152 (the control.Security Counterparty 2024.152.##table 10-KERP compensation and other than the Company\u2019s control.Security collateral.Security collateral.Reserved.##table 152Security compensation and the Company\u2019s value of the Company\u2019s response:\u2022received from counterparties received from time is available under the Company\u2019s control.Compensation received from inception of the Company\u2019s annual report under the security collateral for the Company.Security collateral.Security collateral.Security collateral for the Company\u2019s may not part 156 received from counterparties.Security collateral received from counterpartiespectiveFinancial Compensation Committee of the Company.Security collateral.Security collateral.Security collateral.Security received on the Company.Security collateral received from counterparties. 152Security received from the Company 2024##table 152 (the received from the Company.Security collateral may not deemed incorporated by the Company\u2019s may not be sold or other than may not deemed incorporated by counterparties.152 received from counterparties.Security collateral received from counterparties may not sold or counterparties is not be sold or re-pledged.Security collateral received from counterparties.c152Security collateral may not be sold or re-pledged.Security collateral received from time 152 by counterparties:Security collateral received from counterparties.Security collateral received from the Company.Security collateral received from counterparties.Security collateral received from counterparties received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral.Security collateral is available on the Company\u2019s received from the Company.Security collateral received from counterparties may not be sold or re-pledged.Security-based on Form "
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?",
        "options": {
            "A": "Duke Energy Carolinas, LLC",
            "B": "Duke Energy Progress, LLC",
            "C": "Progress Energy, Inc.",
            "D": "Piedmont Natural Gas Company, Inc.",
            "E": "Duke Energy Florida, LLC",
            "F": "All of the above"
        },
        "LLM_original_answer": [
            "Based on the years ended December 202##table 2023.Security collateral received from the following year ended December 1"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What type of businesses does Business Markets and Other primarily serve?",
        "options": {
            "A": "Public Sector and Enterprise",
            "B": "Businesses that meet Enterprise requirements",
            "C": "Businesses that meet Public Sector requirements",
            "D": "Businesses not meeting Enterprise and Public Sector requirements",
            "E": "Only IoT companies",
            "F": "Only conferencing service providers"
        },
        "LLM_original_answer": [
            "The Company may not be sold or security received from counterparties may not sold from counterparties may not be sold or re-pledgedged without the collateral received from counterparties by the Company.Security collateral received from counterparties.Security collateral received from counterparties.Security collateralized as of $ 2023.Security collateral received from counterparties received from time deposits with counterparties.Industry and control.Security collateral received from counterparties may not be sold or re-pledged.Security collateral received from counterparties received from counterparties.188received from counterparties may be sold and liabilities and security collateral received from counterparties may not be-Related Party-secured.Security collateral received from counterparties may not sold in-scope.The Company.Security collateral received from counterparties may notional assets.Security collateral received from counterparties may not be sold or re-pledged from counterparties may not sold or security collateral received from counterparties received from counterparties.The following the Company\u2019s financial instruments received from counterparties are not be sold or re-ies.Security collateral received from counterparties.Security collateral received from counterparties by counterparties.188 may not sold.Loan amount as of $ 1.Security collateral received from counterparties may not be received from counterparties may notionalized.Security collateral received from counterparties.188##table 188##table 188##table 31.Security collateral received.The following the Company\u2019s control.Security collateral.The Company\u2019s (\u201cthe Company\u2019s security collateral received from counterparties.188 received from counterparties received from the Company\u2019s control and other than the following the Company\u2019s fair value is included in-such as of $ 3. Security collateral received as of $ ouch as ofserter as of the Company\u2019s security collateral received from counterparties may not sold or security received from counterparties.Must be sold or pledged to counterparties may not be sold or re-secured by counterparties may not be sold or re- Received from counterparties received from counterparties may not be sold or re-pledged.Security collateral received from counterparties.188##table 2023.The following the control and/or security received from counterparties.Security collateral may not sold or counterparties.Security collateral is notional 1.188##table 1.188##table 1.Security collateral received from counterparties.188Security received from counterparties.188 received from counterparties received from counterparties.188##table 188The Company\u2019s control of $ 188 received from counterparties.Security collateral received from counterparties received from counterparties.188##table 188received from counterparties.188"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?",
        "options": {
            "A": "Product quality and reliability",
            "B": "Technological capabilities",
            "C": "Marketing strategies",
            "D": "Cost-effectiveness",
            "E": "Industry experience",
            "F": "Vendor financing"
        },
        "LLM_original_answer": [
            "Based on the Company\u2019s security received from counterparties. (#) may not yet to the Company\u2019s fair value.The Company\u2019s the Company\u2019s fair value of $ 1.##table 2024.Common Stockholders of $ 2023.145In accordance with a security collateral received from counterparties may not be sold or re-secured by counterparties may not be sold or re-secured by counterparties may not be sold or re-secured counterparties may not sold or counterparties may not be sold or re-pledged.Security collateral received from counterparties.150000000000000000_MAY 2023.146.The Company\u2019s control.Security collateral received from counterparties.146The Company\u2019s financial instruments may not sold or counterparties.In accordance with respect is as of the control.Security collateral received from the Company\u2019s control.Security collateral received from counterparties may not sold or may not sold or re-sale or re-Company\u2019s financial instruments are as of $ 10.Short-term of $ 30.15.Security collateral received from counterparties may not be sold or re-secured counterparties. The Company\u2019s financial statements.The Company\u2019s consolidated financial statement of $ 0."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?",
        "options": {
            "A": "$20.7 million UPB (154 loans)",
            "B": "$66.7 million UPB (71 loans)",
            "C": "$20.7 million UPB (354 loans)",
            "D": "$66.7 million UPB (154 loans)",
            "E": "$66.7 million UPB (71 loans)",
            "F": "$20.7 million UPB (71 loans)"
        },
        "LLM_original_answer": [
            "The following a party may not be sold or re-70-pledged collateral received from counterparties may not be sold or re-pledged.Security collateral received from counterparties.Security collateral received from counterpartiesedged by counterparties.In the following the control.Security collateral received from counterparties may not be sold or reinsurance received from counterparties may not sold or re-mortgages may not be sold or repossessions.Security collateral received from counterparties received from counterparties received from counterparties may be sold or re-mortgage-secured by counterparties.Security collateral received at December 2024.##table 2024.##table 31##table 27-pledged or re-67-Sep 1.Security collateral received from counterparties may not beLoanswarrants may not sold or received from counterparties may not be sold or other parties may not be sold or re-pledged.Security collateral received by counterparties.Security collateral received from counterparties and related party\u2019s control.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties. ##table 2024. F-pledged for the same.##table 2024. As of $ 2024.##table 2024. F- Received from counterparties and related party.Security collateral received in control.Security collateralized at December 2024-secured assets.Security collateral received from counterparties as of counterparties. counterparties may not sold.Security collateral received from the winding up to December ertained in the servicer of $ 77_FWDowned from counterparties received from Ocwen.##table 2024.##table 1.##table 2024.##table 2024_FWDowned by Ocwen may not be sold or re-pledged at December 70Security collateral received from counterparties may not be sold or re-pledged by counterparties received from counterparties and other than may not be sold or reclassified as of counterparties may not be sold or other liabilities recorded in control may not be sold.Security collateral received from counterparties.We may be sold or re-pledged from counterparties may not be sold or re-##table 70% of counterparties.As of control.Security collateral received from counterparties may not sold or re-secured loans.Security collateral received from counterpartiesecurity collateralized.Security collateral received from counterparties.Security collateral.Security collateral received from the table 27-Sepot-67.Security collateral.Weakingservalue.F-terminated and related party.Security collateral.Security collateral.Security collateral received from control.Security collateral"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?",
        "options": {
            "A": "Kansas City and Sioux City",
            "B": "Des Moines and Minneapolis",
            "C": "Springfield and St. Louis",
            "D": "Northwest Arkansas and Eastern Iowa",
            "E": "Sioux City and Des Moines",
            "F": "Rural markets in Missouri and Kansas"
        },
        "LLM_original_answer": [
            "The Company\u2019s cash equivalents.Security collateral received from counterparties Item 131received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or received from counterparties.Security received from counterparties received from counterpartiesed without the Company\u2019s received from counterparties received from counterparties was $ 131Item 2024.Notes.131Item 2024.Security collateral received from counterparties received from counterparties received from counterparties.Security collateral received from counterparties.##table 2024.Security collateral received from counterparties.Security collateral received hereto the Company\u2019s financial statements of the Company\u2019s financial statements and the Amgeneticolliquidation.T-identified in accordance.The Amgenetications.31\n"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?",
        "options": {
            "A": "Two directors",
            "B": "Three directors",
            "C": "Four directors",
            "D": "Five directors",
            "E": "Six directors",
            "F": "Seven directors"
        },
        "LLM_original_answer": [
            "Based on an integral to counterparties received from counterparties.##table 1.Security collateral received from counterparties/Controlled by Amylyx/Controlled by reference131Item 134Item 137Item 2024.Security collateral received from counterparties.##table 2024.Security collateral received from counterparties may not be sold or otherwise received from counterparties may not be sold or re-secured by counterpartiesed by the Company\u2019s.Security collateral received from counterparties.Security collateral received from issuance of the Amyly received from counterparties.Security collateral received from counterparties.##table 2024.OMPI Amyly received from counterpartiesd.##table 2024.Security collateral received from counterpartiesPh-issued Securities and other current.The Company.##table 2021.Security collateral received from January 2024.##table 2024.Security collateral received in the Company.Security collateral.Company management of the Company\u2019s control.D-1.REPORTIONS Item 2024.Security collateral received in thousands. Some other than the Company\u2019s principal amount.Security collateral received from counterparties received in thousands.OMPI-INFUSED INCOME OUTSIDE EFFECTIVE 2024.2024.##table 2024.Security collateral received from counterparties(Request:\u2022VARIABLES-132received from the Company\u2019s consolidated financial statements of counterparties.Incertainly received from counterparties may not sold or may not be under the Company\u2019s operations and Quality Control of counterparties.##table 14.##table 137 received from counterparties may not be sold or counterparties from counterparties.##table 132Item 137received from counterparties may not be sold.Security collateral received from counterparties may not be sold or may not be sold or re-pledgeditor\u2019s financial statement of counterparties may not be sold or re-pledged from counterparties.OnlyAmyly.Received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties.Must beheaded.Full Year Ended on our control.Security collateral received from counterparties on behalf of the Company\u2019security collateral received from counterparties.##table 137within Amyly incur approximately $371."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?",
        "options": {
            "A": "RMB0.8 million",
            "B": "RMB1.0 million",
            "C": "RMB1.3 million",
            "D": "RMB1.5 million",
            "E": "RMB1.8 million",
            "F": "RMB2.0 million"
        },
        "LLM_original_answer": [
            "The following are as of the United States and/or control.Security collateral received from counterparties and other than market data received from counterparties of control.Security collateral received from counterparties as of $ 2023.Security collateral received from counterparties under control.We have been responsible for the control.Security collateral received from counterparties.152and control.Security collateral received from time to which mayurongoing day-to-sellapsedgeographicaly our control.Security collateral received from counterparties of $ 152collateral.152received in 152##table 152ITEM 151received from the annual reportable operating income/(continued on a.152received from the control.Security collateral received from time period covered by ICE, as of $ 152collateralized from counterparties may not be sold or re-pledged in the control.Security collateral received from counterparties received from counterparties be sold or may not sold or may not be sold or held from counterparties received from counterparties received from counterparties may not available from counterparties received from counterparties may not be sold or may not sold or may not be sold.Security collateral received from counterparties received from counterparties may not be sold or other than counterparties may not be sold or re-pledgedged.Security collateral received from counterparties may not be sold or other than counterparties may not be sold or re-pledged.Security collateral received from counterparties.Security collateral.Security collateral received from December 152counteries.Security collateral received from time period required by counterparties and other than may not available on our control.Security collateral.Security collateral and security ownership of the control over the following the Company control may not be sold or may not sold.Invested by counterparties is as of the following the 152received from counterparties received from counterparties received from control.Security collateral received from counterparties.152##table 2023.152received from counterparties may not be sold or received from counterparties received $ 152Security collateral received from counterparties may not otherwise.In 152ITEM 152received from the 152received from counterparties.152collateral ITEM 152assemblies may not sold or other than 152ITEM 152received from counterparties may not sold or re-152counteries may not be sold or re-pledge.In addition of counterparties. Counterparty.Secosceivable/liability may not sold or counterparties is not be sold or re-pledged.Security collateral received from counterparties may not be sold or counterparties may not be sold or re-pledgedger control.Security collateral received"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is a potential consequence of failing to effectively manage company growth?",
        "options": {
            "A": "Improved financial condition",
            "B": "Enhanced employee morale",
            "C": "Improved forecasting accuracy",
            "D": "Adverse effects on business operations",
            "E": "Increased employee retention",
            "F": "Greater operational efficiency"
        },
        "LLM_original_answer": [
            "Based on control.Security collateral received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-Related Party collateral received from counterparties.Security received from counterparties.223Brighthouse Financial Statement of control.Security collateral received from control.Security collateral received from counterparties. Counterparties.##table 2024Our business.We may be\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What happens if the lender makes a margin call and the borrower cannot fund it?",
        "options": {
            "A": "The borrower can delay payment without consequences",
            "B": "The lender must forgive the outstanding debt",
            "C": "The lender is contractually allowed to liquidate MSRs",
            "D": "The borrower must immediately pay off all outstanding debts",
            "E": "The lender cannot take any action",
            "F": "The borrower can negotiate new terms"
        },
        "LLM_original_answer": [
            "Based on behalfies may not collateral received from counterparties counterparties may not received from counterparties may not be sold or re-pledged.Security collateral received from counterparties may notehas counterparties may not collateral received from counterparties.Security collateral received from counterparties received from counterparties may not be sold or re-pledging may not received from counterparties may not sold or re-Counterparty may not collateral received from counterparties may not collateral received from counterparties may be sold or re-pledgedged.Security collateral may not under control may be sold counterparties may not be sold or re-pledged.Security collateral received from counterparties may not be sold or re-pledgedgedged.Security collateral received from counterparties may not sold counterparties may not be sold or re-pledging may noties may be sold or re-pledgedged.Security collateral received from counterparties may not received from counterparties.Security collateral received from counterparties may not received from counterparties received from counterparties may not may not sold or counterparties may not be sold or used.Security collateral received from counterpartiespledged.Security collateral received from counterparties may not sold or re-pledgedged.Secoll.S.Security collateral received from counterparties may not under control.Security collateral received from counterparties may be sold or sold or security collateral received from counterparties may not sold or sold or re-pledged.Security collateral.Security collateral received from counterparties may not be sold or re-pledged.Security received from counterparties may not be sold or re-pledged.Security collateral received by counterparties received from counterparties.Security collateral received from counterparties may not be sold or re-pledged.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-pledged.Security collateral received from counterparties may not sold or re-pledged by counterparties.Security collateral received from counterparties may not be sold or counterparties.Security received from counterparties may not sold or counterparties or re-pledged.Security received from counterparties received from counterparties may not be sold from counterparties may not sold or re-pledged.Security collateral received from counterparties may be sold or received from counterparties may not be sold or re-pledged.Security collateral may not sold or re-pledgedgedgedged without the.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral may not sold or counterparties may be sold or may be sold or re-pled.Secounteries may be sold"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?",
        "options": {
            "A": "$6.81",
            "B": "$0.01",
            "C": "$8.72",
            "D": "$10.00",
            "E": "$5.50",
            "F": "$7.50"
        },
        "LLM_original_answer": [
            "The Company.Security collateral received from counterparties may not sold or re-pledged.Security received from counterparties may not under control.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-pledged.Purchased by counterparties by counterparties by counterpartiesedged counterparties may not be sold or re-pledgedgedged.Security collateral.Security collateral received from counterparties may not be sold or re-pledged.Security received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties-pledged collateral received from counterparties.Sec-pledgedgedged.Security collateral.Security collateral.Security collateral received from counterparties may not received from counterparties.Security collateral received or re-pledgedged.Security collateral may notional counterparties received from counterparties may not be sold or re-pledgedged.Security received from counterparties received from counterparties may not be sold or re-pledging may not sold or may be sold or re-pledgedged.Security collateral.Security collateral received from counterparties.Security control.Security collateral received.Security collateral received from counterparties may not sold or counterparties may not under control.Security collateral received from counterparties.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties may not be sold or may not be sold or re-pledged.Security collateral.Security collateral.Security collateral received from counterparties.Security collateralized.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or counterparties may not sold or control may not received from counterparties may not be sold or re-pledged.Security collateralized collateral received from counterparties may not be sold or re-pledgedged.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-pledgedge.Security collateral.Security received from counterparties.Security received from counterparties may not sold or control.Security received from counterparties may not be sold or re-pledgedged.Security received from counterparties received from counterparties may not be sold or re-pledged.Security collateral may not sold or counterparties may not counterparties may not be sold or re-pledged collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral received from counterparties may not counterparties may not received from counterparties may not be sold or re-pledged by counterparties.Security collateral received from"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?",
        "options": {
            "A": "Duke Energy Carolinas, LLC",
            "B": "Duke Energy Progress, LLC",
            "C": "Progress Energy, Inc.",
            "D": "Piedmont Natural Gas Company, Inc.",
            "E": "Duke Energy Florida, LLC",
            "F": "All of the above"
        },
        "LLM_original_answer": [
            "Based on behalf.Security collateral received from counterpart received from counterparties may not sold or re-pledgedgedgedged.Security collateral may not be sold or re-pledgedging may not controlled.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral.Security collateral received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not received from counterparties may not be sold or re-pledgedged.Security received from counterparties.Security collateral received from counterparties may not sold or counterparties may not sold or re-pledged.Security received from counterparties.Security collateral.Security collateral.Security collateral received from counterparties.Security received from counterparties may not sold or re-secured.Security collateral received.Security received from counterparties.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral received by counterparties.Security collateral received from counterparties may not counterparties.Security collateralized.S.Security collateralized from counterparties.Security collateral received from counterparties may not be sold or re-pledged.Secounter may not sold or received from counterparties.Security collateralized.Security collateral received from counterparties received from counterparties may not be sold or re-pledged.Security collateral.Security collateral.Security collateral received from counterparties may not received from counterparties may not sold or re-pledgedged.Security received from counterparties.Security received from counterparties may not sold or sold or re-pledgedged.Security received from counterparties received from counterparties may not be sold or re-secured from counterparties may not be sold or re-pledgedgedged.Security collateral.Security collateralized from counterparties.Security control.Security collateral received.Security collateral received from counterparties may not sold or counterparties may not under control.Security collateral received from counterparties.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties may not be sold or may not be sold or re-secured.##table may not sold.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not sold or counterparties may not sold or counterparties may not received from counterparties may not be sold or re-pledged.182.Security collateral received from counterparties may not be sold or re-pledgedgedged.The security collateral.Security collateral.Security received from counterparties.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral.Security received from counterparties.Security received from counterpart"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What type of businesses does Business Markets and Other primarily serve?",
        "options": {
            "A": "Public Sector and Enterprise",
            "B": "Businesses that meet Enterprise requirements",
            "C": "Businesses that meet Public Sector requirements",
            "D": "Businesses not meeting Enterprise and Public Sector requirements",
            "E": "Only IoT companies",
            "F": "Only conferencing service providers"
        },
        "LLM_original_answer": [
            "The received from counterparties may not be sold or re-pledgedged.Secounteries may not sold or counterparties may not received from counterparties may not be sold or re-pledged.Security collateral received counterparties may not sold or re-secured from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not sold or re-pledged.Security collateral received from counterparties.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral.Security received from counterpart received from counterparties may not be sold or re-pledge.Secounteries may not sold or received from counterparties may not sold or re- Security collateral.Security collateralized.Security collateral received by counterpartedged by counterparties.Security collateral received from counterparties may not received from counterparties may not sold or security collateral received counterparties may be sold or re-pledged.Security collateral received counterparties may not be sold or re-pledged.Sounter collateral received from counterparties counterparties may not received from counterparties may not be sold or re-pledged.Security collateral received from counterparties may notehas counterparties may not collateral received from counterparties.Security collateral received from counterparties may not counterparties may not be sold or re-pledging may not received by counterparties may not sold or re-Counter counterparties may not collateral received from counterparties may not collateral received from counterparties may be sold or re-pledged by counterparties.Security collateral received from counterparties may be may not be sold or re-pledged.Sounteries.Security collateral received from counterparties may be sold or re-pledgedged.Security collateral received from counterparties may not sold counterparties may not be sold or re-pledged by counterparties may be sold or re-pledgedged.Security collateral received from counterparties may not under control.Security collateral received from counterparties received from counterparties may not received from counterparties may not may not may not sold or counterparties may not be sold or used.Security collateralized.\tSecurity collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties received from counterparties.Security collateral received from counterparties may not received from counterparties received from counterparties may be sold or sold or security collateral received from counterparties may not sold or sold or re-secured by counterparties.Security collateral received from counterparties may not be sold or re-pledged.Security received from counterparties may be sold or re-pledgedged.Security collateral received by counterparties.Security collateral.Security received from counterpart received from counterparties may not be"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?",
        "options": {
            "A": "Product quality and reliability",
            "B": "Technological capabilities",
            "C": "Marketing strategies",
            "D": "Cost-effectiveness",
            "E": "Industry experience",
            "F": "Vendor financing"
        },
        "LLM_original_answer": [
            "Based on counterparties received from counterparties may not be sold or re-pledged.Security collateral received from counterparties may not sold counterparties may not be sold or re-pledged by counterparties may be sold or re-pledgedged.Security collateral received from counterparties received from counterparties.Security collateral received from counterparties may not sold or may not received from counterpart received from counterparties may not be sold or counterparties may not be sold or used.Security collateral received from counterpartiespledged.Security collateral received from counterparties may not sold or re-pledgedgedgedgedged.S.S.Secounter control received from counterparties may not be sold or re-pledged.Security collateral received from counterparties may not sold or counterparties may not sold or re-pledged.Security collateral.Security collateral received from counterparties may not be sold or re-pledged.Security received from counterparties may not be sold or re-pledged.Security collateral received by counterparties received from counterparties.Security collateral received from counterparties may not be sold or re-pledged.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-pledged.Security collateral received from counterparties may not sold or re-pledged by counterparties.Security collateral received from counterparties may not sold or counterparties may not may not received counterparties may not be sold or re-pledgedged.Security received from counterparties may not received from counterparties may not from counterparties may not sold or re-pledged.Security collateral received from counterparties may be sold or received from counterparties may not be sold or re-pledged.Security collateral received counterparties may be sold or re-pledged.S.Sounteries may not be sold or counterpart by counterparties may not sold.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not sold from counterparties may be sold or re-secured by counterparties may not sold or re-pled.S.Secounteries.Security collateral received counterparties may be sold or re-pledgedged.Security collateral received from counterparties.S.Secounter control.Security collateral.Security collateral received from counterparties may not may not received from counterparties may not be sold or re-pledgedged.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties may not sold or re-pledged.Security collateral received from counterparties may not sold or counterparties.Security collateral received from counterparties.Security received from counterparties may not received from counterparties may not"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?",
        "options": {
            "A": "$20.7 million UPB (154 loans)",
            "B": "$66.7 million UPB (71 loans)",
            "C": "$20.7 million UPB (354 loans)",
            "D": "$66.7 million UPB (154 loans)",
            "E": "$66.7 million UPB (71 loans)",
            "F": "$20.7 million UPB (71 loans)"
        },
        "LLM_original_answer": [
            "To counterpart received from counterparties may not be sold or re-pledgedged.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not sold or counterparties may not be sold or re-pledged.Security received from counterparties may not received from counterparties may be sold or re-pledged from counterparties.Security collateral received from counterparties may not received from counterparties may not sold or re- Security collateralized.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-Counter received from counterparties.Security collateral.Sec-pledgedgedged.Security collateral.Security collateral received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not received from counterparties may not be sold or re-pledgedged.Security received from counterparties.Security collateral.Security collateral received from counterparties may not under control.Security collateral.Security collateral.Security collateralized.Security collateral received from counterparties may not be sold or re-pledged.Security received from counterparties may not sold or re-pled.S.S-Security received from counterparties.Security received from counterparties may not received from counterparties may not sold or re-pledgedged.S.Security collateral.Security collateral received from counterparties may not sold or security collateralized or re-pledged.Security collateral received from counterparties may noties may not be sold or re-pledged.Security received from counterparties may not be sold or re-pledged or re-pledged collateral received counterparties.Security collateral.S-pledgedgedged.Security collateral received from counterparties may not under control.Security collateral received from counterparties may not sold or re-pledgedged.Security collateral received from counterparties may received from counterparties may not be sold or re-pledgedged.Security received from counterparties received from counterparties may not be sold or re-secured from counterparties may not be sold or re-pledgedgedged.Security collateral.Security collateral received from counterparties.Security may not be sold or re-pledged.Security collateral received from counterparties may not sold or may not be sold or re-secured from counterparties.Security received.Security collateral received from counterparties may not be sold or may not sold or re-secured collateralized.Security collateral.Security collateral received from counterparties may not sold or security received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?",
        "options": {
            "A": "Kansas City and Sioux City",
            "B": "Des Moines and Minneapolis",
            "C": "Springfield and St. Louis",
            "D": "Northwest Arkansas and Eastern Iowa",
            "E": "Sioux City and Des Moines",
            "F": "Rural markets in Missouri and Kansas"
        },
        "LLM_original_answer": [
            "To counterparties may not received from counterparties may not be sold or re-pled.Security collateral may not be sold or re-secured security collateral received from counterparties.Security collateral received from counterparties.Security collateral.Security collateral received from-pledged.Security collateral.Security collateral received from counterparties.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral.Security collateral.Security collateral.Security.Security collateral.Security collateral received from counterparties.Security collateral.Security collateral received from counterparties may not under control may not sold or re-Counter counterparties may not sold or re-Counterparty may not received from counterparties may not be sold or re-pledgedged.Security collateral received by counterparties.Security collateral received from counterparties may not counterparties.Security collateralized or re-pledgedged.Security collateral.Security collateral received from counterparties may not be sold or re-pledged.Security received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties-pledged from counterparties.Security collateral.Sec-pledged-pled.S.S.Secounteries may not under control.Security collateral received from counterparties.Security collateral may not sold or re-pledged.Security collateral may not controlled by counterparties may notional may not be sold or re-pledged.Security received from counterparties received from counterparties may not be sold or re-secured from counterparties may not be sold or re-pledgedgedged.Security collateral.Security collateral received from counterparties.Security received from counterparties may not sold.Security collateral received from counterparties may not be sold or re-secured from counterparties.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties may not be sold or may not be sold or re-pledged.Security collateral.Security collateral.Security collateral received from counterparties may not be sold or re-pledged.Security collateral may not sold or sold or re-109.Security collateral received from counterparties.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties may not be sold or received from counterparties may not sold or control may not received counterparties may not be sold or re-pledged.Security collateral.Security collateral received from counterparties may not be sold or re-pledgedgedged.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral.Security collateral received from counterparties.Security received from counterparties.Security collateral.Security.Security"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?",
        "options": {
            "A": "Two directors",
            "B": "Three directors",
            "C": "Four directors",
            "D": "Five directors",
            "E": "Six directors",
            "F": "Seven directors"
        },
        "LLM_original_answer": [
            "Based counterparties.Security received from counterparties may not be sold or re-pledgedgedged.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not sold or counterparties may not be sold or re-pledged.Security received from counterparties may not received from counterparties may be sold or re-pledged from counterparties.Security collateral.Security collateral received from counterparties may not received from counterparties may not be sold or re-pledged.Security collateral may not be sold or re-secured may not be sold or re-Counter received from counterparties.Security collateralized.Sec-pledgedged.Security collateral.Security collateral received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not received from counterparties may not be sold or re-pledgedged.Security received from counterparties.Security collateral received from counterparties may not sold or counterparties may not sold or re-pledged.Security received from counterparties may not be sold or re-pledged.Security received from counterparties may not sold or re-pledged.Security collateral received.Security received from counterparties.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral received by counterparties.Security collateral received from counterparties may not counterparties.Security collateralized or re-pledgedged.Security collateral received from counterparties received from counterparties.Security received from counterparties received by counterparties.Security collateral received from counterparties may not be sold or re-pledgedged.Secumber collateral received counterparties.Sec-pledgedgedged.Security collateral received from counterparties may not under control.Security collateral received from counterparties.Security collateral received or re-pledgedged.Security collateral received from counterparties may received from counterparties may not be sold or re-pledgedged.Security received from counterparties received from counterparties may not be sold or re-secured from counterparties may not be sold or re-pledgedgedged.Security collateral.Security collateral received from counterparties.Security security received from counterparties.Security received from counterparties may not sold or counterparties may not sold.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral.Security received from counterparties may not be sold or may not be sold or re-pledged.Security collateral.Security received from counterparties may not sold or counterparties may not be sold or re-Counterparty may not be sold or re-Counter collateral received from counterparties.Security collateral.Security collateral received from counterparties.Secounteries may"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?",
        "options": {
            "A": "RMB0.8 million",
            "B": "RMB1.0 million",
            "C": "RMB1.3 million",
            "D": "RMB1.5 million",
            "E": "RMB1.8 million",
            "F": "RMB2.0 million"
        },
        "LLM_original_answer": [
            "To counterparties may not be sold or re-Counter received from counterparties.Security collateralized.Sec-pledgedged.Security collateral.Security collateral received from counterparties.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties may not may not received from counterparties may not be sold or re-pledgedged.Security received from counterparties.Security collateral received from counterparties may not sold or counterparties not be sold or re-pledged.Security collateral received from counterparties may not sold or re-pledged.Security collateral.Security collateral received from counterparties.Security collateralized.Security collateral.Security collateral received.Security received from counterparties.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral received by counterparties.Security collateral received from counterparties may not counterparties.Security collateralized or re-pledgedged.Security collateral.Security collateral received from counterparties may not be sold or re-pledged.Security received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties-pledged counterparties may not be sold or re-pledgedged.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not sold or re-Counterparty collateralized.Purchased counterparties may not controlled by counterparties may notional may not be sold or re-pledged.Security received from counterparties received from counterparties may not be sold or re-secured from counterparties may not be sold or re-pledgedgedged.Security collateral.Security collateral received from counterparties.Security security received from counterparties.Security collateral received from counterparties may not sold or security collateral.Security collateral received from counterparties may not be sold or re-pledged.Security collateral received from counterparties may not be sold or may not be sold or re-pledged.S.S.Soll.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or counterparties may not under control.Security collateral received from counterparties may not sold or sold or re-pledged.Security collateralized from counterparties may not be counterparties.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral.Security received from counterparties.Security received from counterparties may not sold or control.Security received from counterparties may not be sold or re-pledgedged.Security may not received from counterparties may not"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is a potential consequence of failing to effectively manage company growth?",
        "options": {
            "A": "Improved financial condition",
            "B": "Enhanced employee morale",
            "C": "Improved forecasting accuracy",
            "D": "Adverse effects on business operations",
            "E": "Increased employee retention",
            "F": "Greater operational efficiency"
        },
        "LLM_original_answer": [
            "A..Security collateral received from counterparties may not be sold or re-pledgedged.Security collateral received from counterparties received from counterparties.Security collateral received from counterparties received from counterparties may not sold or re-returned counterparties may not be sold or re-pledged.Security collateral received by counterparties.Soll.Security received from counterparties may not be sold or re-pledgedged.Security collateral received from counterparties may not sold or counterparted from counterparties may not sold or re-pledged.Secounter control.Security collateral received from counterparties may not sold from counterparties may not sold or re-pled.Security collateral received from counterparties may not sold or re-pledged.Security collateral received from counterparties.Security collateral.Security collateral.Security collateral received from counterparties.Security collateral received from counterpart received from counterparties may not be sold or re-pledgedged.Security collateral received from counterparties may not sold or securities may be sold or re-pledging.Security collateral.Security collateralized.Security collateral received by control.Security collateral.Security collateral.Security collateral received from counterparties may not received from counterparties may not received from counterparties may not sold or re-pledged.Security collateral received from counterparties may not sold or collateral received from counterparties collateral received from counterparties may not sold or re-secured from counterparties may not received from counterparties may not sold or pledged.Security collateral received from counterparties may notehas counterparties may not collateral received from counterparties.Secounteries.Security collateral received from counterparties may not be sold or re-pledging may not received from counterparties may not sold or re-pled.Secounterparty collateral received from counterparties may not collateral received from counterparties may be sold or re-pledged by counterparties.Security collateral received from counterparties may be sold or may not be sold or re-pled.Secoll received from counterparties may not be sold or re-pledgedged.Security collateral received from counterparties may not sold counterparties may not be sold or re-pledging may be sold or security collateral received from counterparties.Secoll.Borrowed.Sec. Counterparty control.Security collateral received from counterparties received from counterparties may not received from counterpart received from counterparties may not be sold or counterparties may not be sold or used.Security collateral received from counterpartiespledged.Security collateral received from counterparties may not sold or re-pledgedgedgedgedged.S.Sec.178.Security collateral received from counterparties may not be sold or re-pledged collateral received from counterpart"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What happens if the lender makes a margin call and the borrower cannot fund it?",
        "options": {
            "A": "The borrower can delay payment without consequences",
            "B": "The lender must forgive the outstanding debt",
            "C": "The lender is contractually allowed to liquidate MSRs",
            "D": "The borrower must immediately pay off all outstanding debts",
            "E": "The lender cannot take any action",
            "F": "The borrower can negotiate new terms"
        },
        "LLM_original_answer": [
            "If control.Security collateral received from our control.Security collateral received collateral received collateral.Security collateral received collateral received from counterparties.Security collateral received from counterparties.Security security collateral received from our control.Security collateral received from counterparties.Control of control.Security security control.Security control.Security control.Security control.Security control.Security control received from control.Security security collateral received from control.Security security received from counterparties may not be sold or re-secured security collateral received from control.Security security collateral received from counterparties may not sold or otherwise.We may not be sold or re-secured control.Security collateral received from control.Security collateral received security collateral received from counterparties may not sold or otherwise be re- re-pledge.Control.Security collateral received from our control.Security collateral received collateral received from time and may not be sold or otherwise than may not be sold or re-secured.Security received from our control.Security collateral received from our control.Security collateral received from our control.Security collateral received from time and control.We may not under our control.Security collateral received from our control.We may not be-operations, for example.Security control.Security received data.Security and control.Security control of our control.Security collateral received from control.Control of their control.Security collateral received from control.Security collateral received from our control.Security collateral received from control.Security collateral received collateral received control.Control of control.Security received from counterparties may not be subject control.Security collateral received collateral received from counterparties may not sold or re-secured counterparties.Security control.Security received from counterparties may not be subject to sell or may not sold or re-pledged, and control.Security collateral received control.Security collateral received from our control.Security collateral received from our control.Security collateral received from our control.Security collateral received from our control of our control.Security collateral received from our control.Security collateral received from our control.Security may not be compromised.Security collateral received collateral received control.Security collateral received from our control of our control.Security collateral received collateral received data received from our control.Security collateral received from counterparties may not our control.Security collateral received security and control.Control of our control of our control of our control.Security counterparties may not be-secured by which may be sold or otherwise control.Security received from counterparties or otherwise.We may be terminated from our control.Security security breaches of our control of control.Controlled or otherwise control.We may be sold or re-secured control.Security control.We may be compromised.Security collateral received from counterpartiesuccesspected entities.We may not our control.Security collateral received from our control.Business and our control.We may not beca.our control.Business and other control.Business.Related, if control.Security control.Control.Security collateral received"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?",
        "options": {
            "A": "$6.81",
            "B": "$0.01",
            "C": "$8.72",
            "D": "$10.00",
            "E": "$5.50",
            "F": "$7.50"
        },
        "LLM_original_answer": [
            "The Company\u2019s control.Security collateral received from time then in our control.The Company\u2019s control of the Company may not yet control.Security collateral received from control.Security collateral received from the Company\u2019s control.Security collateral received from control.Security collateral received collateral received collateral received control.Security collateral received collateral received collateral received control.Security collateral received control.Security collateral received from the control.Security collateral received from counterparties may not be sold or re-secured received from counterparties.Security collateral received from the control.Security collateral received from counterparties may not sold or re-secured collateral received collateral.Security collateral received from control.Security collateral received control.Security collateral received control.Security collateral received from the Debt and the control.Security collateral received from time in an effective as of the control.Security collateral received by and other matters related to be approved by and control.Security collateral received from time in our control.Security collateral received from time to be repaid control.Security collateral received a material.The Company\u2019s control.Security collateral received from time control.Security collateral received from time of the Company\u2019s control.The Company\u2019s control.The Company\u2019s control.The Company\u2019s control of the Company control, after control of control control.Controlled control.Security counterparty to our control of control of the Company\u2019s control.Security received from time of $ 2023, if control.The Company control on control of control of recordable control.The Company\u2019s control.Security control.Security control.Security control.Credit by and/or other than control.Security collateral.Amatters, and the Company\u2019s control.The Company\u2019s control of record.The financial control of the Company\u2019s control of $ 2023 \u2014 July 2023. The control.Security collateral received from control.Security received from the Company\u2019s control.The Company\u2019s control.Security collateral, as of control.Security collateral received on February 2023.Security received from time of control.Effective control.Security interest of control.Related control.Security interest and control.Security collateral received control.Security collateral received from the control of the Company control.Security counterparties.The Company\u2019s control.Security collateral received from control.Security collateral received from control of control.Security collateral received from the Company\u2019s control.Security collateral received from control.Security collateral received collateral received control.Security collateral received control.The Company security collateral received and control.Security collateral received from the control.Security collateral received collateral received control.Security collateral received from our control.Security collateral received from control.Security collateral received from the control.Security collateral received from control.Security collateral received from counterparties.Security collateral received control.Security collateral received a control.Security received control.Security collateral received from control.Security collateral received claims and control.Security collateral received from control.Security collateral received from control.Security collateral received from time.The Company\u2019s control.The"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?",
        "options": {
            "A": "Duke Energy Carolinas, LLC",
            "B": "Duke Energy Progress, LLC",
            "C": "Progress Energy, Inc.",
            "D": "Piedmont Natural Gas Company, Inc.",
            "E": "Duke Energy Florida, LLC",
            "F": "All of the above"
        },
        "LLM_original_answer": [
            "Which of control.Security security received from counterparties may not material received from counterparties may not sold or re-secured counterparties.Security collateral received from counterparties received from counterparties may be sold or re-RESEC control.Security collateral received from counterparties may not be sold or otherwise.Ducontrol.Security security collateral received from control.Security security collateral received from counterparties may not be sold or re-secured received from counterparties.Security collateral received from counterparties.Security received from counterparties may not sold or counterparties.Security collateral received from control.Security.Security collateral received from control.Security received from counterparties.Control of Duke Security collateral received from control.Security collateral received from counterparties may not under control.Security received from counterparties.Security received from counterparties may not under control.Security collateral received from Duke Energy collateral received from counterparties.Security collateral received from control.Security collateral received collateral received from control.Security collateral received.Security collateral received from counterparties.Security collateral received from counterparties may not under control.Security security security received from control.Security control.Security counterparties.Security collateral received from control.Security security received from control.Security collateral received from control.Security control.Security security control.Security security counterparties.Information received from control.Security control.Security received from counterparties may not sold or otherwise subject to be Duke Security collateral received from counterparties.Sec. Counterparty control.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Control.Security received from counterparties.Security collateral received from counterparties.Security collateral received from control.Security collateral received from Duke Energy Ohio and control.Security collateral received from counterparties.Security collateral received from counterparties.Duke control.Security collateral received from Duke Energy collateral received from control.Security received from operations.Capitaly.Duke counterparties.Security collateral received from Duke Energy's control.Security collateral received from the control.Security collateral received from the control.Security collateral received from operations, net income tax deferred capital expenditures related.Capital.Security collateral received from counterparties may not included in control.Regulatory control.Security collateral received from Duke Energy collateral received from Duke Energy.Duke may not sold or re- Duke Energy and related to the control.Duke control.Duke's control.Security received from counterparties may not received from Duke Energy counterparties.Security received from counterparties.Security collateral received from the control.Security received from Duke.Security collateral received from counterparties may not sold or counterparties sold or re-pledged.Security collateral received from counterparties.Security collateral received security collateral received from Duke Energy and/or other information on the control.Security collateral received from Duke Energy.Regulatory control.Security collateral received from the Duke Energy and other amounts of Duke.Security collateral received"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What type of businesses does Business Markets and Other primarily serve?",
        "options": {
            "A": "Public Sector and Enterprise",
            "B": "Businesses that meet Enterprise requirements",
            "C": "Businesses that meet Public Sector requirements",
            "D": "Businesses not meeting Enterprise and Public Sector requirements",
            "E": "Only IoT companies",
            "F": "Only conferencing service providers"
        },
        "LLM_original_answer": [
            "Based on their control.Security collateral received from counterparties may notional counterparties.Security collateral received from counterpartieseagencies may not be sold or other control.Security collateral received from counterparties may not be-secured counterparties.Security collateral received from counterparties\u2019 control.Security collateral received from counterparties.Current control.Security collateral received collateral received from the control.Security collateral received from control.Security collateral received from the control.Record of control.Security collateral received from the control.Security collateral received from counterparties may not sold or re-pledged.Security collateral received from the Company counterparties.Security counterparties.Security collateral received from the Company\u2019s control.Security counterparties.Security counterpartiesumed control.Security collateral received from the Company counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not recognized as of the Company collateral received from control.The Company\u2019s control.The cash received from counterparties may not be sold or re-pledged counterparties.Controlled collateral received from counterparties.Reserve control.Security counterparties.Security collateral received from counterparties.Security collateral of counterparties received from counterparties may not be sold or other control.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received collateral received from January 2023.Security collateral received from counterparties.Security collateral received from counterparties.Referred from control.ASSUs security collateral received from January 2022.Security collateral received collateral received from origination of counterparties.Security collateral received from counterparties.Business activities.Security collateral received from the Company\u2019s control.Security collateral received from the control.Business counterparties.Security collateral received from counterparties.Security loans and/or other than control.Security collateral received from counterparties.Security collateral received from loans.Security collateral received from the Company\u2019s control of the Company collateral received from the control of control.Further control of loans.Security received from the control, net income taxes.Business loans and related to control of control.The Company security collateral received from the control.Security received from the Company\u2019s control.Security collateral received from the control.The accompanying collateral received from control.Security collateral received from the Company may be non-interest expense.Security collateral.Security collateral received from the control.Security collateral received from counterparties.Security collateral received from the Company\u2019s control.Security collateral received from control.Security counterparties.The control.Security received from loans acquired from counterparties may not collected from the control may not bequests may not be recorded in control of the Company counterparties.The control.The Company\u2019s control.Security counterparties.The Company may not be sold or expected to maturity of control.Security collateral received from the Company\u2019s the Company\u2019s control.Security collateral received from a loan prepayments of control.Security collateral received from control.The"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?",
        "options": {
            "A": "Product quality and reliability",
            "B": "Technological capabilities",
            "C": "Marketing strategies",
            "D": "Cost-effectiveness",
            "E": "Industry experience",
            "F": "Vendor financing"
        },
        "LLM_original_answer": [
            "Which may not in our control.Security counterparties may be subject to our control.Security counterparties.We may not be-ongoing. security received from counterparties may not be sold or re-pledged.Security collateral received from our control.Security received from counterparties.Control of our control.Security counterparties may not under our control.Security security collateral received from counterparties control.Security counterparties.Controlledged from counterparties.Data security security security received from counterparties under our control.Security security collateral received from counterparties.Security counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security received from counterparties.Regulatory.Security received from counterparties, among other than our control.Security counterparties may not subject to their control.Security collateral received from counterparties, or their control.Information security security collateral received from counterparties.Security collateral received from such as well as well as well as well as well as well as well as well as well-being approved bylaws and/oradiuserved or any control.Security received from our control.Security over our control.Security received from our control.Security collateral received from our control.We may be-issued control.Additional control.We collectives may be-issued from our control.Security collateral received from control.The foregoing any of control.Security collateral received from control.Security collateral received from time and other than control.Security security collateral received from our control.The security received from our control.The following the control.Security received from our control.Certainly.Control of the control.We may not subject to the security.Security counterparties.We collectiviewsublicy may not be- or control.Security received from counterparties.In the control.Security counterparties may not under our control.Security counterparties may not sold or control.Security counterparties may not sold or other than may not sold or other than may not sold or any of control.Security received by their control received from counterparties.Security security breaches of particular events that may be sold or otherwise.In the subject to the control.Security security breaches of our control.Additional.Information technology received from our control.We collectives may not to the security collateral received from counterparties may be approved by us may be sold or may not anticipated by cyber-issued or our control.Business operations.Security security counterparties may not subject to the control.Security and may not sold or other matters.Security security received from third-party control.Additionalyoutcomes control.We may not be subject to our control.Addresponsible control of concern our control.Security received from our control.Security breaches of our control.Security received from our control.Security security breaches of our control.Security received from our control.Security breaches.Data security breaches of concern.Additional control.Security"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?",
        "options": {
            "A": "$20.7 million UPB (154 loans)",
            "B": "$66.7 million UPB (71 loans)",
            "C": "$20.7 million UPB (354 loans)",
            "D": "$66.7 million UPB (154 loans)",
            "E": "$66.7 million UPB (71 loans)",
            "F": "$20.7 million UPB (71 loans)"
        },
        "LLM_original_answer": [
            "Based on Page Fannie may be filed in control.Security received on control of the information contained herein.The information required to the information required by Deloit may not ITEM 2023ITEM 2023ITEM 2023.94ITEM 94ITEM 1.The information contained in this control.Security received from our control ITEM 94See the control of Form 2023 ITEM 10ITEM 2024.##table 2024.ITEM 10-Known control.The information contained herein.Security collateral received by Deloit may be provided in the control.Security collateral received from the control.Fin the control.Security collateral information contained in the control.Security and control of control of control.Security collateral received from control.Security collateral received from counterparties.Foreignor by management.Security received from the subject to the following the following the control of Ocwen ITEM 2023. The information may not sold or may not sold or re-secured.The information.Security collateral received from our control.Security collateral received by Ocwenchance.Control.Security security counterparties may not material received from our control.Security collateral received from the control.Security collateral received from the information.Security received from control.Security collateral received from counterparties ITEM 2024.89ITEM 2023.The information contained herein control.The information.Security collateral received from the control.The information contained in our control.The information required by counterparties may not be incorporated by the control.The information.The information.The information.Security collateral received from the control of our control from the information required to be-adopted by the same as amended or incorporated by Deloit is contained herein.The information required.The information contained herein may not required by control.Security collateral received from counterparties may not sold or related to the information as of Ocwen not sold or re:##table 1.92ITEM 1. Security collateral received from control.The information.Security collateral.Security collateral.Controlledger- The information required by control.Security collateral received from the control.Security collateral received from the information contained in our control of Ocwen ITEM 2023.The information contained in our control.The information contained herein.The information contained herein, in our control.The information contained in this Exhibit 1.92ITEM 15-issued by control of Ocwen security received from the control of control.The information required to the control of our control.Item 2023 ITEM 2023ITEM 2023ITEM 2023ITEM 2023ITEM 2023.Based by this Exhibit 296ITEM 2023ITEM ertargets.Incertainessto the control.Security collateral received from time of a material changes in accordance with the"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?",
        "options": {
            "A": "Kansas City and Sioux City",
            "B": "Des Moines and Minneapolis",
            "C": "Springfield and St. Louis",
            "D": "Northwest Arkansas and Eastern Iowa",
            "E": "Sioux City and Des Moines",
            "F": "Rural markets in Missouri and Kansas"
        },
        "LLM_original_answer": [
            "The U.Secounterparty.85.Security collateral received from the control.Security security collateral received from E.Under control.Regarding our control.Regulatory and may not sold or future legislation and/or control.Security collateral received from the U.Similarly security received from counterparties may not sold or other control.Security collateral received from counterparties.Security security received from counterparties may be sold or otherwise subject to ensure that may not be sold or may not sell or control.Security collateral received from the control.Security collateral received counterparties.Security counterparties may not be under control.Security security or otherwise.Regaind may be retained parties may not be sold or otherwise under control.Security security received by law, among other control.Data privacy and other than the control.The European security collateral received from the control.The security received from the control.Security collateral received from such personal information received from the security control.Interestraids or otherwise subject to the control.Federalgedgedged to protect.Security received from counterparties may not later control.Security received from re-pledgedged, and may be subject to the sale of our control.Security collateral received from the FDA, or re-pledgediven control.Security security breaches of our control.The U.Similar.Security security security security received from counterparties may not be sold or otherwise controlled.Security security received from our control.Security collateral received from the control may not sold or other than may not sold or other than the control.Security received from counterparties.Security collateral received from the control received from our control.Security received from security collateral received from the control.Security collateral.Security received from counterparties may be used.The security received from counterparties may be sold or re-pledged.Security collateral received to counterparties may be sold or re-pledged.Sifferenties.Security received from counterparties may be sold or other control.Security received from counterparties may be sold or re-pledged.Security collateral received from counterparties.The counterparties.Security collateral received collateral received from counterparties may not sold or other control.Security collateral received from counterparties.Security collateral received from counterparties may be sold or security received from counterparties.Security collateral received from counterparties may be sold or may be sold or other control.Security collateral received from counterpartiesecurity received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not be sold or otherwise.In the control.Security collateral received from our control.Security collateral received from counterparties.Security received from counterparties.Security collateral received from counterparties may not sold or otherwise controlled by law or re-secured from counterparties.Data received from counterparties may not be-pledgedged.Control"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?",
        "options": {
            "A": "Two directors",
            "B": "Three directors",
            "C": "Four directors",
            "D": "Five directors",
            "E": "Six directors",
            "F": "Seven directors"
        },
        "LLM_original_answer": [
            "F.89.Security received from counterparties may not to our control.Security received from counterparties may not be subject to control.Security.Security counterparties may be sold or control.Security collateral received from their control of interest collateral received from our control.Security collateral received from counterparties may not be sold or otherwise.Finally received from time.Regulatory from counterparties.Security received from counterparties may not be subject to a control.Security collateral received from counterparties.Security counterparties may be sold or re-secured from counterparties.Security collateral received from counterparties may not sold or other control.Security received from counterparties may not under control.Security received from counterparties may not sold or re-secured from counterparties may be sold or re-pledge.Control of control.Security received from counterparties.Security received from counterparties may be sold or re-secured counterparties may be-secured collateralized.Security collateral received from counterparties.In the control.Security collateral received from counterparties.Security received under our control.Security collateral received from our control.Security counterparties.Security may not be-AMXAML may not be-secured by their control.Security counterparty may not be88.Security received from control.Security received from our control.Security received from counterparties may not subject to the control.Security received from control.Security received from control.Security collateral received from control.Security control.Security control.Security received from control.Security control received from counterparties.Security security collateral received from our control.Security received from counterparties.Security control.Security counterparties.Security control.Security control.Security collateral received from control.Collongovernment control.Security collateral received from counterparties may not be sold or control.Security control.Security collateral received collateral received from control.Security collateral received from control.Security collateral received from counterparties may not be-pledged.Regulatory control.Security collateral received from time, or terminated.Security counterparties.Security collateral received from our control.Security counterparties may not be-pledged.Regulatory control.Security control.Security received security received from counterparties may not be sold or control.Security received from control.Control of any control.Security collateral received from control.Security collateral received from our control.Security collateral received from our control.Security collateral received from our control.Security counterparties may not sold or other control.Security received from counterparties may not be sold or re- Security collateral received from counterparties.Security collateral received from our control.Security collateral received from counterparties may not be sold or re-secured collateral received from counterparties.Security collateral received from counterparties.Security collateral received or any of our control.Security collateral received from counterparties may not sold or control.Security collateral received from our control.Security collateral received from our control.Security collateral received from counterparties"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?",
        "options": {
            "A": "RMB0.8 million",
            "B": "RMB1.0 million",
            "C": "RMB1.3 million",
            "D": "RMB1.5 million",
            "E": "RMB1.8 million",
            "F": "RMB2.0 million"
        },
        "LLM_original_answer": [
            "The ICE Security collateral received from counterparties.Control.Security collateral received from control.Security collateral received from our control.Security received from counterparties.Security collateral received from our control.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from our control.Security received from the control.Security received from control.Security received from saleable control.Security received from our control.Security received from counterparties.Security received from our control.Security received from the control.Foreignor may not sold or re-Counterparty may be sold or re- Security received from counterparties may be sold or re-pledged.Security received from counterparties may not be sold or re-pledgedged.Security collateral received from counterparties may not sold or collateral received from counterparties may be sold or re-securedes may not be sold or re-pledged.Security collateral received from counterparties.Security collateral received control.Security collateral received from control.Security collateral received from control.Security collateral received from counterparties may be control.Security collateral received from counterparties.Security collateral received collateral received from control.Security collateral received collateral received from counterparties.Security collateral received from counterparties may be sold or control.Security.Security.Security.Security collateral received control.Security collateral received from control.Security collateral received from control.Security received from control.Security collateral received from our control.Security collateral received from control.Security collateral received from our control.Security collateral received from time.Security control of control.Security received from control may not sold or other than be sold or re-pledged.We may not sold or re- Security collateral received from control.Security collateral received from control.Security collateral received from counterparties.Control of control.Security collateral received from counterparties.Security received from counterparties may notional counterparties received from control.Security collateral received from counterparties.Security collateral received from our control.Security collateral received from control.Security collateral received from control.Security collateral received collateral received from counterparties may be-secured.Security collateral received from counterparties.Control.Security.Security collateral received from counterparties.Security received from counterparties may not be sold or counterparties.Control may be sold or re-counterparty.Security collateral received from our control.Security received from counterparties.Security collateral received from counterparties.Security received from counterparties may not be sold or control.Security collateral received from counterparties may not be sold or re-pledged from counterparties may not be sold or re-pledged.Security received from counterparties may not be sold or re-pledged.Security collateral received from counterparties.Security counterparties.Security collateral received from counterparties.Security collateral received from counterpartiesec-pledged.Security collateral received from counterparties may not sold or re-secured collateral received collateral received from counterpart"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is a potential consequence of failing to effectively manage company growth?",
        "options": {
            "A": "Improved financial condition",
            "B": "Enhanced employee morale",
            "C": "Improved forecasting accuracy",
            "D": "Adverse effects on business operations",
            "E": "Increased employee retention",
            "F": "Greater operational efficiency"
        },
        "LLM_original_answer": [
            "A.112.Security collateral received from control.Security collateral received from the control.Security collateral received from the control.Security collateral received from the Company.Security collateral received from the control.Security collateral received from the control.Management.Security collateral received from the control.Security collateral received from the control.Security control, if control.Security received from control.Assum control.Security collateral received from counterparties.Security received from counterparties.Security control.Management of the control.Assum control.Security control.Security collateral received from control.Security collateral received from control.Security collateral received from control.The Company collateral received from counterparties.Security collateral received from control.Security collateral received from counterparties.Internal control.The Company collateral received from the control.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties.Security collateral received from counterparties may not sold or control.Security collateral received from counterparties.Security collateral received from control.Security collateral received from control.Security collateral received from control.Security collateral received from counterparties.Security collateral received from control.Security collateral received from counterparties.Security collateral received from inception and claims.Market control.Security collateral received from the control.Security received control.Security control.Security collateral received from control.The Company may not sold or re-Notes to the control.Foreign control.The Company\u2019s control.Management.Security collateral received experience and control.Management.Security collateral received from control.Security collateral received from issuance.The Company.Security collateral received experience.The Company\u2019s control.The control.The estimated control.The control.The control.Management.Assessentially.Security of control.Security received from counterparties may not included in control.Security collateral received from control.Security received from the control.Security received from counterparties may not sold or their control.Security collateral received from counterparties.Seeased control.Security received from control.Security collateral received from control.Security collateral received from the control.Security collateral received from counterparties.Security received from counterparties\u2019control.Security collateral received from the Company.Security received from counterparties may not sold or re-secured control.Security received from counterparties.Security collateral received from control.Management.Security received from counterparties may not sold or control.Security received from the control.Security collateral received from counterparties may not sold or re-pledgedged.May secured.Security received from counterparties.The control may be sold or counterparties may not be sold or re-received from counterparties.Security collateral received from counterparties may be sold or re-secured.Security collateral received from counterparties.Security collateral received from counterparties control.Security collateral received collateral received collateral received from counterparties.Security collateral received from counterparties.Security collateral received from control.Security collateral received collateral received from control.Security collateral received from counterparties.Security collateral received from counterparties may not sold or other control.Security"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What happens if the lender makes a margin call and the borrower cannot fund it?",
        "options": {
            "A": "The borrower can delay payment without consequences",
            "B": "The lender must forgive the outstanding debt",
            "C": "The lender is contractually allowed to liquidate MSRs",
            "D": "The borrower must immediately pay off all outstanding debts",
            "E": "The lender cannot take any action",
            "F": "The borrower can negotiate new terms"
        },
        "LLM_original_answer": [
            "Based business, business, results of our business, financial condition, liquidity, results of operations and our business, results of operations and our business, financial condition, financial condition, results of operations and our business, financial condition, adversely and our business, liquidity, liquidity, results of operations and our business, results of operations and our business, results of our business, results of our business, results of our business, results of operations and our business, our business, results of our business, results of our business, results of our business, financial condition, results of operations and our business, financial condition, results of our business, results of our business, results of our business, business, results of our business, results of our business, results of operations and our business, results of our business, results of our business, results of our business, liquidity, results of our business, results of operations and our business, business, results of operations and our business, financial condition, results of our business, liquidity, results of operations and our business, results of operations and our business, results of our business, results of operations and adversely affect our business, financial condition, results of operations and our business, results of our business, liquidity, results of operations and our business, financial condition, liquidity, results of operations and our business, results of operations and our business, results of operations and our business, results of operations and our business, adversely affect our business, financial condition, liquidity, results of operations and our business, results of operations and our business, financial condition, results of operations and our business, results of operations and our business, results of our business, our business, adversely and adversely and our business, financial condition, results of operations and our business, financial condition, liquidity, results of operations and our business, results of operations and our business, results of operations and operations and our business, operations and our business, financial condition, liquidity, results of operations and our business, results of operations and our business, results of operations and our business, financial condition, results of operations and our business, results of operations and our business, results of our business, and our business, results of our business, results of our business, business, financial condition, liquidity, results of operations and our business, financial condition, liquidity, results of operations and our business, and our business, and our business, results of our business, financial condition, liquidity, results of operations and our business, business, results of our business, financial condition, business,"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?",
        "options": {
            "A": "$6.81",
            "B": "$0.01",
            "C": "$8.72",
            "D": "$10.00",
            "E": "$5.50",
            "F": "$7.50"
        },
        "LLM_original_answer": [
            "The periods presented:##1.1.2.2 1 2##table 1##table is not presented:##table 1##1:##table 1.2.2.1##table 2.1##table of the periods presented:##table 1.1.2.1.##1:##table 1.2##table 1.##1.2.1.1.2.1.1.2.1.1.2##table 1.1.1.2.2:##1.1.1.1.1:##table 1.1##1##1.##1.1:##1.1:##table 1.1.1.1:##1.1.1##table 1:##table 1.2.1.1.1.1.1.1.1 2.1.1.1.1.1.1.1:##1.2.2.1.1.2.1 1.1 2.2 2 2.2.2.2.2.2.2.2.2.2.2.2.2.1.1.2##1.1.2##1##1##1 2 2 1 1.2.2.1.2.2##table 1.2.2.2.2.2 2.2.1.2.2.2.1.1.2.1.2.2.2.1.1.2.1.##1.2.2.2##1.2.2.1.1.2.2.1.2\u2019s consolidated financials presented:##table 1##table 1##table 2:##table:##1:##1.1.2.2.1.2.2.1.1.2.1.1.1.1.2.2.1.1.1.1.1:##1.2##1.1.1.1##table 1.1##1.1 2.1 2.1 2.1.2.2.2.1.2.2.1.2:##1.1.1.1 1 2.1.1.2.1##1:##1"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?",
        "options": {
            "A": "Duke Energy Carolinas, LLC",
            "B": "Duke Energy Progress, LLC",
            "C": "Progress Energy, Inc.",
            "D": "Piedmont Natural Gas Company, Inc.",
            "E": "Duke Energy Florida, LLC",
            "F": "All of the above"
        },
        "LLM_original_answer": [
            "Which also contracts and also benefiting from the subscription-like contracts at scale and also from technological developments and also benefiting from technological developments and creates ongoing contracts and also benefiting from scale and creates ongoing subscription-like contracts at scale and creates ongoing subscription-like contracts at scale and also benefiting from technological developments and creates ongoing subscription-like contracts and also benefiting from scale and also benefiting from technological developments and technological developments at scale and contracts and also creating ongoing subscription-like contracts at scale and also benefiting from technological developments) (i-like contracts at scale and also creating ongoing subscription-like contracts at scale and also benefiting from technological developments and also benefiting from technological subscription-like contracts) (a) (a) (b) creates ongoing contracts at scale and also benefiting from scale and also benefiting from technological developments and also benefiting from technological developments and also benefiting from scale and also benefiting from technological developments and technological developments and also contracts and also benefiting from technological developments and creates ongoing subscription-like contracts and also benefiting from technological developments and creates ongoing subscription-like contracts and also benefiting from technological developments and also benefiting from technological developments and technological developments and also benefiting from technological developments and also benefiting from scale and also benefiting from technological developments and technological developments and also subscription-like contracts and also benefiting from technological developments and also benefiting from technological developments and also benefiting from scale and also benefiting from technological developments and also benefiting from technological subscription-like contracts and also creating ongoing contracts and also benefiting from scale and also benefiting from scale and also benefiting from technological developments and subscription-like contracts at scale and also benefiting from scale and also benefiting from technological developments and technological developments and subscription-like contracts) (a) (a) (b) and creates ongoing subscription-like contracts at scale and also benefiting from technological developments and creates ongoing subscription-like contracts and also benefiting from the subscription-like contracts at scale and also benefiting from scale and also benefiting from technological developments and creates ongoing contracts and also benefiting from the benefiting from technological developments and creates ongoing subscription-like contracts at scale contracts and creates ongoing subscription-like contracts. Also benefiting from technological developments at scale and creates ongoing subscription-like contracts and also benefiting from technological developments and creates ongoing subscription-like contracts and also benefiting from technological developments and creates a subscription-like contracts and also benefiting from the subscription-like contracts at scale and also benefiting from the subscription-like contracts and also benefiting from technological developments and also benefiting from technological developments and creates ongoing contracts) (b) and also benefiting from technological developments and creates ongoing subscription-like contracts and creates ongoing subscription-like contracts-like contracts-like contracts at scale and also benefiting from technological developments and creates ongoing contracts at scale and also creating ongoing contracts at scale and"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What type of businesses does Business Markets and Other primarily serve?",
        "options": {
            "A": "Public Sector and Enterprise",
            "B": "Businesses that meet Enterprise requirements",
            "C": "Businesses that meet Public Sector requirements",
            "D": "Businesses not meeting Enterprise and Public Sector requirements",
            "E": "Only IoT companies",
            "F": "Only conferencing service providers"
        },
        "LLM_original_answer": [
            "Based on a manner similar to a manner similar to a manner similar to which is evaluated in a manner similar to a manner similar to the manner similar manner similar to a manner similar to the manner similar to the manner similar to the credit risk associated with the credit risk in a manner similar to the mutual-to-stockholders\u2019eturneditsyaccordin a manner similar to the net proceeds of the credit risk associated with a manner similar to the credit risk associated with the net interest rate of which resulted in a manner in a manner similar to the same manner similar manner similar to the credit risk associated with a manner similar to the credit risk resubiqui.evaluations similar to the credit risk associated credit risk associated with these commitments, in a manner similar manner similar to the credit risk associated with the credit risk associated with a manner in a manner similar to a manner similar manner similar manner similar to the manner similar to the stockholders##table 2024##table 2024##table 2024##table 2024 ITEM 10Kresidual to the credit risk associated with respect to the manner similar to the liquidated in a manner similar manner similar to the following the net of the net of the amounts similar to the manner similar to the credit risk associated with the amounts similar to the credit risk associated with the net of the difference between the \u201c##table uments of the credit risk associated with the credit risk associated with respect to the manner similar to a manner similar to the credit risk associated with the manner similar to the manner similar to the manner similar to the manner similar to a manner similar to a manner similar to the manner similar to the credit risk reserving to the net income from the credit risk rescaled 2024##table 10-Knownote\n:message 58##table 56TABLE 2024.##table 64similar to the net income tax risk associated with the manner similar to the credit risk associated with the credit risk in a manner similar to the manner in a manner similar to a manner similar to the manner similar to the manner similar to the credit risk associated with the liquidated in a manner similar to the net of the credit risk associated with respect to a manner similar to the manner similar to the credit risk associated commitments in a manner similar to a manner similar to a manner similar manner similar to the credit risk associated credit risk associated with the credit risk similar to a manner similar to the manner similar to a manner similar to a manner similar to the credit risk associated with the credit risk associated credit risk similar to the credit risk"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?",
        "options": {
            "A": "Product quality and reliability",
            "B": "Technological capabilities",
            "C": "Marketing strategies",
            "D": "Cost-effectiveness",
            "E": "Industry experience",
            "F": "Vendor financing"
        },
        "LLM_original_answer": [
            "Which introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and disclosure initiatives will introduce additional due diligence and disclosure and will introduce additional disclosure initiatives will introduce additional due diligence and disclosure and/or disclosure and disclosure and/or introduce additional due to introduce additional due Diligence will introduce additional due diligence and will introduce additional due diligence and taxonomy initiatives will introduce additional due diligence and disclosure and EU taxonomy initiatives will introduce additional due diligence and will introduce additional due diligence and introduce additional due diligence and EU taxonomy initiatives will introduce additional due and EU taxonomy initiatives will introduce additional due diligence and disclosure and will introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and disclosure and disclosure and disclosure and introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and disclosure and disclosure initiatives will introduce additional due diligence and disclosure and EU taxonomy initiatives will introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and disclosure and disclosure and disclosure and introduce and will introduce additional due diligence and will introduce additional due diligence and disclosure and disclosure and EU taxonomy initiatives will introduce additional due diligence and/or introduce additional due diligence and our taxonomy initiatives will introduce additional due to the will introduce additional due diligence and will introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and introduce additional due diligence and EU taxonomy initiatives will introduce additional initiatives will introduce additional due diligence and disclosure and will introduce initiatives will introduce additional due diligence and disclosure and introduce additional due diligence and disclosure and introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and disclosure initiatives will introduce additional due diligence and disclosure initiatives will introduce additional due diligence and introduce additional disclosure and disclosure and EU taxonomy initiatives will introduce additional due diligence and disclosure initiatives will introduce additional due diligence and disclosure and disclosure and disclosure and disclosure initiatives will introduce additional disclosure and introduce additional due diligence and disclosure and disclosure initiatives will introduce additional due diligence and disclosure and disclosure and disclosure initiatives will introduce additional due diligence and disclosure and EU and disclosure and EU taxonomy initiatives will introduce additional due diligence and disclosure and disclosure and EU taxonomy initiatives will introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and disclosure and EU taxonomy initiatives will introduce additional due diligence and EU taxonomy initiatives will introduce additional due to EU taxonomy initiatives will introduce additional due diligence and EU taxonomy initiatives will introduce additional due diligence and disclosure and disclosure initiatives will introduce additional due diligence and disclosure and disclosure and disclosure and EU taxonomy initiatives will introduce diligence and EU initiatives will introduce additional taxonomy initiatives will"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?",
        "options": {
            "A": "$20.7 million UPB (154 loans)",
            "B": "$66.7 million UPB (71 loans)",
            "C": "$20.7 million UPB (354 loans)",
            "D": "$66.7 million UPB (154 loans)",
            "E": "$66.7 million UPB (71 loans)",
            "F": "$20.7 million UPB (71 loans)"
        },
        "LLM_original_answer": [
            "Based upon, or even forbidding, or even though, or even more than even forbidding, or forbidding, or even forbid, or even to beforbid, or even forbidding, or even forbidding, or impose restrictions upon, or even to select, or even, or even to select, or even forbidding, or impose restrictions or even forbid, or impose restrictions upon, or wholesale loan originations, or even, or even, or even forbid, or even forbid, or even forbidding or even forbid, or even, or even forbidding, or even forbid, or even if, or even, or even forbidding, or even the loan modifications or even forbid, or impose restrictions upon, or even if not only forbidding, or even forbidding, or even if not only forbidding, or even forbid, or even forbid, or even forbid, or even forbidding or even forbidding, or even forbidding, or even forbidding, or even more detailed, or even if a loan modifications, or even forbid, or even if the loan modifications, or impose restrictions or even if not only upon, or even if not to select, or even if, or even from, or even to select an investor disclosures or even to select an investor information technology and/or, or even if, or even if not to select an \u201cor even if not only after the servicers, or impose restrictions or impose restrictions upon, if, or impose restrictions upon, or even if the servicerserve, or even if not-forbidden, or other than even to select a mortgage modifications or even if not only forbid, or even forbidding, or even more than forbid, or even forbidding, or even forbid, or even if, or even on, or even forbid, or even to select an answerable, or even if not only, or impose restrictions upon, or even to beforbid, or even to select, or even forbid, or even forbid, or even if not only, or even forbidding, or even to befor, or even if not to the forbidding, or even forbidding, or even forbid, or even forbid, or even forbidding, or even more than forbid, or even though not-forfeor even though, or even outright forbid, or even forbid, or even forbidding, or even forbidding, or even forbid, or impose restrictions upon, or even to 2022. To select an issuer purchases or even forbid, or even forbid, or"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?",
        "options": {
            "A": "Kansas City and Sioux City",
            "B": "Des Moines and Minneapolis",
            "C": "Springfield and St. Louis",
            "D": "Northwest Arkansas and Eastern Iowa",
            "E": "Sioux City and Des Moines",
            "F": "Rural markets in Missouri and Kansas"
        },
        "LLM_original_answer": [
            "The economic recession that began in 2008.After 2009, after 2009 began in 2009 2009, 2009, 2009 recession that began in 2009, 2009,after 2009, 2009, after 2009,after 2009, the economic recession ended 2009, after 2009, after 2009,2009, after 2009 after 2009 2009, after 2009 economic recession that began in 2009, 2009, 2009, 2009, 2009, 2009, after 2009, the economic recession that began in 2009, 2009, after 2009 began in 2009, 2009, the economic recession that began in 2009 in 2009, 2009, the economic recession ended 2009, the economic recession that began 2009, 2009, 2009, 2009, 2009, after 2009, 2009, after 2009threw that began in 2009, 2009, in 2009 2008 that began in 2009,200 2009, the economic recession that began in 2009, after 2009, after 2009, after 2009, after 2009, after 2009,2009, after 2009 after 2009, 2009, after 2009, after 2009, after 2009 in 2009, the economic recession ended 2009 that began in 2009, 2009, the economic recession, 2009, 2009, after 2009 2009, after 2009, the economic recession that began in 2009, after 2009 began in 2009, after 2009, economic recession that began in 2009, 2009, after 2009,after 2009, 2009, after 2009, after 2009, after 2009 after 2009, after 2009, after 2009, after 2009, after 2009 in 2009, after 2009, after 2009, 2009,2009,2009,2009, after 2009, after 2009, 2009, after 2009 2009"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?",
        "options": {
            "A": "Two directors",
            "B": "Three directors",
            "C": "Four directors",
            "D": "Five directors",
            "E": "Six directors",
            "F": "Seven directors"
        },
        "LLM_original_answer": [
            "F: therefore, therefore, and personnel resources may be costly and may require significant financial and personnel and personnel resources may be may be may be costly and therefore, and therefor the foregoing, and may be approved product candidates for the foregoing significant financial and may be costly and may require significant financial and may be costly and may require significant financial and may be required to comply with respect the foregoing significant financial and therefore, there is there is therefore, and may require significant financial and personnel resources may be may be aware of our business-related resources may be may be costly and personnel resources may require significant financial and personnel resources may be approved product marketing and/or there may be costly and personnel resources may be approved product candidates for AMXOncurrently licensed and personnel resources may be required resources and personnel resources, and may be required resources may be approved by the financial and may be approved by the therefore, or the foregoing, and/or other than may be subject to the foregoing our business and personnel resources may be subject matter of our business operations and may require significant financial and/or may becertain to the foregoing any of the foregoing the foregoing the foregoing is therefore, and personnel resources may require significant financial and may require significant financial and personnel resources may becertainly there is not only therefore, and may be approved by the foregoing the foregoing the foregoing significant financial and may require significant financial and may require significant financial and time-consuming and personnel resources may be a product candidates for the amount of our business and time-consuming, and personnel resources may require significant financial and personnel resources may be may be approved product development of the therefore, or any of the U.Specifically may be may be approved for which may be approved for which may be approved product marketing and personnel and personnel resources may be approved product development and may be may be costly and/or otherwise, or other applicable laws and/or otherwise, or their product candidates for which may be may be approved product candidates for AMXQMRA therefore, and may be may require significant personnel resources may be required to the foregoing may be may be approved by the following the foregoing significant financial and may require significant financial and personnel resources may be required resources may be costly and may be costly and personnel resources may be approved product candidates may be approved product resources may be approved by the therefore, and/or the following the FDA and/or other than may be approved product candidates\u2019\n,rp and personnel resources may be approved product candidates for AMXporter resources may be may require significant financial and personnel resources may be approved products that may be approved product marketing and time-consuming"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?",
        "options": {
            "A": "RMB0.8 million",
            "B": "RMB1.0 million",
            "C": "RMB1.3 million",
            "D": "RMB1.5 million",
            "E": "RMB1.8 million",
            "F": "RMB2.0 million"
        },
        "LLM_original_answer": [
            "The U.S. Notice 2023. Treasury Department and the IRS issued Notice 2023-1, which provides Notice 2023. The U.S. Notice 2023-1, which provides Notice 2023-7, U.S.2023, which provides Notice 2023, which provides Notice 2023, which provides Notice 2023 issued Notice 2023 released Notice 2023 released Notice 2023-7-2023-1. The U.S. U.S. Treasury Department of the U.Sec 2023-1, which provides Notice 202 2023-7-7 Legal 2023. The U.See U.S. Notice 202 2023. The U.S. Notice 2023-7-7 U.Sec issued Notice 2023 released Notice 2023 U.Sec issued Notice 2023 released Notice 2023 issued Notice 2023. Notice 202 released Notice 2023-2023, which Notice 2023, which provides Notice 2023, which provides Notice 2023 released Notice 2023-2023. Notice 2023, U.S. Notice 2023 released Notice 2023-2023-Notice 202 U.S. Treasury Notice 2023-1, which Notice 2023, which includes Notice 2023 Notice 2023-8 Notice 2023-7-issued Notice 2023-2023 U.See Notice 2023\nU.Sec 202 U.S. Treasury Department and the IRS released Notice 2023-1-7, which Notice 2023 released Notice 2023 released Notice 2023-8, which Notice 202 Notice 2023.2-1 and Notice 2023. Notice 2023. Notice 2023. U.S. The U3 U2. The U.Sec 2023 released Notice 2023-7 (U.S. The U.S. U.S. Treasury Department and the U2. 2023-1 and the U.S. The U.Secircs U.S. The U.S. Notice 2023-1, the U.Sec 2023, the U.See Notice 2023 U.S. Notice 2023-IRS released Notice 2023-7 and Notice 2023-1, the U.S. The U.See-1, which includes Notice 2023. Notice 2023 IRS"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is a potential consequence of failing to effectively manage company growth?",
        "options": {
            "A": "Improved financial condition",
            "B": "Enhanced employee morale",
            "C": "Improved forecasting accuracy",
            "D": "Adverse effects on business operations",
            "E": "Increased employee retention",
            "F": "Greater operational efficiency"
        },
        "LLM_original_answer": [
            "AAR-approachitect approach.The estimated fair value includes capital market inputs and option-budgets budget and option-budget approach, as well-being approach, budget and option-budget inputs and budget and option-budget approach includes capital market approach.Underfunding and option-budget approaches.The estimated fair value and option-budget approach approach approach approach.The estimated fair value and option-budget approach.The estimated fair value and option-budget approach to budget and option-budget approach, as well as well-budgets-budget approach, as well-budget approach, which isingridgethedge approach.The estimated fair value of the estimated fair value and option-budget approach includes capital market inputs and option-budget approach to be option-budget approach includes capital market inputs and actuarial option-budget approach.The estimated fair value and option-budget approach.The estimated fair value and option-budgetsensitivity budget and option-budget approach and option-budget approach includes capital market inputs and option-budget approach.The estimated fair value includes capital market inputs and option-budget approaches.The estimated fair value and option-budget approach and option-budget inputs and option-budget inputs and option-budget approach.The estimated fair value and the estimated fair value-budget approach, as well-being approach, as well-being approach, as well-being approach.Under the estimated fair value includes capital market inputs and option-budget approach approach includes capital market inputs and option-budget approach approach approach and option-budget approach and option-budget approach and option-budget approach and option-budget approach approach and other than the option-budget approach. Option-Budget inputs and option-budget approach and option-budget approach approaches and option-budget approach.The estimated fair-value approach approaches to an option-budget approach approach approach approach.The estimated fair value and option-budgets and actuarial value includes capital market inputs and actuarial approach.The estimated fair-value approach.Understanding approach includes capital market inputs and actuarial option-budget approaches and the estimated fair value and option-budget approach.Underwriting of the option-budget approach.Understanding annuity approach and a prior to the estimated fair market inputs and option-budget approach and option-budget approach includes capital market-based approach isother-budget approach.The estimated fair-value approach.The estimated fair value-budget approaches, as well-funded approach.The estimated fair value and ULSGloss-budget approach approach approach approach approach approach approach approach approach approach and ULSGlossesentially budget and the ULSGloss-budget approach.Understanding actuar-budget approach.Underfunding inputs and option-budget approach to be-budget approach to budget, which includes capital market approach. The estimated fair value and option-budget approach, as well-being approach.Underfunding and option-budget approach"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What happens if the lender makes a margin call and the borrower cannot fund it?",
        "options": {
            "A": "The borrower can delay payment without consequences",
            "B": "The lender must forgive the outstanding debt",
            "C": "The lender is contractually allowed to liquidate MSRs",
            "D": "The borrower must immediately pay off all outstanding debts",
            "E": "The lender cannot take any action",
            "F": "The borrower can negotiate new terms"
        },
        "LLM_original_answer": [
            "If the Company's \"as of its internal control over its control over its annual financial reporting. The Company's internal control disclosures and its internal control over financial control over its internal control over financial reporting. PCAOB as of financial reporting. The PCAOB, and other required disclosure and its financial reporting as of which includes financial reporting as of \"B's disclosure of its internal control over financial reporting as of December  December  including its financial reporting and its other than is over financial reporting and is based on its disclosure of which includes its financial reporting. The Company's internal control over its as of its internal control over financial reporting over financial reporting and reported for the the Company's as of the \"as of its disclosure. The PCAOB's internal control over financial control over financial reporting and the Company's of its financial reporting. The PCAOB's internal control over financial reporting. Based on the Company's internal control over financial reporting of the Company's internal control over financial reporting and its internal control over its internal control over financial reporting and and the PCAOB's internal control over financial reporting and the PCAOB's as of its financial reporting (PCAOB as of March 11 as of its internal control over its internal control as of its financial reporting of its financial reporting. The PCAOB), its internal control's internal control over financial reporting and its internal control over financial reporting. The PCAOB as of its disclosure and the PCAOB's internal control over financial reporting as of its annual control over its internal control disclosures related to the Company's annual control over financial reporting as of the PCAOB. The Company's internal control of its internal control over financial reporting (PCAOB), and its internal control over financial reporting as of its internal control over its internal control's internal control. The Company's internal control over financial reporting. The Company's internal control over its internal control over its internal control over financial reporting its other than the Company's financial reporting. The Company's reporting for its financial reporting. The Company's internal control of the Company's internal control over its internal control report on financial reporting as of its internal control over financial reporting and its financial reporting and its financial reporting and its financial reporting and other than as of its financial reporting its as of its financial reporting (PCAOB's financial reporting its financial reporting its financial reporting and financial reporting for each of PCAOB), as of its internal control over financial reporting and its financial reporting of its reporting. The PCAOB's internal control over its financial reporting as of its internal control over its internal control over financial reporting and disclosure"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is the exercise price per share for Tranche 1 Warrants to purchase Core Common Stock?",
        "options": {
            "A": "$6.81",
            "B": "$0.01",
            "C": "$8.72",
            "D": "$10.00",
            "E": "$5.50",
            "F": "$7.50"
        },
        "LLM_original_answer": [
            "What is probable that it is as to be achieved.The performance conditions as not only one or not be achieved.Commonly or as to the performance conditions will be achieved.Common stockholders of the market acceptance of which or not be achieved.Common performance conditions will be achieved performance conditions will be achieved as well as well as to the performance conditions will be achieved or not be achieved.Commonly or not probable that the performance conditions will be achieved.The performance conditions of the performance conditions as a performance conditions as well as well as well as to the Company29probable financial statements.U.Secrevenue.Under or not only as well as well as to the performance conditions as to the performance conditions as of the performance conditions will be achieved as to the performance conditions will be achieved as to the performance will be as to the performance conditions as to the Company29probable or not it is probable that the performance conditions will be met.The extent that the performance conditions as of not probable that the performance conditions will be subject to the conditions as well as of the performance conditions as not to the performance conditions as to the performance conditions will be achieved.The performance conditions will be subject to the performance conditions as to the performance conditions will be as well as well as a reasonable expectations as to the performance conditions as to the performance conditions as to the performance conditions as to the performance conditions are as to the performance conditions as it is probable that it is it is probable that it is probable that the performance conditions will be achieved as to the performance conditions as to the performance conditions and not only one or not be more likely that the performance conditions will be as well as well as of the performance conditions will be achieved.The performance conditions will be met performance conditions as to the performance conditions of the performance conditions of the Company risks related to the performance conditions will be achieved performance conditions will be achieved.Common stock the performance conditions as well as to the performance conditions as to the performance conditions as to the conditions.Common stockholders of the common stockholders of the performance conditions as to be achieved that it is probable that the performance conditions will be achieved as well as to the Company\u2019s as to the performance conditions will be met the performance conditions will be achieved as to be achieved as to the common stockholders29Risks and/or otherwise than the performance conditions will be subject to the Common Stockholders of the Company\u2019s business and/or otherwise as to the Common Stockholders of the performance conditions as to the regulatory framework of the Commonlyseveral asset participants are not only as to the performance conditions will be as to be achieved.Common Stockholders of the performance"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which company's consolidated financial statements include a statement of comprehensive income for Duke Energy entities?",
        "options": {
            "A": "Duke Energy Carolinas, LLC",
            "B": "Duke Energy Progress, LLC",
            "C": "Progress Energy, Inc.",
            "D": "Piedmont Natural Gas Company, Inc.",
            "E": "Duke Energy Florida, LLC",
            "F": "All of the above"
        },
        "LLM_original_answer": [
            "Which receivable arising from the sale of electricity, natural gas and certain electricity and natural gas and natural gas, natural gas and natural gas and CRC, natural gas and natural gas and natural gas and other from the sale of electricity and natural gas and natural gas and other services arising from the sale of electricity, natural gas and other gas and natural gas, natural gas and CRC buys certain accounts receivable arising from the sale of electricity and CRC, electricity and other services and gas and natural gas and other related services arising from the sale of electricity and other products and natural gas and certain accounts receivable electricity, natural gas, natural gas and natural gas and other electricity and natural gas and other gas and other services arising from the sale and renewable energy and other than natural gas and accounts receivable electricity, natural gas and natural gas and natural gas and other accounts receivable, natural gas and other arising from the sale of electricity and other services and certain accounts receivable electricity, natural gas and accounts receivable, natural gas and other gas and gas and other commodities arising from CRC arising from CRC, natural gas and natural gas and natural gas and related services arising from Duke, natural gas and accounts receivable from the sale of electricity and natural gas and CRC, natural gas and CRC and natural gas and natural gas and natural gas and other related services arising from the sale of electricity and natural gas and other and other products and natural gas and related services and related natural gas and CRC buys electricity, natural gas and other accounts receivable, natural gas and natural gas and natural gas and CRC and CRC and natural gas and other gas and natural gas and related from the sale of electricity and other gas and other commodities and natural gas and natural gas and CRC and natural gas and natural gas certain accounts receivable electricity and CRC, natural gas and CRC buys accounts receivable, natural gas and renewable gas and other services and renewable energy and other commodities, natural gas and accounts receivable from the sale of CRC and other commodities and other services and CRC and natural gas and renewable gas and natural gas and other services, natural gas and natural gas and other commodities and other services and other commodities and natural gas and CRC and other services arising from CRC and natural gas arising from the sale of electricity, natural gas and natural gas and natural gas and accounts receivable arising from electricity, natural gas and natural gas and related services arising from the sale of accounts receivable arising the sale of electricity, natural gas and natural gas arising from the sale and natural gas and certain accounts receivable, natural gas and related from the sale"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What type of businesses does Business Markets and Other primarily serve?",
        "options": {
            "A": "Public Sector and Enterprise",
            "B": "Businesses that meet Enterprise requirements",
            "C": "Businesses that meet Public Sector requirements",
            "D": "Businesses not meeting Enterprise and Public Sector requirements",
            "E": "Only IoT companies",
            "F": "Only conferencing service providers"
        },
        "LLM_original_answer": [
            "The non-accrual loans are included in loans.(1)Non-accr.(1)Loans.(1)Non-accrual loans are included in loans.(1)Non-accr.(1)Non-Non-accr(1)Non-accr.(1.(1)Non-accrual loans are included in loans.(1)Loans.(1) are included in loans.(1)Loans.(1) loans.(1)Loans are included in loans are included in loans.(1Non-accr.(1)Non-accr.(1)Non-accr.(1%Non-accrisky.(1)The information.(1Non-accrual loans.(1)Eastern Bank of Eastern Bank Control of Cambridge Bancrual loans.(1)Loans.(1)Non-accrual loans are included in loans.(1)Loans.(1)Loans.(1)Loans.(1)Loans include loans.(1.(1)Loans are included in loans.(Non-accrual loans are included in loans.(1 loans.(1,1)Non-accrual loans are included in loans.(1) are included in loans.(1Non-accrual loans are included in loans.(1)Non-Non-accrural loans.(1.(1)Non-accr(1, loans.(1) are included in loans.(1)Non-accrual loans.(1.(1.(1)Loans.(1.(1)Non-accr.(1% of loans.(1)Loans include loans are included in loans.(1Non-accr(1)(1) are included in loans.(1, loans.(1)Loans.(1 are included in loans.(1.(1)Loans.(1Non-accrNon-accr non-accr(1)Loansrual loans are included in loans.(1)Non-Non-accrual loans are included in loans are included in loans.(1)Non-Non-Non-Non-accrual loans are included in loans.(1)Non-accrual loans.(1)Loans are included in loans are included in loans.(1)Non-Non-Non-accrual loans are included in loans.(1)Non-earning in loans.(1)Non-accr.(1)Non-accrural loans.(1)Non-accrual loans are included"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "Which factor is NOT mentioned as a competitive factor in the markets where the company operates?",
        "options": {
            "A": "Product quality and reliability",
            "B": "Technological capabilities",
            "C": "Marketing strategies",
            "D": "Cost-effectiveness",
            "E": "Industry experience",
            "F": "Vendor financing"
        },
        "LLM_original_answer": [
            "Which the estimated costs of the estimated costs of the Company\u2019s activities based upon the estimated costs of research and development activities based upon the estimated costs of the estimated costs of the estimated costs of the estimated costs of the majority of the estimated costs of the majority of the costs of the estimated costs of the estimated costs of the estimated costs of the costs of the clinical trial activities based upon the estimated costs of research and activities based upon the costs of the costs of the estimated costs of the clinical trials based upon the estimated costs of the estimated costs of the research and activities based upon the research and development activities based upon the estimated costs of the estimated costs of the estimated costs of the research and development activities based upon the estimated costs of the estimated costs of the research and the estimated costs of the estimated costs of the costs of the estimated costs of research and development of the estimated costs of the estimated costs of research and development activities based upon the application of the estimated costs of research and/orphanomission based upon the Company\u2019s based upon the research and/orphan and research and development activities based upon the clinical trials and/orphanetic costs of the costs of the clinical trial and/orphanology of the clinical and the estimated costs of the clinical trial and the estimated costs of the costs of clinical trial and activities based upon the product development and/orphanetic costs of the majority of the estimated costs of the clinical trial and the costs of the clinical trials and development of the costs of the costs of the estimated costs of the estimated costs of the activities based activities based upon the estimated costs of the research and activities based upon the estimated costs of the estimated costs of the costs of the clinical trial and the estimated costs of the costs of the estimated costs of the estimated costs of the research and research and activities based upon the estimated costs of the estimated costs of the estimated costs of the estimated costs of the estimated costs of the costs of the estimated costs of the results of the research and research and/orphanology of the research and development of research and activities based upon the estimated costs of the estimated costs of the research and the costs of the costs of clinical activities based upon the research and/orphanomic costs of the estimated costs of research and activities based upon the estimated costs of the research and activities based upon the clinical trial and preclinical trial and development activities based upon the research and/orphanomission based upon the estimated costs of the estimated costs of research and/orphanomission of the FDA Humanitarian and/orphan and activities based upon the costs of the estimated costs of the clinical trial and/or"
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the total outstanding representation and warranty repurchase demands at December 31, 2023?",
        "options": {
            "A": "$20.7 million UPB (154 loans)",
            "B": "$66.7 million UPB (71 loans)",
            "C": "$20.7 million UPB (354 loans)",
            "D": "$66.7 million UPB (154 loans)",
            "E": "$66.7 million UPB (71 loans)",
            "F": "$20.7 million UPB (71 loans)"
        },
        "LLM_original_answer": [
            "The third quarter 2022. liabilities issued beginning in the ESS financing liabilities issued beginning in the ESS financing liabilities.ESS 2022 quarter of 2022. ESS FINANC Income Tax Rate ESSR.ESS financing market ESSS. See the ESSR.Seefinancing liabilities issued in the business and the ESSFunding Matters Related to refinance.Risked other than we are issued beginning in the third quarter of the ESSuccess 2022. The ESS 22.R.ESS financing liabilities issued beginning in the third quarter of the ESS financing liabilities beginning in the third quarter of our servicing liabilities issued beginning in the third quarter of the third quarter of 2022.S. ESSs issued beginning in the third quarter of 2022.Seclosing beginning in the fourth quarter of the third quarter of total liabilities issued beginning in the ESS Financing beginning in the third quarter of 2022.Servicing beginning in the subject to begin in the third quarter of 2022.See 2022ESS financing liabilities issued beginning in the ESS financing liabilities issued beginning in the total outstanding liabilities issued beginning in the subject to the third quarter of 2022.2 beginning in the third quarter beginning in the ESS:Rising beginning in the third quarter of 2022.The total liabilities issued beginning in the third quarter of 2022nd quarter of our business and RESS financing liabilities issued beginning in the third quarter of 2022.q\nThird quarter of the third quarter of the third quarter of 2022. third quarter of 2022.2022.3rd quarter 2022.See.See beginning in the ESS financing liabilities issued beginning in the ESS financing liabilities issued beginning in the third quarter of the ESS financing liabilities issued beginning in the ESS financing liabilities issued beginning in the ESS financing liabilities issued beginning in our business and ESS Financing financing liabilities issued beginning in the third quarter of 2022.The ESSPand ESS financing liabilities issued in connection to the third quarter of 2024th quarter 2022.2nd 2022. See \u201cSee: 2022nd 2022.See third quarter of our business, and other than the business, and other than the ESS Act issued financing liabilities issued beginning in the ESS.Less beginning in the ESSF.SSMA financing liabilities issued beginning in the third quarter of 2022ndqsthat is the third quarter of 2022."
        ],
        "LLM_extracted_answer": [
            "F"
        ],
        "ground_truth": "F"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "Where are the two largest deposit concentrations of the Company located as of December 31, 2023?",
        "options": {
            "A": "Kansas City and Sioux City",
            "B": "Des Moines and Minneapolis",
            "C": "Springfield and St. Louis",
            "D": "Northwest Arkansas and Eastern Iowa",
            "E": "Sioux City and Des Moines",
            "F": "Rural markets in Missouri and Kansas"
        },
        "LLM_original_answer": [
            "The continued acceptable safety profile.A continued acceptable safety profile of our continued continued acceptable safety profile of our continued continued acceptable safety profile of our safety following approval.A continued continued continued acceptable safety profile.A continued continued continued acceptable safety profile of our therapies following approval.A continued continued continued continued acceptable safety profile of a continued acceptable safety profile of our therapies following approval.A continued continued acceptable safety profile of our therapies following a continued acceptable safety profile of our safety profile of our continued acceptable safety profile of our therapies following approval.A continued acceptable acceptable continued acceptable safety profile of our continued acceptable acceptable acceptable safety profile of our continued acceptable safety profile of our continued acceptable safety following a continued acceptable safety profile of our safety profile of a continued acceptable safety profile of our therapies following approval.A continued acceptable safety.B Continued Acceptable acceptable safety profile of our safety profile of our continued acceptable safety profile of our safety profile of our therapies following approval.A continued acceptable acceptable safety profile of our therapies following approval.The continued acceptable safety profile of a continued acceptable safety profile of a continued acceptable safety profile of our continued acceptable safety profile of an acceptable safety profile of a continued acceptable safety profile following approval.A continued acceptable safety profile of our continued acceptable safety profile of our continued acceptable safety profile of a continued acceptable safety profile.A continued acceptable safety profile of our continued acceptable safety profile of our continued acceptable safety profile.A continued acceptable safety profile of our therapies following approval.A continued acceptable safety profile of our safety profile of our therapies following a continued acceptable safety profile of our therapies following approval.A continued continued acceptable safety profile of a continued acceptable safety profile of our continued acceptable safety profile of our continued acceptable safety profile of our continued acceptable safety profile of our safety profile of our therapies following approval.A continued acceptable safety profile of our continued acceptable safety following a continued acceptable safety profile of our therapies following an acceptable safety following approval.A continued acceptable safety following approval following a continued acceptable safety following approval.A continued acceptable safety profile of our safety profile.A continued acceptable safety profile of our therapies following approval.A continued acceptable safety profile acceptable safety profile of our therapies following approval.A continued acceptable safety profile of our safety profile.A continued acceptable safety following approval of our safety profile of our safety profile of our safety profile of our safety profile of our research.B.B. A continued acceptable safety profile of our therapies following approval.A continued acceptable safety profile.A continued acceptable safety profile of our therapies following approval.A continued acceptable safety profile of our safety profile of our therapies following discovery of our safety profile of our safety.A continued acceptable safety profile of our continued acceptable safety profile of our safety profile of our safety following approval.Brief continued acceptable"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "How many directors are in each class of the QTI Holdings Board following the Effective Time?",
        "options": {
            "A": "Two directors",
            "B": "Three directors",
            "C": "Four directors",
            "D": "Five directors",
            "E": "Six directors",
            "F": "Seven directors"
        },
        "LLM_original_answer": [
            "C, and other regulatory agencies in the EMA, and other regulatory agencies in the EMA, and other regulatory agencies in the EMA, and other regulatory agencies in the EMA, and other regulatory agencies in Canada, Health Canada, and other regulatory agencies, and other regulatory agencies in the the, and other regulatory agencies in the EMA, the EMA, and other regulatory agencies in the EMA, and other regulatory agencies in the EMA, Health Canada, the EMA, the EMA, and other regulatory agencies in the EMA, and other regulatory agencies in the EMA, and other regulatory agencies in the EMA, and other regulatory agencies in the EMA, and other regulatory agencies, and other regulatory agencies in the EMA, and other regulatory agencies in the FDA, and other regulatory agencies in the EMA, and other regulatory agencies in the EMA, and other regulatory agencies in the EMA, and other than other regulatory agencies in the EMA, and other regulatory agencies, and other regulatory agencies in the EMA, and other regulatory agencies in Canada, and other regulatory agencies in 40 and other regulatory agencies in the FDA, and other regulatory agencies in the, and other regulatory agencies in the the FDA, and other regulatory agencies in certain drugs, the EMA, and other than the EMA, and other regulatory agencies in the, Health Canada, the EMA, and other regulatory agencies in other regulatory agencies in the EMA, and other regulatory agencies in the, and other regulatory agencies in the FDA, and other regulatory agencies, and other regulatory agencies in the EMA, and other regulatory agencies, and other regulatory agencies, and other regulatory agencies, and other regulatory agencies in other regulatory agencies in the FDA, Health Canada, and other regulatory agencies, and other regulatory agencies in the the EMA, Health Canada, and other regulatory agencies, and other regulatory agencies in the EMA, and other regulatory agencies in addition, and other than the FDA, and other than the FDA, and other regulatory agencies in the FDA, and other regulatory agencies, and other than other regulatory agencies, Health Canada, and other regulatory agencies, and other regulatory agencies in the FDA, and other regulatory agencies in the FDA, the EMA, and other regulatory agencies in the, the EMA, and other regulatory agencies in the EMA, and other regulatory agencies in addition or other regulatory agencies in the EMA, the FDA, and other regulatory agencies, and other regulatory agencies in the EMA, and other regulatory agencies in"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is the average capital spending for a new Pizza Hut restaurant unit in 2023?",
        "options": {
            "A": "RMB0.8 million",
            "B": "RMB1.0 million",
            "C": "RMB1.3 million",
            "D": "RMB1.5 million",
            "E": "RMB1.8 million",
            "F": "RMB2.0 million"
        },
        "LLM_original_answer": [
            "The following the amount of our share of 2023, and 2022, and the in 1, respectively, respectively, which we continue to acquirements and our businesses, and to the, and other than the promissuingovernment, 2022. Interoperating, 2022, and 2022, respectively, and the following the consumm, and $ 2022, and 2022, respectively, and $ 2021 and, respectively, respectively, respectively, 2022, and  respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, and $  and $  respectively, respectively, respectively, respectively, respectively, respectively, 2022, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, 2021, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively, respectively,  and $ 2021, respectively, respectively, respectively, respectively, respectively, and $  in  and 2023, respectively, respectively, respectively, respectively, respectively, and $ 2022, respectively, respectively, respectively, respectively, and $ 2021, and Black Knight, respectively, and we recorded a $ 1. 2021, and  and $ 2021, and Black Knight, and in 2023, and $  and our and  respectively, respectively, respectively, and we recorded a variety of $ 2023, and other risk management activities and, and the our organizational activities and other regulatory developments in 2023, respectively, and the 2023, and 2021, 2022, and 2021. We continue to acquirements. We continue to date-related activities in connection activities related to date and a variety of $ 2022 and our share of our organizational activities related to date, respectively, and, and $ 2022, respectively, and $ 2022, and $  respectively, 2022, and $ 1. We have a change in 2022, 2022, respectively, respectively, respectively, and  and $ 2021, respectively, respectively, respectively, and $  respectively, respectively, 2022, and 2021, respectively, respectively, and $ 2021, respectively, and $ 2021, respectively, respectively, respectively, respectively, respectively, respectively, 2023, and  in October"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 80,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is a potential consequence of failing to effectively manage company growth?",
        "options": {
            "A": "Improved financial condition",
            "B": "Enhanced employee morale",
            "C": "Improved forecasting accuracy",
            "D": "Adverse effects on business operations",
            "E": "Increased employee retention",
            "F": "Greater operational efficiency"
        },
        "LLM_original_answer": [
            "What is a limited by:\u2022 Net Costs and/or best estimate-based on a decrease in the\u25e6:\u2022 an increase in connection with respect to:\u2022 an increase in the the\u25e6:\u25e6 a decrease in certain of:\u2022 a net costs that may vary in connection with respect to meet:\u25e6 a due to closely related to the, as well as well as a net costs and, as well as well-being activities, as well as well-being activities due to ensure that may vary with respect to the, as well beyond the, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as a decrease in the related to the due to the due to the\u25e6 an increase in-force related to the:\u25e6 in-force markets sensitivities due to the activities due to ensure that are consistent with respect of:##Insurance-activities due to the due to:\u25e6 activities due to:\u25e6:\u25e6 costs due to the the the, which may be a decrease in the under certain of certain of:\u25e6:\u25e6 certain of:\u2022 Costs and/or:\u25e6ments about:\u2022 an increase in the\u25e6 an increase in the\u25e6:\u25e6:\u25e6 a decrease in certain of insurance-related activities due to:\u25e6:\u25e6a decrease in-force related to the\u25e6 due to the activities, as well as well as well as well as well as well as well as well as well as well beyond best estimate; and/or due to the due to the\u25e6:\u2022 Net Costs of certain of our variable annuity of the annuity due to the to:\u25e6 an increase in-sensitivity due to the the the amounts due to the due to ensure that would be applied to:\u2022 a fiduci costs of:\u2022\n_pdu activities under the\u25e6 the the benefits within certain of:\u2022 an increase in the\u25e6 a net costs of certain of the due to:\u2022 an increase in connection with respect to:\u25e6:\u25e6 costs associated with respect to the\u25e6:\u25e6an increase in the due to support due to:\u25e6 a decrease in net costs due to the; a decrease in-such as well as well as well;\u25e6:\u25e6an increase in the related to:\u25e6:\u25e6:\u25e6:\u25e6an increase in net costs due to reflect the the the"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?",
        "options": {
            "A": "Increased interest rates on loans",
            "B": "Federal pre-emption benefits",
            "C": "Adverse consequences",
            "D": "Automatic license renewal",
            "E": "Exemption from state requirements",
            "F": "Reduction in documentation requirements"
        },
        "LLM_original_answer": [
            "Question: What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?\nOptions:\nA: Increased interest rates on loans\nB: Federal pre-emption benefits\nC: Adverse consequences\nD: Automatic license renewal\nE: Exemption from state requirements\nF: Reduction in documentation requirements\nAnswer: C: Adverse consequences"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?",
        "options": {
            "A": "Low operational costs",
            "B": "Exclusive commercial partnerships",
            "C": "Reduced regulation requirements",
            "D": "Access to diverse investment opportunities",
            "E": "Financial strength ratings from multiple agencies",
            "F": "Priority in claim settlements"
        },
        "LLM_original_answer": [
            "Based on the provided document, one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market is:\n\nD: Access to diverse investment opportunities.\n\nThis is because being part of the Lloyd's market allows Syndicate 3456 to benefit from the financial strength ratings from multiple agencies, which can enhance its reputation and credibility in the market. However, the document does not explicitly mention this as a benefit. The document also does not provide information to support options A, B, C, or F as benefits for Syndicate 3456 being part of the Lloyd's market."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one potential reason for future decline in the company's revenue growth?",
        "options": {
            "A": "Decreasing demand for their platform",
            "B": "Expansion into new markets",
            "C": "Improved operational efficiency",
            "D": "Increased revenue from current customers",
            "E": "Successful marketing strategies",
            "F": "Increased demand for their services"
        },
        "LLM_original_answer": [
            "One potential reason for future decline in the company's revenue growth could be:\n\nOption A: Decreasing demand for their platform\n\nThe document indicates that BlackSky has a proprietary satellite constellation and an AI-enabled software platform that provides high-frequency, high-resolution imagery and analytics. The company's services are in demand for various applications, including national security, supply chain intelligence, and crisis management. However, if there is a decrease in demand for their platform, it could be due to several factors such as market saturation, technological advancements by competitors, or a shift in customer preferences."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What potential impact could unfavorable economic conditions have on the organization?",
        "options": {
            "A": "Ease legal constraints on current services",
            "B": "Increase profits from outdated technologies",
            "C": "Reduce affordability and demand for products",
            "D": "Eliminate the need for technological enhancements",
            "E": "Reduce costs associated with competitive advantages",
            "F": "Ensure the rapid adoption of new technologies"
        },
        "LLM_original_answer": [
            "Based on the provided document, the potential impact that unfavorable economic conditions could have on the organization is:\n\nC: Reduce affordability and demand for products\n\nUnfavorable economic conditions, such as a recession or economic slowdown, could negatively affect the affordability of and demand for the organization's products and services. Consumers may seek to reduce discretionary spending by forgoing purchases of the organization's products, electing to use fewer higher margin services, dropping down in price plans, or obtaining lower-cost products and services offered by other companies. Similarly, under these conditions, the business customers that the organization serves may delay purchasing decisions, delay full implementation of service offerings, or reduce their use of services."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is a potential consequence of changes in tax legislation and regulations on the company?",
        "options": {
            "A": "Increase in the number of employees",
            "B": "Decrease in production costs",
            "C": "Reduction in market share",
            "D": "Increase in the complexity and cost of tax compliance",
            "E": "Rise in customer satisfaction",
            "F": "Improved international partnerships"
        },
        "LLM_original_answer": [
            "Based on the provided document, a potential consequence of changes in tax legislation and regulations on the company is:\n\nD: Increase in the complexity and cost of tax compliance\n\nThe document discusses various aspects of the company's operations, including supply chain management, inventory levels, and the impact of semiconductor market fluctuations. It also mentions the company's efforts to manage inventory levels and the potential need for stocking lifetime buy inventories due to shorter supplier product life cycles. Additionally, the company faces risks related to single-source vendors, import duties, and the availability of required materials and components.\n\nHowever, the most relevant information related to the potential consequence of changes in tax legislation and regulations is found in the section discussing the company's tax matters. The document states that the company is subject to income taxes in the U.S. and numerous foreign tax jurisdictions, and that changes in tax laws and accounting principles, valuation of deferred tax assets and liabilities, and the discovery of new information during tax return preparation can impact the company's provision for income taxes and cash tax liability. The document also mentions the impact of the Tax Cuts and Jobs Act of 2017, which required the company to capitalize and amortize research and experimental expenditures over five or fifteen years, resulting in a materially negative impact on cash tax liability.\n\nFurthermore, the document highlights the potential negative impact of tax audits, tax policy efforts, and changes in tax legislation and regulations on the company's financial condition and results of operations. It also mentions the company's exposure to increased costs and potential liability in the event of failure to comply with tax regulations, as well as the potential impact of international tax policies and audits on the taxation of international businesses.\n\nBased on this information, the most relevant potential consequence of changes in tax legislation and regulations on the company is an increase in the complexity and cost of tax compliance."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?",
        "options": {
            "A": "Each procedure is paid individually based on its value",
            "B": "All procedures are paid at a reduced flat rate",
            "C": "The highest valued code is paid at 100%, and additional procedures are bundled",
            "D": "Only cataract procedures are paid separately",
            "E": "The total payment is calculated based on the average of all procedure values",
            "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"
        },
        "LLM_original_answer": [
            "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?\n\nC: The highest valued code is paid at 100%, and additional procedures are bundled."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?",
        "options": {
            "A": "Loan sales",
            "B": "Deposit accounts",
            "C": "Advances from the Federal Home Loan Bank",
            "D": "Loan repayments",
            "E": "Cash flows from operations",
            "F": "Scheduled loan payments"
        },
        "LLM_original_answer": [
            "The principal source of the Bank's funds for lending and other business purposes has traditionally been deposit accounts."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could negatively impact the business if key members of the executive management team cannot be retained?",
        "options": {
            "A": "An increase in stock market volatility",
            "B": "A decrease in operational costs",
            "C": "The implementation of new technologies",
            "D": "A delay in the business plan and growth strategies",
            "E": "A shortage of raw materials",
            "F": "An expansion into new markets"
        },
        "LLM_original_answer": [
            "Based on the provided document, the option that could negatively impact the business if key members of the executive management team cannot be retained is:\n\nD: A delay in the business plan and growth strategies\n\nThe document discusses the importance of the executive management team in the context of the company's business combination and the potential impact of their retention on the company's future. The loss of key members could lead to a delay in the business plan and growth strategies, which could have a negative impact on the business."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?",
        "options": {
            "A": "Cancel the transfer entirely",
            "B": "Impose a penalty on the transferee",
            "C": "Treat it as a direct transfer of Chinese interests",
            "D": "Reduce the applicable tax rate",
            "E": "Exempt the transfer from taxes",
            "F": "Require a local business licence"
        },
        "LLM_original_answer": [
            "Based on the provided document, if the STA (State Administration of Taxation) determines that an indirect transfer of Chinese interests lacks a reasonable commercial purpose, the STA may treat it as a direct transfer of Chinese interests. This action is in line with the STA's Bulletin on Several Issues of Enterprise Income Tax on Income Arising from Indirect Transfers of Property by Non-resident Enterprises (Bulletin 7). The STA has the authority to re-characterize and tax gains from such indirect transfers as if they were direct transfers, potentially subjecting them to Chinese enterprise income tax at a rate of up to 10%."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?",
        "options": {
            "A": "Real-time credit card authorization",
            "B": "Biometric authentication",
            "C": "Blockchain encryption",
            "D": "Virtual private networks",
            "E": "Firewall protection",
            "F": "Antivirus software"
        },
        "LLM_original_answer": [
            "The specific technology they rely on from third parties to authorize and verify credit card transactions is Real-time credit card authorization."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?",
        "options": {
            "A": "Increased interest rates on loans",
            "B": "Federal pre-emption benefits",
            "C": "Adverse consequences",
            "D": "Automatic license renewal",
            "E": "Exemption from state requirements",
            "F": "Reduction in documentation requirements"
        },
        "LLM_original_answer": [
            "One of\u25e6\u25e6\u25e6an increase in the corresponding sellers due to:\u25e6 an increase in istringstream-related activities due to:\u25e6\u25e6\u25e6\u25e6 activities due to\u25e6\u25e6 an increase in 12associated costs associated with the following activities due to:\u25e6\u25e6an increase in the fair value due to fair value due to back pass-through activities due to nonaffiliabilities due to related to activities due to an increase in the 2024 costs due to fair value due to:\u25e6an increase in the 12\u25e6 an increase in insurance-related activities due to fair value due to fair value due to fair value of variable costs due to the Company\u2019s Act\u25e6.\u25e6 activities due to non-A jumbo\u25e6an activities due to:\u25e6an increase in the sale of variable interest and:\u25e6\u25e6"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?",
        "options": {
            "A": "Low operational costs",
            "B": "Exclusive commercial partnerships",
            "C": "Reduced regulation requirements",
            "D": "Access to diverse investment opportunities",
            "E": "Financial strength ratings from multiple agencies",
            "F": "Priority in claim settlements"
        },
        "LLM_original_answer": [
            "One of costs due to:\u25e6 due to:\u25e6"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is one potential reason for future decline in the company's revenue growth?",
        "options": {
            "A": "Decreasing demand for their platform",
            "B": "Expansion into new markets",
            "C": "Improved operational efficiency",
            "D": "Increased revenue from current customers",
            "E": "Successful marketing strategies",
            "F": "Increased demand for their services"
        },
        "LLM_original_answer": [
            "One"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What potential impact could unfavorable economic conditions have on the organization?",
        "options": {
            "A": "Ease legal constraints on current services",
            "B": "Increase profits from outdated technologies",
            "C": "Reduce affordability and demand for products",
            "D": "Eliminate the need for technological enhancements",
            "E": "Reduce costs associated with competitive advantages",
            "F": "Ensure the rapid adoption of new technologies"
        },
        "LLM_original_answer": [
            "Based on leases which was.\u25e6 costs associated activities due to:\u25e6\u25e6an increase in:\u25e6,},\n_ctxt\u25e6\ufeff#_ctxt\u25e6 an increase in the activities due to\u25e6an increase in excess of $ 7\u25e6 activities due to:\u25e6 \u25e6\u25e6\u25e6\u25e6 activities due to the document due to\u25e6an increase in excess of the document\u25e6 \u25e6 an increase in all materialityes\u25e6"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is a potential consequence of changes in tax legislation and regulations on the company?",
        "options": {
            "A": "Increase in the number of employees",
            "B": "Decrease in production costs",
            "C": "Reduction in market share",
            "D": "Increase in the complexity and cost of tax compliance",
            "E": "Rise in customer satisfaction",
            "F": "Improved international partnerships"
        },
        "LLM_original_answer": [
            "Based on a\n"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?",
        "options": {
            "A": "Each procedure is paid individually based on its value",
            "B": "All procedures are paid at a reduced flat rate",
            "C": "The highest valued code is paid at 100%, and additional procedures are bundled",
            "D": "Only cataract procedures are paid separately",
            "E": "The total payment is calculated based on the average of all procedure values",
            "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"
        },
        "LLM_original_answer": [
            "In the outstanding insurance-related activities; \u25e6\u25e6 \u25e6 insurance-related costs due to activities due to activities due to an increase in the document \u25e6 activities due to "
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?",
        "options": {
            "A": "Loan sales",
            "B": "Deposit accounts",
            "C": "Advances from the Federal Home Loan Bank",
            "D": "Loan repayments",
            "E": "Cash flows from operations",
            "F": "Scheduled loan payments"
        },
        "LLM_original_answer": [
            "The principal activity due to:\u25e6an increase in 202 activities due to one-Other activities due to:\u25e6an increase in 2023##table.\u00a7"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could negatively impact the business if key members of the executive management team cannot be retained?",
        "options": {
            "A": "An increase in stock market volatility",
            "B": "A decrease in operational costs",
            "C": "The implementation of new technologies",
            "D": "A delay in the business plan and growth strategies",
            "E": "A shortage of raw materials",
            "F": "An expansion into new markets"
        },
        "LLM_original_answer": [
            "Based on\u25e6an increase in the document\u25e6 an increase in the due to:\u25e6an increase in costs associated with respect to retain costs due to activities due to the increase in-force due to policy costs due to the completed on:"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?",
        "options": {
            "A": "Cancel the transfer entirely",
            "B": "Impose a penalty on the transferee",
            "C": "Treat it as a direct transfer of Chinese interests",
            "D": "Reduce the applicable tax rate",
            "E": "Exempt the transfer from taxes",
            "F": "Require a local business licence"
        },
        "LLM_original_answer": [
            "Based on-going activities due to \u25e6 insurance-related activities due to:\u25e6 an increase in 2023 152activities due to a multiple activities due to:\u25e6an increase in 152\n_TAC\u25e6nownetextacts and related to meet the STA may 2023 202-related activities due to:\u25e6an increase in net costs due to indirect transfer of activities due to activities due to:\u25e6\u25e6\u25e6an increase in 202\uff14\n_TAC\u25e6\u25e6 due to-go activity due to increase in China and/or\u25e6pertinentities due to costs associated with a\u25e6"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?",
        "options": {
            "A": "Real-time credit card authorization",
            "B": "Biometric authentication",
            "C": "Blockchain encryption",
            "D": "Virtual private networks",
            "E": "Firewall protection",
            "F": "Antivirus software"
        },
        "LLM_original_answer": [
            "The document costs due to:\u25e6 an increase in response tows associated costs due to third party due to:\u25e6\u25e6 an increase in our business due to\u25e6\u25e6is a whole sale;\u25e6an increase in 19insurance-related activities due to:\u25e6an increase in\n"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?",
        "options": {
            "A": "Increased interest rates on loans",
            "B": "Federal pre-emption benefits",
            "C": "Adverse consequences",
            "D": "Automatic license renewal",
            "E": "Exemption from state requirements",
            "F": "Reduction in documentation requirements"
        },
        "LLM_original_answer": [
            "One increase in insurance-related activities;\u25e6 an increase in the insurance-related to insurance-related activities;\u25e6\u25e6\u25e6 an increase due to insurance-related activities due to insurance-related activities related costs due to insurance-related to insurance-related activities due to insurance costs due to insurance-related activities due to:\u25e6an increase in insurance-related activities due to costs due to insurance-related activities due to:\u25e6\u25e6\u25e6an increase in claims related to insurance-related activities due to:\u25e6\u25e6:associated activities due to:\u25e6:\u25e6 activities due to:\u25e6an increase in net costs due to:\u25e6##payer.\u25e6 an increase in the\u25e6\u25e6:\u25e6\u25e6 costs associated with insurance-related activities due to:\u25e6an increase in costs due to insurance-related with insurance-related activities due to:\u25e6\u25e6:\u25e6 an increase in insurance-related activities due to insurance-related costs due to an increase in excess pre\u25e6: activities due to:\u25e6an increase in net costs due to insurance-related activities due to insurance-related activities due to insurance-related activities due to insurance-related activities due to:\u25e6an increase in net costs due to insurance-related activities due to insurance-related activities;\u25e6 an increase in excess of insurance-related activities due to:\u25e6 an increase in the due to insurance-related activities due to insurance-related activities due to insurance-related activities due to:\u25e6 an increase in excess due to insurance-related activities due to insurance-related activities due to insurance costs due to insurance-related activities related to insurance-related activities due to:\u25e6 activities due to:\u25e6an increase in the costs due to insurance-related activities due to:\u25e6an increase in insurance-related activities;\u25e6 an increase in the activities due to insurance-related activities due to:\u25e6an increase in net costs due to insurance-related activities related to insurance costs due to:\u25e6:\u25e6an increase in the net costs due to insurance-related activities due to:\u25e6 an increase in net costs due to:\u25e6 an increase in the\u25e6 an increase in the increase in net costs due to:\u25e6:\u25e6an increase in activities due to:\u25e6 an increase in the\u25e6 net costs due to:\u25e6 due to:\u25e6 an increase in the costs of insurance-related activities due to:\u25e6:\u25e6:\u25e6 due to the increase in liability costs due to insurance-related activities due to the\u25e6 an increase in excess of insurance costs due to"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?",
        "options": {
            "A": "Low operational costs",
            "B": "Exclusive commercial partnerships",
            "C": "Reduced regulation requirements",
            "D": "Access to diverse investment opportunities",
            "E": "Financial strength ratings from multiple agencies",
            "F": "Priority in claim settlements"
        },
        "LLM_original_answer": [
            "Based:\u25e6:\u25e6 an increase in the fair value due to insurance balances due to:insurance-related activities due to:\u25e6 an increase in net costs due to insurance-related activities due to insurance-related activities due to:\u25e6an increase in net costs due to the\u25e6 increase in insurance-related activities due to:\u25e6 an increase in insurance-related activities due to insurance-related activities due to insurance costs due to insurance costs associated with respect of insurance due to:\u25e6 an increase due to:\u25e6\u25e6 \u25e6 increase due to:\u25e6 an increase in the\u25e6 net costs associated with no\u25e6 an increase in the\u25e6 an increase in the\u25e6 an increase in the\u25e6 an increase due to:\u25e6 a decrease in the costs associated with insurance-related activities due to:\u25e6an increase in liability-related activities due to:\u25e6 an increase in the costs due to:\u25e6 an increase in-force\u25e6 an increase in the liability-related activities due to the activities due to:\u25e6:\u25e6an increase due to:\u25e6:\u25e6an increase in insurance-related activities due to:\u25e6 due to:\u25e6 an increase in the costs of insurance-related activities due to:\u25e6:\u25e6:\u25e6 ##message an increase in liability-related costs due to the\u25e6 net costs due to insurance costs associated with respect activities due to insurance-related activities due to insurance-related activities due to:\u2014\u25e6 an increase in insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase in the amount of insurance-related activities due to:\u25e6:\u25e6an increase in the\u25e6an increase in liability due to insurance-related activities related to insurance-related activities due to insurance-related activities;\u25e6 due to insurance-related activities due to insurance-related activities related to an increase in the\u25e6 an increase in net costs due to a\u25e6 an increase in the\u25e6 an increase in the\u25e6 a costs due to insurance-related activities due to \u25e6an increase in net costs due to the exit credit-related activities due to:\u25e6 an increase in the issuance of insurance-related activities due to insurance costs due to: \u25ba an increase in:\u25e6 activities due to:\u25e6an increase in liability-related activities due to insurance-related activities due to insurance-related costs due to the costs due to insurance-related activities due to:\u25e6\u25e6\u25e6 increase in excess of insurance-related costs due to insurance-related activities due to:\u25e6\u25e6 costs due"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is one potential reason for future decline in the company's revenue growth?",
        "options": {
            "A": "Decreasing demand for their platform",
            "B": "Expansion into new markets",
            "C": "Improved operational efficiency",
            "D": "Increased revenue from current customers",
            "E": "Successful marketing strategies",
            "F": "Increased demand for their services"
        },
        "LLM_original_answer": [
            "One activities due to insurance-related activities due to:\u25e6\u25e6an increase in net costs due to insurance and related to:\u25e6\u25e6\u25e6 an increase due to: \u25ba\u25e6:\u25e6 due to:\u25e6\u25e6 an increase due to:\u25e6 ##payer\u25e6crease in insurance-related activities due to:\u25e6:\u25e6 costs associated with insurance-related activities due to insurance-related activities due to:\u25e6 ##insurance-related costs associated with insurance-related activities due to insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase in net costs due to insurance-related costs due to an increase due to:\u25e6\u25e6 an increase in net costs due to:\u25e6 an increase in insurance-related activities due to insurance costs due to insurance-related activities due to:\u25e6 net costs due to insurance balances due to insurance-related activities due to:activities due to:\u25e6\u25e6 an increase due to:\u25e6 an increase in insurance-related activities due to the\u25e6 an increase due to insurance-related activities due to insurance-related activities due to: insurance-related activities due to insurance-related activities due to insurance costs due to insurance-related activities due to insurance-related activities due to liability-related activities due to:\ufffd\u00adactivities due to:\u25e6 an increase in net costs due to:\u25e6 ##an increase in insurance-related activities due to insurance and \u25e6 an increase in insurance-related activities due to insurance-related activities due to:\u25e6an increase in net costs due to insurance-related activities related to:\u25e6 an increase in insurance activities due to:\u25e6an increase in liability-related activities due to:\u25e6 an increase in insurance-related activities due to:\u25e6 an increase in insurance-related activities due to:\u25e6\u25e6 an increase in insurance-related activities due to:\u25e6an increase due to:\u25e6:\u25e6an increase in insurance-related activities due to:\u25e6 due to:\u25e6 an increase in the costs due to insurance-related activities due to:due to insurance-related activities due to:\u25e6an increase in liability due to: activities due to:\u25e6an increase in net costs due to:due to insurance-related activities due to insurance-related activities due to:\u25e6 an increase in insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase in insurance-related to the costs due to insurance-related activities due to insurance-related activities due to:\u25e6an increase in liability due to insurance-related to:\u25e6an increase in insurance-related activities"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What potential impact could unfavorable economic conditions have on the organization?",
        "options": {
            "A": "Ease legal constraints on current services",
            "B": "Increase profits from outdated technologies",
            "C": "Reduce affordability and demand for products",
            "D": "Eliminate the need for technological enhancements",
            "E": "Reduce costs associated with competitive advantages",
            "F": "Ensure the rapid adoption of new technologies"
        },
        "LLM_original_answer": [
            "What"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is a potential consequence of changes in tax legislation and regulations on the company?",
        "options": {
            "A": "Increase in the number of employees",
            "B": "Decrease in production costs",
            "C": "Reduction in market share",
            "D": "Increase in the complexity and cost of tax compliance",
            "E": "Rise in customer satisfaction",
            "F": "Improved international partnerships"
        },
        "LLM_original_answer": [
            "Based on:\u25e6 an increase in:\u25e6 an increase due to:\u25e6 an increase in:\u25e6\u25e6an increase in:\u25e6\u25e6 an increase in insurance-related activities due to:\u25e6 an increase in net costs due to:\u25e6 an increase in the\u25e6\u25e6 [Insurance costs due to:\u25e6:\u25e6\u25e6 an increase in-force\u25e6an increase in insurance-related activities due to:\u25e6an increase in insurance-related costs due to insurance-related activities due to:\u2014insurance-related activities due to:\u25e6 an increase in the\u25e6 increase in activities due to:\u25e6 an increase due to:\u25e6 an increase in the\u25e6 an increase in the insurance-related activities due to:\u25e6 an increase in the costs due to insurance-related activities due to:\u25e6an increase in insurance-related activities due to:\u25e6an increase in insurance-related activities due to:\u25e6 an increase in net costs due to insurance-related activities due to:\u25e6 insurance-related activities due to:\u25e6 an increase in the Company\u2019s costs due to insurance-related activities due to:\u25e6an increase in insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase in insurance costs associated with insurance-related activities due to insurance-related activities\u25e6 an increase in the Company's increase costs due to insurance-related activities due to insurance-related activities due to:\u25e6an increase in net costs due to insurance-related activities due to:\u25e6 an increase in insurance-related\u25e6[..."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?",
        "options": {
            "A": "Each procedure is paid individually based on its value",
            "B": "All procedures are paid at a reduced flat rate",
            "C": "The highest valued code is paid at 100%, and additional procedures are bundled",
            "D": "Only cataract procedures are paid separately",
            "E": "The total payment is calculated based on the average of all procedure values",
            "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"
        },
        "LLM_original_answer": [
            "In the insurance-related to insurance-related activities due to insurance-related to insurance-related costs associated costs due to insurance-related to the\u25e6\u25e6 costs due to insurance-related activities due to:\u25e6\u25e6 increase due to insurance-related activities due to insurance-related activities due to:\u25e6 an increase in the\u25e6an increase in net costs due to:\u25e6 \u25e6\u25e6\u25e6 ## Insurance-related activities;\u25e6 an increase in activities due to:\u25e6an increase in connection with respect to the\u25e6\u2014\u2014net costs due to:\u25e6. net costs due to the\u25e6 \u25ba an increase in connection-related activities due to insurance-related activities due to:\u25e6\u25e6 costs associated with insurance-related activities due to:\u25e6an activities due to:\u25e6an increase in insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase due to:\u25e6\u25e6 an increase in insurance-related activities due to:\u25e6 an increase in insurance-related activities due to insurance costs due to:\u25e6an increase in the\u25e6ointment due to insurance-related activities due to insurance-related activities due to:\u25e6an increase in net costs due to:activities due to:\u25e6 activities due to:\u25e6an increase in liability due to the increase in net costs due to:\u25e6 an increase in the insurance-related to insurance-related activities due to insurance-related activities due to insurance costs due to insurance costs associated with an increase due to insurance costs due to insurance-related activities due to:\u25e6\u25e6 \u25e6 [activities due to:\u25e6 an increase in insurance-related activities due to insurance-related to insurance-related activities due to:\u25e6 an increase in insurance-related to:\u25e6\u25e6an increase due to:\u25e6 a decrease in connection with insurance-related activities due to:\u25e6 an increase in insurance-related activities due to:\u25e6 an increase in connection with no longer due to:\u25e6 an increase in connection to:\u25e6 an increase in the amount of insurance-related activities due to:\u25e6:\u25e6:due to:\u25e6:\u25e6an increase in net costs due to:\u25e6:\u25e6 an increase in:\u25e6an increase in the insurance-related activities due to:\u25e6:activities due to:\u25e6an increase in liability-related costs due to:\u25e6due to insurance costs associated with respect of insurance-related activities due to insurance-related activities;\u25e6 due to insurance-related activities due to:\u25e6## insurance-related activities due to:"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?",
        "options": {
            "A": "Loan sales",
            "B": "Deposit accounts",
            "C": "Advances from the Federal Home Loan Bank",
            "D": "Loan repayments",
            "E": "Cash flows from operations",
            "F": "Scheduled loan payments"
        },
        "LLM_original_answer": [
            "The net costs due to insurance-related activities due to insurance-related activities due to:\u25e6\u25e6 an increase in 112 costs due to:\u25e6 an increase in activities due to:\u25e6 an increase in 1 costs incurred due to:\u25e6 an increase in \u25e6 an increase in the related to insurance-related activities due to:\u25e6\u25e6\u25e6 activities;\u25e6\u25e6\u25e6 due to insurance-related activities due to:\u25e6 an increase in the\u25e6 decrease in net costs due to insurance-related activities;\u25e6 an increase in the insurance;\u25e6 costs due to insurance-related activities due to:\u25e6 an increase in net costs due to insurance costs due to insurance-related activities due to insurance-related activities;\u25e6 insurance-related activities; \u25e6 related to:activities due to:\u25e6an increase in costs due to insurance-related activities;\u25e6\u25e6 costs due to insurance-related activities;\u25e6\u25e6a\u25cd costs due to insurance-related activities due to insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase in the activities due to insurance;\u25e6 an increase in net costs due to insurance-related activities due to:\u25e6\u25e6 an increase in the activities;\u25e6 an increase in activities due to insurance-related activities;\u25e6\u25e6\u25e6\u25e6 due to insurance-related to insurance-related activities due to insurance;\u25e6\u25e6 increase in liability-related costs due to insurance-related activities;\u25e6\u25e6 an increase in the costs due to insurance-related activities;\u25e6 an increase in the costs due to insurance-related activities related to insurance-related activities;\u25e6:\u25e6 an increase in the activities due to insurance-related activities due to:\u25e6 costs due to insurance-related activities due to:\u25e6\u25e6 increase in net costs due to insurance-related activities due to:\u25e6\u25e6\u25e6 \u25e6\u25e6\u25e6\u25e6 an increase due to insurance-related activities due to insurance-related\u25e6\u25e6missions and related to:\u25e6\u25e6 \u25e6 related activities due to:\u25e6 an increase in\u25e6net costs due to:\u25e6 insurance-related activities;\u25e6 an increase in net costs due to insurance-related activities due to insurance-related activities;\u25e6 an increase in the\u25e6 costs due to insurance activities;\u25e6\u25e6 insurance-related activities due to insurance-related activities due to insurance-related activities;\u25e6 costs due to:\u25e6 an increase in the\u25e6urements due to insurance-related activities related"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could negatively impact the business if key members of the executive management team cannot be retained?",
        "options": {
            "A": "An increase in stock market volatility",
            "B": "A decrease in operational costs",
            "C": "The implementation of new technologies",
            "D": "A delay in the business plan and growth strategies",
            "E": "A shortage of raw materials",
            "F": "An expansion into new markets"
        },
        "LLM_original_answer": [
            "What-related activities due to:\u25e6 an increase in insurance costs associated costs due to insurance-related activities due to: \u25ba\u25e6 \u25e6an increase in insurance-related activities due to:\u25e6 an increase in the costs due to insurance-related activities due to:\u25e6 due to:\u25e6due to:\u25e6 an increase in part of insurance-related activities;\u25e6 an increase in the insurance-related with insurance-related activities; to:\u25e6\u25e6\u25e6urring activities;\u25e6:\u25e6\u25e6\u25e6 increase in net costs due to insurance-related activities related to increase in insurance-related activities due to:\u25e6 \u25e6an increase in insurance-related activities due to costs due to insurance-related activities due to:\u25e6 activities due to:\u25e6an increase in net costs due to\u25e6 \u25e6\u25e6\u25e6\u25e6\u25e6 \u25e6 an increase related activities due to:\u25e6\u25e6 a decrease in-force due to the\u25e6\u2014\u2014\u25e6\u25e6 net costs associated with respect to the\u25e6\u25e6\u25e6 \u25e6:\u25e6\ufffd\u00ad due to:\u25e6an increase in the costs due to costs due to insurance-related activities due to insurance-related activities due to:\u25e6an increase in insurance-related activities due to:\u25e6bers.\u25e6 an increase in insurance-related activities due to:\u25e6 an increase in insurance and related to:\u25e6 an increase in the related to insurance-related activities due to insurance-related activities due to:\u25e6an increase in net costs due to the ongoing insurance-related activities due to:activities due to:\u25e6 an increase in the related activities;related activities due to:\u25e6 an increase in net costs due to liability-related activities due to a\u25e6\u00adactivities due to:\u25e6 an increase in insurance-related activities due to insurance-related activities due to insurance-related activities due to insurance-related activities due to liability-related activities due to:\u25e6 insurance-related activities;\u25e6 an increase in the due to life due to: due to:\u25e6an increase in the\u25e6 an increase in the\u25e6missions due to insurance-related activities due to:\u25e6 an increase in net costs due to the\u25e6 costs due to the activities due to:\u25e6:\u25e6an increase in the costs associated with respect to:\u25e6 an increase in the\u25e6 an increase in insurance-related activities due to:\u25e6 an increase in net costs due to the in liability-related activities due to:\u25e6:\u25e6an increase due to:"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?",
        "options": {
            "A": "Cancel the transfer entirely",
            "B": "Impose a penalty on the transferee",
            "C": "Treat it as a direct transfer of Chinese interests",
            "D": "Reduce the applicable tax rate",
            "E": "Exempt the transfer from taxes",
            "F": "Require a local business licence"
        },
        "LLM_original_answer": [
            "Based costs due to insurance-related to the\u25e6an increase in insurance-related activities due to:\u25e6 \u25e6an increase in insurance-related activities due to insurance costs due to:\u25e6 an increase in insurance-related to:\u25e6an increase in net costs due to:\u25e6 an increase in the increase in insurance-related activities due to:\u25e6 an increase due to:\u25e6\u25e6\u25e6 an increase due to:\u25e6##net costs due to:\u25e6\u25e6 an increase in the\u25e6 \u25e6 \u25e6:\u25e6\u25e6 due to:\u25e6 an increase in net costs due to costs due to insurance-related activities due to insurance-related activities due to:\u25e6an increase in insurance-related activities due to:\u25e6.\u2014\u25e6 an increase in insurance-related activities due to:\u25e6an increase in insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase due to insurance-related activities due to:\u25e6 an increase in net costs due to insurance-related activities due to:\u25e6:activities due to:\u25e6 an increase in the related to insurance-related activities due to:\u25e6 an increase in the\u25e6crease in-force\u25e6 a decrease in insurance-related activities due to:\u25e6 an increase in insurance-related activities due to insurance-related activities due to insurance-related activities due to insurance-related activities due to liability-related activities due to:\u25e6:\u25e6:\u25e6 an increase in the due to the balances due to insurance-related activities due to:\u25e6 net costs due to:\u25e6 an increase due to insurance-related activities due to:\u25e6 an increase in insurance-related activities related to the\u25e6 a decrease in the related to:\u25e6 an increase in:\u25e6an increase in insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase in the\u25e6 an increase in the related to:\u25e6 an increase in the due to and net costs due to:\u25e6an increase in:\u25e6:\u25e6 an increase in the\u25e6 net costs due to:\u25e6 due to:\u25e6 an increase in the net costs due to insurance related to:\u25e6:\u25e6:\u25e6##message an increase in liability due to reserves due to:\u25e6 an increase in the costs associated with respect activities due to insurance-related activities due to: \u25e6 due to insurance-related activities due to insurance costs due to insurance-related activities due to:\u25e6an increase in net costs associated costs due to the\u25e6 an"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?",
        "options": {
            "A": "Real-time credit card authorization",
            "B": "Biometric authentication",
            "C": "Blockchain encryption",
            "D": "Virtual private networks",
            "E": "Firewall protection",
            "F": "Antivirus software"
        },
        "LLM_original_answer": [
            "To:\u25e6:\u25e6an increase in the insurance-related activities due to:\u25e6:\u25e6an increase in net costs due to insurance-related activities due to:\u25e6\u25e6an increase in net costs due to the increase in insurance-related activities due to insurance-related activities due to:\u25e6 an increase in the\u25e6 net costs due to insurance-related activities due to support activities due to insurance-related activities;\u25e6:insurance-related activities due to:\u25e6an increase in costs due to insurance-related activities due to insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase in the Company-related activities due to:\u25e6\u25e6\u25e6upeased activities due to insurance-related activities due to policy costs due to insurance-related activities due to:\u25e6a\u25e6 net costs due to insurance-related activities due to:\u25e6 an increase in the\u25e6 an increase in the\u25e6 an increase in activities due to:\u25e6 an increase in net costs due to insurance-related activities due to:\u25e6\u25e6 an increase in the activities due to insurance-related activities due to:\u25e6 to:\u25e6 to:\u25e6an increase in net costs due to:\u25e6 activities due to insurance due to:\u25e6 increase in liability due to policy balances due to insurance-related activities due to insurance-related activities related to insurance costs due to insurance-related activities due to insurance-related insurance-related to insurance-related activities due to unearned costs due to insurance-related activities due to:\u25e6 an increase in insurance-related activities due to:\u25e6an activities due to insurance-related activities due to:\u25e6\u25e6an increase in liability due to insurance-related activities due to:\u25e6 an increase in\u25e6 \u25e6 \u25e6\u25e6 a\u25e6. Due to insurance-related activities due to:\u25e6 an increase in insurance-related activities due to:\u25e6\u25e6pertaining activities due to:\u25e6 an increase in\u25e6pertaining activities due to:\u25e6 insurance-related activities due to\u25e6an increase in insurance-related activities due to insurance-related activities due to:\u25e6 an increase in the\u25e6 costs due to insurance due to:\u25e6an increase in insurance-related activities due to:\u25e6:\u25e6\u25e6 costs due to:\u25e6 an increase in\u25e6\u25e6urements due to insurance-related costs due to policy-related to insurance-related activities due to the costs due to policy due to insurance-related activities due to insurance-related activities related to insurance-related activities due to insurance-related activities"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?",
        "options": {
            "A": "Increased interest rates on loans",
            "B": "Federal pre-emption benefits",
            "C": "Adverse consequences",
            "D": "Automatic license renewal",
            "E": "Exemption from state requirements",
            "F": "Reduction in documentation requirements"
        },
        "LLM_original_answer": [
            "One of the activities; and/or insurance-related activities; and/or insurance-related activities; and/or our contractual obligations of our ability to the processing and/or or otherwise.A part of our ability to the cG costs and/or insurance-related activities, which could be:\u25e6 activities; and/or insurance-related activities.In addition to:\u25e6an increase in the maintenance and related to the costs due to:\u25e6:\u25e6 activities; an increase due to:\u25e6 an increase due to the increase in connection with respect to:\u25e6:\u25e6 an increase in connection with respect to:\u25e6:\u25e6 due to:\u25e6an increase in connection with respect to the costs associated with respect to the costs due to the imposition of:\u25e6 due to:\u25e6:\u25e6 an increase due to the maintenance of:\u25e6 an increase due to the increase due to insurance-related activities due to insurance-related activities due to the curregovern costs, which could be due to the foregoing activities; and/or insurance-related activities due to the following the costs due to:\u25e6 due to the following:\u25e6 activities; and/or otherwise associated with respect to insurance-related activities due to the use of insurance-related activities due to our activities due to:\u25e6 due to the ability to the effectiveness of the other than:\uf0a5 an increase in insurance-related activities; and/or in the costs and/or and/or otherwise than can be due to the United States and/or other activities; and/or otherwise, or the costs and/or the subject to the coven due to the effective measures to the coven due to the effective immediately and/or the effective immediately or otherwise than can be due to the effective activities, which could also:\u25e6 an increase in the\u25e6 an increase in particular activities of the cGross, which could apply to the coven due to the subject to:\u25e6 or otherwise related to:\u25e6 an increase due to:\u25e6an increase in some of up to the insurance-related activities due to comply with respect to comply with respect:\u25e6 an increase in the following the costs associated with respect to the exercise due to:\u25e6 due to the following the following the insurance-related activities due to the imposition of insurance-related activities due to the costs due to the cG:\u25e6 an increase in the cG:\u25e6 or otherwise than can be due to the ability to the:\u25e6 an increase in the ability to:\u25e6an increase in connection with respect to:\u25e6 an increase"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?",
        "options": {
            "A": "Low operational costs",
            "B": "Exclusive commercial partnerships",
            "C": "Reduced regulation requirements",
            "D": "Access to diverse investment opportunities",
            "E": "Financial strength ratings from multiple agencies",
            "F": "Priority in claim settlements"
        },
        "LLM_original_answer": [
            "What is due to the Effective Activities due to the Effective December 1.95Chapter 5.\u25e6 due to be due to the Company due to the Company's activities due to the reclassification of $ 5.## Document:\u25e6\u25e6an increase in accordance with respect of insurance-related activities due to the Bankruptcy due to the Effective Date:\u25e6 an increase due to be paid upon the Company\u2019s increase in accordance with respect to the Effective on the Company\u2019s of XPDI of $ 105Core Scientific activities due to the Effective December 4.B.\u25e6 an increase in accordance with respect to the net of:\u25e6 an increase in the Effective Time due to the applicable promissu an increase in accordance with respect to the terms of the Company\u2019s outstanding at the Company\u2019s net of the Company\u2019s:\u25e6 an increase in accordance with respect to the \u201cas of the Company\u2019s activities due to the Company\u2019satisfaction of the Company\u2019s related to the Company\u2019s due to the Company\u2019s the Company\u2019s related to the net of $ 5 costs of the Business Combination activities and the net of the Company\u2019s net of $ 4.Based due to the Business Combination:\u25e6 an increase in the costs due to:\u25e6 an increase in accordance with respect to the Company activities due to:\u25e6:\u25e6 due to:\u25e6:\u25e6 an increase in accordance with respect to the amount due to the Company\u2019s insurance-related activities due to the Company continued due to the Company\u2019s due to be due to be:\u25e6:\u25e6:\u25e6 due to the increase in accordance with respect to the Bankruptcy activities due to:\u25e6 an increase in accordance with respect of the costs due to the effective January 4 associated with respect activities due to:\u25e6an increase in the related to be insurance-related activities due to the Business Combination of $ 5.99Core Scientific, and unexpired activities due to the Business Combination Activities due to the Bankruptcy Cases due to the Business Activities due to:\u25e6an increase in the Company\u2019s activities due to the Business CombinationBalance Sheet of $ 1.### ##table of the effective January 105Net costs associated with respect due to:\u25e6an increase in the Company\u2019s due to the costs due to:\u25e6 net costs due to the effective date of $ 5 costs due to the Bankruptcy due to the Company\u2019s due to the Bankruptcy costs due to the effective date of the Business Combination## net of $ 1."
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is one potential reason for future decline in the company's revenue growth?",
        "options": {
            "A": "Decreasing demand for their platform",
            "B": "Expansion into new markets",
            "C": "Improved operational efficiency",
            "D": "Increased revenue from current customers",
            "E": "Successful marketing strategies",
            "F": "Increased demand for their services"
        },
        "LLM_original_answer": [
            "One of $ 2024.## costs and insurance-related activities as well as a decrease:\u25e6 an increase due to coverages due to:\u25e6 due to:\u25e6 to:\u25e6\u25e6a decrease in the portion of $ 2023.Because of:\u25e6 an increase due to the NCI.##table 2024. On December 2024.##table 202##table 2023.AROEvid related to the increase in the liability and on the increase due to recoveries activities due to:\u25e6an increase in the net of approximately $ 2023.##table due to recoveries due to the costs due to recoveries due to the policyholder of $ 2023.## an increase due to recoveries due to net costs due to the increase in the increase in North costs due to:\u25e6 an increase in insurance-related activities due to recoverable activities due to:\u25e6an increase in the liability due to recoverable activities due to:\u25e6 activities due to recoveries due to the Tax Actuarated activities due to net costs due to net costs due to recoveries associated with respect to recoveries during the NRC due to recoveries related to recoveries due to:\u25e6 an increase in the second quarter costs associated with insurance-related activities due to recoveries due to recoveries due to customers due to insurance-related activities due to:\u25e6\u25e6 an increase in the insurance-related activities due to recoveries due to the net costs associated with respect to the increase in North Carolina Industrial and related to:\u25e6 due to recoveries due to recoveries due to be due to recoveries due to customers as a net costs and related to:\u25e6an increase in the related to recoveries due to the amount of approximately $ 2024.##table 2023.Decourex, with respect to recoveries at the parent due to:\u25e6 an increase in the Tax Actuarrelated activities due to include:\u25e6 an increase in the related to be recovered through the change due to recoveries and related to recoveries related to the parent company activities due to recoveries due to recoveries due to recoveries associated with respect to net book costs and related to recoverable activities due to net costs related to net costs related to:\u25e6 activities, as required to net costs related to recoverable activities due to recoverable activities due to recoveries due to recoverable activities due to recoveries due to recoveries due to cover costs and related to the"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What potential impact could unfavorable economic conditions have on the organization?",
        "options": {
            "A": "Ease legal constraints on current services",
            "B": "Increase profits from outdated technologies",
            "C": "Reduce affordability and demand for products",
            "D": "Eliminate the need for technological enhancements",
            "E": "Reduce costs associated with competitive advantages",
            "F": "Ensure the rapid adoption of new technologies"
        },
        "LLM_original_answer": [
            "Questionnaire and/or other than insurance-related activities for insurance-related activities for the Company\u2019s estimated to the Company\u2019s the Company\u2019s activities due to the Company\u2019s activities of $ 114\u25e6an increase in the Company\u2019s comparative to the Company\u2019s activities for the Company\u2019s activities for which, if applicable to the Company\u2019s activities of the Company\u2019s related to the Company\u2019s activities for the Company\u2019s the CompanyAdmission costs.The Company\u2019s contractual activities due to the Company\u2019s net costs.The Company\u2019s fair value of the Company\u2019s activities of $ 115Insurance-114activities due to the Company\u2019s assets and/or:\u25e6 due to the Company\u2019s activities due to the Company\u2019s activities due to the Company\u2019s assets and/or other than could beInsurance-related activities.The Company\u2019s related to the Company adopted by the Company\u2019s applicable to the Company adopts the Company\u2019s net of the Company\u2019s Company\u2019s 121Refer to the Company\u2019s fair value.The Company\u2019s insurance-related assets.The Company\u2019s adoption of the Company has been adopted by major insurance-related to the Company\u2019s net of the Company\u2019s fair value and/or other than the Company\u2019s insurance-related activities.The Company\u2019s of the Company\u2019s average remaining at the Company\u2019s average remaining service cost of the Company\u2019s income.The Company\u2019s the Company\u2019s net of $ 202 activities of the Company\u2019s cost of:\u25e6 an increase in the Company\u2019s cost of the Company\u2019s of the Company\u2019s insurance-related activities.The Company\u2019s the Company\u2019s cash surrendering-related activities of the Company\u2019s the Company\u2019s activities of the Company\u2019s cost of the Company\u2019s net income due to the related to the Company\u2019s net income and/or a participant\u2019s fair value of the Company\u2019s fair value of the Company\u2019s adoption of the net income tax basis of:112Insurance Activities of the Company\u2019s net of the Company\u2019s net income statement of the Company\u2019s the Company adopted by insurance-related activities due to the Company\u2019s of:\u2022 an increase in the Company\u2019s activities of the Company\u2019s related to the Company\u2019s amortized activities due to the Company\u2019s activities of:\u25e6 an increase in the Company\u2019s related to the Company\u2019s attributable to the Company\u2019s net of:\u25e6 December 116activities due to the Company\u2019s net of the Company\u2019s fair value of the Company\u2019s fair value of the Company\u2019s to:\u25e6an increase in the Company\u2019s activities of:\uf0ad an increase in the Company\u2019s net of up to insurance-related activities of activities.The Company\u2019s of the Company\u2019s activities of the Company\u2019s insurance-related activities.The"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is a potential consequence of changes in tax legislation and regulations on the company?",
        "options": {
            "A": "Increase in the number of employees",
            "B": "Decrease in production costs",
            "C": "Reduction in market share",
            "D": "Increase in the complexity and cost of tax compliance",
            "E": "Rise in customer satisfaction",
            "F": "Improved international partnerships"
        },
        "LLM_original_answer": [
            "What is due to:\u25e6an increase in the number of the insured activities that may bec due to:\u25e6 an increase in the foregoing activities due to the conduct due to the underlying activities due to the insured activities due to the acquisition due to the company operations or our business operations due to theof insurance-related activities due to:\u25e6an increase in-sourced due to the further activities; and/or other than:\u25e6 an increase in the costs due to:\u25e6:\u25e6:\u25e6 an increase in the use of:\u25e6\u00ad related to the acquisition of:\u25e6:\u25e6 an increase in the following the increase in-such activities; and/or other than:\u25e6 an increase:\u25e6 an increase in the following the following insurance-related activities due to the further insurance-related to the use of the foregoing activities due to:\u25e6an increase in certain other than:\u25e6 an increase in response to the:\u25e6an increase in the further due to:\u25e6 an increase in the insured-related activities due to:\u25e6 an increase due to:\u25e6 an increase our net costs and/or other insurance-related activities due to:\u25e6an increase in the activities due to:\u25e6 an increase in the further insurance-related activities due to:\u25e6 an increase due to insurance-related activities due to:\u25e6:\u25e6an increase in insurance-related activities due to:\u25e6 an increase in the following the insurance-related activities due to:\u25e6\u25e6 insurance-related activities due to participate due to the acts and other than:\u25e6 an increase in the:\u25e6 an increase in the imposition of:\u25e6an increase in the of 96An increase in the activities due to:\u25e6an increase in the foregoing activities due to the imposition of:\u25e6\u25e6 an increase due to the FCAUSECv\u25e6\u25e6 an increase in the activities due to:\u25e6 an increase in the ability to the use of our business and/or related to:\u25e6\u25e6 an increase in the related to the ability due to:\u25e6 an increase in the U.Similar activities, which could have insurance-related activities due to the net costs due to the use of:\u25e6an increase in the U.SECRisks due to the following the business.We may have insurance-related activities due to the insured activities due to:\u25e6an increase in the insurance-related activities due to the insured-related activities or other than:\u25e6 activities, which could harm the increase"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?",
        "options": {
            "A": "Each procedure is paid individually based on its value",
            "B": "All procedures are paid at a reduced flat rate",
            "C": "The highest valued code is paid at 100%, and additional procedures are bundled",
            "D": "Only cataract procedures are paid separately",
            "E": "The total payment is calculated based on the average of all procedure values",
            "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"
        },
        "LLM_original_answer": [
            "In the death and related to:\u25e6an increase in our consolidated financial services due to the increase in the activities due to:\u25e6 to:\u25e6 an increase in accordance with respect to the insurance-related activities due to the following the increase in our consolidated financial activities, including:\u25e6 an increase in our credit to the activities due to the amount of our consolidated financial instruments due to the amount of the amounts (insurance-related activities due to the amount to the costs of:\u25e6 insurance-related activities due to:\u25e6an increase in accordance with respect of insurance-related activities due to:\u25e6activities, including:\u25e6 an increase due to the related to:\u25e6 an increase due to be:\u25e6 an increase due to the increase in accordance with respect to the amounts due to:\u25e6:\u25e6an increase in the amounts due to the increase due to insurance-related activities due to the increase in the increase in the Company\u2019s activities due to the increase in accordance with respect of insurance-related activities due to the Company\u2019s due to insurance-related activities due to: activities due to the fair value of Ocwen costs due to the related party\u2019s insurance-related activities due to the Company\u2019s activities due to the Company\u2019s related activities due to:\u25e6 activities due to:\u25e6\u25e6 an increase in our reverse mortgage and insurance-related activities due to insurance-related activities due to the increase in our insurance-related activities due to:\u25e6\u25e6 due to the related to:\u25e6 an increase in the activities due to service activities due to the amount of:\u25e6 an increase in our derivative instruments of Ocwen due to the maximum claim due to the following activities due to the UPON DECEBasis due to determine the maximum claim amount of:\u2022 a copy of the fair value, net of our net of Ocwenetted by valuation at December 98##table  for the Company\u2019s net of $2 due to:\u25e6 an increase in accordance with respect to the related to the following the maximum claim amount (insurance-related activities, less market risk management contractually related to the information costs and other than the net of $9\n_ctxt ITEM 98ITEM  of $1 of $0 of $1.92## insurance-related activities due to the net of $8ITEM 98##Table of $2.99ITEM 98## USER:\u25e6 activities due to:\u25e6 the UPBASF Net Costs and related to the related to the result of the insurance-related activities due to the maximum claim amount"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?",
        "options": {
            "A": "Loan sales",
            "B": "Deposit accounts",
            "C": "Advances from the Federal Home Loan Bank",
            "D": "Loan repayments",
            "E": "Cash flows from operations",
            "F": "Scheduled loan payments"
        },
        "LLM_original_answer": [
            "What has been charged to the87and an increase in insurance-related activities.We are subject to the foregoing insurance-related activities due to:\u25e6 net costs and/or insurance-related activities, or otherwise than:\u25e6 an increase in- related to the:\u2022 an increase in- related to the scope and/or otherwise than any of our ability to our business and/or otherwise violate any of our business and/or insurance-related activities due to the activities due to:\u25e6:\u25e6 an increase in insurance-related activities due to:\u25e6 an increase in the insurance-related activities due to:\u25e6\u25e6 an increase in- related to the following the increase in the rights and/or otherwise due to our business due to the insurance-related activities due to:\u25e6 an increase in the use of:\u25cd costs associated with respect to:\u25e6an increase in insurance-related activities due to:\u25e6:\u25e6 and/or insurance-related activities due to:\u25e6 an increase in insurance-related activities due to resolve any of our ability due to:\u25e6 an increase in-licensed activities due to the scope and/or a non- related to the terms of:\u25e6 an increase in insurance-related activities, if any of:\u25e6 or otherwise not otherwise than our business interruption of:\u25e6 any costs and/or insurance-related activities due to:\u25e6 an increase in-issued or otherwise than any of any of:\u25e6 any of our activities, or otherwise; and/or otherwise than any of our business and/or otherwise not otherwise than the development and/or otherwise than our business activities due to:\u202287activities costs associated with insurance-related activities due to:\u25e6an increase in-activities and/or other than the use of $88 due to the rights and/or insurance-related activities due to:\u25e6:\u25e6an increase in relation to:\u25e6 costs due to:\u25e6:\u25e6an increase due to:\u25e6an increase in insurance-related activities due to activities; and/or insurance-related activities due to the activities due to the competent related to the use of which may be subject matter and/or:\u25e6 an increase in-licensed activities due to the rights and/or similar to the91associated with respect to the activities and/or insurance-related activities due to:\u25e6an increase in-activities due to the costs due to the insurance-related activities due to:\u25e6 an increase in the costs due to the costs due to the use of insurance-related activities; and/or a due to the following the costs due to the increase in- related"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What could negatively impact the business if key members of the executive management team cannot be retained?",
        "options": {
            "A": "An increase in stock market volatility",
            "B": "A decrease in operational costs",
            "C": "The implementation of new technologies",
            "D": "A delay in the business plan and growth strategies",
            "E": "A shortage of raw materials",
            "F": "An expansion into new markets"
        },
        "LLM_original_answer": [
            "What could:\u25e6:\u25e6:\u25e6 any future product candidates due to:\u25e6:\u25e6:\u25e6or:\u25e6 costs and:\u25e6:\u25e6:\u25e6\u25e6 costs and/or any future product candidates, or any of:\u25e6 activities;\u2022 an increase in the costs and:\u25e6\u25e6\u25e6 an increase in accordance with respect to:\u25e6 activities, or may:\u25e6 or any of:\u25e6 activities and/or or, or any of any other insurance-related activities due to:\u25e6 activities, or other than:\u25e6 due to:\u25e6an increase in insurance-related activities; and related to insurance-related activities due to the products and/or:\u25e6 associated with insurance-related activities and/or a)\u25e6an increase in the costs due to the costs due to:\u25e6:\u25e6:\u25e6 due to the costs due to insurance-related activities due to:\u25e6:\u25e6\u25e6 an increase in the activities due to the:\u25e6 or maintain or maintain or the product candidates due to the E91an increase in accordance with respect to the commercial production or the FDA costs and/or insurance-related activities, which could adversely affect insurance-related activities due to:\u25e6an increase in accordance with respect to the activities due to:\u25e6 an increase in the activities due to the costs due to the insurance-related activities due to the costs due to:\u25e6 an increase in the activities due to:\u25e6 due to the costs due to:\u25e6 an increase due to:\u25e6 an increase due to the costs associated with respect activities due to:\u25e6an increase in the under cG-related activities due to:\u25e6 due to the increase due to the costs due to the:\u25e6:\u25e6 an increase in the costs due to:\u25e6 costs due to:\u25e6 an increase in the corporation due to:\u25e6:\u25e6an increase in accordance with respect of:\u25e6 due to:\u25e6\u25e6an increase in accordance with respect to the costs due to:\u25e6 due to the increased costs associated with respect to:\u25e6 due to:\u25e6an increase in our, which could result of any resulting from:\u25e6 due to:\u25e6 due to:\u25e6\u25e6 an increase in accordance with respect to the product candidates, which could be due to the activities due to the development and/or may be\u00adrelated activities, which could be performed by us and/or otherwise than the corporation,"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?",
        "options": {
            "A": "Cancel the transfer entirely",
            "B": "Impose a penalty on the transferee",
            "C": "Treat it as a direct transfer of Chinese interests",
            "D": "Reduce the applicable tax rate",
            "E": "Exempt the transfer from taxes",
            "F": "Require a local business licence"
        },
        "LLM_original_answer": [
            "Based on insurance-related activities due to:\u25e6activities due to the amount due to be held and related to be held and related to the Company's related activities and:\u25e6\u25e6\u25e6an increase due to the costs due to:\u25e6 due to:\u25e6 to:\u25e6 an increase in accordance with respect to be held and:\u25e6:\u25e6 an amounting costs due to the:\u25e6 an increase in the Company's fair value and related to:\u25e6an increase in-process due to the results in the business activities due to address the increase in the activities and related to the increase due to the net of:\u25e6an increase in accordance with respect of $ 89activities due to:\u25e6 activities due to the costs due to be activities due to be held or due to be held and related to activities due to be held and related to insurance-related activities due to the increase in the increase in accordance with respect to be held and related to:\u25e6 costs associated with insurance-related activities due to:\u25e6an increase in process due to be due to:\u25e6 due to:\u25e6 an increase due to the increase in accordance with respect to:\u25e6:\u25e6 due to the net costs of 91associated with respect of $ 0000.91Insurance-Related Information-Related Information-Related to:\u2022Insurance-activities due to:\u25e6 activities due to:\u25e6 an increase in our business activities due to insurance-related activities due to:\u25e6\u25e6 an increase in accordance with original activities due to:\u25e6an increase in our current period of the amounts recorded in our business combinations of $ 91and activities due to the following the related to the net of:\u25e6 an increase in the difference in the following the changes and related to:\u25e6an increase in-process due to the nature and:\u2022 an increase in accordance with respect to the amounting February 94an increase due to the Company\u2019s net of $14net costs associated with respect of $2Net Costs and Note 091an increase in our net of $ 91an increase in-processes associated with respect to the Company's activities due to the Company'supstream costs of the following activities.The net costs of:\u2022activities due to:\u25e6an increase in the amounts recorded in the results due to the period-end related to the amounts due to:\u25e6:\u25d0activities due to:\u25e6\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?",
        "options": {
            "A": "Real-time credit card authorization",
            "B": "Biometric authentication",
            "C": "Blockchain encryption",
            "D": "Virtual private networks",
            "E": "Firewall protection",
            "F": "Antivirus software"
        },
        "LLM_original_answer": [
            "What specific activities due to the Company\u2019s net investment and other than insurance-related activities, and other than the Company\u2019s net investment contracts, and other than the Company\u2019s net of $ 129Brighthouse due to payers associated with respect to the amounts.The net of the Company\u2019s activities due to the net of $ 129Brighthouse: An increase in the Company\u2019s related to the Company\u2019sure:\u25e6 an increase in other than the Company\u2019s activities.The net of the Company\u2019s activities due to the Company\u2019s balances.The Company\u2019s related to conforming activities.The Company\u2019s activities.The Company generally consist of:\u25ba Activities, including:\u25e6an increase in the Company\u2019s financial instruments and other than:\u25e6activities due to the Company\u2019s net of the Company\u2019s activities and related to income-related activities.The Company\u2019s increase in the Company\u2019s net costs.The Company Activities and the Company\u2019s net of the Company\u2019s net of $  due to the increase in the Company\u2019s due to the Company\u2019s related to the increase in the Company due to the insurance-related activities due to:\u25e6an increase in the insurance balances due to insurance costs due to insurance due to:\u25e6\u25e6 an increase in-force balances due to the Company\u2019s activities due to the Company\u2019s due to:\u25e6 due to:\u25e6:\u25e6 an increase in the amount of $ 128Brighthouse costs due to:\u25e6 an increase in the increase in the increase due to the increase in other than the Company\u2019s activities due to:\u25e6:\u25e6:\u25e6\u25e6.\u25e6:\u25e6 an increase in the Company\u2019s net of the Company\u2019s net of the Company\u2019s net of the Company\u2019s net of:\u25e6 an increase in accordance with respect to the adoption of the net derivative instruments due to the Company\u2019s costs and related to:\u25e6:\u25e6:\u25e6.128Brighthouse due to the Company\u2019s activities due to the Company\u2019s net of the amounts.The Company generally recognized in other than expected to the Company\u2019s the Company\u2019s net of $ 133Brighthouse activities due to the Company\u2019s financial statement of $ 129Brighthouse activities due to the Company costs associated with insurance-related activities due to:\u25e6an increase in-force related to the establishment of $ 79Brighthouse due to offset by the host contractually associated with respect to:\u25e6\u25e6an increase in other activities; and insurance costs due to insurance-related activities due to:\u25e6\u25e6 due to offset by:\u25e6 costs"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?",
        "options": {
            "A": "Increased interest rates on loans",
            "B": "Federal pre-emption benefits",
            "C": "Adverse consequences",
            "D": "Automatic license renewal",
            "E": "Exemption from state requirements",
            "F": "Reduction in documentation requirements"
        },
        "LLM_original_answer": [
            "One consequence to be effective or our cloud-based system.The cloud-based system. The cloud-based system will be effective or prove to be effective or other to be effective or desirable or similar to be effective; or PLS\u2019 and PFS\u2019 and PFS system will prove to be effective or effective or P-based system, or our cloud-based system will prove to be effective or other system to be effective or effective or effective or that are effective or that are effective or primary system, which will prove to be effective or PFS\u2019 and other cloud-based system will prove to be effective or effective or effective or effective oratory to be effective or PFS\u2019 and our product to be effective or effective or PLS\u2019 and P cloud-based system to be effective or effective or effective or effective or effective.The cloud-based system will prove to be effective or PFS\u2019 and cloud-based to be effective.The cloud-based system or effective or PFS\u2019 and be effective.The cloud-based system of any one of the effectiveness or approved or PFS\u2019 and cloud-based system be effective or intermediate cloud-based system will prove to be effective or other cloud-based system will prove to be effective or PFS\u2019 and PFS system will prove to be effective in the, as effective or effective. The cloud-based system will prove to be effective or effective or effective or effective or effective.The cloud-based system.The cloud-based system or secondary systems. The cloud-based system will prove to be effective or PFS\u2019 and my cloud-based system, and PFS\u2019 and PDF-based system to be effective or secondary myel system to be effective, especially effective. The cloud-based neoplaci\u2019s cloud-based system to be effective or PFS\u2019 and that are effective or PFS\u2019 and effective or PFS\u2019 and cloud-based system to be effective or other than be effective or effective or PDR. PLS cloud-based system will prove to be effective or effective or that our cloud-based system-based system, and PFS, effective or effective or PFS\u2019 and PFS cloud-based system is effective or effective.\n cloud-based system to be effective. least\nBiology\nUrlParser or that cloud-based system will prove to be effective or effective or effective or effective or effective. least effective or cloud-based system will prove to be effective or effective.The cloud-based system will prove to be effective or\n as effective or cloud-based to be effective. In addition to be effective or effective or effective or effective.The above effective or secondary cloud-based system will prove to be effective or effective or PFS"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?",
        "options": {
            "A": "Low operational costs",
            "B": "Exclusive commercial partnerships",
            "C": "Reduced regulation requirements",
            "D": "Access to diverse investment opportunities",
            "E": "Financial strength ratings from multiple agencies",
            "F": "Priority in claim settlements"
        },
        "LLM_original_answer": [
            "One-time based on the prior year-overweight of $20 as the prior year included accelerated vesting as the prior year included accelerated vesting the prior year-overall items of $1. The Company included as the prior year included accelerated vesting the prior year as the prior year included accelerated vesting of the prior year-end of $20. The Company vesting as the prior year. 2020 as the prior year-over-the prior year included the prior year included accelerated vesting as the prior year-overdue to accelerate vesting the prior year-over the prior year included in the prior year included as the prior year-over $ 651 as the prior year included accelerated vesting of $20 as the prior year-overviewing Revenue Item 5 as the prior year included as the prior year included as the prior year included accelerated vesting as the prior year as the prior year as the prior year included accelerated vesting as the prior year-overlapping the prior year-over-the prior year as the prior year as the prior year-over-the prior year included accelerated vesting as the prior year as the prior year-over accelerated vesting prior year included accelerated vesting of $1 as the prior year-over accelerated vesting as the prior year as the prior year included accelerated vesting of $20 as the prior year-over the prior year as the prior year included accelerated vesting as the prior year included accelerated vesting the prior year as the prior year included accelerated vesting as a prior year-over the prior year included accelerated vesting as the prior year as the prior year as the prior year-over the prior year-over the prior year-over the prior year included accelerated vesting as the prior year as the prior year included accelerated vesting the prior year included accelerated vesting as the prior year as the prior year included accelerated vesting as the prior year-overdue to accelerate vesting the prior year-overheadquartered as the prior year-overall other than the prior year included as the prior year included accelerated vesting of $20. The prior year included accelerated vesting the prior year included accelerated vesting as the prior year included accelerated vesting of $10 year as the $20. The prior year included accelerated vesting as the prior year included accelerated vesting of $20 as the prior year-over-the prior year included accelerated vesting as the prior year as the prior year included accelerated vesting vesting vesting the prior year-over-the prior year-over the prior year included the prior year included accelerated vesting as the prior year included the as the prior year-overall the"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is one potential reason for future decline in the company's revenue growth?",
        "options": {
            "A": "Decreasing demand for their platform",
            "B": "Expansion into new markets",
            "C": "Improved operational efficiency",
            "D": "Increased revenue from current customers",
            "E": "Successful marketing strategies",
            "F": "Increased demand for their services"
        },
        "LLM_original_answer": [
            "One of businesses that could make or could make competitive factors could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could or could make or could make or could make or could make or could make or could make or could make or could make or could make or could or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could or could or could make or could allow businesses that could make or could make or could make or could make or could make or could or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could or could make or could make or could make or could make or could make or could make or could make or could make or could make or could or could or could or could make or could make or could make or could allow businesses that could or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could or could make or could make or could make or could make or could make or could make or could make or could or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or could make or"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What potential impact could unfavorable economic conditions have on the organization?",
        "options": {
            "A": "Ease legal constraints on current services",
            "B": "Increase profits from outdated technologies",
            "C": "Reduce affordability and demand for products",
            "D": "Eliminate the need for technological enhancements",
            "E": "Reduce costs associated with competitive advantages",
            "F": "Ensure the rapid adoption of new technologies"
        },
        "LLM_original_answer": [
            "Unchanged by industry-wide portfolio composition of our securities that are more than the information and loans and loans and loans and more than 91 days past due to 91 days less than 30 days past due to the impact of the net interest-bearing securities portfolio scorecards and the information with respect to the cumulative average tangible shareholders\u2019 book value of the more than ous Asset Quality Loans and loans and loans that are more than 90 days past due to the following the information that are more than 90 days and total outstanding balance sheet##table (less than 1\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is a potential consequence of changes in tax legislation and regulations on the company?",
        "options": {
            "A": "Increase in the number of employees",
            "B": "Decrease in production costs",
            "C": "Reduction in market share",
            "D": "Increase in the complexity and cost of tax compliance",
            "E": "Rise in customer satisfaction",
            "F": "Improved international partnerships"
        },
        "LLM_original_answer": [
            "What the shipment of the shipment of the shipment of the shipment of the shipment of the products and may cause delays in shipping the products and may cause delays in the shipment of the shipment of the shipment of the products and may cause delays in the products and may cause delays in shipping the shipment of the shipment of the shipment of the shipment of the shipment of the the the the shipment of the shipment of the products to the products to the the products and may cause delays in the shipment of the shipment of the products and may cause delays in the shipment of the the products and may cause delays in the the products and may identified prior to the shipment of the the products and may cause delays in the shipment of the shipment of the shipment of the shipment of the the products and may cause delays in-identified prior to the shipment of the shipment of the products and may cause delays in shipping the products and may cause delays in the shipment of the products and may cause delays in the shipment of the shipment of the products and may the shipment of the products and may be identified prior to the products and may cause delays in the shipment of the shipment of the shipment of the products and may cause delays in the shipment of the shipment of the shipment of the shipment of the shipment of the shipment of the products and may cause delays in shipping products and may cause delays in shipping products and may cause delays in the the products and may cause delays in-identified prior to the shipment of the shipment of the shipment of the products and may cause delays in-identified prior to the the products and may cause delays in the shipment of the shipment of the shipment of the products and may cause delays in the shipment of the shipment of the shipment of the shipment of the products and may cause delays in the shipment of the shipment of the shipment of the shipment of the products and may cause delays in the the products and may cause delays in-identified prior to the shipment of the products and may cause delays in the shipment of the shipment prior to the shipment of the the products and may cause delays in the shipment of the products and may cause delays in the the products and prior to the the shipment of the shipment of the the products and may cause delays in the shipment of the products and may cause delays in the products and may cause delays in shipping the products and may cause delays in the products and may cause delays in the shipment of the shipment of the shipment of the products and may cause delays in the the products and may cause delays in the products and may cause delays in shipping the shipment of the shipment of the shipment of"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?",
        "options": {
            "A": "Each procedure is paid individually based on its value",
            "B": "All procedures are paid at a reduced flat rate",
            "C": "The highest valued code is paid at 100%, and additional procedures are bundled",
            "D": "Only cataract procedures are paid separately",
            "E": "The total payment is calculated based on the average of all procedure values",
            "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"
        },
        "LLM_original_answer": [
            "In addition for which MSR sale accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting for which MSR sale accounting for which MSR sale accounting accounting accounting for which MSR sale accounting for which we servicing agreements for which MSR sale accounting cost accounting for which MSR sale accounting accounting accounting accounting accounting accounting accounting for which MSR sale accounting for which MSR sale accounting for which MSR accounting accounting for which MSR sale accounting accounting accounting for which MSR sale accounting accounting accounting accounting accounting accounting for which MSR sale accounting agreements for which servicing agreements for which MSR accounting was not associated MSR sale accounting entries were associated Rithm sale accounting treatment agreements for which MSR sale accounting accounting accounting accounting accounting for which MSR sale accounting for which MSR sale accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting was associated with MSR sale accounting accounting for whichm servicing agreements for which MSR sale accounting accounting for which MSR sale accounting accounting accounting accounting accounting accounting accounting accounting accounting for which MSR sale accounting accounting accounting accounting accounting for which MSR sale accounting for which MSR accounting for which MSR sale accounting accounting accounting accounting for which MSR sale accounting for which MSR sale accounting for which MSR sale accounting accounting accounting accounting for which MSR sale accounting for which MSR sale accounting for which MSR sale accounting for which MSR sale accounting for which MSR sale accounting for which MSR sale accounting accounting for which Rithm sale accounting accounting accounting accounting accounting accounting for which were associated Rithm for which MSR MSR MSR agreements for which MSR sale accounting accounting accounting criteria for which MSR sale accounting accounting for which MSR sale accounting accounting accounting accounting accounting accounting accounting accounting for which is associated with which was associated MSR sale accounting for which were associated MSR sale accounting for which MSR sale accounting for which MSR sale accounting agreements for which MSR sale accounting treatment accounting criteria for which MSR sale accounting MSR sale accounting for which MSR sale accounting for which MSR sale accounting accounting accounting criteria for which MSR sale accounting accounting for which MSR sale accounting accounting MSRs associated with MSR sale accounting accounting accounting accounting accounting accounting accounting for which MSR sale accounting accounting accounting accounting accounting for which MSR sale accounting for which MSR sale accounting treatment accounting accounting accounting accounting criteria are associated with MSR sale accounting accounting accounting for which MSR sale accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting accounting for which MSR sale accounting accounting accounting accounting accounting for which were associated with Rithm servicing agreements for which MSR sale accounting accounting accounting accounting accounting accounting accounting accounting criteria for which MSR sale accounting accounting accounting accounting accounting accounting accounting agreements for which MSR sale accounting agreements for which MSR sale accounting accounting accounting was recorded MSR"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?",
        "options": {
            "A": "Loan sales",
            "B": "Deposit accounts",
            "C": "Advances from the Federal Home Loan Bank",
            "D": "Loan repayments",
            "E": "Cash flows from operations",
            "F": "Scheduled loan payments"
        },
        "LLM_original_answer": [
            "What from non-tradvisually- traditional activities from non-trad as well as well as well as well as well-known activities, as well as well as well as well as well as well as well as well as well-known activities from non-tradverse from non-tradverse activities from non-tradverse activities from non-tradverse activities from non-trad as well as risks from non-tradverse activities from non-tradversus as well as well-known from traditional activities from non-traditional activities from non-traditional activities from non-trad as traditional activities from non-traditional activities from non-tradverse activities from non-traditional activities from traditional activities from non-tradverse an institutionally-credit risk from non-tradvisually-activities from non-tradverse activities from non-tradverse activities from non-tradverse from non-traditional activities, as well as well as well as well-known activities, as well-known activities, as well as well as risks from non-tradverse activities from non-tradverse activities, as well-known traditional activities, as well as well as well as well as well as well as well as well as well as well-credit- traditional activities, as well as well as well-traditional activities, as well as well as well as well-expected activities from non-tradvisually from non-tradverse activities from non-tradversus non-traditional activities from non-traditional activities, as well as well as well as well as well as well as well-known activities, as well as well as well as well as well as well-known activities from non-traditional activities from non-traditional activities from non-trad activities, as well-credit-credit activities, as well as well-known activities from non-traditional activities from non-traditional activities from traditional activities from non-tradverse, as well as well-activities from traditional activities, as well as well as well as well-known from non-tradverse activities from non-tradverse activities, as well as well as well-known as well-known-credit-credit activities from non-tradvis, as well-traditional activities, as well as risks from non-tradverse activities from non-tradverse activities, as well as well as well as well as well-known activities, as well as well as well as well as well as well as well-known-credit activities, as well as well-known activities from non-tradverse activities, as well-credit-credit"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What could negatively impact the business if key members of the executive management team cannot be retained?",
        "options": {
            "A": "An increase in stock market volatility",
            "B": "A decrease in operational costs",
            "C": "The implementation of new technologies",
            "D": "A delay in the business plan and growth strategies",
            "E": "A shortage of raw materials",
            "F": "An expansion into new markets"
        },
        "LLM_original_answer": [
            "What organizations to limit both coverage and the level of reimbursement for newly approved products, as well as well as well as well as well as well as well as well as well as well as well organized organizations to limit both the level of the level of the level of the level of the level of the level of the level of such as well as well as well as well as well approved products, and the level of such as well as well as well as well as well as well as well as well as organizations to limit both the level of the level of reimbursement for newly approved products, as well as well as well as well as well as well as well as well as well as well as well approved organizations to limit both to newly approved organizations that may cause such organizations to limit both to the level of such as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well approved products for newly approved organizations to such organizations to limit both organizations to limit both coverage and the level of reimbursement for newly approved products for newly approved products for newly approved products that may cause such organizations to the level of the level of the level of the level of such organizations\u2019 approval for newly approved organizations to which may cause of newly approved organizations to the level of the level of the level of the level of such organizations to limit both the level of reimbursement for newly approved products approved products, including newly approved products, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well approved products for which may cause such organizations to the level of the level of the level of the level of the level of the level of such as well as well as well as organizations to limit both coverage and the level of such organizations to limit both the level of reimbursement for newly approved products for newly approved for newly approved products for newly approved organizations to the level of such organizations to such organizations to the level of such organizations to such entities to such organizations to the level of the level of the level of the level of the level of the level of the level of the level of the level both the level of the level of such organizations to limit both coverage and the level of such as well as well as well as well as well as well as well as well as well as well"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?",
        "options": {
            "A": "Cancel the transfer entirely",
            "B": "Impose a penalty on the transferee",
            "C": "Treat it as a direct transfer of Chinese interests",
            "D": "Reduce the applicable tax rate",
            "E": "Exempt the transfer from taxes",
            "F": "Require a local business licence"
        },
        "LLM_original_answer": [
            "Based approvals, loss of approvals, approvals, loss of the approvals, approvals, loss of or failure to obtain or loss of the approvals, failure of the approvals, or failure to approvals, renew any approvals, loss or approvals, or any approvals, loss of approvals, failure of approvals, approvals, failure of the approvals, loss of the approvals, the approvals or all or approvals, loss of the approvals, loss of any or all approvals, loss of loss of the following the approvals, loss of any or loss of any or failure to renewability of any approvals, or approvals, or renew any approvals, or all approvals, loss of the failure to renew any or any or all of approvals, or the business of any or all or all of any approvals, licenses, licenses, or any or any of the approvals, or failure to renew any or renew any or all of any approvals, licenses, any or all or failure to obtain any or all or all of the approvals, licenses, licenses, approvals, licenses, failure to obtain or failure to the approvals, the approvals, or failure to the approvals, or all approvals, approvals, licenses, or any or approvals, or failure to the approvals, failure to any or loss of any or obtain or loss of loss of loss of any or failure to any loss of the approvals, any approvals, approvals, approvals, approvals, approvals, or any or any or failure to obtain any approvals, renew any or all of approvals, approvals, licenses, approvals, failure to failure to renew any or failure to or any or any or failure to renew any or all or failure to loss of the approvals, or all of failure to licenses, or all or failure of the approvals, renew any or all of the approvals, or failure to renew any or failure to all of the approvals, licenses, approvals, loss of the failure to renew any or all or all of the approvals, licenses, licenses, licenses, licenses, failure to any or failure to obtain or failure to obtain any of the or any approvals, licenses, licenses, licenses, approvals, approvals, approvals, licenses, approvals, approvals, or all approvals, approvals, or all of the approvals, approvals, approvals, approvals, any approvals, loss of the required approvals, all of any or all or all of all or all of any of any or all of any of any approvals, approvals, approvals, approvals, licenses, or all of approvals, failure to obtain any or failure to obtain or all or all or all of approvals, approvals,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?",
        "options": {
            "A": "Real-time credit card authorization",
            "B": "Biometric authentication",
            "C": "Blockchain encryption",
            "D": "Virtual private networks",
            "E": "Firewall protection",
            "F": "Antivirus software"
        },
        "LLM_original_answer": [
            "What is appropriately positioned to adequately positioned to adequately positioned to Compete_______________BRCDKas adequately positioned to compete in this environment.Regulatory Developmentsumptionsum subsidiaries and BRCDMort regulatory capitalizing insurance subsidiaries and BRCDBRCD are adequately positioned to BRCDKask this environment.Regulatory Developments__________________________Questionnaire insurance subsidiaries and BRCDKemphas BRCDKemphasically positioned to compete in this solution:_________________________ Solution DevelopmentsRegulatory Developmentsurance insurance subsidiaries and BRCDLicensing Developments subsidiaries and BRCDLicensing subsidiaries and BRCDMgmtsufficiently insurance subsidiaries and BRCDLiqui this environment.Regulatory DevelopmentsOur insurance subsidiaries and BRCD are adequately positioned BRCDLicensing subsidiaries and BR Holdings Company Developments and BRCDMergoBRCDLDTIowaught Developments and BRCDLiquationitional Developmentsum insurance subsidiaries and BRCDKPIAAS- Notes to Competency Developments\nBRCDI amenable this solution Developments and BRCDKPIVariance Developmentsion our insurance subsidiaries and BRCDLTDI amply in this environment.Regulatory Developments______________table 19BRCDM&AckRegulatory Developmentsure in this environment.Regulatory DevelopmentsRegulatory insurance subsidiaries are adequately positioned and BRCDMannually Developments and BRCDU.Sec subsidiaries and BRCDLicensing Developmentsum DevelopmentsDevelopmentsinsurance DevelopmentsInsurance Developments of the BRCDKlein our insurance subsidiaries and BRCDMortality Developments and BRCDLicensing Developmentsioned DevelopmentsInsurance Developments adequately positioned in the following DevelopmentsOur insurance subsidiaries and BRCD Financial Developments only BRCDLicensing Developments and BRCDMortnervalue subsidiaries and BRCDKemply answer the in this environment, as well positioned to Competing insurance subsidiaries and BRCDMergo our insurance subsidiaries and BRCDMortain Regulatory DevelopmentsDevelopments subsidiaries and BRCDKPII apologize in this environment.Regulatory Developmentsub insurance subsidiaries and BRCDLiqu insurance subsidiaries and BRCD DevelopmentsDevelopmentsOur insurance subsidiaries and BRCDI amenable this environment.Statewide DevelopmentsBRCDTAXIAI amply in accordance to answer the our insurance subsidiaries and BRCDLicensing DevelopmentsRegulatory Developments and BRCDLicensing subsidiaries and BRCDLicensing subsidiaries and BRCDLicensing Developments and BRCDM Developmentsub Insurance DevelopmentsubjectsolutionsInsurance Developments and BR"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is one consequence of not complying with applicable laws, regulations, and rules by correspondent sellers?",
        "options": {
            "A": "Increased interest rates on loans",
            "B": "Federal pre-emption benefits",
            "C": "Adverse consequences",
            "D": "Automatic license renewal",
            "E": "Exemption from state requirements",
            "F": "Reduction in documentation requirements"
        },
        "LLM_original_answer": [
            "One provision provision related clinical trial for clinical trial related to account for tax positions related to uncertain tax positions related to account for tax positions related to be related to account for tax positions within tax positions related to tax positions related to uncertain tax positions within tax positions related tax positions related to uncertain tax related to post-tr-positions related product related tax positions related to the provision related to and penalties related tax related tax positions related related tax related positions related tax related tax related tax positions related to uncertain tax positions related to behests related to products related to tax positions related to tax positions related to uncertain positions related to account account account account account account for interest and with tax positions related to clinical trial and the tax positions related tax positions related to tax positions related tax positions related tax positions related tax positions within tax positions related to uncertain tax positions related clinical and tax positions within the tax positions related to account account for its tax positions related tax positions tax positions within account account for provision provision within tax positions related tax positions related tax positions related tax positions related to interest and other parties related to and/or related to the following the provision related to uncertain tax positions described within the tax positions related to tax positions related clinical trial for interest and clinical trial related tax positions related tax positions within the provision accounted to account account account account account   or account account accounts account account account account account account account account account account account account 2010-12 accounts related to uncertain tax and tax related to- uncertain tax positions related tax positions related to tax positions related tax positions related to penalties related interest and interest related to the provision within account related interest related to be accounted within tax related to be approved tax positions related positions related tax related to uncertain tax positions within the tax positions within the Company accounts for the provision within the provision, and to account account accounts for the provision of uncertain tax positions related tax positions related to tax positions related tax positions related to the tax positions related to the tax positions related to be accounted for the related to the provision for uncertain tax positions related to uncertain tax positions related to be related tax positions related to account account for all- related related to account for its product and penalties related to and related to the Company accounts interest and the following provision within\nThe provision within the provision within the tax positions related provision provision provision within the provision related to clinical trials related to be related tax positions has been tax positions related related to uncertain tax positions related to account for provision within provision within related to account related to uncertain tax positions related to the provision for the provision for interest and interest orphan\nThe Company accounts"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is one of the benefits for Syndicate 3456 by being part of the Lloyd\u2019s market?",
        "options": {
            "A": "Low operational costs",
            "B": "Exclusive commercial partnerships",
            "C": "Reduced regulation requirements",
            "D": "Access to diverse investment opportunities",
            "E": "Financial strength ratings from multiple agencies",
            "F": "Priority in claim settlements"
        },
        "LLM_original_answer": [
            "What the \u201cExit Credit and guaranty $80.0.0.0.0.0.0.0 million credit and guaranty agreement (the \u201cExit Credit and guaranty80.0. Credit and guaranty0 million credit and guaranty agreement (the \u201cExit Credit and guarant and guaranty agreements (the \u201cExit Credit and guarant $80.0.0. guaranty, guarantyouth $80. The \u201cExit Credit and guaranty guaranty and guaranty and guarantyouth 80.0 million credit and guaranty agreement (the \u201cExit Credit and guaranticip and guarant and guarant and guaranty guaranty guaranty $80. The \u201cand guaranty guaranty guaranticip and guarant and guaranties and guaranties and guarant and guarant and guaranty agreement (the \u201cExit Credit and guarantymoney and guaranty and guarant and guaranty and guaranty and guarant and guarant and guaranty agreement (the \u201cExit Credit and guarant and guaranties and guaranty guaranty and guaranty agreement (the \u201cExit Credit and guarant credit and guarant and guarant and guarant and guaranty and guaranty agreement (the \u201cExit Credit and guaranted and guarant and guarant and guarant and guaranty and guaranty and guarant and guaranty $80.0.0 million credit and guaranty agreement (the \u201cExit Credit and guarant and guarant and guaranty and guarant and guarant and guaranty \u201cExit Credit and guarant and guaranty and guarantyields and guarant and guaranty agreement (the \u201cExit Credit and guaranty\u201d (the \u201cExit Credit and guaranty and guarantyouthand guarant guarantyouthenticity agreement (the \u201cExit Credit and guaranty guarant and guaranty guaranty and guaranticipation agreement (the \u201cExit Credit and guarant (the \u201cExit Credit and guarant and guaranty and guarant and guarant and guaranty agreement (the \u201cExit Credit and guaranty $80.0.0.0.0-secured and guaranty guarant and guaranty guaranty and guaranty agreement\u201d) with the \u201cExit Credit and guaranty and guaranty"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "E"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is one potential reason for future decline in the company's revenue growth?",
        "options": {
            "A": "Decreasing demand for their platform",
            "B": "Expansion into new markets",
            "C": "Improved operational efficiency",
            "D": "Increased revenue from current customers",
            "E": "Successful marketing strategies",
            "F": "Increased demand for their services"
        },
        "LLM_original_answer": [
            "What Energy, Duke Energy Florida, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy Florida, Duke Energy, Progress Energy Progress Energy, Duke Energy Florida, Duke Energy, Duke Energy Progress, Duke Energy Progress Energy Progress, Duke Energy, Progress Energy, Duke Energy Carolinas, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Progress Energy Services, Duke Energy Progress Energy Florida, Duke Energy Progress Energy and Progress, Duke Energy, Duke Energy Progress, Duke Energy Progress, Duke Energy Progress Energy, Duke Energy, Duke Energy Progress, Duke Energy, Duke Energy Progress, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy Carolinas, Duke Energy Progress Energy Progress, Duke Energy Florida, Duke Energy, Duke Energy Florida, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy Progress, Duke Energy, Duke Energy Progress Energy, Duke Energy, Duke Energy Florida, Duke Energy Florida, Duke Energy Carolinas, Duke Energy Florida, Duke Energy Florida, Duke Energy and Duke Energy, Progress, Duke Energy Progress, Duke Energy, Duke Energy Progress, Duke Energy Florida, Duke Energy Progress, Duke Energy Progress Energy, Duke Energy Progress Energy Progress, Duke Energy, Duke Energy Progress Energy, Duke Energy Progress, Duke Energy, Duke Energy, Duke Energy, Duke Energy Progress Energy, Duke Energy Progress Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Progress, Duke Energy, Progress Energy Registrants, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy Carolinas, Duke Energy, Duke Energy, Duke Energy Carolinas Progress, Duke Energy, Duke Energy, Carolinas, Duke Energy, Duke Energy, Duke Energy Carolinas, Progress Energy, Duke Energy, Duke Energy Florida, Duke Energy, Duke Energy Progress Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy Florida Energy Progress Energy, Duke Energy Progress Energy Carolinas, Duke Energy, Duke Energy, Duke Energy Progress, Duke Energy, Duke Energy, and Carolinas, Duke Energy, Duke Energy, Duke Energy Progress, Carolinas, Progress, Duke Energy, Duke Energy, Duke Energy and Duke Energy Florida, Duke Energy Progress Energy Progress, Florida, Duke Energy Progress Energy Progress, Duke Energy Progress, Duke Energy, Duke Energy Progress Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy, Duke Energy Progress"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What potential impact could unfavorable economic conditions have on the organization?",
        "options": {
            "A": "Ease legal constraints on current services",
            "B": "Increase profits from outdated technologies",
            "C": "Reduce affordability and demand for products",
            "D": "Eliminate the need for technological enhancements",
            "E": "Reduce costs associated with competitive advantages",
            "F": "Ensure the rapid adoption of new technologies"
        },
        "LLM_original_answer": [
            "What additional reserves required due to the result of additional reserves required due to additional reserves required reserves required due to increased loan reserves required due to the additional reserves required due to offset by additional reserves required due to offset partially due to offset partially required additional reserves required due to offset due to offset by the result of loan and increased loan losses due to the result of the result of loan losses due to the result of loan loss due to loan losses required due to additional reserves required due to offset by additional reserves required due to coverages due to offset by additional reserves required due to offset partially due to reserves required due to offset due to coverages required due to offsetting increased due to additional reserves required reserves required due to increased reserves required due to offset due to additional reserves required due to a result of additional reserves required due to loan losses due to reserves required due to offset due to additional reserves required due to offset due to loan reserves required due to a result of additional reserves required due to reserves required due to reserves required due to a result of additional reserves required due to reserves required due to offset by additional reserves required due to offset due to loan losses required due to additional reserves required due to the result of additional reserves required due to loan reserves required due to the result of loan losses required due to the result of loans required due to the additional reserves required due to additional reserves required due to the additional reserves required due to the result of additional reserves required due to the additional reserves required due to the reserves required due to increased reserves required due to the result of additional reserves required due to offsetting reserves required due to offsetting required due to meet additional reserves required reserves required due to increased reserves required due to the result of loans due to offset due to loans due to cover increased reserves required reserves required due to increased reserves required due to offsetting due to offsetting increased reserves required due to mitigate required due to the additional reserves required due to additional reserves required due to additional reserves required due to the result of loan loss reserves required due to additional reserves required due to additional reserves required due to offsetting due to offset by additional reserves required due to offset due to increased reserves required due to meet the additional reserves required due to additional reserves required due to offset by additional reserves required due to the result of the result of additional reserves required due to additional reserves required due to the result of additional reserves required reserves required due to increased reserves required due to the result of additional reserves required due to the result of loan losses due to a result of additional reserves required due to offset by increased reserves required due to a)  additional"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is a potential consequence of changes in tax legislation and regulations on the company?",
        "options": {
            "A": "Increase in the number of employees",
            "B": "Decrease in production costs",
            "C": "Reduction in market share",
            "D": "Increase in the complexity and cost of tax compliance",
            "E": "Rise in customer satisfaction",
            "F": "Improved international partnerships"
        },
        "LLM_original_answer": [
            "What the authoritative guidance on the authoritative guidance on the authoritative guidance on fair value measurements and fair value disclosures under U.S. GAAP, the authoritative guidance on U.Specifically, the authoritative guidance on fair value measurements and disclosures under U.S. The authoritative guidance on fair value measurements and disclosures on fair value measurements and disclosures of the U.S. GAAP, the authoritative guidance on fair value, authoritative guidance on fair value measurements and disclosures and disclosure requirements for fair value measurements and disclosures under U.S. GAAPBAPGAAPA non-disclosure of U.Sec, in the U.S. The authoritative guidance on the authoritative guidance on the authoritative guidance on the authoritative guidance on the authoritative guidance on fair value of the authoritative guidance on fair value disclosures under U.Specifically, GAAPA, including the authoritative guidance on fair value measurements and disclosures on the authoritative guidance on the authoritative guidance on fair value under U.Specifically, the authoritative guidance on fair value of the authoritative guidance on fair value of the fair value guidance on the authoritative guidance on fair value measurements and the authoritative guidance on U.Sec, and the authoritative guidance on-going-forwarded the authoritative guidance on the authoritative guidance, the authoritative guidance on fair value guidance on fair value measurements and authoritative guidance on fair value, the authoritative guidance on fair value measurements and disclosures under U.S. The authoritative guidance on fair value of the authoritative guidance on a fair value measurements and disclosures under U.Secological guidance on the authoritative guidance on fair value measurements and disclosures under U.Secapprincipient, the U.S. GAAP, the authoritative guidance on fair value measurements and disclosures under U.Specific authoritative guidance, the authoritative guidance on the guidance on the guidance on fair value measurements and the U.S. The authoritative guidance on the guidance, the fair value measurements and the authoritative guidance on fair value measurements and disclosures, the GAAPAPAP, the authoritative guidance on fair value measurements and disclosures, the authoritative guidance on fair value measurements and disclosures, the authoritative guidance on fair value measurements and disclosures, the authoritative guidance on the authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the authoritative guidance on fair value disclosures of the authoritative guidance on fair value measurements and disclosures, the authoritative guidance, the authoritative guidance on fair value measurements and disclosures under U.S. The authoritative guidance on fair value measurements and disclosures under U.Specific guidance on fair value measurements and disclosures, the U.S. GAAP, the authoritative guidance on fair value guidance on fair value measurements and the authoritative guidance under U.Specific"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "In the HOPD setting, how are additional procedures paid when performed during the same operative session with a higher valued code?",
        "options": {
            "A": "Each procedure is paid individually based on its value",
            "B": "All procedures are paid at a reduced flat rate",
            "C": "The highest valued code is paid at 100%, and additional procedures are bundled",
            "D": "Only cataract procedures are paid separately",
            "E": "The total payment is calculated based on the average of all procedure values",
            "F": "Procedures with lower valued codes are paid first, followed by the highest valued code"
        },
        "LLM_original_answer": [
            "Based on a substantial funds that we are required to the investors increases our business and/or servicing advance facilities that we are required funds that we are subject to the investors increases the investors to the investors and the investors increases that we are required to the the investors increases.We utilize servicing advance facilities that we are subject to the investors that we utilize servicing advance facilities that we are required to the investors increases.We utilize MSR and other investors increases the investors to the investors increases.We utilize the investors increases.We are required to the investors and other than we are required to the investors increases the investors that we are required to the investors to the investors\u2019 s the investors increases to the investors increases.We utilize servicing advance the investors increases.We utilize servicing advances to the investors are required to the investors, among the investors increases the investors that we are required to the investors that we are required funds that we are required to the investors, which we are required funds that we are required to the investors increases.We utilize servicing advance funds that we are subject to the investors increases our investors increases.We utilize servicing advance funds that we utilize servicing advance facilities that we are required to the investors\u2019 s e.given increases.We utilize servicing advance facilities advance facilities advance rates that we are subject to the the investors increases the investors and other than the investors increases.We utilize servicing advance the the investors increases.We are required servicing advance rates that we are required to the investors increases the investors increases that we are required servicing advances to the investors.We utilize servicing advance facilities advance facilities advance facilities advance activities and the investors.We utilize servicing advance financing activities and the investors\u2019 sello Item etailing advance rates and/or other than the investors.We utilize servicing advance facilities that we are required to the utilization of the investors.We utilize servicing advance facilities that we are required to the investors increases the investors increases our covenessing to the investors increases the investors and other than the investors increases.We utilize MSR investors increases the investors increases our debt and the investors to the investors.We utilize servicing advance our debt and the investors increases.We utilize servicing advance match advance funds that we are required to the investors increases the investors increases in the investors and the investors and other than the investors increases.We utilize servicing advance rates and the investors that we are required servicing advance to the investors\u2019 sellofunds.We utilize servicing advance to the investors increases.We utilize servicing advance to the funds that we utilize servicing advance facilities advance facilities advance facilities advance facilities advance funding advance facilities and the that we are required to the investors decreases.We utilize servicing advance the investors increases that we utilize servicing advance facilities and other than"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What has traditionally been the principal source of the Bank\u2019s funds for lending and other business purposes?",
        "options": {
            "A": "Loan sales",
            "B": "Deposit accounts",
            "C": "Advances from the Federal Home Loan Bank",
            "D": "Loan repayments",
            "E": "Cash flows from operations",
            "F": "Scheduled loan payments"
        },
        "LLM_original_answer": [
            "What is not for our management and authorizations of our management, or our management and\u2022Provide reasonable assurances regarding the our management and, when our management and that our directors regarding authorizations regarding the disposition of our directors; directors of our management, or our management.36The term. Regarding the following of our directors, or other than\u2022Incorporate our management and, or other than\u2022Our directors, or our management and authorizations regarding the disclaiming accordance with respect to the:\u2022Provide information.36The following our directors, or our management and with the\u2022\u2022Our board\u2022Regarding our directors, or in accordance with respect to the company\u2022TargetScan Collaboration and commercialization, or, or, or our directors, or our management and, or, in each of our management and with respect to provide reasonable assurances regarding our directors, or, or, in \u2022Incorporate our management and authorizations of our management.36The term\u2022Provide reasonable and regarding the our management and that our management and provide reasonable assurances regarding the\u2022Provide reasonable assurances regarding the\u2022Provide reasonable assurances regarding the our management and directors of our directors and that our management and directors, or our directors of our management and that our directors; and\u2022Provide reasonable assurances regarding the our management and directors of our directors and that we believe that our directors.\u2022Provide reasonable assurances regarding the authorizations of our management and, or directors, including the\u2022Provide reasonable assurances regarding the our management and, or, or our management and authorizations of our management.38that our management of our directors of our management and that that such as well\u2022Provide reasonable assurances regarding the our management, in accordance with respect our directors. regarding the:\u2022Provide reasonable assurances regarding the our directors, or, or our management and directors.33The originalizations regarding the our management.\u2022Our Board.\u2022Intellectualations of our management and authorizations\u2022Board.\u2022Pricing our directors regarding the authorizations of our management of our directors and assets regarding the directors, which, in connection with respect to our management, or our management and directors\u2022Provide information regarding the authorizations regarding authorizations of our management and directors\u2022Provide reasonable assurances regarding the\u2022Provide reasonable assurances regarding our directors\u202233The foregoing:\u2022Provide reasonable assurances regarding the our directors and\u2022Provide reasonable assurances regarding the our management, or our directors of our management, directors.\u202233The term of our directors and authorizations of our management of our directors;34Regarding our directors regarding the our management of our management and directors of our directors"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could negatively impact the business if key members of the executive management team cannot be retained?",
        "options": {
            "A": "An increase in stock market volatility",
            "B": "A decrease in operational costs",
            "C": "The implementation of new technologies",
            "D": "A delay in the business plan and growth strategies",
            "E": "A shortage of raw materials",
            "F": "An expansion into new markets"
        },
        "LLM_original_answer": [
            "What, the 340B program, the Drug Supply of the 340B, the 340B, the 340B program, the U.S. The 340B, the 340B, the 340B, the 340B program, the U.S. The 340B, the 340Bios. The 340Bios, and other than the 340B, and the 340B, the 340B, the 340BiospecificallyB, the the Drug Rebate, the 340B, the U.SimilarlyticB program, the 340Bureau of Defense program, the 340B, the 340B, the 340B program, and other programs, the 340Bureau of the U.S. The 340B, the Drug Rebate program, the 340B program, the 340B program, the 340B program, the Drug RebateB program, the Drug Rebate of the 340BioscGross, the U.S. The 340B, the U.Sever, the 340B, the 340B, the 340B, the 340Biot the U.S. The 340B, the 340B, the 340B program, the 340B program, the 340B program, the 340B, the 340Bios, the 340B, the 340B program, the 340B, the 340B, the 340B, and other U.S. The 340Bios. The 340B, and 340B or other programs, and the 340Bios. 340B, the 340B program, the 340Bios. The 340B and the 340B program, the 340B program, the 340B program, the 340B program, the U.S. S. 340B, the 340B program, the 340B program, the 340B program, the Department of the U.S. The 340Bureau of the U.S. The 340B, the U.S. The 340B, the 340B, the 340B, the 340B, the 340B, the 340B, the 340B program, the Drug Rebate, and other U.S. The U.Safety of the 340B, the 340B, the 340Bureau of the"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What action may the STA take if they determine an indirect transfer of Chinese interests lacks a reasonable commercial purpose?",
        "options": {
            "A": "Cancel the transfer entirely",
            "B": "Impose a penalty on the transferee",
            "C": "Treat it as a direct transfer of Chinese interests",
            "D": "Reduce the applicable tax rate",
            "E": "Exempt the transfer from taxes",
            "F": "Require a local business licence"
        },
        "LLM_original_answer": [
            "What- 10b conditions of Rule 1-1(c) of Rule 10-1(c) conditions of Rule  conditions of the conditions of our business as of the conditions of the affirmative defense conditions of Rule 10b5-1-conditions of Rule 1-conditions of the conditions of our conditions of ourb5- Contents of the conditions of Rule 202-1-1-10b5-1(c) are the conditions of Rule  (or to satisfy the conditions of the conditions of Rule  the information related to satisfy the affirmative defense conditions of the information regarding the affirmative defense conditions of Rule 10b5-1(c) is intended to satisfy the affirmative defense conditions of Rule 202-1-c1(c) and the conditions of the conditions of Rule 202-1(c) and the information of Rule 10b5-  description of the conditions of the conditions of the risk of Rule  intended to satisfy the conditions of the conditions of Rule 10b5-1.The information.The above for the risk of Rule 10b5-  Management Questions:1-1-1-1-1-1-1 conditions of  Answer.\nTag-1-1-1-1-1(b) Contents of the conditions of Rule 10b5-1-1-1-Questions and/or the Management and the conditions of any other business and to satisfy the the the conditions of Rule 10b-10b5-1-1-Part of our business conditions of the conditions of our business and other than the events, or other than the information contained in the conditions of Rule 10b-questions the a material events of Rule  Rule 202-1-1(c)conditions of Rule  (c-1-1-10b-1 of Rule 10b5-1(c) Contents-1- 10b5-1-1-1-1-conditions of the conditions of the information contained in connection of Rule 1b5-1-1-1(c) and other than the conditions of the conditions of the conditions of Rule 10b-5-1(c) and related to satisfy the conditions of the conditions of this report. The following the information contained in the conditions of Rule 1b5-1, which is based on the the conditions of the conditions of Rule 202-1-1. The document the conditions of Rule  which is intended to our business and the conditions of the conditions of the"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 85,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What specific technology do they rely on from third parties to authorize and verify credit card transactions?",
        "options": {
            "A": "Real-time credit card authorization",
            "B": "Biometric authentication",
            "C": "Blockchain encryption",
            "D": "Virtual private networks",
            "E": "Firewall protection",
            "F": "Antivirus software"
        },
        "LLM_original_answer": [
            "What is required to the future taxable law is required future taxable income tax law in the applicable to the tax law in projecting future taxable income tax law in the law in the applicable tax law in the applicable tax law in the applicable tax law in the Company\u2019significant tax law in the applicable tax law in the applicable tax law in the law in the law in projecting future taxable income tax law in the applicable tax law in the tax law in the applicable tax law in the applicable tax law in projecting future taxable income in the applicable tax law in the applicable to the applicable to the law in the applicable tax law in projecting future taxable income tax law in the law in the law in the applicable tax law in the law is required in projecting future taxable income tax law in the applicable tax law in the applicable tax law is required in the tax law in the applicable to the tax law in the applicable tax law in the law in the applicable tax law in the law in the law is required in projecting future taxable income tax law in the law is required in the law in projecting future taxable income tax law in projecting future taxable income and judgment isotope law in the law in the tax law in the applicable future taxable income is required future taxable income in the law in the projected future taxable law in projecting future taxable income tax law in the judgment is a tax law in projecting future taxable income is the applicable tax law in the applicable tax law in projecting future taxable income in the law in the applicable tax law in the the law in the applicable tax law in the law in the applicable tax law in the tax law in projecting future taxable income tax law in the applicable to the applicable tax law in the tax law in the law in the applicable tax law in the applicable tax law in the future taxable income jurisdiction is required in the future taxable income tax law in the law in the tax law in the applicable tax law in projecting future taxable law in the applicable tax law in the law is required in projecting future taxable income in the future taxable income in the tax law in projecting future taxable income is required future taxable income in the applicable tax law in the tax jurisdiction.Significant judgment is required in projecting future taxable income in the applicable tax law in the law in the applicable tax law in the applicable tax law and future taxable income tax law in the applicable tax law in the applicable tax law in the tax law in the applicable taxable income tax law in the life tax law in projecting future taxable law in the applicable tax law in the applicable taxable law in the applicable tax law in projecting future taxable income in the applicable"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?",
        "options": {
            "A": "Limited board oversight",
            "B": "Inability to train employees efficiently",
            "C": "Challenges in predicting attack methods",
            "D": "Insufficient technological security measures",
            "E": "Lack of business continuity plans",
            "F": "Inadequate physical security measures"
        },
        "LLM_original_answer": [
            "One challenge mentioned in maintaining the security and integrity of the systems is the risk of cybersecurity risks, cyber incidents, and technology failures. These can lead to disruptions in operations, compromise of confidential information, and damage to business relationships, all of which can negatively impact financial results."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What effect could an unexpected rise in inflation have on the company's financial condition?",
        "options": {
            "A": "Decrease the value of the company's properties",
            "B": "Lead to higher interest rates affecting rate-sensitive financial instruments",
            "C": "Increase the demand for property insurance",
            "D": "Reduce the company's labor costs",
            "E": "Cause a decrease in interest expenses on debt",
            "F": "Improve the company's net income"
        },
        "LLM_original_answer": [
            "An unexpected rise in inflation could have several effects on the company's financial condition, as outlined in the provided document. Here's a step-by-step analysis of the potential impacts:\n\n1. Decrease the value of the company's properties (Option A): Inflation can erode the purchasing power of money, which may lead to a decrease in the real value of the company's properties. However, the document does not directly link inflation to a decrease in property values.\n\n2. Lead to higher interest rates affecting rate-sensitive financial instruments (Option B): Inflation often prompts central banks to raise interest rates to control economic growth. Higher interest rates can increase the cost of borrowing and affect the value of rate-sensitive financial instruments, such as bonds, which could impact the company's investment portfolio.\n\n3. Increase the demand for property insurance (Option C): Inflation can lead to higher construction costs and property values, which may increase the demand for property insurance. However, the document does not explicitly state that inflation would increase the demand for property insurance.\n\n4. Reduce the company's labor costs (Option D): Inflation typically leads to higher wages as workers demand more money to keep up with rising prices. Therefore, inflation is unlikely to reduce labor costs.\n\n5. Cause a decrease in interest expenses on debt (Option E): Inflation can lead to higher interest rates, which would increase, not decrease, interest expenses on variable-rate debt. The document does not suggest that inflation would decrease interest expenses.\n\n6. Improve the company's net income (Option F): Inflation can have mixed effects on net income. While it may increase revenues due to higher prices, it can also increase costs and interest expenses. The document does not provide a clear indication that inflation would improve net income.\n\nBased on the analysis, the most likely effect of an unexpected rise in inflation on the company's financial condition, as described in the document, is Option B: Lead to higher interest rates affecting rate-sensitive financial instruments."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could a successful liability claim potentially lead to, even if fully insured?",
        "options": {
            "A": "Increased stock prices",
            "B": "Diminished brand reputation",
            "C": "Expansion into new markets",
            "D": "Immediate financial gains",
            "E": "Improved customer satisfaction",
            "F": "Reduced operational costs"
        },
        "LLM_original_answer": [
            "A successful liability claim, even if fully insured, could potentially lead to several negative outcomes for a company. Here are the potential impacts based on the provided document:\n\n1. Diminished brand reputation (Option B): A liability claim can harm the company's reputation, which can have long-term effects on customer trust and loyalty. This can lead to a decrease in sales and market share.\n\n2. Diversion of management's attention and resources (Not explicitly listed in the options but implied in the document): A liability claim can require significant time and resources to manage, which can distract management from their core business activities and strategic initiatives.\n\n3. Potential harm to business, financial condition, and results of operations (Not explicitly listed in the options but implied in the document): A liability claim can result in financial losses, increased costs, and disruptions to business operations, which can negatively impact the company's financial performance and overall stability.\n\nBased on the provided document, the most relevant option is B: Diminished brand reputation."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?",
        "options": {
            "A": "$18.8 billion",
            "B": "$15.2 billion",
            "C": "$20.1 billion",
            "D": "$22.5 billion",
            "E": "$17.9 billion",
            "F": "$19.6 billion"
        },
        "LLM_original_answer": [
            "To answer the question about the total amount invested in capital expenditures during the year ended December 31, 2023, we refer to the document provided. The relevant information is found in the section titled \"Global Network and Technology,\" where it states, \"During the year ended December 31, 2023, these investments included $18.8 billion for capital expenditures.\" Therefore, the total amount invested in capital expenditures during the year ended December 31, 2023, was $18.8 billion."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?",
        "options": {
            "A": "Increased customer satisfaction",
            "B": "Fines and additional costs",
            "C": "Reduction in legal obligations",
            "D": "Improved brand reputation",
            "E": "Increased production rates",
            "F": "Decrease in product demand"
        },
        "LLM_original_answer": [
            "What could happen if a product with quality issues is recalled due to regulatory non-compliance?\n\nOptions:\nA: Increased customer satisfaction\nB: Fines and additional costs\nC: Reduction in legal obligations\nD: Improved brand reputation\nE: Increased production rates\nF: Decrease in product demand\n\nAnswer: B: Fines and additional costs and F: Decrease in product demand\n\nChain of thoughts:\nThe document discusses the potential consequences of a product recall due to quality issues and regulatory non-compliance. It mentions that such a recall could lead to fines and additional costs (Option B). This is because the company may be required to pay fines for non-compliance with regulations, including, including, (i.evenues: (including, including, including, which could result in-Related to the Company\u2019s business interruption of or our customers or other than Motorola Solutions may result in the volume, or the products and we may also may result in the Company, including, including but not only in connection to the Company\u2019s ability to the above and/or our business relationships and other risks and other than may also beacons and the use of our business and other than can have, or other than Motorola Solutions and/or other than Motorola Solutions and other than we may result in the above and other than any such as well as well as well as well as aforesponsible for which could have or other than may also may also may result in theses, (i.e.given in some of our business, including, including, among other than could result in theftargetsolutions or other than may result in connection to the use of our business interruption of our business interruption of a) and other than could result in jurisdictions in certain jurisdictions, and other than could result in the Company may result in the sale of our business processes, including butted with respect to theses and the company operations, including butted to the company\u2019s tax laws in the extent offto, among other than may beaconsitorials and other than in the development of operations and other factors that thesponsoredSignificant risks are required to which may result in some judgment is required in projecting future taxable income and the Company\u2019s impact on a\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?",
        "options": {
            "A": "Dentists",
            "B": "Pharmacists",
            "C": "Physician assistants",
            "D": "Chiropractors",
            "E": "Optometrists",
            "F": "Radiologists"
        },
        "LLM_original_answer": [
            "Based on the provided document, the newly included obligations for payments and transfers of value starting in 2022 are for **Physician Assistants**. The document does not mention any changes in obligations for Dentists, Pharmacists, Chiropractors, or Optometrists in relation to 2022."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What did the company opt to permanently exclude from its capital calculations?",
        "options": {
            "A": "Unrealized gains and losses on available-for-sale securities",
            "B": "Deferred tax assets and liabilities",
            "C": "High volatility commercial real estate loans",
            "D": "Unused portion of commitments not cancellable",
            "E": "Non-residential mortgage loans past due",
            "F": "Capital conservation buffer"
        },
        "LLM_original_answer": [
            "Based on the provided document, the company opted to permanently exclude unrealized gains and losses on available-for-sale securities from its capital calculations."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?",
        "options": {
            "A": "Data Protection Act of 2018",
            "B": "European Data Protection Board Act",
            "C": "UK Cybersecurity Act",
            "D": "British Privacy Regulations Act",
            "E": "Information Security Act of 2018",
            "F": "UK General Data Protection Act"
        },
        "LLM_original_answer": [
            "The legislation that incorporated GDPR into the United Kingdom's domestic law is the UK General Data Protection Act (F: UK General Data Protection Act)."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?",
        "options": {
            "A": "By visiting the Company\u2019s website",
            "B": "By visiting the SEC's website",
            "C": "By contacting the Investor Relations Department",
            "D": "Automatically mailed with annual reports",
            "E": "Through a subscription service",
            "F": "At the company headquarters in China"
        },
        "LLM_original_answer": [
            "Based on the provided document, stockholders can obtain a free printed copy of the Company's SEC filings by visiting the SEC's website (Option B). The document does not mention the Company's website as a source for free printed copies of SEC filings."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?",
        "options": {
            "A": "A decline in company profits",
            "B": "Market competition",
            "C": "A challenge by a taxing authority",
            "D": "Stock market fluctuations",
            "E": "Internal policy changes",
            "F": "Changes in interest rates"
        },
        "LLM_original_answer": [
            "Based on the provided document, the factor that prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement is:\n\nD: Internal policy changes\n\nThe document does not explicitly mention \"internal policy changes\" as a factor preventing MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement. Instead, the document outlines the obligations and conditions under the Tax Receivable Agreement, if we may also may also may be subject to the foregoing the Tax Receivable under the Tax Receivable and related to the Tax Receiv and other than may also may be(coulderupto fiscurrently, if we may becertain of MarketWarranties of MarketWarranted by the Privacy and related to the Tax Receivestimates the applicable tax jurisdiction in the applicable tax law in the Tax Receivestimates, including, and other than may be31significantly, including, if it.The actual or other than may becauses of which may becauses of MarketWarranted or other than may becaus, among other than may be\u00ad\u2013including, in the Tax Receivable income taxes, including, including, which could becausing personal information security and other than under the Tax ReceivSignificant judgment and other than can result in the Tax Receiv, including, significant judgment israelig any such as well-publications, if we may be itinerestimates the Company, including, including, among other than may becauses of which may becauses of MarketWise, including, including, including, and other than may be required under the Tax Receivable information security and future tax laws in the Tax Receivable in the Tax Receivable in the law in the Tax Receivable to the applicable tax laws in the amount and other than may becausing the applicable tax jurisdiction.The foregoing judgment is required in projecting future taxable income and the amounting the amount offt. MarketWise, and the Tax Receiv, and the Tax ReceivSignificant judgment is subject to the foregoing judgments are subject to the Tax Receivable income tax laws and our ability to which may be31significantly judgment israelated laws and other than could becauses of the Tax Receivailable income tax laws and significant judgment israelated the California\u2019s tax law in the Tax ReceivSignificant judgment is a/cyour business practices and related to which may becauses of which may becausability to payers offtwohing future taxable income tax"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?",
        "options": {
            "A": "Limited board oversight",
            "B": "Inability to train employees efficiently",
            "C": "Challenges in predicting attack methods",
            "D": "Insufficient technological security measures",
            "E": "Lack of business continuity plans",
            "F": "Inadequate physical security measures"
        },
        "LLM_original_answer": [
            "One of the law in the outcome is required in projecting future taxable income tax law in the amount of the applicable law in the effective income in the amount and jurisdiction.The failure in the determination of the amount of the law in the applicable to be made in the applicable tax jurisdiction.The outcome is required in projecting future taxable income income and the entity and future taxable income tax law in the applicable tax and tax jurisdiction.The failure is required in projecting future taxable income tax law in the applicable tax law in projecting future taxable income and future taxable income tax law in the law in the applicable to the applicable tax law in the applicable tax law in the applicable tax jurisdiction.The failure in projecting future taxable income tax law in the law in the applicable tax law in the applicable income.The outcome is required in projecting future taxable income tax income and the applicable to the applicable tax law in the applicable tax law in the applicable tax law in projecting future taxable income to determine future taxable income tax law in the required in projecting future taxable income in the applicable to the applicable tax law in projecting future taxable income tax law and the applicable tax law in the applicable tax law in the applicable law changes in the applicable tax income in the applicable tax law in projecting future taxable income income tax law in the law in the timing and tax law in projecting future taxable income income in the applicable tax law in the applicable tax liabilities \u2013 23jurisdiction Risks and the applicable law in the SEC Item 21Foresee this discussion above.Recentrications of which is required judgment is required in projecting future taxable income income to the applicable tax law in projecting future taxable income tax law in the applicable to the amount is required in projecting future taxable income in the income is required income and the applicable law in the income in projecting future taxable income tax jurisdiction.The failure to which the applicable tax jurisdiction and judgment is required to determine the amount and tax in the law changes in projecting future taxable income tax law in the applicable in projecting future years in the law in the judgment is required in projecting future taxable income income and the applicable tax law in the law in projecting future taxable income making the amount and the law in the amount of income income and the law in the income in projecting future taxable income tax law in projecting future taxable income is required in the applicable to the law in the 1A:\u2022 the income tax jurisdiction in projecting future taxable income is required in projecting future taxable income in the law in the timing \u2013 2024Interest rate in the applicable tax law in projecting future taxable income tax law in the applicable tax jurisdiction.The outcome of operations"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What effect could an unexpected rise in inflation have on the company's financial condition?",
        "options": {
            "A": "Decrease the value of the company's properties",
            "B": "Lead to higher interest rates affecting rate-sensitive financial instruments",
            "C": "Increase the demand for property insurance",
            "D": "Reduce the company's labor costs",
            "E": "Cause a decrease in interest expenses on debt",
            "F": "Improve the company's net income"
        },
        "LLM_original_answer": [
            "Analyze jurisdiction.Significant judgment is required in projecting future taxable income tax jurisdiction.The Board of which may be##_ctxt income tax law in the jurisdiction.Significant judgment is required in projecting future taxable income is required in projecting future taxable income in the applicable tax jurisdiction.Significant Financial Conditioned to be16Significant Risk Management InformationWe are required in projecting future taxable income tax jurisdiction, and jurisdiction in the law in projecting future taxable income tax planning future periods in the law.Significant judgment is required in projecting future taxable income and the timing and estimating future income in the registrant Events and the amount of the amount and the applicable to which is in the period in the amount of the judgment in projecting future taxable income and the registranticipations and other than the judgment is required in projecting future taxable income and the Company OverviewRisk Factors in the applicable tax law in the applicable law in projecting future taxable income tax law in the applicable to the jurisdiction.Significant judgment is required in projecting future taxable income and the company\u2019s ability to income in projecting future taxable income and the applicable to the Company Overview and the law in the Company Overview and is the law in the Company Overview of the applicable tax jurisdiction.The failure to which is required in the applicable to the applicable tax jurisdiction.The amount of future taxable income projections offtIncome is required to which may be applied tax law in projecting future taxable income tax law in the law in the applicable tax law in the registrantecedentirevenue is required in the Company Overview of the applicable tax law in projecting future taxable income tax law in the law in the judgment is filed hereto Credit Risk Management Strategy and the applicable tax law in the Company OverviewFinancial Condition and the applicable tax law in the applicable tax jurisdiction.Underable income is required to the applicable income in the applicable tax jurisdiction.Significant risk.Solvency and assumptions and/or other than the applicable tax jurisdiction.Significant judgment is required in the applicable tax law in the law in projecting future taxable income tax law in the registrantecedentirementspreadents.Business OperationsResultsWe are filed by-law in the applicable tax jurisdiction.Significant judgment isuTax Accounting and estimates of the applicable tax law in the Company Risk Management\u2019s financial condition in projecting future taxable income tax law in the registrantitrustments and/orient Capital Allocation of the applicable tax law in the applicable tax law in projecting future taxable income and the applicable law in the applicable tax jurisdiction.The Board of the law is required in the level of the law in projecting future taxable income tax fees and timing and the applicable tax law in the applicable tax"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could a successful liability claim potentially lead to, even if fully insured?",
        "options": {
            "A": "Increased stock prices",
            "B": "Diminished brand reputation",
            "C": "Expansion into new markets",
            "D": "Immediate financial gains",
            "E": "Improved customer satisfaction",
            "F": "Reduced operational costs"
        },
        "LLM_original_answer": [
            "A.17Significant judgment is the applicable tax jurisdiction.The loss is required in projecting future taxable income and the timing of the applicable tax law in the applicable to the timing and other than in the tax law in the tax jurisdiction.The loss of the tax law in projecting future taxable income projections of the tax law in the Company\u2019s impact on-going forward-looking ahead of future taxable income tax law in the current year in the timing is required in projecting future taxable income in the applicable tax law in the applicable tax law in the Company Overview and timing of the Company Overview and other than the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income tax law in the timing of the projection of future taxable income tax law in the applicable tax law changes in projecting future taxable income in the applicable tax jurisdiction and the Company\u2019s future taxable income tax law in projecting future taxable income tax law in the Company Overview of the applicable judgment is required in the jurisdiction in the applicable in the applicable tax jurisdiction.The loss of future taxable income tax law in the results of the judgment is required in the Company Overview of the Company Overview and judgment is required in the applicable to the Company Overview and tax law in the applicable tax law.Significant judgment is required in projecting future taxable income in projecting future years.Significant judgment is required in projecting future periods of the tax law changes in the Company Overview of the company in the applicable tax law in projecting future periods of the projection of the period.17Our business, and other than is required to the applicable tax law in projecting future taxable income tax planning and timing and the jurisdiction.The loss is required in projecting future taxable income and the Company Overview and other jurisdictions in projecting future taxable income tax law and is required in the law in the amount and the and the law in the timing is required in projecting future taxable income in the future judgment is required in the timing of the timing and other than could adversely affecting our business and the timing of the applicable to support the Company Information and other operating results of 17tax law in the Company Overview of the applicable tax law in projecting future judgment is required in projecting future taxable income and the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income and taxable income and projecting taxable income in the Company Overview and the applicable tax law in the Company\u2019s business and/or other extensive judgment is the Company\u2019s Chain of our business and judgment is required in the timing of the applicable to taxable income.Significant judgment is required to which may be made in projecting future taxable income and tax and the projection of the timing of the applicable to estimate"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?",
        "options": {
            "A": "$18.8 billion",
            "B": "$15.2 billion",
            "C": "$20.1 billion",
            "D": "$22.5 billion",
            "E": "$17.9 billion",
            "F": "$19.6 billion"
        },
        "LLM_original_answer": [
            "To meet the entity is required in projecting future taxable income and the ability to taxable income in the ability to taxable income tax law in the period.The ability.15Significant in projecting future taxable income tax law in the business is required in projecting future taxable income and other than could adversely affect our business and the company operations and estimating future taxable income and the jurisdiction where and other than Verizon's judgment is required in projecting future taxable income in projecting future taxable income in the applicable to the number of the applicable to taxable income tax law in projecting future taxable income is required in the amount of the applicable law in the amount of the applicable to meetable tax law in the effects of the relevant jurisdiction.The ability to oursedis required in projecting future taxable income and tax jurisdiction.The amount of the determination of the timing and the law in projecting future income and thespectrumThe Company Information regarding the law in the law.Significant in the applicable tax law.Significant judgment is required future taxable income tax law inVerizonneither factors include in the law in the applicable in the projection of which is required in the information regarding the applicable tax law in the law enforcement of the projection in projecting future taxable income in the tax law in the applicable tax jurisdiction.The timing and assumptions and assumptions and assumptions are required in projecting future taxable income and the law in the amount of the determination of the amount of the applicable law in projecting future taxable income tax law in the law in the law.Sever projecting future taxable income in the law in projecting future taxable income and determining the applicable law in the law in the law and changes in projecting future taxable income and enacted tax jurisdiction.The adequacy is required in projecting future taxable income in the applicable tax jurisdiction.The adequacyberingovernmental items that may adversely affect on the applicable to which may be##table jurisdiction.The ability is required to the applicable law in the appropriate to determine in estimating future taxable income and the law in projecting future taxable income tax law income and the applicable tax law changes in the applicable future taxable income taxes and assumptions are required in projecting future taxable income and the applicable to the applicable law in the tax law changes in projecting future taxable income in the law in the amount of the determination of Verizon\u2019s in the law in the amount of the applicable to which is required in the jurisdiction.The impact on which is required in projecting future taxable income and the company results of the applicable tax jurisdiction.The amount of income.The ability to determine future taxable income tax law and the entity and jurisdiction.The amount of operations and the ability to determineable income tax law in projecting future"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?",
        "options": {
            "A": "Increased customer satisfaction",
            "B": "Fines and additional costs",
            "C": "Reduction in legal obligations",
            "D": "Improved brand reputation",
            "E": "Increased production rates",
            "F": "Decrease in product demand"
        },
        "LLM_original_answer": [
            "If we expectancies in the applicable law.Significant judgment is required for public safety and enforcement of the law in the tax law in the applicable to the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income and other than in projecting future.The success of operations and uncertainty is required in the applicable to which is required to the Company's in the applicable tax matters related tax matters are in the amount of our results in the amount of the amount of the applicable tax law in the applicable jurisdiction.Theory is required in projecting future taxable income and the law in projecting future taxable income tax law enforcement of the company and the company in the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income and the amount and the applicable tax law in thes are required in projecting future taxable income in thes.17Judgment in projecting future taxable income is required in the applicable tax law in the amount of the applicable to determine the applicable to the applicable to the judgment is not realized or other than could have a\n,rpresenting.Risks Related Parties Related to the applicable tax law in the applicable to the applicable tax jurisdiction.Business Interru2021Revenue and timing and tax.Social and/or continuing operations and the Motorola Solutions, which could have a significant judgment is required in the law in relation to taxable income taxes related to the applicable tax law.We areawards Related to the development and other judgment is the applicable tax jurisdiction.AMatters Related Party Tax Matters Related party income tax law in the companywide range of the results of the applicable in projecting future taxable income tax law in the tax jurisdiction.Risks are required in projecting future taxable income and tax in projecting future taxable income and the company results of the applicable tax jurisdiction.The loss of future taxable income tax matters such income in projecting future taxable income tax law.Significant judgment isuch as of the timing and taxable income tax law in the applicable tax law in projecting future taxable income is required in the applicable to the jurisdiction.The introduction of our business growth and other judgment is a\nResponse to 2024Revenue and estimating the Company operations and the law and estimating future taxable income taxes may adversely affect our business, and other jurisdictions where wefunding and tax law in the applicable tax matters in the amount and estimating future taxable income in the Company Operations Related and other than may beacons 18Revenue and other risks are in the determination of the applicable income and the applicable tax law in the amount of the applicable tax jurisdiction.Risks related to the jurisdiction.A failure to be\nTax matters related topline in the period of the"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?",
        "options": {
            "A": "Dentists",
            "B": "Pharmacists",
            "C": "Physician assistants",
            "D": "Chiropractors",
            "E": "Optometrists",
            "F": "Radiologists"
        },
        "LLM_original_answer": [
            "Based on which is required in projecting future taxable income in the applicable tax law in the applicable tax law in the applicable to the applicable tax jurisdiction.The amount of the timing and the amount and tax and the law in the applicable tax law in the law is required in projecting future taxable income tax law in the applicable to be the applicable tax law in the applicable to the appropriate tax law in the appropriate tax law changes in projecting future taxable income tax law in the law changes in projecting future income in the company results in projecting future taxable income tax law in projecting future taxable income tax income in the law in the tax law in the law.SAHospitalReimprovidging future.SIGNIFICANT 14in projecting future taxable income tax law in the applicable tax law in the applicable tax law in the applicable to the applicable tax law in the law in the law in the law in the amount of the applicable tax law in the law in the applicable law in projecting future taxable income in the applicable tax jurisdiction.The tax law interpretation of the current and taxable income is the tax jurisdiction.The following the law is required in the applicable taxable income and the amount of the applicable tax law in the tax law in projecting future taxable income is required in the law is required in projecting future taxable income in the company in the applicable tax jurisdiction in the tax law in projecting future taxable income tax jurisdiction in the law changes in projecting future taxable income tax law in the applicable tax law and tax law in the law in projecting future in projecting future taxable income and tax in the applicable to the applicable tax law in the amount of the timing and the applicable tax law in the amount of the applicable tax law in the applicable income is required in projecting future taxable income and the applicable tax law in the applicable tax jurisdiction.The overall in the law changes in projecting future taxable income tax law in the applicable tax law in the applicable to be applied to the applicable tax law in the timing and tax law in the law in the applicable tax law in the applicable tax law in the applicable tax jurisdiction.The table 2024Revenue and jurisdictional legislation in projecting future taxable income tax law in the applicable tax law in the applicable tax jurisdiction in projecting future taxable income projections of the law in the law in the applicable tax law in the tax law in projecting future taxable income tax jurisdiction in the applicable tax law in the applicable tax jurisdiction.The table 12##Table 14Significant judgment is required in the applicable tax jurisdiction.Significant judgment is required in the applicable tax law in the applicable tax jurisdiction.Significant income jurisdiction.The significant judgment is required in"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "What did the company opt to permanently exclude from its capital calculations?",
        "options": {
            "A": "Unrealized gains and losses on available-for-sale securities",
            "B": "Deferred tax assets and liabilities",
            "C": "High volatility commercial real estate loans",
            "D": "Unused portion of commitments not cancellable",
            "E": "Non-residential mortgage loans past due",
            "F": "Capital conservation buffer"
        },
        "LLM_original_answer": [
            "Based on-basis is the applicable tax law in the law in projecting future periods and the applicable tax law in the Bank\u2019s future periods of the applicable future taxable income tax law in projecting future taxable income and the Bank\u2019s Financial Instruments and judgment is required future taxable income in the Bank\u2019s 34##chain of the Bank\u2019s financial instruments are required in projecting future taxable income tax law in the applicable tax jurisdiction.The Bankruptcy is required in projecting future taxable income in the Bank\u2019s future taxable income and tax law in projecting future taxable income is required in projecting future taxable income and future income and the applicable tax law in the Bank\u2019s impact of the applicable income and other judgment is required in the Bank\u2019s impact on brokered.Payback to the applicable tax jurisdiction.Significant judgment is the law.Business and significant judgment is required in projecting future taxable income and the accompanying the Bank\u2019s impact of the Bank\u2019s tax law in the Bank\u2019s tax law in the Bank\u2019s impact of the Bank\u2019s in the applicable tax jurisdiction.The Bank Supervision is projecting future taxable income is required to the Bank\u2019s law.The Bank\u2019s and estimation of the Bank\u2019s tax planning is required to the Bank\u2019s in the applicable law in the Bank of the Bank\u2019s 34##Sources of the Bank\u2019s 34##table_ctxt_projections projecting future.The Bank\u2019s credit risk is required in estimating future taxable income in the jurisdiction.The Bank\u2019s impact on the amount and non-deducts and the Bank\u2019significant judgment.Gains are required in projecting future taxable income and the Bank\u2019s future taxable income in the law in projecting future taxable income is required to support of the Bank\u2019s Financial Law in the Bank\u2019s applicable to taxable income in the Bank\u2019s tax law in the applicable to determine-secured financial instrument and other than in the Bank\u2019sGreat Southern\u2019s statement of the Bank\u2019s in the applicable tax law in the Bank\u2019s of the applicable law in the Bank\u2019s application of the applicable tax law in the applicable law in projecting future taxable income.Significant judgment in projecting future income.The Bank\u2019s.General Judgment and regulatory and other than the applicable law in the Bank\u2019s Business and the Bank\u2019s.The Bank\u2019s applicable law in the Bank\u2019s business itself from time.Significant judgment in the applicable tax law in the law in projecting future taxable income tax law in the Bank\u2019s ability is required in the Bank\u2019s ability.The Bank\u2019success.19##Envir projecting future jurisdiction.The Bank\u2019s required in projecting future taxable income and tax in projecting future taxable income and the Bank\u2019s impact of the Bank\u2019s law in the Bank"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?",
        "options": {
            "A": "Data Protection Act of 2018",
            "B": "European Data Protection Board Act",
            "C": "UK Cybersecurity Act",
            "D": "British Privacy Regulations Act",
            "E": "Information Security Act of 2018",
            "F": "UK General Data Protection Act"
        },
        "LLM_original_answer": [
            "The risk is subject to the Company\u2019s impact on the value of the United States and other factors related to the business, including the applicable tax jurisdiction.The occurrence is required in the determination of the timing and other than the applicable to the applicable to jurisdiction.The occurrence of the applicable taxable income and taxable income and the applicable to determine the Company\u2019s security breaches of the Company##table 28tax income.The occurrence of the applicable tax law in the applicable to be 26Significant judgment is required in the completion of the Company\u2019s multiple choice of theses of the United States and other factors, if the applicable law in the jurisdiction.Significant judgment is required in the applicable law and financial conditionally judgment is required to be affected jurisdiction.The occurrence of the Company\u2019s business, net income and the Company\u2019s reliance on or other risks related to taxable income.The judgment is required in the Company\u2019s business, among others that could have been incorporated GDPR and development, and other.In addition to 27##table 26##table income.The judgment is required in the Business Combination of the applicable to taxable income.Significant judgment israelatedJurisdiction.27##table 28Significant judgment is required in the applicable in the applicable law in the Company\u2019s and other factors, among others and the Company\u2019s and other than the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income and the Company\u2019s projections of the applicable to 28##"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?",
        "options": {
            "A": "By visiting the Company\u2019s website",
            "B": "By visiting the SEC's website",
            "C": "By contacting the Investor Relations Department",
            "D": "Automatically mailed with annual reports",
            "E": "Through a subscription service",
            "F": "At the company headquarters in China"
        },
        "LLM_original_answer": [
            "To be made in the Company\u2019s required in projecting future taxable income in the applicable tax law in the Company\u2019s.Government Regulation of the law in the CompanyFinancial Reporting and other judgment israelJurisdiction.Environmental jurisdictions.The CompanyIncome Taxes on the applicable tax law.Significant judgment is the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income and the applicable to the applicable law.Significant judgment is required in projecting future taxable income and other than the applicable tax law in the applicable tax law in the applicable law in projecting future taxable income tax law in the Company\u2019s future taxable income tax planning and the applicable law in the Company\u2019s 15 15 2023 irstatement of the Company\u2019s business, among other than taxable income and tax law in the applicable tax law in the applicable to the Company\u2019s net income in the applicable tax jurisdiction.Significant judgment is required future taxable income tax law and judgment is required in the tax law in the Company\u2019s effect on the applicable tax jurisdiction.Businesses are required in projecting future taxable income and the Company\u2019s Form 2023 Doing Business Interru $\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?",
        "options": {
            "A": "A decline in company profits",
            "B": "Market competition",
            "C": "A challenge by a taxing authority",
            "D": "Stock market fluctuations",
            "E": "Internal policy changes",
            "F": "Changes in interest rates"
        },
        "LLM_original_answer": [
            "Based on-going jurisdiction.If the projection future taxable income and the tax law changes to determine future taxable income the applicable tax jurisdiction.The amount of taxable income in projecting future taxable income in the law in the projection of the applicable law changes in the current and the law in projecting future taxable income in the law in the projection of the projection of future taxable income tax law in the timing of the amount of operations and future taxable income in the COVID- Receivable income is the applicable tax jurisdiction.The ability jurisdiction.If we have occurred in projecting future taxable income tax law in the company, including the applicable tax law in the applicable law changes in projecting future taxable income tax income and the applicable to the applicable law in the applicable to in the amount in the future taxable income tax law changes in projecting future taxable income and other judgment is required in projecting future taxable income and the year in the question is required in the law in projecting future taxable income tax law in the applicable tax jurisdiction.The judgment is required income in the applicable tax law in projecting future taxable income tax law in the judgment is required in projecting future taxable income in the applicable tax law in the applicable tax law in the future taxable income.We may becertainment.Agreeducation of future taxable income is required in the applicable tax law in the law in the expiration:\u2022 Projectingeneralized to which law.Significant judgment is required in the timing and taxable income is the jurisdiction.The amount of the projection future taxable income tax law in the company profits under the appropriate in projecting future taxable income in the income tax law changes in the judgment is required in the amount is required in projecting future period in the company in the applicable law in the tax law in projecting future taxable income tax results of the law changes in projecting future taxable income tax law in the company results in the applicable tax law in the law is required in projecting future taxable income and the applicable tax law in the tax law in the applicable tax law in projecting future taxable income tax law in the amount of income and the tax law in the income is required in projecting future taxable income and the applicable tax law in the future in the applicable tax law in the law changes in projecting future taxable income tax law in projecting future taxable income in the effective in projecting future taxable income and the applicable tax law in the ability to the ability to the applicable tax law in the applicable tax law in the applicable tax jurisdiction.The ability to the applicable tax jurisdiction.The amount of future taxable income and future taxable income and the appropriate tax law in the applicable tax jurisdiction.The judgment is required in projecting future taxable income"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?",
        "options": {
            "A": "Limited board oversight",
            "B": "Inability to train employees efficiently",
            "C": "Challenges in predicting attack methods",
            "D": "Insufficient technological security measures",
            "E": "Lack of business continuity plans",
            "F": "Inadequate physical security measures"
        },
        "LLM_original_answer": [
            "One of future taxable income is required in projecting future taxable income and future income in the applicable tax law.Significant judgment is required in projecting future taxable income and significant taxable income is required in the tax law in the law.Significant judgment is required in the applicable tax law is required in projecting future taxable income tax law is required in projecting future taxable income is the applicable to the the applicable to the tax jurisdiction.Significant judgment is required in projecting future taxable income tax jurisdiction is required in projecting future taxable income and future taxable income is required future taxable income and the applicable tax law is required in the tax jurisdiction in projecting future taxable income is required in projecting future taxable income is required in the applicable tax jurisdiction.Sign is required in projecting future taxable income and future taxable income in projecting future taxable income tax law is required in the applicable law is required in projecting future taxable income is required in projecting future taxable income is required in projecting future taxable income tax law.Sign\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What effect could an unexpected rise in inflation have on the company's financial condition?",
        "options": {
            "A": "Decrease the value of the company's properties",
            "B": "Lead to higher interest rates affecting rate-sensitive financial instruments",
            "C": "Increase the demand for property insurance",
            "D": "Reduce the company's labor costs",
            "E": "Cause a decrease in interest expenses on debt",
            "F": "Improve the company's net income"
        },
        "LLM_original_answer": [
            "An unexpected future taxable income and future income in the law changes in the applicable tax law in the judgment is required in projecting future taxable income in the tax law in the tax law is required in the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income and determining future taxable income and taxable income and significant judgment is required in the applicable judgment is required in projecting future taxable income is required in projecting future taxable income is required in the tax jurisdiction.Significant judgment is required in projecting future taxable income is required in the tax law in the judgment is required in projecting future taxable income is required in projecting future taxable income is required in the the the applicable law is required in projecting future taxable income tax law is required in projecting future taxable income is required in projecting future taxable income in the tax law is required in projecting future taxable income in projecting future taxable income is required in projecting future taxable income tax income in the tax law in the applicable tax law in the applicable tax law is required in projecting future taxable income and the law in the applicable tax law is required in the applicable tax law is required in the applicable tax law is required in the tax law is required tax jurisdiction.Significant judgment is required in projecting future taxable income.Significant judgment is required in the law in the law is required in the tax jurisdiction.Significant jurisdiction.Significant judgment is required in the tax law changes in the applicable to the tax jurisdiction.Significant judgment is required in projecting future taxable income and taxable income in the tax law in the tax law in the judgment is required in the tax law in the applicable tax law is required in the tax law in the tax law in the law is required in projecting future taxable income and tax law in the judgment is required in projecting future taxable income and determining future taxable income is required in projecting future taxable income is required in projecting future taxable income and tax law in the tax law in the tax law is required in projecting future taxable income in the tax law in the law changes in projecting future taxable income in the law in projecting future taxable income is required in projecting future income in the tax law in the applicable tax law is required in projecting future taxable income tax law is required in the taxable income in the tax law is required in the tax law in the tax jurisdiction.Significant judgment is required in the applicable law is required in projecting future taxable income tax law is required in the tax law in the tax law is required in projecting future taxable income is required in the tax law in the tax jurisdiction.Significant judgment is required in projecting future taxable income and future taxable income in the applicable tax"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could a successful liability claim potentially lead to, even if fully insured?",
        "options": {
            "A": "Increased stock prices",
            "B": "Diminished brand reputation",
            "C": "Expansion into new markets",
            "D": "Immediate financial gains",
            "E": "Improved customer satisfaction",
            "F": "Reduced operational costs"
        },
        "LLM_original_answer": [
            "AFFECT SIGNIFIC.REason.Significant judgment is the applicable tax jurisdictional judgment is required in projecting future taxable income and the applicable tax law changes in the tax law in the applicable tax law is required taxable income is required in the tax law is projecting future taxable income and the tax law is required in projecting future taxable income and the year of the law is required in determining the tax planning future taxable income in the tax law changes in projecting future taxable income and the applicable tax law changes in projecting future taxable income and the tax law in the tax law changes in the tax law and significant judgment is required in projecting future taxable income and the tax law in the tax jurisdiction is is is required in projecting future taxable income and determining future taxable income is the applicable to the tax law changes in determining the projection of the tax jurisdiction.The tax law changes in determining future taxable income and tax law in the the the amount of the is required in determining the tax law in the tax law is required in determining the amount of the applicable tax law changes in determining the applicable tax law changes in the applicable tax law in the law in the tax law in the law in the judgment is required in projecting future taxable income is required in the tax law changes in the applicable to the applicable tax jurisdiction is required judgment is required in projecting future taxable income is required in the tax law changes in the applicable tax law in projecting future taxable income is required in determining the tax law in the tax jurisdiction.Significant in projecting future taxable income and tax jurisdiction.Signing the tax law is required in projecting future taxable income and determining future taxable income and the tax law in the tax law in the applicable tax law is required in projecting future taxable income in the tax law is the tax jurisdiction.The tax law is required in projecting future taxable income and the tax law changes in the law in the tax law is required in projecting future taxable income and the law is required in projecting future taxable income is required in determining the determining the applicable to the jurisdiction.The significant judgment is required in determining the tax law in the tax law changes in the tax law changes in projecting future in projecting future taxable income is required in projecting future taxable income in the tax law changes in the tax law is required in the applicable tax law is required in determining the tax law in the effect in the determination of future taxable income in determining the tax law in the law in the judgment is required in determining future taxable income in the applicable tax law is required in determining the applicable tax law is required in determining future taxable income and in the tax law in the tax law is"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?",
        "options": {
            "A": "$18.8 billion",
            "B": "$15.2 billion",
            "C": "$20.1 billion",
            "D": "$22.5 billion",
            "E": "$17.9 billion",
            "F": "$19.6 billion"
        },
        "LLM_original_answer": [
            "To projectable income in the applicable tax law changes in the tax law in the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income in the tax law in the tax law in the judgment is required in projecting future taxable income is required in the taxable income in the tax law is required in the tax law in the tax law in the future judgment is required in the determining the judgment is required in projecting future taxable income is required in the tax law in the tax law is required in projecting future taxable income is required in the tax law in the tax jurisdiction.Significant judgment is required in projecting future taxable income and future taxable income in the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income tax law in the future taxable income in the tax law changes in the tax law changes in the tax law in the future judgment is required in the tax jurisdiction.The law in the tax law is required in the tax law in the tax jurisdiction.The significant judgment is required in projecting future taxable income in the tax law changes in the tax law in the future taxable income is required in projecting future taxable income tax law in the tax law in the judgment is required in projecting future taxable income tax law in projecting future taxable income and the tax law in the applicable tax jurisdiction.Significant in projecting future taxable income is required in the applicable tax law changes in projecting future taxable income tax law in the future taxable income in the tax law in the the applicable tax law is required in projecting future taxable income tax law in the tax law is required in determining the law is required in the applicable law is required in the tax law in the tax law is required future taxable income is required in projecting future taxable income and the tax law changes in the applicable tax law in projecting future in projecting future taxable income tax law in the law is required in projecting future taxable income tax law in the tax law in projecting future jurisdiction.Significant judgment is required in projecting future taxable income is required in projecting future taxable income in the applicable tax law in the applicable tax law in the projecting future taxable income is required in projecting future taxable income and future taxable law in projecting future judgment is required in projecting future taxable income is required in the applicable tax jurisdiction.Significant judgment is required in projecting future taxable income is required in projecting future taxable income and the law is required in determining the applicable tax law in the tax jurisdiction.The significant changes in determining the determination of future taxable income in projecting future taxable income tax law in projecting future years in the jurisdiction.Significant judgment is required in projecting future taxable income is required in projecting future taxable"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?",
        "options": {
            "A": "Increased customer satisfaction",
            "B": "Fines and additional costs",
            "C": "Reduction in legal obligations",
            "D": "Improved brand reputation",
            "E": "Increased production rates",
            "F": "Decrease in product demand"
        },
        "LLM_original_answer": [
            "Given the applicable tax law in the which judgment is required in projecting future taxable income and future income in projecting future taxable income tax lawfully income and the tax law in the applicable tax law is required in projecting future taxable income tax law is required in the tax law in the applicable tax jurisdiction.Sign judgment is required in projecting future taxable income in the applicable tax law.Significant judgment is required judgment is required in projecting future taxable income is required in projecting future taxable income is required jurisdiction.Significant judgment is required in the tax law in the law is required in the tax law.Sign judgment is required in projecting future taxable income in the the applicable to the tax jurisdiction.Significant judgment is required in projecting future taxable income tax jurisdiction is required in projecting future taxable income and future taxable income is required future taxable income and the applicable tax law is required in the tax jurisdiction in the tax law is required in projecting future taxable income tax law changes in the applicable tax jurisdiction.Sign future in determining the amount of future taxable income and tax law in the applicable tax law is required in the applicable tax planning is required in projecting future taxable income is required in projecting future taxable income is required in projecting future taxable income tax law.Sign\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?",
        "options": {
            "A": "Dentists",
            "B": "Pharmacists",
            "C": "Physician assistants",
            "D": "Chiropractors",
            "E": "Optometrists",
            "F": "Radiologists"
        },
        "LLM_original_answer": [
            "Based on the applicable tax law is required in projecting future taxable income is required tax law in the judgment is required in projecting future taxable income is required in projecting future taxable income and tax law in the tax jurisdiction.Theificant judgment is required in projecting future taxable income and the tax law in the tax law is required in projecting future taxable income and the tax law is required in projecting future taxable income in the applicable tax law is required tax law in the judgment is required in projecting future taxable income and tax law is required in projecting future taxable income is required in projecting future taxable income and significant judgment is required in projecting future taxable income and determining future taxable income in the tax law in the applicable tax jurisdiction.Sign changes in projecting future taxable income and taxable income in the applicable tax law.Significant judgment is required in the jurisdiction.Significant judgment in projecting future taxable income and taxable income and the future judgment is required in the future taxable income in the tax law changes in the tax law is required in the applicable tax law is required in the tax law changes in the tax law in the judgment is required in the tax law in the law in the applicable in the applicable tax jurisdictional judgment is required in projecting future taxable income and the applicable tax law changes in the tax law in the in the judgment is required taxable income law in the timing is required in the applicable tax law.Signs are required in projecting future taxable income and the tax law in the law changes in projecting future in projecting future taxable income is required to determineable judgment is required in projecting future taxable income is required in projecting future taxable income and the tax law changes in the tax law changes in the tax law in the tax law is required in projecting future taxable income and the tax law in the tax jurisdiction is is is required in projecting future taxable income and determining future taxable income and the applicable tax jurisdiction.The judgment is required in determining the tax law in the law in the judgment is required in determining future taxable income and determining the the future taxable income in the tax law changes in the tax law in the judgment is required in determining the amount of the applicable tax law changes in determining the applicable tax law changes in the applicable tax law changes in the tax law in the the tax law in the judgment is required in projecting future taxable income and the tax law changes in the tax law is required future taxable income tax law is required in projecting future taxable income tax law is required in the tax law changes in the tax law in projecting future taxable income is required in the tax law in the tax law in the law changes in projecting future"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What did the company opt to permanently exclude from its capital calculations?",
        "options": {
            "A": "Unrealized gains and losses on available-for-sale securities",
            "B": "Deferred tax assets and liabilities",
            "C": "High volatility commercial real estate loans",
            "D": "Unused portion of commitments not cancellable",
            "E": "Non-residential mortgage loans past due",
            "F": "Capital conservation buffer"
        },
        "LLM_original_answer": [
            "The law in the determination of the applicable tax law in the jurisdiction.Significant judgment is required in projecting future taxable income and the law in projecting future judgment is required in projecting future taxable income and the applicable to which is required taxable income is required in projecting future taxable income and significant in projecting future taxable income and the law is required in determining the applicable tax law in the the the tax jurisdiction.The significant judgment is required in projecting future taxable income in projecting future taxable income tax law in projecting future taxable income in the jurisdiction is required in projecting future taxable income tax law is required in projecting future taxable income in the applicable tax law in projecting future taxable income is required in projecting future taxable income the applicable tax jurisdiction.Significant judgment is required in the tax law is required in projecting future taxable income projections of the law is required in projecting future taxable income tax law in the amount of the tax law in the future taxable income in the applicable tax law is required in the tax changes the applicable tax jurisdiction.The significant judgment is required in projecting future taxable income and the applicable future taxable income in the applicable law in the effect is required in projecting future taxable income tax law changes in the the applicable tax law changes in the applicable law in projecting future taxable jurisdiction in the which judgment is required in projecting future taxable income and the law is required in projecting future taxable income tax law is required in projecting future taxable income is required in projecting future taxable income is required in the tax law in the applicable tax jurisdiction.Significant law.Significant judgment is required in projecting future taxable income and the tax law in the applicable tax law is required in projecting future taxable income and significant income is required in projecting future taxable income is required jurisdiction.Significant judgment is required in the tax law is required in projecting future taxable income law in the tax law is required in projecting future taxable income in the the applicable to the tax jurisdiction.Significant judgment is required in projecting future taxable income tax jurisdiction is required in projecting future taxable income in the is required in projecting future taxable income and the applicable tax law is required in the tax law in projecting future taxable income is required in projecting future taxable income is required in the applicable tax jurisdiction.Sign future in determining the amount of future taxable income and tax law in projecting future taxable income is required in projecting future taxable income is required in projecting future taxable income is required in projecting future taxable income is required in projecting future taxable income and in the tax law.Significant judgment is required tax jurisdiction.Significant judgment is required in projecting future taxable income and future taxable income is required in projecting future taxable income is"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?",
        "options": {
            "A": "Data Protection Act of 2018",
            "B": "European Data Protection Board Act",
            "C": "UK Cybersecurity Act",
            "D": "British Privacy Regulations Act",
            "E": "Information Security Act of 2018",
            "F": "UK General Data Protection Act"
        },
        "LLM_original_answer": [
            "The significant judgment is required in projecting future taxable income and the law in projecting future taxable income tax law is required in the tax law in the tax jurisdiction.Significant judgment is required in projecting future taxable income and the tax law in the in the tax law is required in the law is required in the tax law in the tax law in the tax jurisdiction.Significant judgment is required in projecting future taxable income in the tax law is required in the tax law in the tax jurisdiction.Significant judgment is required in projecting future taxable income and the law in the significant judgment is required in projecting future taxable income tax law in the judgment is required in the amount of taxable income is required in projecting future taxable income and the tax jurisdiction.Significant judgment is required in the applicable tax law is required in projecting future taxable income is required in the tax law in the law is required in projecting future taxable income tax law in the applicable to be required in the applicable tax law in the law is required in projecting future taxable income and loss in the applicable to the tax jurisdiction.The significant judgment is required tax jurisdiction.Significant judgment is required in projecting future taxable income and determining future taxable income and taxable income and significant judgment is required in the tax law is required in the law is required in projecting future taxable income tax law is required in the tax jurisdiction.Significant judgment is required in projecting future taxable income is required in the tax law in the judgment is required in projecting future taxable income is required in projecting future taxable income is required in the the the applicable tax law is required in projecting future taxable income tax law in projecting future taxable income is required in projecting future taxable income and the in the tax law is required in the tax law in the law in projecting future judgment is required in projecting future income in the tax law in the applicable tax jurisdiction.Significant judgment is required in projecting future judgment is required in projecting future taxable income in the law in projecting future taxable income in projecting future taxable income in the applicable tax law in the applicable tax law is required in the law in the judgment is required in projecting future taxable income in the tax law is required in the law in the tax law is required in the tax in the tax jurisdiction.Significant judgment is required in the tax law changes in the applicable to the applicable tax jurisdiction.Significant judgment is required in the amount of the law in the future taxable income and future taxable income in the judgment is required in the applicable tax law in the applicable law is required in the tax law in the tax jurisdiction.Significant judgment is required in projecting future taxable income law in the tax jurisdiction.Sign"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?",
        "options": {
            "A": "By visiting the Company\u2019s website",
            "B": "By visiting the SEC's website",
            "C": "By contacting the Investor Relations Department",
            "D": "Automatically mailed with annual reports",
            "E": "Through a subscription service",
            "F": "At the company headquarters in China"
        },
        "LLM_original_answer": [
            "To answer future taxable income is required in projecting future taxable income and the tax law in the tax jurisdiction in projecting future changes is required in projecting future income and determining future taxable income and the applicable tax jurisdiction. Significant judgment is required in determining the tax jurisdiction in the law is also is required in determining future taxable income and determining the the the amount of the is required in determining the tax law in the tax law is required in determining the amount of the applicable tax law changes in determining the applicable tax law changes in the applicable tax law in the law in the tax law in the law in the judgment is required in projecting future taxable income is required in the tax law changes in the applicable to the applicable tax jurisdiction is required judgment is required in projecting future taxable income is required in the tax law changes in the tax law in the tax law in the applicable tax law is required in the tax law in the law changes in projecting future taxable income tax law in the tax jurisdiction.The judgment is required in projecting future taxable income and future in the future taxable income and the tax law is required in the applicable tax law changes in the applicable tax law in the tax law changes in the the tax jurisdiction.The significant judgment is required in determining future taxable income and the law in the tax law in the law in the tax law is required in the tax law in the law is required in projecting future taxable income is required in projecting future changes in the applicable tax jurisdiction.The significant judgment is required in determining future taxable income and the tax law changes in the tax law changes in the in the applicable tax law is required in the projection of projecting future taxable income in the tax law changes in the law changes in the applicable tax law is required in determining the tax law in the effect of the determination of future taxable income in determining the tax law in the law in the judgment is required in determining future taxable income in the tax law is required in determining the determining the judgment is required in determining the tax law in the applicable tax law in the applicable tax law is required in the tax law is required judgment is required in projecting future taxable income in the tax jurisdiction where the jurisdiction.Significant in determining the amount of the income in the applicable tax law changes in the tax law changes in projecting future taxable income tax law changes in the tax law in the tax law in the tax changes in projecting future taxable income tax law is required in projecting future taxable income projections of the tax law is required in projecting future taxable income is required in the tax jurisdiction in the law in the judgment is required in projecting future taxable income and the law"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?",
        "options": {
            "A": "A decline in company profits",
            "B": "Market competition",
            "C": "A challenge by a taxing authority",
            "D": "Stock market fluctuations",
            "E": "Internal policy changes",
            "F": "Changes in interest rates"
        },
        "LLM_original_answer": [
            "Based on the in the tax law in the tax law is required in projecting future taxable income is required in the tax law in the applicable tax law.Signs are required in projecting future taxable income and the tax law and tax jurisdiction.Significant judgment is required in the tax law in the tax law changes in projecting future taxable income and determining future taxable income is required in projecting future taxable income in the in the tax law changes to the tax law in the tax law is required in projecting future taxable income and the tax law in the tax jurisdiction is is is required in projecting future taxable income and determining future taxable income and the applicable tax jurisdiction.The judgment is required in determining the tax law in the law in the judgment is required in determining future taxable income and determining the the the amount of the is required in determining the tax law in the tax law is required in determining the amount of the applicable tax law changes in determining the applicable tax law changes in the applicable tax law changes in the tax law in the the tax law in the judgment is required in projecting future taxable income and the tax law changes in the law is required in the applicable tax jurisdiction is required judgment is required in projecting future taxable income is required in the tax law changes in the tax law in the tax law in the applicable law is required in projecting future taxable income in the law changes in projecting future in projecting future taxable income in the tax jurisdiction is required in determining the determination of the current and determining future taxable income tax law in the applicable tax laws in the applicable tax law changes in the applicable tax law in the tax law changes in the the tax jurisdiction.Theificant judgment is required in projecting future taxable income and the law in the tax law in the law in the judgment is required in projecting future taxable income and the law is required in projecting future taxable income in projecting future in projecting future taxable income jurisdiction in the jurisdiction.Sign judgment is required in estimating future taxable income in the tax law changes in the applicable tax law is required in the judgment is required changes are required in projecting future taxable income in the tax law changes in the tax law changes in the applicable tax law is required in determining the tax law in the effect in the determination of future taxable income in determining the tax law in the law in the judgment is required in determining future taxable income and in the tax law is required in determining the applicable tax law is required in determining future taxable income and future taxable income in the applicable tax law is required in the tax law is required judgment is required in projecting future taxable income in the tax jurisdiction where the jurisdiction.Sign"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?",
        "options": {
            "A": "Limited board oversight",
            "B": "Inability to train employees efficiently",
            "C": "Challenges in predicting attack methods",
            "D": "Insufficient technological security measures",
            "E": "Lack of business continuity plans",
            "F": "Inadequate physical security measures"
        },
        "LLM_original_answer": [
            "One significant judgment is projecting future taxable income in projecting future taxable income is required in the applicable law in the applicable law in projecting future taxable income in the applicable tax law in the judgment is required to the market risk is projecting future taxable income is required in the financial results in the significant judgment is projecting future taxable income is required in the market conditions beyond the company and/or signif applicable law in the applicable tax law in the applicable law is required in projecting future taxable income and the applicable lawfully developed in the applicable law in the U.Significant judgment is required in the applicable judgment is required in the applicable law in the value is required in the market judgment is required in the U.Significant judgment is the applicable law in the law is required in the U.Significant judgment is required in the applicable law in projecting future taxable income is required in the judgment is the market judgment is the judgment is required in the market risk is required in projecting future years after the market judgment is required judgment is the applicable law in the market judgment is required in the significant judgment is required in the exercise in the applicable tax law in the tax law in the exercise is projecting future taxable income in projecting future taxable income and future taxable income is required in projecting future taxable income and the applicable law in the law is required in the applicable law.Significant judgment is required in the applicable law in projecting future taxable income and significant judgment is required in the law.Significant judgment is required significant judgment is required significant judgment is the significant judgment is required in projecting future taxable income and the company performance is required in the applicable law in the applicable tax law in projecting future taxable income in the company and the applicable law in the company and/or significant judgment is required in the significant judgment is required in projecting future taxable income in the future taxable income in the law is required in projecting future law in the applicable tax law in the ability to the lawfully taxable income is required in the law in the law in projecting future taxable income in projecting future taxable income in the projection future taxable income and future taxable income is required in projecting future taxable income is required in projecting future taxable income and future taxable income and future tax law in projecting future taxable income is required in projecting future taxable income law in the law in projecting future taxable income is required in the applicable tax law in projecting future taxable income in the applicable law is required in the applicable law in the market risk is required in the market risk is subject to the COVID-issued or the applicable tax law in the applicable law in the U.Signor significant taxable income"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What effect could an unexpected rise in inflation have on the company's financial condition?",
        "options": {
            "A": "Decrease the value of the company's properties",
            "B": "Lead to higher interest rates affecting rate-sensitive financial instruments",
            "C": "Increase the demand for property insurance",
            "D": "Reduce the company's labor costs",
            "E": "Cause a decrease in interest expenses on debt",
            "F": "Improve the company's net income"
        },
        "LLM_original_answer": [
            "An additional taxable income in the Company\u2019s netting taxable income is required in the applicable tax law in the tax law in the Company'signoring future taxable income in the applicable future taxable income in the net assets in the applicable to the net of the Company's future taxable income in the applicable law in the applicable judgment is required in the Company\u2019s 1Core Scientific judgment is required in the Company\u2019s required future taxable income tax law in the amount of the Company Significant in the applicable tax law in the applicable to the applicable future taxable income is required in projecting future taxable income in the applicable taxable income in the applicable tax law in the applicable tax law in the applicable tax law in the applicable taxable income in the amounting future taxable income in the Company significant judgment in the applicable tax law in the Company\u2019s law is required in projecting future taxable income is required in projecting future taxable income law in the tax law is required in projecting future taxable income in the applicable to the applicable taxable income and the Company in the applicable law in the applicable tax law in the applicable law in the applicable tax law in the applicable tax law in the applicable tax law in the applicable tax law in the applicable tax law in the applicable tax law in the tax law in the tax law in the applicable tax law in the judgment is required in projecting future taxable income in the tax law in the applicable tax law in the applicable tax law in the applicable law in the applicable tax law in the Company\u2019s law in the applicable law in the Company's in the tax law in the applicable to the applicable tax law in the tax jurisdiction.Significant judgment is required in the amount of taxable income in the applicable taxable income in the tax law is required in the applicable taxable income in the tax law in the tax law is required in the amounting future taxable income in the tax law in the tax law is required in the taxable income in projecting future in projecting future taxable income and the tax law in the tax law in the tax law is required taxable income is required taxable income is required in projecting future taxable income and projected future taxable income is required in projecting future taxable income in the tax law in the tax law in the significant judgment is required in the future taxable income in the applicable future taxable income is the tax law in the law in the Company\u2019s future taxable income law in the judgment is required in the applicable tax law in the applicable future taxable income in the law in the applicable taxable income law in the applicable tax law in the applicable tax law in the Company\u2019s future taxable income is required in the Company significant judgment is"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What could a successful liability claim potentially lead to, even if fully insured?",
        "options": {
            "A": "Increased stock prices",
            "B": "Diminished brand reputation",
            "C": "Expansion into new markets",
            "D": "Immediate financial gains",
            "E": "Improved customer satisfaction",
            "F": "Reduced operational costs"
        },
        "LLM_original_answer": [
            "A final judgment is filed taxable income in projecting future taxable income is required in projecting future taxable income tax law in the applicable law is required in the applicable law in the applicable in the applicable law in the applicable rate in the evidentiement is effective date is required in the evidentiary period in the law in the evidencing future effective in the required in the year 2023. Significant judgment is effective date.Significant judgment is effective in the applicable law in the applicable law in the applicable in the significant judgment is required in the effective taxable income in projecting future taxable income in the applicable to be required storm law in the applicable in the Commissioned future taxable income tax law in the applicable rates in the Public Staffing future costs associated with respect to recoveries required significant judgment is effective January 2023##tableSignificant judgment is the law in the significant judgment is required significant judgment is the applicable revenue is effective judgment is effective January 2024, after the applicable to be in the same day 12, after the evidentiary judgment is effective January 2024##tax jurisdiction.Significant judgment is required in the judgment is required income.Significant judgment is the applicable tax law in the law is required in the applicable law.Duke income in the applicable in the applicable taxable income tax law in the judgment in the applicable law in the applicable law is required in the FPSCSignificant judgment is required in the effective date of the applicable law is required in the judgment is required judgment is required in the applicable law in the law in the PSCA significant judgment is required judgment is required in projecting future taxable income in the law in the applicable tax law in the applicable law in the law is required in projecting future taxable income tax law is required in the amount of which is the applicable tax law is required in the applicable to flow-throughputting future taxable income tax law in the law is required in the amount of which was the applicable tax jurisdiction.The significant judgment is required in projecting future taxable income in the applicable tax law in the applicable judgment in projecting future taxable income in the law is required in the amount of the applicable taxable income is required in projecting future taxable income in projecting future taxable income in the applicable taxable income in the Company in the applicable tax law in the significant judgment is required in projecting future taxable income law in the applicable law in projecting future taxable income is required in the applicable tax law in the applicable law in the law in the law in projecting future taxable income in the IRA.Duke law in the law in the IRPursignificant judgment is required"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?",
        "options": {
            "A": "$18.8 billion",
            "B": "$15.2 billion",
            "C": "$20.1 billion",
            "D": "$22.5 billion",
            "E": "$17.9 billion",
            "F": "$19.6 billion"
        },
        "LLM_original_answer": [
            "To the amount is required in the Company\u2019s financial statement is the applicable tax law in the applicable tax law in the applicable tax law is required in the date of the law in the tax law in the Company is required in the applicable future taxable income in the Company in the period in the tax law is required in projecting future periods of the law in the tax law is required in the applicable tax law in the tax law in the law in the tax law in the applicable tax law in the law is required in projecting future taxable income tax law in the applicable judgment is required in projecting future taxable income in the tax law in the tax law in the applicable tax law in the law in the significant judgment is required in the future taxable income in the applicable future taxable income in the initial judgment is required in the applicable law in the applicable in the applicable to be made in the applicable judgment is required future taxable income in the Company\u2019significant judgment is required in the Company judgment is required in the Company significant judgment is the tax law in the tax law in the tax law in projecting future income in the law in the applicable future taxable income in projecting future taxable income tax law in the applicable tax law in projecting future taxable income tax law in the tax law in the Company\u2019signoring future taxable income is required in the applicable in the law in the applicable in the income the income is required in the law in the applicable tax law in the applicable law is required in the income tax law is required in the applicable tax law in the tax law in the tax law in the significant judgment is required in the income tax law in the tax jurisdiction.Significant judgment is required in projecting future taxable income and/or projecting future taxable income tax law in the judgment is required in projecting future taxable income in the tax law is required in the applicable in the applicable tax law in the applicable in projecting future periods of the applicable in the applicable judgment is required taxable income is required taxable income is the tax law in the applicable tax law in the tax law in the tax law is required in projecting future taxable income in the tax law in the tax law in the date is required in projecting future periods in the significant judgment is projecting future taxable income in the applicable financialsensitive judgment is required in the judgment is a significant judgment is required in projecting future taxable income is required judgment is required in the significant judgment is required in the applicable tax law in the law in the applicable law in the tax law in the law in the Company is required future period.The significant judgment is required in the investment in the Companywide judgment is the"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?",
        "options": {
            "A": "Increased customer satisfaction",
            "B": "Fines and additional costs",
            "C": "Reduction in legal obligations",
            "D": "Improved brand reputation",
            "E": "Increased production rates",
            "F": "Decrease in product demand"
        },
        "LLM_original_answer": [
            "What significant judgment is required in the number of future taxable income the law is required in the applicable tax law in the law in projecting future taxable income in projecting future taxable income in the exercise of the law in the applicable tax law in the applicable tax law in the future taxable income is required in projecting future taxable income in projecting future taxable income in the applicable tax law in the applicable tax law is required in projecting future taxable income is required in the applicable tax law in the applicable tax law in the applicable tax law in the exercise is required in the applicable tax law in the applicable tax law is required to the applicable law in the applicable law in the applicable taxable income in the applicable to the applicable law in the combined with respect to the applicable law in the applicable tax law in the applicable law in the applicable tax law in the exercise is required in the applicable tax law is required in the exercise in the pre-funded income in the applicable lawfully taxable income and/or our stockholdersignificant judgment is required in the applicable law is required in the applicable law in the number of our common stockholders of our stockholders of our business, among other than the applicable law in the stockholders of the holder in the applicable law is required in the number of our common stock is required in the applicable tax law in the law is required in the applicable future taxable income in the applicable law is required in judgment in projecting future taxable income.Significant judgment is the applicable tax law in the applicable law in projecting future taxable income is required in the applicable law in the applicable stock is required in projecting future taxable income is required in the applicable law in the applicable law in the applicable in the applicable tax law in the applicable stock in the applicable to exercise of the stockholdersignificant judgment is required in the number of common stockholdersignificant judgment is required in the rest in the combined judgment is required in the applicable law in the applicable tax law in the applicable law is required in projecting future taxable income and the exercise of the number of any applicable law in the applicable tax law in registering future taxable income is required future taxable income and/orvesting significant judgment is required in the holders of our common stockholdersignificant judgment is projecting future taxable income or additional stockholdership is required in the applicable law in the significant judgment is required in projecting future taxable income.Significant judgment is required in the judgment is the applicable tax law in the law is required in taking into the effective judgment is required in the common stockholders of our business in our restated tax law in projecting future in the exercise of our common"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?",
        "options": {
            "A": "Dentists",
            "B": "Pharmacists",
            "C": "Physician assistants",
            "D": "Chiropractors",
            "E": "Optometrists",
            "F": "Radiologists"
        },
        "LLM_original_answer": [
            "Based on a result in the fair value in the date judgment is required in projecting future taxable income in the lower of the applicable judgment is when the fair value is required in the significant judgment is required significant judgment is required future taxable income in the applicable tax law is required in the exercise is the judgment is required in the significant judgment is recorded in the applicable judgment is required in the significant judgment is required judgment is the law is required in the date of the judgment is required in the applicable to the life in the fair value of the tax jurisdiction.The significant judgment is required in the significant judgment is required in the applicable in the applicable tax law in the applicable judgment is required in projecting future cash flow-throughoutcomes required in the applicable in the law is required in the significant judgment is required in the applicable law is required in the law in the applicable tax law in the judgment is required in projecting future income in the applicable tax law in the law is required in the significant judgment is required taxable income in the date of the tax law in projecting future taxable income in the carrying the tax law in the law in the amount of the applicable tax law in the significant judgment is required in the amount of the applicable to the applicable in the applicable tax law in the applicable in the fair value is required future taxable income is required in the MSR.Significant judgment is required in the MSR and related taxable income law in the law in the applicable tax law in the amount of future taxable income in the law in the applicable future taxable income in projecting future taxable income is required in the amount of the applicable tax law in the applicable tax law in projecting future cash is required in projecting future taxable income in the applicable in projecting future taxable income in the law in projecting future taxable income projecting future taxable income law in the tax law is required in projecting future taxable income is required in the significant judgment is required significant judgment is required significant judgment is required significant judgment is required in the fair value is a significant judgment is required judgment is required significant judgment is the applicable tax law in the estimated future taxable income the applicable tax law in the tax law in projecting future taxable income in the significant judgment is required future taxable income in the applicable tax law in projecting future taxable income in projecting future taxable income in the applicable in the law in the applicable in the applicable tax law in the tax law in projecting future taxable income tax law in projecting future taxable income and future taxable income in projecting future taxable income is required significant judgment is reported income in the applicable tax law in the applicable law is required in projecting future taxable income in the tax law is"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What did the company opt to permanently exclude from its capital calculations?",
        "options": {
            "A": "Unrealized gains and losses on available-for-sale securities",
            "B": "Deferred tax assets and liabilities",
            "C": "High volatility commercial real estate loans",
            "D": "Unused portion of commitments not cancellable",
            "E": "Non-residential mortgage loans past due",
            "F": "Capital conservation buffer"
        },
        "LLM_original_answer": [
            "Based on the patent law is the product candidates of the patent lawfully required judgment is the product candidates are the price is required in projecting future taxable income is required in the law in the product candidates in the lawfully taxable income in the product candidates in the product candidates\u2019 judgment is required in the product candidates\u2019 or any judgment is not in the product candidates in the product candidates are required in the product candidates are required to the product candidates, and subject matter in the product candidates\u2019\nAnswering future taxable income is required significant judgment is required in the scope of the applicable tax jurisdiction.The significant judgment is required in the product candidates and the product candidates in the product is required in projecting future taxable income in projecting future taxable income is projecting future taxable income is required in the product candidates in the law is required in the product candidates are required in the applicable law is required in the significant judgment is required in the scope is required to our common law in the applicable tax law in the applicable law in the product candidates of the product candidates, which may be required to preventively significant judgment is not to the significant judgment is required in the product candidates\u2019\n"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?",
        "options": {
            "A": "Data Protection Act of 2018",
            "B": "European Data Protection Board Act",
            "C": "UK Cybersecurity Act",
            "D": "British Privacy Regulations Act",
            "E": "Information Security Act of 2018",
            "F": "UK General Data Protection Act"
        },
        "LLM_original_answer": [
            "Which significant judgment is required in projecting future judgment is required future taxable income is required in projecting future taxable income and future in the applicable law is required in the applicable law enforcement of the applicable law in projecting future taxable income and/or significant judgment is required in the applicable law is required in the product candidate in the applicable tax law in the US law in the applicable tax law in the law is required in projecting future taxable income is required in the applicable law is required income in the law in the USPTOngoing judgment is required in projecting future taxable income law in the patent applications of a tax law in the product candidates in the USPT. projecting future taxable income or the patent law in the law in the law in the law in the law is required in the US judgment is the applicable law in the law in the law in the applicable law in the law in the law is required to the applicable law in the law in the applicable law in the applicable law in the applicable tax law in the tax law in the law is required in the tax law in the tax law in the applicable tax law in projecting future judgment is required in projecting future taxable income in the law in the applicable tax law in the applicable law in the applicable tax law in the applicable tax law in projecting future taxable income and/or projecting future taxable income is required in the applicable tax law in the law is required in the applicable law in the applicable tax law in the applicable law in the law in the applicable law in the product development is required in the law in the applicable law in the law in the applicable law in the applicable law in the applicable law in the applicable law in the applicable to the applicable law in the applicable law in the applicable law in the applicable law in the applicable law in the significant judgment is the applicable tax law in projecting future taxable income law in the applicable judgment is required in the outcome of any judgment is required in projecting future taxable income is required to our product candidate judgment is required in projecting future patent law is required in the applicable law in the applicable law in the USP:\u2022future taxable income is the USP.99or other than the applicable law in the product development is required in the law is required in the product candidates in projecting future patentability in the applicable tax law in thes of law is required to the law in the law in projecting future taxable income projecting future patent law in the amount of the tax law in the law in the law in projecting future taxable income is required in projecting future taxable income law in the law in projecting future taxable income in the future taxable"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?",
        "options": {
            "A": "By visiting the Company\u2019s website",
            "B": "By visiting the SEC's website",
            "C": "By contacting the Investor Relations Department",
            "D": "Automatically mailed with annual reports",
            "E": "Through a subscription service",
            "F": "At the company headquarters in China"
        },
        "LLM_original_answer": [
            "Based on the tax law in projecting future taxable income the amount of the law in the applicable tax law in the tax law in the exercise is required in the amount of the applicable taxable income tax law in the applicable taxable income is required in the fair value of the law in the law in the law in the law in the law in the law in the law in the law in the tax law in the law in the tax law in the tax law in the tax law in the relevant tax law in the law is required in the law is required in the tax law in the tax law in the financial reporting future taxable income law in projecting future taxable income in the tax law is required in the law in the tax law in the applicable in the fair value is the amount of the law is required in the law in the law is required in the tax law in the applicable tax law in the law in the law in projecting future taxable income in the tax law in the law in projecting future taxable income in projecting future taxable income is required in projecting future taxable income in the tax law in projecting future taxable income in projecting future taxable income in the amount of the tax in the law in the applicable tax law in the significant judgment is required in projecting future taxable income in the tax law is required future taxable income is required in the tax law is required in the significant judgment is required significant judgment is required significant judgment is required in the law in the law in the law in the applicable in the technology in the applicable tax law in the applicable tax law in the tax law in the tax law in the applicable law in the tax law is required in the amount of the tax law in the amount of future taxable income is required in projecting future taxable income in the tax law in the tax law requires the applicable tax law in which is the tax law in projecting future taxable income in projecting future taxable income in projecting future taxable income is required in projecting future taxable income in the United States significant judgment is required in the tax law is required in projecting future taxable income in the tax law in projecting future taxable income in projecting future taxable income in the applicable taxable income in the estimated future taxable income is required in projecting future taxable income in the law in the tax law in the law in the applicable law in the applicable tax law in the tax law in projecting future taxable income in the tax law in the law in the tax law in the tax law in the tax law in the judgment is required in projecting future taxable income in the tax law in the law in the law in the date of the law is required in the"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?",
        "options": {
            "A": "A decline in company profits",
            "B": "Market competition",
            "C": "A challenge by a taxing authority",
            "D": "Stock market fluctuations",
            "E": "Internal policy changes",
            "F": "Changes in interest rates"
        },
        "LLM_original_answer": [
            "Based on or in projecting future contractually.Significant judgment is required in projecting future taxable income in projecting future taxable income is required in projecting future taxable income in the Company\u2019s significant judgment is required in projecting future taxable income is required judgment is required taxable income is required in projecting future taxable income projection of significant judgment is required in projecting future cash surrender chargesignificant judgment is required in the Company\u2019s judgment is as of $Significant judgment is the Company\u2019s future taxable income is recorded at risk is required in the Company\u2019s future tax law in the Company judgment is required in projecting future cash flowsignificant judgment is the Company\u2019s tax law in effecting future taxable income is required in projecting future cash flow in the applicable jurisdiction in the amount of significant judgment is projecting future cash flowsignificant judgment is required in the Company\u2019s future income is the consolidated assets and in the Company\u2019sign significant judgment is required in projecting future periods of judgment is required in the Company\u2019significant judgment is required taxable income in the law in the applicable judgment is required in projecting future taxable income in the law in the applicable tax law in the future taxable income in the Company\u2019s future taxable income tax law in projecting future taxable income and in the applicable tax law in the Company significant judgment is projecting future taxable income in the Company is required in the Company\u2019s at December judgment is required in the Company\u2019s in the law in the law is required in the Company in projecting future taxable income in the applicable tax law in projecting future taxable income in projecting future taxable income is required in projecting future taxable income and future taxable income is required in projecting future taxable income is required in projecting future taxable income and future taxable income in projecting future taxable income tax law in the significant judgment is required in projecting future taxable income is the law is required in projecting future taxable income is required in projecting future taxable income is a significant judgment is required significant judgment is as well-being-asset signi##table 2024\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?",
        "options": {
            "A": "Limited board oversight",
            "B": "Inability to train employees efficiently",
            "C": "Challenges in predicting attack methods",
            "D": "Insufficient technological security measures",
            "E": "Lack of business continuity plans",
            "F": "Inadequate physical security measures"
        },
        "LLM_original_answer": [
            "One assurance can be given the activities can be the activities can be given that the given that the strategies of the activities independently.The assurance can be given that the activities will be-coll can be given by themselves can be given by the assurance that the activities can be given that the strategies of the strategies of the of the strategies of the activities can be given by the activities of the assurance can be given that the activities can be given that the assurance can be given that the strategies of the strategies of the strategies can be given that the strategies can be given that the activities can be given to perform the activities can be performed independently or assurance can be given that the strategies of the the independent performance of the strategies can be given that the activities can be given that the assurance can be given that the strategies can be the activities can be given that the given that the strategies of the independent capabilities to perform the activities can be given that the strategies can be given that the strategies can be given capabilities to perform the activities independently, and assurance can be given that the strategies of the the PAs the strategies of the of the activities can be given that the strategies can be given that the strategies can be given strategies can be given assurance can be given that the activities can be given that can be given the activities independently.The assurance can be given that the assurance can be given that theo assurance can be given that the activities can be- and no assurance can be given activities can be given that the activities independently.The assurance can be given that the strategies of the of the activities can be performed by the strategies can be independently perform the-competence can be given that the strategies of the the the activities can be given assurance can be given that the strategies of the strategies can be given that the strategies of the strategies can be given can be given that the activities can befitting the assurance can be given that the activities can be given that the activities independently, assurance can be given that the strategies of the the activities can be given that the given that the strategies of the independent assurance can be given the activities independently.No assurance can be given that the strategies of the the P& no assurance can be given assurance can be given that the activities can be given that the activities can be given that the given that the strategies of the independent assurance that the strategies of the assurance can be given that the activities can be given that the activities independently.No assurance can be given activities independently.The assurance can be given activities independently.No assurance can be given that the strategies of the the strategies of the assurance can be given that the strategies can"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What effect could an unexpected rise in inflation have on the company's financial condition?",
        "options": {
            "A": "Decrease the value of the company's properties",
            "B": "Lead to higher interest rates affecting rate-sensitive financial instruments",
            "C": "Increase the demand for property insurance",
            "D": "Reduce the company's labor costs",
            "E": "Cause a decrease in interest expenses on debt",
            "F": "Improve the company's net income"
        },
        "LLM_original_answer": [
            "Anomaly power (known as compared to the decrease 67our hash rate (known as known as \u201chash rate\u201d) for the fair (known as a 2024 \u2014 2024. 2023 known as \u201chash rate\u201d) for the hash rate decreased our hash rate in which we share our hash rate rate in which we share of our hash rate with the year rate (known as compared to our hash rate (known as we determined by which \u201cknown as compared to the Company\u2019s hash rate (known as compared to which is not meaning (known as compared to the hash rate known as \u201chash rate (known as \u201cknown as compared to the hash rate (known as \u201chash rate\u201d) from which we are known as compared to which we are not reasonably assuredly known as compared to which we have been in which we no longer term ended December 2024 \u2014 known as compared to which we have been excluded from the hash rate of which is known as compared to which rendered the year over 2023 \u2014 70known as a result of which we expect to which included in which we exited December 1. 2024.2. 67known as compared to which we have exited during the hash rate our hash rate (known as \u201chash rate with the hash rate (known as \u201cknown as \u201chash rate\u201d) and the hash rate (known as compared to which we measured as compared to the hash rate for the hash rate for the hash rate of the hash rate of which we exited in each of our hash rate for the hash rate of which is known as compared to the hash rate of which resulted in part 63known as a 2024.known as a hash rate of $ rate (known as compared to which known as \u201chash rate (known as well with the hash rate with the hash rate (known as compared to $ 2023 known as of which was $ 67known as compared to the hash rate with the hash rate (known as described as \u201chash rate\u201d) with the hash rate) with the hash rate (known our mining power (known as \u201chash rate with the hash rate (known as compared to the hash rate (known as described in which we share our hash rate for the hash rate of $ 2known as compared to the hash rate (known as described above our hash rate (known as compared to the hash rate (known as described as \u201chash rate (known as described hash rate (known as \u201chash rate (known as described as \u201chash rate (known as known as"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What could a successful liability claim potentially lead to, even if fully insured?",
        "options": {
            "A": "Increased stock prices",
            "B": "Diminished brand reputation",
            "C": "Expansion into new markets",
            "D": "Immediate financial gains",
            "E": "Improved customer satisfaction",
            "F": "Reduced operational costs"
        },
        "LLM_original_answer": [
            "Affect on our business impact on our business. There could be required to sell commercial items necessary to sell commercial items necessary to sell commercial items that impact on our business impact on our business necessary to sell commercial items, which could be a material impact on our business.77##impact on our business commercial items, which could be a material impact on our business items, which could be a commercial items, and a material impact on our business qualifications necessary to sell commercial impact on our business, as well-being a material impact on our ability to our business items, which could to sell commercial items, which could be a material impact on our ability to the necessary to our ability to sell commercial items, which could be a material impact on our ability to sell commercial items, in our business, and a material impact on our business qualifications necessary to qualify to our business impact on our ability to sell commercial items that could be a material to sell commercial items, which could be a material impact on our business.77##table is a material impact on our ability to qualify commercial items, there could be a material impact on our business. There could be a material impact on the a material necessary to sell commercial items, there could be a material impact on our business, as well as well to sell commercial items, or a material impact on our business impact on our business, there necessary to sell commercial items, a material impact on our business, and a material qualifications necessary to sell commercial items necessary to sell commercial sales of a material impact our business commercial items, commercial items necessary to sell commercial items necessary to sell qualifications necessary to qualify to sell commercial items necessary to sell commercial items necessary commercial items, which could be a material impact on our business. There could be a material impact on commercial items, or a material impact on our business. There could be a material impact on our business, and a material impact on our business.77##table.The impact on our business impact on our business, as a material impact on our business impact on our business commercial items that are necessary to sell commercial impact on our business impact on our business necessary to sell commercial items necessary to sell commercial items necessary to our business on our business impact on our business.83##items, which could be a material impact on our business, and/ors on our business, and a material necessary to sell commercial items, or qualifications necessary to sell commercial items, there could be a material impact on commercial items, and a material impact on our business, and a material impact on our ability to the material impact on our business"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?",
        "options": {
            "A": "$18.8 billion",
            "B": "$15.2 billion",
            "C": "$20.1 billion",
            "D": "$22.5 billion",
            "E": "$17.9 billion",
            "F": "$19.6 billion"
        },
        "LLM_original_answer": [
            "Borrow of the investment safety, if the safety considerations.We do not be safe harbor loans receivaultitude requirements and the investment in the investment is 70table 2020. We do not to the the investment and the safety, potential returns and market risk considerations.We do not have a non-accranging in the loan risk considerations.We do not including the allowance for the safety, or loans receivable space considerations.We do not including the safety, if the amount of the potential returns and the safety considerations.We do not have a part of the investment and other than we do not the allowance and non-holding requirements, potential returns and the safety considerations.We do not to the investment risk scorecard-offerective loan balances and other than any potential returns and the investment amount of the investment and business banking and business banking and the investment safety of the safety, potential returns and the investment considerations and market risk considerations and market risk considerations and market risk and market risk considerations.We do not in accordance to the safety considerations.We do not in the market risk considerations.We believe that are not held in our loan loss of the safety considerations.We consider the safety considerations.We do not including the loan balances and the amount of the allowance for our loan balancesheet safety considerations for the safety considerations.We do not held for the safety, or their respective to the loan balances and the safety, net charge-offs and the loan loss and the safety, net interest income accruality requirements.We do not included in the loan loss of the same risk considerations.We do not to meet the potential returns and the safety considerations and market risk considerations of the safety, or non-secured lending requirements and the loan balances and market risk considerations.We do not in the loan loss of the safety, which is considered in this is a discussion of $23, net charge-offs and the safety, if the safety, or other than the safety, or market risk considerations.We do not in accordance to the amount of the income producing a loan loss of the safety, or portions of the investment in which are as of the income and market risk considerations.We do not an income and market risk considerations.We do not fully collateralized to the safety, respectively.We do not included in the loan balances and ORECEMaturity:##table 71Table of the investment safety, the investment safety, if necessary to the investment safety considerations.We do not in our market risk considerations and/or market risk considerations and the safety considerations.We do not to the following the investment safety, and the investment considerations.We do not market risk considerations.We"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?",
        "options": {
            "A": "Increased customer satisfaction",
            "B": "Fines and additional costs",
            "C": "Reduction in legal obligations",
            "D": "Improved brand reputation",
            "E": "Increased production rates",
            "F": "Decrease in product demand"
        },
        "LLM_original_answer": [
            "What is the safety, which may be safe, or the safety, or their market risk considerations and/or the safety, if we do not be-limited to the safety, we do not in-issued in-issued by law of the safety considerations.We do not to which may be it\u2019s ability to the potential returns and/or potential returns.We do not consider the safety, if we or our products and/or market risk and/or other than the investment and/or potential returns and/or potential returns and the safety considerations.We do not only if the safety considerations for the safety considerations.We do not only considera ndirectoriallyability of potential returns on the USPursing the safety, if we do not in-issued safety considerations.We have in the safety considerations and/or market risk considerations.We do not to the potential returns and/or in some of which may be able to the safety considerations.We do not only safety, if we do not to the safety considerations.We do not to the USPTDetermine the investment.We do not only if we do not to name or market risk considerations.We do not only considers the investment considerations.We do not the safety, if we do not to determine the safety considerations.We do not consider the safety considerations.We do not to the safety considerations.We do not to the safety, if the safety of the safety of the safety considerations.We do not only in the USPTI believe we may result in the safety, if necessary to the USP rocessibility considerations.We do not believe we do not to the safety and/or market risk considerations.We do not only have a determination of the safety considerations and/or in addition considerations.We do not only in the safety considerations.We do not only have safety considerations.We do not to which we do not to the safety, if we do not with respect the same considerations.We do not in-126.We docket considerations.We do not to the safety, if the safety, if we do not to the safety, if we believe that may be-issued in the validity considerations.We do not to which may be careful considerations.We do not to which may be able to which may be able to which may not to the United States of the company\u2019s and/or returns and/or returns and market risk considerations the same risk considerations.We do not issued in the market risk considerations and market risk considerations and market risk considerations.We do not always consider the investment safety, or in-issued patents issued by the safety, if we believe that are not the safety, if the potential returns and/or market risk considerations.We do not to the"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?",
        "options": {
            "A": "Dentists",
            "B": "Pharmacists",
            "C": "Physician assistants",
            "D": "Chiropractors",
            "E": "Optometrists",
            "F": "Radiologists"
        },
        "LLM_original_answer": [
            "Based, to $622 in 2024, to $622 in 622 in 2024, to $622, $2024, to $2024, to 2024, to $622 in 2024 in 2024, to $622 in 2024, to $622 in 2024, to $2024 in 2024, to $461 in 2024, to $2024, to $622 in 2024, to $622 in 2024, to $622 in 2024, to $622 in 2024, to $622 in 2024, to $2024 in 2024 $ to $622 in 2024, to $617 in 2024, to $2024, to $538 in 2024 in 2024, to $2024, to $607 in 2024, to $2024, to $2024 in 2024, to $2024 $622 in 2024, to $622 in 2024, to $2024, to $622 in 2024 in 2024, to $622 in 2024, to $4, to $601 in 2024, to $538 in $761 in 2024, to $761 in 2024, to $2024, to $636, to $623, to $623 in 4, to $ and to $622 in 2024, to $622, to $4, to $2024, to $614, to $0, to $ $ $ in 2024, to $510 in 2024, to $4 in 2024 in 2024, to $4, to $461 in 2024, to $504, to $4, to $622 in 2023, to $622 in 2024, to $2024, to $622 in 2024, to $622, to 2024, to $2024, to $4, to $461 in 2024, to $491 in 2024, to $622, to $622 in 2024 in 2024, to $622 in 2022, to $461 in 202, to $622 in 202 in 2024, to $622 in 2024 in 2024, to $622 in 2024, to $461 in 2024, to $615 in "
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What did the company opt to permanently exclude from its capital calculations?",
        "options": {
            "A": "Unrealized gains and losses on available-for-sale securities",
            "B": "Deferred tax assets and liabilities",
            "C": "High volatility commercial real estate loans",
            "D": "Unused portion of commitments not cancellable",
            "E": "Non-residential mortgage loans past due",
            "F": "Capital conservation buffer"
        },
        "LLM_original_answer": [
            "The existing TCR-T candidates and manufacturing process may substantially improved TCR-T candidates and manufacturing process may be substantially improved and the product candidates and manufacturing process and manufacturing process may be substantially improved candidates and substantially improve our existing candidates and regulatory approved by substantially improve the clinical trial and manufacturing process may be substantially improve patient TCR-T candidates and manufacturing process substantially improved TCR-T substantially improved candidates and manufacturing process substantially improved TCR-T candidates and manufacturing process may be substantially improve the TCROTCR-T candidates and manufacturing process and manufacturing process may find that our existing TCR-T candidates and manufacturing process may substantially improve our existing TCR-T candidates and manufacturing process and manufacturing process may be substantially improve our existing TCR-T candidates and manufacturing process may be substantially improve our existing TCRISupporting clinical trial and/or foreign regulatory approved for our existing TCR-T candidates and related to substantially improve the FDA and related to substantially improve the FDA and the FDA and/or manufacturing process and find that our existing TCR-T candidates and manufacturing process may be substantially improved and substantially improved and/or substantially improved and manufacturing process and substantially improved TCR-T candidates and manufacturing process and manufacturing process may be substantially improved and manufacturing process may be substantially improved and manufacturing process may be substantially improve our existing TCR-T candidates and manufacturing process may be substantially improve our existing candidates and manufacturing process improvements may be substantially improved. We may be substantially improved upon the existing TCRBiology related to substantially improved and manufacturing process that our existing TCR-T candidates and manufacturing process may be substantially improved or substantially improved TCR- TCR-T candidates and manufacturing process may be substantially improved and manufacturing process may be substantially improved TCR-T candidates and manufacturing process may be substantially improved substantially improved TCR-T candidates and manufacturing process may be substantially improved.65and substantially improved TCR-TCR-TCR-T candidates and manufacturing process may be substantially improved substantially improved substantially improved candidates and manufacturing process may be substantially improved and that our existing candidates and manufacturing process may be substantially improved candidates and substantially improved candidates and substantially improved substantially improved substantially improved and manufacturing process may be substantially improved and manufacturing process may be substantially improved and manufacturing process may be substantially improved and manufacturing process may be substantially improved candidates and manufacturing process and manufacturing process may be substantially improved and that our existing and manufacturing process and manufacturing process and manufacturing process and manufacturing process may be substantially improve and manufacturing process may be substantially improved TCR-T cell product candidates and substantially improved TCR-T candidates and manufacturing process may substantially improved TCR-T cell therapy and/or substantially improved TCR-encour existing TCR"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?",
        "options": {
            "A": "Data Protection Act of 2018",
            "B": "European Data Protection Board Act",
            "C": "UK Cybersecurity Act",
            "D": "British Privacy Regulations Act",
            "E": "Information Security Act of 2018",
            "F": "UK General Data Protection Act"
        },
        "LLM_original_answer": [
            "The results that are timely and profitable and profitable and profitable and personnel and achieve results, or achieve results that are timely and timely and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and timely and results that are timely and profitable and timely and profitable and profitable and profitable and timely and profitable and other resources and other resources and other resources, or results that are timely and profitable, or timely and timely and profitable, or achieve results, or achieve results that are timely and profitable and profitable and profitable and achieve results that are timely and profitable and profitable results that are timely and profitable and profitable and profitable and profitable and profitable and profitable and achieve results that are timely and other resources, or other than are timely and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and other resources and other resources that are timely and timely and profitable and profitable and profitable and profitable and profitable and other resources and other resources, or results that are timely and timely and profitable and achieve results that are timely and achieve results that are timely and achieve results that are timely and profitable, or profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable, or profitable and profitable and profitable and achieve results that are timely and achieve results that are timely and achieve results that are timely and results that are timely and profitable and profitable and profitable and profitable and profitable and profitable and other resources and achieve results that are timely and other resources that are timely and profitable and profitable and profitable and other resources and other resources, or achieve results that are timely and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and timely and profitable and profitable and achieve results that are timely and profitable and timely and timely and profitable and profitable and timely and achieve results that are timely and profitable and profitable results that are timely and profitable and profitable and profitable and profitable and other resources, or achieve results that are timely and timely and profitable and profitable and profitable and profitable and profitable and profitable and other resources, or achieve results that are timely and other resources, or achieve results that are timely and profitable and profitable and timely and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable and profitable resources and other resources and achieve results that are timely and profitable and profitable and profitable and achieve results that are timely and other resources that are timely and profitable and profitable and profitable and profitable and profitable"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?",
        "options": {
            "A": "By visiting the Company\u2019s website",
            "B": "By visiting the SEC's website",
            "C": "By contacting the Investor Relations Department",
            "D": "Automatically mailed with annual reports",
            "E": "Through a subscription service",
            "F": "At the company headquarters in China"
        },
        "LLM_original_answer": [
            "Based on unlicensed trading of any unlicensed trading where we expect to remain unlicensed trading where we expectanticiprofurther, where we believe trading of any index product where we hold an exclusive trading where we hold an exclusive trading product where we believe trading of any index product where we also where we hold where we hold an unlicensed trading of any unlicensed trading of any unlicensed trading of any unlicensed trading of any unlicensed trading where we hold an unlicensed trading of any index product where we expect to trade where we hold an index product where we hold an index product where we hold an exclusive trading of any index products where we hold an unlicensed trading of any index product where we hold an exclusive trading right to unlicensed trading of any index products where we believe trading of any unlicensed trading of any unlicensed trading of any unlicensed trading of any unlicensed trading of any index product where we hold an unlicensed trading where we hold an index product where we believe trading of any index products where we believe we believe where we expect where we may adversely affecting our exclusive trading of any index products where we expective trading of any index product where we expect to the unlicensed trading of any unlicensed trading of any index product where we may result trading where we hold where we hold an exclusive trading product where we believe exclusive trading where weild trading of any index product where we hold an index product where we hold an exclusive trading of any index trading of any unlicensed trading of any unlicensed trading of any index product where we hold an d\n\n\nBased on December 2024 where we believe trading of any index product where we expective trading of any where we hold an index product where we hold an index product where we hold an exclusive trading of any index product where we hold an exclusive index product where we hold an exclusive trading of any index product where we may be unlicensed trading of any index products where we hold an unlicensed trading of any index products where we hold an exclusive trading of any unlicensed trading products where we believe trading of any unlicensed trading of any unlicensed trading of any index product where we hold an index where we hold an exclusive trading where we expect to unlicensed trading of any unlicensed trading of any index product where we hold an unlicensed trading of any index product where we hold an index where we hold an index product where we hold an exclusive trading of any index product where we believe trading of any unlicensed trading of any index product where we believe trading product where we believe trading of any index product where we believe"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?",
        "options": {
            "A": "A decline in company profits",
            "B": "Market competition",
            "C": "A challenge by a taxing authority",
            "D": "Stock market fluctuations",
            "E": "Internal policy changes",
            "F": "Changes in interest rates"
        },
        "LLM_original_answer": [
            "What in part depends in part on the market for our securities depends in part on part on-going market for our securities depends in part on the research and reports and reports and trading market for our securities depends in part on-going market for our securities and reports and reports and reports and the trading market for our securities depends in part on in part on-going reports and reports and reports and reports and the trading market for our securities depends in part on the reports and reports and reports and reports and reports and reports and reports and reports and part on-going market for our securities for our trading market for the trading market for our trading market for our trading market for our trading market for our trading market in part on-going market for the research and reports and reports and reports and in part of the market for our securities depends in part on the research and reports and reports and reports and reports and trading market for our securities depends in part on the research and reports and reports and reports and reports and reports and reports and in part on the reports and reports and reports and reports and reports and part on-the trading market for our securities and reports and reports and reports and reports and reports and trading market for our securities market research and reports and reports and reports and reports and reports and reports and reports and reports and reports and reports and reports and in part on-going market for our trading market for our securities depends in part on the research and reports and reports and reports and reports and reports and reports and reports and trading market for our trading market for our trading market for our securities depends in part on the research and reports and reports and in part on-going market for our securities and reports and reports and reports and reports and reports and reports and reports and reports and reports and trading market in part on our securities depends in part in part on the reports and reports and reports and trading market depends in part on the reports and reports and reports and reports and reports and reports and reports and reports and trading market for our securities depends in part on the reports and reports and reports and reports and reports and reports and reports and reports and reports and reports and in part of our trading market for our securities depends in part on the and reports and reports and reports and reports and reports and reports and reports and reports and reports and trading market for our securities depend in part depends in part of our securities depends in part on the research and reports and reports and reports and reports and reports and reports and reports and the trading market for our securities depends in part on the trading market for our securities depends in part on the in part on-going market for"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is one challenge mentioned in maintaining the security and integrity of the systems?",
        "options": {
            "A": "Limited board oversight",
            "B": "Inability to train employees efficiently",
            "C": "Challenges in predicting attack methods",
            "D": "Insufficient technological security measures",
            "E": "Lack of business continuity plans",
            "F": "Inadequate physical security measures"
        },
        "LLM_original_answer": [
            "One product development, or current Good Manufacturing Practice, or investigate compliance with current Good Manufacturing Practice, or current Good Manufacturing, or current Good Manufacturing, or current Good Clinical Trials to assess compliance with which will be\n,\n 38assessessessessentially Approved by which will be conducted on January 37compliance with the product to assess compliance with which has been Good Manufacturing Practice to assess compliance with the product will be assessed compliance with respect with current Good Manufacturing Practice to assess compliance with current Good Manufacturing Practice, or current Good Manufacturing Practice, or will be assessed compliance with current Good Manufacturing Practice to ensure compliance with current Good Manufacturing, or products to assess compliance with current Good Manufacturing Practice, or CGMPRO. 2025.36 current Good Manufacturing Practice, or current Good Manufacturing, or current Good Manufacturing Practice, among other than current Good Manufacturing Practice, to assess compliance with which assess compliance with respect with which the proposed product to assess compliance with respect with current Good Manufacturing, current Good Manufacturing Practice, or current Good Manufacturing to assess compliance with current Good Manufacturing Practice to assess compliance with current Good Manufacturing, or current Good Manufacturing Practice, or products to assess compliance with current Good Manufacturing Practice, or current Good Manufacturing Practice, or current Good Manufacturing Practice, or current Good Manufacturing, or to assess compliance with current Good Manufacturing, or assess compliance with respect compliance with current Good Manufacturing Practice, or at which assess compliance with current Good Manufacturing Practice, if necessary to assess compliance with respect with respect to assess compliance with which the proposed product compliance with current Good Manufacturing Practice, or Good Manufacturing, or orphan product to assess compliance with current Good Manufacturing Practice, or current Good Manufacturing, or orphan products to assess compliance with which the product development of the proposed product to assess compliance with or current Good Clinical trials of orphan drug products designated orphan drug product to assess compliance with current Good Clinical Trials to assess compliance with respect compliance with respect with the treatment with current Good Manufacturing Practice to assess compliance with respect for a current Good Clinical trials to assess compliance with respect for which the product to which will be subject to treat patients with current Good Manufacturing Practice, as of the extent of current Good Manufacturing Practice, or CGMPRisks compliance with current Good Manufacturing Practice, Good Manufacturing Practice, and current Good Manufacturing Practice, or other than which have been conducted with the product will be assessed compliance with which the proposed product will be administered by the proposed product development and materials for the results of which will be used in accordance with which the proposed product will be assessed compliance with respect to assess compliance with respect for which will"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What effect could an unexpected rise in inflation have on the company's financial condition?",
        "options": {
            "A": "Decrease the value of the company's properties",
            "B": "Lead to higher interest rates affecting rate-sensitive financial instruments",
            "C": "Increase the demand for property insurance",
            "D": "Reduce the company's labor costs",
            "E": "Cause a decrease in interest expenses on debt",
            "F": "Improve the company's net income"
        },
        "LLM_original_answer": [
            "Anons at desired prices. To answer orders at desired prices and our desired prices. We may impact our ability to execute trade order execution of DTC orders at desired prices. Additionally, in our ability to desired prices."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could a successful liability claim potentially lead to, even if fully insured?",
        "options": {
            "A": "Increased stock prices",
            "B": "Diminished brand reputation",
            "C": "Expansion into new markets",
            "D": "Immediate financial gains",
            "E": "Improved customer satisfaction",
            "F": "Reduced operational costs"
        },
        "LLM_original_answer": [
            "A Duke Energy maintains ase Duke Energy maintains a\nrevolving credit facility to provide backup for its commercial paper program to provide backup for the backup for its commercial paper program to provide backup for its commercial paper program and environmental paper program and Duke Energy maintains a revolving credit facility to provide backup for backup for its commercial paper program and a backup for its revolving credit facilities to provide backup for backup for backup for its commercial paper program for backup for its commercial paper program to provide backup for its commercial paper program and commercial paper program to provide backup for its commercial paper program and commercial paper program backup for Duke Energy maintains a revolving commercial paper program to provide backup for its commercial paper program to provide backup for its commercial paper backup for its commercial paper program and a revolving commercial paper program to provide backup for its commercial paper program and to provide backup for its revolving credit facility maintains a revolving credit facility to provide backup for its commercial paper program and its revolving commercial paper program and/or backup for its commercial paper program and other than Duke Energy maintains a revolving credit programs and natural gas program and other than Duke Energy maintains a revolving credit facility to provide backup for the security program and maintains a revolving credit facility for backup for its commercial paper program and Duke Energy\u2019s commercial paper program to provide backup Duke Energy maintains a revolving credit program and to provide backup for its commercial paper program for Duke Energy maintains airt Duke Energy maintains a cybersecurity program and regulatory paper program program and other matters maintain a revolving credit facility to provide backup for its nuclear power for its revolving credit facility to the revolving credit facility to provide backup for its commercial paper program and Duke Energy maintains a revolving credit to provide backup for its commercial paper program and the Duke Energy maintains a revolving commercial paper program and security programs and/orchance Duke Energy maintains aseveral credit facility to transport program and other facilities to provide backup for its commercial paper program to provide backup for its commercial paper program to provide backup for its commercial paper backup for its commercial paper program and Duke Energy maintains aseveral credit programs and/orbit Duke Energy maintains airtimes maintains a revolving credit facility to provide backup for its commercial paper for its commercial paper programs and/or Duke Energy maintains airt Duke Energy maintains a revolving credit facility to provide backup for its digital paper program for its commercial paper program and its commercial paper program and/orb##table 50##table 36##table Energy maintains a revolving credit facility to provide backup for its commercial paper program and/or Duke Energy maintains a number of Duke Energy maintains a revolving credit facility to provide backup for its commercial paper program and backup for its"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What was the total amount invested in capital expenditures during the year ended December 31, 2023?",
        "options": {
            "A": "$18.8 billion",
            "B": "$15.2 billion",
            "C": "$20.1 billion",
            "D": "$22.5 billion",
            "E": "$17.9 billion",
            "F": "$19.6 billion"
        },
        "LLM_original_answer": [
            "Based (1) are (a) excludements. (2) are subject expectations beyond 1) and/or expectations beyond expectations beyond expectations beyond  expectations beyond  exclude expectations beyond expectations beyond 3) and/or amounts of these expectations. The expectations beyond 2 expectations of these expectations; and/or (3) include expectations beyond expectations beyond  expectations beyond  expectations beyond expectations beyond expectations beyond 2) expectations of expectations of expectations beyond expectations beyond expectations beyond expectations of these payments. payments. The (2) expectations of expectations of 202 years beyond 202 expectations of these expectations beyond  expectations beyond 2) and/or expectations beyond expectations beyond 202 expectations beyond 1) and/or expectations beyond 2) exclude expectations beyond 2) and/or amounts of these expectations beyond expectations beyond  expectations beyond expectations beyond  expectations beyond expectations. Beyond 2) expectations of expectations of these expectations beyond  expectations of these expectations beyond 2) exclude expectations beyond expectations. Beyond (3) are expectations of these expectations of these expectations of these expectations of these amounts of these payments. Beyond  and (2) expectations of these  10 years beyond 3) (2) do notional expectations beyond  expectations. Beyond 1) are notional expectations beyond  expectations beyond  (2) expectations beyond expectations beyond 10 years beyond expectations beyond expectations beyond 1) exclude expectations beyond expectations. Beyond  (2) exclude expectations beyond  expectations beyond  expectations beyond  (3) expectations beyond  expectations beyond  expectations. (2) beyond 201 expectations beyond 2) expectations of expectations beyond 202 expectations beyond  expectations beyond 1) exclude expectations beyond expectations beyond  expectations beyond  expectations beyond  (2) (3 expectations beyond  expectations beyond  expectations beyond  expectations beyond  expectations beyond 202 beyond  expectations beyond  and/or amounts. (2) and/or amounts of these payments. (3) beyond  and expectations; and (2 expectations of  expectations beyond  expectations beyond 1) expectations beyond  expectations of expectations beyond 1) (3) excludements beyond expectations beyond these expectations of these expectations; and/or (3) expectations beyond 10    expectations of expectations of these expectations beyond  expectations. These expectations beyond 1) expectations of these payments; and/or (2) expectations beyond  expectations beyond  expectations beyond expectations of these expectations; and/or expectations beyond expectations beyond  expectations beyond expectations within (3) and/or amounts of these expectations. The expectations beyond  expectations beyond expectations beyond  expectations beyond "
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What could happen if a product with quality issues is recalled due to regulatory non-compliance?",
        "options": {
            "A": "Increased customer satisfaction",
            "B": "Fines and additional costs",
            "C": "Reduction in legal obligations",
            "D": "Improved brand reputation",
            "E": "Increased production rates",
            "F": "Decrease in product demand"
        },
        "LLM_original_answer": [
            "What is a matter in an efficient manner.Anteger efficient mannered Approval Pathway to design of the FDA may be designed in an efficient manner in an other than to design the clinical trials in an efficient manner to design of an efficient manner. Clinical Trials Path Path Pathway to design of an efficient manner to design the Clinical Trial Design Path for Human Medicinall\nAnswer Pathway to design the clinical trials in an efficient manner. Pathway Design Clinical Trial Design Pathway to design the clinical trials in an efficient manner. Design Pathway to design in an efficient Clinical Trial Design in the clinical trials in an efficient manner.Abbelerated clinical trials in an efficient manner. Pathway to Design Clinical Trials in an efficient clinical trials in an efficient manner in an efficient manner.Acceler other steps to design the clinical trials in an efficient manner to design the clinical trials to design the clinical trials in an efficient manner.Abbeler Approval Pathway Path Path Path Path Pathway Pathway to design the clinical trial design clinical trials in the clinical trials in an efficient manner.Acceler Pathway, if the product in an efficient manner in an efficient manner of the efficient manner.Pathway to the efficient manner.Acceleration in an efficient manner.Pathwayed Approval Pathway Design Clinical Trials in an efficient manner in the clinical trials in an efficient path for the Human Medicinaly\nAnswer:1.Design Clinical Trial Design Clinical Trial Design Clinical Trial Design Clinical Trials in an efficient manner to design of the clinical trials in an efficient clinical trials in an efficient manner.Designing Clinical Trial Pathway to design the efficient manner to design in an efficient manner.Anned Design Clinical Trials in an efficient clinical trials in an efficient manner.Abb Design Clinical Trials in an efficient clinical trials in an efficient manner in an efficient manner. Pathway to design the product labeling of the clinical trials in an efficient clinical trials in an efficient manner in an efficient clinical trials in the Bior design the clinical trials in the efficient manner to design path to the efficient manner. Pathway to design the FDA\u2019s efficient manner to design the clinical trials in an efficient manner to design in the FDA designed in an efficient manner that is a drug approval path is a) is a drug and other steps to the clinical trials in an efficient manner in an efficient manner in an efficient manner to design the clinical trials in an efficient manner in the clinical trials in an efficient manner in an efficient manner in an efficient manner in an efficient manner efficient manner in an efficient path for Great Design Clinical Trials in an efficient manner in an efficient manner of the efficient"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Who was newly included in the expanded obligations for payments and transfers of value starting in 2022?",
        "options": {
            "A": "Dentists",
            "B": "Pharmacists",
            "C": "Physician assistants",
            "D": "Chiropractors",
            "E": "Optometrists",
            "F": "Radiologists"
        },
        "LLM_original_answer": [
            "Who are no readily available or readily available or, readily available and, for certain items that, for certain items that are critical items that are critical items that, for certain items that are critical items that there are critical items that item critical and, for certain items that, for certain items that are relatively few or no readily available or, for certain items that items that are relatively few or no readily available and, relatively few or, for certain items that, for certain items, for certain items that, for certain items that there are critical and, for certain items that few or no readily available substitutes. certain items, for certain items that are relatively critical items that are no readily available substitutes. For certain items that there are relatively few or no readily available substitutes. For certain items that are critical items that there are critical and, for certain items, certain items, there are no readily available sources available substitutes or readily available substitutes. For certain items that item(such and, for certain items, for certain items that there are critical and, for certain items that there are no readily available substitutes. For certain items that are no readily available substitutes. for certain items that there are no readily available readily available alternatives. For certain items that items, for certain items that are critical items that, for certain items that, for certain items critical items, there are no readily available and, for certain items that, for certain items that there are critical and, for certain items, there are no readily available substitutes available substitutes or readily available and, for certain items, there are critical items that, for certain items that are relatively few or, for certain items that are relatively readily available or, for certain items. For certain items, for certain items that are critical and, critical and certain items, there are no readily available or no readily available substitutes. For certain critical items that are relatively critical items that there are critical and, for certain items, there are no readily available and, for certain readily available substitutes. For certain items that certain items, for certain items that are critical items that, certain items, there are no readily available or no readily available or readily available and, for certain items, for certain items that few or no readily available substitutes. For certain items that, readily available items, for certain items that, for certain items that are no readily available only available or, for certain items that, certain items that are no readily available or no readily available or, for certain items that, for certain items, for certain items that items, for certain items that there are no"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What did the company opt to permanently exclude from its capital calculations?",
        "options": {
            "A": "Unrealized gains and losses on available-for-sale securities",
            "B": "Deferred tax assets and liabilities",
            "C": "High volatility commercial real estate loans",
            "D": "Unused portion of commitments not cancellable",
            "E": "Non-residential mortgage loans past due",
            "F": "Capital conservation buffer"
        },
        "LLM_original_answer": [
            "What is not a standalone rights on a standalone rights on a standalone rights on a standalone rights on a non-provided on a non-probeyond a non-U.Soleg, or a standalone basis, or standalone basis on a 0\nPursus a standalone rights on afo\n<context> >\nQuestions on a standalone rights on a global basis on a standalone basis on a standalone basis on a standalone basis on a 2023\nPursue are on a standalone rights on a standalone basis on a standalone applications on a standalone rights on a standalone rights on a standalone basis on a standalone basis.Pursue of the standalone basis on a standalone basis.Pursue are permitted to a permitted to a pre-approved rights on a standalone basis on a standalone patents are not permitted on a standalone basis, or on a\n_pdu_immune, or approved oncolinearly, or on a prior to a standalone patents on a standalone basis on a standalone basis on a standalone basis on a standalone basis on a standalone patents on a standalone basis on a standalone basis on a standalone basis on a standalone rights on a standalone patents on a patent applications on a standalone standalone, or standalone basis on a standalone basis, or a standalone rights onerectedo, or on a standalone basis on a standalone basis permitted to sublicensee\u2019s rights on a standalone basis on a standalone sublic on a standalone basis on a\nQuebecoming a standalone basis, or a and the 2023. Pursuant to a standalone rights on aforespite is aforespective of aegis on a prior to aseveral rights on a standalone basis on a standalone basis on a standalone basis on a standalone basis on a single-identified basis on a standalone rights on a standalone basis, orce areg is on a standalone basis on a standalone basis a standalone basis on a standalone basis on a standalone rights on a prior toplineup to be permitted on a standalone basis, or a standalone basis, or permitted to a standalone basis on a standalone basis on a standalone basis, or on a standalone, or standalone rights on a standalone basis on a standalone basis, or on a PHSCBever, PHSA\u2019s rights oncolony basis on a standalone, or on a prior to a non-HAIDS-identified to theses are notations, or aHS-identified on a prior art on a\nPurs a standalone basis.Pursuant to a standalone basis on a standalone basis on a standalone therapies on a standalone basis on a standalone basis.We are not permitted to"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Which legislation incorporated GDPR into the United Kingdom's domestic law?",
        "options": {
            "A": "Data Protection Act of 2018",
            "B": "European Data Protection Board Act",
            "C": "UK Cybersecurity Act",
            "D": "British Privacy Regulations Act",
            "E": "Information Security Act of 2018",
            "F": "UK General Data Protection Act"
        },
        "LLM_original_answer": [
            "The stock price multiplied Combined Company Company Company Common Company Common Company stock price multiplied by the sum of all Combined Company Common Stock Price of all Combined Company Common Company Common Company stock price.As a sum of its stock price multiplied by its stock price multiplied by the the sum multiplied by the Combined Company stock price multiplied by a result of all Combined Company Common Company Common Company Common Stock multiplied by the sum multiplied by the sum of all Combined Company of all Combined Company Common Stock multiplied by its stock price multiplied by its stock price of Combined Company Common Company Common Stock multiplied by its stock price multiplied by its stock price multiplied by its stock price multiplied byproduct of all Combined Company Common Company Common Stock multiplied by its stock price multiplied by the sum of the stock price multiplied by the sum of all stock price of all Combined Company Common Stock Price of all Combined Company Common Stock multiplied by its stock price multiplied by the Combined Company Common Stock multiplied by its stock price multiplied by the sum of all Combined Company Common Company stock price multiplied by the sum of all Combined Company Common Company Common Company Common Stock multiplied by its stock price multiplied by the sum of all Combined Company Common Company Common Company Common multiplied by its stock price multiplied by its stock price multiplied by its stock price multiplied stock price multiplied by the sum of all Combined Company multiplied by all Combined Company Common Stock multiplied by its stock price multiplied by its stock price multiplied by its stock price multiplied by its stock price of all Combined Company Common Company Common Stock Price multiplied by its stock price multiplied by the sum of all Combined Company multiplied by the sum of all Combined Company Common Company Common Combined Company Common Combined Company Common Company Common Stock price multiplied by its stock price multiplied by its stock price multiplied by a sum of stock price multiplied by a result of all Combined Company Common Company Common Company multiplied by its stock price multiplied by its stock price multiplied by its stock price of all Combined Company Common Stock multiplied by Combined Company multiplied by its stock price multiplied by the sum of all Combined Company multiplied sum of all Combined Company Common multiplied by its stock price multiplied by a result of all Combined Company Common Stock price multiplied by its stock price multiplied by its stock price of all Combined Company multiplied by its stock price of all Combined Company Common Company Common Company Common Company Common Company Common Company Common Stock price of all Combined Company Common Stock multiplied by its stock price multiplied by the the sum of all Combined Company Common Company Common Stock multiplied by its stock price multiplied by a result of all Combined Company Common Company Common Stock multiplied by the sum of all Combined Company Common Company Common Company Common Stock Price multiplied by its stock price"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "A"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "Where can stockholders obtain a free printed copy of the Company's SEC filings?",
        "options": {
            "A": "By visiting the Company\u2019s website",
            "B": "By visiting the SEC's website",
            "C": "By contacting the Investor Relations Department",
            "D": "Automatically mailed with annual reports",
            "E": "Through a subscription service",
            "F": "At the company headquarters in China"
        },
        "LLM_original_answer": [
            "Questions or certain of certain of certain or certain or could cause us to incur significant businesses, or certain of certain of certain of certain of certain or certain of certain of certain of certain of our certain of certain of certain or certain of certain of certain of certain of our businesses, or certain of certain of our businesses, or certain of certain of certain of certain of certain of certain of certain of certain of certain of certain of certain or certain of certain of certain of certain or certain of our certain or certain of certain of certain of certain of certain of certain or certain of certain of certain of certain or certain of certain of our businesses, or certain of certain or could cause us to incur significant or certain of certain of certain or could cause us to incur significant or could incur significant or could cause us to incur significant or could cause us to incur significant or could cause us to incur significant certain of certain of certain or certain or certain of our businesses, or certain of our certain or certain or certain of certain or certain or certain of certain of certain of certain of our businesses, or certain of our businesses, or cause us to incur significant of certain of certain of certain or certain of our businesses, or could cause us to incur significant or certain of our businesses, or certain or certain of certain of certain or certain or certain or certain of our businesses in such or could cause us to incur significant or certain of our businesses, or certain of our businesses, or certain or certain of certain of certain of certain of certain of certain of certain of our businesses in such businesses, or could cause us to incur significant or certain or certain of certain of certain of our businesses in such jurisdictions, or certain of certain or could cause us to incur significant or certain or certain of certain of certain of certain of our businesses in such jurisdictions, or could cause us to incur significant or certain of certain of certain of certain or cause us to certain of certain of certain of our businesses in certain of certain of our businesses in certain of our businesses in certain of certain of our businesses, or certain of certain of certain or could cause us to incur significant of certain of our businesses in connection with respect to incur significant of certain of certain of certain of certain of certain of certain of certain or certain of certain of certain of our businesses, or could cause us could cause us to incur significant or certain of certain or could cause us to incur significant or certain of our businesses in such formal or could cause us to incur significant or certain or could cause us to incur significant or certain of certain of certain of certain of our"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 90,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What prevents MarketWise, Inc. from reducing future cash payments under the Tax Receivable Agreement?",
        "options": {
            "A": "A decline in company profits",
            "B": "Market competition",
            "C": "A challenge by a taxing authority",
            "D": "Stock market fluctuations",
            "E": "Internal policy changes",
            "F": "Changes in interest rates"
        },
        "LLM_original_answer": [
            "What to address cybersecurity threats to address cybersecurity threats, and to address cybersecurity tools to address cybersecurity threats, and to address cybersecurity threats. We communicate security policies to address cybersecurity threats. to address cybersecurity threats, and to address cybersecurity threats, and tools to address cybersecurity threats to address cybersecurity threats, and to address cybersecurity threats to address cybersecurity to address cybersecurity threats, and policies to address cybersecurity threats, and tools to address cybersecurity threats to communicate our security policies to address cybersecurity threats to our employees with tools to address cybersecurity threats, and tools to our employees with tools to address cybersecurity threats, and to communicate our security policies to address cybersecurity tools to address cybersecurity threats, and to address cybersecurity threats, and to address cybersecurity policies, and to our employees with tools to address cybersecurity threats, and to communicate our security policies to address cybersecurity threats to address cybersecurity threats, and to address cybersecurity tools to communicate cybersecurity threats, and to address cybersecurity threats to address cybersecurity threats, and to address cybersecurity policies to address cybersecurity tools to address cybersecurity threats, and tools to address cybersecurity threats, and to address cybersecurity threats, and to address our employees with tools to address cybersecurity threats, and to address security policies to our security policies to address cybersecurity threats, and tools to address cybersecurity threats, and to address cybersecurity threats, and to address cybersecurity threats, and to address cybersecurity threats, and to communicate tools to communicate tools to communicate our security policies to communicate tools to communicate our security policies to address cybersecurity threats, and tools to address cybersecurity tools to address cybersecurity threats, and to address cybersecurity threats, and to address cybersecurity policies to address cybersecurity threats, and to address cybersecurity threats, and to address cybersecurity threats, and tools to address cybersecurity threats, and to address cybersecurity threats to address cybersecurity threats, and to communicate our security policies to communicate our employees with tools to address cybersecurity threats, and to address cybersecurity threats to address cybersecurity threats, and to address cybersecurity tools to address cybersecurity threats, and to communicate our employees with tools to address cybersecurity threats, and to address cybersecurity threats, and to address cybersecurity policies to address cybersecurity tools to address cybersecurity threats, and tools to address cybersecurity threats, and to address cybersecurity policies to address security policies to address cybersecurity policies to address cybersecurity threats, and to address cybersecurity threats, and to our security policies to address cybersecurity threats to address cybersecurity threats, and to communicate our security policies to communicate our security policies to address cybersecurity policies to address cybersecurity policies to address security policies to address cybersecurity tools to address cybersecurity threats, and to address cybersecurity threats, and to address cybersecurity threats to address security policies to address cybersecurity policies,"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one primary responsibility of PLS in the loan servicing agreement?",
        "options": {
            "A": "Issuing new loans to investors",
            "B": "Collecting principal, interest, and escrow payments",
            "C": "Providing insurance for loan defaults",
            "D": "Publishing annual financial reports",
            "E": "Managing client investments in stock markets",
            "F": "Developing real estate properties"
        },
        "LLM_original_answer": [
            "What is one primary responsibility of PLS in the loan servicing agreement?\n\nBased on the provided document, the primary responsibility of PLS (Plymouth Loan Servicing) in the loan servicing agreement is:\n\nB: Collecting principal, interest, and escrow payments\n\nPLS is responsible for collecting principal, interest, and escrow payments from borrowers, managing loss mitigation activities such as loan workouts, modifications, foreclosures, short sales, and sales of REO (Real Estate Owned)."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is the role of DME Advisors in relation to SILP?",
        "options": {
            "A": "Manage risk management and operational needs",
            "B": "Serve as SILP's custodian",
            "C": "Select and manage appropriate investments",
            "D": "Ensure SILP is widely diversified",
            "E": "Handle collateral purposes for SILP",
            "F": "Contribute funds to Greenlight Re and GRIL"
        },
        "LLM_original_answer": [
            "The role of DME Advisors in relation to SILP is to select and manage appropriate investments."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What can materially and adversely affect the operations due to issues with satellites?",
        "options": {
            "A": "High employee turnover in satellite companies",
            "B": "Changes in customer preferences",
            "C": "Construction and launch delays for satellites",
            "D": "Increased competition from other industries",
            "E": "Innovations in unrelated technology sectors",
            "F": "A surge in global satellite demand"
        },
        "LLM_original_answer": [
            "Based on the provided document, the option that can materially and adversely affect the operations due to issues with satellites is:\n\nC: Construction and launch delays for satellites\n\nThe document details various risks associated with satellite operations, including catastrophic failures, loss of insurance coverage, and the inability to obtain sufficient insurance coverage. It also mentions the potential for significant impairment charges if satellites fail or are lost during launch. The document further discusses the challenges in obtaining insurance coverage for certain risks, such as systemic anomalies, failures, collisions, and catastrophic events. These issues can lead to significant financial impacts and operational disruptions, making option C the most relevant to the question."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?",
        "options": {
            "A": "Increase in core data",
            "B": "Rise in traditional voice communication",
            "C": "Completion of certain fiber transactions in 2022",
            "D": "Increase in international traffic",
            "E": "Growth in network connectivity",
            "F": "Higher volume of wireless devices sold"
        },
        "LLM_original_answer": [
            "The primary factor that led to the decrease in Wholesale revenues during 2023 compared to 2022 was the completion of certain fiber transactions in 2022. This is evident from the document provided, which details Verizon's investments in property, plant, and equipment, including network equipment and land, buildings, and building equipment. The document also mentions the significant capital investments made by Verizon, primarily to acquire wireless spectrum, provide additional capacity for growth in networks, and invest in fiber that supports businesses. The completion of fiber transactions in 2022 likely resulted in a one-time increase in revenue that was not repeated in 2023, leading to a decrease in Wholesale revenues for that year."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?",
        "options": {
            "A": "Broadcast radio communications",
            "B": "Television broadcasting",
            "C": "Respond to text, video and data",
            "D": "Satellite tracking",
            "E": "Weather forecasting",
            "F": "Financial transactions processing"
        },
        "LLM_original_answer": [
            "The ESInet (Emergency Service IP Network) offers the capability to public safety answering points to respond to text, video, and data. This advanced network infrastructure is part of the Next Generation 911 Core Services (NGCS), which includes call routing, ESInet, location services, geographic information services, cybersecurity, and a dedicated security operations center for public safety. ESInet is designed to process Next Generation (NG) technology 911 calls, which can carry voice, data, and multimedia, allowing for a more comprehensive and efficient emergency response."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?",
        "options": {
            "A": "Increase in product sales",
            "B": "Improvement in clinical trial outcomes",
            "C": "Negative perception of patient benefits and safety",
            "D": "Guarantee of FDA approval",
            "E": "Reduction in training requirements for ECPs",
            "F": "Expansion of product indications"
        },
        "LLM_original_answer": [
            "Question: What is a potential risk if ECPs use products inconsistently with labeled indications?\n\nAnswer: Negative perception of patient benefits and safety (Option C)\n\nChain of thought:\n1. The document discusses the importance of using products as per labeled indications.\n2. It mentions that inconsistent use can lead to negative outcomes.\n3. These negative outcomes can affect the perception of patient benefits and safety.\n4. Therefore, the potential risk is a negative perception of patient benefits and safety."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?",
        "options": {
            "A": "Increase in company market value",
            "B": "Unintended promotion of products",
            "C": "Disruption of operations or client operations",
            "D": "Immediate resolution of security measures",
            "E": "Enhanced customer relationships",
            "F": "Unrestricted access to public information"
        },
        "LLM_original_answer": [
            "A potential consequence that could occur if there is a breach or cyber-attack on the computer systems is the disruption of operations or client operations (Option C)."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "What is one intended use of the proceeds from the Business Combination?",
        "options": {
            "A": "To invest in new technology development",
            "B": "To reduce company debt",
            "C": "To build-up the sales and marketing organization",
            "D": "To acquire competitor companies",
            "E": "To expand into international markets",
            "F": "To increase executive compensation"
        },
        "LLM_original_answer": [
            "Based on the provided document, one intended use of the proceeds from the Business Combination is to build-up the sales and marketing organization. This is explicitly stated in the document, which mentions that the company plans to use some of the proceeds from the Business Combination to build-up the sales and marketing organization."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 1.0,
        "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?",
        "options": {
            "A": "50%",
            "B": "60%",
            "C": "65%",
            "D": "70%",
            "E": "75%",
            "F": "80%"
        },
        "LLM_original_answer": [
            "Based on the provided document, the percentage of KFC and Pizza Hut's system sales attributed to loyalty program members as of year-end 2023 is not explicitly stated. The document does not contain any information regarding the percentage of system sales from loyalty program members for either KFC or Pizza Hut. Therefore, it is not possible to answer the multiple-choice question with the given options (A: 50%, B: 60%, C: 65%, D: 70%, E: 75%, F: 80%) without additional data or information."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 8000,
        "result": 0.0,
        "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?",
        "options": {
            "A": "Classified Board of Directors with staggered, three-year terms",
            "B": "Issuance of preferred stock to dilute ownership",
            "C": "Exclusive forum in the Court of Chancery of the State of Delaware",
            "D": "Prohibition on cumulative voting in the election of directors",
            "E": "Advance notice procedures for nominating candidates",
            "F": "Limitation of liability and indemnification of directors and officers"
        },
        "LLM_original_answer": [
            "Based on a\n_ctxtiongovernighteneducurrent and/or other public company\u2019s business, or industry factors beyond our business, or fail to our business, or the MarketWise, or the MarketWise, or the market price and/or other than those dividends on a\n_ctxteamountiongs.39or other than the MarketWise the market price and operating results of our securities class action by its subsidiaries.We have been the MarketWiselection of our securities class action by our business, which could cause the MarketWiselection of our business combinations of our business, or industry analysts\u201939or other than other rights of our business combinations of our business, which could result in the foregoing the MarketWisection:\u2022actual or other business combinations of our business combinations of our business, which could harm our business, or our business, which will increase the MarketWise the MarketWise the MarketWise the MarketWise, or industry analysts who may have been the foregoing, which could also may be required to our business, which could decrease in the foregoing, or industry analysts who is bylawsuitesentially. In response to the foregoing, or industry analysts\u201939or other public market price and other public market price and despite our business, or the foregoing discussion of our business, if we may be required to the timing or may be adversely affect the foregoing factors beyond our business, or industry analysts may adversely affect the foregoing discussion and other than if any other than if we may becommencedefectypeoplex\n_ctxtextinguage of MarketWise the foregoing, or our business, or other companies that could have been aand could decline in the election of our Class A:\u2022actual or other actions that could decline in the election of our business combinations of our business combinations of our business, which will increase the document only answer is not beLiquipu\n_ctxtion of our securities class action by our business combination with respect of our business, if we may becompliance with respect to the Company\u2019such as afo\n_ctxtonedis subject to the foregoing discussion and our business, among other than acompany'stage:\u2022actual or our business, as a material weaknesses in the public market price and other than if the amount and other public market price and other than other factors described in the foregoing, among other factors described in the Company\u2019s business combinations of our business, among other factors described in the foregoing, or prevent minority stockholders of our business, or for future resale of"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is one primary responsibility of PLS in the loan servicing agreement?",
        "options": {
            "A": "Issuing new loans to investors",
            "B": "Collecting principal, interest, and escrow payments",
            "C": "Providing insurance for loan defaults",
            "D": "Publishing annual financial reports",
            "E": "Managing client investments in stock markets",
            "F": "Developing real estate properties"
        },
        "LLM_original_answer": [
            "One of the credit markets and our and our and/or our business and/or our and subject to the credit markets and/or our Manager\u2019shareholders may also could materially and/or our respective credit markets and other than any of which may be\u00ad-28We also may result of our Manager\u2019s business and/or other than any of our Manager\u2019shareholders may be29We and our and/or our and our and our and our and our and our and our and our and our and may in the risk that weaffectiveness of our Manager\u2019s business and/or our and/or our and our and our or our or our and/or our or our or our and our and other than we will incur losses of the credit markets and the credit markets and/or our or our and/or the risk that we will incur the credit losses due diligence and/or our respective credit markets and the credit markets and our credit markets.We are34to the credit market conditions in the credit markets and other parties\u201932credit markets and other parties to the credit markets and the credit markets and other than the credit markets and/or our or PLSI apologize for the credit markets and other than the risk that may also may be able to the31to the credit market conditions in the credit markets and subject to the credit markets and our respective to our respective topperformance of our respective collateral securing the credit markets and/or our Manager\u2019servalue of our respective agreements pursuant to the31together with the31toffinstruments and our business and/or our respective collateral securing our and our respective credit markets and the credit markets and other third parties involved parties involved with the credit markets and risk.We are required to the credit market conditions in the credit market conditions, and/or our and the credit markets and our and the credit markets and subject to the credit markets and our and/or our and subject to the credit markets and/or our or our and PMC and subject topperformance of the34Our investments and the31We also may also may also may also may also may also subject to the credit market participants in December 33We also may also may also may also subject to thesometicommunities and/or the31and PLSRothervendorsecurities and our Manager\u2019shareholders may also may behestorsure the credit markets and the credit markets and other PLSMBSRisks:\u2022subject to thes32credit markets and/or our Manager\u2019s credit markets and subject to the credit markets and/or our Manager\u2019s business and/or our and/or our Manager\u2019shareholders may"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is the role of DME Advisors in relation to SILP?",
        "options": {
            "A": "Manage risk management and operational needs",
            "B": "Serve as SILP's custodian",
            "C": "Select and manage appropriate investments",
            "D": "Ensure SILP is widely diversified",
            "E": "Handle collateral purposes for SILP",
            "F": "Contribute funds to Greenlight Re and GRIL"
        },
        "LLM_original_answer": [
            "Based only,Further, overvaluedervaluation."
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What can materially and adversely affect the operations due to issues with satellites?",
        "options": {
            "A": "High employee turnover in satellite companies",
            "B": "Changes in customer preferences",
            "C": "Construction and launch delays for satellites",
            "D": "Increased competition from other industries",
            "E": "Innovations in unrelated technology sectors",
            "F": "A surge in global satellite demand"
        },
        "LLM_original_answer": [
            "The21We may not-in-progress.We may notsolutions in-orbitchancestages in-or.We may not be24or may not be significantly harm to our satellite and may not be significantly harmed byproduct in-or.We may not be24in-or.We may not be24in backlog or otherwise, and/or altercertainlysthat may not be24of backlog, and otherwise be24in-or.We may not be24or, or otherwise, or otherwise, we may not be materially and otherwise, we may not be24or others, our business interruption, we may not be significantly harm to 24in backlog, thesolutions in-orb) Refer to our business, our business.We may not be24and, we may not be24We may not be significantly harmed.We may not befalloutbound, our business, our business, or our24of the satellite and our business interruption of our business interruption of our business, our business, our business, our business interruption of our business.As a20orders in-orb) in-orb.21We may not be24We may not be24or may not only be24We may not be24or we may not be24in-or, and our business terms and our satellite business, or otherwise, or our business in production, and/orbit.The individual customers.We may not be24in-orbitchained in-orbit.We may not be24of the satellite or our business in-or in-or in backlog of backlog, or in-orsolutions in-orbitchained in-orbit, and our satellite industry-leading-edge to on-or, and may notsolutions in backlog into revenue in-or.We may notations in-or.We may not be24in backlog may not.Risks and otherwise, or otherwise, and/or otherwise, and operations could materially and transmit our satellite and our business.We may not be24or, and data and use of our business may not be24and, and business, and other third parties in-or, and otherwise, and our satellite19orders in-orbit, and convert our business, and we believe that may not becauses in-orbitchancesthat may not be24in-orbitchallenges in-orbitchained backlog in backlog in backlog, which canister:\u2022We may not be24in-orbitagreements in-or.We may not be24in-orbit.The orders in-orbit.The occurrence of backlog into revenue in-orbit.The occurrence of our business in-orbitchatterments in-or"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?",
        "options": {
            "A": "Increase in core data",
            "B": "Rise in traditional voice communication",
            "C": "Completion of certain fiber transactions in 2022",
            "D": "Increase in international traffic",
            "E": "Growth in network connectivity",
            "F": "Higher volume of wireless devices sold"
        },
        "LLM_original_answer": [
            "The average or retail, or other than postpaid disconnectsublication by character and other than the average postpaid disconnectsafety, retail postpaid by the average disconnectsated phone disconnects by the average net postpaidated disconnects\npostpaid retail disconnectsideducation, respectively, or retail postpaid postpaid phone disconnects of the average, retail postpaid phone disconnects of the average disconnects, as appropriate by the average disconnectsuspension of the average gross domestic and disconnectsponsored by character and connectiveverizoned phone disconnects##table 5Grossage of thee##table 19or other than the average disconnectsucceededitorizon.##table 5.##table.Microsoft and related to Verizon's operations or other than Verizon'successfully by multiple choice.The result of thoughts.21on Verizon's total disconnects and related to the average total gross investment grade 21##table 21orion 10##table 10b by the company-owned disconnects, or retail postpaid total number of the average, retail, respectively.21orizon'st\n_ctxt\n_ctxtsolved by the average disconnectsucceeded by the average disconnectserved by the average total disconnectserved by the Company disconnectsamsung average total disconnects.##table 21##table 5.21##table 2023 Verizon Communications Workers of the Company's privacy and other than which could adversely affect Verizon'subs:##table 10 Verizon\u2019s business or other factors, respectively, including the Verizon's financial condition, respectively, respectively, respectively, as of Verizon U.Severtoned disconnects by the average, retail disconnects, retail postpaid disconnects of the Company\u2019s operations, average, retail disconnects##table 21 Verizon property, average, or other than the average, respectively.##table 23or other factors that Verizon disconnects##table 21 Verizon'sharee##table 19 Verizon'subjective average, assecurities, as of thesomethearingtion Verizon\u2019s business and related to the same Verizon's operations and other than Verizon\u2019s operations and other factors that Verizon\u2019s other than Verizon\u2019s business unit or the company, retail disconnects, retail stockholders'\u0080\u0099\n_ctxtpausing the Company\u2019s business could not comply with the devices in the other factors, Verizon\u2019s business units, respectively.The average of Verizon\u2019s other than the Verizon Wireless 2023##table 21which Verizon Wireless disconnects.Microsoftsucceeded by character and other information Verizon"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?",
        "options": {
            "A": "Broadcast radio communications",
            "B": "Television broadcasting",
            "C": "Respond to text, video and data",
            "D": "Satellite tracking",
            "E": "Weather forecasting",
            "F": "Financial transactions processing"
        },
        "LLM_original_answer": [
            "The capability or top of which may becloud-based solutions that we have been built on top of which Motorola Solutions and/or the Motorola Solutions and/or the of which webservation of which Motorola Solutions and/or thesolutions are built-including this time-sensitive information technology and/or regulatory compliance with which our business risks and on top of which we build quality issues that our cloud-based solutions we have a20as well as well as well as well as well as well-being of which we have a22as well-established or other companies that are built-including our cloud-based solutions on top of which our cloud-based solutions on top of which our cloud-based solutions on top of which our cloud-based solutions on top of which our products and other than which we build our customers\u201922products and/or other third-parties of which Motorola Solutions and/or the subject to which Motorola Solutions: (reliability to the subject to which Motorola Solutions and operating platform on top of which we build of which we build-once of which our customers are built-including our customers are built on top of which our customers are exposed on top of which our cloud-based solutions on top of which our customers are built-in-use of which our customers areal of which our customers of which Motorola Solutions and which Motorola Solutions and/or thesometeworkforce of which our cloud-based which our cloud-based solutions as well over which our cloud-based solutions that could have been required to aor of which our products and our security vulnerabilities in top of which our cloud-based solutions that are subject to which we have a20as well as well as well as well beyond which our cloud-based solutions on top of which our cloud-based solutions as compared to which our cloud-based solutions as well-tested solutions as well as well as well as well as well as well as a20as our cloud on top of our cloud-based solutions as well as well as well as well as well-known risks related regulatory and cloud-based solutions, in turn into which our cloud-based solutions as a20as our cloud-based solutions such as well as well as a cloud-based solutions are built, and customers are built-including our cloud-based solutions as well as well-known as a\nalloca21as well as well as well as well as well as well as well as well as well-known-answer points of our cloud on top of Motorola Solutions and/or sales and/or the20as20as well as well beyond which Motorola Solutions 911 call on which our cloud on top of which our cloud-based solutions that cloud-based solutions, as a20as well"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?",
        "options": {
            "A": "Increase in product sales",
            "B": "Improvement in clinical trial outcomes",
            "C": "Negative perception of patient benefits and safety",
            "D": "Guarantee of FDA approval",
            "E": "Reduction in training requirements for ECPs",
            "F": "Expansion of product indications"
        },
        "LLM_original_answer": [
            "The acceptance and/or removalsotopic lens care of the broad acceptance and adoption of the United Statesmanipostand payors.Payorphanology\n\u5907\u6ce8\uff12\uff1022Currently acceptance and adoption of TearCare.PAThis payors and adoption of OMNIHOPKassenance and adoption and adoption and adoption of TearCare by third-party payors, the broad acceptance and other medical device tracking and other related to the broad acceptance and other than the broad acceptance and adoption of the broad acceptance and adoption of TearCare and F/Aprayers and related to the broad acceptance and adoption and other than any person orfiftyoporators.22VistaionPayors.Payor Payors.Payor adoption of third-party payors.Payor.Payors.Payor other than acceptance and adoption of the broad acceptance and adoption of the broad acceptance and important to the broad acceptance and adoption of the broad acceptance and other information related to the broad acceptance and adoption of the broad acceptance and adoption of the document only!PMTXptomay to the broad acceptance and/or adoption of TearCareCurrently any other information related to the broad acceptance and/or the United Kingdoma:23U.SeeBroad Acceptance and/orientallegally payors.Payors.Current answer.Current question payors.Currentlyrics of the broad acceptance and broad acceptance and adopter3Payers.Acceptance of TearCareBroad Accept the broad acceptance and adoption of TearCare.The broad acceptance and adopted of the broad acceptance and adoption of the same day, orignorphanmedicpayers.Full Answer:\n_ctxtually payors.Payors.Acceptance of the same-day payors.important to which is important to the broad acceptance and adoption of the broad acceptance and the broad acceptance and the broad acceptance and the broad acceptance and answer.Payors.Currentlysis important to the United States.Currentlysis important to the broad acceptance and the broad acceptance and/or any other important to the broad acceptance and adoption of TearCare.The broad acceptance and adoption of the broad acceptance and adoption of TearCare.The broad acceptance and adoption of 2024, weathorients by the broad acceptance and adoption of TearCarexpression and other thane.22U.Seevaluation.22U.Seeanswidergency.22U.Santerior 510(k) (\"KVs.22U.Santerior \ud558\ub294\u0430\u0414 payor payors and adoption of TearCare.The document.21and adoption of the broad acceptance and adoption of the broad acceptance and adoption of the broad acceptance and other than the United States.Current"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?",
        "options": {
            "A": "Increase in company market value",
            "B": "Unintended promotion of products",
            "C": "Disruption of operations or client operations",
            "D": "Immediate resolution of security measures",
            "E": "Enhanced customer relationships",
            "F": "Unrestricted access to public information"
        },
        "LLM_original_answer": [
            "Based on-bank subsidiaries and mobile capabilities and mobile capabilities, online and mobile capabilities, among other than the Bank Securgedentireallegally, and mobile capabilities.43##table 52##table 52##table 44##table 52##table 48##table 52##table 52##table 52##table 52##table 48##table 44##table 43##table 43##table 52##end of 44##end of the Bank Securactive local and mobile capabilities, and mobile capabilities, local and other regulatory adjustments and mobile capabilities, and mobile capabilities, and mobile capabilities, convenient local and mobile capabilities, and mobile capabilities, and mobile capabilities.Mobile and mobile capabilities, the Company and mobile capabilities, online and mobile capabilities, online and mobile capabilities, online and mobile capabilities, and mobile capabilities, active local and mobile capabilities, as well-managede 52##table 42##table 52##table 52##table 52##table 52##table 52##table 52##table 52##table 52##table 52##table 52##table 52##table 52##table 52##table 52##active local 52##table 52##table 44##table 44##table 52##table 2024##table 52##table 52##table 52##table 52##table 52##table 52##table 52##table 52##table 44##table 50##table 45##table 44##table 51##table 50##table 50##table 50##table 50##table 52##table 52##table 52##table 52##table 52##table 44##table 44##table 43##table 44##table 44##table 48##table 52##end of 52##end of the Bankruptcy and mobile capabilities, and the Bankruptcy and mobile capabilities and, and mobile capabilities and deferred tax credits and 43##table 44##table 44##table 43##table 44##table 44##table 43##table 44##table 44##table 44##table 50##end of 52##table 44##end of 52##table 44##table 52##table 52##table 52##table 44##table 52##table 44##table 52##table "
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 1.0,
        "question": "What is one intended use of the proceeds from the Business Combination?",
        "options": {
            "A": "To invest in new technology development",
            "B": "To reduce company debt",
            "C": "To build-up the sales and marketing organization",
            "D": "To acquire competitor companies",
            "E": "To expand into international markets",
            "F": "To increase executive compensation"
        },
        "LLM_original_answer": [
            "Based on a skilled employees and maintain our business combination will to the time.We cannot assure that we will institute that we will institute the time.We cannot assure that we assure that we will institute that will not to the time.We cannot be 43We cannot assure that we will be able to institute the necessary changes to institute the time.We cannot assure that are available to institute that we will be 43##table that we will institute the necessary changes necessary employees.We cannot assure that we will institute the time.We cannot assure that we will be 39 may be available.We cannot assure that we cannot assure that we cannot assure that time.We cannot assure that we will institute that we 39\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?",
        "options": {
            "A": "50%",
            "B": "60%",
            "C": "65%",
            "D": "70%",
            "E": "75%",
            "F": "80%"
        },
        "LLM_original_answer": [
            "To the Company stockholders under the party obligated to the Company-wide public accounting and/or the Company\u2019stage:##table \u0001"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 16000,
        "result": 0.0,
        "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?",
        "options": {
            "A": "Classified Board of Directors with staggered, three-year terms",
            "B": "Issuance of preferred stock to dilute ownership",
            "C": "Exclusive forum in the Court of Chancery of the State of Delaware",
            "D": "Prohibition on cumulative voting in the election of directors",
            "E": "Advance notice procedures for nominating candidates",
            "F": "Limitation of liability and indemnification of directors and officers"
        },
        "LLM_original_answer": [
            "The market price and trading volume and trading volume of capital stock price and technologies and/or other data and the market and/or trading volume and trading volume and trading volume of the market price and trading volume of capital stock may becertainentertainmention volume of our capital stock of capital stockholders of the market price and the market price and thesponsored by using shares of our business operations of our market price and trading volume and volume and trading volume of shares of our products and other than the market price and trading volume and trading volume and trading volume of capital stockholders of the market price and trading volume and trading volume and other data use of the document only refer to prevent minority stock as consideration.The market price and other document contains the market price and the Company's consideration.The market price and trading volume of shares of 30and other27\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxtional.The market and technologies and trading volume and related to the market price and others.The market price and trading volume of our business of our company\u2019s Company\u2019s charter stockholders of capital stockholders of shares of capital stock of shares of shares of capital stock as consideration as consideration.The market price and trading volume and trading volume of shares of shares of shares of our business operations and trading volume and trading price and trading volume and trading volume and volume of shares of shares of our Class A: The document also may be affected companies with which may be\n"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is one primary responsibility of PLS in the loan servicing agreement?",
        "options": {
            "A": "Issuing new loans to investors",
            "B": "Collecting principal, interest, and escrow payments",
            "C": "Providing insurance for loan defaults",
            "D": "Publishing annual financial reports",
            "E": "Managing client investments in stock markets",
            "F": "Developing real estate properties"
        },
        "LLM_original_answer": [
            "One of the Company has evaluated the Company has been evaluated the Company has evaluated the Company has evaluated the Company has been and the Company has been a-issued under the Company has been acquired assets and/or participation certificates of the Company has been evaluated in the Company has evaluated in the negative and negative aspects of the Company has been acquired loans and related to non-recieved the Company has evaluated in the Company has evaluated the Company has been.F-10\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is the role of DME Advisors in relation to SILP?",
        "options": {
            "A": "Manage risk management and operational needs",
            "B": "Serve as SILP's custodian",
            "C": "Select and manage appropriate investments",
            "D": "Ensure SILP is widely diversified",
            "E": "Handle collateral purposes for SILP",
            "F": "Contribute funds to Greenlight Re and GRIL"
        },
        "LLM_original_answer": [
            "Based on February 161Cay. Mr. Mr. Mr. Mr. Mr. Mr. Mr. Mr. Mr. under Cay\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What can materially and adversely affect the operations due to issues with satellites?",
        "options": {
            "A": "High employee turnover in satellite companies",
            "B": "Changes in customer preferences",
            "C": "Construction and launch delays for satellites",
            "D": "Increased competition from other industries",
            "E": "Innovations in unrelated technology sectors",
            "F": "A surge in global satellite demand"
        },
        "LLM_original_answer": [
            "Based on the documentations as of December 2023.Domesticated as of December 2024"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?",
        "options": {
            "A": "Increase in core data",
            "B": "Rise in traditional voice communication",
            "C": "Completion of certain fiber transactions in 2022",
            "D": "Increase in international traffic",
            "E": "Growth in network connectivity",
            "F": "Higher volume of wireless devices sold"
        },
        "LLM_original_answer": [
            "The settlement of certain costs regarding certain Business Transformation Costs During 0. During 2023.2023 Transformation CostsDuring 2023\n2023.Operating Matters Regarding certain Other CostsDuring 2023 regarding certain administrative fees regarding certain transformation costs related to 2020During 2024During 2023During 3During 0During 2023. During 2023. Business Transformation Costs of certain litigation costs during 202 3 regarding certain administrative fees.Business Transformation CostsDuring 2020. During 2024.2024During 2023"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?",
        "options": {
            "A": "Broadcast radio communications",
            "B": "Television broadcasting",
            "C": "Respond to text, video and data",
            "D": "Satellite tracking",
            "E": "Weather forecasting",
            "F": "Financial transactions processing"
        },
        "LLM_original_answer": [
            "Based on aforeshare shall be the exercise price shall beacons of all classes of stock, and the exercise price shall beacons of all classes of stock, and voting power of such that of the lesser of all other than the total combined with respect to the total combined with respect to the exercise of all other thanx\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?",
        "options": {
            "A": "Increase in product sales",
            "B": "Improvement in clinical trial outcomes",
            "C": "Negative perception of patient benefits and safety",
            "D": "Guarantee of FDA approval",
            "E": "Reduction in training requirements for ECPs",
            "F": "Expansion of product indications"
        },
        "LLM_original_answer": [
            "A past, our suppliers have generally met our suppliers have generally timely basis, timely basis, our suppliers have generally, our suppliers have generally meet our suppliers have generally have generally meeting our suppliers have generally met our demand requirements on a timely basis, we have generally, we have generally met our suppliers have generally timely basis, we have generally have generally met our suppliers have generally timely basis, we have generally timely past, we have generally met our suppliers have generally meet our suppliers have generally met our suppliers have generally met our suppliers have generally met our suppliers have generally met our suppliers have generally met our demand requirements on a basis, we have generally past, we have generally met our suppliers have generally met our suppliers have generally met our suppliers have generally met our suppliers have generally meet our suppliers\u2019 s\npast, we have generally timely basis requirements, and demand requirements, we have generally timely basis of suppliers have generally met our suppliers have generally met our suppliers have generally met our suppliers\u2019 basis, generally met our suppliers have generally met our suppliers have generally on a timely basis.We have generally met our suppliers have been on a timely basis.We have generally met our demand requirements on a timely basis.We have generally met our suppliers have generally met our demand requirements on a timely basis, our suppliers have generally met our suppliers have generally timely basis, our suppliers have generally accepted basis, we have generally on a few of course requirements on a timely basis requirements on-time requirements on a timely basis, we have generally met our suppliers have generally met our demand requirements, on-time basis, we have generally timely basis of the past urs suppliers have generally met our demand requirements on a timely basis in and generally met our suppliers have generally met our suppliers have generally timely basis, we have generally met our suppliers have generally met our suppliers have generally met our suppliers have generally met our suppliers have generally met our suppliers have generally met our suppliers have generally met our demand requirements on a timely basis, we have generally met our suppliers have generally meeting our suppliers\u2019 timely delivery requirements on a timely basis in the past, past, we have generally meeting our suppliers have generally past, we have generally met our suppliers have generally timely basis of the past, we have generally met our suppliers have generally meeting our suppliers have generally met our suppliers have generally met our suppliers have generally met our demand requirements in the past, our suppliers have generally met our demand requirements on a timely basis we have generally in the past, we have generally timely basis, we have generally met our past, we have generally met our suppliers have generally met our suppliers have generally"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 1.0,
        "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?",
        "options": {
            "A": "Increase in company market value",
            "B": "Unintended promotion of products",
            "C": "Disruption of operations or client operations",
            "D": "Immediate resolution of security measures",
            "E": "Enhanced customer relationships",
            "F": "Unrestricted access to public information"
        },
        "LLM_original_answer": [
            "Based on December 2023Also in the Company\u2019stable 2024Also in the Company\u2019s table 2024Also in the Company.The Company, which are not-forfebruary 2023approximately $$$$$"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "What is one intended use of the proceeds from the Business Combination?",
        "options": {
            "A": "To invest in new technology development",
            "B": "To reduce company debt",
            "C": "To build-up the sales and marketing organization",
            "D": "To acquire competitor companies",
            "E": "To expand into international markets",
            "F": "To increase executive compensation"
        },
        "LLM_original_answer": [
            "Based on the Company\u2019s December 2024Item 2024Item\u2009urrentlyapplied in the Company\u2019s table 2024Item\u2009at the Company may not only, respectively, respectively.These 2023in the Company (\u201cthe Company\u2019survivorously, the Company\u2019s \u201cQTI Imaging Subsequent 6####table 6 or the Company\u2009upon consummattershandeducurrentlyseriously, as of the Company warrant and the Company\u2019s business combination period of the Company warrant or the Company\u2019s current and the Company.The Company\u2019stowards the Company\u2019s current report.The Company\u2019survivorates and the \u201cin the QTI Imaging Subsequent to effecting the Company warrant agreement.##table 3with the Company 6each of the Company warrant).The Company warrant period of the Company warrant.The Company\u2019s of the Company\u2019stowards the Company\u2019s strategic alliances, as of the Company\u2019selectronicity."
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?",
        "options": {
            "A": "50%",
            "B": "60%",
            "C": "65%",
            "D": "70%",
            "E": "75%",
            "F": "80%"
        },
        "LLM_original_answer": [
            "To open new restaurants profitably.We cannot guarantee that we, we, in a profitable restaurants.We cannot guarantee that we, or that we, or that we, and to operate these restaurants, or that we, or that we, or to operate these restaurants profitably.We cannot guarantee that we, and to the restaurants, or that we, or that we, or that we, in, or that are, and to a restaurant openings these restaurants profitably.We, and to operate these restaurants, or that we, that we, will be able to operate these restaurants, or that we, or that we, or that we, in, and to operate these restaurants.We, or to operate these restaurants.We, and to operate these restaurants profitably.We cannot guarantee that we, and to operate these restaurants profitably, or that we, will be opened restaurants profitably, or that we cannot guarantee that we, and to operate these restaurants, or, or to operate these restaurants.We cannot guarantee that we, and to operate these restaurants profitably.We cannot guarantee that we, or that we, and to open new restaurants profitably.We cannot guarantee that we, in a profitably, and to operate these restaurants profitably.We, in a sufficient numbers.We cannot guarantee that we will be open new restaurants, or that we, or our, or that we, or that we, or that we, or that we, or that we, or that we, and to open new restaurants, and to operate these restaurants successfully.We cannot guarantee that we, or that we, and to open new restaurants.We, or, and to operate these restaurants, in aggregate system-wide-open new restaurants, 1 2023 2023 2023 2023  We, in a sufficient to a profitably.We cannot guarantee that is a 2023 2023 202Form 2023  profitably.We, and to open restaurants profitably.We, and we, or that is, or that we, or that we, or that we, or, or to operate these restaurants profitablyably.We cannot guarantee that we cannot guarantee that we, or that we, in the restaurants profitably.We, and operate these restaurants, or that we, if we, that we, and to operate these restaurants, or to operate these restaurants, or that we, respectively, or that we, or to operate these restaurants.We cannot guarantee that we, or that we, and to operate these restaurants.We cannot guarantee that we, or to operate these restaurants profitably.We"
        ],
        "LLM_extracted_answer": [
            "E"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 32000,
        "result": 0.0,
        "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?",
        "options": {
            "A": "Classified Board of Directors with staggered, three-year terms",
            "B": "Issuance of preferred stock to dilute ownership",
            "C": "Exclusive forum in the Court of Chancery of the State of Delaware",
            "D": "Prohibition on cumulative voting in the election of directors",
            "E": "Advance notice procedures for nominating candidates",
            "F": "Limitation of liability and indemnification of directors and officers"
        },
        "LLM_original_answer": [
            "Based on the Company\u2019s entire investment research product portfolio.We believe that are we believe that we have not material weaknesses, including desktops, and/orientralphableInvestmentors, and/or laptops, including desktopselves, and/or financial results of the entire investment research, which could materially adversely affect our entire investment research product portfolio.We have been desktops, and our operating systems, our entire investment research brands, as well as well as a\n_ctxtsufferedits entire investment research portfolio.We continually workstations, as well, as well beyond the same as a\n_ctxtsolicitations, our entire investment research media, our business, with respect to which we believe our entire investment research, our entire investment research portfolio, our entire investment research portfolio across a14Our entire investment research product portfolio.We have been subject to thesolicit our entire investment research, including desktops, which may also apply the entire investment research and/or otherwise.We continually increasing the Company.We have been subject to which may adversely affect our entire investment research.Risks related toplinearbitstreaming our entire investment research product portfolio management\u2019subjects, laptops, which may also have not to which may have been acquired by the company\u2019s entire investment research, and other media, and other media, which could not provided by us a\n_ctxts, and/or any other than we have been subject to our entire investment research, which could adversely affect our entire investment research product portfolio.We have received a12of the ability to which could have also known to which is across a14acrossing across a. 14and laptops, and/or laptops, our entire investment research product portfolio across a14and\n_ctxts."
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is one primary responsibility of PLS in the loan servicing agreement?",
        "options": {
            "A": "Issuing new loans to investors",
            "B": "Collecting principal, interest, and escrow payments",
            "C": "Providing insurance for loan defaults",
            "D": "Publishing annual financial reports",
            "E": "Managing client investments in stock markets",
            "F": "Developing real estate properties"
        },
        "LLM_original_answer": [
            "Based the internal control of these financial statements, as the Company is not aware of the Company\u2019s the Company is not aware of the Company's financial statements, or financial statements, as of any longer of any material changes in the Company's financial statement of these financial statements.The Company is not aware of these financial statements, if the Company is not aware of the Company is not aware of any significant deficiencies in these financial statements.The date of the date of any of any material weakness in the Company is not aware of the date of the Company\u2019s financial statements, as of the Company is not aware of the date of the Company\u2019s financial statements of these financial statements, as the Company is not aware of these financial and / financial statements required by the date of the Company is not aware of the Company\u2019s financial statements, as of the Company is not aware of these financial statements of the internal control of these financial statements, as of the date of any known or other than the date of the date of any material weaknesses in this date of the date of the subject to be\n_ctxt of these financial and is not aware of these financial statements of these financial or related party to be not aware of these financial statements of the Company is not aware of the Company is not aware of these financial statements of the Company's financial statements of any of these financial statements, or any material weakness, as of any material weaknesses or other than the Company\u2019s financial statements of these financial statements, or any of these financial statements of the Company is not aware of the Company is not aware of these financial statement of these financial statements, the Company is not aware of any known to the Company\u2019s financial statements of these financial statements, as of the Company is not aware of the Company is not aware of these financial statements of the Company\u2019s financial statements, or any of these financial statements of any of any material weaknesses in the Company is not aware of the Company is not aware of the date of these financial statements, as of these financial statements, as of any material adverse effects of any material weaknesses in these financial statements, as of the date of these financial or are not known to these financial statements.The date of these financial statements.The date of the Company is not aware of these financial statements of the date of these financial statements, as of these financial statements are not aware of these financial statements of the Company\u2019s financial statements of the Company is not aware of the date of these financial statements, or aware of the date of any of the Company-wide risk management of the internal controls of these financial statements of these financial statements.The"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is the role of DME Advisors in relation to SILP?",
        "options": {
            "A": "Manage risk management and operational needs",
            "B": "Serve as SILP's custodian",
            "C": "Select and manage appropriate investments",
            "D": "Ensure SILP is widely diversified",
            "E": "Handle collateral purposes for SILP",
            "F": "Contribute funds to Greenlight Re and GRIL"
        },
        "LLM_original_answer": [
            "The Amended 2018 Equity In determining the Amended and/or the Company\u2019s Equity Line of the Amended and Amended and/or the Amended and Restated 2018. Restated and Restated 2018.Fair the Amended 2018.Non-Fin the Amended 2018 Equity Incented 2018 Equity Plan, the Amended and the Company\u2019s Consolidated 2018.Fin Amended and Restated 2018 Equity Incenties, (i.either the Amended and Restated 2018 Equity Incented 2018 Equity Incented 2018 Equity Incent 2018 Equity Plan, the 2018 Equity Plan, the Amended and Restated and Restated 2018 Equity Incented and Restated 2018 Equity Incent 2018 Equity Incentr, (the Amended 2018 Restated 2018 Equity Incentury, the Amended and Restated 2018 Equity Incentated and Restated Amended 2018 Equity Incent 2018 Equity Incented 2018 Equity Plan, the Amended Equity Incent Amended 2018.Findependent and Restated and 2018 Equity Plan, (incented and Restated 2018 Equity Amended Amended 2018 Restated 2018 Restated 2018 Equity Incentated 2018 Equity Incentated and Amended and Restated 2018 Equity Plan, 2018 Equity Incented Equity Plan, (iii) the Amended and Restated 2018 Equity Plan, the Amended and Restated 2018 Equity Plan, Restated 2018.Fair 2023.112Core Scientific 2018 Equity Line of the Company's Consolidated 2023. The Amended 2018.Core Scientifically, the Amended 2023.The Amended 2018. Amended and Amended 2018 Equity Incent 2018. Restated 2018 Equity Incented and Amended Equity Amended Equity Plan, (Amended and Restated 2018. the Amended and Restated 2018 Equity Plan and Restated 2018 Equity Plan, Restated and Restated 2018.COMMIT Amended 2018.Fairated 2018 Equity Plan, Amended 2018.Fair Amended and Restated 2018 Equity Incent Plan, the Amended and Restated 2018 Equity Plan"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What can materially and adversely affect the operations due to issues with satellites?",
        "options": {
            "A": "High employee turnover in satellite companies",
            "B": "Changes in customer preferences",
            "C": "Construction and launch delays for satellites",
            "D": "Increased competition from other industries",
            "E": "Innovations in unrelated technology sectors",
            "F": "A surge in global satellite demand"
        },
        "LLM_original_answer": [
            "The following the following the following the following the following table includes information related to the following table includes information related to the following the following the following the following the following information related to the following the following the following the following the following information related to the following the following the following the following table includes information related to the following table.##table##table##table##table includes information related to the following the following the Company's consolidated balance sheet.##table includes information related to the following the following table includes information related to information related to the following Hurricane Identities##table includes information related to stock-based information related to the Company information related to the following information related to 5.COMMATTERIES and/or##table includes information related to the following information related to $ 204##table 204##table 202##table includes information related to the following table includes information related to the following information related to the following the following the following Duke Energy Efficiency and/or related to the following Duke Energy Efficiency and/or##table 204##table 2021##table includes information related to the following the following the following the following the following the following information related to the following Hurricane and/or other than the following the following table includes information related to the following table includes information related to the following the following the following table includes information related to the following information related to the following the following information related to the following table includes information related to the maximum aggregate information related to the following the following table includes information related to the following information related to the following information related to the following the following information related to stock-based performance awards.##table 2025.Information related to the Price-licensed and/or related to the following information related to the following table includes information related to the following the following table includes information related to the following the following table includes information related to the following table includes information related to the following the following information related to the following table includes information related to the following the following the following table includes information related to the following table includes information related to the following information related to stock-based performance awards.##table includes information related to Duke Energy Efficiency and/or other than the following the following table includes information related to the following the following the following the following a##table includes information related to the following the following table includes information related to stock-based performance awards.##table includes information related to the Duke Energy Efficiency, including information related to the following information related to stock-based performance awards.##table 405##table includes information related to the following the following a##table includes information related to"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?",
        "options": {
            "A": "Increase in core data",
            "B": "Rise in traditional voice communication",
            "C": "Completion of certain fiber transactions in 2022",
            "D": "Increase in international traffic",
            "E": "Growth in network connectivity",
            "F": "Higher volume of wireless devices sold"
        },
        "LLM_original_answer": [
            "The Company\u2019s standards require that we plan and the Company BOCI ize the Company\u2019s effective.The Company AFSAs of the Company\u2019s update 2022.##table 2023The standards require that require that are those product and the Company\u2019s adoption of the Company\u2019s included in the Company did not be reclassify the Company\u2019s the Company\u2019s standards require that amount of the Company\u2019s loans in the Company\u2019s cost basis of the Company\u2019s standards require that is a loan loss reserves for the Companywide of the Company\u2019s as of the Company\u2019s impact the extent to those standards requires that includes those standards.The Company\u2019s those loans and the Company to obtain reasonable assurance that we plan and obtain evidence obtained to obtain and report the loans and perform the Company\u2019s contractual cash flows and plan and/or the PCAOBThose standards require that we plan and perform the Company\u2019st o plan and perform the Company\u2019s effective interest rate of the Company 123The standards of the Company 202 require that we plan and obtain the audit of the extent and obtain the Company.The standards of the Company\u2019s standards of the Company\u2019s standards that we plan and perform the Company\u2019s standards require that are based on or perform the loan and perform the loan and that the Company has not be121required that we plan and uncollected to plan and perform the Company\u2019s accounting for the PCAOBThose standards also require that we plan and that we obtain reasonable assurance that we plan and perform the audit the audit to obtain and that we obtain and that our standards.The PCAOBASU.Suchase and report the audit evidence obtained by obtaining sufficient procedures responsive of the related to obtain the Company\u2019s standards require that we plan and to obtain and reclassified as of the Company\u2019s the Company\u2019s requirements of the Company\u2019s effective date of the Company\u2019s standards require that we plan and that we plan and/or 128as of the loan portfolio of the Company\u2019s the Company\u2019s effective loan syndicated and other than the Company\u2019s loans and other comprehensive income tax loss and the Company 127 require that we plan and obtain and evaluate and obtain evidence obtain and obtain and reportablevPlan and document in accordance with the loan the audit evidence obtained and include the related to obtain evidence obtained and the Company\u2019s standards require that are included in our audit in accordance with respect the obtain reasonable assurance that includes that we evaluate the Company\u2019s requirements that those loan loss and perform the Company 2021 plan and that those loans and any issuer our reports.The audit to evaluate the Company\u2019st plan and perform the audit"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?",
        "options": {
            "A": "Broadcast radio communications",
            "B": "Television broadcasting",
            "C": "Respond to text, video and data",
            "D": "Satellite tracking",
            "E": "Weather forecasting",
            "F": "Financial transactions processing"
        },
        "LLM_original_answer": [
            "Theophen- or, either directly, either directly observable, either market- and, for which all significant inputs, either directly observable, which all significant inputs are based on- and, respectively, or, either directly observable, either directly or for which all significant inputs, either all significant inputs, for which all significant inputs are either directly observable, and/or market-based approaches for which all significant inputs, either directly observable, either directly observable, either directly observable, either directly observable, either directly or, or following the Company-wide, or in- and/or pursuant topline-significant risk-Item ulti\u00ad\u00adally all significant inputs, or other than toplinekaytopology-based approaches, for which, orphans are not applicable for which all significant inputs are either directly observable, either directly based on which all significant inputs, for which all significant inputs, either directly observable, or, either directly observable, or for which all significant inputs are directly observable, either directly observable, either directly observable, orphanspecifically, for which all significant inputs are either all significant inputs are based on- and/or market-based, for which all significant inputs are either directly or market-based approaches that all significant inputs, for which all significant inputs, for which all significant inputs are approved by which all significant inputs are all significant inputs, either directly or, either market-based approaches, or for which all- and/or market-based approaches, either directly or for which all significant inputs are directly or derived from which all significant inputs, for which all significant inputs are based on which all significant inputs for which all significant inputs for which all significant inputs, or other significant inputs, or under which all significant inputs that, orphans, either in- and/or any significant inputs for which all significant- and/oraccompany information- and/orbasiations of our business- and/or any significant inputs for which all significant inputs, for which all significant inputs that all significant inputs, or solid tumorsarrestoration of which all significant inputs that may- and/orMore than for which all material-based approaches for which all significant inputs are all significant inputs, or under the first- and/or for which all material-approachesivable- and for which all significant inputs are, or for which all significant inputs are reasonably based on-going-forward- and/or developmentallyespecifically, orphansusable to datesthepatents, or our business and/orMarket Overview of which all-licensed all significant inputs are observable, for which all significant inputs are observable, either directly or derived"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?",
        "options": {
            "A": "Increase in product sales",
            "B": "Improvement in clinical trial outcomes",
            "C": "Negative perception of patient benefits and safety",
            "D": "Guarantee of FDA approval",
            "E": "Reduction in training requirements for ECPs",
            "F": "Expansion of product indications"
        },
        "LLM_original_answer": [
            "What is for convenience by convenience by October 30. For the not for convenience by October 2023 of the agreements (for example for example for convenience by October 3. The right to facilitate by October 2023. All or some of the agreements (for convenience by convenience by October 2023. See note 2023. The Right to the agreements (for convenience by October 1, for October 1. by October 1stated by October 2023. All or some of the agreements (for convenience by October 2023. for convenience by October 1. The right to the right to convenience by October 1 by October 2023 for convenience by October 2023 for convenience by October 2023) and/or some of the right for convenience by October 2023 for convenience by October 2023 for convenience by convenience by convenience by October 2023 for convenience by October 2023. For convenience by October 1 by October 1, for convenience by October 30 of the agreements (for convenience by October 1 1 by October 1) by October 2023. For convenience by October 2023 for convenience by October 2023) and October 2023. The table 2023. All or some of the agreements (for convenience by convenience of the financial assets (for convenience by October 2023. The table 2023.##table 1. The following the agreements (for convenience by October 2023. See note receivable financial liabilities by October 2023. by convenience by convenience by October 1, for convenience by convenience by convenience by October 30 by October 30.For convenience by October 2023. The right to the convenience by October 1. The right to the agreements (for convenience by October 2023) (for convenience by October 3. for convenience by October 3a-October 2023. 2023A-October 2023. For convenience by October 2023. For convenience by October 2023-October 30 30 days by October 2023 for convenience by October 1 of the not for convenience by October 15. for convenience by October 1) by October 1, for convenience by October 2023. For convenience by October 100%table 2023. For convenience by October 2023. The right to the convenience by October 2023. The table all or some of the agreements (for convenience by convenience by"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?",
        "options": {
            "A": "Increase in company market value",
            "B": "Unintended promotion of products",
            "C": "Disruption of operations or client operations",
            "D": "Immediate resolution of security measures",
            "E": "Enhanced customer relationships",
            "F": "Unrestricted access to public information"
        },
        "LLM_original_answer": [
            "What is our research and/or our ability to the foregoing generally accepted accounting principles, that our receipts and our patents and that our patents that our receipts and that our receipts and that our receipts and our receipts and our and our receipts and willfully licensed from timeframes our receipts and that our receipts and that our receipts and that our receipts and our receipts and that our receipts and that our business and that our patents, or in accordance with respect to the rights.We may be held by third parties, and/or expenditures and that our receipts and our receipts and our receipts and our receipts and that our receipts and our product candidates are in connection with respect to our sales and our receipts and that our operating results and our are not only if necessary to the generally accepted accounting principles, and our product candidates are not only limited or potential or in our research and our research and our patents or our research and our research and our product candidates, or our business and our business and/or our patents or potential consequences of our employees and/or our employees and that our receipts and that our patents, and that our rights and/or our patents or that our patents that our receipts and that our patents that our patents and that our research and that our productively accounting principles, and that our receipts and our receipts and will not only our intellectual property rights and that our receipts and that our patents, which could materially adversely affect our receipts and that our receipts and that our patents or our research and that our rights or our receipts and that our product candidates, or that our product candidates, and our and that our receipts and our business, and that our business opportunities and our product candidates and our rights and that our product candidates, or our patents, our product candidates are receipts and the claims of our receipts and our product candidates, and our business and our business relationships, and our product candidates for our product candidates for our product candidates, our rights, or in accordance with respect to our product candidates in accordance with respect to the rights.We are that our receipts and our receipts and will be our receipts and that our research collaborations with respect to the risks and that our intellectual property.Certainly, or that our patents and that our patents that our patents, and our receipts and our receipts and that our receipts and that our intellectual property rights and that our patents and that our receipts and our patents and that our and our patents and that our product candidates in accordance with respectivestat least likely to the rights and that our receipts and that our receipts and that our assets and that our intellectual property rights and/or our product candidates"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "What is one intended use of the proceeds from the Business Combination?",
        "options": {
            "A": "To invest in new technology development",
            "B": "To reduce company debt",
            "C": "To build-up the sales and marketing organization",
            "D": "To acquire competitor companies",
            "E": "To expand into international markets",
            "F": "To increase executive compensation"
        },
        "LLM_original_answer": [
            "What defendants for alleged violations of the defendants for alleged violations of defendants for alleged defendants for alleged violations of alleged violations of the U.Secertor for any future defendants\u2019 s. The outcome of any such that may be all defendants for alleged to the ability to the defendants for alleged violations of defendants for alleged violations of the defendants for alleged violations of any of any of any of the defendants for alleged violations of our research and may be all defendants for our proprietary rights or our licensors\u2019 defendants may be all defendants for any other than any other than can be able to the FDA regulations on which may be all or otherwise known as necessary business development of our business defendants for any other proprietary rights on which may be successful or at least governmental actions by the FDA and/or the defendants may be assuredly or the subject to the FDA, which may befit for the FDA or at any other intellectual property for alleged violations of the U.Similarities a claim for alleged violations of defendants for alleged violations of defendants for alleged violations of the defendants for alleged violations of the defendants for alleged violations of Section 10(b) of the misappropriations of work product candidates for alleged violations of defendants for alleged violations of Section 10(b) of the U.Such defendants for alleged violations of Section 10(b) or will have a claim for alleged violations of alleged violations of Section 10(b) for alleged violations of the defendants for alleged violations of Section 10(b) and/or unregistered for alleged violations of Section 103 of the U.Secert or defendants for alleged violations of the defendants for any of the U.Secentertain defendants for alleged violations of the defendants for alleged violations of any defendants for alleged violations of the defendants for alleged violations of alleged violations of the Securities and/or alleged violations of the Exchange 10(b) of the Securities 10(b) for alleged violations of Section 10(b) for alleged violations of alleged violations of Section 10(b) of the Securities Act(a) and/or similar to 105claim against all defendants for alleged violations of the defendants for alleged in the defendants for alleged violations of Section 10(b) or other than all defendants for alleged violations of the U.Such violations of such as a claim against the defendants\u2019 s\nPlease continue to the FDA, which could have a100 defendants for alleged violations of any future developments of any other defendants for alleged violations of defendants for alleged violations of Section 10(b) for alleged violations of defendants for alleged violations of alleged violations of the defendants for alleged violations of the Securities and/or the defendants"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 1.0,
        "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?",
        "options": {
            "A": "50%",
            "B": "60%",
            "C": "65%",
            "D": "70%",
            "E": "75%",
            "F": "80%"
        },
        "LLM_original_answer": [
            "As of income below operating income by segments. Therefore, and statements of income below operating income below operating income below operating income below operating income below operating income by operating income by operating income below operating income below operating income below operating income below operating income by operating income by segments; therefore operating income by operating income below operating income below operating income below operating income below operating income below operating income by segments; therefore, and statements of operating income below operating income below operating income by operating income by segments; therefore, therefore operating income by segments; therefore operating income below operating income below operating income below operating income by segments; therefore, by segments; therefore, for operating income below operating income by segments; therefore, statements of operating income below operating income below operating income below operating income by segments; therefore, therefore; therefore of income below operating income by operating income below operating income by segments; therefore, therefore, therefore, therefore, therefore, therefore review operating income below operating income or review total assets; therefore, but operating income by segments; therefore, therefore, and income by operating income by segments; therefore review of operating income below operating income by operating income by segments. Therefore, and operating income by operating income by segments; therefore, respectively; therefore, therefore, below operating income below operating income by segments; therefore, or statements of income by segments; therefore, therefore, income by operating income by segments; therefore not review operating income by segments; therefore operating income by segments; therefore, therefore, statements of income by segments. Therefore, and statements of operating income by segments; therefore operating income by operating income below operating income by segments; therefore, therefore, respectively; therefore operating income by segments; therefore operating income by segments; therefore, respectively, and statements of income below operating income below operating income below operating income below operating income below operating income below operating income below operating income below operating income below operating income by segments; therefore operating income by segments; therefore, therefore, therefore, respectively; therefore operating income by segments. Operating Income by operating income below operating income by segments; therefore operating income by segments. Therefore, and therefore, and operating income by operating income by operating income by operating income by operating income below operating income by segments; therefore, therefore operating income below operating income by segments; therefore, therefore operating income by segments; therefore, therefore, therefore, therefore does not-forfees of income below operating income below operating income below operating income below operating income below operating income below operating income by segments; therefore below operating income below operating income below operating income below operating income by segments;"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 64000,
        "result": 0.0,
        "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?",
        "options": {
            "A": "Classified Board of Directors with staggered, three-year terms",
            "B": "Issuance of preferred stock to dilute ownership",
            "C": "Exclusive forum in the Court of Chancery of the State of Delaware",
            "D": "Prohibition on cumulative voting in the election of directors",
            "E": "Advance notice procedures for nominating candidates",
            "F": "Limitation of liability and indemnification of directors and officers"
        },
        "LLM_original_answer": [
            "Based on the Company\u2019s our competitive disadvantageous disadvantageous could put us at the Company\u2019s the first, which could put at the next year over a prior to the amount at the Company\u2019s fair value of the amount at the amounts on a re-performing at the same.We have a re-performing at the same.The Company\u2019s competitive losses, which at the Company\u2019s are at the Company\u2019s could put us at the longer-term resources than we have a re-performing at the same could put us at the par value.We also could put us at the Company\u2019s uncollective at the aggregate of the difference between the amortized credit loss expense and is as described above the Company\u2019s initial loan-level credit loss-related disadvantageous at-risk management resources are, which we have been at our personnel resources disadvantageous we docket us at the Company at the following year at contract loss, which we at the Company at the next year we are included in the same we do, which could put us at a competitive disadvantageous disadvantageously, which we use of credit spreadsheets do, which we use, which could put us at the Company\u2019s credit losses at our ceded at the next time we have a year-endurance at a credit risk of $ 90Brighthouse Financial Liabilities at risk-based on a credit losses for the difference between the Company\u2019s mortgage loans and/or the Company\u2019s mortgage loan-level loan balance sheet-level credit loss of the present value of our fair value of the greater than we use at a competitive risk-based on a credit and personnel resources than we do a competitive disadvantage.151Brighthouse at a prior to the amounts that amount of credit loss, which we have at December 90Brighthouse disadvantageously disadvantageous uncollective at our credit loss given the related to the Company\u2019s credit loss amounts are we have an impairment losses, which could put us at risk-based on a disadvantage, which could put us at December 90Brighthouse disadvantage than we docket at a credit losses, which we have a credit loss and subsequent impairment, which we have an amount of the Company has been at the aggregate the credit loss experience-related credit loss expense and any subsequent periods of the Company\u2019s net investment and could put us at the Company\u2019s we do notional resources and resources than we have a prior to a loss.____________(2.We also could put us at a reasonable and could put us have, which could put us at the amount of the same period premium and mortgage loan-level credit loss amounts are included in the Company has a reconciliation of the"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is one primary responsibility of PLS in the loan servicing agreement?",
        "options": {
            "A": "Issuing new loans to investors",
            "B": "Collecting principal, interest, and escrow payments",
            "C": "Providing insurance for loan defaults",
            "D": "Publishing annual financial reports",
            "E": "Managing client investments in stock markets",
            "F": "Developing real estate properties"
        },
        "LLM_original_answer": [
            "One of our business activities of our products or, in some cases, in international markets or, in international markets, in international markets, in internationalization of our products in international markets or, in some cases or, in some cases, in some cases, if any of our products in some cases, in some cases, in some cases, if any of our business operations or, in some cases, in some cases, in some of the introduction of the introduction of international markets for which may, if we may, in some cases, in which may, if any of the introduction of international markets, in international introduction of our products, in which may, in some cases, prevent the introduction of our international markets, if any, or, if any of our business or, in international introduction of our products in international markets or, or, if the introduction of the introduction of the introduction of our business operations of the introduction of our products, in international markets, which, in some cases, prevent the introduction of the introduction of the introduction of the introduction of our products, in international introduction of our products in some cases, in international introduction of the introduction of the introduction of the introduction of our products, in the introduction of our products or, in-license or, in some cases, in international markets, in- or, some cases or, in international markets, prevent the introduction of the introduction of our products, in some cases, in international markets or, in some cases, in some cases, if the introduction of our products in some cases, in some cases, in some cases, in some cases, in some cases, in some of the introduction of our products, in some cases, in some cases, in international introduction of our products in international markets, in some cases, in international introduction of our products in international markets, in some cases, in the introduction of our products in international markets or, in international markets or, in international markets or, in some cases, in the introduction of our products or, in some cases, in-63or, in some cases, in some cases or, or, in some of the introduction of the introduction of our products in international markets or, in some cases, in some cases, in some cases, in some of our products in international markets, in international markets, in some cases, in the introduction of international introduction of our products, in international markets or, in some cases, in some cases, in some cases, in some cases, in some cases, in some cases, in some cases, in"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "What is the role of DME Advisors in relation to SILP?",
        "options": {
            "A": "Manage risk management and operational needs",
            "B": "Serve as SILP's custodian",
            "C": "Select and manage appropriate investments",
            "D": "Ensure SILP is widely diversified",
            "E": "Handle collateral purposes for SILP",
            "F": "Contribute funds to Greenlight Re and GRIL"
        },
        "LLM_original_answer": [
            "D 202s as a non-cashistor incentive for incentive for incentive compensation to the incentive for long-term incentive for long-term incentive compensation to our incentive compensation to long-term incentive compensation for long-term incentive compensation to our executive incentive compensation to our incentive for long-term incentive compensation to our long-term incentive compensation to our executive incentive compensation to our incentive for long-term incentive compensation to long-term incentive compensation to our incentive for long-term incentive for long-term incentive compensation to our long-term incentive compensation to long-term incentive for long-term incentive compensation to long-term incentive compensation to our long-term incentive compensation to our long-term incentive for long-term incentive for long-term incentive for incentive for long-term incentive compensation to our long-term incentive for incentive for incentive for incentive compensation to our long-term incentive compensation to our long-term incentive compensation to incentive for long-term incentive compensation to our incentive for long-term incentive for long-term incentive compensation to our long-term incentive for long-term incentive for long-term incentive for long-term incentive for long-term incentive compensation to the incentive for long-term incentive compensation to our executive compensation to our long-term incentive for long-term incentive compensation for long-term incentive compensation to our executive compensation to our long-term incentive compensation to our incentive for long-term incentive compensation to our incentive compensation to our executive incentive compensation to our executive incentive for long-term incentive for long-term incentive for long-term incentive compensation to our long-term incentive for long-term incentive for long-term incentive compensation to our long-term incentive compensation to our long-term incentive for long-term incentive for long-term incentive compensation to our RSUs as an incentive for long-term incentive compensation to long-term incentive compensation to our executive compensation to our executive incentive compensation to our RSUs to our long-term incentive for long-term incentive for long-term incentive compensation to our long-term incentive compensation to our incentive for long-term incentive for long-term incentive compensation to the long-term compensation to our long-term incentive compensation to long-term incentive compensation to our incentive for long-term incentive compensation to long-term incentive compensation to our long-term incentive compensation to our executive compensation to long-term incentive compensation to our incentive compensation to our long-term incentive compensation to our RSUs as an incentive compensation to RSUs as a long-term incentive for long-term incentive compensation to our executive incentive compensation to our incentive for incentive for incentive compensation for long-term incentive compensation to our long-term incentive compensation to our long-term incentive compensation to incentivize long-term incentive compensation to our long-term as a long-term incentive for long-term incentive compensation to our executive compensation to incentivive incentive for long-term incentive compensation to our long-term"
        ],
        "LLM_extracted_answer": [
            "D"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What can materially and adversely affect the operations due to issues with satellites?",
        "options": {
            "A": "High employee turnover in satellite companies",
            "B": "Changes in customer preferences",
            "C": "Construction and launch delays for satellites",
            "D": "Increased competition from other industries",
            "E": "Innovations in unrelated technology sectors",
            "F": "A surge in global satellite demand"
        },
        "LLM_original_answer": [
            "The critical tax equity retirement of the impacts are included in the Duke Energy submitted to the Duke Energy submitted in rate regulation are included in rate base are included in the submitted the submitted in the tax rate regulation of Duke Energy submitted tax equity and submitted in accordance with portions are included in the Duke Energy submitted in rate base base base base. Duke Energy submitted the submitted portions are included in the Registrants are included in rate regulation (mPortions are included inclusions are included in connection to the Duke Energy submitted in accordance with respect to the Duke Energy submitted the Duke Energy submitted to be included in rate regulation of the Duke Energy Portions are included in the Duke Energy Portions.Portions are included in rate regulation (matters are included in the impacts are included in the Duke Energy submitted in rate base case 2023##table 2024##table 2024##table\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?",
        "options": {
            "A": "Increase in core data",
            "B": "Rise in traditional voice communication",
            "C": "Completion of certain fiber transactions in 2022",
            "D": "Increase in international traffic",
            "E": "Growth in network connectivity",
            "F": "Higher volume of wireless devices sold"
        },
        "LLM_original_answer": [
            "The following timely detection of the following timely detection of the timely detection of total detection of the prevention or timely detection of the following timely detection of the timely detection of the timely detection of timely detection of total acquisition, or timely detection of $0 or timely detection of the following acquisition, prevention or timely detection of prevention or timely detection of timely detection or timely detection or disposition of the acquisition, use or disposition of the disposition of acquisition, timely detection of timely detection of timely detection of timely detection of the acquisition, use or disposition of the Bank\u2019s timely detection of timely detection of timely detection of the acquisition, respectively, use or disposition of the timely detection of timely detection of prevention or use or other than timely detection of timely detection of prevention or timely detection of consumer, prevention of prevention or detection of prevention or detection of prevention of timely detection of acquisition, use or timely detection or disposition of the Company\u2019s disposition of the use or timely detection of prevention or use or timely detection of which are as of the timely detection of timely detection of prevention or disposition, use or that prevention of prevention or timely detection or fraudulent acquisition, or detection of the use or disposition of the use by prevention or disposition of the Company\u2019s or timely detection of the of acquisition, or disposition of prevention or timely detection of the acquisition, or disposition of the Company\u2019s timely detection of the following timely detection or timely detection of the timely detection of acquisition, use of assets or disposition of the prevention or disposition of the Company\u2019s timely detection of timely detection of timely detection or timely detection or timely detection of cash, and timely detection of the disposition of acquisition, use of disposition of the following or use of $ 2023\nor timely detection of timely detection of timely detection of the timely detection of timely detection of the timely detection of timely detection of prevention or timely detection or disposition or timely detection of the Company\u2019s timely detection of timely detection of unauthorized acquisition, use or timely detection of prevention of timely detection of prevention of prevention of the use of prevention of unauthorized acquisition, or use or otherwise timely detection or timely detection of the or timely detection of the foregoing timely detection of prevention or timely detection or timely detection of timely detection of unauthorized acquisition, unauthorized acquisition, use, or timely detection of prevention of timely detection or disposition or use or disposition of authorized acquisition, use or timely detection of the later detection of the Company\u2019s timely detection of the later discussed within this document prevention or other than timely detection of the later detection of the timely detection of timely detection of residential or timely detection of the timely detection of timely detection of"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?",
        "options": {
            "A": "Broadcast radio communications",
            "B": "Television broadcasting",
            "C": "Respond to text, video and data",
            "D": "Satellite tracking",
            "E": "Weather forecasting",
            "F": "Financial transactions processing"
        },
        "LLM_original_answer": [
            "The following our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations or changes in which may be\n,rplications of stock, or changes in which may be\n_ctxt\n_ctxt\n_ctxt\n_ctxt\n_ctxt_answer analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analysts may have a\n_ctxt_answer regarding our stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market stock market analyst recommendations or other stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our common stock market analyst recommendations regarding our"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?",
        "options": {
            "A": "Increase in product sales",
            "B": "Improvement in clinical trial outcomes",
            "C": "Negative perception of patient benefits and safety",
            "D": "Guarantee of FDA approval",
            "E": "Reduction in training requirements for ECPs",
            "F": "Expansion of product indications"
        },
        "LLM_original_answer": [
            "What is not accruing for loss cannot be made cannot be made, we do not accrued for loss cannot accrual reasonable estimate of loss cannot accrue for loss, we do not accruing accrual for loss, but do not accrued loss, we do not accrualsufficient estimate of loss, we do not accrue, we do not accrued loss, or a reasonable estimate of loss cannot accrual cannot be made, we do not accrue, we do not accrue for loss, but do not accrued loss cannot be made, or estimate of loss, we do not accrue, but do not accrued loss, but we do not accrued loss, we do not accrued for loss cannot accrual for loss cannot be[for loss cannot be paid for loss cannot becertain for loss, we do not accrued for loss estimate of loss cannot accrue do not accrue not accruals loss, we do not accruing accrue for loss, we do not accrued, we do not accrual for loss estimate of loss, or reasonably estimate of course for loss, disclose of loss. If a reasonable estimate of loss cannot be made, we do not accrual cannot accrual cannot be made, we do not accrued, we do not accrue, but accrual estimate of loss, we do not accrue for loss, but do not accrued for sale of loss, or accrualsells not accrual for which we do not accruing for loss, net servicing related to which a reasonable estimate of loss, or a reasonable estimate of loss cannot accrual reasonable estimate of loss, or accrue do not accrue for loss, we do not accrual for loss, or loss cannot accrualsponsored for loss, or other than accrual for loss, we do not accruing for loss, or do not accrued for loss on a reasonable estimate of loss cannot be a reasonable estimate of loss cannot be accrued for the best estimate of loss cannot accrualserved for which is not accrued for loss, we do not accrual reasonable estimate of loss cannot be made, we do not accrue for loss, we do not accrued loss cannot be made, but reasonable estimate of loss cannot be made, we not accrue for loss, but do not accrue we do not accrued loss, but do not accrued loss estimate of loss cannot be accrued loss estimate of loss, we do not accruing accrue for loss, but do not accrued, we do not accrue for loss, or accrualsellers do not accrue for loss"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?",
        "options": {
            "A": "Increase in company market value",
            "B": "Unintended promotion of products",
            "C": "Disruption of operations or client operations",
            "D": "Immediate resolution of security measures",
            "E": "Enhanced customer relationships",
            "F": "Unrestricted access to public information"
        },
        "LLM_original_answer": [
            "What product candidates or the product candidates will be able to the therapeutic products on the product candidates that product candidates that are effective or diseasespecific characteristics of the product candidates will be entitled to the product candidates wean invention-specifically licensed T cell therapy of the product candidates will be entitled to a patent on the invention regardless of the product candidates for the product had been developed on the product candidates will be\u00adt ertaining the product candidates had been developed by the invention will be limited to be entitled to the invention, the product candidates in vitro\na patient the product candidates in the product candidates may be approved by the product candidates will be able to the product candidates on the product candidates on the product candidates in the product candidates with respect to which are recognized as well enough to a\n\u00f6munity on the invention, if another inventor had been developed the product candidates will be approved for the product candidates we expectantagoncertain clinical trial therapy may be may be entitled to a product candidates may be able to the product candidates that we expect to the product candidates may be licensed to the TCR-TCR-69patentitlement of the product candidates will be entitled to a product candidates will becertain indications of the product candidates for a product candidates will be able to the product candidates.TCRB.Clinen inventor had been recognized as a\n\u2022the invention, if the invention, for a product candidates will be entitled to the product.Certain other inventorsimilar to a patent on the invention, which may have been developed by whom the product candidates in vivo\n.\nClinical trials or related to which may have been inventor had been working the invention, or the invention, for the product candidates may have been entitled to a product candidates may be\u00adrelated to the invention or simultaneously or to the invention regardless of the invention regardless of the invention will be entitled to a patent on the invention.The FDA or had been the invention had a clinical development of the invention.TCRNA, for the invention.The COVID-identified the product candidates will be entitled to a product candidates that we may be-whether the clinical trial the invention regardless of the invention regardless of the invention generally will be entitled to which had been developed the invention had already had previously had been developed a clinical trial had been entitled to a clinical trials on the product candidates for a patent on the invention regardless of the invention or whether another inventor had previously had been developed from the invention, among other inventorsuch as well as well established by the product candidates may be entitled to a clinical trial candidates will be able to which will be entitled"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "What is one intended use of the proceeds from the Business Combination?",
        "options": {
            "A": "To invest in new technology development",
            "B": "To reduce company debt",
            "C": "To build-up the sales and marketing organization",
            "D": "To acquire competitor companies",
            "E": "To expand into international markets",
            "F": "To increase executive compensation"
        },
        "LLM_original_answer": [
            "Based on August 2017 and as incurred, as incurred, as incurred.Royalty Payments\u2014Between August 2016 and the February 2023\u2014Between August 2016\u2014Between August 1\u2014Between August ellenies.Royalty Payments\u2014In August 1.2020.2016\u2014Between August 2023\nRoyalty Payments\u2014In February 21, as between August 3402016 and February 2017 2017\u2014February 2016\u2014Between August 2016\u2014Between August 2016 and 6 and as incurred, as incurred, as of August 2016\n2016\u2014Between August 2016\u2014Between August 2018. Royalty Payments\u2014Between August 1\u2014In August 2016\u2014As Incurred and Royalty and February 2016\u2014Between August 2016 and/or February 2016. and February 2016. Royalty payments, as incurred.Royalty payments, as incurred, as incurred, as 2016 2016, as February 2016\u2014As incurred.Royalty and February 340BET Royalty Payments\u2014Between August 2016 and February 2016 and February 2018\u2014Between August 2016\u2014Between August 2016 and February 2017.2016 and our royalty payments, as incurred, as incurred and February 2016 and February 2017\u2014As of our royalty payments\u2014Between August 2016 and February 2016 August 1 August 2016 and/or as incurred, as incurred.Royalty payments, as incurred.The August 2016 and February 2017. Royalty Payments\u2014Between August 2019. R&D, as incurred, as incurred, as incurred, as incurred, as incurred, as incurred.Royalties, as, as incurred, as incurred, as incurred, as, as, as, as incurred, as incurred, as and February 2016 and February 2019.EMD\u2014As incurred, As incurred\u2014Between August 1\u2014Between August 2016\u2014As of our February 2016\u2014Between August 2016 and February 2016 and February 2016\u2014Between August 2016 and February 2018 2016. Royalty Payments\u2014Between August 2016 and February 6 August 2017 and/or\u2014between August 1\u2014As of our royalty payments between royalty payments, as incurred\u2014Between August 2018, as incurred, as"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 1.0,
        "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?",
        "options": {
            "A": "50%",
            "B": "60%",
            "C": "65%",
            "D": "70%",
            "E": "75%",
            "F": "80%"
        },
        "LLM_original_answer": [
            "As of our aging based on a disaggregated based on a disaggregated based on a disaggregated based on a\n_CHIP 2023TABLE SOLUTIONSPECIAL ANSWING ITEM 52TABLE 2024TABLE SOLUTIONS&PART, disaggregated based on an aging method, disaggregated based on a disaggregated based on a method, disaggregated based on a49ITEM 45TABLE 46TABLE 100percentages for doubtful accounts disaggregated based on an aging method, disaggregated based on a disaggregated based on a disaggregated based on a method, disaggregated based on a disaggregated based on a\n:eqregaggregated based on a disaggregated based on a disaggregated based on a\n\u30fb\u30fb\u30fb\n\n_ctxt\n"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 96000,
        "result": 0.0,
        "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?",
        "options": {
            "A": "Classified Board of Directors with staggered, three-year terms",
            "B": "Issuance of preferred stock to dilute ownership",
            "C": "Exclusive forum in the Court of Chancery of the State of Delaware",
            "D": "Prohibition on cumulative voting in the election of directors",
            "E": "Advance notice procedures for nominating candidates",
            "F": "Limitation of liability and indemnification of directors and officers"
        },
        "LLM_original_answer": [
            "Question: ##table 159##table 2020. Commission\u2019s website at www.sec.gov.)##table 1.##table 2020.)##table 1)##table 159##table 159##table 2020. (www.sec.gov.)##table 1.)##table.gov.)##table.com.)##table 1. (www.sec.gov.)##table 1.)##table ........................##table  www.sec.gov.)##table 160##table 2020.)##table 1.##table 202.##table 160##table 2023.##table 1. (www.)##table 2020. (www.sec.gov.)##table 202. See www.)##table  www.sec.gov.)##table 202.htm.)##table 159##table 1-Insurance Company website at www.sec.gov.)##table 1)##table.##table 1.##.)##table.sec.gov.)##table ........................##.##table 160####table 160##table 0.)##table 159##table 1.##table 0##table 202##table 1600. Exchange Commission website at www.sec.gov.)##table 160##table  ##table  ##table 202.##)##table 159##)##table.com.)##table 202.##table 159##table 159##table 2020)##table.com.)####table 202##table  ##table 2020.)##)##.)##table 1-0.)##table 160####table 2020. Exchange Commission website at www.sec.gov.)##table 1. [www.sec.gov.)##. (www.sec.gov.)##table 1. .gov.com.)##table.sec.gov.)##table 160##table 202.))##table 1.##)##.)##table ........................##table_www.sec.gov.)##table 1.##.)##table.)##table. ##table 1)## Exchange Commission)##table.sec.gov.)##table 159##table 1##table 1)##table ##table  ##table 2020.)##table 2023.##table 159##table 202. ##table 2020.)##table 202.##table.gov.)##table at www.sec.gov.)##table 160##table 202.##table 1.##table"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is one primary responsibility of PLS in the loan servicing agreement?",
        "options": {
            "A": "Issuing new loans to investors",
            "B": "Collecting principal, interest, and escrow payments",
            "C": "Providing insurance for loan defaults",
            "D": "Publishing annual financial reports",
            "E": "Managing client investments in stock markets",
            "F": "Developing real estate properties"
        },
        "LLM_original_answer": [
            "One product candidates for which may obtain regulatory authorities in the product candidates for which we obtain orphan product community community for which we, which are required post-which we obtain which we obtain which we obtain which we obtain the medical community are granted for which we obtain orphan drug or which we obtain are not for which we obtain a product candidates for which we obtain the product candidates for which we have any product candidates for which we obtain orphan drug and others in which we obtain which we obtain the product candidates for which we obtain which we obtain product candidates for which we obtain regulatory approval is a product candidates for which we obtain community, including the medical community, including the product candidate(such product candidate for which we obtain an NDA obtained product candidate are for which we obtain an NDAvant community for which we obtain a risk evaluation and/or BLA\n"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "B"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is the role of DME Advisors in relation to SILP?",
        "options": {
            "A": "Manage risk management and operational needs",
            "B": "Serve as SILP's custodian",
            "C": "Select and manage appropriate investments",
            "D": "Ensure SILP is widely diversified",
            "E": "Handle collateral purposes for SILP",
            "F": "Contribute funds to Greenlight Re and GRIL"
        },
        "LLM_original_answer": [
            "Dene and/or the Company\u2019s the Company\u2019s Legal Officer\u2019s the Company\u2019s Legal Officer\u2019s Company and/or the Company\u2019s Company\u2019s compensation and/or the Company\u2019s annual Legal Officer while the Company\u2019s compliance with the Company\u2019s compensation continued to the Company\u2019s compensation as the the Company\u2019s Legal Officer\u2019s Legal Officer while DuChen continued to serve as the Company\u2019s Chief Legal Officer while continuing to serve as the Legal Officer while continuing to serve as the Company\u2019s Chief Legal Officer\u2019s Chief Legal Officer while continuing to serve as the Company\u2019s Chief Legal Officer while the Company\u2019s Company\u2019s continued to the Company\u2019s compensation of the Company\u2019s Chief Legal Officer\u2019s the Company\u2019s Chief Legal Officer DuChene continued to serve as the Company\u2019s continued to serve as the Company\u2019s Chief Legal Officer while the Company\u2019s Legal Officer continued to the Company\u2019s the Company\u2019s Chief Legal Officer DuChene continued to serve as the Company\u2019s Chief Legal Officer while the Company\u2019s the Company\u2019s Legal Officer while continuing to serve as the Company\u2019s legal and/or the Company\u2019s legal and the Company\u2019s Company\u2019s compensation continued to the Company\u2019s Chief Legal Officer while the Company\u2019s Chief Legal Officer\u2019s annual compliance with the Company\u2019s annual served as the Company\u2019s Chief Legal Officer while the Company\u2019s Chief Legal Officer\u2019s DuChenChane Chief Legal Officer\u2019s the Company\u2019s DuChene while the Company\u2019s Chief Legal Officer\u2019s Chief Legal Officer while the Company\u2019s continued to serve as the Company\u2019s Chief Legal Officer while continuing to the Company\u2019s Chief Legal Officer while the Company\u2019s Chief Legal and continued to the Company\u2019s compensation DuChenet continued to serve as the Company\u2019s Chief Legal Officer DuChene continued to serve as the Company\u2019s Chief Legal Officer while the Company\u2019s Company\u2019s DuChenChen DuChene\u2019s Chief Legal Officer as the Company\u2019s Chief Legal Officer while continuing to serve as the Company while the Company\u2019s Chief Legal Officer while continuing to the Company\u2019s Chief Legal Officer while the Company\u2019s Company\u2019s Chief Legal Officer while the Company\u2019s DuChene continued to serve as the Company\u2019s Chief Legal Officer while continuing to the Company\u2019s the Company\u2019s Chene\u2019s compensation and the Company\u2019s Chief Legal Officer while continuing to the Company\u2019s Chief Legal Officer while the the Company\u2019s Chief Legal Officer while serving as the Company\u2019s Chief Legal Officer DuChene continued to serve as the Company\u2019s Chief Legal Officer\u2019s Chief Legal Officer\u2019s Chief Legal Officer while the the Company\u2019s the Company\u2019s Legal Officer 33Chene\u2019s DuChChene continued to serve as the Company\u2019s Chief"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What can materially and adversely affect the operations due to issues with satellites?",
        "options": {
            "A": "High employee turnover in satellite companies",
            "B": "Changes in customer preferences",
            "C": "Construction and launch delays for satellites",
            "D": "Increased competition from other industries",
            "E": "Innovations in unrelated technology sectors",
            "F": "A surge in global satellite demand"
        },
        "LLM_original_answer": [
            "What is not otherwise counsel opinions of internal counsel opinions of internal counsel regarding the status of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel regarding the status of internal counsel and opinions of internal counsel regarding the status of internal counsel opinions of internal counsel opinions of internal counsel\u2019s status of internal counsel regarding the status of internal counsel and opinions of internal counsel opinions of internal counsel\u2019s opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal distribution and/or opinions of internal counsel of internal counsel opinions of internal counsel opinions of internal counsel\u2019s internal counsel opinions of Duke Energy Company\u2019s status of internal counsel opinions of internal counsel and related to the status of internal counsel opinions of internal counsel opinions of internal counsel regarding the status of internal counsel regarding the status of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel and inspected opinions of internal counsel opinions of internal counsel\u2019s opinions of internal capital markets of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel of internal counsel regarding the status of internal counsel and opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal capital markets of internal counsel calculations of internal counsel opinions of internal counsel opinions of internal counsel\u2019s opinions of internal counsel opinions of internal counsel opinions of internal counsel\u2019s opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of Duke Energy and opinions of internal counsel\u2019s opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of counsel opinions of internal counsel opinions of counsel opinions of internal counsel opinions of internal counsel opinions of internal capital markets and related to the status of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal counsel\u2019s and inspected opinions of internal counsel opinions of internal counsel\u2019s status of internal capital and related to internal counsel\u2019s status of internal counsel opinions of internal capital markets of internal counsel opinions of internal counsel opinions of internal counsel opinions of internal"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What primarily led to the decrease in Wholesale revenues during 2023 compared to 2022?",
        "options": {
            "A": "Increase in core data",
            "B": "Rise in traditional voice communication",
            "C": "Completion of certain fiber transactions in 2022",
            "D": "Increase in international traffic",
            "E": "Growth in network connectivity",
            "F": "Higher volume of wireless devices sold"
        },
        "LLM_original_answer": [
            "The Company\u2019s financial and/or its Board of Directors, directors, that bearers, among other, by the Board of Directors, to the Company\u2019s Directors, as to the Board of the Board of such as to the Board of which are effected by the Board of the Board of Directors, and audited by the Board of the Company\u2019s Board of Directors, Board of Directors, the Company\u2019s auditors, to have been Board of its management and, as appropriate audit and applicable to establish by the Company\u2019s Board of Directors, management, financial officers, in accordance with the Company\u2019s Board of Directors, to the Company\u2019s principal financial officers and its Board of its Board of directors, Directors, among the Company, management and that is to be directors, among, to the Company\u2019s principal and financial officers of its Board of Directors, including, among the Company, Board, directors, and its employees, Directors, principal and principal financial and/or effected: (a and/or its Board of its audit, among its, as to be and so as to achieve, to have been to be\u00ad \u2013 as to its Board of its Board of such that: Directors, to the Company\u2019s Board of Directors, and its Directors and, and applicable to the Company\u2019s Board of Directors, Directors, as to: (or Directors, among the Company that are to the Company\u2019s Board of its Directors, directors and/or financial officers and, to provide of Directors, that are directors, to the Company personnel, to the Company\u2019s Board of Directors, management and that are or for the Company\u2019s Board of Directors, management and employees to the Company\u2019s Board of the Company\u2019s Board of the Company\u2019s effectiveness of the financial officers and effected by-limited by the Directors, and effected by the principal financial officers of the Board of Directors, as and its Board of which, to the Board of the Company financial officers\u2019 and/or its Board of over which, as required, and effected by the principal financial officers of which, in officers to the principal financial officers of $, Board of which, whereof directors to be their respective auditors and/or its audited by the Board of its Board of Directors, to achieve the Company to the Board of the Company\u2019s audit, and in the Company to: Directors, to achieve, to the Company\u2019s Board of Directors, principal financial officers, to the Company, to the Company\u2019s Board of the Company, to have been directors, to provide, as to the Company, Directors, to achieve its Directors, as to the Board"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What capability does the ESInet offer to 911 call takers at public safety answering points?",
        "options": {
            "A": "Broadcast radio communications",
            "B": "Television broadcasting",
            "C": "Respond to text, video and data",
            "D": "Satellite tracking",
            "E": "Weather forecasting",
            "F": "Financial transactions processing"
        },
        "LLM_original_answer": [
            "What is subject to required third-party intellectual property rights, the required third-party intellectual property rights to be it is not maintain the existing intellectual property rights, in the existing intellectual property rights to required third-party intellectual property rights to be it is not be granted by the existing intellectual property rights, or existing intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights, the required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required intellectual property rights to required third-party intellectual property rights to required third-party rights to be granted exclusivity rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to be granted intellectual property rights to be it is subject to be approved products, the existing intellectual property rights to required third-party intellectual property rights, the existing intellectual property rights to the existing intellectual property intellectual property rights to required third-party intellectual property rights to be granted exclusivity rights, the existing intellectual property rights to required third-party intellectual property rights to the existing marketing authorization, or existing marketing authorization, the required third-party intellectual property rights to be subject to required third-party intellectual property rights to be subject to required third-party intellectual property rights to be approved product or maintain the required third-party intellectual property intellectual property intellectual property rights, the existing intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to be granted medicinal product rights to be approved by the existing intellectual property rights to required third-party intellectual property rights, the existing intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to be subject to required third-party intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required intellectual property rights to required third-party intellectual property rights to required third-party intellectual property rights to required"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What is a potential risk if ECPs use products inconsistently with labeled indications?",
        "options": {
            "A": "Increase in product sales",
            "B": "Improvement in clinical trial outcomes",
            "C": "Negative perception of patient benefits and safety",
            "D": "Guarantee of FDA approval",
            "E": "Reduction in training requirements for ECPs",
            "F": "Expansion of product indications"
        },
        "LLM_original_answer": [
            "What \u201cRegulatory and further below), and/or \u201cdiscussed under \u201cRegulatory Agencies, and other than \u201cRegulatory below), and \u201cRegulatory below, and/or \u201cRegulatory below, and/or \u201cLegal below, and/or \u201cRegulatory below, and/or \u201cdiscussed further below), and \u201cRegulatory, and \u201cRegulatory below, and \u201c), and \u201cLegal and/or \u201cRegulatory below, and \u201cRegulatory, and former borrowers, and \u201cRegulatory below), and discussed below), and \u201cRegulatory\u201d\u201d and \u201cdiscussed further below), and \u201cRegulatory\u201dRegulatory\u201d below, and/or current, current, and/or \u201cRegulatory\u201d and/or \u201cRegulatory\u201d below), and current\u201d below), and other, and other borrowers, and/or \u201cdiscussed further below, and \u201cRegulatory\u201dRegulatory agencies and other below), and \u201cRegulatory\u201d and \u201cRegulatory agencies, and/or \u201cdiscussed further below), and \u201cRegulatory agencies, and former, and other borrowers, and/or \u201cRegulatory agencies, and/or current\u201d and/or former, and/or former borrowers, and/or \u201cRegulatory and \u201cRegulatory below), and \u201cRegulatory agencies and/or former and \u201cRegulatory agencies and \u201cRegulatory below\u201d), and \u201cRegulatory below, former\u201d below), and \u201cRegulatory, and \u201cRegulatory\u201d below, current and/or \u201cRegulatory below), and/or \u201cRegulatory, and former\u201d and \u201cRegulatory\u201d and/or servicers, and/or \u201cRegulatory below, and discussed further below) and/or former, and \u201cRegulatory\u201d and/or \u201cRegulatory and \u201cRegulatory agencies\u201d and \u201c\u201d and/or other, and discussed further below), and/or \u201cRegulatory, and former and/or \u201cRegulatory agencies\u201d below) and \u201cRegulatory, current under \u201cRegulatory\u201dRegulatory below, and/or \u201cRegulatory\u201d and/or \u201c\u201d below), and/or current and other than borrowers, and/or \u201cdiscussed below) and discussed below)\u201d, discussed further under \u201cDiscussed further below, and/or \u201cRegulatory), and \u201cRegulatory\u201d below), and/or current borrowers (discussed below, and/or \u201cRegulatory below, and/or \u201cRegulatory below, and other than we discuss below), and discussed below), and \u201c\u201d below) and \u201cRegulatory\u201d below, and/or \u201cRegulatory below, and/or borrowers, and \u201cRegulators) and/or other than discussed further below, discussed below"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 1.0,
        "question": "What potential consequence could occur if there is a breach or cyber-attack on the computer systems?",
        "options": {
            "A": "Increase in company market value",
            "B": "Unintended promotion of products",
            "C": "Disruption of operations or client operations",
            "D": "Immediate resolution of security measures",
            "E": "Enhanced customer relationships",
            "F": "Unrestricted access to public information"
        },
        "LLM_original_answer": [
            "The U.S. Patients, as well as well as well as well as well as well as well-being U.S. Patients, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well-defined patients, as well as well as well as well-defined U.S. The U.S. Patients, as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well-being communities and foreign and the U.SARS, as well-being patients, as well as well as well as well as well as well as well-being, as well-being, as well as well as well as well as well as well-being and U.S. As well as well as well as well as well as well as well as well-being and global economy, as well-being and communities and communities and business operations, as well as well as well as well as well as well as well as well as well as well as well-being operations, as well-being operations, as well as the U.S. government operations, as well as well as well as well as well as well and U.S. The U.S. As of the U.Safety, as well as well as well as well-being patients, as well as well-being U.S. The U.S. The U.S. U.S. Patients and other patients, as well as well as well as well as well as well as well as well as well as well-being U.S. As of the U.S. economy and other U.S. The U.S. On May 2023S. We have been issued and other than the U.Safety and business operations, as well as well as well as well-being U.S. The U.S. The U.S. The U.S. as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well as well-known patients, as well as well-established U.Safety Scanova, as well as well as well as well as well as well as well as well as well as well as well as well as well-being operations, as well as well as well as well as well as well as well as well as well as well-defined U.Safety Scan Technology and the U.S"
        ],
        "LLM_extracted_answer": [
            "C"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "What is one intended use of the proceeds from the Business Combination?",
        "options": {
            "A": "To invest in new technology development",
            "B": "To reduce company debt",
            "C": "To build-up the sales and marketing organization",
            "D": "To acquire competitor companies",
            "E": "To expand into international markets",
            "F": "To increase executive compensation"
        },
        "LLM_original_answer": [
            "What (ii) cash proceeds resulting from revenue generating from revenue generating for and (ii for and (ii 3 % of cash proceeds resulting from revenue generating from revenue generating for revenue generating for and (ii from revenue generating from revenue generating for from revenue generating for and (i for and (for 3 % of 3 % resulting from revenue generating for and (i 3 % of 3 % of cash proceeds resulting from revenue generating for revenue generating for the (iii) and (ii 3 % of cash proceeds from revenue generating revenue generating for revenue generating for 3 % of 3 % of 3 % of 3 % of 3 % for and (ii) 3 % of cash proceeds resulting from revenue generating for and (i for revenue generating for and (ii) 3 % of cash proceeds resulting from revenue generating for and (ii for and (ii for revenue generating for revenue generating for any revenue generating for and/or (i for and/or (i for and 3 % of 3 % of the cash proceeds resulting from for and/or (i) 3 % of revenue resulting from revenue generating revenue generating cash proceeds resulting from revenue generating cash proceeds resulting from revenue generating for and/or revenue generating for products for example for. The FDA proceeds resulting from revenue generating cash proceeds resulting from revenue generating and the 3 % of the 3 % of the product cash proceeds resulting from revenue generating cash proceeds from cash proceeds resulting from revenue generating from revenue generating cash proceeds resulting from revenue generating from revenue generating cash proceeds resulting from revenue generating from revenue generating for products resulting from revenue generating for and 3 % of the 3 % of cash proceeds resulting from revenue generating for and revenue generating for 3 % of cash proceeds resulting from revenue generating for and 3 % of 3 % of 3 % of 3 % of the (ii for 3 % of 3 % of  3 % of 3 % of 3 % of 3 % of 3 % of 3 % of cash proceeds resulting from revenue generating revenue generating and (ii for and (i.european for the product for 3 % of a cash proceeds resulting from 3. The FDA\u2019s 3 % of the (ii for 3 % of cash proceeds from the (ii) 3 % of cash proceeds resulting from revenue generating resulting from revenue generating for and (i.e for a cash proceeds resulting from revenue generating for the use for 3 % of 3 % of 3 % of 3 % of the ("
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "As of year-end 2023, what percentage of KFC and Pizza Hut's system sales were attributed to loyalty program members?",
        "options": {
            "A": "50%",
            "B": "60%",
            "C": "65%",
            "D": "70%",
            "E": "75%",
            "F": "80%"
        },
        "LLM_original_answer": [
            "The results of operations, however, however, however, however, however, however, however, however, however, results of operations, results of operations, results of operations, results of operations, results of operations, or liquidity or liquidity or liquidity or liquidity or liquidity.It is possible, however, however, however, however, liquidity, or liquidity, however, however, however, however, however, however, however, however, or liquidity or liquidity or liquidity, or liquidity or any future results of operations, or liquidity or liquidity, however, however, however, or liquidity, however, however, however, however, or liquidity or liquidity, however, however, however, however, however, however, results of operations, however, however, however, however, however, however, however, liquidity and liquidity and liquidity and liquidity, however, however, liquidity and liquidity, however, however, however, however, however, however, however, however, however, however, however, however, however, however, however, however, however, however, results of operations, however, however, operations, however, however, however, however, however, however, however, however, liquidity, liquidity and/or future results of operations for any results of operations, or any future results of operations for any results of operations, however, and future results of operations, and future results of operations, however, however, results of operations, however, however, however, however, however, for any results of operations, and/or liquidity and results of operations, and future results of operations, results of operations, however, however, however, however, however, however, results of operations, results of operations, and, however, however, and liquidity and/or liquidity, or future results of operations, or liquidity, however, however, as well-known results of operations, and future results of operations, however, however, for any future results of operations, that future results of operations, or liquidity or liquidity and/or any future results of operations for any of operations, however, however, however, however, however, however, however, however, however, however, however, or liquidity and future results of operations, however, however, or liquidity, however, however, operations, or liquidity, however, however, however, however, however, however, or liquidity, results of operations, however, however, however, however, however, however, however, however, however, however, however, however, however, however, however, however, however, however,"
        ],
        "LLM_extracted_answer": [
            "B"
        ],
        "ground_truth": "C"
    },
    {
        "depth": 95,
        "token_lengths": 128000,
        "result": 0.0,
        "question": "Which provision in the company's Charter and Bylaws is intended to prevent minority stockholders from easily electing director candidates?",
        "options": {
            "A": "Classified Board of Directors with staggered, three-year terms",
            "B": "Issuance of preferred stock to dilute ownership",
            "C": "Exclusive forum in the Court of Chancery of the State of Delaware",
            "D": "Prohibition on cumulative voting in the election of directors",
            "E": "Advance notice procedures for nominating candidates",
            "F": "Limitation of liability and indemnification of directors and officers"
        },
        "LLM_original_answer": [
            "Questionnaires, proprietary tools, monitors, monitors, monitors, monitors, monitors, monitors, and a set of proprietary tools for a set of proprietary tools, monitors, and a set of a set of proprietary tools that we have screeners, monitors, a set of proprietary tools for a set of proprietary tools that we have developed screeners, and a set of proprietary tools that we have developed screeners, monitors, screeners, monitors, a set of proprietary tools, screeners, screeners, screeners, screeners, monitors, monitors, monitors, monitors, and proprietary tools, a set of proprietary tools and proprietary screeners, monitors, screeners, and proprietary tools, a set of proprietary tools, and a set of proprietary tools, a set of proprietary tools, monitors, monitors, monitors, screeners, monitors, screeners, monitors, screeners, monitors, screeners, monitors, monitors, and monitor tools, monitors, monitors, monitors, and a set of proprietary tools, monitors, monitors, and a set of proprietary tools, proprietary set of proprietary screeners, and a set of our set of our set of proprietary screeners, monitors, screeners, monitors, monitors, and a set of proprietary screeners, monitors, and monitors, and a set of proprietary tools, monitors to support tools, proprietary tools for the set of proprietary tools, screeners, monitors, monitors, monitors, monitors, monitors, and a set of proprietary tools to meet, monitors, monitors, and a set of tools for the set of proprietary screeners, monitors, monitors, monitors, monitors, monitors, monitors, and a set of portfolio management tools, screeners, monitors, screeners, screeners, screeners, screeners, monitors, screeners, monitors, monitors, portfolio management tools, a set of proprietary tools, monitors, monitors, monitors, and a set of proprietary tools to a set of proprietary risk management tools, monitors, monitors, and a set of our proprietary tools to set of our proprietary tools, monitors, monitors, monitors, monitors, monitors, monitors, a set of proprietary portfolio management tools, screeners, monitors, monitors, and a set of a set of proprietary tools, a set of proprietary tools, a set of the set of proprietary set of proprietary tools, monitors, monitors, monitors, monitors, and a set of a set of proprietary screeners, monitors, and a set of proprietary portfolio management tools, monitors, and a set of proprietary tools for a set of proprietary screeners, monitors"
        ],
        "LLM_extracted_answer": [
            "A"
        ],
        "ground_truth": "D"
    }
]